<SEC-DOCUMENT>0001014739-21-000011.txt : 20210311
<SEC-HEADER>0001014739-21-000011.hdr.sgml : 20210311
<ACCEPTANCE-DATETIME>20210311163633
ACCESSION NUMBER:		0001014739-21-000011
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		100
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210311
DATE AS OF CHANGE:		20210311

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Option Care Health, Inc.
		CENTRAL INDEX KEY:			0001014739
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOME HEALTH CARE SERVICES [8082]
		IRS NUMBER:				050489664
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11993
		FILM NUMBER:		21733817

	BUSINESS ADDRESS:	
		STREET 1:		1600 BROADWAY
		STREET 2:		SUITE 700
		CITY:			DENVER
		STATE:			CO
		ZIP:			80202
		BUSINESS PHONE:		720 697 5200

	MAIL ADDRESS:	
		STREET 1:		1600 BROADWAY
		STREET 2:		SUITE 700
		CITY:			DENVER
		STATE:			CO
		ZIP:			80202

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioScrip, Inc.
		DATE OF NAME CHANGE:	20050314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MIM CORP
		DATE OF NAME CHANGE:	19960516
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>bios-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:67699b3b-5a42-424d-a4a2-736d8be0bc5f,g:dc7394d0-f9c6-4f46-91d7-369b9ff9f10f,d:c913b68a604e4ff38c42375d3fa7a17b--><html xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:bios="http://www.bioscrip.com/20201231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bios-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl80L2ZyYWc6OWJkYTllZTA5MWRjNGYxMWI4YmJiYWEwZTIwNGE0OTkvdGFibGU6NjBhOTYwMDM3NmIwNGMwMzhlOGQxNmYyYWExYjliN2EvdGFibGVyYW5nZTo2MGE5NjAwMzc2YjA0YzAzOGU4ZDE2ZjJhYTFiOWI3YV80LTEtMS0xLTA_efa5fc0f-1004-4975-9381-6f7d202e7741">0001014739</ix:nonNumeric><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl80L2ZyYWc6OWJkYTllZTA5MWRjNGYxMWI4YmJiYWEwZTIwNGE0OTkvdGFibGU6NjBhOTYwMDM3NmIwNGMwMzhlOGQxNmYyYWExYjliN2EvdGFibGVyYW5nZTo2MGE5NjAwMzc2YjA0YzAzOGU4ZDE2ZjJhYTFiOWI3YV85LTEtMS0xLTA_216588ad-8c20-4291-b332-b28b365356e2">2020</ix:nonNumeric><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl80L2ZyYWc6OWJkYTllZTA5MWRjNGYxMWI4YmJiYWEwZTIwNGE0OTkvdGFibGU6NjBhOTYwMDM3NmIwNGMwMzhlOGQxNmYyYWExYjliN2EvdGFibGVyYW5nZTo2MGE5NjAwMzc2YjA0YzAzOGU4ZDE2ZjJhYTFiOWI3YV8xMC0xLTEtMS0w_bcf68923-e1da-4d44-b824-4ded91e46c87">FY</ix:nonNumeric><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl80L2ZyYWc6OWJkYTllZTA5MWRjNGYxMWI4YmJiYWEwZTIwNGE0OTkvdGFibGU6NjBhOTYwMDM3NmIwNGMwMzhlOGQxNmYyYWExYjliN2EvdGFibGVyYW5nZTo2MGE5NjAwMzc2YjA0YzAzOGU4ZDE2ZjJhYTFiOWI3YV8xMS0xLTEtMS0w_d5c81dc9-bc14-4901-8043-8ffa4397aba3">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="if944e5d57702478f96edf0c0c5780426_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc0Mjk_9e7f6967-ecc8-4667-930f-df6f18fbc07d">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="i8055d11ca77a46d49b7be5efb799bf4f_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc1Mjc_c3c88249-a6e5-407f-ae8b-52445dccabe5">P2Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i510ad1073fee46da8c18efb16f7e06c6_D20200203-20200203" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDkvZnJhZzowOTBmZjMwMzIxZjU0ZDM1YTY0MTM5MTViMmYwZTY3NS90ZXh0cmVnaW9uOjA5MGZmMzAzMjFmNTRkMzVhNjQxMzkxNWIyZjBlNjc1XzMw_7ef279f8-fcf8-4fd2-9905-f82761e2cfb0">.25</ix:nonFraction><ix:nonNumeric contextRef="ic76cb4e523aa47e994e82af3ea50d75e_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzgxMA_5835ea03-79c7-4f33-bae1-42d73cd55de9">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="ib40babb4ce544cecb8d62a5b59792213_D20200101-20201231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzEwNTU_96670979-bd52-4453-a4dd-ea37a865d80c">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="i66ddd3962e684353b2b33793e60d1e69_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzI2Mjc_ef3f1c14-105f-4e27-b582-034c0b01b496">P1Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i510ad1073fee46da8c18efb16f7e06c6_D20200203-20200203" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjkvZnJhZzo3YTc1MDk0YmQ4MjQ0Yjg4YmVjZmIxMzhjODBmYmFiNC90ZXh0cmVnaW9uOjdhNzUwOTRiZDgyNDRiODhiZWNmYjEzOGM4MGZiYWI0XzMw_77e65154-2f67-47af-b495-d0620c60d26b">.25</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bios-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i69a30465d231407487ede25fc216cb88_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i82ad3941737a494abf218dc777dd09e4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i936b65ce9acd48b496cb2d8b52c39297_I20210308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27919b5d127146ec960f50ee2587df9f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i757f7525fd514729825051239d54094e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40c908a9b2de45bcab117c93611972e9_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia256a7852ef04c1fbe74e288a706e7b1_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0c4db4796fe410bb862ec15526051d4_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i422568febabe4f8583b8153a15287b3d_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4ff3448393941ecb196d60a1c0c6507_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac5e68b371e846bcb5595487faa64440_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bios:ManagementNotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i405e4a30b4e7443da8c3cc601af2d472_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife86991b5c864d3ba7c27b4e2b6eaec8_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aaa306bfeb44033b42625ce53fced06_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d20553c1ddf4029b82e7a98557f08a6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bios:ManagementNotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f517132d94447c1a7f4a0703dfdad24_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d5f5d47071547e88ec2cc2a2ed79b64_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id159556253844660bd62dda5634d2366_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05ad22c7cb124eb7bc29475754fc1e50_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec2447edc67648968195e4c9c57c9044_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb3d7b08eaa94aeca766b6bd2235a557_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ca7471b8b564de0a7a5d385352e5b15_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bios:ManagementNotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38e87c4a7aae447680dde06b054bed9f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22b30bb4310a44029a5f94758c5ae210_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a948d96b8124ca49264e48dfa5b84ea_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58814d8f92d24190888892748720a464_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadfb96c7240b4bf2bc10824cee106ac1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bios:ManagementNotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06325eb29ded4dda8dad34622c87bed3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0217dbc311b4109a34f7a05e30c523d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc4c4a7abaf64793a8cca9faa42d501d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61291993f8a54aecbb68907a9140b3d1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6342b5959154862925fe574bb199b16_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6648a71bd04469e8bd6b625f8e26ce2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07bbcf8ebdcc452490830f429f1ef4ed_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4967cf0ba59b4694a935eb9c0d502a5d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bios:ManagementNotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1960cd3413c4497a8cb7b8ba588bf2b3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30b362b8cb0f4fa291d203acfe67091d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83ec2897c370475281d08a6233255f4d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib48648d60adf4dfda6254c20ebbb4a83_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65faadc1ce524e7297267901419cec15_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70d31c15efcd4ad091a5d18b9108dc8e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a81bc38266c4980843d89e190c3d8fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b7fd52d93044460ac7028d03c0b79f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacd1399421844f9795aff5870a8f8063_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f8587ff958a4c948e809015b40868e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if42702eefc1b4929ba571e14ece46dce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bios:ManagementNotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i510f7fb44d8047fe951f7d247dbdd5a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8178b1fbc0284245938041d60d5a050b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i368d5fdb13b94d2c99546a5791f3e988_D20190806-20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:OptionCareEnterprisesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-06</xbrli:startDate><xbrli:endDate>2019-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2ea7ddad6aa46c5900f0df09030bb8e_I20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:OptionCareEnterprisesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a95667076af42cc8fbcf3661b5bbacb_D20190806-20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:OptionCareEnterprisesInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-06</xbrli:startDate><xbrli:endDate>2019-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1860c3f1464545dd964c4595d8b8b205_D20190806-20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:OptionCareEnterprisesInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-06</xbrli:startDate><xbrli:endDate>2019-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c72c8c6a63c487d89bfa93db278f761_I20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i119e1c16609d4ae2a8c7779f88a837f0_I20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:OptionCareEnterprisesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="location"><xbrli:measure>bios:location</xbrli:measure></xbrli:unit><xbrli:unit id="site"><xbrli:measure>bios:site</xbrli:measure></xbrli:unit><xbrli:context id="i53e06ff77c484235837649f43bbe2b5d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bios:LegacyHealthSystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i086f47aad02f4c3598246e2234bcfcb9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">us-gaap:HurricaneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eb197b8c371412db224c1301352b49f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">us-gaap:HurricaneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fc719df4b5d4d1f874963db8ef3704c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">us-gaap:HurricaneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48a8600720a94bbf87db1dbe3e875b03_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d430ba49f0c4e89b1371f12b3bbf397_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if944e5d57702478f96edf0c0c5780426_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if76a9379d5a5462faea6e4911c09e610_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8055d11ca77a46d49b7be5efb799bf4f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ad7ffbd4bbb4311af7b6cd327201826_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bff063b20b44971b7a869047927c0a9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bios:InfusionPumpsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9646cc5252f40eabde3fb89431c23a5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie12e4e114a18499d9effec6a2ee61dbe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a9ad7e932754e6bbc1e427751b3bf94_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i158605824c6c423d867ee0566aa0ca47_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i484daecca47b416e99281851405afa48_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3503095cd1c346c3968c0a9058c5e025_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90930859b5a244fd919dfe2f357f7c23_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2f3781893ae44f498e20de51cd69b29_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0026d0842d3a4359a1692dd699b20cad_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6527aad98d3a47a69d34f668ffe88a0a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if236b13a6b0a4994a585e5cf622ca3f3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i464c8f864f8d49899ce600f0ac27fe32_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7851f95217d9442598cc88ba1ed517d1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6edfcb49cb0b4b1e8a63a9955b1aaab1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3753cbfa17174608809f4f34d4a104ac_I20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f090775b2c24e07909f7019308c4cc6_I20190805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-06</xbrli:startDate><xbrli:endDate>2019-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96e2bd7b43e2425892cf80e8dee1fa59_D20190806-20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-06</xbrli:startDate><xbrli:endDate>2019-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7a44592cb4a40fcbd91c004c84b7ef6_I20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0eab475192224276bc1b5ceb023d5037_D20190806-20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-06</xbrli:startDate><xbrli:endDate>2019-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida7f446eea274d038568171224dfb7f8_I20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8355aa59ded14d9c91a83db76fedede8_D20190806-20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-06</xbrli:startDate><xbrli:endDate>2019-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e8a900d790f44dabb629a7f9c87c6db_I20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf29203bfe714c69b132146d9352ba77_D20190806-20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-06</xbrli:startDate><xbrli:endDate>2019-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceee29a996a54c498d570461cc70c139_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fbf8d8eaeb1483aa65584975ad1895d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05bb7e7e8c7a426695f64056c9f39f0e_D20180808-20180808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BaptistHealthInLittleRockArkansasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-08</xbrli:startDate><xbrli:endDate>2018-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id730cf15243f442bbd04361989c01f84_I20180918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeI.V.SpecialistsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b6760c7c28a4a18988a26e4abe977de_D20180918-20180918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeI.V.SpecialistsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-18</xbrli:startDate><xbrli:endDate>2018-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2bd7b4025e94630bcabed85e8c697ea_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeI.V.SpecialistsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd5c46c0f3284d40848b80f8fbcc8415_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeI.V.SpecialistsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i510ad1073fee46da8c18efb16f7e06c6_D20200203-20200203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-03</xbrli:startDate><xbrli:endDate>2020-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba4469ba333d4f7dbcf906562ff59670_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:GovernmentCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b9dd506f11d4d1ebc70f70232a583f7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:GovernmentCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a18e871b4144c43920f2fdc837570dd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:GovernmentCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i511cdc2e39494cd4a860f9e7863bcf07_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:CommercialCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic52f5f00fdae408788e5edb2d3115ade_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:CommercialCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcb18262ac0749ab80774f8e983c5642_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:CommercialCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idedfd2fd8cf84679ad22ff62c6589c11_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:PatientCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bebf74e986b4a3fb16e367620def213_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:PatientCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia18fe7d576a24a3d959b4a7ade77e1ee_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:PatientCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i280e53dfa7f14ec79d051ef96fd2eb67_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">bios:MergerOperatingLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifee0c9a38e2f4f44872874da3bcaf823_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">bios:MergerOperatingLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dabb20864b5445da36520a3109bba91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">bios:MergerOperatingLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd78dc026a994a25a4f56b834ce3acf0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">bios:FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0615275335554e94b35841a1370fe6bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacbc724b23f14da8a2fcb2d0d2bbb77f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9602bc3ce024fae8e231c5a4c022557_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">bios:InterestLimitationCarryforwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8d455c8b67347889e5acbbbe86eb799_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">bios:InterestLimitationCarryforwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d46ec2aaebb419db2fc4d41c2c5a93d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">bios:FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaf8d37ccf224f66a6484b8ac7d64519_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">bios:FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c0ef9b611e047a885c26ca5f6249fad_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bios:ChargedBenefitToCostsAndExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied56fb2881f649038e93ac0e7055d693_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bios:ChargedToOtherAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66543252b74f4364a367c91ae3431b87_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bios:ChargedBenefitToCostsAndExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbd22998422e476a94384ec9ca9af121_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bios:ChargedToOtherAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5195060bc61421e96d7fc5e6a7b58ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bios:ChargedBenefitToCostsAndExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68b7bf1c254348648f33112353badc89_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bios:ChargedToOtherAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icea968011f094587b49f49e976287324_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9887caa100349b3a4635013ba8aa601_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i325067265d5c4ed789bfde38719b21ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bios:RestrictedStockAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i986fbe9ede1e4f4bae9e708842b5ac55_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie31db4918e8647d0bd750eeab70451ed_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5756cc875db64a44922ff59197c0da6e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bios:RestrictedStockAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida6b0075f5a24266b586c0f92806b056_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bios:InfusionPumpsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i625ed602cf134da6abbf0c62370735cd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bios:InfusionPumpsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifee0705a51c84a4980d98bc3cf7443e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bios:EquipmentFurnitureAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc52cce51e6a4f36a08c80fcdd124e59_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bios:EquipmentFurnitureAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb84e173e738405780c00bcbe867cc0e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3509723008544588453b805365b676c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8cc880af6414d95b4c0dd61dbdebe7c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7055866745ae4cc595c938f55c549586_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33147d91bdd64411a910c1922f1e30ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie319aae0a4334d4ea6a4c29ad036bd48_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71540503946547bfb71bcf7399158709_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d7863206f284422a8c9baba7551456b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8bb4cd176114cedb1143d6017295c52_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d387c31f86c420698ca7b00dcb79be8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5caeb9d9df24859839e8059a6e70cb6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e6f1790eb1b4698bc41fd69f2fe9033_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6683b8adaec142929fcdb6cc820b86c8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">us-gaap:HurricaneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc00aa48c5dd4893801fa8c1ebcb07c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d301d39dafd4e68a587b0a3fa40fcfb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie817018869a64452a6fc78f5f9440a38_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45131573f0bb479e8f31cf95f78845cb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if428d92bc279403486726eacba9956e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff982c3170b046f39f50b17cf259e515_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ead4afeb6274fe391c370a8ab570027_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia70d084d67ce4667b22225e30b5f6b8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i660fc6279c714085b9bafae194ba5b7d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:SecondLienTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6a9df1dd28e4f1680a018dc49429873_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6074931e160e4e02be724a84dde0758b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bb20cde57584d28ab6a5c4446839bc2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:SecondLienTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f59152bb9c048a5b50b44067271f613_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a4bc3c15e894757bc0a5393777c3429_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bios:BankOfAmericaN.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i640bd2ca162d4110821356fb395847f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4386145a348444218987e663e802f1b3_I20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f24d9bf71984546b8af671666297e21_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12c898e6c2bf4a57a2d2293e3f85537e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cc1c613272d407fb68c66233b0884da_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id826c60086164891b7f61e86c7d17b78_I20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04c60dc2cb4949a08701ec5516562884_I20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i209bb88d77ec42248db74bf4e55edb38_I20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib286938752c04504a3b00f4071a94634_I20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46f31629752b4d81875255a5a98e87a7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5331a479244a11b7005f9b4a1e7c11_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4ff2a32df6c4734a1ec9790fd2b3c90_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99995e13205b43628f9807043e807bce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaba77b7ae34c4fb7b5163a1d2f78b481_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id771c21da6a248498802851c5776c07e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i415f019222e24e949930ede6b5b65dd1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i483af9de03bc4422b957661fc1119a22_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cf4138b86814ddaa06ddcb7b782f15a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c4f5e9ea300456ca3c311e588f2d512_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13a144a884e94b6a93b74bea5f331c3e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c10e2b1b78c46e2bae9d7a6747cce9c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2723f056763c4dedbc445d2f9855f372_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4574bb7e56b34190bb053a4f1bcd1b5b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5b446b6a97f4f90ac9242bc18f5059d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab4208b4c10d4bc0b8f34fe22bd51432_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a10d18e244645e5b6a89c8ab446ff90_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i607cf3ad83fa4d68a7f532e446e0e21f_D20190806-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-06</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0792b3cd668b435abf755519d30889a2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bd2ac4c3a7b43a292acc61f6fdf6853_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d4c5bb322c04877b86cf39e32da703f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i325d52df30ad4c278d90566dd27aaf21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedf0847627fa4c459cc17c612b6e2b9e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic49d785c7256408c93023d39c4d914d8_D20190806-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-06</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5a9e86640d24df0a4a74f644bec401b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bios:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41a866b1933d4b50a03ed2090fc52f3b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bios:NotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb7255dc5f1449f88b65c6161c741c55_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd11813edd424004b8d01f7794f0116c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a1d6fa62d594e16b4173eb1cda83c73_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83c91152b1744cdda0bc77a72cef0072_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia288006c93754808b4fb52473eb70d95_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia334515f9b054e84a1cdb130df9a3d17_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5330b1241c9f450aabf19a6470f3deeb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8915c98904a74bd98e03842b6725688d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ea39b7659c64974ab62326385972ecc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015ModifiedLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i475c18c38aea40bfa20cc795a9a0586e_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b688f43690d4a10bb658649d8f26b91_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bios:NotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d71acb5790f4712b5fe4d979c0e2bd2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46dc5fdf0022473d841d625d8ca2e5cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a157555439142d78694bcf7b01379aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie94a2f3b1fce4b9abcfcd916988d3eb8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:SecondLienTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15aa1aad0d3744a0abc478e642582276_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:SecondLienTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb5343b6a2e9432f8e58f2bd9a3d07ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:SecondLienTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0851f5015634259990ba26f9a4a889e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d3c87930eb1479888f34f3af43a0440_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fa3ac11591f4ece89016cc369ba0e2b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d7bc9bd670f4ffb91c21fb59c7c7fb1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85d077a5e93842429e329f0dcb9d0f2d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadaac97b718242739dbbd6f6ed2e6ae0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76f46d4be96544528533fb90947e87a4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:SecondLienTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bd8c01514d84331992e13473d81c16b_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa2b883648c2436f83ec2369cdbc149b_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddb4b3d5aafc422db864143a1b1aa819_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fbd469711e34b0cb074a178241284d8_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65baa1ec1f4d461b86b9b6f2542d2c72_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdd8047975e647288143981c8762166c_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70568db5bcc649c5bd6104996dd8bf09_I20191106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0cf4d78796d429d879bce469f3f3150_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b483f33dcad4616a569483ce451b1b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bios:AccruedExpensesandOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2467317320d4c409705b0b02f8ab210_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bios:AccruedExpensesandOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79e4af3f2d204d8f95b5b4ad2982893d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bios:AccruedExpensesandOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc9a7eafdb69419ba693d8dffce79f3b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bios:AccruedExpensesandOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eefd11356ef4acfa576e05c36eec86e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19aaeb7b2301410c8ace359b4aae0a61_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e6745feb32545bd99b8438f4cb65e42_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idadf3e087514415d9e588230d1e4c8e8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie42dd3293f1047ffb0d1d1e673596db2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5536ba9ef240436f8685941bf069832f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc8999935b584fbe93f3edcbbb32aa8b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf3e87fd34a94950b1dfab02c0351ccb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a2d963d4b4c4bf0bc68ff139a36a0d1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2ffe75f1b2e4b789fd671082186d2f2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if51a0a2416fc4efaa81e5964f060685f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77b199f5d9fe42879ba86a116b6460d8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieea161291d5e4067a3bf1b40c8e4dac7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe4cf21bfb5140d997a613e6c5626e64_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eb1d1e629ac4a0ba804cec14a4547ea_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iada07b387c4c497182b71cd727197396_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie78754462d4f48648b6dde71360bba63_I20180503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bios:A2018PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic76cb4e523aa47e994e82af3ea50d75e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24920ce6c3624d32867b35ecb74cd412_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib40babb4ce544cecb8d62a5b59792213_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd470f5e6054ec5b5f94411ed707e82_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1599283f6d184d1b9aa7b7fa0b2e0ce8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i760b317cd0fd4b0d9e286a06610ffaec_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7593332c92344b60ad9b41ff0c66bfb8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53bc279beb0d4676ba828340fd063ce9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e711f6fe89d4907a952226e5df765bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied37c8390b9e43a68cb9da71a0ccb303_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic297998b32b84faa88fcfec2d9f9afaa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e5ee81d05914bbbb9c62c51c01221b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia22152ff44814391aef12293b8db163f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63a51e68f4934ca4aa97b767de686c2e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic98475680f7349638688cb46f1e41606_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fd061fe54554bc695ee04673aa61e17_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie25037f6e33c47f0b726fabf6b0be7a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6dce6cca08246afbc1f71bef99be371_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55f1b01e1ac646989939a0659a3141e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42e2317cc254448dba231db5776669d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0053d6570a4144ac906506c3b03aab72_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d816e895c844acba36b041455ff1817_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30fe04022dfb468d8d0ab7e1e5130cbc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7776b739ae0444bfa9bc3151bd3de57d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabac5d7169c74416abc3eb400b77e659_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6111e845e8ac4ee9941a74fef21be93b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66ddd3962e684353b2b33793e60d1e69_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3c12b1e25aa48848f6b9795aa9375a0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30a276240cc149b2b70ea64be64b1594_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71d89cba29a940fcb26b394671b41837_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51298007a376435784a5fb2e3b738530_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7cbfe6f12b34fedb3c55e90bc01b102_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2de6cb92e6b546deac3f264b1d51d725_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7250472ce2a241aa9fa3993c11938e71_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b7d2377ab7d4bc99608fd62fc228d0a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5acddac984ac471cad45cd822b74b0b6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bios:HCIIncentiveUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f5821f9020a4063acb746c7833a5115_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bios:HCIIncentiveUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie95cb408d1a745e48ca026ce6e263566_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bios:HCIIncentiveUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b196dfce1974680a1c28c5ea237cbf5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bios:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if168c646a7a54828a528116373a38538_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bios:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bios:OptionCareHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc639cc9d59342c992cf094de275e8c8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bios:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bios:HCGroupHoldingsILLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33bae88b85d44fbca1b188c77d873669_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bios:SecondaryOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91057a8b01954ab2b5e6178ac8a1653d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bios:HCGroupHoldingsILLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d4a2b07f09440698f0d0e140a1f931b_I20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2017WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i535849efb80c49c89802c2c1e9ff8d05_I20170629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2017WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d17de0af863439a8ae94e0d74a3cb43_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2017WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1039614a70d44672a1b9b67e279fb604_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2017WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7318e00da4034c3e90a2e212df26a625_I20190805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i219745e510624e329c043ef1592af4c1_I20150309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3aa39a0d3d547f5ac6cd2902b94a3cc_I20150309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3a9e03e121545df913cf6c60ded20b6_I20150309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf01e47aa17741d5850517700e659acc_I20190806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac71a41a43944594bf483f7a54f70817_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea509be9731f4fb6830bb71b36a2b3bc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd4a7b857bfc47ff96783a5d70cfd61b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>bios:day</xbrli:measure></xbrli:unit><xbrli:context id="i75edeee42f0440a9ae3db5c126a6ee59_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifefcdf706a3e409c8661a5f8661ff527_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15e537579ddd49499464fe98320efa5a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:OptionCareEnterprisesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e27ad48b6e845aab11f9dc6d36cc68d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bios:RestrictedStockAndStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib70cc65c7351474ca9d26740937a57b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bios:RestrictedStockAndStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13dda31dc46244a296faff43e8f63ba2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bios:RestrictedStockAndStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i960724d691c94ef7990ec38c99826855_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bios:MadisonDearbornPartnersVIBL.P.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bios:OptionCareAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if80a7156fb6f4e92b4633b71b42884d2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia181037e051e4e948fa5f02cec18ae01_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i284ee94026ab44078607e6ba90095ac0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bios:LoansFundedForMembershipUnitPurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib849ab96bb7143929a677ea83f9f24a1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bios:LoansFundedForMembershipUnitPurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bb7590e2fd64c32b7a9e48da3b76727_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bios:LoansFundedForMembershipUnitPurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34486d66c41947448069be17a3002902_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bios:SaleOfNotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibab2cb958b58428e93eac229c0d7b02d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bios:SaleOfNotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i822483b16b124c4596a91869aa597cb8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6555353edfee47bd86374a705cce7c7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58a5c478533d40c4ae5cf5901b523252_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3802608a5ccb4cafbdc104d570a82e52_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51011fdb3a8b4c218ad62e0a5f46e49f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e67b5985f2447a4a6bba9e8bc275f82_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5e84b8b2d0c4dc7a263964004d01b50_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72c86c11f53e4fe297072ffdc6b4277f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15449ea65247465890f60bdac030ba0a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaae3340f01f44ee699ccd0262c23dc33_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic66518c22fa740f7b245ba8a1d6615fd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3afb9f5919b84a45a2a45351ff5c3f16_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec2211f718164003b67adb468a0ae8fe_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib556381e0e774b77af5202ac495cedbb_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib309aaac6dde42acbdc774c94fb918ad_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70f18d581b7c4638bce49ebbbfa4f31b_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bbb595569b4462e84f37fd4195a043b_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0bfb220dbad4d1ca83ebb1bd6d1b4c6_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8995bda2010f4ab3b9f72d0a8e9683f7_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i843047af1ab74b56ac1a994dd504c5cb_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bios:SecondaryOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e6ee715bd2943e5b275bef6b90641f2_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bios:HCGroupHoldingsILLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_1"></div><div style="min-height:22.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.311%"><tr><td style="width:1.0%"></td><td style="width:23.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.766%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:4pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:4pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:4pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:4pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:4pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzMy_e7178629-47af-4f53-9da2-1367dbdb894d">10-K</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.081%"><tr><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Mark One)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6YWRlZGM3NmZmYjQyNDFkMzk0YzYyMjE1Y2NkYmQ4NjUvdGFibGVyYW5nZTphZGVkYzc2ZmZiNDI0MWQzOTRjNjIyMTVjY2RiZDg2NV8xLTAtMS0xLTIyMw_9d43ea9c-2997-445c-aa34-6f61df7f43c4">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the fiscal year ended <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6YWRlZGM3NmZmYjQyNDFkMzk0YzYyMjE1Y2NkYmQ4NjUvdGFibGVyYW5nZTphZGVkYzc2ZmZiNDI0MWQzOTRjNjIyMTVjY2RiZDg2NV8yLTEtMS0xLTIwNy90ZXh0cmVnaW9uOjUxMzhjZTc2ZDk2YjQ3MWViODA0MTE2MDc2MjI3NjYwXzMyOTg1MzQ4ODMzOTI_a5aa6d2b-896e-44cd-8060-c93605204f7d"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6YWRlZGM3NmZmYjQyNDFkMzk0YzYyMjE1Y2NkYmQ4NjUvdGFibGVyYW5nZTphZGVkYzc2ZmZiNDI0MWQzOTRjNjIyMTVjY2RiZDg2NV8yLTEtMS0xLTIwNy90ZXh0cmVnaW9uOjUxMzhjZTc2ZDk2YjQ3MWViODA0MTE2MDc2MjI3NjYwXzMyOTg1MzQ4ODMzOTI_124050ce-9640-4135-b1e4-5f7c6807f70f">December&#160;31</ix:nonNumeric>, 2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OR</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6YWRlZGM3NmZmYjQyNDFkMzk0YzYyMjE1Y2NkYmQ4NjUvdGFibGVyYW5nZTphZGVkYzc2ZmZiNDI0MWQzOTRjNjIyMTVjY2RiZDg2NV80LTAtMS0xLTIyNg_24b50294-fd0a-4eee-8239-4ea8067c0fde">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the transition period from &#160;&#160;&#160;                  to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzM1_4f00fdf7-402a-4906-854d-9e697567a5be">001-11993</ix:nonNumeric></span></div><div style="text-align:center"><img src="bios-20201231_g1.jpg" alt="bios-20201231_g1.jpg" style="height:61px;margin-bottom:5pt;vertical-align:text-bottom;width:158px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzM4_8e5d29e2-47d9-4224-83f9-958aa76eaadd">OPTION CARE HEALTH, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.448%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NDExODE0Y2ZkYjZjNDYwNDhhNWE0NTljYTgwM2RhMTgvdGFibGVyYW5nZTo0MTE4MTRjZmRiNmM0NjA0OGE1YTQ1OWNhODAzZGExOF8wLTAtMS0xLTI0MQ_e5fb72d8-98a2-4fd5-9a26-807c067e3842">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NDExODE0Y2ZkYjZjNDYwNDhhNWE0NTljYTgwM2RhMTgvdGFibGVyYW5nZTo0MTE4MTRjZmRiNmM0NjA0OGE1YTQ1OWNhODAzZGExOF8wLTEtMS0xLTI0NA_62ae8ef1-7e12-43ce-ab63-9794914fff6a">05-0489664</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(State of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NDExODE0Y2ZkYjZjNDYwNDhhNWE0NTljYTgwM2RhMTgvdGFibGVyYW5nZTo0MTE4MTRjZmRiNmM0NjA0OGE1YTQ1OWNhODAzZGExOF8yLTAtMS0xLTIxMi90ZXh0cmVnaW9uOjkyMmI2YjU3NGMzMTRiZDJiY2YzYjUyMjM3MDM0ODE3XzMyOTg1MzQ4ODMzOTQ_824ab45d-a0c7-4df0-9e3e-86780213fca9">3000 Lakeside Dr.</ix:nonNumeric> <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NDExODE0Y2ZkYjZjNDYwNDhhNWE0NTljYTgwM2RhMTgvdGFibGVyYW5nZTo0MTE4MTRjZmRiNmM0NjA0OGE1YTQ1OWNhODAzZGExOF8yLTAtMS0xLTIxMi90ZXh0cmVnaW9uOjkyMmI2YjU3NGMzMTRiZDJiY2YzYjUyMjM3MDM0ODE3XzMyOTg1MzQ4ODM0MDc_a95fe5ad-b05a-4570-965d-7b6db22dcf05">Suite 300N</ix:nonNumeric>, <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NDExODE0Y2ZkYjZjNDYwNDhhNWE0NTljYTgwM2RhMTgvdGFibGVyYW5nZTo0MTE4MTRjZmRiNmM0NjA0OGE1YTQ1OWNhODAzZGExOF8yLTAtMS0xLTIxMi90ZXh0cmVnaW9uOjkyMmI2YjU3NGMzMTRiZDJiY2YzYjUyMjM3MDM0ODE3XzMyOTg1MzQ4ODM0MjE_9883c2aa-40eb-4e95-a473-06fb94da46db">Bannockburn</ix:nonNumeric>, <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NDExODE0Y2ZkYjZjNDYwNDhhNWE0NTljYTgwM2RhMTgvdGFibGVyYW5nZTo0MTE4MTRjZmRiNmM0NjA0OGE1YTQ1OWNhODAzZGExOF8yLTAtMS0xLTIxMi90ZXh0cmVnaW9uOjkyMmI2YjU3NGMzMTRiZDJiY2YzYjUyMjM3MDM0ODE3XzMyOTg1MzQ4ODM0MjY_e911d163-a291-4bae-a662-59ab98427504">IL</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NDExODE0Y2ZkYjZjNDYwNDhhNWE0NTljYTgwM2RhMTgvdGFibGVyYW5nZTo0MTE4MTRjZmRiNmM0NjA0OGE1YTQ1OWNhODAzZGExOF8yLTEtMS0xLTI0Ng_625f84a9-bdd1-47f2-b40f-2a59d85e4403">60015</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzUw_d2a3078d-d7a2-4027-a49c-459bf4a54a0f">312</ix:nonNumeric>-<ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzQ0_234d6158-bc83-4df7-96b9-55e1577580b2">940-2443</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.863%"><tr><td style="width:1.0%"></td><td style="width:32.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.280%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NjMxZmMyMzVlMDUxNGM2YmI2ZTExMzZkZDc1MWViOTMvdGFibGVyYW5nZTo2MzFmYzIzNWUwNTE0YzZiYjZlMTEzNmRkNzUxZWI5M18xLTAtMS0xLTI2Mw_888ba286-0a97-4dc0-a5c1-5dd68837bc87">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NjMxZmMyMzVlMDUxNGM2YmI2ZTExMzZkZDc1MWViOTMvdGFibGVyYW5nZTo2MzFmYzIzNWUwNTE0YzZiYjZlMTEzNmRkNzUxZWI5M18xLTEtMS0xLTI2Mw_1e9d54be-ef93-4976-b23a-2bce19193bfc">OPCH</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NjMxZmMyMzVlMDUxNGM2YmI2ZTExMzZkZDc1MWViOTMvdGFibGVyYW5nZTo2MzFmYzIzNWUwNTE0YzZiYjZlMTEzNmRkNzUxZWI5M18xLTItMS0xLTI2Mw_8a4bc247-eb84-4cb9-bf84-64907dfe4d6a">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to section&#160;12(g) of the Act: None</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzUx_172cd748-2904-4ab2-b9b0-25b01f44dc10">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzUy_02f481a6-bdaf-4462-bbd8-1969614b745f">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;<ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzUz_f5a95213-6594-4f4c-9a9f-6f7c78d3fcb5">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzU0_686f6ef8-1ce4-4c37-a788-413dd8adf0f5">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;No </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Large accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzU1_6a2cdc4c-4b76-41b9-9ba8-91d5f326aabe">Accelerated filer</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Non-accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;Smaller reporting company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzU4_2a6c8f7b-8b4b-4925-bb7a-eab5eb5a9fb9">&#9744;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzYx_a0702839-8da9-4d60-bea9-7edac62736eb">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2OTM4_205cdd75-9057-4f1d-a565-7442616a11b9">&#9745;</ix:nonNumeric></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzY0_a7b360f0-8dab-4bca-8fa7-c482a1cbbf1b">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the registrant&#8217;s Common Stock held by non-affiliates of the registrant as of June&#160;30, 2020, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="i82ad3941737a494abf218dc777dd09e4_I20200630" decimals="0" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8yNDY4_ba59ec09-7244-4f79-8744-4fab28f2ee73">473,322,477</ix:nonFraction> based on the closing price of the registrant&#8217;s Common Stock on the Nasdaq Global Select Market on such date.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;8, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i936b65ce9acd48b496cb2d8b52c39297_I20210308" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8yNjAy_ecfc3b22-3272-4992-a21d-93df7e7d4c73">179,814,189</ix:nonFraction> shares of the registrant&#8217;s Common Stock outstanding.</span></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2OTM5_4a6c5103-f70e-486e-8053-df08c01947ae" escape="true">Portions of the registrant&#8217;s definitive proxy statement for its 2021 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) within 120&#160;days after the close of the registrant&#8217;s fiscal year are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K.</ix:nonNumeric></span></div><div style="height:13.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.686%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page<br/>Number</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART I</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_19">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_19">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_22">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_22">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_25">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_25">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_28">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_28">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_31">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_31">29</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART II</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_37">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_37">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_40">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_40">Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_40">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_43">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_43">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_70">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_70">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_70">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_73">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_73">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_73">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_187">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_187">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_187">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_190">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_190">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_190">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_193">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_193">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_193">83</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART III</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_199">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_199">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_199">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_202">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_202">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_202">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_205">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_205">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_205">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_208">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_208">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_208">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_211">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_211">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_211">83</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART IV</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_217">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_217">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_217">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_220">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_220">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_220">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_223">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_223">87</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K (&#8220;Annual Report&#8221;) contains statements not purely historical and which may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8217;), including statements regarding our expectations, beliefs, future plans and strategies, anticipated events or trends concerning matters that are not historical facts or that necessarily depend upon future events. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; and similar expressions. This Annual Report contains, among others, forward-looking statements based upon current expectations that involve numerous risks and uncertainties, including those described in Item 1A &#8220;Risk Factors&#8221;. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors are cautioned that any such forward-looking statements are not guarantees of future performance, involve risks and uncertainties and that actual results may differ materially from those possible results discussed in the forward-looking statements as a result of various factors.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do not place undue reliance on such forward-looking statements as they speak only as of the date they are made. Except as required by law, Option Care Health, Inc. assumes no obligation to publicly update or revise any forward-looking statement even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_16"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option Care Health, Inc. (&#8220;Option Care Health&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, or the &#8220;Company&#8221;) is the largest independent provider of home and alternate site infusion services through its national network of 145 locations in 45 states. Option Care Health draws on nearly 40 years of clinical care experience to offer patient-centered, cost-effective infusion therapy. Option Care Health&#8217;s infusion services include the clinical management of infusion therapy, nursing support and care coordination. Option Care Health&#8217;s multidisciplinary team of approximately 2,900 clinicians, including pharmacists, pharmacy technicians, nurses and dietitians, are able to provide infusion service coverage for nearly all patients across the United States needing treatment for complex and chronic medical conditions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HC Group Holdings II, Inc. (&#8220;HC II&#8221;) was incorporated under the laws of the State of Delaware on January 7, 2015, with its sole shareholder being HC Group Holdings I, LLC. (&#8220;HC I&#8221;). On April 7, 2015, HC I and HC II collectively acquired Walgreens Infusion Services, Inc. and its subsidiaries from Walgreen Co., and the business was rebranded as Option Care, Inc. (&#8220;Option Care&#8221;).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2019, HC I and HC II entered into a definitive agreement (the &#8220;Merger Agreement&#8221;) to merge with and into a wholly-owned subsidiary of BioScrip, Inc. (&#8220;BioScrip&#8221;), a national provider of infusion and home care management solutions, along with certain other subsidiaries of BioScrip and HC II. The merger contemplated by the Merger Agreement (the &#8220;Merger&#8221;) was completed on August 6, 2019 (the &#8220;Merger Date&#8221;). The Merger was accounted for as a reverse merger under the acquisition method of accounting for business combinations with Option Care being considered the accounting acquirer and BioScrip being considered the legal acquirer. Following the close of the transaction, BioScrip was rebranded as Option Care Health, Inc.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option Care Health contracts with managed care organizations, third-party payers, hospitals, physicians and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients&#8217; homes or other nonhospital settings. The Company operates in one segment, infusion services.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating model enables it to provide favorable outcomes to its stakeholders as follows:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Patients</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company improves patients&#8217; quality of life by allowing them to receive infusion therapy at home or at one of its ambulatory infusion suites. In addition, the Company helps manage patients&#8217; conditions through counseling and education regarding their treatment and by providing ongoing monitoring to encourage patient compliance with the prescribed therapy. The Company also provides services to help patients receive reimbursement benefits.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Payers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company provides payers with a comprehensive approach to meeting their pharmacy service needs and providing a cost-effective solution. The Company&#8217;s provision of infusion pharmacy services in the patient&#8217;s home or at one of its local ambulatory infusion suites offers a lower cost alternative to providing these therapies in a hospital setting. The Company also provides payers with utilization and outcome data to evaluate therapy effectiveness.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Physicians</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company provides physicians with timely patient clinical support by providing care management related to their patients&#8217; pharmacy needs and improving compliance with therapy protocols. The Company eliminates the need for physicians to carry inventories of high cost prescriptions by distributing the medications directly to patients&#8217; homes.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Pharmaceutical Manufacturers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company collaborates with pharmaceutical manufacturers to provide a broad distribution channel for their existing pharmaceuticals and their new product launches. The Company implements patient monitoring programs that encourage compliance with the prescribed therapy. The Company also provides valuable clinical information in the form of outcomes and compliance data to manufacturers to aid in their evaluation of the efficacy of their products.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality is at the core of the Company&#8217;s mission as it strives to deliver quality healthcare, leading to favorable outcomes and more cost-effective care. The Company offers comprehensive services that align with specific healthcare provider needs and has demonstrated success in improving outcomes across a broad range of therapies through improved clinical-reported patient adherence rates and decreased rates of un-planned hospital re-admissions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s commitment to continuous quality improvement to provide optimal outcomes for its patients is evidenced by its national accreditations, including accreditations from Accreditation Commission for Health Care (&#8220;ACHC&#8221;), Pharmacy Compounding Accreditation Board (&#8220;PCAB&#8221;), American Society of Health-System Pharmacists (&#8220;ASHP&#8221;) and Utilization Review Accreditation Commission (&#8220;URAC&#8221;).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACHC accreditation is awarded to healthcare organizations that meet regulatory requirements and accreditation standards, and PCAB accreditation offers the most comprehensive compliance solution in the industry based on more than 40 sterile compounding standards in the U.S. Pharmacopeia Pharmaceutical Compounding - Sterile Preparations Standards (&#8220;USP 797&#8221;).</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the largest independent provider of home and alternate site infusion services. The Company&#8217;s services are most typically provided in the patient&#8217;s home, but may also be provided at clinics, the physician&#8217;s office or at one of its ambulatory infusion suites. The Company provides a broad therapy portfolio through its network of 99 full service pharmacies and 46 stand-alone ambulatory infusion suites. The Company&#8217;s home infusion services include medication and supplies for administration and use at home or within one of its ambulatory infusion suites, consultation and education regarding the patient&#8217;s condition and the prescribed medication nursing support, clinical monitoring and assistance in monitoring potential side effects, and assistance in obtaining reimbursement. The Company administers a wide variety of therapies and services, including the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Anti-Infectives Infusion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company provides comprehensive home infusion services to combat serious infections in patients of all ages. The Company&#8217;s anti-infective therapy and services help avoid hospitalizations for many infections that can be safely treated at home.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Heart Failure.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company administers home infusion services to treat heart failure, either in anticipation of cardiac transplant or to provide palliation of heart failure symptoms.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Chronic Inflammatory Disorders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.   The Company treats chronic inflammatory disorders, which include Crohn&#8217;s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Immunoglobulin Infusion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company offers industry-leading expertise, access, and support in immunoglobulin (&#8220;IG&#8221;) infusion therapy designed to treat immune deficiencies. Immune deficiencies are disorders that reduce the patient&#8217;s ability to identify and destroy substances that do not belong in the human body and are characterized by reduced levels of antibodies. Intravenous IG infusions are concentrated antibodies that have been purified from large numbers of human blood donors.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Bleeding Disorders Infusion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   As a leading provider of home infusion therapy for hemophilia and von Willebrand disease, the Company streamlines the administrative burdens associated with infusion therapies for bleeding disorders. The Company works with medical specialists across the country to offer access to all approved factor products, a full range of therapies, and dedicated support services. Hemophilia is one of the most costly diseases to treat. The treatment goal is to raise the level of the deficient clotting factor and maintain it to stop the bleeding. Treatments include infusion of the clotting factor products and other biologic prescription drugs. The length of treatment depends on the severity of the bleeding episode, and the need for treatment continues throughout the life of the patient.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Nutrition Support Infusion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company delivers comprehensive nutrition support across pediatric, adult, and geriatric patients. The Company&#8217;s expert team provides home parenteral nutrition and enteral nutrition support for numerous acute and chronic conditions negatively affecting nutritional status, such as stroke, cancer, and gastrointestinal diseases.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Women&#8217;s Health.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company offers therapies that women need to survive and thrive through high-risk pregnancies. Personalized programs in prematurity, nausea and vomiting hyperemesis, diabetes in pregnancy, and hypertension help meet the needs of each mother.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Neurological Disorders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company provides an array of treatments to manage the progression of neurological disorders such as Amyotrophic Lateral Sclerosis (&#8220;ALS&#8221; or &#8220;Lou Gehrig&#8217;s disease&#8221;) and Duchenne Muscular Dystrophy.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Other.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company offers a range of other infusion therapies to treat a variety of conditions, including pain management, chemotherapy and respiratory medication.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also provides nursing services to support the above therapies, comprised of its nursing team of approximately 1,300 employees, and through its network of sub-contracted nursing agencies.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s sales and marketing efforts focus on three primary objectives: (1) building new relationships and expanding existing contracts with managed care organizations; (2) establishing, maintaining and strengthening relationships with local and regional patient referral sources; and (3) maintaining existing and developing new relationships with pharmaceutical manufacturers to gain distribution access as they release new products.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s sales structure is focused on maintaining and expanding its relationships with drug manufacturers to establish its position as a participating provider when they release new products. In addition, the Company&#8217;s sales structure allows it to leverage its national managed care relationships to provide sales and contract pull-through by the Company&#8217;s local field-based sales personnel. This cross-utility enables the Company to market its services to numerous sources of patient referrals, including physicians, hospital discharge planners, hospital personnel, Health Maintenance Organizations (&#8220;HMOs&#8221;) and Preferred Provider Organizations (&#8220;PPOs&#8221;).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company competes in the large and highly fragmented home infusion market for contracts with managed care organizations and other third party payers to receive referrals from physicians, case managers and hospital discharge planners. Competition in the home infusion market is based on quality of care, clinical outcomes, pricing and cost of service, reputation, and reliability of service. Its competitors within the home infusion market include Coram CVS/specialty infusion services (a division of CVS Health), Accredo Health Group, Inc. (a unit of Cigna), Briova (a subsidiary of OptumRx, which is a unit of the United Healthcare Insurance Company) and various regional and local providers. The Company believes that its reputation for providing quality services, the strength of its national presence and its ability to effectively market its services at national, regional and local levels places it in a strong position against existing and potential competitors. The Company believes that the value created by the Merger has put the Company in a unique position to efficiently capture market share through its expanded footprint and synergies.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns a variety of trademarks, licenses, and service marks, including but not limited to: &#8220;Option Care Health&#8221;, &#8220;Option Care&#8221;, &#8220;Critical Care Systems&#8221;, &#8220;Clinical Specialties&#8221;, &#8220;BioScrip&#8221;, &#8220;BioScrip Infusion Services&#8221;, &#8220;BioScrip Nursing Services&#8221;, &#8220;BioScrip Pharmacy Services&#8221;, &#8220;CarePoint Partners&#8221;, &#8220;HomeChoice Partners&#8221;, &#8220;InfuScience&#8221;, &#8220;InfusionCare&#8221;, &#8220;Infusion Partners&#8221;, &#8220;Infusion Solutions&#8221;, &#8220;New England Home Therapies&#8221;, &#8220;Option Health&#8221;, &#8220;Professional Home Care Services&#8221;, &#8220;Wilcox Home Infusion&#8221;, &#8220;Home Solutions&#8221;, as well as several others.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suppliers</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company purchases pharmaceuticals and medical supplies through pharmaceutical manufacturers, distributors and group purchasing organizations. Through the coverage and clinical expertise of its 99 full service pharmacies, the Company provides pharmaceutical manufacturers with a broad distribution channel for its existing pharmaceutical products. Many of the pharmaceuticals that the Company purchases are available from multiple sources and are available in sufficient quantities to meet its needs and the needs of its patients. However, some drugs are only available through the manufacturer and may be subject to limits on distribution. In such cases, it is important the Company establishes and maintains good working relations with the manufacturer to secure sufficient supply to meet its patients&#8217; needs. Additionally, certain drugs may become subject to supply shortages. Such shortages can result in cost increases or hamper the Company&#8217;s ability to obtain sufficient quantities to meet the needs of its patients. The Company actively manages its relationships with direct manufacturers and distributors to ensure consistent supply and cost-effective procurement. These relationships provide the Company the opportunity to become a selected partner in the launch of their new products. The Company may receive fees, which it records as revenue, from certain biotech manufacturers for providing them with clinical outcomes data. The Company&#8217;s continued growth will be dependent on maintaining its existing relationships with manufacturers and establishing new relationships with additional manufacturers as the Company launches new products.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, approximately 70% of the Company&#8217;s pharmaceutical and medical supply purchases are from three vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company&#8217;s financial condition or operating results.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the purchasing power of its national platform, the Company is able to negotiate favorable terms and economics, including volume purchase rebates and vendor administration fees. Such fees are recorded as reductions to cost of revenue when the pharmaceuticals are delivered to the patient.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Billing &amp; Significant Payers</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates most of its revenue from contracts with third party payers, including managed care organizations, insurance companies, self-insured employers, Medicare, and Medicaid programs. Where permissible, the Company bills patients for any amounts not reimbursed by third party payers. The majority of the Company&#8217;s infusion pharmacy revenue consists of reimbursement for both the cost of the pharmaceuticals sold and the cost of services provided. Pharmaceuticals are typically reimbursed on a percentage discount from the published average wholesale price (&#8220;AWP&#8221;) of each drug or on a percentage premium to average sales price (&#8220;ASP&#8221;). Nursing services are typically billed separately, while other patient support services, such as pharmacy compounding service, delivery service and ancillary medical supplies are reimbursed either separately or on a per diem basis, where applicable.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s largest payer is United Health Group, which represented approximately 15% of its revenue for the year ended December&#160;31, 2020. No other single payer represented more than 10% of its revenue. The Company also provides services that are directly reimbursable through government healthcare programs such as Medicare and state Medicaid programs. For the year ended December&#160;31, 2020, approximately 15% of the Company&#8217;s revenue was reimbursable through direct governmental programs, such as Medicare and Medicaid.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Regulation</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The home infusion industry is subject to extensive regulation by a number of federal, state and local governmental entities. The industry is also subject to frequent regulatory change. Laws and regulations in the healthcare industry are complex and, in many instances, the industry does not benefit from significant regulatory or judicial interpretation that would clarify how these laws and regulations should be applied. Moreover, the Company&#8217;s business is also impacted by certain laws and regulations that are applicable to its managed care and other clients. If the Company fails to comply with the laws and regulations directly applicable to its business, the Company could suffer civil and/or criminal penalties, and the Company could be excluded from participating in Medicare, Medicaid and other federal and state healthcare programs, which would have an adverse impact on its business.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Professional Licensure</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nurses, pharmacists and certain other healthcare professionals employed by the Company are required to be individually licensed or certified under applicable state law. The Company performs criminal and other background checks on employees and takes steps to ensure that its employees possess all necessary licenses and certifications, and the Company believes that its employees comply in all material respects with applicable licensure laws.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmacy Licensing and Registration</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State laws require that each of its pharmacy locations be licensed as an in-state pharmacy to dispense pharmaceuticals in that state. Certain states also require that its pharmacy locations be licensed as an out-of-state pharmacy if the Company delivers prescription pharmaceuticals into those states from locations outside of the state. The Company believes that it materially complies with all applicable state licensing laws. If the Company is unable to maintain its licenses or if states place burdensome regulations on non-resident pharmacies, its ability to operate in some states would be limited, which could have an adverse impact on its business. Laws enforced by the Drug Enforcement Administration (&#8220;DEA&#8221;), as well as some similar state agencies, require its pharmacy locations to individually register in order to handle controlled substances, including prescription pharmaceuticals. A separate registration is required at each principal place of business where the Company dispenses controlled substances. Federal and state laws also require that the Company follow specific labeling, reporting and record-keeping requirements for controlled substances. The Company maintains federal and state controlled substance registrations for each of its facilities that require such registration and follows procedures intended to comply with all applicable federal and state requirements regarding controlled substances.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many states in which the Company operates also require home infusion companies to be licensed as home health agencies. The Company believes it is in compliance with these laws, as applicable.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it materially complies with all applicable state licensing laws, including any applicable change of control requirements that may have triggered in connection with the Merger.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Matters Affecting Drug Prices</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing benchmarks in the pharmacy industry are periodically published by third parties such as First DataBank, Medi-Span, RJ Health, and the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), and the benchmark reimbursement varies by payer contract. The most commonly used benchmarks are AWP and ASP. AWP is based on self-reported prices charged by wholesalers and manufacturers. Reimbursement is generally AWP minus a percentage and may include a per diem fee or a fixed dispensing fee. ASP is based on actual sales transactions reported by wholesalers, and is generally lower than AWP. Reimbursement is generally ASP plus a percentage. The Company may also receive a fixed dispensing fee or a per diem fee for each day a patient is on service. Changes to these pricing benchmarks may have a significant impact on the profitability of the Company&#8217;s business.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Privacy and Security Requirements</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and its implementing regulations regulate the use, disclosure, confidentiality, availability and integrity of individually identifiable health information, known as &#8220;protected health information,&#8221; and provide for a number of individual rights with respect to such information. The federal privacy regulations (the &#8220;Privacy Regulations&#8221;) are designed to protect health-related information that could be used to identify an individual&#8217;s protected health information.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirements imposed by HIPAA are extensive, and the Company has taken and intends to continue to take steps to ensure its policies and procedures are in compliance with the applicable provisions.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulations</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Food, Drug and Cosmetic Act. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain provisions of the Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;) govern the handling and distribution of pharmaceutical products. This law exempts many pharmaceuticals and medical devices from federal labeling and packaging requirements as long as they are not adulterated or misbranded and are dispensed in accordance with and pursuant to a valid prescription. The Company believes it complies with all applicable requirements. The FDCA also governs interstate commerce for pharmaceutical products. The Company cannot predict the impact of any proposed FDCA regulations on its ability to ship drugs to different states from its pharmacies.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Drug Quality and Security Act (&#8220;DQSA&#8221;) amended the FDCA to grant the Food and Drug Administration (&#8220;FDA&#8221;) authority to regulate the manufacturing of compounded pharmaceutical drugs. The Company complies with the PCAB and Accreditation Standards for Sterile and Non-Sterile Pharmacy Compounding, and aggressively pursues accreditation from quality associations. The Company believes it complies in all material respects with all applicable requirements of a non-outsourcing-facility pharmacy.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also regulates certain medical devices, such as infusion pumps the Company uses to provide its services. In recent years, the FDA has increased its oversight of infusion pumps, resulting in additional requirements around patient education and adverse event reporting. The Company believes it complies in all material respects with all applicable requirements and that its employees have the level of proficiency required to use these devices and provide training to its patients.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-Kickback Statute</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.   The federal Anti-Kickback Statute prohibits individuals and entities from knowingly and willfully paying, offering, receiving, or soliciting money or anything else of value in order to induce the referral of patients or to induce a person to purchase, lease, order, arrange for, or recommend services or goods covered by Medicare, Medicaid, or other government healthcare programs. The Anti-Kickback Statute is broad and potentially covers many standard business arrangements. A number of states also have statutes and regulations that prohibit the same general types of conduct as those prohibited by the Anti-Kickback Statute described above. Violations can lead to significant criminal or civil penalties, including imprisonment. The Office of the Inspector General (&#8220;OIG&#8221;) of the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) has published clarifying regulations that identify a limited number of safe harbors from criminal enforcement or civil administrative actions. The Company attempts to structure its business relationships to comply with these statutes and to satisfy an applicable safe harbor where applicable. However, in situations where a business relationship does not fully satisfy the elements of a safe harbor, or where no safe harbor exists, the Company attempts to satisfy as many elements of an applicable safe harbor as possible.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">False Claims Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.   The Company is subject to state and federal laws that govern the submission of claims for reimbursement. These laws generally prohibit an individual or entity from knowingly and willfully presenting a claim or causing a claim to be presented for payment from a federal healthcare program that is false or fraudulent. The standard for &#8220;knowing and willful&#8221; may include conduct that amounts to a reckless disregard for the accuracy of information presented to payers. Penalties under these statutes include substantial civil and criminal fines, exclusion from the Medicare or Medicaid programs and imprisonment. One of the most prominent of these laws is the federal False Claims Act, which may be enforced by the federal government directly or by a private plaintiff by filing a qui tam lawsuit on the government&#8217;s behalf. Under the False Claims Act, the government and private plaintiffs, if any, may recover monetary penalties in the amount of $11,665 to $23,331 per false claim, as well as an amount equal to three times the amount of damages sustained by the government as a result of the false claim. A number of states, including states in which the Company operates, have adopted their own false claims statutes as well as statutes that allow individuals to bring </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions. The Company believes that it has procedures in place to ensure the accuracy of its claims.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health CY 2020 Home Health Prospective Payment Systems Rate Update</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On October 31, 2019, the CMS issued a final rule that includes updates to payment policies, payment rates, and quality provisions for services. The final rule set forth routine updates to the home infusion therapy services for calendar year 2021 and subsequent years, and solicits comments on options to enhance future efforts to improve policies related to coverage of eligible drugs for home infusion therapy.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ethics in Patient Referrals Law (Stark Law)</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Stark Law exempts certain business relationships that meet its exception requirements. However, unlike the Anti-Kickback Statute under which an activity may fall outside a safe harbor and still be lawful, a referral for certain Designated Health Services (&#8220;DHS&#8221;) that does not fall within an exception is strictly prohibited by the Stark Law. In addition to the Stark Law, many of the states in which the Company operates have comparable restrictions on the ability of physicians to refer patients for certain services to entities with which the Company has a financial relationship. Certain of these state statutes mirror the Stark Law while others may be more restrictive. The Company attempts to structure all of its business relationships with physicians to comply with the Stark Law and any applicable state self-referral laws.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Stark Law generally prohibits a physician from making referrals for certain DHS, reimbursable by Medicare or Medicaid, to entities with which the physician or an immediate family member has a financial relationship, unless an exception applies. A financial relationship is generally defined as an ownership, investment or compensation relationship. DHS includes outpatient pharmaceuticals, parenteral and enteral nutrition products, home health services, durable medical equipment, physical and occupational therapy services, and inpatient and outpatient hospital services. Among other sanctions, a civil monetary penalty may be imposed for each bill or claim for a service a person knows or should know is for a service for which payment may not be made due to the Stark Law. Such persons or entities are also subject to exclusion from the Medicare and Medicaid programs. Any person or entity participating in a circumvention scheme to avoid the referral prohibitions is liable for civil monetary penalties, and additional fines may be imposed for failure to comply with reporting requirements regarding an entity&#8217;s ownership, investment and compensation arrangements for each day for which reporting is required to have been made under the Stark Law.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company employed 5,146 persons on a full-time basis and 706 persons on a part-time basis. The majority of its part-time employees are clinicians due to the nature and timing of the services the Company provides.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business relies on our ability to attract and retain nursing staff, pharmacists and other professionals who possess the skills, experience and licenses necessary to meet the requirements of their job responsibilities. Our ability to attract and retain personnel depends on several factors, including our ability to provide them with engaging assignments and competitive salaries and benefits.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s corporate headquarters is located at 3000 Lakeside Drive, Suite 300N, Bannockburn, IL 60015. The Company maintains a website at http://www.optioncarehealth.com. The information contained on its website is not incorporated by reference into this Annual Report and should not be considered part of this report. The Company&#8217;s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and Proxy Statements are available through the website at https://investors.optioncarehealth.com/, free of charge, as soon as reasonably practicable after they are filed with or furnished to the SEC.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_19"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-bottom:10pt;margin-top:8.4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors should carefully consider the following Company-specific and general risk factors.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Company-Specific Risk Factors</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenue and profitability will decline if the pharmaceutical industry undergoes certain changes, including limiting or discontinuing research, development, production and marketing of the pharmaceuticals that are compatible with the services we provide. </span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is highly dependent on the ability of pharmaceutical manufacturers to develop, supply and market pharmaceuticals that are compatible with the services we provide. Our revenue and profitability will decline if those companies were to sell pharmaceuticals directly to the public, fail to support existing pharmaceuticals or develop new pharmaceuticals with different administration requirements than our service offerings are currently equipped to handle. Our business could also be harmed if the pharmaceutical industry experiences any supply shortages, pharmaceutical recalls, changes in the FDA approval processes, or changes to how pharmaceutical manufacturers finance, promote or sell pharmaceutical products. A reduction in the supply of and market for pharmaceuticals that are compatible with the services we provide may have a material adverse effect on our financial condition and results of operations. </span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose relationships with managed care organizations (&#8220;MCOs&#8221;) and other non-governmental third party payers, we could lose access to a significant number of patients and our revenue and profitability could decline.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on reimbursement from MCOs, government programs such as Medicare and Medicaid and commercial insurers (collectively, &#8220;Third Party Payers&#8221;). For the year ended December&#160;31, 2020, 85% of our revenue came from managed care organizations and other nongovernmental payers, including Medicare Advantage plans, Managed Medicaid plans, pharmacy benefit managers (&#8220;PBM&#8217;s&#8221;), and self-pay patients. Many payers seek to limit the number of providers that supply pharmaceuticals to their enrollees in order to build volume that justifies their discounted pricing. From time to time, payers with whom we have relationships require that we bid against our competitors to keep their business. As a result of this bidding process, we may not be retained, and even if we are retained, the prices at which we are able to retain the business may be reduced. The loss of a payer relationship could significantly reduce the number of patients we serve and have a material adverse effect on our revenue and net income, and a reduction in pricing could reduce our gross margins and net income.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The healthcare industry is highly competitive. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is highly competitive. We compete directly with national, regional and local healthcare providers. There are many other companies and individuals currently providing healthcare services that we provide, many of which have been in business longer and/or have substantially more resources. Other companies could enter the healthcare industry in the future and divert some or all of our business. We expect to continue to encounter competition in the future that could limit our ability to grow revenue and/or maintain acceptable pricing levels. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our competitors have vertically integrated business models with commercial payers, or are under common control with, or owned by, pharmaceutical wholesalers and distributors, managed care organizations, PBMs or retail pharmacy chains and may be better positioned with respect to the cost-effective distribution of pharmaceuticals. In addition, some of our competitors may have secured long-term supply or distribution arrangements for prescription pharmaceuticals necessary to treat certain chronic disease states on price terms substantially more favorable than the terms currently available to us. Consequently, we may be less price competitive than some of these competitors with respect to certain pharmaceutical products. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accountable Care Organizations (&#8220;ACOs&#8221;) and other clinical integration models may result in lower reimbursement rates. Some of our competitors may negotiate exclusivity provisions with managed care plans or otherwise interfere with the ability of managed care companies to contract with us. Increasing consolidation in the payer and supplier industries, including vertical integration efforts among insurers, providers, and suppliers, and cost-reduction strategies by large employer groups and their affiliates may limit our ability to negotiate favorable terms and conditions in our contracts and otherwise intensify competitive pressure. In addition, our competitive position could be adversely affected by any inability to obtain access to new biotech pharmaceutical products.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain relationships with existing patient referral sources, our business and consolidated financial condition, results of operations, and cash flows could be materially adversely affected.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on referrals from physicians, hospitals, and other sources in the communities we serve and on our ability to maintain good relationships with existing referral sources. Our referral sources are not contractually obligated to refer patients to us and may refer their patients to other providers. Our growth and profitability depends, in part, on our ability to establish and maintain close working relationships with these patient referral sources, and to increase awareness and acceptance of the benefits of home infusion by our referral sources and their patients. Our loss of, or failure to maintain, existing relationships or our failure to develop new referral relationships could have a material adverse effect on our business and consolidated financial condition, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in industry pricing benchmarks could adversely affect our financial performance.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts generally use certain published benchmarks to establish pricing for the reimbursement of prescription medications we dispense. These benchmarks include AWP, wholesale acquisition cost, ASP and average manufacturer price. Many of our contracts utilize the AWP benchmark. Publication of the AWP benchmark was expected to cease in 2011 as a result of the settlement of class-action lawsuits brought against First DataBank and Medi-Span, third-party publishers of various pricing benchmarks. However, Medi-Span continues to publish the AWP benchmark and has indicated that it will continue to do so until a new benchmark is widely accepted. Several industry participants have explored establishing a new benchmark but there is not currently a viable generally accepted alternative to the AWP benchmark. Without a suitable pricing benchmark in place, many of our contracts will have to be modified and could potentially change the economic structure of our agreements. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in our relationships with pharmaceutical suppliers, including changes in drug availability or pricing, could adversely affect our business and financial results.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have contractual relationships with pharmaceutical manufacturers to purchase the pharmaceuticals that we dispense. In order to have access to these pharmaceuticals, and to be able to participate in the launch of new pharmaceuticals, we must maintain a good working relationship with these manufacturers. Most of the manufacturers of the pharmaceuticals we sell have the right to cancel their supply contracts with us without cause and after giving only minimal notice. Any changes to these relationships, including, but not limited to, the loss of a manufacturer relationship, drug shortages or changes in pricing, could have an adverse effect on our business and financial results.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some pharmaceutical manufacturers attempt to limit the number of preferred distributors that may market certain of their pharmaceutical products. We cannot provide assurance that we will be selected and retained as a preferred distributor or can remain a preferred distributor to market these products. Although we believe we can effectively meet our suppliers&#8217; requirements, we cannot provide assurance that we will be able to compete effectively with other providers to retain our position as a distributor of each of our core products. Adverse developments with respect to this trend could have a material adverse effect on our financial condition and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A disruption in pharmaceutical and medical supply could adversely impact our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, approximately 70% of our pharmaceutical and medical supply purchases are from three vendors. Most of the pharmaceuticals that we purchase are available from multiple sources, and we believe they are available in sufficient quantities to meet our needs and the needs of our patients. We keep safety stock to ensure continuity of service for reasonable, but limited, periods of time. Should a supply disruption result in the inability to obtain especially high margin drugs and compound components necessary for patient care, our consolidated financial statements could be negatively impacted. The COVID-19 pandemic has led to a constrained supply environment which could result in higher cost to procure, and potential unavailability of, critical personal protection equipment, pharmaceuticals and medical supplies. As of December&#160;31, 2020 we have not experienced a significant impact in the availability of supplies from the COVID-19 pandemic.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A shortage of qualified registered nursing staff, pharmacists and other professionals could adversely affect our ability to attract, train and retrain qualified personnel and could increase operating costs.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business relies on our ability to attract and retain nursing staff, pharmacists and other professionals who possess the skills, experience and licenses necessary to meet the requirements of their job responsibilities. From time to time and particularly in recent years, there have been shortages of nursing staff, pharmacists and other professionals in certain local and regional markets. As a result, we are often required to compete for personnel with other healthcare systems and our competitors. Our ability to attract and retain personnel depends on several factors, including our ability to provide them with engaging assignments and competitive salaries and benefits. We may not be successful in any of these areas.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, where labor shortages arise in markets in which we operate, we may face higher costs to attract personnel, and we may have to provide them with more attractive benefit packages than originally anticipated or are being paid in other markets where such shortages do not exist at the time. In either case, such circumstances could cause our profitability to decline. Finally, if we expand our operations into geographic areas where healthcare providers historically have unionized or unionization occurs in our existing geographic areas, negotiating collective bargaining agreements may have a negative effect on our ability to timely and successfully recruit qualified personnel and on our financial results. If we are unable to attract and retain nursing staff, pharmacists and other professionals, the quality of our services may decline and we could lose patients and referral sources, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Introduction of new drugs or accelerated adoption of existing lower margin drugs could cause us to experience lower revenues and profitability when prescribers prescribe these drugs for their patients or they are mandated by Third Party Payers.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry pipeline of new drugs includes many drugs that over the long term may replace older, more expensive therapies. As a result of such older drugs losing patent protection and being replaced by generic substitutes, new and less expensive delivery methods (such as when an infusion or injectable drug is replaced with an oral drug) or additional products are added to a therapeutic class, thereby increasing price competition among competing manufacturer&#8217;s products in that therapeutic category. In such cases, manufacturers have the ability to increase drug acquisition costs or lower the selling price of replaced products. This could negatively impact our revenues and/or margins.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to develop new services or adapt to changes and trends within the healthcare industry may adversely affect our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive environment. We develop new services from time to time to assist our clients. If we are unsuccessful in developing innovative services, our ability to attract new clients and retain existing clients may suffer. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology, including the ability to capture and report outcomes, is also an important component of our business as we continue to utilize new and better channels to communicate and interact with our clients, members and business partners. If our competitors are more successful than us in employing this technology, our ability to attract new clients, retain existing clients and operate efficiently may suffer. Any significant shifts in the structure of the healthcare products and services industry in general could alter the industry dynamics and adversely affect our ability to attract or retain clients. Our failure to anticipate or appropriately adapt to changes in the industry could negatively impact our competitive position and adversely affect our business and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in future business conditions could cause business investments and/or recorded goodwill to become impaired, and our financial condition and results of operations could suffer if there is an impairment of goodwill.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our acquisitions resulted in significant goodwill reported on our financial statements. Goodwill results when the purchase price exceeds the fair value of the net identifiable tangible and intangible assets acquired. We may not realize the full value of this goodwill. As such, we evaluate on at least an annual basis whether events and circumstances indicate that all or some of the carrying value of goodwill is no longer recoverable, in which case we would recognize the unrecoverable goodwill as a charge against our earnings. When evaluating goodwill for potential impairment, we compare the fair value of our reporting&#160;units to their respective carrying amounts. We estimate the fair value of our reporting&#160;units using the income approach. If the carrying amount of a reporting unit exceeds its estimated fair value, a goodwill impairment loss is recognized in an amount equal to the excess to the extent of the goodwill balance. The income approach requires us to estimate a number of factors for our reporting units, including projected future operating results, economic projections, anticipated future cash flows, and discount rates. The fair value determined using the income approach is then compared to marketplace fair value data from within a comparable industry grouping for reasonableness. Because of the significance of our goodwill, any future impairment could result in material non-cash charges to our results of operations, which could have an adverse effect on our financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant change in, or noncompliance with, governmental regulations and other legal requirements could have a material adverse effect on our reputation and profitability.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in complex, highly regulated environments and could be materially and adversely affected by changes to applicable legal requirements including the related interpretations and enforcement practices, new legal requirements and/or any failure to comply with applicable regulations. Our home infusion and alternate site infusion businesses are subject to numerous federal, state and local regulations including licensing and other requirements for pharmacies and reimbursement arrangements. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal and state statutes and regulations to which we are subject include, but are not limited to, laws requiring the registration and regulation of pharmacies; laws governing the dispensing of pharmaceuticals and controlled substances; laws regulating the protection of the environment and health and safety matters, including those governing exposure to, and the management and disposal of, hazardous substances; laws regarding food and drug safety, including those of the FDA and DEA; applicable governmental payer regulations, including those applicable to Medicare and Medicaid; data privacy and security laws, including HIPAA and its associated regulations; federal and state fraud and abuse laws, including, but not limited to, the anti-kickback statute and false claims laws; trade regulations, including those of the U.S. Federal Trade Commission (&#8220;FTC&#8221;); the U.S. Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;) and similar anti-corruption laws in connection with the services provided by certain of our contractors; and the consumer protection and safety laws, including those of the Consumer Product Safety Commission. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to hold valid DEA and state-level licenses, meet various security and operating standards and comply with the federal and various state controlled substance acts and related regulations governing the sale, dispensing, disposal, holding and distribution of controlled substances. The DEA, FDA and state regulatory authorities have broad enforcement powers, including the ability to seize or recall products and impose significant criminal, civil and administrative sanctions for violations of these laws and regulations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use, disclose and otherwise process personally identifiable information, including health information, making us subject to HIPAA and other federal and state privacy and security regulations and failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm and, in turn, have a material adverse effect on our patient base and revenue.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also governed by federal and state laws of general applicability, including laws regulating matters of working conditions, health and safety and equal employment opportunity and other labor and employment matters as well as employee benefit, competition, antitrust, taxation and escheatment matters. In addition, we could have significant exposure if we are found to have infringed another party&#8217;s intellectual property rights.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in laws, regulations and policies and the related interpretations and enforcement practices may alter the landscape in which we do business and may significantly affect our cost of doing business. The impact of new laws, regulations and policies and the related interpretations and enforcement practices generally cannot be predicted, and changes in applicable laws, regulations and policies and the related interpretations and enforcement practices may require extensive system and operational changes, be difficult to implement, increase our operating costs and require significant capital expenditures. Untimely compliance or noncompliance with applicable laws and regulations could result in the imposition of civil and criminal penalties that could adversely affect the continued operation of our businesses, including:&#160; suspension of payments from government programs; loss of required government certifications; loss of authorizations to participate in or exclusion from government programs, including the Medicare and Medicaid programs; loss of licenses; and significant fines or monetary penalties. Any failure to comply with applicable regulatory requirements could result in significant legal and financial exposure, damage our reputation, and have a material adverse effect on our business operations, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Affordable Care Act and other healthcare reform efforts could have a material adverse effect on our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, healthcare reform efforts at federal and state levels of government have resulted in sweeping changes to the delivery and funding of health care. The Affordable Care Act is the most prominent of these efforts. However, there is substantial uncertainty regarding its net effect and its future. The Affordable Care Act has been subject to legislative and regulatory changes and court challenges. Effective January 2019, Congress eliminated the financial penalty associated with the individual mandate to maintain health insurance coverage. Because the penalty associated with the individual mandate was eliminated, a federal court in Texas ruled in December 2018 that the entire Affordable Care Act was unconstitutional. However, the law remains in place pending appeal. It is impossible to predict the full impact of the Affordable Care Act and related regulations or the impact of its modification on our operations in light of the uncertainty regarding whether, when or how the law will be changed and what alternative reforms, such as single-payer proposals, may be enacted. Health reform efforts may adversely affect our customers, which may cause them to reduce or delay use of our products and services. As such, we cannot predict the impact of the Affordable Care Act on our business, operations or financial performance.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal actions and legislation may reduce reimbursement rates from governmental payers and adversely affect our results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, Congress has passed legislation reducing payments to health care providers. The Budget Control Act of 2011, as amended, requires automatic spending reductions to reduce the federal deficit, including Medicare spending reductions of up to 2% per fiscal year that extend through 2027. The Center for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) began imposing a 2% reduction on Medicare claims on April 1, 2013. The Affordable Care Act provides for material reductions in the growth of Medicare program spending. More recently, the Cures Act significantly reduced the amount paid by Medicare for drug costs, while delaying the implementation of a clinical services payment, although Congress also passed a temporary transitional service payment that took effect January 1, 2019. In addition, from time to time, CMS revises the reimbursement systems used to reimburse health care providers, which may result in reduced Medicare payments.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, 15% of our revenue is derived from reimbursement by direct federal and state programs such as Medicare and Medicaid. Reimbursement from these and other government programs is subject to statutory and regulatory requirements, administrative rulings, interpretations of policy, implementation of reimbursement procedures, retroactive payment adjustments, governmental funding restrictions and changes to or new legislation, all of which may materially affect the amount and timing of reimbursement payments to us. Changes to the way Medicare pays for our services, including mandatory payment reductions such as sequestration, may reduce our revenue and profitability on services provided to Medicare patients and increase our working capital requirements. In addition, we are sensitive to possible changes in state Medicaid programs.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because most states must operate with balanced budgets and because the Medicaid program is often a state&#8217;s largest program, some states have enacted or may consider enacting legislation designed to reduce their Medicaid expenditures. Further, many states have taken steps to reduce coverage and/or enroll Medicaid recipients in managed care programs. The current economic environment has increased the budgetary pressures on many states, and these budgetary pressures have resulted, and likely will continue to result, in decreased spending, or decreased spending growth, for Medicaid programs and the Children&#8217;s Health Insurance Program in many states. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, Third Party Payers rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from Third Party Payers. Current or future healthcare reform and deficit reduction efforts, changes in other laws or regulations affecting government healthcare programs, changes in the administration of government healthcare programs and changes by Third Party Payers could have a material, adverse effect on our financial position and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in reimbursement may adversely affect our liquidity, cash flows and operating results.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reimbursement process for the services we provide is complex, resulting in delays between the time we bill for a service and receipt of payment that can be significant. Reimbursement and procedural issues often require us to resubmit claims multiple times and respond to multiple administrative requests before payment is remitted. The collection of accounts receivable is challenging, and requires constant focus and involvement by management and ongoing enhancements to information systems and billing center operating procedures. While management believes that our controls and processes are satisfactory, there can be no assurance that collections of accounts receivable will continue at historical rates. The risks associated with Third Party Payers and the inability to collect outstanding accounts receivable could have a material adverse effect on our liquidity, cash flows and operating results.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to pricing pressures and other risks involved with Third Party Payers.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition to provide healthcare services, efforts by traditional Third Party Payers to contain or reduce healthcare costs, and the increasing influence of managed care payers such as health maintenance organizations, has resulted in reduced rates of reimbursement for home infusion and specialty pharmacy services. Changes in reimbursement policies of governmental Third Party Payers, including policies relating to Medicare, Medicaid and other federal and state funded programs, could reduce the amounts reimbursed to our customers for our products and, in turn, the amount these customers would be willing to pay for our products and services, or could directly reduce the amounts payable to us by such payers. Pricing pressures by Third Party Payers may continue, and these trends may adversely affect our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, continued growth in managed care plans has pressured healthcare providers to find ways of becoming more cost competitive. MCOs have grown substantially in terms of the&#160;percentage of the population they cover and in terms of the portion of the healthcare economy they control. MCOs have continued to consolidate to enhance their ability to influence the delivery of healthcare services and to exert pressure to control healthcare costs. A rapid concentration of revenue derived from individual managed care payers could harm our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face periodic reviews and billing audits by governmental and private payers, and these audits could have adverse findings that may negatively impact our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our participation in the Medicare and Medicaid programs, we are subject to various governmental reviews and audits to verify our compliance with these programs and applicable laws and regulations. We also are subject to audits under various government programs in which third party firms engaged by CMS conduct extensive reviews of claims data and medical and other records to identify potential improper payments under the Medicare program. Third Party Payers may also conduct audits. Disputes with payers can arise from these reviews. Payers can claim that payments based on certain billing practices or billing errors were made incorrectly. If billing errors are identified in the sample of reviewed claims, the billing error can be extrapolated to all claims filed which could result in a larger overpayment than originally identified in the sample of reviewed claims. Our costs to respond to and defend claims, reviews and audits may be significant and could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. Moreover, an adverse claim, review or audit could result in:</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">required refunding or retroactive adjustment of amounts we have been paid by governmental payers or Third Party Payers;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state or federal agencies imposing fines, penalties and other sanctions on us;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or exclusion from the Medicare program, state programs, or one or more third party payer networks; or</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">damage to our business and reputation in various markets.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These results could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our pharmacies fail to comply with the conditions of participation in the Medicare program, that pharmacy could be terminated from Medicare, which could adversely affect our consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pharmacies must comply with the extensive conditions of participation in the Medicare program. If a pharmacy fails to meet any of the Medicare supplier standards, that pharmacy could be terminated from the Medicare program. We respond in the ordinary course to deficiency notices issued by surveyors, and none of our pharmacies has ever been terminated from the Medicare program for failure to comply with the supplier standards. Any termination of one or more of our pharmacies from the Medicare program for failure to satisfy the Medicare supplier standards could adversely affect our consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We cannot predict the impact of changing requirements on compounding pharmacies.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compounding pharmacies are closely monitored by federal and state governmental agencies. We believe that our compounding is performed in safe environments and we have clinically appropriate policies and procedures in place. We only compound pursuant to a patient-specific prescription and do so in compliance with USP 797 standards. In 2013, Congress passed the DQSA, which creates a new category of compounding facilities called outsourcing facilities, which are regulated by the FDA. We do not believe that our current compounding practices qualify us as an outsourcing facility and therefore we continue to operate consistently with USP 797 standards and applicable state pharmacy laws. Should state regulators or the FDA disagree, or should our business practices change to qualify us as an outsourcing facility, there is a risk of regulatory action and/or increased resources required to comply with federal requirements imposed pursuant to the DQSA on outsourcing facilities that could significantly increase our costs or otherwise affect our results of operations. Furthermore, we cannot predict the overall impact of increased scrutiny on compounding pharmacies.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards to offset future taxable income for U.S. federal tax purposes is subject to limitation and risk that could further limit our ability to utilize our net operating losses.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. federal income tax law, a corporation&#8217;s ability to utilize its net operating losses (&#8220;NOLs&#8221;) to offset future taxable income may be significantly limited if it experiences an &#8220;ownership change&#8221; as defined in Section 382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). In general, an ownership change will occur if there is a cumulative change in a corporation&#8217;s ownership by &#8220;5-percent shareholders&#8221; that exceeds 50 percentage points over a rolling three-year period. A corporation that experiences an ownership change will generally be subject to an annual limitation on the use of its pre-ownership change NOLs equal to the value of the corporation immediately before the ownership change, multiplied by the long-term tax-exempt rate (subject to certain adjustments). At December 31, 2020, we had U.S. federal NOLs of approximately $577.9 million, of which $139.8 million are expected to expire unutilized due to limitations under Section 382 of the Code. We also had $600.1 million of cumulative gross state NOL carryforwards available to offset future taxable income in various states.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any limitation to our annual use of NOLs could require us to pay a greater amount of U.S. federal (and in some cases, state) income taxes, which could reduce our after-tax income from operations for future taxable years and adversely impact our financial condition. At December 31, 2020, we maintained a full valuation allowance against all of our net U.S. federal and state deferred tax assets with the exception of $0.4 million of estimated state NOLs.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Relating to Our Indebtedness</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing indebtedness could adversely affect our business and growth prospects.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had $1,161.5 million of outstanding borrowings, including (i) $915.8 million under our First Lien Term Loan and (ii) $245.8 million under our Second Lien Notes. All obligations under the credit agreements and indenture governing these facilities and notes are secured by first-priority perfected security interests in substantially all of our assets and the assets of our subsidiaries, subject to permitted liens and other exceptions. Our indebtedness, or any additional indebtedness we may incur, could require us to divert funds identified for other purposes for debt service and impair our liquidity position. If we cannot generate sufficient cash flow from operations to service our debt, we may need to refinance our debt, dispose of assets or issue equity to obtain necessary funds. We do not know whether we will be able to take any of these actions on a timely basis, on terms satisfactory to us or at all.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness, the cash flow needed to satisfy our debt and the covenants contained in our credit agreement and indenture have important consequences, including but not limited to:</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">limiting funds otherwise available for financing our capital expenditures by requiring us to dedicate a portion of our cash flows from operations to the repayment of debt and the interest on this debt;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">limiting our ability to incur additional indebtedness;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">limiting our ability to capitalize on significant business opportunities;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">making us more vulnerable to rising interest rates; and</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">making us more vulnerable in the event of a downturn in our business.</span></div><div style="padding-left:54pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our level of indebtedness may place us at a competitive disadvantage to our competitors that are not as highly leveraged. Fluctuations in interest rates can increase borrowing costs. Increases in interest rates may directly impact the amount of interest we are required to pay and reduce earnings accordingly. In addition, developments in tax policy, such as the disallowance of tax deductions for interest paid on outstanding indebtedness, could have an adverse effect on our liquidity and our business, financial conditions and results of operations. Further, our credit agreements and indenture contain customary affirmative and negative covenants and certain restrictions on operations that could impose operating and financial limitations and restrictions on us, including restrictions on our ability to enter into particular transactions and to engage in other actions that we may believe are advisable or necessary for our business. Our term loan facility is also subject to mandatory prepayments in certain circumstances and requires a prepayment of a certain percentage of our excess cash flow. This excess cash flow payment, and future required prepayments, will reduce our cash available for investment in our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to use cash flow from operations to meet current and future financial obligations, including funding our operations, debt service requirements and capital expenditures. The ability to make these payments depends on our financial and operating performance, which is subject to prevailing economic, industry and competitive conditions and to certain financial, business, economic and other factors beyond our control.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Despite our substantial indebtedness, we may still need to incur significantly more debt. This could exacerbate the risks associated with our substantial leverage.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to incur substantial additional indebtedness, including additional secured indebtedness, in the future, in connection with future acquisitions, strategic investments and strategic relationships. Although the financing documents governing our indebtedness contain covenants and restrictions on the incurrence of additional debt, these restrictions are subject to a number of qualifications and exceptions and, under certain circumstances, debt incurred in compliance with these restrictions, including secured debt, could be substantial. Adding additional debt to current debt levels could exacerbate the leverage-related risks described above.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to generate sufficient cash flow to service all of our indebtedness, and may be forced to take other actions to satisfy our obligations under such indebtedness, which may not be successful.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make scheduled payments or to refinance outstanding debt obligations depends on our financial and operating performance, which will be affected by prevailing economic, industry and competitive conditions and by financial, business and other factors beyond our control. We may not be able to maintain a sufficient level of cash flow from operating activities to permit us to pay the principal, premium, if any, and interest on our indebtedness. Any failure to make payments of interest and principal on our outstanding indebtedness on a timely basis would likely result in a reduction of our credit rating, which would also harm our ability to incur additional indebtedness.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our cash flows and capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay capital expenditures, sell assets, seek additional capital or seek to restructure or refinance our indebtedness. Any refinancing of our indebtedness could be at higher interest rates and may require us to comply with more onerous covenants. These alternative measures may not be successful and may not permit us to meet our scheduled debt service obligations. In the absence of such cash flows and resources, we could face substantial liquidity problems and might be required to sell material assets or operations to attempt to meet our debt service obligations. The financing documents governing our First Lien Term Loan, our ABL Facility and our Second Lien Notes restrict our ability to conduct asset sales and/or use the proceeds from asset sales. We may not be able to consummate these asset sales to raise capital or sell assets at prices and on terms that we believe are fair and any proceeds that we do receive may not be adequate to meet any debt service obligations then due. If we cannot meet our debt service obligations, the holders of our indebtedness may accelerate such indebtedness and, to the extent such indebtedness is secured, foreclose on our assets. In such an event, we may not have sufficient assets to repay all of our indebtedness.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration:underline">Risks Relating to Our Common Stock</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are a &#8220;controlled company&#8221; within the meaning of the rules of Nasdaq and, as a result, qualify for and rely on, exemptions from certain corporate governance standards, which limit the presence of independent directors on our board of directors or board committees. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, approximately 64% of the outstanding shares of our common stock is held by HC Group Holdings I, LLC. As a result, we are a &#8220;controlled company&#8221; for purposes of the Nasdaq listing rules and are exempt from certain governance requirements otherwise required by Nasdaq, including requirements that: </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a majority of our board of directors consist of independent directors;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have a nominating and corporate governance committee that is composed entirely of independent directors with a written charter addressing the committee's purpose and responsibilities;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee's purpose and responsibilities;</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we conduct annual performance evaluation of the nominating and corporate governance and compensation committees. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, you will not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of the Nasdaq. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant portion of our total outstanding shares may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of our common stock issued in the Merger to HC Group Holdings I, LLC as Merger consideration, or approximately 64% of the outstanding shares of our common stock as of December&#160;31, 2020, are generally eligible for resale. The market price of our common stock could decline as a result of sales of a large number of shares of our common stock in the market or even the perception that these sales could occur. Subsequent to December 31, 2020, HC Group Holdings I, LLC completed a secondary offering of 17,250,000 shares of common stock. Following the offering, HC Group Holdings I, LLC holds approximately 54% of the Company&#8217;s common stock.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As of December&#160;31, 2020, Madison Dearborn Partners is our largest stockholder, controlling approximately 64% of our common stock, and has the ability to exercise significant influence over decisions requiring our stockholders&#8217; approval. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, Madison Dearborn Partners controls approximately 64% of our common stock through its control of HC Group Holding I, LLC, with an economic interest in approximately 31% of our common stock. As a result, Madison Dearborn Partners has the ability to exercise significant influence over decisions requiring approval of our stockholders including the election of directors, amendments to our certificate of incorporation and approval of significant corporate transactions, such as a Merger or other sale of us or our assets. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This concentration of ownership may have the effect of delaying, preventing or deterring a change in control of us and may negatively affect the market price of our common stock. Also, Madison Dearborn Partners is in the business of making investments in companies and may from time to time acquire and hold interests in businesses that compete with us. Madison Dearborn Partners or its affiliates may also pursue acquisition opportunities that are complementary to our business and, as a result, those acquisition opportunities may not be available to us.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions of our corporate governance documents could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management, even if beneficial to our stockholders. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to HC Group Holding I, LLC&#8217;s beneficial ownership of approximately 64% of our common stock, our third amended and restated certificate of incorporation contains provisions that could make it more difficult for a third party to acquire us, even if doing so might be beneficial to our stockholders. Among other things: </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">these provisions allow us to authorize the issuance of undesignated preferred stock, the terms of which may be established and the shares of which may be issued without stockholder approval, and which may include supermajority voting, special approval, dividend, or other rights or preferences superior to the rights of stockholders; </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">these provisions provide that, at any time when HC Group Holdings I, LLC beneficially owns, in the aggregate, less than 50% in voting power of our stock entitled to vote generally in the election of directors, directors may be removed with or without cause only by the affirmative vote of holders of at least 66 2&#8725;3% in voting power of all the then-outstanding vote thereon, voting together as a single class; </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">these provisions prohibit stockholder action by written consent from and after the date on which HC Group Holding I, LLC beneficially owns, in the aggregate, less than 50% in voting power of our stock entitled to vote generally in the election of directors; and </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">these provisions provide that for as long as HC Group Holdings I, LLC beneficially owns, in the aggregate, 50% or more in voting power of our stock entitled to vote generally in the election of directors, any amendment, alteration, rescission or repeal of our bylaws or certificate of incorporation by our stockholders will require the affirmative vote of at least a majority in voting power of the outstanding shares of our stock and at any time when HC Group Holdings I, LLC beneficially owns, in the aggregate, less than 50% in voting power of all outstanding shares of our stock entitled to vote generally in the election of directors, any amendment, alteration, rescission or repeal of our bylaws or certificate of incorporation by our stockholders will require the affirmative vote of the holders of at least 66 2&#8725;3% in voting power of all the then-outstanding shares of our stock entitled to vote thereon, voting together as a single class.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other provisions in our certificate of incorporation, bylaws and Delaware law could make it more difficult for shareholders or potential acquirers to obtain control of our Board or initiate actions that are opposed by our then-current Board, including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities to realize value in a corporate transaction.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, Section 203 of the General Corporation Law of the State of Delaware (&#8220;DGCL&#8221;) may discourage, delay, or prevent a change of control of our company. Section 203 imposes certain restrictions on mergers, business combinations, and other transactions between us and holders of 15% or more of our common stock.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our third amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our third amended and restated certificate of incorporation, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (1)&#160;any derivative action or proceeding brought on our behalf, (2)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees and stockholders to us or our stockholders, (3)&#160;any action asserting a claim against us arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, our third amended and restated certificate of incorporation or our bylaws or (4)&#160;any other action asserting a claim against us that is governed by the internal affairs doctrine; provided that for the avoidance of doubt, the forum selection provision that identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any &#8220;derivative action&#8221;, will not apply to suits to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Our third amended and restated certificate of incorporation will further provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the provisions of our certificate of incorporation described above. The forum selection clause in our third amended and restated certificate of incorporation may have the effect of discouraging lawsuits against us or our directors and officers and may limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may issue shares of preferred stock in the future, which could make it difficult for another company to acquire us or could otherwise adversely affect holders of our common stock, which could depress the price of our common stock.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third amended and restated certificate of incorporation authorizes us to issue one or more series of preferred stock. Our Board has the authority to determine the preferences, limitations and relative rights of the shares of preferred stock and to fix the number of shares constituting any series and the designation of such series, without any further vote or action by our stockholders. Our preferred stock could be issued with voting, liquidation, dividend and other rights superior to the rights of our common stock. The potential issuance of preferred stock may delay or prevent a change in control, discouraging bids for our common stock at a premium to the market price, and materially adversely affect the market price and the voting and other rights of the holders of our common stock.</span></div><div style="margin-bottom:10pt;margin-top:8.4pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:8.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">General Risk Factors</span></div><div style="margin-bottom:10pt;margin-top:8.4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The recent COVID-19 pandemic and other potential pandemic events could adversely impact our business operations, results of operations, cash flows and financial position.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus (COVID-19) was reported in Wuhan, China. The World Health Organization has declared COVID-19 a pandemic and public health emergency of international concern. In March 2020, the President of the United States declared a State of National Emergency due to the COVID-19 outbreak. Other countries affected by the outbreak took similar measures. Consequently, the COVID-19 pandemic has had a material impact on the U.S. and global economies.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business, including how it will impact our patients, teammates, suppliers, vendors, referral sources, and third party payers.  The COVID-19 pandemic has created significant volatility, uncertainty and economic disruption, which may adversely affect our business operations and may materially and adversely affect our results of operations, cash flows and financial position.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we cannot predict the impact that COVID-19 will have on our patients, suppliers, vendors, and third party payers and each of their financial conditions, we believe the following factors could lead to a material adverse impact on the Company&#8217;s business:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Variability in acute therapy patient referrals from hospitals based on changes in hospital-based procedures and treatment patterns;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Variability in chronic therapy patient referrals based on disruptions in the diagnosis of chronic conditions requiring infusion therapy;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inefficiencies in clinical labor expenses and higher labor costs from staffing disruptions and availability, potential overtime due to inefficient clinical staffing and utilization of contract labor;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Higher costs to procure, and potential unavailability of, critical personal protection equipment, pharmaceuticals and medical supplies given a constrained supply environment; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Heightened operational risks from an extended period of remote work arrangements, which could strain our business continuity plans, including but not limited to cybersecurity risks, and could impair our ability to manage our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The situation is changing rapidly and additional consequences may arise that we are not aware of currently. The extent to which the COVID-19 pandemic impacts us will depend on numerous evolving factors and future developments that we are not able to predict, including: the severity and duration of the outbreak; governmental, business and other actions; the promotion of social distancing and the adoption of shelter-in-place orders affecting our referral sources; the impacts on our supply chain; the impact of the pandemic on economic activity; the health of and the effect on our workforce; any impairment in value of our tangible or intangible assets which could be recorded as a result of a weaker economic conditions; and the potential effects on our internal controls including those over financial reporting as a result of changes in working environments such as shelter-in-place and similar orders that are applicable to our teammates.  In addition, if the pandemic continues to create disruptions or turmoil in the credit or financial markets, or impacts our credit ratings or stock price, it could adversely affect our ability to access capital on favorable terms and continue to meet our liquidity needs, all of which are highly uncertain and cannot be predicted.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot predict the impact that COVID-19 will have on our patients, suppliers, vendors, and third party payers, and each of their financial conditions; however, any material effect on these parties could adversely impact us. The impact of COVID-19 may also exacerbate other risks, any of which could have a material effect on us. This situation is changing rapidly and additional impacts may arise that we are not aware of currently.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pending and future litigation could subject us to significant monetary damages and/or require us to change our business practices.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ pharmacists, dieticians, nurses and other health care professionals. We are subject to liability for negligent acts, omissions, or injuries occurring at one of these clinics or caused by one of our employees. We are subject to risks relating to asserted claims, litigation and other proceedings in connection with our operations. We are or may face claims or become a party to a variety of legal actions that affect our business, including breach of contract actions, employment and employment discrimination-related suits, employee benefit claims, stockholder suits and other securities laws claims, and tort claims. Due to the nature of our business, we, through our employees and caregivers who provide services on our behalf, may be the subject of medical malpractice claims. A court could find these individuals should be considered our agents, and, as a result, we could be held liable for their acts or omissions. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may incur substantial expenses in defending such claims or litigation, regardless of merit, and such claims or litigation could result in a significant diversion of the efforts of our management personnel. Successful claims against us may result in monetary liability or a material disruption in the conduct of our business. Similarly, if we settle such legal proceedings, it may affect how we operate our business. See Item 3 for a description of material proceedings pending against us. We believe that these suits are without merit and, to the extent not already concluded, intend to contest them vigorously. However, an adverse outcome in one or more of these suits may have a material adverse effect on our consolidated results of operations, consolidated financial position, and/or consolidated cash flow from operations, or may require us to make material changes to our business practices.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to liability claims for damages and other expenses that are not covered by insurance.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of operating in the home infusion industry, our business entails an inherent risk of claims, losses and potential lawsuits alleging incidents involving our employees that are likely to occur in a patient&#8217;s home. We maintain professional liability insurance to provide coverage to us and our subsidiaries against these risks. A successful product or professional liability claim in excess of our insurance coverage could harm our consolidated financial statements. Various aspects of our business may subject us to litigation and liability for damages. For example, a prescription drug dispensing error could result in a patient receiving the wrong or incorrect amount of medication, leading to personal injury or death. Our business and consolidated financial statements could suffer if we pay damages or defense costs in connection with a claim that is outside the scope of any applicable contractual indemnity or insurance coverage.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our insurance coverage also includes fire, property damage and general liability with varying limits. We cannot assure that the insurance we maintain will satisfy claims made against us or that insurance coverage will continue to be available to us at commercially reasonable rates, in adequate amounts or on satisfactory terms. Any claims made against us, regardless of their merit or eventual outcome, could damage our reputation and business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pressures relating to downturns in the economy could adversely affect our business and consolidated financial statements. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare and other federal and state payers account for a portion of our revenues. During economic downturns and periods of stagnant or slow economic growth, federal and state budgets are typically negatively affected, resulting in reduced reimbursements or delayed payments by the federal and state government health care coverage programs in which we participate, including Medicare, Medicaid, and other federal or state assistance plans. Government programs could also slow or temporarily suspend payments, negatively impacting our cash flow and increasing our working capital needs and interest payments. We have seen, and believe we will continue to see, Medicare and state Medicaid programs institute measures aimed at controlling spending growth, including reductions in reimbursement rates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Higher unemployment rates and significant employment layoffs and downsizings may lead to lower numbers of patients enrolled in employer-provided plans. Adverse economic conditions could also cause employers to stop offering, or limit, healthcare coverage, or modify program designs, shifting more costs to the individual and exposing us to greater credit risk from patients or the discontinuance of therapy. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions, strategic investments and strategic relationships involve certain risks.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may pursue acquisitions, strategic investments in, or strategic relationships with businesses and technologies. Acquisitions may entail numerous risks, including difficulties in assessing values for acquired businesses, intangible assets and technologies, difficulties in the assimilation of acquired operations and products, diversion of management&#8217;s attention from other business concerns, assumption of unknown material liabilities of acquired companies, amortization of acquired intangible assets which could reduce future reported earnings, and potential loss of clients or key employees of acquired companies. We may not be able to successfully fully integrate the operations, personnel, services or products that we have acquired or may acquire in the future. Strategic investments may also entail some of the risks described above. If these investments are unsuccessful, we may need to incur charges against earnings. We may also pursue a number of strategic relationships. These relationships and others we may enter into in the future may be important to our business and growth prospects. We may not be able to maintain these relationships or develop new strategic alliances.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity risks could compromise our information and expose us to liability, which may harm our ability to operate effectively and may cause our business and reputation to suffer.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity refers to the combination of technologies, processes and procedures established to protect information technology systems and data from unauthorized access, attack, or damage. We rely on our information systems to provide security for processing, transmission and storage of confidential information about our patients, customers and personnel, such as names, addresses and other individually identifiable information protected by HIPAA and other privacy laws. Cyber incidents can result from deliberate attacks or unintentional events. Cyber-attacks are increasingly more common, including in the health care industry. The regulatory environment surrounding information security and privacy is increasingly demanding, with the frequent imposition of new and changing requirements. Compliance with changes in privacy and information security laws and with rapidly evolving industry standards may result in our incurring significant expense due to increased investment in technology and the development of new operational processes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not experienced any known attacks on our information technology systems that compromised any confidential information. We maintain our information technology systems with safeguard protection against cyber-attacks including passive intrusion protection, firewalls and virus detection software. However, these safeguards do not ensure that a significant cyber-attack could not occur. Although we have taken steps to protect the security of our information systems and the data maintained in those systems, it is possible that our safety and security measures will not prevent the systems&#8217; improper functioning or damage or the improper access or disclosure of personally identifiable information such as in the event of cyber-attacks.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Security breaches, including physical or electronic break-ins, computer viruses, attacks by hackers and similar breaches can create system disruptions or shutdowns or the unauthorized use or disclosure of confidential information. If personal information or protected health information is improperly accessed, tampered with or disclosed as a result of a security breach, we may incur significant costs to notify and mitigate potential harm to the affected individuals, and we may be subject to sanctions and civil or criminal penalties if we are found to be in violation of the privacy or security rules under HIPAA or other similar federal or state laws protecting confidential personal information. In addition, a security breach of our information systems could damage our reputation, subject us to liability claims or regulatory penalties for compromised personal information and could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is dependent on the services provided by third party information technology vendors.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information technology infrastructure includes hosting services provided by third parties. While we believe these third parties are high-performing organizations with secure platforms and customary certifications, they could suffer a security breach or business interruption which in turn could impact our operations negatively. In addition, changes in pricing terms charged by our technology vendors may adversely affect our financial performance.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to maintain effective internal control over our financial reporting could have an adverse effect on our ability to report our financial results on a timely and accurate basis.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule&#160;13a-15(f)&#160;under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), and is required to evaluate the effectiveness of these controls and procedures on a periodic basis and publicly disclose the results of these evaluations and related matters in accordance with the requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002. Effective internal control over financial reporting is necessary for us to provide reliable financial reports, to help mitigate the risk of fraud and to operate successfully. Any failure to implement and maintain effective internal controls could result in material weaknesses or material misstatements in our consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to maintain effective internal control over financial reporting, or our independent registered public accounting firm is unable to provide us with an unqualified attestation report on our internal control, we may be required to take corrective measures or restate the affected historical financial statements. In addition, we may be subjected to investigations and/or sanctions by federal and state securities regulators, and/or civil lawsuits by security holders. Any of the foregoing could also cause investors to lose confidence in our reported financial information and in us and would likely result in a decline in the market price of our stock and in our ability to raise additional financing if needed in the future.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acts of God such as major weather disturbances could disrupt our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a network of prescribers, providers, patients and facilities that can be negatively impacted by local weather disturbances and other force majeure events. For example, in anticipation of major weather events, patients with impaired health may be moved to alternate sites. After a major weather event, availability of electricity, clean water and transportation can impact our ability to provide service in the home. Similarly, such events could impact key suppliers or vendors, disrupting the services or materials they provide us. In addition, acts of God and other force majeure events may cause a reduction in our business or increased costs, such as increased costs in our operations as we incur overtime charges or redirect services to other locations, delays in our ability to work with payers, hospitals, physicians and other strategic partners on new business initiatives, and disruption to referral patterns as patients are moved out of facilities affected by such events or are unable to return to sites of service in the home.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The transition from the London Interbank Offered Rate (&#8220;LIBOR&#8221;) could negatively affect our interest rates and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the U.K. Financial Conduct Authority announced that it intends to phase out LIBOR by the end of 2021. In addition, other regulators have suggested reforming or replacing other benchmark rates. The discontinuation, reform, or replacement of LIBOR or any other benchmark rates may result in fluctuating interest rates that may have a negative impact on our interest expense and our profitability.</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_22"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unresolved Staff Comments</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Properties</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease all of our properties from third parties under various lease terms expiring over periods extending through 2035, in addition to a number of non-material, month-to-month leases. Our corporate headquarters are located at 3000 Lakeside Drive, Suite 300N, Bannockburn, IL 60015. Our other properties mainly consist of infusion pharmacies equipped with clean room and compounding capabilities. Some infusion pharmacies are co-located with an ambulatory infusion center where patients receive infusion treatments. As of December&#160;31, 2020 our material property locations, consisting of our pharmacies, all in support of our infusion services business, were as follows:</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hoover, AL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peachtree Corners, GA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charlotte, NC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cranston, RI</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mobile, AL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Savannah, GA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fayetteville, NC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Duncan, SC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonesboro, AR</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Honolulu, HI</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Morrisville, NC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mount Pleasant, SC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Little Rock, AR</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Urbandale, IA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wilmington, NC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Knoxville, TN</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tempe, AZ</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meridian, ID</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lincoln, NE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Memphis, TN</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bakersfield, CA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Itasca, IL (2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omaha, NE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nashville, TN</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chico, CA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carmel, IN</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bedford, NH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austin, TX</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hayward, CA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Overland Park, KS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eatontown, NJ</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Houston, TX</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Irvine, CA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ashland, KY</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Morris Plains, NJ</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Irving, TX</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, CA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lexington, KY</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Somers Point, NJ</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Antonio, TX</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sacramento, CA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Louisville, KY</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Las Vegas, NV</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salt Lake City, UT</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Diego, CA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baton Rouge, LA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reno, NV</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ashland, VA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Santa Fe Springs, CA (2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Orleans, LA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">College Point, NY</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chantilly, VA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun Valley, CA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shreveport, LA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orchard Park, NY</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norfolk, VA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Englewood, CO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marlborough, MA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brecksville, OH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Roanoke, VA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shelton, CT</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Columbia, MD</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canfield, OH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rutland, VT</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Newark, DE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auburn, ME</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dublin, OH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Everett, WA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fort Myers, FL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farmington Hills, MI</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milford, OH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spokane Valley, WA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gainesville, FL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grand Rapids, MI</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sylvania, OH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tukwila, WA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacksonville, FL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Roseville, MN</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oklahoma City, OK</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wauwatosa, WI</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melbourne, FL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sauk Rapids, MN</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bend, OR</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charleston, WV</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miramar, FL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Columbia, MO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portland, OR</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">White Hall, WV</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St. Petersburg, FL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fenton, MO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audubon, PA</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Albany, GA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pearl, MS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dunmore, PA</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Augusta, GA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bozeman, MT</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">York, PA</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_28"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a summary of material legal proceedings, if any, refer to Note 14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the consolidated financial statements included in Item 8 of this report.</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_31"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_37"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to February 3, 2020, our Common Stock, par value $0.0001 per share, was traded on the Nasdaq Capital Market under the symbol &#8220;BIOS&#8221;. On February 3, 2020, we changed our symbol to &#8220;OPCH&#8221; and began trading on the Nasdaq Global Select Market.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 8, 2021, there were 142 stockholders of record of our Common Stock.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our Common Stock and do not anticipate doing so in the foreseeable future.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 12, &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.&#8221;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sale of Unregistered Securities and Use of Proceeds</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the total cumulative returns of BioScrip through August 6, 2019 and Option Care Health from August 7, 2019 through December&#160;31, 2020 with the total cumulative returns of the Nasdaq Composite Index and the Nasdaq Health Services Index for the five-year period from December 31, 2015 through December&#160;31, 2020. The graph shows the performance of a $100 investment in our Common Stock and each index as of December 31, 2015.</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><img src="bios-20201231_g2.jpg" alt="bios-20201231_g2.jpg" style="height:391px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"/></div><div style="margin-bottom:17pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:32.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2015</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2016</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Option Care Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213.14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223.43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nasdaq Composite Index</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nasdaq Health Services Index</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* $100 invested on December 31, 2015 in stock or index, including reinvestment of dividends.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selected Financial Data</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The selected consolidated financial data presented below should be read in conjunction with, and is qualified in its entirety by reference to, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and our consolidated financial statements and the Notes thereto appearing elsewhere in this Annual Report. The selected consolidated financial data for the years ended December&#160;31, 2020, 2019 and 2018 reflect the adoption of ASU 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;) and the selected financial data for the year ended December&#160;31, 2020 and 2019 reflect the adoption of ASU 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 842&#8221;). See Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the consolidated financial statements included in Item 8 of this report for further discussion on our accounting policies related to revenue and leases. The below periods include the results of operations from BioScrip, Inc. from the August 6, 2019 Merger Date onward. </span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Balance Sheets Data:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Working capital (1) (2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,647,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,589,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,428,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,429,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,405,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,286,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">539,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,015,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">906,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Working capital consists of total current assets less total current liabilities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Working capital and total assets for the year ended December&#160;31, 2020 and 2019 reflect the adoption of ASU 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and are, therefore, not comparable to prior periods. See Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in Item 8 of this report for further discussion on our accounting policies related to leases.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:24.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Statements of Comprehensive Income (Loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue (2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,032,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,310,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,939,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,828,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,711,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">682,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">422,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">445,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">449,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(319)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,053)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,959)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) earnings per share, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) 2020 and 2019 include the results of operations of BioScrip from August 6, 2019 onward and are, therefore, not comparable to prior periods.</span></div><div style="margin-bottom:1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Net revenue and gross profit for the years ended December&#160;31, 2020, 2019 and 2018 reflect the adoption of ASU 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and are, therefore, not comparable to prior periods. See Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in Item 8 of this report for further discussion on our accounting policies related to revenue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_43"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_46"></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is designed to assist the reader in understanding our consolidated financial statements, the changes in certain key items in those financial statements from year-to-year and the primary factors that accounted for those changes as well as how certain accounting principles affect our consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the historical information contained herein, the following discussion contains forward-looking statements that are subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements. We discuss such risks, uncertainties and other factors throughout this Annual Report and specifically under the caption &#8220;Forward-Looking Statements&#8221; in this Annual Report. In addition, the following discussion of financial condition and results of operations should be read in conjunction with the consolidated financial statements and notes thereto appearing in Item 8 in this Annual Report.</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_49"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 145 locations around the United States. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients&#8217; homes or other nonhospital settings. Our services are provided in coordination with, and under the direction of, the patient&#8217;s physician. Our multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to each patient&#8217;s specific needs. We provide home infusion services consisting of anti-infectives, nutrition support, bleeding disorder therapies, immunoglobulin therapy, and other therapies for chronic and acute conditions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HC Group Holdings II, Inc. (&#8220;HC II&#8221;) was incorporated under the laws of the State of Delaware on January 7, 2015, with its sole shareholder being HC Group Holdings I, LLC. (&#8220;HC I&#8221;). On April 7, 2015, HC I and HC II collectively acquired Walgreens Infusion Services, Inc. and its subsidiaries from Walgreen Co., and the business was rebranded as Option Care, Inc. (&#8220;Option Care&#8221;).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2019, HC I and HC II entered into a definitive agreement (the &#8220;Merger Agreement&#8221;) to merge with and into a wholly-owned subsidiary of BioScrip, Inc. (&#8220;BioScrip&#8221;) (the &#8220;Merger&#8221;), a national provider of infusion and home care management solutions, which was completed on August 6, 2019 (the &#8220;Merger Date&#8221;). The Merger was accounted for as a reverse merger under the acquisition method of accounting for business combinations with Option Care being considered the accounting acquirer and BioScrip being considered the legal acquirer. Following the close of the transaction, BioScrip was rebranded as Option Care Health, Inc. and the combined company&#8217;s stock, par value $0.0001, was listed on the Nasdaq Capital Market. Effective February 3, 2020, the Company was listed on the Nasdaq Global Select Market under the ticker symbol &#8220;OPCH&#8221;. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the consolidated financial statements for further discussion of the Merger.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Update on the Impact of the COVID-19 Pandemic</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary operations of the Company focus on providing infusion therapy services and based on the recent impact of the pandemic across the healthcare ecosystem, the Company began experiencing a related impact across a number of facets beginning in March 2020.  </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies upon patient referrals from multiple sources, including but not limited to patients discharged from acute care settings (e.g., hospitals) and patients requiring treatment for chronic conditions from specialty physicians.  As expected, the pandemic has negatively affected new patient referrals for both acute and chronic conditions; however, the Company did experience an increase in patient transfers from hospital and outpatient settings which positively affected revenues.  For the year ended December&#160;31, 2020, the revenue results reflect flat acute revenues relative to the prior year while chronic revenue grew in the mid-teens. Option Care Health continues to collaborate with payers and health systems to transition patients into the home or one of our alternate treatment sites to receive vital infusion therapy.  </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company experienced cost inefficiencies during the year ended December&#160;31, 2020 with respect to clinical labor and other staffing challenges, as well as higher costs to procure personal protection equipment.  Offsetting the negative impacts resulting from the COVID-19 pandemic, the Company managed spending and accelerated many integration-related initiatives as discussed below.  Further, to date, the Company experienced no material deceleration in cash collections and collaboration with payers continues to be productive. The Company anticipates that the pandemic could affect its operations for an extended period; however, at this time it cannot confidently forecast the duration nor the ultimate financial impact on its operations. See Item 1A. &#8220;Risk Factors&#8221; under the caption &#8220;The COVID-19 pandemic could adversely impact our business, results of operations, cash flows and financial position&#8221; for further discussion of risks.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company received approximately $11.7 million from the Public Health and Social Services Emergency Fund as part of the Coronavirus Aid, Relief, and Economics Security Act (&#8220;CARES Act&#8221;).  The $11.7 million was reflected in the second quarter 2020 as a cash inflow from financing activities. Given the Company&#8217;s ability to largely offset the cost inefficiencies experienced from the COVID-19 pandemic with spending reductions and accelerated integration net cost synergies, the Company returned these CARES Act funds to the federal government during the third quarter of 2020. This was reflected as a cash outflow from financing activities during the third quarter of 2020.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Merger Integration Execution</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger of Option Care and BioScrip into Option Care Health has created an opportunity to realize cost synergies while continuing to drive organic growth in chronic and acute therapies through our expanded national platform. Option Care Health is well-positioned to leverage the investments in corporate infrastructure and drive economies of scale as a result of the Merger. The synergy categories are as follows:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Selling, General and Administrative Expenses Savings.  Merged corporate infrastructure has created significant opportunity for streamlining corporate and administrative costs, including headcount and functional spend.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Network Optimization. The previous investments in technology and compounding pharmacies, along with the overlapping geographic footprint, allow for facility rationalization and the optimization of assets. </span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Procurement Savings. The enhanced scale of the Company generates supply chain efficiencies through increased purchasing leverage. The Company&#8217;s platform is also positioned to be the partner of choice for pharmaceutical manufacturers seeking innovative distribution channels and patient support models to access the market.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Merger, we have worked to align our field and sales teams. We have also made strides at combining our procurement process and contracts, all while continuing to focus on serving our patients. Patient health is personal to us, which is why, throughout the integration process, we strive to improve and set the standard for quality care that is matched by best-in-class service. After completion of the Merger, we have additional resources to invest in our people, processes and systems, providing us improved strength and scale to drive better patient outcomes. The Company accelerated its integration activities during the second quarter of 2020 to offset the negative impacts resulting from COVID-19 pandemic, and as a result we fully achieved the articulated goal of at least $60 million in net cost synergies.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes to Medicare Reimbursement</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, legislative changes have resulted in reductions in reimbursement under government healthcare programs. In December 2016, the Cures Act legislation was signed into law, which decreased reimbursement for Medicare Part B Durable Medical Equipment infusion drugs administered in an alternate site setting effective January 1, 2017. The original legislation did not provide for reimbursement for the service component until 2021. Center for Medicare and Medicaid Services issued a final rule in October 2018 implementing a temporary transition benefit for Medicare Part B home infusion services, which will continue from January 1, 2019 until January 1, 2021. This temporary transition benefit defines professional services as only including nursing, and not pharmacy, care planning, care coordination, or monitoring, and only pays for an infusion day when the nurse is in the home.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option Care&#160;merged&#160;with BioScrip on August 6, 2019.&#160;BioScrip&#160;was a national provider of infusion and home care management, who partnered with physicians, hospital systems, payers, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services.&#160;The fair value of purchase consideration transferred, net of cash acquired, on the closing date of $1,087.2 million includes the value of the number of shares of the combined company to be owned by BioScrip shareholders at closing of the Merger, the value of common shares to be issued to certain warrant and preferred shareholders in conjunction with the Merger, the value of stock-based instruments that were vested or earned as of the Merger, and cash payments made in conjunction with the Merger. On February 3, 2020, the Company completed a one share for four reverse stock split. In connection with the reverse stock split, the Company changed its ticker symbol from &#8220;BIOS&#8221; to &#8220;OPCH&#8221; and transferred the Company&#8217;s common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market. The par value of the Company&#8217;s common stock remained unchanged as a result of the reverse stock split, resulting in a decrease to the aggregate par value of common stock and corresponding increase to paid-in capital in the Company&#8217;s consolidated financial statements, which was retrospectively applied to all periods presented in the consolidated financial statements. For additional information on this Merger, see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Acquisitions,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Composition of Results of Operations </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following results of operations include the accounts of Option Care Health and our subsidiaries for the years ended December&#160;31, 2020 and 2019. The BioScrip results have been included since the August 6, 2019 Merger Date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit represents our net revenue less cost of revenue.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Infusion and related health care services revenue is reported at the estimated net realizable amounts from third-party payers and patients for goods sold and services rendered. When pharmaceuticals are provided to a patient, revenue is recognized upon delivery of the goods. When nursing services are provided, revenue is recognized when the services are rendered.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the health care industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payers may result in adjustments to amounts originally recorded.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists of the actual cost of pharmaceuticals and other medical supplies dispensed to patients. In addition to product costs, cost of revenue includes warehousing costs, purchasing costs, depreciation expense relating to revenue-generating assets, such as infusion pumps, shipping and handling costs, and wages and related costs for the pharmacists, nurses, and all other employees and contracted workers directly involved in providing service to the patient.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives volume-based rebates and prompt payment discounts from some of its pharmaceutical and medical supplies vendors. These payments are recorded as a reduction of inventory and are accounted for as a reduction of cost of revenue when the related inventory is sold.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Costs and Expenses</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling, general and administrative expenses consist principally of salaries for administrative employees that directly and indirectly support the operations, occupancy costs, marketing expenditures, insurance, and professional fees.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation within this caption includes infrastructure items such as computer hardware and software, office equipment and leasehold improvements. Depreciation of revenue-generating assets, such as infusion pumps, is included in cost of revenue.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Interest expense consists principally of interest payments on the Company&#8217;s outstanding borrowings under the First Lien Term Loan and Second Lien Notes, amortization of discount and deferred financing fees and changes in derivatives not designated as hedging instruments related to the interest rate swaps. Refer to the &#8220;Liquidity and Capital Resources&#8221; section below for further discussion of these outstanding borrowings.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in Earnings of Joint Ventures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Equity in earnings of joint ventures consists of our proportionate share of equity earnings or losses from equity investments in two infusion joint ventures with health systems.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Other income (expense) primarily includes current year loss on extinguishment of debt incurred in connection with 2020 debt prepayments. Prior year amounts relate to third-party fees paid in conjunction with our 2019 debt issuance of the Loan Facilities and Second Lien Notes and loss on extinguishment of debt for the Company&#8217;s Previous Credit Facilities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense (Benefit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company is subject to taxation in the United States and various states. The Company&#8217;s income tax (benefit) expense is reflective of the current federal tax rates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in unrealized (losses) gains on cash flow hedges, net of income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Change in unrealized (losses) gains on cash flow hedges, net of income taxes, consists of the gains and losses associated with the changes in the fair value of hedging instruments related to the interest rate caps and interest rate swaps, net of income taxes.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents Option Care Health&#8217;s consolidated results of operations for the years ended December&#160;31, 2020 and 2019 (in thousands). For discussion of Option Care Health&#8217;s consolidated results of operations for the year ended December&#160;31, 2019 compared to 2018, refer to Part II, Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2019 Annual Report on 10-K filed with the Securities and Exchange Commission on March 5, 2020.</span></div><div style="margin-bottom:17pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.565%"><tr><td style="width:1.0%"></td><td style="width:47.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.987%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NET REVENUE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,032,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,310,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">COST OF REVENUE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,350,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,797,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.8%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GROSS PROFIT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">682,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OPERATING COSTS AND EXPENSES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.9%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571,509&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513,318&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OPERATING INCOME (LOSS)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(319)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTHER INCOME (EXPENSE):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(107,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.6)%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.2)%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of joint ventures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,541)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,991)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total other expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115,998)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.8)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77,875)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.4)%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LOSS BEFORE INCOME TAXES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78,194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.4)%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">INCOME TAX EXPENSE (BENEFIT)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NET LOSS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,076)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75,920)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.3)%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTHER COMPREHENSIVE LOSS, NET OF TAX:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized losses on cash flow hedges, net of income taxes of $0 and $259, respectively</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,039)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTHER COMPREHENSIVE LOSS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,977)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,039)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NET COMPREHENSIVE LOSS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,053)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83,959)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.6)%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) 2020 includes the results of operations from BioScrip for the full year. 2019 includes the results of operations of BioScrip from the August 6, 2019 Merger Date onward and are, therefore, not comparable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2020 Compared to Year Ended December&#160;31, 2019</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present selected consolidated comparative results of operations for the years ended December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.023%"><tr><td style="width:1.0%"></td><td style="width:44.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Variance</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except for percentages)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,032,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,310,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">722,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,350,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,797,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">682,264&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512,999&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169,265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 31.3% increase in net revenue was primarily driven by additional revenue following the Merger, as the prior year included the results of BioScrip from the August 6, 2019 Merger Date, along with organic growth in the Company&#8217;s portfolio of therapies. For the year ended December 31, 2020, the revenue results reflect flat revenues for acute therapies relative to the prior year due to the impact of the COVID-19 pandemic, while revenue for chronic therapies grew in the mid-teens. The increase in cost of revenue was driven by the impact of the Merger and revenue growth. The increase in gross profit was primarily related to contribution margin from additional revenue from the Merger. The slight increase in gross profit margin was primarily driven by the positive impact from the merger integration net cost synergies, partially offset by the incremental wage costs and personal protective equipment costs related to the COVID-19 pandemic and mix shift toward lower profit chronic therapies.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.023%"><tr><td style="width:1.0%"></td><td style="width:44.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Variance</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except for percentages)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571,509&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513,318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,191&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased for the year ended December 31, 2020 primarily due to the impact of the Merger, but has decreased as a percentage of revenue to 16.5% for the year ended December 31, 2020 as compared to 19.9% for the year ended December 31, 2019 primarily due to synergy realization from Merger integration activities as well as spending reductions to offset the negative impacts of the COVID-19 pandemic.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in depreciation and amortization was primarily related to the deprecation of fixed assets acquired and the amortization of intangibles acquired from the Merger along with depreciation of additional investments in our pharmacies and infrastructure.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.023%"><tr><td style="width:1.0%"></td><td style="width:44.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Variance</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except for percentages)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(107,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,046)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of joint ventures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,541)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,991)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total other expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115,998)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77,875)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,123)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in interest expense was primarily attributable to the additional expense related to the new debt issued at the close of the Merger, partially offset by the savings from the combined $174.0 million prepayment of principal on the Second Lien Notes in the third and fourth quarters of 2020. The prior year included interest expense on the new debt from the Merger Date. See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in other, net of was the result of the loss on extinguishment of debt of $11.5 million incurred during the year ended December 31, 2020 in conjunction with the $174.0 million prepayment of principal on the Second Lien Notes, compared to the loss on extinguishment of debt of $5.5 million incurred during the year ended December 31, 2019 in conjunction with the extinguishment of debt related to the Merger.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense (Benefit)</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.023%"><tr><td style="width:1.0%"></td><td style="width:44.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Variance</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except for percentages)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(224.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s tax expense for the year ended December 31, 2020 is comprised of a change in deferred tax assets and liabilities, partially offset by a change in valuation allowance, and state tax liabilities, resulting in a negative effective tax rate of 54.0%. The Company&#8217;s tax benefit for the year ended December 31, 2019 is comprised of a deferred tax benefit partially offset by a change in valuation allowance and state tax liabilities. This results in an effective tax rate of 2.9% for the year ended December 31, 2019. These effective tax rates differ from the Company&#8217;s 21% federal statutory rate primarily due to a change in valuation allowance, certain state and local taxes and non-deductible costs.</span></div><div style="margin-bottom:10pt;margin-top:5.05pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:5.05pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss and Other Comprehensive Loss</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.023%"><tr><td style="width:1.0%"></td><td style="width:44.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Variance</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except for percentages)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,076)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75,920)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(89.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in unrealized losses on cash flow hedges, net of income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,039)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,977)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,039)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,053)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83,959)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,906&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss decreased primarily driven by the growth in gross profit, which more than offset the incremental operating expenses and interest expense incurred in conjunction with the Merger. The decrease in net loss is also impacted by the full realization of $60 million of Merger synergies in 2020 following the Merger, which more than offset the negative impacts of the COVID-19 pandemic during 2020.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in unrealized losses on cash flow hedges, net of income taxes, decreased as the interest rate swap nears maturity in August 2021.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net comprehensive loss decreased for the year ended December 31, 2020 as a result of the changes in net loss, discussed above, further reduced by the impact of the hedging instruments.</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_58"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020 and 2019, the Company&#8217;s primary sources of liquidity were cash on hand of $99.3 million and $67.1 million, respectively, as well as borrowings under its credit facilities, described further below. During the years ended December&#160;31, 2020 and 2019, the Company&#8217;s positive cash flows from operations have enabled investments in pharmacy and information technology infrastructure to support growth and create additional capacity in the future, as well as pursue acquisitions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary uses of cash include supporting our ongoing business activities, integration efforts, and investment in various acquisitions and our infrastructure to support additional business volumes. Ongoing operating cash outflows are associated with procuring and dispensing prescription drugs, personnel and other costs associated with servicing patients, as well as paying cash interest on the outstanding debt. Ongoing investing cash flows are primarily associated with capital projects related to business acquisitions, the improvement and maintenance of our pharmacy facilities and investment in our information technology systems. Ongoing financing cash flows are primarily associated with the quarterly principal payments on our outstanding debt. In addition to these ongoing investing and financing activities, during the year ended December&#160;31, 2020, the Company prepaid $174.0 million of outstanding debt principal balance. During the year ended December&#160;31, 2019, the Company entered into the Merger Agreement, and the Merger resulted in cash used in investing activities of $700.2 million and net cash provided by financing activities for net proceeds of indebtedness of $724.3 million.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy includes the selective acquisition of additional infusion pharmacies and other related healthcare businesses. We continue to evaluate acquisition opportunities and view acquisitions as a key part of our growth strategy. The Company historically has funded its acquisitions with cash with the exception of the Merger. The Company may require additional capital in excess of current availability in order to complete future acquisitions. It is impossible to predict the amount of capital that may be required for acquisitions, and there is no assurance that sufficient financing for these activities will be available on acceptable terms.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term and Long-Term Liquidity Requirements</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to make principal and interest payments on any borrowings under our credit facilities and our ability to fund planned capital expenditures will depend on our ability to generate cash in the future, which, to a certain extent, is subject to general economic, financial, competitive, regulatory and other conditions. Based on our current level of operations and planned capital expenditures, we believe that our existing cash balances and expected cash flows generated from operations will be sufficient to meet our operating requirements for at least the next 12 months. We may require additional borrowings under our credit facilities and alternative forms of financings or investments to achieve our longer-term strategic plans.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facilities</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2015, Option Care entered into two credit arrangements administered by Bank of America, N.A. and U.S. Bank. The agreements provided for up to $645.0 million in senior secured credit facilities through an $80.0 million revolving credit facility (the &#8220;Previous Revolving Credit Facility&#8221;), a $415.0 million first lien term loan (the &#8220;Previous First Lien Term Loan&#8221;), and a $150.0 million second lien term loan (the &#8220;Previous Second Lien Term Loan&#8221;, and together with the Previous First Lien Term Loan, the &#8220;Previous Term Loans&#8221;, and the Previous Term Loans, together with the Previous Revolving Credit Facility, the &#8220;Previous Credit Facilities&#8221;). Amounts borrowed under the credit agreements were secured by substantially all of the assets of the Company.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2019, the Company repaid the outstanding balance of the Previous Term Loans and retired the outstanding credit arrangements for $551.7 million. Proceeds of $575.0 million from the two new credit arrangements and indenture, discussed below, were also used, in part, to repay the outstanding debt of BioScrip as of the Merger.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Merger, the Company entered into two credit agreements and an indenture that initially provided for up to $1,475.0 million in senior secured credit facilities through a $150.0 million asset-based lending revolving credit facility (the &#8220;ABL Facility&#8221;), a $925.0 million first lien term loan facility (the &#8220;First Lien Term Loan&#8221;, and together with the ABL Facility, the &#8220;Loan Facilities&#8221;), and a $400.0 million senior secured second lien PIK toggle floating rate notes due 2027 (the &#8220;Second Lien Notes&#8221;). Amounts borrowed under the credit agreements are secured by substantially all of the assets of the Company.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ABL Facility credit agreement initially provided for borrowings up to $150.0 million, and matures on August&#160;6, 2024. During the year ended December 31, 2020, the Company increased the borrowing capacity to $175.0 million. The ABL Facility bears interest at a per annum rate that is determined by the Company&#8217;s periodic selection of rate type, either the Base Rate or the Eurocurrency Rate. The Base Rate is charged between 1.25% and 1.75% and the Eurocurrency Rate is charged between 2.25% and 2.75% based on the historical excess availability as a percentage of the Line Cap, as defined in the ABL Facility credit agreement. The revolving credit facility contains commitment fees payable on the unused portion of the ABL ranging from 0.25% to 0.375%, depending on various factors including the Company&#8217;s leverage ratio, type of loan and rate type, and letter of credit fees of 2.50%. The Company did not borrow against the ABL Facility at any time during 2020, and had no outstanding borrowings under the ABL Facility at December&#160;31, 2020. The Company had $9.6 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the ABL of $165.4 million as of December&#160;31, 2020. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal balance of the First Lien Term Loan is repayable in quarterly installments of $2.3 million plus interest, with a final payment of all remaining outstanding principal due on August&#160;6, 2026. The quarterly principal payments commenced in March of 2020. Interest on the First Lien Term Loan is payable monthly on Base Rate loans at Base Rate, as defined, plus 3.25% to 3.50%, depending on the Company&#8217;s leverage ratio. Interest is charged on Eurocurrency Rate loans at the Eurocurrency Rate, as defined, plus 4.25% to 4.50%, depending on the Company&#8217;s leverage ratio. The interest rate on the First Lien Term Loan was 4.40% as of December&#160;31, 2020. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Second Lien Notes mature on August&#160;6, 2027. Interest on the Second Lien Notes is payable quarterly at LIBOR, plus 8.75%. The Company elected to pay-in-kind the quarterly interest payment due in November 2019, which resulted in the Company capitalizing the interest payment to the principal balance on the interest payment date. The Company paid the second and third quarterly interest payments, due in February 2020 and May 2020. The Company elected to pay-in-kind the quarterly interest payment due in August 2020, which resulted in the Company capitalizing the interest payment to the principal balance on the interest payment date. In August 2020, the Company used the proceeds from a stock offering to prepay $125.0 million of the outstanding principal balance. In December 2020, the Company utilized available cash on hand to prepay an additional $49.0 million of the outstanding principal balance. As a result of these actions, the outstanding principal balance of the Second Lien Notes is $245.8 million as of December&#160;31, 2020. The interest rate on the Second Lien Notes was 8.98% as of December&#160;31, 2020. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into an amendment on the First Lien Term Loan (the &#8220;First Lien Credit Agreement Amendment&#8221;). The First Lien Credit Agreement Amendment resulted in an additional $250.0 million of incremental First Lien Term Loan indebtedness being issued and reduced the interest rate on all outstanding First Lien Term Loan indebtedness from LIBOR plus 4.25% to LIBOR plus 3.75%. The proceeds of the $250.0 million incremental First Lien Term Loan indebtedness were used to prepay the remaining $245.8 million outstanding balance of the Second Lien Notes. Following the First  Lien Credit Agreement Amendment, the First Lien Term Loan is repayable in quarterly installments of $2.9 million plus interest, with a final payment of all remaining outstanding principal due on August 6, 2026.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2020 Compared to Year Ended December&#160;31, 2019</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents selected data from Option Care Health&#8217;s consolidated statements of cash flows for the years ended December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.368%"><tr><td style="width:1.0%"></td><td style="width:56.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Variance</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,334)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(727,826)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">701,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68,849)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">719,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(787,873)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents - beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents - end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,265&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,056&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in cash provided by operating activities for the year ended December 31, 2020 was primarily driven by the improvement in net loss during 2020. In addition, working capital efficiencies also contributed to this increase, as additional investment in accounts receivable and inventories in conjunction with the growth in business volumes were more than offset by increases in accounts payable due to the timing of vendor payments.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in cash flows used in investing activities is primarily due to the Merger completed in the prior year.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in cash (used in) provided by financing activities is related to the prior year proceeds from the issuance of new debt of $981.1 million, which was partially offset by the retirement of the Company&#8217;s previous debt of $226.7 million and the payment of deferred financing costs of $30.0 million related to the Merger. In 2020, the cash used in financing activities consisted of the $174.0 million prepayment of the Second Lien Notes, which was partially offset by $118.9 million of proceeds from the issuance of common stock, as well as principal payments on the First Lien Term Loan.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments and Contractual Obligations</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents Option Care Health&#8217;s commitments and contractual obligations as of December&#160;31, 2020, as well as its long-term obligations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:43.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 1 year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1 - 3 years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3-5 years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">More than 5 years</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,161,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,115,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payments on long-term debt obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">391,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,662,843&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,059&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,360&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,225,680&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes aggregate principal payment on the indebtedness from the First Lien Term Loan and the Second Lien Notes incurred in 2019.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Interest payments calculated based on LIBOR rate as of December&#160;31, 2020. Actual payments are based on changes in LIBOR. Calculated interest payments exclude interest rate swap agreements the Company entered into in connection with the new indebtedness incurred in 2019.</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_61"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;December&#160;31, 2020, Option Care Health did not have any off-balance sheet arrangements, as defined in Item&#160;303(a)(4)(ii) of Regulation&#160;S-K.</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_67"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its consolidated financial statements in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;), which requires the Company to make estimates and assumptions. The Company evaluates its estimates and judgments on an ongoing basis. Estimates and judgments are based on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. The Company&#8217;s actual results may differ from these estimates, and different assumptions or conditions may yield different estimates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion is not intended to be a comprehensive list of all the accounting policies, estimates or judgments made in the preparation of our financial statements. A discussion of our significant accounting policies, including further discussion of the accounting policies described below, can be found in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, within the notes to the consolidated financial statements included in Item 8 of this Annual Report.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition and Accounts Receivable</span></div><div style="margin-bottom:10pt;margin-top:4.8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services. Revenues are from commercial payers, government payers, and patients for goods and services provided and are based on a gross price based on payer contracts, fee schedules, or other arrangements less any implicit price concessions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the health care industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the expected consideration to be received at the time of patient acceptance based on the verification of the patient&#8217;s insurance coverage, historical information with the patient, similar patients, or the payer. Performance obligations are determined based on the nature of the services provided by the Company. The majority of the Company&#8217;s performance obligations are to provide infusion services to deliver medicine, nutrients, or fluids directly into the body. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a variety of infusion-related therapies to patients, which frequently include multiple deliverables of pharmaceutical drugs and related nursing services. After applying the criteria from ASC 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third-party payer contracts. Pharmaceutical drug revenue is recognized at the time the pharmaceutical drug is delivered to the patient, and nursing revenue is recognized on the date of service.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services, which is inclusive of adjustments for price concessions. The majority of accounts receivable are due from private insurance carriers and governmental health care programs, such as Medicare and Medicaid.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Price concessions may result from patient hardships, patient uncollectible accounts sent to collection agencies, lack of recovery due to not receiving prior authorization, differing interpretations of covered therapies in payer contracts, different pricing methodologies, or various other reasons. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in accounts receivable are earned but unbilled gross receivables. Delays ranging from one day up to several weeks between the date of service and billing can occur due to delays in obtaining certain required payer-specific documentation from internal and external sources.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After applying the criteria from ASC 606, an allowance for doubtful accounts is established only as a result of an adverse change in the payers&#8217; ability to pay outstanding billings. The Company did not have an allowance for doubtful accounts as of December 31, 2020 or 2019. The Company recorded an allowance for implicit price concessions based on its historical experience of additional revenue being recorded or revenue being written off when amounts received are greater than or less than the originally estimated net realizable value. The detailed assessments included, among other factors, (i) current over/under payments which had not yet been applied to an account, (ii) historical contractual adjustments, and (iii) an estimate for contractual adjustments expected to be realized in the future. Contractual allowance estimates are adjusted to actual amounts as cash is received and claims are settled.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company tests goodwill for impairment annually, or more frequently whenever events or circumstances indicate impairment may exist. Goodwill is stated at cost less accumulated impairment losses. The Company completes its goodwill impairment test annually in the fourth quarter.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Circumstances that could trigger an interim impairment test include: a significant adverse change in the business climate or legal factors; an adverse action or assessment by a regulator; unanticipated competition; the loss of key personnel; a change in reporting units; the likelihood that a reporting unit or significant portion of a reporting unit will be sold or otherwise disposed of; and the results of testing for recoverability of a significant asset group within a reporting unit.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A qualitative impairment analysis was performed in the fourth quarter of 2020 and 2019 to assess whether it is more likely than not that the fair value of the Company&#8217;s reporting unit is less than its carrying value. The Company assessed relevant events and circumstances including macroeconomic conditions, industry and market considerations, overall financial performance, entity-specific events, and changes in the Company&#8217;s stock price. The Company determined that there was no goodwill impairment in 2020 or 2019.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A quantitative impairment analysis was performed in the fourth quarter of 2018, and the Company estimated the fair value of its reporting unit using an income approach. The income approach requires the Company to estimate a number of factors for its reporting unit, including projected future operating results, economic projections, anticipated future cash flows, and discount rates. The fair value determined using the income approach was then compared to marketplace fair value data from within a comparable industry grouping for reasonableness. The Company determined that there was no goodwill impairment in 2018.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of fair value and the allocation of that value to individual assets and liabilities within the reporting unit requires the Company to make significant estimates and assumptions. These estimates and assumptions primarily include, but are not limited to, the selection of appropriate peer group companies; control premiums appropriate for acquisitions in the industries in which the Company competes; the discount rate; terminal growth rates; and forecasts of revenue, operating income, depreciation and amortization, and capital expenditures. Actual financial results could differ from those estimates due to inherent uncertainty involved in making such estimates. Changes in assumptions concerning future financial results or other underlying assumptions could have a significant impact on either the fair value of the reporting unit, the amount of the goodwill impairment charge, or both.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Acquisitions</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business acquisitions in accordance with ASC Topic 805 (&#8220;ASC 805&#8221;), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with assets and liabilities being recorded at their acquisition date fair values and goodwill being calculated as the purchase price in excess of the net identifiable assets. The application of ASC 805 requires management to make estimates and assumptions when determining the acquisition date fair values of acquired assets and assumed liabilities. Management&#8217;s estimates and assumptions include, but are not limited to, the future cash flows an asset is expected to generate and the weighted-average cost of capital.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_70"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary market risk exposure is changing LIBOR&#8209;based interest rates. Interest rate risk is highly sensitive due to many factors, including U.S. monetary and tax policies, U.S. and international economic factors and other factors beyond our control. Our First Lien Term Loan bears interest at the Eurocurrency Rate, as defined, plus 4.25%, based on our leverage ratio as of December 31, 2020. Our Second Lien Notes bear interest at LIBOR, plus 8.75%. Our ABL Facility bears interest at the greater of the Eurocurrency Rate, as defined, or 0.25% plus 1.25% to 1.75%. At December&#160;31, 2020, we had total outstanding debt of $915.8 million under our First Lien Term Loan and $245.8 million under our Second Lien Notes. We had no outstanding borrowings under the ABL Facility as of December&#160;31, 2020.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To minimize interest rate risk, the Company entered into two interest rate swap contracts to hedge against fluctuations in LIBOR rates on the First Lien Term Loan and Second Lien Term Loan. The first interest rate swap for $925.0 million notional was effective in August 2019 with $911.1 million designated as a cash flow hedge against the underlying interest rate on the First Lien Term Loan indexed to one-month LIBOR through August 2021. The second interest rate swap for $400.0 million notional was effective in November 2019 and was designated as a cash flow hedge against the underlying interest rate on the Second Lien Notes interest payment indexed to three-month LIBOR through November 2020. In May 2020, upon electing to pay-in-kind the Second Lien Notes&#8217; quarterly interest payment, the Company discontinued hedge accounting on the $400.0 million notional interest rate swap. The $400.0 million notional interest rate swap matured in November 2020 and as of December 31, 2020 the Company does not maintain a hedge against the underlying interest rate on the Second Lien Notes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the amounts outstanding coupled with interest rate swaps, a 100-basis point increase or decrease in market interest rates over a twelve-month period would result in a change to interest expense of $6.4 million. We do not anticipate a significant impact from a change in market interest rates through the period of the interest rate swaps, discussed further in Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the consolidated financial statements and the notes related thereto included in Item 8 of this report. Subsequent to December 31, 2020, the Company entered into an amendment on the First Lien Term Loan, which resulted in an additional $250.0 million of incremental First Lien Term Loan indebtedness being issued. The proceeds of the $250.0 million incremental First Lien Term Loan indebtedness were used to prepay the remaining $245.8 million outstanding balance of the Second Lien  Notes. See Note 19, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the consolidated financial statements and the notes related thereto included in Item 8 of this report for further discussion.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Rate Risk</span></div><div style="margin-bottom:10pt;margin-top:4.7pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its analysis of the periods presented, the Company believes that inflation has not had a material effect on its operating results. There can be no assurance that future inflation will not have an adverse impact on the Company&#8217;s operating results and financial condition.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Statements and Supplementary Data</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:3pt;padding-right:303.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div style="margin-bottom:6pt;padding-right:303.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option Care Health, Inc.:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Option Care Health, Inc. and subsidiaries (the Company) as of December 31, 2020 and 2019, the related consolidated statements of comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2020, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated March 11, 2021 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span></div><div style="margin-bottom:6pt;padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Accounting Principle</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 8 to the consolidated financial statements, the Company has changed its method of accounting for leases as of January 1, 2019 due to the adoption of the Financial Acccounting Standards Board&#8217;s Accounting Standards Codification Topic 842 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which they relate.</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of transaction price adjustments</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 2 and 4 to the consolidated financial statements, net revenue is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services.  Revenues are from government payers, commercial payers, and patients for infusion therapy and other ancillary health care services. The Company estimates the transaction price adjustments based on the verification of the patient&#8217;s insurance coverage and historical price concessions, historical payments, and management&#8217;s manual price concession adjustments.</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the evaluation of the transaction price adjustments related to recognizing revenue as a critical audit matter.  Subjective and complex auditor judgment was required to evaluate the transaction price adjustments. Specifically, auditor judgment was required to evaluate the relevance and reliability of historical price concessions, historical payments, and management&#8217;s manual price concession adjustments. </span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Company&#8217;s transaction price adjustment process, including controls related to the historical price concessions, historical payments, and management&#8217;s manual price concession adjustments. We tested the relevance and reliability of the underlying data that served as the basis for the transaction price adjustments which included the historical price concessions and historical payments within the classes of payors by selecting certain historical price concessions and historical payments and agreeing to underlying support. We evaluated management&#8217;s manual price concession adjustments by comparing management&#8217;s prior-year recorded balance to actual write-offs during the current year.</span></div><div style="margin-top:4.65pt;text-align:center"><span><br/></span></div><div style="margin-top:4.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-top:4.65pt;text-align:center"><span><br/></span></div><div style="margin-top:4.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2015.</span></div><div style="margin-top:0.2pt"><span><br/></span></div><div style="margin-top:0.05pt;padding-right:389.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chicago, Illinois </span></div><div style="margin-top:0.05pt;padding-right:389.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 11, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTION CARE HEALTH, INC. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN THOUSANDS, EXCEPT SHARES AND PER SHARE AMOUNTS)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNC0xLTEtMS0w_6e398e19-f99e-4349-8897-0ff0d332d0b5">99,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNC0zLTEtMS0w_3b89b874-b2fc-49a8-9bfe-f84691152ef9">67,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNS0xLTEtMS0w_6c137121-cb78-4221-94a0-a793d38ffbed">328,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNS0zLTEtMS0w_c3cc7463-1b64-4888-83c1-1d48e7fe4cca">324,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNi0xLTEtMS0w_bc8e3bb4-b30e-4a11-9fda-6e85536f4d15">158,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNi0zLTEtMS0w_879d464f-b225-470f-a47e-58c27db4feff">115,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNy0xLTEtMS0w_972cd268-6eae-4b0f-a201-5fb2478f1bce">70,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNy0zLTEtMS0w_3ddaa413-8d22-4989-93c0-f05d012b263f">51,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfOC0xLTEtMS0w_49487242-5c6f-4c7c-b8db-3631b5c0cb06">657,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfOC0zLTEtMS0w_9f3638e7-33e2-4b51-b5ab-3f5de2cc61f7">558,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NONCURRENT ASSETS: </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTEtMS0xLTEtMA_98147447-a09a-42b8-a19f-cf0025123c2f">121,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTEtMy0xLTEtMA_ad3b6a2f-c915-4111-8da9-82027acd120a">133,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTItMS0xLTEtMA_021be26d-8373-4ac4-a83a-9a0d9d50c62b">68,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTItMy0xLTEtMA_d7cd69c7-fe43-429c-a40d-1951e70e9f1d">63,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTMtMS0xLTEtMA_f803e92f-7305-414d-afe2-e62f64813f31">351,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTMtMy0xLTEtMA_ef9b83a1-7e7e-4304-8fe2-5fb3a61abb1d">385,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTQtMS0xLTEtMA_8f2cdd61-86a0-4413-b3e5-8f73693f8cbb">1,428,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTQtMy0xLTEtMA_b37ff4a5-b0bb-4f49-98b8-946df4972bca">1,425,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTUtMS0xLTEtMA_7a468c1a-5037-4551-b6ea-37d490b98a24">20,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTUtMy0xLTEtMA_9e9b7fcb-b108-43ce-b720-b82912d1b0cf">22,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTYtMS0xLTEtMA_be19e392-4ffa-4420-9645-ea269cb3c0d2">1,990,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTYtMy0xLTEtMA_b9536c24-3d20-416c-9977-5be63a2884b5">2,030,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TOTAL ASSETS </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTctMS0xLTEtMA_2b82e8d1-e95b-47e2-acf7-188705084a1f">2,647,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTctMy0xLTEtMA_70a62f41-4eb5-445e-a9d0-5cf012677bf9">2,589,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CURRENT LIABILITIES:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjEtMS0xLTEtMA_187dca05-adfa-406f-a052-db3b724dbde9">282,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjEtMy0xLTEtMA_bc694be1-2b8d-4814-9c47-83ce2b8281db">221,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjItMS0xLTEtMA_ced72720-f5ba-4c86-b4f0-9b99ae3cb9ba">58,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjItMy0xLTEtMA_6b9e0eb6-0465-4373-81b0-05612288bb1b">45,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="bios:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjMtMS0xLTEtMA_8204c6cf-0991-4efc-8508-775e6c9b8ccd">64,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="bios:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjMtMy0xLTEtMA_bf0a8258-d0a8-47dc-b187-acbeee43ff9d">33,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjQtMS0xLTEtMA_d7b2ba8b-be01-4c06-ba89-f5a8807677b5">18,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjQtMy0xLTEtMA_59469c34-bcb4-4788-ad67-bedb8205a48b">20,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjUtMS0xLTEtMA_7b707494-199a-4f1d-8008-2f24afd551ea">9,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjUtMy0xLTEtMA_d5affc64-5556-4027-8f4f-4a57e3852a8c">9,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjYtMS0xLTEtMA_50b48da5-5129-403f-90b9-a74313062dd6">434,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjYtMy0xLTEtMA_7aca2216-5bf1-4803-b59d-6657f6e9eb54">330,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NONCURRENT LIABILITIES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, net of discount, deferred financing costs and current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjktMS0xLTEtMA_f6124c6e-901e-4920-b05d-c7512431dc07">1,115,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjktMy0xLTEtMA_7168557f-b3d3-467a-8707-23b9be796d09">1,277,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzAtMS0xLTEtMA_ecf8321e-aa18-4272-a435-b1708e9ff973">70,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzAtMy0xLTEtMA_484b0ff5-d154-448d-b465-e16d92e3524f">58,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzEtMS0xLTEtMA_31fefdbc-4a4b-4f38-8317-6c493f2bbf61">3,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzEtMy0xLTEtMA_fe63ae55-f904-40b7-a1d2-f6945eeead72">2,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzItMS0xLTEtMA_6c48e4d2-c7ea-4437-8318-661ef4c2f6a9">8,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzItMy0xLTEtMA_19028f1e-e9fb-4bb3-9643-ae48b0e6a1db">15,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzMtMS0xLTEtMA_a8c59129-804a-41e5-99ef-96af8afcd3cf">1,197,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzMtMy0xLTEtMA_aa840dc3-9d70-4654-84e7-b0ac5e4cf8c5">1,352,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzQtMS0xLTEtMA_975d08d7-3d2d-427e-83f0-add1fc93724f">1,631,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzQtMy0xLTEtMA_9430526e-aacb-4a67-a3f7-c3360006b890">1,682,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">STOCKHOLDERS&#8217; EQUITY: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjQzNDQwYzFlMjA5NjQzOTdhOTUxZjY1OWY5MjYwNDFjXzU0OTc1NTgxMzkwMzg_18188a17-5026-4ce4-829a-4fec88df9307"><ix:nonFraction unitRef="usdPerShare" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjQzNDQwYzFlMjA5NjQzOTdhOTUxZjY1OWY5MjYwNDFjXzU0OTc1NTgxMzkwMzg_dcdec827-9c88-4d64-8d8a-4133825d0dac">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjQzNDQwYzFlMjA5NjQzOTdhOTUxZjY1OWY5MjYwNDFjXzU0OTc1NTgxMzkwNTE_3db90ed1-b803-4ab8-b1c3-c50945f7edce"><ix:nonFraction unitRef="shares" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjQzNDQwYzFlMjA5NjQzOTdhOTUxZjY1OWY5MjYwNDFjXzU0OTc1NTgxMzkwNTE_975d7a79-7237-4655-a550-ff77beb8815f">12,500,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjQzNDQwYzFlMjA5NjQzOTdhOTUxZjY1OWY5MjYwNDFjXzU0OTc1NTgxMzkwNTY_272cdadf-4e39-42c1-9e9c-0eaec17f127d"><ix:nonFraction unitRef="shares" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjQzNDQwYzFlMjA5NjQzOTdhOTUxZjY1OWY5MjYwNDFjXzU0OTc1NTgxMzkwNTY_7a4d7e73-c125-4c21-a293-cda9fd552c2f">no</ix:nonFraction></ix:nonFraction> shares outstanding as of December 31, 2020 and 2019, respectively.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzctMS0xLTEtMA_6dd9090c-6562-4dbc-8dec-f1f96d54babe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzctMy0xLTEtMA_c35358e8-5beb-47c9-88ce-025233c9ce51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjExZjYxYTYwMGRmMjQ0ZTI4NDczMzFiOWNiYjllYmMzXzU0OTc1NTgxMzkyMDA_1f26c26c-a0c8-4022-99e0-ea2fd4b1c364"><ix:nonFraction unitRef="usdPerShare" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjExZjYxYTYwMGRmMjQ0ZTI4NDczMzFiOWNiYjllYmMzXzU0OTc1NTgxMzkyMDA_526c8c60-18f3-45ef-84ad-660bf676ddd8">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="shares" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjExZjYxYTYwMGRmMjQ0ZTI4NDczMzFiOWNiYjllYmMzXzU0OTc1NTgxMzkxOTA_0c09725d-bb1b-49d5-8df5-325697a81a71"><ix:nonFraction unitRef="shares" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjExZjYxYTYwMGRmMjQ0ZTI4NDczMzFiOWNiYjllYmMzXzU0OTc1NTgxMzkxOTA_9e4c5bce-5e84-48cf-b487-d47617a41640">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjExZjYxYTYwMGRmMjQ0ZTI4NDczMzFiOWNiYjllYmMzXzU0OTc1NTgxMzkxNjI_ad939896-b0bd-43f1-908d-0c90a83db630">180,178,308</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjExZjYxYTYwMGRmMjQ0ZTI4NDczMzFiOWNiYjllYmMzXzU0OTc1NTgxMzkxNzY_6814260f-f2ed-42ab-84cc-2c74c774aca2">179,794,586</ix:nonFraction> shares outstanding as of December 31, 2020; <ix:nonFraction unitRef="shares" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjExZjYxYTYwMGRmMjQ0ZTI4NDczMzFiOWNiYjllYmMzXzU0OTc1NTgxMzkxMzM_ed7dc004-c268-435b-95b0-3c358ef7de8b">176,975,628</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjExZjYxYTYwMGRmMjQ0ZTI4NDczMzFiOWNiYjllYmMzXzU0OTc1NTgxMzkxNDg_471f2275-203f-46e2-9021-00978d74a21f">176,591,907</ix:nonFraction> shares outstanding as of December 31, 2019.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMS0xLTEtMA_d211ed69-5849-4022-88b6-314bcc04b144">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMy0xLTEtMA_66512a81-9668-4db5-aa07-e8cc5eb2fbcc">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock; <ix:nonFraction unitRef="shares" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM2MzAwZWYxMzhiNzQ4NTc4NDY3YTk3NTVjYzJmZDZmXzU0OTc1NTgxMzkwMjI_5cd8b660-2185-46cd-893c-23536e1c072b"><ix:nonFraction unitRef="shares" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM2MzAwZWYxMzhiNzQ4NTc4NDY3YTk3NTVjYzJmZDZmXzU0OTc1NTgxMzkwMjI_806caff3-bf2a-48dc-99ba-372b778065fc">383,722</ix:nonFraction></ix:nonFraction> shares outstanding, at cost, as of December 31, 2020 and 2019, respectively.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzktMS0xLTEtMA_d6ac7be2-e499-405e-a4bb-4e26f605a39c">2,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzktMy0xLTEtMA_bd082a51-788a-487b-9ecb-d71c1bcb7462">2,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDAtMS0xLTEtMA_0737d910-6492-4f2e-afa4-691714f932c7">1,129,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDAtMy0xLTEtMA_5f010ae0-250b-4b8a-af32-e9ef75f1798c">1,008,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDItMS0xLTEtMA_2a9c6aa9-3326-4441-9fb9-b543ed8cf737">100,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDItMy0xLTEtMA_dc40172c-a302-4896-acdf-14addb08d9bf">91,955</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDMtMS0xLTEtMA_ffc105b4-7bf5-4189-a854-b3784e40c062">11,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDMtMy0xLTEtMA_5e661aa8-5560-4706-9dcc-932d15d74367">7,195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDQtMS0xLTEtMA_2a544a36-e2e6-4a98-9157-54c9796e2f1c">1,015,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDQtMy0xLTEtMA_a6ae43d1-d86d-4857-baa2-69e023c5b1f2">906,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDUtMS0xLTEtMA_4f3c89ea-bf21-4286-b393-cba184f3c274">2,647,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDUtMy0xLTEtMA_69e2a26b-f4db-4bcc-930f-3aa8eb1b7ff0">2,589,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The notes to consolidated financial statements are an integral part of these statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTION CARE HEALTH, INC. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:62.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.210%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NET REVENUE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMi0yLTEtMS0w_a4204c76-a2a3-41c9-9950-ff9273a57add">3,032,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMi00LTEtMS0w_ca3f5f9c-501e-49bf-a512-01140f42fd9d">2,310,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMi02LTEtMS0w_269b5bb2-124b-4d70-b399-ff5f444e737a">1,939,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">COST OF REVENUE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMy0yLTEtMS0w_fbfc3fbf-5b52-40dd-82dd-f5a79b1e6bbd">2,350,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMy00LTEtMS0w_6bf1a42f-ba1d-470d-aaf8-ae737ac69db7">1,797,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMy02LTEtMS0w_c4d46129-f0a6-466a-90fb-77ad8881aed6">1,517,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GROSS PROFIT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfNC0yLTEtMS0w_d15b7557-c363-4e4c-98fb-a99699979284">682,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfNC00LTEtMS0w_c4caac76-d3cd-4989-a3f6-31b5d55dd97d">512,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfNC02LTEtMS0w_1c7db7a0-c6d8-4c10-b7ea-3ccc21c00095">422,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OPERATING COSTS AND EXPENSES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfNy0yLTEtMS0w_0a75c879-30dc-45c2-9c32-fb6c601f0728">500,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfNy00LTEtMS0w_10cf3843-b00c-46d5-bafc-138c9752de6b">459,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfNy02LTEtMS0w_799955b0-8cd3-4f01-b393-10927f6ce593">345,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfOS0yLTEtMS0w_617dc53c-c824-4f65-a52a-30e8f9346de4">71,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfOS00LTEtMS0w_898bd230-d5a8-47ac-879a-f61341ec771f">53,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfOS02LTEtMS0w_4c0c2dae-7b78-443f-8f7d-535f67bc40c3">38,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTAtMi0xLTEtMA_9d7ae511-b48a-463d-a3cd-9a8e6aaa5d86">571,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTAtNC0xLTEtMA_ce60e5b8-878c-4a1d-af05-d67496486796">513,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTAtNi0xLTEtMA_9772fd7e-651b-417e-b77e-491a3429a0ae">383,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OPERATING INCOME (LOSS)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTEtMi0xLTEtMA_9b12632f-cd39-47e4-9068-c17e79e057f8">110,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTEtNC0xLTEtMA_bbbf32f2-c8c1-4ccd-a157-01ae5cd91131">319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTEtNi0xLTEtMA_446c2b00-db5c-4d4f-b312-b36789e7bd91">38,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTHER INCOME (EXPENSE):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTQtMi0xLTEtMA_439cf143-3255-4307-8675-454aa9b6c0c6">107,770</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTQtNC0xLTEtMA_78f1cdd8-5d4b-4e8b-a9ad-083f4e842e8a">73,724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTQtNi0xLTEtMA_2e63a955-a130-4be6-9225-7dc7a15d7d4d">45,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of joint ventures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTUtMi0xLTEtMA_8cd72263-390a-4a94-a283-ec37a851fd07">3,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTUtNC0xLTEtMA_56455ec3-e08a-43dd-b5f3-efd7777c9f9d">2,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTUtNi0xLTEtMA_9a2d4878-d053-4093-a060-eea2f0f2ad22">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTYtMi0xLTEtMA_5953b1e1-d864-4b04-aecd-d88b268bffea">11,541</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTYtNC0xLTEtMA_9fdc8203-fa13-41d1-8cc2-f2c20b8fa656">6,991</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTYtNi0xLTEtMA_9ceaeb34-81ff-436c-97e3-faef13c9a775">2,233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total other expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTctMi0xLTEtMA_97bd4ef6-0ef1-4772-8cb5-91f119c2e1f8">115,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTctNC0xLTEtMA_672e1f61-d131-45e1-892e-1017bc11a083">77,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTctNi0xLTEtMA_c720d0f4-38ec-42fc-860b-5c0d66a58606">47,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LOSS BEFORE INCOME TAXES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTktMi0xLTEtMA_f6c5a22d-f19f-402e-b1f2-b536f3b05ac8">5,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTktNC0xLTEtMA_5ffa8cf0-e775-449f-b9b2-2deab50d708b">78,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTktNi0xLTEtMA_edb7d41d-4995-4533-a8da-c95fcda5f972">8,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">INCOME TAX EXPENSE (BENEFIT)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjAtMi0xLTEtMA_b189eb0b-d8eb-426a-9112-380369adec9e">2,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjAtNC0xLTEtMA_ac717e94-9061-44a6-89e2-36fa7b25d1b4">2,274</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjAtNi0xLTEtMA_3fe6126d-8eee-4a88-a951-140587996f7a">2,653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NET LOSS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjItMi0xLTEtMA_e4433798-0e4b-4460-b68b-0e247d9a8d63">8,076</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjItNC0xLTEtMA_5f08947f-c8c1-4265-9215-c03ba650ef80">75,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjItNi0xLTEtMA_f63e4a8d-ad0f-4a6c-abe6-ae88be6a0bed">6,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized (losses) gains on cash flow hedges, net of income taxes of $<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NTNjMjVlMWU5NjRlN2Y4NzdiOWMxZjg1MmM5NDYzXzU0OTc1NTgxMzg5OTc_796699c9-c474-4670-8493-c6066b9064d5">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NTNjMjVlMWU5NjRlN2Y4NzdiOWMxZjg1MmM5NDYzXzU0OTc1NTgxMzkwMDQ_6e623468-5dd0-46d2-851e-cfc96a85de7a">259</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NTNjMjVlMWU5NjRlN2Y4NzdiOWMxZjg1MmM5NDYzXzU0OTc1NTgxMzkwMTE_ca1b888d-9796-432c-b1eb-1417ef22114c">234</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjUtMi0xLTEtMA_3c5fe473-c139-4030-8f52-917dd09385e7">3,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjUtNC0xLTEtMA_b6d969ec-c44c-415a-bbf8-032dca352768">8,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjUtNi0xLTEtMA_960ea9d4-f71f-4f1a-a30f-a8cd3f0f642c">774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTHER COMPREHENSIVE (LOSS) INCOME</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjYtMi0xLTEtMA_c37f1aab-bd2f-4830-a752-56a8a05c9623">3,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjYtNC0xLTEtMA_94221c11-b74a-4ab7-8be2-7cd65e5cb4bb">8,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjYtNi0xLTEtMA_70bd590d-6cf8-4f75-a597-26664fa35742">774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NET COMPREHENSIVE LOSS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjctMi0xLTEtMA_a3b5a52a-2965-4b10-994f-5a65c7443154">12,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjctNC0xLTEtMA_2b092db7-6941-42f1-8374-cae0674c6be3">83,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjctNi0xLTEtMA_6aeb471c-0a7e-41f9-af09-392d7d82795e">5,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LOSS PER COMMON SHARE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMzAtMi0xLTEtMA_f3652413-a315-4a13-a789-dec27aec8ff7">0.04</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMzAtNC0xLTEtMA_d9ad31d7-93b6-4060-bc16-ebae7171c157">0.49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMzAtNi0xLTEtMA_0f173885-76e0-4de7-9bd9-d19f9e8b9354">0.04</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMzItMi0xLTEtMA_36d04614-758e-41ba-ab71-5c97c6048d8b">180,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMzItNC0xLTEtMA_9742b4cd-31c2-46a4-9a85-dd8290ff0711">156,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMzItNi0xLTEtMA_fa30ee20-fd48-4688-811d-8d5b876253a1">142,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The notes to consolidated financial statements are an integral part of these statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_88"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTION CARE HEALTH, INC. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN THOUSANDS)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.710%"><tr><td style="width:1.0%"></td><td style="width:68.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.347%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.347%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMy0xLTEtMS0w_e4433798-0e4b-4460-b68b-0e247d9a8d63">8,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMy0zLTEtMS0w_5f08947f-c8c1-4265-9215-c03ba650ef80">75,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMy01LTEtMS0w_6203d940-c0aa-4548-bb0b-64800fd84d77">6,115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by operations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNS0xLTEtMS0w_1b0e3557-a3c5-4d9e-8c03-1b9e76938928">77,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNS0zLTEtMS0w_621f3f2c-5b42-415e-9f09-eb434e794b2f">57,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNS01LTEtMS0w_f4320286-8a79-45a7-860d-127452acc34b">41,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash operating lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNi0xLTEtMS0w_fcaeb4ec-e787-42f2-a2a5-79c1df65a6cb">18,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNi0zLTEtMS0w_b7f84b7d-679d-4aee-af9f-62b98504fec8">19,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNi01LTEtMS0w_795906fa-4480-45be-ab7b-b03349124365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes - net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNy0xLTEtMS0w_3da9c522-d8f6-4ba1-bcd8-f3c6775b7cf0">1,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNy0zLTEtMS0w_d0487954-800b-4252-9adb-0f30eb4a7ed3">4,607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNy01LTEtMS0w_ed68fd8b-48b8-4cec-8119-264c4d10d16d">3,595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on sale of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfOC0xLTEtMS0w_a1a85b87-cdd6-41ce-9f48-ab17779fd598">742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfOC0zLTEtMS0w_78d704cf-e80e-48ec-9f0f-cd74a14e39a8">3,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfOC01LTEtMS0w_cbda9c45-fcfe-49a7-8d4f-84c8e9880b0b">1,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Business casualty loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfBusiness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfOS0xLTEtMS0w_125a2a15-987c-41db-8391-ea075232acc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfOS0zLTEtMS0w_ba38abd0-45f7-436d-b9bd-e9206ff8c73c">626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfBusiness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfOS01LTEtMS0w_b05e0027-2a5d-4a89-a5c5-e3fa00378d40">3,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTAtMS0xLTEtMA_3bcab461-e324-4bf9-aaaa-1cbef1c07666">11,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTAtMy0xLTEtMA_f16b396f-9dc0-414a-bf05-291888a68733">5,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTAtNS0xLTEtMA_1c2cb9e6-09fb-4de5-8767-98a690ac9f5c">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTEtMS0xLTEtMA_375ef26d-244b-49a4-b969-919ea271874e">5,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTEtMy0xLTEtMA_070443ad-a4e0-4f55-9014-79852a9982e4">4,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTEtNS0xLTEtMA_5fadbe83-fe66-4c4d-878a-646319e45ba3">3,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on interest rate swaps upon discontinuing hedge accounting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="bios:LossOnDiscontinuanceOfCashFlowHedgeDerivative" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTItMS0xLTEtNTE2MQ_ac25902a-3395-4a44-96dd-2daf7d9c0303">3,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="bios:LossOnDiscontinuanceOfCashFlowHedgeDerivative" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTItMy0xLTEtNTE2MQ_e8a49048-af79-474b-82df-d8ef749c94e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="bios:LossOnDiscontinuanceOfCashFlowHedgeDerivative" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTItNS0xLTEtNTE2MQ_68c35e29-b176-4ea4-9fdd-7a0a71053efc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Paid-in-kind interest capitalized as principal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTItMS0xLTEtMA_5d2ebe43-15d5-4e7f-98a7-9c086c92e202">7,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTItMy0xLTEtMA_00205b98-86bf-4740-aa0b-3ad02dbb3cbc">12,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTItNS0xLTEtMA_5b09d103-4d2b-4199-a507-1cb516685bbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTMtMS0xLTEtMA_f09dfc58-8a42-4f9b-9c4e-a68d02a57e0b">3,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTMtMy0xLTEtMA_7b64ba3b-d134-4384-8f31-8980bfea0115">2,840</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTMtNS0xLTEtMA_217bf781-ee74-4691-95e8-07620d3618b6">1,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based incentive compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTQtMS0xLTEtMA_b54f5673-2fb8-42df-bc41-900bf07ca806">2,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTQtMy0xLTEtMA_77ee996a-98d0-4282-9a57-f13e76094956">4,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTQtNS0xLTEtMA_0d43b9bf-8eeb-4838-b505-3d7c0ce92b26">2,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on management notes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="bios:InterestGainLossOnManagementNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTUtMS0xLTEtMA_df6d47d8-ab24-4ec9-9887-5044590bcfec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" name="bios:InterestGainLossOnManagementNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTUtMy0xLTEtMA_51d88f56-be4f-4c53-8a02-a784329b398b">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" name="bios:InterestGainLossOnManagementNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTUtNS0xLTEtMA_5d5b577c-f3b3-465e-9d43-2b98866a4c95">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital distribution from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTYtMS0xLTEtMA_14e5ce26-ff19-4cea-8a7d-44523d9055a6">3,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTYtMy0xLTEtMA_9f9475b9-30cc-4776-acaa-a3c7fcfdd756">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTYtNS0xLTEtMA_28df7865-84b9-442c-8188-577ad434c42e">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in contingent consideration liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTctMS0xLTEtMA_efff9a94-2402-4043-ac11-9f4aff3d9dec">1,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTctMy0xLTEtMA_9b858f24-b281-4e90-b996-ecacb4a6a56d">300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTctNS0xLTEtMA_af4bcefb-d091-433e-9dd5-c9db6b6d5026">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTktMS0xLTEtMA_01893643-93a4-4d70-924d-b62101fd0822">3,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTktMy0xLTEtMA_d855523c-3a79-485e-a80c-3b0a27da2bf8">82,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTktNS0xLTEtMA_f8b37b9b-7468-4889-9672-f84280d7aeae">21,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjAtMS0xLTEtMA_8335b090-26fc-4630-848f-5a738e303da7">42,725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjAtMy0xLTEtMA_d72a5fd5-846d-4c9a-a181-61e4bc3588e3">12,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjAtNS0xLTEtMA_93ed6f3a-b1f5-4bf9-a415-8a9c2d276df9">2,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjEtMS0xLTEtMA_c8e35451-07c4-44eb-99c0-40b54277e20b">19,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjEtMy0xLTEtMA_3707e3eb-f1fb-4bfa-a17f-dda6b9bd31e1">2,940</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjEtNS0xLTEtMA_87d90751-a542-4475-a05f-5c8cd295c9b4">4,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjItMS0xLTEtMA_f1b4db45-5f19-49f0-810a-6dee1f3e0d29">59,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjItMy0xLTEtMA_186fa0b4-a30a-4960-951f-5127fde1e168">30,856</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjItNS0xLTEtMA_20e39d69-7291-403d-b3ab-d3f86c9d9337">10,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjMtMS0xLTEtMA_d33dde44-ffed-4844-8851-048c1d68280a">13,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjMtMy0xLTEtMA_2695d0ad-c868-41a0-ae0e-19f7da0b66a0">2,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjMtNS0xLTEtMA_dc89908d-1806-4e21-bf92-25b262abc63a">5,586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjQtMS0xLTEtMA_a44ac668-e07b-486a-8a8a-3424354b12a3">22,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjQtMy0xLTEtMA_7cc96124-1fbf-4f85-bec8-dbc33f727d4c">317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjQtNS0xLTEtMA_d3186ba8-8dab-4208-aedc-f9403e9bbfd5">1,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjUtMS0xLTEtMA_8610cfd4-188c-409f-8c06-5c696cc57481">18,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjUtMy0xLTEtMA_c17e7f15-3fab-4f10-ae94-2d574ae11865">17,253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjUtNS0xLTEtMA_0554cbf5-5a2d-4df4-902f-d507566a432c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjYtMS0xLTEtMA_8642c934-35a1-4d1d-a82a-1555ec0ef1d0">3,790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjYtMy0xLTEtMA_6251da7b-da4c-41b8-b662-7252eb82f383">4,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjYtNS0xLTEtMA_f20e1b39-c4cd-4c42-a7ee-92a60bbe4d6f">1,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjctMS0xLTEtMA_4b7d3218-c60e-4d6e-8d0a-ff99fcb2324b">127,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjctMy0xLTEtMA_ec86eed5-545d-4bd9-a6e7-1e4cf61f30ad">39,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjctNS0xLTEtMA_5a3978fb-1344-4daa-9b1e-d75dd84965cc">24,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzAtMS0xLTEtMA_a4ef146c-cbab-495d-bf80-216e61c69a2d">26,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzAtMy0xLTEtMA_d1221d3e-cc66-4cbc-93c4-75b29d45e900">28,292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzAtNS0xLTEtMA_69c1586f-3e91-4b54-805b-c2e72130f89e">26,276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzEtMS0xLTEtMA_d77bce80-7792-4c69-a6bb-f7c1f9be2ad0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzEtMy0xLTEtMA_f8d10c43-4563-4219-97ba-921224054ae7">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzEtNS0xLTEtMA_ee2ef004-c30e-4b2c-bdf6-dcad7137eb86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance proceeds from business casualty loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromInsuranceSettlementInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzItMS0xLTEtMA_07758d51-1a68-48dd-98ad-db3a540bff8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromInsuranceSettlementInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzItMy0xLTEtMA_233fdf3b-6633-4e61-ac86-aea2a7b9ad9b">626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromInsuranceSettlementInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzItNS0xLTEtMA_9f67b70e-8151-4b9b-aef7-64ba8007479a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Business acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzMtMS0xLTEtMA_0beffe69-29ee-4325-a39e-a56985002d71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzMtMy0xLTEtMA_9f9e7c5d-7d2b-4ec5-95d2-108ba5e28d8c">700,170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzMtNS0xLTEtMA_b20b4c82-eecb-493b-8175-a0ad076382a1">10,727</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other investing cash flows</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzUtMS0xLTEtNTE3MA_22f7173c-63f5-4d51-b844-5ebabc04d879">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzUtMy0xLTEtNTE3MA_c4d7bf97-70c1-4970-b114-85dc983981aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzUtNS0xLTEtNTE3MA_79a9f321-c111-40a8-b35d-c56f299663e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzQtMS0xLTEtMA_1c8163b5-4529-48fe-b175-83c43f3307f3">26,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzQtMy0xLTEtMA_83e7d822-48fa-4746-b5a1-770f63307d57">727,826</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzQtNS0xLTEtMA_ac70055d-987d-458c-97c1-033b2ecb35d5">37,003</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redemptions to related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzctMS0xLTEtMA_fa823a39-1b0b-4ba4-9b37-d13df54e8f26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzctMy0xLTEtMA_174af4a8-fd13-4d87-82ca-891e4c2df385">2,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzctNS0xLTEtMA_0600fd29-e092-41a7-acb9-43860bf5acda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sale of management notes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="bios:ProceedsFromSaleOfManagementNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzgtMS0xLTEtMA_b81d2fcc-0a4d-4a32-9920-f5f3c0b83d34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="bios:ProceedsFromSaleOfManagementNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzgtMy0xLTEtMA_c4433ca6-d14a-48d0-a7c7-cf9b1ae61a9b">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="bios:ProceedsFromSaleOfManagementNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzgtNS0xLTEtMA_dbac2380-5106-41f5-8410-1a0dd5d6aa8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options, vesting of restricted stock, and related tax withholdings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzktMS0xLTEtMA_09c2a60a-f953-4e9d-bb7d-5ae3b5fb8746">904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzktMy0xLTEtMA_cfcc82d3-36ee-4e9f-a716-c3128370fafc">2,501</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzktNS0xLTEtMA_e88d6fc6-e0a6-4f3f-b6ac-ddf0b2fc8700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDAtMS0xLTEtMA_86f43a57-e2c8-4298-89e6-b052a57b0cc8">118,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDAtMy0xLTEtMA_953fabe3-c8d9-4472-ac0c-e371dbaed208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDAtNS0xLTEtMA_6e6e6c81-322f-436a-a28d-f9f83eccb0fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDEtMS0xLTEtMA_cd5144ef-4ce1-4325-ae53-0ded556049c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDEtMy0xLTEtMA_b787376b-e5b5-4a8a-b42a-ede6171eb3a9">981,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDEtNS0xLTEtMA_7d43e5cf-1302-45c9-9de6-2f72b0cefc9f">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of debt principal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDItMS0xLTEtMA_2f749019-40ea-4b7b-9b34-49ffcf707a66">9,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDItMy0xLTEtMA_e0cd5360-19db-4175-83ea-fe344741e734">2,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDItNS0xLTEtMA_e83126cd-0a2e-42f0-a85f-b6b5446285ea">5,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement of debt obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForDepositsAppliedToDebtRetirements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDMtMS0xLTEtMA_d9ff5106-01ec-4af0-bfea-5105d07236bc">174,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForDepositsAppliedToDebtRetirements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDMtMy0xLTEtMA_246b683a-486a-4fc1-900a-c3f968627cb6">226,738</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForDepositsAppliedToDebtRetirements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDMtNS0xLTEtMA_a8e53180-3755-4d38-b7b4-31edcf3e1cc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDQtMS0xLTEtMA_be8aeb33-d052-42f1-9545-e409c4ce9ae1">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDQtMy0xLTEtMA_53ab4af8-e2a0-4d87-be58-0c01c279b4ac">30,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDQtNS0xLTEtMA_ac4278d1-3d63-440c-88c4-cb705015adb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt prepayment fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDctMS0xLTEtNTE5MA_7a9614db-1401-4c8c-af27-fa07d2dd45a2">3,480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDctMy0xLTEtNTE5MA_dcedab9e-2077-4d16-b8e7-28413dde1f95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDctNS0xLTEtNTE5MA_dd3fd208-1361-4cc6-be22-c37d0a1caf01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDUtMS0xLTEtMA_e1f3f0c2-1ea0-4b44-a46b-e388f668e21f">68,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDUtMy0xLTEtMA_f345c3c8-b8a1-405f-98e7-47bf500a51e4">719,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDUtNS0xLTEtMA_e6a3daee-2aa0-409c-8dff-071fcbd74b4a">4,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDYtMS0xLTEtMA_148d3f2a-eccb-4988-9210-12c0fa8a4e45">32,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDYtMy0xLTEtMA_b074b8ef-d9eb-4767-a249-17d363dfaad8">30,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDYtNS0xLTEtMA_3b457e84-046b-44e8-a9b6-f960164c7e55">16,725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents - beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDctMS0xLTEtMA_c009385a-a2ef-4205-9e5f-dc56b43ee64a">67,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i757f7525fd514729825051239d54094e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDctMy0xLTEtMA_f0f70fb5-a62b-4b65-8a00-164da9f973bb">36,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40c908a9b2de45bcab117c93611972e9_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDctNS0xLTEtMA_28d09f43-9082-4866-b84c-4066c4dc1550">53,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASH AND CASH EQUIVALENTS - END OF PERIOD</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDgtMS0xLTEtMA_c3150fe7-c48b-4e28-9f99-c8dab0f52c0e">99,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDgtMy0xLTEtMA_3ac58fcd-3a8c-4d35-8347-e7b469a4a6ad">67,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i757f7525fd514729825051239d54094e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDgtNS0xLTEtMA_7a4c5190-65d6-4763-9d4d-4a6774816a77">36,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNTEtMS0xLTEtMA_5972cc87-2ea8-44a0-815e-5675234913d2">97,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNTEtMy0xLTEtMA_854a56f7-2a4c-4777-8671-213e6a54af9b">50,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNTEtNS0xLTEtMA_8b07b98c-7121-49e4-8070-2c78c680caf6">47,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNTItMS0xLTEtMA_957adebb-6cb8-4df2-bc2d-669e6f7beee3">2,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNTItMy0xLTEtMA_0a579889-e6a1-4c7d-8cac-a39f1c8971ea">2,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNTItNS0xLTEtMA_22d5cfb2-657a-4214-8538-38eace71a579">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePaymentsUse" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNTMtMS0xLTEtMA_52229466-fbe2-45b2-933c-e8d8c0b8cb6b">26,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePaymentsUse" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNTMtMy0xLTEtMA_04c3b44d-8670-48d7-9590-410be94484c3">18,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The notes to consolidated financial statements are an integral part of these statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTION CARE HEALTH, INC. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN THOUSANDS)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Management Notes Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated   Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance - December 31, 2017</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia256a7852ef04c1fbe74e288a706e7b1_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMS0xLTEtMS0w_fbce7482-620b-46d1-bea9-a15c3225791c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0c4db4796fe410bb862ec15526051d4_I20171231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMS0zLTEtMS0w_2859d898-d9be-4837-b8ee-9128a7e9b83e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i422568febabe4f8583b8153a15287b3d_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMS01LTEtMS0w_d6ad6e8b-9302-4ad2-b709-c1d2fbd39363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4ff3448393941ecb196d60a1c0c6507_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMS03LTEtMS0w_bc0b9e2d-149c-4452-a739-4f8282913202">617,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac5e68b371e846bcb5595487faa64440_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMS05LTEtMS0w_c5f1107e-0c5e-4f0a-90ac-228495be5c8d">1,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i405e4a30b4e7443da8c3cc601af2d472_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMS0xMS0xLTEtMA_752fefa2-0ea7-428b-a9d6-050245f71984">9,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife86991b5c864d3ba7c27b4e2b6eaec8_I20171231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMS0xMy0xLTEtMA_d6612f98-7314-4ad2-8916-86b9856c0142">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40c908a9b2de45bcab117c93611972e9_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMS0xNS0xLTEtMA_e113c1f2-46e1-4349-8f01-7a42ec6ca1d3">606,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders' contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aaa306bfeb44033b42625ce53fced06_D20180101-20181231" decimals="-3" name="bios:AdjustmentsToAdditionalPaidInCapitalStockholdersContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMi03LTEtMS0w_6b2ac1f6-6c66-4d7f-92ad-0d05fbe78097">425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d20553c1ddf4029b82e7a98557f08a6_D20180101-20181231" decimals="-3" sign="-" name="bios:AdjustmentsToAdditionalPaidInCapitalStockholdersContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMi05LTEtMS0w_90ffd65d-3d82-4a6f-9927-ef56f06e1324">425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="bios:AdjustmentsToAdditionalPaidInCapitalStockholdersContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMi0xNS0xLTEtMA_27ba363a-c290-44bf-98b0-744397f89ad1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on management notes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d20553c1ddf4029b82e7a98557f08a6_D20180101-20181231" decimals="-3" name="bios:InterestOnManagementNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMy05LTEtMS0w_cf7149cb-2f8a-4d27-bb38-a5d8a26ee9ec">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" name="bios:InterestOnManagementNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMy0xNS0xLTEtMA_efb83bfb-30bc-49d9-9cbb-509ca575a793">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based incentive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aaa306bfeb44033b42625ce53fced06_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfNC03LTEtMS0w_1c0b98e1-77d3-4fbe-a651-476405d0a8d9">2,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f517132d94447c1a7f4a0703dfdad24_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfNC0xMS0xLTEtMA_a3faae65-ff67-403a-aef2-be1f5c634fac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfNC0xNS0xLTEtMA_18332ff9-6d62-480c-afe3-159ce27d4af4">2,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f517132d94447c1a7f4a0703dfdad24_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfNS0xMS0xLTEtMA_d816241e-5227-45cc-80c3-d56849ebcd90">6,115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfNS0xNS0xLTEtMA_20b779e5-d485-49af-beba-2223285b0172">6,115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d5f5d47071547e88ec2cc2a2ed79b64_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfNy0xMy0xLTEtMA_78eb5a52-63cd-4bd1-ba81-65a3749ff0cf">774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfNy0xNS0xLTEtMA_6e77b76a-c4d8-436d-9bb0-dab0e0869ca8">774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance - December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id159556253844660bd62dda5634d2366_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOC0xLTEtMS0w_f83fd657-482d-42ce-994d-1e3212996ac0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05ad22c7cb124eb7bc29475754fc1e50_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOC0zLTEtMS0w_af05dd1e-944d-4e68-a00b-09144dcf1d7b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec2447edc67648968195e4c9c57c9044_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOC01LTEtMS0w_4bda1fc8-d541-4c5b-a28e-0e420bf3efb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb3d7b08eaa94aeca766b6bd2235a557_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOC03LTEtMS0w_e8752a05-7a8e-4293-839a-714a8aeae059">619,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ca7471b8b564de0a7a5d385352e5b15_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOC05LTEtMS0w_195c01e9-54df-4912-bcdb-02239d9f6887">1,619</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38e87c4a7aae447680dde06b054bed9f_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOC0xMS0xLTEtMA_4e5c23d3-693a-4c37-a087-4b6f45946840">16,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22b30bb4310a44029a5f94758c5ae210_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOC0xMy0xLTEtMA_ca748da0-082d-43ce-9a23-7868864b0fc8">844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i757f7525fd514729825051239d54094e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOC0xNS0xLTEtMA_f93a101a-07f5-4dd0-9e5d-59504028c18a">602,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of BioScrip, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a948d96b8124ca49264e48dfa5b84ea_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOS0zLTEtMS0w_9e60964b-03d5-40e0-8437-3e96cc44ab72">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58814d8f92d24190888892748720a464_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOS03LTEtMS0w_ee3a10be-b86a-4f96-a3c7-5667ca3c2ba4">387,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOS0xNS0xLTEtMA_3a559a3e-5160-4a46-bee7-9884df81f404">387,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on management notes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadfb96c7240b4bf2bc10824cee106ac1_D20190101-20191231" decimals="-3" name="bios:InterestOnManagementNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTAtOS0xLTEtMA_9e5ebc2c-75a3-4156-a545-6eb0e74c6515">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" name="bios:InterestOnManagementNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTAtMTUtMS0xLTA_5848b878-7734-45e6-ab19-2f81f41b1d81">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of management notes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadfb96c7240b4bf2bc10824cee106ac1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="bios:RepaymentOfManagementNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTEtOS0xLTEtMA_4d34886f-fbee-468b-9db5-8a8edb509356">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="bios:RepaymentOfManagementNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTEtMTUtMS0xLTA_c063f774-304f-4ea5-b010-a223192c51be">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders' redemptions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58814d8f92d24190888892748720a464_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="bios:AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTItNy0xLTEtMA_a0b93cf1-6e6e-4302-b7ab-b752831c11ff">2,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadfb96c7240b4bf2bc10824cee106ac1_D20190101-20191231" decimals="-3" sign="-" name="bios:AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTItOS0xLTEtMA_e35756d9-61a5-4f7a-8da0-9ffdf864fe32">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="bios:AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTItMTUtMS0xLTA_c514df7e-a9a0-466c-ac6d-696efb6f0949">2,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based incentive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58814d8f92d24190888892748720a464_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTItNy0xLTEtMjkyMw_c3395f32-3b70-4de3-8181-3235f6480163">4,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTItMTUtMS0xLTI5MzY_d613f447-cfb3-4a5c-9139-9d77e1dc46dc">4,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options, vesting of restricted stock, and related tax withholdings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06325eb29ded4dda8dad34622c87bed3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="bios:StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTMtNS0xLTEtMjkyMw_1773d919-14b0-4cc0-939f-6cc647bc9c20">2,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58814d8f92d24190888892748720a464_D20190101-20191231" decimals="-3" name="bios:StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTMtNy0xLTEtMjkyMw_23d66d2e-328b-40df-8760-09b9cb8862aa">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="bios:StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTMtMTUtMS0xLTI5MzY_95c6a8fd-ed89-4484-94c5-ea9b63d23f02">2,501</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0217dbc311b4109a34f7a05e30c523d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtMTEtMS0xLTI5MjM_ad2c7824-0a59-41d9-8cb8-63e80e54aad5">75,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtMTUtMS0xLTI5MzY_fa7a2560-ade3-43ee-a2ce-97e3053e3845">75,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc4c4a7abaf64793a8cca9faa42d501d_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTMtMTMtMS0xLTA_420a9128-1eb5-4d4f-8735-04787b53a658">8,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTMtMTUtMS0xLTA_bbf3aec6-6bab-4856-aac9-3ab65098e674">8,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance - December 31, 2019</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61291993f8a54aecbb68907a9140b3d1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtMS0xLTEtMA_20cd2459-29b7-402f-a071-25fe9ff34800">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6342b5959154862925fe574bb199b16_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtMy0xLTEtMA_d3ea0819-b6b9-4a98-a34e-d7cfaa7786b4">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6648a71bd04469e8bd6b625f8e26ce2_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtNS0xLTEtMA_160c87eb-175b-4976-8487-4586ad2635a9">2,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07bbcf8ebdcc452490830f429f1ef4ed_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtNy0xLTEtMA_71b3e5cc-9308-4a08-bc19-f6dc22dea90d">1,008,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4967cf0ba59b4694a935eb9c0d502a5d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtOS0xLTEtMA_6d1a4383-962d-41d7-81d2-58cf31511dcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1960cd3413c4497a8cb7b8ba588bf2b3_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtMTEtMS0xLTA_ff75f4b4-6666-4be3-8cf7-a4bb5b6bb0a2">91,955</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30b362b8cb0f4fa291d203acfe67091d_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtMTMtMS0xLTA_06985d47-0d5d-49e3-9b44-87d3cbff4f6a">7,195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtMTUtMS0xLTA_5f874cc2-5bdc-4eed-8c2b-eb5bba287651">906,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based incentive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83ec2897c370475281d08a6233255f4d_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTUtNy0xLTEtMA_d02d99c9-454d-467f-82a0-5643e06d07f8">2,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTUtMTUtMS0xLTA_7482e9e2-4155-4489-bf8e-8dc2ae8541c6">2,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options, vesting of restricted stock, and related tax withholdings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83ec2897c370475281d08a6233255f4d_D20200101-20201231" decimals="-3" name="bios:StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTYtNy0xLTEtMA_42c8c9e1-6b04-4cee-8bd2-56a874b55a09">904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" name="bios:StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTYtMTUtMS0xLTA_c884b0fb-a72b-4c82-8f1b-79477d3cae64">904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net proceeds from the  issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48648d60adf4dfda6254c20ebbb4a83_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTctMy0xLTEtMA_ec2b46d8-657b-4b14-9740-7aa9cf861313">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83ec2897c370475281d08a6233255f4d_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTctNy0xLTEtMA_cb30c84c-5ae5-41ad-9917-dc98d2b1fe12">118,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTctMTUtMS0xLTA_294b86f0-5a23-4fc8-8074-598c30a923a8">118,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancellation of common stock - see Note 16</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib48648d60adf4dfda6254c20ebbb4a83_D20200101-20201231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjEtMy0xLTEtMA_9aa9fd93-df1b-4cb7-a8fc-936c08cf3f54">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83ec2897c370475281d08a6233255f4d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjEtNy0xLTEtMA_875bcc67-ec90-48a7-a1c1-ba14af639705">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjEtMTUtMS0xLTA_c911ea72-968b-4f34-b9c4-4e4abf23b01d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65faadc1ce524e7297267901419cec15_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjEtMTEtMS0xLTU2NjY_d26e6f2a-c458-4f6b-8cd7-21b66691b77f">8,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjEtMTUtMS0xLTU2NzI_03f4697d-d5f3-4fbc-b6de-9c7f148653be">8,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70d31c15efcd4ad091a5d18b9108dc8e_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjItMTMtMS0xLTA_3b558298-87e5-4b02-b722-be18a0c9834a">3,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjItMTUtMS0xLTA_8c364953-e32c-403b-b389-172c204dadf2">3,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance - December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a81bc38266c4980843d89e190c3d8fe_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjMtMS0xLTEtMA_485456be-7dc9-42b3-9bb0-1814d80ffe27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7fd52d93044460ac7028d03c0b79f7_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjMtMy0xLTEtMA_48337ac1-8e98-4ee7-8c0a-a3ce6bf8fadc">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacd1399421844f9795aff5870a8f8063_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjMtNS0xLTEtMA_4054577a-8423-4d3a-9721-42829887e09e">2,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8587ff958a4c948e809015b40868e8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjMtNy0xLTEtMA_2a521e91-0dcb-4578-b9f2-fe388f925593">1,129,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if42702eefc1b4929ba571e14ece46dce_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjMtOS0xLTEtMA_bf0ae208-68ca-4e3d-984c-943577622765">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i510f7fb44d8047fe951f7d247dbdd5a0_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjMtMTEtMS0xLTA_41be216c-795b-4b47-a9c9-4d5396cee554">100,031</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8178b1fbc0284245938041d60d5a050b_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjMtMTMtMS0xLTA_4c0d2bb9-5fc6-481f-acb7-6ea03e85c897">11,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjMtMTUtMS0xLTA_0179e279-5143-44a0-9191-0d3b71f77c33">1,015,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The notes to consolidated financial statements are an integral part of these statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTION CARE HEALTH, INC.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_97"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfNDMzMA_446e536e-f353-4600-897e-861dce626851" continuedAt="i75ce39ede10c4cb78c406e9f228d0838" escape="true">NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS</ix:nonNumeric></span></div><ix:continuation id="i75ce39ede10c4cb78c406e9f228d0838"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Organization and Business </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; HC Group Holdings II, Inc. (&#8220;HC II&#8221;) was incorporated under the laws of the State of Delaware on January 7, 2015, with its sole shareholder being HC Group Holdings I, LLC. (&#8220;HC I&#8221;). On April 7, 2015, HC I and HC II collectively acquired Walgreens Infusion Services, Inc. and its subsidiaries from Walgreen Co., and the business was rebranded as Option Care (&#8220;Option Care&#8221;).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2019, HC I and HC II entered into a definitive agreement (the &#8220;Merger Agreement&#8221;) to merge with and into a wholly-owned subsidiary of BioScrip, Inc. (&#8220;BioScrip&#8221;), a national provider of infusion and home care management solutions, along with certain other subsidiaries of BioScrip and HC II. The merger contemplated by the Merger Agreement (the &#8220;Merger&#8221;) was completed on August 6, 2019 (the &#8220;Merger Date&#8221;). The Merger was accounted for as a reverse merger under the acquisition method of accounting for business combinations with Option Care being considered the accounting acquirer and BioScrip being considered the legal acquirer.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Merger Agreement, shares of HC II common stock issued and outstanding immediately prior to the Merger Date were converted into <ix:nonFraction unitRef="shares" contextRef="i368d5fdb13b94d2c99546a5791f3e988_D20190806-20190806" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMTI5MA_9210634b-122d-40e6-8bb8-462a6d865b1b">135,565,392</ix:nonFraction> shares of BioScrip common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ia2ea7ddad6aa46c5900f0df09030bb8e_I20190806" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMTQ1MA_ff82edb0-5bc5-46e8-8c16-3b46dda123e4">0.0001</ix:nonFraction> (the &#8220;BioScrip common stock&#8221;). BioScrip also issued an additional <ix:nonFraction unitRef="shares" contextRef="i368d5fdb13b94d2c99546a5791f3e988_D20190806-20190806" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMTUzMA_f832fa6b-0ec0-4334-b0d1-6547bf0c0c98">7,048,357</ix:nonFraction> shares to HC I in respect of certain outstanding unvested contingent restricted stock units of BioScrip, which were set aside to prevent dilution related to potential additional vesting on certain share-based instruments. See Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional discussion of these shares set aside. In conjunction with the Merger, holders of BioScrip preferred shares and certain warrants received <ix:nonFraction unitRef="shares" contextRef="i1a95667076af42cc8fbcf3661b5bbacb_D20190806-20190806" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMjAyOQ_aeda6254-8565-4686-b3df-e7d24700b485">864,603</ix:nonFraction> additional shares of BioScrip common stock and preferred shares were repurchased for $<ix:nonFraction unitRef="usd" contextRef="i1860c3f1464545dd964c4595d8b8b205_D20190806-20190806" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMjE2Mg_ed0a52f2-28be-4bc8-9854-aa7741f51045">125.8</ix:nonFraction> million of cash. In addition, all legacy BioScrip debt was settled for $<ix:nonFraction unitRef="usd" contextRef="i4c72c8c6a63c487d89bfa93db278f761_I20190806" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMjIyOA_be3614a9-083c-4f84-b3b1-42f5c0b8bd3e">575.0</ix:nonFraction> million. As a result of the Merger, BioScrip&#8217;s stockholders held approximately <ix:nonFraction unitRef="number" contextRef="ia2ea7ddad6aa46c5900f0df09030bb8e_I20190806" decimals="3" name="bios:BusinessCombinationOwnershipInterestRetained" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMjMwMg_02fa8aca-d75e-4b7d-8774-26bc376a6e31">19.2</ix:nonFraction>% of the combined company, and HC I held approximately <ix:nonFraction unitRef="number" contextRef="i119e1c16609d4ae2a8c7779f88a837f0_I20190806" decimals="3" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMjM1OQ_6f0dd718-9ee7-409c-99e2-6d12fc7de128">80.8</ix:nonFraction>% of the combined company. Following the close of the transaction, BioScrip was rebranded as Option Care Health, Inc. (&#8220;Option Care Health&#8221;, or the &#8220;Company&#8221;). The combined company&#8217;s stock was listed on the Nasdaq Global Select Market as of December&#160;31, 2020. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Merger.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of <ix:nonFraction unitRef="location" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="0" name="bios:NumberOfServiceLocations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfNTQ5NzU1ODE0MzkwNw_1b83c8ed-0e53-437b-a384-6d1e39886724">99</ix:nonFraction> full service pharmacies and <ix:nonFraction unitRef="site" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="INF" name="bios:NumberOfInfusionSites" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfNTQ5NzU1ODE0Mzk2OA_4e209edb-9b1d-471d-a9f2-6d5f94296162">46</ix:nonFraction> stand-alone ambulatory infusion sites. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients&#8217; homes or other nonhospital settings. The Company operates in one segment, infusion services.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfNDM0MA_fd9f66d1-0477-4ac4-a5da-788f4622b374" continuedAt="ia06c814bd34e47b49d319f6f33bbcb7c" escape="true">Basis of Presentation </ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia06c814bd34e47b49d319f6f33bbcb7c">&#8212;  The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States.</ix:continuation> These principals require management to make certain estimates and assumptions in determining assets, liabilities, revenue, expenses, and related disclosures. Actual amounts could differ materially from those estimates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfNDMzNA_df1725d8-2133-43f2-8bc1-7e02b9ac33b6" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. The BioScrip results have been included in the consolidated financial results since the Merger Date. All intercompany transactions and balances are eliminated in consolidation.</span></ix:nonNumeric></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has investments in companies that are <ix:nonFraction unitRef="number" contextRef="i53e06ff77c484235837649f43bbe2b5d_I20201231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMzk2NQ_09929988-b36f-4ce9-9161-9edb7a9f8b38">50</ix:nonFraction>% owned and are accounted for as equity-method investments. The Company&#8217;s share of earnings from equity-method investments is included in the line entitled &#8220;Equity in earnings of joint ventures&#8221; in the consolidated statements of comprehensive income (loss). See &#8220;Equity-Method Investments&#8221; within Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Company&#8217;s equity-method investments.</span></div></ix:continuation><div id="ic913b68a604e4ff38c42375d3fa7a17b_100"></div><div style="margin-bottom:10pt;margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 2. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTYw_cd6a5954-01b0-4f69-a005-1c39cf94c14b" continuedAt="ib670803879ca45aa97c849f3e9182107" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="ib670803879ca45aa97c849f3e9182107" continuedAt="i482519a00eb342a998d28799f0630bd0"><div style="margin-bottom:10pt;text-indent:18pt"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTU2_d86dc900-d8ae-4e95-8bd2-f7ec447e3163" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.</span></ix:nonNumeric></div><div style="margin-bottom:10pt;text-indent:18pt"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTU3_feb0339f-b199-4c12-9573-01674ec87158" continuedAt="i76db186d91c94a04a93b7269b528b960" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s accounts receivable is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services, which is inclusive of adjustments for price concessions. The majority of accounts receivable are due from private insurance carriers and governmental health care programs, such as Medicare and Medicaid.</span></ix:nonNumeric></div><div style="margin-bottom:1pt;text-indent:18pt"><ix:continuation id="i76db186d91c94a04a93b7269b528b960" continuedAt="i593026a72d324640b17ad152d8db7a57"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Price concessions may result from patient hardships, patient uncollectible accounts sent to collection agencies, lack of recovery due to not receiving prior authorization, differing interpretations of covered therapies in payer contracts, different pricing methodologies, or various other reasons. In accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i593026a72d324640b17ad152d8db7a57"> (&#8220;ASC 606&#8221;), an allowance for doubtful accounts is established only as a result of an adverse change in the Company&#8217;s payers&#8217; ability to pay outstanding billings.</ix:continuation> The allowance for doubtful accounts balance is $<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzEyODc_ccfa2a8d-cfb8-43b3-90d4-398985511813"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzEyODc_d2858a82-796e-4abc-bc18-43352c8dbaa7">0</ix:nonFraction></ix:nonFraction> as of December&#160;31, 2020 and 2019, respectively. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in accounts receivable are earned but unbilled gross receivables of $<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnbilledReceivablesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzIyMDM_4810a6d2-b3e6-4c19-8b33-4e03beda4776">79.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnbilledReceivablesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzIyMTA_5e0e1dbf-3649-43cc-8637-259f6340fb3f">68.7</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively. Delays ranging from one day up to several weeks between the date of service and billing can occur due to delays in obtaining certain required payer-specific documentation from internal and external sources.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a further discussion of the Company&#8217;s revenue recognition policy.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTU4_501d4bbd-5768-47f8-a831-4dca045cc743" continuedAt="i1f05b6ad03da4fb08525d4a1325fb45c" escape="true">Inventory </ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1f05b6ad03da4fb08525d4a1325fb45c">&#8212; Inventory, which consists primarily of pharmaceuticals, is stated at the lower of first&#8209;in, first&#8209;out cost or net realizable value basis, which the Company believes is reflective of the physical flow of inventories.</ix:continuation> </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2018, one Company location was destroyed by a hurricane, resulting in a loss of $<ix:nonFraction unitRef="usd" contextRef="i086f47aad02f4c3598246e2234bcfcb9_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI4NzQ_167a2081-2e78-40b6-8d49-1302da34c7a2">2.9</ix:nonFraction> million of inventory. This business casualty loss was recorded as a component of operating costs and expenses within the consolidated statements of comprehensive income (loss). The Company received insurance proceeds of $<ix:nonFraction unitRef="usd" contextRef="i086f47aad02f4c3598246e2234bcfcb9_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzMwODk_50e11a6c-0b2c-4134-994d-59020a4bbc10">0.8</ix:nonFraction> million during the year ended December&#160;31, 2018, and recorded a receivable of $<ix:nonFraction unitRef="usd" contextRef="i7eb197b8c371412db224c1301352b49f_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InsuranceSettlementsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzMxMzk_af93c8cc-6056-4cad-9c43-a37716cee9bb">1.0</ix:nonFraction> million. Both of these amounts were recorded as a partial offset to the business casualty loss in the consolidated statements of comprehensive income (loss). The $<ix:nonFraction unitRef="usd" contextRef="i086f47aad02f4c3598246e2234bcfcb9_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzM0MDE_50e11a6c-0b2c-4134-994d-59020a4bbc10">0.8</ix:nonFraction> million of insurance proceeds were reflected as a component of cash flows from operating activities in the consolidated statements of cash flows. During the year ended December&#160;31, 2019, $<ix:nonFraction unitRef="usd" contextRef="i9fc719df4b5d4d1f874963db8ef3704c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzM1NTc_6c89e5c4-9d47-4ed8-9742-aa54bba98aa7">3.0</ix:nonFraction> million in proceeds were received related to recovery of inventory and business interruption and was included as a component of cash flows from operating activities in the consolidated statements of cash flows. These proceeds resulted in a gain on business casualty loss of $<ix:nonFraction unitRef="usd" contextRef="i9fc719df4b5d4d1f874963db8ef3704c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzM4MjY_08d46fee-abef-4fef-94e1-5644a5c11552">2.0</ix:nonFraction> million recorded as a component of selling, general and administrative expense in the consolidated statement of comprehensive income (loss).</span></div><div style="margin-bottom:1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Prepaid expenses and other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212; Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODYwMTE_7555c415-e6d8-4f09-a4d4-b47f8a60a7e1">35.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODYwMjc_264ef5b2-187e-4cd4-9cc6-1d35ab40b0fb">13.9</ix:nonFraction> million for the years ended December&#160;31, 2020 and 2019, respectively. There were no other items included in prepaid expenses and other current assets that comprised 5% or more of the balance.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><ix:continuation id="i482519a00eb342a998d28799f0630bd0" continuedAt="id0da8eef419d490992e4701206429198"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTQ3_38e4ea95-aeae-418c-8377-eab3a33c5741" continuedAt="ic577c1e96c074cae81a62b6c3302a4e2" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company has lease agreements for facilities, warehouses, office space and property and equipment. Effective as of January 1, 2019, at the inception of a contract, the Company determines if the contract is a lease or contains an embedded lease arrangement. Operating leases are included in the operating lease right-of-use asset (&#8220;ROU asset&#8221;) and operating lease liabilities in the consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, which represent the Company&#8217;s right to use the leased assets, and operating lease liabilities, which represent the present value of unpaid lease payments, are both recognized by the Company at the lease commencement date. The Company utilizes its estimated incremental borrowing rate at the lease commencement date to determine the present value of unpaid lease obligations. The&#160;rates&#160;are&#160;estimated primarily&#160;using a methodology dependent&#160;on the&#160;Company&#8217;s financial&#160;condition, creditworthiness, and availability&#160;of certain observable data. In particular, the Company considers its actual cost of borrowing for collateralized loans and its credit rating, along with the corporate bond yield curve in estimating its incremental borrowing rates. ROU assets are recorded as the amount of operating lease liability, adjusted for prepayments, accrued lease payments, initial direct costs, lease incentives, and impairment of the ROU asset. Tenant improvement allowances used to fund leasehold improvements are recognized when earned and reduce the related ROU asset. Tenant improvement allowances are recognized through the ROU asset as a reduction of expense over the term of the lease.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases may contain rent escalations, however the Company recognizes the lease expense on a straight-line basis over the expected lease term. The Company reviews the terms of any lease renewal options to determine if it is reasonably certain that the renewal options will be exercised. The Company has determined that the expected lease term is typically the minimum non-cancelable period of the lease.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic577c1e96c074cae81a62b6c3302a4e2">The Company has lease agreements that contain both lease and non-lease components which the Company has elected to account for as a single lease component for all asset classes. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the term of the lease. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.</ix:continuation> See Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of leases.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTQ4_9309fb40-1119-4959-a8fe-aaaa48834b5c" continuedAt="ic9ba50fe38a64ae294ea53091fb980a9" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill, Intangible Assets, and Property and Equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company accounts for goodwill under ASC Topic&#160;350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests goodwill for impairment annually, or more frequently whenever events or circumstances indicate impairment may exist. Goodwill is stated at cost less accumulated impairment losses. The Company completes its goodwill impairment test annually in the fourth quarter. See Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Company&#8217;s goodwill and other intangible assets.</span></ix:nonNumeric></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic9ba50fe38a64ae294ea53091fb980a9">Intangible assets arising from the Company&#8217;s acquisitions are amortized on a straight&#8209;line basis over the estimated useful life of each asset. Referral sources have a useful life of <ix:nonNumeric contextRef="i48a8600720a94bbf87db1dbe3e875b03_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzczNjc_e5efb1eb-9cda-4d2d-bfbc-17a4c3d8dc8e">15</ix:nonNumeric>-<ix:nonNumeric contextRef="i2d430ba49f0c4e89b1371f12b3bbf397_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzczNzA_ec6d00a9-d7ed-481d-a166-565c8fdce84c">20</ix:nonNumeric> years. Trademarks/names have a useful life ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc0Mjk_9e7f6967-ecc8-4667-930f-df6f18fbc07d">two</span> to <ix:nonNumeric contextRef="if76a9379d5a5462faea6e4911c09e610_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc0MzU_7e890b84-de6c-4190-b413-f54e3e17a309">fifteen years</ix:nonNumeric>. The useful lives for other amortizable intangible assets range from approximately <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc1Mjc_c3c88249-a6e5-407f-ae8b-52445dccabe5">two</span> to <ix:nonNumeric contextRef="i6ad7ffbd4bbb4311af7b6cd327201826_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc1MzM_88f9687a-55cb-485b-89db-57748edd57b9">nine years</ix:nonNumeric>.</ix:continuation> The Company does not have any indefinite&#8209;lived intangible assets.</span></div><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTQx_b828d084-d601-448d-87af-1f3abd7b2679" escape="true"><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation on owned property and equipment is provided for on a straight&#8209;line basis over the estimated useful lives of owned assets. Leasehold improvements are amortized over the estimated useful life of the property or over the term of the lease, whichever is shorter. Estimated useful lives are <ix:nonNumeric contextRef="i2bff063b20b44971b7a869047927c0a9_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc5ODU_9f4fff8c-8421-45cf-8448-0e3c867b7393">seven years</ix:nonNumeric> for infusion pumps and <ix:nonNumeric contextRef="if9646cc5252f40eabde3fb89431c23a5_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzgwMTc_97b813a4-5736-4b15-b650-574563f14968">three years</ix:nonNumeric> to <ix:nonNumeric contextRef="ie12e4e114a18499d9effec6a2ee61dbe_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzgwMjk_a9bd67b7-f19a-4257-9303-0768fae1a7e8">thirteen years</ix:nonNumeric> for equipment. Major repairs, which extend the useful life of an asset, are capitalized in the property and equipment accounts. Routine maintenance and repairs are expensed as incurred. Computer software is included in property and equipment and consists of purchased software and internally-developed software. The Company capitalizes application-stage development costs for significant internally-developed software projects. Once the software is ready for its intended use, these costs are amortized on a straight&#8209;line basis over the software&#8217;s estimated useful life, generally <ix:nonNumeric contextRef="i3a9ad7e932754e6bbc1e427751b3bf94_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzg2MTk_edbf49c3-1fb1-416f-9eb0-d7b752c4c516">five years</ix:nonNumeric>. Costs recognized in the preliminary project phase and the post-implementation phase, as well as maintenance and training costs, are expensed as incurred.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests long&#8209;lived assets for impairment whenever events or circumstances indicate that a certain asset or asset group may be impaired. Once identified, the amount of the impairment is computed by comparing the carrying value of the respective asset or asset group to its fair value, which is based on the discounted estimated future cash flows.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:10pt;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><ix:continuation id="id0da8eef419d490992e4701206429198" continuedAt="i5bf2184ebfd844b7a69ceeb9c4c9b4de"><div style="margin-bottom:10pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTU5_53d3d48c-1740-4f3f-94e4-4f75119ffeea" continuedAt="i050f4209205d4fc68e5fb6a5e89494db" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Method Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying consolidated balance sheets. As of December&#160;31, 2020 and 2019, the balance of the investments was $<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODQ0ODQ_fd0b26fe-d7a4-4d8a-b07e-47cdc2796f34">17.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODIxMDU_ea8c2805-fcfa-4cda-9ad2-9859c3f9e482">17.0</ix:nonFraction>&#160;million, respectively. The investments are increased to reflect the Company&#8217;s capital contributions and equity in earnings of the investees. The investments are decreased to reflect the Company&#8217;s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company&#8217;s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying consolidated statements of comprehensive income (loss). The Company&#8217;s proportionate share of earnings was $<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODIzMDQ_dba7b68d-81e5-41e8-895d-57f51626ef8b">3.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODIzMDk_733a54f9-b2d9-4dee-91c1-7c15e0d3edf0">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODIzMjI_6d07684a-f6e8-4dfb-8de3-11d97dcb0234">1.0</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Distributions from the investees are treated as cash inflows from operating activities in the consolidated statements of cash flows. During the years ended December&#160;31, 2020, 2019 and 2018, the Company received distributions from the investees of $<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODIyMzY_15bcf672-3350-47f9-a682-f76710fb8954">3.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODIyNDU_599d2f1b-a09d-4bc9-ada4-d753bc8eda26">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODIyNzc_590b1ec5-f4c0-4719-821e-f2df6a7e0792">2.0</ix:nonFraction>&#160;million, respectively. See Footnote 17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i050f4209205d4fc68e5fb6a5e89494db">, for discussion of related-party transactions with these investees.</ix:continuation> </span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzMyOTg1MzQ5MzI2NzY_daf7703e-9b03-46c5-a1ec-59ba97aa1ac8" continuedAt="i478ea727eb55454aa9fccf0e3df57965" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hedging Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company uses derivative financial instruments to limit its exposure to increases in the interest rate of its variable rate debt instruments. The derivative financial instruments are recognized on the consolidated balance sheets at fair value. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></ix:nonNumeric></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i478ea727eb55454aa9fccf0e3df57965">At inception of the hedge, the Company designated the derivative instruments as a hedge of the cash flows related to the interest on the variable rate debt. For all instruments designated as hedges, the Company documents the hedging relationships and its risk management objective of the hedging relationship. For all hedging instruments, the terms of the hedge perfectly offset the hedged expected cash flows.</ix:continuation> </span></div><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTQy_f43be403-f0f9-483f-8e24-cb9f4e735896" continuedAt="i439032fefc8843eea751597733b576ac" escape="true"><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Net revenue is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services. Revenues are from government payers, commercial payers, and patients for goods and services provided and are based on a gross price based on payer contracts, fee schedules, or other arrangements less any implicit price concessions.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the health care industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. </span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the expected consideration to be received at the time of patient acceptance based on the verification of the patient&#8217;s insurance coverage, historical information with the patient, similar patients, or the payer. Performance obligations are determined based on the nature of the services provided by the Company. The majority of the Company&#8217;s performance obligations are to provide infusion services to deliver medicine, nutrients, or fluids directly into the body. </span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a variety of infusion-related therapies to patients, which frequently include multiple deliverables of pharmaceutical drugs and related nursing services. After applying the criteria from ASC 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third-party payer contracts. Pharmaceutical drug revenue is recognized at the time the pharmaceutical drug is delivered to the patient, and nursing revenue is recognized on the date of service. </span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i439032fefc8843eea751597733b576ac">The Company's outstanding performance obligations relate to contracts with a duration of less than one year. Therefore, the Company has elected to apply the practical expedient provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. Any unsatisfied or partially unsatisfied performance obligations at the end of a reporting period are generally completed prior to the patient being discharged.</ix:continuation> See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a further discussion of revenue.</span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><ix:continuation id="i5bf2184ebfd844b7a69ceeb9c4c9b4de" continuedAt="ib9ad363eb71a42cb9c0d7c46ddb91bd6"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTQz_1cba042f-0b3c-4f3d-a299-aeb50fef6e44" escape="true"><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Cost of revenue consists of the actual cost of pharmaceuticals and other medical supplies dispensed to patients, as well as all other costs directly related to the production of revenue. These costs include warehousing costs, purchasing costs, freight costs, cash discounts, wages and related costs for pharmacists and nurses, along with depreciation expense relating to revenue-generating assets, such as infusion pumps.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives prompt payment discounts from some of its pharmaceutical and medical supplies vendors. These prompt payment discounts are recorded as a reduction of inventory and are accounted for as a reduction of cost of goods sold when the related inventory is sold.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also receives rebates from pharmaceutical and medical supply manufacturers. Rebates are generally volume-based incentives and are recorded as a reduction of inventory and are accounted for as a reduction of cost of goods sold when the related inventory is sold.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTYx_aa48b9f6-bdc7-467f-bd4e-b3bdb4abaea0" continuedAt="ie587ff7f59d74b09982a7eb50054d344" escape="true">Selling, General and Administrative Expenses </ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie587ff7f59d74b09982a7eb50054d344">&#8212; Selling, general and administrative expenses mainly consist of salaries for administrative employees that directly and indirectly support the operations, occupancy costs, marketing expenditures, insurance, and professional fees.</ix:continuation> </span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTQ5_25564597-1868-43a7-9288-9eee148f201f" continuedAt="if6fc74af14614037b1476d892cbddb38" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Based Incentive Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -  The Company accounts for stock-based incentive compensation expense in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 718&#8221;). Stock-based incentive compensation expense is based on the grant date fair value. The Company estimates the fair value of stock option awards using a Black-Scholes option pricing model and the fair value of restricted stock unit awards using the closing price of the Company&#8217;s common stock on the grant date. For awards with a service-based vesting condition, the Company recognizes expense on a straight-line basis over the service period of the award. For awards with performance-based vesting conditions, the Company will recognize expense when it is probable that the performance-based conditions will be met. When the Company determines that it is probable that the performance-based conditions will be met, a cumulative catch-up of expense will be recorded as if the award had been vesting on a straight-line basis from the award date. The award will continue to be expensed on a straight-line basis through the remainder of the vesting period and will be updated if the Company determines that there has been a change in the probability of achieving the performance-based conditions. The Company records the impact of forfeited awards in the period in which the forfeiture occurs. </span></ix:nonNumeric></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if6fc74af14614037b1476d892cbddb38">Prior to the Merger, HCI issued incentive units to certain employees of Option Care, who remained employees of the Company following the Merger. In accordance with ASC 718, the Company recognizes compensation expense on a straight-line basis over the shorter of the vesting period of the award or the employee&#8217;s expected eligibility date. HC I also issued equity incentive units to certain members of the Option Care Board of Directors, who remained members of the Board of Directors following the Merger.</ix:continuation> See Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Incentive Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a further discussion of equity incentive plans.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTUw_329f7436-7920-468f-a618-addb28acdae9" continuedAt="i25887d166286458ea71aac69b38f3131" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -  The Company accounts for business acquisitions in accordance with ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i25887d166286458ea71aac69b38f3131">, with assets and liabilities being recorded at their acquisition date fair value and goodwill being calculated as the purchase price in excess of the net identifiable assets</ix:continuation>. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Company&#8217;s business acquisitions.</span></div><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTUx_f7457d93-f93e-4fdc-97ba-cecaab52aeb2" continuedAt="i82135b576c674c9697041983791db12c" escape="true"><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are reported for book-tax basis differences and are measured based on currently enacted tax laws using rates expected to apply to taxable income in the years in which the differences are expected to reverse. The effect of a change in tax rate on deferred taxes is recognized in income tax expense in the period that includes the enactment date of the change. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized. </span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i82135b576c674c9697041983791db12c">The Company recognizes income tax positions that are more likely than not to be sustained on their technical merits. The Company measures recognized income tax positions at the maximum benefit that is more likely than not, based on cumulative probability, realizable upon final settlement of the position. Interest and penalties related to unrecognized tax benefits are reported in income tax expense.</ix:continuation> </span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><ix:continuation id="ib9ad363eb71a42cb9c0d7c46ddb91bd6"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="bios:ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTUy_437222fb-bcd5-4ad7-8d4e-732c73b892ae" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Business Risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company&#8217;s largest payer was approximately <ix:nonFraction unitRef="number" contextRef="i158605824c6c423d867ee0566aa0ca47_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzE5MjE2_4f2453f8-4c7d-4f3a-85c4-cc262042948e">15</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i484daecca47b416e99281851405afa48_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzE5MjIw_264b751b-c640-4df9-905c-9970c245f1d6">16</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3503095cd1c346c3968c0a9058c5e025_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzE5MjI3_575010f1-010c-4454-809e-140e8d923d57">17</ix:nonFraction>% for the years ended December&#160;31, 2020, 2019 and 2018, respectively. In December 2019, the Company renewed and expanded its multi-year contract with this payer. The contract renewal was effective in February 2020 for a <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" format="ixt-sec:durwordsen" name="bios:BusinessCombinationRenewalTermLength" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzMyOTg1MzQ5MzI3Mzg_25dda4aa-a590-430a-9d34-d96cc6e3028b">two-year</ix:nonNumeric> term and auto-renews at the end of that term. There were no other managed care contracts that represent greater than 10% of revenue for the years presented.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the years ended December&#160;31, 2020, 2019 and 2018, approximately <ix:nonFraction unitRef="number" contextRef="i90930859b5a244fd919dfe2f357f7c23_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzE5NjI2_360a353b-a791-4b7c-9f9a-51984e36d29f">15</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ib2f3781893ae44f498e20de51cd69b29_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzE5NjMw_f0419f48-1ee9-4b9c-891b-ae3f9816b5cc">12</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0026d0842d3a4359a1692dd699b20cad_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzE5NjM3_7f67911c-e516-4fcc-b42d-207b33d49076">12</ix:nonFraction>%, respectively, of the Company&#8217;s revenue was reimbursable through direct government healthcare programs such as Medicare and Medicaid. As of December&#160;31, 2020 and 2019, approximately <ix:nonFraction unitRef="number" contextRef="i6527aad98d3a47a69d34f668ffe88a0a_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzE5ODA1_d8a09e5e-1b4b-4d82-b88e-cc7e048d481f">15</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if236b13a6b0a4994a585e5cf622ca3f3_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzE5ODEy_cdc4b76e-708e-4523-b668-d01b29287ff8">12</ix:nonFraction>%, respectively, of the Company&#8217;s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not require its patients nor other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentrations of credit risk relating to trade accounts receivable is limited due to the Company&#8217;s diversity of patients and payers. Further, the Company generally does not provide charity care.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020 and 2019, approximately <ix:nonFraction unitRef="number" contextRef="i464c8f864f8d49899ce600f0ac27fe32_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzIwNjI2_ed343167-a9da-40bb-aef5-d38a79c32216">70</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7851f95217d9442598cc88ba1ed517d1_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODIxODk_d0c2a849-48ed-4b4f-9ebc-2cfa054dffa9">70</ix:nonFraction>%, respectively, of the Company&#8217;s pharmaceutical and medical supply purchases were from three vendors. For the year ended December&#160;31, 2018, approximately  <ix:nonFraction unitRef="number" contextRef="i6edfcb49cb0b4b1e8a63a9955b1aaab1_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzIwNzU4_0254a3a2-1c6e-4c9c-be3b-c29c64361d4e">66</ix:nonFraction>% of the Company&#8217;s pharmaceutical and medical supply purchases were from two vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company&#8217;s financial condition or operating results. Although there is uncertainty regarding the COVID-19 pandemic, as of December&#160;31, 2020 the Company has been able to maintain adequate levels of supplies and pharmaceuticals to support its operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTYy_d68b203c-168a-4fc1-8ff4-d371d701eb9f" continuedAt="ifd48ba5046b34e7bb2565b79cedcd7e4" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The fair value measurement accounting standard, ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), provides a framework for measuring fair value and defines fair value as the price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The standard establishes a valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on independent market data sources. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available. The valuation hierarchy is composed of three categories. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The categories within the valuation hierarchy are described as follows: </span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:10pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Inputs to the fair value measurement are unobservable inputs or valuation techniques.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:18pt"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTU1_38c076c0-0d3b-490c-bbae-4530c71c7fa0" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently-Adopted Accounting Pronouncements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;  In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires measurement and recognition of expected credit losses for financial assets held. The amendments in ASU 2016-13 eliminate the probable threshold for initial recognition of a credit loss in current GAAP and reflect an entity&#8217;s current estimate of all expected credit losses. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019 and is to be applied using a modified retrospective transition method. The Company adopted the standard as of January 1, 2020. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</span></ix:nonNumeric></div></ix:continuation><div id="ic913b68a604e4ff38c42375d3fa7a17b_106"></div><div style="margin-bottom:10pt;margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzY5Mzg_3786a352-a718-460b-a157-3714ff7a7f04" continuedAt="ic356e25a36bb4d399399b1500064baae" escape="true">BUSINESS ACQUISITIONS</ix:nonNumeric></span></div><ix:continuation id="ic356e25a36bb4d399399b1500064baae" continuedAt="iea93c64ad68c4841a2000d836d1c44ca"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Merger with BioScrip, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; As discussed in Note&#160;1,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature of Operations and Presentation of Financial Statements,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option Care&#160;merged with BioScrip&#160;on August 6, 2019.&#160;BioScrip&#160;was a national provider of infusion and home care management solutions.&#160;The Merger of Option Care and BioScrip into Option Care Health created an expanded national platform and the opportunity to drive economies of scale through procurement savings, facility rationalization and other operating cost savings.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of purchase consideration transferred on the closing date includes the value of the number of shares of the combined company owned by BioScrip shareholders at closing of the Merger, the value of common shares issued to certain warrant and preferred shareholders in conjunction with the Merger, the fair value of stock-based instruments that were vested or earned as of the Merger, and cash payments made in conjunction with the Merger. The fair value per share of BioScrip&#8217;s common stock was $<ix:nonFraction unitRef="usdPerShare" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzEwMjM_8d6779f1-c62c-4583-87f8-12237b2e89ce">2.67</ix:nonFraction> per share. This is the closing price of the BioScrip common stock on August&#160;6, 2019.</span></div><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzY5Mzk_aa9fde8f-7dc3-4c04-a872-2cd001177f08" continuedAt="i42023f0cf01e4314991317f0721479a6" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, the calculation of total consideration exchanged is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of BioScrip common shares outstanding at time of the Merger (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f090775b2c24e07909f7019308c4cc6_I20190805" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzEtMi0xLTEtMA_da434ea9-5967-4828-9f2b-19c6432f81a8">129,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares issued to warrant and preferred stockholders at time of the Merger (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzItMi0xLTEtMA_0548ae4c-9b34-423f-9ef7-e05a56d5bf65">3,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total shares of BioScrip common stock outstanding at time of the Merger (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzMtMi0xLTEtMA_3b26fccc-61e3-43cf-8d5f-f887a45068ea">132,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BioScrip share price as of August 6, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzQtMi0xLTEtMA_8d6779f1-c62c-4583-87f8-12237b2e89ce">2.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzUtMi0xLTEtMA_f4ba14cc-8c17-49cd-8f0e-7401c6b04a0d">354,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of share-based instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzYtMi0xLTEtMA_cd0e8ab8-efa7-4174-9026-3e2ef3b1f09f">32,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid in conjunction with the Merger included in purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzctMi0xLTEtMA_33ad09b9-6390-42dd-b12a-a7aa7e630819">714,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzgtMi0xLTEtMA_9446a300-5bea-446d-a73f-0746633f03b1">1,102,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: cash acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAcquiredFromAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzktMi0xLTEtMA_eea4b0c3-9b3e-4498-b5b3-54d0d7cd0a9a">14,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of total consideration acquired, net of cash acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzEwLTItMS0xLTA_d8b4e86f-4387-46dd-9796-d6c36475b90c">1,087,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i42023f0cf01e4314991317f0721479a6">(1) These shares were not adjusted for the one share for four share reverse stock split, which occurred on February 3, 2020.</ix:continuation> </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid in conjunction with the Merger includes payments made for settlement of $<ix:nonFraction unitRef="usd" contextRef="i96e2bd7b43e2425892cf80e8dee1fa59_D20190806-20190806" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzE1MTk_96a4dca9-a09e-48c6-bdba-bc5f68b16cb4">575.0</ix:nonFraction> million in legacy BioScrip debt, $<ix:nonFraction unitRef="usd" contextRef="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzE1NDc_221dc7f5-cb06-4c13-b5be-fec0afa00c9a">125.8</ix:nonFraction> million in existing BioScrip preferred shares, and $<ix:nonFraction unitRef="usd" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzE1OTM_0f58ae09-15c4-4412-b670-a557bbba40ba">14.1</ix:nonFraction> million in legacy BioScrip success-based fees owed to third-party advisors. HC II financed these payments primarily through cash on hand and debt financing, which is discussed in Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><ix:continuation id="iea93c64ad68c4841a2000d836d1c44ca" continuedAt="id1a87c07914e49c68d179762a955d8a7"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzY5NDA_954e4654-fc6c-4a59-a9fc-805cc04b4259" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s allocation of consideration exchanged to the net tangible and intangible assets acquired and liabilities assumed, net of cash acquired, in the Merger is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.807%"><tr><td style="width:1.0%"></td><td style="width:22.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzEtNC0xLTEtMA_88d68d27-fa2a-40c7-acbe-c40cab28219f">96,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzItNC0xLTEtMA_3bd90066-8fd3-46e1-b95f-21c67614b337">19,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzMtNC0xLTEtMA_963ce80a-ae9c-49cd-ae45-5f9bc703684f">48,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net (4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzQtNC0xLTEtMA_2cd094d3-fc61-4c14-aa1c-3bd26af26ed1">193,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net of deferred tax liabilities (5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzUtNC0xLTEtMA_1448c7f0-a7af-4d3d-826e-be9a4d05597c">26,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset (6)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="-3" format="ixt:numdotdecimal" name="bios:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzYtNC0xLTEtMA_7245f837-ad98-4579-b594-6fbd4b714798">22,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liability (6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzctNC0xLTEtMA_1f382d22-041e-4804-9356-fe1b5717832e">28,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable  (7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzgtNC0xLTEtMA_c771ebf3-21a0-4390-946e-9a4b7e31f2a9">66,668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assumed liabilities, net of other acquired assets (7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzktNC0xLTEtMA_c469b43d-a1fd-4634-b134-7746895c222a">20,663</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total acquired identifiable assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzEwLTQtMS0xLTA_a0b2f1a6-c14a-47d1-991f-6115d1aa647a">291,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzExLTQtMS0xLTA_4f99af42-ff77-44f9-a670-a1de2549361a">796,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzEyLTQtMS0xLTA_906bcbd4-0baf-4901-a596-b25701625f8d">1,087,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Management has valued accounts receivables based on the estimated future collectability of the receivables portfolio.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Inventories are stated at fair value as of the Merger Date.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The fair value of the property and equipment was determined based upon the best and highest use of the property with final values determined based upon an analysis of the cost, sales comparison, and income capitalization approaches for each property appraised.</span></div><div style="margin-bottom:10pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzY5NDE_29302317-484d-4b31-aef0-d16305e78d44" continuedAt="i2266d1cd5c4b4330ae787a65078ee8fe" escape="true">The allocation of consideration exchanged to intangible assets acquired is as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i2266d1cd5c4b4330ae787a65078ee8fe"><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.771%"><tr><td style="width:1.0%"></td><td style="width:53.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.672%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.672%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Estimated Life (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks/Names</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7a44592cb4a40fcbd91c004c84b7ef6_I20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTphODFiYzc3MDM4M2M0YmJjODY1ZTFlNDgxM2E5OWFjYi90YWJsZXJhbmdlOmE4MWJjNzcwMzgzYzRiYmM4NjVlMWU0ODEzYTk5YWNiXzEtMi0xLTEtMA_40c3f8de-c341-46fb-b322-74569c5ba7ac">12,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0eab475192224276bc1b5ceb023d5037_D20190806-20190806" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTphODFiYzc3MDM4M2M0YmJjODY1ZTFlNDgxM2E5OWFjYi90YWJsZXJhbmdlOmE4MWJjNzcwMzgzYzRiYmM4NjVlMWU0ODEzYTk5YWNiXzEtNC0xLTEtMA_80b901e0-2bd0-4be6-bc4d-a2631836ff57">2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient referral sources</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida7f446eea274d038568171224dfb7f8_I20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTphODFiYzc3MDM4M2M0YmJjODY1ZTFlNDgxM2E5OWFjYi90YWJsZXJhbmdlOmE4MWJjNzcwMzgzYzRiYmM4NjVlMWU0ODEzYTk5YWNiXzItMi0xLTEtMA_2bbc840d-9de9-46ad-821b-b40d98fc4ef4">180,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8355aa59ded14d9c91a83db76fedede8_D20190806-20190806" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTphODFiYzc3MDM4M2M0YmJjODY1ZTFlNDgxM2E5OWFjYi90YWJsZXJhbmdlOmE4MWJjNzcwMzgzYzRiYmM4NjVlMWU0ODEzYTk5YWNiXzItNC0xLTEtMA_a13ba7ee-33d8-4cfd-b456-21cb7522c656">20</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e8a900d790f44dabb629a7f9c87c6db_I20190806" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTphODFiYzc3MDM4M2M0YmJjODY1ZTFlNDgxM2E5OWFjYi90YWJsZXJhbmdlOmE4MWJjNzcwMzgzYzRiYmM4NjVlMWU0ODEzYTk5YWNiXzMtMi0xLTEtMA_98337d67-549a-4d72-898d-ef3f20f8e241">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icf29203bfe714c69b132146d9352ba77_D20190806-20190806" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTphODFiYzc3MDM4M2M0YmJjODY1ZTFlNDgxM2E5OWFjYi90YWJsZXJhbmdlOmE4MWJjNzcwMzgzYzRiYmM4NjVlMWU0ODEzYTk5YWNiXzMtNC0xLTEtMA_f320d5c6-ce19-4ff6-9e08-d8d623714c9c">1.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTphODFiYzc3MDM4M2M0YmJjODY1ZTFlNDgxM2E5OWFjYi90YWJsZXJhbmdlOmE4MWJjNzcwMzgzYzRiYmM4NjVlMWU0ODEzYTk5YWNiXzQtMi0xLTEtMA_7a090db7-2beb-48fa-af58-53260e0ca423">193,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTphODFiYzc3MDM4M2M0YmJjODY1ZTFlNDgxM2E5OWFjYi90YWJsZXJhbmdlOmE4MWJjNzcwMzgzYzRiYmM4NjVlMWU0ODEzYTk5YWNiXzQtNC0xLTEtMA_272ca92d-2450-412c-ad97-2b9faf90d57c">18.8</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company valued trademarks/names utilizing the relief of royalty method and patient referral sources utilizing the multi-period excess earnings method, a form of the income approach.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net deferred tax&#160;assets&#160;represented the expected future tax consequences of temporary differences between the fair values of the assets acquired and liabilities assumed and their tax bases. See Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional discussion of the Company&#8217;s combined income tax position subsequent to the Merger.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The fair value of the operating lease liability and corresponding right-of-use asset (current and long-term) was based on current market rates available to the&#160;Company.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Accounts payable as well as certain other current and non-current assets and liabilities are stated at fair value as of the&#160;Merger Date. </span></div><div style="margin-bottom:10pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The&#160;Merger resulted in&#160;$<ix:nonFraction unitRef="usd" contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzM5MDc_acc8af7d-86a5-4768-b21c-8ccd6988696c">796.1</ix:nonFraction> million of goodwill, which is attributable to cost synergies resulting from procurement and operational efficiencies and elimination of duplicative administrative costs. The goodwill created in the Merger&#160;is not expected to be deductible for tax purposes.</span></div></ix:continuation></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><ix:continuation id="id1a87c07914e49c68d179762a955d8a7"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzY5NDI_1c387ee1-8a2d-42d5-834a-b714aa89293a" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming BioScrip had been acquired as of January 1, 2018, and the results of BioScrip had been included in operations beginning on January 1, 2018, the following tables provide estimated unaudited pro forma results of operations for the&#160;years ended December&#160;31, 2019 and 2018 (in thousands). The estimated pro forma net income adjusts for the effect of fair value adjustments related to the Merger, transaction costs and other non-recurring costs directly attributable to the Merger and the impact of the additional debt to finance the Merger. </span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:64.912%"><tr><td style="width:1.0%"></td><td style="width:45.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceee29a996a54c498d570461cc70c139_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTo3YzBmMTBjM2UzYjk0ZmYxOWQ3MDk5YzZhNjNmOWJkZi90YWJsZXJhbmdlOjdjMGYxMGMzZTNiOTRmZjE5ZDcwOTljNmE2M2Y5YmRmXzItMi0xLTEtMA_13db4ed6-e125-4d52-ae18-a09d526267c4">2,755,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fbf8d8eaeb1483aa65584975ad1895d_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTo3YzBmMTBjM2UzYjk0ZmYxOWQ3MDk5YzZhNjNmOWJkZi90YWJsZXJhbmdlOjdjMGYxMGMzZTNiOTRmZjE5ZDcwOTljNmE2M2Y5YmRmXzItNC0xLTEtMA_15f3f086-cde7-474e-8d22-3b7bac919ce5">2,648,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iceee29a996a54c498d570461cc70c139_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTo3YzBmMTBjM2UzYjk0ZmYxOWQ3MDk5YzZhNjNmOWJkZi90YWJsZXJhbmdlOjdjMGYxMGMzZTNiOTRmZjE5ZDcwOTljNmE2M2Y5YmRmXzMtMi0xLTEtMA_766cfb94-12f4-4626-8543-f024eab82449">49,566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fbf8d8eaeb1483aa65584975ad1895d_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTo3YzBmMTBjM2UzYjk0ZmYxOWQ3MDk5YzZhNjNmOWJkZi90YWJsZXJhbmdlOjdjMGYxMGMzZTNiOTRmZjE5ZDcwOTljNmE2M2Y5YmRmXzMtNC0xLTEtMA_185afd96-76c7-474c-80a5-9ffa9097822a">70,932</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated unaudited pro forma information is not necessarily indicative of the results that actually would have occurred had the&#160;Merger&#160;been completed on the date indicated or the future operating results.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods subsequent to the&#160;Merger Date&#160;that are included in the results of operations for the year ended December&#160;31, 2019, BioScrip had net revenue of&#160;$<ix:nonFraction unitRef="usd" contextRef="iceee29a996a54c498d570461cc70c139_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzUwMjY_e81a7dd7-4ced-4323-926f-22c923bc0a5a">308.9</ix:nonFraction> million&#160;and a net loss of&#160;$<ix:nonFraction unitRef="usd" contextRef="iceee29a996a54c498d570461cc70c139_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzUwNDc_831f0cd9-5e79-4c35-bfc1-3447c7aa11ee">30.1</ix:nonFraction> million.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related costs were expensed as incurred, with the exception of BioScrip success-based fees that are included in consideration transferred. The Company recorded transaction costs that are expensed in selling, general and administrative expenses during the year ended December&#160;31, 2019 of approximately $<ix:nonFraction unitRef="usd" contextRef="iceee29a996a54c498d570461cc70c139_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForMergerRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzUzMzg_e7307d12-9600-450e-a78e-f317c43544ea">25.8</ix:nonFraction> million. Transaction expenses consisted of professional fees for advisory, consulting and underwriting services as well as other incremental costs directly related to the acquisition.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Baptist Health Asset Acquisition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;  In August 2018, pursuant to the Purchase and Sale Agreement dated August 8, 2018, Option Care completed the acquisition of certain assets of Baptist Health in Little Rock, Arkansas for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i05bb7e7e8c7a426695f64056c9f39f0e_D20180808-20180808" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzU3NTg_2097db6e-a8ba-49cf-87a0-4c9ee24b85f9">1.0</ix:nonFraction> million.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Home I.V. Specialists, Inc. Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; In September 2018, pursuant to the Stock Purchase Agreement dated September 18, 2018, Option Care completed the acquisition of <ix:nonFraction unitRef="number" contextRef="id730cf15243f442bbd04361989c01f84_I20180918" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzU5MzE_9f434bf9-219d-4e6e-b6bb-04e07e251373">100</ix:nonFraction>% of the outstanding shares of Home I.V. Specialists, Inc. (&#8220;Home I.V.&#8221;) for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i8b6760c7c28a4a18988a26e4abe977de_D20180918-20180918" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzYwMjk_15e16399-0f8f-4676-8882-31d38e871d4d">11.6</ix:nonFraction> million, net of cash acquired. The total consideration was comprised of cash paid of $<ix:nonFraction unitRef="usd" contextRef="i8b6760c7c28a4a18988a26e4abe977de_D20180918-20180918" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzYxMDk_2eda246e-0aca-4899-8874-ec5295157fde">9.8</ix:nonFraction> million and a contingent payment of $<ix:nonFraction unitRef="usd" contextRef="i8b6760c7c28a4a18988a26e4abe977de_D20180918-20180918" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzYxNDA_bb1845cd-137e-463e-9a0c-735c9b1df926">1.8</ix:nonFraction> million payable one year after the acquisition date. During the year ended December&#160;31, 2019, the Company reduced the contingent liability by $<ix:nonFraction unitRef="usd" contextRef="ib2bd7b4025e94630bcabed85e8c697ea_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="bios:BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzYyNTE_4bc961fa-0b41-4696-a992-c41bec86bfcb">0.3</ix:nonFraction> million. During the year ended December&#160;31, 2020, the Company determined that the contingent payment was not payable and reduced the remaining contingent liability by $<ix:nonFraction unitRef="usd" contextRef="ibd5c46c0f3284d40848b80f8fbcc8415_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="bios:BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzU0OTc1NTgxNDg2MzI_1265b033-bed2-4b8d-a6df-c61c79a8a4bb">1.5</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="ic913b68a604e4ff38c42375d3fa7a17b_112"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90ZXh0cmVnaW9uOjg4NWE4YjdkODAwNDQyZDE5OTQ0NzgxNTdkZTRhNDdhXzE1MzE_91172847-3385-457a-8967-acb9f5dcefee" continuedAt="i68193e8e085745f8b3b456a0c9661df2" escape="true">REVENUE </ix:nonNumeric></span></div><div style="text-indent:18pt"><span><br/></span></div><ix:continuation id="i68193e8e085745f8b3b456a0c9661df2"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90ZXh0cmVnaW9uOjg4NWE4YjdkODAwNDQyZDE5OTQ0NzgxNTdkZTRhNDdhXzE1MzY_f39ee42f-5683-4d98-8f02-eabd18340c08" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the net revenue earned by category of payer for the&#160;years ended December&#160;31, 2020, 2019 and 2018 (in thousands): </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:54.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial payers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba4469ba333d4f7dbcf906562ff59670_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzItMi0xLTEtMA_571a52f1-fdf1-48bc-bae7-970ea0c4b6a5">2,542,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b9dd506f11d4d1ebc70f70232a583f7_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzItNC0xLTEtMA_61dfcdb5-92da-4854-9205-7b331e2807e8">2,001,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a18e871b4144c43920f2fdc837570dd_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzItNi0xLTEtMA_d39f223b-0334-4273-88de-491c220930ee">1,699,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i511cdc2e39494cd4a860f9e7863bcf07_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzMtMi0xLTEtMA_0ecf7ffe-0863-4515-b1cd-a7a26c77b967">450,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic52f5f00fdae408788e5edb2d3115ade_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzMtNC0xLTEtMA_b7b81b09-f48f-42ca-9437-b0a379481538">285,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcb18262ac0749ab80774f8e983c5642_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzMtNi0xLTEtMA_768e44e8-e4ae-4eb0-a691-3d4c1b28257e">217,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedfd2fd8cf84679ad22ff62c6589c11_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzQtMi0xLTEtMA_dd9db3b7-35ec-42f6-bc7f-dac19855bb83">39,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bebf74e986b4a3fb16e367620def213_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzQtNC0xLTEtMA_65790d1f-231e-4c74-b9a5-f01444fde828">24,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia18fe7d576a24a3d959b4a7ade77e1ee_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzQtNi0xLTEtMA_5c0cc65d-b9e4-4911-a366-718665e50b60">22,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzUtMi0xLTEtMA_763b2b6d-d4c1-4f66-8ac6-3632cb58eefe">3,032,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzUtNC0xLTEtMA_516746e8-39fe-410b-a2e6-75f79369c646">2,310,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzUtNi0xLTEtMA_00b653ca-b498-4f70-929f-722be4562f86">1,939,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ic913b68a604e4ff38c42375d3fa7a17b_115"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzM1NQ_aecfdbfb-45bb-4de8-885c-df780dc72c69" continuedAt="i5fec696024f84bf78a849a01de0e26cd" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5fec696024f84bf78a849a01de0e26cd">The Company maintains a 401(k) plan and matches <ix:nonFraction unitRef="number" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzgw_2f9655c9-87d5-4aef-9161-71db7a623429">100</ix:nonFraction>% of employee contributions, up to <ix:nonFraction unitRef="number" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzExNg_0394ab98-9850-49af-9590-a81400886e20">4</ix:nonFraction>% of employee compensation. The Company recorded expense for the defined contribution plan of $<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzIxMQ_afb461e5-7224-42ba-a35d-646bc5626186">9.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzIxNQ_231d872c-e620-4ace-8b00-a6f7245521dc">6.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzIyMg_81cf3b7e-3fee-4908-852b-1a3f2ea53512">6.3</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. In the years ended December&#160;31, 2020, 2019 and 2018, Company contributions of $<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzMxNQ_07cabaae-58e8-411d-b13f-31482b10041d">8.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzMxOQ_3df75da3-0ca4-4c3c-bcea-88b6333516ec">6.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzMyNg_261dd24e-54ec-4999-b95d-57a417aad1b4">6.3</ix:nonFraction> million, respectively, were paid.</ix:continuation> </span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_118"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzI5MDU_8dfd4651-e708-4e43-81e3-01f0155bc981" continuedAt="ic87440244fed443ea432691edf8dc72e" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="ic87440244fed443ea432691edf8dc72e" continuedAt="iab745cddc6934233afe897875c6dd587"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzI5MDk_98ddff55-b7cf-44f6-9960-635ce3d15f06" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense (benefit) consists of the following for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.356%"><tr><td style="width:1.0%"></td><td style="width:54.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.764%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.013%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.764%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.013%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US federal income tax expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzItMS0xLTEtMA_041c8ff7-8383-4ae5-a4a9-c9f7fa97466f">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzItMy0xLTEtMA_bd436abf-dfd2-4a8c-858a-244fa8485d0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzItNS0xLTEtMA_87325cc2-431c-46b1-917d-1170742901c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzMtMS0xLTEtMA_feb3411c-ff73-4cdf-acdb-629ea387e037">996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzMtMy0xLTEtMA_c958eb0f-d20f-42e3-8dea-0aca0aae02ff">3,072</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzMtNS0xLTEtMA_51574d89-55cd-4fe9-87f0-dfffd0c64b7d">2,688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzQtMS0xLTEtMA_512d0b98-8e6c-4349-99f6-2313281ed7c9">927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzQtMy0xLTEtMA_71be44e6-24ed-4bdb-8926-649af2998e3a">3,072</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzQtNS0xLTEtMA_9785c264-48df-4bf1-802c-1b807a38e387">2,688</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzYtMS0xLTEtMA_d4c25217-9974-4ac9-9194-b9f946a9787b">1,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzYtMy0xLTEtMA_b6e81954-11ef-4038-ab6c-b6d2956be8fd">2,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzYtNS0xLTEtMA_0b90520f-2bf3-4ab5-b336-be0dc639d8f5">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzctMS0xLTEtMA_7b4bf53a-70af-4910-b62e-e347fed81415">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzctMy0xLTEtMA_ab0af676-dadc-4287-8fb2-5e492ffc0739">1,276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzctNS0xLTEtMA_5e9dc5d5-0123-48ff-979d-26b12121b3e8">1,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzgtMS0xLTEtMA_fec5d416-b0e9-4906-aed6-2544f12919ed">1,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzgtMy0xLTEtMA_f6807a08-a46a-40d9-839c-255279b80797">798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzgtNS0xLTEtMA_8232c271-8a3c-427f-b1ba-a49e1f8bfc42">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzktMS0xLTEtMA_18150cad-170d-4df6-ae97-660601b2590a">2,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzktMy0xLTEtMA_c917d69a-e784-4505-9225-00003ea9204f">2,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzktNS0xLTEtMA_b2fdd8b5-179d-4554-a1b4-c29632398051">2,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzI5MDI_75d5d4d7-f21a-4519-a400-f000c3182ccd" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the statutory federal income tax rate and the effective tax rate is as follows for the years ended December&#160;31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.356%"><tr><td style="width:1.0%"></td><td style="width:54.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.764%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.013%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.764%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.013%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzEtMS0xLTEtMA_6283a8a9-c2ae-4f60-be9d-c69178a07ce4">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzEtMy0xLTEtMA_a6e70055-bfee-466a-815d-bfbbd92d615b">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzEtNS0xLTEtMA_1242c446-134c-426a-803a-86e28b2a6860">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local income taxes net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzMtMS0xLTEtMA_3026b455-71d9-4498-8158-b85f189cd44d">29.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzMtMy0xLTEtMA_50488022-c5e2-4c9e-bb90-2c4b93c7026b">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzMtNS0xLTEtMA_c91da5c2-534a-4694-9a23-0d721e5c56d8">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzQtMS0xLTEtMA_dfbcc7a9-2a1f-43d1-b2e0-94978708ded4">29.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzQtMy0xLTEtMA_56c61e38-f1eb-43bc-b158-a0d07ccfaf9e">13.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzQtNS0xLTEtMA_ebd5e136-c23b-4d3a-867d-0905e529d423">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzQtMS0xLTEtNjU2NA_e09b0d49-aee7-4068-90bd-7da91054691c">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzQtMy0xLTEtNjU2NA_133da906-7dd6-4d4c-a2ae-164ddd440a84">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzQtNS0xLTEtNjU2NA_303c26fe-7ec5-41d8-bb90-ff5c8a52716c">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzUtMS0xLTEtNjU2NA_36e0332d-6665-44d4-976d-c7aa9740dcce">16.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzUtMy0xLTEtNjU2NA_7cc62a63-64d3-408b-a0e9-2c2729064ff5">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzUtNS0xLTEtNjU2NA_1e8c0778-3ae3-493c-9d9e-16f9f4845ee8">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="3" name="bios:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzUtMS0xLTEtMA_3923ba9f-eb3b-49b0-98a1-d123263f2e9d">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="3" name="bios:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzUtMy0xLTEtMA_d88dba19-43e1-4615-b05f-008a72c3dc14">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="3" name="bios:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzUtNS0xLTEtMA_30ccefe8-e9d9-4500-9ec8-7170dc04db64">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzYtMS0xLTEtMA_24064fb8-3790-48a5-a17a-41db051c7f5a">8.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzYtMy0xLTEtMA_8c914e8e-1f93-4c50-a778-e639393dc8cb">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzYtNS0xLTEtMA_cf77b2d1-b092-4439-b1c3-e7d3b13f7418">7.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzctMS0xLTEtMA_57c2ac9d-d68f-4b62-8f72-46763458b00b">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzctMy0xLTEtMA_caba43a5-9fa3-4f74-95b7-920f301be921">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzctNS0xLTEtMA_41f96798-762a-426c-bbd4-07b594b48684">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzgtMS0xLTEtMA_507e826b-5766-433b-9ae7-e8806252dbdc">54.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzgtMy0xLTEtMA_dfc0d2d0-1893-497c-bad9-13a547a07409">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzgtNS0xLTEtMA_c26bfa95-24e7-4b01-9d75-8e54c7aa0f48">30.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><ix:continuation id="iab745cddc6934233afe897875c6dd587" continuedAt="ib8788d863dbc4046af71802fac50086c"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzI5MDM_77a69a51-b6de-4903-8b04-6af4572d5b00" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred income tax assets and liabilities using the 21% U.S. Federal statutory tax rate were as follows as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.608%"><tr><td style="width:1.0%"></td><td style="width:67.029%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.169%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Price concessions</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="bios:DeferredTaxAssetsBadDebtReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzItMS0xLTEtMA_c14c339d-410d-4b69-b749-7c005bde4ac5">6,907</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="bios:DeferredTaxAssetsBadDebtReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzItMy0xLTEtMA_ebc52ca8-bfcd-40d7-8aca-bfa625c95d19">12,302</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzMtMS0xLTEtMA_40397b3d-d58e-422a-9189-866385ce767e">4,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzMtMy0xLTEtMA_171513a9-d682-42be-9b92-2677ab49fefa">3,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest limitation carryforward</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetInterestCarryforward" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzQtMS0xLTEtMA_c43c599b-3c4f-4eee-9f78-1d30c77f8226">39,094</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetInterestCarryforward" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzQtMy0xLTEtMA_b6401999-5809-4a25-a397-455b0f0166ff">38,623</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="bios:DeferredTaxAssetsLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzUtMS0xLTEtMA_f9a0f914-27fe-4fbf-a8c8-8d1fdad03c6d">22,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="bios:DeferredTaxAssetsLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzUtMy0xLTEtMA_686faa9b-bff5-460b-b7f3-3789e262abfe">19,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzYtMS0xLTEtMA_edab8338-b45b-4b52-b1a7-1ed78d969207">155,922</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzYtMy0xLTEtMA_7ea6ca18-c49f-4a3a-8022-6d9c21460433">147,749</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzctMS0xLTEtMA_972f077c-b82d-423f-8afb-21cd08b2e294">8,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzctMy0xLTEtMA_8fae3174-fa36-4f0c-a693-7479e26c9693">5,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzgtMS0xLTEtMA_2aeaa728-9e0e-4359-a08f-39aaea072942">237,307</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzgtMy0xLTEtMA_b26d8132-f489-4d40-8224-fa8b065478ee">227,314</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzktMS0xLTEtMA_e229691f-9918-4ad3-a084-a7fbb563f7b3">112,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzktMy0xLTEtMA_bd5e4140-0703-4fe5-adc3-2be62194da30">109,531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets net of valuation allowance</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzEwLTEtMS0xLTA_e75ea20b-d776-475d-8625-7504dff9f83b">125,222</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzEwLTMtMS0xLTA_860c61f0-6586-4f35-91ee-4bbd4fd1e26c">117,783</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="bios:DeferredTaxLiabilitiesAcceleratedDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzEzLTEtMS0xLTA_3ad03628-709d-4ee3-9a9c-cb6ba67d0619">12,593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="bios:DeferredTaxLiabilitiesAcceleratedDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzEzLTMtMS0xLTA_c7f415ae-3b96-4178-bff4-eaf532d3afdd">10,376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="bios:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE0LTEtMS0xLTA_87ba78d8-693c-4d0c-a654-debcc3dda82b">17,186</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="bios:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE0LTMtMS0xLTA_d7c31306-3a20-4427-960f-af1d659d45ef">15,442</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE1LTEtMS0xLTA_b4100a96-4ead-4b76-8c1a-75b326c52604">67,127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE1LTMtMS0xLTA_aaed192d-f3fa-4f82-aff2-70153eb09204">71,204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE2LTEtMS0xLTA_4ec218e3-c962-47a2-828a-7bb78f79f847">28,976</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE2LTMtMS0xLTA_dc3a731c-3167-4bac-95dd-0e1469b978ff">20,250</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE3LTEtMS0xLTA_e05891fa-2bd0-481c-8972-7235f26eed8a">2,679</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE3LTMtMS0xLTA_b282d425-9560-4d18-b54e-b4a89b14ace2">2,654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE4LTEtMS0xLTA_2ab928f7-4d0b-4644-b228-a8cbdd12e466">128,561</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE4LTMtMS0xLTA_c4974449-e38d-46b4-843e-c171e96dd5d5">119,926</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE5LTEtMS0xLTA_f80f2641-9321-480b-bdab-3b0f919d26f6">3,339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE5LTMtMS0xLTA_548fa508-e856-49f8-8381-04df0e1a161b">2,143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Merger, the Company recorded a full valuation allowance against all of its net U.S. federal and state deferred tax assets except for certain state net operating losses (&#8220;NOL&#8221;) which were estimated to be $<ix:nonFraction unitRef="usd" contextRef="i280e53dfa7f14ec79d051ef96fd2eb67_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzU2Mw_e1a01644-6453-4549-b2c2-c644cf7554da">0.4</ix:nonFraction> million as of December&#160;31, 2020. The initial recognition of this valuation allowance by the Company was reflected in the opening balance sheet of BioScrip and, to that extent, did not impact the Company&#8217;s tax expense (benefit) for the years ended December&#160;31, 2020 and 2019. The valuation allowance for deferred tax assets as of December&#160;31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzg5Mw_5565f39b-6d0a-4b8c-8f95-730c4370da12">112.1</ix:nonFraction> million.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. The Company considers the scheduled reversal of deferred tax liabilities (including the effect in available carryback and carryforward periods), projected taxable income, and tax-planning strategies in making this assessment. On a quarterly basis, the Company evaluates the positive and negative evidence in determining if the valuation allowance is fairly stated. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is subject to taxation in the United States and various states. As a result of the Merger, BioScrip carried over $<ix:nonFraction unitRef="usd" contextRef="ifee0c9a38e2f4f44872874da3bcaf823_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzE3Mzk_af740474-bd38-4560-8255-cce566c79b78">458.9</ix:nonFraction> million of federal net operating losses, $<ix:nonFraction unitRef="usd" contextRef="i9dabb20864b5445da36520a3109bba91_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzE3NzU_cb3896ac-e8e5-4898-9f4d-bcec4ebecc90">479.6</ix:nonFraction> million of state net operating losses, and $<ix:nonFraction unitRef="usd" contextRef="i280e53dfa7f14ec79d051ef96fd2eb67_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetInterestCarryforward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzE4MTM_186c7517-5d9e-409a-afff-f29f0c1f5c5e">85.0</ix:nonFraction> million of interest limitation carryforwards. At December&#160;31, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="ifee0c9a38e2f4f44872874da3bcaf823_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzE4Nzc_6ff9f8e6-0056-4a90-a07f-7ea34d28a1e3">577.9</ix:nonFraction> million of gross federal NOL carryforwards of which $<ix:nonFraction unitRef="usd" contextRef="ifd78dc026a994a25a4f56b834ce3acf0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzE5MjQ_e73c9606-0507-4b47-b249-e653bf72cd45">438.1</ix:nonFraction> million are available to offset future taxable income in the United States. These NOL&#8217;s will begin to expire in 2026 if not utilized. The remaining gross federal NOL&#8217;s of $<ix:nonFraction unitRef="usd" contextRef="i0615275335554e94b35841a1370fe6bd_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzIwOTA_a812d608-2ce3-48e1-9f81-499873ef0fa2">139.8</ix:nonFraction> million at December&#160;31, 2020 are expected to expire unutilized due to limitations under Internal Revenue Code Section 382. At December&#160;31, 2019, the Company had $<ix:nonFraction unitRef="usd" contextRef="iacbc724b23f14da8a2fcb2d0d2bbb77f_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzIyMTY_48f6842d-ac7b-443e-b350-4bfc21bbe039">548.0</ix:nonFraction> million of gross federal NOL&#8217;s. At December&#160;31, 2020 and 2019, the Company had $<ix:nonFraction unitRef="usd" contextRef="ib9602bc3ce024fae8e231c5a4c022557_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetInterestCarryforward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzIyNzM_4ef78c70-230d-4aa4-809a-f6deb46300cf">154.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id8d455c8b67347889e5acbbbe86eb799_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetInterestCarryforward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzIyODA_ef27e8d5-ae28-4ba8-9fb6-e084ce492db9">145.6</ix:nonFraction> million of interest limitation carryforwards. At December&#160;31, 2020 and 2019, the Company also had $<ix:nonFraction unitRef="usd" contextRef="i3d46ec2aaebb419db2fc4d41c2c5a93d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzIzNTY_25ee7216-6cc6-46b3-ae78-4721900e2223">600.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifaf8d37ccf224f66a6484b8ac7d64519_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzIzNjM_30a649fa-0642-4281-8c81-70a3f9400f09">578.5</ix:nonFraction> million of cumulative gross state NOL carryforwards available to offset future taxable income in various states. These state NOL&#8217;s will begin to expire starting in 2021 if not utilized.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, the unrecognized tax benefits for uncertain tax positions was $<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzI1NDg_19ee7480-ae03-4bd3-a13a-04026c17d9df"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzI1NDg_8190f871-08ca-4038-9364-e0dcb5b510c6">0</ix:nonFraction></ix:nonFraction>. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><ix:continuation id="ib8788d863dbc4046af71802fac50086c"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzI5MTA_e83acd2d-d748-4e2a-aa45-2dcdb3deb5f3" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the valuation allowance for deferred tax assets for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:42.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charged (Benefit) to Costs and Expenses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charged to Other Accounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at End Period</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2018: Valuation allowance for deferred tax assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40c908a9b2de45bcab117c93611972e9_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzMtMS0xLTEtMA_4a7cfaab-cbd9-44c8-8e67-ef709de5047b">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0ef9b611e047a885c26ca5f6249fad_D20180101-20181231" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzMtMy0xLTEtMA_81f6977a-c20c-490c-a546-78e5045fd6cf">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied56fb2881f649038e93ac0e7055d693_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzMtNS0xLTEtMA_12062175-3e6a-492f-a663-9d14566fa2f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i757f7525fd514729825051239d54094e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzMtNy0xLTEtMA_780daa0f-a2b6-4ee0-a0e8-9d846adb6c02">1,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019: Valuation allowance for deferred tax assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i757f7525fd514729825051239d54094e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzUtMS0xLTEtMA_48954fca-6da0-41c6-9900-4deefc57b424">1,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66543252b74f4364a367c91ae3431b87_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzUtMy0xLTEtMA_12fdd567-c0da-4e1a-bec5-bccbd2dfd22e">15,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbd22998422e476a94384ec9ca9af121_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzUtNS0xLTEtMA_921cfc85-2651-4687-9a77-cd86ec2141fd">92,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzUtNy0xLTEtMA_7bd8cd7d-a8fe-4295-b16e-e2b8aa06047c">109,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020: Valuation allowance for deferred tax assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzctMS0xLTEtMA_35411e2f-7566-41f5-b895-8ffa75702a23">109,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5195060bc61421e96d7fc5e6a7b58ec_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzctMy0xLTEtMA_7b5d8bc3-786a-4582-80b1-81e916f55960">1,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b7bf1c254348648f33112353badc89_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzctNS0xLTEtMA_149b716a-b2d7-4c62-820a-79c8e8ce328b">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzctNy0xLTEtMA_deb9aa74-80f4-45df-9644-0d31ef142885">112,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, the Company is not subject to any U.S. Federal income tax audits. The Company is subject to various state tax audits, and believes that the outcome of these audits will not have a material impact on the Company.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded <ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="bios:IncomeTaxExpenseBenefitCARESAct" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzMyOTg1MzQ4OTMwMDI_9fdb8ff6-27b4-4a37-b459-2bfe759c6684">no</ix:nonFraction> income tax expense or benefit for the year ended December&#160;31, 2020 associated with the tax provisions of the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;). However, certain adjustments were made to the Company&#8217;s components of deferred tax assets and liabilities to reflect the tax provisions of the CARES Act. These adjustments were the result of the CARES Act&#8217;s tax provisions associated with interest expense limitations and bonus depreciation on leasehold improvements. These adjustments to the Company&#8217;s components of deferred tax assets and liabilities were offset by one another or the Company&#8217;s valuation allowance.</span></div></ix:continuation><div id="ic913b68a604e4ff38c42375d3fa7a17b_124"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzE2MTU_0697591f-664b-4f8b-8b2f-a9b01f74c907" continuedAt="ie1c8b9a6763e4a75ac71ca23924dcaa6" escape="true">(LOSS) EARNINGS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="ie1c8b9a6763e4a75ac71ca23924dcaa6"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents basic and diluted (loss) earnings per share for its common stock. Basic (loss) earnings per share is calculated by dividing the net (loss) income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted (loss) earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all dilutive potential common shares.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the&#160;Merger, all historical per share data and number of shares and equity awards were retroactively adjusted. The (loss) earnings is used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. Accordingly, the computation of diluted shares for the years ended December&#160;31, 2020 and 2019 excludes the effect of shares that would be issued in connection with warrants, stock options and restricted stock awards, as their inclusion would be anti-dilutive to the loss per share. As of December&#160;31, 2020 there were <ix:nonFraction unitRef="shares" contextRef="icea968011f094587b49f49e976287324_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzU0OTc1NTgxNDEyMDQ_6bf6906d-a0e1-4302-9cac-3ea23835888a">2,285,784</ix:nonFraction> warrants, <ix:nonFraction unitRef="shares" contextRef="ic9887caa100349b3a4635013ba8aa601_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzU0OTc1NTgxNDExNzI_ed44a870-7525-45d7-a021-77d7d3d7e325">412,831</ix:nonFraction> stock options and <ix:nonFraction unitRef="shares" contextRef="i325067265d5c4ed789bfde38719b21ed_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzU0OTc1NTgxNDExODI_d56e0c1b-36b2-4489-be80-631a5860efdb">549,650</ix:nonFraction> restricted stock awards outstanding that were excluded from the calculation as they would be anti-dilutive. As of December&#160;31, 2019 there were <ix:nonFraction unitRef="shares" contextRef="i986fbe9ede1e4f4bae9e708842b5ac55_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzU0OTc1NTgxNDExMjY_ff98aa07-cee3-4b5f-8122-5a2a94549671">2,328,120</ix:nonFraction> warrants, <ix:nonFraction unitRef="shares" contextRef="ie31db4918e8647d0bd750eeab70451ed_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzU0OTc1NTgxNDExMzY_2059c048-72a0-458d-8105-f143f082b23c">644,975</ix:nonFraction> stock options and <ix:nonFraction unitRef="shares" contextRef="i5756cc875db64a44922ff59197c0da6e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzU0OTc1NTgxNDExNDY_fa0e449d-61fc-456c-87e3-cc7a49d1796c">231,562</ix:nonFraction> restricted stock awards outstanding that were excluded from the calculation as they were anti-dilutive. There were <ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DilutiveSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzExODc_9ba40272-0d6b-436b-a7d0-e4c1e4fad4e2">no</ix:nonFraction> dilutive potential common shares for the years ended December&#160;31, 2018.</span></div><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzE2MTk_0819a29a-22bc-4b72-889c-13225417d960" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s basic and diluted (loss) earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.941%"><tr><td style="width:1.0%"></td><td style="width:57.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzMtMS0xLTEtMA_e4433798-0e4b-4460-b68b-0e247d9a8d63">8,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzMtMy0xLTEtMA_5f08947f-c8c1-4265-9215-c03ba650ef80">75,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzMtNS0xLTEtMA_f63e4a8d-ad0f-4a6c-abe6-ae88be6a0bed">6,115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzUtMS0xLTEtMA_cb73c644-6fce-4f7f-8c87-519cc01053dc">180,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzUtMy0xLTEtMA_1f495e09-445c-4b8e-8672-a2c49e95842d">156,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzUtNS0xLTEtMA_c0293f4c-2e85-482a-957c-472fb1b81d26">142,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss per Common Share: </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss per common share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzctMS0xLTEtMA_f3652413-a315-4a13-a789-dec27aec8ff7">0.04</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzctMy0xLTEtMA_d9ad31d7-93b6-4060-bc16-ebae7171c157">0.49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzctNS0xLTEtMA_0f173885-76e0-4de7-9bd9-d19f9e8b9354">0.04</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ic913b68a604e4ff38c42375d3fa7a17b_130"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzk4OA_7671b32f-b89f-4b43-a327-53c6d70239bb" continuedAt="id55a34e6605246d38842cb5aad9365b7" escape="true"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzk4OQ_044e59d9-a16f-49d2-8571-a6438894f6e2" continuedAt="i6cc35ee1bfe74bbd83599d8dd2e7d2b1" escape="true">LEASES</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="id55a34e6605246d38842cb5aad9365b7"><ix:continuation id="i6cc35ee1bfe74bbd83599d8dd2e7d2b1"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, the Company adopted ASC 842, Leases, using an optional transition method that permitted application of the standards as of the effective date without requiring the standard to be applied to the comparative periods presented in the consolidated financial statements. The Company elected the transition package of three practical expedients, which allowed the Company not to reassess prior conclusions about lease identification, lease classification and initial, direct costs. The Company did not elect the practical expedient to use hindsight and accordingly, the initial lease term did not differ under the new standards versus prior accounting practice.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020 and 2019, the Company incurred operating lease expenses of $<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzU0OTc1NTgxNDA5Mzc_b9f14a5e-8148-413b-9cbb-9df1edb27d12">30.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzU0OTc1NTgxNDA5MzE_348aa76a-f62a-4a00-8d23-898a96391dd4">25.8</ix:nonFraction> million including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the consolidated statements of comprehensive income (loss). As of December&#160;31, 2020, the weighted-average remaining lease term was <ix:nonNumeric contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzU0OTc1NTgxNDEwMDE_7f97eceb-6f90-44e5-8cb4-a3630cf31be7">6.7</ix:nonNumeric> years and the weighted-average discount rate was <ix:nonFraction unitRef="number" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzU0OTc1NTgxNDEwMTU_1133fb72-09ac-4407-be21-8a08ea17c1b6">5.18</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzk4Mg_1b7cc208-a2de-4b45-8b35-be583cd48052" escape="true"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzk4Mw_405cdde8-76bb-4e05-b5c6-7a33e294cc76" escape="true"><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands): </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.040%"><tr><td style="width:1.0%"></td><td style="width:64.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzEtMi0xLTEtMA_2e41df40-9b8b-4022-b376-3787bcfc1e80">23,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzItMi0xLTEtMA_70c40b0a-cee6-4820-91f3-9672a3b83eb6">19,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzMtMi0xLTEtMA_a7181e1f-14d9-483f-a215-5c06e682cb27">15,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzQtMi0xLTEtMA_3c556b57-3884-4316-b56c-1cb3560bb370">11,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzUtMi0xLTEtMA_12301a5b-3ecc-4bcd-8c03-dcc29c44ac25">9,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 and beyond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzYtMi0xLTEtMA_2fcc30c4-b64a-4898-8f67-f610dd6a8e68">30,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzctMi0xLTEtMA_9104394d-4906-4b80-9245-c316551bcd1f">110,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzgtMi0xLTEtMA_f8144894-d84a-4deb-b1bc-ccbf29906b13">20,349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzktMi0xLTEtMA_38239bc7-efbb-4bf2-ae0d-176fa14c117c">89,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company commenced new leases, extensions and amendments, resulting in non-cash investing and financing activities in the consolidated statements of cash flows of $<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzU0OTc1NTgxNDA5NjA_fd918921-c0ad-401c-ac3b-34addc495dc0">29.1</ix:nonFraction> million related to the increases in the operating lease right-of-use asset and operating lease liabilities, respectively. During the year ended December&#160;31, 2019, the Company did not enter into any significant new operating or financing leases. As of December&#160;31, 2020, the Company did not have any significant operating or financing leases that had not yet commenced.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2018, the Company incurred rent expense of $<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzc5Mg_dcf230b6-ecdc-469c-bf30-65fbd5c37e41">17.3</ix:nonFraction> million, under ASC Topic 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was included as a component of selling, general and administrative expenses in the consolidated statements of comprehensive income (loss).</span></div></ix:continuation></ix:continuation><div id="ic913b68a604e4ff38c42375d3fa7a17b_136"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90ZXh0cmVnaW9uOmZlM2Q1YWUwY2Q1NTQ5OTE5MDUyMmQ4YWViNmZjYzNhXzE0NTk_fedea5af-419d-4400-8fab-2055ef5a2c62" continuedAt="i13e5169f320c4accaef2c8b5ae33b2d6" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="i13e5169f320c4accaef2c8b5ae33b2d6" continuedAt="i0bbc5d5ec4a8455985795dc87bc97c67"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90ZXh0cmVnaW9uOmZlM2Q1YWUwY2Q1NTQ5OTE5MDUyMmQ4YWViNmZjYzNhXzE0NTc_c06197f0-9f14-4b52-90ed-628251789114" continuedAt="i30b58cb939364d0a826610426aad1a16" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment was as follows as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.456%"><tr><td style="width:1.0%"></td><td style="width:50.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.483%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infusion pumps</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida6b0075f5a24266b586c0f92806b056_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzEtMS0xLTEtMA_ae129695-0e99-4040-9ae6-1f9d8aa9db0f">31,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625ed602cf134da6abbf0c62370735cd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzEtMy0xLTEtMA_1f55bb33-0a28-4d46-886d-8780db5ab325">30,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equipment, furniture and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee0705a51c84a4980d98bc3cf7443e1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzItMS0xLTEtMA_13d82eb8-1d87-4cbf-9c9f-a17cdc086108">47,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc52cce51e6a4f36a08c80fcdd124e59_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzItMy0xLTEtMA_2bb61fce-4113-4cbf-b863-c9890e24e1a4">51,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb84e173e738405780c00bcbe867cc0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzMtMS0xLTEtMA_e0bfda09-1b1a-463a-9982-91c068e76415">87,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3509723008544588453b805365b676c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzMtMy0xLTEtMA_f23a655a-4e7d-46b9-8a4a-99e51ab26ca2">80,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software, purchased and internally developed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8cc880af6414d95b4c0dd61dbdebe7c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzQtMS0xLTEtMA_065ddef4-f66a-44a0-9bb4-657ad7a28a2a">27,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7055866745ae4cc595c938f55c549586_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzQtMy0xLTEtMA_62faad95-6868-4c0a-a2da-dedabd79f54f">34,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets under development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33147d91bdd64411a910c1922f1e30ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzUtMS0xLTEtMA_fe42d0f6-f6a7-43e2-9767-517f52b5f231">10,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie319aae0a4334d4ea6a4c29ad036bd48_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzUtMy0xLTEtMA_5e4380bd-b168-4f50-b457-b667bfb91e4a">14,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzYtMS0xLTEtMA_d510e52d-3da2-41a2-addb-3424191d14d6">205,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzYtMy0xLTEtMA_95e74b94-ba05-4bd7-91a2-df1c6e34dcdb">211,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzctMS0xLTEtMA_50925f6a-f87c-4fe7-891b-8d80243a0f27">84,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzctMy0xLTEtMA_9971b768-e5d9-4e0a-87ef-3916cf0b6aa1">78,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzgtMS0xLTEtMA_3a8dbf87-a54b-4471-8b39-9707bb1937bc">121,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzgtMy0xLTEtMA_3652a3a2-9103-46b9-9300-f89578fca456">133,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense is recorded within cost of revenue and operating expenses within the consolidated statements of comprehensive income (loss), depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. <ix:continuation id="i30b58cb939364d0a826610426aad1a16" continuedAt="i54bbd20ecf62452bbfdeffb0c8b63879">The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands):</ix:continuation></span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><ix:continuation id="i54bbd20ecf62452bbfdeffb0c8b63879"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.941%"><tr><td style="width:1.0%"></td><td style="width:48.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71540503946547bfb71bcf7399158709_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzItMS0xLTEtMA_4ad7e488-927b-4e8d-8068-cd82ca066da9">6,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7863206f284422a8c9baba7551456b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzItMy0xLTEtMA_d31ed7a6-93cd-4cd1-99f2-827a11e328d2">4,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8bb4cd176114cedb1143d6017295c52_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzItNS0xLTEtMA_f97800e2-84c4-4281-a361-08625011efae">2,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d387c31f86c420698ca7b00dcb79be8_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzMtMS0xLTEtMA_bcfe89ad-b41c-4dfc-bc56-78c67f99a201">36,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5caeb9d9df24859839e8059a6e70cb6_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzMtMy0xLTEtMA_c1b293f6-afc3-47d0-95c2-6c3fbb62b3c2">27,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e6f1790eb1b4698bc41fd69f2fe9033_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzMtNS0xLTEtMA_20092821-0717-4cd9-bab4-01aee9ad21be">18,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzQtMS0xLTEtMA_4ff59b91-a0b0-4e8f-b5ec-7280089ab6fb">42,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzQtMy0xLTEtMA_c953f0f7-bf27-41e1-b8de-002ce993f650">31,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzQtNS0xLTEtMA_3667ca1c-8a40-4da6-a8cd-ab45e1793aed">21,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0bbc5d5ec4a8455985795dc87bc97c67">During the year ended December&#160;31, 2018, one company location was destroyed by a hurricane, resulting in a loss of $<ix:nonFraction unitRef="usd" contextRef="i086f47aad02f4c3598246e2234bcfcb9_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90ZXh0cmVnaW9uOmZlM2Q1YWUwY2Q1NTQ5OTE5MDUyMmQ4YWViNmZjYzNhXzgzOQ_e8abd3b4-eccc-474f-a83f-c79db7e220c5">0.6</ix:nonFraction> million of property and equipment. A business casualty loss was recorded as a component of operating costs and expenses within the consolidated statements of comprehensive income (loss). During the year ended December&#160;31, 2019, $<ix:nonFraction unitRef="usd" contextRef="i6683b8adaec142929fcdb6cc820b86c8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90ZXh0cmVnaW9uOmZlM2Q1YWUwY2Q1NTQ5OTE5MDUyMmQ4YWViNmZjYzNhXzEwMzY_e870db90-4d8e-4284-b3f8-9dbe38134ee3">0.6</ix:nonFraction> million in proceeds were received related to recovery of property and equipment. These proceeds resulted in a gain on business casualty loss of $<ix:nonFraction unitRef="usd" contextRef="i6683b8adaec142929fcdb6cc820b86c8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90ZXh0cmVnaW9uOmZlM2Q1YWUwY2Q1NTQ5OTE5MDUyMmQ4YWViNmZjYzNhXzExNzU_e83dd00d-9957-4ab9-ae24-b8fb8daa872e">0.6</ix:nonFraction> million recorded as a component of selling, general, and administrative expenses in the consolidated statements of comprehensive income (loss) during the year ended December&#160;31, 2019. These proceeds were reflected as a component of cash flows from investing activities in the consolidated statement of cash flows.</ix:continuation> </span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_139"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzM2MjI_aaec6421-a106-4fb1-a5a8-b97adf2ef4de" continuedAt="ib418b7ad6f3a458e9b6fd6f4f8ce6464" escape="true">GOODWILL AND OTHER INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="ib418b7ad6f3a458e9b6fd6f4f8ce6464" continuedAt="i46a760ed2d534ea08e80f62a3478fd56"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized, but is evaluated for impairment annually in the fourth quarter of the fiscal year, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Circumstances that could trigger an interim impairment test include: a significant adverse change in the business climate or legal factors; an adverse action or assessment by a regulator; unanticipated competition; the loss of key personnel; a change in reporting units; the likelihood that a reporting unit or significant portion of a reporting unit will be sold or otherwise disposed of; and the results of testing for recoverability of a significant asset group within a reporting unit.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A qualitative impairment analysis was performed in the fourth quarter of 2020 and 2019 to assess whether it is more likely than not that the fair value of the Company&#8217;s reporting unit is less than its carrying value. The Company assessed relevant events and circumstances including macroeconomic conditions, industry and market considerations, overall financial performance, entity-specific events, and changes in the Company&#8217;s stock price. The Company determined that there was <ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzEyODA_356210a6-bf57-4ec0-94d5-4081ac7537b6"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzEyODA_f0ef9e25-35ec-4369-903b-f00684db081f">no</ix:nonFraction></ix:nonFraction> goodwill impairment in 2020 or 2019.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A quantitative impairment analysis was performed in the fourth quarter of 2018, and the Company estimated the fair value of its reporting unit using an income approach. The income approach requires management to estimate a number of factors for its reporting unit, including projected future operating results, economic projections, anticipated future cash flows, and discount rates. The fair value determined using the income approach was then compared to marketplace fair value data from within a comparable industry grouping for reasonableness. The Company determined that there was <ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzE5MDM_44db50e3-0128-4d3f-8907-39519e2e4137">no</ix:nonFraction> goodwill impairment in 2018.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of fair value and the allocation of that value to individual assets and liabilities within the reporting unit requires the Company to make significant estimates and assumptions. These estimates and assumptions primarily include, but are not limited to, the selection of appropriate peer group companies; control premiums appropriate for acquisitions in the industries in which the Company competes; the discount rate; terminal growth rates; and forecasts of revenue, operating income, depreciation and amortization, and capital expenditures. Actual financial results could differ from those estimates due to the inherent uncertainty involved in making such estimates. Changes in assumptions concerning future financial results or other underlying assumptions could have a significant impact on either the fair value of the reporting unit, the amount of the goodwill impairment charge, or both.</span></div><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzM2MjM_8fbc8f45-63ae-4c9c-bed3-d56eff367ccc" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill consist of the following activity for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands): </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:46.929%"><tr><td style="width:1.0%"></td><td style="width:63.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40c908a9b2de45bcab117c93611972e9_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZToxYTgwZTYyYzAxN2I0NGJkOGQ5OTkwZmIyZDY3YWQ2Yy90YWJsZXJhbmdlOjFhODBlNjJjMDE3YjQ0YmQ4ZDk5OTBmYjJkNjdhZDZjXzAtMi0xLTEtMzMwNQ_8c4c11e9-cdb2-42bb-96cc-69c2a0756f89">627,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZToxYTgwZTYyYzAxN2I0NGJkOGQ5OTkwZmIyZDY3YWQ2Yy90YWJsZXJhbmdlOjFhODBlNjJjMDE3YjQ0YmQ4ZDk5OTBmYjJkNjdhZDZjXzEtMi0xLTEtMzMwNQ_37845654-5711-418f-880e-47a15afa767f">5,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i757f7525fd514729825051239d54094e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZToxYTgwZTYyYzAxN2I0NGJkOGQ5OTkwZmIyZDY3YWQ2Yy90YWJsZXJhbmdlOjFhODBlNjJjMDE3YjQ0YmQ4ZDk5OTBmYjJkNjdhZDZjXzAtMi0xLTEtMA_3f67a340-025d-4a4f-a850-f61bdd6e9487">632,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZToxYTgwZTYyYzAxN2I0NGJkOGQ5OTkwZmIyZDY3YWQ2Yy90YWJsZXJhbmdlOjFhODBlNjJjMDE3YjQ0YmQ4ZDk5OTBmYjJkNjdhZDZjXzEtMi0xLTEtMA_566d35eb-5e1a-41e0-abb1-a650f4bebc2c">793,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZToxYTgwZTYyYzAxN2I0NGJkOGQ5OTkwZmIyZDY3YWQ2Yy90YWJsZXJhbmdlOjFhODBlNjJjMDE3YjQ0YmQ4ZDk5OTBmYjJkNjdhZDZjXzItMi0xLTEtMA_1aa82d44-d776-460b-8d09-a01244d4de25">1,425,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZToxYTgwZTYyYzAxN2I0NGJkOGQ5OTkwZmIyZDY3YWQ2Yy90YWJsZXJhbmdlOjFhODBlNjJjMDE3YjQ0YmQ4ZDk5OTBmYjJkNjdhZDZjXzMtMi0xLTEtMA_85b6c713-9d13-41bb-b63c-a0dcaa23d1ba">3,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZToxYTgwZTYyYzAxN2I0NGJkOGQ5OTkwZmIyZDY3YWQ2Yy90YWJsZXJhbmdlOjFhODBlNjJjMDE3YjQ0YmQ4ZDk5OTBmYjJkNjdhZDZjXzQtMi0xLTEtMA_1ebc6cb3-f85c-432d-8523-7a5aeb1ae1fe">1,428,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><ix:continuation id="i46a760ed2d534ea08e80f62a3478fd56"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzM2MjQ_67b10466-0c8e-49e0-9cbd-b599df3ab319" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and accumulated amortization of intangible assets consists of the following as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.538%"><tr><td style="width:1.0%"></td><td style="width:47.210%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.752%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross intangible assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc00aa48c5dd4893801fa8c1ebcb07c1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzItMi0xLTEtMA_45987aac-a78b-483f-8d89-c61ee6b8816f">438,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d301d39dafd4e68a587b0a3fa40fcfb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzItNC0xLTEtMA_27979309-aa61-42cf-976c-755aa18a7d3e">438,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie817018869a64452a6fc78f5f9440a38_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzMtMi0xLTEtMA_984d12ed-0ec4-4872-a666-d790776e7f7b">44,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45131573f0bb479e8f31cf95f78845cb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzMtNC0xLTEtMA_60167e97-f99a-44c1-8efe-f00353137030">44,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if428d92bc279403486726eacba9956e2_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzQtMi0xLTEtMA_e616127d-9bd6-4bd3-8202-3b07a359dae3">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff982c3170b046f39f50b17cf259e515_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzQtNC0xLTEtMA_9b96d8ea-a48f-46cc-9613-01163e603b31">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzUtMi0xLTEtMA_0197ed0d-aa20-4b6f-aacf-353edd91e5fe">483,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzUtNC0xLTEtMA_0d6b5a55-913d-4982-8217-89eda67e5157">483,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc00aa48c5dd4893801fa8c1ebcb07c1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzgtMi0xLTEtMA_83dbed0b-0f0e-406d-909e-0769dcaa3133">110,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d301d39dafd4e68a587b0a3fa40fcfb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzgtNC0xLTEtMA_11b8d2f0-78b2-4688-8526-aaf0c8d29a93">84,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie817018869a64452a6fc78f5f9440a38_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzktMi0xLTEtMA_f05c9490-215f-4aef-9018-98701a9bde87">21,146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45131573f0bb479e8f31cf95f78845cb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzktNC0xLTEtMA_1e93421d-e853-44a8-b43d-8d0e4a09447f">12,748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if428d92bc279403486726eacba9956e2_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzEwLTItMS0xLTA_2795baf0-39c2-4940-8268-5ad2e44a39dc">363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff982c3170b046f39f50b17cf259e515_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzEwLTQtMS0xLTA_61c6309d-a414-4c72-9a90-5f70f2943f27">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzExLTItMS0xLTA_7ec0a884-e196-451c-b225-95223923713b">132,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzExLTQtMS0xLTA_e7241c37-d318-4753-b47f-ac5cfd81ca72">97,149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzEyLTItMS0xLTA_289bd412-171a-41e4-b7a8-bdf5c865bc2b">351,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzEyLTQtMS0xLTA_3b5a0316-407a-4be6-a2a7-1d1b1eebc91d">385,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzMyMjE_1aa481fe-7501-4e9b-a299-6dc5001283f9">35.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzMyMjU_6d0da1d9-59a4-4246-8cf1-d1135e47d810">26.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzMyMzI_56c4a2aa-32e4-426f-ae5b-dc6a338f330b">19.6</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </span></div><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzM2MjE_4ef58ce4-441f-4876-8a19-cf0f9226d846" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization expense for intangible assets recorded at December&#160;31, 2020, is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.918%"><tr><td style="width:1.0%"></td><td style="width:32.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.903%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTphNjIzN2ExZTM2NWI0YzFlYmZiZTQ1MzAyYjQ1OTU2Ni90YWJsZXJhbmdlOmE2MjM3YTFlMzY1YjRjMWViZmJlNDUzMDJiNDU5NTY2XzAtMi0xLTEtMA_19675282-6f6d-480f-b8b9-50a917ab0af5">32,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTphNjIzN2ExZTM2NWI0YzFlYmZiZTQ1MzAyYjQ1OTU2Ni90YWJsZXJhbmdlOmE2MjM3YTFlMzY1YjRjMWViZmJlNDUzMDJiNDU5NTY2XzEtMi0xLTEtMA_4f3a61d7-ea44-468d-bedc-ed8cf59b829b">28,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTphNjIzN2ExZTM2NWI0YzFlYmZiZTQ1MzAyYjQ1OTU2Ni90YWJsZXJhbmdlOmE2MjM3YTFlMzY1YjRjMWViZmJlNDUzMDJiNDU5NTY2XzItMi0xLTEtMA_7b4abcf8-b327-4346-b0fa-f8d8067d4e34">28,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTphNjIzN2ExZTM2NWI0YzFlYmZiZTQ1MzAyYjQ1OTU2Ni90YWJsZXJhbmdlOmE2MjM3YTFlMzY1YjRjMWViZmJlNDUzMDJiNDU5NTY2XzMtMi0xLTEtMA_cc8b009a-31d7-4d29-a950-765bd5598b5e">28,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTphNjIzN2ExZTM2NWI0YzFlYmZiZTQ1MzAyYjQ1OTU2Ni90YWJsZXJhbmdlOmE2MjM3YTFlMzY1YjRjMWViZmJlNDUzMDJiNDU5NTY2XzQtMi0xLTEtMA_b93b39e2-a551-4bc2-b285-84fe500df380">28,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and beyond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTphNjIzN2ExZTM2NWI0YzFlYmZiZTQ1MzAyYjQ1OTU2Ni90YWJsZXJhbmdlOmE2MjM3YTFlMzY1YjRjMWViZmJlNDUzMDJiNDU5NTY2XzUtMi0xLTEtMA_35d3c80d-87e5-4ff0-a09d-791629c2902e">205,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTphNjIzN2ExZTM2NWI0YzFlYmZiZTQ1MzAyYjQ1OTU2Ni90YWJsZXJhbmdlOmE2MjM3YTFlMzY1YjRjMWViZmJlNDUzMDJiNDU5NTY2XzYtMi0xLTEtMA_f89a8d4a-598e-4e74-8ef7-1aaae6d40175">351,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ic913b68a604e4ff38c42375d3fa7a17b_148"></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzk3NzA_94b36fdc-37ab-4fda-9003-bf21dcaa568b" continuedAt="i7c30b837eefa4fd28b98e428fdf08f23" escape="true">INDEBTEDNESS</ix:nonNumeric></span></div><ix:continuation id="i7c30b837eefa4fd28b98e428fdf08f23" continuedAt="i2b1dd23cf27a4f6a9ad29baca9fb6e70"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzk3NTg_37772ade-68f0-4bf1-904d-344e9356e48f" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ABL Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ead4afeb6274fe391c370a8ab570027_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzEtMi0xLTEtMA_85ee407b-576b-4e54-b3d0-047d4819da9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ead4afeb6274fe391c370a8ab570027_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzEtNC0xLTEtMA_c5b88df7-65d4-458d-9344-424e43a3f4b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ead4afeb6274fe391c370a8ab570027_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzEtNi0xLTEtMA_5eaedb76-1d5d-4b1e-9486-027e6d84fcd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ead4afeb6274fe391c370a8ab570027_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzEtOC0xLTEtMA_cbeb1b60-1c3e-4e41-b830-6d7346f5963d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia70d084d67ce4667b22225e30b5f6b8c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzItMi0xLTEtMA_670f6aa0-b6be-4d5a-8267-6e3f6ed96a4d">915,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia70d084d67ce4667b22225e30b5f6b8c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzItNC0xLTEtMA_6a8c3b90-895e-43e4-bcc6-40011ab4078d">7,253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia70d084d67ce4667b22225e30b5f6b8c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzItNi0xLTEtMA_a6dcc8e7-d27d-4709-8574-9364630846c0">19,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia70d084d67ce4667b22225e30b5f6b8c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzItOC0xLTEtMA_5a851b9d-2f3c-4757-a303-020f89ddffaa">888,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Lien Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660fc6279c714085b9bafae194ba5b7d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzMtMi0xLTEtMA_7ac048d8-4dd1-4533-bc1e-67ecbbc712a6">245,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i660fc6279c714085b9bafae194ba5b7d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzMtNC0xLTEtMA_83ddfd6e-efd5-4411-9019-9499d526c5c3">6,102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i660fc6279c714085b9bafae194ba5b7d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzMtNi0xLTEtMA_b0545a2e-5a34-4773-a3d3-ec399fe23ea4">4,113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660fc6279c714085b9bafae194ba5b7d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzMtOC0xLTEtMA_a8c34c83-1cfd-4a5c-98ab-a83f02c05710">235,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzQtMi0xLTEtMA_d05bb343-d7ce-48f3-b897-de505b2de353">1,161,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzQtNC0xLTEtMA_3f83e4d6-5f5d-4137-8b85-54f7eb80d59f">13,355</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzQtNi0xLTEtMA_56b29ce5-2a99-4f11-a006-a1103fb2cf02">23,823</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzQtOC0xLTEtMA_7bc8d559-29f5-47ff-a3ef-d002128974cf">1,124,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzUtOC0xLTEtMA_9a4f461c-c08b-4298-9e0e-6c12bb445726">9,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzYtOC0xLTEtMA_7d7d6ab8-02c4-4240-b475-c1fc7e85cd90">1,115,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of December&#160;31, 2019 (in thousands):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ABL Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6a9df1dd28e4f1680a018dc49429873_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzEtMi0xLTEtMA_01262327-5541-4a4f-94d1-d06feec94918">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6a9df1dd28e4f1680a018dc49429873_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzEtNC0xLTEtMA_1acd5748-17dd-4fcd-9875-be9e73b347da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6a9df1dd28e4f1680a018dc49429873_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzEtNi0xLTEtMA_4970de3c-46f3-455e-9a03-9e40337a5512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6a9df1dd28e4f1680a018dc49429873_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzEtOC0xLTEtMA_410f3876-a837-4177-9136-7233d2c178ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074931e160e4e02be724a84dde0758b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzItMi0xLTEtMA_77702b1a-a7e6-4bcc-8b4a-8d8a1efef0d7">925,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074931e160e4e02be724a84dde0758b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzItNC0xLTEtMA_18e932cc-079c-440a-9d01-63e121b234e5">8,399</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074931e160e4e02be724a84dde0758b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzItNi0xLTEtMA_fe713d10-4b27-4d8a-88ea-423ad26719af">22,825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074931e160e4e02be724a84dde0758b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzItOC0xLTEtMA_7c09ad36-bb1d-4a16-b047-e8e49e19e256">893,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Lien Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bb20cde57584d28ab6a5c4446839bc2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzMtMi0xLTEtMA_adc44d7f-878b-4f49-a4bc-548276d377cc">412,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bb20cde57584d28ab6a5c4446839bc2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzMtNC0xLTEtMA_ce8e88b0-5348-4344-8f05-7ee5799db187">11,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bb20cde57584d28ab6a5c4446839bc2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzMtNi0xLTEtMA_d565eef1-f12a-4a2b-bde6-feb60e40c2ea">7,864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bb20cde57584d28ab6a5c4446839bc2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzMtOC0xLTEtMA_ed5d8d89-1104-4402-83a0-7dd53fe90764">392,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzQtMi0xLTEtMA_6528f77d-90b4-4097-8dd7-c05ab8f6f549">1,337,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzQtNC0xLTEtMA_54b4a82d-660a-4100-bd1b-a1f389cc3f15">20,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzQtNi0xLTEtMA_b2e499f6-fa0a-489b-9b1b-09cdb2edf1e9">30,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzQtOC0xLTEtMA_f89365ad-e844-47b1-9520-d8f21bdba733">1,286,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzUtOC0xLTEtMA_7779fe00-d6a9-4b3e-ba24-bfbb678158ad">9,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzYtOC0xLTEtMA_19e7129e-8b84-4d8d-9e2f-19be45a20c09">1,277,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retired Debt Obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Prior to the Merger, the Company had two credit arrangements that provided for up to $<ix:nonFraction unitRef="usd" contextRef="i7f59152bb9c048a5b50b44067271f613_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzMzNg_d1fa0d0b-2c03-4ad4-bc96-bae8a2a2eb78">645.0</ix:nonFraction> million in senior secured credit facilities through an $<ix:nonFraction unitRef="usd" contextRef="i1a4bc3c15e894757bc0a5393777c3429_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzM4Ng_8917c6cc-cc14-4fec-901a-8a45ea92108b">80.0</ix:nonFraction> million revolving credit facility (the &#8220;Previous Revolving Credit Facility&#8221;), a $<ix:nonFraction unitRef="usd" contextRef="i640bd2ca162d4110821356fb395847f8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQ2MQ_755826f7-2591-4aaa-9913-add78ac0e610">415.0</ix:nonFraction> million first lien term loan (the &#8220;Previous First Lien Term Loan&#8221;), and a $<ix:nonFraction unitRef="usd" contextRef="i4386145a348444218987e663e802f1b3_I20190806" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzUzMA_ce37b3ba-c265-42b1-89d6-b98c76771a7a">150.0</ix:nonFraction> million second lien term loan (the &#8220;Previous Second Lien Term Loan&#8221;, and together with the Previous First Lien Term Loan, the &#8220;Previous Term Loans&#8221;, and the Previous Term Loans, together with the Previous Revolving Credit Facility, the &#8220;Previous Credit Facilities&#8221;). The principal balance on the Previous First Lien Term Loan was repayable in quarterly installments of $<ix:nonFraction unitRef="usd" contextRef="i7f24d9bf71984546b8af671666297e21_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1MjU5Njk_581d70ac-c5df-4e6b-b162-3caf3e3fc953">1.0</ix:nonFraction> million.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2019, the Company repaid the outstanding balance of Previous Term Loans and retired the outstanding Previous Credit Facilities by entering into two new credit arrangements and a notes indenture, described below under &#8220;New Debt Obligations&#8221;. The weighted average interest rate paid on the Previous First Lien Term Loan was <ix:nonFraction unitRef="number" contextRef="i12c898e6c2bf4a57a2d2293e3f85537e_I20191231" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzI3MjE_b43a6b3c-db10-4cc7-9961-066a964a3d8b">6.20</ix:nonFraction>% for the year ended December&#160;31, 2019, prior to the retirement of the debt obligations. The weighted average interest paid on the Previous Second Lien Term Loan was <ix:nonFraction unitRef="number" contextRef="i0cc1c613272d407fb68c66233b0884da_D20190101-20191231" decimals="4" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzI4OTM_c58715f7-8918-4a3c-8456-c2304f5b1909">11.36</ix:nonFraction>% for the year ended December&#160;31, 2019, prior to the retirement of the debt obligations. </span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><ix:continuation id="i2b1dd23cf27a4f6a9ad29baca9fb6e70" continuedAt="i7bafc1f7299444ef94942dae34b2435e"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Debt Obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; In conjunction with the Merger, the Company entered into an asset-based-lending revolving credit facility administered by Bank of America, N.A. The Company also issued senior secured second lien PIK toggle floating rate notes due 2027 (the &#8220;Second Lien Notes&#8221;) under an indenture with Ankura Trust Company, LLC. The two new credit agreements and the indenture were entered into on August 6, 2019 and initially provided for up to $<ix:nonFraction unitRef="usd" contextRef="id826c60086164891b7f61e86c7d17b78_I20190806" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzM0MzA_e741a3b9-c449-42ad-a0bf-3ae12b375197">1,475.0</ix:nonFraction> million in senior secured credit facilities through a $<ix:nonFraction unitRef="usd" contextRef="i04c60dc2cb4949a08701ec5516562884_I20190806" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1Mjk3MjQ_57494c54-f12f-4c45-9ede-8d28aa3e0f6b">150.0</ix:nonFraction> million asset-based-lending revolving credit facility (the &#8220;ABL Facility&#8221;), a $<ix:nonFraction unitRef="usd" contextRef="i209bb88d77ec42248db74bf4e55edb38_I20190806" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzM1NTI_ae31f174-04f9-49db-986c-314640270529">925.0</ix:nonFraction> million first lien term loan (the &#8220;First Lien Term Loan&#8221;, and together with the ABL Facility, the &#8220;Loan Facilities&#8221;), and a $<ix:nonFraction unitRef="usd" contextRef="ib286938752c04504a3b00f4071a94634_I20190806" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzM2NzE_75a877fc-ff7e-49a7-9d7a-a32ae9f055f6">400.0</ix:nonFraction> million issuance of Second Lien Notes. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ABL Facility initially provided for borrowings up to $<ix:nonFraction unitRef="usd" contextRef="i04c60dc2cb4949a08701ec5516562884_I20190806" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1Mjk3MzI_57494c54-f12f-4c45-9ede-8d28aa3e0f6b">150.0</ix:nonFraction> million, which matures on August&#160;6, 2024. During the year ended December&#160;31, 2020, the Company increased the borrowing capacity of its ABL Facility from $<ix:nonFraction unitRef="usd" contextRef="i4386145a348444218987e663e802f1b3_I20190806" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU0OTc1NTgxNTcwMzA_ce37b3ba-c265-42b1-89d6-b98c76771a7a">150.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i46f31629752b4d81875255a5a98e87a7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU0OTc1NTgxNTcwMjA_cd591f52-8f88-4e08-a414-83580212012c">175.0</ix:nonFraction> million. The ABL Facility bears interest at a per annum rate initially provided that is determined by the Company&#8217;s periodic selection of rate type, either the Base Rate or the Eurocurrency Rate. Interest on the ABL Facility is charged on Base Rate loans at the greater of Base Rate, as defined, or <ix:nonFraction unitRef="number" contextRef="idc5331a479244a11b7005f9b4a1e7c11_D20200101-20201231" decimals="4" name="bios:DebtInstrumentBaseRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzcxNDY4MjU2MDA1Mjk_ec51e27c-c8b9-405d-bdfc-2f07c051ae1c">0.25</ix:nonFraction>% plus <ix:nonFraction unitRef="number" contextRef="ie4ff2a32df6c4734a1ec9790fd2b3c90_D20200101-20201231" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQwMzY_92e538c2-13d2-411d-b169-e384e5161959">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i99995e13205b43628f9807043e807bce_D20200101-20201231" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQwNDI_d9a95dec-fc37-42a1-a02d-3c34ad68d2c3">1.75</ix:nonFraction>%, depending on the historical excess availability as a percentage of the Line Cap, as defined in the ABL Facility credit agreement. Interest on the ABL Facility is charged on Eurocurrency Rate Loans at the Eurocurrency Rate, as defined, plus <ix:nonFraction unitRef="number" contextRef="iaba77b7ae34c4fb7b5163a1d2f78b481_D20200101-20201231" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQyODc_20b29a79-8e5d-4611-bf0e-5e1a307fbb57">2.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id771c21da6a248498802851c5776c07e_D20200101-20201231" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQyOTM_e4a60f31-aee7-451e-aa7b-75db71d1e0e1">2.75</ix:nonFraction>%, depending on the historical excess availability as a percentage of the Line Cap, as defined in the ABL Facility credit agreement. The ABL Facility contains commitment fees payable on the unused portion ranging from <ix:nonFraction unitRef="number" contextRef="i415f019222e24e949930ede6b5b65dd1_D20200101-20201231" decimals="4" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQ1MTI_eeee4871-7d77-4ebd-a72a-6006b577f05e">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i483af9de03bc4422b957661fc1119a22_D20200101-20201231" decimals="5" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQ1MTg_819c73f6-a08a-4f62-a4d9-b2c462234bee">0.375</ix:nonFraction>%, depending on various factors including the Company&#8217;s leverage ratio, type of loan and rate type, and letter of credit fees of <ix:nonFraction unitRef="number" contextRef="idc5331a479244a11b7005f9b4a1e7c11_D20200101-20201231" decimals="4" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQ2NDg_bcff61b8-012b-41c1-b468-8632b625345a">2.50</ix:nonFraction>%. Borrowings under the ABL Facility are secured by a first priority security interest in the Company&#8217;s and each of its subsidiaries&#8217; inventory, accounts receivable, cash, deposit accounts and certain assets and property related thereto (the &#8220;ABL Priority Collateral&#8221;), in each case subject to certain exceptions, and a third priority security interest in the Term Loan Priority Collateral, as defined below. The Company had <ix:nonFraction unitRef="usd" contextRef="i3cf4138b86814ddaa06ddcb7b782f15a_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzUwNzQ_3a47c7c2-8188-4cde-bf2b-e6fa1177457f"><ix:nonFraction unitRef="usd" contextRef="i46f31629752b4d81875255a5a98e87a7_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzUwNzQ_a92f55f1-ce09-48c6-904f-8d54a92a9f19">no</ix:nonFraction></ix:nonFraction> outstanding borrowings under the ABL Facility at December&#160;31, 2020 and 2019. The Company had $<ix:nonFraction unitRef="usd" contextRef="i8c4f5e9ea300456ca3c311e588f2d512_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzUxNDY_ea236e19-0553-43d1-b7a3-3d7370b7f7cf">9.6</ix:nonFraction> million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the ABL of $<ix:nonFraction unitRef="usd" contextRef="i46f31629752b4d81875255a5a98e87a7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzUyNTk_9c1f39f1-9264-472e-8094-ab9e50aaa6a9">165.4</ix:nonFraction> million as of December&#160;31, 2020. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal balance of the First Lien Term Loan is repayable in quarterly installments which commenced in March 2020 of $<ix:nonFraction unitRef="usd" contextRef="i13a144a884e94b6a93b74bea5f331c3e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzUzOTA_2d5ef587-9468-4183-8109-ff8ef000895e">2.3</ix:nonFraction> million plus interest, with a final payment of all remaining outstanding principal due on August&#160;6, 2026. Interest on the First Lien Term Loan is payable monthly on Base Rate loans at Base Rate, as defined, plus <ix:nonFraction unitRef="number" contextRef="i1c10e2b1b78c46e2bae9d7a6747cce9c_D20200101-20201231" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU1ODU_de97e93b-6f30-4f61-953c-457f91308569">3.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i2723f056763c4dedbc445d2f9855f372_D20200101-20201231" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU1OTE_a9419112-444c-414e-a6b9-c0f2a9a25e37">3.50</ix:nonFraction>%, depending on the Company&#8217;s leverage ratio. Interest is charged on Eurocurrency Rate loans at the Eurocurrency Rate, as defined, plus <ix:nonFraction unitRef="number" contextRef="i4574bb7e56b34190bb053a4f1bcd1b5b_D20200101-20201231" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU3Mjg_25374547-e313-4989-94ec-7292c6fa7257">4.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id5b446b6a97f4f90ac9242bc18f5059d_D20200101-20201231" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU3MzQ_4cf2f6d4-77de-414a-ac75-657e943c7ebb">4.50</ix:nonFraction>%, depending on the Company&#8217;s leverage ratio. The interest rate on the First Lien Term Loan was <ix:nonFraction unitRef="number" contextRef="iab4208b4c10d4bc0b8f34fe22bd51432_I20201231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1Mjk3NDQ_86bfe4a6-2eae-4931-9dfc-73cb21992cc2">4.40</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3a10d18e244645e5b6a89c8ab446ff90_I20191231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU4MzE_032499fe-2bd7-4b2a-af0b-995987a0b6ea">6.20</ix:nonFraction>% as of December&#160;31, 2020 and 2019, respectively. The weighted average interest rate incurred was <ix:nonFraction unitRef="number" contextRef="i13a144a884e94b6a93b74bea5f331c3e_D20200101-20201231" decimals="4" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1Mjk3NTI_a012662a-f4c7-485b-9436-54606db493cf">5.09</ix:nonFraction>% for the year ended December&#160;31, 2020. The weighted average interest rate incurred was <ix:nonFraction unitRef="number" contextRef="i607cf3ad83fa4d68a7f532e446e0e21f_D20190806-20191231" decimals="4" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU4OTI_b86224b5-003b-48eb-8157-488b7ba75a76">6.47</ix:nonFraction>% for the period August 6, 2019 through December&#160;31, 2019. Amounts borrowed under the First Lien Term Loan are secured by a first priority security interest in each of the Company&#8217;s subsidiaries&#8217; capital stock (subject to certain exceptions) and substantially all of the Company&#8217;s property and assets (other than the ABL Priority Collateral), (the &#8220;Term Loan Priority Collateral&#8221;), in each case subject to certain exceptions, and a second priority security interest in the ABL Priority Collateral.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Second Lien Notes mature on August&#160;6, 2027. Interest on the Second Lien Notes is payable quarterly and is at London Interbank Offered Rate (&#8220;LIBOR&#8221;), plus <ix:nonFraction unitRef="number" contextRef="i0792b3cd668b435abf755519d30889a2_D20200101-20201231" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzY1NDg_e6c48ab4-dadc-40a2-804d-a271bc08879e">8.75</ix:nonFraction>%. The Company elected to pay-in-kind (&#8220;PIK&#8221;) the first quarterly interest payment, due in November 2019, which resulted in the Company capitalizing $<ix:nonFraction unitRef="usd" contextRef="i1bd2ac4c3a7b43a292acc61f6fdf6853_D20191101-20191130" decimals="-5" format="ixt:numdotdecimal" name="bios:InterestCapitalizedToDebtPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzY2OTg_98b354be-e56a-477e-a4e7-59222a48fea5">12.3</ix:nonFraction> million in interest to the principal balance on the interest payment date. The Company also elected to PIK the quarterly interest payment due in August 2020, which resulted in the Company capitalizing $<ix:nonFraction unitRef="usd" contextRef="i6d4c5bb322c04877b86cf39e32da703f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU0OTc1NTgxNTczNzM_0daa375d-1c9e-46bd-8044-fdd7617f2fe8">7.5</ix:nonFraction> million in interest expense to the principal balance of the Second Lien Notes on the interest payment date. In connection with the PIK elections, the Company was charged an additional <ix:nonFraction unitRef="number" contextRef="i325d52df30ad4c278d90566dd27aaf21_I20201231" decimals="2" name="bios:PaidInKindInterestAdditionalInterestExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzY4NDM_33666e42-55f6-4449-a248-be5148a7c141">1.00</ix:nonFraction>% in interest expense on those quarterly interest payments. The interest rate on the Second Lien Notes was <ix:nonFraction unitRef="number" contextRef="i325d52df30ad4c278d90566dd27aaf21_I20201231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1Mjk3NTg_70bd0a1a-06f2-4752-b2ce-f4906b8c413f">8.98</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="iedf0847627fa4c459cc17c612b6e2b9e_I20191231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzY5NTQ_c3e2e30f-ef0c-460c-ad54-0ef4eb00bb4a">10.66</ix:nonFraction>% as of December&#160;31, 2020 and 2019. The weighted average interest incurred was <ix:nonFraction unitRef="number" contextRef="i6d4c5bb322c04877b86cf39e32da703f_D20200101-20201231" decimals="4" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1Mjk3NjY_17bee043-b738-42a9-bcad-d7b1f8265298">9.39</ix:nonFraction>% for the year ended December&#160;31, 2020. The weighted average interest incurred was <ix:nonFraction unitRef="number" contextRef="ic49d785c7256408c93023d39c4d914d8_D20190806-20191231" decimals="4" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzcwMTA_dd594499-1e1e-49d8-96c9-c36331f3076c">11.45</ix:nonFraction>% for the period August 6, 2019 through December&#160;31, 2019.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company completed a public offering of stock for proceeds of $<ix:nonFraction unitRef="usd" contextRef="ib5a9e86640d24df0a4a74f644bec401b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU0OTc1NTgxNTc0MzI_0460f5b2-e477-43f2-b669-72220f776b1c">118.9</ix:nonFraction>&#160;million. Those proceeds, along with additional cash on hand, were used to prepay $<ix:nonFraction unitRef="usd" contextRef="i41a866b1933d4b50a03ed2090fc52f3b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU0OTc1NTgxNTc0NTE_d61f73bc-8c89-4a75-8e15-dea3ba2d5de7">174.0</ix:nonFraction>&#160;million of the Second Lien Notes, which is reflected as a cash outflow from financing activities in the Company&#8217;s consolidated statements of cash flows. The Company recognized a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="idb7255dc5f1449f88b65c6161c741c55_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1Mjk3ODc_372bce60-a99b-4dc0-b5b9-ce4f5bcbabd2">11.5</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="icd11813edd424004b8d01f7794f0116c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="bios:FinancingReceivablePrepaymentPenalty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU0OTc1NTgxNTc0ODU_47edb4d3-c420-4a33-8ce5-90b3f8bf2945">3.5</ix:nonFraction>&#160;million related to the prepayment penalty and $<ix:nonFraction unitRef="usd" contextRef="icd11813edd424004b8d01f7794f0116c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinancingReceivableDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1Mjk4MjY_9151f2ee-ac5b-4b82-b4c9-7403049e25a4">8.0</ix:nonFraction>&#160;million related to deferred financing fees which were written off upon extinguishment. The $<ix:nonFraction unitRef="usd" contextRef="icd11813edd424004b8d01f7794f0116c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="bios:FinancingReceivablePrepaymentPenalty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU0OTc1NTgxNTc0Njg_47edb4d3-c420-4a33-8ce5-90b3f8bf2945">3.5</ix:nonFraction>&#160;million prepayment penalty was reflected as a cash outflow from financing activities in the Company&#8217;s consolidated statements of cash flows. The loss on extinguishment was recorded as a component of other, net in the Company&#8217;s consolidated statements of comprehensive income (loss). See Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the public offering.</span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><ix:continuation id="i7bafc1f7299444ef94942dae34b2435e" continuedAt="iac8689c4636141738166b1d71a450111"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company assessed whether the repayment of the Previous Term Loans and subsequent issuance of the First Lien Term Loan and the Second Lien Notes resulted in an insubstantial modification or an extinguishment of the existing debt for each loan in the syndication by grouping lenders as follows: (i) Lenders participating in both the Previous Credit Facilities and the new Loan Facilities and Second Lien Notes; (ii) previous lenders that exited; and (iii) new lenders. The Company determined that $<ix:nonFraction unitRef="usd" contextRef="i6a1d6fa62d594e16b4173eb1cda83c73_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzc1NTQ_10db0e85-9996-4731-bae6-b5fc7e3ea686">226.7</ix:nonFraction> million of the Previous First Lien Term Loan was extinguished and <ix:nonFraction unitRef="usd" contextRef="i83c91152b1744cdda0bc77a72cef0072_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RepaymentsOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzc2MTU_2b90857d-1762-45b2-a456-f112dfb85383">none</ix:nonFraction> of the Previous Second Lien Term Loan was extinguished, which is disclosed as an outflow from financing activities in the consolidated statements of cash flows. The Company determined that $<ix:nonFraction unitRef="usd" contextRef="i6a1d6fa62d594e16b4173eb1cda83c73_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzc4MDc_aa8e47ab-a4b5-4bfd-900f-8b4afef13056">752.4</ix:nonFraction> million of new debt was issued related to the First Lien Term Loan and $<ix:nonFraction unitRef="usd" contextRef="i83c91152b1744cdda0bc77a72cef0072_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzc4NzM_4526d1ce-0fff-4aca-9a7a-58015166eab2">250.0</ix:nonFraction> million of new debt was issued related to the Second Lien Notes, which is disclosed as an inflow from financing activities in the consolidated statements of cash flows. In connection with the issuance of the First Lien Term Loan, the Second Lien Notes, and the ABL Facility, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="ia288006c93754808b4fb52473eb70d95_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzgxNjQ_4d481f21-f66e-4c95-9a49-551660b91092">52.6</ix:nonFraction> million in debt issuance costs and third-party fees, of which $<ix:nonFraction unitRef="usd" contextRef="ia288006c93754808b4fb52473eb70d95_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzgyMjE_0947da03-27a3-4248-8bd5-bc8e663017c4">48.1</ix:nonFraction> million was capitalized, $<ix:nonFraction unitRef="usd" contextRef="ia288006c93754808b4fb52473eb70d95_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedAmortizationDeferredFinanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzgyNDE_91d23d54-5045-4817-ad9e-85eb0dd75334">1.3</ix:nonFraction> million was expensed as a component of other expense and $<ix:nonFraction unitRef="usd" contextRef="i83c91152b1744cdda0bc77a72cef0072_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzgyOTM_e66ae97b-6ca7-4c2b-b147-a22b0352e42a">3.2</ix:nonFraction> million was expensed as a loss on extinguishment as a component of other expense. Further, $<ix:nonFraction unitRef="usd" contextRef="ia334515f9b054e84a1cdb130df9a3d17_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzgzNzk_ca3afda9-094f-480e-bf2d-22ce1f51681a">21.3</ix:nonFraction> million of the total fees incurred of $<ix:nonFraction unitRef="usd" contextRef="ia288006c93754808b4fb52473eb70d95_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzg0MTI_4d481f21-f66e-4c95-9a49-551660b91092">52.6</ix:nonFraction> million was netted against the $<ix:nonFraction unitRef="usd" contextRef="ia334515f9b054e84a1cdb130df9a3d17_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzg0Mzg_e56e82b4-2e13-4d3d-bccf-a66fa65ffaaf">981.1</ix:nonFraction> million of proceeds from debt as a component of the cash flows from financing activities, $<ix:nonFraction unitRef="usd" contextRef="ia334515f9b054e84a1cdb130df9a3d17_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzg1MjM_29480bad-1a6e-41cd-bbcd-1d127a4461e1">30.0</ix:nonFraction> million was presented as deferred financing costs as a component of cash flows from financing activities, and the remaining $<ix:nonFraction unitRef="usd" contextRef="ia334515f9b054e84a1cdb130df9a3d17_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="bios:PaymentsOfDebtIssuanceCostsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzg2NDI_a1e311c2-64d5-4dfe-8140-71af89b40153">1.3</ix:nonFraction> million was included in cash flows from operating activities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company recognized a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i5330b1241c9f450aabf19a6470f3deeb_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzg3NTk_3a055071-e548-40d0-a4e1-959b750e40e9">5.5</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i83c91152b1744cdda0bc77a72cef0072_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzg3NzI_e66ae97b-6ca7-4c2b-b147-a22b0352e42a">3.2</ix:nonFraction> million related to debt issue costs incurred with the issuance of the Loan Facilities and Second Lien Notes, as discussed above, and $<ix:nonFraction unitRef="usd" contextRef="i8915c98904a74bd98e03842b6725688d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzg5MDA_0bfc9281-a029-4c52-932e-bdd965cbe3d2">2.3</ix:nonFraction> million related to deferred financing fees on the Previous Credit Facilities, which were written off upon extinguishment. All remaining deferred financing fees related to the Previous Credit Facilities of $<ix:nonFraction unitRef="usd" contextRef="i5ea39b7659c64974ab62326385972ecc_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzkxMDA_f0fa6944-8f12-44c3-92ae-73b6e0543dc2">7.6</ix:nonFraction> million were attributed to modified loans, which are capitalized and will be amortized over the remaining term of the Loan Facilities and Second Lien Notes.</span></div><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzk3ODE_3fd5d461-42f9-4e8d-9eaf-5075bc850510" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt matures as follows (in thousands):</span></div><div style="margin-bottom:10pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:54.239%"><tr><td style="width:1.0%"></td><td style="width:61.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpjNmU4Mjg2YmNmZTE0ZDUzYmI3MWY0NTE4NjU3YzEwYS90YWJsZXJhbmdlOmM2ZTgyODZiY2ZlMTRkNTNiYjcxZjQ1MTg2NTdjMTBhXzEtMi0xLTEtMA_97a90c6a-37f5-4b18-9f4d-f04ba56319ff">9,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpjNmU4Mjg2YmNmZTE0ZDUzYmI3MWY0NTE4NjU3YzEwYS90YWJsZXJhbmdlOmM2ZTgyODZiY2ZlMTRkNTNiYjcxZjQ1MTg2NTdjMTBhXzItMi0xLTEtMA_67e86c9f-b075-4b36-85d4-d4f906e6d241">9,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpjNmU4Mjg2YmNmZTE0ZDUzYmI3MWY0NTE4NjU3YzEwYS90YWJsZXJhbmdlOmM2ZTgyODZiY2ZlMTRkNTNiYjcxZjQ1MTg2NTdjMTBhXzMtMi0xLTEtMA_3cd35b40-bd0a-4aa8-9e81-3449d908a446">9,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpjNmU4Mjg2YmNmZTE0ZDUzYmI3MWY0NTE4NjU3YzEwYS90YWJsZXJhbmdlOmM2ZTgyODZiY2ZlMTRkNTNiYjcxZjQ1MTg2NTdjMTBhXzQtMi0xLTEtMA_871bb0f8-6ec2-4413-81a8-42c6bd7b0276">9,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpjNmU4Mjg2YmNmZTE0ZDUzYmI3MWY0NTE4NjU3YzEwYS90YWJsZXJhbmdlOmM2ZTgyODZiY2ZlMTRkNTNiYjcxZjQ1MTg2NTdjMTBhXzUtMi0xLTEtMA_c280a0fe-4dc4-4510-8e79-3e176ba3aa5f">9,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 and beyond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpjNmU4Mjg2YmNmZTE0ZDUzYmI3MWY0NTE4NjU3YzEwYS90YWJsZXJhbmdlOmM2ZTgyODZiY2ZlMTRkNTNiYjcxZjQ1MTg2NTdjMTBhXzYtMi0xLTEtMA_c2e48073-465c-4dc3-aa8f-78c32e91425c">1,115,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpjNmU4Mjg2YmNmZTE0ZDUzYmI3MWY0NTE4NjU3YzEwYS90YWJsZXJhbmdlOmM2ZTgyODZiY2ZlMTRkNTNiYjcxZjQ1MTg2NTdjMTBhXzctMi0xLTEtMA_57dacae4-6cdf-49d5-86cf-eb36b78e5442">1,161,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into an amendment on the First Lien Term Loan, which resulted in an additional $<ix:nonFraction unitRef="usd" contextRef="i475c18c38aea40bfa20cc795a9a0586e_I20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1MzEwNDY_63bc1a78-ee8a-4452-8a59-a1e267e4221d">250.0</ix:nonFraction> million of incremental First Lien Term Loan indebtedness being issued, which was used to prepay the remaining $<ix:nonFraction unitRef="usd" contextRef="i6b688f43690d4a10bb658649d8f26b91_D20210101-20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1MzEwNjY_b3a257ce-64f4-4cd8-9d35-f8ea1e624121">245.8</ix:nonFraction> million outstanding balance of the Second Lien Notes. See Note 19, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion.</span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><ix:continuation id="iac8689c4636141738166b1d71a450111"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzk3NzY_9b7b71f7-c762-43f0-97a3-80df04c5c9b7" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated fair values of the Company&#8217;s debt obligations as of December&#160;31, 2020  (in thousands):</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.356%"><tr><td style="width:1.0%"></td><td style="width:27.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value as of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Markets for Identical Item (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Note Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia70d084d67ce4667b22225e30b5f6b8c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzEtMi0xLTEtMA_685f75fa-3049-41f5-84aa-2cc8281c651a">888,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d71acb5790f4712b5fe4d979c0e2bd2_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzEtNC0xLTEtMA_17c482df-8ac1-4370-996a-348d13e0d61d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46dc5fdf0022473d841d625d8ca2e5cf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzEtNi0xLTEtMA_76ea6244-845d-481a-a4c5-7e1d080827be">913,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a157555439142d78694bcf7b01379aa_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzEtOC0xLTEtMA_0de17d12-83e7-4e1e-9924-cd7c9e3ac32f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Lien Note Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660fc6279c714085b9bafae194ba5b7d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzItMi0xLTEtMA_1dd0d107-0eb9-4085-a9a8-db4409c2029c">235,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie94a2f3b1fce4b9abcfcd916988d3eb8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzItNC0xLTEtMA_50bfb28b-9f66-4670-b4a2-3c94b0900344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15aa1aad0d3744a0abc478e642582276_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzItNi0xLTEtMA_18e14f5c-01c2-4521-b541-809ceb0f7416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb5343b6a2e9432f8e58f2bd9a3d07ed_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzItOC0xLTEtMA_18d99c20-6d1c-4584-a8fc-6cf34882b37c">266,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0851f5015634259990ba26f9a4a889e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzMtMi0xLTEtMA_5d960dc3-251c-4700-af90-b45d32100258">1,124,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d3c87930eb1479888f34f3af43a0440_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzMtNC0xLTEtMA_04c47dee-fdc9-4b19-aeed-89b04f9f4582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa3ac11591f4ece89016cc369ba0e2b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzMtNi0xLTEtMA_32e7af6b-7288-4c2e-bc86-e92802362411">913,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d7bc9bd670f4ffb91c21fb59c7c7fb1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzMtOC0xLTEtMA_1fcd807e-c7aa-48a5-b82d-5ed6343cc41e">266,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the changes in Level 3 measurements for the year ended December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:68.128%"><tr><td style="width:1.0%"></td><td style="width:69.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3 Measurements</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Lien Notes fair value as of January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d077a5e93842429e329f0dcb9d0f2d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo0Y2Q3MmYzM2UwNmI0OTViODI3YzJjNDg4OTA5YzNjYi90YWJsZXJhbmdlOjRjZDcyZjMzZTA2YjQ5NWI4MjdjMmM0ODg5MDljM2NiXzEtMi0xLTEtMA_34e4b616-a09a-4146-973a-a1e996664785">411,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal prepayment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadaac97b718242739dbbd6f6ed2e6ae0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo0Y2Q3MmYzM2UwNmI0OTViODI3YzJjNDg4OTA5YzNjYi90YWJsZXJhbmdlOjRjZDcyZjMzZTA2YjQ5NWI4MjdjMmM0ODg5MDljM2NiXzMtMi0xLTEtMA_a69db675-8b89-4f6b-8df2-1a5c251b3ce9">174,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate PIK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f46d4be96544528533fb90947e87a4_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo0Y2Q3MmYzM2UwNmI0OTViODI3YzJjNDg4OTA5YzNjYi90YWJsZXJhbmdlOjRjZDcyZjMzZTA2YjQ5NWI4MjdjMmM0ODg5MDljM2NiXzYtMi0xLTEtMA_2afaf8b0-06c8-4c10-b4bd-f240b7b9a89c">7,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f46d4be96544528533fb90947e87a4_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo0Y2Q3MmYzM2UwNmI0OTViODI3YzJjNDg4OTA5YzNjYi90YWJsZXJhbmdlOjRjZDcyZjMzZTA2YjQ5NWI4MjdjMmM0ODg5MDljM2NiXzctMi0xLTEtMA_1e0aa949-694b-4243-9228-c7ac219e188c">21,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Lien Notes fair value as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb5343b6a2e9432f8e58f2bd9a3d07ed_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo0Y2Q3MmYzM2UwNmI0OTViODI3YzJjNDg4OTA5YzNjYi90YWJsZXJhbmdlOjRjZDcyZjMzZTA2YjQ5NWI4MjdjMmM0ODg5MDljM2NiXzgtMi0xLTEtMA_4ee1424d-d763-4163-99cb-8627ccaaa7c0">266,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion.</span></div></ix:continuation><div id="ic913b68a604e4ff38c42375d3fa7a17b_151"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzM2OTc_992a2899-3f23-4fc5-87c1-2db1b9dc4a5e" continuedAt="ide05cb11a384456ca11f5e34d536c2bd" escape="true">DERIVATIVE INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="ide05cb11a384456ca11f5e34d536c2bd" continuedAt="i20a550aaff4447a0adf1b5130b6f1cea"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes derivative financial instruments for hedging and non-trading purposes to limit the Company&#8217;s exposure to its variable interest rate risk. Use of derivative financial instruments in hedging strategies subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company&#8217;s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company&#8217;s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2017, Option Care entered into interest rate caps that reduce the risk of increased interest payments due to rising interest rates. The hedges offset the risk of rising interest rates through 2020 on the first $<ix:nonFraction unitRef="usd" contextRef="i0bd8c01514d84331992e13473d81c16b_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzExMTk_23247f58-d887-4f10-aeec-1013c9662600">250.0</ix:nonFraction> million of the Previous First Lien Term Loan. The interest rate caps perfectly offset the terms of the interest rates associated with the variable interest rate Previous First Lien Term Loan. Option Care entered into the interest rate caps as a cash flow hedge for a notional amount of $<ix:nonFraction unitRef="usd" contextRef="iaa2b883648c2436f83ec2369cdbc149b_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzE0MDA_c21b1f02-2e60-4851-82b9-c46522e2ad07">1.9</ix:nonFraction> million. In April 2019, Option Care terminated its interest rate caps and received cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="iddb4b3d5aafc422db864143a1b1aa819_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzE0OTU_e490af99-d841-42e2-9302-29463669d2ac">1.7</ix:nonFraction> million, net of early termination fees. In conjunction with the termination of the interest rate caps, Option Care discontinued the hedge accounting associated with the interest rate caps. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company entered into interest rate swap agreements that reduce the variability in the interest rates on the newly-issued debt obligations. The first interest rate swap for $<ix:nonFraction unitRef="usd" contextRef="i8fbd469711e34b0cb074a178241284d8_I20190831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzE4NzI_7e83ff62-c0b5-45bb-a8d7-3c07eaecd461">925.0</ix:nonFraction> million notional was effective in August 2019 with $<ix:nonFraction unitRef="usd" contextRef="i65baa1ec1f4d461b86b9b6f2542d2c72_I20190831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzE5MTg_d0a3936b-295e-46a4-96ec-c4b64aab8245">911.1</ix:nonFraction> million designated as a cash flow hedge against the underlying interest rate on the First Lien Term Loan interest payments indexed to one-month LIBOR through August 2021. In accordance with ASU 2017-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Targeted Improvements to Accounting for Hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has determined that the $<ix:nonFraction unitRef="usd" contextRef="i65baa1ec1f4d461b86b9b6f2542d2c72_I20190831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzU0OTc1NTgxNDQ2MTA_d0a3936b-295e-46a4-96ec-c4b64aab8245">911.1</ix:nonFraction> million designated cash flow hedge is perfectly effective. The remaining $<ix:nonFraction unitRef="usd" contextRef="icdd8047975e647288143981c8762166c_I20190831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzU0OTc1NTgxNDQ2MzA_335a90b5-b9ad-4eee-94e0-02bf21e941ae">13.9</ix:nonFraction> million notional amount of the first interest rate swap is not designated as a hedging instrument. The second interest rate swap for $<ix:nonFraction unitRef="usd" contextRef="i70568db5bcc649c5bd6104996dd8bf09_I20191106" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzIxMTg_1a825bc1-4330-4a2a-85ef-38c6cdaeb484">400.0</ix:nonFraction> million notional was effective in November 2019 and was designated as a cash flow hedge against the underlying interest rate on the Second Lien Notes interest payment indexed to three-month LIBOR through November 2020. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company elected to PIK the Second Lien Notes&#8217; quarterly interest payment due in August 2020. Upon making the PIK election, the Company determined that the hedged interest payment would no longer occur, resulting in an ineffective hedge, so the Company discontinued hedge accounting on its $<ix:nonFraction unitRef="usd" contextRef="i70568db5bcc649c5bd6104996dd8bf09_I20191106" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzU0OTc1NTgxNDQ2NTE_1a825bc1-4330-4a2a-85ef-38c6cdaeb484">400.0</ix:nonFraction> million notional interest rate swap.  As a result, the Company reclassified accumulated comprehensive loss of $<ix:nonFraction unitRef="usd" contextRef="ib0cf4d78796d429d879bce469f3f3150_D20200501-20200531" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzU0OTc1NTgxNDQ2OTE_b5b8d971-0cd4-40d2-8920-fbbfadce6884">3.7</ix:nonFraction> million to interest expense, net in the consolidated statements of comprehensive income (loss). The gains and losses associated with the $<ix:nonFraction unitRef="usd" contextRef="i70568db5bcc649c5bd6104996dd8bf09_I20191106" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzU0OTc1NTgxNDQ2NzI_1a825bc1-4330-4a2a-85ef-38c6cdaeb484">400.0</ix:nonFraction> million notional swap were recognized in net income (loss) through interest expense until the swap expired in November 2020. See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the PIK.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><ix:continuation id="i20a550aaff4447a0adf1b5130b6f1cea"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzM2OTg_9cf69f08-8cbe-49f3-b753-40b935102fde" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and location of the Company&#8217;s derivative instruments in the consolidated balance sheets (in thousands):</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:44.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.257%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value - Derivatives in liability position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b483f33dcad4616a569483ce451b1b9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzItNC0xLTEtMA_54e99372-ea2c-470e-87df-7775ad40bbd9">11,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2467317320d4c409705b0b02f8ab210_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzItNi0xLTEtMA_1333701c-68f1-4aae-8ecf-1c057c26183f">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e4af3f2d204d8f95b5b4ad2982893d_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzMtNC0xLTEtNDcxNA_c5fdf96c-2b58-4187-8b13-22b74ba4c8c5">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc9a7eafdb69419ba693d8dffce79f3b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzMtNi0xLTEtNDcxNA_7f91217e-d93f-4018-8b2e-20652a38e465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eefd11356ef4acfa576e05c36eec86e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzMtNC0xLTEtMA_d9cfc311-9524-4d02-9b7d-ea611b94d785">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19aaeb7b2301410c8ace359b4aae0a61_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzMtNi0xLTEtMA_a5995e39-6432-4473-abcd-c5c25e5d2848">5,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6745feb32545bd99b8438f4cb65e42_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzQtNC0xLTEtMA_6a36349b-572b-441b-9233-8f35ba887ef2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idadf3e087514415d9e588230d1e4c8e8_I20191231" decimals="-3" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzQtNi0xLTEtMA_6b71a34d-5ff5-4d5e-a6c0-758f4dac8cbe">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzUtNC0xLTEtMA_1dde57e4-bef6-4ae6-8bdc-44ed2a68a4c4">11,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzUtNi0xLTEtMA_c1e9de54-3705-45c1-bbda-be364968c221">7,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain and loss associated with the changes in the fair value of the effective portion of the hedging instrument are recorded into other comprehensive (loss) income. The gain and loss associated with the changes in the fair value of the $<ix:nonFraction unitRef="usd" contextRef="i70568db5bcc649c5bd6104996dd8bf09_I20191106" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzU0OTc1NTgxNDQ3MTQ_1a825bc1-4330-4a2a-85ef-38c6cdaeb484">400.0</ix:nonFraction> million notional swap and the $<ix:nonFraction unitRef="usd" contextRef="icdd8047975e647288143981c8762166c_I20190831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzI5Nzg_335a90b5-b9ad-4eee-94e0-02bf21e941ae">13.9</ix:nonFraction> million notional amount not designated as a hedging instrument are recognized in net income (loss) through interest expense. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzM2OTk_71f2e874-f1e7-40df-9e67-26ebb4663315" continuedAt="i5ddbbad533834863b05febfd1177e67c" escape="true">The following table presents the pre-tax gains (losses) from derivative instruments recognized in other comprehensive (loss) income in the Company&#8217;s consolidated statements of comprehensive income (loss) (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i5ddbbad533834863b05febfd1177e67c"><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.754%"><tr><td style="width:1.0%"></td><td style="width:58.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate caps designated as cash flow hedges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie42dd3293f1047ffb0d1d1e673596db2_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzItMS0xLTEtMA_3c26827d-d3b2-4812-bf6b-894af28d6d54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5536ba9ef240436f8685941bf069832f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzItMy0xLTEtMA_8041d68d-b58a-43cb-a6db-da3d5f3615f4">1,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc8999935b584fbe93f3edcbbb32aa8b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzItNS0xLTEtMA_c16cc54a-3598-45f0-9cd5-4740fbdb80de">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf3e87fd34a94950b1dfab02c0351ccb_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzMtMS0xLTEtMA_aa4fa35f-0d46-43c7-beec-ea2de2a44d8d">7,723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a2d963d4b4c4bf0bc68ff139a36a0d1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzMtMy0xLTEtMA_103f082d-a2be-4fb0-aa67-e6bcc79de040">7,195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2ffe75f1b2e4b789fd671082186d2f2_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzMtNS0xLTEtMA_de37a152-e2e0-424a-972c-60514880d52d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps that discontinued hedge accounting</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf3e87fd34a94950b1dfab02c0351ccb_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="bios:OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzQtMS0xLTEtNDcxOQ_ea179bb8-07b0-4101-b444-efcd7b583e2f">3,746</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a2d963d4b4c4bf0bc68ff139a36a0d1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="bios:OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzQtMy0xLTEtNDcxOQ_68bf8a6c-b39d-4a9b-87af-b13b24525d67">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2ffe75f1b2e4b789fd671082186d2f2_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="bios:OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzQtNS0xLTEtNDcxOQ_dae4c75f-7828-46db-b4d0-92397c109436">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzQtMS0xLTEtMA_2d82ec98-2c4b-4282-947b-0857dc2d3c9d">3,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzQtMy0xLTEtMA_7724532d-c79e-4af4-95dc-b715779d134e">8,298</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzQtNS0xLTEtMA_b3845324-3c2b-4907-ae6c-34b76da2b569">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amount and location of pre-tax income (loss) recognized in the Company&#8217;s consolidated statement of comprehensive income (loss) related to the Company&#8217;s derivative instruments (in thousands):</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:47.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.168%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.168%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate caps designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if51a0a2416fc4efaa81e5964f060685f_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzItMy0xLTEtMA_9957efdd-ab7e-41fe-8396-81368b2275e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77b199f5d9fe42879ba86a116b6460d8_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzItNS0xLTEtMA_063d52cc-b3e8-4529-83cf-1db67f76af0a">125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieea161291d5e4067a3bf1b40c8e4dac7_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzItNy0xLTEtMA_fb93fd7a-0b98-460a-93b4-8ce6c2d17fb1">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe4cf21bfb5140d997a613e6c5626e64_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzMtMy0xLTEtMA_67a338dd-d9d9-4864-81de-9d50b0a59652">12,799</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8eb1d1e629ac4a0ba804cec14a4547ea_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzMtNS0xLTEtMA_c880a5a4-543c-4b70-8d8a-cc057bb853cf">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada07b387c4c497182b71cd727197396_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzMtNy0xLTEtMA_6478b57c-01d1-42bf-81da-bdaae14a6563">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps not designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe4cf21bfb5140d997a613e6c5626e64_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzQtMy0xLTEtMA_3c37d047-0048-4ee5-85ff-6146d11b1236">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8eb1d1e629ac4a0ba804cec14a4547ea_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzQtNS0xLTEtMA_0978a87a-b4d9-4fc8-b4cc-15ae314fbe04">92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada07b387c4c497182b71cd727197396_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzQtNy0xLTEtMA_d5e428a7-b3dc-4f85-850a-c4aef8b0bade">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps that discontinued hedge accounting</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe4cf21bfb5140d997a613e6c5626e64_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzUtMy0xLTEtNDczMA_036b85cc-7cf2-458f-916e-e9cfa24abab5">3,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb1d1e629ac4a0ba804cec14a4547ea_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzUtNS0xLTEtNDczMA_423b5f3d-31b0-482e-b3a3-f65928b9a040">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada07b387c4c497182b71cd727197396_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzUtNy0xLTEtNDczMA_1dcd9503-2d04-4d16-a9ff-f7b45cc5c2ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzUtMy0xLTEtMA_f09efd68-05ce-46ee-a454-9f4bff833484">16,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzUtNS0xLTEtMA_e3635b14-6975-472b-a851-e3be93a51d69">332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzUtNy0xLTEtMA_921d6c56-7971-4968-a2b6-850500ccdea0">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to reclassify $<ix:nonFraction unitRef="usd" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzM1NzM_57b53f5a-32bc-4ffb-8bac-760e832d1e86">11.2</ix:nonFraction> million of total interest rate costs from accumulated other comprehensive loss against interest expense during the next 12 months.</span></div></ix:continuation><div id="ic913b68a604e4ff38c42375d3fa7a17b_154"></div><div style="margin-bottom:10pt;margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:continuation id="ifd48ba5046b34e7bb2565b79cedcd7e4" continuedAt="i28ff4fd2666442a695eac48639cbecd5"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTQvZnJhZzphYTkwZTA2MzdmZTI0MjExOTcyNjU0N2UxMjU2NDMxNi90ZXh0cmVnaW9uOmFhOTBlMDYzN2ZlMjQyMTE5NzI2NTQ3ZTEyNTY0MzE2XzIzMDQ_c5e8c4ce-a67d-4df8-ae00-99e69b04ec90" continuedAt="i51938f29633549d3b155ccc2faf8543e" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></ix:continuation></span></div><ix:continuation id="i51938f29633549d3b155ccc2faf8543e"><ix:continuation id="i28ff4fd2666442a695eac48639cbecd5" continuedAt="i9d90fe7cd32a4ee1a1e5018d03794b19"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs.  The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements).  The three levels of inputs within the fair value hierarchy are defined in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Lien Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Lien Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the Second Lien Notes is derived from a cash flow model that discounted the cash flows based on market interest rates (Level 3 inputs). See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the Second Lien Notes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate swaps</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair values of interest rate swaps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the fair value of the interest rate swaps. </span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i9d90fe7cd32a4ee1a1e5018d03794b19" continuedAt="i25b6c9deab364ace85dbaa2c2edb6415">Interest rate caps</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i25b6c9deab364ace85dbaa2c2edb6415">: The fair values of interest rate caps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers.</ix:continuation> In April 2019, Option Care terminated its interest rate caps. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the fair value of the interest rate caps.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other assets or liabilities measured at fair value at December&#160;31, 2020 or 2019.</span></div></ix:continuation><div id="ic913b68a604e4ff38c42375d3fa7a17b_157"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTcvZnJhZzowYTNkNDYwMWQ5MjM0ZThiOGI3ZGIzYTExOWFiZTUxZS90ZXh0cmVnaW9uOjBhM2Q0NjAxZDkyMzRlOGI4YjdkYjNhMTE5YWJlNTFlXzE2MTU_36d293b4-71dc-4c45-984b-88ae77eb2380" continuedAt="i2adf76f6cf8141c5a1598e03064a8405" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2adf76f6cf8141c5a1598e03064a8405">The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company&#8217;s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized. The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company&#8217;s consolidated balance sheets. However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.</ix:continuation></span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_160"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQ4OTY_379b51c7-b2aa-4399-8ba0-d6e47fbdf88b" continuedAt="ie9b00e9a0ec6441b841fdee444ef7c36" escape="true">STOCK-BASED INCENTIVE COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="ie9b00e9a0ec6441b841fdee444ef7c36" continuedAt="i0a8ba7bfe68e4518b7ab0ab284b0912b"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Under the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), approved at the annual meeting by the BioScrip stockholders on May 3, 2018, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors. The 2018 plan is administered by the Company&#8217;s Compensation Committee, a standing committee of the Board of Directors. A total of <ix:nonFraction unitRef="shares" contextRef="ie78754462d4f48648b6dde71360bba63_I20180503" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzU0OTc1NTgxNDYzNjE_34046d31-aee5-4175-a39d-e853ba1e3cc1">4,101,735</ix:nonFraction> shares of common stock were initially authorized for issuance under the 2018 Plan. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Options granted under the 2018 Plan typically vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzgxMA_5835ea03-79c7-4f33-bae1-42d73cd55de9">three</span>- or <ix:nonNumeric contextRef="i24920ce6c3624d32867b35ecb74cd412_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzMyOTg1MzQ4OTEzNzY_12ccc3b1-4a39-4d87-b13d-2c6b34c87da8">four-year</ix:nonNumeric> period and, in certain instances, may fully vest upon a change in control of the Company. The options also typically have an exercise price that may not be less than 100% of its fair market value on the date of grant and are exercisable <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzEwNTU_96670979-bd52-4453-a4dd-ea37a865d80c">seven</span> to <ix:nonNumeric contextRef="i1cd470f5e6054ec5b5f94411ed707e82_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzEwNjE_daca59e8-1799-4290-b6f8-81cfa052fe50">ten years</ix:nonNumeric> after the date of grant, subject to earlier termination in certain circumstances.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense from stock options is recognized on a straight-line basis over the requisite service period. During the years ended December&#160;31, 2020 and 2019, the Company recognized compensation expense related to stock options of $<ix:nonFraction unitRef="usd" contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzU0OTc1NTgxNDYzOTg_09353308-9e11-4e54-ad02-a3d769fc7f55">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1599283f6d184d1b9aa7b7fa0b2e0ce8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzU0OTc1NTgxNDYzODE_26ee021b-3d6e-45ad-a230-718f3918d8bf">0.4</ix:nonFraction> million. The Company did not recognize any compensation expense related to stock options prior to the Merger.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value of options granted during the year ended December&#160;31, 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQzOTgwNDY1MTg2Mzg_b3eca1d3-5e04-43c3-94f5-bab1a98d413d">5.94</ix:nonFraction>. The Company did <ix:nonFraction unitRef="shares" contextRef="i1599283f6d184d1b9aa7b7fa0b2e0ce8_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzE0Nzg_496c49a8-398d-497c-aad5-f9ba8b2400de"><ix:nonFraction unitRef="shares" contextRef="i760b317cd0fd4b0d9e286a06610ffaec_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzE0Nzg_7c6c8bb7-04df-4435-a544-56b73e0f85e0">no</ix:nonFraction></ix:nonFraction>t grant any options during the years ended December&#160;31, 2019 or 2018. The fair value of stock options granted was estimated on the date of grant using a Black-Scholes pricing model. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzMyOTg1MzQ4OTEzNzc_fc39b4bf-6202-4996-94c5-53f531046cab" continuedAt="iea2ac800860240d49ec72100863df537" escape="true">The assumptions used to compute the fair value of options for the year ended December&#160;31, 2020 are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:10pt"><ix:continuation id="iea2ac800860240d49ec72100863df537" continuedAt="ic5b5122be69649aeaa35c7d5cad71043"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.350%"><tr><td style="width:1.0%"></td><td style="width:49.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpiZWIwMjhkYWUwZGU0ZjFlOWY3YmFiOWQyZWZjMTgyOS90YWJsZXJhbmdlOmJlYjAyOGRhZTBkZTRmMWU5ZjdiYWI5ZDJlZmMxODI5XzAtMS0xLTEtMzQ3NQ_0d6b43cc-f066-4b5e-be2b-a89646aefb2d">45.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpiZWIwMjhkYWUwZGU0ZjFlOWY3YmFiOWQyZWZjMTgyOS90YWJsZXJhbmdlOmJlYjAyOGRhZTBkZTRmMWU5ZjdiYWI5ZDJlZmMxODI5XzEtMS0xLTEtMzQ3NQ_22a3e59d-be0c-4f48-a10f-9332cb0bd31b">0.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life of options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpiZWIwMjhkYWUwZGU0ZjFlOWY3YmFiOWQyZWZjMTgyOS90YWJsZXJhbmdlOmJlYjAyOGRhZTBkZTRmMWU5ZjdiYWI5ZDJlZmMxODI5XzItMS0xLTEtMzQ3NQ_3ce0723c-5874-4092-a12f-cb09844ac233">6.3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" decimals="3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpiZWIwMjhkYWUwZGU0ZjFlOWY3YmFiOWQyZWZjMTgyOS90YWJsZXJhbmdlOmJlYjAyOGRhZTBkZTRmMWU5ZjdiYWI5ZDJlZmMxODI5XzMtMS0xLTEtMzQ3NQ_70a16ab3-c314-43b8-89f3-c21e1fc89fab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQ4ODQ_70f7d339-59cc-4e91-95c0-51c427cad2fa" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the year ended December&#160;31, 2020 is as follows: </span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:28.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7593332c92344b60ad9b41ff0c66bfb8_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzEtMS0xLTEtMA_4704f9bd-ea85-40cf-aa7f-8c66d7f7d5ff">644,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7593332c92344b60ad9b41ff0c66bfb8_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzEtMy0xLTEtMA_038dd7f3-d8fd-4147-acb2-f0c30f99e90c">15.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7593332c92344b60ad9b41ff0c66bfb8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzEtNS0xLTEtMA_56d683e9-7437-4681-9e33-c3da1871290c">2,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzMtMS0xLTEtMA_3a07114e-04e1-40f5-bc31-81d730d04f14">204,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzMtMy0xLTEtMA_14c6bede-8f67-438f-acde-60539308954c">13.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" decimals="-3" name="bios:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzMtNS0xLTEtMA_dcd788a6-5b10-42b4-b7f3-97e1db2a7cd4">471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzQtMS0xLTEtMA_2e57e8af-86d0-4ac7-aa9b-56db2e1bd02a">266,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzQtMy0xLTEtMA_a8642026-14b7-4655-9d04-eae082b7f006">7.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzQtNS0xLTEtMA_eaf18f5c-4c68-4a25-9966-99b374338571">2,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzUtMS0xLTEtMA_bdcd0806-992b-4e32-8872-326008437895">171,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzUtMy0xLTEtMA_6d99140d-c59d-44e0-8110-46192c6ecf0b">26.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" decimals="-3" name="bios:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzUtNS0xLTEtMA_4a29ea3e-0580-479d-ad99-7c3efc6b8768">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i53bc279beb0d4676ba828340fd063ce9_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzYtMS0xLTEtMA_97ae3866-57f4-4505-b8cc-bfe4ae916e76">412,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i53bc279beb0d4676ba828340fd063ce9_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzYtMy0xLTEtMA_e3e083bf-41b3-42db-9995-1af446e032e3">14.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53bc279beb0d4676ba828340fd063ce9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzYtNS0xLTEtMA_74ddef99-beac-46e7-ad2c-40052e2e239a">1,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzYtNy0xLTEtMA_399d83d1-4d24-46f1-960c-794aa91723c9">6.7</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i53bc279beb0d4676ba828340fd063ce9_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzctMS0xLTEtMA_60fcd79a-f19a-41c0-81ee-a28431c9e1f4">197,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i53bc279beb0d4676ba828340fd063ce9_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzctMy0xLTEtMA_bab73b5d-5cbb-4cf5-a267-bbf20882e156">16.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53bc279beb0d4676ba828340fd063ce9_I20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzctNS0xLTEtMA_fd05bad3-0b3f-4363-be39-f300e54c7a8d">789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzctNy0xLTEtMA_972b2d61-67e9-4177-8472-839906e1db4d">4.2</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, shares were surrendered to satisfy tax withholding obligations on the exercise of stock options with a cost basis of $<ix:nonFraction unitRef="usd" contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQzOTgwNDY1MTg2ODQ_472c1497-2cfd-4b4d-abf9-52784faeb096">2.7</ix:nonFraction>&#160;million. During the year ended December&#160;31, 2019, shares were surrendered to satisfy tax withholding obligations on the exercise of stock options with a cost basis of $<ix:nonFraction unitRef="usd" contextRef="i1599283f6d184d1b9aa7b7fa0b2e0ce8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzE4MjA_59c0fe36-1aad-47d6-a662-a5ff93129bc6">0.4</ix:nonFraction> million, which are all held as treasury stock as of December&#160;31, 2020. During the year ended December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQzOTgwNDY1MTg5MjQ_a7297a5c-36ea-4228-b136-cdcb07af43cf">0.4</ix:nonFraction> million of cash was received from stock option exercises under share-based payment arrangements. <ix:nonFraction unitRef="usd" contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzMyOTg1MzQ4OTEzNDM_75eb0bda-603e-4ade-a6b1-c10333322bf2"><ix:nonFraction unitRef="usd" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzMyOTg1MzQ4OTEzNDM_b3435fdd-e3be-414e-a06a-f0f7d1d72d3d">No</ix:nonFraction></ix:nonFraction> cash was received from stock option exercises under share-based payment arrangements for the years ended December 31, 2019 or 2018.</span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><ix:continuation id="i0a8ba7bfe68e4518b7ab0ab284b0912b" continuedAt="id664ffed03cd4b78ad38a136d8b7366f"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum term of stock options under these plans is <ix:nonNumeric contextRef="i1cd470f5e6054ec5b5f94411ed707e82_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzIwMzk_fc04c786-d56e-401e-95a2-1cb81cfd4307">ten years</ix:nonNumeric>. Options outstanding as of December&#160;31, 2020 expire on various dates ranging from January 2021 through March 2030. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQ4OTQ_fb5de6ef-6447-45ec-955b-875ff680278a" continuedAt="i2f78f852d7d04da0869c5315d3460e54" escape="true">The following table outlines the outstanding and exercisable stock options as of December&#160;31, 2020:</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-align:center"><ix:continuation id="i2f78f852d7d04da0869c5315d3460e54"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:14.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Option Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i9e711f6fe89d4907a952226e5df765bd_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzItMC0xLTEtMC90ZXh0cmVnaW9uOmZlN2M2MjNjOTMyOTRmYjJiNzQ5NTkwN2U2M2I3OTE1XzQzOTgwNDY1MTExMDg_07abcf08-af81-4346-bb05-232c31ab1512">0.00</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i9e711f6fe89d4907a952226e5df765bd_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzItMC0xLTEtMC90ZXh0cmVnaW9uOmZlN2M2MjNjOTMyOTRmYjJiNzQ5NTkwN2U2M2I3OTE1XzQzOTgwNDY1MTExMTQ_d9f220b0-16c1-4c9c-aa34-cd6abd1044fa">8.24</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied37c8390b9e43a68cb9da71a0ccb303_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzItMi0xLTEtMA_a90a2873-89e0-4f77-9e3f-6cb2412c9ebc">9,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ied37c8390b9e43a68cb9da71a0ccb303_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzItNC0xLTEtMA_d99553ab-8ed7-4071-9107-8a6e2165bbd5">6.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9e711f6fe89d4907a952226e5df765bd_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzItNi0xLTEtMA_77bd24de-e4c9-42f6-85af-739dbd22a0ad">6.1</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied37c8390b9e43a68cb9da71a0ccb303_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzItOC0xLTEtMA_6f51fc46-8249-42a1-bc4b-2c6458bcbda2">9,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ied37c8390b9e43a68cb9da71a0ccb303_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzItMTAtMS0xLTA_625e7ae9-3e25-4971-9456-6f5b8a1357b4">6.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic297998b32b84faa88fcfec2d9f9afaa_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjg0MDkwNzMwNDkxOTQ1YmFiMGNhMGU1YzExNGUwNjVjXzQzOTgwNDY1MTExMDg_e845548a-e834-46f4-896b-040a985666df">8.24</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="ic297998b32b84faa88fcfec2d9f9afaa_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjg0MDkwNzMwNDkxOTQ1YmFiMGNhMGU1YzExNGUwNjVjXzQzOTgwNDY1MTExMTQ_9c5dbcfa-a525-4780-b00f-52107e517624">16.52</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e5ee81d05914bbbb9c62c51c01221b7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzMtMi0xLTEtMA_6c0ac378-67f1-4af8-b592-19e51acdebc3">345,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e5ee81d05914bbbb9c62c51c01221b7_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzMtNC0xLTEtMA_d51e128e-53b6-4f4a-b81d-1509a6c36ef4">12.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic297998b32b84faa88fcfec2d9f9afaa_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzMtNi0xLTEtMA_04e40689-8031-44ac-b5e7-9624d5a67a58">7.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e5ee81d05914bbbb9c62c51c01221b7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzMtOC0xLTEtMA_e4eaea44-b9d9-4bf5-bf54-0e8958f2a9ff">130,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e5ee81d05914bbbb9c62c51c01221b7_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzMtMTAtMS0xLTA_d2fea265-471f-4e8d-8c69-d78ea655f0d8">10.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ia22152ff44814391aef12293b8db163f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjcxMzdiZjlmMzIwYjRmNTRiOWUwOTNlZmFjOTVlOWY2XzQzOTgwNDY1MTExMDg_82f90eb7-2c75-4c8b-b79d-040642fa99f1">16.52</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="ia22152ff44814391aef12293b8db163f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjcxMzdiZjlmMzIwYjRmNTRiOWUwOTNlZmFjOTVlOWY2XzQzOTgwNDY1MTExMTQ_46327e3f-3442-4fbb-931e-d161996012d1">24.76</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i63a51e68f4934ca4aa97b767de686c2e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzQtMi0xLTEtMA_644b1501-919e-402f-bad0-8d3d785f434c">25,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i63a51e68f4934ca4aa97b767de686c2e_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzQtNC0xLTEtMA_67fb5e43-5f95-42f1-908f-d0239c832581">22.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia22152ff44814391aef12293b8db163f_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzQtNi0xLTEtMA_b7502299-485a-4512-8019-49caf8fd8343">2.7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i63a51e68f4934ca4aa97b767de686c2e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzQtOC0xLTEtMA_2140e149-4537-4b60-a1f8-9fa1413a4afb">25,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i63a51e68f4934ca4aa97b767de686c2e_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzQtMTAtMS0xLTA_082812dd-4470-406a-a33b-5bdb2b234fad">22.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic98475680f7349638688cb46f1e41606_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQyN2I0MThjYjFmYzRmMGQ5MmFhY2Q0NzEyOWRkZTZlXzQzOTgwNDY1MTExMDg_ac32f161-dfd6-4d6a-81f4-116b2e3d0299">24.76</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="ic98475680f7349638688cb46f1e41606_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQyN2I0MThjYjFmYzRmMGQ5MmFhY2Q0NzEyOWRkZTZlXzQzOTgwNDY1MTExMTQ_484d3ea7-bf6e-4385-b745-e193bcd0e457">33.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fd061fe54554bc695ee04673aa61e17_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzUtMi0xLTEtMA_c64e41fa-6ee2-4be0-be02-58c4f367fd07">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7fd061fe54554bc695ee04673aa61e17_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzUtNC0xLTEtMA_a528e37a-685c-44da-ab7d-a08ba5f88f62">30.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic98475680f7349638688cb46f1e41606_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzUtNi0xLTEtMA_3c884cc4-460d-4d34-8f22-69b63d99797b">2.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fd061fe54554bc695ee04673aa61e17_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzUtOC0xLTEtMA_8b39cb42-3b2c-4301-9fc6-fa9a39dee606">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7fd061fe54554bc695ee04673aa61e17_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzUtMTAtMS0xLTA_d2b349e3-3611-4aa5-acaa-ed528d030255">30.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ie25037f6e33c47f0b726fabf6b0be7a6_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjIxODhhNmUxN2Y5YTRkZjQ5M2RkY2M5ZjNjZWVmMmI5XzQzOTgwNDY1MTExMDg_1c997a8d-dad9-4693-a143-e1501fa56049">33.00</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="ie25037f6e33c47f0b726fabf6b0be7a6_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjIxODhhNmUxN2Y5YTRkZjQ5M2RkY2M5ZjNjZWVmMmI5XzQzOTgwNDY1MTExMTQ_c4de4bf4-db2d-41e3-a5c9-1ca050cd74bc">41.28</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6dce6cca08246afbc1f71bef99be371_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzYtMi0xLTEtMA_a0b9c4b9-7883-48c2-a48b-fa899732b8d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if6dce6cca08246afbc1f71bef99be371_I20201231" decimals="2" format="ixt:zerodash" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzYtNC0xLTEtMA_289972d1-97ae-498a-a249-f37b63c962bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie25037f6e33c47f0b726fabf6b0be7a6_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzYtNi0xLTEtMA_ab9848be-f63c-469d-a297-95be9581c712">0.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6dce6cca08246afbc1f71bef99be371_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzYtOC0xLTEtMA_0ace7e1f-48a5-4015-8437-461be0be047d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if6dce6cca08246afbc1f71bef99be371_I20201231" decimals="2" format="ixt:zerodash" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzYtMTAtMS0xLTA_251aa12d-862c-4571-86f6-f333f639a5e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i55f1b01e1ac646989939a0659a3141e6_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzctMC0xLTEtMC90ZXh0cmVnaW9uOmEyMTk4ZmUyNjVhNjQwZTY5YmNkMzgxYmNlMTZmMGJiXzQzOTgwNDY1MTExMDg_1009490e-366c-435f-b839-dbff2bf23c0f">41.28</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i55f1b01e1ac646989939a0659a3141e6_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzctMC0xLTEtMC90ZXh0cmVnaW9uOmEyMTk4ZmUyNjVhNjQwZTY5YmNkMzgxYmNlMTZmMGJiXzQzOTgwNDY1MTExMTQ_426ea4c1-5ea0-41f5-bcf5-e97fdda32c4e">49.52</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42e2317cc254448dba231db5776669d8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzctMi0xLTEtMA_a0c2d65c-0c54-43cb-9eed-b137fd2c0533">12,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i42e2317cc254448dba231db5776669d8_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzctNC0xLTEtMA_1284a1de-747a-40a4-b152-0651492a8997">44.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i55f1b01e1ac646989939a0659a3141e6_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzctNi0xLTEtMA_67cf71f3-068a-477d-9996-21748b99669a">1.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42e2317cc254448dba231db5776669d8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzctOC0xLTEtMA_686dcdeb-162f-4d6a-9897-a84bb96dea66">12,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i42e2317cc254448dba231db5776669d8_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzctMTAtMS0xLTA_3ca3e839-9120-4c16-8f8d-3d33dfb5e6cc">44.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0053d6570a4144ac906506c3b03aab72_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzgtMC0xLTEtMC90ZXh0cmVnaW9uOjc2MTBmY2ZiYWQwNjQ1YmY4ZjVmNTc5NGE5YjM1YmJjXzQzOTgwNDY1MTExMDg_f1328492-2be9-48d1-8ff6-8695d4c8c231">49.52</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i0053d6570a4144ac906506c3b03aab72_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzgtMC0xLTEtMC90ZXh0cmVnaW9uOjc2MTBmY2ZiYWQwNjQ1YmY4ZjVmNTc5NGE5YjM1YmJjXzQzOTgwNDY1MTExMTQ_6a628004-4040-4f51-a973-675a830fa9ca">57.76</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d816e895c844acba36b041455ff1817_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzgtMi0xLTEtMA_a6855842-2416-4558-9df3-6259025e9804">3,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3d816e895c844acba36b041455ff1817_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzgtNC0xLTEtMA_96928fc8-833e-4fb5-b5cd-916c05c2fd33">56.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0053d6570a4144ac906506c3b03aab72_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzgtNi0xLTEtMA_9e52763e-9bf2-46aa-a3fe-f4203de90920">2.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d816e895c844acba36b041455ff1817_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzgtOC0xLTEtMA_fdbff91f-54f2-4085-a2e3-62a33c700665">3,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3d816e895c844acba36b041455ff1817_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzgtMTAtMS0xLTA_dd56e798-09e7-49df-8bb7-1d549e21a8b9">56.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i30fe04022dfb468d8d0ab7e1e5130cbc_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzktMC0xLTEtMC90ZXh0cmVnaW9uOjczMmIzNWRjYzYyNTRmZjJiNmMyY2E4ZmE4ZTJiZTJjXzQzOTgwNDY1MTExMDg_85bd3a97-7288-4fff-b31b-0d26901bb3b9">57.76</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i30fe04022dfb468d8d0ab7e1e5130cbc_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzktMC0xLTEtMC90ZXh0cmVnaW9uOjczMmIzNWRjYzYyNTRmZjJiNmMyY2E4ZmE4ZTJiZTJjXzQzOTgwNDY1MTExMTQ_1c2489cb-9df5-44b6-806a-e81102e0328e">66.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7776b739ae0444bfa9bc3151bd3de57d_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzktMi0xLTEtMA_2908bbe6-2a2f-4b00-bbcd-453aec32e6b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7776b739ae0444bfa9bc3151bd3de57d_I20201231" decimals="2" format="ixt:zerodash" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzktNC0xLTEtMA_45723c23-c139-4cac-a979-8cc9285780c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i30fe04022dfb468d8d0ab7e1e5130cbc_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzktNi0xLTEtMA_a5eb16ae-2755-4169-a295-061701c77f81">0.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7776b739ae0444bfa9bc3151bd3de57d_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzktOC0xLTEtMA_1417a879-f563-4872-a945-8e6a49f209d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7776b739ae0444bfa9bc3151bd3de57d_I20201231" decimals="2" format="ixt:zerodash" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzktMTAtMS0xLTA_310149f3-912e-40f1-8961-f39d4c9f43be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iabac5d7169c74416abc3eb400b77e659_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzEwLTAtMS0xLTAvdGV4dHJlZ2lvbjpjZGU0Mzk5Njk2Yjc0NGZkOGQwZDY4N2NkM2M1ZjQxN180Mzk4MDQ2NTExMTA4_bdba1d4f-82de-475f-a57b-518fc795c69b">66.00</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="iabac5d7169c74416abc3eb400b77e659_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzEwLTAtMS0xLTAvdGV4dHJlZ2lvbjpjZGU0Mzk5Njk2Yjc0NGZkOGQwZDY4N2NkM2M1ZjQxN180Mzk4MDQ2NTExMTE0_9f11234b-a3ba-4f46-bffd-bfb952bee982">74.28</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6111e845e8ac4ee9941a74fef21be93b_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzEwLTItMS0xLTA_d5b21000-9923-4bd0-8c31-69b3a512d6cf">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6111e845e8ac4ee9941a74fef21be93b_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzEwLTQtMS0xLTA_94c2a060-166d-4cc7-9dc6-38d4b63f9379">66.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iabac5d7169c74416abc3eb400b77e659_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzEwLTYtMS0xLTA_28185e83-b76e-4e45-81b8-ea22459ea711">2.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6111e845e8ac4ee9941a74fef21be93b_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzEwLTgtMS0xLTA_225e3f70-88c1-4cf5-9594-dbaa92338ac1">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6111e845e8ac4ee9941a74fef21be93b_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzEwLTEwLTEtMS0w_16e5fe91-a6ee-4a7a-b912-d25c6fb6a6f4">66.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzExLTItMS0xLTA_946229db-0db0-438a-968d-bd32dfc378f1">412,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzExLTgtMS0xLTA_4d48c774-83e0-4036-b103-e5acabd3241a">197,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="i53bc279beb0d4676ba828340fd063ce9_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzIzMjk_d6e806b0-70da-4010-929f-f8354c8a84f1">1.0</ix:nonFraction> million of unrecognized compensation expense related to unvested option grants that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzI0NzE_d3a9adb3-e5a0-41f4-8f45-4338072e46b1">1.8</ix:nonNumeric> years.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Restricted stock grants subject solely to an employee&#8217;s continued service with the Company generally will become fully vested within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzI2Mjc_ef3f1c14-105f-4e27-b582-034c0b01b496">one</span> to <ix:nonNumeric contextRef="if3c12b1e25aa48848f6b9795aa9375a0_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzMyOTg1MzQ4OTEzNjE_46b4e753-583d-4bae-9840-4de1a8088278">four years</ix:nonNumeric> from the grant date and, in certain instances, may fully vest upon a change in control of the Company. Restricted stock grants subject solely to a Director&#8217;s continued service with the Company generally will become fully vested within <ix:nonNumeric contextRef="i30a276240cc149b2b70ea64be64b1594_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzI4Nzc_7af4ab18-9b55-44c8-953f-55bb400846ef">one year</ix:nonNumeric> from the date of grant. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense from restricted stock is recognized on a straight-line basis over the requisite service period. During the years ended December&#160;31, 2020 and 2019, the Company recognized compensation expense related to restricted stock awards of $<ix:nonFraction unitRef="usd" contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQzOTgwNDY1MTg3MDc_6b072713-3bcb-4c17-9626-08f717d3643e">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i51298007a376435784a5fb2e3b738530_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzMxMjI_37f27e37-c622-4a28-8fd9-91eb6da498ee">1.9</ix:nonFraction> million, respectively. The Company did not recognize any compensation expense related to restricted stock awards prior to the Merger.</span></div><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQ4OTA_82fc44d6-10e3-4607-884a-3604594aa237" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock award activity for the year ended December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.801%"><tr><td style="width:1.0%"></td><td style="width:48.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.575%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7cbfe6f12b34fedb3c55e90bc01b102_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzEtMS0xLTEtMA_db0ab291-3b7d-4413-a731-b71f29ad9b6d">231,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic7cbfe6f12b34fedb3c55e90bc01b102_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzEtMy0xLTEtMA_37787456-c57b-4b0c-b4bd-06e654b392f0">10.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzMtMS0xLTEtMA_4a433651-0083-4613-8967-c34b7e08b257">490,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzMtMy0xLTEtMA_c85d0f49-2e16-44a7-a607-51bcdf386f0f">13.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzQtMS0xLTEtMA_41f8957c-07c3-437f-adc9-bc0a6a0a588d">120,782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzQtMy0xLTEtMA_0636820f-c7ec-4460-85ad-d881f1504dfc">12.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzUtMS0xLTEtMA_5069f7fd-0f2b-4699-a05e-657f65ec42da">51,687</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzUtMy0xLTEtMA_715b16a1-cf61-47cd-8b2b-0df743cce99e">12.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2de6cb92e6b546deac3f264b1d51d725_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzYtMS0xLTEtMA_7832fd66-4bd5-47e7-9170-b3ea25c41f28">549,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2de6cb92e6b546deac3f264b1d51d725_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzYtMy0xLTEtMA_3a305bbc-9ed3-4ec1-8d19-801ec26023fd">13.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, shares were surrendered to satisfy tax withholding obligations on the vesting of restricted stock awards with a cost basis of $<ix:nonFraction unitRef="usd" contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQzOTgwNDY1MTg3MjU_8c20f2d3-781e-4018-a461-438111c5dc24">0.3</ix:nonFraction> million. During the year ended December&#160;31, 2019, shares were surrendered to satisfy tax withholding obligations on the vesting of restricted stock awards with a cost basis of $<ix:nonFraction unitRef="usd" contextRef="i51298007a376435784a5fb2e3b738530_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzM2Njg_0c2e914a-7286-41cc-9494-e26524d40540">2.1</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i7250472ce2a241aa9fa3993c11938e71_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzM2ODE_d32c6eb4-851b-40e4-87ce-aaf6d0f07c06">2.0</ix:nonFraction> million is held as treasury stock as of December&#160;31, 2019.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="i2de6cb92e6b546deac3f264b1d51d725_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzM3NTU_156b5815-87b8-4603-9861-58b8ac6fa723">6.0</ix:nonFraction> million in unrecognized compensation expense related to unvested restricted stock awards that is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzM5MDc_48343500-6cc2-468b-be76-f018f6feb624">1.7</ix:nonNumeric> years. The total fair value of restricted stock awards vested during the years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzM5OTg_1a1098d4-9900-4169-91f6-ef9b52be888c">1.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i51298007a376435784a5fb2e3b738530_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQzOTgwNDY1MTg3Nzc_906180a2-6045-4161-beb0-c3eb4642f0fd">1.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7b7d2377ab7d4bc99608fd62fc228d0a_D20180101-20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQwMDk_c745510f-3990-42f8-89e3-bf54c774a8b1">0</ix:nonFraction>, respectively.</span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><ix:continuation id="id664ffed03cd4b78ad38a136d8b7366f"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HC I Incentive Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;  Beginning in October 2015, HC I implemented an equity incentive plan for certain officers and employees of the Company. Incentive units are equity-based awards subject to time and performance vesting restrictions. The compensation expense related to this plan has been reflected in the Company&#8217;s financial statements.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, compensation expense is recognized on a straight-line basis over the vesting period of the award or the employee&#8217;s retirement eligible date, if earlier. During the years ended December&#160;31, 2020, 2019 and 2018, the Company recognized compensation expense related to the HC I incentive units of $<ix:nonFraction unitRef="usd" contextRef="i5acddac984ac471cad45cd822b74b0b6_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQ3MDE_ebf7e593-4e93-4350-9041-7b8978c31b39">0.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7f5821f9020a4063acb746c7833a5115_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQ3MDU_c2a21260-9edf-47be-b451-5a486d851972">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie95cb408d1a745e48ca026ce6e263566_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQ3MTI_d76a6a43-e2d9-40e3-abc7-e82b948e512b">2.1</ix:nonFraction> million, respectively. </span></div><div style="margin-bottom:10pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No awards were issued during the year ended December&#160;31, 2020. <ix:continuation id="ic5b5122be69649aeaa35c7d5cad71043" continuedAt="i7654c300200c48179866b23225246278">The fair value of each award was determined using a Monte-Carlo simulation with the following weighted average assumptions: </ix:continuation></span></div><div style="margin-bottom:10pt;text-align:center"><ix:continuation id="i7654c300200c48179866b23225246278"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.707%"><tr><td style="width:1.0%"></td><td style="width:54.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpmMTZjY2Y5NDBmYmE0ZDMyOGE1YzQ0NGNjMTZiYzJjYi90YWJsZXJhbmdlOmYxNmNjZjk0MGZiYTRkMzI4YTVjNDQ0Y2MxNmJjMmNiXzAtMi0xLTEtMA_1e19bdfc-0c1b-43cf-b440-e73e2775ea5b">2.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average time to liquidity (years) (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpmMTZjY2Y5NDBmYmE0ZDMyOGE1YzQ0NGNjMTZiYzJjYi90YWJsZXJhbmdlOmYxNmNjZjk0MGZiYTRkMzI4YTVjNDQ0Y2MxNmJjMmNiXzEtMi0xLTEtMA_11686913-ab03-48a9-94ea-24eb16b807c5">2.1</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Volatility (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpmMTZjY2Y5NDBmYmE0ZDMyOGE1YzQ0NGNjMTZiYzJjYi90YWJsZXJhbmdlOmYxNmNjZjk0MGZiYTRkMzI4YTVjNDQ0Y2MxNmJjMmNiXzItMi0xLTEtMA_3b72a4a9-d18c-41bc-a286-f675142d16fd">47.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount for lack of marketability (4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpmMTZjY2Y5NDBmYmE0ZDMyOGE1YzQ0NGNjMTZiYzJjYi90YWJsZXJhbmdlOmYxNmNjZjk0MGZiYTRkMzI4YTVjNDQ0Y2MxNmJjMmNiXzMtMi0xLTEtMA_45d2d584-6cb8-4532-bd27-4ad58d169f59">30.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpmMTZjY2Y5NDBmYmE0ZDMyOGE1YzQ0NGNjMTZiYzJjYi90YWJsZXJhbmdlOmYxNmNjZjk0MGZiYTRkMzI4YTVjNDQ0Y2MxNmJjMmNiXzQtMi0xLTEtMA_2ca208a2-570e-4ac6-a845-460d4665c666">1.13</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1) Represents the US Treasury security rate for the expected time to liquidity event.</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2) Represents the period of time expected prior to liquidity event.</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3) Based on historical volatility of comparable public companies.</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4) Represents a discount taken to reflect the private nature of the investment.</span></td></tr></table></ix:continuation></div></ix:continuation><div id="ic913b68a604e4ff38c42375d3fa7a17b_166"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 16. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzQ1Mjk_37dcbb7a-eb76-40fb-b136-552ed50d634c" continuedAt="i22407bce5db342ed8aed1074274ce334" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="i22407bce5db342ed8aed1074274ce334"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2020, the Company&#8217;s board of directors and HC I, the stockholder of a majority of the Company&#8217;s common stock, approved a reverse stock split of the Company&#8217;s issued and outstanding common stock on a one share for four share basis and appropriately amended the Company&#8217;s Third Amended and Restated Certificate of Incorporation to reflect the change. On February 3, 2020, the reverse stock split became effective. In connection with the reverse stock split, the Company changed its ticker symbol from &#8220;BIOS&#8221; to &#8220;OPCH&#8221; and transferred the Company&#8217;s common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market. The par value of the Company&#8217;s common stock remained unchanged as a result of the reverse stock split, resulting in a decrease to the aggregate par value of common stock and corresponding increase to paid-in capital in the Company&#8217;s consolidated financial statements, which was retrospectively applied to all periods presented in the financial statements. All common shares, warrants and stock awards presented in the consolidated financial statements have been retrospectively adjusted for the reverse stock split. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company completed a public offering of <ix:nonFraction unitRef="shares" contextRef="ib5a9e86640d24df0a4a74f644bec401b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTA5MDA_6e240d9e-8aac-4d10-a504-e877dbbd10df">20,700,000</ix:nonFraction> shares of the Company&#8217;s common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7b196dfce1974680a1c28c5ea237cbf5_I20201231" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTA5MDk_cd7fb64b-7d21-4247-a811-298fadc47351">12.50</ix:nonFraction> per share, consisting of <ix:nonFraction unitRef="shares" contextRef="if168c646a7a54828a528116373a38538_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTA5NDI_0c95cdbc-c103-461f-afb0-898d0a3cc0a2">10,000,000</ix:nonFraction> shares of common stock issued and sold by the Company and <ix:nonFraction unitRef="shares" contextRef="icc639cc9d59342c992cf094de275e8c8_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTA5NTU_00dcba4d-202b-4157-901f-5bd489a32eab">10,700,000</ix:nonFraction> shares of common stock sold by HC I. The Company received net proceeds from the offering of $<ix:nonFraction unitRef="usd" contextRef="ib5a9e86640d24df0a4a74f644bec401b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTA5NjQ_b06a1ee9-be0e-4158-9fc5-917e815a1db5">118.9</ix:nonFraction> million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. Also, during the year ended December&#160;31, 2020, HC I completed an additional secondary offering of <ix:nonFraction unitRef="shares" contextRef="i33bae88b85d44fbca1b188c77d873669_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTA5ODk_e7c3951f-7c60-40bd-acc7-c7ebf489be20">10,600,000</ix:nonFraction> shares of common stock. Following the offerings, HC I holds approximately <ix:nonFraction unitRef="number" contextRef="i91057a8b01954ab2b5e6178ac8a1653d_D20200101-20201231" decimals="3" name="bios:CommonStockOutstandingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTE4OTE_cf9a5c2c-9776-4c65-a908-399aebd7b447">63.6</ix:nonFraction>% of the common stock of the Company. The Company used the proceeds from the offering, along with additional cash on hand, to repay $<ix:nonFraction unitRef="usd" contextRef="i41a866b1933d4b50a03ed2090fc52f3b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTA5OTg_d61f73bc-8c89-4a75-8e15-dea3ba2d5de7">174.0</ix:nonFraction> million on the principal balance of its Second Lien Notes outstanding. See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the repayment of the Second Lien Notes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2017 Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Prior to the Merger, BioScrip issued warrants to certain debt holders pursuant to a Warrant Purchase Agreement dated as of June 29, 2017. In conjunction with the Merger, the 2017 Warrants were amended to entitle the purchasers of the warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i5d4a2b07f09440698f0d0e140a1f931b_I20190806" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzMyOTg1MzQ4OTY0ODU_7f0b04c3-364a-41dc-a250-5c801c4ae7fb">2.1</ix:nonFraction>&#160;million shares of common stock. The 2017 Warrants have a <ix:nonNumeric contextRef="i535849efb80c49c89802c2c1e9ff8d05_I20170629" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzMyOTg1MzQ4OTY0OTc_c08747d5-336b-4f33-b86c-8f29252470c2">10-year</ix:nonNumeric> term and an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i535849efb80c49c89802c2c1e9ff8d05_I20170629" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTEwMTk_91c77582-2f0e-4ca9-bca8-23f3641a7158">8.00</ix:nonFraction> per share and may be exercised by payment of the exercise price in cash or surrender of shares of common stock into which the 2017 Warrants are being converted in an aggregate amount sufficient to pay the exercise price. The 2017 Warrants are classified as equity instruments, and the fair value of these warrants of $<ix:nonFraction unitRef="usd" contextRef="i5d4a2b07f09440698f0d0e140a1f931b_I20190806" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzExNTk_619079a3-b208-49ae-a7e1-918c1e8441d3">14.1</ix:nonFraction> million was recorded in paid-in capital as of the Merger Date. During the years ended December&#160;31, 2020 and 2019, warrant holders exercised warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i2d17de0af863439a8ae94e0d74a3cb43_I20201231" decimals="-5" format="ixt:numdotdecimal" name="bios:ClassofWarrantorRightSecuritiesExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTE5NDY_2bd5c948-f8e5-4851-afb4-4dde777bb218">0.0</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i1039614a70d44672a1b9b67e279fb604_I20191231" decimals="-5" format="ixt:numdotdecimal" name="bios:ClassofWarrantorRightSecuritiesExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzEzMzI_203859a7-e296-483a-9439-398a43127b07">0.7</ix:nonFraction> million shares of common stock. No proceeds were received from these exercises as the warrant holders elected to surrender shares to pay the exercise price. At December&#160;31, 2020 and 2019, the remaining warrant holders are entitled to purchase <ix:nonFraction unitRef="shares" contextRef="i2d17de0af863439a8ae94e0d74a3cb43_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTE5MTA_269fec88-f97a-47ad-af84-bee6f013d55f"><ix:nonFraction unitRef="shares" contextRef="i1039614a70d44672a1b9b67e279fb604_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTE5MTA_4f727f40-5da5-4c8e-9d33-089a4ea86246">1.4</ix:nonFraction></ix:nonFraction>&#160;million shares of common stock, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2015 Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Prior to the Merger, BioScrip issued warrants pursuant to a Common Stock Warrant Agreement dated as of March 9, 2015 which entitle the holders to purchase <ix:nonFraction unitRef="shares" contextRef="i7318e00da4034c3e90a2e212df26a625_I20190805" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzE4OTM_58717794-b839-4e24-9dfe-d1f455ab5451">0.9</ix:nonFraction> million shares of common stock. The 2015 Warrants have a <ix:nonNumeric contextRef="i219745e510624e329c043ef1592af4c1_I20150309" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzMyOTg1MzQ4OTY0OTg_7feaf012-8842-46c4-b15b-b0477c71ea56">10-year</ix:nonNumeric> term and have exercise prices in a range of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib3aa39a0d3d547f5ac6cd2902b94a3cc_I20150309" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzIwODM_fe4e33c5-7ad4-4f79-a917-21effb56b060">20.68</ix:nonFraction> per share to $<ix:nonFraction unitRef="usdPerShare" contextRef="if3a9e03e121545df913cf6c60ded20b6_I20150309" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzIwOTk_564cbd9f-1c3f-4239-bfb7-03582bf8f09a">25.80</ix:nonFraction> per share.  The 2015 Warrants were assumed by the Company in conjunction with the Merger and are classified as equity instruments, and the fair value of these warrants of $<ix:nonFraction unitRef="usd" contextRef="icf01e47aa17741d5850517700e659acc_I20190806" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzIzMTg_d2f9dcc5-23fe-41d2-a11b-c7e54cf51134">4.6</ix:nonFraction> million was recorded in paid in capital as of the Merger Date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Home Solutions Restricted Stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; In conjunction with BioScrip&#8217;s 2016 acquisition of Home Solutions, Inc., <ix:nonFraction unitRef="shares" contextRef="iac71a41a43944594bf483f7a54f70817_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzI0ODc_5a15c1ba-a2b7-4594-8ad4-cba99fd1be31">1.8</ix:nonFraction> million restricted shares of common stock were issued, of which <ix:nonFraction unitRef="shares" contextRef="iea509be9731f4fb6830bb71b36a2b3bc_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzI2MTM_86bfd9dd-7a72-40b2-a3ff-8003605f1124">0.8</ix:nonFraction> million of these units vest upon the closing price of the Company&#8217;s common stock averaging at or above $<ix:nonFraction unitRef="usdPerShare" contextRef="ifd4a7b857bfc47ff96783a5d70cfd61b_I20191231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzI3ODg_802aa6bf-a65a-461d-9760-3fd05a7a7c96">16.00</ix:nonFraction> per share over <ix:nonFraction unitRef="day" contextRef="iea509be9731f4fb6830bb71b36a2b3bc_D20190101-20191231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzI4NTE_d68d061e-57de-4013-97dd-79cb4d9cda80">20</ix:nonFraction> consecutive trading days prior to December&#160;31, 2019 and <ix:nonFraction unitRef="shares" contextRef="i75edeee42f0440a9ae3db5c126a6ee59_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTEwODU_6cf94798-1a74-465e-84e3-0f33cb80e3a4">1.0</ix:nonFraction> million of these units vest upon the closing price of the Company&#8217;s common stock averaging at or above $<ix:nonFraction unitRef="usdPerShare" contextRef="ifefcdf706a3e409c8661a5f8661ff527_I20191231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzMwNzQ_f69b4ce7-312b-45a8-b7ea-10db9bd65714">20.00</ix:nonFraction> per share over <ix:nonFraction unitRef="day" contextRef="i75edeee42f0440a9ae3db5c126a6ee59_D20190101-20191231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzMxMzc_ecece5cf-d1f2-432e-bcff-7bca865d7879">20</ix:nonFraction> consecutive trading days prior to December&#160;31, 2019. The restricted stock expired on December&#160;31, 2019. As discussed in Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature of Operations and Presentation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="shares" contextRef="i368d5fdb13b94d2c99546a5791f3e988_D20190806-20190806" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzMzMTk_45a42142-13f9-4469-969a-e82734a4c8c3">7,048,357</ix:nonFraction> common shares issued to HC I in conjunction with the Merger were set aside to prevent dilution related to the vesting of the Home Solutions restricted stock. During the year ended December&#160;31, 2020, this matter was resolved with no common shares being issued to Home Solutions, Inc., and the <ix:nonFraction unitRef="shares" contextRef="i15e537579ddd49499464fe98320efa5a_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTA4ODc_880b719f-4a8f-4814-9a49-dde64ff06abe">7,048,357</ix:nonFraction> shares, at $<ix:nonFraction unitRef="usdPerShare" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzMyOTg1MzQ4OTY1MTA_032c5a17-161f-41dd-a3e2-53ec4663c17a">0.0001</ix:nonFraction> par value, set aside were cancelled as unvested and removed from the Company&#8217;s common shares issued and outstanding.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treasury Stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; During the year ended December&#160;31, 2019, <ix:nonFraction unitRef="shares" contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzM4OTg_c69feed9-660c-4740-a385-ab74421c2f8d">290,117</ix:nonFraction> shares were surrendered to satisfy tax withholding obligations on the exercise of stock options and the vesting of restricted stock awards with a cost basis of $<ix:nonFraction unitRef="usd" contextRef="i2e27ad48b6e845aab11f9dc6d36cc68d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzQxMTc_ed7d2d8a-bf6b-415e-8899-84d20fa47d50">2.5</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="ib70cc65c7351474ca9d26740937a57b3_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzQxMzA_cfcfbaf7-3ccf-42a4-9e57-653d54c9a65a"><ix:nonFraction unitRef="usd" contextRef="i13dda31dc46244a296faff43e8f63ba2_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzQxMzA_f06a37ac-0881-4354-b04f-4534d586e738">2.4</ix:nonFraction></ix:nonFraction> million remains held in treasury as of December&#160;31, 2020 and 2019. At December&#160;31, 2020 and 2019, the Company held <ix:nonFraction unitRef="shares" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzQyMDM_e2e66b24-a938-4fd6-a2b5-4950dd954506"><ix:nonFraction unitRef="shares" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzQyMDM_f60bcb3a-0a7d-4a1e-9095-a1cd2b177b6b">383,722</ix:nonFraction></ix:nonFraction> shares of treasury stock. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; In conjunction with the Merger, all legacy BioScrip preferred stock was settled, and <ix:nonFraction unitRef="shares" contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzQ0Mzk_8346193c-1422-46cc-99d7-912a0a91023b"><ix:nonFraction unitRef="shares" contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzQ0Mzk_d975b9a5-6187-4be2-a796-9b4304ac81e0">no</ix:nonFraction></ix:nonFraction> preferred stock is outstanding as of December&#160;31, 2020 or 2019.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzM1MzA_67460054-94fb-4f41-a7cc-c27420494fd4" continuedAt="i87a6d107ac2d448dbafba130daf907e7" escape="true">RELATED-PARTY TRANSACTIONS</ix:nonNumeric></span></div><ix:continuation id="i87a6d107ac2d448dbafba130daf907e7"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; In conjunction with the Option Care acquisition from Walgreen Co. in 2015, the Company entered into two separate Management Services Agreements with Madison Dearborn Partners VI-B, L.P. and Walgreen Co. Each Management Services Agreement required the Company to pay $<ix:nonFraction unitRef="usd" contextRef="i960724d691c94ef7990ec38c99826855_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzI5OA_bbbde15d-ca06-48a1-86a0-ad9ed3c8f0f5">0.3</ix:nonFraction> million to each party quarterly beginning July 1, 2015 for on-going management, consulting and financial services provided to the Company. Following the close of the Merger, both Management Services Agreements were terminated. The Company did not incur any management services expense during the year ended December&#160;31, 2020. In 2019, prior to the Merger, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="if80a7156fb6f4e92b4633b71b42884d2_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzU3MQ_df7ef721-672e-4dbc-b90d-04dcc4eea471">1.5</ix:nonFraction> million of management services expense, which has been reflected as a component of selling, general and administrative expense in the consolidated statements of comprehensive income (loss) for the year ended December&#160;31, 2019. During the year ended December&#160;31, 2018, management services expense of $<ix:nonFraction unitRef="usd" contextRef="ia181037e051e4e948fa5f02cec18ae01_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzgyMw_4f792661-760f-491a-930e-cca7aeef695c">2.0</ix:nonFraction> million was recorded as a component of selling, general, and administrative expense in the consolidated statements of comprehensive income (loss). </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management Equity Ownership Plan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;  In October 2015, HC I implemented an equity ownership and incentive plan for certain officers and employees of Option Care. The officers were able to purchase membership units in HC I and could fund a portion of the purchase with a loan from Option Care. These loans were treated as a shareholder contribution in Option Care. For the years ended December&#160;31, 2020, 2019 and 2018, $<ix:nonFraction unitRef="usd" contextRef="i284ee94026ab44078607e6ba90095ac0_D20200101-20201231" decimals="INF" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzU0OTc1NTgxNDQzNjk_7a6c3e49-99e8-4b13-89ac-9d144158c042">0</ix:nonFraction>,  $<ix:nonFraction unitRef="usd" contextRef="ib849ab96bb7143929a677ea83f9f24a1_D20190101-20191231" decimals="INF" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzEzNTI_479fd804-995b-4819-a956-0a3ffe776526">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1bb7590e2fd64c32b7a9e48da3b76727_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzEzNTc_550b9ac5-2684-4044-b54c-e3fd240f2672">0.4</ix:nonFraction> million, respectively, were credited to paid-in capital related to HC I membership units purchased with a loan from Option Care. There were <ix:nonFraction unitRef="usd" contextRef="i284ee94026ab44078607e6ba90095ac0_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PartnersCapitalAccountRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzMyOTg1MzQ4ODkxMjI_afe5692a-c506-4608-9f25-1fa6738da8c5">no</ix:nonFraction> shareholder redemptions during the year ended December&#160;31, 2020.  During the year ended December&#160;31, 2019, shareholder redemptions totaled $<ix:nonFraction unitRef="usd" contextRef="ib849ab96bb7143929a677ea83f9f24a1_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PartnersCapitalAccountRedemptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzE1MzY_b81e866e-e831-4b3b-bb40-0b217b97a603">2.4</ix:nonFraction> million, comprised of a cash distribution to HC I of $<ix:nonFraction unitRef="usd" contextRef="ib849ab96bb7143929a677ea83f9f24a1_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzE1ODQ_6bb59b16-9dce-4349-95e3-d03d305f6c39">2.0</ix:nonFraction> million and notes redeemed of $<ix:nonFraction unitRef="usd" contextRef="ib849ab96bb7143929a677ea83f9f24a1_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzE2MDk_eec31924-bf4b-4544-9aeb-820ad8e28600">0.4</ix:nonFraction> million. There were <ix:nonFraction unitRef="usd" contextRef="i1bb7590e2fd64c32b7a9e48da3b76727_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PartnersCapitalAccountRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzE2MjQ_e2ea6e94-a12f-4607-bee1-dcb1f896da6e">no</ix:nonFraction> shareholder redemptions during the year ended December&#160;31, 2018.  </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2019, prior to the Merger, Option Care sold its notes receivable from management, along with all accrued interest expense, to a third-party bank. Option Care received cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i34486d66c41947448069be17a3002902_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfNotesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzIwMjU_bec3e596-074b-4463-8545-3ab9355827e5">1.3</ix:nonFraction> million, which represented payment of $<ix:nonFraction unitRef="usd" contextRef="ibab2cb958b58428e93eac229c0d7b02d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfNotesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzIwNTg_c27cccea-8406-449b-ba20-e5b277c7752c">1.1</ix:nonFraction> million in outstanding notes receivable from management and payment of $<ix:nonFraction unitRef="usd" contextRef="ibab2cb958b58428e93eac229c0d7b02d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzIxMjQ_de82e01f-d1cf-4a91-b054-4ee1a3e462e5">0.2</ix:nonFraction> million in accrued interest expense. There were <ix:nonFraction unitRef="usd" contextRef="i822483b16b124c4596a91869aa597cb8_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NotesReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzMyOTg1MzQ4ODkxMTQ_9b94ae46-77e5-4d3a-8cc8-75bdac027c65"><ix:nonFraction unitRef="usd" contextRef="i6555353edfee47bd86374a705cce7c7e_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NotesReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzMyOTg1MzQ4ODkxMTQ_bb987280-fc5e-4930-a32f-05cbe9b654cb">no</ix:nonFraction></ix:nonFraction> notes receivable from management outstanding as of December&#160;31, 2020 and 2019. As of December&#160;31, 2018, notes receivable from management and associated interest receivable of $<ix:nonFraction unitRef="usd" contextRef="i58a5c478533d40c4ae5cf5901b523252_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzU0OTc1NTgxNDQzMzk_28474e3a-3c99-46a2-a035-d733ccda9f3b">1.6</ix:nonFraction> million are recorded in management notes receivable as a reduction to equity in the Company&#8217;s consolidated statements of stockholders&#8217; equity.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions with Equity-Method Investees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $<ix:nonFraction unitRef="usd" contextRef="i3802608a5ccb4cafbdc104d570a82e52_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzI3MzE_642f95ab-2c6a-4d24-a364-abb0631a6514">2.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i51011fdb3a8b4c218ad62e0a5f46e49f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzI3MzU_4d4b3978-afb5-4eef-9b83-72340ffbbebd">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4e67b5985f2447a4a6bba9e8bc275f82_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzI3NDI_4f090295-b9df-40dc-9d8f-676e2f5ea07e">2.2</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Management fees are recorded in net revenues in the accompanying consolidated statements of comprehensive income (loss).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had amounts due from its joint ventures of $<ix:nonFraction unitRef="usd" contextRef="ia5e84b8b2d0c4dc7a263964004d01b50_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzU0OTc1NTgxNDQzNTc_d16da2dc-cd92-4e5e-90cd-0ddead3821e2">2.4</ix:nonFraction>&#160;million as of December&#160;31, 2020. The Company had amounts due to its joint ventures of $<ix:nonFraction unitRef="usd" contextRef="i72c86c11f53e4fe297072ffdc6b4277f_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzI5NTk_1ead7e8c-653f-43f2-9f6f-a44e4fc93460">4.3</ix:nonFraction> million as of December&#160;31, 2019. These receivables were included in prepaid expenses and other current assets in the accompanying balance sheets and these payables were included in accrued expenses and other current liabilities in the accompanying balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories purchased by the Company on behalf of the joint ventures.</span></div></ix:continuation><div id="ic913b68a604e4ff38c42375d3fa7a17b_178"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90ZXh0cmVnaW9uOjllY2UwY2Y4OTc1NzRkMzFiMzBlZjdjMzUxMTUzMThkXzM2Mg_0fe79aef-1ce3-417b-b859-454d517102b1" continuedAt="i8ba04eae2d8b4694bb5001ebebec1c09" escape="true">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</ix:nonNumeric></span></div><ix:continuation id="i8ba04eae2d8b4694bb5001ebebec1c09"><ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90ZXh0cmVnaW9uOjllY2UwY2Y4OTc1NzRkMzFiMzBlZjdjMzUxMTUzMThkXzM2Mw_c17d22d3-34c5-4f36-b17a-5f8d6d2c6e98" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of unaudited quarterly financial information for the years ended December&#160;31, 2020 and 2019 is as follows (in thousands except per share amounts).</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:35.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15449ea65247465890f60bdac030ba0a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzItMS0xLTEtMA_756aeecc-518e-4059-a84b-2af041a4179d">705,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaae3340f01f44ee699ccd0262c23dc33_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzItMy0xLTEtMA_db998fb6-2a42-445b-b875-c0b0dfb2ed57">740,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic66518c22fa740f7b245ba8a1d6615fd_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzItNS0xLTEtMA_fb1fc6f0-3482-403f-a6df-366a4369c570">781,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3afb9f5919b84a45a2a45351ff5c3f16_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzItNy0xLTEtMA_b5be412f-c470-43bd-8755-6cd52ad5ec3c">804,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15449ea65247465890f60bdac030ba0a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzMtMS0xLTEtMA_b9e2e6c1-d83d-4264-92a4-de80244ba159">158,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaae3340f01f44ee699ccd0262c23dc33_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzMtMy0xLTEtMA_56789d7f-9eaf-4ab1-8a85-43df478b133b">166,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic66518c22fa740f7b245ba8a1d6615fd_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzMtNS0xLTEtMA_0a281509-8dfb-4bde-a159-7d87da972161">174,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3afb9f5919b84a45a2a45351ff5c3f16_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzMtNy0xLTEtMA_3f18f7b1-b20e-42d3-afb7-1a537eb05cec">183,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15449ea65247465890f60bdac030ba0a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzQtMS0xLTEtMA_9b87dc70-6f3b-46af-99c7-0e28d55ff746">8,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaae3340f01f44ee699ccd0262c23dc33_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzQtMy0xLTEtMA_dea79b8e-f3ab-4710-a704-4f0b6c02bdc4">23,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic66518c22fa740f7b245ba8a1d6615fd_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzQtNS0xLTEtMA_bd4f7338-9e21-4d83-ae49-64169f9541e7">34,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3afb9f5919b84a45a2a45351ff5c3f16_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzQtNy0xLTEtMA_09759d27-f948-4069-8381-aec98248f9e9">44,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15449ea65247465890f60bdac030ba0a_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzUtMS0xLTEtMA_bd7c02e6-0ae8-4b94-b2af-bbee8c94ec69">19,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaae3340f01f44ee699ccd0262c23dc33_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzUtMy0xLTEtMA_a2e70fc3-4629-497c-85cf-fc5fc4aa1285">7,668</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic66518c22fa740f7b245ba8a1d6615fd_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzUtNS0xLTEtMA_7af0674f-3f26-46e3-8d5a-41c24c7247aa">1,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3afb9f5919b84a45a2a45351ff5c3f16_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzUtNy0xLTEtMA_a208cf47-bea5-4edc-a064-edf85025dccd">17,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) earnings per share, basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i15449ea65247465890f60bdac030ba0a_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzctMS0xLTEtMA_aaa87172-a03b-4f53-82e8-8c1c38e24eb3">0.11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaae3340f01f44ee699ccd0262c23dc33_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzctMy0xLTEtMA_98b410c7-104a-4810-9aa6-b08441e6472a">0.04</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic66518c22fa740f7b245ba8a1d6615fd_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzctNS0xLTEtMA_0dd2a094-494f-42f1-8ba3-9fd17c22a355">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3afb9f5919b84a45a2a45351ff5c3f16_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzctNy0xLTEtMA_d0497556-a98e-4244-a601-087593328269">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) earnings per share, diluted</span></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i15449ea65247465890f60bdac030ba0a_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzgtMS0xLTEtMzIxMg_5ec110d9-c936-48b1-b77a-43731e27a9c1">0.11</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaae3340f01f44ee699ccd0262c23dc33_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzgtMy0xLTEtMzIxMg_ac216704-2ebd-49cb-ad16-436bab6554a6">0.04</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic66518c22fa740f7b245ba8a1d6615fd_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzgtNS0xLTEtMzIxMg_46b8b042-d40e-4fea-97f6-2ca8f12cdc94">0.01</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3afb9f5919b84a45a2a45351ff5c3f16_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzgtNy0xLTEtMzIxMg_be28569a-750b-45a6-93cf-b429062af081">0.10</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec2211f718164003b67adb468a0ae8fe_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzExLTEtMS0xLTA_8492810e-16a2-4767-9e4d-6e913dc41255">476,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib556381e0e774b77af5202ac495cedbb_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzExLTMtMS0xLTA_c02c2e82-8816-4f62-ace6-f404d0024151">497,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib309aaac6dde42acbdc774c94fb918ad_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzExLTUtMS0xLTA_6e41d773-448e-4ab6-91f7-03af6e019ba8">615,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f18d581b7c4638bce49ebbbfa4f31b_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzExLTctMS0xLTA_3d035515-a4cf-4d08-a18e-8aaea2cd8f52">720,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec2211f718164003b67adb468a0ae8fe_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzEyLTEtMS0xLTA_22258f2d-c133-46e4-9555-9bb3cbc40791">98,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib556381e0e774b77af5202ac495cedbb_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzEyLTMtMS0xLTA_4488b1ef-856e-4254-8653-97b950243e05">101,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib309aaac6dde42acbdc774c94fb918ad_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzEyLTUtMS0xLTA_ccd31f7c-1bfe-4209-8fcf-cfe1218037f8">137,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f18d581b7c4638bce49ebbbfa4f31b_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzEyLTctMS0xLTA_8ef68c0f-1811-454e-9e64-593240e4c6b1">175,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec2211f718164003b67adb468a0ae8fe_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzEzLTEtMS0xLTA_d8128188-7b67-4d9d-b925-8f8252ff423d">5,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib556381e0e774b77af5202ac495cedbb_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzEzLTMtMS0xLTA_f8a65a66-5577-4097-a987-a2c0853585ec">8,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib309aaac6dde42acbdc774c94fb918ad_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzEzLTUtMS0xLTA_bffded93-1ac6-46e9-a5cf-eb95d586544c">11,725</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f18d581b7c4638bce49ebbbfa4f31b_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzEzLTctMS0xLTA_d9778d35-9302-4c87-ae29-01ea02aedc37">13,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec2211f718164003b67adb468a0ae8fe_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE0LTEtMS0xLTA_bc42cb2c-5fc6-4272-81c5-262e87eca241">3,712</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib556381e0e774b77af5202ac495cedbb_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE0LTMtMS0xLTA_2d0077c3-07c7-4072-bcea-cc239c0bad10">13,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib309aaac6dde42acbdc774c94fb918ad_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE0LTUtMS0xLTA_b553e6c8-cca0-4de5-9a99-a10d3bd30a7e">42,794</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70f18d581b7c4638bce49ebbbfa4f31b_D20191001-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE0LTctMS0xLTA_dd4748a1-5049-44be-a0e4-385a373f3adb">15,811</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss per share, basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iec2211f718164003b67adb468a0ae8fe_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE2LTEtMS0xLTA_88650aa0-8ddc-4c60-a140-0ceab82e2598">0.03</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib556381e0e774b77af5202ac495cedbb_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE2LTMtMS0xLTA_bd102bfa-0247-47f0-8ba7-2450fce40fd9">0.10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib309aaac6dde42acbdc774c94fb918ad_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE2LTUtMS0xLTA_6083426a-f07c-42ee-a519-a1324b7201ff">0.26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i70f18d581b7c4638bce49ebbbfa4f31b_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE2LTctMS0xLTA_3a923835-aff2-4b75-a6de-e11536457908">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss per share, diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iec2211f718164003b67adb468a0ae8fe_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE4LTEtMS0xLTMyMTg_27afa25e-4422-4da9-be20-2b788ed39e11">0.03</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib556381e0e774b77af5202ac495cedbb_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE4LTMtMS0xLTMyMTg_b277a141-08e9-4e88-9194-e324544cebdc">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib309aaac6dde42acbdc774c94fb918ad_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE4LTUtMS0xLTMyMTg_5dbd8295-8897-4b27-a6fc-59066a84447a">0.26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i70f18d581b7c4638bce49ebbbfa4f31b_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE4LTctMS0xLTMyMTg_5c7f1d69-20f2-4e4e-99d4-d2c666f27ba8">0.09</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net loss in the third quarter of 2019 included transaction expenses, integration costs and loss on extinguishment of debt incurred in conjunction with the Merger.</span></div></ix:continuation><div id="ic913b68a604e4ff38c42375d3fa7a17b_181"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">    19. <ix:nonNumeric contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzExNTg_cfb84db4-61b7-4adf-8d41-9515248bb7db" continuedAt="i0428c2164def42208625b2aa1e3d315f" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="i0428c2164def42208625b2aa1e3d315f"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated whether any subsequent events occurred since December&#160;31, 2020 and noted the following subsequent event:</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, the Company entered into an amendment on the First Lien Term Loan (the &#8220;First Lien Credit Agreement Amendment&#8221;). The First Lien Credit Agreement Amendment resulted in an additional $<ix:nonFraction unitRef="usd" contextRef="i475c18c38aea40bfa20cc795a9a0586e_I20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzQzOTgwNDY1MTQ5MjM_4da8690d-4ff8-4746-be21-c37c1faf45e6">250.0</ix:nonFraction>&#160;million of incremental First Lien Term Loan indebtedness being issued and reduced the interest rate on all outstanding First Lien Term Loan indebtedness from LIBOR plus <ix:nonFraction unitRef="number" contextRef="i13a144a884e94b6a93b74bea5f331c3e_D20200101-20201231" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzQzOTgwNDY1MTQ5NDQ_6f609168-c553-4fc9-b0fa-0746746b4856">4.25</ix:nonFraction>% to LIBOR plus <ix:nonFraction unitRef="number" contextRef="i0bbb595569b4462e84f37fd4195a043b_D20210101-20210131" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzQzOTgwNDY1MTQ5NTI_3aa69461-286e-432c-ac80-addff415f524">3.75</ix:nonFraction>%. The proceeds of the $<ix:nonFraction unitRef="usd" contextRef="i475c18c38aea40bfa20cc795a9a0586e_I20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzQzOTgwNDY1MTQ5MDU_4da8690d-4ff8-4746-be21-c37c1faf45e6">250.0</ix:nonFraction>&#160;million incremental First Lien Term Loan indebtedness were used to prepay the remaining $<ix:nonFraction unitRef="usd" contextRef="i6b688f43690d4a10bb658649d8f26b91_D20210101-20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzU0OTc1NTgxNDMzMzM_36e4cef4-aebc-46f7-bd57-8000e1f99359">245.8</ix:nonFraction>&#160;million outstanding balance of the Second Lien Notes. In connection with the First Lien Credit Agreement Amendment and prepayment of the Second Lien Notes the Company incurred debt prepayment penalties of $<ix:nonFraction unitRef="usd" contextRef="ic0bfb220dbad4d1ca83ebb1bd6d1b4c6_I20210131" decimals="-5" format="ixt:numdotdecimal" name="bios:FinancingReceivablePrepaymentPenalty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzU0OTc1NTgxNDMyNTQ_da01dc51-6126-427f-adad-2d4ab00fa8a2">4.9</ix:nonFraction> million, third party fees of $<ix:nonFraction unitRef="usd" contextRef="i8995bda2010f4ab3b9f72d0a8e9683f7_D20210101-20210131" decimals="-5" format="ixt:numdotdecimal" name="bios:DebtInstrumentThirdPartyFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzU0OTc1NTgxNDMyNzQ_e3c3a100-00a6-415c-85ed-fd0911afcf05">1.3</ix:nonFraction> million and original issue discount of $<ix:nonFraction unitRef="usd" contextRef="ic0bfb220dbad4d1ca83ebb1bd6d1b4c6_I20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzU0OTc1NTgxNDMyOTM_16b0fd72-f187-485a-9872-3ed29cac1d5e">1.0</ix:nonFraction> million. Following the First Lien Credit Agreement Amendment, the First Lien Term Loan is repayable in quarterly installments of $<ix:nonFraction unitRef="usd" contextRef="i0bbb595569b4462e84f37fd4195a043b_D20210101-20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzQzOTgwNDY1MTQ5NjA_639fa473-4748-478b-896e-2dc3839c008a">2.9</ix:nonFraction>&#160;million plus interest, with a final payment of all remaining outstanding principal due on August 6, 2026. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2021, HC I completed a secondary offering of <ix:nonFraction unitRef="shares" contextRef="i843047af1ab74b56ac1a994dd504c5cb_D20210201-20210228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzU0OTc1NTgxNDMzMTY_6828aed6-f0f4-405a-a314-189a0657a95e">17,250,000</ix:nonFraction> shares of the Company&#8217;s common stock. Following the offering, HC I holds approximately <ix:nonFraction unitRef="number" contextRef="i5e6ee715bd2943e5b275bef6b90641f2_D20210201-20210228" decimals="3" name="bios:CommonStockOutstandingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzU0OTc1NTgxNDMzMDM_67152c63-5f4c-4ffd-93ed-4428ff155d22">54</ix:nonFraction>% of the Company&#8217;s common stock.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_190"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures   </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains disclosure controls and procedures (as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act) that are designed to ensure that information required to be disclosed by the Company in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to the Company&#8217;s management, including its Chief Executive Officer (&#8220;CEO&#8221;) and Chief Financial Officer (&#8220;CFO&#8221;), as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control system is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company&#8217;s financial statements for external purposes in accordance with U.S. GAAP. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of the CEO and CFO, assessed the effectiveness of the Company&#8217;s internal control over financial reporting. Based on the criteria for effective internal control over financial reporting established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;), management concluded that the internal control over financial reporting was effective as of December 31, 2020.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All internal control systems, no matter how well designed, have inherent limitations and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Controls over Financial Reporting</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Part II, Item 9a of our Annual Report on form 10-K for the year ended December 31, 2019, the Merger with BioScrip was completed on August 6, 2019, and represented a change in internal control over financial reporting. During the year ended December 31, 2020 management consolidated and integrated BioScrip&#8217;s system of controls. The processes and controls for significant areas, including business combinations, intangibles and goodwill valuations, income taxes, treasury, consolidations and the preparation of financial statements and related disclosures, compensation and benefits, procure to pay, inventory and order to receipt have all been substantially impacted by the integration activities. The primary changes in these areas are related to the consolidation of process owner leadership and control owners, and where required, the modification of inputs, processes and associated systems. For all areas of change noted, management believes the control design and implementation thereof are being appropriately modified to address underlying risks.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other changes during the year ended December 31, 2020 that have materially affected, or reasonably likely to materially affect, our internal controls over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:4.5pt;padding-right:306pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:4.5pt;padding-right:306pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option Care Health, Inc.:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;padding-left:4.5pt;padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Option Care Health, Inc.and subsidiaries (the Company) internal control over financial reporting as of December 31, 2020, based on criteria established in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission.  </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:4.5pt;padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2020 and 2019, the related consolidated statements of comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes (collectively, the consolidated financial statements), and our report dated March 11, 2021 expressed an unqualified opinion on those consolidated financial statements.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:4.5pt;padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:4.5pt;padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:4.5pt;padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:4.5pt;padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:4.5pt;padding-right:427.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chicago, Illinois March 11, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_196"></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_199"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Directors, Executive Officers and Corporate Governance</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Ethics that applies to all of our directors, officers and employees, including our principal executive, principal financial and principal accounting officers, or persons performing similar functions. Our Code of Ethics is posted on our website located at http://investors.optioncarehealth.com/corporate-governance/highlights. We intend to disclose future amendments to certain provisions of the Code of Ethics, and waivers of the Code of Ethics granted to executive officers and directors, on our website.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other information required by this item is incorporated by reference from the information contained in our definitive proxy statement to be filed with the SEC no later than 120 days after December 31, 2020 in connection with our 2021 Annual Meeting of Stockholders.</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_202"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Compensation</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the information contained in our definitive proxy statement to be filed with the SEC no later than 120 days after December 31, 2020 in connection with our 2021 Annual Meeting of Stockholders.</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_205"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the information contained in our definitive proxy statement to be filed with the SEC no later than 120 days after December 31, 2020 in connection with our 2021 Annual Meeting of Stockholders.</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_208"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the information contained in our definitive proxy statement to be filed with the SEC no later than 120 days after December 31, 2020 in connection with our 2021 Annual Meeting of Stockholders.</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_211"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principal Accountant Fees and Services</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the information contained in our definitive proxy statement to be filed with the SEC no later than 120 days after December 31, 2020 in connection with our 2021 Annual Meeting of Stockholders.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_214"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_217"></div><div style="-sec-extract:summary;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:19.02pt">Exhibits, Financial Statement Schedules</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:93.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)(1) Financial Statements.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial statements appear in Part II, Item 8:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Independent Registered Public Accounting Firm</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_73">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets as of December 31, 2020 and 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_76">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2020, 2019 and 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_82">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows for the years ended December 31, 2020, 2019 and 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_88">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2020, 2019 and 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_91">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_94">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other schedules not listed above have been omitted since they are not applicable or are not required.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(3) Exhibits. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Exhibits</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Number&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.1+</span></div></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000095012310005446/y81669aexv2w1.htm">Agreement and Plan of Merger, dated as of January&#160;24, 2010, by and among BioScrip, Inc. (the &#8220;Company&#8221;), and the parties set forth on the signature page&#160;(Incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed on January 27, 2010, SEC File Number 0-28740).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.2+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420413005855/v333776_ex2-1.htm">Stock Purchase Agreement, dated as of December 12, 2012, by and among HomeChoice Partners, Inc., DaVita HealthCare Partners Inc., Mary Ann Cope, R.Ph., Kathy F. Puglise, RN, CRNI, Joseph W. Boyd, R.Ph., Barbara J. Exum, PharmD and the Company&#160;&#160;(Incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed on February 4, 2013, SEC File Number 0-28740).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420416107943/v442184_ex2-1.htm">Asset Purchase Agreement, dated June 11, 2016, by and among HS Infusion Holdings, Inc., the direct and indirect subsidiaries of HS Infusion Holdings, Inc. set forth on the signature pages, the Company and HomeChoice Partners, Inc. (the &#8220;Home Solutions Agreement&#8221;).&#160;(Incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed on June 13, 2016, SEC File Number 000-28740).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420416108823/v442470_ex2-1.htm">First Amendment, dated June 16, 2016, to the Home Solutions Agreement&#160;(Incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K/A filed on June 20, 2016, SEC File Number 000-28740).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420416122940/v448404_ex2-1.htm">Second Amendment, dated September 2, 2016, to the Home Solutions Agreement&#160;(Incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed on September 7, 2016, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420416123640/v448690_ex2-1.htm">Third Amendment, dated September 9, 2016, to the Home Solutions Agreement&#160;(Incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed on September 12, 2016, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.7+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420419014367/tv516369_ex2-1.htm">Agreement and Plan of Merger, dated as of March 14, 2019, by and among BioScrip, Inc., Beta Sub, Inc., Beta Sub, LLC, HC Group Holdings I, LLC, HC Group Holdings II, Inc. and HC Group Holdings III, Inc. (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed on March 15, 2019, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420419038047/tv526734_ex3-1.htm">Third Amended and Restated Certificate of Incorporation of BioScrip, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on August 7, 2019, SEC File Number 001-11993). </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420419038047/tv526734_ex3-3.htm">Certificate of Amendment to Certificate of Incorporation, amending the Third Amended and Restated Certificate of Incorporation of BioScrip, Inc.  (incorporated by reference to Exhibit 3.3 to the Company&#8217;s Current Report on Form 8-K filed on August 7, 2019, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420419038047/tv526734_ex3-4.htm">Amended and Restated Bylaws of Option Care Health, Inc., formerly known as BioScrip, Inc. (incorporated by reference to Exhibit 3.4 to the Company&#8217;s Current Report on Form 8-K filed on August 7, 2019, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000110465920009797/tm206375d1_ex3-1.htm">Certificate of Amendment of the Certificate of Incorporation, filed January 30, 2020.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420415014933/v403951_ex4-1.htm">Registration Rights Agreement, dated as of March 9, 2015, by and among the Company, Coliseum Capital Partners, L.P., Coliseum Capital Partners II, L.P., and Blackwell Partners, LLC, Series A.&#160;(Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on March 10, 2015, SEC File Number 000-28740).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420416107943/v442184_ex4-1.htm">Amendment No. 1 to the Registration Rights Agreement dated June 10, 2016, by and among the Company, Coliseum Capital Partners, L.P., Coliseum Capital Partners II, L.P. and Blackwell Partners, LLC Series A.&#160;(Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on June 13, 2016, SEC File Number 000-28740).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420416108111/v442259_ex4-1.htm">Amendment No. 2 to the Registration Rights Agreement dated June 14, 2016, by and among the Company and the PIPE Investors.&#160;(Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on June 14, 2016, SEC File Number 000-28740).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420415034216/v411770_ex4-1.htm">Form of Subscription Rights Certificate.&#160;(Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-3/A filed on May 29, 2015, SEC File Number 000-28740).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420415044654/v416452_ex4-1.htm">Common Stock Warrant Agreement, dated July 28, 2015, by and between the Company and the American Stock Transfer &amp; Trust Company, LLC.&#160;(Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on July 28, 2015, SEC File Number 000-28740).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420417012539/v460823_ex4-1.htm">Registration Rights Agreement, dated March 1, 2017, by and among the Company and the investors named therein.&#160;(Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on March 2, 2017, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420417034758/v469985_ex4-2.htm">Registration Rights Agreement, dated June 29, 2017, by and among the Company and the parties signatory thereto&#160;(Incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed on June 29, 2017, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420419014367/tv516369_ex10-4.htm">Amendment No. 1 to Registration Rights Agreement by and between BioScrip, Inc. and the stockholders of the Company signatory thereto (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed on March 15, 2019, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420417034758/v469985_ex4-1.htm">Warrant Agreement, dated June 29, 2017, by and among the Company and the subscribers signatory thereto&#160;(Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on June 29, 2017, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420419038047/tv526734_ex4-1.htm">Second Lien Notes Indenture, dated as of August 6, 2019, among HC Group Holdings II, LLC, as the Initial Issuer, BioScrip, Inc., as the Parent Issuer, subsidiary issuers and guarantors party thereto from time to time, and Ankura Trust Company, LLC, as the Trustee and Collateral Agent (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on August 7, 2019, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000110465919065468/tm1923335d1_ex4-1.htm">Supplemental Indenture, dated November 18, 2019, by and between Option Care Health, Inc., as parent issuer, and Ankura Trust Company, LLC, as trustee and collateral agent (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on November 19, 2019, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000101473920000013/bios-ex412x20191231x10k.htm">Description of Option Care Health Inc.&#8217;s registered securities.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420418019098/tv490005-def14a.htm">BioScrip, Inc. 2018 Equity Incentive Plan&#160;(Incorporated by reference to Appendix A to the definitive proxy statement filed on April 4, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420419014367/tv516369_ex10-2.htm">Amended and Restated Warrant Agreement, dated as of March 14, 2019, by and among BioScrip, Inc. and the Holders (as defined therein) signatory thereto (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on March 15, 2019, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420419014367/tv516369_ex10-3.htm">Form of Letter Agreement, dated March 14, 2019, by and among BioScrip, Inc. and each of the Holders (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on March 15, 2019, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420419038047/tv526734_ex10-1.htm">Registration Rights Agreement, dated as of August 6, 2019, by and among BioScrip, Inc. and HC Group Holdings I, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on August 7, 2019, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420419038047/tv526734_ex10-2.htm">Director Nomination Agreement, dated as of August 6, 2019, by and among the BioScrip, Inc. and HC Group Holdings I, LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on August 7, 2019, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420419038047/tv526734_ex10-3.htm">First Lien Credit Agreement, dated as of August 6, 2019, among HC Group Holdings II, LLC, as the Initial Borrower, BioScrip, Inc., as the Parent Borrower, the guarantors party thereto from time to time, Bank of America, N.A., as the Administrative Agent, the lenders party thereto from time to time, BofA Securities, Inc., as Lead Arranger and Bookrunner and as Syndication Agent and Documentation Agent (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on August 7, 2019, SEC File Number 001-11993). </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420419038047/tv526734_ex10-4.htm">ABL Credit Agreement, dated as of August 6, 2019, among HC Group Holdings II, LLC, as the Initial Borrower, BioScrip, Inc., as the Parent Borrower, and Bank of America N.A., as the Administrative Agent, Issuing Bank and Swing Line Lender, the other lenders party thereto from time to time and Bank of America, N.A. and ACF Finco I LP as Joint Lead Arrangers and Joint Lead Bookrunners (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed on August 7, 2019, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420419038047/tv526734_ex10-5.htm">Note Purchase Agreement, dated as of August 6, 2019, among HC Group Holdings II, LLC, as the Initial Issuer, BioScrip, Inc., as the Parent Issuer, subsidiary issuers and guarantors party thereto from time to time, and the several initial purchasers party thereto (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K filed on August 7, 2019, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420419038051/tv526894_ex10-1.htm">John Rademacher Amended and Restated Employment Agreement entered into on February 23, 2018 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on August 7, 2019, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420419038051/tv526894_ex10-2.htm">Michael Shapiro Employment Agreement entered into on October 13, 2015 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on August 7, 2019, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000114420419038051/tv526894_ex10-3.htm">Harriet Booker Employment Agreement entered into on June 3, 2019 (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on August 7, 2019, SEC File Number 001-11993).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.12&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="opch-ex1012x20201231x10k.htm">Rich Denness Employment Agreement entered into on June 8, 2019 (filed herewith).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.13&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="opch-ex1013x20201231x10k.htm">Cliff Berman Employment Agreement entered into on August 3, 2015 (filed herewith).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000101473920000031/a101_firstxamendmentxtox.htm">First Amendment to ABL Credit Agreement, dated as of October 5, 2020, among Option Care Health, Inc. (f/k/a BioScrip, Inc.), each Guarantor party hereto, each lender party hereto and Bank of America, N.A., as administrative agent</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1014739/000101473920000031/a101_firstxamendmentxtox.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="opch-ex211x20201231x10k.htm">List of subsidiaries of Option Care Health, Inc. (filed herewith).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="opch-ex231x20201231x10k.htm">Consent of Independent Registered Public Accounting Firm (filed herewith).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="opch-ex311x20201231x10k.htm">Certification of Chief Executive Officer pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="opch-ex312x20201231x10k.htm">Certification of Chief Financial Officer pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="opch-ex321x20201231x10k.htm">Certification of Chief Executive Officer pursuant to 18 U.S.&#160;C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="opch-ex322x20201231x10k.htm">Certification of Chief Financial Officer pursuant to 18 U.S.&#160;C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The following financial information from the Company&#8217;s Form 10-K for the fiscal year ended December 31, 2020, formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Statements of Comprehensive Income (Loss) for the fiscal years ended December 31, 2020, 2019 and 2018, (ii) Consolidated Balance Sheets as of December 31, 2020 and 2019, (iii) Consolidated Statements of Stockholders&#8217; Equity for the fiscal years ended December 31, 2020, 2019 and 2018, (iv) Consolidated Statements of Cash Flows for the fiscal years ended December 31, 2020, 2019 and 2018, and (v) Notes to Consolidated Financial Statements.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Formatted Cover Page</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.679%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Designates the Company&#8217;s management contracts or compensatory plan or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+</span></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain schedules attached to the Agreement and Plan of Merger have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company will furnish copies of the omitted schedules to the Securities and Exchange Commission upon request by the Commission.</span></td></tr></table></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_220"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Form 10-K Summary</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic913b68a604e4ff38c42375d3fa7a17b_7">Table of Contents</a></span></div></div><div style="text-indent:18pt"><span><br/></span></div><div id="ic913b68a604e4ff38c42375d3fa7a17b_223"></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March&#160;11, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;OPTION CARE HEALTH, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">/s/&#160;&#160;Michael Shapiro</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Shapiro</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8.4pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Senior Vice President (Principal Financial Officer and Duly Authorized Officer)</span></div></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities on the dates indicated.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:32.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 73pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Title(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">s/ John C. Rademacher</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John C. Rademacher</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer, President and Director<br/> (Principal Executive Officer) </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;11, 2021</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">s/ Michael Shapiro</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Shapiro</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Senior Vice President<br/> (Principal Financial Officer) </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;11, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Robert R. Kampstra</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert R. Kampstra</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Finance and Chief Accounting Officer<br/>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;11, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Harry M. Jansen Kraemer, Jr.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harry M. Jansen Kraemer, Jr.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Executive Chairman of the Board</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;11, 2021</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ John J. Arlotta</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John J. Arlotta</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;11, 2021</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Elizabeth Q. Betten</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elizabeth Q. Betten</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;11, 2021</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ David W. Golding</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David W. Golding</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;11, 2021</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Alan Nielsen</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alan Nielsen</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;11, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ R. Carter Pate</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Carter Pate</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;11, 2021</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Nitin Sahney</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nitin Sahney</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;11, 2021</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Timothy P. Sullivan</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy P. Sullivan</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;11, 2021</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Mark Vainisi</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Vainisi</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;11, 2021</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>2
<FILENAME>opch-ex1012x20201231x10k.htm
<DESCRIPTION>EX-10.12
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic717c92bea994c5e9025aa0ee9982158_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 10.12&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Executed Version</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 8, 2019</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rich Denness</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1600 Broadway</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Suite 700</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Denver, CO 80202</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Dear Rich,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We are pleased to offer you the position of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Chief Strategy Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> at Option Care Enterprises, under the management of John Rademacher, the Chief Executive Officer, following the closing of the combination of Option Care Enterprises and BioScrip (the &#34;Merger&#34;). This offer is conditioned upon the Merger and you would start in this position effective upon the completion of the Merger. Below are the terms of our offer&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#58; Your salary will be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">$360,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> less all applicable tax withholdings and benefit deduction s.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Annual Bonus Target&#58; Your annual incentive opportunity for the portion of the 2019 plan year prior to the Merger will be paid pursuant to the merger agreement. Beginning with the portion of the 2019 fiscal year following the Merger, you will be eligible for an annual bonus target of 75% of base salary (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">$270,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">), prorated based on your official start date, and on the same criteria as other senior executives of Option Care. These terms will be evaluated and determined by the Compensation Committee after the Merger.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Equity Awards&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> Assuming the merger between Option Care and BioScrip is finalized, at the first Compensation Committee Meeting after the close of the transaction, you will be awarded a Long Term Incentive (LTI) equity grant consisting of time-vesting Restricted Stock Units with respect to number of shares of common stock of BioScrip Inc. having a value of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">$250,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> at the time of grant (the &#34;Sign-on Award&#34;). Your Sign-on Award will fully vest on the first anniversary of the Merger, subject to continued employment through such date or earlier termination of your employment by Option Care without Cause, your resignation with Good Reason, or following your death or Disability (each as defined in the long-term incentive plan documents). If you voluntarily resign from the Company without Good Reason prior to the one-year anniversary of the deal closing or are terminated for Cause, the RSUs would be forfeited.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Going forward, the Compensation Committee will evaluate the appropriate LTI awards and terms to align and integrate the combined business and incent the Executive Team, and therefore, at this time, there is no guarantee of minimum future grant size, incentive components or vesting terms provided, however, that to the extent any such going-forward equity or equity-based awards are granted to the Executive Team, you shall participate at the time or times, in the amounts and&#47;or at levels, and under terms and conditions, in each case substantially commensurate with those provided to such other members of the Executive Team.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Change in Control and &#34;Good Reason&#34; Severance Protections&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> You will receive a cash Retention Bonus equal to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">$648,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> on the first anniversary of the Merger if you are employed on such date, or experience an involuntary termination (i.e., termination by Option Care without Cause, resignation with Good Reason, death&#47; disability). The Retention Bonus will be forfeited if you voluntarily resign from employment other than with Good Reason. Notwithstanding the forgoing, in the event of a change in control (for the purposes of the equity incentive plan of the Company) prior to the first anniversary of the Merger, the Retention Bonus will be paid out in full within 30 days of the change of control. Eligibility to receive the Retention Bonus is expressly conditioned upon your waiver of any right to receive severance payments or benefits under the Offer Letter and the Severance Agreement attached thereto (as modified from time to time, including the addendum on June 11, 2018).</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#34;Good Reason &#34; shall mean a resignation of your employment with Option Care following (a) a reduction in base salary, (b) material diminution in duties, responsibilities, or authorities from the Chief Strategy Officer role, (c) a change in title from the Chief Strategy Officer title, (d) a requirement to change primary work location outside of your home office, or (e) no longer reporting to the CEO, provided that you give notice to Option Care of your resignation with Good Reason within 30 days of any such event, Option Care fails to cure such events within 10 days of such notice, and your resignation is effective immediately upon such failure to cure.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Additionally, upon your termination of employment by the Company without Cause, but not due to death or Disability, at any time following the first anniversary of the Merger, subject to your execution and non-revocation of the Company' s standard release of claims within forty-five (45) days of such termination, you will be entitled to the sum of (a) your annual base salary, plus (b) a pro rata bonus for the fiscal year in which such termination occurs, which sum shall be payable in accordance with the normal payroll process, until 12 months from the date of such termination, and (c) should you choose to elect COBRA coverage for any Company Group Health Plan coverage you have with the Company at the time of termination, the Company will subsidize a portion of your medical premium for twelve (12) months, in order to continue healthcare coverage at active employee rates, provided you make timely premium payments and maintain your cover age.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#34;Cause&#34; shall mean any of the following&#58; (a) your gross negligence, insubordination, or intentional misconduct in connection with the performance of your job duties, (b) your conviction of, or plea of guilty or nolo contendere to, any felony or crime </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">involving moral turpitude, (c) your violation of Option Care' s substance abuse policy, (d) your breach of any material provision of this or any other agreement between you and Option Care (or prior to the merger with BioScrip), which breach is not cured within 30 days following written notice of the breach by the Company, or (e) your intentional or willful violation of any rule or regulation of any government agency, or self  regulatory body, applicable to Option Care' s business. For the avoidance of doubt, this definition of &#34;Cause&#34; will not apply to any other post-Merger equity or other compensation arrangements entered into or offered by Option Care.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#34;Disability&#34; shall have the meaning set forth in the Company's then-current long-term disability benefit program.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Employee Benefits&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> You will continue to be eligible to participate in such Company employee benefit plans and policies, and to receive such other fringe benefits, as the Company may in its discretion make available to its employees generally, subject to all present and future terms and conditions of such benefit plans and other fringe benefits. These plans and benefits may change at any time, for any reason, with or without notice, by the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Section 409A&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> The intent of the parties is that payments and benefits under this offer letter comply with, or be exempt from, Internal Revenue Code Section 409A and the regulations and guidance promulgated thereunder (collectively &#34;Code Section 409A&#34;) and, accordingly, to the maximum extent permitted, this offer letter shall be interpreted to be in compliance therewith. Each payment under this letter shall be treated as a separate payment for purposes of Code Section 409A. A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amount or benefit that constitutes &#34;nonqualified deferred compensation&#34; upon or following a termination of employment unless such termination is also a &#34;separation from service&#34; within the meaning of Code Section 409A and, for purposes of any such provision of this offer letter, references to a &#34;termination,&#34; &#34;termination of employment&#34; or like terms shall mean &#34;separation from service.&#34; Notwithstanding anything to the contrary in this Agreement, if on the date of termination you are deemed to be a &#34;specified employee&#34; within the meaning of that term under Code Section 409A(a)(2)(B), then with regard to any payment or the provision of any benefit that is considered &#34;nonqualified deferred compensation&#34; under Code Section 409A payable on account of a &#34;separation from service,&#34; such payment or benefit shall not be made or provided until the date which is the earlier of (A) the expiration of the six (6)-month period measured from the date of such &#34;separation from service&#34;, and (B) the date of your death, to the extent required under Code Section 409A. Upon the expiration of the foregoing delay period, all payments and benefits delayed pursuant to this Agreement (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to you in a lump sum, and all remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. Whenever a payment under this Agreement specifies a payment period with reference to a number of days, the actual date of payment within the specified period shall be within the sole discretion of the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">This offer is not a contract of employment, but merely an explanation of the offer. Employment at Option Care Enterprises is at will, for no definite term, and is subject to Option Care's policies, which can be changed from time to time.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">If you would like to accept this offer of employment, please sign your name on the line below, fill in the date, and return the signed letter via email. Your signature will acknowledge that you have read, understood and agreed to the terms and conditions of this offer letter.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Rich, we believe you will make a significant contribution to the newly combined organization and help to make the new company an exciting and dynamic place to work.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We look forward to the opportunity to welcome you to Executive Leadership Team.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Sincerely,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Mike Rude</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Mike Rude</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Senior Vice President &#38; Chief Human Resources Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Mike.rude&#64;optioncare.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">I have read and understood this offer letter and hereby acknowledge, accept and agree to the terms as set forth above and further acknowledge that no other commitments were made to me as part of my employment offer except as specifically set forth herein.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Rich Denness              </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                                                                                                                            Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"> June 10, 2019           </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>3
<FILENAME>opch-ex1013x20201231x10k.htm
<DESCRIPTION>EX-10.13
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ibf2861ebf5c7419b848043d2c6595dc7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 10.13&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Executed Version</font></div><div style="text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EMPLOYMENT AGREEMENT</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">THIS EMPLOYMENT AGREEMENT (this &#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Agreement</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">&#34;) is made as of August 3, 2015 by and between Walgreens Infusion Services, Inc., an Illinois corporation (the &#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Company</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">&#34;), and Cliff Berman (&#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Executive</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">&#34;).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">In consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Employment</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The  Company  shall  employ  Executive,  and  Executive hereby accepts employment with the Company, upon the terms and conditions set forth in this Agreement for the period beginning on the date hereof and ending as provided in </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4 </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(the &#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Period</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;).</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 2.        </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Position and Duties</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">(a) During the Employment Period, Executive shall serve as the Senior Vice President and General Counsel of the Company and shall have the normal duties, responsibilities, functions and authority of such position. Executive shall render such administrative, financial and other executive and managerial services to the Company Group that are consistent with Executive's position as the officer to which Executive reports or the Company's board of  directors (the &#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Board</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">&#34;), as applicable, may from time to time direct.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">(b) During the Employment Period, Executive shall report to the Chief Executive Officer and shall devote Executive's best efforts and Executive's full business time and attention (except for permitted vacation periods and reasonable periods of illness or other incapacity) to the business and affairs of the Company Group. Executive shall perform Executive's duties, responsibilities and functions for the Company Group hereunder to the best of Executive's abilities in a diligent, trustworthy, professional and efficient manner and shall  comply with the Company's and its subsidiaries' policies and procedures in all material respects. In performing Executive's duties and exercising Executive's authority under this Agreement, Executive shall support and implement the business and strategic plans approved from time to time by the Board and shall support and cooperate with the Company's and its subsidiaries' efforts to expand their businesses and operate profitably and in conformity with the business and strategic plans approved by the Board. During the Employment Period, Executive shall not serve as an officer, manager or director of, or otherwise perform services for compensation for, any other person or entity without the prior written consent of the Board&#59; provided that Executive may serve as an officer, manager or director of, or otherwise participate in, solely charitable, educational, welfare, social, religious and civic organizations so long as such activities do not interfere with Executive's employment with the Company.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 3.        </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Compensation and Benefits</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">(a) During the Employment Period, Executive's base salary shall be $275,000 per annum or such higher rate as the Board may determine from time to time (as adjusted from time to time, the &#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Base Salary</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">&#34;), which salary shall be payable by the Company in regular installments in accordance with the Company's general payroll practices in effect from time to time, but in no event less frequently than monthly. In addition, during the Employment Period, Executive shall be entitled to participate in all of the Company's employee benefit programs for which senior executive employees of the Company and its subsidiaries are generally eligible.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(b) During the Employment Period, the Company shall reimburse Executive for all reasonable business expenses incurred by Executive in the course of performing Executive's duties and responsibilities under this Agreement which are consistent with the Company's policies in effect from time to time with respect to travel, entertainment and other business expenses, subject to the Company's requirements with respect to reporting and documentation of such expenses.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">(c) In addition to the Base Salary, Executive shall be eligible to receive an annual cash bonus in an amount equal to 60% of the Base Salary for achievement of target-level performance objectives (&#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Target Bonus</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">&#34;) (with the eligible amount of such bonus being more or less than the Target Bonus in the event of achievement below or above target-performance objectives, in each case as determined by the Board in its discretion). The annual bonus, to the extent earned in a given fiscal year as determined in the sole discretion of the Board, will be paid to Executive within 30 days following the completion of the audit for such fiscal year during the Employment Period based upon Executive's performance and the Company's achievement of financial, operating and other objectives set by the Board and communicated to Executive not later than 90 days after the commencement of the applicable fiscal year.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">(d) All amounts payable to Executive as compensation hereunder shall be subject to all required and customary withholding by the Company and its subsidiaries.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 4.        </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Term</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">(a) The Employment Period shall begin on the date of this Agreement and terminate upon the first to occur of (i) Executive's resignation, (ii) Executive's death or Disability and (iii) the Company's termination of Executive for Cause or without Cause.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">(b) If the Employment Period is terminated by the Company without Cause (or by Executive's resignation within 30 days following a Sale of the Company (as defined in the LLC Agreement) in which Executive is not retained in his current or a comparable position at a principal work location located within 75 miles of Executive's principal work location at the time of such Sale of the Company), Executive shall be entitled to receive Executive's Base Salary, accrued unused vacation (in accordance with the Company's vacation plan) and employee benefits through the date of termination and shall not be entitled to any other salary, compensation or benefits from the Company Group thereafter, except as follows&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">(i) subject to the terms and conditions of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Section 10</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">, Executive shall be entitled to continue to receive a cash amount equal to Executive's Base Salary, payable in regular payroll installments, and to continue to participate in health benefit plans for senior executive employees  of  the Company to the extent permitted  under the terms   of such plans and programs and such participation would not result in excise or other similar taxes payable by the Company Group or loss of benefits by the Company Group, for a period of 12 months after the date of such termination (the &#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Severance Period</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">&#34;). As a result of such termination, Executive shall also be entitled to payment of (x) any unpaid annual bonus earned for any completed fiscal year (&#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Prior Year Bonus</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">&#34;), which bonus shall be payable at such time as such bonus is otherwise payable pursuant to </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Section 3(c), </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">and (y) a pro rata bonus for the fiscal year in which such termination occurs in an amount equal to (A) 60% of the Base Salary, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">multiplied </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">by (B) the ratio of the number of days Executive is employed in such fiscal year to 365 (&#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Pro Rata Bonus</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">&#34;), which bonus shall be payable in equal installments over the Severance Period on regular payroll dates. The foregoing amounts under this </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Section 4(b)(i) </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">shall be payable to Executive if and only if Executive has executed and delivered to the Company a general release substantially in form and substance as set forth in </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Exhibit A </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">attached hereto (the &#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">General Release</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">&#34;) and the General Release has become effective and is no longer subject to revocation within sixty (60) days following the date of such termination, and only so long as Executive has not revoked or breached the provisions of the General Release or breached the provisions of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Section 5, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Section 6 or </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Section 7 </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">and does not apply for unemployment compensation chargeable to the Company or any subsidiary during the Severance Period, and</font></div><div style="padding-left:18pt;text-indent:18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">(ii) Executive shall not be entitled to any other salary, compensation or benefits after termination of the Employment Period, except as otherwise specifically provided for under the Company's employee benefit plans or as expressly required by applicable law.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">(iii) In no event shall Executive be obliged to seek other employment or take any other action by way of mitigation of the amounts payable to Executive under </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Section </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:106%;text-decoration:underline">4(b</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">)(i), </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">nor shall the amount of any payment hereunder be reduced by any compensation earned by the Executive as a result of employment by another employer.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Any amounts payable pursuant to </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Section 4(b)(i) </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">shall not be paid until the first scheduled payment date following the date the General Release is executed and no longer subject to revocation, with the first such payment being in an amount equal to the total amount to which Executive would otherwise have been entitled during the period following the date of termination if such deferral had not been required&#59; </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">provided, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">however, that any such amounts that constitute nonqualified deferred compensation within the meaning of Code &#167;409A shall not be paid until the 60th day following such termination to the extent necessary to avoid adverse tax consequences under Code &#167;409A, and, if such payments are required to be so deferred, the first payment shall be in an amount equal to the total amount to which Executive would otherwise have been entitled during the period following the date of termination if such deferral had not been required. Notwithstanding any other provision of this Agreement, if following the termination of the Employment Period, Executive is entitled to payments or other benefits under this </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Section 4(b), </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">but it is later determined that Executive was terminable for Cause, (i) Executive shall not be entitled to any payments or other benefits pursuant to this </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Section 4(b), </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">(ii) any and all payments to be made by the Company Group shall cease and (iii) any such payments previously made to Executive shall be returned immediately to the Company by Executive.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">(c) If the Employment Period is terminated due to Executive's death, Disability or resignation, or due to Executive's termination for Cause, Executive shall be entitled to receive Executive's Base Salary, accrued and unused vacation (in accordance with the Company's vacation plan), and employee benefits through the date of such termination and Executive shall not be entitled to any other salary, compensation or benefits from the Company Group thereafter, except as otherwise specifically provided for under the Company's employee benefit plans or as expressly required by applicable law&#59; provided, if such termination is due to Executive's death or Disability, Executive shall also be entitled to receive any Prior Year Bonus and a Pro Rata Bonus, in each case as payable at the times provided in </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Section </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:101%;text-decoration:underline">4(b)(i)</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:101%">.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">(d) Except as otherwise expressly provided in this Agreement, all of Executive's rights to salary, bonuses, employee benefits and other compensation hereunder which would have accrued or become payable after the termination of the Employment Period shall cease upon such termination or expiration, other than those expressly required under applicable law (such as COBRA). Nothing contained herein is intended to limit or otherwise restrict the availability of any COBRA benefits to Executive required to be provided pursuant to Section 601 of Title I of the Employee Retirement Income Security Act of 1974 and Section 49808 of the Internal Revenue Code. Except as otherwise provided in </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Section 10</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">, the Company may offset any undisputed amounts Executive owes the Company Group against any amounts the Company Group owes Executive.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">(e) &#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Cause</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">&#34; shall mean with respect to Executive one or more of the following&#58; (i) the commission of a felony or other crime involving moral turpitude&#59; (ii) the commission of any act or omission involving dishonesty, disloyalty or fraud with respect to the Company Group&#59; (iii) reporting to work under the influence of alcohol or illegal drugs, the use of illegal drugs (whether or not at the workplace) or other repeated conduct causing the Company Group substantial public disgrace or substantial economic harm&#59; (iv) substantial and repeated failure to perform duties as reasonably directed by the officer to which Executive reports or the Board&#59; (v) any intentional act or omission aiding or abetting a competitor, supplier or customer  of the Company Group to the material disadvantage of the Company Group&#59; (vi) breach of fiduciary duty or willful misconduct with respect to the Company Group or (vii) any other material breach of this Agreement&#59; </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">provided, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">Executive shall be entitled to notice and an opportunity to cure any act or omission (if curable) under clause (vii) which is not cured to the Board's reasonable satisfaction within 30 days after written notice thereof to Executive.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">(f) &#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Company Group</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">&#34; means the Company and its subsidiaries and, for so long as the Company is a subsidiary of Holdings, Holdings and its subsidiaries.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">(g) &#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Disability</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">&#34; shall mean Executive's inability to perform the essential duties, responsibilities and functions of Executive's position with the Company and its subsidiaries for such period as entitles Executive to monthly income replacement benefits under the Company's long-term disability plan in which Executive participates&#59; provided, if there shall not be such a plan in which Executive is a participant, such period shall be for 90 consecutive days or for a total of 180 days during any 12-month period as a result of any mental or physical illness, disability or incapacity even with reasonable accommodations for such illness, disability or incapacity provided by the Company and its subsidiaries or if providing such accommodations would be unreasonable, all as determined by the Board in its reasonable good faith judgment. Executive shall cooperate in all respects with the Company if a question arises as to whether Executive has become disabled (including, without limitation, submitting to reasonable examinations by one or more medical doctors and other health care specialists selected by the Company and authorizing such medical doctors and other health care specialists to discuss Executive's condition with the Company).</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(h) &#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Holdings</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#34; means HC Group Holdings I, LLC, a Delaware limited liability company.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i) &#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">LLC  Agreement</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#34;  means the Amended  and  Restated  Limited  Liability Company Agreement of Holdings, dated as of April 7, 2015, among the parties from time to time party thereto, as further amended from time to time pursuant to its terms.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 5.        </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Confidential Information</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">(a) Executive acknowledges that the information, observations and data (including trade secrets) obtained by Executive while employed by the Company Group both before and after the date of this Agreement concerning the business or affairs of the Company Group (&#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Confidential Information</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">&#34;) are the property of the Company Group. In addition, Executive shall not disclose to any person or entity or use for Executive's own purposes any Confidential Information or any confidential or proprietary information of other persons or entities in the possession of the Company Group (&#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Third Party Information</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">&#34;), without the prior written consent of the Board except as necessary for Executive to discharge Executive's duties hereunder as determined in Executive's reasonable discretion, unless and to the extent that the Confidential Information or Third Party Information (i) becomes generally known to and available for use by the public other than as a result of Executive's acts or omissions or (ii) is required to be disclosed pursuant to applicable law or a court order or decree (in which case Executive shall give prior written notice to the Company of such disclosure). Executive shall deliver to the Company at the termination or expiration of the Employment Period, or at any other time the Company may reasonably request, all memoranda, notes, plans, records, reports, computer files, disks and tapes, printouts and software and other documents and data (and copies thereof) embodying or relating to Confidential Information, Third Party Information, Work Product or the business of the Company Group which Executive may then possess or have under Executive's control.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">(b) In connection with rendering services to the Company Group hereunder, Executive shall be prohibited from using or disclosing any confidential information or trade secrets that Executive learned in connection with any prior employment with the Company or its affiliates at such time and that Executive is prohibited from using or disclosing by law or by contract. If at any time during the Employment Period Executive believes that Executive is being asked to engage in work that will, or will be likely to, jeopardize any confidentiality or other obligations Executive may have to former employers, Executive shall immediately advise the Board so that Executive's duties can be modified appropriately.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">Section 6. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Intellectual  Property.  Inventions  and  Patents</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">.  Executive acknowledges that all discoveries, concepts, ideas, inventions, innovations, improvements, developments, methods, designs, analyses, drawings, reports, patent applications, copyrightable work and mask work (whether or not including any Confidential Information) and all  registrations or applications related thereto, all other proprietary information and all similar or related information (whether or not patentable) which relate to the Company Group's actual or anticipated business, research and development or existing or future products or services and which are conceived, developed or made by Executive (whether alone or jointly with others) while employed by the Company or its predecessor and its subsidiaries, whether before or after the date of this Agreement (collectively referred to as &#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Work Product</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">&#34;), are the property of the Company or such other member of the Company Group. Executive shall promptly disclose such Work Product to the Board and, at the Company's expense, perform all actions reasonably requested by the Board (whether during or after the Employment Period) to establish and confirm such ownership (including, without limitation, executing and delivering assignments, consents, powers of attorney and other instruments). Executive acknowledges that all Work Product shall be deemed to constitute &#34;works made for hire&#34; under the U.S. Copyright Act of 1976, as amended.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">In accordance with the Illinois Employee Patent Act, Executive is hereby advised that this </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Section 6 </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">regarding the Company Group's ownership of Work Product does not apply to any invention for which no equipment, supplies, facilities or trade secret information of the Company Group was used and which was developed entirely on Executive's own time, unless (i) the invention relates to the business of the Company Group or to any member of the Company Group's actual or demonstrably anticipated research or development or (ii) the invention results from any work performed by Executive for a member of the Company Group.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 7.        </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Non-Compete. Non-Solicitation</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">(a) As additional consideration for the compensation to be paid to Executive under this Agreement, Executive acknowledges that during the course  of  Executive's employment with the Company Executive shall have access to and shall become familiar with  the Company Group's trade secrets and with other Confidential Information concerning the Company Group and that Executive's services have been and shall continue to be of special, unique and extraordinary value to the Company Group, and therefore, Executive agrees that, during the Employment Period and for 12 months thereafter (the &#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;text-decoration:underline">Non-compete Period</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">&#34;), Executive shall not directly or indirectly own any interest in, manage, control, participate in, consult with, render services for, be employed by, or in any manner engage in, any person, business or entity that engages in the Business or is otherwise competing with the Company Group as such businesses exist or are substantially in process on the date of the termination of  the Employment Period, within any geographical area in which a member of the Company Group engages or substantially plans to engage in such businesses. Nothing herein shall prohibit Executive from being a passive owner of not more than 2% of the outstanding stock of any class of a corporation which is publicly traded, so long as Executive has no active participation in the business of such corporation. For purposes of this Agreement, &#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;text-decoration:underline">Business</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">&#34; shall mean  the  business carried on by the Company Group from time to time, and which shall include the business of providing (i) infusion therapy to patients in their homes or in an ambulatory  infusion suite, (ii) case coordination services for home infusion therapy and (iii) home infusion network management services.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(b) In addition, during the Non-compete Period, Executive shall not directly or indirectly through another person, business or entity (i) induce or attempt to induce any employee of the Company Group to leave the employ of the Company Group, or in any way interfere with the relationship between the Company Group and any employee thereof, (ii) hire any person who was  an  employee  of  the  Company  Group  at  any  time  during  the  Employment  Period  or (iii) induce or attempt to induce any customer, supplier, licensee, licensor, franchisee or other business relation of the Company Group to cease doing business with the Company Group, or in any way interfere with the relationship between any such customer, supplier, licensee or business relation and the Company Group.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(c) During the Non-compete Period, Executive shall not make any negative or disparaging statements or communications regarding the Company Group or any of their officers, directors or employees, and no member of the Board or the Holdings board of directors (&#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Holdings Board</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#34;) shall make any negative or disparaging statements or communications regarding Executive&#59; </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">provided, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">however, that nothing in this </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Section 7(c) </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">shall prevent Executive from providing truthful testimony or information in any proceeding or in response to any request from any governmental agency, or judicial, arbitral or self-regulatory forum, nor prevent the Company Group from assessing Executive's performance and sharing such information with Company Group employees and members of the Board or Holdings Board who have a need to know such information.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(d) If, at the time of enforcement of this </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Section 7, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">a court shall hold that the duration, scope or area restrictions stated herein are unreasonable under circumstances then existing, the parties agree that the maximum duration, scope or geographical area reasonable under such circumstances shall be substituted for the stated duration, scope or area and that the court shall be allowed to revise the restrictions contained herein to cover the maximum period, scope and area permitted by law. Executive acknowledges that the restrictions contained in this </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Section 7 </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">are reasonable and that Executive has reviewed the provisions of this Agreement with Executive's legal counsel.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(e) In the event of the breach or a threatened breach by Executive of any of the provisions of this </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Section 7, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">the Company Group would suffer irreparable harm, and in addition and supplementary to other rights and remedies existing in its favor, the Company shall be entitled to specific performance and&#47;or injunctive or other equitable relief from a court of competent jurisdiction in order to enforce or prevent any violations of the provisions hereof (without posting a bond or other security). In addition, in the event of a breach or violation by Executive of this </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Section 7, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">the Non-compete Period shall be extended automatically by the amount of time between the initial occurrence of the breach or violation and when such breach or violation has been duly cured.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Section 8. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Additional Acknowledgments</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">. Executive acknowledges that the provisions of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Section 5, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Section 6 and </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Section 7 </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">are in consideration of employment with the Company, other good and valuable consideration as set forth in this Agreement and the grant  of equity in Holdings to Executive pursuant to the Unit Award Agreement. Executive also acknowledges that (i) the restrictions contained in </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Section 5</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">, Section 6 and </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Section 7 </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">do not preclude Executive from earning a livelihood, nor do they unreasonably impose limitations on Executive's ability to earn a living, (ii) the business of the Company Group will be national in scope and (iii) notwithstanding the jurisdiction of formation or principal office of the Company or residence of any of its executives or employees (including Executive), it is expected that the Company Group will have business activities and have valuable business relationships within its industry throughout the United States. Executive agrees and acknowledges that the potential harm to the Company Group resulting from the non-enforcement of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Section 5, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Section 6 and </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%;text-decoration:underline">Section 7 </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">outweighs any potential harm to Executive of the enforcement of such provisions by injunction or otherwise. Executive acknowledges that Executive has carefully read this Agreement and has given careful consideration to the restraints </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">imposed upon Executive by this Agreement and is in full agreement regarding their necessity for the reasonable and proper protection of the business goodwill, competitive positions and confidential and proprietary information of the Company Group now existing or to be developed in the future and that each and every restraint imposed by this Agreement is reasonable with respect to subject matter, time period and geographical area.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Section 9. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Executive's Representations</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">. Executive hereby represents and warrants to the Company that (i) the execution, delivery and performance of this Agreement by Executive do not and shall not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order, judgment or decree to which Executive is a party or by which Executive is bound, (ii) Other than continuing obligations of confidentiality in Executive's employment agreements with prior employers and a one year post-employment non-compete obligation (through July 24, 2016) in Executive's employment agreement with Catamaran LLC (flea SXC Health Solutions, Inc.). Executive is not a party to or bound by any employment agreement, non-compete agreement or confidentiality agreement with any other person, business or entity or any agreement or contract requiring Executive to assign inventions to another party and (iii) upon the execution and delivery of this Agreement by the Company, this Agreement shall be the valid and binding obligation of Executive, enforceable in accordance with its terms. Executive hereby acknowledges and represents that Executive has consulted with independent legal counsel regarding Executive's rights and obligations under this Agreement and that Executive fully understands the terms and conditions contained herein.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 10.      </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Deferred Compensation Matters.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(a) It is the intent of the Company and Executive that the payments and benefits under this Agreement shall comply with or be exempt from Internal Revenue Code Section  409A  and the regulations  and guidance  promulgated  thereunder  (collectively, &#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline">Code &#167;409A</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#34;), and accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance with or exempt from Code &#167;409A. Executive agrees and acknowledges that the Company and its respective Subsidiaries make no representations with respect to the application of Code &#167;409A and other tax consequences to any payments hereunder and, by entering into this Agreement, Executive agrees to accept the potential application of Code &#167;409A and the other tax consequences of any payments made hereunder.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">(b) A termination of the Employment Period shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment unless such termination is also a &#34;separation from service&#34; within the meaning of Code  &#167;409A, and for purposes  of any such provision of this Agreement, references to a &#34;termination&#34;, &#34;termination of the Employment Period&#34;, &#34;termination of employment&#34; or similar terms shall mean &#34;separation from service.&#34; Notwithstanding anything to the contrary in this Agreement, if Executive is deemed on the date  of  termination  to  be  a  &#34;specified  employee&#34;  within  the  meaning  of  that  term  under   Code &#167;409A(a)(2)(B), then with regard to any payment or the provision of any benefit that is considered deferred compensation under Code &#167;409A payable on account of a &#34;separation from service,&#34; such payment or benefit shall not be made or provided until the date which is the earlier of (A) the expiration of the six (6)-month period measured from the date of such  &#34;separation from service&#34; of Executive, and (B) the date of the Executive's death, to the extent required under Code Section 409A. Upon the expiration of the foregoing delay period,  all  payments  and benefits delayed pursuant to this </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Section lO(b) </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">(whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to Executive in a lump sum, and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">(c) To the extent any reimbursements or in-kind benefits under  this Agreement constitute &#34;non-qualified deferred compensation&#34; for purposes of Code &#167;409A, (i) all such expenses or other reimbursements under this Agreement shall be made on or prior to the last day of the taxable year following the taxable year in which such expenses were incurred by Executive, (ii) any right to such reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit and (iii) no such reimbursement, expenses eligible for reimbursement or in-kind benefits provided in any taxable year shall in any way affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">(d) For purposes of Code &#167;409A, Executive's right to receive any installment payment pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a payment period with reference to a number of days </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:101%">(e.g., </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">&#34;payment shall be made within 30 days following the date of termination&#34;), the actual date of payment within the specified period shall be within the Company's sole discretion. Notwithstanding any other provision of this Agreement to the contrary, in no event shall any payment under this Agreement that constitutes &#34;non-qualified deferred compensation&#34; for purposes of Code &#167;409A be subject to offset, counterclaim or recoupment by any other amount unless otherwise permitted by Code &#167;409A.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">Section 11. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;text-decoration:underline">Survival</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">. Section 4 through </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;text-decoration:underline">Section 24, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">inclusive, shall survive and continue in full force in accordance with their terms notwithstanding the termination of the Employment Period.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">Section 12. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;text-decoration:underline">Notices. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">All notices, demands,  or  other  communications  to  be  given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given or made (i) when delivered personally to the recipient, (ii) when telecopied to the recipient, or delivered by means of electronic mail (with hard copy sent to the recipient by reputable overnight courier service (charges prepaid) that same day) if telecopied&#47;emailed before 5&#58;00 p.m. Chicago, Illinois time on a business day, and otherwise on the next business day, or (iii) one (1) business day after being sent to the recipient by reputable overnight courier service (charges prepaid). Such notices, demands, and other communications shall </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">be sent to the Company at the following address and to Executive at Executive's Address or to the address for Executive set forth from time to time in the Company's books and records (and if Executive has notified the Company that he or she is represented by legal counsel in connection with the transactions contemplated hereby, with a copy (which shall not constitute notice) to such counsel's address as listed by Executive on the signature page hereto), or to such other address or to the attention of such other person as the recipient party has specified by prior written notice to the sending party.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Walgreens Infusion Services, Inc. 1411 Lake Cook Road, MS 321</font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deerfield, Illinois 60015</font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Facsimile&#58; 847-964-4678</font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Telephone&#58; 847-964-4950</font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Electronic mail&#58; Paul Mastrapa</font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Attention&#58; Chief Executive Officer</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">with copies to (which shall not constitute notice)</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#58; Madison Dearborn Partners, LLC</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Three First National Plaza</font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Suite 4600</font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chicago, IL 60602</font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Facsimile&#58; (312) 895-1001</font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Telephone&#58; (312) 895-1000</font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Electronic mail&#58; mtresnowski&#64;MDCP.com</font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Attention&#58; General Counsel</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Kirkland &#38; Ellis LLP 300 North LaSalle</font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chicago, IL 60654</font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Facsimile&#58; (312) 862-2200</font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Telephone&#58; (312) 862-2000</font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">Electronic mail&#58; sperl&#64;kirkland.com&#59; mfennell&#64;kirkland.com </font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">Attention&#58; Sanford E. Perl, P.C.</font></div><div style="text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">                  Mark A. Fennell, P.C.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">or such other address or to the attention of such other person as the recipient party shall have specified by prior written notice to the sending party. Any notice under this Agreement shall be deemed to have been given when so delivered, sent or mailed.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">Section 14. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Severability</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement or any action in any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">Section 15. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Complete Agreement</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">. This Agreement, and any other agreement expressly referred to herein embody the complete agreement and understanding among  the parties and supersede and preempt any prior understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in  anyway.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 16.   </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">No Strict Construction</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The language used in this Agreement shall  be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">Section 17. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Counterparts</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">. This Agreement may be executed in separate counterparts, each of which is deemed to be an original and all of which taken together constitute one and the same agreement.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">Section 18. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Successors and Assigns</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">.  This Agreement is intended to bind and  inure to the benefit of and be enforceable by Executive, the Company and their respective heirs, successors and assigns, except that Executive may not assign Executive's rights or delegate Executive's duties or obligations hereunder without the prior written consent of the Company.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">Section 19. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;text-decoration:underline">Choice of Law</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">. All issues and  questions  concerning  the  construction, validity, enforcement and interpretation of this Agreement and the exhibits and schedules hereto shall be governed by, and construed in accordance with, the laws of the State of Illinois, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Illinois or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Illinois.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">Section 20. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Amendment and Waiver. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">The provisions of this Agreement may be amended or waived only with the prior written consent of the Company (as approved by the Board) and Executive, and except as expressly provided herein, no course </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">of conduct or course of dealing or failure or delay by any party hereto in enforcing or exercising any of the provisions of this Agreement (including, without limitation, the Company's right to terminate the Employment Period for Cause) shall affect the validity, binding effect or enforceability of this Agreement or  be deemed to be an implied waiver of any provision of this Agreement.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">Section 21. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;text-decoration:underline">Insurance. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">The Company may, at its discretion,  apply  for  and  procure in its own name and for its own benefit life and&#47;or disability insurance on Executive in any amount or amounts considered advisable. Executive shall cooperate in any medical or other examination,   supply   any   information   and  execute   and  deliver  any  applications   or  other instruments in writing as may be reasonably necessary to obtain and maintain such insurance. Executive hereby represents that Executive has no reason to believe that Executive's life is not insurable at rates now prevailing for healthy men of Executive's age. The  Company  will maintain in strictest confidence all information obtained in connection with such medical or other examination and use such information only for the purposes of this </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;text-decoration:underline">Section 21</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">Section 22.   </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Withholding Tax Indemnification and Reimbursement of Payments on Behalf of Executive</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">. The Company Group shall be entitled to deduct or withhold from any amounts owing from the Company Group to Executive any federal, state, local or foreign withholding taxes, excise tax or employment taxes (&#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Taxes</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">&#34;) imposed with respect to Executive's compensation or other payments from the Company Group or Executive's ownership interest in the Company Group (including, without limitation, wages, bonuses, dividends, the receipt or exercise of equity options and&#47;or the receipt or vesting of restricted equity). In the event the Company Group does not make such deductions or withholdings, Executive shall indemnify the Company Group for any amounts paid with respect to any such Taxes, together with any interest, penalties and related expenses thereto.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">Section 23.  </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Waiver  of Jury  Trial</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">.  As a specifically  bargained for inducement for each of the parties hereto to enter into this Agreement (after having the opportunity to consult with legal counsel), the Company and Executive each expressly waives the right to trial by jury  in any lawsuit or proceeding relating to or arising in any way from this Agreement or the matters contemplated hereby.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">Section 24. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Executive's Cooperation</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">. During the Employment Period and thereafter, Executive shall cooperate with the Company Group in any internal investigation, any administrative, regulatory or judicial investigation or proceeding or any dispute with a third party as reasonably requested by the Company (including, without limitation,  Executive  being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company's request to give testimony without requiring service of a subpoena or other legal process, volunteering to the Company all pertinent information and turning over to the Company all relevant documents which are or may come into Executive's possession, all at times and on schedules that are reasonably consistent with Executive's other permitted activities and commitments). In the event the Company requires Executive's cooperation in accordance with this </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline">Section 24, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">the Company shall reimburse Executive solely for reasonable travel expenses (including lodging and meals) upon submission of receipts.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written above.</font></div><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-indent:297pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:101%">WALGREENS INFUSION SERVICES, INC.</font></div><div style="text-indent:297pt"><font><br></font></div><div style="text-indent:297pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">By&#58; </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline"> Paul Mastrapa                                                </font></div><div style="text-indent:297pt"><font><br></font></div><div style="text-indent:297pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">Its&#58; </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline"> CEO                                                               </font></div><div style="text-indent:297pt"><font><br></font></div><div style="text-indent:297pt"><font><br></font></div><div style="text-indent:297pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">&#47;s&#47; </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;text-decoration:underline"> Cliff Berman                                                    </font></div><div style="text-indent:297pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">      Cliff Berman</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right;text-indent:297pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:101%;text-decoration:underline">Exhibit A</font></div><div style="text-align:right;text-indent:297pt"><font><br></font></div><div style="text-align:center;text-indent:297pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">GENERAL RELEASE</font></div><div><font><br></font></div><div style="text-indent:42.89pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Cliff Berman, in consideration of and subject to the performance by Walgreens Infusion Services,  Inc.,  an  Illinois  corporation  (together  with  its  subsidiaries,  the  &#34;</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;),  of its obligations   under   my   employment   agreement,   dated   as of August 3, 2015 (the &#34;</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Agreement</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;), do hereby release and forever discharge as of the date hereof the Company, HC Group Holdings I, LLC, a Delaware limited liability company (&#34;</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Holdings</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;), and their respective subsidiaries and affiliates and all present and former directors, officers, agents, representatives, employees, successors and assigns of the Company, Holdings and  their respective subsidiaries and affiliates and the Company's and Holdings' respective direct or  indirect owners (collectively, the &#34;</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Released Parties</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;) to the extent provided below.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">1.</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;padding-left:24pt">I understand that any payments or benefits paid or granted to me under Section 4(b) of the Employment Agreement represent, in part, consideration for signing this General Release and are not salary, wages or benefits to which I was already entitled. I  understand and agree that I shall not receive the payments and benefits specified in Section 4(b) of the Employment Agreement unless I execute this General Release and do not revoke this General Release within the time period permitted hereafter or breach this General Release. Such payments and benefits shall not be considered compensation for purposes of any  employee benefit plan, program, policy or arrangement maintained or hereafter established by the Company or its affiliates. I also acknowledge and represent that I have received all payments and benefits that I am entitled to receive (as of the date hereof) by virtue of any employment by the Company.</font></div><div style="text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">2.</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;padding-left:24pt">Except as provided in paragraph 4 below and except for the provisions of the Employment Agreement that expressly survive the termination of my employment with the Company, I knowingly and voluntarily (for myself, my heirs, executors, administrators and assigns) release and forever discharge the Company and the other Released Parties from any and all claims, suits, controversies, actions, causes of action, cross-claims, counter-claims, demands, debts, compensatory damages, liquidated damages, punitive or exemplary damages, other damages, claims for costs and attorneys' fees, or liabilities of any nature whatsoever in law and in equity, both past and present (through the date this General Release becomes effective and enforceable) and whether known or unknown, suspected, or claimed against the Company or any of the Released Parties which I, my spouse, or any of my heirs, executors, administrators or assigns, may have, which arise out of or are connected with my employment with, or my separation or termination from, the Company, Holdings and their respective subsidiaries (including, but not limited to, any allegation, claim or violation, arising under&#58; Title VII of the Civil Rights Act of 1964, as amended&#59; the Civil Rights Act of 1991&#59; the Age Discrimination in Employment Act of 1967, as amended (including the Older Workers Benefit Protection Act)&#59; the Equal Pay Act of 1963, as amended&#59; the Americans with Disabilities Act of 1990&#59; the Family and Medical Leave Act of 1993&#59; the Worker Adjustment Retraining and Notification Act&#59; the Employee Retirement Income Security Act of 1974&#59; any applicable Executive Order Programs&#59; the Fair Labor Standards Act&#59; or their state or local counterparts&#59; or under any other federal, state or local civil or human rights law, or under any other local, state, or federal law, regulation or ordinance&#59; or under any public policy, contract or tort, or under common law&#59; or arising under </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">any policies, practices or procedures of the Company&#59; or any claim for wrongful discharge, breach of contract, infliction of emotional distress, defamation&#59; or any claim for costs, fees, or other expenses, including attorneys' fees incurred in these matters) (all of the foregoing collectively referred to herein as the &#34;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;text-decoration:underline">Claims</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">&#34;).<br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">3.</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;padding-left:24pt">I represent that I have made no assignment or transfer of any right, claim, demand, cause of action, or other matter covered by paragraph 2 above.<br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">4.</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;padding-left:24pt">I agree that this General Release does not waive or release any rights or claims that I may have under the Age Discrimination in Employment Act of 1967 which arise after the date I execute this General Release. I acknowledge and agree that my separation from employment with the Company in compliance with the terms of the Employment Agreement  shall not serve as the basis for any claim or action (including, without limitation, any claim under the Age Discrimination in Employment Act of 1967).<br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">5.</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;padding-left:24pt">I agree that I am waiving all rights to sue or obtain equitable, remedial or punitive relief from any or all Released Parties of any kind whatsoever (including, without limitation, reinstatement, back pay, front pay, attorneys' fees and any form of injunctive relief). Notwithstanding the above, I further acknowledge that I am not waiving and am not being required to waive any right that cannot be waived under law (including, without limitation, the right to file an administrative charge or participate in an administrative investigation or proceeding)&#59; provided that I disclaim and waive any right to share or participate in any monetary award resulting from the prosecution of such charge or investigation or proceeding.<br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">6.</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;padding-left:24pt">In signing this General Release, I acknowledge and intend that it shall be effective as a bar to each and every one of the Claims hereinabove mentioned or implied. I expressly consent that this General Release shall be given full force and effect according to each and all of its express terms and provisions, including, without limitation, those relating to unknown and unsuspected Claims (notwithstanding any state statute that expressly limits the effectiveness of a general release of unknown, unsuspected and unanticipated Claims), if any, as well as those relating to any other Claims hereinabove mentioned or implied. I acknowledge and agree that this waiver is an essential and material term of this General Release and that without such waiver the Company would not have agreed to the terms of the Employment Agreement. I further agree that in the event I should bring a Claim seeking damages against the Company or any other Released Party, or in the event I should seek to recover against the Company or any other Released Party in any Claim brought by a governmental agency on my behalf, this General Release shall serve as a complete defense to such Claims to the maximum extent permitted by law. I further agree that I am not aware of any pending claim of the type described in paragraph 2 above as of the execution of this General Release.<br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">7.</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;padding-left:24pt">I agree that neither this General Release, nor the furnishing of the consideration for this General Release, shall be deemed or construed at any time to be an admission by the Company, any other Released Party or myself of any improper or unlawful conduct.<br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">8.</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;padding-left:24pt">I agree that I will forfeit all amounts payable by the Company, Holdings and their respective subsidiaries pursuant to the Employment Agreement if I challenge the validity of this General Release. I also agree that if I violate this General Release by suing the Company or any other Released Parties, I shall pay all costs and expenses of defending against the suit incurred by the Released Parties (including, without limitation, reasonable attorneys' fees, and return all payments received by me pursuant to the Employment Agreement).<br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">9.</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;padding-left:24pt">I agree that this General Release and the Employment Agreement are confidential and agree not to disclose any information regarding the terms of this General Release or the Employment Agreement, except to my immediate family and any tax, legal or other counsel I have consulted regarding the meaning or effect hereof or as required by law, and I shall instruct each of the foregoing not to disclose the same to anyone. Notwithstanding anything herein to the contrary, each of the parties (and each affiliate and person acting on behalf of any such party) agree that each party (and each employee, representative, and other agent of such party) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of this transaction contemplated in this Agreement and all materials of any kind (including opinions or other tax analyses) that are provided to such party or such person relating to such tax treatment and tax structure, except to the extent necessary to comply with any applicable federal or state securities laws. This authorization is not intended to permit disclosure of any other information including (without limitation) (i) any portion of any materials to the extent not related to the tax treatment or tax structure of this transaction, (ii) the identities of participants or potential participants in this Agreement, (iii) any financial information (except to the extent such information is related to the tax treatment or tax structure of this transaction), or (iv) any other term or detail not relevant to the tax treatment or the tax structure of this transaction.<br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">10.</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;padding-left:19pt">The non-disclosure provisions in this General Release do not prohibit or restrict me (or my attorney) from responding to any inquiry about this General Release or its underlying facts and circumstances by the Securities and Exchange Commission, the National Association of Securities Dealers, Inc., any other self-regulatory organization or governmental entity.<br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">11.</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;padding-left:19pt">I affirm my obligations of confidentiality under Section 5 of the Employment Agreement. I agree not to disparage the Company Group or any of their past or present affiliates, investors, officers, managers, directors or employees. I further agree that as of the date hereof, I have returned to the Company and Holdings any and all property, tangible or intangible, relating to their respective subsidiaries' business, which I possessed or had control over at any time (including, but not limited to, company-provided credit cards, building or office access cards, keys, computer equipment, manuals, files, documents, records, software, customer data base and other data) and that I shall not retain any copies, compilations, extracts, excerpts, summaries or other notes of any such manuals, files, documents, records, software, customer data base or other data.<br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">12.</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;padding-left:19pt">Notwithstanding anything in this General Release to the contrary, this General Release shall not relinquish, diminish, or in any way affect any rights or claims (a) arising  out  of  any  breach  by  the  Company  or  by  any  Released  Party  of  the Employment Agreement after the date hereof, (b) respecting my rights of indemnification and coverage as an insured under directors and officers liability insurance or pursuant to the limited liability agreement of Holdings, (c) any accrued and vested benefits in accordance with the employee benefits plans in which I am a participant, (d) unpaid expenses subject to reimbursement in accordance with Section 3(b) of the Employment Agreement, (e) pursuant to my rights not to be disparaged under Section 7(c) of the Employment Agreement  and (f) respecting  my member units in Holdings (or any successor).<br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">13.</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;padding-left:19pt">Whenever possible, each provision of this General Release shall be interpreted in, such manner as to be effective and valid under applicable law, but if any provision of this General Release is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or any other jurisdiction, but this General Release shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.<br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">14.</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%;padding-left:19pt">Holdings   shall  be  an  express  third-party   beneficiary  of  this   General Release.</font></div><div><font><br></font></div><div style="text-indent:6.65pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">BY SIGNING THIS GENERAL RELEASE, I REPRESENT AND AGREE THAT&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">I HAVE READ IT CAREFULLY&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">b.</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;padding-left:10.5pt">I UNDERSTAND ALL OF ITS TERMS AND KNOW THAT I AM GIVING UP IMPORTANT RIGHTS, INCLUDING BUT NOT LIMITED TO, RIGHTS  UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, AS AMENDED, TITLE VII OF THE CIVIL RIGHTS ACT OF 1964, AS AMENDED&#59; THE EQUAL PAY ACT OF 1963, THE AMERICANS WITH DISABILITIES ACT OF 1990&#59; AND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974, AS AMENDED&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">I VOLUNTARILY CONSENT TO EVERYTHING IN IT&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">d.</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%;padding-left:10.5pt">I HAVE BEEN ADVISED IN WRITING BY MEANS OF THIS GENERAL RELEASE AGREEMENT TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING IT AND I HAVE DONE SO OR, AFTER CAREFUL READING AND  CONSIDERATION, I HAVE CHOSEN NOT TO DO SO OF MY OWN VOLITION&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">I HAVE HAD AT LEAST 21 DAYS FROM THE DATE OF MY RECEIPT OF THIS RELEASE SUBSTANTIALLY  IN ITS FINAL FORM ON AUGUST 3, 2015 TO CONSIDER  IT AND THE CHANGES  MADE SINCE  THE AUGUST 3, 2015 , VERSION OF THIS GENERAL RELEASE ARE NOT MATERIAL AND SHALL NOT RESTART THE REQUIRED 21-DAY PERIOD </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#91;or&#93; </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">I HAVE ELECTED TO SIGN THIS RELEASE PRIOR TO THE END OF SUCH 21-DAY PERIOD&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f.</font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.17pt">THE CHANGES TO THE EMPLOYMENT AGREEMENT  SINCE AUGUST 3, 2015 EITHER ARE NOT MATERIAL OR WERE MADE AT MY REQUEST.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">g.</font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:10.5pt">I UNDERSTAND THAT I HAVE SEVEN DAYS AFTER THE EXECUTION OF THIS RELEASE TO REVOKE IT AND THAT THIS RELEASE SHALL NOT BECOME EFFECTIVE OR ENFORCEABLE UNTIL THE REVOCATION PERIOD HAS EXPIRED&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">h.</font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:10.5pt">I HAVE SIGNED THIS GENERAL RELEASE KNOWINGLY AND VOLUNTARILY AND WITH THE ADVICE OF ANY ATTORNEY RETAINED TO ADVISE ME WITH RESPECT TO IT&#59; AND</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">i.</font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:12.73pt">I AGREE THAT THE PROVISIONS OF THIS GENERAL RELEASE MAY NOT BE AMENDED, WAIVED</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">CHANGED OR MODIFIED EXCEPT BY AN INSTRUMENT IN WRITING SIGNED BY AN AUTHORIZED REPRESENTATIVE OF THE COMPANY AND BY ME.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">DATE&#58; AUGUST 3, 2015&#160;&#160;&#160;&#160;&#47;s&#47; </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline"> Cliff Berman                   </font></div><div style="text-indent:414pt"><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Cliff Berman     </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>opch-ex211x20201231x10k.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic09117498a2e42dfa84439ab9225a50f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 21.1&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">OPTION CARE HEALTH, INC. AND ITS SUBSIDIARIES</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Entity Name</font></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State of Incorporation</font></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Doing Business As</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Applied Health Care, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioScrip Infusion Management, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioScrip Infusion Services, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioScrip Infusion Services, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioScrip Medical Supply Services, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioScrip Nursing Services, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioScrip PBM Services, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioScrip Pharmacy (NY), Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioScrip Pharmacy Services, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioScrip Pharmacy, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bradhurst Specialty Pharmacy, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHI Holding Corp.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronimed, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHS Holdings, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Holdings, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Specialties Network Services of Illinois, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Specialties, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crescent Healthcare, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crescent Therafusion, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Critical Care Systems of New York, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Critical Care Systems, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Critical Homecare Solutions, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CSI Managed Care, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CSI Medical Billing Services, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CSI Network Services of Indiana, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CSI Network Services of Kentucky, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CSI Network Services of Michigan, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deaconess Enterprises, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deaconess HomeCare, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">East Goshen Pharmacy, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HC Group Holdings II, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HC Group Holdings III, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthy Connections Homecare Services, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home I.V. Specialists, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arkansas</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HomeChoice Partners, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">InfuCenters, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusal Partners</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">InfuScience HHA, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">InfuScience South Carolina, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">InfuScience Sub, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">InfuScience, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Partners of Brunswick, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Partners of Melbourne, LLC</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Partners, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Solutions, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Hampshire</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Therapy Specialists, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nebraska</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Knoxville Home Therapies, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedNow Infusion, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">National Health Infusion, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Natural Living, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New England Home Therapies, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nutri USA Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Enterprises, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Enterprises, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health, Inc. (f&#47;k&#47;a BioScrip, Inc.)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Home Care, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Illinois</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Home Health, L.L.C.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washington</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Infusion Services, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Infusion Suites, LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care of New York, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OPTION CARE, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Health, Ltd.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Illinois</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Home Health, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OptioNet, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHCS Acquisition Co, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Home Care Services, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regional Ambulatory Diagnostics, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">River City Pharmacy, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott-Wilson, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kentucky</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Pharma, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Springville Pharmacy Infusion Therapy, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trinity Homecare, L.L.C.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">University Option Care, L.L.C.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wilcox Medical, Inc.</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vermont</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option Care Health</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>opch-ex231x20201231x10k.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i98e37d12df5e48b0a43760059e4b6425_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 23.1&#160;</font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div style="padding-left:110.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-right:369pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors </font></div><div style="margin-bottom:10pt;padding-right:369pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option Care Health, Inc.&#58;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the registration statement (Nos. 333&#8209;210530, 333-214039, 333-216630, 333-216631, and 333-239504) on Form S-3 and (Nos. 333-228312 and 333-228310) on Form S-8 of Option Care Health, Inc. of our reports dated March 11, 2021, with respect to the consolidated balance sheets of Option Care Health, Inc. as of December 31, 2020 and 2019, the related consolidated statements of comprehensive income (loss),  stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes, and the effectiveness of internal control over financial reporting as of December 31, 2020, which reports appear in the December 31, 2020 annual report on Form 10&#8209;K of Option Care Health, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our report dated March 11, 2021, on the consolidated financial statements, refers to a change in method of accounting for leases.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; KPMG LLP</font></div><div style="margin-top:0.2pt;text-align:center"><font><br></font></div><div style="padding-left:4.5pt;padding-right:400.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chicago, Illinois </font></div><div style="padding-left:4.5pt;padding-right:400.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 11, 2021</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>opch-ex311x20201231x10k.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i181b93b429264f5187521d4409c18b7d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 31.1&#160;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Rademacher, certify that&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. &#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Option Care Health, Inc.&#59; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. &#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. &#160;&#160;&#160;&#160;The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (c)&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;11, 2021 </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; John Rademacher</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">John Rademacher</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer, President and Director (Principal Executive Officer)</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>opch-ex312x20201231x10k.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6a7a18f7b3b340958a4fc27be7b99463_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael Shapiro, certify that&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. &#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Option Care Health, Inc.&#59; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. &#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. &#160;&#160;&#160;&#160;The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (c)&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;11, 2021 </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#47;s&#47; Michael Shapiro</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Shapiro</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer and Senior Vice President (Principal Financial Officer) </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>opch-ex321x20201231x10k.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i584fc721723a4259975158d5d52ccfcb_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with the Annual Report of Option Care Health, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, John Rademacher, Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  March&#160;11, 2021 </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; John Rademacher</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">John Rademacher</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer, President and Director (Principal Executive Officer)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>opch-ex322x20201231x10k.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i814a593a74f949c7ba4ee21d54e69057_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with the Annual Report of Option Care Health, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Michael Shapiro, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  March&#160;11, 2021 </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#47;s&#47; Michael Shapiro</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Shapiro</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer and Senior Vice President (Principal Financial Officer) </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>bios-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:67699b3b-5a42-424d-a4a2-736d8be0bc5f,g:dc7394d0-f9c6-4f46-91d7-369b9ff9f10f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bios="http://www.bioscrip.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bioscrip.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bios-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bios-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bios-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bios-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="COVERPAGE" roleURI="http://www.bioscrip.com/role/COVERPAGE">
        <link:definition>0001001 - Document - COVER PAGE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" roleURI="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS" roleURI="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS">
        <link:definition>2101101 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" roleURI="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails">
        <link:definition>2402401 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>2405402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONS" roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONS">
        <link:definition>2106103 - Disclosure - BUSINESS ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONSTables" roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSTables">
        <link:definition>2307301 - Disclosure - BUSINESS ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONSAdditionalInformationDetails" roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails">
        <link:definition>2408403 - Disclosure - BUSINESS ACQUISITIONS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONSConsiderationExchangedDetails" roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails">
        <link:definition>2409404 - Disclosure - BUSINESS ACQUISITIONS - Consideration Exchanged (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails" roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails">
        <link:definition>2410405 - Disclosure - BUSINESS ACQUISITIONS - Acquired Identifiable Assets and Assumed Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails" roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails">
        <link:definition>2411406 - Disclosure - BUSINESS ACQUISITIONS - Consideration Allocated to Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONSProFormaFinancialInformationDetails" roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSProFormaFinancialInformationDetails">
        <link:definition>2412407 - Disclosure - BUSINESS ACQUISITIONS - Pro Forma Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUE" roleURI="http://www.bioscrip.com/role/REVENUE">
        <link:definition>2113104 - Disclosure - REVENUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUETables" roleURI="http://www.bioscrip.com/role/REVENUETables">
        <link:definition>2314302 - Disclosure - REVENUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUENetRevenueEarnedbyCategoryofPayerDetails" roleURI="http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails">
        <link:definition>2415408 - Disclosure - REVENUE - Net Revenue Earned by Category of Payer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANS" roleURI="http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANS">
        <link:definition>2116105 - Disclosure - EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSDetails" roleURI="http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails">
        <link:definition>2417409 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.bioscrip.com/role/INCOMETAXES">
        <link:definition>2118106 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESIncomeTaxesTables" roleURI="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables">
        <link:definition>2319303 - Disclosure - INCOME TAXES Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESIncomeTaxBenefitDetails" roleURI="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails">
        <link:definition>2420410 - Disclosure - INCOME TAXES - Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESIncomeTaxReconciliationDetails" roleURI="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails">
        <link:definition>2421411 - Disclosure - INCOME TAXES - Income Tax Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" roleURI="http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails">
        <link:definition>2422412 - Disclosure - INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>2423413 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails" roleURI="http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails">
        <link:definition>2424414 - Disclosure - INCOME TAXES - Valuation Allowance for Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSEARNINGSPERSHARE" roleURI="http://www.bioscrip.com/role/LOSSEARNINGSPERSHARE">
        <link:definition>2125107 - Disclosure - (LOSS) EARNINGS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSEARNINGSPERSHARETables" roleURI="http://www.bioscrip.com/role/LOSSEARNINGSPERSHARETables">
        <link:definition>2326304 - Disclosure - (LOSS) EARNINGS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSEARNINGSPERSHAREDetails" roleURI="http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails">
        <link:definition>2427415 - Disclosure - (LOSS) EARNINGS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.bioscrip.com/role/LEASES">
        <link:definition>2128108 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.bioscrip.com/role/LEASESTables">
        <link:definition>2329305 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESAdditionalInformationDetails" roleURI="http://www.bioscrip.com/role/LEASESAdditionalInformationDetails">
        <link:definition>2430416 - Disclosure - LEASES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>2431417 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>2431417 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>2132109 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>2333306 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTDetails" roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails">
        <link:definition>2434418 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETS" roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS">
        <link:definition>2135110 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSTables" roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables">
        <link:definition>2336307 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails">
        <link:definition>2437419 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails" roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails">
        <link:definition>2438420 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails">
        <link:definition>2439421 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails" roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails">
        <link:definition>2440422 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESS" roleURI="http://www.bioscrip.com/role/INDEBTEDNESS">
        <link:definition>2141111 - Disclosure - INDEBTEDNESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSTables" roleURI="http://www.bioscrip.com/role/INDEBTEDNESSTables">
        <link:definition>2342308 - Disclosure - INDEBTEDNESS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSSummaryofDebtDetails" roleURI="http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails">
        <link:definition>2443423 - Disclosure - INDEBTEDNESS - Summary of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSSummaryofDebtDetails_1" roleURI="http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails_1">
        <link:definition>2443423 - Disclosure - INDEBTEDNESS - Summary of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSAdditionalInformationDetails" roleURI="http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails">
        <link:definition>2444424 - Disclosure - INDEBTEDNESS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSLongtermDebtMaturitiesDetails" roleURI="http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails">
        <link:definition>2445425 - Disclosure - INDEBTEDNESS - Long-term Debt Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" roleURI="http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails">
        <link:definition>2446426 - Disclosure - INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTS" roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS">
        <link:definition>2147112 - Disclosure - DERIVATIVE INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTSTables" roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables">
        <link:definition>2348309 - Disclosure - DERIVATIVE INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTSAdditionalInformationDetails" roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails">
        <link:definition>2449427 - Disclosure - DERIVATIVE INSTRUMENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails">
        <link:definition>2450428 - Disclosure - DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails">
        <link:definition>2451429 - Disclosure - DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASURMENTS" roleURI="http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS">
        <link:definition>2152113 - Disclosure - FAIR VALUE MEASURMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2153114 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDINCENTIVECOMPENSATION" roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION">
        <link:definition>2154115 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables" roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables">
        <link:definition>2355310 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION Stock-Based Incentive Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDINCENTIVECOMPENSATIONDetails" roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails">
        <link:definition>2456430 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails" roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails">
        <link:definition>2457431 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Assumptions Used to Compute Fair Value of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails">
        <link:definition>2458432 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails">
        <link:definition>2459433 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Outstanding and Exercisable Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails">
        <link:definition>2460434 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Restricted Stock Award Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails" roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails">
        <link:definition>2461435 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Fair Value of Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.bioscrip.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2162116 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDetails" roleURI="http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails">
        <link:definition>2463436 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>2164117 - Disclosure - RELATED-PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>2465437 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SELECTEDQUARTERLYFINANCIALDATAUNAUDITED" roleURI="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED">
        <link:definition>2166118 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables" roleURI="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables">
        <link:definition>2367311 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails" roleURI="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails">
        <link:definition>2468438 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.bioscrip.com/role/SUBSEQUENTEVENTS">
        <link:definition>2169119 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>2470439 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bios_OptionExercisePriceRangeTwoMember" abstract="true" name="OptionExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_InterestLimitationCarryforwardsMember" abstract="true" name="InterestLimitationCarryforwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_A2017WarrantsMember" abstract="true" name="A2017WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_A2018PlanMember" abstract="true" name="A2018PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_HCIIncentiveUnitsMember" abstract="true" name="HCIIncentiveUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative" abstract="false" name="LossOnDiscontinuanceOfCashFlowHedgeDerivative" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_RestrictedStockAndStockOptionsMember" abstract="true" name="RestrictedStockAndStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" abstract="false" name="ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="bios_OptionExercisePriceRangeFourMember" abstract="true" name="OptionExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_GovernmentCustomerMember" abstract="true" name="GovernmentCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_OptionCareHealthIncMember" abstract="true" name="OptionCareHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_AccruedExpensesandOtherCurrentLiabilitiesMember" abstract="true" name="AccruedExpensesandOtherCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_PaidInKindInterestAdditionalInterestExpense" abstract="false" name="PaidInKindInterestAdditionalInterestExpense" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bios_DebtInstrumentBaseRate" abstract="false" name="DebtInstrumentBaseRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bios_InterestCapitalizedToDebtPrincipal" abstract="false" name="InterestCapitalizedToDebtPrincipal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_BankOfAmericaN.A.Member" abstract="true" name="BankOfAmericaN.A.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bios_HCGroupHoldingsILLCMember" abstract="true" name="HCGroupHoldingsILLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_OptionsExercisableAbstract" abstract="true" name="OptionsExercisableAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bios_OptionExercisePriceRangeOneMember" abstract="true" name="OptionExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_LegacyHealthSystemsMember" abstract="true" name="LegacyHealthSystemsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_CommonStockOutstandingPercentage" abstract="false" name="CommonStockOutstandingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bios_ManagementNotesReceivableMember" abstract="true" name="ManagementNotesReceivableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_DebtInstrumentChangesInLongTermDebtRollForward" abstract="true" name="DebtInstrumentChangesInLongTermDebtRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bios_EquipmentFurnitureAndOtherMember" abstract="true" name="EquipmentFurnitureAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_OptionExercisePriceRangeEightMember" abstract="true" name="OptionExercisePriceRangeEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_BusinessCombinationOwnershipInterestRetained" abstract="false" name="BusinessCombinationOwnershipInterestRetained" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bios_FirstLienTermLoanMember" abstract="true" name="FirstLienTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_BioScripMember" abstract="true" name="BioScripMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_OptionExercisePriceRangeSixMember" abstract="true" name="OptionExercisePriceRangeSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_PaymentsOfDebtIssuanceCostsInvestingActivities" abstract="false" name="PaymentsOfDebtIssuanceCostsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_NumberOfInfusionSites" abstract="false" name="NumberOfInfusionSites" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bios_NotesPayableMember" abstract="true" name="NotesPayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings" abstract="false" name="StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_PatientCustomerMember" abstract="true" name="PatientCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_SecondaryOfferingMember" abstract="true" name="SecondaryOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_MergerOperatingLossCarryforwardMember" abstract="true" name="MergerOperatingLossCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_ChargedBenefitToCostsAndExpensesMember" abstract="true" name="ChargedBenefitToCostsAndExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_DeferredTaxLiabilitiesAcceleratedDepreciation" abstract="false" name="DeferredTaxLiabilitiesAcceleratedDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_DebtInstrumentThirdPartyFees" abstract="false" name="DebtInstrumentThirdPartyFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax" abstract="false" name="OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_CreditAgreementsEnteredInto2019Member" abstract="true" name="CreditAgreementsEnteredInto2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_AggregateIntrinsicValueAbstract" abstract="true" name="AggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bios_SecondLienTermLoanMember" abstract="true" name="SecondLienTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_FinancingReceivablePrepaymentPenalty" abstract="false" name="FinancingReceivablePrepaymentPenalty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_InfusionPumpsMember" abstract="true" name="InfusionPumpsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_ClassofWarrantorRightSecuritiesExercised" abstract="false" name="ClassofWarrantorRightSecuritiesExercised" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bios_InterestOnManagementNotesReceivable" abstract="false" name="InterestOnManagementNotesReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalStockholdersContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_BaptistHealthInLittleRockArkansasMember" abstract="true" name="BaptistHealthInLittleRockArkansasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_LoansFundedForMembershipUnitPurchaseMember" abstract="true" name="LoansFundedForMembershipUnitPurchaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_OptionsOutstandingAbstract" abstract="true" name="OptionsOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bios_OptionCareEnterprisesInc.Member" abstract="true" name="OptionCareEnterprisesInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_CreditArrangementsEnteredInto2015ModifiedLoansMember" abstract="true" name="CreditArrangementsEnteredInto2015ModifiedLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_InterestGainLossOnManagementNotesReceivable" abstract="false" name="InterestGainLossOnManagementNotesReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember" abstract="true" name="FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_OptionCareAcquisitionMember" abstract="true" name="OptionCareAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_HomeI.V.SpecialistsInc.Member" abstract="true" name="HomeI.V.SpecialistsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_OptionExercisePriceRangeNineMember" abstract="true" name="OptionExercisePriceRangeNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_RestrictedStockAwardMember" abstract="true" name="RestrictedStockAwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_IncomeTaxExpenseBenefitCARESAct" abstract="false" name="IncomeTaxExpenseBenefitCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_BusinessCombinationRenewalTermLength" abstract="false" name="BusinessCombinationRenewalTermLength" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bios_ProceedsFromSaleOfManagementNotesReceivable" abstract="false" name="ProceedsFromSaleOfManagementNotesReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_NumberOfServiceLocations" abstract="false" name="NumberOfServiceLocations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bios_CreditArrangementsEnteredInto2015Member" abstract="true" name="CreditArrangementsEnteredInto2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_ChargedToOtherAccountsMember" abstract="true" name="ChargedToOtherAccountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_DeferredTaxAssetsBadDebtReserve" abstract="false" name="DeferredTaxAssetsBadDebtReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_SaleOfNotesReceivableMember" abstract="true" name="SaleOfNotesReceivableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred" abstract="false" name="BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_HomeSolutionsMember" abstract="true" name="HomeSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_A2015WarrantsMember" abstract="true" name="A2015WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_CommercialCustomerMember" abstract="true" name="CommercialCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_RepaymentOfManagementNotesReceivable" abstract="false" name="RepaymentOfManagementNotesReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_MadisonDearbornPartnersVIBL.P.Member" abstract="true" name="MadisonDearbornPartnersVIBL.P.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_OptionExercisePriceRangeThreeMember" abstract="true" name="OptionExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_OptionExercisePriceRangeSevenMember" abstract="true" name="OptionExercisePriceRangeSevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward" abstract="true" name="ChangeinDeferredTaxAssetValuationAllowanceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bios_OptionExercisePriceRangeFiveMember" abstract="true" name="OptionExercisePriceRangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>bios-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:67699b3b-5a42-424d-a4a2-736d8be0bc5f,g:dc7394d0-f9c6-4f46-91d7-369b9ff9f10f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bioscrip.com/role/COVERPAGE" xlink:type="simple" xlink:href="bios-20201231.xsd#COVERPAGE"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/COVERPAGE" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bios-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c4ef9486-bafd-4350-8552-13836759015b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cfcd0282-a178-4b33-9819-060d2b42c2db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c4ef9486-bafd-4350-8552-13836759015b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cfcd0282-a178-4b33-9819-060d2b42c2db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d6867d3b-d75d-4671-aba2-8511f7cc62dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c4ef9486-bafd-4350-8552-13836759015b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d6867d3b-d75d-4671-aba2-8511f7cc62dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_06424a11-2b09-49e8-b30a-8fd57f464f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c4ef9486-bafd-4350-8552-13836759015b" xlink:to="loc_us-gaap_InventoryNet_06424a11-2b09-49e8-b30a-8fd57f464f4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b39a1568-1839-46a2-b8df-5303c35e765d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c4ef9486-bafd-4350-8552-13836759015b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b39a1568-1839-46a2-b8df-5303c35e765d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0083fdbe-5c72-484d-a99a-02f861b6a2e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cb9520ec-e8ba-433a-82bf-0718bd653d78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0083fdbe-5c72-484d-a99a-02f861b6a2e1" xlink:to="loc_us-gaap_LiabilitiesCurrent_cb9520ec-e8ba-433a-82bf-0718bd653d78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_fe73815a-c3cf-486e-a38a-4f6bf14e0044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0083fdbe-5c72-484d-a99a-02f861b6a2e1" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_fe73815a-c3cf-486e-a38a-4f6bf14e0044" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8c736733-c82d-4367-a559-bd718d9e33af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4dcfb1a2-100f-4535-90b8-72b40765a306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8c736733-c82d-4367-a559-bd718d9e33af" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4dcfb1a2-100f-4535-90b8-72b40765a306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2152e252-557c-4689-951e-8d318c237c0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8c736733-c82d-4367-a559-bd718d9e33af" xlink:to="loc_us-gaap_AccountsPayableCurrent_2152e252-557c-4689-951e-8d318c237c0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d218691e-d69e-4bbd-ad85-a6f7b302a48f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8c736733-c82d-4367-a559-bd718d9e33af" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d218691e-d69e-4bbd-ad85-a6f7b302a48f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AccruedExpensesAndOtherCurrentLiabilities_a6eb2661-c43f-4697-b16f-496fb5f7e4b0" xlink:href="bios-20201231.xsd#bios_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8c736733-c82d-4367-a559-bd718d9e33af" xlink:to="loc_bios_AccruedExpensesAndOtherCurrentLiabilities_a6eb2661-c43f-4697-b16f-496fb5f7e4b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_2811bebb-18cc-4912-847e-e4cfa715d13f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8c736733-c82d-4367-a559-bd718d9e33af" xlink:to="loc_us-gaap_LongTermDebtCurrent_2811bebb-18cc-4912-847e-e4cfa715d13f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_364c3b7e-ebb5-4a9c-9389-b8f754bb0748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0b84f5b7-bac5-4160-94df-504493a560a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_364c3b7e-ebb5-4a9c-9389-b8f754bb0748" xlink:to="loc_us-gaap_AssetsCurrent_0b84f5b7-bac5-4160-94df-504493a560a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_30a79ac7-a547-43b1-bead-d4aab4a0f3a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_364c3b7e-ebb5-4a9c-9389-b8f754bb0748" xlink:to="loc_us-gaap_AssetsNoncurrent_30a79ac7-a547-43b1-bead-d4aab4a0f3a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_32bf0d54-db31-47ab-914a-494d51ba0d15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_64f3ea5c-b8f7-4a45-83ae-529c081b675b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_32bf0d54-db31-47ab-914a-494d51ba0d15" xlink:to="loc_us-gaap_PreferredStockValue_64f3ea5c-b8f7-4a45-83ae-529c081b675b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c98c9bbf-2d93-4f3b-a062-c2bba7c146fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_32bf0d54-db31-47ab-914a-494d51ba0d15" xlink:to="loc_us-gaap_CommonStockValue_c98c9bbf-2d93-4f3b-a062-c2bba7c146fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_b6d1faeb-1c5a-402c-b292-752edd26db6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_32bf0d54-db31-47ab-914a-494d51ba0d15" xlink:to="loc_us-gaap_TreasuryStockValue_b6d1faeb-1c5a-402c-b292-752edd26db6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ad3aa32c-3dfa-4c1e-809a-78cf0997f3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_32bf0d54-db31-47ab-914a-494d51ba0d15" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ad3aa32c-3dfa-4c1e-809a-78cf0997f3e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e5296596-c252-42a2-bf8e-c87b5b71a24e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_32bf0d54-db31-47ab-914a-494d51ba0d15" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e5296596-c252-42a2-bf8e-c87b5b71a24e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1a6c33d7-4591-43e1-9228-2678cf3367e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_32bf0d54-db31-47ab-914a-494d51ba0d15" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1a6c33d7-4591-43e1-9228-2678cf3367e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f270b1b3-4916-498d-8771-bd1872f3c1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2a904c12-0684-4919-bb25-81a78d977bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f270b1b3-4916-498d-8771-bd1872f3c1f5" xlink:to="loc_us-gaap_StockholdersEquity_2a904c12-0684-4919-bb25-81a78d977bd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fe2309fe-2aa1-4307-b057-6fd16fe87120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f270b1b3-4916-498d-8771-bd1872f3c1f5" xlink:to="loc_us-gaap_Liabilities_fe2309fe-2aa1-4307-b057-6fd16fe87120" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_0ff69b84-073b-40df-858c-71647e975c19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b99e4703-9a91-438f-b651-c1bccfb0c580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_0ff69b84-073b-40df-858c-71647e975c19" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b99e4703-9a91-438f-b651-c1bccfb0c580" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d6f79006-844a-4afa-8d04-0d4dd2b86f6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_0ff69b84-073b-40df-858c-71647e975c19" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d6f79006-844a-4afa-8d04-0d4dd2b86f6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_222e0803-62b8-478f-ba62-be3d92bb7335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_0ff69b84-073b-40df-858c-71647e975c19" xlink:to="loc_us-gaap_Goodwill_222e0803-62b8-478f-ba62-be3d92bb7335" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ae6226d0-0261-4369-b38c-0ac4f92ce28b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_0ff69b84-073b-40df-858c-71647e975c19" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ae6226d0-0261-4369-b38c-0ac4f92ce28b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2d265844-6046-4a39-909a-89304c8c0e66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_0ff69b84-073b-40df-858c-71647e975c19" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2d265844-6046-4a39-909a-89304c8c0e66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_fa9dbb02-ac00-475e-8dac-80cfbbf58f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c6722cbc-ad9f-40e5-b852-f551274f7d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_fa9dbb02-ac00-475e-8dac-80cfbbf58f4e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c6722cbc-ad9f-40e5-b852-f551274f7d6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dc9febb8-250b-444a-bc09-f2bf6813d742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_fa9dbb02-ac00-475e-8dac-80cfbbf58f4e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dc9febb8-250b-444a-bc09-f2bf6813d742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ca0cd0cd-dca4-4c14-8bf6-f2bb6bc6c7a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_fa9dbb02-ac00-475e-8dac-80cfbbf58f4e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ca0cd0cd-dca4-4c14-8bf6-f2bb6bc6c7a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b7d377bd-1ad4-4491-80eb-925374a46e97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_fa9dbb02-ac00-475e-8dac-80cfbbf58f4e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b7d377bd-1ad4-4491-80eb-925374a46e97" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="bios-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="bios-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_8698a4b9-608b-4be5-84df-fbc1383b272f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ac286e96-d18a-4b98-bd03-a53ea7cff8e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_8698a4b9-608b-4be5-84df-fbc1383b272f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ac286e96-d18a-4b98-bd03-a53ea7cff8e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_22b75047-4f23-4207-a915-5f17ddb3810b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_8698a4b9-608b-4be5-84df-fbc1383b272f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_22b75047-4f23-4207-a915-5f17ddb3810b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_63ffec68-3e70-49bd-9870-8ee03bc098c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_5c1c7996-9cb3-462f-afbe-b79170f559dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_63ffec68-3e70-49bd-9870-8ee03bc098c0" xlink:to="loc_us-gaap_GrossProfit_5c1c7996-9cb3-462f-afbe-b79170f559dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8f8ec3cc-75a7-4efa-99eb-6c94dba11129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_63ffec68-3e70-49bd-9870-8ee03bc098c0" xlink:to="loc_us-gaap_OperatingExpenses_8f8ec3cc-75a7-4efa-99eb-6c94dba11129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0d84e36e-df3a-40d8-afbf-482a2d2364ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f57b8d35-f7f2-4578-b974-c86b1c84b5f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0d84e36e-df3a-40d8-afbf-482a2d2364ad" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f57b8d35-f7f2-4578-b974-c86b1c84b5f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_90a30fa3-cf6f-4641-95b6-32914bb17f38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0d84e36e-df3a-40d8-afbf-482a2d2364ad" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_90a30fa3-cf6f-4641-95b6-32914bb17f38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c765dd63-5118-45db-8553-23ab1ff31761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_89004e29-769c-406b-a9c8-7106742f599f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c765dd63-5118-45db-8553-23ab1ff31761" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_89004e29-769c-406b-a9c8-7106742f599f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d88bc8b1-a743-4178-8c66-c19ddb3d4a3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d3ec8df5-7310-4213-b398-ee1a5bc3ec15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d88bc8b1-a743-4178-8c66-c19ddb3d4a3d" xlink:to="loc_us-gaap_NetIncomeLoss_d3ec8df5-7310-4213-b398-ee1a5bc3ec15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f111ab1f-bf81-4f25-95df-9a7386e19585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d88bc8b1-a743-4178-8c66-c19ddb3d4a3d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f111ab1f-bf81-4f25-95df-9a7386e19585" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_5231c8a0-ce7a-4a31-a014-8dd914764666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_82d09b13-bcdc-4f31-bc8d-d97a5652424b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_5231c8a0-ce7a-4a31-a014-8dd914764666" xlink:to="loc_us-gaap_OperatingIncomeLoss_82d09b13-bcdc-4f31-bc8d-d97a5652424b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7bcfebc0-07cd-4c98-987f-a4e07e0ae78d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_5231c8a0-ce7a-4a31-a014-8dd914764666" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7bcfebc0-07cd-4c98-987f-a4e07e0ae78d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d85ac95f-ae96-4c6d-a0c1-ee451341c73e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_e9e51a96-fca0-484a-ab5b-49c233bbaad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d85ac95f-ae96-4c6d-a0c1-ee451341c73e" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_e9e51a96-fca0-484a-ab5b-49c233bbaad0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d7830d24-81ea-42fa-9fe7-f9127481393c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d85ac95f-ae96-4c6d-a0c1-ee451341c73e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d7830d24-81ea-42fa-9fe7-f9127481393c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_32f2d634-aa3e-440b-9c5a-e61e04c974aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_2341e500-39d1-4b87-a96a-d46491156c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_32f2d634-aa3e-440b-9c5a-e61e04c974aa" xlink:to="loc_us-gaap_InvestmentIncomeNet_2341e500-39d1-4b87-a96a-d46491156c04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8b3a9687-fe33-4dbd-8919-b74c3f8f4915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_32f2d634-aa3e-440b-9c5a-e61e04c974aa" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8b3a9687-fe33-4dbd-8919-b74c3f8f4915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f54a4c03-89f8-41ba-94d9-0e5c4a7d1bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_32f2d634-aa3e-440b-9c5a-e61e04c974aa" xlink:to="loc_us-gaap_InterestExpense_f54a4c03-89f8-41ba-94d9-0e5c4a7d1bb1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="simple" xlink:href="bios-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bios-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c550b1f-6520-476f-a6d1-aaf6f30780ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ea076e34-185c-4a8b-9f7c-eefb0ddf6f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c550b1f-6520-476f-a6d1-aaf6f30780ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ea076e34-185c-4a8b-9f7c-eefb0ddf6f0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58e03ac3-3fb4-46d0-8fea-6ed1f6259c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c550b1f-6520-476f-a6d1-aaf6f30780ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58e03ac3-3fb4-46d0-8fea-6ed1f6259c8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7d0c806-7534-417c-9c35-685cb7fe3c74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c550b1f-6520-476f-a6d1-aaf6f30780ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7d0c806-7534-417c-9c35-685cb7fe3c74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_255b0de7-5395-4621-93ab-c401c45f40ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_NetIncomeLoss_255b0de7-5395-4621-93ab-c401c45f40ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_4548d670-ceb4-4095-8a40-101e83550583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_4548d670-ceb4-4095-8a40-101e83550583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1ca66ae9-9a5e-46a5-a171-70e5c874491d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1ca66ae9-9a5e-46a5-a171-70e5c874491d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_62e5efbd-ab95-458d-9d80-e52d0bfa711d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_62e5efbd-ab95-458d-9d80-e52d0bfa711d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_06016d59-2a09-4d2a-a149-7d5c0ccb42c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_06016d59-2a09-4d2a-a149-7d5c0ccb42c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_62ebd0a8-2dcd-4ba9-abe9-21b191d05cbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_62ebd0a8-2dcd-4ba9-abe9-21b191d05cbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_63be4e47-8c3b-44e2-80d6-27ac24e8b605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_63be4e47-8c3b-44e2-80d6-27ac24e8b605" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ba51e699-f635-459e-81e7-753aaec149d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ba51e699-f635-459e-81e7-753aaec149d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_959346ad-2158-43ab-a628-2e095587a2ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_PaidInKindInterest_959346ad-2158-43ab-a628-2e095587a2ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9aa3e07a-b84d-4704-9bed-970fb290e3c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9aa3e07a-b84d-4704-9bed-970fb290e3c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_971ed58e-39b3-4427-ac6f-f5602964cdca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_ShareBasedCompensation_971ed58e-39b3-4427-ac6f-f5602964cdca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InterestGainLossOnManagementNotesReceivable_44b9bc20-01d2-4cd9-9636-f9e6f0d04709" xlink:href="bios-20201231.xsd#bios_InterestGainLossOnManagementNotesReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_bios_InterestGainLossOnManagementNotesReceivable_44b9bc20-01d2-4cd9-9636-f9e6f0d04709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_83d59c45-247a-4e42-a5ef-becdf0051ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_83d59c45-247a-4e42-a5ef-becdf0051ae5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_dfda9ef7-31a7-4bf4-8892-dc1581e8ab40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_dfda9ef7-31a7-4bf4-8892-dc1581e8ab40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_100a2104-e66c-4593-8095-ac78245e263d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_100a2104-e66c-4593-8095-ac78245e263d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_866d2882-9237-4b8c-a910-e6143200986c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_866d2882-9237-4b8c-a910-e6143200986c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3fda8fc5-1f50-4e93-8106-a53365628baa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3fda8fc5-1f50-4e93-8106-a53365628baa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_6a2f522c-6137-428f-9d0a-31c717a06ea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_6a2f522c-6137-428f-9d0a-31c717a06ea3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_80ff266f-0043-47aa-862e-a0c763c1d0cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_80ff266f-0043-47aa-862e-a0c763c1d0cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_51c9e530-8bc1-48e8-aca6-0fe401ae6cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_51c9e530-8bc1-48e8-aca6-0fe401ae6cb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_8157ffab-c3dd-48e6-975f-748747a50f4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_OperatingLeasePayments_8157ffab-c3dd-48e6-975f-748747a50f4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_9e5c7364-ce29-49ec-8e11-ab31d1f12ca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet"/>
    <link:calculationArc order="22" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_9e5c7364-ce29-49ec-8e11-ab31d1f12ca3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative_dc43ff5d-5761-42d0-838c-4dd8b0210a7f" xlink:href="bios-20201231.xsd#bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative"/>
    <link:calculationArc order="23" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_757112ad-a422-45fe-a34c-bad301c91247" xlink:to="loc_bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative_dc43ff5d-5761-42d0-838c-4dd8b0210a7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4c0ec05-52af-4850-83d5-95bebb3c4553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e0e905a0-bd47-4a8c-b24e-77c958b955c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4c0ec05-52af-4850-83d5-95bebb3c4553" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e0e905a0-bd47-4a8c-b24e-77c958b955c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ProceedsFromSaleOfManagementNotesReceivable_e47ab746-d9d1-4326-b5f3-f9dd20fd41ba" xlink:href="bios-20201231.xsd#bios_ProceedsFromSaleOfManagementNotesReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4c0ec05-52af-4850-83d5-95bebb3c4553" xlink:to="loc_bios_ProceedsFromSaleOfManagementNotesReceivable_e47ab746-d9d1-4326-b5f3-f9dd20fd41ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_70695e11-5bf5-497d-8d3d-9d655d7862e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4c0ec05-52af-4850-83d5-95bebb3c4553" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_70695e11-5bf5-497d-8d3d-9d655d7862e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_867d5822-2e47-4f60-a99b-e4184e182c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4c0ec05-52af-4850-83d5-95bebb3c4553" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_867d5822-2e47-4f60-a99b-e4184e182c80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_8747b0f3-8518-40e5-a273-ce020392f316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4c0ec05-52af-4850-83d5-95bebb3c4553" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_8747b0f3-8518-40e5-a273-ce020392f316" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_9a2e55fd-36c4-4a3a-8449-dcc66d5c5456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4c0ec05-52af-4850-83d5-95bebb3c4553" xlink:to="loc_us-gaap_RepaymentsOfDebt_9a2e55fd-36c4-4a3a-8449-dcc66d5c5456" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4409f343-73f9-4370-a407-42f627aaa301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4c0ec05-52af-4850-83d5-95bebb3c4553" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4409f343-73f9-4370-a407-42f627aaa301" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDepositsAppliedToDebtRetirements_d3ef0613-828f-4b0a-91fe-4a9884b3c8de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForDepositsAppliedToDebtRetirements"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4c0ec05-52af-4850-83d5-95bebb3c4553" xlink:to="loc_us-gaap_PaymentsForDepositsAppliedToDebtRetirements_d3ef0613-828f-4b0a-91fe-4a9884b3c8de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_43539ee5-e1db-4e58-a3a6-052c2df26cd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4c0ec05-52af-4850-83d5-95bebb3c4553" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_43539ee5-e1db-4e58-a3a6-052c2df26cd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e947051-73c6-43c0-9c2d-ca8612386287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_2357e673-305c-49a7-b539-91da8646e6e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e947051-73c6-43c0-9c2d-ca8612386287" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_2357e673-305c-49a7-b539-91da8646e6e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e7362281-1daf-404f-a576-ecc115790671" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e947051-73c6-43c0-9c2d-ca8612386287" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e7362281-1daf-404f-a576-ecc115790671" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_3fd81948-0d5d-42de-bf03-0fa3b5f75392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e947051-73c6-43c0-9c2d-ca8612386287" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_3fd81948-0d5d-42de-bf03-0fa3b5f75392" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1e6e12db-0064-4f2c-8375-98fee7604fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e947051-73c6-43c0-9c2d-ca8612386287" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1e6e12db-0064-4f2c-8375-98fee7604fb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_62c408bb-a90c-4cd5-ac50-9f6db560715c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e947051-73c6-43c0-9c2d-ca8612386287" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_62c408bb-a90c-4cd5-ac50-9f6db560715c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bios-20201231.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="bios-20201231.xsd#NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bios-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bios-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONS" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONS"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSTables" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSTables"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSConsiderationExchangedDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a3bd79b6-d701-4497-8805-3fbff1ef58d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_03bea46e-e174-4ffc-9879-9d0ab1f91de5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a3bd79b6-d701-4497-8805-3fbff1ef58d2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_03bea46e-e174-4ffc-9879-9d0ab1f91de5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_2a6e543b-750f-4253-a0e0-96bd56cba080" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a3bd79b6-d701-4497-8805-3fbff1ef58d2" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_2a6e543b-750f-4253-a0e0-96bd56cba080" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_7ca55226-d427-494f-8374-af807e10bc3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_968c91d9-0a91-43d8-a848-82896a40eb66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_7ca55226-d427-494f-8374-af807e10bc3d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_968c91d9-0a91-43d8-a848-82896a40eb66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_db67c904-5644-4885-93e1-66651a2df418" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_7ca55226-d427-494f-8374-af807e10bc3d" xlink:to="loc_us-gaap_Goodwill_db67c904-5644-4885-93e1-66651a2df418" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8ccb775c-b7ed-43a2-bd2f-b8d38d178596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1d8d5cb3-e081-4a08-b15c-4e47069efcca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8ccb775c-b7ed-43a2-bd2f-b8d38d178596" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1d8d5cb3-e081-4a08-b15c-4e47069efcca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_f4070dc2-5734-4e48-a14a-904e94fac9f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8ccb775c-b7ed-43a2-bd2f-b8d38d178596" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_f4070dc2-5734-4e48-a14a-904e94fac9f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_e245b092-152b-4203-8afe-d72b4cca71e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8ccb775c-b7ed-43a2-bd2f-b8d38d178596" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_e245b092-152b-4203-8afe-d72b4cca71e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_48b69860-1ce1-4117-b19c-839549399d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8ccb775c-b7ed-43a2-bd2f-b8d38d178596" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_48b69860-1ce1-4117-b19c-839549399d1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_89f4f395-1a3c-4f3d-b641-861e345cf52c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8ccb775c-b7ed-43a2-bd2f-b8d38d178596" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_89f4f395-1a3c-4f3d-b641-861e345cf52c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_5e45c643-182b-4ad0-a4e1-3dc11ab0d406" xlink:href="bios-20201231.xsd#bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8ccb775c-b7ed-43a2-bd2f-b8d38d178596" xlink:to="loc_bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_5e45c643-182b-4ad0-a4e1-3dc11ab0d406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_17db0fd8-7ec5-46b4-90a3-ad2f47163610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8ccb775c-b7ed-43a2-bd2f-b8d38d178596" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_17db0fd8-7ec5-46b4-90a3-ad2f47163610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_da1c3429-7784-4f84-901c-0d2e8ddd5f93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8ccb775c-b7ed-43a2-bd2f-b8d38d178596" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_da1c3429-7784-4f84-901c-0d2e8ddd5f93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_dd88c09f-7462-4d4b-bf1d-bfe9ff36636e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8ccb775c-b7ed-43a2-bd2f-b8d38d178596" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_dd88c09f-7462-4d4b-bf1d-bfe9ff36636e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSProFormaFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSProFormaFinancialInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/REVENUE" xlink:type="simple" xlink:href="bios-20201231.xsd#REVENUE"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/REVENUE" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/REVENUETables" xlink:type="simple" xlink:href="bios-20201231.xsd#REVENUETables"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/REVENUETables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#REVENUENetRevenueEarnedbyCategoryofPayerDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="bios-20201231.xsd#EMPLOYEEBENEFITPLANS"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXES" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXES"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/INCOMETAXES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESIncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESIncomeTaxBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_319f3ff1-a2af-4e2c-b9d5-3c0dc91b6f02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b31abfb8-d68f-4572-b7ef-448303d95b96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_319f3ff1-a2af-4e2c-b9d5-3c0dc91b6f02" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b31abfb8-d68f-4572-b7ef-448303d95b96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_933484f5-c86f-4026-9734-2b48b1727e1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_319f3ff1-a2af-4e2c-b9d5-3c0dc91b6f02" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_933484f5-c86f-4026-9734-2b48b1727e1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_d09109cd-ed88-40bc-89a4-d3e5a1344282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_bfb999cc-5f43-44be-abe5-629303b4b9a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_d09109cd-ed88-40bc-89a4-d3e5a1344282" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_bfb999cc-5f43-44be-abe5-629303b4b9a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1d7f9e3e-f7ea-4f2c-8450-969c26385385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_d09109cd-ed88-40bc-89a4-d3e5a1344282" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1d7f9e3e-f7ea-4f2c-8450-969c26385385" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b2671bda-2462-470c-bfc4-faa67e37a3f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_08feed57-b94d-4670-ac69-01c8e462361e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b2671bda-2462-470c-bfc4-faa67e37a3f4" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_08feed57-b94d-4670-ac69-01c8e462361e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_6dfd061b-0ee3-46fc-bdec-92b5ce726737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b2671bda-2462-470c-bfc4-faa67e37a3f4" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_6dfd061b-0ee3-46fc-bdec-92b5ce726737" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESIncomeTaxReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cb439407-69a2-4e3a-b8ca-0d8e0937eccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_491d205e-faa5-4b42-8821-b6438797fe7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cb439407-69a2-4e3a-b8ca-0d8e0937eccf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_491d205e-faa5-4b42-8821-b6438797fe7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0c4b4da1-0c54-4e4c-9473-37456f1d0eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cb439407-69a2-4e3a-b8ca-0d8e0937eccf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0c4b4da1-0c54-4e4c-9473-37456f1d0eb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_f4fc0f3c-7969-45bb-9fcf-5e65579f905a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cb439407-69a2-4e3a-b8ca-0d8e0937eccf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_f4fc0f3c-7969-45bb-9fcf-5e65579f905a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_8480d891-5189-4317-854f-3fb90e9a70bb" xlink:href="bios-20201231.xsd#bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cb439407-69a2-4e3a-b8ca-0d8e0937eccf" xlink:to="loc_bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_8480d891-5189-4317-854f-3fb90e9a70bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_9bb27bb9-489f-48ff-ad3d-98ad6e703a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cb439407-69a2-4e3a-b8ca-0d8e0937eccf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_9bb27bb9-489f-48ff-ad3d-98ad6e703a1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_691e38ab-861b-403d-8efc-3f5cdcb83c09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cb439407-69a2-4e3a-b8ca-0d8e0937eccf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_691e38ab-861b-403d-8efc-3f5cdcb83c09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_e1f57d94-b250-48c0-b67c-aca5fb7578f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cb439407-69a2-4e3a-b8ca-0d8e0937eccf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_e1f57d94-b250-48c0-b67c-aca5fb7578f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_ac7604d1-7097-4463-9468-7d7ae0b1004b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cb439407-69a2-4e3a-b8ca-0d8e0937eccf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_ac7604d1-7097-4463-9468-7d7ae0b1004b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_74a928c7-ac8e-4bf5-8820-2049df9009f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_3ca3d59a-02f4-452c-96df-4633342d2f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_74a928c7-ac8e-4bf5-8820-2049df9009f3" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_3ca3d59a-02f4-452c-96df-4633342d2f7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ca5acc8a-c279-47fd-bf3c-c8e0b4a02033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_74a928c7-ac8e-4bf5-8820-2049df9009f3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_ca5acc8a-c279-47fd-bf3c-c8e0b4a02033" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c8a132bf-3dd1-4347-8c69-0efd74aef42c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DeferredTaxAssetsBadDebtReserve_9a25b287-b75f-4d8b-84e0-6f5b87b51144" xlink:href="bios-20201231.xsd#bios_DeferredTaxAssetsBadDebtReserve"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c8a132bf-3dd1-4347-8c69-0efd74aef42c" xlink:to="loc_bios_DeferredTaxAssetsBadDebtReserve_9a25b287-b75f-4d8b-84e0-6f5b87b51144" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_e7ef03da-4c49-4013-bd10-2c615a9c2ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c8a132bf-3dd1-4347-8c69-0efd74aef42c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_e7ef03da-4c49-4013-bd10-2c615a9c2ff8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_63be7bb1-be4e-4e94-8c86-d8a1f00e97c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c8a132bf-3dd1-4347-8c69-0efd74aef42c" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_63be7bb1-be4e-4e94-8c86-d8a1f00e97c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DeferredTaxAssetsLeaseLiability_f68401e5-7d2a-409e-9a48-19e7c45f2ddc" xlink:href="bios-20201231.xsd#bios_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c8a132bf-3dd1-4347-8c69-0efd74aef42c" xlink:to="loc_bios_DeferredTaxAssetsLeaseLiability_f68401e5-7d2a-409e-9a48-19e7c45f2ddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ff7fc589-d32f-47dd-85e1-5d511e9d6da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c8a132bf-3dd1-4347-8c69-0efd74aef42c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ff7fc589-d32f-47dd-85e1-5d511e9d6da4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_c2062dcd-f54f-4fc4-b382-61080898bcee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c8a132bf-3dd1-4347-8c69-0efd74aef42c" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_c2062dcd-f54f-4fc4-b382-61080898bcee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_a5dd71cf-e152-4b2f-9c99-91e1cb5626ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DeferredTaxLiabilitiesAcceleratedDepreciation_8e830619-0eca-4156-bd26-3dafac160690" xlink:href="bios-20201231.xsd#bios_DeferredTaxLiabilitiesAcceleratedDepreciation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_a5dd71cf-e152-4b2f-9c99-91e1cb5626ea" xlink:to="loc_bios_DeferredTaxLiabilitiesAcceleratedDepreciation_8e830619-0eca-4156-bd26-3dafac160690" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_2296ebcc-8a08-49c2-b3bf-b6fccf94aee2" xlink:href="bios-20201231.xsd#bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_a5dd71cf-e152-4b2f-9c99-91e1cb5626ea" xlink:to="loc_bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_2296ebcc-8a08-49c2-b3bf-b6fccf94aee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_0e66dc9a-6d05-47f9-86fc-97210551e87c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_a5dd71cf-e152-4b2f-9c99-91e1cb5626ea" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_0e66dc9a-6d05-47f9-86fc-97210551e87c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_f2719f5f-3984-4cbc-9fbe-f6d79c14e5d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_a5dd71cf-e152-4b2f-9c99-91e1cb5626ea" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_f2719f5f-3984-4cbc-9fbe-f6d79c14e5d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_bf294807-097f-4ed5-a6bd-80b09fe6428a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_a5dd71cf-e152-4b2f-9c99-91e1cb5626ea" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_bf294807-097f-4ed5-a6bd-80b09fe6428a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_6d1e3827-5ff1-4e41-9b1a-583b0bfb4c61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8dba43f0-e24b-4fa9-a439-102dd34c6234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_6d1e3827-5ff1-4e41-9b1a-583b0bfb4c61" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_8dba43f0-e24b-4fa9-a439-102dd34c6234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_21f5fb19-34e0-47f9-b7ef-abd467ec963a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_6d1e3827-5ff1-4e41-9b1a-583b0bfb4c61" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_21f5fb19-34e0-47f9-b7ef-abd467ec963a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LOSSEARNINGSPERSHARE" xlink:type="simple" xlink:href="bios-20201231.xsd#LOSSEARNINGSPERSHARE"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/LOSSEARNINGSPERSHARE" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LOSSEARNINGSPERSHARETables" xlink:type="simple" xlink:href="bios-20201231.xsd#LOSSEARNINGSPERSHARETables"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/LOSSEARNINGSPERSHARETables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#LOSSEARNINGSPERSHAREDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASES" xlink:type="simple" xlink:href="bios-20201231.xsd#LEASES"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/LEASES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASESTables" xlink:type="simple" xlink:href="bios-20201231.xsd#LEASESTables"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/LEASESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#LEASESAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e519fd4-ae35-4fd5-9e99-92d08a8818c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_81844e4c-53f7-4b93-835f-433aa717ec8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e519fd4-ae35-4fd5-9e99-92d08a8818c2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_81844e4c-53f7-4b93-835f-433aa717ec8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2ad392fc-f74f-44a2-9e88-0fe55a0b7ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e519fd4-ae35-4fd5-9e99-92d08a8818c2" xlink:to="loc_us-gaap_OperatingLeaseLiability_2ad392fc-f74f-44a2-9e88-0fe55a0b7ca4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="bios-20201231.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b306bd38-ee64-49a9-b172-b1f2220c8432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7b5989f0-4ecd-4050-a3b9-fb164b04691a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b306bd38-ee64-49a9-b172-b1f2220c8432" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7b5989f0-4ecd-4050-a3b9-fb164b04691a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d6db35b1-6f5b-4723-9edb-9cb063166991" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b306bd38-ee64-49a9-b172-b1f2220c8432" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d6db35b1-6f5b-4723-9edb-9cb063166991" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1228bb2e-7586-4664-a0ae-04a353665c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b306bd38-ee64-49a9-b172-b1f2220c8432" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1228bb2e-7586-4664-a0ae-04a353665c3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fb87a58d-06de-4428-a66a-2178cd661ac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b306bd38-ee64-49a9-b172-b1f2220c8432" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fb87a58d-06de-4428-a66a-2178cd661ac1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e130ed06-5715-41d0-bc15-3406cf9be61d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b306bd38-ee64-49a9-b172-b1f2220c8432" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e130ed06-5715-41d0-bc15-3406cf9be61d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b4b55c3c-b857-4de6-a010-510061c02e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b306bd38-ee64-49a9-b172-b1f2220c8432" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b4b55c3c-b857-4de6-a010-510061c02e7d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="bios-20201231.xsd#PROPERTYANDEQUIPMENT"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="bios-20201231.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#PROPERTYANDEQUIPMENTDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_27d098b1-1f26-40fc-803f-82807be52859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0ec2ba6f-b19a-43df-8a1f-e27bbe907e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_27d098b1-1f26-40fc-803f-82807be52859" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0ec2ba6f-b19a-43df-8a1f-e27bbe907e95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6c474dfa-42fe-4034-95aa-a6e678536f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_27d098b1-1f26-40fc-803f-82807be52859" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6c474dfa-42fe-4034-95aa-a6e678536f8f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETS"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSTables"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f32a079c-87b7-44bf-8450-2d5c7fb1a972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_68553767-3831-44bf-a041-8cdb41f13722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f32a079c-87b7-44bf-8450-2d5c7fb1a972" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_68553767-3831-44bf-a041-8cdb41f13722" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_87a7d24a-8cfa-48ff-ac36-52ae1ab88567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f32a079c-87b7-44bf-8450-2d5c7fb1a972" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_87a7d24a-8cfa-48ff-ac36-52ae1ab88567" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aa099cf7-21ef-4c9d-993c-1c76631cad88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6e1fef1e-312c-4213-ad23-6394833d00c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aa099cf7-21ef-4c9d-993c-1c76631cad88" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6e1fef1e-312c-4213-ad23-6394833d00c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_381a3399-a822-4c4f-a558-557777eb8f36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aa099cf7-21ef-4c9d-993c-1c76631cad88" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_381a3399-a822-4c4f-a558-557777eb8f36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_94d44992-eee5-4ff5-9a02-116bff82b8a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aa099cf7-21ef-4c9d-993c-1c76631cad88" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_94d44992-eee5-4ff5-9a02-116bff82b8a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f3b4858e-c1ed-4430-b5a4-6ed8e4adb05f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aa099cf7-21ef-4c9d-993c-1c76631cad88" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f3b4858e-c1ed-4430-b5a4-6ed8e4adb05f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a5caf4eb-f087-48a3-a869-135523f19872" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aa099cf7-21ef-4c9d-993c-1c76631cad88" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a5caf4eb-f087-48a3-a869-135523f19872" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2fc66777-1ef2-43de-ae37-3c6228615bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aa099cf7-21ef-4c9d-993c-1c76631cad88" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2fc66777-1ef2-43de-ae37-3c6228615bb0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESS" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESS"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSTables" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESSTables"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESSSummaryofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_35bd022d-47e9-4bcc-9952-9e200cd54a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_8c273f99-4cc2-41d8-bf59-abd2c4aede97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_35bd022d-47e9-4bcc-9952-9e200cd54a52" xlink:to="loc_us-gaap_LongTermDebtCurrent_8c273f99-4cc2-41d8-bf59-abd2c4aede97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3bd9fe1f-2c27-49ee-a776-daadc92e77d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_35bd022d-47e9-4bcc-9952-9e200cd54a52" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3bd9fe1f-2c27-49ee-a776-daadc92e77d5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails_1" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESSSummaryofDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1e03af2c-5793-4097-8272-e236f9d3f228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a973538c-2589-47bd-abf1-c28a07d2b193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1e03af2c-5793-4097-8272-e236f9d3f228" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_a973538c-2589-47bd-abf1-c28a07d2b193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9c27d2d2-062c-4d7c-a351-7bbffb25c941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1e03af2c-5793-4097-8272-e236f9d3f228" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9c27d2d2-062c-4d7c-a351-7bbffb25c941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_dbb1349c-b37d-4ce7-baa7-0582dc3441d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1e03af2c-5793-4097-8272-e236f9d3f228" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_dbb1349c-b37d-4ce7-baa7-0582dc3441d5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESSAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESSLongtermDebtMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5d6eda6d-34b1-4e5f-a4e6-9e7ab9b017f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2e2be296-d1d2-4b1d-b0ed-8e76003054bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_5d6eda6d-34b1-4e5f-a4e6-9e7ab9b017f0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2e2be296-d1d2-4b1d-b0ed-8e76003054bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3e1842e9-d101-471a-88d8-af9d2feb0898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_5d6eda6d-34b1-4e5f-a4e6-9e7ab9b017f0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3e1842e9-d101-471a-88d8-af9d2feb0898" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_dbe92b2e-ddfe-4d72-91d9-062deb048983" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_5d6eda6d-34b1-4e5f-a4e6-9e7ab9b017f0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_dbe92b2e-ddfe-4d72-91d9-062deb048983" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_603cb350-75ca-431c-a6f3-6e4428c07da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_5d6eda6d-34b1-4e5f-a4e6-9e7ab9b017f0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_603cb350-75ca-431c-a6f3-6e4428c07da7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_c538101b-8275-472f-902b-680af850528b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_5d6eda6d-34b1-4e5f-a4e6-9e7ab9b017f0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_c538101b-8275-472f-902b-680af850528b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_641af41b-4b07-4250-9715-8fc5f0449932" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_5d6eda6d-34b1-4e5f-a4e6-9e7ab9b017f0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_641af41b-4b07-4250-9715-8fc5f0449932" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS" xlink:type="simple" xlink:href="bios-20201231.xsd#DERIVATIVEINSTRUMENTS"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables" xlink:type="simple" xlink:href="bios-20201231.xsd#DERIVATIVEINSTRUMENTSTables"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#DERIVATIVEINSTRUMENTSAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6c13aabe-5b39-47d7-8181-4e2a8e7b0098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_1386bda1-f38e-4e53-91dd-86e9e8284c43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_6c13aabe-5b39-47d7-8181-4e2a8e7b0098" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_1386bda1-f38e-4e53-91dd-86e9e8284c43" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_6a15fa97-28b0-4906-90f1-89d3b33805dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_6c4e8d3d-332d-40de-9a3c-35be4fa16c07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet_6a15fa97-28b0-4906-90f1-89d3b33805dd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_6c4e8d3d-332d-40de-9a3c-35be4fa16c07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_82992053-f023-455f-866a-392d7751266a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet_6a15fa97-28b0-4906-90f1-89d3b33805dd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_82992053-f023-455f-866a-392d7751266a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_a8012bac-be10-4c67-b204-22eb94043fe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet_6a15fa97-28b0-4906-90f1-89d3b33805dd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_a8012bac-be10-4c67-b204-22eb94043fe8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS" xlink:type="simple" xlink:href="bios-20201231.xsd#FAIRVALUEMEASURMENTS"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="bios-20201231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATION"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/STOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="bios-20201231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED" xlink:type="simple" xlink:href="bios-20201231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables" xlink:type="simple" xlink:href="bios-20201231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="bios-20201231.xsd#SUBSEQUENTEVENTS"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/SUBSEQUENTEVENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>bios-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:67699b3b-5a42-424d-a4a2-736d8be0bc5f,g:dc7394d0-f9c6-4f46-91d7-369b9ff9f10f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/COVERPAGE" xlink:type="simple" xlink:href="bios-20201231.xsd#COVERPAGE"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/COVERPAGE" xlink:type="extended" id="iaa395eb3e9a04c479ce8c1dc429ec444_COVERPAGE"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bios-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i371543795778407bab16e5b671d43a38_CONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="bios-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="ie00dbbe2b13b4b989167c5692f32cd35_CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="bios-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended" id="ibc7fd76811db4facb3721d665d624f3f_CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="simple" xlink:href="bios-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="extended" id="i19a42e4aa0da4905a8c26b47a6f77408_CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bios-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i6112f3919c71493fa75af3548913ec13_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bios-20201231.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i11ea8dacbc024753b6342fef1863dd21_UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_376e0788-64d7-49ed-a41b-b315e295d4cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_376e0788-64d7-49ed-a41b-b315e295d4cd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8df17c07-ef91-4fb9-b54f-bf09251c64cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_us-gaap_StockholdersEquity_8df17c07-ef91-4fb9-b54f-bf09251c64cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution_c217fdb2-539b-42fa-bd2d-eabfe4af0161" xlink:href="bios-20201231.xsd#bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution_c217fdb2-539b-42fa-bd2d-eabfe4af0161" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_12f05788-20c6-4490-9c76-a9a35fc8aefe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_12f05788-20c6-4490-9c76-a9a35fc8aefe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InterestOnManagementNotesReceivable_3ddbc908-5d45-41fd-bdc1-18918a449896" xlink:href="bios-20201231.xsd#bios_InterestOnManagementNotesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_bios_InterestOnManagementNotesReceivable_3ddbc908-5d45-41fd-bdc1-18918a449896" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_RepaymentOfManagementNotesReceivable_6d7fa90a-36a0-4439-bcfd-ed0c07446c38" xlink:href="bios-20201231.xsd#bios_RepaymentOfManagementNotesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_bios_RepaymentOfManagementNotesReceivable_6d7fa90a-36a0-4439-bcfd-ed0c07446c38" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption_341104d8-c6b1-467e-8450-e5f9151eda2b" xlink:href="bios-20201231.xsd#bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption_341104d8-c6b1-467e-8450-e5f9151eda2b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_33988910-c668-4e68-b3eb-de4313c9eea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_33988910-c668-4e68-b3eb-de4313c9eea9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings_a1c30161-f418-40fb-a901-48683761fc7b" xlink:href="bios-20201231.xsd#bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings_a1c30161-f418-40fb-a901-48683761fc7b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c7ea1e40-bbc4-4e5b-a77c-ed0a465a2ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c7ea1e40-bbc4-4e5b-a77c-ed0a465a2ed4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_d0bca324-a246-4008-8aa3-476e6892db1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_d0bca324-a246-4008-8aa3-476e6892db1e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f8c22330-dae4-4319-bce1-c733a8d0e250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_us-gaap_NetIncomeLoss_f8c22330-dae4-4319-bce1-c733a8d0e250" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_38cf5042-8352-4767-8200-a6616b8a6aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_38cf5042-8352-4767-8200-a6616b8a6aab" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6f741031-3439-414b-8e11-cc2e7362f54e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0cba1883-9595-4fbe-82a6-1d9b67774f44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_376e0788-64d7-49ed-a41b-b315e295d4cd" xlink:to="loc_us-gaap_StatementTable_0cba1883-9595-4fbe-82a6-1d9b67774f44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3b8339b1-bcbd-49ee-8f21-ce07d00d1737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0cba1883-9595-4fbe-82a6-1d9b67774f44" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3b8339b1-bcbd-49ee-8f21-ce07d00d1737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3b8339b1-bcbd-49ee-8f21-ce07d00d1737_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3b8339b1-bcbd-49ee-8f21-ce07d00d1737" xlink:to="loc_us-gaap_EquityComponentDomain_3b8339b1-bcbd-49ee-8f21-ce07d00d1737_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3b8339b1-bcbd-49ee-8f21-ce07d00d1737" xlink:to="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_f45cdd2e-2b33-41c5-a9d0-02ebbb2e6e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:to="loc_us-gaap_PreferredStockMember_f45cdd2e-2b33-41c5-a9d0-02ebbb2e6e0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4f3bd666-a137-47fc-aa3c-567dcd5134a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:to="loc_us-gaap_CommonStockMember_4f3bd666-a137-47fc-aa3c-567dcd5134a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_df72c61a-8d31-4d11-99d0-b4a97cfc110a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:to="loc_us-gaap_TreasuryStockMember_df72c61a-8d31-4d11-99d0-b4a97cfc110a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4fd6e652-96d7-4cc8-bfda-65fb3ffce8bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4fd6e652-96d7-4cc8-bfda-65fb3ffce8bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ManagementNotesReceivableMember_83efacb5-8c65-4633-9c51-1c1d2ce0ed8e" xlink:href="bios-20201231.xsd#bios_ManagementNotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:to="loc_bios_ManagementNotesReceivableMember_83efacb5-8c65-4633-9c51-1c1d2ce0ed8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cc163f75-8380-480f-86de-56fdb7fa83df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:to="loc_us-gaap_RetainedEarningsMember_cc163f75-8380-480f-86de-56fdb7fa83df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6c5e8c27-1e8e-458e-abfc-1af8b4783432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6c5e8c27-1e8e-458e-abfc-1af8b4783432" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="bios-20201231.xsd#NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="extended" id="i16ab651bc2524bbda880d7633d18aaf0_NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" xlink:type="extended" id="i05363ff6612c40e99a9f7264c93db181_NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_300b1687-c191-4474-93c2-257a3e342a9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_300b1687-c191-4474-93c2-257a3e342a9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_792ba727-25c1-48df-9483-43e3b53c1fff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_792ba727-25c1-48df-9483-43e3b53c1fff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03432770-7a46-4196-958d-35b86f94043d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03432770-7a46-4196-958d-35b86f94043d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a67d0381-e021-4429-ab43-26379e75c73d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a67d0381-e021-4429-ab43-26379e75c73d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c988c862-563a-46d7-86b7-81e53b95b33e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_us-gaap_LongTermDebt_c988c862-563a-46d7-86b7-81e53b95b33e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BusinessCombinationOwnershipInterestRetained_ce2ce4f5-72c6-4a63-9c27-17e0d577efad" xlink:href="bios-20201231.xsd#bios_BusinessCombinationOwnershipInterestRetained"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_bios_BusinessCombinationOwnershipInterestRetained_ce2ce4f5-72c6-4a63-9c27-17e0d577efad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_dded1a57-5fdf-4602-9b98-234702e78721" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_dded1a57-5fdf-4602-9b98-234702e78721" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NumberOfServiceLocations_18c711e8-ff26-4175-971b-03917640bb87" xlink:href="bios-20201231.xsd#bios_NumberOfServiceLocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_bios_NumberOfServiceLocations_18c711e8-ff26-4175-971b-03917640bb87" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NumberOfInfusionSites_5f0ebd9f-7ab7-413f-8063-f33b7cd79683" xlink:href="bios-20201231.xsd#bios_NumberOfInfusionSites"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_bios_NumberOfInfusionSites_5f0ebd9f-7ab7-413f-8063-f33b7cd79683" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_87378ea5-f139-452d-9917-9a031c7ea308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_87378ea5-f139-452d-9917-9a031c7ea308" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_88b5e106-5d61-40e1-ab40-948bdebf4859" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_88b5e106-5d61-40e1-ab40-948bdebf4859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_88b5e106-5d61-40e1-ab40-948bdebf4859_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_88b5e106-5d61-40e1-ab40-948bdebf4859" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_88b5e106-5d61-40e1-ab40-948bdebf4859_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1a34b89e-be78-4f66-82ff-1c6ccafeae3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_88b5e106-5d61-40e1-ab40-948bdebf4859" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1a34b89e-be78-4f66-82ff-1c6ccafeae3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LegacyHealthSystemsMember_14647324-1266-4f46-a2d6-ec37644dfff4" xlink:href="bios-20201231.xsd#bios_LegacyHealthSystemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1a34b89e-be78-4f66-82ff-1c6ccafeae3a" xlink:to="loc_bios_LegacyHealthSystemsMember_14647324-1266-4f46-a2d6-ec37644dfff4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_99584ef1-ddf3-49a6-8b2f-909711ce7f60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_99584ef1-ddf3-49a6-8b2f-909711ce7f60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_99584ef1-ddf3-49a6-8b2f-909711ce7f60_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_99584ef1-ddf3-49a6-8b2f-909711ce7f60" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_99584ef1-ddf3-49a6-8b2f-909711ce7f60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a9426c1c-55f7-4dc7-b20e-59a3843fde58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_99584ef1-ddf3-49a6-8b2f-909711ce7f60" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a9426c1c-55f7-4dc7-b20e-59a3843fde58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_d4aca62a-ccb1-4043-9c99-bb3cfb9b91c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a9426c1c-55f7-4dc7-b20e-59a3843fde58" xlink:to="loc_us-gaap_SeniorNotesMember_d4aca62a-ccb1-4043-9c99-bb3cfb9b91c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryAxis_9e019599-8618-4e29-999d-735bdfee8723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:to="loc_us-gaap_LienCategoryAxis_9e019599-8618-4e29-999d-735bdfee8723" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_9e019599-8618-4e29-999d-735bdfee8723_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LienCategoryAxis_9e019599-8618-4e29-999d-735bdfee8723" xlink:to="loc_us-gaap_LienCategoryDomain_9e019599-8618-4e29-999d-735bdfee8723_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_67971522-6ecc-44d3-b30c-d4f83e52bb1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LienCategoryAxis_9e019599-8618-4e29-999d-735bdfee8723" xlink:to="loc_us-gaap_LienCategoryDomain_67971522-6ecc-44d3-b30c-d4f83e52bb1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLienMember_cd4708b6-9646-416c-8986-89b2fbc43cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorLienMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LienCategoryDomain_67971522-6ecc-44d3-b30c-d4f83e52bb1c" xlink:to="loc_us-gaap_SeniorLienMember_cd4708b6-9646-416c-8986-89b2fbc43cdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_530cfd56-9ade-4f1d-a4d0-91ebb12eece0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_530cfd56-9ade-4f1d-a4d0-91ebb12eece0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_530cfd56-9ade-4f1d-a4d0-91ebb12eece0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_530cfd56-9ade-4f1d-a4d0-91ebb12eece0" xlink:to="loc_us-gaap_RelatedPartyDomain_530cfd56-9ade-4f1d-a4d0-91ebb12eece0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_275091b7-16a6-4aa7-beed-bc6cf9cc577f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_530cfd56-9ade-4f1d-a4d0-91ebb12eece0" xlink:to="loc_us-gaap_RelatedPartyDomain_275091b7-16a6-4aa7-beed-bc6cf9cc577f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorityShareholderMember_21db980e-c587-44db-941f-0aeb7ecbd51e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorityShareholderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_275091b7-16a6-4aa7-beed-bc6cf9cc577f" xlink:to="loc_us-gaap_MajorityShareholderMember_21db980e-c587-44db-941f-0aeb7ecbd51e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4a9c4243-65d7-4c42-9073-a4d8dd7fbbce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4a9c4243-65d7-4c42-9073-a4d8dd7fbbce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4a9c4243-65d7-4c42-9073-a4d8dd7fbbce_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4a9c4243-65d7-4c42-9073-a4d8dd7fbbce" xlink:to="loc_us-gaap_EquityComponentDomain_4a9c4243-65d7-4c42-9073-a4d8dd7fbbce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_89b9503f-dfc6-488c-989c-cbcf23ff05f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4a9c4243-65d7-4c42-9073-a4d8dd7fbbce" xlink:to="loc_us-gaap_EquityComponentDomain_89b9503f-dfc6-488c-989c-cbcf23ff05f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_75475d13-ae17-4d49-980e-3ea0d621f74d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_89b9503f-dfc6-488c-989c-cbcf23ff05f6" xlink:to="loc_us-gaap_PreferredStockMember_75475d13-ae17-4d49-980e-3ea0d621f74d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fddd0df0-f9ba-417a-905f-c38e4f4b01cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fddd0df0-f9ba-417a-905f-c38e4f4b01cd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_fddd0df0-f9ba-417a-905f-c38e4f4b01cd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fddd0df0-f9ba-417a-905f-c38e4f4b01cd" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_fddd0df0-f9ba-417a-905f-c38e4f4b01cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_8d629efa-02b8-4b9f-addb-5d714380cad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fddd0df0-f9ba-417a-905f-c38e4f4b01cd" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_8d629efa-02b8-4b9f-addb-5d714380cad8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b8262d42-ba8b-4b96-b111-5a97d559a268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_8d629efa-02b8-4b9f-addb-5d714380cad8" xlink:to="loc_us-gaap_CommonStockMember_b8262d42-ba8b-4b96-b111-5a97d559a268" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_303ec724-4233-4f4b-8b93-a38549e95aec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_303ec724-4233-4f4b-8b93-a38549e95aec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_303ec724-4233-4f4b-8b93-a38549e95aec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_303ec724-4233-4f4b-8b93-a38549e95aec" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_303ec724-4233-4f4b-8b93-a38549e95aec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44868a8b-24f8-4f9a-8845-db52b0927447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_303ec724-4233-4f4b-8b93-a38549e95aec" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44868a8b-24f8-4f9a-8845-db52b0927447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionCareEnterprisesInc.Member_3939ee6a-1c01-4a67-9620-9e2be31eb503" xlink:href="bios-20201231.xsd#bios_OptionCareEnterprisesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44868a8b-24f8-4f9a-8845-db52b0927447" xlink:to="loc_bios_OptionCareEnterprisesInc.Member_3939ee6a-1c01-4a67-9620-9e2be31eb503" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bios-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended" id="ibbadeac4d70c440c9d8b987f9f2caec9_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bios-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended" id="i8d4f1f7b402b4530ab2d065d41d1d40c_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended" id="i2832b95f13414744afe75a187cca3d7e_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_2156a6a1-b752-4429-bd74-559503acc8f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_2156a6a1-b752-4429-bd74-559503acc8f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_d18a4222-c7eb-49bd-ab13-e784e4f4bc61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledReceivablesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_d18a4222-c7eb-49bd-ab13-e784e4f4bc61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_7495cc97-d9b3-465e-8d2a-1f464a03508a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_InventoryWriteDown_7495cc97-d9b3-465e-8d2a-1f464a03508a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_c51ebe88-efe4-42ee-a79c-43a9ff599224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_c51ebe88-efe4-42ee-a79c-43a9ff599224" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceSettlementsReceivable_59ac4c68-6c02-41df-91b5-87d9a8c2705d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceSettlementsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_InsuranceSettlementsReceivable_59ac4c68-6c02-41df-91b5-87d9a8c2705d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_a7c0161f-b22d-463b-9614-267db1338548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_a7c0161f-b22d-463b-9614-267db1338548" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_2159a25f-366c-4eda-a499-aebc64085864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_2159a25f-366c-4eda-a499-aebc64085864" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9655034c-eead-434a-aa0d-4270d997dc87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9655034c-eead-434a-aa0d-4270d997dc87" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b3307a85-95b6-4ea0-86a6-cd2ac6a671ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_EquityMethodInvestments_b3307a85-95b6-4ea0-86a6-cd2ac6a671ff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_350583ec-dcdb-40f2-8c5e-bdba0a760364" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_350583ec-dcdb-40f2-8c5e-bdba0a760364" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_d3d38d53-ba7a-4329-84dc-db44cd96547a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_d3d38d53-ba7a-4329-84dc-db44cd96547a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_5b0d3cf4-519b-42d1-9ba0-fe8b438fa2c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_5b0d3cf4-519b-42d1-9ba0-fe8b438fa2c2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BusinessCombinationRenewalTermLength_fe626994-1897-425d-a7fb-4408c17912bd" xlink:href="bios-20201231.xsd#bios_BusinessCombinationRenewalTermLength"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_bios_BusinessCombinationRenewalTermLength_fe626994-1897-425d-a7fb-4408c17912bd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_574f0717-1df9-48f6-ac05-f9b6ccae800f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_ConcentrationRiskTable_574f0717-1df9-48f6-ac05-f9b6ccae800f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f0b89ea1-83f7-4c6c-902c-7cf7a8d9c09a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_574f0717-1df9-48f6-ac05-f9b6ccae800f" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f0b89ea1-83f7-4c6c-902c-7cf7a8d9c09a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f0b89ea1-83f7-4c6c-902c-7cf7a8d9c09a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f0b89ea1-83f7-4c6c-902c-7cf7a8d9c09a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f0b89ea1-83f7-4c6c-902c-7cf7a8d9c09a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c9143a86-324a-4104-900b-89e62fbb9b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f0b89ea1-83f7-4c6c-902c-7cf7a8d9c09a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c9143a86-324a-4104-900b-89e62fbb9b9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_437cad00-1fd1-4e2b-b45e-67c949db88a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c9143a86-324a-4104-900b-89e62fbb9b9b" xlink:to="loc_us-gaap_InventoriesMember_437cad00-1fd1-4e2b-b45e-67c949db88a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_211e5c4f-cc42-4b15-b2e9-826fbb1c5e17" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_574f0717-1df9-48f6-ac05-f9b6ccae800f" xlink:to="loc_srt_RangeAxis_211e5c4f-cc42-4b15-b2e9-826fbb1c5e17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_211e5c4f-cc42-4b15-b2e9-826fbb1c5e17_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_211e5c4f-cc42-4b15-b2e9-826fbb1c5e17" xlink:to="loc_srt_RangeMember_211e5c4f-cc42-4b15-b2e9-826fbb1c5e17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fcde92f7-1470-4c7d-b5f2-a48f6e7b03de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_211e5c4f-cc42-4b15-b2e9-826fbb1c5e17" xlink:to="loc_srt_RangeMember_fcde92f7-1470-4c7d-b5f2-a48f6e7b03de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_94f72d66-457f-4f5b-94b0-60a7548906cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fcde92f7-1470-4c7d-b5f2-a48f6e7b03de" xlink:to="loc_srt_MinimumMember_94f72d66-457f-4f5b-94b0-60a7548906cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_99ba62c8-70ee-485b-ac36-65fa82c71513" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fcde92f7-1470-4c7d-b5f2-a48f6e7b03de" xlink:to="loc_srt_MaximumMember_99ba62c8-70ee-485b-ac36-65fa82c71513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69cdc403-30be-4356-9ebd-3d8e3129ad2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_574f0717-1df9-48f6-ac05-f9b6ccae800f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69cdc403-30be-4356-9ebd-3d8e3129ad2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69cdc403-30be-4356-9ebd-3d8e3129ad2e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69cdc403-30be-4356-9ebd-3d8e3129ad2e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69cdc403-30be-4356-9ebd-3d8e3129ad2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a9b1330-6271-467a-a271-d9500683666d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69cdc403-30be-4356-9ebd-3d8e3129ad2e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a9b1330-6271-467a-a271-d9500683666d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerListsMember_39c75736-922a-4fd5-91a4-57c0658b26bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerListsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a9b1330-6271-467a-a271-d9500683666d" xlink:to="loc_us-gaap_CustomerListsMember_39c75736-922a-4fd5-91a4-57c0658b26bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_bedd8bcb-79ce-4041-be21-c0133bf1ee75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a9b1330-6271-467a-a271-d9500683666d" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_bedd8bcb-79ce-4041-be21-c0133bf1ee75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_844181e0-74e3-4181-a7a2-d2777c2493b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a9b1330-6271-467a-a271-d9500683666d" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_844181e0-74e3-4181-a7a2-d2777c2493b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InfusionPumpsMember_da0675c7-13aa-49b0-a7bb-bdce06d7bbf1" xlink:href="bios-20201231.xsd#bios_InfusionPumpsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a9b1330-6271-467a-a271-d9500683666d" xlink:to="loc_bios_InfusionPumpsMember_da0675c7-13aa-49b0-a7bb-bdce06d7bbf1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_87f4d18a-20db-4ccd-b794-5df5d7ea43f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a9b1330-6271-467a-a271-d9500683666d" xlink:to="loc_us-gaap_EquipmentMember_87f4d18a-20db-4ccd-b794-5df5d7ea43f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_5f9e5347-0f3f-4e9a-98a7-604bf4e2b763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a9b1330-6271-467a-a271-d9500683666d" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_5f9e5347-0f3f-4e9a-98a7-604bf4e2b763" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_b2c32c01-26bd-44df-a756-a9c005e6781d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_574f0717-1df9-48f6-ac05-f9b6ccae800f" xlink:to="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_b2c32c01-26bd-44df-a756-a9c005e6781d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CatastrophicEventDomain_b2c32c01-26bd-44df-a756-a9c005e6781d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CatastrophicEventDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_b2c32c01-26bd-44df-a756-a9c005e6781d" xlink:to="loc_us-gaap_CatastrophicEventDomain_b2c32c01-26bd-44df-a756-a9c005e6781d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CatastrophicEventDomain_d470df77-d06f-410d-aed6-46879edaa146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CatastrophicEventDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_b2c32c01-26bd-44df-a756-a9c005e6781d" xlink:to="loc_us-gaap_CatastrophicEventDomain_d470df77-d06f-410d-aed6-46879edaa146" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HurricaneMember_0391526c-b0b9-44e1-a5b0-f962fdb2ba20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HurricaneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CatastrophicEventDomain_d470df77-d06f-410d-aed6-46879edaa146" xlink:to="loc_us-gaap_HurricaneMember_0391526c-b0b9-44e1-a5b0-f962fdb2ba20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_44e273cb-5ba0-4c04-bc67-fc462699077b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_574f0717-1df9-48f6-ac05-f9b6ccae800f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_44e273cb-5ba0-4c04-bc67-fc462699077b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44e273cb-5ba0-4c04-bc67-fc462699077b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_44e273cb-5ba0-4c04-bc67-fc462699077b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44e273cb-5ba0-4c04-bc67-fc462699077b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d484532b-1d9b-4878-a3eb-cfffc7bd4c19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_44e273cb-5ba0-4c04-bc67-fc462699077b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d484532b-1d9b-4878-a3eb-cfffc7bd4c19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_718887cb-736a-4875-9bf0-3c011fd4587a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d484532b-1d9b-4878-a3eb-cfffc7bd4c19" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_718887cb-736a-4875-9bf0-3c011fd4587a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_2e9a771c-2307-4e0f-9ca8-f6c556a772a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d484532b-1d9b-4878-a3eb-cfffc7bd4c19" xlink:to="loc_us-gaap_AccountsReceivableMember_2e9a771c-2307-4e0f-9ca8-f6c556a772a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsProductLineMember_577f9cc3-3b5f-4dc5-9b1e-02fc270e4eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d484532b-1d9b-4878-a3eb-cfffc7bd4c19" xlink:to="loc_us-gaap_CostOfGoodsProductLineMember_577f9cc3-3b5f-4dc5-9b1e-02fc270e4eb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c411f003-09ce-4f74-b716-9a1d72ffb399" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_574f0717-1df9-48f6-ac05-f9b6ccae800f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c411f003-09ce-4f74-b716-9a1d72ffb399" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c411f003-09ce-4f74-b716-9a1d72ffb399_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c411f003-09ce-4f74-b716-9a1d72ffb399" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c411f003-09ce-4f74-b716-9a1d72ffb399_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2c3059cb-330b-4295-a2fe-2f3241816868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c411f003-09ce-4f74-b716-9a1d72ffb399" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2c3059cb-330b-4295-a2fe-2f3241816868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a4cc7438-4a3a-420c-9160-590a3e939df4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2c3059cb-330b-4295-a2fe-2f3241816868" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a4cc7438-4a3a-420c-9160-590a3e939df4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_88abd781-5355-4559-9b79-821618cccd05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2c3059cb-330b-4295-a2fe-2f3241816868" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_88abd781-5355-4559-9b79-821618cccd05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_d1bec7af-6e19-4fb5-b67a-8444cbcd6b3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2c3059cb-330b-4295-a2fe-2f3241816868" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_d1bec7af-6e19-4fb5-b67a-8444cbcd6b3a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONS" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONS"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONS" xlink:type="extended" id="if356352d81a94fc29cfa8574672fdd35_BUSINESSACQUISITIONS"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSTables" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSTables"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSTables" xlink:type="extended" id="i03ecce1cb2ea4e458c6383c33ee8b2dd_BUSINESSACQUISITIONSTables"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails" xlink:type="extended" id="i0d03275aa3634568a84f5294e179c14a_BUSINESSACQUISITIONSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_9dce9c50-35e6-443e-bf58-31870524fe66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_9dce9c50-35e6-443e-bf58-31870524fe66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_9488c555-ede9-4dc0-aa03-9c4f5e16dd31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_9488c555-ede9-4dc0-aa03-9c4f5e16dd31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e32d1da5-ed4a-4377-8d13-a372a02dcc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e32d1da5-ed4a-4377-8d13-a372a02dcc3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_25f8d465-fa03-4540-adab-a09664fd7735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_25f8d465-fa03-4540-adab-a09664fd7735" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2270d444-da50-4fb3-bd9a-886d769a030e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_Goodwill_2270d444-da50-4fb3-bd9a-886d769a030e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_7273e906-fa3a-4e7a-b2ef-bd17f4d7ca84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_7273e906-fa3a-4e7a-b2ef-bd17f4d7ca84" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_f88f0d21-ddfc-45d3-a8ea-c6ef05ab40b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_f88f0d21-ddfc-45d3-a8ea-c6ef05ab40b3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForMergerRelatedCosts_6d30702e-ff92-4031-917a-b7dc0d5b9292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForMergerRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_PaymentsForMergerRelatedCosts_6d30702e-ff92-4031-917a-b7dc0d5b9292" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bac35bd2-4706-465f-80bf-20b1b5a4de3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bac35bd2-4706-465f-80bf-20b1b5a4de3b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1a504937-758b-4806-a901-d83067a84f88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1a504937-758b-4806-a901-d83067a84f88" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_94b0bea8-dcb9-47c2-b4f4-1a563e0811fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_94b0bea8-dcb9-47c2-b4f4-1a563e0811fb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6f1a455c-1296-497a-9c07-10b13b4878d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6f1a455c-1296-497a-9c07-10b13b4878d7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred_6468f09e-9a60-4bec-856b-47590f012767" xlink:href="bios-20201231.xsd#bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred_6468f09e-9a60-4bec-856b-47590f012767" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_778488a7-c353-4358-91fa-2a4306304630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_778488a7-c353-4358-91fa-2a4306304630" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryAxis_43982d7f-40e3-46a1-a2dd-4f5f8b71fa78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_778488a7-c353-4358-91fa-2a4306304630" xlink:to="loc_us-gaap_LienCategoryAxis_43982d7f-40e3-46a1-a2dd-4f5f8b71fa78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_43982d7f-40e3-46a1-a2dd-4f5f8b71fa78_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LienCategoryAxis_43982d7f-40e3-46a1-a2dd-4f5f8b71fa78" xlink:to="loc_us-gaap_LienCategoryDomain_43982d7f-40e3-46a1-a2dd-4f5f8b71fa78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_78ed2674-09fa-430b-81c3-8bc359efe600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LienCategoryAxis_43982d7f-40e3-46a1-a2dd-4f5f8b71fa78" xlink:to="loc_us-gaap_LienCategoryDomain_78ed2674-09fa-430b-81c3-8bc359efe600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLienMember_d1c07d3a-00c5-4e6b-9144-5456f67e92ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorLienMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LienCategoryDomain_78ed2674-09fa-430b-81c3-8bc359efe600" xlink:to="loc_us-gaap_SeniorLienMember_d1c07d3a-00c5-4e6b-9144-5456f67e92ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dba9a56e-98f2-46c0-8c9b-e4641f927f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_778488a7-c353-4358-91fa-2a4306304630" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dba9a56e-98f2-46c0-8c9b-e4641f927f40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dba9a56e-98f2-46c0-8c9b-e4641f927f40_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dba9a56e-98f2-46c0-8c9b-e4641f927f40" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dba9a56e-98f2-46c0-8c9b-e4641f927f40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334a3dcd-7f53-441a-a567-00605bd63ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dba9a56e-98f2-46c0-8c9b-e4641f927f40" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334a3dcd-7f53-441a-a567-00605bd63ccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BioScripMember_aabc6247-d5a8-451a-a0d5-cb9deba8fc15" xlink:href="bios-20201231.xsd#bios_BioScripMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334a3dcd-7f53-441a-a567-00605bd63ccc" xlink:to="loc_bios_BioScripMember_aabc6247-d5a8-451a-a0d5-cb9deba8fc15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BaptistHealthInLittleRockArkansasMember_600f5daf-ae7e-4b14-9661-eb6dd59ef2aa" xlink:href="bios-20201231.xsd#bios_BaptistHealthInLittleRockArkansasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334a3dcd-7f53-441a-a567-00605bd63ccc" xlink:to="loc_bios_BaptistHealthInLittleRockArkansasMember_600f5daf-ae7e-4b14-9661-eb6dd59ef2aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HomeI.V.SpecialistsInc.Member_c008d34c-c300-4bb0-8b3c-e53352ac371f" xlink:href="bios-20201231.xsd#bios_HomeI.V.SpecialistsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334a3dcd-7f53-441a-a567-00605bd63ccc" xlink:to="loc_bios_HomeI.V.SpecialistsInc.Member_c008d34c-c300-4bb0-8b3c-e53352ac371f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3094be6f-d248-4639-bf95-f4dd6891284c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_778488a7-c353-4358-91fa-2a4306304630" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3094be6f-d248-4639-bf95-f4dd6891284c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3094be6f-d248-4639-bf95-f4dd6891284c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3094be6f-d248-4639-bf95-f4dd6891284c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3094be6f-d248-4639-bf95-f4dd6891284c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8548726a-c41e-4063-b0d3-324901f71b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3094be6f-d248-4639-bf95-f4dd6891284c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8548726a-c41e-4063-b0d3-324901f71b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_c9f439a3-1bb5-4b15-b475-901236a4e04c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8548726a-c41e-4063-b0d3-324901f71b5e" xlink:to="loc_us-gaap_SeniorNotesMember_c9f439a3-1bb5-4b15-b475-901236a4e04c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSConsiderationExchangedDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails" xlink:type="extended" id="i7ef23af8b8c34ab3a2dc7aa9eb21d5a5_BUSINESSACQUISITIONSConsiderationExchangedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_95293e81-fb74-44f5-a327-ca47aaf5c353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_95293e81-fb74-44f5-a327-ca47aaf5c353" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5c3da56f-1593-4036-9c6c-7dd2706b460e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5c3da56f-1593-4036-9c6c-7dd2706b460e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_6ed26cfc-eeb7-45ce-b0d3-684ae3386f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_6ed26cfc-eeb7-45ce-b0d3-684ae3386f1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_06a2507a-c90e-46a0-9eab-a46f7e812883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_CommonStockValueOutstanding_06a2507a-c90e-46a0-9eab-a46f7e812883" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0be46b40-5655-4f0d-83b8-c043986d78cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0be46b40-5655-4f0d-83b8-c043986d78cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b23f627a-0298-4e92-8502-111d459e5277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b23f627a-0298-4e92-8502-111d459e5277" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9f69339f-ed25-4c01-b801-616e0efeb019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9f69339f-ed25-4c01-b801-616e0efeb019" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_7b7bee45-6850-4d19-bfee-c1eac7a0ea56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_7b7bee45-6850-4d19-bfee-c1eac7a0ea56" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c043c0d8-5af7-4f70-8013-bb86243ad3a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c043c0d8-5af7-4f70-8013-bb86243ad3a6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ba6e6501-335f-4752-bf9f-d17aa48a2bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ba6e6501-335f-4752-bf9f-d17aa48a2bf6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f1677e9-47dc-494f-8247-95163134092d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f1677e9-47dc-494f-8247-95163134092d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_57300927-2f39-47c1-8ac6-4694339f678c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f1677e9-47dc-494f-8247-95163134092d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_57300927-2f39-47c1-8ac6-4694339f678c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57300927-2f39-47c1-8ac6-4694339f678c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_57300927-2f39-47c1-8ac6-4694339f678c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57300927-2f39-47c1-8ac6-4694339f678c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8adafe2e-3370-4b74-b297-67ec3c4ef381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_57300927-2f39-47c1-8ac6-4694339f678c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8adafe2e-3370-4b74-b297-67ec3c4ef381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BioScripMember_32a72760-0847-4961-b9fd-b048712e51ae" xlink:href="bios-20201231.xsd#bios_BioScripMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8adafe2e-3370-4b74-b297-67ec3c4ef381" xlink:to="loc_bios_BioScripMember_32a72760-0847-4961-b9fd-b048712e51ae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails" xlink:type="extended" id="id02003f2c7154f9aaa85ec43441d094c_BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1338a126-5267-47dc-98f3-c5d58606afd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1338a126-5267-47dc-98f3-c5d58606afd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e1bfac2e-2bff-43a5-be93-78db6b09a81d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e1bfac2e-2bff-43a5-be93-78db6b09a81d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d489cf49-ba34-4b93-beff-cc852daef013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d489cf49-ba34-4b93-beff-cc852daef013" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_989042a1-eb5e-46d9-aa5c-a7f55b354512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_989042a1-eb5e-46d9-aa5c-a7f55b354512" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_0c92d207-9227-4e51-b31f-1aa0a64e6e37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_0c92d207-9227-4e51-b31f-1aa0a64e6e37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_7a77e3b5-0858-4713-b760-f43938432e4a" xlink:href="bios-20201231.xsd#bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_7a77e3b5-0858-4713-b760-f43938432e4a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_a92817e0-e49f-4e24-a327-e0d2770c9207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_a92817e0-e49f-4e24-a327-e0d2770c9207" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_6131ed38-6e49-417c-ba22-227308da78c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_6131ed38-6e49-417c-ba22-227308da78c4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_01555845-6ea1-4cfe-864b-1eb1cd751fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_01555845-6ea1-4cfe-864b-1eb1cd751fb8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fc5a88e6-0d48-4d23-a6a2-5a82fa3deafb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fc5a88e6-0d48-4d23-a6a2-5a82fa3deafb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6cf091ae-c365-4930-822e-1fa3d587a406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_Goodwill_6cf091ae-c365-4930-822e-1fa3d587a406" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_7599963c-c3d6-42e2-aa15-97ff54e95238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_7599963c-c3d6-42e2-aa15-97ff54e95238" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c894384-ab89-4799-8057-487173557a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c894384-ab89-4799-8057-487173557a52" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6a48f86b-0128-496c-a2a4-c90d032660c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c894384-ab89-4799-8057-487173557a52" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6a48f86b-0128-496c-a2a4-c90d032660c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6a48f86b-0128-496c-a2a4-c90d032660c3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6a48f86b-0128-496c-a2a4-c90d032660c3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6a48f86b-0128-496c-a2a4-c90d032660c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a13689db-52da-4998-98da-427b38032ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6a48f86b-0128-496c-a2a4-c90d032660c3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a13689db-52da-4998-98da-427b38032ee3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BioScripMember_1687a4ed-bc26-4153-b1e8-fe5f43f3ab62" xlink:href="bios-20201231.xsd#bios_BioScripMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a13689db-52da-4998-98da-427b38032ee3" xlink:to="loc_bios_BioScripMember_1687a4ed-bc26-4153-b1e8-fe5f43f3ab62" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails" xlink:type="extended" id="i418751998af84ffd9ec255e05b8a06c8_BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7182f34c-cbb6-4406-816e-58a67f2748da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_29ad44c4-ede1-472c-9011-7fda4c8d8215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7182f34c-cbb6-4406-816e-58a67f2748da" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_29ad44c4-ede1-472c-9011-7fda4c8d8215" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_fdfeacb1-67f8-42e4-903b-c7c98d8944d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7182f34c-cbb6-4406-816e-58a67f2748da" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_fdfeacb1-67f8-42e4-903b-c7c98d8944d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7cd19738-0fb2-40e9-8b67-42e0fc0d0003" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7182f34c-cbb6-4406-816e-58a67f2748da" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7cd19738-0fb2-40e9-8b67-42e0fc0d0003" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1eacdda7-89cc-4142-878a-b8cd7c6445c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7cd19738-0fb2-40e9-8b67-42e0fc0d0003" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1eacdda7-89cc-4142-878a-b8cd7c6445c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1eacdda7-89cc-4142-878a-b8cd7c6445c2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1eacdda7-89cc-4142-878a-b8cd7c6445c2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1eacdda7-89cc-4142-878a-b8cd7c6445c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_21200746-fd14-4576-b6b4-310d74ee8333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1eacdda7-89cc-4142-878a-b8cd7c6445c2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_21200746-fd14-4576-b6b4-310d74ee8333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_38a1c2db-b77e-4e84-af2d-a5cf40980b4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_21200746-fd14-4576-b6b4-310d74ee8333" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_38a1c2db-b77e-4e84-af2d-a5cf40980b4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerListsMember_0a13086e-4e01-4cc1-8188-22fa880349ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerListsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_21200746-fd14-4576-b6b4-310d74ee8333" xlink:to="loc_us-gaap_CustomerListsMember_0a13086e-4e01-4cc1-8188-22fa880349ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_a485b767-7556-4595-83b8-ae13acff756f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_21200746-fd14-4576-b6b4-310d74ee8333" xlink:to="loc_us-gaap_LicensingAgreementsMember_a485b767-7556-4595-83b8-ae13acff756f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3412a259-0b9a-4b5e-b088-d84d2456e8a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7cd19738-0fb2-40e9-8b67-42e0fc0d0003" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3412a259-0b9a-4b5e-b088-d84d2456e8a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3412a259-0b9a-4b5e-b088-d84d2456e8a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3412a259-0b9a-4b5e-b088-d84d2456e8a1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3412a259-0b9a-4b5e-b088-d84d2456e8a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8af83578-5850-4da9-b8f5-a635b8e12e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3412a259-0b9a-4b5e-b088-d84d2456e8a1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8af83578-5850-4da9-b8f5-a635b8e12e83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BioScripMember_90c05836-ad2f-4e3a-bb0f-84eff8cd09cf" xlink:href="bios-20201231.xsd#bios_BioScripMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8af83578-5850-4da9-b8f5-a635b8e12e83" xlink:to="loc_bios_BioScripMember_90c05836-ad2f-4e3a-bb0f-84eff8cd09cf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSProFormaFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSProFormaFinancialInformationDetails" xlink:type="extended" id="i1accc51775ad4e7ab5b638d273e8f31f_BUSINESSACQUISITIONSProFormaFinancialInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a2e72dd5-6f34-418b-a9d0-eeb83b04c1aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_e5c84aa5-5053-4684-a89a-6d81f7342ed3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2e72dd5-6f34-418b-a9d0-eeb83b04c1aa" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_e5c84aa5-5053-4684-a89a-6d81f7342ed3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_75cb52ad-75b9-4ecb-aef8-f4eee8efdc15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2e72dd5-6f34-418b-a9d0-eeb83b04c1aa" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_75cb52ad-75b9-4ecb-aef8-f4eee8efdc15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_df85ad33-afb0-4c7a-a866-efe0bbd0475d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2e72dd5-6f34-418b-a9d0-eeb83b04c1aa" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_df85ad33-afb0-4c7a-a866-efe0bbd0475d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f86537e3-431e-420b-8aee-ab8338b1fafe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_df85ad33-afb0-4c7a-a866-efe0bbd0475d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f86537e3-431e-420b-8aee-ab8338b1fafe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f86537e3-431e-420b-8aee-ab8338b1fafe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f86537e3-431e-420b-8aee-ab8338b1fafe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f86537e3-431e-420b-8aee-ab8338b1fafe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96b2e284-a1fe-4903-9f6b-e2cbd3418ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f86537e3-431e-420b-8aee-ab8338b1fafe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96b2e284-a1fe-4903-9f6b-e2cbd3418ecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BioScripMember_087e70f3-a04a-42d6-8d97-56fa26ee6e4c" xlink:href="bios-20201231.xsd#bios_BioScripMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96b2e284-a1fe-4903-9f6b-e2cbd3418ecf" xlink:to="loc_bios_BioScripMember_087e70f3-a04a-42d6-8d97-56fa26ee6e4c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/REVENUE" xlink:type="simple" xlink:href="bios-20201231.xsd#REVENUE"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/REVENUE" xlink:type="extended" id="ic2511a5c0425471f8918bb66727fa219_REVENUE"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/REVENUETables" xlink:type="simple" xlink:href="bios-20201231.xsd#REVENUETables"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/REVENUETables" xlink:type="extended" id="i4f4981c1b9b64c29b32e83dc1b5cb9ce_REVENUETables"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#REVENUENetRevenueEarnedbyCategoryofPayerDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" xlink:type="extended" id="ie50e4a4e044348ffa44e515c0f9fec13_REVENUENetRevenueEarnedbyCategoryofPayerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_aa1a2b7b-6308-41e8-ab60-bd553059861e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1b7dd87a-38c5-4a47-b87f-51916162f2b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_aa1a2b7b-6308-41e8-ab60-bd553059861e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1b7dd87a-38c5-4a47-b87f-51916162f2b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_15c22f39-87a6-4c6c-b5e1-6e97a28e80ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_aa1a2b7b-6308-41e8-ab60-bd553059861e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_15c22f39-87a6-4c6c-b5e1-6e97a28e80ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_09c35c34-bb75-4eab-a255-13f406e90b6c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_15c22f39-87a6-4c6c-b5e1-6e97a28e80ba" xlink:to="loc_srt_MajorCustomersAxis_09c35c34-bb75-4eab-a255-13f406e90b6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_09c35c34-bb75-4eab-a255-13f406e90b6c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_09c35c34-bb75-4eab-a255-13f406e90b6c" xlink:to="loc_srt_NameOfMajorCustomerDomain_09c35c34-bb75-4eab-a255-13f406e90b6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_733b0db7-6c4c-47dd-be9b-2e7a5e7e6577" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_09c35c34-bb75-4eab-a255-13f406e90b6c" xlink:to="loc_srt_NameOfMajorCustomerDomain_733b0db7-6c4c-47dd-be9b-2e7a5e7e6577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_GovernmentCustomerMember_3b5028c1-aba3-4caf-a977-14f451b80795" xlink:href="bios-20201231.xsd#bios_GovernmentCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_733b0db7-6c4c-47dd-be9b-2e7a5e7e6577" xlink:to="loc_bios_GovernmentCustomerMember_3b5028c1-aba3-4caf-a977-14f451b80795" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CommercialCustomerMember_4c9ece38-38aa-434e-b4c6-7c321b92d94a" xlink:href="bios-20201231.xsd#bios_CommercialCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_733b0db7-6c4c-47dd-be9b-2e7a5e7e6577" xlink:to="loc_bios_CommercialCustomerMember_4c9ece38-38aa-434e-b4c6-7c321b92d94a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PatientCustomerMember_cbe42535-ac0c-433a-95eb-1b7c7e61c94b" xlink:href="bios-20201231.xsd#bios_PatientCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_733b0db7-6c4c-47dd-be9b-2e7a5e7e6577" xlink:to="loc_bios_PatientCustomerMember_cbe42535-ac0c-433a-95eb-1b7c7e61c94b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="bios-20201231.xsd#EMPLOYEEBENEFITPLANS"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANS" xlink:type="extended" id="i663a3f587c2940199439a8d69ff28279_EMPLOYEEBENEFITPLANS"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended" id="i933b4ce04dce4a178f12d49b75dab792_EMPLOYEEBENEFITPLANSDetails"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXES" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXES"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/INCOMETAXES" xlink:type="extended" id="i6049d70fab274770a184bb87615451a2_INCOMETAXES"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESIncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables" xlink:type="extended" id="iefcd7d509c5843f68b976932c75a3d87_INCOMETAXESIncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESIncomeTaxBenefitDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails" xlink:type="extended" id="ib262852e433e46c0ad1461a757fd9fe9_INCOMETAXESIncomeTaxBenefitDetails"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESIncomeTaxReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails" xlink:type="extended" id="ifd455c2e4c264709b69ae2abb2a7c079_INCOMETAXESIncomeTaxReconciliationDetails"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" xlink:type="extended" id="if3d8958d216c4f3e8748055a48e91faf_INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended" id="i485c7e5573a440cc9b3384632b5dceae_INCOMETAXESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a2cc342d-209c-477b-9154-eb9e619aa33b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a2cc342d-209c-477b-9154-eb9e619aa33b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0144ccc0-d25d-4b6d-8035-68759959318a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0144ccc0-d25d-4b6d-8035-68759959318a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_f7a79a54-38e3-47c1-8b33-168f1fc57e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_f7a79a54-38e3-47c1-8b33-168f1fc57e0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ccf6d77b-e36e-46de-8bb1-dd3483f3c0c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ccf6d77b-e36e-46de-8bb1-dd3483f3c0c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_b83d7655-b3d1-4dca-9134-6fc00a04bdc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_b83d7655-b3d1-4dca-9134-6fc00a04bdc2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_b5daf924-d3c0-461f-a6e0-20f82a7c18d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_b5daf924-d3c0-461f-a6e0-20f82a7c18d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_IncomeTaxExpenseBenefitCARESAct_ed4fbf11-02bd-43cd-b45d-63666b1103c3" xlink:href="bios-20201231.xsd#bios_IncomeTaxExpenseBenefitCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:to="loc_bios_IncomeTaxExpenseBenefitCARESAct_ed4fbf11-02bd-43cd-b45d-63666b1103c3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_74c14cee-ae26-4437-ad2e-de3d628fa9dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_74c14cee-ae26-4437-ad2e-de3d628fa9dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_c1031c9c-e3ad-473b-aade-38aab3e1677f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_74c14cee-ae26-4437-ad2e-de3d628fa9dc" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_c1031c9c-e3ad-473b-aade-38aab3e1677f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_c1031c9c-e3ad-473b-aade-38aab3e1677f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_c1031c9c-e3ad-473b-aade-38aab3e1677f" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_c1031c9c-e3ad-473b-aade-38aab3e1677f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7b03580f-417b-4e68-8e04-b152772f51c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_c1031c9c-e3ad-473b-aade-38aab3e1677f" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7b03580f-417b-4e68-8e04-b152772f51c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_MergerOperatingLossCarryforwardMember_e243f212-c7cd-4375-a9cb-4959b8748a8a" xlink:href="bios-20201231.xsd#bios_MergerOperatingLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7b03580f-417b-4e68-8e04-b152772f51c2" xlink:to="loc_bios_MergerOperatingLossCarryforwardMember_e243f212-c7cd-4375-a9cb-4959b8748a8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember_472145ef-e52a-4eab-86d3-0967c115bde3" xlink:href="bios-20201231.xsd#bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7b03580f-417b-4e68-8e04-b152772f51c2" xlink:to="loc_bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember_472145ef-e52a-4eab-86d3-0967c115bde3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InterestLimitationCarryforwardsMember_44efcc74-6203-4f01-8969-07d419f768e9" xlink:href="bios-20201231.xsd#bios_InterestLimitationCarryforwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7b03580f-417b-4e68-8e04-b152772f51c2" xlink:to="loc_bios_InterestLimitationCarryforwardsMember_44efcc74-6203-4f01-8969-07d419f768e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_46b3bcd4-0ba8-412e-9a96-b28fe0553be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_74c14cee-ae26-4437-ad2e-de3d628fa9dc" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_46b3bcd4-0ba8-412e-9a96-b28fe0553be6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_46b3bcd4-0ba8-412e-9a96-b28fe0553be6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_46b3bcd4-0ba8-412e-9a96-b28fe0553be6" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_46b3bcd4-0ba8-412e-9a96-b28fe0553be6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_418b0cd6-8ce4-4f07-aa4c-2bafdec74f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_46b3bcd4-0ba8-412e-9a96-b28fe0553be6" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_418b0cd6-8ce4-4f07-aa4c-2bafdec74f84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_c5bb6754-eeef-4218-bca2-eb0c5d8d0b16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_418b0cd6-8ce4-4f07-aa4c-2bafdec74f84" xlink:to="loc_us-gaap_DomesticCountryMember_c5bb6754-eeef-4218-bca2-eb0c5d8d0b16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_076adaa5-e1ca-4c59-9047-eb3fef8df2f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_418b0cd6-8ce4-4f07-aa4c-2bafdec74f84" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_076adaa5-e1ca-4c59-9047-eb3fef8df2f8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails" xlink:type="extended" id="i6e9980b22cab41c79b0efa8df08208fb_INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_00acce69-02dd-43fd-b7e3-91a256b70d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward_2bfff339-5daa-4ecc-8f8d-0437b7d2fd27" xlink:href="bios-20201231.xsd#bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_00acce69-02dd-43fd-b7e3-91a256b70d14" xlink:to="loc_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward_2bfff339-5daa-4ecc-8f8d-0437b7d2fd27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46a4ec6c-7647-4ff9-be3a-d21688c7e0f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward_2bfff339-5daa-4ecc-8f8d-0437b7d2fd27" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46a4ec6c-7647-4ff9-be3a-d21688c7e0f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_498b087d-72a3-4725-8cc8-b1550b078a56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward_2bfff339-5daa-4ecc-8f8d-0437b7d2fd27" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_498b087d-72a3-4725-8cc8-b1550b078a56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9825ff4f-411c-4953-a113-3ec92e06b491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable_ca8111a2-096b-4d90-88a4-9ae5408209cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_00acce69-02dd-43fd-b7e3-91a256b70d14" xlink:to="loc_us-gaap_ValuationAllowanceTable_ca8111a2-096b-4d90-88a4-9ae5408209cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_8e26053a-a6a8-4bff-8837-64828c66c34a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAllowanceTable_ca8111a2-096b-4d90-88a4-9ae5408209cb" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_8e26053a-a6a8-4bff-8837-64828c66c34a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_8e26053a-a6a8-4bff-8837-64828c66c34a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_8e26053a-a6a8-4bff-8837-64828c66c34a" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_8e26053a-a6a8-4bff-8837-64828c66c34a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_768672ee-f918-4119-be4f-b89588d700bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_8e26053a-a6a8-4bff-8837-64828c66c34a" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_768672ee-f918-4119-be4f-b89588d700bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ChargedBenefitToCostsAndExpensesMember_d74965c7-c8a4-4148-b4eb-79f1e23aafd1" xlink:href="bios-20201231.xsd#bios_ChargedBenefitToCostsAndExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_768672ee-f918-4119-be4f-b89588d700bc" xlink:to="loc_bios_ChargedBenefitToCostsAndExpensesMember_d74965c7-c8a4-4148-b4eb-79f1e23aafd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ChargedToOtherAccountsMember_82db0f05-537e-49d6-a578-106c2dc30877" xlink:href="bios-20201231.xsd#bios_ChargedToOtherAccountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_768672ee-f918-4119-be4f-b89588d700bc" xlink:to="loc_bios_ChargedToOtherAccountsMember_82db0f05-537e-49d6-a578-106c2dc30877" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LOSSEARNINGSPERSHARE" xlink:type="simple" xlink:href="bios-20201231.xsd#LOSSEARNINGSPERSHARE"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/LOSSEARNINGSPERSHARE" xlink:type="extended" id="i6a8c312838f74d7db5179fbe71018d4c_LOSSEARNINGSPERSHARE"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LOSSEARNINGSPERSHARETables" xlink:type="simple" xlink:href="bios-20201231.xsd#LOSSEARNINGSPERSHARETables"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/LOSSEARNINGSPERSHARETables" xlink:type="extended" id="i118062b1f4eb40b483b6639476cbd6cb_LOSSEARNINGSPERSHARETables"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#LOSSEARNINGSPERSHAREDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails" xlink:type="extended" id="i49896e24fae44039b5a5d200a2cefb6c_LOSSEARNINGSPERSHAREDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53b9e3e-59f2-4463-bc3d-9d413fd7640f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_05cc884a-c803-4e0b-9539-ec03720d6e88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53b9e3e-59f2-4463-bc3d-9d413fd7640f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_05cc884a-c803-4e0b-9539-ec03720d6e88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecurities_02adcf49-b17e-416b-99f9-0a44dba36e58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53b9e3e-59f2-4463-bc3d-9d413fd7640f" xlink:to="loc_us-gaap_DilutiveSecurities_02adcf49-b17e-416b-99f9-0a44dba36e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_55e5180b-57ae-4d9c-9e97-322012274914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53b9e3e-59f2-4463-bc3d-9d413fd7640f" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_55e5180b-57ae-4d9c-9e97-322012274914" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e72c41d4-280a-4282-9aa1-5ea3c964c8e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_55e5180b-57ae-4d9c-9e97-322012274914" xlink:to="loc_us-gaap_NetIncomeLoss_e72c41d4-280a-4282-9aa1-5ea3c964c8e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_db169c75-fcac-4f99-9790-56c40d338176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53b9e3e-59f2-4463-bc3d-9d413fd7640f" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_db169c75-fcac-4f99-9790-56c40d338176" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_55448621-8030-47e2-a88f-bb30926d485d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_db169c75-fcac-4f99-9790-56c40d338176" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_55448621-8030-47e2-a88f-bb30926d485d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a10b159f-a06a-440e-8821-3fb2db0f4389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53b9e3e-59f2-4463-bc3d-9d413fd7640f" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a10b159f-a06a-440e-8821-3fb2db0f4389" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_4e0156c6-84a4-4118-905d-00f795c991dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a10b159f-a06a-440e-8821-3fb2db0f4389" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_4e0156c6-84a4-4118-905d-00f795c991dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_034bda29-0e3b-4635-a480-003c8115022d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53b9e3e-59f2-4463-bc3d-9d413fd7640f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_034bda29-0e3b-4635-a480-003c8115022d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_23db3a83-18a9-4693-81de-7c5d3e1632c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_034bda29-0e3b-4635-a480-003c8115022d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_23db3a83-18a9-4693-81de-7c5d3e1632c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23db3a83-18a9-4693-81de-7c5d3e1632c4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_23db3a83-18a9-4693-81de-7c5d3e1632c4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23db3a83-18a9-4693-81de-7c5d3e1632c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4e96c88a-c3ca-40a8-bc4e-d3cfca8caa9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_23db3a83-18a9-4693-81de-7c5d3e1632c4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4e96c88a-c3ca-40a8-bc4e-d3cfca8caa9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_727215ae-1be0-4693-9717-fecb3521ad78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4e96c88a-c3ca-40a8-bc4e-d3cfca8caa9a" xlink:to="loc_us-gaap_WarrantMember_727215ae-1be0-4693-9717-fecb3521ad78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_002a9ae6-be23-4934-bf11-6b097edf0ade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4e96c88a-c3ca-40a8-bc4e-d3cfca8caa9a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_002a9ae6-be23-4934-bf11-6b097edf0ade" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_RestrictedStockAwardMember_222dca34-349c-42ae-9d00-82b44b9da6f3" xlink:href="bios-20201231.xsd#bios_RestrictedStockAwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4e96c88a-c3ca-40a8-bc4e-d3cfca8caa9a" xlink:to="loc_bios_RestrictedStockAwardMember_222dca34-349c-42ae-9d00-82b44b9da6f3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASES" xlink:type="simple" xlink:href="bios-20201231.xsd#LEASES"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/LEASES" xlink:type="extended" id="id913bc64c3924779bf081eadfe0e0a77_LEASES"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASESTables" xlink:type="simple" xlink:href="bios-20201231.xsd#LEASESTables"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/LEASESTables" xlink:type="extended" id="idd1f0e684b074061833755ffbb70a9a8_LEASESTables"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#LEASESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" xlink:type="extended" id="i615db3a4b5fc498d9c4eebcfe5aafdc3_LEASESAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended" id="i07f11087ea8446e4850d979f1623884f_LEASESMaturitiesofLeaseLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="bios-20201231.xsd#PROPERTYANDEQUIPMENT"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended" id="id13f28e267b64fe8b9330ace697727ae_PROPERTYANDEQUIPMENT"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="bios-20201231.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended" id="i51bb379e2fb6424daaad0ef553d685cd_PROPERTYANDEQUIPMENTTables"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#PROPERTYANDEQUIPMENTDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="extended" id="i464e700db12040d981b6c4d9ba29e09d_PROPERTYANDEQUIPMENTDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_29edfb28-0b1a-456d-8ed9-af3ffdc06b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_29edfb28-0b1a-456d-8ed9-af3ffdc06b91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f3b4f3b3-e7dc-46cc-a79c-62c6b39d35c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f3b4f3b3-e7dc-46cc-a79c-62c6b39d35c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b29d7883-2e77-4963-a12a-3e6c842621a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b29d7883-2e77-4963-a12a-3e6c842621a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_36a63915-fda3-4012-a61c-66dd2182e408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:to="loc_us-gaap_Depreciation_36a63915-fda3-4012-a61c-66dd2182e408" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_00a8a70e-352f-4a07-877a-310df01669e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_00a8a70e-352f-4a07-877a-310df01669e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83a056df-2a82-483e-bf76-9c5a89d350f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83a056df-2a82-483e-bf76-9c5a89d350f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_87baff48-62b4-47f1-b43f-51a4b6a027e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_87baff48-62b4-47f1-b43f-51a4b6a027e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2fbecea-c08d-4f44-b8bc-501b6081ddae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2fbecea-c08d-4f44-b8bc-501b6081ddae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7e3d5e2-f29c-4d21-b858-4f3e85c8cdac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2fbecea-c08d-4f44-b8bc-501b6081ddae" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7e3d5e2-f29c-4d21-b858-4f3e85c8cdac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7e3d5e2-f29c-4d21-b858-4f3e85c8cdac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7e3d5e2-f29c-4d21-b858-4f3e85c8cdac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7e3d5e2-f29c-4d21-b858-4f3e85c8cdac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4968d08e-b506-4437-8627-085b8a7907d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7e3d5e2-f29c-4d21-b858-4f3e85c8cdac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4968d08e-b506-4437-8627-085b8a7907d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InfusionPumpsMember_5ab9ce1c-6346-4b0e-807f-c8f2a950ba58" xlink:href="bios-20201231.xsd#bios_InfusionPumpsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4968d08e-b506-4437-8627-085b8a7907d9" xlink:to="loc_bios_InfusionPumpsMember_5ab9ce1c-6346-4b0e-807f-c8f2a950ba58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_EquipmentFurnitureAndOtherMember_9692b0e9-9c82-4e42-8ffb-24c3531eaccf" xlink:href="bios-20201231.xsd#bios_EquipmentFurnitureAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4968d08e-b506-4437-8627-085b8a7907d9" xlink:to="loc_bios_EquipmentFurnitureAndOtherMember_9692b0e9-9c82-4e42-8ffb-24c3531eaccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ef68e25e-605c-492e-b3e0-7a1d1abcef02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4968d08e-b506-4437-8627-085b8a7907d9" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ef68e25e-605c-492e-b3e0-7a1d1abcef02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_659f3c26-e320-4a0f-ba2a-5142c37fba5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4968d08e-b506-4437-8627-085b8a7907d9" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_659f3c26-e320-4a0f-ba2a-5142c37fba5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember_f7cd3785-6bbf-46bb-9d0d-f8b37e1d952f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4968d08e-b506-4437-8627-085b8a7907d9" xlink:to="loc_us-gaap_AssetUnderConstructionMember_f7cd3785-6bbf-46bb-9d0d-f8b37e1d952f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9d5efdf1-719f-4f73-a574-b372c6a26b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2fbecea-c08d-4f44-b8bc-501b6081ddae" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9d5efdf1-719f-4f73-a574-b372c6a26b3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9d5efdf1-719f-4f73-a574-b372c6a26b3e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9d5efdf1-719f-4f73-a574-b372c6a26b3e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9d5efdf1-719f-4f73-a574-b372c6a26b3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d2f0e9c3-a861-4528-b642-f2a21ad477ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9d5efdf1-719f-4f73-a574-b372c6a26b3e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d2f0e9c3-a861-4528-b642-f2a21ad477ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_11d76b22-dd8a-42ea-aeaf-2cbacdf5a98e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2f0e9c3-a861-4528-b642-f2a21ad477ad" xlink:to="loc_us-gaap_CostOfSalesMember_11d76b22-dd8a-42ea-aeaf-2cbacdf5a98e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_0f725301-b07c-48a1-a9da-66e787496c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2f0e9c3-a861-4528-b642-f2a21ad477ad" xlink:to="loc_us-gaap_OperatingExpenseMember_0f725301-b07c-48a1-a9da-66e787496c0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f521dd6a-40a4-4e48-9091-f888632de666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2fbecea-c08d-4f44-b8bc-501b6081ddae" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f521dd6a-40a4-4e48-9091-f888632de666" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f521dd6a-40a4-4e48-9091-f888632de666_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f521dd6a-40a4-4e48-9091-f888632de666" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f521dd6a-40a4-4e48-9091-f888632de666_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7adaa63a-c33e-4393-a292-c9ca9b234c88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f521dd6a-40a4-4e48-9091-f888632de666" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7adaa63a-c33e-4393-a292-c9ca9b234c88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_3e46824a-e20e-46ba-8dd5-9a97e4d8663a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7adaa63a-c33e-4393-a292-c9ca9b234c88" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_3e46824a-e20e-46ba-8dd5-9a97e4d8663a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_fdfeeb99-4f10-4c4a-890f-32216557c2f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2fbecea-c08d-4f44-b8bc-501b6081ddae" xlink:to="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_fdfeeb99-4f10-4c4a-890f-32216557c2f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CatastrophicEventDomain_fdfeeb99-4f10-4c4a-890f-32216557c2f1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CatastrophicEventDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_fdfeeb99-4f10-4c4a-890f-32216557c2f1" xlink:to="loc_us-gaap_CatastrophicEventDomain_fdfeeb99-4f10-4c4a-890f-32216557c2f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CatastrophicEventDomain_b85bb116-98b5-4308-b376-abafe70850e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CatastrophicEventDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_fdfeeb99-4f10-4c4a-890f-32216557c2f1" xlink:to="loc_us-gaap_CatastrophicEventDomain_b85bb116-98b5-4308-b376-abafe70850e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HurricaneMember_f84fabbc-d662-4cad-a694-95f12726a746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HurricaneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CatastrophicEventDomain_b85bb116-98b5-4308-b376-abafe70850e3" xlink:to="loc_us-gaap_HurricaneMember_f84fabbc-d662-4cad-a694-95f12726a746" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETS"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" xlink:type="extended" id="i9d10518ee46945acaa1dde1038677167_GOODWILLANDOTHERINTANGIBLEASSETS"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSTables"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" xlink:type="extended" id="i4a46ffb073514ccf8788dbf20751663f_GOODWILLANDOTHERINTANGIBLEASSETSTables"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" xlink:type="extended" id="i00d79cecc9d34f1da4b0312d2440684b_GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails" xlink:type="extended" id="i8058d165e12d46468f17a5c17dbcf27c_GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="extended" id="i3a34c781caaf4cb482b40d0585e4e23c_GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b0897608-c4e6-4bde-afb4-b9f665135e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_38990b2d-1336-4d2a-9134-612f7722a468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b0897608-c4e6-4bde-afb4-b9f665135e9a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_38990b2d-1336-4d2a-9134-612f7722a468" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_361dac1a-6da1-448e-8fc1-72c4b3d35cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b0897608-c4e6-4bde-afb4-b9f665135e9a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_361dac1a-6da1-448e-8fc1-72c4b3d35cf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a01e23f-6828-4572-beb1-90f92503fdc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b0897608-c4e6-4bde-afb4-b9f665135e9a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a01e23f-6828-4572-beb1-90f92503fdc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9601ddfa-657d-4488-a0ab-65593b464fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b0897608-c4e6-4bde-afb4-b9f665135e9a" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9601ddfa-657d-4488-a0ab-65593b464fa2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44fcc267-ea95-4c85-8d7b-a669625fed0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9601ddfa-657d-4488-a0ab-65593b464fa2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44fcc267-ea95-4c85-8d7b-a669625fed0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_44fcc267-ea95-4c85-8d7b-a669625fed0d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44fcc267-ea95-4c85-8d7b-a669625fed0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_44fcc267-ea95-4c85-8d7b-a669625fed0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59f710f3-a202-452d-ab5c-4c6aed168ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44fcc267-ea95-4c85-8d7b-a669625fed0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59f710f3-a202-452d-ab5c-4c6aed168ec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerListsMember_41362766-c3f7-4f12-aedf-59952193a38d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerListsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59f710f3-a202-452d-ab5c-4c6aed168ec0" xlink:to="loc_us-gaap_CustomerListsMember_41362766-c3f7-4f12-aedf-59952193a38d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_8f02eeb2-f74e-4c9b-a0e0-e05b191ea4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59f710f3-a202-452d-ab5c-4c6aed168ec0" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_8f02eeb2-f74e-4c9b-a0e0-e05b191ea4fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_0e9d1b1a-0f83-41eb-af50-4d6535386559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59f710f3-a202-452d-ab5c-4c6aed168ec0" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_0e9d1b1a-0f83-41eb-af50-4d6535386559" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails" xlink:type="extended" id="i5092a66961594956a1a3e0bf1fb8f8e5_GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESS" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESS"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESS" xlink:type="extended" id="i4ae2188813e0439db7814a6e6d0dc6e0_INDEBTEDNESS"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSTables" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESSTables"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSTables" xlink:type="extended" id="ia4781e5a1818412a8b78f809329015fe_INDEBTEDNESSTables"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESSSummaryofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" xlink:type="extended" id="i7b61db58321b4f729b5df97bdf7e5ccd_INDEBTEDNESSSummaryofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ad5892e1-cd6d-4f54-8c7a-7d32bb57705b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_273517e2-6009-4637-903a-59588ba6d477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad5892e1-cd6d-4f54-8c7a-7d32bb57705b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_273517e2-6009-4637-903a-59588ba6d477" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2f5d077d-c32e-4eab-823f-60dcaccb4aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad5892e1-cd6d-4f54-8c7a-7d32bb57705b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2f5d077d-c32e-4eab-823f-60dcaccb4aa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_70193fd1-fbf9-4b96-a731-d15da5055310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad5892e1-cd6d-4f54-8c7a-7d32bb57705b" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_70193fd1-fbf9-4b96-a731-d15da5055310" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e4e7daf5-8ede-4e7d-87b1-ef63fde09f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad5892e1-cd6d-4f54-8c7a-7d32bb57705b" xlink:to="loc_us-gaap_LongTermDebt_e4e7daf5-8ede-4e7d-87b1-ef63fde09f26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f61fcec7-fe68-4e14-8065-c14e2e4b1198" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad5892e1-cd6d-4f54-8c7a-7d32bb57705b" xlink:to="loc_us-gaap_LongTermDebtCurrent_f61fcec7-fe68-4e14-8065-c14e2e4b1198" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_581ec676-79cb-45e8-b1f4-0cd3560081f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad5892e1-cd6d-4f54-8c7a-7d32bb57705b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_581ec676-79cb-45e8-b1f4-0cd3560081f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_997d616d-0305-4736-8414-13c381da1ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad5892e1-cd6d-4f54-8c7a-7d32bb57705b" xlink:to="loc_us-gaap_DebtInstrumentTable_997d616d-0305-4736-8414-13c381da1ea7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_64ce7404-62c8-4124-afba-0f6e58210055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_997d616d-0305-4736-8414-13c381da1ea7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_64ce7404-62c8-4124-afba-0f6e58210055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_64ce7404-62c8-4124-afba-0f6e58210055_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_64ce7404-62c8-4124-afba-0f6e58210055" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_64ce7404-62c8-4124-afba-0f6e58210055_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2765174b-889e-4b38-88a5-8e1fb809109d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_64ce7404-62c8-4124-afba-0f6e58210055" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2765174b-889e-4b38-88a5-8e1fb809109d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_7db989d6-1802-41dd-9d04-c076cb1a8216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2765174b-889e-4b38-88a5-8e1fb809109d" xlink:to="loc_us-gaap_SeniorNotesMember_7db989d6-1802-41dd-9d04-c076cb1a8216" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7b8d3fc4-c1d3-43bf-ae30-5be46dd32985" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_997d616d-0305-4736-8414-13c381da1ea7" xlink:to="loc_us-gaap_CreditFacilityAxis_7b8d3fc4-c1d3-43bf-ae30-5be46dd32985" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7b8d3fc4-c1d3-43bf-ae30-5be46dd32985_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_7b8d3fc4-c1d3-43bf-ae30-5be46dd32985" xlink:to="loc_us-gaap_CreditFacilityDomain_7b8d3fc4-c1d3-43bf-ae30-5be46dd32985_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c2eae316-b128-4c51-9f93-78dc705d72f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_7b8d3fc4-c1d3-43bf-ae30-5be46dd32985" xlink:to="loc_us-gaap_CreditFacilityDomain_c2eae316-b128-4c51-9f93-78dc705d72f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4c4a6512-c057-4b3c-998d-7b0421bf94f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c2eae316-b128-4c51-9f93-78dc705d72f4" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4c4a6512-c057-4b3c-998d-7b0421bf94f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_843255ac-da07-4cfd-a2ee-cdc3b32a0d36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_997d616d-0305-4736-8414-13c381da1ea7" xlink:to="loc_us-gaap_DebtInstrumentAxis_843255ac-da07-4cfd-a2ee-cdc3b32a0d36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_843255ac-da07-4cfd-a2ee-cdc3b32a0d36_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_843255ac-da07-4cfd-a2ee-cdc3b32a0d36" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_843255ac-da07-4cfd-a2ee-cdc3b32a0d36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e5dad105-ad7e-49d4-b118-bf7faa0c5c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_843255ac-da07-4cfd-a2ee-cdc3b32a0d36" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e5dad105-ad7e-49d4-b118-bf7faa0c5c38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FirstLienTermLoanMember_a879747e-6bfd-475b-83c8-e262c5aca284" xlink:href="bios-20201231.xsd#bios_FirstLienTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5dad105-ad7e-49d4-b118-bf7faa0c5c38" xlink:to="loc_bios_FirstLienTermLoanMember_a879747e-6bfd-475b-83c8-e262c5aca284" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SecondLienTermLoanMember_d074efe4-5a1e-4e8c-aeb4-0cf353207a7e" xlink:href="bios-20201231.xsd#bios_SecondLienTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5dad105-ad7e-49d4-b118-bf7faa0c5c38" xlink:to="loc_bios_SecondLienTermLoanMember_d074efe4-5a1e-4e8c-aeb4-0cf353207a7e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" xlink:type="extended" id="i1fc8f53b902b4de382118944618cbdea_INDEBTEDNESSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_91b4c5cb-1e1b-40e3-adca-837eba3cac9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_91b4c5cb-1e1b-40e3-adca-837eba3cac9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_555a448b-7115-466e-b84d-31b107430811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_555a448b-7115-466e-b84d-31b107430811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_9386dc7a-a0c2-4fc9-9d6c-94a2499d2cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_9386dc7a-a0c2-4fc9-9d6c-94a2499d2cee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_c2f4a72b-84e3-4120-b838-86f055cf5884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_c2f4a72b-84e3-4120-b838-86f055cf5884" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DebtInstrumentBaseRate_624c0055-d1e5-48e2-8d6c-1086e8b19114" xlink:href="bios-20201231.xsd#bios_DebtInstrumentBaseRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_bios_DebtInstrumentBaseRate_624c0055-d1e5-48e2-8d6c-1086e8b19114" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_008f44be-f599-4cad-b060-ce99790357d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_008f44be-f599-4cad-b060-ce99790357d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_c82d49c9-a52e-4628-b6dc-8e92d4024dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_c82d49c9-a52e-4628-b6dc-8e92d4024dd4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_bd4968d4-d92e-46a0-ab6d-cc6beae4f0fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_bd4968d4-d92e-46a0-ab6d-cc6beae4f0fd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5eb58b0d-ea54-4ba0-8625-b9af438ee45e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_LongTermDebt_5eb58b0d-ea54-4ba0-8625-b9af438ee45e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_929b73e3-9195-4542-bdbf-d98e2d8a803c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_929b73e3-9195-4542-bdbf-d98e2d8a803c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_399aabb2-a4e2-4fab-8b32-c42e4ff2a716" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_399aabb2-a4e2-4fab-8b32-c42e4ff2a716" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a927c817-184c-4db6-83e6-146adbe6d56f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a927c817-184c-4db6-83e6-146adbe6d56f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InterestCapitalizedToDebtPrincipal_e335e7fb-a024-4f62-a145-c1154243f876" xlink:href="bios-20201231.xsd#bios_InterestCapitalizedToDebtPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_bios_InterestCapitalizedToDebtPrincipal_e335e7fb-a024-4f62-a145-c1154243f876" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_a14766e1-690e-4c9e-9680-749cda5e70ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_PaidInKindInterest_a14766e1-690e-4c9e-9680-749cda5e70ef" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PaidInKindInterestAdditionalInterestExpense_ece92e20-6080-449f-ac3a-18c67533504c" xlink:href="bios-20201231.xsd#bios_PaidInKindInterestAdditionalInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_bios_PaidInKindInterestAdditionalInterestExpense_ece92e20-6080-449f-ac3a-18c67533504c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_d8157a7a-0467-4be0-bdc6-dc2cee7a57f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_d8157a7a-0467-4be0-bdc6-dc2cee7a57f2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_87f02b37-987a-44f1-811e-ab4e2cfa86f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_RepaymentsOfDebt_87f02b37-987a-44f1-811e-ab4e2cfa86f2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a29917b3-dd5b-4ad5-a730-f207b3dbec7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a29917b3-dd5b-4ad5-a730-f207b3dbec7f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FinancingReceivablePrepaymentPenalty_13775e08-b079-44bf-aa1a-fa814ac7953b" xlink:href="bios-20201231.xsd#bios_FinancingReceivablePrepaymentPenalty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_bios_FinancingReceivablePrepaymentPenalty_13775e08-b079-44bf-aa1a-fa814ac7953b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableDeferredIncome_20115ea9-d0c1-4e15-9b6e-c33ffe62f962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancingReceivableDeferredIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_FinancingReceivableDeferredIncome_20115ea9-d0c1-4e15-9b6e-c33ffe62f962" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_567cc616-e985-488a-8bb0-f4a65f104d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_567cc616-e985-488a-8bb0-f4a65f104d3b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_beb6cc81-1c94-4022-ba6d-47baa483614e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_beb6cc81-1c94-4022-ba6d-47baa483614e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_57db3626-b106-4314-961a-a9ebacdd8f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_57db3626-b106-4314-961a-a9ebacdd8f80" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_d2de36bd-d2a9-4e78-bbdb-0d507898c535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_d2de36bd-d2a9-4e78-bbdb-0d507898c535" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1135fe6d-b213-4b26-b764-f6dd9f881371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1135fe6d-b213-4b26-b764-f6dd9f881371" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_11265340-9a09-4b9f-a37b-042538bcf13e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_11265340-9a09-4b9f-a37b-042538bcf13e" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PaymentsOfDebtIssuanceCostsInvestingActivities_e4fcf761-58a3-457e-ae22-b82de6489a81" xlink:href="bios-20201231.xsd#bios_PaymentsOfDebtIssuanceCostsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_bios_PaymentsOfDebtIssuanceCostsInvestingActivities_e4fcf761-58a3-457e-ae22-b82de6489a81" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_edca0877-891e-46c9-ac1d-4b7571ffa30f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_edca0877-891e-46c9-ac1d-4b7571ffa30f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_edca0877-891e-46c9-ac1d-4b7571ffa30f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_edca0877-891e-46c9-ac1d-4b7571ffa30f" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_edca0877-891e-46c9-ac1d-4b7571ffa30f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_637ec220-d380-4064-ba24-903a691d4771" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_edca0877-891e-46c9-ac1d-4b7571ffa30f" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_637ec220-d380-4064-ba24-903a691d4771" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BankOfAmericaN.A.Member_0cd98bb2-7659-488c-a024-d3ed43ddfaba" xlink:href="bios-20201231.xsd#bios_BankOfAmericaN.A.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_637ec220-d380-4064-ba24-903a691d4771" xlink:to="loc_bios_BankOfAmericaN.A.Member_0cd98bb2-7659-488c-a024-d3ed43ddfaba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryAxis_9a0c4dc6-cfc0-4755-b2a3-0f5b2e6d2d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_LienCategoryAxis_9a0c4dc6-cfc0-4755-b2a3-0f5b2e6d2d13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_9a0c4dc6-cfc0-4755-b2a3-0f5b2e6d2d13_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LienCategoryAxis_9a0c4dc6-cfc0-4755-b2a3-0f5b2e6d2d13" xlink:to="loc_us-gaap_LienCategoryDomain_9a0c4dc6-cfc0-4755-b2a3-0f5b2e6d2d13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_241b0337-32b3-4cbd-887e-4ceb34811d1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LienCategoryAxis_9a0c4dc6-cfc0-4755-b2a3-0f5b2e6d2d13" xlink:to="loc_us-gaap_LienCategoryDomain_241b0337-32b3-4cbd-887e-4ceb34811d1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLienMember_7dc49d07-34ac-44a3-b18d-af419f74a462" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorLienMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LienCategoryDomain_241b0337-32b3-4cbd-887e-4ceb34811d1b" xlink:to="loc_us-gaap_SeniorLienMember_7dc49d07-34ac-44a3-b18d-af419f74a462" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JuniorLienMember_2622b45e-df5f-4147-be96-78f1a55e9ea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_JuniorLienMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LienCategoryDomain_241b0337-32b3-4cbd-887e-4ceb34811d1b" xlink:to="loc_us-gaap_JuniorLienMember_2622b45e-df5f-4147-be96-78f1a55e9ea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f7fce659-8825-4c53-a692-002dd9673423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_CreditFacilityAxis_f7fce659-8825-4c53-a692-002dd9673423" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f7fce659-8825-4c53-a692-002dd9673423_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_f7fce659-8825-4c53-a692-002dd9673423" xlink:to="loc_us-gaap_CreditFacilityDomain_f7fce659-8825-4c53-a692-002dd9673423_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d9308b40-708c-4ef6-807d-60970e7591d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_f7fce659-8825-4c53-a692-002dd9673423" xlink:to="loc_us-gaap_CreditFacilityDomain_d9308b40-708c-4ef6-807d-60970e7591d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_aee0c9c3-0ebd-4860-9ab8-ab398778280c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d9308b40-708c-4ef6-807d-60970e7591d1" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_aee0c9c3-0ebd-4860-9ab8-ab398778280c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_a03f6440-24a4-48d1-a410-0508a5801767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d9308b40-708c-4ef6-807d-60970e7591d1" xlink:to="loc_us-gaap_LetterOfCreditMember_a03f6440-24a4-48d1-a410-0508a5801767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_14b0093c-8dab-4d5b-85eb-4554822c7971" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_srt_RangeAxis_14b0093c-8dab-4d5b-85eb-4554822c7971" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_14b0093c-8dab-4d5b-85eb-4554822c7971_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_14b0093c-8dab-4d5b-85eb-4554822c7971" xlink:to="loc_srt_RangeMember_14b0093c-8dab-4d5b-85eb-4554822c7971_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2550336d-e78b-4907-a5fa-7830eb1b037e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_14b0093c-8dab-4d5b-85eb-4554822c7971" xlink:to="loc_srt_RangeMember_2550336d-e78b-4907-a5fa-7830eb1b037e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8d7f8d24-51c9-4c0e-a707-292a41020303" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2550336d-e78b-4907-a5fa-7830eb1b037e" xlink:to="loc_srt_MinimumMember_8d7f8d24-51c9-4c0e-a707-292a41020303" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9128bcae-357f-479f-bb29-047034adcbb2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2550336d-e78b-4907-a5fa-7830eb1b037e" xlink:to="loc_srt_MaximumMember_9128bcae-357f-479f-bb29-047034adcbb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5bc4ab4a-4800-45ff-8d28-a1551316bab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_DebtInstrumentAxis_5bc4ab4a-4800-45ff-8d28-a1551316bab3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5bc4ab4a-4800-45ff-8d28-a1551316bab3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5bc4ab4a-4800-45ff-8d28-a1551316bab3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5bc4ab4a-4800-45ff-8d28-a1551316bab3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d22b2a4a-9b99-46fc-b062-f638dcf0110c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5bc4ab4a-4800-45ff-8d28-a1551316bab3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d22b2a4a-9b99-46fc-b062-f638dcf0110c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditArrangementsEnteredInto2015Member_81e7782b-67bf-4de5-8f4c-d3ffee9ed169" xlink:href="bios-20201231.xsd#bios_CreditArrangementsEnteredInto2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d22b2a4a-9b99-46fc-b062-f638dcf0110c" xlink:to="loc_bios_CreditArrangementsEnteredInto2015Member_81e7782b-67bf-4de5-8f4c-d3ffee9ed169" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditAgreementsEnteredInto2019Member_6742e895-2dc2-40e0-b34d-2b612de382d6" xlink:href="bios-20201231.xsd#bios_CreditAgreementsEnteredInto2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d22b2a4a-9b99-46fc-b062-f638dcf0110c" xlink:to="loc_bios_CreditAgreementsEnteredInto2019Member_6742e895-2dc2-40e0-b34d-2b612de382d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditArrangementsEnteredInto2015ModifiedLoansMember_61046455-ba45-444b-b679-e99c5588973c" xlink:href="bios-20201231.xsd#bios_CreditArrangementsEnteredInto2015ModifiedLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d22b2a4a-9b99-46fc-b062-f638dcf0110c" xlink:to="loc_bios_CreditArrangementsEnteredInto2015ModifiedLoansMember_61046455-ba45-444b-b679-e99c5588973c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2158126e-b078-4ae2-b8b7-11f26ce9b859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2158126e-b078-4ae2-b8b7-11f26ce9b859" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2158126e-b078-4ae2-b8b7-11f26ce9b859_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2158126e-b078-4ae2-b8b7-11f26ce9b859" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2158126e-b078-4ae2-b8b7-11f26ce9b859_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_206067e5-4d94-408c-8ead-b59f54bac587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2158126e-b078-4ae2-b8b7-11f26ce9b859" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_206067e5-4d94-408c-8ead-b59f54bac587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e7165bba-aad7-4aff-a826-dbd02b702db6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_206067e5-4d94-408c-8ead-b59f54bac587" xlink:to="loc_us-gaap_SeniorNotesMember_e7165bba-aad7-4aff-a826-dbd02b702db6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NotesPayableMember_0544e21a-2d52-4073-bc18-6610de2ae31d" xlink:href="bios-20201231.xsd#bios_NotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_206067e5-4d94-408c-8ead-b59f54bac587" xlink:to="loc_bios_NotesPayableMember_0544e21a-2d52-4073-bc18-6610de2ae31d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c3d077c1-6dfb-4fad-98cb-ab4d846cc128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_VariableRateAxis_c3d077c1-6dfb-4fad-98cb-ab4d846cc128" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c3d077c1-6dfb-4fad-98cb-ab4d846cc128_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_c3d077c1-6dfb-4fad-98cb-ab4d846cc128" xlink:to="loc_us-gaap_VariableRateDomain_c3d077c1-6dfb-4fad-98cb-ab4d846cc128_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_471c0935-cede-4e60-a80c-d5ac6e2dfdf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_c3d077c1-6dfb-4fad-98cb-ab4d846cc128" xlink:to="loc_us-gaap_VariableRateDomain_471c0935-cede-4e60-a80c-d5ac6e2dfdf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_71e48756-9b07-43f3-9dee-f326ccb4ff1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_471c0935-cede-4e60-a80c-d5ac6e2dfdf8" xlink:to="loc_us-gaap_BaseRateMember_71e48756-9b07-43f3-9dee-f326ccb4ff1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_49dd7622-3d27-4313-ac88-b6b28b59a770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_471c0935-cede-4e60-a80c-d5ac6e2dfdf8" xlink:to="loc_us-gaap_EurodollarMember_49dd7622-3d27-4313-ac88-b6b28b59a770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d7cca4ac-03d7-468b-83da-5442e903d905" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_471c0935-cede-4e60-a80c-d5ac6e2dfdf8" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d7cca4ac-03d7-468b-83da-5442e903d905" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f5cbde33-157a-4047-bb86-784e00f11ca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f5cbde33-157a-4047-bb86-784e00f11ca3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f5cbde33-157a-4047-bb86-784e00f11ca3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f5cbde33-157a-4047-bb86-784e00f11ca3" xlink:to="loc_us-gaap_ClassOfStockDomain_f5cbde33-157a-4047-bb86-784e00f11ca3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_27956f08-0065-47f3-bb8b-be0559223687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f5cbde33-157a-4047-bb86-784e00f11ca3" xlink:to="loc_us-gaap_ClassOfStockDomain_27956f08-0065-47f3-bb8b-be0559223687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cc9262e7-a899-4856-8dae-38f6d4dc7dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_27956f08-0065-47f3-bb8b-be0559223687" xlink:to="loc_us-gaap_CommonStockMember_cc9262e7-a899-4856-8dae-38f6d4dc7dc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bf8e7a87-459e-4be7-afe7-614ed3db8acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bf8e7a87-459e-4be7-afe7-614ed3db8acf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf8e7a87-459e-4be7-afe7-614ed3db8acf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bf8e7a87-459e-4be7-afe7-614ed3db8acf" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf8e7a87-459e-4be7-afe7-614ed3db8acf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0ab52c5-9489-4eac-bcf7-82abdbf1dc74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bf8e7a87-459e-4be7-afe7-614ed3db8acf" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0ab52c5-9489-4eac-bcf7-82abdbf1dc74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PublicOfferingMember_c2f9a8e3-0d48-4ebb-b6da-8f51842f2c0e" xlink:href="bios-20201231.xsd#bios_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0ab52c5-9489-4eac-bcf7-82abdbf1dc74" xlink:to="loc_bios_PublicOfferingMember_c2f9a8e3-0d48-4ebb-b6da-8f51842f2c0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6881f7aa-0b6f-48dc-9b9f-5e2c8814d89a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6881f7aa-0b6f-48dc-9b9f-5e2c8814d89a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6881f7aa-0b6f-48dc-9b9f-5e2c8814d89a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6881f7aa-0b6f-48dc-9b9f-5e2c8814d89a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6881f7aa-0b6f-48dc-9b9f-5e2c8814d89a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_94121ca5-26df-4503-bf34-c3a84b3ecf71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6881f7aa-0b6f-48dc-9b9f-5e2c8814d89a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_94121ca5-26df-4503-bf34-c3a84b3ecf71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_39b3e3c8-f8b7-4c5a-ae7e-3101e2e16287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_94121ca5-26df-4503-bf34-c3a84b3ecf71" xlink:to="loc_us-gaap_SubsequentEventMember_39b3e3c8-f8b7-4c5a-ae7e-3101e2e16287" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESSLongtermDebtMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails" xlink:type="extended" id="if0dcaaea4c3140d9b0b897f705a7f0a2_INDEBTEDNESSLongtermDebtMaturitiesDetails"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" xlink:type="extended" id="i37883b33c3b64a30b4ec48c443be1580_INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0946708f-70ba-41ca-a10d-3d13939ff654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_1e78819d-186f-44e7-a93d-7c3c20d43ce5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0946708f-70ba-41ca-a10d-3d13939ff654" xlink:to="loc_us-gaap_LongTermDebtFairValue_1e78819d-186f-44e7-a93d-7c3c20d43ce5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DebtInstrumentChangesInLongTermDebtRollForward_b123bed2-3b98-4294-a0b5-acc51c7a9e13" xlink:href="bios-20201231.xsd#bios_DebtInstrumentChangesInLongTermDebtRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0946708f-70ba-41ca-a10d-3d13939ff654" xlink:to="loc_bios_DebtInstrumentChangesInLongTermDebtRollForward_b123bed2-3b98-4294-a0b5-acc51c7a9e13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_c4bf5548-a27a-4d7f-a1da-70b77e1d0036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_588ce86c-9cc6-4622-9f5f-6a68cca0014c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bios_DebtInstrumentChangesInLongTermDebtRollForward_b123bed2-3b98-4294-a0b5-acc51c7a9e13" xlink:to="loc_us-gaap_RepaymentsOfDebt_588ce86c-9cc6-4622-9f5f-6a68cca0014c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_382fef08-fc2f-4a2a-96db-fbfea7db4eff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bios_DebtInstrumentChangesInLongTermDebtRollForward_b123bed2-3b98-4294-a0b5-acc51c7a9e13" xlink:to="loc_us-gaap_PaidInKindInterest_382fef08-fc2f-4a2a-96db-fbfea7db4eff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_a076a18d-fc9d-41d6-abb3-d670b5ebc763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bios_DebtInstrumentChangesInLongTermDebtRollForward_b123bed2-3b98-4294-a0b5-acc51c7a9e13" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_a076a18d-fc9d-41d6-abb3-d670b5ebc763" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_02b8410c-50dd-40f5-97a9-3c09aaa6bd2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3b1a3fcc-db71-44a5-8c70-88bef0052fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0946708f-70ba-41ca-a10d-3d13939ff654" xlink:to="loc_us-gaap_DebtInstrumentTable_3b1a3fcc-db71-44a5-8c70-88bef0052fbd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_276e9ca0-a3a5-4b24-ae8f-4c75ed5d1ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3b1a3fcc-db71-44a5-8c70-88bef0052fbd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_276e9ca0-a3a5-4b24-ae8f-4c75ed5d1ce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_276e9ca0-a3a5-4b24-ae8f-4c75ed5d1ce4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_276e9ca0-a3a5-4b24-ae8f-4c75ed5d1ce4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_276e9ca0-a3a5-4b24-ae8f-4c75ed5d1ce4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c2ba7550-e9cf-481e-b1b0-10c2bd8215b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_276e9ca0-a3a5-4b24-ae8f-4c75ed5d1ce4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c2ba7550-e9cf-481e-b1b0-10c2bd8215b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ab0fa876-8437-4762-ab46-c6b729929c17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c2ba7550-e9cf-481e-b1b0-10c2bd8215b3" xlink:to="loc_us-gaap_SeniorNotesMember_ab0fa876-8437-4762-ab46-c6b729929c17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_766a723e-3179-47d0-897b-3fac41586256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3b1a3fcc-db71-44a5-8c70-88bef0052fbd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_766a723e-3179-47d0-897b-3fac41586256" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_766a723e-3179-47d0-897b-3fac41586256_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_766a723e-3179-47d0-897b-3fac41586256" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_766a723e-3179-47d0-897b-3fac41586256_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e8cdc36-21f1-4c0b-b7ac-05fd295784c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_766a723e-3179-47d0-897b-3fac41586256" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e8cdc36-21f1-4c0b-b7ac-05fd295784c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_69d55468-61cb-487d-b605-e293ac7d558c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e8cdc36-21f1-4c0b-b7ac-05fd295784c0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_69d55468-61cb-487d-b605-e293ac7d558c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f9d19ba5-2a6d-4b9c-b215-af9f98d36826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e8cdc36-21f1-4c0b-b7ac-05fd295784c0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f9d19ba5-2a6d-4b9c-b215-af9f98d36826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_52dee3ed-28c3-4ad9-a8df-ef3b691eb0ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e8cdc36-21f1-4c0b-b7ac-05fd295784c0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_52dee3ed-28c3-4ad9-a8df-ef3b691eb0ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_715bd3e7-80fd-4f75-952e-f312f3f2ec61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3b1a3fcc-db71-44a5-8c70-88bef0052fbd" xlink:to="loc_us-gaap_DebtInstrumentAxis_715bd3e7-80fd-4f75-952e-f312f3f2ec61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_715bd3e7-80fd-4f75-952e-f312f3f2ec61_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_715bd3e7-80fd-4f75-952e-f312f3f2ec61" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_715bd3e7-80fd-4f75-952e-f312f3f2ec61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8b496d16-e5d4-4fb3-aad6-ea8c4d6390e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_715bd3e7-80fd-4f75-952e-f312f3f2ec61" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8b496d16-e5d4-4fb3-aad6-ea8c4d6390e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FirstLienTermLoanMember_47dac977-2788-496c-963a-c3004de7acca" xlink:href="bios-20201231.xsd#bios_FirstLienTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b496d16-e5d4-4fb3-aad6-ea8c4d6390e8" xlink:to="loc_bios_FirstLienTermLoanMember_47dac977-2788-496c-963a-c3004de7acca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SecondLienTermLoanMember_c1fa72a0-77c3-499a-bea9-7d3779fbcd54" xlink:href="bios-20201231.xsd#bios_SecondLienTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b496d16-e5d4-4fb3-aad6-ea8c4d6390e8" xlink:to="loc_bios_SecondLienTermLoanMember_c1fa72a0-77c3-499a-bea9-7d3779fbcd54" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS" xlink:type="simple" xlink:href="bios-20201231.xsd#DERIVATIVEINSTRUMENTS"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS" xlink:type="extended" id="i6b968cbe172a417c891c12466b1402cd_DERIVATIVEINSTRUMENTS"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables" xlink:type="simple" xlink:href="bios-20201231.xsd#DERIVATIVEINSTRUMENTSTables"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables" xlink:type="extended" id="ic166ace2a8fc452b8a2e75f04f63bbfd_DERIVATIVEINSTRUMENTSTables"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#DERIVATIVEINSTRUMENTSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails" xlink:type="extended" id="i0780da0abddb46179df4f06d1b6cddcc_DERIVATIVEINSTRUMENTSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_379f731f-b012-4344-bb8e-ae301589775a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_54d9e69e-b42c-422f-8cd4-d729082d0458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_379f731f-b012-4344-bb8e-ae301589775a" xlink:to="loc_us-gaap_DerivativeNotionalAmount_54d9e69e-b42c-422f-8cd4-d729082d0458" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_5f0ab66b-91fe-4cdd-9f84-2f7bb4adef51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_379f731f-b012-4344-bb8e-ae301589775a" xlink:to="loc_us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_5f0ab66b-91fe-4cdd-9f84-2f7bb4adef51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_1c98b98b-3c26-49ec-9325-9a25e43cad4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_379f731f-b012-4344-bb8e-ae301589775a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_1c98b98b-3c26-49ec-9325-9a25e43cad4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_19f5abdf-25f6-4cb9-82f0-226eb3f8eb3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_379f731f-b012-4344-bb8e-ae301589775a" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_19f5abdf-25f6-4cb9-82f0-226eb3f8eb3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_379f731f-b012-4344-bb8e-ae301589775a" xlink:to="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_51c57f26-5beb-48e0-ac48-426bf4b4050c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_51c57f26-5beb-48e0-ac48-426bf4b4050c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_51c57f26-5beb-48e0-ac48-426bf4b4050c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_51c57f26-5beb-48e0-ac48-426bf4b4050c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_51c57f26-5beb-48e0-ac48-426bf4b4050c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7373bb40-4788-4111-aca9-a9990b609955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_51c57f26-5beb-48e0-ac48-426bf4b4050c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7373bb40-4788-4111-aca9-a9990b609955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_ec89c6d7-4395-47f8-8c6c-9a93dfb7aff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7373bb40-4788-4111-aca9-a9990b609955" xlink:to="loc_us-gaap_CashFlowHedgingMember_ec89c6d7-4395-47f8-8c6c-9a93dfb7aff4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_24a2579d-9327-4c97-8f1e-99594cae7da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:to="loc_us-gaap_HedgingDesignationAxis_24a2579d-9327-4c97-8f1e-99594cae7da8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_24a2579d-9327-4c97-8f1e-99594cae7da8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_24a2579d-9327-4c97-8f1e-99594cae7da8" xlink:to="loc_us-gaap_HedgingDesignationDomain_24a2579d-9327-4c97-8f1e-99594cae7da8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_14f5b446-543c-444b-bd79-6b87f9ac66dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_24a2579d-9327-4c97-8f1e-99594cae7da8" xlink:to="loc_us-gaap_HedgingDesignationDomain_14f5b446-543c-444b-bd79-6b87f9ac66dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_fef6cfd6-f752-430b-b48e-eace97aebfdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_14f5b446-543c-444b-bd79-6b87f9ac66dd" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_fef6cfd6-f752-430b-b48e-eace97aebfdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8392d2fa-fa44-46ba-be4d-6fa41db505fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_14f5b446-543c-444b-bd79-6b87f9ac66dd" xlink:to="loc_us-gaap_NondesignatedMember_8392d2fa-fa44-46ba-be4d-6fa41db505fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_eb0a8302-e52a-4ec8-bd95-ed9062df4234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_eb0a8302-e52a-4ec8-bd95-ed9062df4234" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_eb0a8302-e52a-4ec8-bd95-ed9062df4234_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_eb0a8302-e52a-4ec8-bd95-ed9062df4234" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_eb0a8302-e52a-4ec8-bd95-ed9062df4234_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e5822e95-3076-4b65-a7a3-404ce0090da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_eb0a8302-e52a-4ec8-bd95-ed9062df4234" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e5822e95-3076-4b65-a7a3-404ce0090da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_58727431-fb82-4305-b9d9-9427d18f17c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e5822e95-3076-4b65-a7a3-404ce0090da4" xlink:to="loc_us-gaap_SeniorNotesMember_58727431-fb82-4305-b9d9-9427d18f17c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryAxis_e4d048e2-3b5c-4895-b91b-ae3371bc045d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:to="loc_us-gaap_LienCategoryAxis_e4d048e2-3b5c-4895-b91b-ae3371bc045d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_e4d048e2-3b5c-4895-b91b-ae3371bc045d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LienCategoryAxis_e4d048e2-3b5c-4895-b91b-ae3371bc045d" xlink:to="loc_us-gaap_LienCategoryDomain_e4d048e2-3b5c-4895-b91b-ae3371bc045d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_c0fbce8f-3ea0-4b74-af04-f87ed2b8d954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LienCategoryAxis_e4d048e2-3b5c-4895-b91b-ae3371bc045d" xlink:to="loc_us-gaap_LienCategoryDomain_c0fbce8f-3ea0-4b74-af04-f87ed2b8d954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLienMember_52e5ac53-3189-4298-b8ca-d3ee049e5dd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorLienMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LienCategoryDomain_c0fbce8f-3ea0-4b74-af04-f87ed2b8d954" xlink:to="loc_us-gaap_SeniorLienMember_52e5ac53-3189-4298-b8ca-d3ee049e5dd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JuniorLienMember_f644fea6-1be5-44af-bf8e-99991f0ecc95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_JuniorLienMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LienCategoryDomain_c0fbce8f-3ea0-4b74-af04-f87ed2b8d954" xlink:to="loc_us-gaap_JuniorLienMember_f644fea6-1be5-44af-bf8e-99991f0ecc95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3a0897c8-e292-4bd3-b6d0-e5bc539ea889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:to="loc_us-gaap_DebtInstrumentAxis_3a0897c8-e292-4bd3-b6d0-e5bc539ea889" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3a0897c8-e292-4bd3-b6d0-e5bc539ea889_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3a0897c8-e292-4bd3-b6d0-e5bc539ea889" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3a0897c8-e292-4bd3-b6d0-e5bc539ea889_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_44692f62-a969-4d1a-8621-4eeb784e91c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3a0897c8-e292-4bd3-b6d0-e5bc539ea889" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_44692f62-a969-4d1a-8621-4eeb784e91c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditAgreementsEnteredInto2019Member_f2cd9b43-59eb-4581-a6ff-467cece6806f" xlink:href="bios-20201231.xsd#bios_CreditAgreementsEnteredInto2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44692f62-a969-4d1a-8621-4eeb784e91c7" xlink:to="loc_bios_CreditAgreementsEnteredInto2019Member_f2cd9b43-59eb-4581-a6ff-467cece6806f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4adf9cf2-2f99-4178-9327-eded391a51e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4adf9cf2-2f99-4178-9327-eded391a51e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4adf9cf2-2f99-4178-9327-eded391a51e5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4adf9cf2-2f99-4178-9327-eded391a51e5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4adf9cf2-2f99-4178-9327-eded391a51e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_67c417ce-1538-4758-906b-d272d2d8f631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4adf9cf2-2f99-4178-9327-eded391a51e5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_67c417ce-1538-4758-906b-d272d2d8f631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_c244d486-d32a-4913-a381-f259596f361a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateCapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_67c417ce-1538-4758-906b-d272d2d8f631" xlink:to="loc_us-gaap_InterestRateCapMember_c244d486-d32a-4913-a381-f259596f361a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_ee4822cd-cb51-49d1-b113-5b0d9175fd1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_67c417ce-1538-4758-906b-d272d2d8f631" xlink:to="loc_us-gaap_InterestRateSwapMember_ee4822cd-cb51-49d1-b113-5b0d9175fd1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_909e0b8b-3707-437d-9865-360cc61c9eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_909e0b8b-3707-437d-9865-360cc61c9eed" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_909e0b8b-3707-437d-9865-360cc61c9eed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_909e0b8b-3707-437d-9865-360cc61c9eed" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_909e0b8b-3707-437d-9865-360cc61c9eed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e9a8182c-589f-4a30-9df5-f46e0b50c8e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_909e0b8b-3707-437d-9865-360cc61c9eed" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e9a8182c-589f-4a30-9df5-f46e0b50c8e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_f51e0b29-d0a8-40cf-9b59-f79e4dfe6cfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e9a8182c-589f-4a30-9df5-f46e0b50c8e4" xlink:to="loc_us-gaap_InterestExpenseMember_f51e0b29-d0a8-40cf-9b59-f79e4dfe6cfa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" xlink:type="extended" id="iea74ed3bb094428b81518e41c00c8847_DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_0c94e690-777b-4628-b737-0f3deb004054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract_d437154d-684f-422a-941b-bd21eeaa65ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0c94e690-777b-4628-b737-0f3deb004054" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract_d437154d-684f-422a-941b-bd21eeaa65ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_2cac656d-6366-417b-acff-d4d81e637118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract_d437154d-684f-422a-941b-bd21eeaa65ae" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_2cac656d-6366-417b-acff-d4d81e637118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_f242bb36-6570-4f6a-9eae-a90329fed606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract_d437154d-684f-422a-941b-bd21eeaa65ae" xlink:to="loc_us-gaap_DerivativeLiabilities_f242bb36-6570-4f6a-9eae-a90329fed606" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_703c8d09-cebf-4eb5-9d4e-77219d0af3c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_0c94e690-777b-4628-b737-0f3deb004054" xlink:to="loc_us-gaap_DerivativeTable_703c8d09-cebf-4eb5-9d4e-77219d0af3c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f562554e-7feb-4742-8307-ee8d6b49a70e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_703c8d09-cebf-4eb5-9d4e-77219d0af3c3" xlink:to="loc_us-gaap_HedgingDesignationAxis_f562554e-7feb-4742-8307-ee8d6b49a70e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f562554e-7feb-4742-8307-ee8d6b49a70e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_f562554e-7feb-4742-8307-ee8d6b49a70e" xlink:to="loc_us-gaap_HedgingDesignationDomain_f562554e-7feb-4742-8307-ee8d6b49a70e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1ea3f0d5-641d-4136-8af7-d84d33410bb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_f562554e-7feb-4742-8307-ee8d6b49a70e" xlink:to="loc_us-gaap_HedgingDesignationDomain_1ea3f0d5-641d-4136-8af7-d84d33410bb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a97b8a50-7c5d-4bf2-8477-01720a941939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1ea3f0d5-641d-4136-8af7-d84d33410bb7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a97b8a50-7c5d-4bf2-8477-01720a941939" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_bc4d941e-f7cb-4540-a2fa-dee1a5e89775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1ea3f0d5-641d-4136-8af7-d84d33410bb7" xlink:to="loc_us-gaap_NondesignatedMember_bc4d941e-f7cb-4540-a2fa-dee1a5e89775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_291e8f69-9f86-4dee-97d9-9878e56ce998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_703c8d09-cebf-4eb5-9d4e-77219d0af3c3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_291e8f69-9f86-4dee-97d9-9878e56ce998" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_291e8f69-9f86-4dee-97d9-9878e56ce998_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_291e8f69-9f86-4dee-97d9-9878e56ce998" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_291e8f69-9f86-4dee-97d9-9878e56ce998_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5d57f556-0188-4036-b707-dc9cd3467cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_291e8f69-9f86-4dee-97d9-9878e56ce998" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5d57f556-0188-4036-b707-dc9cd3467cc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AccruedExpensesandOtherCurrentLiabilitiesMember_58cb8e84-36ec-4151-83e9-e0ab54a1482a" xlink:href="bios-20201231.xsd#bios_AccruedExpensesandOtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5d57f556-0188-4036-b707-dc9cd3467cc7" xlink:to="loc_bios_AccruedExpensesandOtherCurrentLiabilitiesMember_58cb8e84-36ec-4151-83e9-e0ab54a1482a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a6da8b00-9c7d-4beb-af97-0c6471c8dfdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5d57f556-0188-4036-b707-dc9cd3467cc7" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a6da8b00-9c7d-4beb-af97-0c6471c8dfdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_466e0338-aa6c-4975-a088-74e953f52d5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_703c8d09-cebf-4eb5-9d4e-77219d0af3c3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_466e0338-aa6c-4975-a088-74e953f52d5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_466e0338-aa6c-4975-a088-74e953f52d5c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_466e0338-aa6c-4975-a088-74e953f52d5c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_466e0338-aa6c-4975-a088-74e953f52d5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_479dc1e7-c06c-4ceb-af21-40fbac9ab35d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_466e0338-aa6c-4975-a088-74e953f52d5c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_479dc1e7-c06c-4ceb-af21-40fbac9ab35d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_c0b62377-78ef-4579-9afa-14c6ad12d86b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_479dc1e7-c06c-4ceb-af21-40fbac9ab35d" xlink:to="loc_us-gaap_InterestRateSwapMember_c0b62377-78ef-4579-9afa-14c6ad12d86b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" xlink:type="extended" id="i611ad23904c34b6ebca3187fab437618_DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_b179a496-d155-479e-b468-aacecb428a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_a08ffe94-a2a1-4c1b-b257-fa20b1a796dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b179a496-d155-479e-b468-aacecb428a68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_a08ffe94-a2a1-4c1b-b257-fa20b1a796dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax_0c6d42f1-74cf-4aff-8bbb-90e7e431654e" xlink:href="bios-20201231.xsd#bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b179a496-d155-479e-b468-aacecb428a68" xlink:to="loc_bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax_0c6d42f1-74cf-4aff-8bbb-90e7e431654e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_3cddcc11-6493-45e2-b458-03f02d262d04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b179a496-d155-479e-b468-aacecb428a68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_3cddcc11-6493-45e2-b458-03f02d262d04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_da506004-ce1a-4374-8cda-444b7df0e84d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b179a496-d155-479e-b468-aacecb428a68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_da506004-ce1a-4374-8cda-444b7df0e84d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_959ac9f8-0a97-4246-9987-4a442f1f1e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b179a496-d155-479e-b468-aacecb428a68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_959ac9f8-0a97-4246-9987-4a442f1f1e9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_6041228d-38ab-4f5d-bea6-dbd427c4585c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b179a496-d155-479e-b468-aacecb428a68" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_6041228d-38ab-4f5d-bea6-dbd427c4585c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_dc1d631e-83ae-4429-9aec-ed26855f3ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_b179a496-d155-479e-b468-aacecb428a68" xlink:to="loc_us-gaap_DerivativeTable_dc1d631e-83ae-4429-9aec-ed26855f3ccc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0f4327ba-6ab3-4916-9e04-206d0b967853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_dc1d631e-83ae-4429-9aec-ed26855f3ccc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0f4327ba-6ab3-4916-9e04-206d0b967853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0f4327ba-6ab3-4916-9e04-206d0b967853_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0f4327ba-6ab3-4916-9e04-206d0b967853" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0f4327ba-6ab3-4916-9e04-206d0b967853_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d5fe3492-b30e-4196-85ce-45a0b923c105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0f4327ba-6ab3-4916-9e04-206d0b967853" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d5fe3492-b30e-4196-85ce-45a0b923c105" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_3db90c3f-ce0c-4c70-9923-af1f09977ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d5fe3492-b30e-4196-85ce-45a0b923c105" xlink:to="loc_us-gaap_InterestExpenseMember_3db90c3f-ce0c-4c70-9923-af1f09977ac8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_899687f1-7b77-45f3-ad33-33779d41b156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_dc1d631e-83ae-4429-9aec-ed26855f3ccc" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_899687f1-7b77-45f3-ad33-33779d41b156" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_899687f1-7b77-45f3-ad33-33779d41b156_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_899687f1-7b77-45f3-ad33-33779d41b156" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_899687f1-7b77-45f3-ad33-33779d41b156_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2f9a7124-0b1c-4ffc-aa5e-88d5f8878213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_899687f1-7b77-45f3-ad33-33779d41b156" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2f9a7124-0b1c-4ffc-aa5e-88d5f8878213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_549e5031-6870-46f3-b1a1-f1cc0bd57578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateCapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f9a7124-0b1c-4ffc-aa5e-88d5f8878213" xlink:to="loc_us-gaap_InterestRateCapMember_549e5031-6870-46f3-b1a1-f1cc0bd57578" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_ae3155c5-f40d-43d2-a707-82bb4c55a65b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f9a7124-0b1c-4ffc-aa5e-88d5f8878213" xlink:to="loc_us-gaap_InterestRateSwapMember_ae3155c5-f40d-43d2-a707-82bb4c55a65b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS" xlink:type="simple" xlink:href="bios-20201231.xsd#FAIRVALUEMEASURMENTS"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS" xlink:type="extended" id="i6309d7c7438545e3ab798dac3146eba8_FAIRVALUEMEASURMENTS"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="bios-20201231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended" id="i2999996a96034f97a27e32cfac2d2382_COMMITMENTSANDCONTINGENCIES"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATION"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION" xlink:type="extended" id="i1496c63708c746a3a7581898129ceddc_STOCKBASEDINCENTIVECOMPENSATION"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables" xlink:type="extended" id="i7fafb2c72e5f4ac0a30241dcfeb627dc_STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" xlink:type="extended" id="i243aa966e78d430eb00d0209ca3327de_STOCKBASEDINCENTIVECOMPENSATIONDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_542a9d7f-9585-481d-a80c-cd53b1a8b52e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_542a9d7f-9585-481d-a80c-cd53b1a8b52e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_78ab10f4-8776-4635-95d0-08d094510f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_78ab10f4-8776-4635-95d0-08d094510f0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_0c4347b8-6362-4368-8bfb-061af0169243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_0c4347b8-6362-4368-8bfb-061af0169243" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d259c632-04fe-4db8-864f-8a73efaffdb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d259c632-04fe-4db8-864f-8a73efaffdb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d1cedbf-2c4b-4f48-9757-5faa4dbb3b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d1cedbf-2c4b-4f48-9757-5faa4dbb3b7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30755f1f-714a-4c6e-8757-071f907ac5f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30755f1f-714a-4c6e-8757-071f907ac5f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_bb2586a6-6649-413e-bbb1-df959ac1b496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_bb2586a6-6649-413e-bbb1-df959ac1b496" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_31cb5da6-c66a-4373-84ff-ed4bebb26ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_31cb5da6-c66a-4373-84ff-ed4bebb26ba2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b2467e66-3879-44ef-99f3-963619e63cae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b2467e66-3879-44ef-99f3-963619e63cae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a17f656f-c8ed-4c98-8cab-4e96258cf308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a17f656f-c8ed-4c98-8cab-4e96258cf308" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_14ec6a2b-e38f-4786-a57f-b659ee7b2c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_14ec6a2b-e38f-4786-a57f-b659ee7b2c76" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_acec6211-86ad-47f2-8ecd-73192b3fb2da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_acec6211-86ad-47f2-8ecd-73192b3fb2da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_803690df-e496-4181-980f-e0330e2bc6fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_acec6211-86ad-47f2-8ecd-73192b3fb2da" xlink:to="loc_srt_TitleOfIndividualAxis_803690df-e496-4181-980f-e0330e2bc6fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_803690df-e496-4181-980f-e0330e2bc6fb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_803690df-e496-4181-980f-e0330e2bc6fb" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_803690df-e496-4181-980f-e0330e2bc6fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e5f2e0e6-9790-4600-a5a8-6f92cb3cdb1a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_803690df-e496-4181-980f-e0330e2bc6fb" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e5f2e0e6-9790-4600-a5a8-6f92cb3cdb1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_85fbaad7-0a6b-413f-9976-e82aceddd484" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e5f2e0e6-9790-4600-a5a8-6f92cb3cdb1a" xlink:to="loc_srt_DirectorMember_85fbaad7-0a6b-413f-9976-e82aceddd484" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f2f8b79b-c60d-40de-9c2f-e048720b51c6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_acec6211-86ad-47f2-8ecd-73192b3fb2da" xlink:to="loc_srt_RangeAxis_f2f8b79b-c60d-40de-9c2f-e048720b51c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f2f8b79b-c60d-40de-9c2f-e048720b51c6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f2f8b79b-c60d-40de-9c2f-e048720b51c6" xlink:to="loc_srt_RangeMember_f2f8b79b-c60d-40de-9c2f-e048720b51c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_78ef74ce-8cee-45cb-a257-4bc7ef124aaf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f2f8b79b-c60d-40de-9c2f-e048720b51c6" xlink:to="loc_srt_RangeMember_78ef74ce-8cee-45cb-a257-4bc7ef124aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b3c924ca-f48c-4c02-8dc7-860ee66be996" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_78ef74ce-8cee-45cb-a257-4bc7ef124aaf" xlink:to="loc_srt_MinimumMember_b3c924ca-f48c-4c02-8dc7-860ee66be996" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_eacd5c37-4a49-4d17-b3f9-ec068f2cac1d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_78ef74ce-8cee-45cb-a257-4bc7ef124aaf" xlink:to="loc_srt_MaximumMember_eacd5c37-4a49-4d17-b3f9-ec068f2cac1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cf4f222c-3946-44ec-a11f-8769bce6011e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_acec6211-86ad-47f2-8ecd-73192b3fb2da" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cf4f222c-3946-44ec-a11f-8769bce6011e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cf4f222c-3946-44ec-a11f-8769bce6011e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cf4f222c-3946-44ec-a11f-8769bce6011e" xlink:to="loc_us-gaap_EquityComponentDomain_cf4f222c-3946-44ec-a11f-8769bce6011e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_344c9125-0abf-4542-a0b4-99521f75bb7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cf4f222c-3946-44ec-a11f-8769bce6011e" xlink:to="loc_us-gaap_EquityComponentDomain_344c9125-0abf-4542-a0b4-99521f75bb7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_bd1a15b1-c5a5-48e1-a6b2-a273a887e467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_344c9125-0abf-4542-a0b4-99521f75bb7f" xlink:to="loc_us-gaap_TreasuryStockMember_bd1a15b1-c5a5-48e1-a6b2-a273a887e467" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_de2ea485-397e-40fc-aad7-c6200596fb22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_acec6211-86ad-47f2-8ecd-73192b3fb2da" xlink:to="loc_us-gaap_PlanNameAxis_de2ea485-397e-40fc-aad7-c6200596fb22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_de2ea485-397e-40fc-aad7-c6200596fb22_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_de2ea485-397e-40fc-aad7-c6200596fb22" xlink:to="loc_us-gaap_PlanNameDomain_de2ea485-397e-40fc-aad7-c6200596fb22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2299a532-d531-4a74-9c85-abb5a989ba3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_de2ea485-397e-40fc-aad7-c6200596fb22" xlink:to="loc_us-gaap_PlanNameDomain_2299a532-d531-4a74-9c85-abb5a989ba3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2018PlanMember_22844e5a-66c5-4c35-b9ee-f86fd6aee595" xlink:href="bios-20201231.xsd#bios_A2018PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2299a532-d531-4a74-9c85-abb5a989ba3a" xlink:to="loc_bios_A2018PlanMember_22844e5a-66c5-4c35-b9ee-f86fd6aee595" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e5158f44-5da1-4b4e-9ae2-5558c16ba8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_acec6211-86ad-47f2-8ecd-73192b3fb2da" xlink:to="loc_us-gaap_AwardTypeAxis_e5158f44-5da1-4b4e-9ae2-5558c16ba8fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5158f44-5da1-4b4e-9ae2-5558c16ba8fd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e5158f44-5da1-4b4e-9ae2-5558c16ba8fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5158f44-5da1-4b4e-9ae2-5558c16ba8fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09caff95-9682-4af0-99ca-b741d8ffcce8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e5158f44-5da1-4b4e-9ae2-5558c16ba8fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09caff95-9682-4af0-99ca-b741d8ffcce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_93f97ba8-5438-432d-97ec-bdb34c0b293a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09caff95-9682-4af0-99ca-b741d8ffcce8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_93f97ba8-5438-432d-97ec-bdb34c0b293a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_4e4b7507-c792-4fc9-b868-faf2bc0ba2d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09caff95-9682-4af0-99ca-b741d8ffcce8" xlink:to="loc_us-gaap_RestrictedStockMember_4e4b7507-c792-4fc9-b868-faf2bc0ba2d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HCIIncentiveUnitsMember_0c93d7e2-f370-4491-8cf3-97c186255d72" xlink:href="bios-20201231.xsd#bios_HCIIncentiveUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09caff95-9682-4af0-99ca-b741d8ffcce8" xlink:to="loc_bios_HCIIncentiveUnitsMember_0c93d7e2-f370-4491-8cf3-97c186255d72" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails" xlink:type="extended" id="i8fd2e9f9743b417a9c35177a3eda180d_STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4b36e9d-c9c4-4bbd-9b6c-57ea5765970b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ee782460-9860-495f-a77e-f763d09baf4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4b36e9d-c9c4-4bbd-9b6c-57ea5765970b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ee782460-9860-495f-a77e-f763d09baf4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0b41db5d-f0f5-46a2-a335-e2b304987044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4b36e9d-c9c4-4bbd-9b6c-57ea5765970b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0b41db5d-f0f5-46a2-a335-e2b304987044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_38ade6fe-1087-4f4a-b8a3-caee23426e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4b36e9d-c9c4-4bbd-9b6c-57ea5765970b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_38ade6fe-1087-4f4a-b8a3-caee23426e7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9a641d1d-d37b-4978-9ec2-6a77a2394bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4b36e9d-c9c4-4bbd-9b6c-57ea5765970b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9a641d1d-d37b-4978-9ec2-6a77a2394bd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f693323a-3137-47c5-9717-3606dd77b165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4b36e9d-c9c4-4bbd-9b6c-57ea5765970b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f693323a-3137-47c5-9717-3606dd77b165" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e18bc7d8-85d3-4be7-9ee5-173b1157c10a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f693323a-3137-47c5-9717-3606dd77b165" xlink:to="loc_us-gaap_AwardTypeAxis_e18bc7d8-85d3-4be7-9ee5-173b1157c10a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e18bc7d8-85d3-4be7-9ee5-173b1157c10a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e18bc7d8-85d3-4be7-9ee5-173b1157c10a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e18bc7d8-85d3-4be7-9ee5-173b1157c10a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70297449-a908-4f51-b501-7112b04864ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e18bc7d8-85d3-4be7-9ee5-173b1157c10a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70297449-a908-4f51-b501-7112b04864ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a4ba8104-721d-40f7-bce3-24395380e6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70297449-a908-4f51-b501-7112b04864ac" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a4ba8104-721d-40f7-bce3-24395380e6f5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" xlink:type="extended" id="i179b9e4ef6904241afc5173daee2531f_STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4a73fab1-70fd-410a-90c2-33bf43b81fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4a73fab1-70fd-410a-90c2-33bf43b81fe7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6306eabd-d8f5-485a-837b-ebcb80b43fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4a73fab1-70fd-410a-90c2-33bf43b81fe7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6306eabd-d8f5-485a-837b-ebcb80b43fbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e010d2e7-2943-4917-b05f-7244f8c36353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4a73fab1-70fd-410a-90c2-33bf43b81fe7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e010d2e7-2943-4917-b05f-7244f8c36353" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_99b493bc-eeb7-42d9-a6c9-27cd7e577c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4a73fab1-70fd-410a-90c2-33bf43b81fe7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_99b493bc-eeb7-42d9-a6c9-27cd7e577c23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_7f13c1dd-d669-47df-b025-3e3e49bbb25d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4a73fab1-70fd-410a-90c2-33bf43b81fe7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_7f13c1dd-d669-47df-b025-3e3e49bbb25d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_059d270f-6cd4-4850-ab70-5a7114a54e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_62ab23c6-92c3-44b3-9e3d-f7b3c6a1486f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_62ab23c6-92c3-44b3-9e3d-f7b3c6a1486f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2364de45-0ee9-478f-9fc7-a98492492501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2364de45-0ee9-478f-9fc7-a98492492501" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8443d622-c427-42ce-961f-d847a43fe28a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2364de45-0ee9-478f-9fc7-a98492492501" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8443d622-c427-42ce-961f-d847a43fe28a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f5ef5061-2962-4ed7-80b6-e15ea629f182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2364de45-0ee9-478f-9fc7-a98492492501" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f5ef5061-2962-4ed7-80b6-e15ea629f182" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a03c6102-84e4-419d-b793-0473ee6b6e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2364de45-0ee9-478f-9fc7-a98492492501" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a03c6102-84e4-419d-b793-0473ee6b6e2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_8fb950b8-97cc-4668-a813-53236a21b7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2364de45-0ee9-478f-9fc7-a98492492501" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_8fb950b8-97cc-4668-a813-53236a21b7d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d668f3fc-a131-4079-94bd-2428d9e41841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c2afa470-f1fb-4161-97af-153e0d3b3d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c2afa470-f1fb-4161-97af-153e0d3b3d6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AggregateIntrinsicValueAbstract_48d98286-2345-4246-8de9-4bd89ae24a30" xlink:href="bios-20201231.xsd#bios_AggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:to="loc_bios_AggregateIntrinsicValueAbstract_48d98286-2345-4246-8de9-4bd89ae24a30" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c47da61c-258d-4f00-ac85-4ad2d15ef199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bios_AggregateIntrinsicValueAbstract_48d98286-2345-4246-8de9-4bd89ae24a30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c47da61c-258d-4f00-ac85-4ad2d15ef199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue_9221d1a5-2b2d-4a20-884a-69be79fec83a" xlink:href="bios-20201231.xsd#bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bios_AggregateIntrinsicValueAbstract_48d98286-2345-4246-8de9-4bd89ae24a30" xlink:to="loc_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue_9221d1a5-2b2d-4a20-884a-69be79fec83a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_08eb55b0-96c6-4b35-ba53-79bc2beb39bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bios_AggregateIntrinsicValueAbstract_48d98286-2345-4246-8de9-4bd89ae24a30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_08eb55b0-96c6-4b35-ba53-79bc2beb39bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue_701cee09-eeec-4101-ba49-57ee034042f0" xlink:href="bios-20201231.xsd#bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bios_AggregateIntrinsicValueAbstract_48d98286-2345-4246-8de9-4bd89ae24a30" xlink:to="loc_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue_701cee09-eeec-4101-ba49-57ee034042f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_da4e0601-bab0-4727-b7be-ecab0951bf4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c8e7527e-4a82-4da4-8b28-7979f96c4490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c8e7527e-4a82-4da4-8b28-7979f96c4490" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b30ae52c-4a56-495d-8ad3-02fe5fa55113" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b30ae52c-4a56-495d-8ad3-02fe5fa55113" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_87ada89b-b593-419c-b430-2133642491a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_87ada89b-b593-419c-b430-2133642491a0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea3c5dba-da58-4b44-bc06-43d3267109de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea3c5dba-da58-4b44-bc06-43d3267109de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_604226c1-0ada-4126-9b9c-4738ad1619e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea3c5dba-da58-4b44-bc06-43d3267109de" xlink:to="loc_us-gaap_AwardTypeAxis_604226c1-0ada-4126-9b9c-4738ad1619e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_604226c1-0ada-4126-9b9c-4738ad1619e2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_604226c1-0ada-4126-9b9c-4738ad1619e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_604226c1-0ada-4126-9b9c-4738ad1619e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5af62565-32fe-454b-8d06-ef7113cb0fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_604226c1-0ada-4126-9b9c-4738ad1619e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5af62565-32fe-454b-8d06-ef7113cb0fb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_566ff87d-469d-409d-b6dc-95b2752e8317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5af62565-32fe-454b-8d06-ef7113cb0fb3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_566ff87d-469d-409d-b6dc-95b2752e8317" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" xlink:type="extended" id="i6c2e9896c7244c21ba978b6c920f43b8_STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3077bcca-0e55-489f-9f0d-2b2497a4855f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_e6663132-d418-4137-a824-f71eca225064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3077bcca-0e55-489f-9f0d-2b2497a4855f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_e6663132-d418-4137-a824-f71eca225064" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_38c7a2e8-69b5-4e1c-a2fd-3064e8b68599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3077bcca-0e55-489f-9f0d-2b2497a4855f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_38c7a2e8-69b5-4e1c-a2fd-3064e8b68599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionsOutstandingAbstract_724d81e4-cde7-416f-a597-86ce8e6219a5" xlink:href="bios-20201231.xsd#bios_OptionsOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3077bcca-0e55-489f-9f0d-2b2497a4855f" xlink:to="loc_bios_OptionsOutstandingAbstract_724d81e4-cde7-416f-a597-86ce8e6219a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_747f70c3-6a48-4874-877f-b78dd4a0150d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bios_OptionsOutstandingAbstract_724d81e4-cde7-416f-a597-86ce8e6219a5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_747f70c3-6a48-4874-877f-b78dd4a0150d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_72eae7f7-c159-4c07-afd0-5c957a4e41b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bios_OptionsOutstandingAbstract_724d81e4-cde7-416f-a597-86ce8e6219a5" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_72eae7f7-c159-4c07-afd0-5c957a4e41b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_ab141791-cfde-45d7-b5c1-621c5670cc82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bios_OptionsOutstandingAbstract_724d81e4-cde7-416f-a597-86ce8e6219a5" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_ab141791-cfde-45d7-b5c1-621c5670cc82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionsExercisableAbstract_1fd827e2-234d-406d-aff0-7e7b4fdffb5a" xlink:href="bios-20201231.xsd#bios_OptionsExercisableAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3077bcca-0e55-489f-9f0d-2b2497a4855f" xlink:to="loc_bios_OptionsExercisableAbstract_1fd827e2-234d-406d-aff0-7e7b4fdffb5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_e8425df4-d51a-43f1-a2bb-e643253ed2f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bios_OptionsExercisableAbstract_1fd827e2-234d-406d-aff0-7e7b4fdffb5a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_e8425df4-d51a-43f1-a2bb-e643253ed2f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_e7b1cf2b-e914-48e5-9a7e-cca969ec7a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bios_OptionsExercisableAbstract_1fd827e2-234d-406d-aff0-7e7b4fdffb5a" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_e7b1cf2b-e914-48e5-9a7e-cca969ec7a27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_995488a1-2e53-4944-969a-b83001e28051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3077bcca-0e55-489f-9f0d-2b2497a4855f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_995488a1-2e53-4944-969a-b83001e28051" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e3f5d401-742d-472d-9d91-aefa440d76e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_995488a1-2e53-4944-969a-b83001e28051" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e3f5d401-742d-472d-9d91-aefa440d76e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e3f5d401-742d-472d-9d91-aefa440d76e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e3f5d401-742d-472d-9d91-aefa440d76e3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e3f5d401-742d-472d-9d91-aefa440d76e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e3f5d401-742d-472d-9d91-aefa440d76e3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeOneMember_229a08a3-d03f-4e2e-9985-732b4c3d816d" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeOneMember_229a08a3-d03f-4e2e-9985-732b4c3d816d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeTwoMember_09713568-f9b0-42d1-bb56-8ae19ff5face" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeTwoMember_09713568-f9b0-42d1-bb56-8ae19ff5face" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeThreeMember_1fb87617-4c06-41a1-8e69-f81914344528" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeThreeMember_1fb87617-4c06-41a1-8e69-f81914344528" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeFourMember_2fd39869-024d-4d1b-aada-4ec32fd5d6fb" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeFourMember_2fd39869-024d-4d1b-aada-4ec32fd5d6fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeFiveMember_139c345d-34fc-451b-9b8a-9bae373f3631" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeFiveMember_139c345d-34fc-451b-9b8a-9bae373f3631" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeSixMember_1addb3d1-a4ea-418f-a98c-97b8798e5957" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeSixMember_1addb3d1-a4ea-418f-a98c-97b8798e5957" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeSevenMember_bd033708-fc1d-43d4-b03f-4feb9cea5df8" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeSevenMember_bd033708-fc1d-43d4-b03f-4feb9cea5df8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeEightMember_e0eb045c-9b42-42ee-9924-03d5dd9c196c" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeEightMember_e0eb045c-9b42-42ee-9924-03d5dd9c196c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeNineMember_ccf03741-6cd7-49b2-a216-0630f93fa53c" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeNineMember_ccf03741-6cd7-49b2-a216-0630f93fa53c" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" xlink:type="extended" id="i50e7e7b83809433ca1ad1fec2e17f792_STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da96c022-90d2-4155-9ceb-1986a75ec138" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eacca8eb-a5ed-4586-9f45-48998e22db30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da96c022-90d2-4155-9ceb-1986a75ec138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eacca8eb-a5ed-4586-9f45-48998e22db30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07dca9b6-dacf-4ba3-a4f9-8e0083f3fd9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eacca8eb-a5ed-4586-9f45-48998e22db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07dca9b6-dacf-4ba3-a4f9-8e0083f3fd9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0d405f98-104e-40fe-afe5-e3ac053aaa5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eacca8eb-a5ed-4586-9f45-48998e22db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0d405f98-104e-40fe-afe5-e3ac053aaa5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6c239143-52a9-460a-9075-6558a189abb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eacca8eb-a5ed-4586-9f45-48998e22db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6c239143-52a9-460a-9075-6558a189abb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_21dcd536-5704-484a-860e-4321753b4a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eacca8eb-a5ed-4586-9f45-48998e22db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_21dcd536-5704-484a-860e-4321753b4a52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d5308f0-d586-46c2-9883-49791b92364c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_af9ffe75-1ca8-4bf2-9ed1-fc6f193b116e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da96c022-90d2-4155-9ceb-1986a75ec138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_af9ffe75-1ca8-4bf2-9ed1-fc6f193b116e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_675ff383-25ab-48de-a16d-a1dde6529ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_af9ffe75-1ca8-4bf2-9ed1-fc6f193b116e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_675ff383-25ab-48de-a16d-a1dde6529ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ab0cf0fa-90e4-47bb-b60c-80b7337c8381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_af9ffe75-1ca8-4bf2-9ed1-fc6f193b116e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ab0cf0fa-90e4-47bb-b60c-80b7337c8381" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_879f511b-1df0-466c-b6d0-4b833286aef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_af9ffe75-1ca8-4bf2-9ed1-fc6f193b116e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_879f511b-1df0-466c-b6d0-4b833286aef3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6e1aba4a-feae-48d6-8984-3af7bacbfd67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_af9ffe75-1ca8-4bf2-9ed1-fc6f193b116e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6e1aba4a-feae-48d6-8984-3af7bacbfd67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b76e5933-5c35-4abe-bc3d-4ce95b5931f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60eb4c49-c0c5-4269-ba03-6797ce4efca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da96c022-90d2-4155-9ceb-1986a75ec138" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60eb4c49-c0c5-4269-ba03-6797ce4efca3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1346cfdc-1fe6-4c8f-b4a8-81257f86ebed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60eb4c49-c0c5-4269-ba03-6797ce4efca3" xlink:to="loc_us-gaap_AwardTypeAxis_1346cfdc-1fe6-4c8f-b4a8-81257f86ebed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1346cfdc-1fe6-4c8f-b4a8-81257f86ebed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1346cfdc-1fe6-4c8f-b4a8-81257f86ebed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1346cfdc-1fe6-4c8f-b4a8-81257f86ebed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa7e6fd6-05be-4dd8-a278-9c3404310f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1346cfdc-1fe6-4c8f-b4a8-81257f86ebed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa7e6fd6-05be-4dd8-a278-9c3404310f2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_891a385b-ab79-4ef6-969a-2b4b2cd43c83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa7e6fd6-05be-4dd8-a278-9c3404310f2d" xlink:to="loc_us-gaap_RestrictedStockMember_891a385b-ab79-4ef6-969a-2b4b2cd43c83" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails" xlink:type="extended" id="i9eea4ac2691a4f8fb2bd0385cdf2d95c_STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/STOCKHOLDERSEQUITY" xlink:type="extended" id="i50a37c4860d14b8baf21674e8a1c25a6_STOCKHOLDERSEQUITY"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended" id="i09988b2ed3bf46e0902948a5195b0ae6_STOCKHOLDERSEQUITYDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_57167188-77af-453b-80df-1ff502c81335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_57167188-77af-453b-80df-1ff502c81335" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aee0ae78-bb02-4cb9-b49b-5f4e653ac385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aee0ae78-bb02-4cb9-b49b-5f4e653ac385" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_81d3b04a-280e-47fc-9656-ce6f76e1680d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_81d3b04a-280e-47fc-9656-ce6f76e1680d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5e6dffb8-74b6-4be8-9dbb-1a9d0a6af5de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5e6dffb8-74b6-4be8-9dbb-1a9d0a6af5de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CommonStockOutstandingPercentage_2a63128c-18a2-43c2-a187-10f1971a5d44" xlink:href="bios-20201231.xsd#bios_CommonStockOutstandingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_bios_CommonStockOutstandingPercentage_2a63128c-18a2-43c2-a187-10f1971a5d44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_98d6af3b-d612-4258-97b2-2ad2af62774c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_RepaymentsOfDebt_98d6af3b-d612-4258-97b2-2ad2af62774c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_20bcf2aa-bcda-49d7-af19-f63cd5b9ebb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_20bcf2aa-bcda-49d7-af19-f63cd5b9ebb4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_800dcaa7-40f9-4aab-8eca-70c55694f013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_800dcaa7-40f9-4aab-8eca-70c55694f013" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c39b53ab-c928-4a04-98c2-161a99e8761d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c39b53ab-c928-4a04-98c2-161a99e8761d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_d84fac46-1cad-46c4-9ccb-44b6b32b6bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_d84fac46-1cad-46c4-9ccb-44b6b32b6bdb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ClassofWarrantorRightSecuritiesExercised_48a6bbc1-bb78-436b-bc3b-ad04d977d1ba" xlink:href="bios-20201231.xsd#bios_ClassofWarrantorRightSecuritiesExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_bios_ClassofWarrantorRightSecuritiesExercised_48a6bbc1-bb78-436b-bc3b-ad04d977d1ba" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5e664513-5347-4d43-b077-20cf25c930ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5e664513-5347-4d43-b077-20cf25c930ac" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_a06b8df9-e9d1-42ca-961a-7d824b7ee200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_a06b8df9-e9d1-42ca-961a-7d824b7ee200" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_245c6253-0a81-4fe9-b0ce-6ccae632dd85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_SharePrice_245c6253-0a81-4fe9-b0ce-6ccae632dd85" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_95a30372-c5bc-43f7-b0d0-2a0132e0a568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_95a30372-c5bc-43f7-b0d0-2a0132e0a568" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_22b733e4-5ed2-4c36-ba87-6419b6401fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_22b733e4-5ed2-4c36-ba87-6419b6401fc4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4662ea4f-d206-4c4a-bef3-3b031f9374cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4662ea4f-d206-4c4a-bef3-3b031f9374cb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2b001289-54c7-48df-80a4-cd4eff7da8cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2b001289-54c7-48df-80a4-cd4eff7da8cc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_42d25d69-5ee5-4696-ad8f-c4869a5fc839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_TreasuryStockShares_42d25d69-5ee5-4696-ad8f-c4869a5fc839" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9eee8e96-e0e0-4e37-a968-ad382ee61494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9eee8e96-e0e0-4e37-a968-ad382ee61494" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_98c31098-e1c0-4bb9-89e7-f8a4bab6b1f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_VestingAxis_98c31098-e1c0-4bb9-89e7-f8a4bab6b1f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_98c31098-e1c0-4bb9-89e7-f8a4bab6b1f3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_98c31098-e1c0-4bb9-89e7-f8a4bab6b1f3" xlink:to="loc_us-gaap_VestingDomain_98c31098-e1c0-4bb9-89e7-f8a4bab6b1f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_2f1fb94a-ad83-45dd-b956-83a1b91900bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_98c31098-e1c0-4bb9-89e7-f8a4bab6b1f3" xlink:to="loc_us-gaap_VestingDomain_2f1fb94a-ad83-45dd-b956-83a1b91900bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a7caee0b-98c9-4c8a-8485-869ee28d88ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2f1fb94a-ad83-45dd-b956-83a1b91900bf" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a7caee0b-98c9-4c8a-8485-869ee28d88ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_f0edcc78-6a74-4d22-8f84-789c287ea08f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2f1fb94a-ad83-45dd-b956-83a1b91900bf" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_f0edcc78-6a74-4d22-8f84-789c287ea08f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c6d2d07c-791c-4335-af44-c9b32ae7472a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_AwardTypeAxis_c6d2d07c-791c-4335-af44-c9b32ae7472a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6d2d07c-791c-4335-af44-c9b32ae7472a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c6d2d07c-791c-4335-af44-c9b32ae7472a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6d2d07c-791c-4335-af44-c9b32ae7472a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8b05bae-c968-46f5-8303-a87a541d0bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c6d2d07c-791c-4335-af44-c9b32ae7472a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8b05bae-c968-46f5-8303-a87a541d0bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7c5ac67f-6040-4975-888c-0ff2d7661585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8b05bae-c968-46f5-8303-a87a541d0bd1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7c5ac67f-6040-4975-888c-0ff2d7661585" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_RestrictedStockAndStockOptionsMember_3cc9bc46-0268-47ad-9bb8-878718af2c6a" xlink:href="bios-20201231.xsd#bios_RestrictedStockAndStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8b05bae-c968-46f5-8303-a87a541d0bd1" xlink:to="loc_bios_RestrictedStockAndStockOptionsMember_3cc9bc46-0268-47ad-9bb8-878718af2c6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_30f747d7-9db3-4680-b917-e494cc0c0406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_30f747d7-9db3-4680-b917-e494cc0c0406" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_30f747d7-9db3-4680-b917-e494cc0c0406_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_30f747d7-9db3-4680-b917-e494cc0c0406" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_30f747d7-9db3-4680-b917-e494cc0c0406_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e2e89fba-ac1a-4322-9cce-d8725ca4d073" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_30f747d7-9db3-4680-b917-e494cc0c0406" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e2e89fba-ac1a-4322-9cce-d8725ca4d073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HomeSolutionsMember_c77d697d-6caf-4b89-9ace-3f9841901e72" xlink:href="bios-20201231.xsd#bios_HomeSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e2e89fba-ac1a-4322-9cce-d8725ca4d073" xlink:to="loc_bios_HomeSolutionsMember_c77d697d-6caf-4b89-9ace-3f9841901e72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionCareEnterprisesInc.Member_963a901e-c634-49a1-85f0-62e4cbf20c2f" xlink:href="bios-20201231.xsd#bios_OptionCareEnterprisesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e2e89fba-ac1a-4322-9cce-d8725ca4d073" xlink:to="loc_bios_OptionCareEnterprisesInc.Member_963a901e-c634-49a1-85f0-62e4cbf20c2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b0f38b13-0fc9-497b-b174-7c5f66c80389" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_srt_RangeAxis_b0f38b13-0fc9-497b-b174-7c5f66c80389" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b0f38b13-0fc9-497b-b174-7c5f66c80389_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b0f38b13-0fc9-497b-b174-7c5f66c80389" xlink:to="loc_srt_RangeMember_b0f38b13-0fc9-497b-b174-7c5f66c80389_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8c67e7b0-8c79-47dc-8b65-58e829eb20fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b0f38b13-0fc9-497b-b174-7c5f66c80389" xlink:to="loc_srt_RangeMember_8c67e7b0-8c79-47dc-8b65-58e829eb20fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_25e01759-465f-4210-9822-2af0f66b34b1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8c67e7b0-8c79-47dc-8b65-58e829eb20fe" xlink:to="loc_srt_MinimumMember_25e01759-465f-4210-9822-2af0f66b34b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d536702c-afa1-4263-871c-f75dfe3f099e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8c67e7b0-8c79-47dc-8b65-58e829eb20fe" xlink:to="loc_srt_MaximumMember_d536702c-afa1-4263-871c-f75dfe3f099e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9165ad3a-ac98-4180-9a40-66261bfbda92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9165ad3a-ac98-4180-9a40-66261bfbda92" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9165ad3a-ac98-4180-9a40-66261bfbda92_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9165ad3a-ac98-4180-9a40-66261bfbda92" xlink:to="loc_us-gaap_EquityComponentDomain_9165ad3a-ac98-4180-9a40-66261bfbda92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_74f8872c-f6ed-4d1e-9593-a5aca15bd3dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9165ad3a-ac98-4180-9a40-66261bfbda92" xlink:to="loc_us-gaap_EquityComponentDomain_74f8872c-f6ed-4d1e-9593-a5aca15bd3dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_97e0f121-1809-40fa-97cc-40a609247ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_74f8872c-f6ed-4d1e-9593-a5aca15bd3dc" xlink:to="loc_us-gaap_CommonStockMember_97e0f121-1809-40fa-97cc-40a609247ada" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_212fcb99-33fc-4979-b4e6-02f807d52884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_74f8872c-f6ed-4d1e-9593-a5aca15bd3dc" xlink:to="loc_us-gaap_TreasuryStockMember_212fcb99-33fc-4979-b4e6-02f807d52884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_070216ad-d5f4-4130-9a3f-84066bb90fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_070216ad-d5f4-4130-9a3f-84066bb90fbf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_070216ad-d5f4-4130-9a3f-84066bb90fbf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_070216ad-d5f4-4130-9a3f-84066bb90fbf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_070216ad-d5f4-4130-9a3f-84066bb90fbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1bb13725-356e-4638-9264-36419b2e24ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_070216ad-d5f4-4130-9a3f-84066bb90fbf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1bb13725-356e-4638-9264-36419b2e24ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2017WarrantsMember_86622268-e27e-4003-b7e0-b44cbf821f46" xlink:href="bios-20201231.xsd#bios_A2017WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1bb13725-356e-4638-9264-36419b2e24ec" xlink:to="loc_bios_A2017WarrantsMember_86622268-e27e-4003-b7e0-b44cbf821f46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2015WarrantsMember_9ec09326-15ab-4574-be16-74b78592d575" xlink:href="bios-20201231.xsd#bios_A2015WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1bb13725-356e-4638-9264-36419b2e24ec" xlink:to="loc_bios_A2015WarrantsMember_9ec09326-15ab-4574-be16-74b78592d575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8887931c-181d-42ac-9fa8-e15254054bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8887931c-181d-42ac-9fa8-e15254054bbf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8887931c-181d-42ac-9fa8-e15254054bbf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8887931c-181d-42ac-9fa8-e15254054bbf" xlink:to="loc_us-gaap_ClassOfStockDomain_8887931c-181d-42ac-9fa8-e15254054bbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6e39acb5-92e1-47b9-89b4-76e46950a103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8887931c-181d-42ac-9fa8-e15254054bbf" xlink:to="loc_us-gaap_ClassOfStockDomain_6e39acb5-92e1-47b9-89b4-76e46950a103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_36c640d9-df59-41bd-8517-ad87d7dad277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6e39acb5-92e1-47b9-89b4-76e46950a103" xlink:to="loc_us-gaap_CommonStockMember_36c640d9-df59-41bd-8517-ad87d7dad277" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8956a5b6-bd1a-4998-99cb-9d114046e099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8956a5b6-bd1a-4998-99cb-9d114046e099" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8956a5b6-bd1a-4998-99cb-9d114046e099_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8956a5b6-bd1a-4998-99cb-9d114046e099" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8956a5b6-bd1a-4998-99cb-9d114046e099_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f222fc9-7b75-4342-88be-f06d38bd9e84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8956a5b6-bd1a-4998-99cb-9d114046e099" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f222fc9-7b75-4342-88be-f06d38bd9e84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PublicOfferingMember_194f69a5-04f6-4e33-9259-f431bb512e3b" xlink:href="bios-20201231.xsd#bios_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f222fc9-7b75-4342-88be-f06d38bd9e84" xlink:to="loc_bios_PublicOfferingMember_194f69a5-04f6-4e33-9259-f431bb512e3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SecondaryOfferingMember_2e227648-da34-4043-b70f-551c1a366946" xlink:href="bios-20201231.xsd#bios_SecondaryOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f222fc9-7b75-4342-88be-f06d38bd9e84" xlink:to="loc_bios_SecondaryOfferingMember_2e227648-da34-4043-b70f-551c1a366946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b09ca1c6-e9c8-4c3f-bba1-c475bba01001" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_dei_LegalEntityAxis_b09ca1c6-e9c8-4c3f-bba1-c475bba01001" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b09ca1c6-e9c8-4c3f-bba1-c475bba01001_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_b09ca1c6-e9c8-4c3f-bba1-c475bba01001" xlink:to="loc_dei_EntityDomain_b09ca1c6-e9c8-4c3f-bba1-c475bba01001_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f8db92e7-48e3-4bf3-9504-72f9b1e0dea9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_b09ca1c6-e9c8-4c3f-bba1-c475bba01001" xlink:to="loc_dei_EntityDomain_f8db92e7-48e3-4bf3-9504-72f9b1e0dea9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionCareHealthIncMember_47c28d3f-3a9f-48be-b59a-f282f28d5cae" xlink:href="bios-20201231.xsd#bios_OptionCareHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f8db92e7-48e3-4bf3-9504-72f9b1e0dea9" xlink:to="loc_bios_OptionCareHealthIncMember_47c28d3f-3a9f-48be-b59a-f282f28d5cae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HCGroupHoldingsILLCMember_7fa497ca-26aa-4ab5-bed4-f3a9e9731eb6" xlink:href="bios-20201231.xsd#bios_HCGroupHoldingsILLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f8db92e7-48e3-4bf3-9504-72f9b1e0dea9" xlink:to="loc_bios_HCGroupHoldingsILLCMember_7fa497ca-26aa-4ab5-bed4-f3a9e9731eb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_992cd850-7da3-416c-b3d9-1e559a953125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_DebtInstrumentAxis_992cd850-7da3-416c-b3d9-1e559a953125" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_992cd850-7da3-416c-b3d9-1e559a953125_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_992cd850-7da3-416c-b3d9-1e559a953125" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_992cd850-7da3-416c-b3d9-1e559a953125_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e9825035-7c6d-4733-8647-6339f1b63e05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_992cd850-7da3-416c-b3d9-1e559a953125" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e9825035-7c6d-4733-8647-6339f1b63e05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditAgreementsEnteredInto2019Member_4baf65bf-f642-44eb-ae00-adedf8fe6966" xlink:href="bios-20201231.xsd#bios_CreditAgreementsEnteredInto2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9825035-7c6d-4733-8647-6339f1b63e05" xlink:to="loc_bios_CreditAgreementsEnteredInto2019Member_4baf65bf-f642-44eb-ae00-adedf8fe6966" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fb48a632-5bc1-47dd-81c9-3f7ea1b36f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fb48a632-5bc1-47dd-81c9-3f7ea1b36f5a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fb48a632-5bc1-47dd-81c9-3f7ea1b36f5a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fb48a632-5bc1-47dd-81c9-3f7ea1b36f5a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fb48a632-5bc1-47dd-81c9-3f7ea1b36f5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0ced86f7-c561-45a1-b588-2535f09fdf44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fb48a632-5bc1-47dd-81c9-3f7ea1b36f5a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0ced86f7-c561-45a1-b588-2535f09fdf44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NotesPayableMember_81267153-7b89-453c-a18a-47368cb82fbe" xlink:href="bios-20201231.xsd#bios_NotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0ced86f7-c561-45a1-b588-2535f09fdf44" xlink:to="loc_bios_NotesPayableMember_81267153-7b89-453c-a18a-47368cb82fbe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="bios-20201231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended" id="i06d9009445c2490787631220643a5e76_RELATEDPARTYTRANSACTIONS"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended" id="i57960001cc0d40088133746a62a708cd_RELATEDPARTYTRANSACTIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_f38a1fbf-5270-46e0-a6cc-98c2725e27c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_f38a1fbf-5270-46e0-a6cc-98c2725e27c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_267f475d-11dd-4d53-b936-a8ac82db435d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_267f475d-11dd-4d53-b936-a8ac82db435d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_7e60ffb2-4fcb-4157-8002-03e62fdbfe01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_7e60ffb2-4fcb-4157-8002-03e62fdbfe01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountRedemptions_7ead6b41-569f-4b2a-b708-33001d39f772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PartnersCapitalAccountRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_PartnersCapitalAccountRedemptions_7ead6b41-569f-4b2a-b708-33001d39f772" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid_da05b589-a217-4eaa-9b53-c37f47c5e58d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid_da05b589-a217-4eaa-9b53-c37f47c5e58d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_a3d0695a-2097-413b-98ec-c121620eac50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_a3d0695a-2097-413b-98ec-c121620eac50" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfNotesReceivable_a248e375-20e0-492b-be58-e375a789539e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_ProceedsFromSaleOfNotesReceivable_a248e375-20e0-492b-be58-e375a789539e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_0af88440-f368-4790-9179-b3e883d40f27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_InterestExpenseRelatedParty_0af88440-f368-4790-9179-b3e883d40f27" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedParties_06d8b652-2ea1-4d42-a362-17246c2a6dac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_NotesReceivableRelatedParties_06d8b652-2ea1-4d42-a362-17246c2a6dac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_d275f4bb-3fc7-4f5b-b1eb-fd918732f0af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_RevenueFromRelatedParties_d275f4bb-3fc7-4f5b-b1eb-fd918732f0af" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_dc2da172-fc7f-42ca-8aff-4ccbd5e80321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_DueFromRelatedParties_dc2da172-fc7f-42ca-8aff-4ccbd5e80321" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa17e114-dff5-47b9-81a0-2b47c48d80b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa17e114-dff5-47b9-81a0-2b47c48d80b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3211823c-11d7-4428-9f00-74b66998d479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa17e114-dff5-47b9-81a0-2b47c48d80b0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3211823c-11d7-4428-9f00-74b66998d479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3211823c-11d7-4428-9f00-74b66998d479_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3211823c-11d7-4428-9f00-74b66998d479" xlink:to="loc_us-gaap_RelatedPartyDomain_3211823c-11d7-4428-9f00-74b66998d479_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_78b6d22e-2ee2-45c4-ae32-fe93a5b341c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3211823c-11d7-4428-9f00-74b66998d479" xlink:to="loc_us-gaap_RelatedPartyDomain_78b6d22e-2ee2-45c4-ae32-fe93a5b341c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_MadisonDearbornPartnersVIBL.P.Member_8a5fe1e5-cd95-466a-bb2f-5919fdd6ed30" xlink:href="bios-20201231.xsd#bios_MadisonDearbornPartnersVIBL.P.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_78b6d22e-2ee2-45c4-ae32-fe93a5b341c1" xlink:to="loc_bios_MadisonDearbornPartnersVIBL.P.Member_8a5fe1e5-cd95-466a-bb2f-5919fdd6ed30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_fe1f9dc5-158a-47ff-9571-93e25fe355f3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_78b6d22e-2ee2-45c4-ae32-fe93a5b341c1" xlink:to="loc_srt_ManagementMember_fe1f9dc5-158a-47ff-9571-93e25fe355f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorityShareholderMember_89323d68-de28-4933-a349-750f96d5a9f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorityShareholderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_78b6d22e-2ee2-45c4-ae32-fe93a5b341c1" xlink:to="loc_us-gaap_MajorityShareholderMember_89323d68-de28-4933-a349-750f96d5a9f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_f4a1e368-51dc-446b-bf26-1f40ef371aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_78b6d22e-2ee2-45c4-ae32-fe93a5b341c1" xlink:to="loc_us-gaap_CorporateJointVentureMember_f4a1e368-51dc-446b-bf26-1f40ef371aaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b2f6516a-f056-4374-b7c9-65fe5a745d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa17e114-dff5-47b9-81a0-2b47c48d80b0" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b2f6516a-f056-4374-b7c9-65fe5a745d82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b2f6516a-f056-4374-b7c9-65fe5a745d82_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b2f6516a-f056-4374-b7c9-65fe5a745d82" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b2f6516a-f056-4374-b7c9-65fe5a745d82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_eaab13d3-4c5a-4875-a833-aabb74182e8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b2f6516a-f056-4374-b7c9-65fe5a745d82" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_eaab13d3-4c5a-4875-a833-aabb74182e8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionCareAcquisitionMember_48fe8a89-01ff-457a-8e0d-7fc659eee8ce" xlink:href="bios-20201231.xsd#bios_OptionCareAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_eaab13d3-4c5a-4875-a833-aabb74182e8d" xlink:to="loc_bios_OptionCareAcquisitionMember_48fe8a89-01ff-457a-8e0d-7fc659eee8ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LoansFundedForMembershipUnitPurchaseMember_923218f1-6e9d-4115-807c-ef53778d9234" xlink:href="bios-20201231.xsd#bios_LoansFundedForMembershipUnitPurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_eaab13d3-4c5a-4875-a833-aabb74182e8d" xlink:to="loc_bios_LoansFundedForMembershipUnitPurchaseMember_923218f1-6e9d-4115-807c-ef53778d9234" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SaleOfNotesReceivableMember_04230b8c-2d1d-4354-ac0b-53305e5c7d7d" xlink:href="bios-20201231.xsd#bios_SaleOfNotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_eaab13d3-4c5a-4875-a833-aabb74182e8d" xlink:to="loc_bios_SaleOfNotesReceivableMember_04230b8c-2d1d-4354-ac0b-53305e5c7d7d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED" xlink:type="simple" xlink:href="bios-20201231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITED"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED" xlink:type="extended" id="i095e3f4ce7764cd197855ef156387d14_SELECTEDQUARTERLYFINANCIALDATAUNAUDITED"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables" xlink:type="simple" xlink:href="bios-20201231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables" xlink:type="extended" id="i96465a9635ec4123a8c27fa3536b243a_SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails" xlink:type="extended" id="i4739dc237f1442b681d0d09bc51ef276_SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="bios-20201231.xsd#SUBSEQUENTEVENTS"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/SUBSEQUENTEVENTS" xlink:type="extended" id="if9ab4759cf6548cd92c236d89e9653af_SUBSEQUENTEVENTS"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended" id="i14c4c2145bef46af9419ca021ea1141a_SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_99b95a3d-c617-4236-a74f-f1c7eefb6090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_99b95a3d-c617-4236-a74f-f1c7eefb6090" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a2e76118-4c17-4f4b-85b9-379a39ef1be1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a2e76118-4c17-4f4b-85b9-379a39ef1be1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_0dce728e-bae8-4f65-a5ff-78970e8608d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_us-gaap_RepaymentsOfDebt_0dce728e-bae8-4f65-a5ff-78970e8608d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FinancingReceivablePrepaymentPenalty_df81f860-e431-434c-8bd8-185f770573f6" xlink:href="bios-20201231.xsd#bios_FinancingReceivablePrepaymentPenalty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_bios_FinancingReceivablePrepaymentPenalty_df81f860-e431-434c-8bd8-185f770573f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DebtInstrumentThirdPartyFees_36938c3a-4276-4dff-ac42-804bdcce9163" xlink:href="bios-20201231.xsd#bios_DebtInstrumentThirdPartyFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_bios_DebtInstrumentThirdPartyFees_36938c3a-4276-4dff-ac42-804bdcce9163" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7d3b4fd6-a575-48cf-879d-45135b0fd717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7d3b4fd6-a575-48cf-879d-45135b0fd717" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_806b1c08-3710-4fa5-9579-7aedc268ac32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_806b1c08-3710-4fa5-9579-7aedc268ac32" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f75f6de4-f09e-41c0-87a8-7433d62a92c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f75f6de4-f09e-41c0-87a8-7433d62a92c1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CommonStockOutstandingPercentage_02e003e4-7944-4c8b-ad19-f1ca4adb326a" xlink:href="bios-20201231.xsd#bios_CommonStockOutstandingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_bios_CommonStockOutstandingPercentage_02e003e4-7944-4c8b-ad19-f1ca4adb326a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_531018e4-eb45-4ea5-9602-57b1e018bf1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_531018e4-eb45-4ea5-9602-57b1e018bf1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_531018e4-eb45-4ea5-9602-57b1e018bf1c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_531018e4-eb45-4ea5-9602-57b1e018bf1c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_531018e4-eb45-4ea5-9602-57b1e018bf1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cc5746a4-cb3c-4bdf-9b3a-a86f86a4a561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_531018e4-eb45-4ea5-9602-57b1e018bf1c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cc5746a4-cb3c-4bdf-9b3a-a86f86a4a561" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c1ad2384-cf7d-4a8e-a732-f991fd331834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cc5746a4-cb3c-4bdf-9b3a-a86f86a4a561" xlink:to="loc_us-gaap_SubsequentEventMember_c1ad2384-cf7d-4a8e-a732-f991fd331834" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9f04cae0-ca69-4421-8e49-a220a3afffe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:to="loc_us-gaap_DebtInstrumentAxis_9f04cae0-ca69-4421-8e49-a220a3afffe9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9f04cae0-ca69-4421-8e49-a220a3afffe9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9f04cae0-ca69-4421-8e49-a220a3afffe9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9f04cae0-ca69-4421-8e49-a220a3afffe9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6f72daa7-15d5-49d8-85b9-77a095e075d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9f04cae0-ca69-4421-8e49-a220a3afffe9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6f72daa7-15d5-49d8-85b9-77a095e075d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditAgreementsEnteredInto2019Member_82063c67-ac67-4298-874e-dfee16d19966" xlink:href="bios-20201231.xsd#bios_CreditAgreementsEnteredInto2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6f72daa7-15d5-49d8-85b9-77a095e075d4" xlink:to="loc_bios_CreditAgreementsEnteredInto2019Member_82063c67-ac67-4298-874e-dfee16d19966" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryAxis_b53353b3-b8dd-4fcf-95cf-a1bace82bc88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:to="loc_us-gaap_LienCategoryAxis_b53353b3-b8dd-4fcf-95cf-a1bace82bc88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_b53353b3-b8dd-4fcf-95cf-a1bace82bc88_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LienCategoryAxis_b53353b3-b8dd-4fcf-95cf-a1bace82bc88" xlink:to="loc_us-gaap_LienCategoryDomain_b53353b3-b8dd-4fcf-95cf-a1bace82bc88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_24daf885-f2d3-46c4-87ec-93fbdde2314d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LienCategoryAxis_b53353b3-b8dd-4fcf-95cf-a1bace82bc88" xlink:to="loc_us-gaap_LienCategoryDomain_24daf885-f2d3-46c4-87ec-93fbdde2314d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLienMember_34322a83-d28a-4663-83c5-cdbdf1eb8112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorLienMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LienCategoryDomain_24daf885-f2d3-46c4-87ec-93fbdde2314d" xlink:to="loc_us-gaap_SeniorLienMember_34322a83-d28a-4663-83c5-cdbdf1eb8112" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JuniorLienMember_d4f1bfee-717f-4809-a296-8a38654ba072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_JuniorLienMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LienCategoryDomain_24daf885-f2d3-46c4-87ec-93fbdde2314d" xlink:to="loc_us-gaap_JuniorLienMember_d4f1bfee-717f-4809-a296-8a38654ba072" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_052ddc6c-d0cc-4729-bb4e-09c8ca7f5ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_052ddc6c-d0cc-4729-bb4e-09c8ca7f5ad7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_052ddc6c-d0cc-4729-bb4e-09c8ca7f5ad7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_052ddc6c-d0cc-4729-bb4e-09c8ca7f5ad7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_052ddc6c-d0cc-4729-bb4e-09c8ca7f5ad7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_eaa24ad2-1a9e-40d1-9b2d-0f5bfd8a10db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_052ddc6c-d0cc-4729-bb4e-09c8ca7f5ad7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_eaa24ad2-1a9e-40d1-9b2d-0f5bfd8a10db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_fa9ef4bf-ab01-4737-858a-2a5205213f34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eaa24ad2-1a9e-40d1-9b2d-0f5bfd8a10db" xlink:to="loc_us-gaap_SeniorNotesMember_fa9ef4bf-ab01-4737-858a-2a5205213f34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NotesPayableMember_c76a5b94-356e-47d6-b0f7-a223e7dab6cf" xlink:href="bios-20201231.xsd#bios_NotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eaa24ad2-1a9e-40d1-9b2d-0f5bfd8a10db" xlink:to="loc_bios_NotesPayableMember_c76a5b94-356e-47d6-b0f7-a223e7dab6cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_60ac1cf6-8917-41b5-99f6-b10f72c37f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:to="loc_us-gaap_StatementClassOfStockAxis_60ac1cf6-8917-41b5-99f6-b10f72c37f95" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_60ac1cf6-8917-41b5-99f6-b10f72c37f95_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_60ac1cf6-8917-41b5-99f6-b10f72c37f95" xlink:to="loc_us-gaap_ClassOfStockDomain_60ac1cf6-8917-41b5-99f6-b10f72c37f95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9992dce4-d09b-45ac-bbb1-305885ab6606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_60ac1cf6-8917-41b5-99f6-b10f72c37f95" xlink:to="loc_us-gaap_ClassOfStockDomain_9992dce4-d09b-45ac-bbb1-305885ab6606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_28efb599-9b6f-4444-8ae3-128df4b6b94c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9992dce4-d09b-45ac-bbb1-305885ab6606" xlink:to="loc_us-gaap_CommonStockMember_28efb599-9b6f-4444-8ae3-128df4b6b94c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d79f9418-53a1-43c7-97fb-aa77853586a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d79f9418-53a1-43c7-97fb-aa77853586a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d79f9418-53a1-43c7-97fb-aa77853586a2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d79f9418-53a1-43c7-97fb-aa77853586a2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d79f9418-53a1-43c7-97fb-aa77853586a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58874c8c-f3b8-44a6-9f20-28e0a53dedbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d79f9418-53a1-43c7-97fb-aa77853586a2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58874c8c-f3b8-44a6-9f20-28e0a53dedbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SecondaryOfferingMember_0d8b0732-27f2-4898-a46e-59f986e0a264" xlink:href="bios-20201231.xsd#bios_SecondaryOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58874c8c-f3b8-44a6-9f20-28e0a53dedbc" xlink:to="loc_bios_SecondaryOfferingMember_0d8b0732-27f2-4898-a46e-59f986e0a264" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d8e4f653-d63b-4da3-b81e-097d652f7996" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:to="loc_dei_LegalEntityAxis_d8e4f653-d63b-4da3-b81e-097d652f7996" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d8e4f653-d63b-4da3-b81e-097d652f7996_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d8e4f653-d63b-4da3-b81e-097d652f7996" xlink:to="loc_dei_EntityDomain_d8e4f653-d63b-4da3-b81e-097d652f7996_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2c5e79e8-09c1-4a72-8ef1-b387305327bc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d8e4f653-d63b-4da3-b81e-097d652f7996" xlink:to="loc_dei_EntityDomain_2c5e79e8-09c1-4a72-8ef1-b387305327bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HCGroupHoldingsILLCMember_b0e71eda-e052-4a8c-ae90-4fcbf7ca5cc0" xlink:href="bios-20201231.xsd#bios_HCGroupHoldingsILLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2c5e79e8-09c1-4a72-8ef1-b387305327bc" xlink:to="loc_bios_HCGroupHoldingsILLCMember_b0e71eda-e052-4a8c-ae90-4fcbf7ca5cc0" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>bios-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:67699b3b-5a42-424d-a4a2-736d8be0bc5f,g:dc7394d0-f9c6-4f46-91d7-369b9ff9f10f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_53937ce7-61d8-4124-9baa-b5254d6e9428_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_853af196-6387-4635-9838-dc875cdbfa57_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6da364a2-ee67-4c75-a5b3-6b343a69a0e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_09798b65-ce38-42b9-9cc3-db29b6354361_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_f1a67000-e9ce-423d-943b-89501190b188_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9d0704c3-77e5-42b1-971a-df4a99c8735a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2019</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_39066dd2-27ad-4e33-8609-004e199256d8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_fe4a600b-07cc-43a7-b51d-172e873c8e5f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8aa7df92-355f-40d7-83bb-ceaed8917935_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a18e7e42-eafd-41a5-b5b4-514e881eca7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2412a761-e15d-4d6c-9626-19bd6e5d0f88_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_82cddf10-85cc-4e8e-a9a2-a6286e615b4f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_c7c7ac42-7fdf-4fd0-8ae6-20758468edb0_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_bef2211e-f77c-46fd-b58f-2ed646a1e9a4_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_DebtInstrumentThirdPartyFees_e390cd22-54cb-4e92-8a61-c884d23fdf5b_terseLabel_en-US" xlink:label="lab_bios_DebtInstrumentThirdPartyFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party fees</link:label>
    <link:label id="lab_bios_DebtInstrumentThirdPartyFees_label_en-US" xlink:label="lab_bios_DebtInstrumentThirdPartyFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Third Party Fees</link:label>
    <link:label id="lab_bios_DebtInstrumentThirdPartyFees_documentation_en-US" xlink:label="lab_bios_DebtInstrumentThirdPartyFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Third Party Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DebtInstrumentThirdPartyFees" xlink:href="bios-20201231.xsd#bios_DebtInstrumentThirdPartyFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_DebtInstrumentThirdPartyFees" xlink:to="lab_bios_DebtInstrumentThirdPartyFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ad32e831-0d6f-482f-abce-7edc7bd4c065_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and issued (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_A2017WarrantsMember_35e265bc-7086-477e-866d-f52d7d65b922_terseLabel_en-US" xlink:label="lab_bios_A2017WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Warrants</link:label>
    <link:label id="lab_bios_A2017WarrantsMember_label_en-US" xlink:label="lab_bios_A2017WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Warrants [Member]</link:label>
    <link:label id="lab_bios_A2017WarrantsMember_documentation_en-US" xlink:label="lab_bios_A2017WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2017WarrantsMember" xlink:href="bios-20201231.xsd#bios_A2017WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_A2017WarrantsMember" xlink:to="lab_bios_A2017WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_820c1158-e8c7-4c00-8753-af6829f311ea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_1476af51-3d0e-4872-b04a-302a8280fb40_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_aeab5296-38f1-4a29-9815-0514ea8516ea_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_00e84e15-9e7c-4e08-a300-b422f9656ebb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_08933ffd-fc72-4c67-b3c3-06afbd815312_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_bc843863-aee2-42da-9674-2987fe285ce5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs and third party fees</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_LegacyHealthSystemsMember_cab9f9a0-f787-44a1-b9fe-e9928452f6de_terseLabel_en-US" xlink:label="lab_bios_LegacyHealthSystemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Health Systems</link:label>
    <link:label id="lab_bios_LegacyHealthSystemsMember_label_en-US" xlink:label="lab_bios_LegacyHealthSystemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Health Systems [Member]</link:label>
    <link:label id="lab_bios_LegacyHealthSystemsMember_documentation_en-US" xlink:label="lab_bios_LegacyHealthSystemsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Health Systems [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LegacyHealthSystemsMember" xlink:href="bios-20201231.xsd#bios_LegacyHealthSystemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_LegacyHealthSystemsMember" xlink:to="lab_bios_LegacyHealthSystemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_856f5eae-8711-4cff-9e6d-c0f7c4791eed_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ae5c6e72-35e4-400b-be23-dd496375acf3_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_493870a8-9899-4c5a-8292-ae2d575b867a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorLienMember_aa25da8b-afde-49c2-99a6-b197b1aec3ea_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorLienMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Lien Term Loan</link:label>
    <link:label id="lab_us-gaap_SeniorLienMember_label_en-US" xlink:label="lab_us-gaap_SeniorLienMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Lien [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLienMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorLienMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorLienMember" xlink:to="lab_us-gaap_SeniorLienMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_606cee44-12d0-42fd-8aef-dfab605c2647_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4479e7d-817f-4ba1-b77c-fd6afe4b2ae2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_0dea686a-fef7-4e62-981a-173e0662b42e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_f8f971b0-2807-476b-aeb5-ab476a7c76c9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_ad895812-dd1b-4ef8-898e-fdb3e7ab5e80_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_6bbcf022-3faa-4f86-a46c-5712197e4044_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock and Certain Warrants</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_9b7ba674-4ab1-4fd1-b986-0fa33eb8be3a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_16a46da2-917c-4879-9c54-eeb199281a48_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f84b40ae-475b-44ab-98b3-e23facf3cae7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_IncomeTaxExpenseBenefitCARESAct_f3efda65-e2db-4f39-be00-6f76979259a8_terseLabel_en-US" xlink:label="lab_bios_IncomeTaxExpenseBenefitCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit) related to CARES Act</link:label>
    <link:label id="lab_bios_IncomeTaxExpenseBenefitCARESAct_label_en-US" xlink:label="lab_bios_IncomeTaxExpenseBenefitCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), CARES Act</link:label>
    <link:label id="lab_bios_IncomeTaxExpenseBenefitCARESAct_documentation_en-US" xlink:label="lab_bios_IncomeTaxExpenseBenefitCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_IncomeTaxExpenseBenefitCARESAct" xlink:href="bios-20201231.xsd#bios_IncomeTaxExpenseBenefitCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_IncomeTaxExpenseBenefitCARESAct" xlink:to="lab_bios_IncomeTaxExpenseBenefitCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_67ad29da-3729-4da4-87fb-0ddf0647e084_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_55e2d063-68ab-46f7-98d6-040cb1f36c78_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount for lack of marketability</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_fcbb09af-c0c4-48ce-9176-b48279d30011_verboseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks/Names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_0aaa0ee9-1b3d-4448-96cc-f8acc71393a2_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks/names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_929df5e6-9e88-455f-b778-b900bc33ab23_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING INCOME (LOSS)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b04971a6-023a-484c-adb5-ecd705391d3e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_b3aaa455-65df-4ad8-bd38-db13f609ef15_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_56d2372a-443a-4ae5-8878-dda69a508f24_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees incurred netted against proceeds</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid_10a5259b-fb04-44c2-8039-6ba5fb909133_terseLabel_en-US" xlink:label="lab_us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash distributions</link:label>
    <link:label id="lab_us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid_label_en-US" xlink:label="lab_us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Made to Limited Liability Company (LLC) Member, Cash Distributions Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid" xlink:to="lab_us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_a70d5d1e-8803-47d4-b702-9259822ca621_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_c25a0d0b-c8ab-4c11-8d15-ce45cbcdf9e5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_AccruedExpensesAndOtherCurrentLiabilities_a68ab373-d6c2-47bf-8cbd-9721735f11c6_terseLabel_en-US" xlink:label="lab_bios_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_bios_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_bios_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_bios_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_bios_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities, combined with the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="bios-20201231.xsd#bios_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_bios_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_61a12378-5af1-46ed-808f-0777ef3bc4e1_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_be8901f5-6707-43c9-affc-5df590a1e5b5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2c20bddd-c616-4bce-9271-a1232cc18be8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2019 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1e9a9525-6ae3-4df2-940e-fdc15ded37de_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2020 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_817f6f3c-5c8f-469e-b8e2-aa6f2d282e25_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_ee0698f1-1d76-4d91-bf66-99889f04f29f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a37cf9c4-cd46-458b-bcc7-bf79aecdc75d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8cca3221-9808-4187-8390-3002dbe862f8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares surrendered to satisfy tax withholding obligations</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_5126bea7-9af8-4cf6-8890-97a8884fad33_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4d17f90e-c432-43a3-b33f-5a184b53b163_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_58452608-2a71-4841-8939-67e11837d88f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4a91c52a-ffd7-48fd-b0b6-50149660c5aa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ace35f06-66cc-49ba-a50c-c8f09a5d93a2_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_75413711-11fc-466a-8626-ce97700a78d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_9e9260f5-976b-4410-8642-e0434bfb3018_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash acquired</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_efc37995-7fc1-4aad-b36e-4cba34618db3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b4a8e010-8d37-4571-8420-1a8ddedd88f9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 and beyond</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_be143ab3-753b-435d-9a3b-0637bd494734_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of share-based instruments</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_113d90ca-077d-4bdb-b27a-c935097c2149_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_be7a449e-4fe5-45f9-813f-be0eabea7388_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_e7988dcd-b6dc-4ac4-86d9-a76bdd5ee0c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_5991e4b9-7315-4be8-b182-5c381901b959_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_OptionExercisePriceRangeFiveMember_1607451c-f754-4744-96e4-63bdd76dfa18_terseLabel_en-US" xlink:label="lab_bios_OptionExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">33</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeFiveMember_label_en-US" xlink:label="lab_bios_OptionExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range Five [Member]</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeFiveMember_documentation_en-US" xlink:label="lab_bios_OptionExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeFiveMember" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_OptionExercisePriceRangeFiveMember" xlink:to="lab_bios_OptionExercisePriceRangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_40b244b2-d3a2-4f1c-83c6-effe0db096b9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1e64b3d1-f0fd-4b40-b41e-2176993efba8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_64fce648-5151-4326-b423-b56e919a486a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_86701f7f-f98d-4d9f-93dd-478eeb34fad1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_efbdfce7-fd18-4336-bbd7-6d8c1066aebb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original issue discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_45bbc085-23ed-4557-8e72-4b1380253bcf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_RestrictedStockAndStockOptionsMember_10f8c6b4-5122-453c-b675-676e559d4803_terseLabel_en-US" xlink:label="lab_bios_RestrictedStockAndStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock And Stock Options</link:label>
    <link:label id="lab_bios_RestrictedStockAndStockOptionsMember_label_en-US" xlink:label="lab_bios_RestrictedStockAndStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock And Stock Options [Member]</link:label>
    <link:label id="lab_bios_RestrictedStockAndStockOptionsMember_documentation_en-US" xlink:label="lab_bios_RestrictedStockAndStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock And Stock Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_RestrictedStockAndStockOptionsMember" xlink:href="bios-20201231.xsd#bios_RestrictedStockAndStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_RestrictedStockAndStockOptionsMember" xlink:to="lab_bios_RestrictedStockAndStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_cd631dff-aa56-4457-87a4-1d993c6dfbdc_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Estimated Life (in years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_InterestOnManagementNotesReceivable_50f79d10-d746-46fe-a804-e46db6966163_negatedLabel_en-US" xlink:label="lab_bios_InterestOnManagementNotesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on management notes receivable</link:label>
    <link:label id="lab_bios_InterestOnManagementNotesReceivable_label_en-US" xlink:label="lab_bios_InterestOnManagementNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest On Management Notes Receivable</link:label>
    <link:label id="lab_bios_InterestOnManagementNotesReceivable_documentation_en-US" xlink:label="lab_bios_InterestOnManagementNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest On Management Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InterestOnManagementNotesReceivable" xlink:href="bios-20201231.xsd#bios_InterestOnManagementNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_InterestOnManagementNotesReceivable" xlink:to="lab_bios_InterestOnManagementNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_312d01f3-9e0e-4467-8f99-e54b909b3638_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dd9e10e8-788b-4ae1-991e-67eafbc9d4fc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2019 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d240705c-bf12-45a0-a495-33d431730257_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2020 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1465cb1b-cf88-43d3-a7e6-57cf13473fc7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a136ead0-05f8-44dc-955e-dfb6e01a2b0e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6441a41a-24f8-4dba-8e83-1e13873bceeb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_3e702b7f-4a64-42d8-972a-55ee45943148_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_PublicOfferingMember_6d9a7c86-e79c-4fe2-b3a9-4ac0cf008928_terseLabel_en-US" xlink:label="lab_bios_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_bios_PublicOfferingMember_label_en-US" xlink:label="lab_bios_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_bios_PublicOfferingMember_documentation_en-US" xlink:label="lab_bios_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PublicOfferingMember" xlink:href="bios-20201231.xsd#bios_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_PublicOfferingMember" xlink:to="lab_bios_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_MergerOperatingLossCarryforwardMember_b9df67b3-4b81-49fe-8ab0-372d172b92fc_terseLabel_en-US" xlink:label="lab_bios_MergerOperatingLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Operating Loss Carryforward</link:label>
    <link:label id="lab_bios_MergerOperatingLossCarryforwardMember_label_en-US" xlink:label="lab_bios_MergerOperatingLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Operating Loss Carryforward [Member]</link:label>
    <link:label id="lab_bios_MergerOperatingLossCarryforwardMember_documentation_en-US" xlink:label="lab_bios_MergerOperatingLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Operating Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_MergerOperatingLossCarryforwardMember" xlink:href="bios-20201231.xsd#bios_MergerOperatingLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_MergerOperatingLossCarryforwardMember" xlink:to="lab_bios_MergerOperatingLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1ed0791b-9cce-4da6-97d7-a812535b270c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_e0d8dc66-f597-4dd5-9ad6-074924421616_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of December 31, 2020 and 2019, respectively.</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_dfea766f-d262-40dd-b197-999067ac368a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lower range limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecurities_dd1ef365-8052-4cfe-b744-5e6c4b0894c5_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_DilutiveSecurities_label_en-US" xlink:label="lab_us-gaap_DilutiveSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecurities" xlink:to="lab_us-gaap_DilutiveSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_df6aa096-8288-43cc-85fe-5fd83ae715f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_3fae40ef-5d89-4564-bdda-5db66551aec5_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_19c99284-d700-4f29-ae48-bf5312c50692_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_e187cb5a-171e-49ed-b798-413520475c58_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_cb3f05b1-8f0c-411c-bffe-d0f36278823d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at December 31, 2020 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ab2d36c9-bec8-474f-9454-446145dbcc6d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_5dc79407-d91e-4310-b097-42dd7518025d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt prepayment fees</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_c003854b-fbc5-477a-9990-f0d4aa5b235c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_797bdc7a-e452-4ecb-aeb9-b9ce3c614b59_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_bfcb65c6-97ce-482b-b6c6-8e7ac1c126d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited and expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_03166431-50e3-432e-9e96-132655dcda90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing cash flows</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6d638b62-dc29-45dc-bcde-f334dc7b13d3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based incentive compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_eb05a958-cffa-4dc8-b665-aa7f91b77b02_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited and expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledReceivablesCurrent_2e89bd10-1ba2-4652-9050-27375929c38e_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled receivables</link:label>
    <link:label id="lab_us-gaap_UnbilledReceivablesCurrent_label_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledReceivablesCurrent" xlink:to="lab_us-gaap_UnbilledReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_bed48baa-dc8b-4769-b842-ae59cf748b9d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_ed9bdc3d-ac7a-41eb-b938-8b365a4325bf_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 and beyond</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6bf2b9cb-8c41-4575-9f2c-ca9e5e787fab_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET REVENUE</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_74fa02fa-f607-4f0b-bb71-15f238faeb9f_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_86d18e4b-ded8-42c9-a723-7b76da647e09_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price threshold (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_3b100490-c92f-40cc-81ee-33420a64ba52_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_e8b48439-ef17-4fa6-a4a6-206f515a71f5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_ed06a537-4cdf-40c8-aeef-b8cd0934f670_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_9cfb62c5-ece4-4aa0-8dc6-e74dd6559930_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_415190c6-2c9d-4c14-8132-dbaa807b7050_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8e7fdf9f-43b0-4a20-a531-3de874f59d0e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LOSS PER COMMON SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ac90aa63-1eaa-466a-af9e-167cf0762b91_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per Common Share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_LoansFundedForMembershipUnitPurchaseMember_62c8c89b-cd31-413a-900e-7ae58f63930c_terseLabel_en-US" xlink:label="lab_bios_LoansFundedForMembershipUnitPurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Funded For Membership Unit Purchase</link:label>
    <link:label id="lab_bios_LoansFundedForMembershipUnitPurchaseMember_label_en-US" xlink:label="lab_bios_LoansFundedForMembershipUnitPurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Funded For Membership Unit Purchase [Member]</link:label>
    <link:label id="lab_bios_LoansFundedForMembershipUnitPurchaseMember_documentation_en-US" xlink:label="lab_bios_LoansFundedForMembershipUnitPurchaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Funded For Membership Unit Purchase [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LoansFundedForMembershipUnitPurchaseMember" xlink:href="bios-20201231.xsd#bios_LoansFundedForMembershipUnitPurchaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_LoansFundedForMembershipUnitPurchaseMember" xlink:to="lab_bios_LoansFundedForMembershipUnitPurchaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_cd98c507-f25e-4d61-b489-d9aefb4d0097_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract_f6e2de5a-ee56-489f-9456-4810d9f5b1cf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value - Derivatives in liability position</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_d2cd16e4-0270-4f66-9e59-3b8300e24b8a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a674b321-d5d2-4fe9-9123-f28c44a48f6b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_e159652e-be3e-40ea-874d-f7ab9deee84c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 and beyond</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_2ed78dd7-171c-48dc-9089-5bf66939ee51_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and benefits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue_a0efabea-29b7-457e-95c8-8f9fa29723ac_terseLabel_en-US" xlink:label="lab_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited and expired</link:label>
    <link:label id="lab_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue_label_en-US" xlink:label="lab_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited And Expirations, Intrinsic Value</link:label>
    <link:label id="lab_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue_documentation_en-US" xlink:label="lab_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited And Expirations, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue" xlink:href="bios-20201231.xsd#bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue" xlink:to="lab_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_9af28447-b672-43d5-9690-a9a3654590f6_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock_0b585101-7149-4c99-94e7-4873c7d8ec39_terseLabel_en-US" xlink:label="lab_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Business Risk</link:label>
    <link:label id="lab_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock_label_en-US" xlink:label="lab_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Business Risk, Policy [Policy Text Block]</link:label>
    <link:label id="lab_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Business Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" xlink:href="bios-20201231.xsd#bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" xlink:to="lab_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_98d61427-08df-41b3-b813-59768ce6a30b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_9c864a4a-4000-4c4b-b9c2-6104bf247ab8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_HCIIncentiveUnitsMember_b9ce41c8-4110-492c-9cf6-d7e6b2c260d0_terseLabel_en-US" xlink:label="lab_bios_HCIIncentiveUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HC I Incentive Units</link:label>
    <link:label id="lab_bios_HCIIncentiveUnitsMember_label_en-US" xlink:label="lab_bios_HCIIncentiveUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HC I Incentive Units [Member]</link:label>
    <link:label id="lab_bios_HCIIncentiveUnitsMember_documentation_en-US" xlink:label="lab_bios_HCIIncentiveUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HC I Incentive Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HCIIncentiveUnitsMember" xlink:href="bios-20201231.xsd#bios_HCIIncentiveUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_HCIIncentiveUnitsMember" xlink:to="lab_bios_HCIIncentiveUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_aff6a4a3-61b1-4f9e-ba2f-b79d1f992d4e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_BioScripMember_b05d20e9-1e10-4674-8d7b-abc1bf7ef015_terseLabel_en-US" xlink:label="lab_bios_BioScripMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioScrip</link:label>
    <link:label id="lab_bios_BioScripMember_label_en-US" xlink:label="lab_bios_BioScripMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioScrip [Member]</link:label>
    <link:label id="lab_bios_BioScripMember_documentation_en-US" xlink:label="lab_bios_BioScripMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioScrip [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BioScripMember" xlink:href="bios-20201231.xsd#bios_BioScripMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_BioScripMember" xlink:to="lab_bios_BioScripMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_0e671a5d-d995-49e7-93cf-236204ef04d3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated comprehensive loss reclassified</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_f8c15715-c343-4533-8081-449ab9e724ce_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) location of derivative instruments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_181ddf62-07b1-4a5d-9ea4-919dc8ad7656_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_9d106ccc-6161-4cd9-8e35-f8a27aea203b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebate receivable</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_f6234cd6-1029-48c0-964b-cf69a5a3eb18_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_cb74fb68-b225-49a9-96f0-a5d3d03a68b6_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_db1ff6db-8c55-4dfa-a662-d1a269a13050_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_9eea0f57-399b-48a6-bc44-311107dee380_terseLabel_en-US" xlink:label="lab_bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in uncertain tax positions</link:label>
    <link:label id="lab_bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_label_en-US" xlink:label="lab_bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Percent</link:label>
    <link:label id="lab_bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_documentation_en-US" xlink:label="lab_bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:href="bios-20201231.xsd#bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:to="lab_bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_55e8baa5-d258-4ec1-a7ac-89e7f979b769_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss since acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_d62f69c0-6fff-42cb-ae72-97fb504fb65f_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2dcbb73-b637-496c-aade-0a9fc39ab214_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b4da3998-7aa6-4ddf-a8e5-01842a87e664_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_5e3e787a-cae7-48e9-8b77-2c9ed458b248_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance proceeds from business casualty loss</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Insurance Settlement, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities" xlink:to="lab_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc0d6874-0a68-43b5-9b3d-0743d21f88e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_257c199e-1068-4b8f-b9fe-21b2f4fc2c0e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4238e734-a860-4b4d-8ea6-5924770b006b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life Exercisable at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_d38314db-2a41-4643-a526-ceab9a76108a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_FirstLienTermLoanMember_1e5fa8ba-a5e9-486c-8a88-8bf862252372_terseLabel_en-US" xlink:label="lab_bios_FirstLienTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Lien Term Loan</link:label>
    <link:label id="lab_bios_FirstLienTermLoanMember_3981d5cd-86df-4376-b8b9-571d3ec63fba_verboseLabel_en-US" xlink:label="lab_bios_FirstLienTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Lien Term Loan</link:label>
    <link:label id="lab_bios_FirstLienTermLoanMember_label_en-US" xlink:label="lab_bios_FirstLienTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Lien Term Loan [Member]</link:label>
    <link:label id="lab_bios_FirstLienTermLoanMember_documentation_en-US" xlink:label="lab_bios_FirstLienTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Lien Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FirstLienTermLoanMember" xlink:href="bios-20201231.xsd#bios_FirstLienTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_FirstLienTermLoanMember" xlink:to="lab_bios_FirstLienTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_729cbb6b-dbfc-4099-b439-2c8fe103306d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_69477f29-39c5-42a5-a0ec-f25a0fbbc203_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ab6952ce-22a2-492b-985a-0af79cdc0f61_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_711b6296-3f18-45b9-9ed0-bc2131208660_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Basic and Diluted Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember_3c006f9d-b984-49b0-b010-9f547ad6a6a3_terseLabel_en-US" xlink:label="lab_bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Net Operating Loss Carryfowards Available To Offset Future Taxable Income</link:label>
    <link:label id="lab_bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember_label_en-US" xlink:label="lab_bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Net Operating Loss Carryfowards Available To Offset Future Taxable Income [Member]</link:label>
    <link:label id="lab_bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember_documentation_en-US" xlink:label="lab_bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Net Operating Loss Carryfowards Available To Offset Future Taxable Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember" xlink:href="bios-20201231.xsd#bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember" xlink:to="lab_bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_97e00d64-dd3a-4b97-8580-2cb872645934_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_A2015WarrantsMember_784ad8ef-3ed4-46e9-875b-8d30900ef7e7_terseLabel_en-US" xlink:label="lab_bios_A2015WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Warrants</link:label>
    <link:label id="lab_bios_A2015WarrantsMember_label_en-US" xlink:label="lab_bios_A2015WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Warrants [Member]</link:label>
    <link:label id="lab_bios_A2015WarrantsMember_documentation_en-US" xlink:label="lab_bios_A2015WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2015WarrantsMember" xlink:href="bios-20201231.xsd#bios_A2015WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_A2015WarrantsMember" xlink:to="lab_bios_A2015WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1e884e61-94a8-431c-a9b7-6a09feb41d26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_532c83b7-5be4-4461-a740-4f511ed39ca3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1eaaacbd-1208-42be-87ba-faf5853bcfb4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Identifiable Assets and Assumed Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_8337bfc9-a298-4b40-9241-c867f4c471be_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c4171ebe-ddcb-40fd-b59b-9ca672f268df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePaymentsUse_03899257-70a8-4b00-8c79-9b62d8be314d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePaymentsUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePaymentsUse_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePaymentsUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments, Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePaymentsUse" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePaymentsUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePaymentsUse" xlink:to="lab_us-gaap_OperatingLeasePaymentsUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_67b0b3fc-a727-4c25-b8ab-9e084f341d63_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt principal</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_aa1be6d6-382a-4836-b61d-8bf1f4fbac1e_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to extinguish debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_c1b630c7-285f-4527-a2f3-4e5667d435c1_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal prepayment</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_7cdeb389-431c-48f3-b4c2-8b3eed54fb6b_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemptions to related parties</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Related Party Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_377981bf-5cff-4c39-9d0c-36d7cebe9a81_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_81fadc92-007a-44f3-a929-ddd2c5024395_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_88c90a23-68a4-42f6-bb09-07fc47ac3bda_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_217f0ad6-6f10-4055-a2ac-6eba02c4b96d_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_3c816158-1e47-4dfd-9b6e-a286e7bb0185_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_1435655c-d040-4363-bde1-e67f1805cc6d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_ee133b16-4a37-4f4a-a423-fa2bcdc2f109_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Fair Values of Debt Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_988960c7-8cfc-4b03-b177-0397a3a0c342_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_bc0053b4-21be-4ef7-bdb6-e5ea154cf250_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_dfb010d8-c842-47d4-b6b4-1c3207d40600_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gain (loss) on derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_45a930ac-ebbd-48c1-8bf4-c06fa1642e5d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedParties_6d57d69c-92f9-42a1-a393-0303c7b965fd_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from joint ventures</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties" xlink:to="lab_us-gaap_DueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_PaymentsOfDebtIssuanceCostsInvestingActivities_216c96dc-5f85-435b-9a76-db01b4c95dba_terseLabel_en-US" xlink:label="lab_bios_PaymentsOfDebtIssuanceCostsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs, investing activities</link:label>
    <link:label id="lab_bios_PaymentsOfDebtIssuanceCostsInvestingActivities_label_en-US" xlink:label="lab_bios_PaymentsOfDebtIssuanceCostsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Debt Issuance Costs, Investing Activities</link:label>
    <link:label id="lab_bios_PaymentsOfDebtIssuanceCostsInvestingActivities_documentation_en-US" xlink:label="lab_bios_PaymentsOfDebtIssuanceCostsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Debt Issuance Costs, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PaymentsOfDebtIssuanceCostsInvestingActivities" xlink:href="bios-20201231.xsd#bios_PaymentsOfDebtIssuanceCostsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_PaymentsOfDebtIssuanceCostsInvestingActivities" xlink:to="lab_bios_PaymentsOfDebtIssuanceCostsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_0d249ef4-756c-4d88-bb79-71dad96a9258_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_SecondLienTermLoanMember_70dc5561-7273-48fe-ba22-dbd426eecd7d_terseLabel_en-US" xlink:label="lab_bios_SecondLienTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Lien Notes</link:label>
    <link:label id="lab_bios_SecondLienTermLoanMember_6e7d0d7d-26cd-4608-a49b-01b97cf9c878_verboseLabel_en-US" xlink:label="lab_bios_SecondLienTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Lien Notes</link:label>
    <link:label id="lab_bios_SecondLienTermLoanMember_label_en-US" xlink:label="lab_bios_SecondLienTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Lien Term Loan [Member]</link:label>
    <link:label id="lab_bios_SecondLienTermLoanMember_documentation_en-US" xlink:label="lab_bios_SecondLienTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Lien Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SecondLienTermLoanMember" xlink:href="bios-20201231.xsd#bios_SecondLienTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_SecondLienTermLoanMember" xlink:to="lab_bios_SecondLienTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_d1acefac-b4fe-48fe-94c9-2879dc2085f1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ManagementMember_e195bacb-a4b8-4ce2-9d69-f5dbdb8aeb0c_terseLabel_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management</link:label>
    <link:label id="lab_srt_ManagementMember_label_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ManagementMember" xlink:to="lab_srt_ManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_79a67af8-e37c-495b-ba47-9a430d728ec7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c3dc3601-22ac-472b-b0b8-feaabf7d924c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued pursuant to acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_OptionsExercisableAbstract_763d4954-68bd-4cf3-82f2-3815fb011406_terseLabel_en-US" xlink:label="lab_bios_OptionsExercisableAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Exercisable</link:label>
    <link:label id="lab_bios_OptionsExercisableAbstract_label_en-US" xlink:label="lab_bios_OptionsExercisableAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Exercisable [Abstract]</link:label>
    <link:label id="lab_bios_OptionsExercisableAbstract_documentation_en-US" xlink:label="lab_bios_OptionsExercisableAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Exercisable [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionsExercisableAbstract" xlink:href="bios-20201231.xsd#bios_OptionsExercisableAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_OptionsExercisableAbstract" xlink:to="lab_bios_OptionsExercisableAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_AggregateIntrinsicValueAbstract_1221d93c-1d58-491e-82f7-4f000e877ddc_terseLabel_en-US" xlink:label="lab_bios_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_bios_AggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_bios_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_bios_AggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_bios_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AggregateIntrinsicValueAbstract" xlink:href="bios-20201231.xsd#bios_AggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_AggregateIntrinsicValueAbstract" xlink:to="lab_bios_AggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_caed7e59-66ae-4bc6-a349-4ce11c75663a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_9e193b90-8cc3-4c3d-bad5-d9ef697f5e88_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_373e4966-1254-4cd1-883b-2ff655b4a013_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_53484eaa-e4ce-43ac-9595-0b3c717b37b4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_1efaa1ef-b430-478c-8d85-b9321e546a99_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LOSS BEFORE INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f8242e94-bf57-46cf-9324-afb6a1f84935_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_8b6c03d7-3ffc-4a4a-ab71-638e8a4748fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MajorityShareholderMember_96be23db-0fc6-44f6-8490-22a8ec8ccf42_terseLabel_en-US" xlink:label="lab_us-gaap_MajorityShareholderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HC Group Holdings I, LLC</link:label>
    <link:label id="lab_us-gaap_MajorityShareholderMember_label_en-US" xlink:label="lab_us-gaap_MajorityShareholderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Majority Shareholder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorityShareholderMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorityShareholderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorityShareholderMember" xlink:to="lab_us-gaap_MajorityShareholderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_RepaymentOfManagementNotesReceivable_68898965-5438-43c6-a18f-d8f4af0db26d_terseLabel_en-US" xlink:label="lab_bios_RepaymentOfManagementNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of management notes receivable</link:label>
    <link:label id="lab_bios_RepaymentOfManagementNotesReceivable_label_en-US" xlink:label="lab_bios_RepaymentOfManagementNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Management Notes Receivable</link:label>
    <link:label id="lab_bios_RepaymentOfManagementNotesReceivable_documentation_en-US" xlink:label="lab_bios_RepaymentOfManagementNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Management Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_RepaymentOfManagementNotesReceivable" xlink:href="bios-20201231.xsd#bios_RepaymentOfManagementNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_RepaymentOfManagementNotesReceivable" xlink:to="lab_bios_RepaymentOfManagementNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_227933b4-9566-4278-8eab-1199f32eb8e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_d4c724cb-7a35-4738-8198-5064a4d448d1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1ad32f06-7c73-453f-aa19-7bf6a8872ea1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of BioScrip, Inc.</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_dd956c70-cdc5-4751-b460-6d2ec4ac28a1_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_d7192c5d-1392-400f-8de8-7a4767ec720d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ca074797-b431-4eb4-ba38-fb9407e14c80_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4c57f66d-c7d2-49e9-8f85-08945eb6e4f1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_fc524a7e-affd-4e6e-9584-0a788e3c6b74_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fe2ee663-f91a-472a-acb0-9a21d8158fd3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_47ac21cc-85a1-461d-a511-e5fbf339530b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest rate costs expected to reclassify during next 12 months</link:label>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_label_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:to="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_cca2cd4e-8c9d-42ad-bf94-b6e916824965_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_2911fb25-6e9b-41ac-8ce0-49b2fa85c6f6_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_2e38eee3-e5df-4454-93c3-0b57469d2954_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount of derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_0d7703e1-bb8e-4868-b003-af45b01ae39c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense for intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8a8da263-9bfa-4ee2-98de-8eaa0d940868_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ca82b41e-602f-48be-b3be-55495567857f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_dfea8fa1-81f7-4196-802c-6ea589cd3b4d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_efc93a3b-840c-4808-9656-b49960bea12e_totalLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_d94829cf-632a-419e-bf12-87f1e4744e53_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from the issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_a7dfdcf0-5d6b-443f-9609-0d69caec7f1d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_CreditArrangementsEnteredInto2015Member_4ad22d2f-44da-4f2c-b5da-e19920b61ec7_terseLabel_en-US" xlink:label="lab_bios_CreditArrangementsEnteredInto2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Arrangements Administered By Bank Of America, N.A.</link:label>
    <link:label id="lab_bios_CreditArrangementsEnteredInto2015Member_label_en-US" xlink:label="lab_bios_CreditArrangementsEnteredInto2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Arrangements, Entered Into 2015 [Member]</link:label>
    <link:label id="lab_bios_CreditArrangementsEnteredInto2015Member_documentation_en-US" xlink:label="lab_bios_CreditArrangementsEnteredInto2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Arrangements, Entered Into 2015 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditArrangementsEnteredInto2015Member" xlink:href="bios-20201231.xsd#bios_CreditArrangementsEnteredInto2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_CreditArrangementsEnteredInto2015Member" xlink:to="lab_bios_CreditArrangementsEnteredInto2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_f42cec90-265c-4792-95ef-75a5a73a9cab_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e2e4c27a-0588-480c-9fd1-dd5b98a6d223_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_0aae64ca-c10c-4804-95f1-d0deb105abfc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_30140b7f-5219-46b0-9814-e38ab7aa3992_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8f90864d-5cdb-4b24-a5df-6654c4f7af56_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2019 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_56a7c042-3a95-4413-bb23-e72732547257_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2020 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_226bc35f-e43a-4cd2-b3fa-dad80da9ced5_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_a11ccbc7-1505-4ec4-86c0-df7b6f68d313_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_3ceb1b81-5816-4571-b7db-aeeb789d5f11_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Catastrophic Event [Axis]</link:label>
    <link:label id="lab_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_label_en-US" xlink:label="lab_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Catastrophic Event [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis" xlink:to="lab_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_77220cb5-a95d-4a18-9425-b1fae170ff38_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from early termination of hedge</link:label>
    <link:label id="lab_us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_label_en-US" xlink:label="lab_us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Discontinuation of Interest Rate Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:to="lab_us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_db5c0bad-7d00-417d-aecc-1e26679f7e92_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_ac4949d5-f45e-4ff0-b3e2-a24a5c65aa46_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5d836353-f3d4-4c6a-be82-8bd841a15173_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LienCategoryDomain_4ef57190-023a-4c8f-838d-eee419c340c6_terseLabel_en-US" xlink:label="lab_us-gaap_LienCategoryDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lien Category [Domain]</link:label>
    <link:label id="lab_us-gaap_LienCategoryDomain_label_en-US" xlink:label="lab_us-gaap_LienCategoryDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lien Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LienCategoryDomain" xlink:to="lab_us-gaap_LienCategoryDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_b663f196-180c-48b8-853c-004638e81289_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c38e260b-0bf1-4456-a984-65837b909efc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7a41629b-5e45-4fbd-a4d9-9aad0a906302_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations and Presentation of Financial Statements</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_41456bb0-4257-4654-b06e-ff9e67dec5b9_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense in cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_f21d907b-36fc-4ffb-906a-2bdca1c5e54d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_fabb254b-546c-4cfa-8bd2-3a34497262d7_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_ab4e2a2f-c6ea-45c4-a131-511e1e80f20e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Lease Liabilities, Financing</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_dbc0aa21-e509-4192-9aae-c64bf4943bf1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_DeferredTaxAssetsLeaseLiability_9ac0fde6-2513-4a15-b918-e022dd3ba796_terseLabel_en-US" xlink:label="lab_bios_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_bios_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_bios_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_bios_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_bios_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DeferredTaxAssetsLeaseLiability" xlink:href="bios-20201231.xsd#bios_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_DeferredTaxAssetsLeaseLiability" xlink:to="lab_bios_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_85c4dd94-fb8f-4932-badd-77699d736ada_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_49c5076c-123a-410f-b4ae-091fce818b22_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_09f5e9d6-1706-495e-93ca-ccc0b8629b04_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_55715d0f-00a8-443c-abe1-08ff78000cf1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_b803e8d8-10e8-443f-859d-730645b184e8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7fbdae71-a41b-47b4-8891-de565cff8e7a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_OptionCareEnterprisesInc.Member_6dfc41b2-1260-4d09-b4fb-3ba68124a0b8_terseLabel_en-US" xlink:label="lab_bios_OptionCareEnterprisesInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OptionCare Enterprises, Inc.</link:label>
    <link:label id="lab_bios_OptionCareEnterprisesInc.Member_label_en-US" xlink:label="lab_bios_OptionCareEnterprisesInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OptionCare Enterprises, Inc. [Member]</link:label>
    <link:label id="lab_bios_OptionCareEnterprisesInc.Member_documentation_en-US" xlink:label="lab_bios_OptionCareEnterprisesInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OptionCare Enterprises, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionCareEnterprisesInc.Member" xlink:href="bios-20201231.xsd#bios_OptionCareEnterprisesInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_OptionCareEnterprisesInc.Member" xlink:to="lab_bios_OptionCareEnterprisesInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_SecondaryOfferingMember_3451ab1e-8327-4481-98a3-dfb653740cd0_terseLabel_en-US" xlink:label="lab_bios_SecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secondary Offering</link:label>
    <link:label id="lab_bios_SecondaryOfferingMember_label_en-US" xlink:label="lab_bios_SecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secondary Offering [Member]</link:label>
    <link:label id="lab_bios_SecondaryOfferingMember_documentation_en-US" xlink:label="lab_bios_SecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secondary Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SecondaryOfferingMember" xlink:href="bios-20201231.xsd#bios_SecondaryOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_SecondaryOfferingMember" xlink:to="lab_bios_SecondaryOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_ChargedBenefitToCostsAndExpensesMember_edf5a265-28cf-4fb3-8a36-e1bd0eb1a190_terseLabel_en-US" xlink:label="lab_bios_ChargedBenefitToCostsAndExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged (Benefit) to Costs and Expenses</link:label>
    <link:label id="lab_bios_ChargedBenefitToCostsAndExpensesMember_label_en-US" xlink:label="lab_bios_ChargedBenefitToCostsAndExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged (Benefit) To Costs And Expenses [Member]</link:label>
    <link:label id="lab_bios_ChargedBenefitToCostsAndExpensesMember_documentation_en-US" xlink:label="lab_bios_ChargedBenefitToCostsAndExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged (Benefit) To Costs And Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ChargedBenefitToCostsAndExpensesMember" xlink:href="bios-20201231.xsd#bios_ChargedBenefitToCostsAndExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_ChargedBenefitToCostsAndExpensesMember" xlink:to="lab_bios_ChargedBenefitToCostsAndExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0edc2e5a-228e-4277-b1d0-d27a21a7d164_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period of recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8f351093-7e4a-42b9-9d56-c4e9b97fede7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_7fa24a03-bf84-4981-90d5-045120857169_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d33b05b5-c5d2-4d9e-908e-694445ea16cd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_ClassofWarrantorRightSecuritiesExercised_a16b5b15-4418-4140-bc1e-c9942e827933_terseLabel_en-US" xlink:label="lab_bios_ClassofWarrantorRightSecuritiesExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchased from exercise of warrants (in shares)</link:label>
    <link:label id="lab_bios_ClassofWarrantorRightSecuritiesExercised_label_en-US" xlink:label="lab_bios_ClassofWarrantorRightSecuritiesExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Securities Exercised</link:label>
    <link:label id="lab_bios_ClassofWarrantorRightSecuritiesExercised_documentation_en-US" xlink:label="lab_bios_ClassofWarrantorRightSecuritiesExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Securities Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ClassofWarrantorRightSecuritiesExercised" xlink:href="bios-20201231.xsd#bios_ClassofWarrantorRightSecuritiesExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_ClassofWarrantorRightSecuritiesExercised" xlink:to="lab_bios_ClassofWarrantorRightSecuritiesExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c165bf37-b9f0-4935-850a-41e31f851884_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c634e825-5414-4eb2-87ba-0efb8ff5c024_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_12c030b9-ea8a-406f-9eb1-9b1ee0751592_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0365ec0b-c9e6-40f5-a4f3-e7861f9c8d83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Markets for Identical Item (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_fc698825-690e-407e-981e-96577c11b348_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_3e516cd9-27c5-4309-9e5b-b7bff5677c20_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax gains (losses) on interest rate derivatives recognized</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_aa275239-ce73-4244-959f-29bc01fa1077_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_ba53ddac-93b0-402e-af1c-9a1f0a471822_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_InterestCapitalizedToDebtPrincipal_0705678d-e2c7-4a5b-bdbd-aba4de4c0333_terseLabel_en-US" xlink:label="lab_bios_InterestCapitalizedToDebtPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest capitalized to debt principal</link:label>
    <link:label id="lab_bios_InterestCapitalizedToDebtPrincipal_label_en-US" xlink:label="lab_bios_InterestCapitalizedToDebtPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Capitalized To Debt Principal</link:label>
    <link:label id="lab_bios_InterestCapitalizedToDebtPrincipal_documentation_en-US" xlink:label="lab_bios_InterestCapitalizedToDebtPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Capitalized To Debt Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InterestCapitalizedToDebtPrincipal" xlink:href="bios-20201231.xsd#bios_InterestCapitalizedToDebtPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_InterestCapitalizedToDebtPrincipal" xlink:to="lab_bios_InterestCapitalizedToDebtPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_453ee17e-ac9e-4ef8-a196-f06439ee293c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6cd969b9-caed-4339-b3d4-bda160f0156e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset, additions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_DeferredTaxLiabilitiesAcceleratedDepreciation_efb97feb-7bf8-4328-9815-69671f8f50e3_negatedTerseLabel_en-US" xlink:label="lab_bios_DeferredTaxLiabilitiesAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated depreciation</link:label>
    <link:label id="lab_bios_DeferredTaxLiabilitiesAcceleratedDepreciation_label_en-US" xlink:label="lab_bios_DeferredTaxLiabilitiesAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Accelerated Depreciation</link:label>
    <link:label id="lab_bios_DeferredTaxLiabilitiesAcceleratedDepreciation_documentation_en-US" xlink:label="lab_bios_DeferredTaxLiabilitiesAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Accelerated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DeferredTaxLiabilitiesAcceleratedDepreciation" xlink:href="bios-20201231.xsd#bios_DeferredTaxLiabilitiesAcceleratedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_DeferredTaxLiabilitiesAcceleratedDepreciation" xlink:to="lab_bios_DeferredTaxLiabilitiesAcceleratedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_OptionsOutstandingAbstract_e072df65-0116-480a-9bbf-2abb6f3f7e85_terseLabel_en-US" xlink:label="lab_bios_OptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_bios_OptionsOutstandingAbstract_label_en-US" xlink:label="lab_bios_OptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding [Abstract]</link:label>
    <link:label id="lab_bios_OptionsOutstandingAbstract_documentation_en-US" xlink:label="lab_bios_OptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionsOutstandingAbstract" xlink:href="bios-20201231.xsd#bios_OptionsOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_OptionsOutstandingAbstract" xlink:to="lab_bios_OptionsOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_27038f33-15a3-476a-a69a-c41cc2bcc005_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b7db8d63-0ab5-43c0-8ca1-a779d2aee00f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_5c2e71cd-914b-4e05-95a5-4f8cb424131b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs expensed</link:label>
    <link:label id="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_label_en-US" xlink:label="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization, Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:to="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_5b486a2c-446c-4913-b8eb-429a0200ea34_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2aa477f3-d850-4115-9a9d-c95c8fc595fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Quarterly Financial Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_4b56f4b1-fd3a-42ca-80d4-b46b5942ab98_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6006f29b-31da-4f7d-a71a-8146c29e2205_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_62345d6c-2a80-45df-9171-68df495a5445_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_9204166e-0c26-4dc4-83cd-88a5e850ae6c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_a34b4f31-0aa5-4f36-bbd9-0b89b456e17d_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_865c1ee6-9cad-4150-99f9-6795cc6cbb48_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by operations:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution_b69a8d82-adcc-4d6b-96bd-b4193587124f_terseLabel_en-US" xlink:label="lab_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' contributions</link:label>
    <link:label id="lab_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution_label_en-US" xlink:label="lab_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Stockholders' Contribution</link:label>
    <link:label id="lab_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution_documentation_en-US" xlink:label="lab_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Stockholders' Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution" xlink:href="bios-20201231.xsd#bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution" xlink:to="lab_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_043fddce-9b75-48b1-a3da-684f2266ae50_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_f1ff1ab5-d9f6-4f99-abb6-be3b5a7877a9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity-method investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4771bdd8-f64c-4c7d-a896-67676d97518c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_01828c90-d0df-4a56-9146-ab9b588802d2_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of BioScrip common shares outstanding at time of the merger (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_0e525069-c01a-4770-a980-1f7aa21c1a12_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableDeferredIncome_a9f576d4-593f-4d4c-8944-79cf306153cd_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred commitment fee</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableDeferredIncome_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Deferred Commitment Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableDeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancingReceivableDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableDeferredIncome" xlink:to="lab_us-gaap_FinancingReceivableDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_275e8cff-f495-40da-b31f-36d2025eb2a8_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_70df5c90-851a-43bc-ae8a-428a35647b78_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_JuniorLienMember_b29b6d19-a694-455a-a974-e8a20132e6dc_terseLabel_en-US" xlink:label="lab_us-gaap_JuniorLienMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Lien Term Loan</link:label>
    <link:label id="lab_us-gaap_JuniorLienMember_label_en-US" xlink:label="lab_us-gaap_JuniorLienMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Junior Lien [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JuniorLienMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_JuniorLienMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JuniorLienMember" xlink:to="lab_us-gaap_JuniorLienMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_BusinessCombinationRenewalTermLength_8a9a4ab1-ffd5-4cfb-9cd0-f5e5fec76cde_terseLabel_en-US" xlink:label="lab_bios_BusinessCombinationRenewalTermLength" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term length</link:label>
    <link:label id="lab_bios_BusinessCombinationRenewalTermLength_label_en-US" xlink:label="lab_bios_BusinessCombinationRenewalTermLength" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Renewal Term Length</link:label>
    <link:label id="lab_bios_BusinessCombinationRenewalTermLength_documentation_en-US" xlink:label="lab_bios_BusinessCombinationRenewalTermLength" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Renewal Term Length</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BusinessCombinationRenewalTermLength" xlink:href="bios-20201231.xsd#bios_BusinessCombinationRenewalTermLength"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_BusinessCombinationRenewalTermLength" xlink:to="lab_bios_BusinessCombinationRenewalTermLength" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LienCategoryAxis_19cc79f4-339f-431d-bd42-72f71e959997_terseLabel_en-US" xlink:label="lab_us-gaap_LienCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lien Category [Axis]</link:label>
    <link:label id="lab_us-gaap_LienCategoryAxis_label_en-US" xlink:label="lab_us-gaap_LienCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lien Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LienCategoryAxis" xlink:to="lab_us-gaap_LienCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_35371e1c-e091-4b65-b8f0-6845272be4c4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_bff529eb-2edd-4309-9d46-48295d50a134_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_7420f3ce-99d3-4c6d-afa5-4a48b61c5ebb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d7a3c86-4e17-4bf0-adde-909a1074f58b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2019 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_22df684b-1dfc-4a53-9f8e-f30e80567828_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2020 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_550defde-c4fc-4d9a-ada6-864ca67b7319_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_492ad31a-ecc7-4645-93c6-3e9c632a57e1_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undrawn letters of credit issued and outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_095f7643-642d-4d89-9335-0d4cbbe07f67_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a41d87f3-a3bb-41be-aa72-64ac17f1b1a3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_006d8075-05e6-446e-81ce-aba5c2555f4b_totalLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of total consideration acquired, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_2ce2d826-ce51-4caf-9c65-a1da21794f19_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_85cc8576-a388-492d-932c-2759bb261a9f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_ff398b9b-42ee-4e34-8a27-9987d874a1c2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the combined company held</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_bf098246-420a-4719-94b8-30db1f70ba92_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding shares purchased</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_e683b260-f1b7-4948-866c-ef99b9cc38b6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_41e01337-fcec-4be8-808f-873bff4adaf7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_DeferredTaxAssetsBadDebtReserve_07d64a70-d3b6-459a-95b3-140d7a43fe95_terseLabel_en-US" xlink:label="lab_bios_DeferredTaxAssetsBadDebtReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price concessions</link:label>
    <link:label id="lab_bios_DeferredTaxAssetsBadDebtReserve_label_en-US" xlink:label="lab_bios_DeferredTaxAssetsBadDebtReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Bad Debt Reserve</link:label>
    <link:label id="lab_bios_DeferredTaxAssetsBadDebtReserve_documentation_en-US" xlink:label="lab_bios_DeferredTaxAssetsBadDebtReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Bad Debt Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DeferredTaxAssetsBadDebtReserve" xlink:href="bios-20201231.xsd#bios_DeferredTaxAssetsBadDebtReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_DeferredTaxAssetsBadDebtReserve" xlink:to="lab_bios_DeferredTaxAssetsBadDebtReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8463dfa9-3208-43fe-8e7c-7e036b3e2a52_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_4a5e0dae-4ff2-419b-804a-c11f29cf811d_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_ff60b8ba-735d-4a3e-8435-3b559ec686d2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense in operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_86df9235-467a-4e35-839b-b621099659eb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment in settlement of debt</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0bfac35d-876c-4e94-b341-3f81697ca228_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_84c80fe3-e50a-4aa5-86d0-5eeade28e177_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cbfa7e23-3d2c-4bce-897b-98fb64a18563_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0aaa499e-726b-4711-b7b2-394747efe739_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fa8b1877-9dce-4af3-b102-ae22932cc57d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ec3c7329-e83a-44de-8c6e-bc59d97d6b1c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_03f7b62c-bdd1-4c1e-b8f9-adac16201821_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HurricaneMember_1a76ec39-de7e-4950-9990-b1f211fc45c5_terseLabel_en-US" xlink:label="lab_us-gaap_HurricaneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hurricane</link:label>
    <link:label id="lab_us-gaap_HurricaneMember_label_en-US" xlink:label="lab_us-gaap_HurricaneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hurricane [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HurricaneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HurricaneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HurricaneMember" xlink:to="lab_us-gaap_HurricaneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_OptionExercisePriceRangeSevenMember_e7d4a973-f0a7-4693-8ba2-a2da4e4c3e68_terseLabel_en-US" xlink:label="lab_bios_OptionExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">49.52</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeSevenMember_label_en-US" xlink:label="lab_bios_OptionExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range Seven [Member]</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeSevenMember_documentation_en-US" xlink:label="lab_bios_OptionExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeSevenMember" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeSevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_OptionExercisePriceRangeSevenMember" xlink:to="lab_bios_OptionExercisePriceRangeSevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_cdfa9c9c-facb-482a-80c7-08ce6dd6e48e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c0f9566f-106d-4ff2-8420-4cda8aca6617_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_bf7b5305-9824-4b47-a0bf-f522290c9229_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_30e7da04-22f4-444a-b5be-d3f9ec35aff0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Consideration to Intangible Assets Acquired</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_78541edd-391c-46d4-a272-247c5c61e9c2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_0df2cd9f-f753-47c9-8c17-1920c97a026d_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software, purchased and internally developed</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred_292c41b6-9c94-497b-b5ce-1bc243a96d70_terseLabel_en-US" xlink:label="lab_bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of liabilities incurred</link:label>
    <link:label id="lab_bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred_label_en-US" xlink:label="lab_bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Adjustment To Liabilities Incurred</link:label>
    <link:label id="lab_bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred_documentation_en-US" xlink:label="lab_bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Adjustment To Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred" xlink:href="bios-20201231.xsd#bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred" xlink:to="lab_bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9549d213-a1fc-4a33-9655-83247160997a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ab1b5a67-99f6-4b7d-b973-7ab24ee9c35e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_919788c6-066b-4143-87d9-486f0434b0b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6bc2bc51-7953-4f33-a9f4-5079ee9dcc9a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_64287b57-e1c1-40de-aedc-369842980e8f_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9960f6a2-4b39-452f-b950-e0b3b06032a8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9f501b16-51b4-4ec3-995f-987a4fca0b09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_f4e7a9cf-f2e6-4732-8d4d-1d0b13aa838e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCapMember_c2b06e36-f1c4-4aaa-aa5b-8a22fe3f9acb_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateCapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cap</link:label>
    <link:label id="lab_us-gaap_InterestRateCapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateCapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateCapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCapMember" xlink:to="lab_us-gaap_InterestRateCapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_160165b9-54e5-45b7-b4b5-b1aa68ec9c5d_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_664726f8-4031-44d6-996d-6b49f568ecee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_74c73031-1e20-4099-b09c-b3a34082b2a9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_28d7557c-dc80-432f-8267-fbc6c1d385a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_18a237b5-4f1f-4078-9687-f986b1376cde_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseRelatedParty_5d744880-8334-476d-846e-cc1c39d5ec4d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseRelatedParty_label_en-US" xlink:label="lab_us-gaap_InterestExpenseRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseRelatedParty" xlink:to="lab_us-gaap_InterestExpenseRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_44b1fd9a-2553-473e-b70e-ed384325f435_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_f59fcdbb-2937-4b4d-b38f-61753e85b6b4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_OptionCareHealthIncMember_a0636352-420e-4a97-85a1-cf269898b273_terseLabel_en-US" xlink:label="lab_bios_OptionCareHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Care Health, Inc</link:label>
    <link:label id="lab_bios_OptionCareHealthIncMember_label_en-US" xlink:label="lab_bios_OptionCareHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Care Health, Inc [Member]</link:label>
    <link:label id="lab_bios_OptionCareHealthIncMember_documentation_en-US" xlink:label="lab_bios_OptionCareHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Care Health, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionCareHealthIncMember" xlink:href="bios-20201231.xsd#bios_OptionCareHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_OptionCareHealthIncMember" xlink:to="lab_bios_OptionCareHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceSettlementsReceivable_637cbadc-2202-450c-bd85-e54a03e4bf66_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceSettlementsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance receivable</link:label>
    <link:label id="lab_us-gaap_InsuranceSettlementsReceivable_label_en-US" xlink:label="lab_us-gaap_InsuranceSettlementsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Settlements Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceSettlementsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceSettlementsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceSettlementsReceivable" xlink:to="lab_us-gaap_InsuranceSettlementsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_58f690d5-31aa-4ac7-b56e-e503ce535337_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceTable_4550000e-2eab-46f6-9498-f108ac25eadd_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceTable_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceTable" xlink:to="lab_us-gaap_ValuationAllowanceTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_91574ef2-d6bf-4216-abfd-f679b96f2155_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings of joint ventures</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_7911654d-05a8-404d-b57b-e3b75665d6d4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportionate share of earnings in equity-method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_NumberOfInfusionSites_c4cb284c-207e-4d66-a737-73de8e9cff99_terseLabel_en-US" xlink:label="lab_bios_NumberOfInfusionSites" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of infusion sites</link:label>
    <link:label id="lab_bios_NumberOfInfusionSites_label_en-US" xlink:label="lab_bios_NumberOfInfusionSites" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Infusion Sites</link:label>
    <link:label id="lab_bios_NumberOfInfusionSites_documentation_en-US" xlink:label="lab_bios_NumberOfInfusionSites" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Infusion Sites</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NumberOfInfusionSites" xlink:href="bios-20201231.xsd#bios_NumberOfInfusionSites"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_NumberOfInfusionSites" xlink:to="lab_bios_NumberOfInfusionSites" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_df898d0d-96d4-4d64-9ed0-9faed463856d_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Revenue Earned by Category of Payer</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerListsMember_dc8e88ea-6b03-4c5d-9cdf-d17da58dad25_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerListsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Referral sources</link:label>
    <link:label id="lab_us-gaap_CustomerListsMember_b080876f-8c41-41af-a210-632f72bd8838_verboseLabel_en-US" xlink:label="lab_us-gaap_CustomerListsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient referral sources</link:label>
    <link:label id="lab_us-gaap_CustomerListsMember_label_en-US" xlink:label="lab_us-gaap_CustomerListsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Lists [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerListsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerListsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerListsMember" xlink:to="lab_us-gaap_CustomerListsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_9331198c-4a41-4e72-9227-5457218d9a91_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings_1bce6a24-85a0-40b8-ba7a-5d8558a003e1_negatedTerseLabel_en-US" xlink:label="lab_bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options, vesting of restricted stock, and related tax withholdings</link:label>
    <link:label id="lab_bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings_label_en-US" xlink:label="lab_bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued, Value, Restricted Stock and Stock Options Exercised, Net Of Tax Withholdings</link:label>
    <link:label id="lab_bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings_documentation_en-US" xlink:label="lab_bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued, Value, Restricted Stock and Stock Options Exercised, Net Of Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings" xlink:href="bios-20201231.xsd#bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings" xlink:to="lab_bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_eb6c5f6c-82b0-4faf-8f7c-4feab0589a5b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_cc929f09-cf5c-412f-ae6a-74712108b0a9_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_4037d5c5-3584-47e6-bcfe-eed3ebb6fa76_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d45eb819-0e1f-49ce-b124-0780ce8ea9ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based incentive compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_c1a56717-f658-4062-9286-304108202e68_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_EquipmentFurnitureAndOtherMember_9a1527ff-ee80-4ebe-8818-3173997abbef_terseLabel_en-US" xlink:label="lab_bios_EquipmentFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment, furniture and other</link:label>
    <link:label id="lab_bios_EquipmentFurnitureAndOtherMember_label_en-US" xlink:label="lab_bios_EquipmentFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment, Furniture, And Other [Member]</link:label>
    <link:label id="lab_bios_EquipmentFurnitureAndOtherMember_documentation_en-US" xlink:label="lab_bios_EquipmentFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment, Furniture, And Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_EquipmentFurnitureAndOtherMember" xlink:href="bios-20201231.xsd#bios_EquipmentFurnitureAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_EquipmentFurnitureAndOtherMember" xlink:to="lab_bios_EquipmentFurnitureAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d7412163-39ee-4896-b138-cd7706c0e9bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options, vesting of restricted stock, and related tax withholdings</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_545951bb-620b-4a14-82bc-4e320e57cf73_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_30262928-805a-4f26-a8ef-9009047c6fcb_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_80178525-9a59-4a40-8d05-e1122756d1cb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_792eb674-cce7-4f83-9923-a55f896650d6_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_SaleOfNotesReceivableMember_5871af73-a239-4120-b8c4-dccc4b3079a5_terseLabel_en-US" xlink:label="lab_bios_SaleOfNotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Notes Receivable</link:label>
    <link:label id="lab_bios_SaleOfNotesReceivableMember_label_en-US" xlink:label="lab_bios_SaleOfNotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Notes Receivable [Member]</link:label>
    <link:label id="lab_bios_SaleOfNotesReceivableMember_documentation_en-US" xlink:label="lab_bios_SaleOfNotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Notes Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SaleOfNotesReceivableMember" xlink:href="bios-20201231.xsd#bios_SaleOfNotesReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_SaleOfNotesReceivableMember" xlink:to="lab_bios_SaleOfNotesReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9dc0f348-ea23-482b-847d-177bb650e4b4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution percent of employees' gross pay</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_6dec9c0d-8ab4-4e79-8c24-bc67d2e8f771_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:to="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_0af09b9b-4c99-4338-ab5f-d72391e7f88f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_11c21545-da12-44b3-923b-9d71c353ecc8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital distribution from equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_d8726285-05fa-4be4-a444-b6425d0b7f2b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_d6642588-2feb-45c7-9dc3-6f78167e72a9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_97fde753-e33a-481d-917a-289ea94abf8f_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_c8a30a8e-5a6e-4ddb-ae68-368e1ae59057_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_InfusionPumpsMember_00eb67ca-b48d-4923-9183-310b5d15c1c4_terseLabel_en-US" xlink:label="lab_bios_InfusionPumpsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infusion pumps</link:label>
    <link:label id="lab_bios_InfusionPumpsMember_label_en-US" xlink:label="lab_bios_InfusionPumpsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infusion Pumps [Member]</link:label>
    <link:label id="lab_bios_InfusionPumpsMember_documentation_en-US" xlink:label="lab_bios_InfusionPumpsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infusion Pumps [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InfusionPumpsMember" xlink:href="bios-20201231.xsd#bios_InfusionPumpsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_InfusionPumpsMember" xlink:to="lab_bios_InfusionPumpsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_069ef0e1-2c6b-4ecd-87eb-0e94d674db24_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_3bdab9d1-9c63-45e4-87e4-eeb6ba0964e0_totalLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForDepositsAppliedToDebtRetirements_85852db9-f755-4c5a-9bb4-3becd4352800_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForDepositsAppliedToDebtRetirements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of debt obligations</link:label>
    <link:label id="lab_us-gaap_PaymentsForDepositsAppliedToDebtRetirements_label_en-US" xlink:label="lab_us-gaap_PaymentsForDepositsAppliedToDebtRetirements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Deposits Applied to Debt Retirements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDepositsAppliedToDebtRetirements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForDepositsAppliedToDebtRetirements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForDepositsAppliedToDebtRetirements" xlink:to="lab_us-gaap_PaymentsForDepositsAppliedToDebtRetirements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_4026c24f-a96f-42ad-bfc2-00008e83e642_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_8c932b4e-c6f0-4bdc-8ba5-4312b83232a6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_7852079c-ee86-487d-8f5b-035d1305bdc0_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COST OF REVENUE</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_725b91c1-738a-4a0e-9a42-ad81ecf53a98_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9151ba40-6c27-464b-82f8-3e1344ec6316_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3f3625a9-8450-49ca-a4a6-4d02df79a70b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized (losses) gains on cash flow hedges, net of income taxes of $0, $259 and $234, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_c1bf2d90-839b-47d8-8c7e-4ffe1c644779_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_55c5f535-e0cd-4efa-87bc-258b4f67eb69_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_BankOfAmericaN.A.Member_d0605325-4b93-42e6-b1e5-6b6ffe9558d3_terseLabel_en-US" xlink:label="lab_bios_BankOfAmericaN.A.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Of America, N.A.</link:label>
    <link:label id="lab_bios_BankOfAmericaN.A.Member_label_en-US" xlink:label="lab_bios_BankOfAmericaN.A.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Of America, N.A. [Member]</link:label>
    <link:label id="lab_bios_BankOfAmericaN.A.Member_documentation_en-US" xlink:label="lab_bios_BankOfAmericaN.A.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Of America, N.A. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BankOfAmericaN.A.Member" xlink:href="bios-20201231.xsd#bios_BankOfAmericaN.A.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_BankOfAmericaN.A.Member" xlink:to="lab_bios_BankOfAmericaN.A.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c717ec38-4301-462c-be4e-f1816d788a56_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2f6bfbf8-6c74-441d-929d-de95b558d74e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_9a430e3e-47ea-4c58-aad2-32a5f4117409_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_cff37b2f-226f-4162-a014-cc20a8cf6080_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_9b15ea80-ee56-4a62-a85b-ca84939bcee1_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_OptionCareAcquisitionMember_d4b5a16e-e229-4905-a92c-d088dad7f53e_terseLabel_en-US" xlink:label="lab_bios_OptionCareAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Care Acquisition</link:label>
    <link:label id="lab_bios_OptionCareAcquisitionMember_label_en-US" xlink:label="lab_bios_OptionCareAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Care Acquisition [Member]</link:label>
    <link:label id="lab_bios_OptionCareAcquisitionMember_documentation_en-US" xlink:label="lab_bios_OptionCareAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Care Acquisition [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionCareAcquisitionMember" xlink:href="bios-20201231.xsd#bios_OptionCareAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_OptionCareAcquisitionMember" xlink:to="lab_bios_OptionCareAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_8c7e6c89-ce38-4943-a34b-fa5cdb8a79a0_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes redeemed</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_68678567-d97d-4b82-986f-0420dece6ce0_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_HomeSolutionsMember_689487ec-50fc-47af-9ae3-ac8ccc50bd36_terseLabel_en-US" xlink:label="lab_bios_HomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Solutions</link:label>
    <link:label id="lab_bios_HomeSolutionsMember_label_en-US" xlink:label="lab_bios_HomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Solutions [Member]</link:label>
    <link:label id="lab_bios_HomeSolutionsMember_documentation_en-US" xlink:label="lab_bios_HomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Solutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HomeSolutionsMember" xlink:href="bios-20201231.xsd#bios_HomeSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_HomeSolutionsMember" xlink:to="lab_bios_HomeSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_82be4611-b863-4329-81ad-b07a846a156b_terseLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US federal income tax expense (benefit):</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_f26a0fac-34e9-4df7-a181-c6cbf80fc98b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pre-tax Income (Loss) Recognized in the Statements of Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c6eba262-55f7-44d9-aa9d-c69240c6598f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited and expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_152d97a0-a4f8-4244-8be5-805df9526efd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_76c1c2ef-594e-4508-ac95-10743bab771b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_ad341782-c4c5-4ba4-aeff-90008891e1e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_376f9198-392a-4031-be3a-705edbc42474_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_f8fb24d2-173f-4034-8479-b57c1889bc68_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Amount and Location of Derivatives in the Balance Sheet</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_14186508-9d27-4d7d-85ca-5066d1a4cea2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8f2f357f-8c4c-4276-9e8c-af67032753de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_caa3ba03-b7db-4101-92fc-5f5be73b930d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c242fd69-45e9-4606-a080-19f6e721ddb1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9f87914b-26c5-4940-9c27-cced0d179a4c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_439037e8-9039-4eed-801b-26a85699ac9b_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_8afd2cd9-1148-4604-9572-c2605e32b563_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_e8b83185-4a00-40d8-b177-bcdaa07f3556_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_92eb0347-5e70-406f-9c87-b16839d90b13_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c1399969-a72f-4eae-8552-930754c8cf36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Based Incentive Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_4497c2d1-726d-48dd-b632-c63878a5f67c_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_b55bd1c8-4583-4433-83a3-2dbf7ea77f57_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_645ca358-e279-406c-a62a-97f0310ce3cc_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_label_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_766daf9f-bf61-4f01-8483-b93f5ac35326_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_5ba675a5-1c39-4e9c-9065-9682b212bcb3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_daa5e3d7-0f1c-42a9-ba56-1704e3a9e8f4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_445e11bb-9570-41bc-8587-3ed93547bc21_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_150d824f-556c-4ce4-ad21-b729c4501e50_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_47d09aa0-9a2d-4eaa-93ae-f5340fe97391_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_211f225a-c4f7-4120-9169-a10396d3f1a3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate, operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_e1e83c5e-2b07-4b6a-afd4-56932020c3e1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_de8d40bf-4355-4b8d-b1e7-ca636ff9a557_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_be198d10-3f7d-4c47-afba-444e56f9d7e2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_5eb90ac6-defc-4c9c-a715-ba9ec4a6cc62_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_c816afe8-d493-463c-89f5-8896a1dabbb8_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_0b03c7b1-45c3-49d9-9621-bc55233ccdc2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_ac9e7318-7314-4b84-8444-c3b73003de03_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_InterestGainLossOnManagementNotesReceivable_357b699b-01db-4fcf-82b8-3b7657eb01c6_negatedTerseLabel_en-US" xlink:label="lab_bios_InterestGainLossOnManagementNotesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on management notes receivable</link:label>
    <link:label id="lab_bios_InterestGainLossOnManagementNotesReceivable_label_en-US" xlink:label="lab_bios_InterestGainLossOnManagementNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Gain (Loss) On Management Notes Receivable</link:label>
    <link:label id="lab_bios_InterestGainLossOnManagementNotesReceivable_documentation_en-US" xlink:label="lab_bios_InterestGainLossOnManagementNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Gain (Loss) On Management Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InterestGainLossOnManagementNotesReceivable" xlink:href="bios-20201231.xsd#bios_InterestGainLossOnManagementNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_InterestGainLossOnManagementNotesReceivable" xlink:to="lab_bios_InterestGainLossOnManagementNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d391975b-7146-4a3f-942c-f4b213089304_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0f939304-5e76-4298-8ef1-ce2fc7cb568d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_2b57bee1-2e64-4ab0-ab02-3b85039f3619_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_31a6a8e0-2422-4c42-a5ee-c7ff54754394_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_35a6d18f-6e71-42fa-9d66-ce3db7d853ec_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Doubtful Accounts, Premiums and Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_ManagementNotesReceivableMember_de088ba4-b43d-4aeb-a5e9-c7e5aa113ec5_terseLabel_en-US" xlink:label="lab_bios_ManagementNotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Notes Receivable</link:label>
    <link:label id="lab_bios_ManagementNotesReceivableMember_label_en-US" xlink:label="lab_bios_ManagementNotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Notes Receivable [Member]</link:label>
    <link:label id="lab_bios_ManagementNotesReceivableMember_documentation_en-US" xlink:label="lab_bios_ManagementNotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Notes Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ManagementNotesReceivableMember" xlink:href="bios-20201231.xsd#bios_ManagementNotesReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_ManagementNotesReceivableMember" xlink:to="lab_bios_ManagementNotesReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_c5290463-8d5a-430f-a34b-4d4ef6eb5f16_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective rate on term loans at end of period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_6fdd1c74-4479-4c78-b7c8-b71706dbd3e9_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-kind interest capitalized as principal</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_e30e2ab3-be2a-44a9-8d9e-262cf343a21f_verboseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate PIK</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_OptionExercisePriceRangeFourMember_0cbe8204-6674-4a7e-b9c6-ac89a873fc26_terseLabel_en-US" xlink:label="lab_bios_OptionExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">24.76</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeFourMember_label_en-US" xlink:label="lab_bios_OptionExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range Four [Member]</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_bios_OptionExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeFourMember" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_OptionExercisePriceRangeFourMember" xlink:to="lab_bios_OptionExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_6e5a11d7-8359-4476-9dfc-78960f0689b7_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7aad5eab-ef60-4ca4-9c5f-ea1298108ee9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_1a0e7f48-0bf7-4032-b4d2-8fd95494efb8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f59bb4ea-21e5-454c-81ce-9f5d7da16f77_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a1cf77ac-cc5f-42a8-9e72-a0726e93c4ed_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_3ba82c40-64db-4618-ae65-5beb8e4e5b74_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_57ed7438-bf68-4db0-bbe5-426447e880f9_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_0736ce1c-0105-4a15-bd8f-eda6998eb8b9_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_BaptistHealthInLittleRockArkansasMember_1bfd6a66-be64-4846-8c89-2e1062aaba20_terseLabel_en-US" xlink:label="lab_bios_BaptistHealthInLittleRockArkansasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baptist Health In Little Rock, Arkansas</link:label>
    <link:label id="lab_bios_BaptistHealthInLittleRockArkansasMember_label_en-US" xlink:label="lab_bios_BaptistHealthInLittleRockArkansasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baptist Health In Little Rock, Arkansas [Member]</link:label>
    <link:label id="lab_bios_BaptistHealthInLittleRockArkansasMember_documentation_en-US" xlink:label="lab_bios_BaptistHealthInLittleRockArkansasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baptist Health In Little Rock, Arkansas [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BaptistHealthInLittleRockArkansasMember" xlink:href="bios-20201231.xsd#bios_BaptistHealthInLittleRockArkansasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_BaptistHealthInLittleRockArkansasMember" xlink:to="lab_bios_BaptistHealthInLittleRockArkansasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_46d7a870-459b-42e2-b1a7-c64f42b843fe_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9913a167-429d-4ef4-845f-696e8625c1a1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_93dac650-b0f2-4f0f-b937-b48158305494_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_838e05e5-8d16-4676-bf4e-b16239c4dd82_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_17c9269c-285a-497c-b2d0-d27c7bc72b15_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_RestrictedStockAwardMember_d2dae9eb-1ef6-4efe-8bdd-e9ea2a7c06c7_terseLabel_en-US" xlink:label="lab_bios_RestrictedStockAwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Award</link:label>
    <link:label id="lab_bios_RestrictedStockAwardMember_label_en-US" xlink:label="lab_bios_RestrictedStockAwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Award [Member]</link:label>
    <link:label id="lab_bios_RestrictedStockAwardMember_documentation_en-US" xlink:label="lab_bios_RestrictedStockAwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Award [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_RestrictedStockAwardMember" xlink:href="bios-20201231.xsd#bios_RestrictedStockAwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_RestrictedStockAwardMember" xlink:to="lab_bios_RestrictedStockAwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_946047ca-397b-483f-b95b-270778403982_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_ff836803-ce30-4ee2-8760-e79e6509b344_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill - net book value, begging of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_00b5e43a-8edb-4d53-9024-8b6d2ab5b697_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill - net book value, end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_d67f8893-be9d-4fb6-8a51-695d0e2d5be4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Consideration Exchanged</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_41e5fe9b-77ea-463e-ac3f-8425a5d3aee4_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_defd946d-0cf2-4b7d-a819-a04cf5ef18f5_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_c66fc41b-5794-4f68-9c4a-11235270419e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_7e107fbc-2c5e-4c3b-8509-0be481cba291_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_d10dd32b-71d0-4ecf-8a9c-2ed72f5e611e_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_a320cca2-8c6d-4e6e-b10f-098d23197ec2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-based fees</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2c9dd6d6-883a-4875-a2cf-e81a6fb0563d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_119dae4b-50f1-42b0-9e38-4cec5db2f76f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_NumberOfServiceLocations_f399123d-a2c5-4449-84c3-f6892aaa57a9_terseLabel_en-US" xlink:label="lab_bios_NumberOfServiceLocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of service locations</link:label>
    <link:label id="lab_bios_NumberOfServiceLocations_label_en-US" xlink:label="lab_bios_NumberOfServiceLocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Service Locations</link:label>
    <link:label id="lab_bios_NumberOfServiceLocations_documentation_en-US" xlink:label="lab_bios_NumberOfServiceLocations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Service Locations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NumberOfServiceLocations" xlink:href="bios-20201231.xsd#bios_NumberOfServiceLocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_NumberOfServiceLocations" xlink:to="lab_bios_NumberOfServiceLocations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_d9c9f71f-6231-4427-8a89-654127a515a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_f6450d1a-3482-4820-bd45-b1501f423afb_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount of debt instruments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c22031bd-3944-4396-9d99-9bfd56f7787f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_37861e3a-4385-479c-a129-1b5edb836e0e_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_bcb752b3-51cc-4eee-8b94-df25098c8985_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Carrying Amount of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5f385275-2e9b-4a31-b2bd-cee69e36a458_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_CommonStockOutstandingPercentage_be1460e3-402e-4025-ba7a-c66aa5756b1c_terseLabel_en-US" xlink:label="lab_bios_CommonStockOutstandingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding common stock</link:label>
    <link:label id="lab_bios_CommonStockOutstandingPercentage_label_en-US" xlink:label="lab_bios_CommonStockOutstandingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Outstanding, Percentage</link:label>
    <link:label id="lab_bios_CommonStockOutstandingPercentage_documentation_en-US" xlink:label="lab_bios_CommonStockOutstandingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Outstanding, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CommonStockOutstandingPercentage" xlink:href="bios-20201231.xsd#bios_CommonStockOutstandingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_CommonStockOutstandingPercentage" xlink:to="lab_bios_CommonStockOutstandingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_b80366de-1a01-457f-9646-b96d5fb603c4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_d6e72beb-2637-4e46-8db2-9d07c1c74397_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6ab9e0ff-0bf2-42ac-86d3-78ae5fe3ce94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_OptionExercisePriceRangeNineMember_fe50f8d7-58a8-4ad7-bf70-1a0dcd53b8e1_terseLabel_en-US" xlink:label="lab_bios_OptionExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">66</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeNineMember_label_en-US" xlink:label="lab_bios_OptionExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range Nine [Member]</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeNineMember_documentation_en-US" xlink:label="lab_bios_OptionExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range Nine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeNineMember" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_OptionExercisePriceRangeNineMember" xlink:to="lab_bios_OptionExercisePriceRangeNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_6b893eae-5ce4-4379-8c69-20ac036dff6a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_184cbd93-29a6-45d0-8aa6-53d8f670f711_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_698dec9f-aede-4620-ad5e-0fdf87076c61_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's Largest Payer</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_eb97d2fe-d0e1-45f2-a3f4-072e2c147ce5_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_ffd61117-f968-42b4-a390-02b3e9b05a5c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_60b28362-cad4-4984-b28e-1f86b99b3089_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Amortization Expense for Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b77c54c5-5b3e-4361-916c-3c179f03d381_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) earnings per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_f25bc25b-8920-4441-916b-df859fe18a72_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_f1e106c8-c3ce-44c6-8e9a-589151ba4aa7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assumed liabilities, net of other acquired assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_321e51cb-241b-45cf-ab18-3526cc7015ec_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life of options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fb8c2ca9-6e77-4e7d-9e1a-4018fa33690a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_141a4a6d-c8bf-4ab4-bf9d-06afa49b6dda_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited and expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_b528a22b-a367-4159-8aca-d82e0dabc8b0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) location of derivative instruments not designated</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_267677eb-7449-4eaf-9e10-402649b54276_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_71ac0b03-49a8-48c4-ada2-f760801547f3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term, operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative_d02e4b83-2d68-40d2-956a-fbc5c50948f9_terseLabel_en-US" xlink:label="lab_bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on interest rate swaps upon discontinuing hedge accounting</link:label>
    <link:label id="lab_bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative_label_en-US" xlink:label="lab_bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss On Discontinuance Of Cash Flow Hedge Derivative</link:label>
    <link:label id="lab_bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative_documentation_en-US" xlink:label="lab_bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss On Discontinuance Of Cash Flow Hedge Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative" xlink:href="bios-20201231.xsd#bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative" xlink:to="lab_bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_ProceedsFromSaleOfManagementNotesReceivable_a138089b-0e06-4342-92ea-65482b788932_terseLabel_en-US" xlink:label="lab_bios_ProceedsFromSaleOfManagementNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of management notes receivable</link:label>
    <link:label id="lab_bios_ProceedsFromSaleOfManagementNotesReceivable_label_en-US" xlink:label="lab_bios_ProceedsFromSaleOfManagementNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Management Notes Receivable</link:label>
    <link:label id="lab_bios_ProceedsFromSaleOfManagementNotesReceivable_documentation_en-US" xlink:label="lab_bios_ProceedsFromSaleOfManagementNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Management Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ProceedsFromSaleOfManagementNotesReceivable" xlink:href="bios-20201231.xsd#bios_ProceedsFromSaleOfManagementNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_ProceedsFromSaleOfManagementNotesReceivable" xlink:to="lab_bios_ProceedsFromSaleOfManagementNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bd1de95b-2dfc-47cd-a720-206b5b499d46_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract_d1ff8862-f233-4e49-b0c6-5cf40dbfd9cf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_30fe36f2-42b9-4248-93d6-13bbb6110129_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of common shares</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5e12be39-9c1d-401e-8d73-4bf778582b09_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_PatientCustomerMember_66df5f3b-ea09-4dec-be89-4656522b2bab_terseLabel_en-US" xlink:label="lab_bios_PatientCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients</link:label>
    <link:label id="lab_bios_PatientCustomerMember_label_en-US" xlink:label="lab_bios_PatientCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Customer [Member]</link:label>
    <link:label id="lab_bios_PatientCustomerMember_documentation_en-US" xlink:label="lab_bios_PatientCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PatientCustomerMember" xlink:href="bios-20201231.xsd#bios_PatientCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_PatientCustomerMember" xlink:to="lab_bios_PatientCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_03f32965-a4a5-45cf-ac8c-d3551dede0ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Outstanding Options by Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfDebt_b36b9934-3ea4-4118-9c97-2a029d09ad1c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_CreditAgreementsEnteredInto2019Member_abc17fc6-df0c-45ae-9c26-c7c6977ce9d7_terseLabel_en-US" xlink:label="lab_bios_CreditAgreementsEnteredInto2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreements, Entered Into 2019</link:label>
    <link:label id="lab_bios_CreditAgreementsEnteredInto2019Member_label_en-US" xlink:label="lab_bios_CreditAgreementsEnteredInto2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreements, Entered Into 2019 [Member]</link:label>
    <link:label id="lab_bios_CreditAgreementsEnteredInto2019Member_documentation_en-US" xlink:label="lab_bios_CreditAgreementsEnteredInto2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreements, Entered Into 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditAgreementsEnteredInto2019Member" xlink:href="bios-20201231.xsd#bios_CreditAgreementsEnteredInto2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_CreditAgreementsEnteredInto2019Member" xlink:to="lab_bios_CreditAgreementsEnteredInto2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c68068a2-81c8-45b6-aee1-aa817f3d410d_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_A2018PlanMember_7106038c-27a0-4659-a244-67f26875a41f_terseLabel_en-US" xlink:label="lab_bios_A2018PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2018 Plan</link:label>
    <link:label id="lab_bios_A2018PlanMember_label_en-US" xlink:label="lab_bios_A2018PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan [Member]</link:label>
    <link:label id="lab_bios_A2018PlanMember_documentation_en-US" xlink:label="lab_bios_A2018PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2018PlanMember" xlink:href="bios-20201231.xsd#bios_A2018PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_A2018PlanMember" xlink:to="lab_bios_A2018PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_34306384-e03c-4db0-b6e1-1d1debf8c963_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_30d6616e-149c-437c-840c-939ea996b8ff_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_464377d2-3cc9-4759-9d5a-aed12b6aef3f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_b7203882-2749-4058-a074-02100cdf28cf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f1e8e11f-2d43-4ebf-b634-ed20a7d5d1f1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock; $0.0001 par value: 250,000,000 shares authorized, 180,178,308 shares issued and 179,794,586 shares outstanding as of December 31, 2020; 176,975,628 shares issued and 176,591,907 shares outstanding as of December 31, 2019.</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2f042922-0a17-4df8-8cde-625d5d8955b2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_6a9f163c-87f9-45b6-bbbc-66debdc9352f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8c4ecca1-3de9-4666-af5c-29d35d714d84_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_NotesPayableMember_88a9bdaa-2ee6-4bbc-96ad-066fb4808dfc_terseLabel_en-US" xlink:label="lab_bios_NotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:label id="lab_bios_NotesPayableMember_label_en-US" xlink:label="lab_bios_NotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable [Member]</link:label>
    <link:label id="lab_bios_NotesPayableMember_documentation_en-US" xlink:label="lab_bios_NotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NotesPayableMember" xlink:href="bios-20201231.xsd#bios_NotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_NotesPayableMember" xlink:to="lab_bios_NotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_243b818b-7a8d-4071-9b76-b7caa8baea49_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net of deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_3bd23b31-872a-40da-9ce1-d4f7e85f5897_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_38eeb0e8-f8d2-449e-a1c3-72a48ec5c96e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_9443789b-1e97-41e7-8dd4-195fed4d6e33_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NONCURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a8c10cb8-1dc8-44ca-baa3-3fd8b4d3a4eb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_34041cf7-500b-4adb-9710-25ce464b7ac7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_7281e712-719b-46c1-bb16-ad6f2f2ae31d_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_740fa8ae-8ec5-46c3-ba95-08936c34b064_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_fd683c49-040a-4ccb-a552-afefb0abbabb_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_0c042256-36d6-4212-a156-6d763de4bc39_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_a2c13f4a-8423-4cc6-aa15-d09a65f0617a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_0c707b66-dccc-480b-af2c-e1ad408f6742_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_feb5afc3-99c3-4eca-a690-0380b7b8aed4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5c170c39-f4e7-45e4-9e90-4d7ca9ad0654_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total acquired identifiable assets and liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_90541cb6-2116-4cb2-9a39-a415bbad5df2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_2f4be1c5-ac55-427b-a7fe-4c4623bb097b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_0655f9b7-439b-40d5-b7be-482114b35b21_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioScrip share price as of August 6, 2019 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_877ccabe-fdff-40c8-a89d-f7bc2f6dbe88_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_09dfae81-d81c-4e50-b33a-0b8999647328_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3ec8ff9-b82b-4f71-96c7-3832da8fc491_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_HomeI.V.SpecialistsInc.Member_5383e307-c898-47d0-bbf3-2ed76e6abde4_terseLabel_en-US" xlink:label="lab_bios_HomeI.V.SpecialistsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home I.V. Specialists, Inc.</link:label>
    <link:label id="lab_bios_HomeI.V.SpecialistsInc.Member_label_en-US" xlink:label="lab_bios_HomeI.V.SpecialistsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home I.V. Specialists, Inc. [Member]</link:label>
    <link:label id="lab_bios_HomeI.V.SpecialistsInc.Member_documentation_en-US" xlink:label="lab_bios_HomeI.V.SpecialistsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home I.V. Specialists, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HomeI.V.SpecialistsInc.Member" xlink:href="bios-20201231.xsd#bios_HomeI.V.SpecialistsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_HomeI.V.SpecialistsInc.Member" xlink:to="lab_bios_HomeI.V.SpecialistsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EurodollarMember_58bea0e6-cbc2-4ba1-8bf1-979b420e1017_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurocurrency Rate</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_label_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_d932b07a-5e56-4a95-be55-6cdc66e77bb0_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_7bc330f3-2a7b-4001-8f37-23f4f80cb26a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_OptionExercisePriceRangeEightMember_b036c9b0-33b8-4923-8ae1-535fd7135b35_terseLabel_en-US" xlink:label="lab_bios_OptionExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">57.76</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeEightMember_label_en-US" xlink:label="lab_bios_OptionExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range Eight [Member]</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeEightMember_documentation_en-US" xlink:label="lab_bios_OptionExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeEightMember" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_OptionExercisePriceRangeEightMember" xlink:to="lab_bios_OptionExercisePriceRangeEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_b4ba4b24-8e91-4e96-a068-70776b3a9226_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_157b93a3-2699-4694-8714-9d815421b337_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_c1c6ad8a-37d1-411f-ba27-fe2f1269b3d9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_fa3d09e3-4e09-4e00-b6f9-ac3f7c5716ee_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of discount, deferred financing costs and current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_e5b60f03-c104-4748-ad5a-9011909d94de_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_3e572ecb-bb4c-4149-a42d-1568d424c93a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_cba895ec-637c-4cfc-96e4-7bcb1f84a982_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a4f12d85-f433-4d55-9566-a1ef0b07d68c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a53ca34c-0b41-4b13-a6e3-be6077ca7cfe_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9b62774d-8cba-4ebe-b3c7-acdb9f92c4fd_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetInterestCarryforward_775023e1-7de7-48a0-9d08-a05eea63dd4e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest limitation carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetInterestCarryforward_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Interest Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2850d9d1-5b2e-4676-9851-8693c64f632e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_767a6c6d-0e5d-46f7-92ed-bb91c939f5d2_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of total consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_1cbaaba7-22ee-4b3c-a9c1-f2a69ffce1c2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_HCGroupHoldingsILLCMember_99e3f0f1-d8c6-4b9a-bb0c-8193dee33c97_terseLabel_en-US" xlink:label="lab_bios_HCGroupHoldingsILLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HC Group Holdings I, LLC</link:label>
    <link:label id="lab_bios_HCGroupHoldingsILLCMember_label_en-US" xlink:label="lab_bios_HCGroupHoldingsILLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HC Group Holdings I, LLC [Member]</link:label>
    <link:label id="lab_bios_HCGroupHoldingsILLCMember_documentation_en-US" xlink:label="lab_bios_HCGroupHoldingsILLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HC Group Holdings I, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HCGroupHoldingsILLCMember" xlink:href="bios-20201231.xsd#bios_HCGroupHoldingsILLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_HCGroupHoldingsILLCMember" xlink:to="lab_bios_HCGroupHoldingsILLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_e5d9bb38-269e-4fd2-ae71-bfc552363903_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_DebtInstrumentChangesInLongTermDebtRollForward_4a283c71-ec17-4bd7-91db-7030a228546f_terseLabel_en-US" xlink:label="lab_bios_DebtInstrumentChangesInLongTermDebtRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Changes In Long-Term Debt [Roll Forward]</link:label>
    <link:label id="lab_bios_DebtInstrumentChangesInLongTermDebtRollForward_label_en-US" xlink:label="lab_bios_DebtInstrumentChangesInLongTermDebtRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Changes In Long-Term Debt [Roll Forward]</link:label>
    <link:label id="lab_bios_DebtInstrumentChangesInLongTermDebtRollForward_documentation_en-US" xlink:label="lab_bios_DebtInstrumentChangesInLongTermDebtRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Changes In Long-Term Debt [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DebtInstrumentChangesInLongTermDebtRollForward" xlink:href="bios-20201231.xsd#bios_DebtInstrumentChangesInLongTermDebtRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_DebtInstrumentChangesInLongTermDebtRollForward" xlink:to="lab_bios_DebtInstrumentChangesInLongTermDebtRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_096f6fcf-3abd-42fc-8660-5bb48929df31_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares converted in merger (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a0f776bd-9197-448e-8d60-d530f83b74fa_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_10a584c6-5386-4eb9-b3c3-edd0d314f720_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_d2999c68-ed32-4392-93f7-cd1c33cbd617_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes on unrealized gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_e9a02ea4-7541-416f-a0d3-00e415749e0c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d47213e5-b328-4fe5-9f57-7eec4dccf770_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_FinancingReceivablePrepaymentPenalty_089fa706-4333-499b-9495-549103e60e7e_terseLabel_en-US" xlink:label="lab_bios_FinancingReceivablePrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty</link:label>
    <link:label id="lab_bios_FinancingReceivablePrepaymentPenalty_label_en-US" xlink:label="lab_bios_FinancingReceivablePrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Prepayment Penalty</link:label>
    <link:label id="lab_bios_FinancingReceivablePrepaymentPenalty_documentation_en-US" xlink:label="lab_bios_FinancingReceivablePrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Prepayment Penalty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FinancingReceivablePrepaymentPenalty" xlink:href="bios-20201231.xsd#bios_FinancingReceivablePrepaymentPenalty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_FinancingReceivablePrepaymentPenalty" xlink:to="lab_bios_FinancingReceivablePrepaymentPenalty" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_ceb31f74-470a-4e44-bfcd-0b96ba840b08_negatedTerseLabel_en-US" xlink:label="lab_bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right-Of-Use Asset</link:label>
    <link:label id="lab_bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:href="bios-20201231.xsd#bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="lab_bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_f4ea7f4f-85f5-4aab-8f8c-93f79e54f66d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_82b5ad90-e9c3-4364-a78a-f341a33d51c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForMergerRelatedCosts_fe77fcca-3de2-427d-978d-a538d3a0ddb5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForMergerRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of transaction costs</link:label>
    <link:label id="lab_us-gaap_PaymentsForMergerRelatedCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsForMergerRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Merger Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForMergerRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForMergerRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForMergerRelatedCosts" xlink:to="lab_us-gaap_PaymentsForMergerRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_64b083d7-d7c6-4d27-8cec-dcd468261c3c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6e79b072-c4a7-4d68-8de7-cfa68eac020e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward_68e6bd4b-2348-4c83-912b-7091ac5afc92_terseLabel_en-US" xlink:label="lab_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Deferred Tax Asset Valuation Allowance</link:label>
    <link:label id="lab_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward_label_en-US" xlink:label="lab_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Deferred Tax Asset Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward_documentation_en-US" xlink:label="lab_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Deferred Tax Asset Valuation Allowance [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward" xlink:href="bios-20201231.xsd#bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward" xlink:to="lab_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6bd6209d-8f1a-4fd0-850d-7c11bed431e7_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d8e61151-96ce-42d5-ac6e-95402dbedd83_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CatastrophicEventDomain_894ca2a6-daf4-4153-994f-fc0c9f936749_terseLabel_en-US" xlink:label="lab_us-gaap_CatastrophicEventDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Catastrophic Event [Domain]</link:label>
    <link:label id="lab_us-gaap_CatastrophicEventDomain_label_en-US" xlink:label="lab_us-gaap_CatastrophicEventDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Catastrophic Event [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CatastrophicEventDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CatastrophicEventDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CatastrophicEventDomain" xlink:to="lab_us-gaap_CatastrophicEventDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92ec12c7-85b6-4245-95f2-8ee31255906e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_PaidInKindInterestAdditionalInterestExpense_43817b2d-e8ae-4180-b20c-9a2d9c3a2aee_terseLabel_en-US" xlink:label="lab_bios_PaidInKindInterestAdditionalInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest expense charge</link:label>
    <link:label id="lab_bios_PaidInKindInterestAdditionalInterestExpense_label_en-US" xlink:label="lab_bios_PaidInKindInterestAdditionalInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-In-Kind Interest, Additional Interest Expense</link:label>
    <link:label id="lab_bios_PaidInKindInterestAdditionalInterestExpense_documentation_en-US" xlink:label="lab_bios_PaidInKindInterestAdditionalInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-In-Kind Interest, Additional Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PaidInKindInterestAdditionalInterestExpense" xlink:href="bios-20201231.xsd#bios_PaidInKindInterestAdditionalInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_PaidInKindInterestAdditionalInterestExpense" xlink:to="lab_bios_PaidInKindInterestAdditionalInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_596eff6d-b2bc-4c73-9873-dbc7fd0f809d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposition of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e651a6e7-5db9-4477-867a-ed1bf34c4d9c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_403d4438-6ae8-4873-b8f5-756f69eceddf_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_e9881207-b917-4846-9b8d-95f617866032_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_8e5aada3-2085-498f-963b-15f36e38c4d7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_9cccf9df-7beb-4f7d-a7e6-ff8411057919_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at Beginning of Period</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_a5088b35-a92e-493f-ad75-81a48b343e9b_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at End Period</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_4fec19ae-91ee-43a4-b2d5-68a2303979b0_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GROSS PROFIT</link:label>
    <link:label id="lab_us-gaap_GrossProfit_7bcf94c7-92c2-4d4b-adaf-661d41a07b09_verboseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ea07ac5e-8df1-45ff-b8ff-7dc8bfbf1eff_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1b704af0-e2f3-438d-8c0c-6601a939c5f7_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_346476d8-80f8-4821-8895-f4f08fc5a481_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_fb33cf80-45f5-4ff7-a81a-b878aac0b59f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8363d2c8-0190-4961-8ebe-8f4358269dd4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_8638071d-3884-42e3-baa3-835fdbfa8478_totalLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_d816775b-0ded-4cfa-b637-ed881bc2a44e_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4d9711ec-ddaa-4aa0-9a40-c6be0957924e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Incentive Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ad711216-2d7d-403a-9914-dadc85dcfa80_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_618f0765-5f9d-4650-90e5-81deffaeb471_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_835178b3-509e-49db-9a42-86ee03f2423f_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9885ff02-a24f-4b15-89ac-46997f67c3dc_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_OptionExercisePriceRangeOneMember_91a172be-be69-426e-bedc-ce7f89549276_terseLabel_en-US" xlink:label="lab_bios_OptionExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeOneMember_label_en-US" xlink:label="lab_bios_OptionExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range One [Member]</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_bios_OptionExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeOneMember" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_OptionExercisePriceRangeOneMember" xlink:to="lab_bios_OptionExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6f593bd-0bb7-4253-a784-b01fddc0a261_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_05d5d791-b153-42c5-a3f2-ae228bc4f22c_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_20eb6176-d3ab-4f8a-9763-075020f1c20f_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_313f3fe0-461f-4f45-a42f-4690af191eaa_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER COMPREHENSIVE (LOSS) INCOME</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4d6e8d49-b55f-4c6c-bcdc-5a3b49536ddc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_c2b80f3a-5806-46b1-831e-74e74af56274_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_359d3486-4a61-4c0a-9650-033817e3fc91_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_0006aa28-5ade-4589-be1f-b7caaee4cf26_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_028daad1-69d4-43c5-b28b-aa40ebbfd4fc_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_4f243c96-67c7-4037-915b-3aa4c689fc1f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING COSTS AND EXPENSES:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1b9ed1a9-3b1a-4620-a52a-f5fd3158c3ef_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_636f05b5-de33-4d94-83fc-83494f59e3bc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_132d6232-d2fc-4ec4-898b-d6a255b1982c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_InterestLimitationCarryforwardsMember_f741108e-501b-4d67-b402-c6cdd07ba13f_terseLabel_en-US" xlink:label="lab_bios_InterestLimitationCarryforwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Limitation Carryforwards</link:label>
    <link:label id="lab_bios_InterestLimitationCarryforwardsMember_label_en-US" xlink:label="lab_bios_InterestLimitationCarryforwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Limitation Carryforwards [Member]</link:label>
    <link:label id="lab_bios_InterestLimitationCarryforwardsMember_documentation_en-US" xlink:label="lab_bios_InterestLimitationCarryforwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Limitation Carryforwards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InterestLimitationCarryforwardsMember" xlink:href="bios-20201231.xsd#bios_InterestLimitationCarryforwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_InterestLimitationCarryforwardsMember" xlink:to="lab_bios_InterestLimitationCarryforwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_56b749ce-9aa5-4d8c-9254-fb2f26bf5802_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_aa0faca8-923b-4e94-9a45-bc462fc5940b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local income taxes net of federal tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue_94f53c0b-b433-4543-a78d-2bd5b79a104e_terseLabel_en-US" xlink:label="lab_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue_label_en-US" xlink:label="lab_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Intrinsic Value</link:label>
    <link:label id="lab_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue_documentation_en-US" xlink:label="lab_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue" xlink:href="bios-20201231.xsd#bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue" xlink:to="lab_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_767cc28d-9bfc-4421-b183-3b206e4f13cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business casualty loss</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_06b49707-1d17-40aa-956d-e238535b8469_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on business casualty loss</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_ef82c73b-679e-4568-be24-ecde5f8e9755_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) location of discontinued derivative instruments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsProductLineMember_75919bc1-d64f-4cd8-b0fa-ed35759e94db_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Product and Service Benchmark</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsProductLineMember_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsProductLineMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsProductLineMember" xlink:to="lab_us-gaap_CostOfGoodsProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9abd86de-fb90-4154-b2f4-8f6b7e00a05c_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares purchasable through warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec24a583-0ac6-411e-a725-1fd68838af19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1cd1b89d-a0f1-4d8f-b2d2-dec17e1c6302_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_03be98da-39d8-48ce-834b-e402b36bcaff_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_MadisonDearbornPartnersVIBL.P.Member_057b83ef-218e-44a9-a5c0-2e8dc260f691_terseLabel_en-US" xlink:label="lab_bios_MadisonDearbornPartnersVIBL.P.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Madison Dearborn Partners VI-B, L.P.</link:label>
    <link:label id="lab_bios_MadisonDearbornPartnersVIBL.P.Member_label_en-US" xlink:label="lab_bios_MadisonDearbornPartnersVIBL.P.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Madison Dearborn Partners VI-B, L.P. [Member]</link:label>
    <link:label id="lab_bios_MadisonDearbornPartnersVIBL.P.Member_documentation_en-US" xlink:label="lab_bios_MadisonDearbornPartnersVIBL.P.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Madison Dearborn Partners VI-B, L.P. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_MadisonDearbornPartnersVIBL.P.Member" xlink:href="bios-20201231.xsd#bios_MadisonDearbornPartnersVIBL.P.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_MadisonDearbornPartnersVIBL.P.Member" xlink:to="lab_bios_MadisonDearbornPartnersVIBL.P.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_6437ccca-b857-4b9a-9cf8-15a06230d582_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Supply Vendors</link:label>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierConcentrationRiskMember" xlink:to="lab_us-gaap_SupplierConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_AccruedExpensesandOtherCurrentLiabilitiesMember_e2d222e0-9f3c-486b-8714-479520551245_terseLabel_en-US" xlink:label="lab_bios_AccruedExpensesandOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_bios_AccruedExpensesandOtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_bios_AccruedExpensesandOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities [Member]</link:label>
    <link:label id="lab_bios_AccruedExpensesandOtherCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_bios_AccruedExpensesandOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AccruedExpensesandOtherCurrentLiabilitiesMember" xlink:href="bios-20201231.xsd#bios_AccruedExpensesandOtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_AccruedExpensesandOtherCurrentLiabilitiesMember" xlink:to="lab_bios_AccruedExpensesandOtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_624fcfaa-62b5-40fc-bdee-9e6538fa65f8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain" xlink:to="lab_us-gaap_DeferredTaxAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_f46041b3-3765-4be6-ba11-a340348cea2d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentContractsConcentrationRiskMember_fce194ba-529e-4189-b07d-8160f98a3fb5_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Governmental Programs</link:label>
    <link:label id="lab_us-gaap_GovernmentContractsConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Contracts Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:to="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_cae392aa-a23f-4fab-adbd-d5e630fda637_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_e244c4ff-f9a1-4d20-ba80-b0de80eb8200_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_7a804bcd-4ba3-4723-9a9b-ce7645611c12_terseLabel_en-US" xlink:label="lab_us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER INCOME (EXPENSE):</link:label>
    <link:label id="lab_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_label_en-US" xlink:label="lab_us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expense, Nonoperating [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenseDisclosureNonoperatingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:to="lab_us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_70bf1420-5fa2-4337-99a0-f4e4fbc923af_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture</link:label>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_label_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember" xlink:to="lab_us-gaap_CorporateJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_a020e33e-8653-4da9-a323-e4e1dcd32796_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_65939a7b-280d-452d-8234-2084863fda2b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_95e7e320-3959-421f-a31c-8e41c523f1c0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_a25715d6-7a86-4a1a-aa2f-a3907ffbca09_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_15e42d20-357e-463b-bec5-c39756871932_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableRelatedParties_5fdd06bc-684c-43a2-976b-96213d298cc4_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes receivable</link:label>
    <link:label id="lab_us-gaap_NotesReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedParties" xlink:to="lab_us-gaap_NotesReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_c2242754-bc02-462f-8235-4454f5861c91_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly installment payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_de7d2401-551f-4886-8018-ed827efd2ab9_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to joint ventures</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_cb078561-201b-4e81-92eb-677a04081c7f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_5fec1a0c-27aa-4c27-bca7-d552d0688498_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan expense</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_faa886ad-5f8b-4d29-856f-528c87f49444_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_27f41664-335c-4311-a772-a4e5b08b6fd6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net borrowing availability</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aa67d896-2c73-4bfb-badb-7888cef49e81_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bb3bf32b-b594-4304-b3f4-571cce8116c0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued to warrant and preferred stockholders at time of the merger (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_OptionExercisePriceRangeTwoMember_88466a38-9760-4cda-bdb4-cbbf9fc56b1d_terseLabel_en-US" xlink:label="lab_bios_OptionExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.24</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_bios_OptionExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range Two [Member]</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_bios_OptionExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeTwoMember" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_OptionExercisePriceRangeTwoMember" xlink:to="lab_bios_OptionExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetUnderConstructionMember_794c7a95-eebf-4646-94f0-5ceb6ecf6ab2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetUnderConstructionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets under development</link:label>
    <link:label id="lab_us-gaap_AssetUnderConstructionMember_label_en-US" xlink:label="lab_us-gaap_AssetUnderConstructionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset under Construction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetUnderConstructionMember" xlink:to="lab_us-gaap_AssetUnderConstructionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_9e95bbd7-f2a7-4b70-bc39-c5f83540068e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_378136de-76f3-403e-a0e5-0f8c20f5eaa3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_CreditArrangementsEnteredInto2015ModifiedLoansMember_863bcd17-c771-4c76-a6f5-8cbf7d9d9595_terseLabel_en-US" xlink:label="lab_bios_CreditArrangementsEnteredInto2015ModifiedLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Arrangements, Entered Into 2015, Modified Loans</link:label>
    <link:label id="lab_bios_CreditArrangementsEnteredInto2015ModifiedLoansMember_label_en-US" xlink:label="lab_bios_CreditArrangementsEnteredInto2015ModifiedLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Arrangements, Entered Into 2015, Modified Loans [Member]</link:label>
    <link:label id="lab_bios_CreditArrangementsEnteredInto2015ModifiedLoansMember_documentation_en-US" xlink:label="lab_bios_CreditArrangementsEnteredInto2015ModifiedLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Arrangements, Entered Into 2015, Modified Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditArrangementsEnteredInto2015ModifiedLoansMember" xlink:href="bios-20201231.xsd#bios_CreditArrangementsEnteredInto2015ModifiedLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_CreditArrangementsEnteredInto2015ModifiedLoansMember" xlink:to="lab_bios_CreditArrangementsEnteredInto2015ModifiedLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_32919e01-ffe2-42e6-b746-6356286df990_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_DebtInstrumentBaseRate_7b6e5453-da85-4e4d-8baa-d52e1dd797d2_terseLabel_en-US" xlink:label="lab_bios_DebtInstrumentBaseRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rate</link:label>
    <link:label id="lab_bios_DebtInstrumentBaseRate_label_en-US" xlink:label="lab_bios_DebtInstrumentBaseRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Base Rate</link:label>
    <link:label id="lab_bios_DebtInstrumentBaseRate_documentation_en-US" xlink:label="lab_bios_DebtInstrumentBaseRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Base Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DebtInstrumentBaseRate" xlink:href="bios-20201231.xsd#bios_DebtInstrumentBaseRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_DebtInstrumentBaseRate" xlink:to="lab_bios_DebtInstrumentBaseRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_352a2afb-4e5f-4fa7-9167-e218fe0f768e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate paid on term loans during period</link:label>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_label_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Weighted Average Interest Rate, over Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:to="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_484973ac-e7ea-4d5c-a1d6-c474767875bf_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_f1441f2e-4159-4786-8867-22d94fa1e120_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_654d6190-86cf-4837-b25a-84a60fad882a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_c4f5728a-02b0-47e6-9884-ed4acdf2f1a7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_2367dedc-9bbb-49b8-a412-25e762e6e4d3_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_bfb37cb7-d0fd-4fac-ac25-a9f61d371461_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Lease Liabilities, Operating</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_GovernmentCustomerMember_359abf1b-21d9-4cb7-8fc9-1b5da9597f1d_terseLabel_en-US" xlink:label="lab_bios_GovernmentCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial payers</link:label>
    <link:label id="lab_bios_GovernmentCustomerMember_label_en-US" xlink:label="lab_bios_GovernmentCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Customer [Member]</link:label>
    <link:label id="lab_bios_GovernmentCustomerMember_documentation_en-US" xlink:label="lab_bios_GovernmentCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_GovernmentCustomerMember" xlink:href="bios-20201231.xsd#bios_GovernmentCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_GovernmentCustomerMember" xlink:to="lab_bios_GovernmentCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_fdc4d003-b4e1-4cb1-a84e-81cae3f31800_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fc9d4de0-6add-487b-8dea-c6c73f60e24a_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_50447fe0-91f6-4e83-a150-2d657f93c24b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5a2839bd-4836-4745-a198-119630419ba1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_f36e2225-3d7f-4df6-b201-96f6251e5322_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax_30722583-cb69-4d52-97ee-ebb77d4ae6b5_terseLabel_en-US" xlink:label="lab_bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps that discontinued hedge accounting</link:label>
    <link:label id="lab_bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax_label_en-US" xlink:label="lab_bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Discontinuance Before Reclassification And Tax</link:label>
    <link:label id="lab_bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax_documentation_en-US" xlink:label="lab_bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Discontinuance Before Reclassification And Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax" xlink:href="bios-20201231.xsd#bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax" xlink:to="lab_bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_ed5c4153-490b-40e6-97c2-f847124d61f0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_176f1a3e-d528-437f-848e-7c4fcaec134f_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_2187ec37-47b8-4dc9-b0be-d7d7b5e45035_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock held (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_d77abcf3-c514-42f5-951e-09650b8e721e_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_52ba40d7-35f1-4298-81c0-dddca9e3664c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e93bcc2b-951c-4a2c-8622-0e1093282c87_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_6d7e2746-d472-4ca2-84f5-93d50cbe6d22_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_ee7068d2-74cc-4835-ae0e-1f84f3f8bb05_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_15725e33-6836-45d1-9d2a-bf85d2a56c40_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_12e1f834-84be-40dd-900b-a399a3e7b68e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_7e757f2c-70f1-48a2-8d54-5831f39bb118_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_f155f131-f30a-429a-a105-6376df708f72_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption_f38a21d0-781b-4838-9650-5092eef45bf2_negatedTerseLabel_en-US" xlink:label="lab_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' redemptions</link:label>
    <link:label id="lab_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption_label_en-US" xlink:label="lab_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Stockholders' Redemption</link:label>
    <link:label id="lab_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption_documentation_en-US" xlink:label="lab_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Stockholders' Redemption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption" xlink:href="bios-20201231.xsd#bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption" xlink:to="lab_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_444d8621-91eb-49a3-ab6d-4df35fbbec0e_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_OptionExercisePriceRangeThreeMember_afc0b8f9-068a-46e1-b905-b4159eb57b2e_terseLabel_en-US" xlink:label="lab_bios_OptionExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">16.52</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_bios_OptionExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range Three [Member]</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_bios_OptionExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeThreeMember" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_OptionExercisePriceRangeThreeMember" xlink:to="lab_bios_OptionExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_1816493b-29b3-4956-ba4e-4b41cf2ddbca_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt instruments</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_1e22c986-b2af-46de-b3e2-60f38400ebf1_periodStartLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Lien Notes fair value as of January 1, 2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_317b580a-4bf0-4524-b735-5dd0303564eb_periodEndLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Lien Notes fair value as of December 31, 2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d95d554d-e7d7-432b-8620-279d6c4b3935_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ed237015-558f-4ca1-a5a8-d872c6e37b68_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_50a65454-92fc-43a6-b220-366e58547e0b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_0ce0b5a3-f849-4cc9-9f36-cce75c8d30c1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_75913d56-0491-4d6c-a9cb-ec6749567e37_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAX EXPENSE (BENEFIT)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3615ada3-2a90-4c18-9beb-82b54df6e3ac_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_62549ee0-8185-45aa-bc76-c9ae6bdd73df_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ad97ad81-7921-424e-9234-faa81ee1305c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents - beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d38b60af-60b2-43dd-b743-362b0904504e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND CASH EQUIVALENTS - END OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_03b41709-5f48-44e7-b8d6-8ad292ae4ae6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_70203615-d47b-49b9-a1b8-578913b4b7ca_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_c42e7669-0a11-4818-8def-a6b9e53dcef6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_c3a5467c-3b49-4560-bd5e-aca6d8d78b45_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_763eba41-3f55-457a-9c20-78a076328f96_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) earnings per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d5811eef-22c9-49f4-91b1-6f42e3d1699c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_e5ccc417-2552-4b10-8457-743037ab5d0b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_243be46c-f6d5-433f-887e-bfee2c873215_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid in conjunction with the Merger included in purchase consideration</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_125627c6-24ec-4029-9602-4753a3618743_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pro Forma Financial Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_4d8c4e10-5161-4aac-a73f-77f5c5d4a691_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_54ecb251-01d4-4b35-bc16-29cee9ad867e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1d407957-d060-4ec7-9dc5-af4b14024a68_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4ba185fe-909a-4ce4-b77c-550659efb90b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_082029ec-c745-4340-a1de-f9a5d2957359_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of shares in acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_90de50de-6f97-4aa5-b578-f178d7d2b0c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_d857daa1-a61e-43e1-8c82-2be79e385a9a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_fc176b49-9482-4022-841b-5b85b3a31397_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales since acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_ed9830d4-e797-4961-a13e-5823d3e11161_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_BusinessCombinationOwnershipInterestRetained_877af1ff-9c73-4a0a-b081-eb1fb76f17f9_terseLabel_en-US" xlink:label="lab_bios_BusinessCombinationOwnershipInterestRetained" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership retained by shareholders after merger</link:label>
    <link:label id="lab_bios_BusinessCombinationOwnershipInterestRetained_label_en-US" xlink:label="lab_bios_BusinessCombinationOwnershipInterestRetained" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Ownership Interest Retained</link:label>
    <link:label id="lab_bios_BusinessCombinationOwnershipInterestRetained_documentation_en-US" xlink:label="lab_bios_BusinessCombinationOwnershipInterestRetained" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Company ownership shareholders retained after merger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BusinessCombinationOwnershipInterestRetained" xlink:href="bios-20201231.xsd#bios_BusinessCombinationOwnershipInterestRetained"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_BusinessCombinationOwnershipInterestRetained" xlink:to="lab_bios_BusinessCombinationOwnershipInterestRetained" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_0fd23594-9750-4a50-b6f8-54199997d33c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upper range limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_dd74efa2-b484-49f4-8db1-5c1a609fc898_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_c96e3ec0-af81-4882-bbab-eba98d8ec726_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable range of years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_30a81757-9f9a-4215-af91-a2a099b313fc_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings of joint ventures</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_1aa35975-770c-4bb6-9682-fe03ad049468_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_380dd2b0-84bd-473d-b973-a85d31defb9b_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_6e638896-9095-41a9-bdde-024c7b323bb8_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfNotesReceivable_603d2deb-636c-44b6-8a81-428ca1be9f80_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of management notes receivable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfNotesReceivable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:to="lab_us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_CommercialCustomerMember_ec17b660-fe54-46eb-806f-fa434d9d2fe3_terseLabel_en-US" xlink:label="lab_bios_CommercialCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government payers</link:label>
    <link:label id="lab_bios_CommercialCustomerMember_label_en-US" xlink:label="lab_bios_CommercialCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Customer [Member]</link:label>
    <link:label id="lab_bios_CommercialCustomerMember_documentation_en-US" xlink:label="lab_bios_CommercialCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CommercialCustomerMember" xlink:href="bios-20201231.xsd#bios_CommercialCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_CommercialCustomerMember" xlink:to="lab_bios_CommercialCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_54b075b8-4871-462a-8df7-fb477d43b6d7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_f9b587a4-ab6c-41a8-9fb5-13c6d7430164_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_ChargedToOtherAccountsMember_59bbdb41-b919-4611-9b35-f369d1782c37_terseLabel_en-US" xlink:label="lab_bios_ChargedToOtherAccountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to Other Accounts</link:label>
    <link:label id="lab_bios_ChargedToOtherAccountsMember_label_en-US" xlink:label="lab_bios_ChargedToOtherAccountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged To Other Accounts [Member]</link:label>
    <link:label id="lab_bios_ChargedToOtherAccountsMember_documentation_en-US" xlink:label="lab_bios_ChargedToOtherAccountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged To Other Accounts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ChargedToOtherAccountsMember" xlink:href="bios-20201231.xsd#bios_ChargedToOtherAccountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_ChargedToOtherAccountsMember" xlink:to="lab_bios_ChargedToOtherAccountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_e8add1f8-c861-4589-8054-f4cdb5b8bc0c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_cf983535-ae28-43d3-8688-90c238ad4cd4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2aa2ddcc-216d-467f-8f44-7678b40e4c2e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive trading days threshold</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1f7414d5-6417-4bfb-b9ee-96ed3280ac54_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_a76e52f5-0b50-46c6-babc-cc61c0df567e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2266f39a-1640-4a08-80dc-fe1db751da13_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes - net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_f14a1302-451e-4332-9288-a0cfe9a266b8_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7aeb984e-9d18-41df-abcc-568e59f72e8b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fd945f80-4caf-49d2-a084-76ccd4ee5d73_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceLineItems_ee73132b-da66-4ade-a260-6e867779698f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceLineItems_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceLineItems" xlink:to="lab_us-gaap_ValuationAllowanceLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c193c4e4-cc19-4d44-81c8-b108255250d3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_7f3ecbe4-f6be-4175-886d-c160281dd270_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares vested in period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_3f8da665-4bba-4603-b663-10320aaed825_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_cfd7cc81-038d-40cd-ac08-cfe3fbb13bb0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_c1881e80-b304-40af-ac0c-c68cfaeb0c94_terseLabel_en-US" xlink:label="lab_bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-Of-Use Assets</link:label>
    <link:label id="lab_bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:href="bios-20201231.xsd#bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="lab_bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_8eb14fca-a491-4cb8-94a2-ee277da188bd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_655a0904-db6c-497a-962f-3d18672926a6_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c10459d9-82e8-4e38-91a8-231d112445b6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_f7d89f2a-9075-4735-a2c0-a844bfdbcaa0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount credited to paid-in capital for membership units sold and funded</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PartnersCapitalAccountRedemptions_0d199d98-027f-426b-a32c-74ab78497387_terseLabel_en-US" xlink:label="lab_us-gaap_PartnersCapitalAccountRedemptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder redemptions</link:label>
    <link:label id="lab_us-gaap_PartnersCapitalAccountRedemptions_label_en-US" xlink:label="lab_us-gaap_PartnersCapitalAccountRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partners' Capital Account, Redemptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountRedemptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PartnersCapitalAccountRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnersCapitalAccountRedemptions" xlink:to="lab_us-gaap_PartnersCapitalAccountRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_OptionExercisePriceRangeSixMember_ccfa1d70-c66f-483f-8d0b-851334d510e1_terseLabel_en-US" xlink:label="lab_bios_OptionExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">41.28</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeSixMember_label_en-US" xlink:label="lab_bios_OptionExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range Six [Member]</link:label>
    <link:label id="lab_bios_OptionExercisePriceRangeSixMember_documentation_en-US" xlink:label="lab_bios_OptionExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price, Range Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeSixMember" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_OptionExercisePriceRangeSixMember" xlink:to="lab_bios_OptionExercisePriceRangeSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cf4421c7-d866-4477-a613-f88f0be96533_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_dc6d65f8-a375-4cb9-8bca-c467f2272641_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6e2ca79b-835e-4207-b254-d60ddd4fce69_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fd28a649-f58e-4965-b4fc-64fd1e17a436_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2bcbb77d-63df-4051-a86c-2eb7068ea059_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average time to liquidity (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_933759a8-821a-4bea-a2ae-fe7c927fb4a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_0d31e131-04dc-4a2c-9a08-6e1d138bdc93_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0cf206f7-01ea-492b-acd6-ea89ffe32798_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_c7dfde40-703f-4d2e-95c5-0c0603b4df8a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NONCURRENT LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_62649ac5-7f87-4903-8eb8-3af1bde07520_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9d0e696c-0b7b-42d5-a418-99388f9340ab_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_88d76f66-2eef-4970-a882-dfdcbfd56396_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fee income</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e8e1a070-6c78-4304-80c0-71a4f2cc73e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at December 31, 2020 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_117121d0-5e96-4975-b5d1-9e4d54ddaca5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_4fb22eae-258d-416a-9e91-60d19ad07383_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee, unused portion</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_efb08ed1-778f-4b83-b70f-b430dce84b5e_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_a065e6b1-cf28-46ab-81eb-33187415c047_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock; 383,722 shares outstanding, at cost, as of December 31, 2020 and 2019, respectively.</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ba38d592-3158-4b88-9927-3c3ab31a3c12_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28fb9250-fe8d-40e0-bc03-ee2b8f67367b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_8b0a97e2-2484-4ad9-9c54-762f18270c50_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ae6e43e6-ac9b-4f15-b119-7f86f76a2113_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b8580b61-5a3b-472a-a81f-f91d07756459_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a4aca7b6-796d-4e9c-8aac-0f26921e9544_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_ee665b72-c94f-4576-9720-a1608840e32d_terseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares surrendered to satisfy tax withholding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d5bbe227-e8b2-4656-9570-9c7aa6782d05_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_059f8926-7dac-4157-838c-252eaf12b3a3_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_cb87ca60-b477-4f0a-907e-dc2b5af5f6c9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated balance sheet data:</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>bios-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:67699b3b-5a42-424d-a4a2-736d8be0bc5f,g:dc7394d0-f9c6-4f46-91d7-369b9ff9f10f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bioscrip.com/role/COVERPAGE" xlink:type="simple" xlink:href="bios-20201231.xsd#COVERPAGE"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/COVERPAGE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_52067010-bc36-450e-b052-c05afa3ad95f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_DocumentType_52067010-bc36-450e-b052-c05afa3ad95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_c56d6fb3-0ee1-4717-a779-186c053034fa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_DocumentAnnualReport_c56d6fb3-0ee1-4717-a779-186c053034fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5a6d30f0-6adf-4f78-a1b8-0c6674a2334d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_DocumentPeriodEndDate_5a6d30f0-6adf-4f78-a1b8-0c6674a2334d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_78e3e0b5-feb1-4aec-8841-133d2d2eda01" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_CurrentFiscalYearEndDate_78e3e0b5-feb1-4aec-8841-133d2d2eda01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3f2e8b3e-c4c5-4630-aa4c-402e585fcc05" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_DocumentTransitionReport_3f2e8b3e-c4c5-4630-aa4c-402e585fcc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3777a4ca-9683-4f6f-92a8-863345378a88" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityFileNumber_3777a4ca-9683-4f6f-92a8-863345378a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9de5f36f-b350-44b4-b5b2-7c861dffcd58" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityRegistrantName_9de5f36f-b350-44b4-b5b2-7c861dffcd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c7f47d4d-ba9e-43ab-bb19-2440aeac122c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c7f47d4d-ba9e-43ab-bb19-2440aeac122c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d6df8be2-97fa-4f1e-aa5a-2cb7b73fe2b9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityTaxIdentificationNumber_d6df8be2-97fa-4f1e-aa5a-2cb7b73fe2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6b37aad8-4b74-4aae-910b-6dbefd8496e7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityAddressAddressLine1_6b37aad8-4b74-4aae-910b-6dbefd8496e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_53f3e436-c41d-46b5-a324-9e763827bc6c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityAddressAddressLine2_53f3e436-c41d-46b5-a324-9e763827bc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4ac37e74-83a0-4948-86e9-26cd3c6ab59a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityAddressCityOrTown_4ac37e74-83a0-4948-86e9-26cd3c6ab59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_99154ce9-9247-4d48-bd65-303b0795ff8e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityAddressStateOrProvince_99154ce9-9247-4d48-bd65-303b0795ff8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b38fe4e6-95e8-4def-9b73-836f1330d795" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityAddressPostalZipCode_b38fe4e6-95e8-4def-9b73-836f1330d795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_47137887-6108-492b-bbb4-912f05c89dee" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_CityAreaCode_47137887-6108-492b-bbb4-912f05c89dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c9ec9209-b619-4736-ada1-f32e1b7cbd1b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_LocalPhoneNumber_c9ec9209-b619-4736-ada1-f32e1b7cbd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_32123da8-7423-4c4f-a449-4dfccb737096" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_Security12bTitle_32123da8-7423-4c4f-a449-4dfccb737096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0a864a6b-253d-4e13-abc3-3254681ad78d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_TradingSymbol_0a864a6b-253d-4e13-abc3-3254681ad78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_603cf93b-442e-431d-bdc1-d330c98d6734" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_SecurityExchangeName_603cf93b-442e-431d-bdc1-d330c98d6734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_09208ea9-4080-49a0-826b-942e8250c1b1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_09208ea9-4080-49a0-826b-942e8250c1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_06409e56-c8c2-4902-8b96-b52982c8dece" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityVoluntaryFilers_06409e56-c8c2-4902-8b96-b52982c8dece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_37046efe-ba5c-4e53-82b6-2267f9f54c1a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityCurrentReportingStatus_37046efe-ba5c-4e53-82b6-2267f9f54c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_823bb893-2bfb-48a2-a3ec-a7eb416593ba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityInteractiveDataCurrent_823bb893-2bfb-48a2-a3ec-a7eb416593ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_9e10ad0b-2695-4eef-a10f-ed60c3b72a8f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityFilerCategory_9e10ad0b-2695-4eef-a10f-ed60c3b72a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c7b4038e-9cf2-4d82-a366-a859050a4efb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntitySmallBusiness_c7b4038e-9cf2-4d82-a366-a859050a4efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1c319c60-961f-4c65-85ec-dd4b8af80d76" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityEmergingGrowthCompany_1c319c60-961f-4c65-85ec-dd4b8af80d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_4542c2ce-4367-4d3f-8691-8c534a7c90a0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_IcfrAuditorAttestationFlag_4542c2ce-4367-4d3f-8691-8c534a7c90a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_780a9994-7f7d-48d1-b7d9-8783fd8da3e9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityShellCompany_780a9994-7f7d-48d1-b7d9-8783fd8da3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_c5cdf29d-e706-46de-9c7d-835823221957" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityPublicFloat_c5cdf29d-e706-46de-9c7d-835823221957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_539007f3-eb4c-49d3-b08c-d0baf69ccbae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_539007f3-eb4c-49d3-b08c-d0baf69ccbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_9455fed3-104e-4803-a908-1971e9bbb82c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_9455fed3-104e-4803-a908-1971e9bbb82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_92500c0c-e057-4d2c-9845-e388f5230476" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_EntityCentralIndexKey_92500c0c-e057-4d2c-9845-e388f5230476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1d6cc86f-7490-4e59-b940-27f9dbcd46ae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_DocumentFiscalYearFocus_1d6cc86f-7490-4e59-b940-27f9dbcd46ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_27f6007e-32f8-446d-8303-71065ef7bac3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_DocumentFiscalPeriodFocus_27f6007e-32f8-446d-8303-71065ef7bac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_514491ff-15d1-46a3-ae08-1f2e5a069998" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ef34992b-b94f-4d67-ae2d-ab8856c6b8de" xlink:to="loc_dei_AmendmentFlag_514491ff-15d1-46a3-ae08-1f2e5a069998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bios-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a8bcf910-1d21-4c20-aede-6b6fcc290586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_75db6148-34cf-42be-96c2-6f770cdc5c93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a8bcf910-1d21-4c20-aede-6b6fcc290586" xlink:to="loc_us-gaap_AssetsAbstract_75db6148-34cf-42be-96c2-6f770cdc5c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1f07a24e-192d-4342-bb3c-f745ca319e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75db6148-34cf-42be-96c2-6f770cdc5c93" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1f07a24e-192d-4342-bb3c-f745ca319e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9d24ac75-eb41-462b-b97a-85312c38aaf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f07a24e-192d-4342-bb3c-f745ca319e79" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9d24ac75-eb41-462b-b97a-85312c38aaf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b9718add-c17d-41a9-a1e2-dad51628a5d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f07a24e-192d-4342-bb3c-f745ca319e79" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b9718add-c17d-41a9-a1e2-dad51628a5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7f4f1888-b3ba-4420-ad56-de2382cb7dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f07a24e-192d-4342-bb3c-f745ca319e79" xlink:to="loc_us-gaap_InventoryNet_7f4f1888-b3ba-4420-ad56-de2382cb7dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ecdd2d5-509e-4454-9d9a-44c54a5c7bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f07a24e-192d-4342-bb3c-f745ca319e79" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ecdd2d5-509e-4454-9d9a-44c54a5c7bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dcc854c9-103c-4c1f-99ae-29dfdee152f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f07a24e-192d-4342-bb3c-f745ca319e79" xlink:to="loc_us-gaap_AssetsCurrent_dcc854c9-103c-4c1f-99ae-29dfdee152f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_2ef31945-560d-48b3-982c-b8cf30bcbca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75db6148-34cf-42be-96c2-6f770cdc5c93" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_2ef31945-560d-48b3-982c-b8cf30bcbca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9726f2a5-bd5f-451a-8cda-b866e206ba9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_2ef31945-560d-48b3-982c-b8cf30bcbca1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9726f2a5-bd5f-451a-8cda-b866e206ba9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_45c562a2-c6c7-4979-aada-332ba6095baf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_2ef31945-560d-48b3-982c-b8cf30bcbca1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_45c562a2-c6c7-4979-aada-332ba6095baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dcb9bdcd-7f07-40a5-ab36-ab80da4d7d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_2ef31945-560d-48b3-982c-b8cf30bcbca1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dcb9bdcd-7f07-40a5-ab36-ab80da4d7d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ecd9a70f-abe8-4859-bf70-2b27ed5f9bc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_2ef31945-560d-48b3-982c-b8cf30bcbca1" xlink:to="loc_us-gaap_Goodwill_ecd9a70f-abe8-4859-bf70-2b27ed5f9bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_474c8f9a-d809-4c26-be66-20a5bbfbfc02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_2ef31945-560d-48b3-982c-b8cf30bcbca1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_474c8f9a-d809-4c26-be66-20a5bbfbfc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_ce3786cd-50f9-42de-a09d-27c05831af94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_2ef31945-560d-48b3-982c-b8cf30bcbca1" xlink:to="loc_us-gaap_AssetsNoncurrent_ce3786cd-50f9-42de-a09d-27c05831af94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_eb689cc9-a6f1-4e81-ae49-2a268dd4d40e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75db6148-34cf-42be-96c2-6f770cdc5c93" xlink:to="loc_us-gaap_Assets_eb689cc9-a6f1-4e81-ae49-2a268dd4d40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_068ed21c-1340-4f9f-a77e-edec1290807a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a8bcf910-1d21-4c20-aede-6b6fcc290586" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_068ed21c-1340-4f9f-a77e-edec1290807a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1bbd82e8-3df3-47b9-8b51-42da47c38d4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_068ed21c-1340-4f9f-a77e-edec1290807a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1bbd82e8-3df3-47b9-8b51-42da47c38d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_38459320-ecb1-420e-8fc5-117ddc5f3c09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1bbd82e8-3df3-47b9-8b51-42da47c38d4b" xlink:to="loc_us-gaap_AccountsPayableCurrent_38459320-ecb1-420e-8fc5-117ddc5f3c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0f9ef83f-9522-49e3-a461-726f408917d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1bbd82e8-3df3-47b9-8b51-42da47c38d4b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0f9ef83f-9522-49e3-a461-726f408917d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AccruedExpensesAndOtherCurrentLiabilities_13c74bc5-5497-45af-97d4-66689df6e56c" xlink:href="bios-20201231.xsd#bios_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1bbd82e8-3df3-47b9-8b51-42da47c38d4b" xlink:to="loc_bios_AccruedExpensesAndOtherCurrentLiabilities_13c74bc5-5497-45af-97d4-66689df6e56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ffd39040-ae89-4122-8c55-cea780ae2d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1bbd82e8-3df3-47b9-8b51-42da47c38d4b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ffd39040-ae89-4122-8c55-cea780ae2d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_8f477221-caef-41a9-bdfb-51f77db2d333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1bbd82e8-3df3-47b9-8b51-42da47c38d4b" xlink:to="loc_us-gaap_LongTermDebtCurrent_8f477221-caef-41a9-bdfb-51f77db2d333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3532d12d-e311-4dab-b372-a0bd39ea5e44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1bbd82e8-3df3-47b9-8b51-42da47c38d4b" xlink:to="loc_us-gaap_LiabilitiesCurrent_3532d12d-e311-4dab-b372-a0bd39ea5e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_3e0b1532-f844-45ae-86f9-b4355aaeee36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_068ed21c-1340-4f9f-a77e-edec1290807a" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_3e0b1532-f844-45ae-86f9-b4355aaeee36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_848e9204-0490-465e-8e4d-a9f699b20231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3e0b1532-f844-45ae-86f9-b4355aaeee36" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_848e9204-0490-465e-8e4d-a9f699b20231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_444d4f7e-bdef-41da-8a31-839d2ac40c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3e0b1532-f844-45ae-86f9-b4355aaeee36" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_444d4f7e-bdef-41da-8a31-839d2ac40c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_77754f0d-db3a-4c8b-ad29-73ef34866803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3e0b1532-f844-45ae-86f9-b4355aaeee36" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_77754f0d-db3a-4c8b-ad29-73ef34866803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ac7684f1-a2f8-401f-9a53-e97a88cace44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3e0b1532-f844-45ae-86f9-b4355aaeee36" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ac7684f1-a2f8-401f-9a53-e97a88cace44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_0870b4f0-f326-42ce-b801-217688a91b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3e0b1532-f844-45ae-86f9-b4355aaeee36" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_0870b4f0-f326-42ce-b801-217688a91b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_05893d58-74ee-4f84-8dd7-81580aad42af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_068ed21c-1340-4f9f-a77e-edec1290807a" xlink:to="loc_us-gaap_Liabilities_05893d58-74ee-4f84-8dd7-81580aad42af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2c3aba9e-eb0c-4042-a497-816e47f1d212" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_068ed21c-1340-4f9f-a77e-edec1290807a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2c3aba9e-eb0c-4042-a497-816e47f1d212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_793d7ed0-950d-44cd-bd4c-281aa9f460ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2c3aba9e-eb0c-4042-a497-816e47f1d212" xlink:to="loc_us-gaap_PreferredStockValue_793d7ed0-950d-44cd-bd4c-281aa9f460ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_96df675d-99b7-4b24-8887-89fe951d0782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2c3aba9e-eb0c-4042-a497-816e47f1d212" xlink:to="loc_us-gaap_CommonStockValue_96df675d-99b7-4b24-8887-89fe951d0782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_c8bb5113-0490-4dcd-ada8-ea775e675f89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2c3aba9e-eb0c-4042-a497-816e47f1d212" xlink:to="loc_us-gaap_TreasuryStockValue_c8bb5113-0490-4dcd-ada8-ea775e675f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3d9a3534-ff13-4b5f-a94b-f84475eaca94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2c3aba9e-eb0c-4042-a497-816e47f1d212" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3d9a3534-ff13-4b5f-a94b-f84475eaca94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e81a4fb7-6956-4f86-ade7-ae8f177e1ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2c3aba9e-eb0c-4042-a497-816e47f1d212" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e81a4fb7-6956-4f86-ade7-ae8f177e1ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a9936d6e-f300-418a-8685-54aa4baa0f5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2c3aba9e-eb0c-4042-a497-816e47f1d212" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a9936d6e-f300-418a-8685-54aa4baa0f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_619d949c-0661-46e8-b057-5ca26bafb955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2c3aba9e-eb0c-4042-a497-816e47f1d212" xlink:to="loc_us-gaap_StockholdersEquity_619d949c-0661-46e8-b057-5ca26bafb955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b8a2ab4d-6ff5-4600-ad62-b83aa845cbc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_068ed21c-1340-4f9f-a77e-edec1290807a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b8a2ab4d-6ff5-4600-ad62-b83aa845cbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="bios-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e77f3331-2a6a-4e3e-b91c-7ebe618d75b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_76951ddf-1ab8-4e93-8b4e-03523f65d600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e77f3331-2a6a-4e3e-b91c-7ebe618d75b6" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_76951ddf-1ab8-4e93-8b4e-03523f65d600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8a43a108-7d72-49c5-9219-a2be65c2b4e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e77f3331-2a6a-4e3e-b91c-7ebe618d75b6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8a43a108-7d72-49c5-9219-a2be65c2b4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c0da1be1-ce2d-402d-92c8-4def9ce735c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e77f3331-2a6a-4e3e-b91c-7ebe618d75b6" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c0da1be1-ce2d-402d-92c8-4def9ce735c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4dbd0b0a-bfc0-4cc7-9a06-7484bc62acd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e77f3331-2a6a-4e3e-b91c-7ebe618d75b6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4dbd0b0a-bfc0-4cc7-9a06-7484bc62acd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1b8909ca-dc18-4f9d-9fed-70c4f7bba35b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e77f3331-2a6a-4e3e-b91c-7ebe618d75b6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1b8909ca-dc18-4f9d-9fed-70c4f7bba35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0a32d505-77ae-4b2c-a81a-437693599947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e77f3331-2a6a-4e3e-b91c-7ebe618d75b6" xlink:to="loc_us-gaap_CommonStockSharesIssued_0a32d505-77ae-4b2c-a81a-437693599947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e57aacf2-037e-4337-9ead-af466129171f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e77f3331-2a6a-4e3e-b91c-7ebe618d75b6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e57aacf2-037e-4337-9ead-af466129171f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_2bfe0e2c-34d1-48fc-b1f2-3f483e529945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e77f3331-2a6a-4e3e-b91c-7ebe618d75b6" xlink:to="loc_us-gaap_TreasuryStockShares_2bfe0e2c-34d1-48fc-b1f2-3f483e529945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="bios-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_234887c7-6d09-44d1-b58c-d330be54435b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ddc25468-2e2b-4314-8586-de5713ecfcf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_234887c7-6d09-44d1-b58c-d330be54435b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ddc25468-2e2b-4314-8586-de5713ecfcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_76d00c3b-dac2-4d79-b8d7-a3b29aa3170e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_234887c7-6d09-44d1-b58c-d330be54435b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_76d00c3b-dac2-4d79-b8d7-a3b29aa3170e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_2d39418a-9dbf-492e-9951-e4ad9f72eedf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_234887c7-6d09-44d1-b58c-d330be54435b" xlink:to="loc_us-gaap_GrossProfit_2d39418a-9dbf-492e-9951-e4ad9f72eedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8371c1e6-5305-49d8-8293-7e91326ba36a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_234887c7-6d09-44d1-b58c-d330be54435b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8371c1e6-5305-49d8-8293-7e91326ba36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cb03d891-217b-445b-a1b8-a72fbf86f4ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8371c1e6-5305-49d8-8293-7e91326ba36a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cb03d891-217b-445b-a1b8-a72fbf86f4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4ab2560f-6f22-4768-9b73-f7f3ab023ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8371c1e6-5305-49d8-8293-7e91326ba36a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4ab2560f-6f22-4768-9b73-f7f3ab023ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b7bc14a6-747c-4f4e-a19f-59eb0750584a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8371c1e6-5305-49d8-8293-7e91326ba36a" xlink:to="loc_us-gaap_OperatingExpenses_b7bc14a6-747c-4f4e-a19f-59eb0750584a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_28b9c3ae-54e8-4247-8556-8264de7ac355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_234887c7-6d09-44d1-b58c-d330be54435b" xlink:to="loc_us-gaap_OperatingIncomeLoss_28b9c3ae-54e8-4247-8556-8264de7ac355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_5d18586c-0a7f-4ae9-87d5-1a6af99060c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenseDisclosureNonoperatingAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_234887c7-6d09-44d1-b58c-d330be54435b" xlink:to="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_5d18586c-0a7f-4ae9-87d5-1a6af99060c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fbed4261-b20f-40d0-9ade-e676b695508a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_5d18586c-0a7f-4ae9-87d5-1a6af99060c0" xlink:to="loc_us-gaap_InterestExpense_fbed4261-b20f-40d0-9ade-e676b695508a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_01a357a7-eb12-46dc-8359-63a93916c4d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_5d18586c-0a7f-4ae9-87d5-1a6af99060c0" xlink:to="loc_us-gaap_InvestmentIncomeNet_01a357a7-eb12-46dc-8359-63a93916c4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2aa98fc2-72ea-4598-91b6-51e49e22aa02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_5d18586c-0a7f-4ae9-87d5-1a6af99060c0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2aa98fc2-72ea-4598-91b6-51e49e22aa02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d60443ed-c45b-4af8-9439-f4331c91f4ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_5d18586c-0a7f-4ae9-87d5-1a6af99060c0" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d60443ed-c45b-4af8-9439-f4331c91f4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_92523d25-edc1-48e8-9d3a-2e07b738735d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_234887c7-6d09-44d1-b58c-d330be54435b" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_92523d25-edc1-48e8-9d3a-2e07b738735d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c007aac9-7466-4299-95a7-35f0b03d2ac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_234887c7-6d09-44d1-b58c-d330be54435b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c007aac9-7466-4299-95a7-35f0b03d2ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_07ca814d-3669-4992-9a00-d042df4d46f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_234887c7-6d09-44d1-b58c-d330be54435b" xlink:to="loc_us-gaap_NetIncomeLoss_07ca814d-3669-4992-9a00-d042df4d46f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_876031a5-79ad-4cad-ad2b-aad99b897c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_234887c7-6d09-44d1-b58c-d330be54435b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_876031a5-79ad-4cad-ad2b-aad99b897c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1631e88e-8f33-4637-8d79-47122fc267ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_876031a5-79ad-4cad-ad2b-aad99b897c98" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1631e88e-8f33-4637-8d79-47122fc267ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b68fec03-fbd1-4704-a23c-06674db3f5f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_876031a5-79ad-4cad-ad2b-aad99b897c98" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b68fec03-fbd1-4704-a23c-06674db3f5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_dfa1282b-136d-44a5-9d37-c35c441123c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_234887c7-6d09-44d1-b58c-d330be54435b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_dfa1282b-136d-44a5-9d37-c35c441123c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3877dfdd-0ba1-4044-8741-1b7b8531a2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_234887c7-6d09-44d1-b58c-d330be54435b" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3877dfdd-0ba1-4044-8741-1b7b8531a2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_522693c3-a2f9-421d-b21a-1a3e43899506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3877dfdd-0ba1-4044-8741-1b7b8531a2f5" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_522693c3-a2f9-421d-b21a-1a3e43899506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_234445ee-8a8e-4b9e-a0ce-b4ace36954e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_234887c7-6d09-44d1-b58c-d330be54435b" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_234445ee-8a8e-4b9e-a0ce-b4ace36954e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="simple" xlink:href="bios-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_728f01be-5858-4916-9297-a07cecd329a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_e031140d-2e35-448a-a302-28df273bc14a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_728f01be-5858-4916-9297-a07cecd329a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_e031140d-2e35-448a-a302-28df273bc14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bios-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_42db8420-589e-4934-a9b2-c0afcadc447b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1b22eb14-eee4-4ea6-8fce-4b15dc503d3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_42db8420-589e-4934-a9b2-c0afcadc447b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1b22eb14-eee4-4ea6-8fce-4b15dc503d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5881cd85-fe5e-46a9-9f14-ffbeec5265d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1b22eb14-eee4-4ea6-8fce-4b15dc503d3a" xlink:to="loc_us-gaap_NetIncomeLoss_5881cd85-fe5e-46a9-9f14-ffbeec5265d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d7b7f00-6ce1-494b-9e63-a58dac992054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1b22eb14-eee4-4ea6-8fce-4b15dc503d3a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d7b7f00-6ce1-494b-9e63-a58dac992054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_f56711c2-5699-440a-9618-1749ce7d35d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d7b7f00-6ce1-494b-9e63-a58dac992054" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_f56711c2-5699-440a-9618-1749ce7d35d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_edb53c7a-de6a-40b3-ba5c-e6422a0384a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d7b7f00-6ce1-494b-9e63-a58dac992054" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_edb53c7a-de6a-40b3-ba5c-e6422a0384a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3777bc01-c8fd-42c3-a831-3b56494de847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d7b7f00-6ce1-494b-9e63-a58dac992054" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3777bc01-c8fd-42c3-a831-3b56494de847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_d96f639f-6c4a-4901-82e4-09ea23747b29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d7b7f00-6ce1-494b-9e63-a58dac992054" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_d96f639f-6c4a-4901-82e4-09ea23747b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_f3a1fae3-9d87-4db5-8e67-09a0fb467205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d7b7f00-6ce1-494b-9e63-a58dac992054" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_f3a1fae3-9d87-4db5-8e67-09a0fb467205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3011472d-fca2-465b-b48d-d036faa86216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d7b7f00-6ce1-494b-9e63-a58dac992054" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3011472d-fca2-465b-b48d-d036faa86216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_d1553853-4f1f-4b5b-bb0e-4141738f9158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d7b7f00-6ce1-494b-9e63-a58dac992054" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_d1553853-4f1f-4b5b-bb0e-4141738f9158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative_ed1c7e9a-125b-460c-95bf-e89400daff61" xlink:href="bios-20201231.xsd#bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d7b7f00-6ce1-494b-9e63-a58dac992054" xlink:to="loc_bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative_ed1c7e9a-125b-460c-95bf-e89400daff61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_4675dc78-c46b-484d-a56d-d36792e107e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d7b7f00-6ce1-494b-9e63-a58dac992054" xlink:to="loc_us-gaap_PaidInKindInterest_4675dc78-c46b-484d-a56d-d36792e107e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b4753789-0642-4fa9-8561-afa06ac315b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d7b7f00-6ce1-494b-9e63-a58dac992054" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b4753789-0642-4fa9-8561-afa06ac315b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f9771966-e2dd-4ad1-800c-7a83f06b6589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d7b7f00-6ce1-494b-9e63-a58dac992054" xlink:to="loc_us-gaap_ShareBasedCompensation_f9771966-e2dd-4ad1-800c-7a83f06b6589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InterestGainLossOnManagementNotesReceivable_6be3729c-e0dc-47bb-91fd-6e387fe2417c" xlink:href="bios-20201231.xsd#bios_InterestGainLossOnManagementNotesReceivable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d7b7f00-6ce1-494b-9e63-a58dac992054" xlink:to="loc_bios_InterestGainLossOnManagementNotesReceivable_6be3729c-e0dc-47bb-91fd-6e387fe2417c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_c9ac0612-50b6-4792-9531-5deb86abed84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d7b7f00-6ce1-494b-9e63-a58dac992054" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_c9ac0612-50b6-4792-9531-5deb86abed84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0bca1b06-cfb5-4268-868c-bea46936fc4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d7b7f00-6ce1-494b-9e63-a58dac992054" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0bca1b06-cfb5-4268-868c-bea46936fc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112de075-697d-458b-8d2f-506d3807cfde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7d7b7f00-6ce1-494b-9e63-a58dac992054" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112de075-697d-458b-8d2f-506d3807cfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_2c37a297-0a6e-43ce-8ddf-ad9a1cf34357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112de075-697d-458b-8d2f-506d3807cfde" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_2c37a297-0a6e-43ce-8ddf-ad9a1cf34357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_af2a31d3-56f8-4b9f-8a95-1efd1a9768f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112de075-697d-458b-8d2f-506d3807cfde" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_af2a31d3-56f8-4b9f-8a95-1efd1a9768f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_64a0ed52-54d4-413b-a297-91db0779e202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112de075-697d-458b-8d2f-506d3807cfde" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_64a0ed52-54d4-413b-a297-91db0779e202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_ed6218c1-5ffd-4bd6-9151-6be2ded1fc74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112de075-697d-458b-8d2f-506d3807cfde" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_ed6218c1-5ffd-4bd6-9151-6be2ded1fc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1a07a396-e3d0-423b-8638-9fe63a363038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112de075-697d-458b-8d2f-506d3807cfde" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1a07a396-e3d0-423b-8638-9fe63a363038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_24da5c4b-db2a-4878-9872-41b7f5d0be4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112de075-697d-458b-8d2f-506d3807cfde" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_24da5c4b-db2a-4878-9872-41b7f5d0be4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_6cfb45ee-0b79-422a-a587-4433a5a7bc42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112de075-697d-458b-8d2f-506d3807cfde" xlink:to="loc_us-gaap_OperatingLeasePayments_6cfb45ee-0b79-422a-a587-4433a5a7bc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_1d624535-ae88-4dab-883a-25e88feb4b52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112de075-697d-458b-8d2f-506d3807cfde" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_1d624535-ae88-4dab-883a-25e88feb4b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d3b3e3b5-f78f-4548-afbf-9e1d23332d29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1b22eb14-eee4-4ea6-8fce-4b15dc503d3a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d3b3e3b5-f78f-4548-afbf-9e1d23332d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c21380ea-a199-4239-ae35-5ebdfbebbb18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_42db8420-589e-4934-a9b2-c0afcadc447b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c21380ea-a199-4239-ae35-5ebdfbebbb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_95c7fa25-16e6-48c8-a370-9469c08d6172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c21380ea-a199-4239-ae35-5ebdfbebbb18" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_95c7fa25-16e6-48c8-a370-9469c08d6172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_265185dd-6424-4492-b84d-007e64a0a72e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c21380ea-a199-4239-ae35-5ebdfbebbb18" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_265185dd-6424-4492-b84d-007e64a0a72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_d505ad6e-a05e-426d-b5b9-ad82b84d1c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c21380ea-a199-4239-ae35-5ebdfbebbb18" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_d505ad6e-a05e-426d-b5b9-ad82b84d1c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c98bc60b-7b4f-43ee-bf43-e01e4c678550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c21380ea-a199-4239-ae35-5ebdfbebbb18" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c98bc60b-7b4f-43ee-bf43-e01e4c678550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6af52644-b718-4b7e-b1d6-77a200ae9adc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c21380ea-a199-4239-ae35-5ebdfbebbb18" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6af52644-b718-4b7e-b1d6-77a200ae9adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d3b90c45-b2f1-4dd8-9ec6-c08900a78b88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c21380ea-a199-4239-ae35-5ebdfbebbb18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d3b90c45-b2f1-4dd8-9ec6-c08900a78b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_44e67efc-4550-47d5-8725-87d95b22fdea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_42db8420-589e-4934-a9b2-c0afcadc447b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_44e67efc-4550-47d5-8725-87d95b22fdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_98e6ab76-a54d-4255-88b9-fbb4a3392834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_44e67efc-4550-47d5-8725-87d95b22fdea" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_98e6ab76-a54d-4255-88b9-fbb4a3392834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ProceedsFromSaleOfManagementNotesReceivable_f53960c3-9fdc-472b-99fb-44c6f2e2426b" xlink:href="bios-20201231.xsd#bios_ProceedsFromSaleOfManagementNotesReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_44e67efc-4550-47d5-8725-87d95b22fdea" xlink:to="loc_bios_ProceedsFromSaleOfManagementNotesReceivable_f53960c3-9fdc-472b-99fb-44c6f2e2426b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2a291b45-9d76-40a8-99b5-04d7889b9928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_44e67efc-4550-47d5-8725-87d95b22fdea" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2a291b45-9d76-40a8-99b5-04d7889b9928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f94ad9c1-0192-4817-857d-7850fba74175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_44e67efc-4550-47d5-8725-87d95b22fdea" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f94ad9c1-0192-4817-857d-7850fba74175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_c4e1849e-e4a3-461b-b7cd-79e673389d86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_44e67efc-4550-47d5-8725-87d95b22fdea" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_c4e1849e-e4a3-461b-b7cd-79e673389d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_bfbcb996-1f1e-4f81-8bb6-f3b68ff87598" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_44e67efc-4550-47d5-8725-87d95b22fdea" xlink:to="loc_us-gaap_RepaymentsOfDebt_bfbcb996-1f1e-4f81-8bb6-f3b68ff87598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDepositsAppliedToDebtRetirements_111c90b2-2070-4023-bd23-2a50a0ac0710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForDepositsAppliedToDebtRetirements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_44e67efc-4550-47d5-8725-87d95b22fdea" xlink:to="loc_us-gaap_PaymentsForDepositsAppliedToDebtRetirements_111c90b2-2070-4023-bd23-2a50a0ac0710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3b146f38-fd1e-4e03-b18d-6f094fd928f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_44e67efc-4550-47d5-8725-87d95b22fdea" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3b146f38-fd1e-4e03-b18d-6f094fd928f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_fa49d1d7-e335-42c6-abc5-0af23d4ede17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_44e67efc-4550-47d5-8725-87d95b22fdea" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_fa49d1d7-e335-42c6-abc5-0af23d4ede17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4677a2e6-3631-4471-a3a4-08dcd52938b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_44e67efc-4550-47d5-8725-87d95b22fdea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4677a2e6-3631-4471-a3a4-08dcd52938b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e96b9070-5fa7-409e-ac70-dea4f9ae92e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_42db8420-589e-4934-a9b2-c0afcadc447b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e96b9070-5fa7-409e-ac70-dea4f9ae92e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b6c11720-d85e-4818-b030-98da1cc661f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_42db8420-589e-4934-a9b2-c0afcadc447b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b6c11720-d85e-4818-b030-98da1cc661f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c0712c78-26c6-4021-9088-ff0c029ac3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_42db8420-589e-4934-a9b2-c0afcadc447b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c0712c78-26c6-4021-9088-ff0c029ac3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_38cb974c-b864-452f-8173-fd306b57244d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_42db8420-589e-4934-a9b2-c0afcadc447b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_38cb974c-b864-452f-8173-fd306b57244d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_08ecbe28-5bb8-4555-beee-bf8632585946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_38cb974c-b864-452f-8173-fd306b57244d" xlink:to="loc_us-gaap_InterestPaidNet_08ecbe28-5bb8-4555-beee-bf8632585946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_369cdd5f-8ca1-4953-bf56-6809937640f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_38cb974c-b864-452f-8173-fd306b57244d" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_369cdd5f-8ca1-4953-bf56-6809937640f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePaymentsUse_217f0607-f8b9-4880-885c-04046f831243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePaymentsUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_38cb974c-b864-452f-8173-fd306b57244d" xlink:to="loc_us-gaap_OperatingLeasePaymentsUse_217f0607-f8b9-4880-885c-04046f831243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bios-20201231.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e44281e2-5efd-4d27-bee7-cda5c072aef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0cba1883-9595-4fbe-82a6-1d9b67774f44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e44281e2-5efd-4d27-bee7-cda5c072aef8" xlink:to="loc_us-gaap_StatementTable_0cba1883-9595-4fbe-82a6-1d9b67774f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3b8339b1-bcbd-49ee-8f21-ce07d00d1737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0cba1883-9595-4fbe-82a6-1d9b67774f44" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3b8339b1-bcbd-49ee-8f21-ce07d00d1737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3b8339b1-bcbd-49ee-8f21-ce07d00d1737" xlink:to="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_f45cdd2e-2b33-41c5-a9d0-02ebbb2e6e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:to="loc_us-gaap_PreferredStockMember_f45cdd2e-2b33-41c5-a9d0-02ebbb2e6e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4f3bd666-a137-47fc-aa3c-567dcd5134a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:to="loc_us-gaap_CommonStockMember_4f3bd666-a137-47fc-aa3c-567dcd5134a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_df72c61a-8d31-4d11-99d0-b4a97cfc110a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:to="loc_us-gaap_TreasuryStockMember_df72c61a-8d31-4d11-99d0-b4a97cfc110a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4fd6e652-96d7-4cc8-bfda-65fb3ffce8bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4fd6e652-96d7-4cc8-bfda-65fb3ffce8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ManagementNotesReceivableMember_83efacb5-8c65-4633-9c51-1c1d2ce0ed8e" xlink:href="bios-20201231.xsd#bios_ManagementNotesReceivableMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:to="loc_bios_ManagementNotesReceivableMember_83efacb5-8c65-4633-9c51-1c1d2ce0ed8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cc163f75-8380-480f-86de-56fdb7fa83df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:to="loc_us-gaap_RetainedEarningsMember_cc163f75-8380-480f-86de-56fdb7fa83df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6c5e8c27-1e8e-458e-abfc-1af8b4783432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_194876ac-3270-4f7f-a15f-287fc874ae02" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6c5e8c27-1e8e-458e-abfc-1af8b4783432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_376e0788-64d7-49ed-a41b-b315e295d4cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0cba1883-9595-4fbe-82a6-1d9b67774f44" xlink:to="loc_us-gaap_StatementLineItems_376e0788-64d7-49ed-a41b-b315e295d4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_376e0788-64d7-49ed-a41b-b315e295d4cd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8df17c07-ef91-4fb9-b54f-bf09251c64cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_us-gaap_StockholdersEquity_8df17c07-ef91-4fb9-b54f-bf09251c64cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution_c217fdb2-539b-42fa-bd2d-eabfe4af0161" xlink:href="bios-20201231.xsd#bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution_c217fdb2-539b-42fa-bd2d-eabfe4af0161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_12f05788-20c6-4490-9c76-a9a35fc8aefe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_12f05788-20c6-4490-9c76-a9a35fc8aefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InterestOnManagementNotesReceivable_3ddbc908-5d45-41fd-bdc1-18918a449896" xlink:href="bios-20201231.xsd#bios_InterestOnManagementNotesReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_bios_InterestOnManagementNotesReceivable_3ddbc908-5d45-41fd-bdc1-18918a449896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_RepaymentOfManagementNotesReceivable_6d7fa90a-36a0-4439-bcfd-ed0c07446c38" xlink:href="bios-20201231.xsd#bios_RepaymentOfManagementNotesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_bios_RepaymentOfManagementNotesReceivable_6d7fa90a-36a0-4439-bcfd-ed0c07446c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption_341104d8-c6b1-467e-8450-e5f9151eda2b" xlink:href="bios-20201231.xsd#bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption_341104d8-c6b1-467e-8450-e5f9151eda2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_33988910-c668-4e68-b3eb-de4313c9eea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_33988910-c668-4e68-b3eb-de4313c9eea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings_a1c30161-f418-40fb-a901-48683761fc7b" xlink:href="bios-20201231.xsd#bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings_a1c30161-f418-40fb-a901-48683761fc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c7ea1e40-bbc4-4e5b-a77c-ed0a465a2ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c7ea1e40-bbc4-4e5b-a77c-ed0a465a2ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_d0bca324-a246-4008-8aa3-476e6892db1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_d0bca324-a246-4008-8aa3-476e6892db1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f8c22330-dae4-4319-bce1-c733a8d0e250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_us-gaap_NetIncomeLoss_f8c22330-dae4-4319-bce1-c733a8d0e250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_38cf5042-8352-4767-8200-a6616b8a6aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_38cf5042-8352-4767-8200-a6616b8a6aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6f741031-3439-414b-8e11-cc2e7362f54e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_982eb8f4-c70e-4dc4-b39f-7d29885849b5" xlink:to="loc_us-gaap_StockholdersEquity_6f741031-3439-414b-8e11-cc2e7362f54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="bios-20201231.xsd#NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5cb81b02-a257-415c-9ca1-6297cf59c0fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_5ed3e977-d6d2-46c4-891e-8663312c9d95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5cb81b02-a257-415c-9ca1-6297cf59c0fa" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_5ed3e977-d6d2-46c4-891e-8663312c9d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e5391371-cff2-4ae8-95da-687b45418c44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e5391371-cff2-4ae8-95da-687b45418c44" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_88b5e106-5d61-40e1-ab40-948bdebf4859" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_88b5e106-5d61-40e1-ab40-948bdebf4859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1a34b89e-be78-4f66-82ff-1c6ccafeae3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_88b5e106-5d61-40e1-ab40-948bdebf4859" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1a34b89e-be78-4f66-82ff-1c6ccafeae3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LegacyHealthSystemsMember_14647324-1266-4f46-a2d6-ec37644dfff4" xlink:href="bios-20201231.xsd#bios_LegacyHealthSystemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1a34b89e-be78-4f66-82ff-1c6ccafeae3a" xlink:to="loc_bios_LegacyHealthSystemsMember_14647324-1266-4f46-a2d6-ec37644dfff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_99584ef1-ddf3-49a6-8b2f-909711ce7f60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_99584ef1-ddf3-49a6-8b2f-909711ce7f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a9426c1c-55f7-4dc7-b20e-59a3843fde58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_99584ef1-ddf3-49a6-8b2f-909711ce7f60" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a9426c1c-55f7-4dc7-b20e-59a3843fde58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_d4aca62a-ccb1-4043-9c99-bb3cfb9b91c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a9426c1c-55f7-4dc7-b20e-59a3843fde58" xlink:to="loc_us-gaap_SeniorNotesMember_d4aca62a-ccb1-4043-9c99-bb3cfb9b91c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryAxis_9e019599-8618-4e29-999d-735bdfee8723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:to="loc_us-gaap_LienCategoryAxis_9e019599-8618-4e29-999d-735bdfee8723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_67971522-6ecc-44d3-b30c-d4f83e52bb1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LienCategoryAxis_9e019599-8618-4e29-999d-735bdfee8723" xlink:to="loc_us-gaap_LienCategoryDomain_67971522-6ecc-44d3-b30c-d4f83e52bb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLienMember_cd4708b6-9646-416c-8986-89b2fbc43cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorLienMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LienCategoryDomain_67971522-6ecc-44d3-b30c-d4f83e52bb1c" xlink:to="loc_us-gaap_SeniorLienMember_cd4708b6-9646-416c-8986-89b2fbc43cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_530cfd56-9ade-4f1d-a4d0-91ebb12eece0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_530cfd56-9ade-4f1d-a4d0-91ebb12eece0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_275091b7-16a6-4aa7-beed-bc6cf9cc577f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_530cfd56-9ade-4f1d-a4d0-91ebb12eece0" xlink:to="loc_us-gaap_RelatedPartyDomain_275091b7-16a6-4aa7-beed-bc6cf9cc577f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorityShareholderMember_21db980e-c587-44db-941f-0aeb7ecbd51e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorityShareholderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_275091b7-16a6-4aa7-beed-bc6cf9cc577f" xlink:to="loc_us-gaap_MajorityShareholderMember_21db980e-c587-44db-941f-0aeb7ecbd51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4a9c4243-65d7-4c42-9073-a4d8dd7fbbce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4a9c4243-65d7-4c42-9073-a4d8dd7fbbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_89b9503f-dfc6-488c-989c-cbcf23ff05f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4a9c4243-65d7-4c42-9073-a4d8dd7fbbce" xlink:to="loc_us-gaap_EquityComponentDomain_89b9503f-dfc6-488c-989c-cbcf23ff05f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_75475d13-ae17-4d49-980e-3ea0d621f74d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_89b9503f-dfc6-488c-989c-cbcf23ff05f6" xlink:to="loc_us-gaap_PreferredStockMember_75475d13-ae17-4d49-980e-3ea0d621f74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fddd0df0-f9ba-417a-905f-c38e4f4b01cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fddd0df0-f9ba-417a-905f-c38e4f4b01cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_8d629efa-02b8-4b9f-addb-5d714380cad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fddd0df0-f9ba-417a-905f-c38e4f4b01cd" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_8d629efa-02b8-4b9f-addb-5d714380cad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b8262d42-ba8b-4b96-b111-5a97d559a268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_8d629efa-02b8-4b9f-addb-5d714380cad8" xlink:to="loc_us-gaap_CommonStockMember_b8262d42-ba8b-4b96-b111-5a97d559a268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_303ec724-4233-4f4b-8b93-a38549e95aec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_303ec724-4233-4f4b-8b93-a38549e95aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44868a8b-24f8-4f9a-8845-db52b0927447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_303ec724-4233-4f4b-8b93-a38549e95aec" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44868a8b-24f8-4f9a-8845-db52b0927447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionCareEnterprisesInc.Member_3939ee6a-1c01-4a67-9620-9e2be31eb503" xlink:href="bios-20201231.xsd#bios_OptionCareEnterprisesInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44868a8b-24f8-4f9a-8845-db52b0927447" xlink:to="loc_bios_OptionCareEnterprisesInc.Member_3939ee6a-1c01-4a67-9620-9e2be31eb503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b63a260f-0c13-46d8-bf3f-7642f5d88f06" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_300b1687-c191-4474-93c2-257a3e342a9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_300b1687-c191-4474-93c2-257a3e342a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_792ba727-25c1-48df-9483-43e3b53c1fff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_792ba727-25c1-48df-9483-43e3b53c1fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03432770-7a46-4196-958d-35b86f94043d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03432770-7a46-4196-958d-35b86f94043d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a67d0381-e021-4429-ab43-26379e75c73d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a67d0381-e021-4429-ab43-26379e75c73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c988c862-563a-46d7-86b7-81e53b95b33e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_us-gaap_LongTermDebt_c988c862-563a-46d7-86b7-81e53b95b33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BusinessCombinationOwnershipInterestRetained_ce2ce4f5-72c6-4a63-9c27-17e0d577efad" xlink:href="bios-20201231.xsd#bios_BusinessCombinationOwnershipInterestRetained"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_bios_BusinessCombinationOwnershipInterestRetained_ce2ce4f5-72c6-4a63-9c27-17e0d577efad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_dded1a57-5fdf-4602-9b98-234702e78721" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_dded1a57-5fdf-4602-9b98-234702e78721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NumberOfServiceLocations_18c711e8-ff26-4175-971b-03917640bb87" xlink:href="bios-20201231.xsd#bios_NumberOfServiceLocations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_bios_NumberOfServiceLocations_18c711e8-ff26-4175-971b-03917640bb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NumberOfInfusionSites_5f0ebd9f-7ab7-413f-8063-f33b7cd79683" xlink:href="bios-20201231.xsd#bios_NumberOfInfusionSites"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_bios_NumberOfInfusionSites_5f0ebd9f-7ab7-413f-8063-f33b7cd79683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_87378ea5-f139-452d-9917-9a031c7ea308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a46bfe99-5078-4a63-b34a-abd3fe3206e0" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_87378ea5-f139-452d-9917-9a031c7ea308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bios-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4bdb0eca-498c-4c2a-abe2-f4db8f52b428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_294516b9-c8e4-4889-abe4-1d62ba832650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4bdb0eca-498c-4c2a-abe2-f4db8f52b428" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_294516b9-c8e4-4889-abe4-1d62ba832650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bios-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_adca5fbe-4057-4148-bf8e-1314e94bc7d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_adca5fbe-4057-4148-bf8e-1314e94bc7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_637afc38-4ac7-451d-bf70-8761c1e2aab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_637afc38-4ac7-451d-bf70-8761c1e2aab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0c81f192-2072-47b4-a23f-6b7c58814805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0c81f192-2072-47b4-a23f-6b7c58814805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_892ed5fc-db88-42df-a21b-100798512b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_892ed5fc-db88-42df-a21b-100798512b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_c795ca0d-8b75-4bc4-9bc2-d023e22724d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_c795ca0d-8b75-4bc4-9bc2-d023e22724d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_5383525c-2eab-4a18-ae15-cf28e1cdfa73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_5383525c-2eab-4a18-ae15-cf28e1cdfa73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_edf4f8e7-798f-4a3b-8e09-b2cd57998724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_edf4f8e7-798f-4a3b-8e09-b2cd57998724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0764c704-2a89-488c-8ba2-584062d208f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0764c704-2a89-488c-8ba2-584062d208f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_604ea5ec-7b89-44dd-a17f-b75ba6f1f369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_604ea5ec-7b89-44dd-a17f-b75ba6f1f369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_463c290f-dbb3-4599-a108-0de95163c432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_463c290f-dbb3-4599-a108-0de95163c432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_cd1a161a-47b2-477c-b749-896606b061a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_cd1a161a-47b2-477c-b749-896606b061a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_f7458806-888c-4c24-9dfd-2ce3acc28290" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_f7458806-888c-4c24-9dfd-2ce3acc28290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_e5a8555f-30f4-4bc5-85b4-763710d8544a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_e5a8555f-30f4-4bc5-85b4-763710d8544a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_149d482f-9fb6-4568-a850-3de6a6d67cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_149d482f-9fb6-4568-a850-3de6a6d67cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_ed8e3d22-bb17-4ed6-a6c5-2cc05acc1f54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_ed8e3d22-bb17-4ed6-a6c5-2cc05acc1f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_b24b6d69-10a1-40a5-aa33-c2c093f6ad60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_b24b6d69-10a1-40a5-aa33-c2c093f6ad60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock_75e3fe96-41c3-41b3-bd67-c4d8ac3e6bf4" xlink:href="bios-20201231.xsd#bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock_75e3fe96-41c3-41b3-bd67-c4d8ac3e6bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_92c30547-4790-4bea-ae74-75c334c0e130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_92c30547-4790-4bea-ae74-75c334c0e130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_51379020-35ee-4969-bbfb-29bdb2f2ad45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2cd07a1c-a741-4ff2-a014-6088e6be9dee" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_51379020-35ee-4969-bbfb-29bdb2f2ad45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8e249e6a-fde1-4a80-9335-898d1805ddd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_574f0717-1df9-48f6-ac05-f9b6ccae800f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e249e6a-fde1-4a80-9335-898d1805ddd7" xlink:to="loc_us-gaap_ConcentrationRiskTable_574f0717-1df9-48f6-ac05-f9b6ccae800f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f0b89ea1-83f7-4c6c-902c-7cf7a8d9c09a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_574f0717-1df9-48f6-ac05-f9b6ccae800f" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f0b89ea1-83f7-4c6c-902c-7cf7a8d9c09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c9143a86-324a-4104-900b-89e62fbb9b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f0b89ea1-83f7-4c6c-902c-7cf7a8d9c09a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c9143a86-324a-4104-900b-89e62fbb9b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_437cad00-1fd1-4e2b-b45e-67c949db88a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c9143a86-324a-4104-900b-89e62fbb9b9b" xlink:to="loc_us-gaap_InventoriesMember_437cad00-1fd1-4e2b-b45e-67c949db88a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_211e5c4f-cc42-4b15-b2e9-826fbb1c5e17" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_574f0717-1df9-48f6-ac05-f9b6ccae800f" xlink:to="loc_srt_RangeAxis_211e5c4f-cc42-4b15-b2e9-826fbb1c5e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fcde92f7-1470-4c7d-b5f2-a48f6e7b03de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_211e5c4f-cc42-4b15-b2e9-826fbb1c5e17" xlink:to="loc_srt_RangeMember_fcde92f7-1470-4c7d-b5f2-a48f6e7b03de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_94f72d66-457f-4f5b-94b0-60a7548906cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fcde92f7-1470-4c7d-b5f2-a48f6e7b03de" xlink:to="loc_srt_MinimumMember_94f72d66-457f-4f5b-94b0-60a7548906cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_99ba62c8-70ee-485b-ac36-65fa82c71513" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fcde92f7-1470-4c7d-b5f2-a48f6e7b03de" xlink:to="loc_srt_MaximumMember_99ba62c8-70ee-485b-ac36-65fa82c71513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69cdc403-30be-4356-9ebd-3d8e3129ad2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_574f0717-1df9-48f6-ac05-f9b6ccae800f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69cdc403-30be-4356-9ebd-3d8e3129ad2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a9b1330-6271-467a-a271-d9500683666d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69cdc403-30be-4356-9ebd-3d8e3129ad2e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a9b1330-6271-467a-a271-d9500683666d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerListsMember_39c75736-922a-4fd5-91a4-57c0658b26bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerListsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a9b1330-6271-467a-a271-d9500683666d" xlink:to="loc_us-gaap_CustomerListsMember_39c75736-922a-4fd5-91a4-57c0658b26bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_bedd8bcb-79ce-4041-be21-c0133bf1ee75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a9b1330-6271-467a-a271-d9500683666d" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_bedd8bcb-79ce-4041-be21-c0133bf1ee75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_844181e0-74e3-4181-a7a2-d2777c2493b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a9b1330-6271-467a-a271-d9500683666d" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_844181e0-74e3-4181-a7a2-d2777c2493b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InfusionPumpsMember_da0675c7-13aa-49b0-a7bb-bdce06d7bbf1" xlink:href="bios-20201231.xsd#bios_InfusionPumpsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a9b1330-6271-467a-a271-d9500683666d" xlink:to="loc_bios_InfusionPumpsMember_da0675c7-13aa-49b0-a7bb-bdce06d7bbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_87f4d18a-20db-4ccd-b794-5df5d7ea43f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a9b1330-6271-467a-a271-d9500683666d" xlink:to="loc_us-gaap_EquipmentMember_87f4d18a-20db-4ccd-b794-5df5d7ea43f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_5f9e5347-0f3f-4e9a-98a7-604bf4e2b763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a9b1330-6271-467a-a271-d9500683666d" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_5f9e5347-0f3f-4e9a-98a7-604bf4e2b763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_b2c32c01-26bd-44df-a756-a9c005e6781d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_574f0717-1df9-48f6-ac05-f9b6ccae800f" xlink:to="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_b2c32c01-26bd-44df-a756-a9c005e6781d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CatastrophicEventDomain_d470df77-d06f-410d-aed6-46879edaa146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CatastrophicEventDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_b2c32c01-26bd-44df-a756-a9c005e6781d" xlink:to="loc_us-gaap_CatastrophicEventDomain_d470df77-d06f-410d-aed6-46879edaa146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HurricaneMember_0391526c-b0b9-44e1-a5b0-f962fdb2ba20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HurricaneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CatastrophicEventDomain_d470df77-d06f-410d-aed6-46879edaa146" xlink:to="loc_us-gaap_HurricaneMember_0391526c-b0b9-44e1-a5b0-f962fdb2ba20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_44e273cb-5ba0-4c04-bc67-fc462699077b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_574f0717-1df9-48f6-ac05-f9b6ccae800f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_44e273cb-5ba0-4c04-bc67-fc462699077b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d484532b-1d9b-4878-a3eb-cfffc7bd4c19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_44e273cb-5ba0-4c04-bc67-fc462699077b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d484532b-1d9b-4878-a3eb-cfffc7bd4c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_718887cb-736a-4875-9bf0-3c011fd4587a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d484532b-1d9b-4878-a3eb-cfffc7bd4c19" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_718887cb-736a-4875-9bf0-3c011fd4587a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_2e9a771c-2307-4e0f-9ca8-f6c556a772a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d484532b-1d9b-4878-a3eb-cfffc7bd4c19" xlink:to="loc_us-gaap_AccountsReceivableMember_2e9a771c-2307-4e0f-9ca8-f6c556a772a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsProductLineMember_577f9cc3-3b5f-4dc5-9b1e-02fc270e4eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d484532b-1d9b-4878-a3eb-cfffc7bd4c19" xlink:to="loc_us-gaap_CostOfGoodsProductLineMember_577f9cc3-3b5f-4dc5-9b1e-02fc270e4eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c411f003-09ce-4f74-b716-9a1d72ffb399" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_574f0717-1df9-48f6-ac05-f9b6ccae800f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c411f003-09ce-4f74-b716-9a1d72ffb399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2c3059cb-330b-4295-a2fe-2f3241816868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c411f003-09ce-4f74-b716-9a1d72ffb399" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2c3059cb-330b-4295-a2fe-2f3241816868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a4cc7438-4a3a-420c-9160-590a3e939df4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2c3059cb-330b-4295-a2fe-2f3241816868" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a4cc7438-4a3a-420c-9160-590a3e939df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_88abd781-5355-4559-9b79-821618cccd05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2c3059cb-330b-4295-a2fe-2f3241816868" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_88abd781-5355-4559-9b79-821618cccd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_d1bec7af-6e19-4fb5-b67a-8444cbcd6b3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2c3059cb-330b-4295-a2fe-2f3241816868" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_d1bec7af-6e19-4fb5-b67a-8444cbcd6b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_574f0717-1df9-48f6-ac05-f9b6ccae800f" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_2156a6a1-b752-4429-bd74-559503acc8f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_2156a6a1-b752-4429-bd74-559503acc8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_d18a4222-c7eb-49bd-ab13-e784e4f4bc61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledReceivablesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_d18a4222-c7eb-49bd-ab13-e784e4f4bc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_7495cc97-d9b3-465e-8d2a-1f464a03508a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_InventoryWriteDown_7495cc97-d9b3-465e-8d2a-1f464a03508a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_c51ebe88-efe4-42ee-a79c-43a9ff599224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_c51ebe88-efe4-42ee-a79c-43a9ff599224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceSettlementsReceivable_59ac4c68-6c02-41df-91b5-87d9a8c2705d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceSettlementsReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_InsuranceSettlementsReceivable_59ac4c68-6c02-41df-91b5-87d9a8c2705d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_a7c0161f-b22d-463b-9614-267db1338548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_a7c0161f-b22d-463b-9614-267db1338548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_2159a25f-366c-4eda-a499-aebc64085864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_2159a25f-366c-4eda-a499-aebc64085864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9655034c-eead-434a-aa0d-4270d997dc87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9655034c-eead-434a-aa0d-4270d997dc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b3307a85-95b6-4ea0-86a6-cd2ac6a671ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_EquityMethodInvestments_b3307a85-95b6-4ea0-86a6-cd2ac6a671ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_350583ec-dcdb-40f2-8c5e-bdba0a760364" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_350583ec-dcdb-40f2-8c5e-bdba0a760364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_d3d38d53-ba7a-4329-84dc-db44cd96547a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_d3d38d53-ba7a-4329-84dc-db44cd96547a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_5b0d3cf4-519b-42d1-9ba0-fe8b438fa2c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_5b0d3cf4-519b-42d1-9ba0-fe8b438fa2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BusinessCombinationRenewalTermLength_fe626994-1897-425d-a7fb-4408c17912bd" xlink:href="bios-20201231.xsd#bios_BusinessCombinationRenewalTermLength"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f24b3dd0-e363-4b1e-beee-f29804af7da7" xlink:to="loc_bios_BusinessCombinationRenewalTermLength_fe626994-1897-425d-a7fb-4408c17912bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONS" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_00b7cd86-efb2-4e9c-bdc3-cacf7ae5323a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_a2b5391d-3681-4fe0-831d-81b0433b7e07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_00b7cd86-efb2-4e9c-bdc3-cacf7ae5323a" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_a2b5391d-3681-4fe0-831d-81b0433b7e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSTables" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSTables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_879aad4f-533b-49ec-b4da-75a3c631b495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_6800f95d-4b41-4d7e-8134-e0a8edb3f0d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_879aad4f-533b-49ec-b4da-75a3c631b495" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_6800f95d-4b41-4d7e-8134-e0a8edb3f0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_7e5881c9-c99d-4a8f-8149-16a5dd57f4ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_879aad4f-533b-49ec-b4da-75a3c631b495" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_7e5881c9-c99d-4a8f-8149-16a5dd57f4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_7eb7ed7d-3635-454a-a10b-13966c256b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_879aad4f-533b-49ec-b4da-75a3c631b495" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_7eb7ed7d-3635-454a-a10b-13966c256b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_0d4ee89a-1044-4b43-bfc9-7bd9794bdbaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_879aad4f-533b-49ec-b4da-75a3c631b495" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_0d4ee89a-1044-4b43-bfc9-7bd9794bdbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_689e6ef9-9812-490a-9284-eb23f974041c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_778488a7-c353-4358-91fa-2a4306304630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_689e6ef9-9812-490a-9284-eb23f974041c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_778488a7-c353-4358-91fa-2a4306304630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryAxis_43982d7f-40e3-46a1-a2dd-4f5f8b71fa78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_778488a7-c353-4358-91fa-2a4306304630" xlink:to="loc_us-gaap_LienCategoryAxis_43982d7f-40e3-46a1-a2dd-4f5f8b71fa78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_78ed2674-09fa-430b-81c3-8bc359efe600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LienCategoryAxis_43982d7f-40e3-46a1-a2dd-4f5f8b71fa78" xlink:to="loc_us-gaap_LienCategoryDomain_78ed2674-09fa-430b-81c3-8bc359efe600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLienMember_d1c07d3a-00c5-4e6b-9144-5456f67e92ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorLienMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LienCategoryDomain_78ed2674-09fa-430b-81c3-8bc359efe600" xlink:to="loc_us-gaap_SeniorLienMember_d1c07d3a-00c5-4e6b-9144-5456f67e92ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dba9a56e-98f2-46c0-8c9b-e4641f927f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_778488a7-c353-4358-91fa-2a4306304630" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dba9a56e-98f2-46c0-8c9b-e4641f927f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334a3dcd-7f53-441a-a567-00605bd63ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dba9a56e-98f2-46c0-8c9b-e4641f927f40" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334a3dcd-7f53-441a-a567-00605bd63ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BioScripMember_aabc6247-d5a8-451a-a0d5-cb9deba8fc15" xlink:href="bios-20201231.xsd#bios_BioScripMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334a3dcd-7f53-441a-a567-00605bd63ccc" xlink:to="loc_bios_BioScripMember_aabc6247-d5a8-451a-a0d5-cb9deba8fc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BaptistHealthInLittleRockArkansasMember_600f5daf-ae7e-4b14-9661-eb6dd59ef2aa" xlink:href="bios-20201231.xsd#bios_BaptistHealthInLittleRockArkansasMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334a3dcd-7f53-441a-a567-00605bd63ccc" xlink:to="loc_bios_BaptistHealthInLittleRockArkansasMember_600f5daf-ae7e-4b14-9661-eb6dd59ef2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HomeI.V.SpecialistsInc.Member_c008d34c-c300-4bb0-8b3c-e53352ac371f" xlink:href="bios-20201231.xsd#bios_HomeI.V.SpecialistsInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334a3dcd-7f53-441a-a567-00605bd63ccc" xlink:to="loc_bios_HomeI.V.SpecialistsInc.Member_c008d34c-c300-4bb0-8b3c-e53352ac371f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3094be6f-d248-4639-bf95-f4dd6891284c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_778488a7-c353-4358-91fa-2a4306304630" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3094be6f-d248-4639-bf95-f4dd6891284c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8548726a-c41e-4063-b0d3-324901f71b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3094be6f-d248-4639-bf95-f4dd6891284c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8548726a-c41e-4063-b0d3-324901f71b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_c9f439a3-1bb5-4b15-b475-901236a4e04c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8548726a-c41e-4063-b0d3-324901f71b5e" xlink:to="loc_us-gaap_SeniorNotesMember_c9f439a3-1bb5-4b15-b475-901236a4e04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_778488a7-c353-4358-91fa-2a4306304630" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_9dce9c50-35e6-443e-bf58-31870524fe66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_9dce9c50-35e6-443e-bf58-31870524fe66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_9488c555-ede9-4dc0-aa03-9c4f5e16dd31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_9488c555-ede9-4dc0-aa03-9c4f5e16dd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e32d1da5-ed4a-4377-8d13-a372a02dcc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e32d1da5-ed4a-4377-8d13-a372a02dcc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_25f8d465-fa03-4540-adab-a09664fd7735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_25f8d465-fa03-4540-adab-a09664fd7735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2270d444-da50-4fb3-bd9a-886d769a030e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_Goodwill_2270d444-da50-4fb3-bd9a-886d769a030e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_7273e906-fa3a-4e7a-b2ef-bd17f4d7ca84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_7273e906-fa3a-4e7a-b2ef-bd17f4d7ca84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_f88f0d21-ddfc-45d3-a8ea-c6ef05ab40b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_f88f0d21-ddfc-45d3-a8ea-c6ef05ab40b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForMergerRelatedCosts_6d30702e-ff92-4031-917a-b7dc0d5b9292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForMergerRelatedCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_PaymentsForMergerRelatedCosts_6d30702e-ff92-4031-917a-b7dc0d5b9292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bac35bd2-4706-465f-80bf-20b1b5a4de3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bac35bd2-4706-465f-80bf-20b1b5a4de3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1a504937-758b-4806-a901-d83067a84f88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1a504937-758b-4806-a901-d83067a84f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_94b0bea8-dcb9-47c2-b4f4-1a563e0811fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_94b0bea8-dcb9-47c2-b4f4-1a563e0811fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6f1a455c-1296-497a-9c07-10b13b4878d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6f1a455c-1296-497a-9c07-10b13b4878d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred_6468f09e-9a60-4bec-856b-47590f012767" xlink:href="bios-20201231.xsd#bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b30ef90f-7948-4643-b030-1f79bda4cc46" xlink:to="loc_bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred_6468f09e-9a60-4bec-856b-47590f012767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSConsiderationExchangedDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1a8bd830-b1be-40dc-b838-b15978286527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f1677e9-47dc-494f-8247-95163134092d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1a8bd830-b1be-40dc-b838-b15978286527" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f1677e9-47dc-494f-8247-95163134092d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_57300927-2f39-47c1-8ac6-4694339f678c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f1677e9-47dc-494f-8247-95163134092d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_57300927-2f39-47c1-8ac6-4694339f678c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8adafe2e-3370-4b74-b297-67ec3c4ef381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_57300927-2f39-47c1-8ac6-4694339f678c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8adafe2e-3370-4b74-b297-67ec3c4ef381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BioScripMember_32a72760-0847-4961-b9fd-b048712e51ae" xlink:href="bios-20201231.xsd#bios_BioScripMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8adafe2e-3370-4b74-b297-67ec3c4ef381" xlink:to="loc_bios_BioScripMember_32a72760-0847-4961-b9fd-b048712e51ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f1677e9-47dc-494f-8247-95163134092d" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_95293e81-fb74-44f5-a327-ca47aaf5c353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_95293e81-fb74-44f5-a327-ca47aaf5c353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5c3da56f-1593-4036-9c6c-7dd2706b460e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5c3da56f-1593-4036-9c6c-7dd2706b460e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_6ed26cfc-eeb7-45ce-b0d3-684ae3386f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_6ed26cfc-eeb7-45ce-b0d3-684ae3386f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_06a2507a-c90e-46a0-9eab-a46f7e812883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_CommonStockValueOutstanding_06a2507a-c90e-46a0-9eab-a46f7e812883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0be46b40-5655-4f0d-83b8-c043986d78cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0be46b40-5655-4f0d-83b8-c043986d78cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b23f627a-0298-4e92-8502-111d459e5277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b23f627a-0298-4e92-8502-111d459e5277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9f69339f-ed25-4c01-b801-616e0efeb019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9f69339f-ed25-4c01-b801-616e0efeb019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_7b7bee45-6850-4d19-bfee-c1eac7a0ea56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_7b7bee45-6850-4d19-bfee-c1eac7a0ea56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c043c0d8-5af7-4f70-8013-bb86243ad3a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c043c0d8-5af7-4f70-8013-bb86243ad3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ba6e6501-335f-4752-bf9f-d17aa48a2bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a6f17a12-1c76-4c57-ab72-28b2bf54e68e" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ba6e6501-335f-4752-bf9f-d17aa48a2bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_459aebb1-68e0-4828-9197-92b408c7675e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c894384-ab89-4799-8057-487173557a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_459aebb1-68e0-4828-9197-92b408c7675e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c894384-ab89-4799-8057-487173557a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6a48f86b-0128-496c-a2a4-c90d032660c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c894384-ab89-4799-8057-487173557a52" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6a48f86b-0128-496c-a2a4-c90d032660c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a13689db-52da-4998-98da-427b38032ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6a48f86b-0128-496c-a2a4-c90d032660c3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a13689db-52da-4998-98da-427b38032ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BioScripMember_1687a4ed-bc26-4153-b1e8-fe5f43f3ab62" xlink:href="bios-20201231.xsd#bios_BioScripMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a13689db-52da-4998-98da-427b38032ee3" xlink:to="loc_bios_BioScripMember_1687a4ed-bc26-4153-b1e8-fe5f43f3ab62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c894384-ab89-4799-8057-487173557a52" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1338a126-5267-47dc-98f3-c5d58606afd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1338a126-5267-47dc-98f3-c5d58606afd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e1bfac2e-2bff-43a5-be93-78db6b09a81d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e1bfac2e-2bff-43a5-be93-78db6b09a81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d489cf49-ba34-4b93-beff-cc852daef013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d489cf49-ba34-4b93-beff-cc852daef013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_989042a1-eb5e-46d9-aa5c-a7f55b354512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_989042a1-eb5e-46d9-aa5c-a7f55b354512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_0c92d207-9227-4e51-b31f-1aa0a64e6e37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_0c92d207-9227-4e51-b31f-1aa0a64e6e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_7a77e3b5-0858-4713-b760-f43938432e4a" xlink:href="bios-20201231.xsd#bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_7a77e3b5-0858-4713-b760-f43938432e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_a92817e0-e49f-4e24-a327-e0d2770c9207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_a92817e0-e49f-4e24-a327-e0d2770c9207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_6131ed38-6e49-417c-ba22-227308da78c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_6131ed38-6e49-417c-ba22-227308da78c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_01555845-6ea1-4cfe-864b-1eb1cd751fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_01555845-6ea1-4cfe-864b-1eb1cd751fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fc5a88e6-0d48-4d23-a6a2-5a82fa3deafb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fc5a88e6-0d48-4d23-a6a2-5a82fa3deafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6cf091ae-c365-4930-822e-1fa3d587a406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_Goodwill_6cf091ae-c365-4930-822e-1fa3d587a406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_7599963c-c3d6-42e2-aa15-97ff54e95238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0bf1118a-022e-4ea8-8f60-a129a057f1f6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_7599963c-c3d6-42e2-aa15-97ff54e95238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_c869ebfa-8587-421c-a64e-709924e8abc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7cd19738-0fb2-40e9-8b67-42e0fc0d0003" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_c869ebfa-8587-421c-a64e-709924e8abc0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7cd19738-0fb2-40e9-8b67-42e0fc0d0003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1eacdda7-89cc-4142-878a-b8cd7c6445c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7cd19738-0fb2-40e9-8b67-42e0fc0d0003" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1eacdda7-89cc-4142-878a-b8cd7c6445c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_21200746-fd14-4576-b6b4-310d74ee8333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1eacdda7-89cc-4142-878a-b8cd7c6445c2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_21200746-fd14-4576-b6b4-310d74ee8333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_38a1c2db-b77e-4e84-af2d-a5cf40980b4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_21200746-fd14-4576-b6b4-310d74ee8333" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_38a1c2db-b77e-4e84-af2d-a5cf40980b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerListsMember_0a13086e-4e01-4cc1-8188-22fa880349ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerListsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_21200746-fd14-4576-b6b4-310d74ee8333" xlink:to="loc_us-gaap_CustomerListsMember_0a13086e-4e01-4cc1-8188-22fa880349ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_a485b767-7556-4595-83b8-ae13acff756f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_21200746-fd14-4576-b6b4-310d74ee8333" xlink:to="loc_us-gaap_LicensingAgreementsMember_a485b767-7556-4595-83b8-ae13acff756f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3412a259-0b9a-4b5e-b088-d84d2456e8a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7cd19738-0fb2-40e9-8b67-42e0fc0d0003" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3412a259-0b9a-4b5e-b088-d84d2456e8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8af83578-5850-4da9-b8f5-a635b8e12e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3412a259-0b9a-4b5e-b088-d84d2456e8a1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8af83578-5850-4da9-b8f5-a635b8e12e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BioScripMember_90c05836-ad2f-4e3a-bb0f-84eff8cd09cf" xlink:href="bios-20201231.xsd#bios_BioScripMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8af83578-5850-4da9-b8f5-a635b8e12e83" xlink:to="loc_bios_BioScripMember_90c05836-ad2f-4e3a-bb0f-84eff8cd09cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7182f34c-cbb6-4406-816e-58a67f2748da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7cd19738-0fb2-40e9-8b67-42e0fc0d0003" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7182f34c-cbb6-4406-816e-58a67f2748da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_29ad44c4-ede1-472c-9011-7fda4c8d8215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7182f34c-cbb6-4406-816e-58a67f2748da" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_29ad44c4-ede1-472c-9011-7fda4c8d8215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_fdfeacb1-67f8-42e4-903b-c7c98d8944d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7182f34c-cbb6-4406-816e-58a67f2748da" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_fdfeacb1-67f8-42e4-903b-c7c98d8944d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/BUSINESSACQUISITIONSProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#BUSINESSACQUISITIONSProFormaFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/BUSINESSACQUISITIONSProFormaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_943756b1-be0a-4875-9764-84434805a5b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_df85ad33-afb0-4c7a-a866-efe0bbd0475d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_943756b1-be0a-4875-9764-84434805a5b8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_df85ad33-afb0-4c7a-a866-efe0bbd0475d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f86537e3-431e-420b-8aee-ab8338b1fafe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_df85ad33-afb0-4c7a-a866-efe0bbd0475d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f86537e3-431e-420b-8aee-ab8338b1fafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96b2e284-a1fe-4903-9f6b-e2cbd3418ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f86537e3-431e-420b-8aee-ab8338b1fafe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96b2e284-a1fe-4903-9f6b-e2cbd3418ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BioScripMember_087e70f3-a04a-42d6-8d97-56fa26ee6e4c" xlink:href="bios-20201231.xsd#bios_BioScripMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96b2e284-a1fe-4903-9f6b-e2cbd3418ecf" xlink:to="loc_bios_BioScripMember_087e70f3-a04a-42d6-8d97-56fa26ee6e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a2e72dd5-6f34-418b-a9d0-eeb83b04c1aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_df85ad33-afb0-4c7a-a866-efe0bbd0475d" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a2e72dd5-6f34-418b-a9d0-eeb83b04c1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_e5c84aa5-5053-4684-a89a-6d81f7342ed3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2e72dd5-6f34-418b-a9d0-eeb83b04c1aa" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_e5c84aa5-5053-4684-a89a-6d81f7342ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_75cb52ad-75b9-4ecb-aef8-f4eee8efdc15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2e72dd5-6f34-418b-a9d0-eeb83b04c1aa" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_75cb52ad-75b9-4ecb-aef8-f4eee8efdc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/REVENUE" xlink:type="simple" xlink:href="bios-20201231.xsd#REVENUE"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/REVENUE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_76d6cd53-7c75-49ab-b7a3-dbad42642daa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_3ff61547-bacd-4ac6-9c25-718bda871acd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_76d6cd53-7c75-49ab-b7a3-dbad42642daa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_3ff61547-bacd-4ac6-9c25-718bda871acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/REVENUETables" xlink:type="simple" xlink:href="bios-20201231.xsd#REVENUETables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/REVENUETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3696f5fa-338b-471e-aa4f-65f76a894549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_3007b4d4-e288-4cf2-b35e-7559edfd81ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3696f5fa-338b-471e-aa4f-65f76a894549" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_3007b4d4-e288-4cf2-b35e-7559edfd81ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#REVENUENetRevenueEarnedbyCategoryofPayerDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aae19ae7-4af4-44a1-a1ef-b7eac0adbe6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_15c22f39-87a6-4c6c-b5e1-6e97a28e80ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aae19ae7-4af4-44a1-a1ef-b7eac0adbe6b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_15c22f39-87a6-4c6c-b5e1-6e97a28e80ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_09c35c34-bb75-4eab-a255-13f406e90b6c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_15c22f39-87a6-4c6c-b5e1-6e97a28e80ba" xlink:to="loc_srt_MajorCustomersAxis_09c35c34-bb75-4eab-a255-13f406e90b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_733b0db7-6c4c-47dd-be9b-2e7a5e7e6577" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_09c35c34-bb75-4eab-a255-13f406e90b6c" xlink:to="loc_srt_NameOfMajorCustomerDomain_733b0db7-6c4c-47dd-be9b-2e7a5e7e6577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_GovernmentCustomerMember_3b5028c1-aba3-4caf-a977-14f451b80795" xlink:href="bios-20201231.xsd#bios_GovernmentCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_733b0db7-6c4c-47dd-be9b-2e7a5e7e6577" xlink:to="loc_bios_GovernmentCustomerMember_3b5028c1-aba3-4caf-a977-14f451b80795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CommercialCustomerMember_4c9ece38-38aa-434e-b4c6-7c321b92d94a" xlink:href="bios-20201231.xsd#bios_CommercialCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_733b0db7-6c4c-47dd-be9b-2e7a5e7e6577" xlink:to="loc_bios_CommercialCustomerMember_4c9ece38-38aa-434e-b4c6-7c321b92d94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PatientCustomerMember_cbe42535-ac0c-433a-95eb-1b7c7e61c94b" xlink:href="bios-20201231.xsd#bios_PatientCustomerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_733b0db7-6c4c-47dd-be9b-2e7a5e7e6577" xlink:to="loc_bios_PatientCustomerMember_cbe42535-ac0c-433a-95eb-1b7c7e61c94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_aa1a2b7b-6308-41e8-ab60-bd553059861e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_15c22f39-87a6-4c6c-b5e1-6e97a28e80ba" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_aa1a2b7b-6308-41e8-ab60-bd553059861e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1b7dd87a-38c5-4a47-b87f-51916162f2b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_aa1a2b7b-6308-41e8-ab60-bd553059861e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1b7dd87a-38c5-4a47-b87f-51916162f2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="bios-20201231.xsd#EMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c52d3023-3705-465c-80af-8f5a015fc749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_44d0ff50-9656-4fe5-9c59-f2f1a342616e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c52d3023-3705-465c-80af-8f5a015fc749" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_44d0ff50-9656-4fe5-9c59-f2f1a342616e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_25e3121d-8b0b-4c9f-bc45-8535d18f3579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_69d78344-f405-4b72-923d-0e0e0d954c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_25e3121d-8b0b-4c9f-bc45-8535d18f3579" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_69d78344-f405-4b72-923d-0e0e0d954c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_e52efa36-4dc6-457a-9e53-71be86f27c74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_25e3121d-8b0b-4c9f-bc45-8535d18f3579" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_e52efa36-4dc6-457a-9e53-71be86f27c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_6d95078a-07b5-4df4-b899-e10f13984b50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_25e3121d-8b0b-4c9f-bc45-8535d18f3579" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_6d95078a-07b5-4df4-b899-e10f13984b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_e38fff71-9149-491e-9fde-31b5d44da1bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_25e3121d-8b0b-4c9f-bc45-8535d18f3579" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_e38fff71-9149-491e-9fde-31b5d44da1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXES" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b68395e4-0e66-482c-9d31-251e6b14a5ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_afb6397d-9fa6-4148-bd78-818890763e63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b68395e4-0e66-482c-9d31-251e6b14a5ac" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_afb6397d-9fa6-4148-bd78-818890763e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESIncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_830a6333-4e48-4060-b300-c09912a1459b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_75eda2ed-dafb-4192-b892-bc27de989471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_830a6333-4e48-4060-b300-c09912a1459b" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_75eda2ed-dafb-4192-b892-bc27de989471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b6a885b0-6c04-4dee-859f-e3897222ffcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_830a6333-4e48-4060-b300-c09912a1459b" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b6a885b0-6c04-4dee-859f-e3897222ffcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_509120a8-aaab-4287-8bf3-58785bc8175f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_830a6333-4e48-4060-b300-c09912a1459b" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_509120a8-aaab-4287-8bf3-58785bc8175f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_0f3d5a31-1a58-48a0-90d5-9af0d8cc8973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_830a6333-4e48-4060-b300-c09912a1459b" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_0f3d5a31-1a58-48a0-90d5-9af0d8cc8973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESIncomeTaxBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4d8c4d42-7cf5-46f8-9758-7a4cbbdcbfa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_cd4a900f-4094-4e0b-8d51-25424fc73a44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4d8c4d42-7cf5-46f8-9758-7a4cbbdcbfa2" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_cd4a900f-4094-4e0b-8d51-25424fc73a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_78d69240-b489-4801-bc5b-ad113fe61870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_cd4a900f-4094-4e0b-8d51-25424fc73a44" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_78d69240-b489-4801-bc5b-ad113fe61870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_56927fcb-e87f-43b7-a446-367a3068e74e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_cd4a900f-4094-4e0b-8d51-25424fc73a44" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_56927fcb-e87f-43b7-a446-367a3068e74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_fcd244a2-92f1-4ee0-b79b-8d37bc10c78e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_cd4a900f-4094-4e0b-8d51-25424fc73a44" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_fcd244a2-92f1-4ee0-b79b-8d37bc10c78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_3bcf7709-ea7e-4cf1-a3c1-df0492e4ef77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4d8c4d42-7cf5-46f8-9758-7a4cbbdcbfa2" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_3bcf7709-ea7e-4cf1-a3c1-df0492e4ef77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_15a1906f-79dd-400f-8f1f-5059be55b486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_3bcf7709-ea7e-4cf1-a3c1-df0492e4ef77" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_15a1906f-79dd-400f-8f1f-5059be55b486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_cad3afa8-52c7-4868-9c12-53f54e68955e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_3bcf7709-ea7e-4cf1-a3c1-df0492e4ef77" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_cad3afa8-52c7-4868-9c12-53f54e68955e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_86aee99b-6af5-47f8-b06f-4144b65083c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_3bcf7709-ea7e-4cf1-a3c1-df0492e4ef77" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_86aee99b-6af5-47f8-b06f-4144b65083c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_979936c0-3876-4eec-b471-42d82d783b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4d8c4d42-7cf5-46f8-9758-7a4cbbdcbfa2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_979936c0-3876-4eec-b471-42d82d783b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESIncomeTaxReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f966d008-8b58-4091-abc3-ea9a6b937e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7936b2b8-f3d1-40a5-a9e2-b75eae09e33c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f966d008-8b58-4091-abc3-ea9a6b937e27" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7936b2b8-f3d1-40a5-a9e2-b75eae09e33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c7e14f21-5a76-40b3-89a6-187875a50092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f966d008-8b58-4091-abc3-ea9a6b937e27" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c7e14f21-5a76-40b3-89a6-187875a50092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_edb75403-9bcb-4308-8387-d6a14a1f2a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f966d008-8b58-4091-abc3-ea9a6b937e27" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_edb75403-9bcb-4308-8387-d6a14a1f2a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_901d51c8-c7a3-46d8-84dc-0bac3a4fdfca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f966d008-8b58-4091-abc3-ea9a6b937e27" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_901d51c8-c7a3-46d8-84dc-0bac3a4fdfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_73bd005f-0e60-4d78-a830-6716170d8f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f966d008-8b58-4091-abc3-ea9a6b937e27" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_73bd005f-0e60-4d78-a830-6716170d8f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_8f0e07bb-6835-438e-9bd2-1e3629e0d10f" xlink:href="bios-20201231.xsd#bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f966d008-8b58-4091-abc3-ea9a6b937e27" xlink:to="loc_bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_8f0e07bb-6835-438e-9bd2-1e3629e0d10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2f84f591-8a93-4da4-9baa-baf89e9573e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f966d008-8b58-4091-abc3-ea9a6b937e27" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2f84f591-8a93-4da4-9baa-baf89e9573e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1d07164a-843c-4d09-baff-889d61c0006c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f966d008-8b58-4091-abc3-ea9a6b937e27" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1d07164a-843c-4d09-baff-889d61c0006c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8fb23f74-e67b-4204-ae84-9a4d989f9bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f966d008-8b58-4091-abc3-ea9a6b937e27" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8fb23f74-e67b-4204-ae84-9a4d989f9bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c7520a5d-e768-41ed-942c-710b8ebc9a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_f66feeb9-ddbc-4aaf-9f7f-9c25308e45b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c7520a5d-e768-41ed-942c-710b8ebc9a2a" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_f66feeb9-ddbc-4aaf-9f7f-9c25308e45b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DeferredTaxAssetsBadDebtReserve_d5c0a077-7993-4d18-b682-c14638d2ab9d" xlink:href="bios-20201231.xsd#bios_DeferredTaxAssetsBadDebtReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_f66feeb9-ddbc-4aaf-9f7f-9c25308e45b9" xlink:to="loc_bios_DeferredTaxAssetsBadDebtReserve_d5c0a077-7993-4d18-b682-c14638d2ab9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_c50257dc-b19a-4a0f-9eb6-ec3caee494a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_f66feeb9-ddbc-4aaf-9f7f-9c25308e45b9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_c50257dc-b19a-4a0f-9eb6-ec3caee494a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_f8e838ca-b712-416d-a4ca-74123e051757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_f66feeb9-ddbc-4aaf-9f7f-9c25308e45b9" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_f8e838ca-b712-416d-a4ca-74123e051757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DeferredTaxAssetsLeaseLiability_b2c12616-a0be-4069-94d2-3f8be5f96f44" xlink:href="bios-20201231.xsd#bios_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_f66feeb9-ddbc-4aaf-9f7f-9c25308e45b9" xlink:to="loc_bios_DeferredTaxAssetsLeaseLiability_b2c12616-a0be-4069-94d2-3f8be5f96f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d2a95ec3-b0e4-4046-8253-3cb26f70e3e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_f66feeb9-ddbc-4aaf-9f7f-9c25308e45b9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d2a95ec3-b0e4-4046-8253-3cb26f70e3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_008307cf-f541-4a12-a465-872e4653c580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_f66feeb9-ddbc-4aaf-9f7f-9c25308e45b9" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_008307cf-f541-4a12-a465-872e4653c580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_676bbc34-846a-4852-973c-0ec31ad92e09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_f66feeb9-ddbc-4aaf-9f7f-9c25308e45b9" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_676bbc34-846a-4852-973c-0ec31ad92e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6a010dbc-b3ac-4d2d-bdbf-dd223f33d7e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_f66feeb9-ddbc-4aaf-9f7f-9c25308e45b9" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6a010dbc-b3ac-4d2d-bdbf-dd223f33d7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_fbe073db-cb32-40c7-82d4-b378a07f3ade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_f66feeb9-ddbc-4aaf-9f7f-9c25308e45b9" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_fbe073db-cb32-40c7-82d4-b378a07f3ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract_80dcafed-30e5-43bb-b126-2bdbb38f484a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c7520a5d-e768-41ed-942c-710b8ebc9a2a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract_80dcafed-30e5-43bb-b126-2bdbb38f484a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DeferredTaxLiabilitiesAcceleratedDepreciation_e929fe02-3a38-4f5c-a537-1f321828e7b3" xlink:href="bios-20201231.xsd#bios_DeferredTaxLiabilitiesAcceleratedDepreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract_80dcafed-30e5-43bb-b126-2bdbb38f484a" xlink:to="loc_bios_DeferredTaxLiabilitiesAcceleratedDepreciation_e929fe02-3a38-4f5c-a537-1f321828e7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_313d686f-6340-496a-9e37-95c1f65b9301" xlink:href="bios-20201231.xsd#bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract_80dcafed-30e5-43bb-b126-2bdbb38f484a" xlink:to="loc_bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_313d686f-6340-496a-9e37-95c1f65b9301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_c692183e-8e90-42ea-938a-d1c1b507c026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract_80dcafed-30e5-43bb-b126-2bdbb38f484a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_c692183e-8e90-42ea-938a-d1c1b507c026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_f102f09c-6ee3-4d86-9691-0050b6c00ed3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract_80dcafed-30e5-43bb-b126-2bdbb38f484a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_f102f09c-6ee3-4d86-9691-0050b6c00ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_1ce93a2d-1b2a-45c5-8594-a77a273f148b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract_80dcafed-30e5-43bb-b126-2bdbb38f484a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_1ce93a2d-1b2a-45c5-8594-a77a273f148b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_d636fbbb-6d78-4440-99b6-3944ed6af946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract_80dcafed-30e5-43bb-b126-2bdbb38f484a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_d636fbbb-6d78-4440-99b6-3944ed6af946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_2f4a6750-973e-4ba4-b7c7-654f5d2db869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract_80dcafed-30e5-43bb-b126-2bdbb38f484a" xlink:to="loc_us-gaap_DeferredTaxLiabilities_2f4a6750-973e-4ba4-b7c7-654f5d2db869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_82b219b4-9e7e-425f-a9bc-e0f57ec0f79e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_74c14cee-ae26-4437-ad2e-de3d628fa9dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_82b219b4-9e7e-425f-a9bc-e0f57ec0f79e" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_74c14cee-ae26-4437-ad2e-de3d628fa9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_c1031c9c-e3ad-473b-aade-38aab3e1677f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_74c14cee-ae26-4437-ad2e-de3d628fa9dc" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_c1031c9c-e3ad-473b-aade-38aab3e1677f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7b03580f-417b-4e68-8e04-b152772f51c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_c1031c9c-e3ad-473b-aade-38aab3e1677f" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7b03580f-417b-4e68-8e04-b152772f51c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_MergerOperatingLossCarryforwardMember_e243f212-c7cd-4375-a9cb-4959b8748a8a" xlink:href="bios-20201231.xsd#bios_MergerOperatingLossCarryforwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7b03580f-417b-4e68-8e04-b152772f51c2" xlink:to="loc_bios_MergerOperatingLossCarryforwardMember_e243f212-c7cd-4375-a9cb-4959b8748a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember_472145ef-e52a-4eab-86d3-0967c115bde3" xlink:href="bios-20201231.xsd#bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7b03580f-417b-4e68-8e04-b152772f51c2" xlink:to="loc_bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember_472145ef-e52a-4eab-86d3-0967c115bde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InterestLimitationCarryforwardsMember_44efcc74-6203-4f01-8969-07d419f768e9" xlink:href="bios-20201231.xsd#bios_InterestLimitationCarryforwardsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7b03580f-417b-4e68-8e04-b152772f51c2" xlink:to="loc_bios_InterestLimitationCarryforwardsMember_44efcc74-6203-4f01-8969-07d419f768e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_46b3bcd4-0ba8-412e-9a96-b28fe0553be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_74c14cee-ae26-4437-ad2e-de3d628fa9dc" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_46b3bcd4-0ba8-412e-9a96-b28fe0553be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_418b0cd6-8ce4-4f07-aa4c-2bafdec74f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_46b3bcd4-0ba8-412e-9a96-b28fe0553be6" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_418b0cd6-8ce4-4f07-aa4c-2bafdec74f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_c5bb6754-eeef-4218-bca2-eb0c5d8d0b16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_418b0cd6-8ce4-4f07-aa4c-2bafdec74f84" xlink:to="loc_us-gaap_DomesticCountryMember_c5bb6754-eeef-4218-bca2-eb0c5d8d0b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_076adaa5-e1ca-4c59-9047-eb3fef8df2f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_418b0cd6-8ce4-4f07-aa4c-2bafdec74f84" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_076adaa5-e1ca-4c59-9047-eb3fef8df2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_74c14cee-ae26-4437-ad2e-de3d628fa9dc" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a2cc342d-209c-477b-9154-eb9e619aa33b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a2cc342d-209c-477b-9154-eb9e619aa33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0144ccc0-d25d-4b6d-8035-68759959318a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0144ccc0-d25d-4b6d-8035-68759959318a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_f7a79a54-38e3-47c1-8b33-168f1fc57e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_f7a79a54-38e3-47c1-8b33-168f1fc57e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ccf6d77b-e36e-46de-8bb1-dd3483f3c0c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ccf6d77b-e36e-46de-8bb1-dd3483f3c0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_b83d7655-b3d1-4dca-9134-6fc00a04bdc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_b83d7655-b3d1-4dca-9134-6fc00a04bdc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_b5daf924-d3c0-461f-a6e0-20f82a7c18d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_b5daf924-d3c0-461f-a6e0-20f82a7c18d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_IncomeTaxExpenseBenefitCARESAct_ed4fbf11-02bd-43cd-b45d-63666b1103c3" xlink:href="bios-20201231.xsd#bios_IncomeTaxExpenseBenefitCARESAct"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e6c5c225-6361-4d38-81ba-641507f91b79" xlink:to="loc_bios_IncomeTaxExpenseBenefitCARESAct_ed4fbf11-02bd-43cd-b45d-63666b1103c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5f7e19e9-63d2-4fb9-9fe9-e26a4671edec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable_ca8111a2-096b-4d90-88a4-9ae5408209cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5f7e19e9-63d2-4fb9-9fe9-e26a4671edec" xlink:to="loc_us-gaap_ValuationAllowanceTable_ca8111a2-096b-4d90-88a4-9ae5408209cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_8e26053a-a6a8-4bff-8837-64828c66c34a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_ca8111a2-096b-4d90-88a4-9ae5408209cb" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_8e26053a-a6a8-4bff-8837-64828c66c34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_768672ee-f918-4119-be4f-b89588d700bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_8e26053a-a6a8-4bff-8837-64828c66c34a" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_768672ee-f918-4119-be4f-b89588d700bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ChargedBenefitToCostsAndExpensesMember_d74965c7-c8a4-4148-b4eb-79f1e23aafd1" xlink:href="bios-20201231.xsd#bios_ChargedBenefitToCostsAndExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_768672ee-f918-4119-be4f-b89588d700bc" xlink:to="loc_bios_ChargedBenefitToCostsAndExpensesMember_d74965c7-c8a4-4148-b4eb-79f1e23aafd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ChargedToOtherAccountsMember_82db0f05-537e-49d6-a578-106c2dc30877" xlink:href="bios-20201231.xsd#bios_ChargedToOtherAccountsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_768672ee-f918-4119-be4f-b89588d700bc" xlink:to="loc_bios_ChargedToOtherAccountsMember_82db0f05-537e-49d6-a578-106c2dc30877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_00acce69-02dd-43fd-b7e3-91a256b70d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_ca8111a2-096b-4d90-88a4-9ae5408209cb" xlink:to="loc_us-gaap_ValuationAllowanceLineItems_00acce69-02dd-43fd-b7e3-91a256b70d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward_2bfff339-5daa-4ecc-8f8d-0437b7d2fd27" xlink:href="bios-20201231.xsd#bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_00acce69-02dd-43fd-b7e3-91a256b70d14" xlink:to="loc_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward_2bfff339-5daa-4ecc-8f8d-0437b7d2fd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46a4ec6c-7647-4ff9-be3a-d21688c7e0f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward_2bfff339-5daa-4ecc-8f8d-0437b7d2fd27" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46a4ec6c-7647-4ff9-be3a-d21688c7e0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_498b087d-72a3-4725-8cc8-b1550b078a56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward_2bfff339-5daa-4ecc-8f8d-0437b7d2fd27" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_498b087d-72a3-4725-8cc8-b1550b078a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9825ff4f-411c-4953-a113-3ec92e06b491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward_2bfff339-5daa-4ecc-8f8d-0437b7d2fd27" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9825ff4f-411c-4953-a113-3ec92e06b491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LOSSEARNINGSPERSHARE" xlink:type="simple" xlink:href="bios-20201231.xsd#LOSSEARNINGSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/LOSSEARNINGSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b1624b17-5956-43d0-9be6-66f1ffc29b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_63e92e45-fb00-45ea-848c-9d09855a84a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b1624b17-5956-43d0-9be6-66f1ffc29b9f" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_63e92e45-fb00-45ea-848c-9d09855a84a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LOSSEARNINGSPERSHARETables" xlink:type="simple" xlink:href="bios-20201231.xsd#LOSSEARNINGSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/LOSSEARNINGSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_58453fd1-c159-4e61-a60d-17e48411ba89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c41a0902-798a-4267-98bd-b9dd5bcd3301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_58453fd1-c159-4e61-a60d-17e48411ba89" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c41a0902-798a-4267-98bd-b9dd5bcd3301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#LOSSEARNINGSPERSHAREDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4212e80b-5207-4501-9aba-8e8ee2328e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_034bda29-0e3b-4635-a480-003c8115022d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4212e80b-5207-4501-9aba-8e8ee2328e14" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_034bda29-0e3b-4635-a480-003c8115022d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_23db3a83-18a9-4693-81de-7c5d3e1632c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_034bda29-0e3b-4635-a480-003c8115022d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_23db3a83-18a9-4693-81de-7c5d3e1632c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4e96c88a-c3ca-40a8-bc4e-d3cfca8caa9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_23db3a83-18a9-4693-81de-7c5d3e1632c4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4e96c88a-c3ca-40a8-bc4e-d3cfca8caa9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_727215ae-1be0-4693-9717-fecb3521ad78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4e96c88a-c3ca-40a8-bc4e-d3cfca8caa9a" xlink:to="loc_us-gaap_WarrantMember_727215ae-1be0-4693-9717-fecb3521ad78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_002a9ae6-be23-4934-bf11-6b097edf0ade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4e96c88a-c3ca-40a8-bc4e-d3cfca8caa9a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_002a9ae6-be23-4934-bf11-6b097edf0ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_RestrictedStockAwardMember_222dca34-349c-42ae-9d00-82b44b9da6f3" xlink:href="bios-20201231.xsd#bios_RestrictedStockAwardMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4e96c88a-c3ca-40a8-bc4e-d3cfca8caa9a" xlink:to="loc_bios_RestrictedStockAwardMember_222dca34-349c-42ae-9d00-82b44b9da6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53b9e3e-59f2-4463-bc3d-9d413fd7640f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_034bda29-0e3b-4635-a480-003c8115022d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53b9e3e-59f2-4463-bc3d-9d413fd7640f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_05cc884a-c803-4e0b-9539-ec03720d6e88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53b9e3e-59f2-4463-bc3d-9d413fd7640f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_05cc884a-c803-4e0b-9539-ec03720d6e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecurities_02adcf49-b17e-416b-99f9-0a44dba36e58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53b9e3e-59f2-4463-bc3d-9d413fd7640f" xlink:to="loc_us-gaap_DilutiveSecurities_02adcf49-b17e-416b-99f9-0a44dba36e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_55e5180b-57ae-4d9c-9e97-322012274914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53b9e3e-59f2-4463-bc3d-9d413fd7640f" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_55e5180b-57ae-4d9c-9e97-322012274914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e72c41d4-280a-4282-9aa1-5ea3c964c8e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_55e5180b-57ae-4d9c-9e97-322012274914" xlink:to="loc_us-gaap_NetIncomeLoss_e72c41d4-280a-4282-9aa1-5ea3c964c8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_db169c75-fcac-4f99-9790-56c40d338176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53b9e3e-59f2-4463-bc3d-9d413fd7640f" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_db169c75-fcac-4f99-9790-56c40d338176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_55448621-8030-47e2-a88f-bb30926d485d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_db169c75-fcac-4f99-9790-56c40d338176" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_55448621-8030-47e2-a88f-bb30926d485d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a10b159f-a06a-440e-8821-3fb2db0f4389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53b9e3e-59f2-4463-bc3d-9d413fd7640f" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a10b159f-a06a-440e-8821-3fb2db0f4389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_4e0156c6-84a4-4118-905d-00f795c991dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a10b159f-a06a-440e-8821-3fb2db0f4389" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_4e0156c6-84a4-4118-905d-00f795c991dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASES" xlink:type="simple" xlink:href="bios-20201231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_61e49102-2222-442c-8d06-3e9f5f37dbc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_6fdb4e73-8041-419a-91dd-bfc399c2f18e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_61e49102-2222-442c-8d06-3e9f5f37dbc5" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_6fdb4e73-8041-419a-91dd-bfc399c2f18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_68eb8fcd-7f97-447e-894d-07f26db9262d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_61e49102-2222-442c-8d06-3e9f5f37dbc5" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_68eb8fcd-7f97-447e-894d-07f26db9262d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASESTables" xlink:type="simple" xlink:href="bios-20201231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3e372a43-8f08-4c36-b163-2e5ba7c96426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ed9b7d52-f03b-41d0-83b9-ad89fe32c867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e372a43-8f08-4c36-b163-2e5ba7c96426" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ed9b7d52-f03b-41d0-83b9-ad89fe32c867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_41eb4121-d479-41a1-a3f5-3aa1d91446e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e372a43-8f08-4c36-b163-2e5ba7c96426" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_41eb4121-d479-41a1-a3f5-3aa1d91446e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#LEASESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4ebc8811-f017-4844-81eb-0014702eb694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_73c2f89f-f328-4d93-9247-41159b3e285f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4ebc8811-f017-4844-81eb-0014702eb694" xlink:to="loc_us-gaap_OperatingLeaseExpense_73c2f89f-f328-4d93-9247-41159b3e285f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_dcb23127-fa6a-4b4d-b962-92cc7fe15b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4ebc8811-f017-4844-81eb-0014702eb694" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_dcb23127-fa6a-4b4d-b962-92cc7fe15b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_161dbba2-c17f-4db8-b02d-bbcb9346a0b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4ebc8811-f017-4844-81eb-0014702eb694" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_161dbba2-c17f-4db8-b02d-bbcb9346a0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1de99022-3a61-4371-a1bb-0004c679fa59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4ebc8811-f017-4844-81eb-0014702eb694" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1de99022-3a61-4371-a1bb-0004c679fa59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_787ea8c4-2607-41bc-8fab-c4d17c54c243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4ebc8811-f017-4844-81eb-0014702eb694" xlink:to="loc_us-gaap_LeaseAndRentalExpense_787ea8c4-2607-41bc-8fab-c4d17c54c243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_32276649-24e6-4db4-82f3-0bffdb9edd63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3496f806-44df-49bf-a319-f83a0f731c3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_32276649-24e6-4db4-82f3-0bffdb9edd63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3496f806-44df-49bf-a319-f83a0f731c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a4ba3d96-a049-4a88-9968-c8e4bf5a3bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_32276649-24e6-4db4-82f3-0bffdb9edd63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a4ba3d96-a049-4a88-9968-c8e4bf5a3bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b4d33098-f04e-4b67-9d26-3c6b78bdb443" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_32276649-24e6-4db4-82f3-0bffdb9edd63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b4d33098-f04e-4b67-9d26-3c6b78bdb443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8c4e9f44-cf28-4ee5-874d-99779e492188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_32276649-24e6-4db4-82f3-0bffdb9edd63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8c4e9f44-cf28-4ee5-874d-99779e492188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4e809f24-fe0b-4008-9fce-b25985a6499d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_32276649-24e6-4db4-82f3-0bffdb9edd63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4e809f24-fe0b-4008-9fce-b25985a6499d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2e5de8ed-ce04-46f3-9db9-d0f66f7fdf06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_32276649-24e6-4db4-82f3-0bffdb9edd63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2e5de8ed-ce04-46f3-9db9-d0f66f7fdf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cd6fa173-f775-497a-8198-b9f9105ed40d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_32276649-24e6-4db4-82f3-0bffdb9edd63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cd6fa173-f775-497a-8198-b9f9105ed40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a96adeca-2a70-4de0-996d-8fff23535a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_32276649-24e6-4db4-82f3-0bffdb9edd63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a96adeca-2a70-4de0-996d-8fff23535a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_42ae0045-357d-45c6-9d2b-e36f5de21084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_32276649-24e6-4db4-82f3-0bffdb9edd63" xlink:to="loc_us-gaap_OperatingLeaseLiability_42ae0045-357d-45c6-9d2b-e36f5de21084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="bios-20201231.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="bios-20201231.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_33580ff3-c741-4444-9d36-e6d34010b772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_449c2edd-eda0-47dd-8185-76b13bd3e1e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_33580ff3-c741-4444-9d36-e6d34010b772" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_449c2edd-eda0-47dd-8185-76b13bd3e1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="bios-20201231.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f396883f-4613-4012-a56d-e9be9ff4ec9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f04c37e6-1236-4e9e-ae78-4d7b5352cf10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f396883f-4613-4012-a56d-e9be9ff4ec9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f04c37e6-1236-4e9e-ae78-4d7b5352cf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#PROPERTYANDEQUIPMENTDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c152ad73-8a98-4dce-ae99-418597a59e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2fbecea-c08d-4f44-b8bc-501b6081ddae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c152ad73-8a98-4dce-ae99-418597a59e39" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2fbecea-c08d-4f44-b8bc-501b6081ddae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7e3d5e2-f29c-4d21-b858-4f3e85c8cdac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2fbecea-c08d-4f44-b8bc-501b6081ddae" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7e3d5e2-f29c-4d21-b858-4f3e85c8cdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4968d08e-b506-4437-8627-085b8a7907d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7e3d5e2-f29c-4d21-b858-4f3e85c8cdac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4968d08e-b506-4437-8627-085b8a7907d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InfusionPumpsMember_5ab9ce1c-6346-4b0e-807f-c8f2a950ba58" xlink:href="bios-20201231.xsd#bios_InfusionPumpsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4968d08e-b506-4437-8627-085b8a7907d9" xlink:to="loc_bios_InfusionPumpsMember_5ab9ce1c-6346-4b0e-807f-c8f2a950ba58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_EquipmentFurnitureAndOtherMember_9692b0e9-9c82-4e42-8ffb-24c3531eaccf" xlink:href="bios-20201231.xsd#bios_EquipmentFurnitureAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4968d08e-b506-4437-8627-085b8a7907d9" xlink:to="loc_bios_EquipmentFurnitureAndOtherMember_9692b0e9-9c82-4e42-8ffb-24c3531eaccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ef68e25e-605c-492e-b3e0-7a1d1abcef02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4968d08e-b506-4437-8627-085b8a7907d9" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ef68e25e-605c-492e-b3e0-7a1d1abcef02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_659f3c26-e320-4a0f-ba2a-5142c37fba5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4968d08e-b506-4437-8627-085b8a7907d9" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_659f3c26-e320-4a0f-ba2a-5142c37fba5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember_f7cd3785-6bbf-46bb-9d0d-f8b37e1d952f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4968d08e-b506-4437-8627-085b8a7907d9" xlink:to="loc_us-gaap_AssetUnderConstructionMember_f7cd3785-6bbf-46bb-9d0d-f8b37e1d952f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9d5efdf1-719f-4f73-a574-b372c6a26b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2fbecea-c08d-4f44-b8bc-501b6081ddae" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9d5efdf1-719f-4f73-a574-b372c6a26b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d2f0e9c3-a861-4528-b642-f2a21ad477ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9d5efdf1-719f-4f73-a574-b372c6a26b3e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d2f0e9c3-a861-4528-b642-f2a21ad477ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_11d76b22-dd8a-42ea-aeaf-2cbacdf5a98e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2f0e9c3-a861-4528-b642-f2a21ad477ad" xlink:to="loc_us-gaap_CostOfSalesMember_11d76b22-dd8a-42ea-aeaf-2cbacdf5a98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_0f725301-b07c-48a1-a9da-66e787496c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2f0e9c3-a861-4528-b642-f2a21ad477ad" xlink:to="loc_us-gaap_OperatingExpenseMember_0f725301-b07c-48a1-a9da-66e787496c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f521dd6a-40a4-4e48-9091-f888632de666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2fbecea-c08d-4f44-b8bc-501b6081ddae" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f521dd6a-40a4-4e48-9091-f888632de666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7adaa63a-c33e-4393-a292-c9ca9b234c88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f521dd6a-40a4-4e48-9091-f888632de666" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7adaa63a-c33e-4393-a292-c9ca9b234c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_3e46824a-e20e-46ba-8dd5-9a97e4d8663a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7adaa63a-c33e-4393-a292-c9ca9b234c88" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_3e46824a-e20e-46ba-8dd5-9a97e4d8663a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_fdfeeb99-4f10-4c4a-890f-32216557c2f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2fbecea-c08d-4f44-b8bc-501b6081ddae" xlink:to="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_fdfeeb99-4f10-4c4a-890f-32216557c2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CatastrophicEventDomain_b85bb116-98b5-4308-b376-abafe70850e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CatastrophicEventDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis_fdfeeb99-4f10-4c4a-890f-32216557c2f1" xlink:to="loc_us-gaap_CatastrophicEventDomain_b85bb116-98b5-4308-b376-abafe70850e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HurricaneMember_f84fabbc-d662-4cad-a694-95f12726a746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HurricaneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CatastrophicEventDomain_b85bb116-98b5-4308-b376-abafe70850e3" xlink:to="loc_us-gaap_HurricaneMember_f84fabbc-d662-4cad-a694-95f12726a746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f2fbecea-c08d-4f44-b8bc-501b6081ddae" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_29edfb28-0b1a-456d-8ed9-af3ffdc06b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_29edfb28-0b1a-456d-8ed9-af3ffdc06b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f3b4f3b3-e7dc-46cc-a79c-62c6b39d35c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f3b4f3b3-e7dc-46cc-a79c-62c6b39d35c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b29d7883-2e77-4963-a12a-3e6c842621a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b29d7883-2e77-4963-a12a-3e6c842621a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_36a63915-fda3-4012-a61c-66dd2182e408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:to="loc_us-gaap_Depreciation_36a63915-fda3-4012-a61c-66dd2182e408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_00a8a70e-352f-4a07-877a-310df01669e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_00a8a70e-352f-4a07-877a-310df01669e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83a056df-2a82-483e-bf76-9c5a89d350f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83a056df-2a82-483e-bf76-9c5a89d350f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_87baff48-62b4-47f1-b43f-51a4b6a027e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0048c5db-01b7-4114-b88e-40556963afc6" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_87baff48-62b4-47f1-b43f-51a4b6a027e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5072f81a-df30-4411-9f29-8038b9ee76e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_94efd323-cb50-4a15-99d7-562dde1dee31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5072f81a-df30-4411-9f29-8038b9ee76e8" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_94efd323-cb50-4a15-99d7-562dde1dee31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSTables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_38ccaf6f-6efb-4d77-b43c-5238ace2a193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_40a46824-bd3e-4cc1-8e30-feb255209767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_38ccaf6f-6efb-4d77-b43c-5238ace2a193" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_40a46824-bd3e-4cc1-8e30-feb255209767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_1c892e88-9098-4e5f-b883-9189205cb5b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_38ccaf6f-6efb-4d77-b43c-5238ace2a193" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_1c892e88-9098-4e5f-b883-9189205cb5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_373ea26a-120a-47a6-975d-973e03dbb078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_38ccaf6f-6efb-4d77-b43c-5238ace2a193" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_373ea26a-120a-47a6-975d-973e03dbb078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24e2b5f6-bebc-49e4-b798-ea4400c15533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_418a349a-6bd7-4a8f-8586-13e5f0b3e0ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24e2b5f6-bebc-49e4-b798-ea4400c15533" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_418a349a-6bd7-4a8f-8586-13e5f0b3e0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_097abfae-98df-482a-a63e-6faf9f43ee8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24e2b5f6-bebc-49e4-b798-ea4400c15533" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_097abfae-98df-482a-a63e-6faf9f43ee8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0508ac06-6f16-462d-a0f6-dff69a2cb1cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_f9da3ed1-e20b-4cce-aff9-d324ed1c45cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0508ac06-6f16-462d-a0f6-dff69a2cb1cf" xlink:to="loc_us-gaap_GoodwillRollForward_f9da3ed1-e20b-4cce-aff9-d324ed1c45cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c519b8cf-36a5-497a-b335-b17c6892f3af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f9da3ed1-e20b-4cce-aff9-d324ed1c45cb" xlink:to="loc_us-gaap_Goodwill_c519b8cf-36a5-497a-b335-b17c6892f3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_a4abe8d0-9d78-46d1-a40f-0bdac98a9af7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f9da3ed1-e20b-4cce-aff9-d324ed1c45cb" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_a4abe8d0-9d78-46d1-a40f-0bdac98a9af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bf8d7609-2e3b-4d68-b223-03df3194a323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f9da3ed1-e20b-4cce-aff9-d324ed1c45cb" xlink:to="loc_us-gaap_Goodwill_bf8d7609-2e3b-4d68-b223-03df3194a323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f1ed3fe7-4080-46c9-b516-f7c415e6e033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9601ddfa-657d-4488-a0ab-65593b464fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f1ed3fe7-4080-46c9-b516-f7c415e6e033" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9601ddfa-657d-4488-a0ab-65593b464fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44fcc267-ea95-4c85-8d7b-a669625fed0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9601ddfa-657d-4488-a0ab-65593b464fa2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44fcc267-ea95-4c85-8d7b-a669625fed0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59f710f3-a202-452d-ab5c-4c6aed168ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44fcc267-ea95-4c85-8d7b-a669625fed0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59f710f3-a202-452d-ab5c-4c6aed168ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerListsMember_41362766-c3f7-4f12-aedf-59952193a38d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerListsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59f710f3-a202-452d-ab5c-4c6aed168ec0" xlink:to="loc_us-gaap_CustomerListsMember_41362766-c3f7-4f12-aedf-59952193a38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_8f02eeb2-f74e-4c9b-a0e0-e05b191ea4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59f710f3-a202-452d-ab5c-4c6aed168ec0" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_8f02eeb2-f74e-4c9b-a0e0-e05b191ea4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_0e9d1b1a-0f83-41eb-af50-4d6535386559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59f710f3-a202-452d-ab5c-4c6aed168ec0" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_0e9d1b1a-0f83-41eb-af50-4d6535386559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b0897608-c4e6-4bde-afb4-b9f665135e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9601ddfa-657d-4488-a0ab-65593b464fa2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b0897608-c4e6-4bde-afb4-b9f665135e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_38990b2d-1336-4d2a-9134-612f7722a468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b0897608-c4e6-4bde-afb4-b9f665135e9a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_38990b2d-1336-4d2a-9134-612f7722a468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_361dac1a-6da1-448e-8fc1-72c4b3d35cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b0897608-c4e6-4bde-afb4-b9f665135e9a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_361dac1a-6da1-448e-8fc1-72c4b3d35cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a01e23f-6828-4572-beb1-90f92503fdc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b0897608-c4e6-4bde-afb4-b9f665135e9a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a01e23f-6828-4572-beb1-90f92503fdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9541966a-70ec-4b42-a0f4-951b5c9f6b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5df4f3c8-022a-46ea-a740-2427fcd5a359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9541966a-70ec-4b42-a0f4-951b5c9f6b2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5df4f3c8-022a-46ea-a740-2427fcd5a359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c8890e14-2b10-4208-9c09-85fb38e9ef08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9541966a-70ec-4b42-a0f4-951b5c9f6b2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c8890e14-2b10-4208-9c09-85fb38e9ef08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b0af73b1-9b96-4308-921d-1c0d61a4676e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9541966a-70ec-4b42-a0f4-951b5c9f6b2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b0af73b1-9b96-4308-921d-1c0d61a4676e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fc85eac8-213b-469c-a1bb-4ad363961caa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9541966a-70ec-4b42-a0f4-951b5c9f6b2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fc85eac8-213b-469c-a1bb-4ad363961caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_98bbe513-4bc0-4303-aa5f-88818ada52b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9541966a-70ec-4b42-a0f4-951b5c9f6b2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_98bbe513-4bc0-4303-aa5f-88818ada52b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_198b06c3-1f3b-46ba-8cec-24361d743fe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9541966a-70ec-4b42-a0f4-951b5c9f6b2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_198b06c3-1f3b-46ba-8cec-24361d743fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7fe69b0b-8b3a-4cba-8d2f-646c9a52489f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9541966a-70ec-4b42-a0f4-951b5c9f6b2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7fe69b0b-8b3a-4cba-8d2f-646c9a52489f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESS" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9f6e6489-2543-439c-b3c6-99bb088855b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_7ec79352-e3ce-4d87-ad69-8bd715f68ef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9f6e6489-2543-439c-b3c6-99bb088855b4" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_7ec79352-e3ce-4d87-ad69-8bd715f68ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSTables" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESSTables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_670afef8-977f-4fb6-9b28-2688a428eaec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_e0c34a9d-7593-4cfa-84fb-52babfaff25f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_670afef8-977f-4fb6-9b28-2688a428eaec" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_e0c34a9d-7593-4cfa-84fb-52babfaff25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_3601bbd2-6856-4618-8e0b-d082cfd2a41d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_670afef8-977f-4fb6-9b28-2688a428eaec" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_3601bbd2-6856-4618-8e0b-d082cfd2a41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_e43f5085-08bc-457d-abb1-ed333a711e17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_670afef8-977f-4fb6-9b28-2688a428eaec" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_e43f5085-08bc-457d-abb1-ed333a711e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESSSummaryofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bad98a3d-7f3c-4389-b146-3d8c2c9632a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_997d616d-0305-4736-8414-13c381da1ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bad98a3d-7f3c-4389-b146-3d8c2c9632a0" xlink:to="loc_us-gaap_DebtInstrumentTable_997d616d-0305-4736-8414-13c381da1ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_64ce7404-62c8-4124-afba-0f6e58210055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_997d616d-0305-4736-8414-13c381da1ea7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_64ce7404-62c8-4124-afba-0f6e58210055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2765174b-889e-4b38-88a5-8e1fb809109d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_64ce7404-62c8-4124-afba-0f6e58210055" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2765174b-889e-4b38-88a5-8e1fb809109d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_7db989d6-1802-41dd-9d04-c076cb1a8216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2765174b-889e-4b38-88a5-8e1fb809109d" xlink:to="loc_us-gaap_SeniorNotesMember_7db989d6-1802-41dd-9d04-c076cb1a8216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7b8d3fc4-c1d3-43bf-ae30-5be46dd32985" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_997d616d-0305-4736-8414-13c381da1ea7" xlink:to="loc_us-gaap_CreditFacilityAxis_7b8d3fc4-c1d3-43bf-ae30-5be46dd32985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c2eae316-b128-4c51-9f93-78dc705d72f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_7b8d3fc4-c1d3-43bf-ae30-5be46dd32985" xlink:to="loc_us-gaap_CreditFacilityDomain_c2eae316-b128-4c51-9f93-78dc705d72f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4c4a6512-c057-4b3c-998d-7b0421bf94f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c2eae316-b128-4c51-9f93-78dc705d72f4" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4c4a6512-c057-4b3c-998d-7b0421bf94f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_843255ac-da07-4cfd-a2ee-cdc3b32a0d36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_997d616d-0305-4736-8414-13c381da1ea7" xlink:to="loc_us-gaap_DebtInstrumentAxis_843255ac-da07-4cfd-a2ee-cdc3b32a0d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e5dad105-ad7e-49d4-b118-bf7faa0c5c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_843255ac-da07-4cfd-a2ee-cdc3b32a0d36" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e5dad105-ad7e-49d4-b118-bf7faa0c5c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FirstLienTermLoanMember_a879747e-6bfd-475b-83c8-e262c5aca284" xlink:href="bios-20201231.xsd#bios_FirstLienTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5dad105-ad7e-49d4-b118-bf7faa0c5c38" xlink:to="loc_bios_FirstLienTermLoanMember_a879747e-6bfd-475b-83c8-e262c5aca284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SecondLienTermLoanMember_d074efe4-5a1e-4e8c-aeb4-0cf353207a7e" xlink:href="bios-20201231.xsd#bios_SecondLienTermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5dad105-ad7e-49d4-b118-bf7faa0c5c38" xlink:to="loc_bios_SecondLienTermLoanMember_d074efe4-5a1e-4e8c-aeb4-0cf353207a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ad5892e1-cd6d-4f54-8c7a-7d32bb57705b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_997d616d-0305-4736-8414-13c381da1ea7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ad5892e1-cd6d-4f54-8c7a-7d32bb57705b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_273517e2-6009-4637-903a-59588ba6d477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad5892e1-cd6d-4f54-8c7a-7d32bb57705b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_273517e2-6009-4637-903a-59588ba6d477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2f5d077d-c32e-4eab-823f-60dcaccb4aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad5892e1-cd6d-4f54-8c7a-7d32bb57705b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2f5d077d-c32e-4eab-823f-60dcaccb4aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_70193fd1-fbf9-4b96-a731-d15da5055310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad5892e1-cd6d-4f54-8c7a-7d32bb57705b" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_70193fd1-fbf9-4b96-a731-d15da5055310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e4e7daf5-8ede-4e7d-87b1-ef63fde09f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad5892e1-cd6d-4f54-8c7a-7d32bb57705b" xlink:to="loc_us-gaap_LongTermDebt_e4e7daf5-8ede-4e7d-87b1-ef63fde09f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f61fcec7-fe68-4e14-8065-c14e2e4b1198" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad5892e1-cd6d-4f54-8c7a-7d32bb57705b" xlink:to="loc_us-gaap_LongTermDebtCurrent_f61fcec7-fe68-4e14-8065-c14e2e4b1198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_581ec676-79cb-45e8-b1f4-0cd3560081f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad5892e1-cd6d-4f54-8c7a-7d32bb57705b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_581ec676-79cb-45e8-b1f4-0cd3560081f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails_1" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESSSummaryofDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_19b36218-7f80-4cba-94ef-f27e9c01ce63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_19b36218-7f80-4cba-94ef-f27e9c01ce63" xlink:to="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_edca0877-891e-46c9-ac1d-4b7571ffa30f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_edca0877-891e-46c9-ac1d-4b7571ffa30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_637ec220-d380-4064-ba24-903a691d4771" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_edca0877-891e-46c9-ac1d-4b7571ffa30f" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_637ec220-d380-4064-ba24-903a691d4771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_BankOfAmericaN.A.Member_0cd98bb2-7659-488c-a024-d3ed43ddfaba" xlink:href="bios-20201231.xsd#bios_BankOfAmericaN.A.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_637ec220-d380-4064-ba24-903a691d4771" xlink:to="loc_bios_BankOfAmericaN.A.Member_0cd98bb2-7659-488c-a024-d3ed43ddfaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryAxis_9a0c4dc6-cfc0-4755-b2a3-0f5b2e6d2d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_LienCategoryAxis_9a0c4dc6-cfc0-4755-b2a3-0f5b2e6d2d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_241b0337-32b3-4cbd-887e-4ceb34811d1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LienCategoryAxis_9a0c4dc6-cfc0-4755-b2a3-0f5b2e6d2d13" xlink:to="loc_us-gaap_LienCategoryDomain_241b0337-32b3-4cbd-887e-4ceb34811d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLienMember_7dc49d07-34ac-44a3-b18d-af419f74a462" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorLienMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LienCategoryDomain_241b0337-32b3-4cbd-887e-4ceb34811d1b" xlink:to="loc_us-gaap_SeniorLienMember_7dc49d07-34ac-44a3-b18d-af419f74a462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JuniorLienMember_2622b45e-df5f-4147-be96-78f1a55e9ea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_JuniorLienMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LienCategoryDomain_241b0337-32b3-4cbd-887e-4ceb34811d1b" xlink:to="loc_us-gaap_JuniorLienMember_2622b45e-df5f-4147-be96-78f1a55e9ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f7fce659-8825-4c53-a692-002dd9673423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_CreditFacilityAxis_f7fce659-8825-4c53-a692-002dd9673423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d9308b40-708c-4ef6-807d-60970e7591d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_f7fce659-8825-4c53-a692-002dd9673423" xlink:to="loc_us-gaap_CreditFacilityDomain_d9308b40-708c-4ef6-807d-60970e7591d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_aee0c9c3-0ebd-4860-9ab8-ab398778280c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d9308b40-708c-4ef6-807d-60970e7591d1" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_aee0c9c3-0ebd-4860-9ab8-ab398778280c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_a03f6440-24a4-48d1-a410-0508a5801767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d9308b40-708c-4ef6-807d-60970e7591d1" xlink:to="loc_us-gaap_LetterOfCreditMember_a03f6440-24a4-48d1-a410-0508a5801767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_14b0093c-8dab-4d5b-85eb-4554822c7971" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_srt_RangeAxis_14b0093c-8dab-4d5b-85eb-4554822c7971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2550336d-e78b-4907-a5fa-7830eb1b037e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_14b0093c-8dab-4d5b-85eb-4554822c7971" xlink:to="loc_srt_RangeMember_2550336d-e78b-4907-a5fa-7830eb1b037e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8d7f8d24-51c9-4c0e-a707-292a41020303" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2550336d-e78b-4907-a5fa-7830eb1b037e" xlink:to="loc_srt_MinimumMember_8d7f8d24-51c9-4c0e-a707-292a41020303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9128bcae-357f-479f-bb29-047034adcbb2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2550336d-e78b-4907-a5fa-7830eb1b037e" xlink:to="loc_srt_MaximumMember_9128bcae-357f-479f-bb29-047034adcbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5bc4ab4a-4800-45ff-8d28-a1551316bab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_DebtInstrumentAxis_5bc4ab4a-4800-45ff-8d28-a1551316bab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d22b2a4a-9b99-46fc-b062-f638dcf0110c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5bc4ab4a-4800-45ff-8d28-a1551316bab3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d22b2a4a-9b99-46fc-b062-f638dcf0110c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditArrangementsEnteredInto2015Member_81e7782b-67bf-4de5-8f4c-d3ffee9ed169" xlink:href="bios-20201231.xsd#bios_CreditArrangementsEnteredInto2015Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d22b2a4a-9b99-46fc-b062-f638dcf0110c" xlink:to="loc_bios_CreditArrangementsEnteredInto2015Member_81e7782b-67bf-4de5-8f4c-d3ffee9ed169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditAgreementsEnteredInto2019Member_6742e895-2dc2-40e0-b34d-2b612de382d6" xlink:href="bios-20201231.xsd#bios_CreditAgreementsEnteredInto2019Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d22b2a4a-9b99-46fc-b062-f638dcf0110c" xlink:to="loc_bios_CreditAgreementsEnteredInto2019Member_6742e895-2dc2-40e0-b34d-2b612de382d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditArrangementsEnteredInto2015ModifiedLoansMember_61046455-ba45-444b-b679-e99c5588973c" xlink:href="bios-20201231.xsd#bios_CreditArrangementsEnteredInto2015ModifiedLoansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d22b2a4a-9b99-46fc-b062-f638dcf0110c" xlink:to="loc_bios_CreditArrangementsEnteredInto2015ModifiedLoansMember_61046455-ba45-444b-b679-e99c5588973c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2158126e-b078-4ae2-b8b7-11f26ce9b859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2158126e-b078-4ae2-b8b7-11f26ce9b859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_206067e5-4d94-408c-8ead-b59f54bac587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2158126e-b078-4ae2-b8b7-11f26ce9b859" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_206067e5-4d94-408c-8ead-b59f54bac587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e7165bba-aad7-4aff-a826-dbd02b702db6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_206067e5-4d94-408c-8ead-b59f54bac587" xlink:to="loc_us-gaap_SeniorNotesMember_e7165bba-aad7-4aff-a826-dbd02b702db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NotesPayableMember_0544e21a-2d52-4073-bc18-6610de2ae31d" xlink:href="bios-20201231.xsd#bios_NotesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_206067e5-4d94-408c-8ead-b59f54bac587" xlink:to="loc_bios_NotesPayableMember_0544e21a-2d52-4073-bc18-6610de2ae31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c3d077c1-6dfb-4fad-98cb-ab4d846cc128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_VariableRateAxis_c3d077c1-6dfb-4fad-98cb-ab4d846cc128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_471c0935-cede-4e60-a80c-d5ac6e2dfdf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_c3d077c1-6dfb-4fad-98cb-ab4d846cc128" xlink:to="loc_us-gaap_VariableRateDomain_471c0935-cede-4e60-a80c-d5ac6e2dfdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_71e48756-9b07-43f3-9dee-f326ccb4ff1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_471c0935-cede-4e60-a80c-d5ac6e2dfdf8" xlink:to="loc_us-gaap_BaseRateMember_71e48756-9b07-43f3-9dee-f326ccb4ff1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_49dd7622-3d27-4313-ac88-b6b28b59a770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_471c0935-cede-4e60-a80c-d5ac6e2dfdf8" xlink:to="loc_us-gaap_EurodollarMember_49dd7622-3d27-4313-ac88-b6b28b59a770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d7cca4ac-03d7-468b-83da-5442e903d905" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_471c0935-cede-4e60-a80c-d5ac6e2dfdf8" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d7cca4ac-03d7-468b-83da-5442e903d905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f5cbde33-157a-4047-bb86-784e00f11ca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f5cbde33-157a-4047-bb86-784e00f11ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_27956f08-0065-47f3-bb8b-be0559223687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f5cbde33-157a-4047-bb86-784e00f11ca3" xlink:to="loc_us-gaap_ClassOfStockDomain_27956f08-0065-47f3-bb8b-be0559223687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cc9262e7-a899-4856-8dae-38f6d4dc7dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_27956f08-0065-47f3-bb8b-be0559223687" xlink:to="loc_us-gaap_CommonStockMember_cc9262e7-a899-4856-8dae-38f6d4dc7dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bf8e7a87-459e-4be7-afe7-614ed3db8acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bf8e7a87-459e-4be7-afe7-614ed3db8acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0ab52c5-9489-4eac-bcf7-82abdbf1dc74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bf8e7a87-459e-4be7-afe7-614ed3db8acf" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0ab52c5-9489-4eac-bcf7-82abdbf1dc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PublicOfferingMember_c2f9a8e3-0d48-4ebb-b6da-8f51842f2c0e" xlink:href="bios-20201231.xsd#bios_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0ab52c5-9489-4eac-bcf7-82abdbf1dc74" xlink:to="loc_bios_PublicOfferingMember_c2f9a8e3-0d48-4ebb-b6da-8f51842f2c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6881f7aa-0b6f-48dc-9b9f-5e2c8814d89a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6881f7aa-0b6f-48dc-9b9f-5e2c8814d89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_94121ca5-26df-4503-bf34-c3a84b3ecf71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6881f7aa-0b6f-48dc-9b9f-5e2c8814d89a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_94121ca5-26df-4503-bf34-c3a84b3ecf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_39b3e3c8-f8b7-4c5a-ae7e-3101e2e16287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_94121ca5-26df-4503-bf34-c3a84b3ecf71" xlink:to="loc_us-gaap_SubsequentEventMember_39b3e3c8-f8b7-4c5a-ae7e-3101e2e16287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09f61b61-2bbc-4289-b798-17950058ae9f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_91b4c5cb-1e1b-40e3-adca-837eba3cac9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_91b4c5cb-1e1b-40e3-adca-837eba3cac9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_555a448b-7115-466e-b84d-31b107430811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_555a448b-7115-466e-b84d-31b107430811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_9386dc7a-a0c2-4fc9-9d6c-94a2499d2cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_9386dc7a-a0c2-4fc9-9d6c-94a2499d2cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_c2f4a72b-84e3-4120-b838-86f055cf5884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_c2f4a72b-84e3-4120-b838-86f055cf5884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DebtInstrumentBaseRate_624c0055-d1e5-48e2-8d6c-1086e8b19114" xlink:href="bios-20201231.xsd#bios_DebtInstrumentBaseRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_bios_DebtInstrumentBaseRate_624c0055-d1e5-48e2-8d6c-1086e8b19114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_008f44be-f599-4cad-b060-ce99790357d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_008f44be-f599-4cad-b060-ce99790357d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_c82d49c9-a52e-4628-b6dc-8e92d4024dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_c82d49c9-a52e-4628-b6dc-8e92d4024dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_bd4968d4-d92e-46a0-ab6d-cc6beae4f0fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_bd4968d4-d92e-46a0-ab6d-cc6beae4f0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5eb58b0d-ea54-4ba0-8625-b9af438ee45e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_LongTermDebt_5eb58b0d-ea54-4ba0-8625-b9af438ee45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_929b73e3-9195-4542-bdbf-d98e2d8a803c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_929b73e3-9195-4542-bdbf-d98e2d8a803c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_399aabb2-a4e2-4fab-8b32-c42e4ff2a716" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_399aabb2-a4e2-4fab-8b32-c42e4ff2a716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a927c817-184c-4db6-83e6-146adbe6d56f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a927c817-184c-4db6-83e6-146adbe6d56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InterestCapitalizedToDebtPrincipal_e335e7fb-a024-4f62-a145-c1154243f876" xlink:href="bios-20201231.xsd#bios_InterestCapitalizedToDebtPrincipal"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_bios_InterestCapitalizedToDebtPrincipal_e335e7fb-a024-4f62-a145-c1154243f876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_a14766e1-690e-4c9e-9680-749cda5e70ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_PaidInKindInterest_a14766e1-690e-4c9e-9680-749cda5e70ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PaidInKindInterestAdditionalInterestExpense_ece92e20-6080-449f-ac3a-18c67533504c" xlink:href="bios-20201231.xsd#bios_PaidInKindInterestAdditionalInterestExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_bios_PaidInKindInterestAdditionalInterestExpense_ece92e20-6080-449f-ac3a-18c67533504c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_d8157a7a-0467-4be0-bdc6-dc2cee7a57f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_d8157a7a-0467-4be0-bdc6-dc2cee7a57f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_87f02b37-987a-44f1-811e-ab4e2cfa86f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_RepaymentsOfDebt_87f02b37-987a-44f1-811e-ab4e2cfa86f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a29917b3-dd5b-4ad5-a730-f207b3dbec7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a29917b3-dd5b-4ad5-a730-f207b3dbec7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FinancingReceivablePrepaymentPenalty_13775e08-b079-44bf-aa1a-fa814ac7953b" xlink:href="bios-20201231.xsd#bios_FinancingReceivablePrepaymentPenalty"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_bios_FinancingReceivablePrepaymentPenalty_13775e08-b079-44bf-aa1a-fa814ac7953b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableDeferredIncome_20115ea9-d0c1-4e15-9b6e-c33ffe62f962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancingReceivableDeferredIncome"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_FinancingReceivableDeferredIncome_20115ea9-d0c1-4e15-9b6e-c33ffe62f962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_567cc616-e985-488a-8bb0-f4a65f104d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_567cc616-e985-488a-8bb0-f4a65f104d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_beb6cc81-1c94-4022-ba6d-47baa483614e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_beb6cc81-1c94-4022-ba6d-47baa483614e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_57db3626-b106-4314-961a-a9ebacdd8f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_57db3626-b106-4314-961a-a9ebacdd8f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_d2de36bd-d2a9-4e78-bbdb-0d507898c535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_d2de36bd-d2a9-4e78-bbdb-0d507898c535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1135fe6d-b213-4b26-b764-f6dd9f881371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1135fe6d-b213-4b26-b764-f6dd9f881371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_11265340-9a09-4b9f-a37b-042538bcf13e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_11265340-9a09-4b9f-a37b-042538bcf13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PaymentsOfDebtIssuanceCostsInvestingActivities_e4fcf761-58a3-457e-ae22-b82de6489a81" xlink:href="bios-20201231.xsd#bios_PaymentsOfDebtIssuanceCostsInvestingActivities"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ff8399c-ccd4-4def-8ba2-81f7d49974f1" xlink:to="loc_bios_PaymentsOfDebtIssuanceCostsInvestingActivities_e4fcf761-58a3-457e-ae22-b82de6489a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESSLongtermDebtMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_42921cad-89e5-4231-888b-30065c94a6cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_32e29853-0971-477f-998c-9ba9b2c8d5c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_42921cad-89e5-4231-888b-30065c94a6cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_32e29853-0971-477f-998c-9ba9b2c8d5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fd131f61-dc16-43f5-9353-166b2b011806" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_42921cad-89e5-4231-888b-30065c94a6cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fd131f61-dc16-43f5-9353-166b2b011806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2e22141c-78c5-40e7-ab21-e3b64df78aad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_42921cad-89e5-4231-888b-30065c94a6cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2e22141c-78c5-40e7-ab21-e3b64df78aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e472809c-f7bd-4e5b-b323-4c8a58f1d6af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_42921cad-89e5-4231-888b-30065c94a6cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e472809c-f7bd-4e5b-b323-4c8a58f1d6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7b96378e-0895-4d9b-a427-c70a90d006bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_42921cad-89e5-4231-888b-30065c94a6cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7b96378e-0895-4d9b-a427-c70a90d006bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_b4649efb-fb05-4098-bddc-28f7c6055958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_42921cad-89e5-4231-888b-30065c94a6cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_b4649efb-fb05-4098-bddc-28f7c6055958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_637db97c-d593-4991-a63f-e8590c170009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_42921cad-89e5-4231-888b-30065c94a6cc" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_637db97c-d593-4991-a63f-e8590c170009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d4620207-9ec8-426e-a0c8-75d5b64ac7aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3b1a3fcc-db71-44a5-8c70-88bef0052fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d4620207-9ec8-426e-a0c8-75d5b64ac7aa" xlink:to="loc_us-gaap_DebtInstrumentTable_3b1a3fcc-db71-44a5-8c70-88bef0052fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_276e9ca0-a3a5-4b24-ae8f-4c75ed5d1ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3b1a3fcc-db71-44a5-8c70-88bef0052fbd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_276e9ca0-a3a5-4b24-ae8f-4c75ed5d1ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c2ba7550-e9cf-481e-b1b0-10c2bd8215b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_276e9ca0-a3a5-4b24-ae8f-4c75ed5d1ce4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c2ba7550-e9cf-481e-b1b0-10c2bd8215b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ab0fa876-8437-4762-ab46-c6b729929c17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c2ba7550-e9cf-481e-b1b0-10c2bd8215b3" xlink:to="loc_us-gaap_SeniorNotesMember_ab0fa876-8437-4762-ab46-c6b729929c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_766a723e-3179-47d0-897b-3fac41586256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3b1a3fcc-db71-44a5-8c70-88bef0052fbd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_766a723e-3179-47d0-897b-3fac41586256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e8cdc36-21f1-4c0b-b7ac-05fd295784c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_766a723e-3179-47d0-897b-3fac41586256" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e8cdc36-21f1-4c0b-b7ac-05fd295784c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_69d55468-61cb-487d-b605-e293ac7d558c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e8cdc36-21f1-4c0b-b7ac-05fd295784c0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_69d55468-61cb-487d-b605-e293ac7d558c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f9d19ba5-2a6d-4b9c-b215-af9f98d36826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e8cdc36-21f1-4c0b-b7ac-05fd295784c0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f9d19ba5-2a6d-4b9c-b215-af9f98d36826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_52dee3ed-28c3-4ad9-a8df-ef3b691eb0ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e8cdc36-21f1-4c0b-b7ac-05fd295784c0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_52dee3ed-28c3-4ad9-a8df-ef3b691eb0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_715bd3e7-80fd-4f75-952e-f312f3f2ec61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3b1a3fcc-db71-44a5-8c70-88bef0052fbd" xlink:to="loc_us-gaap_DebtInstrumentAxis_715bd3e7-80fd-4f75-952e-f312f3f2ec61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8b496d16-e5d4-4fb3-aad6-ea8c4d6390e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_715bd3e7-80fd-4f75-952e-f312f3f2ec61" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8b496d16-e5d4-4fb3-aad6-ea8c4d6390e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FirstLienTermLoanMember_47dac977-2788-496c-963a-c3004de7acca" xlink:href="bios-20201231.xsd#bios_FirstLienTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b496d16-e5d4-4fb3-aad6-ea8c4d6390e8" xlink:to="loc_bios_FirstLienTermLoanMember_47dac977-2788-496c-963a-c3004de7acca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SecondLienTermLoanMember_c1fa72a0-77c3-499a-bea9-7d3779fbcd54" xlink:href="bios-20201231.xsd#bios_SecondLienTermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b496d16-e5d4-4fb3-aad6-ea8c4d6390e8" xlink:to="loc_bios_SecondLienTermLoanMember_c1fa72a0-77c3-499a-bea9-7d3779fbcd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0946708f-70ba-41ca-a10d-3d13939ff654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3b1a3fcc-db71-44a5-8c70-88bef0052fbd" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0946708f-70ba-41ca-a10d-3d13939ff654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_1e78819d-186f-44e7-a93d-7c3c20d43ce5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0946708f-70ba-41ca-a10d-3d13939ff654" xlink:to="loc_us-gaap_LongTermDebtFairValue_1e78819d-186f-44e7-a93d-7c3c20d43ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DebtInstrumentChangesInLongTermDebtRollForward_b123bed2-3b98-4294-a0b5-acc51c7a9e13" xlink:href="bios-20201231.xsd#bios_DebtInstrumentChangesInLongTermDebtRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0946708f-70ba-41ca-a10d-3d13939ff654" xlink:to="loc_bios_DebtInstrumentChangesInLongTermDebtRollForward_b123bed2-3b98-4294-a0b5-acc51c7a9e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_c4bf5548-a27a-4d7f-a1da-70b77e1d0036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_DebtInstrumentChangesInLongTermDebtRollForward_b123bed2-3b98-4294-a0b5-acc51c7a9e13" xlink:to="loc_us-gaap_LongTermDebtFairValue_c4bf5548-a27a-4d7f-a1da-70b77e1d0036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_588ce86c-9cc6-4622-9f5f-6a68cca0014c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_DebtInstrumentChangesInLongTermDebtRollForward_b123bed2-3b98-4294-a0b5-acc51c7a9e13" xlink:to="loc_us-gaap_RepaymentsOfDebt_588ce86c-9cc6-4622-9f5f-6a68cca0014c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_382fef08-fc2f-4a2a-96db-fbfea7db4eff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_DebtInstrumentChangesInLongTermDebtRollForward_b123bed2-3b98-4294-a0b5-acc51c7a9e13" xlink:to="loc_us-gaap_PaidInKindInterest_382fef08-fc2f-4a2a-96db-fbfea7db4eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_a076a18d-fc9d-41d6-abb3-d670b5ebc763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_DebtInstrumentChangesInLongTermDebtRollForward_b123bed2-3b98-4294-a0b5-acc51c7a9e13" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_a076a18d-fc9d-41d6-abb3-d670b5ebc763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_02b8410c-50dd-40f5-97a9-3c09aaa6bd2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_DebtInstrumentChangesInLongTermDebtRollForward_b123bed2-3b98-4294-a0b5-acc51c7a9e13" xlink:to="loc_us-gaap_LongTermDebtFairValue_02b8410c-50dd-40f5-97a9-3c09aaa6bd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS" xlink:type="simple" xlink:href="bios-20201231.xsd#DERIVATIVEINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9ea29efe-86bf-49eb-9d20-1f48455a38b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_162b0b43-ffc7-4425-913a-ee5bed0c91b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9ea29efe-86bf-49eb-9d20-1f48455a38b9" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_162b0b43-ffc7-4425-913a-ee5bed0c91b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables" xlink:type="simple" xlink:href="bios-20201231.xsd#DERIVATIVEINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_98398f65-af58-4155-a508-bdbc1f346077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_cfeea089-0931-44b2-971e-4033b3244d4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_98398f65-af58-4155-a508-bdbc1f346077" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_cfeea089-0931-44b2-971e-4033b3244d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_cdb0d687-a4e5-4911-b2f1-b74695d5b56d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_98398f65-af58-4155-a508-bdbc1f346077" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_cdb0d687-a4e5-4911-b2f1-b74695d5b56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#DERIVATIVEINSTRUMENTSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_933f211f-439a-4368-a40f-7e14aeca5640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_933f211f-439a-4368-a40f-7e14aeca5640" xlink:to="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_51c57f26-5beb-48e0-ac48-426bf4b4050c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_51c57f26-5beb-48e0-ac48-426bf4b4050c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7373bb40-4788-4111-aca9-a9990b609955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_51c57f26-5beb-48e0-ac48-426bf4b4050c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7373bb40-4788-4111-aca9-a9990b609955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_ec89c6d7-4395-47f8-8c6c-9a93dfb7aff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7373bb40-4788-4111-aca9-a9990b609955" xlink:to="loc_us-gaap_CashFlowHedgingMember_ec89c6d7-4395-47f8-8c6c-9a93dfb7aff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_24a2579d-9327-4c97-8f1e-99594cae7da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:to="loc_us-gaap_HedgingDesignationAxis_24a2579d-9327-4c97-8f1e-99594cae7da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_14f5b446-543c-444b-bd79-6b87f9ac66dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_24a2579d-9327-4c97-8f1e-99594cae7da8" xlink:to="loc_us-gaap_HedgingDesignationDomain_14f5b446-543c-444b-bd79-6b87f9ac66dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_fef6cfd6-f752-430b-b48e-eace97aebfdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_14f5b446-543c-444b-bd79-6b87f9ac66dd" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_fef6cfd6-f752-430b-b48e-eace97aebfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8392d2fa-fa44-46ba-be4d-6fa41db505fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_14f5b446-543c-444b-bd79-6b87f9ac66dd" xlink:to="loc_us-gaap_NondesignatedMember_8392d2fa-fa44-46ba-be4d-6fa41db505fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_eb0a8302-e52a-4ec8-bd95-ed9062df4234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_eb0a8302-e52a-4ec8-bd95-ed9062df4234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e5822e95-3076-4b65-a7a3-404ce0090da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_eb0a8302-e52a-4ec8-bd95-ed9062df4234" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e5822e95-3076-4b65-a7a3-404ce0090da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_58727431-fb82-4305-b9d9-9427d18f17c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e5822e95-3076-4b65-a7a3-404ce0090da4" xlink:to="loc_us-gaap_SeniorNotesMember_58727431-fb82-4305-b9d9-9427d18f17c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryAxis_e4d048e2-3b5c-4895-b91b-ae3371bc045d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:to="loc_us-gaap_LienCategoryAxis_e4d048e2-3b5c-4895-b91b-ae3371bc045d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_c0fbce8f-3ea0-4b74-af04-f87ed2b8d954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LienCategoryAxis_e4d048e2-3b5c-4895-b91b-ae3371bc045d" xlink:to="loc_us-gaap_LienCategoryDomain_c0fbce8f-3ea0-4b74-af04-f87ed2b8d954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLienMember_52e5ac53-3189-4298-b8ca-d3ee049e5dd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorLienMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LienCategoryDomain_c0fbce8f-3ea0-4b74-af04-f87ed2b8d954" xlink:to="loc_us-gaap_SeniorLienMember_52e5ac53-3189-4298-b8ca-d3ee049e5dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JuniorLienMember_f644fea6-1be5-44af-bf8e-99991f0ecc95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_JuniorLienMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LienCategoryDomain_c0fbce8f-3ea0-4b74-af04-f87ed2b8d954" xlink:to="loc_us-gaap_JuniorLienMember_f644fea6-1be5-44af-bf8e-99991f0ecc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3a0897c8-e292-4bd3-b6d0-e5bc539ea889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:to="loc_us-gaap_DebtInstrumentAxis_3a0897c8-e292-4bd3-b6d0-e5bc539ea889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_44692f62-a969-4d1a-8621-4eeb784e91c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3a0897c8-e292-4bd3-b6d0-e5bc539ea889" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_44692f62-a969-4d1a-8621-4eeb784e91c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditAgreementsEnteredInto2019Member_f2cd9b43-59eb-4581-a6ff-467cece6806f" xlink:href="bios-20201231.xsd#bios_CreditAgreementsEnteredInto2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44692f62-a969-4d1a-8621-4eeb784e91c7" xlink:to="loc_bios_CreditAgreementsEnteredInto2019Member_f2cd9b43-59eb-4581-a6ff-467cece6806f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4adf9cf2-2f99-4178-9327-eded391a51e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4adf9cf2-2f99-4178-9327-eded391a51e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_67c417ce-1538-4758-906b-d272d2d8f631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4adf9cf2-2f99-4178-9327-eded391a51e5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_67c417ce-1538-4758-906b-d272d2d8f631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_c244d486-d32a-4913-a381-f259596f361a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateCapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_67c417ce-1538-4758-906b-d272d2d8f631" xlink:to="loc_us-gaap_InterestRateCapMember_c244d486-d32a-4913-a381-f259596f361a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_ee4822cd-cb51-49d1-b113-5b0d9175fd1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_67c417ce-1538-4758-906b-d272d2d8f631" xlink:to="loc_us-gaap_InterestRateSwapMember_ee4822cd-cb51-49d1-b113-5b0d9175fd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_909e0b8b-3707-437d-9865-360cc61c9eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_909e0b8b-3707-437d-9865-360cc61c9eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e9a8182c-589f-4a30-9df5-f46e0b50c8e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_909e0b8b-3707-437d-9865-360cc61c9eed" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e9a8182c-589f-4a30-9df5-f46e0b50c8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_f51e0b29-d0a8-40cf-9b59-f79e4dfe6cfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e9a8182c-589f-4a30-9df5-f46e0b50c8e4" xlink:to="loc_us-gaap_InterestExpenseMember_f51e0b29-d0a8-40cf-9b59-f79e4dfe6cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_379f731f-b012-4344-bb8e-ae301589775a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2162ead4-c766-4af3-9c6d-2bf396075e71" xlink:to="loc_us-gaap_DerivativeLineItems_379f731f-b012-4344-bb8e-ae301589775a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_54d9e69e-b42c-422f-8cd4-d729082d0458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_379f731f-b012-4344-bb8e-ae301589775a" xlink:to="loc_us-gaap_DerivativeNotionalAmount_54d9e69e-b42c-422f-8cd4-d729082d0458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_5f0ab66b-91fe-4cdd-9f84-2f7bb4adef51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_379f731f-b012-4344-bb8e-ae301589775a" xlink:to="loc_us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_5f0ab66b-91fe-4cdd-9f84-2f7bb4adef51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_1c98b98b-3c26-49ec-9325-9a25e43cad4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_379f731f-b012-4344-bb8e-ae301589775a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_1c98b98b-3c26-49ec-9325-9a25e43cad4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_19f5abdf-25f6-4cb9-82f0-226eb3f8eb3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_379f731f-b012-4344-bb8e-ae301589775a" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_19f5abdf-25f6-4cb9-82f0-226eb3f8eb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8a082d2f-2ba7-465d-83d9-a74799bd1552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_703c8d09-cebf-4eb5-9d4e-77219d0af3c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8a082d2f-2ba7-465d-83d9-a74799bd1552" xlink:to="loc_us-gaap_DerivativeTable_703c8d09-cebf-4eb5-9d4e-77219d0af3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f562554e-7feb-4742-8307-ee8d6b49a70e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_703c8d09-cebf-4eb5-9d4e-77219d0af3c3" xlink:to="loc_us-gaap_HedgingDesignationAxis_f562554e-7feb-4742-8307-ee8d6b49a70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1ea3f0d5-641d-4136-8af7-d84d33410bb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_f562554e-7feb-4742-8307-ee8d6b49a70e" xlink:to="loc_us-gaap_HedgingDesignationDomain_1ea3f0d5-641d-4136-8af7-d84d33410bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a97b8a50-7c5d-4bf2-8477-01720a941939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1ea3f0d5-641d-4136-8af7-d84d33410bb7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a97b8a50-7c5d-4bf2-8477-01720a941939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_bc4d941e-f7cb-4540-a2fa-dee1a5e89775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1ea3f0d5-641d-4136-8af7-d84d33410bb7" xlink:to="loc_us-gaap_NondesignatedMember_bc4d941e-f7cb-4540-a2fa-dee1a5e89775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_291e8f69-9f86-4dee-97d9-9878e56ce998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_703c8d09-cebf-4eb5-9d4e-77219d0af3c3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_291e8f69-9f86-4dee-97d9-9878e56ce998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5d57f556-0188-4036-b707-dc9cd3467cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_291e8f69-9f86-4dee-97d9-9878e56ce998" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5d57f556-0188-4036-b707-dc9cd3467cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AccruedExpensesandOtherCurrentLiabilitiesMember_58cb8e84-36ec-4151-83e9-e0ab54a1482a" xlink:href="bios-20201231.xsd#bios_AccruedExpensesandOtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5d57f556-0188-4036-b707-dc9cd3467cc7" xlink:to="loc_bios_AccruedExpensesandOtherCurrentLiabilitiesMember_58cb8e84-36ec-4151-83e9-e0ab54a1482a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a6da8b00-9c7d-4beb-af97-0c6471c8dfdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5d57f556-0188-4036-b707-dc9cd3467cc7" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a6da8b00-9c7d-4beb-af97-0c6471c8dfdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_466e0338-aa6c-4975-a088-74e953f52d5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_703c8d09-cebf-4eb5-9d4e-77219d0af3c3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_466e0338-aa6c-4975-a088-74e953f52d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_479dc1e7-c06c-4ceb-af21-40fbac9ab35d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_466e0338-aa6c-4975-a088-74e953f52d5c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_479dc1e7-c06c-4ceb-af21-40fbac9ab35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_c0b62377-78ef-4579-9afa-14c6ad12d86b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_479dc1e7-c06c-4ceb-af21-40fbac9ab35d" xlink:to="loc_us-gaap_InterestRateSwapMember_c0b62377-78ef-4579-9afa-14c6ad12d86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_0c94e690-777b-4628-b737-0f3deb004054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_703c8d09-cebf-4eb5-9d4e-77219d0af3c3" xlink:to="loc_us-gaap_DerivativeLineItems_0c94e690-777b-4628-b737-0f3deb004054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract_d437154d-684f-422a-941b-bd21eeaa65ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0c94e690-777b-4628-b737-0f3deb004054" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract_d437154d-684f-422a-941b-bd21eeaa65ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_2cac656d-6366-417b-acff-d4d81e637118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract_d437154d-684f-422a-941b-bd21eeaa65ae" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_2cac656d-6366-417b-acff-d4d81e637118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_f242bb36-6570-4f6a-9eae-a90329fed606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract_d437154d-684f-422a-941b-bd21eeaa65ae" xlink:to="loc_us-gaap_DerivativeLiabilities_f242bb36-6570-4f6a-9eae-a90329fed606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a995c37d-18c1-4c33-9524-b8440cf98eee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_dc1d631e-83ae-4429-9aec-ed26855f3ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a995c37d-18c1-4c33-9524-b8440cf98eee" xlink:to="loc_us-gaap_DerivativeTable_dc1d631e-83ae-4429-9aec-ed26855f3ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0f4327ba-6ab3-4916-9e04-206d0b967853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dc1d631e-83ae-4429-9aec-ed26855f3ccc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0f4327ba-6ab3-4916-9e04-206d0b967853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d5fe3492-b30e-4196-85ce-45a0b923c105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0f4327ba-6ab3-4916-9e04-206d0b967853" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d5fe3492-b30e-4196-85ce-45a0b923c105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_3db90c3f-ce0c-4c70-9923-af1f09977ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d5fe3492-b30e-4196-85ce-45a0b923c105" xlink:to="loc_us-gaap_InterestExpenseMember_3db90c3f-ce0c-4c70-9923-af1f09977ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_899687f1-7b77-45f3-ad33-33779d41b156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dc1d631e-83ae-4429-9aec-ed26855f3ccc" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_899687f1-7b77-45f3-ad33-33779d41b156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2f9a7124-0b1c-4ffc-aa5e-88d5f8878213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_899687f1-7b77-45f3-ad33-33779d41b156" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2f9a7124-0b1c-4ffc-aa5e-88d5f8878213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_549e5031-6870-46f3-b1a1-f1cc0bd57578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateCapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f9a7124-0b1c-4ffc-aa5e-88d5f8878213" xlink:to="loc_us-gaap_InterestRateCapMember_549e5031-6870-46f3-b1a1-f1cc0bd57578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_ae3155c5-f40d-43d2-a707-82bb4c55a65b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f9a7124-0b1c-4ffc-aa5e-88d5f8878213" xlink:to="loc_us-gaap_InterestRateSwapMember_ae3155c5-f40d-43d2-a707-82bb4c55a65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_b179a496-d155-479e-b468-aacecb428a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dc1d631e-83ae-4429-9aec-ed26855f3ccc" xlink:to="loc_us-gaap_DerivativeLineItems_b179a496-d155-479e-b468-aacecb428a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_a08ffe94-a2a1-4c1b-b257-fa20b1a796dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b179a496-d155-479e-b468-aacecb428a68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_a08ffe94-a2a1-4c1b-b257-fa20b1a796dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax_0c6d42f1-74cf-4aff-8bbb-90e7e431654e" xlink:href="bios-20201231.xsd#bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b179a496-d155-479e-b468-aacecb428a68" xlink:to="loc_bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax_0c6d42f1-74cf-4aff-8bbb-90e7e431654e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_3cddcc11-6493-45e2-b458-03f02d262d04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b179a496-d155-479e-b468-aacecb428a68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_3cddcc11-6493-45e2-b458-03f02d262d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_da506004-ce1a-4374-8cda-444b7df0e84d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b179a496-d155-479e-b468-aacecb428a68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_da506004-ce1a-4374-8cda-444b7df0e84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_959ac9f8-0a97-4246-9987-4a442f1f1e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b179a496-d155-479e-b468-aacecb428a68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_959ac9f8-0a97-4246-9987-4a442f1f1e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_6041228d-38ab-4f5d-bea6-dbd427c4585c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b179a496-d155-479e-b468-aacecb428a68" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_6041228d-38ab-4f5d-bea6-dbd427c4585c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS" xlink:type="simple" xlink:href="bios-20201231.xsd#FAIRVALUEMEASURMENTS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2f23f94f-49e6-4d58-b74d-46fcc58b3b7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_87ccd51b-336d-4cf2-8270-945c4cc7fc6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2f23f94f-49e6-4d58-b74d-46fcc58b3b7b" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_87ccd51b-336d-4cf2-8270-945c4cc7fc6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="bios-20201231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_313a7817-7c29-4349-b9a8-b03a6b45ee6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1d2cde5d-d88c-4515-ac14-9869c1b5209f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_313a7817-7c29-4349-b9a8-b03a6b45ee6d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1d2cde5d-d88c-4515-ac14-9869c1b5209f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ae45c1d2-e935-4dfb-9d7e-856bcb5a370b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_063b835f-bdca-48eb-a964-283829ccd68b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ae45c1d2-e935-4dfb-9d7e-856bcb5a370b" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_063b835f-bdca-48eb-a964-283829ccd68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_122370df-701e-42c8-b239-feecc78fee91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f5afdf7d-8e09-4dfd-8ac4-a64ffcac91c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_122370df-701e-42c8-b239-feecc78fee91" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f5afdf7d-8e09-4dfd-8ac4-a64ffcac91c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3bdf38b3-62b6-447b-a6fd-b36b0ef0312a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_122370df-701e-42c8-b239-feecc78fee91" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3bdf38b3-62b6-447b-a6fd-b36b0ef0312a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_923c8a0d-da45-4628-9706-d8b03089ca6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_122370df-701e-42c8-b239-feecc78fee91" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_923c8a0d-da45-4628-9706-d8b03089ca6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_50c80791-2d88-409d-b5f5-02a6bd4406f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_122370df-701e-42c8-b239-feecc78fee91" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_50c80791-2d88-409d-b5f5-02a6bd4406f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7c2066d8-742b-4162-a643-ca6621ad7679" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_acec6211-86ad-47f2-8ecd-73192b3fb2da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7c2066d8-742b-4162-a643-ca6621ad7679" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_acec6211-86ad-47f2-8ecd-73192b3fb2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_803690df-e496-4181-980f-e0330e2bc6fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_acec6211-86ad-47f2-8ecd-73192b3fb2da" xlink:to="loc_srt_TitleOfIndividualAxis_803690df-e496-4181-980f-e0330e2bc6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e5f2e0e6-9790-4600-a5a8-6f92cb3cdb1a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_803690df-e496-4181-980f-e0330e2bc6fb" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e5f2e0e6-9790-4600-a5a8-6f92cb3cdb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_85fbaad7-0a6b-413f-9976-e82aceddd484" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e5f2e0e6-9790-4600-a5a8-6f92cb3cdb1a" xlink:to="loc_srt_DirectorMember_85fbaad7-0a6b-413f-9976-e82aceddd484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f2f8b79b-c60d-40de-9c2f-e048720b51c6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_acec6211-86ad-47f2-8ecd-73192b3fb2da" xlink:to="loc_srt_RangeAxis_f2f8b79b-c60d-40de-9c2f-e048720b51c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_78ef74ce-8cee-45cb-a257-4bc7ef124aaf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f2f8b79b-c60d-40de-9c2f-e048720b51c6" xlink:to="loc_srt_RangeMember_78ef74ce-8cee-45cb-a257-4bc7ef124aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b3c924ca-f48c-4c02-8dc7-860ee66be996" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_78ef74ce-8cee-45cb-a257-4bc7ef124aaf" xlink:to="loc_srt_MinimumMember_b3c924ca-f48c-4c02-8dc7-860ee66be996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_eacd5c37-4a49-4d17-b3f9-ec068f2cac1d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_78ef74ce-8cee-45cb-a257-4bc7ef124aaf" xlink:to="loc_srt_MaximumMember_eacd5c37-4a49-4d17-b3f9-ec068f2cac1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cf4f222c-3946-44ec-a11f-8769bce6011e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_acec6211-86ad-47f2-8ecd-73192b3fb2da" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cf4f222c-3946-44ec-a11f-8769bce6011e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_344c9125-0abf-4542-a0b4-99521f75bb7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cf4f222c-3946-44ec-a11f-8769bce6011e" xlink:to="loc_us-gaap_EquityComponentDomain_344c9125-0abf-4542-a0b4-99521f75bb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_bd1a15b1-c5a5-48e1-a6b2-a273a887e467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_344c9125-0abf-4542-a0b4-99521f75bb7f" xlink:to="loc_us-gaap_TreasuryStockMember_bd1a15b1-c5a5-48e1-a6b2-a273a887e467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_de2ea485-397e-40fc-aad7-c6200596fb22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_acec6211-86ad-47f2-8ecd-73192b3fb2da" xlink:to="loc_us-gaap_PlanNameAxis_de2ea485-397e-40fc-aad7-c6200596fb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2299a532-d531-4a74-9c85-abb5a989ba3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_de2ea485-397e-40fc-aad7-c6200596fb22" xlink:to="loc_us-gaap_PlanNameDomain_2299a532-d531-4a74-9c85-abb5a989ba3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2018PlanMember_22844e5a-66c5-4c35-b9ee-f86fd6aee595" xlink:href="bios-20201231.xsd#bios_A2018PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2299a532-d531-4a74-9c85-abb5a989ba3a" xlink:to="loc_bios_A2018PlanMember_22844e5a-66c5-4c35-b9ee-f86fd6aee595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e5158f44-5da1-4b4e-9ae2-5558c16ba8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_acec6211-86ad-47f2-8ecd-73192b3fb2da" xlink:to="loc_us-gaap_AwardTypeAxis_e5158f44-5da1-4b4e-9ae2-5558c16ba8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09caff95-9682-4af0-99ca-b741d8ffcce8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e5158f44-5da1-4b4e-9ae2-5558c16ba8fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09caff95-9682-4af0-99ca-b741d8ffcce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_93f97ba8-5438-432d-97ec-bdb34c0b293a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09caff95-9682-4af0-99ca-b741d8ffcce8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_93f97ba8-5438-432d-97ec-bdb34c0b293a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_4e4b7507-c792-4fc9-b868-faf2bc0ba2d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09caff95-9682-4af0-99ca-b741d8ffcce8" xlink:to="loc_us-gaap_RestrictedStockMember_4e4b7507-c792-4fc9-b868-faf2bc0ba2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HCIIncentiveUnitsMember_0c93d7e2-f370-4491-8cf3-97c186255d72" xlink:href="bios-20201231.xsd#bios_HCIIncentiveUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09caff95-9682-4af0-99ca-b741d8ffcce8" xlink:to="loc_bios_HCIIncentiveUnitsMember_0c93d7e2-f370-4491-8cf3-97c186255d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_acec6211-86ad-47f2-8ecd-73192b3fb2da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_542a9d7f-9585-481d-a80c-cd53b1a8b52e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_542a9d7f-9585-481d-a80c-cd53b1a8b52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_78ab10f4-8776-4635-95d0-08d094510f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_78ab10f4-8776-4635-95d0-08d094510f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_0c4347b8-6362-4368-8bfb-061af0169243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_0c4347b8-6362-4368-8bfb-061af0169243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d259c632-04fe-4db8-864f-8a73efaffdb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d259c632-04fe-4db8-864f-8a73efaffdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d1cedbf-2c4b-4f48-9757-5faa4dbb3b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d1cedbf-2c4b-4f48-9757-5faa4dbb3b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30755f1f-714a-4c6e-8757-071f907ac5f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30755f1f-714a-4c6e-8757-071f907ac5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_bb2586a6-6649-413e-bbb1-df959ac1b496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_bb2586a6-6649-413e-bbb1-df959ac1b496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_31cb5da6-c66a-4373-84ff-ed4bebb26ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_31cb5da6-c66a-4373-84ff-ed4bebb26ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b2467e66-3879-44ef-99f3-963619e63cae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b2467e66-3879-44ef-99f3-963619e63cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a17f656f-c8ed-4c98-8cab-4e96258cf308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a17f656f-c8ed-4c98-8cab-4e96258cf308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_14ec6a2b-e38f-4786-a57f-b659ee7b2c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dacf3c7f-b655-4a3e-bff3-be64130f8efe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_14ec6a2b-e38f-4786-a57f-b659ee7b2c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_bfcda557-382b-4e1b-823e-337ef5812ad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f693323a-3137-47c5-9717-3606dd77b165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_bfcda557-382b-4e1b-823e-337ef5812ad5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f693323a-3137-47c5-9717-3606dd77b165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e18bc7d8-85d3-4be7-9ee5-173b1157c10a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f693323a-3137-47c5-9717-3606dd77b165" xlink:to="loc_us-gaap_AwardTypeAxis_e18bc7d8-85d3-4be7-9ee5-173b1157c10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70297449-a908-4f51-b501-7112b04864ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e18bc7d8-85d3-4be7-9ee5-173b1157c10a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70297449-a908-4f51-b501-7112b04864ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a4ba8104-721d-40f7-bce3-24395380e6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70297449-a908-4f51-b501-7112b04864ac" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a4ba8104-721d-40f7-bce3-24395380e6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4b36e9d-c9c4-4bbd-9b6c-57ea5765970b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f693323a-3137-47c5-9717-3606dd77b165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4b36e9d-c9c4-4bbd-9b6c-57ea5765970b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ee782460-9860-495f-a77e-f763d09baf4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4b36e9d-c9c4-4bbd-9b6c-57ea5765970b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ee782460-9860-495f-a77e-f763d09baf4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0b41db5d-f0f5-46a2-a335-e2b304987044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4b36e9d-c9c4-4bbd-9b6c-57ea5765970b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0b41db5d-f0f5-46a2-a335-e2b304987044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_38ade6fe-1087-4f4a-b8a3-caee23426e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4b36e9d-c9c4-4bbd-9b6c-57ea5765970b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_38ade6fe-1087-4f4a-b8a3-caee23426e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9a641d1d-d37b-4978-9ec2-6a77a2394bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4b36e9d-c9c4-4bbd-9b6c-57ea5765970b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9a641d1d-d37b-4978-9ec2-6a77a2394bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1249c1aa-158d-43b3-bc93-93db7c71c8b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea3c5dba-da58-4b44-bc06-43d3267109de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1249c1aa-158d-43b3-bc93-93db7c71c8b7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea3c5dba-da58-4b44-bc06-43d3267109de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_604226c1-0ada-4126-9b9c-4738ad1619e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea3c5dba-da58-4b44-bc06-43d3267109de" xlink:to="loc_us-gaap_AwardTypeAxis_604226c1-0ada-4126-9b9c-4738ad1619e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5af62565-32fe-454b-8d06-ef7113cb0fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_604226c1-0ada-4126-9b9c-4738ad1619e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5af62565-32fe-454b-8d06-ef7113cb0fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_566ff87d-469d-409d-b6dc-95b2752e8317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5af62565-32fe-454b-8d06-ef7113cb0fb3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_566ff87d-469d-409d-b6dc-95b2752e8317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea3c5dba-da58-4b44-bc06-43d3267109de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4a73fab1-70fd-410a-90c2-33bf43b81fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4a73fab1-70fd-410a-90c2-33bf43b81fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6306eabd-d8f5-485a-837b-ebcb80b43fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4a73fab1-70fd-410a-90c2-33bf43b81fe7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6306eabd-d8f5-485a-837b-ebcb80b43fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e010d2e7-2943-4917-b05f-7244f8c36353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4a73fab1-70fd-410a-90c2-33bf43b81fe7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e010d2e7-2943-4917-b05f-7244f8c36353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_99b493bc-eeb7-42d9-a6c9-27cd7e577c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4a73fab1-70fd-410a-90c2-33bf43b81fe7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_99b493bc-eeb7-42d9-a6c9-27cd7e577c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_7f13c1dd-d669-47df-b025-3e3e49bbb25d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4a73fab1-70fd-410a-90c2-33bf43b81fe7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_7f13c1dd-d669-47df-b025-3e3e49bbb25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_059d270f-6cd4-4850-ab70-5a7114a54e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4a73fab1-70fd-410a-90c2-33bf43b81fe7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_059d270f-6cd4-4850-ab70-5a7114a54e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_62ab23c6-92c3-44b3-9e3d-f7b3c6a1486f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_62ab23c6-92c3-44b3-9e3d-f7b3c6a1486f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2364de45-0ee9-478f-9fc7-a98492492501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2364de45-0ee9-478f-9fc7-a98492492501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8443d622-c427-42ce-961f-d847a43fe28a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2364de45-0ee9-478f-9fc7-a98492492501" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8443d622-c427-42ce-961f-d847a43fe28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f5ef5061-2962-4ed7-80b6-e15ea629f182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2364de45-0ee9-478f-9fc7-a98492492501" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f5ef5061-2962-4ed7-80b6-e15ea629f182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a03c6102-84e4-419d-b793-0473ee6b6e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2364de45-0ee9-478f-9fc7-a98492492501" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a03c6102-84e4-419d-b793-0473ee6b6e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_8fb950b8-97cc-4668-a813-53236a21b7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2364de45-0ee9-478f-9fc7-a98492492501" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_8fb950b8-97cc-4668-a813-53236a21b7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d668f3fc-a131-4079-94bd-2428d9e41841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2364de45-0ee9-478f-9fc7-a98492492501" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d668f3fc-a131-4079-94bd-2428d9e41841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c2afa470-f1fb-4161-97af-153e0d3b3d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c2afa470-f1fb-4161-97af-153e0d3b3d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AggregateIntrinsicValueAbstract_48d98286-2345-4246-8de9-4bd89ae24a30" xlink:href="bios-20201231.xsd#bios_AggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:to="loc_bios_AggregateIntrinsicValueAbstract_48d98286-2345-4246-8de9-4bd89ae24a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c47da61c-258d-4f00-ac85-4ad2d15ef199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_AggregateIntrinsicValueAbstract_48d98286-2345-4246-8de9-4bd89ae24a30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c47da61c-258d-4f00-ac85-4ad2d15ef199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue_9221d1a5-2b2d-4a20-884a-69be79fec83a" xlink:href="bios-20201231.xsd#bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_AggregateIntrinsicValueAbstract_48d98286-2345-4246-8de9-4bd89ae24a30" xlink:to="loc_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue_9221d1a5-2b2d-4a20-884a-69be79fec83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_08eb55b0-96c6-4b35-ba53-79bc2beb39bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_AggregateIntrinsicValueAbstract_48d98286-2345-4246-8de9-4bd89ae24a30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_08eb55b0-96c6-4b35-ba53-79bc2beb39bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue_701cee09-eeec-4101-ba49-57ee034042f0" xlink:href="bios-20201231.xsd#bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_AggregateIntrinsicValueAbstract_48d98286-2345-4246-8de9-4bd89ae24a30" xlink:to="loc_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue_701cee09-eeec-4101-ba49-57ee034042f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_da4e0601-bab0-4727-b7be-ecab0951bf4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_AggregateIntrinsicValueAbstract_48d98286-2345-4246-8de9-4bd89ae24a30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_da4e0601-bab0-4727-b7be-ecab0951bf4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c8e7527e-4a82-4da4-8b28-7979f96c4490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c8e7527e-4a82-4da4-8b28-7979f96c4490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b30ae52c-4a56-495d-8ad3-02fe5fa55113" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b30ae52c-4a56-495d-8ad3-02fe5fa55113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_87ada89b-b593-419c-b430-2133642491a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b330fa86-d9fc-4742-a83b-4e77c87824dc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_87ada89b-b593-419c-b430-2133642491a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71690e85-ffaa-440a-adfb-840ce3cd160d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_995488a1-2e53-4944-969a-b83001e28051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71690e85-ffaa-440a-adfb-840ce3cd160d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_995488a1-2e53-4944-969a-b83001e28051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e3f5d401-742d-472d-9d91-aefa440d76e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_995488a1-2e53-4944-969a-b83001e28051" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e3f5d401-742d-472d-9d91-aefa440d76e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e3f5d401-742d-472d-9d91-aefa440d76e3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeOneMember_229a08a3-d03f-4e2e-9985-732b4c3d816d" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeOneMember_229a08a3-d03f-4e2e-9985-732b4c3d816d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeTwoMember_09713568-f9b0-42d1-bb56-8ae19ff5face" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeTwoMember_09713568-f9b0-42d1-bb56-8ae19ff5face" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeThreeMember_1fb87617-4c06-41a1-8e69-f81914344528" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeThreeMember_1fb87617-4c06-41a1-8e69-f81914344528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeFourMember_2fd39869-024d-4d1b-aada-4ec32fd5d6fb" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeFourMember_2fd39869-024d-4d1b-aada-4ec32fd5d6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeFiveMember_139c345d-34fc-451b-9b8a-9bae373f3631" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeFiveMember_139c345d-34fc-451b-9b8a-9bae373f3631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeSixMember_1addb3d1-a4ea-418f-a98c-97b8798e5957" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeSixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeSixMember_1addb3d1-a4ea-418f-a98c-97b8798e5957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeSevenMember_bd033708-fc1d-43d4-b03f-4feb9cea5df8" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeSevenMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeSevenMember_bd033708-fc1d-43d4-b03f-4feb9cea5df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeEightMember_e0eb045c-9b42-42ee-9924-03d5dd9c196c" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeEightMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeEightMember_e0eb045c-9b42-42ee-9924-03d5dd9c196c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionExercisePriceRangeNineMember_ccf03741-6cd7-49b2-a216-0630f93fa53c" xlink:href="bios-20201231.xsd#bios_OptionExercisePriceRangeNineMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_86b899de-2ed9-43e6-840a-d332b23f6aec" xlink:to="loc_bios_OptionExercisePriceRangeNineMember_ccf03741-6cd7-49b2-a216-0630f93fa53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3077bcca-0e55-489f-9f0d-2b2497a4855f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_995488a1-2e53-4944-969a-b83001e28051" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3077bcca-0e55-489f-9f0d-2b2497a4855f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_e6663132-d418-4137-a824-f71eca225064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3077bcca-0e55-489f-9f0d-2b2497a4855f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_e6663132-d418-4137-a824-f71eca225064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_38c7a2e8-69b5-4e1c-a2fd-3064e8b68599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3077bcca-0e55-489f-9f0d-2b2497a4855f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_38c7a2e8-69b5-4e1c-a2fd-3064e8b68599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionsOutstandingAbstract_724d81e4-cde7-416f-a597-86ce8e6219a5" xlink:href="bios-20201231.xsd#bios_OptionsOutstandingAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3077bcca-0e55-489f-9f0d-2b2497a4855f" xlink:to="loc_bios_OptionsOutstandingAbstract_724d81e4-cde7-416f-a597-86ce8e6219a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_747f70c3-6a48-4874-877f-b78dd4a0150d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_OptionsOutstandingAbstract_724d81e4-cde7-416f-a597-86ce8e6219a5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_747f70c3-6a48-4874-877f-b78dd4a0150d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_72eae7f7-c159-4c07-afd0-5c957a4e41b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_OptionsOutstandingAbstract_724d81e4-cde7-416f-a597-86ce8e6219a5" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_72eae7f7-c159-4c07-afd0-5c957a4e41b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_ab141791-cfde-45d7-b5c1-621c5670cc82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_OptionsOutstandingAbstract_724d81e4-cde7-416f-a597-86ce8e6219a5" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_ab141791-cfde-45d7-b5c1-621c5670cc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionsExercisableAbstract_1fd827e2-234d-406d-aff0-7e7b4fdffb5a" xlink:href="bios-20201231.xsd#bios_OptionsExercisableAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3077bcca-0e55-489f-9f0d-2b2497a4855f" xlink:to="loc_bios_OptionsExercisableAbstract_1fd827e2-234d-406d-aff0-7e7b4fdffb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_e8425df4-d51a-43f1-a2bb-e643253ed2f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_OptionsExercisableAbstract_1fd827e2-234d-406d-aff0-7e7b4fdffb5a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_e8425df4-d51a-43f1-a2bb-e643253ed2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_e7b1cf2b-e914-48e5-9a7e-cca969ec7a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bios_OptionsExercisableAbstract_1fd827e2-234d-406d-aff0-7e7b4fdffb5a" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_e7b1cf2b-e914-48e5-9a7e-cca969ec7a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d07425dc-3ad1-42a4-a8ac-07dacef083e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60eb4c49-c0c5-4269-ba03-6797ce4efca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d07425dc-3ad1-42a4-a8ac-07dacef083e6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60eb4c49-c0c5-4269-ba03-6797ce4efca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1346cfdc-1fe6-4c8f-b4a8-81257f86ebed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60eb4c49-c0c5-4269-ba03-6797ce4efca3" xlink:to="loc_us-gaap_AwardTypeAxis_1346cfdc-1fe6-4c8f-b4a8-81257f86ebed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa7e6fd6-05be-4dd8-a278-9c3404310f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1346cfdc-1fe6-4c8f-b4a8-81257f86ebed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa7e6fd6-05be-4dd8-a278-9c3404310f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_891a385b-ab79-4ef6-969a-2b4b2cd43c83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa7e6fd6-05be-4dd8-a278-9c3404310f2d" xlink:to="loc_us-gaap_RestrictedStockMember_891a385b-ab79-4ef6-969a-2b4b2cd43c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da96c022-90d2-4155-9ceb-1986a75ec138" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60eb4c49-c0c5-4269-ba03-6797ce4efca3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da96c022-90d2-4155-9ceb-1986a75ec138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eacca8eb-a5ed-4586-9f45-48998e22db30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da96c022-90d2-4155-9ceb-1986a75ec138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eacca8eb-a5ed-4586-9f45-48998e22db30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07dca9b6-dacf-4ba3-a4f9-8e0083f3fd9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eacca8eb-a5ed-4586-9f45-48998e22db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07dca9b6-dacf-4ba3-a4f9-8e0083f3fd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0d405f98-104e-40fe-afe5-e3ac053aaa5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eacca8eb-a5ed-4586-9f45-48998e22db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0d405f98-104e-40fe-afe5-e3ac053aaa5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6c239143-52a9-460a-9075-6558a189abb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eacca8eb-a5ed-4586-9f45-48998e22db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6c239143-52a9-460a-9075-6558a189abb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_21dcd536-5704-484a-860e-4321753b4a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eacca8eb-a5ed-4586-9f45-48998e22db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_21dcd536-5704-484a-860e-4321753b4a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d5308f0-d586-46c2-9883-49791b92364c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eacca8eb-a5ed-4586-9f45-48998e22db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d5308f0-d586-46c2-9883-49791b92364c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_af9ffe75-1ca8-4bf2-9ed1-fc6f193b116e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da96c022-90d2-4155-9ceb-1986a75ec138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_af9ffe75-1ca8-4bf2-9ed1-fc6f193b116e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_675ff383-25ab-48de-a16d-a1dde6529ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_af9ffe75-1ca8-4bf2-9ed1-fc6f193b116e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_675ff383-25ab-48de-a16d-a1dde6529ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ab0cf0fa-90e4-47bb-b60c-80b7337c8381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_af9ffe75-1ca8-4bf2-9ed1-fc6f193b116e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ab0cf0fa-90e4-47bb-b60c-80b7337c8381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_879f511b-1df0-466c-b6d0-4b833286aef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_af9ffe75-1ca8-4bf2-9ed1-fc6f193b116e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_879f511b-1df0-466c-b6d0-4b833286aef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6e1aba4a-feae-48d6-8984-3af7bacbfd67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_af9ffe75-1ca8-4bf2-9ed1-fc6f193b116e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6e1aba4a-feae-48d6-8984-3af7bacbfd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b76e5933-5c35-4abe-bc3d-4ce95b5931f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_af9ffe75-1ca8-4bf2-9ed1-fc6f193b116e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b76e5933-5c35-4abe-bc3d-4ce95b5931f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6da44e3-f356-49e3-b011-6138dd522c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0df72c4d-0480-4b88-a2da-682f0e921069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6da44e3-f356-49e3-b011-6138dd522c90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0df72c4d-0480-4b88-a2da-682f0e921069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_128fc4f1-9787-4512-8597-2114d0d0641c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6da44e3-f356-49e3-b011-6138dd522c90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_128fc4f1-9787-4512-8597-2114d0d0641c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_38c3f40a-e33b-431b-9ac8-1848cc0a26e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6da44e3-f356-49e3-b011-6138dd522c90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_38c3f40a-e33b-431b-9ac8-1848cc0a26e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_28442b22-968d-4b5e-8821-eb3658b42a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6da44e3-f356-49e3-b011-6138dd522c90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_28442b22-968d-4b5e-8821-eb3658b42a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a13b942e-5aaf-4351-a63e-b23a16eb290f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6da44e3-f356-49e3-b011-6138dd522c90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a13b942e-5aaf-4351-a63e-b23a16eb290f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_375881d1-03fe-427f-a452-b6d9bee2cf60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c19b0d11-2046-4651-9be9-0eda11521e98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_375881d1-03fe-427f-a452-b6d9bee2cf60" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c19b0d11-2046-4651-9be9-0eda11521e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9a8cc530-df19-43e7-9b67-82fc71502b8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a8cc530-df19-43e7-9b67-82fc71502b8a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_98c31098-e1c0-4bb9-89e7-f8a4bab6b1f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_VestingAxis_98c31098-e1c0-4bb9-89e7-f8a4bab6b1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_2f1fb94a-ad83-45dd-b956-83a1b91900bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_98c31098-e1c0-4bb9-89e7-f8a4bab6b1f3" xlink:to="loc_us-gaap_VestingDomain_2f1fb94a-ad83-45dd-b956-83a1b91900bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a7caee0b-98c9-4c8a-8485-869ee28d88ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2f1fb94a-ad83-45dd-b956-83a1b91900bf" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a7caee0b-98c9-4c8a-8485-869ee28d88ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_f0edcc78-6a74-4d22-8f84-789c287ea08f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2f1fb94a-ad83-45dd-b956-83a1b91900bf" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_f0edcc78-6a74-4d22-8f84-789c287ea08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c6d2d07c-791c-4335-af44-c9b32ae7472a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_AwardTypeAxis_c6d2d07c-791c-4335-af44-c9b32ae7472a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8b05bae-c968-46f5-8303-a87a541d0bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c6d2d07c-791c-4335-af44-c9b32ae7472a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8b05bae-c968-46f5-8303-a87a541d0bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7c5ac67f-6040-4975-888c-0ff2d7661585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8b05bae-c968-46f5-8303-a87a541d0bd1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7c5ac67f-6040-4975-888c-0ff2d7661585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_RestrictedStockAndStockOptionsMember_3cc9bc46-0268-47ad-9bb8-878718af2c6a" xlink:href="bios-20201231.xsd#bios_RestrictedStockAndStockOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8b05bae-c968-46f5-8303-a87a541d0bd1" xlink:to="loc_bios_RestrictedStockAndStockOptionsMember_3cc9bc46-0268-47ad-9bb8-878718af2c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_30f747d7-9db3-4680-b917-e494cc0c0406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_30f747d7-9db3-4680-b917-e494cc0c0406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e2e89fba-ac1a-4322-9cce-d8725ca4d073" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_30f747d7-9db3-4680-b917-e494cc0c0406" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e2e89fba-ac1a-4322-9cce-d8725ca4d073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HomeSolutionsMember_c77d697d-6caf-4b89-9ace-3f9841901e72" xlink:href="bios-20201231.xsd#bios_HomeSolutionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e2e89fba-ac1a-4322-9cce-d8725ca4d073" xlink:to="loc_bios_HomeSolutionsMember_c77d697d-6caf-4b89-9ace-3f9841901e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionCareEnterprisesInc.Member_963a901e-c634-49a1-85f0-62e4cbf20c2f" xlink:href="bios-20201231.xsd#bios_OptionCareEnterprisesInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e2e89fba-ac1a-4322-9cce-d8725ca4d073" xlink:to="loc_bios_OptionCareEnterprisesInc.Member_963a901e-c634-49a1-85f0-62e4cbf20c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b0f38b13-0fc9-497b-b174-7c5f66c80389" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_srt_RangeAxis_b0f38b13-0fc9-497b-b174-7c5f66c80389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8c67e7b0-8c79-47dc-8b65-58e829eb20fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b0f38b13-0fc9-497b-b174-7c5f66c80389" xlink:to="loc_srt_RangeMember_8c67e7b0-8c79-47dc-8b65-58e829eb20fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_25e01759-465f-4210-9822-2af0f66b34b1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8c67e7b0-8c79-47dc-8b65-58e829eb20fe" xlink:to="loc_srt_MinimumMember_25e01759-465f-4210-9822-2af0f66b34b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d536702c-afa1-4263-871c-f75dfe3f099e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8c67e7b0-8c79-47dc-8b65-58e829eb20fe" xlink:to="loc_srt_MaximumMember_d536702c-afa1-4263-871c-f75dfe3f099e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9165ad3a-ac98-4180-9a40-66261bfbda92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9165ad3a-ac98-4180-9a40-66261bfbda92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_74f8872c-f6ed-4d1e-9593-a5aca15bd3dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9165ad3a-ac98-4180-9a40-66261bfbda92" xlink:to="loc_us-gaap_EquityComponentDomain_74f8872c-f6ed-4d1e-9593-a5aca15bd3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_97e0f121-1809-40fa-97cc-40a609247ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_74f8872c-f6ed-4d1e-9593-a5aca15bd3dc" xlink:to="loc_us-gaap_CommonStockMember_97e0f121-1809-40fa-97cc-40a609247ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_212fcb99-33fc-4979-b4e6-02f807d52884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_74f8872c-f6ed-4d1e-9593-a5aca15bd3dc" xlink:to="loc_us-gaap_TreasuryStockMember_212fcb99-33fc-4979-b4e6-02f807d52884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_070216ad-d5f4-4130-9a3f-84066bb90fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_070216ad-d5f4-4130-9a3f-84066bb90fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1bb13725-356e-4638-9264-36419b2e24ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_070216ad-d5f4-4130-9a3f-84066bb90fbf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1bb13725-356e-4638-9264-36419b2e24ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2017WarrantsMember_86622268-e27e-4003-b7e0-b44cbf821f46" xlink:href="bios-20201231.xsd#bios_A2017WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1bb13725-356e-4638-9264-36419b2e24ec" xlink:to="loc_bios_A2017WarrantsMember_86622268-e27e-4003-b7e0-b44cbf821f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2015WarrantsMember_9ec09326-15ab-4574-be16-74b78592d575" xlink:href="bios-20201231.xsd#bios_A2015WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1bb13725-356e-4638-9264-36419b2e24ec" xlink:to="loc_bios_A2015WarrantsMember_9ec09326-15ab-4574-be16-74b78592d575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8887931c-181d-42ac-9fa8-e15254054bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8887931c-181d-42ac-9fa8-e15254054bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6e39acb5-92e1-47b9-89b4-76e46950a103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8887931c-181d-42ac-9fa8-e15254054bbf" xlink:to="loc_us-gaap_ClassOfStockDomain_6e39acb5-92e1-47b9-89b4-76e46950a103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_36c640d9-df59-41bd-8517-ad87d7dad277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6e39acb5-92e1-47b9-89b4-76e46950a103" xlink:to="loc_us-gaap_CommonStockMember_36c640d9-df59-41bd-8517-ad87d7dad277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8956a5b6-bd1a-4998-99cb-9d114046e099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8956a5b6-bd1a-4998-99cb-9d114046e099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f222fc9-7b75-4342-88be-f06d38bd9e84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8956a5b6-bd1a-4998-99cb-9d114046e099" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f222fc9-7b75-4342-88be-f06d38bd9e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PublicOfferingMember_194f69a5-04f6-4e33-9259-f431bb512e3b" xlink:href="bios-20201231.xsd#bios_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f222fc9-7b75-4342-88be-f06d38bd9e84" xlink:to="loc_bios_PublicOfferingMember_194f69a5-04f6-4e33-9259-f431bb512e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SecondaryOfferingMember_2e227648-da34-4043-b70f-551c1a366946" xlink:href="bios-20201231.xsd#bios_SecondaryOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f222fc9-7b75-4342-88be-f06d38bd9e84" xlink:to="loc_bios_SecondaryOfferingMember_2e227648-da34-4043-b70f-551c1a366946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b09ca1c6-e9c8-4c3f-bba1-c475bba01001" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_dei_LegalEntityAxis_b09ca1c6-e9c8-4c3f-bba1-c475bba01001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f8db92e7-48e3-4bf3-9504-72f9b1e0dea9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_b09ca1c6-e9c8-4c3f-bba1-c475bba01001" xlink:to="loc_dei_EntityDomain_f8db92e7-48e3-4bf3-9504-72f9b1e0dea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionCareHealthIncMember_47c28d3f-3a9f-48be-b59a-f282f28d5cae" xlink:href="bios-20201231.xsd#bios_OptionCareHealthIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f8db92e7-48e3-4bf3-9504-72f9b1e0dea9" xlink:to="loc_bios_OptionCareHealthIncMember_47c28d3f-3a9f-48be-b59a-f282f28d5cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HCGroupHoldingsILLCMember_7fa497ca-26aa-4ab5-bed4-f3a9e9731eb6" xlink:href="bios-20201231.xsd#bios_HCGroupHoldingsILLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f8db92e7-48e3-4bf3-9504-72f9b1e0dea9" xlink:to="loc_bios_HCGroupHoldingsILLCMember_7fa497ca-26aa-4ab5-bed4-f3a9e9731eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_992cd850-7da3-416c-b3d9-1e559a953125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_DebtInstrumentAxis_992cd850-7da3-416c-b3d9-1e559a953125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e9825035-7c6d-4733-8647-6339f1b63e05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_992cd850-7da3-416c-b3d9-1e559a953125" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e9825035-7c6d-4733-8647-6339f1b63e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditAgreementsEnteredInto2019Member_4baf65bf-f642-44eb-ae00-adedf8fe6966" xlink:href="bios-20201231.xsd#bios_CreditAgreementsEnteredInto2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9825035-7c6d-4733-8647-6339f1b63e05" xlink:to="loc_bios_CreditAgreementsEnteredInto2019Member_4baf65bf-f642-44eb-ae00-adedf8fe6966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fb48a632-5bc1-47dd-81c9-3f7ea1b36f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fb48a632-5bc1-47dd-81c9-3f7ea1b36f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0ced86f7-c561-45a1-b588-2535f09fdf44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fb48a632-5bc1-47dd-81c9-3f7ea1b36f5a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0ced86f7-c561-45a1-b588-2535f09fdf44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NotesPayableMember_81267153-7b89-453c-a18a-47368cb82fbe" xlink:href="bios-20201231.xsd#bios_NotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0ced86f7-c561-45a1-b588-2535f09fdf44" xlink:to="loc_bios_NotesPayableMember_81267153-7b89-453c-a18a-47368cb82fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f7cef2f6-6857-4278-9d44-bde0a3cd3519" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_57167188-77af-453b-80df-1ff502c81335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_57167188-77af-453b-80df-1ff502c81335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aee0ae78-bb02-4cb9-b49b-5f4e653ac385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aee0ae78-bb02-4cb9-b49b-5f4e653ac385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_81d3b04a-280e-47fc-9656-ce6f76e1680d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_81d3b04a-280e-47fc-9656-ce6f76e1680d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5e6dffb8-74b6-4be8-9dbb-1a9d0a6af5de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5e6dffb8-74b6-4be8-9dbb-1a9d0a6af5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CommonStockOutstandingPercentage_2a63128c-18a2-43c2-a187-10f1971a5d44" xlink:href="bios-20201231.xsd#bios_CommonStockOutstandingPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_bios_CommonStockOutstandingPercentage_2a63128c-18a2-43c2-a187-10f1971a5d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_98d6af3b-d612-4258-97b2-2ad2af62774c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_RepaymentsOfDebt_98d6af3b-d612-4258-97b2-2ad2af62774c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_20bcf2aa-bcda-49d7-af19-f63cd5b9ebb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_20bcf2aa-bcda-49d7-af19-f63cd5b9ebb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_800dcaa7-40f9-4aab-8eca-70c55694f013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_800dcaa7-40f9-4aab-8eca-70c55694f013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c39b53ab-c928-4a04-98c2-161a99e8761d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c39b53ab-c928-4a04-98c2-161a99e8761d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_d84fac46-1cad-46c4-9ccb-44b6b32b6bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_d84fac46-1cad-46c4-9ccb-44b6b32b6bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ClassofWarrantorRightSecuritiesExercised_48a6bbc1-bb78-436b-bc3b-ad04d977d1ba" xlink:href="bios-20201231.xsd#bios_ClassofWarrantorRightSecuritiesExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_bios_ClassofWarrantorRightSecuritiesExercised_48a6bbc1-bb78-436b-bc3b-ad04d977d1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5e664513-5347-4d43-b077-20cf25c930ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5e664513-5347-4d43-b077-20cf25c930ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_a06b8df9-e9d1-42ca-961a-7d824b7ee200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_a06b8df9-e9d1-42ca-961a-7d824b7ee200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_245c6253-0a81-4fe9-b0ce-6ccae632dd85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_SharePrice_245c6253-0a81-4fe9-b0ce-6ccae632dd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_95a30372-c5bc-43f7-b0d0-2a0132e0a568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_95a30372-c5bc-43f7-b0d0-2a0132e0a568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_22b733e4-5ed2-4c36-ba87-6419b6401fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_22b733e4-5ed2-4c36-ba87-6419b6401fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4662ea4f-d206-4c4a-bef3-3b031f9374cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4662ea4f-d206-4c4a-bef3-3b031f9374cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2b001289-54c7-48df-80a4-cd4eff7da8cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2b001289-54c7-48df-80a4-cd4eff7da8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_42d25d69-5ee5-4696-ad8f-c4869a5fc839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_TreasuryStockShares_42d25d69-5ee5-4696-ad8f-c4869a5fc839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9eee8e96-e0e0-4e37-a968-ad382ee61494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9c5ad5fd-23bd-4ffb-90b5-590268c95f8a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9eee8e96-e0e0-4e37-a968-ad382ee61494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="bios-20201231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_f0009d61-c5ba-4cda-be2b-dede47b3342f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d605b9a6-f4b9-4c4b-a2fc-a0dd0a437094" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_f0009d61-c5ba-4cda-be2b-dede47b3342f" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d605b9a6-f4b9-4c4b-a2fc-a0dd0a437094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_669c48c7-3d42-4359-a863-6cc8748ae46a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa17e114-dff5-47b9-81a0-2b47c48d80b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_669c48c7-3d42-4359-a863-6cc8748ae46a" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa17e114-dff5-47b9-81a0-2b47c48d80b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3211823c-11d7-4428-9f00-74b66998d479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa17e114-dff5-47b9-81a0-2b47c48d80b0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3211823c-11d7-4428-9f00-74b66998d479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_78b6d22e-2ee2-45c4-ae32-fe93a5b341c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3211823c-11d7-4428-9f00-74b66998d479" xlink:to="loc_us-gaap_RelatedPartyDomain_78b6d22e-2ee2-45c4-ae32-fe93a5b341c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_MadisonDearbornPartnersVIBL.P.Member_8a5fe1e5-cd95-466a-bb2f-5919fdd6ed30" xlink:href="bios-20201231.xsd#bios_MadisonDearbornPartnersVIBL.P.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_78b6d22e-2ee2-45c4-ae32-fe93a5b341c1" xlink:to="loc_bios_MadisonDearbornPartnersVIBL.P.Member_8a5fe1e5-cd95-466a-bb2f-5919fdd6ed30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_fe1f9dc5-158a-47ff-9571-93e25fe355f3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ManagementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_78b6d22e-2ee2-45c4-ae32-fe93a5b341c1" xlink:to="loc_srt_ManagementMember_fe1f9dc5-158a-47ff-9571-93e25fe355f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorityShareholderMember_89323d68-de28-4933-a349-750f96d5a9f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorityShareholderMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_78b6d22e-2ee2-45c4-ae32-fe93a5b341c1" xlink:to="loc_us-gaap_MajorityShareholderMember_89323d68-de28-4933-a349-750f96d5a9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_f4a1e368-51dc-446b-bf26-1f40ef371aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_78b6d22e-2ee2-45c4-ae32-fe93a5b341c1" xlink:to="loc_us-gaap_CorporateJointVentureMember_f4a1e368-51dc-446b-bf26-1f40ef371aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b2f6516a-f056-4374-b7c9-65fe5a745d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa17e114-dff5-47b9-81a0-2b47c48d80b0" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b2f6516a-f056-4374-b7c9-65fe5a745d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_eaab13d3-4c5a-4875-a833-aabb74182e8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b2f6516a-f056-4374-b7c9-65fe5a745d82" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_eaab13d3-4c5a-4875-a833-aabb74182e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_OptionCareAcquisitionMember_48fe8a89-01ff-457a-8e0d-7fc659eee8ce" xlink:href="bios-20201231.xsd#bios_OptionCareAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_eaab13d3-4c5a-4875-a833-aabb74182e8d" xlink:to="loc_bios_OptionCareAcquisitionMember_48fe8a89-01ff-457a-8e0d-7fc659eee8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LoansFundedForMembershipUnitPurchaseMember_923218f1-6e9d-4115-807c-ef53778d9234" xlink:href="bios-20201231.xsd#bios_LoansFundedForMembershipUnitPurchaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_eaab13d3-4c5a-4875-a833-aabb74182e8d" xlink:to="loc_bios_LoansFundedForMembershipUnitPurchaseMember_923218f1-6e9d-4115-807c-ef53778d9234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SaleOfNotesReceivableMember_04230b8c-2d1d-4354-ac0b-53305e5c7d7d" xlink:href="bios-20201231.xsd#bios_SaleOfNotesReceivableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_eaab13d3-4c5a-4875-a833-aabb74182e8d" xlink:to="loc_bios_SaleOfNotesReceivableMember_04230b8c-2d1d-4354-ac0b-53305e5c7d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa17e114-dff5-47b9-81a0-2b47c48d80b0" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_f38a1fbf-5270-46e0-a6cc-98c2725e27c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_f38a1fbf-5270-46e0-a6cc-98c2725e27c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_267f475d-11dd-4d53-b936-a8ac82db435d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_267f475d-11dd-4d53-b936-a8ac82db435d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_7e60ffb2-4fcb-4157-8002-03e62fdbfe01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_7e60ffb2-4fcb-4157-8002-03e62fdbfe01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountRedemptions_7ead6b41-569f-4b2a-b708-33001d39f772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PartnersCapitalAccountRedemptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_PartnersCapitalAccountRedemptions_7ead6b41-569f-4b2a-b708-33001d39f772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid_da05b589-a217-4eaa-9b53-c37f47c5e58d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid_da05b589-a217-4eaa-9b53-c37f47c5e58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_a3d0695a-2097-413b-98ec-c121620eac50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_a3d0695a-2097-413b-98ec-c121620eac50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfNotesReceivable_a248e375-20e0-492b-be58-e375a789539e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_ProceedsFromSaleOfNotesReceivable_a248e375-20e0-492b-be58-e375a789539e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_0af88440-f368-4790-9179-b3e883d40f27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_InterestExpenseRelatedParty_0af88440-f368-4790-9179-b3e883d40f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedParties_06d8b652-2ea1-4d42-a362-17246c2a6dac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedParties"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_NotesReceivableRelatedParties_06d8b652-2ea1-4d42-a362-17246c2a6dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_d275f4bb-3fc7-4f5b-b1eb-fd918732f0af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_RevenueFromRelatedParties_d275f4bb-3fc7-4f5b-b1eb-fd918732f0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_dc2da172-fc7f-42ca-8aff-4ccbd5e80321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_076b5659-7002-4112-a97f-329661b9a8e5" xlink:to="loc_us-gaap_DueFromRelatedParties_dc2da172-fc7f-42ca-8aff-4ccbd5e80321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED" xlink:type="simple" xlink:href="bios-20201231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_aaa92385-6a15-4086-9f3b-0625daa52f44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_3374c600-8e16-4be8-be52-f19982f71ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_aaa92385-6a15-4086-9f3b-0625daa52f44" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_3374c600-8e16-4be8-be52-f19982f71ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables" xlink:type="simple" xlink:href="bios-20201231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_81c712ad-260c-4491-a908-bc459e4232e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_cde1c48b-37f0-4702-a81a-e782c162a234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_81c712ad-260c-4491-a908-bc459e4232e7" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_cde1c48b-37f0-4702-a81a-e782c162a234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9d221043-14d0-4118-9de0-06cfb8c58707" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8a4f2162-e132-43bd-9b8d-08b7bb7fe690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9d221043-14d0-4118-9de0-06cfb8c58707" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8a4f2162-e132-43bd-9b8d-08b7bb7fe690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_734f6004-5989-49e0-8e07-e84ddf5d5bcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9d221043-14d0-4118-9de0-06cfb8c58707" xlink:to="loc_us-gaap_GrossProfit_734f6004-5989-49e0-8e07-e84ddf5d5bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9a5cdbbb-63ea-4556-8dbd-e9a65d89e75c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9d221043-14d0-4118-9de0-06cfb8c58707" xlink:to="loc_us-gaap_OperatingIncomeLoss_9a5cdbbb-63ea-4556-8dbd-e9a65d89e75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_850dd676-f1ba-4188-8bc8-0f6074535d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9d221043-14d0-4118-9de0-06cfb8c58707" xlink:to="loc_us-gaap_NetIncomeLoss_850dd676-f1ba-4188-8bc8-0f6074535d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1d378820-f4f1-4a09-a774-95350ac82cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9d221043-14d0-4118-9de0-06cfb8c58707" xlink:to="loc_us-gaap_EarningsPerShareBasic_1d378820-f4f1-4a09-a774-95350ac82cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b8defcc8-9f15-4316-b03f-f41e27979388" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9d221043-14d0-4118-9de0-06cfb8c58707" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b8defcc8-9f15-4316-b03f-f41e27979388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="bios-20201231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_c9a86ebd-efbe-42b3-83a0-39db8bd27e53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_f8996550-5c79-4743-ac10-214057b480a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_c9a86ebd-efbe-42b3-83a0-39db8bd27e53" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_f8996550-5c79-4743-ac10-214057b480a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="bios-20201231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_c124c084-19ae-46b2-98c3-845f46f27b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_c124c084-19ae-46b2-98c3-845f46f27b1c" xlink:to="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_531018e4-eb45-4ea5-9602-57b1e018bf1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_531018e4-eb45-4ea5-9602-57b1e018bf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cc5746a4-cb3c-4bdf-9b3a-a86f86a4a561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_531018e4-eb45-4ea5-9602-57b1e018bf1c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cc5746a4-cb3c-4bdf-9b3a-a86f86a4a561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c1ad2384-cf7d-4a8e-a732-f991fd331834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cc5746a4-cb3c-4bdf-9b3a-a86f86a4a561" xlink:to="loc_us-gaap_SubsequentEventMember_c1ad2384-cf7d-4a8e-a732-f991fd331834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9f04cae0-ca69-4421-8e49-a220a3afffe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:to="loc_us-gaap_DebtInstrumentAxis_9f04cae0-ca69-4421-8e49-a220a3afffe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6f72daa7-15d5-49d8-85b9-77a095e075d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9f04cae0-ca69-4421-8e49-a220a3afffe9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6f72daa7-15d5-49d8-85b9-77a095e075d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditAgreementsEnteredInto2019Member_82063c67-ac67-4298-874e-dfee16d19966" xlink:href="bios-20201231.xsd#bios_CreditAgreementsEnteredInto2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6f72daa7-15d5-49d8-85b9-77a095e075d4" xlink:to="loc_bios_CreditAgreementsEnteredInto2019Member_82063c67-ac67-4298-874e-dfee16d19966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryAxis_b53353b3-b8dd-4fcf-95cf-a1bace82bc88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:to="loc_us-gaap_LienCategoryAxis_b53353b3-b8dd-4fcf-95cf-a1bace82bc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_24daf885-f2d3-46c4-87ec-93fbdde2314d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LienCategoryDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LienCategoryAxis_b53353b3-b8dd-4fcf-95cf-a1bace82bc88" xlink:to="loc_us-gaap_LienCategoryDomain_24daf885-f2d3-46c4-87ec-93fbdde2314d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLienMember_34322a83-d28a-4663-83c5-cdbdf1eb8112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorLienMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LienCategoryDomain_24daf885-f2d3-46c4-87ec-93fbdde2314d" xlink:to="loc_us-gaap_SeniorLienMember_34322a83-d28a-4663-83c5-cdbdf1eb8112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JuniorLienMember_d4f1bfee-717f-4809-a296-8a38654ba072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_JuniorLienMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LienCategoryDomain_24daf885-f2d3-46c4-87ec-93fbdde2314d" xlink:to="loc_us-gaap_JuniorLienMember_d4f1bfee-717f-4809-a296-8a38654ba072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_052ddc6c-d0cc-4729-bb4e-09c8ca7f5ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_052ddc6c-d0cc-4729-bb4e-09c8ca7f5ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_eaa24ad2-1a9e-40d1-9b2d-0f5bfd8a10db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_052ddc6c-d0cc-4729-bb4e-09c8ca7f5ad7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_eaa24ad2-1a9e-40d1-9b2d-0f5bfd8a10db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_fa9ef4bf-ab01-4737-858a-2a5205213f34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eaa24ad2-1a9e-40d1-9b2d-0f5bfd8a10db" xlink:to="loc_us-gaap_SeniorNotesMember_fa9ef4bf-ab01-4737-858a-2a5205213f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NotesPayableMember_c76a5b94-356e-47d6-b0f7-a223e7dab6cf" xlink:href="bios-20201231.xsd#bios_NotesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eaa24ad2-1a9e-40d1-9b2d-0f5bfd8a10db" xlink:to="loc_bios_NotesPayableMember_c76a5b94-356e-47d6-b0f7-a223e7dab6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_60ac1cf6-8917-41b5-99f6-b10f72c37f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:to="loc_us-gaap_StatementClassOfStockAxis_60ac1cf6-8917-41b5-99f6-b10f72c37f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9992dce4-d09b-45ac-bbb1-305885ab6606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_60ac1cf6-8917-41b5-99f6-b10f72c37f95" xlink:to="loc_us-gaap_ClassOfStockDomain_9992dce4-d09b-45ac-bbb1-305885ab6606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_28efb599-9b6f-4444-8ae3-128df4b6b94c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9992dce4-d09b-45ac-bbb1-305885ab6606" xlink:to="loc_us-gaap_CommonStockMember_28efb599-9b6f-4444-8ae3-128df4b6b94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d79f9418-53a1-43c7-97fb-aa77853586a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d79f9418-53a1-43c7-97fb-aa77853586a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58874c8c-f3b8-44a6-9f20-28e0a53dedbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d79f9418-53a1-43c7-97fb-aa77853586a2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58874c8c-f3b8-44a6-9f20-28e0a53dedbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SecondaryOfferingMember_0d8b0732-27f2-4898-a46e-59f986e0a264" xlink:href="bios-20201231.xsd#bios_SecondaryOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58874c8c-f3b8-44a6-9f20-28e0a53dedbc" xlink:to="loc_bios_SecondaryOfferingMember_0d8b0732-27f2-4898-a46e-59f986e0a264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d8e4f653-d63b-4da3-b81e-097d652f7996" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:to="loc_dei_LegalEntityAxis_d8e4f653-d63b-4da3-b81e-097d652f7996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2c5e79e8-09c1-4a72-8ef1-b387305327bc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d8e4f653-d63b-4da3-b81e-097d652f7996" xlink:to="loc_dei_EntityDomain_2c5e79e8-09c1-4a72-8ef1-b387305327bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HCGroupHoldingsILLCMember_b0e71eda-e052-4a8c-ae90-4fcbf7ca5cc0" xlink:href="bios-20201231.xsd#bios_HCGroupHoldingsILLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2c5e79e8-09c1-4a72-8ef1-b387305327bc" xlink:to="loc_bios_HCGroupHoldingsILLCMember_b0e71eda-e052-4a8c-ae90-4fcbf7ca5cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_53646234-e14d-423a-ab21-3a27b4fc7895" xlink:to="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_99b95a3d-c617-4236-a74f-f1c7eefb6090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_99b95a3d-c617-4236-a74f-f1c7eefb6090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a2e76118-4c17-4f4b-85b9-379a39ef1be1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a2e76118-4c17-4f4b-85b9-379a39ef1be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_0dce728e-bae8-4f65-a5ff-78970e8608d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_us-gaap_RepaymentsOfDebt_0dce728e-bae8-4f65-a5ff-78970e8608d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FinancingReceivablePrepaymentPenalty_df81f860-e431-434c-8bd8-185f770573f6" xlink:href="bios-20201231.xsd#bios_FinancingReceivablePrepaymentPenalty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_bios_FinancingReceivablePrepaymentPenalty_df81f860-e431-434c-8bd8-185f770573f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_DebtInstrumentThirdPartyFees_36938c3a-4276-4dff-ac42-804bdcce9163" xlink:href="bios-20201231.xsd#bios_DebtInstrumentThirdPartyFees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_bios_DebtInstrumentThirdPartyFees_36938c3a-4276-4dff-ac42-804bdcce9163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7d3b4fd6-a575-48cf-879d-45135b0fd717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7d3b4fd6-a575-48cf-879d-45135b0fd717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_806b1c08-3710-4fa5-9579-7aedc268ac32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_806b1c08-3710-4fa5-9579-7aedc268ac32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f75f6de4-f09e-41c0-87a8-7433d62a92c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f75f6de4-f09e-41c0-87a8-7433d62a92c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CommonStockOutstandingPercentage_02e003e4-7944-4c8b-ad19-f1ca4adb326a" xlink:href="bios-20201231.xsd#bios_CommonStockOutstandingPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_eec89b4e-1d50-46bb-ba4d-249f53acd35d" xlink:to="loc_bios_CommonStockOutstandingPercentage_02e003e4-7944-4c8b-ad19-f1ca4adb326a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>bios-20201231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bios-20201231_g1.jpg
M_]C_X0XN17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    D    <@$R  (    4
M    EH=I  0    !    K    -@ +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-#(#(P,3D@*$UA8VEN=&]S:"D ,C Q.3HP.#HP-2 Q,SHP,CHS
M-P     #H $  P    $  0  H ( !     $   ?#H , !     $   ,.
M      8! P #     0 &   !&@ %     0   28!&P %     0   2X!*  #
M     0 "   " 0 $     0   38" @ $     0  #/          2     $
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M*<9S'X^!]:<-F&_IF*.EB^G =8VP,=8SJ-=MS&4/NHQO6^SU[J*;-GZ+U?\
M"JSD]&Z;D]=Z(ZZG><O%N?>=SQN=57ALI/M<-NQO[BM.^KW1VOZGZG5+C=?B
MNJZRY]U)<ZNQMWHY&4UU6S#]"JR[[+Z#,7']/_!65JYG=*P\JWIPJS[,/*QJ
MWMQ+*75&RRIS:F9 V7UW,L;M;1^EKK_1)*<KH_U?Z;U6_K%W4:W9&WJ60RAA
M>]K:A^CW64BIS/3R'O\ =]I;^G_X16?J_A_MCZNX.5F6O=DV4"JR\1O<&"_&
M<;'D>YUM5S_4_E_I%K=*Q,'&^V?8[O7]?*MNO]S7;+G[?5I_1ANS9'\V_P#2
M)=#Q,'"Z3CXO3[OM.)4TBJ[<U^X%SG?SE0;6[W?NI*?_V?_M%EQ0:&]T;W-H
M;W @,RXP #A"24T$!       $1P"   "   < @4 !5!R:6YT #A"24T$)0
M    $-<*4!6_#"L%^KX\7@C4@0$X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L     0 ! 2P
M   !  $X0DE-!"8       X             /X   #A"24T$#0      !
M !XX0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300        "   X0DE-! (       (  #A"24T$,        0$ .$))
M300M       &  $    ".$))300(       0     0   D    )      #A"
M24T$'@      !      X0DE-!!H      V$    &              ,.   '
MPP   !8 3P!0 %0 20!/ $X 7P!# $$ 4@!% %\ 2 !% $$ 3 !4 $@ 7P!2
M $< 0@    $                          0             'PP   PX
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   PX
M    4F=H=&QO;F<   ?#    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$%       !     (X0DE-! P     #0P
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
M @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@ , P$  A$#$0 _ /54DDDE*22224I))))2E7S\_"Z=BV9F=<W'QZA+['F!
MY-'YSWN_,K9[WJPO+/\ &=U&_(Z]3TV3]GPZ6V-K'!NN+]UD?G.;4QE=?[F^
M[_2)^*''*OJ5#=T^M?XSL:VDT='KO8]SH=E6,:V&^-%;W[][_P#AJF;%S(Z@
M[)>;3=99=R7V.<;/CN<=_P#FJA1TRZP2][:_(^X_]'VH[^B=3JH.9339?CUR
M3?56\AH'TG'V[=K?S_<II80!H"'1^'?%>5Q3]F&3&92WT]4O^K_S?^#QO7?5
MSZZ9&*[[)U(V95+OYFS1UK7?N/=8YOJUN_EN]1G_ )[[; ZGA=1J-F)9OVP'
MM((<TGL]CO<U>+TVESJW-Y+FD1XR%V'1,M^-U?&LK/\ .6"EX\66'TX/]5Q;
M8J/,9)8LD.L)Z2[Q_K-SF^1PYHSRXQP3KB]/R2_P?ZSZ$DDDI7"4DDDDI222
M22E))))*?__0]522224I))))2DDDDE*7F7^,,XW_ #FK=6/T[<1C;G=M7VFK
M^WLW[_Y'IKTU>:_XR^F78_5*>KM!.+DUMHL?V9;67;-_[OKUV?H_Y=/_ !:F
MY8CW->Q8L\3+&0.OY(?JY@U7,LS+P'MK);16>"YHW.>[^I]%G\M>C8.5BW=/
MJR:'!N.:PX$D#: /<U_[OI_GKSCH.6&]-J Y:YX=\=Q=_P!2Y2?B8]SB'M#A
M.AX,*/G\LL1&20)Q68RK]#]PH^"XN7S9,O+RG[64$&&G%[D8<?NQX>*'J^1R
MWX^([JV3DX;=F!ZSWXC(B6DG:]K(;LI_/I9^YZ:Z'ZMXWK]3Q[7@^A38"3XO
M_P $P?U;-KWH./TK%W2X/?Y%VG_1#5T71\4OOJ96T-KI(<=H@- ]S1_;<L;F
MOB/NY<<,,3*<I1B.(:"/%KH]5GR8\6"4(7\I!G+?;A_QGIDDDEKO-J22224I
M))))2DDDDE/_T?54DDDE*253JV=^S>E9G4=GJ_8Z+<CTYV[O28ZW9OA^S?L^
MEL4[LJVO*QJ&XUEK,C?ZE[-NRK8W>WU]SFV?IOYNOTZ[/Y:2FPDDDDI2'?13
MD4OHR*VW4V MLKL <UP/+7L=[7-1$DE/+9OU'P*,=[NB,^S6EV\T.>YU3M(+
M6>HY_H._<V?H_P#OG.OZ=U>JPL.'D!X,>VMSAIX/K#JW?YR]+24L<\J(D!,'
M]YIY^0QY,@R1E+'/0W#O':7]YYCH7U?S' W]6&UI'Z/'!AW]>U]?T?\ BV_V
MUT=-%-#!72P,8.P1$E7&'#&1G#%#'(_N1C#_ *+<$LG (2R3R5URREDE_P Y
M22SNO=2MZ7TQ^92QMCVVT5AKY BVZK&?]']UENY:*>I22222E)*GUC-LP.D9
MV?4T/LQ,>V]C'3M+JV.M:UT?F^U '5WC-Z9B&D$]1HMN=8'0&&IM+MNS;[_4
M^T?OI*=-)9W1NI7=0^W>JQK/LF9;BLVSJVO;M>[=^>[<M%)3_]+K.D=$P>O=
M)KZOU'>_J&>#<W*98]EN.'.<ZBG!>UWZK]D;MK_1_P [8S?D>KZEBSNC;OK+
MU# ?U5[K:[.D5VY- <657V"^RIM]M5196^OV/M]+;Z7Z6O\ T=:VZ^@XUE=Y
MZ=U;(HZ7DV6ONQL=]3J@]SG?;&X^2^JW)Q&OO];UJZ,AGHW>KZ'V94#A8F3]
M:,>KIN2<-E71ZST^_$<P@4^JYFVMEK;\;)Q75_9_YRJW_ V5>G9LL24U.L].
MQ:<'ZQ]+&ZS$Z=T\9^!6Y[W?9[+:LVI]+'.>7>C^IMOJHL_1U^M9_@_36MD8
M6/T[K/0,7##J:'6Y;G5A[R"30]WNWN=N]W[R-7TGHM73^KX61F^O9DL?^V<R
MVRL7AME1;NR',:RK$KJQ/Z-7Z-5%5/O_ -(C-Z717E].?G=0MR<W&?<[&-QI
M8ZTOK-5K/2IJI:]M-/O_ $+/^$M24Y?1>B877^B4=7ZB7OZEU"OUQEUV/9;C
M[RZRFK L#OU5N(UWI_H_YW9^L>KZEBK8#K/K';]7W]1?86Y'2\FW+KK<:V7N
M;9T^O]*VK9^@L>_U_39_Q7\QZE;].KH.'91<>F]6OHZ1D/M?;C8SZ74@N<[[
M6S'R756Y&+6^[UO6KHR6>C;ZOH?9E?QL7I/VO R,2U@]+"LJP::GL-;L9[L5
M[K:F-]SZZ_0Q&,LK=Z7Z7_A*TE-/H>.SI_7.J=+Q2YF!53BY%&.27-J?><ME
M[:-T^G4_[+6_T?YIEGJ;/YQ"OQ*>N?67,PNHAUN#TS'QW589<1399D&]UF3D
M5MV_:/39CLJH9;OJK_3_ */U%K48N&SJ^9E5V[LRZFAE].YIV,K.0<=_I@>H
MSU779'N?_.>E^C^@JV?TW&R^HB[%SGX'5:J0'.H-;GNQW.=Z;<C&R&7L?1ZS
M;?1L]/V6>MZ5O\ZDIH=5Z7@]-Z:W#;E9=>%D9+2.GT[[K+6ACG/Z7A;/UJC'
MN]+U[OTWIU5>O7^@PT'HE?V3ZR,HQNG6=&Q,G"NM.(ZRLBQ]5N(QE_V;%LR*
M<:RMF0]F_P!3?D>I^D_F%=?T/IXKKQW=2N'4_M3LBK-=96<DY)J(>UE3Z_LN
MS]G^S['7B>C]E_2^E_ATL?H>%3UJK*?U.^[K+:B;-]E.^S&+F-])V&VEM56&
MVZMOOQ:*'^M_A_4L24\YC8[L3ZH=(SZ'7V=4ZJ,7"LS!:3>VB]S7OQL2W(?Z
M.+^CK;C8[_T>RW]8_I/Z5:6+TW.PL[#NZ/T:[IH%S&9Q?D5/KMQSN9<_(8S)
MN?=E4[O7IOV>O[/3]7T['K6JZ;T1OU:Q^FG(%G2VUTU491M:"8<P8=M>55Z;
M/7]?T?L]E7^']/TU ]&HIR<7(ZQU6[-;3:T85.6:*Z_7=[:'[<:C%^TY;?\
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M!M;O=^ZDI__9.$))300A      !=     0$    / $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P    %P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H
M &\ <  @ $, 0P @ #( ,  Q #D    ! #A"24T$!@      !P (     0$
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M #$  &%C<W!-4T94     $E%0R!S4D="               !  #VU@ !
M -,M2% @(
M            $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P
M%&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)865H   )
M    %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<
M  /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')4
M4D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P
M>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M         !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#
M-C$Y-C8M,BXQ
M                  !865H@        \U$  0    $6S%A96B
M            6%E:(        &^B   X]0   Y!865H@        8ID  +>%
M   8VEA96B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z
M+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M
M &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L
M="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M  !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@
M245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N
M9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(
M    3 E6 %    !7'^=M96%S          $                        "
MCP    )S:6<@     $-25"!C=7)V        !      %  H #P 4 !D '@ C
M "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )
ME0": )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$'
M 0T!$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!
MH0&I ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )=
M F<"<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#
M3P-: V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C
M!'$$?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%
MM07%!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K
M!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((
MYPC["1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%
M"MP*\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,
M\PT-#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!
M#UX/>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1
MZ!('$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M
M%,X4\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7
MTA?W&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4
M&SL;8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>
MOA[I'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"
M(J\BW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<F
MMR;H)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"
M*S8K:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$O
MQR_^,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>
M--@U$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY
M^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A
M/Z(_XD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%
M546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M3
M2YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1
MYE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]
M6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?
MLV %8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H
M9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMN
MQ&\>;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;
M=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_
M(W^$?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?
MB 2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0
MUI$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\
MFFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:C
MYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VX
MKBVNH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X
M6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;
MPUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.
M-LZVSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-EL
MV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SE
MA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R
M\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^
M2_[<_VW____N  Y!9&]B90!D0     '_VP"$  $! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$" 0$! 0$! @(" @(" @(" @(" @(# P,# P,# P,# P,#
M P,! 0$! 0$! @$! @," @(# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# __  !$( PX'PP,!$0 "$0$#$0'_W0 $
M /G_Q &B    !@(# 0             '" 8%! D#"@(!  L!   & P$! 0
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MFJ*FIG*I&B*"S.[  "Y-O?N/#IZWM[B[G2UM(VEED(5$12S,Q- JJ 2Q)P
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M,R'\<?ZW_%?>PHZ;+CK@6_)_VY_XW[M3ILN>'6,R*/S?_6_XW[]U35UQ\A_
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MR3_L3_Q'NU:8'3#/Y#K$S_@<#_>?>POF>F&>G6%F ^O^V_)]VZ9+5ZPERW^
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MWNG52PZQF0#ZD#_>_P#;>]A2>JZSY=8S*/Q<_P"L/^*^[:#UJI\^N)E/]/\
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M"2L00,Q.3^?N6.>;3ZG8;@,Z@%X7[9HZ_P :5./(.I9"<!B:]<QO<WV<Y_\
M:3<OH><+(QQ.2(KF.LEK/3_?<H &JF3&X251ED (),#[&?47=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_]'?
MX]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=%'^9'S?^._P3ZMJ.U/D!O),+23_<TVT]G8A(,GO[L+-4\/E_@>RMMM+$
MU1+ZD$]3-)#24P='JZF"-@Q/=@Y<W7F6]%EM<>HBFISA$'J[9I\@*L?P@GIV
M*%YFTH/\PZT#?YCG\Y#Y-?S \ID]J35]1U!\=(ZXR83I3:.5J/%F8(9 ]+7=
MH;CA6"7/U6I5E6GDCBH(&5&@I%F5JB3)OE7D'9^5T68#Q[NG=,PX?*-<A!\\
ML?-J8 BL[&.'/%O7_-Z=5%#V-F/1Y$M3UR^@_P!]]?;+'HRC7KB?Z>V2:FO2
MV-<]<E'MEC7I:@\^LG^'^W]T)\^EL2]9%'MACY]+D6O63_>A[9Z7Q+BO7,#V
MTQZ6*O64<#VT3TKC3KM1?VV3TL1>N7UX'T]M$]+8TZR >V6;I8B]<K7X'T_W
MOW3I7&G7,#W1FITJ5>N8'M.S5Z4JG64+[;)Z4JG7+_6_V_\ QKW4D#CTI2*O
M7(+[;+$]*5C ZYA?]A[H3T^L?2YVIV!N#:3JE%4&KQVHF3%U9:2E.H^IH#?5
M$WYU1FU_U!OI[*=PVFSW$5E&E_)A@_GZC[?R(ZE?V_\ =KG+V^D6';9O'LJU
M:UF):(UXE,ZHF\]2$ G+JXQT:/:?8&"W=$%I9?M,DJ%IL55,HJ5"B[O3L.)D
M'^J7D#]2K<#V MPVF[VYN\:D\G'#\_0_;^1/6=O('NURO[A0!+%_I[T"KVLI
M'B"G%HSPE0?Q+D"A=4J!TKWE_P!]^?9:%]>I)+5ZC-(?=^FR0./4=I ./S_0
M?7W8+7JA8GK"78_G2/Z#Z_[?VX% Z;+J/GUB+ ?[ZY]V^WIEI3Y=<2Q_'OU>
MF6DZXW_Q]ZZ9,PZZN/?NFC*>NM7O=.FS)ZGKK5[]3ILR#KJY]^H.J^*.O7/^
M'OV.M>-U[GWO'6O%Z]<^_8Z]XW7KGWJ@ZWXPZ/5T'NPY[9_\'J9-5?MB2.A-
MS=GQDRE\8Y_X*%D@ _ C']??-_[S7)(Y:Y[_ '[:+2VWA3-\A<(0+@?[8LDI
M/FTK 8'1)?(%FUKP;/Y^?^?H<_>.'2+KWOW7NO>_=>Z][]U[KWOW7NE%M/=V
MY]B;AQFZ]FY[*[9W)AJA:K&9K"ULU!D*.9>#XYX""5=24DC:ZNI*.K*2"MV[
M<MPVB]CW':YGMYXC5'1BK*?D1Y'@1P(J""#3HJWO8MFYEVN;9.8+6.\M+A=,
MD4J!T8?-2#D'*L*,K ,I! /5_/P[_FB8/?38OKGY&5&-VKN^3PT6)[*40X[:
M>Y)R?''#N:$!8L55MP?N011R$M<4ED23,?VR^\!:;N8]DYW9;>Y-%2ZPL,IX
M 2C A<_Q?V3&O]G@-S"]^_N9[ERV)N;/:=)+VP%7EL,R7, XDVYRUS$,_IFM
MP@I0SU9EN.!# ,I#*P!!!!!!%P01[R=XY'6 I!!H>N_?NM=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_TM_CW[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=57_ ,SW^:ETU_+A
MZY!RGVF^_D!O'$5=3U7T[2U>B>L"R&CCW?OBIIR7QN!@F##RD":MDCDIZ,$I
M434PUY,Y)W#FZ[[*Q6L9'B2D<//0G\3D>7!006X@,_# TS>@'$]?.R^3WRF[
MP^87;.>[H[\WK7;QWCFY6CI86U4NWMJX5)"]#M?9V"1C#C\;2@Z8H(KL[:II
MWFJ))9I,K-GV7;=ALEV_:XQ'&OYLQ\V=N+,?,G[!0  'MM$L8TJ.B]^UY-37
MHUB7SZYC^G]/;;'HRA6@KUV?Z?T_WL^V&/1A&//KC]?;3&@ITMC6@ZRJ/]X]
MLGI;&OEUR'MMSY=+XUZRC@?[P/:=C4TZ6Q+US ]ML<=&"+UE4>V2>E2+UR^I
M]M$]+D6@IUS^@M^3]?;;'I9$G7(#VRQZ6HO63_ ?['VU\^ED:=<@/=&:G2Q5
M\NLH'M.S5Z5(G64"WMHGI2B==@7_ -;^G_%?=2U.'2N./UZR!?;1/2M$ZY\#
M@<GW0GI2D?7K$_7_ (U[H3TH6/KF%]U)Z>"=9899*>6.:"62&:)P\4L+M'+&
MZFZO&\9!4C\$'W1M+J585!X@\/Y]*K:2YM9TN;5VBDC(971BK*PR&5E(((\B
M"".A]V7VR)/%C-TR!'-HX,SI"HU^%7(HO"G\>91;_5@6+D([GL-"9[$8\T_Z
M!_S?L].LN_;+W],OA[%SXX5L+'>4 !\@+@#"GR\90%X&0"C2$;/,)%#(P*,
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M$A7@+D8XG\^D!151SA56,Q@]$O9SW!'/?+(%ZP.X66F.X'F^/TYJ?\, .JE
M)%>@"Z>N)/WGO9=O:'GUCM49&R[IKGLSDB/(\:U)]8&8:*U)A>(DLVL]'K]R
MYUC9U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__];?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6O[_P *$?GS)\5/BF.C=@9AZ'NCY0TV
M:VG35-#.T5?M+J6DB2F[#W*LU.XD@J*Y:B'"4#%1J%1631.)*.WN5?:?E8;Y
MOO[SNEK;61#&O!I3_9K\PM"[?8H.&Z]YTZ^>R/>5AX]+$&0.N:^VWX]+TZY_
MT]L'B3TMA'7+VQT9Q#'7(?7VTW'HSB';UX_4_P"^^GMANC",8Z\OX]M.<]+X
MQUE_'^N?;72V(=9%]L,?/HP0>763\_ZWMGHPB&.L@]LL<]+$'60_@>V6Z7Q#
MKG^/]?VTW2Z(=<@/;+GI>@ZR?G_6]M=+XEZR >V9#TLC%3UF4>TQZ6H.N8Y/
M^\#W1C04Z7Q+Y]9EX%_;)/2Z->N2CVR3TOC6G7/_  ]M,>EL2>?7)1[8)Z6(
MO67Z>Z$]*46O7K7]T)Z5(G7,+[;9J=*53K(%]M%B>E"IUS"^ZUZ<"==Z?>J]
M7T'KVGWZO7BAZXE?>Z]4*="EL7<[IHP=;)=3QCIG/*GZFC9C^#]8[_\ !?\
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M2"T4T; QSPO0:X94>-Z#4I(%"-]F],Y/99FRV':;+;:U%FE*AJ_%*3PM>D8
M:/\  G0 ?ZM4X+17OW*UQM=;FUK+!Z_B3_3>H_I#\P//Z-ON>_W@W)OW@5M^
M1>?EBV/F\@*L88K9[DP&6LF=BT<QH2UG*S/2A@DG&L1@A["P%./71=W ZZ)]
MN**YZ2.]<GK"Q]O =(W:N>L+'VX!TD=NIF(J?MLI12WL/.L;'_:)OV7)_P!@
MQ/N\BUB(^72[8+WZ+?+:XK0:PI^Q^P_R8GH6BW^Q_P!Z]E@4GJ?&DZQEK^[
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MDLPCC/SHV/.G1F]O?R@OG!G]!R6QMH[.$C*"=R]A[6J#&A8^MUVG/E"!8 D
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M>J>/DA\2>S^HJJ;,9OK#?FP4>2=J_;N[]HY_;%1!*EY99\33YJG@+QA;L\*
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MP/\  _[Q[HW31Z>H6_X@_P#$'VE<=6'F.G:!O]Y_Y%S[8;UZ]Y]."'Z?X?\
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M_P"NQ Y]IKRZM["TDOKI@D4*L[L> 502Q_(#I99PSWMS':6RZY)65% XEF(
M'YD]6J;*VU3;.VOAMN4Q5QC:1(ZB95T_<ULA,U=56^O[DK.P!Y ('X]\_P#F
MO>I^9=^N=[N*@SN2JG.E!VHG^U0 'U-3Y]9H[#L\6Q;/!M45#X2@,1^)SEV_
M-B2*\!0=*Y6_WW]?879>C0CK)_K>T[+U3K*C?\;_ .*^V&6N.JG'68&W(]IV
M'D>M$5ZDHU_:5TZ984ZY@V_UO:1UZJ<]2$;VCD7IEAU)4_\ &O:-UZ98=24;
M\?[$>T4B]4^74A3_ +S_ +W[1,M.FV'68<^TS#RZ;ZSQ*TCHB*SO(P1$0%F9
MV-E55'))/  ]IF4UH//IMRJJ68T R2?3K=@^-_6O^A_H;J?K:2-8JW:NR,)1
MYE570K;BJ:49'<LJK^ ^0FJ7 ///))Y]]!^4MH_<'+-CM!%&@A0-_IR-4G[7
M+'KYW?=OF_\ K[[F;YS<IU1WMY,\5<GP%;P[<?E D8],8Z&SV(NH[Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[K__3W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=4I?S^OC&_R-_ET=E9K#X]:W>?QXR-!WWMXI')]P<-M.FGQ_8U/Y80S^)=NU
MF2KVC(*/+20%M.E9$D?VKWK]T<W0QR&D=V# WVL08_S\0*OR#'[#[KYPOO+[
MK70@]?;9&;R1K:N/5C<:Z.ZL+I4U?ZH:<WX*C]<@YXL#^KWOJ)_=CG-N6]E_
M=M@]+R\!4$',<7!Y,9!/PH<9U,#5.C*QG@?[[_7]WXCK"V9>I<9M<?T-Q_L?
M>QD=%<R]3XSS_K\^]>7V=%[C'4Q#R/\ '_B/>CTB<=34/ _P^O\ K?[#W[HO
MF7SZD*?]X_XCW93T27<=#4=24-_]C[<'1'<QU%>ID+V-C^?K_KCW[HJ84/3@
MC?3^H]U/2>1>I -[$?[X^] TZ*KB.O#J;#):Q_VX_P!Z/O9'1<ZUSTYQ/]/]
MX_XI[H1TG(ICIQC<$#G_ (T?=>/V]-D=#_\ '[H[=??.\H]MX+_(,1CUAK-S
M[EGB:2BP6,>30&T@KY:F:S)2TP8%V!)*Q))(A!S!OEIL-G]3/W.V$3S9O\BC
MBS>7S) (DY5Y5ON:MQ%G:]D:4,DA&(UK_-CP5>)->"@D;!76_6^T^J=IX[9N
MS<<M#BJ!=<LKZ9*_*5\B@565RM4 IFJ)BH+O8  *B*D:(BX_;EN5WNMVUY>-
MJ=OV*/)5'D!_LFI)/66NR[+M^P;>FV[:FB-.)_$S>;N?-CYGRP    %Y[0=&
MO7O?NO=>]^Z]T>'X:=?K79;-]BU\ :##!L%@BZW'\4JX!+E*J,_AH:9TB'UN
M)V^A7V%^9+O3&MFARW<WV#@/S.?RZG;V5Y>$]W/S)<+58?THJ_QL*NP^:H0O
MS\0^G5B7L']9'=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW0)_)#HG9GR<Z)[4Z#[ IEGVKVEL[*[7K9?&DL^)K:B,5
M&"W'0+)=?N\7D(J7)4;,"%G@C8@@6*JQNY;"[CO(?BC8'[?4?814'Y'HUV/=
M[K8-WM]XLC22W<./F!AE/R=25;Y$]?*_[7ZSW;TSV=V!U'OR@;%[RZTWCN+8
M^YJ(ZRD69VUE9<37-2R.!Y()'B,D$P&F2-ED4E6!]Y"6LT=U;I<PFJR*&'V$
M5ZZ 6.YV^Z6$.XVC:HIT613_ $6 (KZ'.1Y''4JB3Q45)']--/%?_7* M]?\
M?95*:RL?F>LC=GB\#9[6$\1$E?M*@G^9/61S[KTJD;J.Q][Z1.W6!F][ ].D
MKO3K&7][H.F3)UV']^IZ=;63HUOQIV,:[*5.^<A"?L\0TE#A@X&F?)S1::JK
M4'ZB")M*FUM;W!U1GW OO9S2+6P3E:S;]2XH\U/PQ U5?MD85/\ 16A%''4]
M>S/*[7EV_,UVOZ<%4AKP:0CN;[$4T'])L&J'H\*M_P :/]?>+3IUD<1UF5O]
M]_3VE=.FB.LRM_OOZ^TCKY=-$=9?\1[3,O5?EUF1OQ_7Z?X'^GMAUKU7AUF1
MK&WX]IV6HZJPKU)!N/:-UZ9..N:G_>/]Z]I'7JK#J6C>T,B])V'4A3_Q4?Z_
MM'(O31'4E3?_ &//^Q]H9%ZJ>I"G_>?][]I7'33#HY?P%ZA/<_RIZNV]4TAJ
M\!MW+?Z0-TAH3/3+A=F%<M'!7)]/#65JT>/>_'^4 ?GV,_;;8?W_ ,YV=LZZ
MHHF\>3%1HB[J'Y,^A#_INL?OO/<]CV^]E-ZW6&31=7<7T5MFC>-=UB+(?XXH
M3+.*?[Z/6X5[SHZX*=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_U-_CW[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3=E\1B]P8G*8'-T%)E<+F\=6XC+XNO
M@2IH<EB\E3-1U]!6TTH*R131.\<B,"&4D'@^[QR/%(LL1*LI!!'$$&H(^8/7
MNOE5?.?XJ9_X?_+WNCXVUL%=+2[,WQ5P[%R%<A$VXNO-P,N:Z]SS2@:'>HQ5
M32FJ,;,L=0)H2VJ)K9Q\K[W'S%L-MNZ4K*@U@?AD';(OY,#3U%#Y]);V[M]O
MM);Z[;3%"K.Q]%45/\AP\^F_;V*@PF+I<;#8^*,--(!8S5#^J:8_Z[?0'Z"P
M_'L_ZP<YJWVYYGWF?=KG'B'L7^",81?R7C3BU3Y]*&,V-OZ\^[CH$S)U+0V(
M/^P/O8].BN5?/J:A_P!X/O9X]%CK0]3D-Q_O(]ZZ12+U,C;_ 'GWKATBE6H^
MWJ4A_P!X_P!\/?N!Z*IX]2D>G6=#_P 5'_$^W >B*:/BIZDJ?S_O@?Q[OQZ)
M9DHW3A$]Q_C^?=3TD8=3$;\?@_[P?=>D<J5ZSJVDW_V_^/O8-<=%,T94UZGQ
M2C@7X/T/]/?B.D;KT*G4_6VZ.WM[X78NTZ;S9/*S7GJI%?[+$XR(@UV8R4B
MZ((%-V/U9BL: NZ*2O==RM=HL7O[LT5. \V;R4?,_P N)P#T8;+LUYO^Y1[9
M8BKN<GR51\3MZ*!^TT R0.MC[I[J3:O2NQ\9LG:D'[-,HJ,KE)D5:_/9B6-5
MK<OD&!/KD*@)&"5CC"QIZ5'O'/>-WN][OFOKLY.%4<$7R4?9YGB34G)ZRYY>
MV"QY;VQ-ML1@99C\3N>+M\SY#@!0# Z%+V5]'G7O?NO=>]^Z]UX D@ $DFP
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M?RM?E/%UUOBHZ&WGD?!L[LC)1U&SJJJ?_)\%O^5%I4H-;$:(<Q&L<'Y JHX
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M2"9/,=.,4EP/]Y]MD>72(CIQB>Q'MLBO5"/+IRBD!'^!^O\ K^Z=-,*BAZE
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M,1/V*X8_E09Z)>9)/"V"\<8_1D'YLI4?X>OF/ ^\YQZ=8G74-#U)1O\ >/\
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M&A-.CF+G[E:88NPI]&21?YE:?L/33)UUOF C7M#<;\LH\&'KJ@77Z\TZ,/\
M6/T/X]B*'W?]K[H5CYAV\8![[N"/C_S4=37U'$>8'2U>:>791VWT ^V5%_X\
M1U$?9^[HV*/M;<:.OU1\'DU9>+BZF*_M:ON)R#,@EBWS;W4\"+RV(_(B2G3R
M[[LC#4MY 0?/QH_^@NI<&P][S*LD>SMTR(U]#IM_+,AL=).H0VX/'U]EMS[I
M>VL#F*?F';$9>(:_M0>%>!EKD9'KTS)S)R^AT-?6X(XUFCK_ ,>Z?J7J7LFL
M-H=GYA>2/\IACHQ<#4>:QH^/Z'\_0<^PM?>_/L_8BLW,%HV*_INTO$T_T)7_
M #'$#)QGHMFYUY4@S)?1?[4EO^.@]+;%_'7LRLT"HH,7B@3R:_+TL@7DBY_A
MGW/'%^+\?X^X[W?[V/L[8 _275S>T_WS:R+7' ?4>!]F:9'IGH.WGNERE!7P
MI))O])&P_P"KFCH4,/\ %2OD,;9S=U)3J#>6#%8Z:K+"]M,=56/#I_US"?\
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MT^5"TT,9$&XV6LJFX;?(ZFXM7.0K'2LMO*5;P;F.*4JZJR,FFA*,5;Z@V/\
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MH%W%K+;R&.04(_U?F.@722_LSZ1L@.#UG#>_ ])I(>LJO[M7I$\)'#J0LO\
M7_;CW[I,R>O6=7_H;^]=,-'UG67WOI.T0/0^?&[?8V-VUMNKGF,.,SDC;8RI
MUZ4%-F72.FED/T"152T\KD_15/M)>Q>-;L!Q&1^7^QU#7OKR>W-GMM?V\*ZY
M[,?5PXJ=4 )<#U+Q&1 !Q+#JYI9?\0?I]>#[#=".N6M1UE$MOR1_O(]ZH#UN
MIZRB7_6/^L;'W72.K!B.LHFM_4?[S[UHZL'ZYBH_VK_;W]UT'JPDZY_<'^J_
M[<>]:>K"4^O^K]G7?G_UO]N/?M)ZWXO7ON/]8?[$>_:3U[Q>NO.?ZC_;CW[3
MU4RGU_U?LZX&?_:O][][T'K1DZQF8_XG_>/=M'53)UC:7_$#_>3[V%'52Q/6
M(RW_ "3_ +P/=J =5J3UB:7_ ! _P')][ )ZU4=.6*S]5B9;Q_NTSM>6GD8Z
M6_JT9_LM_B/K^0?>.WO]]V;D/W\VBF[K]#O$"%;;<8D!E3B1%,M5%Q;ZC7PF
M8,E6,,D19BV;'W.OOW>[OW/.8RW+<G[UY:NY U_LMQ(PMY3@-/:O1C97FD:1
M/&K)( BW,,ZQQA!<Q.4H<O#Y:.0,P \L#V6>$G\21\\?T87!_!]\*/>/V0]P
MO8[?SLG.]H5B<GZ>[B#/:72C\4,Q5>X"A>)PDT=1KC 92?K1^[3][+V9^]=R
M<O-7M7N0DGB53>;;.4CW';W;\%U;AF(0FHCN(FDMIB&$4K,KJKVL?]>3[AEI
M">LD2:=9U3VF>7R'39;J0J7]IF?S/33-U+2/Z<>TDDG39/KU)5?P/^1>TCO7
MIMFZE1Q_\;/M@GS/2=WZG1I]/]X]M,W29VZGQ1VMQS[22R=)V/4Y$_'^W/LO
MD?IAFZG1)[0NU>DKMY=3XUMS[9)ITPQ\NID:_3VAGDITPQZGQI_OO\/9-*^H
M],N?+J?$OY_VW^M[3,=(KTG8U-.I\:_[Q_O?LME?IAVZG1KQ_K^RR9ZFGITR
M3Y].$2?3VF/2:1NG"-?S[17,E!3I.<#IQB7_ (J?9%.]6Z3,:GIQA7\^T!-6
MZ3R'RZ<H4^GMN1J#I(QSTZ1+R![*)GXGI*YZ-]T%\;<GV#+1[IW=!48K8\;Q
MST\#!H*[= 4W$-'R'BI#8>2IL"X.F$WU21Y^?=#^Y!OOO-=VWN![D12;?RHC
M*\:&L<^ZT-=$.0\5H:#Q+J@,BDI;$L6F@Q]]V?>BRY1CDV+EYEGW0@JS"C):
M_-^(:7^&/\)[I,41[0L=C:#$4%)B\71TV/QU!!'34=%1PI!34U/$NF.*&&,!
M5 'X ]]\-DV39^6]HM]@Y?M8K*RM(UBA@A18XHHU%%1$4!54#R ^?'K!F\O+
MO<;J2^OY&FFE8L[N2S,QXDDY)ZF^S3I-U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=?_T=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T3;YI_!#X[_//K.7KGO;:GW550I4S;
M*[!P)IL=V#U[E:B/0V2VMG9(I0$<A34T%5%-1U&E?- [)&R"+EOFG=^5;WZS
M:Y* TUQM4QR#T9:C\F!##R.35-=6D-VFB4?8?,?9_JIUH,_S#OY2GR9_E]9R
MKS&X\7+V;T/55QAVWWEL_%UK8&*.>I,./QF_\9^[)M_)N#&!#4RR4LSMHI*N
MI99 F5G*//\ LO-L0CA;P+H#NA<C5PR4./$7Y@!A^)1BH0O=LFM34C4O\0_R
M^G^#JK99"/\ $?[[\>QUT5LA'4A9 ?S[]TPT8/64-[W7I,\'657]^KTC> CA
MUG64_GG_ 'OWOIAHZ8(ZSI*00R,592"I!(8$&X(8<C_7]Z^WIAH0P(.0>KL>
MBNPU[(ZTV]GYIUER]/!_!MP*7#2KFL8H@J)9>>#4)XZH"_Z90/K?V'+F+P9B
M@X<1]G^K'7(_WCY*DY ]P;[9$33;.WCVV* P3$LJK\HFU0D_Q1GRIT,0D(_)
M'^\CVGP>HQ$G602_ZQ_W@^]:1U</US$O^N/]8^_:3U;5UR\W^U?[Q[UI/6]0
MZY>7_%?>J'KU1UWY?\5_V_OU#UZHZ]Y?\5_V_OU#UZHZZ,O^(_V'/OU#UZHZ
MX^;_ &K_ 'CWO2>O:AUQ,O\ KG_7/O>GK6KK&93_ (#_ 'D^]Z1U4N.N!DO^
M2?\ >![]@<.J&3K$9+?G_;<GWOJA<GK&TG^P_P 3[]U7KE35]313I4TD\D$\
M9NLD;:;#\@CZ$'\J18_GV'.;.3>5^?-BFY9YQL8=QL+@4>&90RDY 93AHY%K
M5)(RLB'N1E.>AO[=>Y7/OM)S;:\]>VN[7.R[M9FL5S;2%' J"R.,I+"] )8)
M5>&5>V1&4D="QM[L.CJ2E+FM%'.;*M:@/VDA^@,PY,9/]>5_J5'OD!]X/^[T
MYFY9\;F?V3>3=[ 59MND(-]".)%N_:MV@'!*)<THJK<,2W7T>?= _ODN2N>U
MMN1?O0I%R[NQTQQ[S"K#:KIN -W'W/MTK&FJ0&2R)+.[6<8"="I"$E1)8G62
M-U#I(C!T=6%PR,MP0?P1[YE7]M>;;=R[?N$3P3PL4DCD5DDC=31D=& 964BA
M5@"#@CKMSMNZ[=O>WP[OLUQ%=VERBR0S0R++%+&X#))'(A9'1E(*NI*L""#3
MJ8J6]E;R=*R:=9U2_P!/:9GKTVS=2HX_]@/;1/KTG=^IB1_\:]M,W2=GZGQ1
M6Y/M+))Y#IAFZFHG^W_WKVADDZ89NID<?T]H9'KTF=^I\:>TY/GTP33/4Q%]
MII7H*=,,>IT2?[<_7_BGLHN):X'31-!U.C2_'^W]H2>DSMU/C7Z?[Q[1S2>7
M3+&@IU.C7Z?T'U_U_97-)05Z88U/4Z-;G_??[#V@8],NU!TXQK_MS[:=M*UZ
M2,:GJ?$GT'^Q_P"*>R:YEX],NW3C&OT']?\ >O91(W2<FF>G&-?H/;(P*GI(
M[>?2AP^*R.8KZ3%XFAJ\EDJZ58*.@H:>6JJZJ9_TQ000@LQ^IL!].?I[?VS9
M]YYDW6#8>7K66^O;MQ'#!!&TLLKG@J1H"S'B<#A4G Z++^^L]MM)+[<)4@AC
M&IW=@J*H\V8D #[3QZL:Z1^(\&+-)N?M2*"LR"F.HHMGI)'44%(P]2OGYDNE
M0X/_ "C1L8A;UM)<HO7O[L']W=9[,]MSU[_1I=7:E9(-G5EDMXB,@[@ZU2X<
M'_B-&S6XI^J\X9HDP[]S?O!2WPDV3D1FCB-5>[(*R-Y$0 T,:T_T1@)#^%4H
M&)[D1(T6.-51$541$4*B(HTJJJO  '  ]]8(XXX8UBB4*B@!5    %  !@ #
M  P!UBNS,[%W-2<DG))/F>N7N_6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO_]+?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TVYG#8C<6)R> W!BL;G<%FJ
M"KQ69PN9H:7)XG+8NO@:EKL;D\;6J\,]/-$S1RPRHR.I*L""1[O'))#(LL+%
M64@@@D$$9!!&00>!'6B 10Y'6LI\^_\ A-_U-VS49GLCX49O$]&[ZJY)\A6]
M2;C?(3].9NID5I9DVU6TJ5-=MN220EE@CBJJ!;K%!3T40N)JY4]X]PV\+9\R
M*;J(8$JT\8#^D#19/MJK^99CT27>RQ2U>V[#Z>7^Q_@ZU"?D=\3OD9\2-Y2[
M&^0_4N[>M,UYIX\;69>@\VVMR14[%7K=I;NQYFQF5I^.9:"KE53=7TN&49![
M-O\ L^_VXNMHN$F7S /<OR=#1D/R8#H-7%G- VF92/\  ?L/1>UD(_Q'^^_'
MLXZ1E".LRR _GW[IIHP>LH?WZO2=X.L@?WNO25[?HW_Q![07:6^)MG92I$>%
MWOX*:F:5K1TNY*>XQC G]/W*L]*0!ZI##?A?:&_A\2/Q!Q7_  >?^?K%7[T_
MMQ)S+R:O->W1Z[O9]3O09>T:GC#Y^"0LPK\*"6@JW5JHDM^2/]Y'LDTGKFIU
MD$O^(_V/!]ZH>O=<Q)_@1_K'WKKU3UR$G^)'^N/>^MZFZ[\H_K_O!]^ZWK;K
MOR?XK_M_?J]>UGKWD_Q'OU>O:SUUY1_7_>#[]U[6>NC)_B3_ *P]^ZUJ;KB9
M/\"?]<^]=:J>L9E_Q'^PY][H>O=<#)?^I_WKWO3U[K&TG^-OK].3[W0=:ZQ-
M)^?]Y)][Z]U@:7_7/^\#WNG6BPZP-(3^?]@/I[V!TVT@Z4."WCF]NN/L:K73
M:KO05(,U(_-S9"04)_+1LI/Y)]X_>]'W8?:#WUMBW.6W"/< M(]PM2(+U,4&
MJ0*R3JHPL=S',BU)15)KUEQ]VK[\GWB_NL7BQ^V^\F;9RVJ7:+\-=;9+DEM,
M)=9+5W)J\ME+;2O0"1W4:>ARV[VAM_+&.GR+?P6L:PM5.IH7?\Z*W@+_ %_=
M"C\7)]\?O>K^[W]Y?;@3;OR4HYJVM"2/I$9;^-/+Q+*K-*> _P 4>X8FK-'&
MO7T0?=L_O>/NY^\WT_+_ +E,>1-\D"J?KY%;:I9",^#N8")"*@L?KX[1%!"+
M-*W0K0A)$21&61'4,C(P='5A<,K+P01]"/>!-U;W-E<26EY&T4T3%71U*NC*
M:,K*P#*P."" 0<'KJ=:;A9[E:1;AMTR3V\ZJ\<L;*\<B,*JZ.I*LK @JRD@@
M@@D=34C_ ,/]A[1LW6V?J='%:W'/M-))Z=,ENIB)_M_]Z]H9).F6;J7''?@?
M[$^T4DG2=WZG1Q^TQ-<GI@GS/4Q$_'X]LN]!TRS=3(T_P_UO^*^RN>;RZ9)\
M^IT:?3V6,U3TP[=3HTM_Q/MB5](H.F"?/J=&OT_VP]EDC],.W4V-?H/]O[+9
M'U&O31-.G")/^-^V>DLC=3XU_/M#<RT%!TR30=.$2?\ &_9'-)4])F-3TXP1
MEF  +,Q 50+DDFR@ ?GVBHTCA$%230 <2?( >O2>5PHR: =&OZH^*78G8'VV
M2S$#;*VU(4<Y#-4TJY2L@;U:L7A6T2,"+%9)VBC(.I&>UCFM['_<5]W/=LP[
MOO\ $>6]E>C&>[C87,J'-;:S.B1JBA$D[01%3J1I*:3 W/GOQRAREKLMN8;G
M>BH\.%AX2-Z2S"JBGFJ!W!PP7CU9?UGTSL3JBB\&V,7JR4T2QU^X,B4J\W7V
MY*O5:56*,\?LP(D? )4MZCV5]E/NW^U?L-MWT_)-CJO9%"SW]Q26]G]09=*B
M*,X_1@2*(T!9&<:CA=SM[C\U<^W/B[W/2%35+>.JPI]BU)9OZ<A9LD @8Z%7
MW/'0#Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO__3W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2*[!ZWZ^[9VGE-B=H[(VGV
M)LK-QB++;4WKM_%[FV_D%7F,U6)S$4T+,A]4;E-2-9E(8 ^U-I>7=A.MU8RM
M#*O!D8JP^P@@]5=$D72X!!\CGK7D^5__  FF^+/:CY+<OQEWMN;XW[KJI9ZM
M=KURU/8W54\TDGF:"EQF5J(LSC0[%QKARL\$*E1%1A4"&7-A]Y]]L L.]1+>
M1C&H4CE_,@%&_-03YMT3W&R6\G="2A].(_S_ ,^M<KY(_P C?^8Q\<#7Y&7I
MB3NK:-$7(W?T%6S=B1RQ(ID:5]FQ04VYHE5!JDDDP@B7G]T@7]S%LWN?R?O%
M$%S]-(?P3CP_^-U,?V /7Y=$=QM%W%G3J'JN?Y<?Y=5-Y3&9; 9*MPV<QN0P
MV8QM0]+D<3EJ*IQN2H*J(VDIJVAK%26*1?[22("/R/8^CDCF021$,IR""""/
MD1T5-&RFAZB"7^O'N_313U'4JGJI:>:&HIY7@G@DCF@FB<QRPRQ.'CEC=>0R
MD @@W!]Z/H>DT]I#<Q/!.H='!5E85#*PH5(\P14$'B.KH.B.U8.TMA8_+2R*
M-P8P1XG<U.ME*Y2GB'^6K&/I%5):9+"P):,$F,^R*XA\&0J.!X=<???#VUG]
MK^>I]IC4_07-9[-^(,+,?TR?XX6K&U<D!7( <=#4)O\ $?['CVQU$%1US$G^
M'^Q!]ZZ]UR$O^)_V//OU!U[KEY?]J_WCWJ@Z]U[R_P"U?[Q[]0=>Z]Y?]J_W
MCWZ@Z]U[R_[5_O'OU!U[KCY?\6][H.O=<3)_A_L2??NO=8S-_M0_V'/O?6JC
MK&9?]<_Z_ ]^IUK4.L9E/]0/];WNG52X'6(O_P C)][ITV7)X=8R_P#L?]Z]
M[QUKN/'K&7_Q_P!M[]GK87KA<G_#WN@ZN%ZZ) ^OOW5P!TH,)N_<6W7!Q&3J
M*:+46:E<K/1N2?46I9PR G_5!0W]#[ACW3^[[[.^\L!7W"V.WO+B@"W2@P7B
M #M"W4)CG*KY1N[1'@R$8ZR.]COO9_>&^[K<JWM+S/=[?:ZBS6+LMSMTA8U<
MM8W(EM@[YK-'&DXK595-#T-.![WA4)%N/#LC<!JS$,'4WXNU#5," /J2)C_@
MOX]\T_='^ZUO TE][/<PJZ9*V>ZJ58>=%O;9"K$\%5[1 ,:I34D=C_9;^^]L
MY$AVO[P7*;1OA7W#8W#H:XU/MUY*K(!\3M'?RD@G1 " K#/@]^;/SP08[/4+
M3R<"EJI/L:S5]"BTU9H9C?BZ C^A/OGG[D?==]__ &N:1^;>6+U;>*I-S;1_
M66H7B&:XM3-'&",TE*,.#*""!U4]J/OM?=:]ZXXEY$YSV]KJ:@6SNY?W?>ZJ
MT*+:WH@EE()I6%94/%792"5W''[QR>2O63[OU-CC]IR:Y/3!/F>I:)^![:=P
MHZ:9NI4:7_''^]^RZ>:G3)->I\:?[[_B/95(Y8],LW4R-/S^?Q[9=@HSTG)K
M]G4Z-/9=+)7CTT[=38T_/^V]ELTGX1TP3U-B3Z'_ &WM*37IEVZ<(T^@_P!O
M[9E?2O24FIKTO]H=>;WWQ.*?:.U,[N ABLDN-QU1/20$?7[JNTB"(<@7DD47
M('Y'L1<I>V?N-[CW/TO(NR7FZ-6A:W@=XD_YJ34$48R!61U%2!6I'08Y@YNY
M9Y9B\7?[^"T]!)(H<_Z5*ZV_VJD]''V#\%][Y;P5>_<YC=HT;!7DQF/*9W._
M0$P2O"RT<7!MK6>:Q!]!%O>;?MI_=K>Y&_F.^]SMRM]BMS0M;P4O+SR)1BA6
MUB)K36LUQ0@UC(I7'GFK[T'+.WA[?E6UDW"48$DE8(/M (,S?Z4I'4?BZ/5U
MS\?>K>L?!4X#;T=9FH+%=Q9TIE<RL@X\M--*HBIFMQ>EBCN/K?WTG]H_NI^R
M?LP8[WE?:5N-QCR+^](N;L-_%&S*([<^5;:*&HPU<]8O<X^[7/'.VJ'=;LQV
MS?\ $>"L4-/1@"6D'_-5GH>%.AJ]Y&]1KU[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_]3?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= KV]\;OC[\@*'^'=W])]6]L4Z4
MYIJ=]_;&VYN>MH(B2P_A>2RM/)4TC*68K)32HRDDJ03[,MOWG=MI?7MES+;G
MC^F[*#]H! /Y@]-200S"DJAOM /54G;/_">+^6CV6U14;>V#V'TM7U1EDEJ^
MJNR\UX?/*=0DBP_8Z[BH(54_2*FI8HP. H]CRP]W>=+*@FECN0/*6,?X8_#8
M_:23T7R[-8R<%*_8?\]>J[.P?^$K>SJF26HZI^8FYL'$K7AQ78/4N+W3)*K3
M@6ES^W,WAQ&4C+&XQKZV %D!NHPM/?6Y44O]N5OG'*5_XRR/Y_TL?/I!)RZA
M_LY"/M%?\!'^#H).OO\ A.M\U>C]UR9[9?>/QZWQMVKIC3;BP&0K^P]I97+T
M,5.U1$<5#_!,A1_?0SV6E^YJX8F5G62>%9&(.Q[T\MW2A+JUN(CZ@1N!GS[U
M-*9- 3Z ]0=[Z^Q1]U.2I=MMFC&Y6FJ:RD8E:2@9B9J8CG "-4T5M$A!\,#H
MJ>7QF3P&5R6"S=!58K,X:OJ\7E<97P24M;C\C03M2UM%5T\H#)+%(K(Z,+@@
M@^Y)BDBGB6:%@R. RD&H((J"#Z$=<6[VTOMMO)=OW"-H9X':.2-P5='0E61E
M.0RL""#D$=0 _P#O@?=Z=)M9\QUR\A_JW^W]^IUOQ.N_*?ZG_;#WJG6_$'7?
ME/\ JO\ >![]3K?B#UZ]Y3_JO]X'OU.O>(/7KKRG^I_VP]^IUKQ!UUY#_5O]
MO[W3K1DZXE_]\3[]3K6LGRZXE_\ '_;>_4'6M3'KB7_US_K^]]:H3Q/7 O\
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M\2N;?[L3[M7,&I]A&Y[$V2HM;WQHQZ!EOX[N1E'H)5;'Q<:YQ<D_WQ'WNN6
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M?_6M R2;@W;N[.NC7\5%_"\'1RC_ %$T9AJIK?\ !)U-_P _CW,G+O\ =O\
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M(^W*G-">N5ON'[5<\>UVZ_NKG*R>WU$^%,.^WG _%#,.Q\4)0TD0$>(BDTZ
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MW5E__03Y\^/^?1_$'_T >Y__ +/_ '[2.M]>_P"@GSY\?\^C^(/_ * /<_\
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M'NCM/<,#ZOMI*+:='(II()BCK#D,M-1T3,K)]SK&GWL GKW6K=\E_P#A3?\
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MNEJBFJ.J/DAW=L%:36(Z#;?9F[\?A9(Y'\LD%9@4J_LJB-G]9BGIW0N VG4
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MC1M";R14]%LG#T6\-ZO22-J"93?6]J>H7S+]!48K&8\V_%^?=M(Z]U3WV?\
M)OY&=UU%55=O=\=O]EO6N[SQ;W[%W9N2BLZ-$8H<?E*N2"*(([1K%%&J*A*J
MH7CWNG6N@.]^Z]U[W[KW3S@=Q[AVKD(\OMC/9G;F5B4+%D\#E*[#Y"-1(LP6
M.MQ[QR :T1[!OJH/U ]^Z]T?;IC^;#_,1Z'J*5]D?*WM3)X^E8!=O]D9E>V=
MO&G))DI(L5V4F42GC:[7-(8G4G4C*UF&J#KW5\/Q._X4\UAJ\7MCYG]+47V<
MLD-+/VMT?]S#)1(;Q+69SK/<E3/YARLE3/CLNA4!S#0N2L8T5].M];2W0OR*
MZ1^3_7^/[1Z$[)VUV9LG($1?Q3;]6S5.,KA&)9,1N+"UBQ5V,KD5E:2AR%-#
M.JLK&,*RDUZ]T-/OW7NO>_=>Z][]U[KWOW7NO>_=>Z(C_- _[=V_-+_Q7'M/
M_P!Y>?WL<>O=?+^]WZUT8[X=?]E=?%C_ ,6.Z/\ _?FXOW[KW7U8?;?6^O>_
M=>ZU$_YH'\\'YG?#_P"<W>'QUZGQ?2E1L#KS_1I_ )MV['SV8W"_][>H-O[Y
MRO\ $,C19JDBDM6Y.I$6FG33$$4ZBI8V %.O=$&_Z"5OYB7_ #I?CC_Z+3='
M_P!D?O=!U[KW_02M_,2_YTOQQ_\ 1:;H_P#LC]^H.O=%L^6G\Z[YB_,[H_<G
MQ_[?QG3--L3=.0VYD\G-L[9.=PN>6IVOG8-PXT4N0KLS61HIGIXQ*#3MJ2X!
M4FX]0=:ZJ(][Z]T9/XE_*CLWX8]X;;^0'4$&UZG?>UL?N/&8R'>.*J\U@6IM
MT8.?;V2-5CZ&JHY'805$AB(G72]B0P%C[CU[JW?_ *"5OYB7_.E^./\ Z+3=
M'_V1^]4'6^O?]!*W\Q+_ )TOQQ_]%INC_P"R/WZ@Z]U[_H)6_F)?\Z7XX_\
MHM-T?_9'[]0=>ZVCOY.WS-[>^=GQ+R/=G=E-LZEWC2]N[QV/%%L?"UV!PO\
M!<#A<1D*%FH<A65TAG,E=-Y)/-8C2 HL2:GCU[JU?WKKW5*?_"@S_MUUW1_X
M>'37_OT\7[LO'KW7SO/=NM=6F?R4?^WHOQ'_ /#PWA_[ZS/>_'AU[KZ4?MOK
M?1;_ )-_+CX\_#S8,G8WR&[+P>P,%(9X,-15335^YMUY&"+RG$[1VMC5EKLC
M46TZQ3P,D0(DG>*(-(-@5Z]UJF?*W_A3IVCN"NR6W?AUU#@^OMN++-3TO8_<
M$2;KWSD*>W[.0QNR<14)A\3*#_NNLJLLC+R0C&R[T]>ZHK[;_F0_/+O*IGG[
M*^6/=V5IZEVDFPF#WMD]C;4>1@1Y!LW89QF)! 9E4K1 J"56P)'NU!UKHG.5
MS.7SM6:_-Y7)9FN*",UF5KJK(59C5BZQFHJV=](+,0+VN2?S[]U[IRVYO+=^
MSZ@U>TMU;DVM5EUD-5MS.9/"5!D1&B60S8R6)KA7=0;WLQ'T)]^Z]T?;I?\
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M]VJ_ ;?QE%#XZ*-98/NJ"HTS79]:?MC8->O=7M?] P?P'_Y^Y\OO_0^Z8_\
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M>Z][]U[KYEO\W?\ [>5_,7_Q+^2_]U5)[N.'7NJXO>^M=?2C_DH_]NNOB/\
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MYJ_S>^553)_>#HWX?=-=G8OK6H$WW6$GEV_L[,; ZD?'LK%EAR=<FX=\4IU
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M8;(Z]J,]3XW$8"3'09J;:-#1M5)3M-,T"SE@A=RH!9K[''KW6I[[MUKK9O\
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M\IDZRFQ^-QN/IIJVOR%?6S+34=#0T=,K22S2R,L<44:EF8A5!) ][ZUUM+_
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MW]U=?]#],[%W10[KZCAHMR;.ZOV1MC/4D-;V7C:2LBI<QA*&"HC6:)VBE5)
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M^$OOR!K-S]*?(#XV9BN>9NJ=Y8#L?9L,X4LFW.RZ6IQ^X<=0LG/AI,EB%JI
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M_P#@FJKW9>O=;?'NO7ND?V%_QX&^/_#/W-_[I9_>QQZ]UK+?\):?^9!_*?\
M\2_LW_WC'][;CU[H/_Y]^P-S?$[Y>?$#^9SU3CBN1QVZ,#M/?ZQ:J>AR6[>N
MY_X]M2GS-2A+L-Q;=.4P=4%  I<<JCU.2?#A3KW3%_-)[7Q/\T3YP?R^_@ST
MQN"JRW56Y,-LOO#?V0Q<BK/#B^U]M1;]DKJ^G42+%683K^"7)TUI"NK+-&Q+
M 6\,"O7NMECY78G&8#X8?)3!86@I<5AL+\8>X\3B<90PI34.-QF.ZIR-'04%
M'3Q +'%#$B1QHH 50 .![KU[KY5WMSK77__6VTOYM7RRG^&_P5[B[-P>1_AG
M8>YJ"'JGJFHCF\%9!O\ [ AFQU+F,;)?_@3A\<F1SL*D$,U%I8%21[V!4]>Z
M^9NS,[,[LS.S%F9B69F8W9F8\DD_4^[]:Z6W6G7FZNW.Q-B]6;&Q[97>78V[
MMO;(VOCAY *O/;GRL6&Q<4KQ*[)'YID,DFDZ$NQ%@??NO=?4H^(WQFV+\/\
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M=>Z][]U[K4W_ .%4?_'@?#/_ ,/#NG_W2[<]V7CU[K38]VZUUMD?\)7/^/\
M_F9_X9_2W_NZW'[TW#K?6Y/[IU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z^9;_
M #=_^WE?S%_\2_DO_=52>[CAU[JN+WOK77TH_P"2C_VZZ^(__AG[P_\ ?IY[
MW0\>M]6F>]=>Z][]U[KWOW7NM'G_ (4N_+2H[#^1FQ/B9MW):MI]!8&EW;OB
ME@9PE9VKV#C(\A0P5JW*2?PO;TE$U*ZV*/D:M&N0 ME'GU[K66]VZUUL _\
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M6^O>_=>Z][]U[I']A?\ '@;X_P##/W-_[I9_>QQZ]U\D#W?K77O?NO=;)?\
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:XO_"GS_L@?J/\ \6^V#_[YC?\
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M%^_=>Z^K#[;ZWU[W[KW7O?NO=>]^Z]U[W[KW5*?_  H,_P"W77='_AX=-?\
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M:F1A8,U3N&AS%42 +"0*;D%C<<.O=4[>]]:ZWJ?^$Q6_)<]\)NV=B54[S3;
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M#M5< DZ\"X$%#!'^>4//X%UX=>ZHU][ZUUO;_P#"8K.G(? [M3"S58FGV_\
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M\.H/_1E[,_\ JWW[KW7O]F$Z#_Y_AU!_Z,O9G_U;[]U[KW^S"=!_\_PZ@_\
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M;B_?NO=?5A]M];Z][]U[KWOW7NO>_=>Z][]U[JE/_A09_P!NNNZ/_#PZ:_\
M?IXOW9>/7NOG>>[=:ZNL_P"$^?\ V]%Z7_\ #/[E_P#?693WIN'6^OHA^Z=>
MZ][]U[KWOW7NO>_=>Z][]U[JE/\ X4&?]NNNZ/\ P\.FO_?IXOW9>/7NOG>>
M[=:ZM#_DMT=-7?S0/B)#5PI/$F^=QUB(]RJU./ZXS5?13"WYCFBCD7_%1[T>
M'7NOI6>Z=;Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K38_X51_\
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M9L],)(F8!8'H&A6,FZ!0C!64J+CAUKJL7WOKW7TH_P"2C_VZZ^(__AG[P_\
M?IY[W0\>M]6F>]=>Z][]U[KWOW7NB(_S0/\ MW;\TO\ Q7'M/_WEY_>QQZ]U
M\O[W?K71COAU_P!E=?%C_P 6.Z/_ /?FXOW[KW7U8?;?6^O>_=>Z][]U[KWO
MW7NO>_=>ZI3_ .%!G_;KKNC_ ,/#IK_WZ>+]V7CU[KYWGNW6NKK/^$^?_;T7
MI?\ \,_N7_WUF4]Z;AUOKZ(?NG7NO>_=>Z][]U[KWOW7NO>_=>ZI3_X4&?\
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MMQ^]-PZWUN3^Z=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NOF6_S=_^WE?S%_\
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M:>4EW3M[S0N R218.;%4TBMSJC-[7L*'CUOJU'WKKW7O?NO=(_L+_CP-\?\
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MI#5(A/CG@AP62E"-9O'5(]M+J39>O=:H_NW6NMCK_A,'_P!E\=N?^*@[^_\
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M255/*NN*>GJ("R.C @JRD@CD'W[KW4GW[KW7O?NO=>]^Z]UH9_\ "E;O*N[
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MM,N\]UU>X8J,QJSA!"E0L2QJQ5%4*OI ]N=:Z"#W[KW7TH_Y*/\ VZZ^(_\
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M/6^EA[UU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JE/\ X4&?]NNNZ/\
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MV<KFKZ0C/1T(6G-145]":];ZOF]ZZ]U[W[KW7O?NO=>]^Z]UIL?\*H_^/_\
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M[KWOW7ND?V%_QX&^/_#/W-_[I9_>QQZ]U\D#W?K77O?NO=?6_P"O?^/ V/\
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MYFRTQ3$=$_&*AK-:%9\EB.U<K3",']Q324NZ*-R3^&\X _(/O6GKW16NT?\
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MY40L5B37-)'&_NO=?0U_E??RQNM_Y<O5-9BZ>MH-]]X[[2FJ>U.U!C4I?NQ
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MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM-C_ (51_P#'_P#PS_\
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MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UIL?\ "J/_ (__ .&?_AG]T_\
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M>]^Z]UIL?\*H_P#C_P#X9_\ AG]T_P#NZVY[NO#KW6IO[WUKK;(_X2N?\?\
M_,S_ ,,_I;_W=;C]Z;AUOK<G]TZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU__7W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UIL?\*H_P#C_P#X9_\
MAG]T_P#NZVY[NO#KW6IO[WUKK;(_X2N?\?\ _,S_ ,,_I;_W=;C]Z;AUOK<G
M]TZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__0W^/?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]UIL?\*H_P#C_P#X9_\ AG]T_P#NZVY[NO#KW6IO[WUK
MK;(_X2N?\?\ _,S_ ,,_I;_W=;C]Z;AUOK<G]TZ]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
,W7O?NO=>]^Z]U__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>bios-20201231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bios-20201231_g2.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *O!!T# 2(  A$! Q$!_\0
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M0T6VN)[;S)7W;FWL,X8CL?05I_\ "'Z1_P ^G_D5_P#&CP?_ ,BY:?\  _\
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M:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_GT_\
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M:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_GT_\
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M:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_GT_\
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M:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_GT_\
M(K_XT?\ "'Z1_P ^G_D5_P#&MJB@#%_X0_2/^?3_ ,BO_C1_PA^D?\^G_D5_
M\:VJ* ,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\ D5_\:VJ* ,7_ (0_2/\ GT_\
MBO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_GT_\ (K_XT?\ "'Z1_P ^G_D5
M_P#&MJB@#%_X0_2/^?3_ ,BO_C1_PA^D?\^G_D5_\:VJ* ,7_A#](_Y]/_(K
M_P"-'_"'Z1_SZ?\ D5_\:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_Y%?_
M !K:HH Q?^$/TC_GT_\ (K_XT?\ "'Z1_P ^G_D5_P#&MJB@#%_X0_2/^?3_
M ,BO_C1_PA^D?\^G_D5_\:VJ* ,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\ D5_\
M:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_GT_\
M(K_XT?\ "'Z1_P ^G_D5_P#&MJB@#%_X0_2/^?3_ ,BO_C1_PA^D?\^G_D5_
M\:VJ* ,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\ D5_\:VJ* ,7_ (0_2/\ GT_\
MBO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_GT_\ (K_XT?\ "'Z1_P ^G_D5
M_P#&MJB@#%_X0_2/^?3_ ,BO_C1_PA^D?\^G_D5_\:VJ* ,7_A#](_Y]/_(K
M_P"-<AXPTVVTO4HHK6/RHVA#%=Q/.YAW/L*])KS_ .('_(9A_P"O=?\ T)J
M.F\'_P#(N6G_  /_ -#:MJL7P?\ \BY:?\#_ /0VK:H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO.OC
MQ\9;#X&_#^Y\0W</VRZ9Q;V5GNVF>9@2 3V4 %B?0>N* /1:*^=_@5H'BSXR
M^$[;QQX^\3ZQ&FIL\NGZ'H=[+IEM;P;B%+&!DD<G!(W.?E(SDGCH?%GA'Q;X
M-\8>$+KP]XMU:7PE-JL-OJFCZA+]J95;A'2XD#3;=P 96<YW>F10![/161XB
M\7:%X/MH[C7M:T[1+>1MJ2ZC=1VZ,?0%R 35BWU[3+O1_P"UH-1M)M+\LS?;
MHYU:#8 27W@[=H /.<<4 7Z*Y?3?BIX+UJWO9]/\7Z#?06,?G74EMJ<$BV\>
M<;Y"K':N>YP*NV?CCPYJ.@S:Y:>(-+NM$ASYFI0WL;VR8Z[I VT8]S0!MT5B
M6?CCPYJ'A^;7;7Q!I=SHD(8RZE#>QO;1[?O;I VT8[Y-9</QB\!7%E<7D7C?
MPY):6[(LUPFK6YCB+9VAFWX!.#C/7!H Z^BJ6CZUI_B#3XK_ $J_MM2L9AF.
MZLYEEB<>H920?PK)UKXD>$O#>I)I^K>*-%TN_DQLM;W4(896R<#"LP)_*@#H
MZ*S-<\4:-X7TW^T=9U:QTG3]RK]KOKE(8LGH-[$#)[<UG)\3/"$EC8WJ^*M$
M:ROYC;VEPNHPF.XE!P8XVW8=L\8&30!TE%?/=U=:AK7[3VFZCI?QAT(^'88C
M:S>$8=65KAYE5P\?V8':S;OF+GYUP1CY17M6I>-?#VC:Q:Z3J&O:98ZK= &"
MQN;R..>;/ V(S!FZ'H* -JBH%OK9K,W:W$1M0I<SAQLVCJ=W3'O63X?\>>&?
M%L\\&A^(M)UJ:#_6QZ??13M'SCY@C''XT ;M%<WJWQ+\(:#K TG4_%6B:=JI
M*@6-WJ,,4^6QM&QF#<Y&..<U;L?&GA_4]<N=%L]=TV[UFUR9].@O(WN(L8SO
MC#;EZCJ.] &S1110 45S^E_$+PMKFKR:5IWB71]0U2/.^QM;^*2=<=<HK%AC
MZ5Y;^UQ\:KGX0_#29]"U*RM?%%Y)'%;1RRQF>.(D[YDB;E\8VYP0"V>U 'N5
M%?*_P%T7Q?XQO? 7C+1?B0VHZ*NG*GB?2[S5IKZ1[LAV(\IF9(B0R# *%=N0
M#DY]^^)7A^'Q!X1U!9+W4["6V@EGAGTK49[*17$;8):)UW#_ &6ROM0!U5%?
M#/[$-]K'Q>U#Q;%XN\4^*M62QBMFMQ_PDE_#L+F0-_JYESG:.N>E>\>&_#0\
M)^/K3QA9^,=>G\"7.EW@NK?7M9FN;2SD1X]DP>5V"J5$G+$XQUYP #VZBOG;
MX"ZI<^%]2\=ZOXJ^,WA_QAHKW"SP^3K*31V,;2,%>0L=L ;<JB-3MR.#TKV3
M0?B9X0\4S3PZ+XKT35Y;>(SS1V&HPSM'&.KL%8X49')XYH Z6BL7PWXU\/>,
MXYY/#^O:9KL=N0LS:;>1W C)S@,48X)P>OI4>E^/O#&MZQ-I.G>(])O]5ASY
MMC:WT4D\>.NY%8L,>XH WJ*CN(5NK>6%RX212A,;LC $8X92"#[@@BO@']HQ
MO&_[/_Q<TRY?Q;XNU7P%?S+<Q6C>(+Q28U8>=:F42;@P'1LYPRYR0: /T"HK
M@/%7B/1=4^%$6HV=S?7MAJ,$"Z:=-U":"ZN99"H@19D<.&9BH)+?WMW :F^
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MC'N: -NBL?3?&6@:QH<VM6&N:;?:/"KM+J%M=QR6Z!!ERT@)4 #KD\5G:?\
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M3Y]P^OOA'^S;H_PO\/\ B2UFU&XUO5_$@<:IJKH('D#!@5C4$[!EV/4G)Z\
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M =AK?P7UN_\ #/B/P_:>,5&D>()[N6[@U/2UNC;K<2,S);$2)Y>-QQO\P9Y
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MWPD_8W\=^&O%>HV&I?9H7:P:QFDE$4#,A\LET0\-N(P/XJZ?]@K_ )-\M/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M*FJZ;#K.FW%C<M,L%PAC<V]Q)!)@]=LD;*RGW4@UP'@/]G/P!\,M:_M7PQH]
MSI%Z1M=H=5O&24<\2(TI5QSG# X//6O2J* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS_ .('_(9A_P"O=?\
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M^%']J:O_ - 3_P FT_PH VJ*Q?[4U?\ Z G_ )-I_A1_:FK_ /0$_P#)M/\
M"@#:HK%_M35_^@)_Y-I_A1_:FK_] 3_R;3_"@#:HK%_M35_^@)_Y-I_A1_:F
MK_\ 0$_\FT_PH VJ*Q?[4U?_ * G_DVG^%']J:O_ - 3_P FT_PH VJ*Q?[4
MU?\ Z G_ )-I_A1_:FK_ /0$_P#)M/\ "@#:HK%_M35_^@)_Y-I_A1_:FK_]
M 3_R;3_"@#:HK%_M35_^@)_Y-I_A1_:FK_\ 0$_\FT_PH VJ*Q?[4U?_ * G
M_DVG^%']J:O_ - 3_P FT_PH VJ*Q?[4U?\ Z G_ )-I_A1_:FK_ /0$_P#)
MM/\ "@#:HK%_M35_^@)_Y-I_A1_:FK_] 3_R;3_"@#:HK%_M35_^@)_Y-I_A
M1_:FK_\ 0$_\FT_PH VJ*Q?[4U?_ * G_DVG^%']J:O_ - 3_P FT_PH VJ*
MQ?[4U?\ Z G_ )-I_A1_:FK_ /0$_P#)M/\ "@#:HK%_M35_^@)_Y-I_A1_:
MFK_] 3_R;3_"@#:HK%_M35_^@)_Y-I_A1_:FK_\ 0$_\FT_PH VJ*Q?[4U?_
M * G_DVG^%']J:O_ - 3_P FT_PH VJ*Q?[4U?\ Z G_ )-I_A1_:FK_ /0$
M_P#)M/\ "@#:HK%_M35_^@)_Y-I_A1_:FK_] 3_R;3_"@#:HK%_M35_^@)_Y
M-I_A1_:FK_\ 0$_\FT_PH VJ*Q?[4U?_ * G_DVG^%']J:O_ - 3_P FT_PH
M VJ*Q?[4U?\ Z G_ )-I_A1_:FK_ /0$_P#)M/\ "@#:HK%_M35_^@)_Y-I_
MA1_:FK_] 3_R;3_"@#:HK%_M35_^@)_Y-I_A1_:FK_\ 0$_\FT_PH VJ*Q?[
M4U?_ * G_DVG^%']J:O_ - 3_P FT_PH VJ*Q?[4U?\ Z G_ )-I_A1_:FK_
M /0$_P#)M/\ "@#:HK%_M35_^@)_Y-I_A1_:FK_] 3_R;3_"@#:HK%_M35_^
M@)_Y-I_A1_:FK_\ 0$_\FT_PH VJ*Q?[4U?_ * G_DVG^%']J:O_ - 3_P F
MT_PH VJ*Q?[4U?\ Z G_ )-I_A1_:FK_ /0$_P#)M/\ "@#:HK%_M35_^@)_
MY-I_A1_:FK_] 3_R;3_"@#:HK%_M35_^@)_Y-I_A1_:FK_\ 0$_\FT_PH VJ
M*Q?[4U?_ * G_DVG^%']J:O_ - 3_P FT_PH VJ*Q?[4U?\ Z G_ )-I_A1_
M:FK_ /0$_P#)M/\ "@#:HK%_M35_^@)_Y-I_A1_:FK_] 3_R;3_"@#:HK%_M
M35_^@)_Y-I_A1_:FK_\ 0$_\FT_PH VJ*Q?[4U?_ * G_DVG^%']J:O_ - 3
M_P FT_PH VJ*Q?[4U?\ Z G_ )-I_A1_:FK_ /0$_P#)M/\ "@#:HK%_M35_
M^@)_Y-I_A1_:FK_] 3_R;3_"@#:HK%_M35_^@)_Y-I_A1_:FK_\ 0$_\FT_P
MH VJ*Q?[4U?_ * G_DVG^%']J:O_ - 3_P FT_PH VJ*Q?[4U?\ Z G_ )-I
M_A1_:FK_ /0$_P#)M/\ "@#:HK%_M35_^@)_Y-I_A1_:FK_] 3_R;3_"@#:H
MK%_M35_^@)_Y-I_A1_:FK_\ 0$_\FT_PH VJ*Q?[4U?_ * G_DVG^%']J:O_
M - 3_P FT_PH VJ*Q?[4U?\ Z G_ )-I_A1_:FK_ /0$_P#)M/\ "@#:HK%_
MM35_^@)_Y-I_A1_:FK_] 3_R;3_"@#:HK%_M35_^@)_Y-I_A1_:FK_\ 0$_\
MFT_PH VJ*Q?[4U?_ * G_DVG^%']J:O_ - 3_P FT_PH VJ*Q?[4U?\ Z G_
M )-I_A1_:FK_ /0$_P#)M/\ "@#:HK%_M35_^@)_Y-I_A1_:FK_] 3_R;3_"
M@#:HK%_M35_^@)_Y-I_A1_:FK_\ 0$_\FT_PH VJ*Q?[4U?_ * G_DVG^%']
MJ:O_ - 3_P FT_PH VJ*Q?[4U?\ Z G_ )-I_A1_:FK_ /0$_P#)M/\ "@#:
MHK%_M35_^@)_Y-I_A1_:FK_] 3_R;3_"@#:HK%_M35_^@)_Y-I_A1_:FK_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7G_Q _P"0S#_U[K_Z$U>@5Y_\
M0/\ D,P_]>Z_^A-0!TW@_P#Y%RT_X'_Z&U;58O@__D7+3_@?_H;5M4 %%%%
M!1110 4444 %?*O[ O\ S<;_ -EF\1_^V]?55?*O[ O_ #<;_P!EF\1_^V]
M'U51110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7G_Q _P"0S#_U[K_Z$U>@5Y_\0/\ D,P_]>Z_
M^A-0!TW@_P#Y%RT_X'_Z&U;58O@__D7+3_@?_H;5M4 %%%% !1110 4444 %
M?*O[ O\ S<;_ -EF\1_^V]?55?*O[ O_ #<;_P!EF\1_^V] 'U51110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7G_Q _P"0S#_U[K_Z$U>@5Y_\0/\ D,P_]>Z_^A-0!TW@_P#Y
M%RT_X'_Z&U;58O@__D7+3_@?_H;5M4 %%5H]2LYM0GL8[J![V!$EFMED!DC1
MRP1F7.0&*M@GKM/I5F@ HHHH **** "OE7]@7_FXW_LLWB/_ -MZ^JJ^5?V!
M?^;C?^RS>(__ &WH ^JJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXB)-.FEZ5X8N8)8$,4EYJ=Q"UM*5PZLJV[B90W((,1(X('6N1L?@GJ?@?1_
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M:HH Q?\ A,-(_P"?O_R$_P#A1_PF&D?\_?\ Y"?_  K:HH Q?^$PTC_G[_\
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M"?\ PK:HH Q?^$PTC_G[_P#(3_X4?\)AI'_/W_Y"?_"MJB@#%_X3#2/^?O\
M\A/_ (4?\)AI'_/W_P"0G_PK:HH Q?\ A,-(_P"?O_R$_P#A1_PF&D?\_?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[RD]V_T71:!7E_QR_::^&?[-MKI%Q\1O%$?AR/5GECL0;2XN7G,84R86&-V
M7>F20!\PYYKU"OE7]HC_ )/L_9&_[F[_ --<5>>>P'_#T;]F+_HIG_E U3_Y
M&K9\%_\ !1?]GCX@^+='\,Z#\1$O-;U>ZCL;*VDT?4(!--(P5$WR0*H+,0!D
MCDBNT^)7[5'P]^%7Q3\&?#K6=3FE\7>*[J.VLM/L8#.T/F-L22?!_=HS' )]
M"<85B/,OV^O^;<O^RS>'/_;B@#ZJKS_X@?\ (9A_Z]U_]":O0*\_^('_ "&8
M?^O=?_0FH Z;P?\ \BY:?\#_ /0VK:K%\'_\BY:?\#_]#:MJ@ HHHH ****
M"BBB@ KY5_8%_P";C?\ LLWB/_VWKZJKY5_8%_YN-_[+-XC_ /;>@#ZJHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *\O_:$_:$T']F_PCI6NZ[I6N:Z=6U>WT/3]+\.6:W5[=W<RNT<<<9=021&W
M&<DX !) KK/B)\1O#7PG\'ZAXI\7:Q;:%H-@F^>\NFPHR<!0!RS$X 5022<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2<5]GU\J_L"_\W&_]EF\1_\ MO0!](?\(U_U%=3_ / C_P"M1_PC7_45U/\
M\"/_ *U;5% &+_PC7_45U/\ \"/_ *U'_"-?]174_P#P(_\ K5M44 8O_"-?
M]174_P#P(_\ K4?\(U_U%=3_ / C_P"M6U10!B_\(U_U%=3_ / C_P"M1_PC
M7_45U/\ \"/_ *U;5% &+_PC7_45U/\ \"/_ *U'_"-?]174_P#P(_\ K5M4
M4 8O_"-?]174_P#P(_\ K4?\(U_U%=3_ / C_P"M6U10!B_\(U_U%=3_ / C
M_P"M1_PC7_45U/\ \"/_ *U;5% &+_PC7_45U/\ \"/_ *U'_"-?]174_P#P
M(_\ K5M44 8O_"-?]174_P#P(_\ K4?\(U_U%=3_ / C_P"M6U10!B_\(U_U
M%=3_ / C_P"M1_PC7_45U/\ \"/_ *U;5% &+_PC7_45U/\ \"/_ *U'_"-?
M]174_P#P(_\ K5M44 8O_"-?]174_P#P(_\ K4?\(U_U%=3_ / C_P"M6U10
M!B_\(U_U%=3_ / C_P"M1_PC7_45U/\ \"/_ *U;5% &+_PC7_45U/\ \"/_
M *U'_"-?]174_P#P(_\ K5M44 8O_"-?]174_P#P(_\ K4?\(U_U%=3_ / C
M_P"M6U10!B_\(U_U%=3_ / C_P"M1_PC7_45U/\ \"/_ *U;5% &+_PC7_45
MU/\ \"/_ *U'_"-?]174_P#P(_\ K5M44 8O_"-?]174_P#P(_\ K4?\(U_U
M%=3_ / C_P"M6U10!B_\(U_U%=3_ / C_P"M1_PC7_45U/\ \"/_ *U;5% &
M+_PC7_45U/\ \"/_ *U'_"-?]174_P#P(_\ K5M44 8O_"-?]174_P#P(_\
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M1_PC7_45U/\ \"/_ *U;5% &+_PC7_45U/\ \"/_ *U'_"-?]174_P#P(_\
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M[:5] T 8O_"-?]174_\ P(_^M1_PC7_45U/_ ,"/_K5M44 8O_"-?]174_\
MP(_^M1_PC7_45U/_ ,"/_K5M44 8O_"-?]174_\ P(_^M1_PC7_45U/_ ,"/
M_K5M44 8O_"-?]174_\ P(_^M1_PC7_45U/_ ,"/_K5M44 8O_"-?]174_\
MP(_^M1_PC7_45U/_ ,"/_K5M44 8O_"-?]174_\ P(_^M1_PC7_45U/_ ,"/
M_K5M44 8O_"-?]174_\ P(_^M1_PC7_45U/_ ,"/_K5M44 8O_"-?]174_\
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MZ#XS3_A&M<8<)O\ EA$DA] DL##_ *]37Z%T 8O_  C7_45U/_P(_P#K4?\
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M_P#\)>Q_^-4J?LH_!*-E9?@[X 5E.0R^&+$$'U_U5 'JE%%% !1110 4444
M%>?_ ! _Y#,/_7NO_H35Z!7G_P 0/^0S#_U[K_Z$U '3>#_^1<M/^!_^AM6U
M6+X/_P"1<M/^!_\ H;5M4 %%%% !1110 4444 %?*O[ O_-QO_99O$?_ +;U
M]55\J_L"_P#-QO\ V6;Q'_[;T ?55%%% !1110 4444 %%%% !1110 4444
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MGL9MZ0;\L <X9V.]_P#9!VCTBW^/_P"TQ9V\<$'[(20PQJ$2./XD:6JJH&
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MGV()%? __!*/5+GP#<?&GX'ZI*QOO!?B226W$AY>%RT+E?\ 9W6ZO_VVSWH
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M4X Q(% .Y0,C;P<8KVK_ (9@^&?_ $+7_D_=?_':MZ/^SM\/=!U6SU*Q\/\
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M.O4WD[_\#Y;'K8#!4LNPM/"4%[L%;_-OS;U?F%%%%<IWA1110 4444 %%%%
M!1110 4444 %%%% !7G_ ,0/^0S#_P!>Z_\ H35Z!7G_ ,0/^0S#_P!>Z_\
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M,1JO'7/)/J_P6^#7A?X!_#G2?!7A"P%EI&GI@LV#+<RG[\TK8^:1CR3]
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M?&7Q5_:!^(7AG4/#OB7]C&UUO0]0B,-U8WGQ&TMXY%/J#'P0<$$<@@$$$ T
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M\^&/_"XOV9OB-X42'S[J\TB:6TCQG=<P@30#_OY&E>B_\5#_ -0S_P B4?\
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M$1_:3X?;S9#_ !,S;\Y)R?QJ#3?%?B>\^,^G>(-+\%:_IBZG$NG:I]OTJ6*
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MWVB/7=)M=1V)T1I(E9D^JL2OX4 =?1110 4444 %%%% !1110 4444 %%%%
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M7+3_ ('_ .AM6U6+X/\ ^1<M/^!_^AM6U0 4444 %%%% !1110 5\J_L"_\
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M:37V#^R;^Q%X%_93T<W&GH?$/C:[3&H^*;^,&XE)Y9(ASY49/\())XW,V!@
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MOJJOE7]@7_FXW_LLWB/_ -MZ /JJBBB@ HIKNL:LS,%51DLQP /6OAOX^?\
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M<8^,I48U>5)V]RT5\N6UT?H6$X;RBI"&(J8?FDTG^]YI25]=5-NS[JQ@^'_
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M112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKBOBA\9?"'P<T?\
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M:P@&5+68&2('H70_,N?<#I6/MJ?/[/F7-VOK]QZ+RW&QP_UQT)>R_FY7R_\
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M2?\ "8?M!?\ 0C:!_P!_T_\ DJO*_L>IUK4__!D?\SZ'_66CTPU=_P#<&?\
MD<3_ ,$N?B'_ ,+ _8S\'1R2>;>:!)<:).?3RI"T0_"&2$5]95^;W['MWK7P
M4\9_$GX4?#.SAU37K34#JVLZ#JYVC3G8+&?)?=$K)CRQPS\!>?7ZE_X3#]H+
M_H1M _[_ *?_ "51_8\_^?\ 2_\ !D?\P_UDI?\ 0+7_ /!,_P#(]=\>>+[7
MP'X1U/7;OF*SA+K'G!D<\(@]V8@?C7'_  1^(FL>++/4](\50+9^*M+D4W$
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M_JZ^V:*V_LVG/^-.4_5Z?<K(\Q<:XO"O_A,PU'#VZPIIR_\  JG/+\4?GO\
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M;;;NS%_X27_J%:G_ . __P!>C_A)?^H5J?\ X#__ %ZVJ*!&+_PDO_4*U/\
M\!__ *]'_"2_]0K4_P#P'_\ KUM44 8O_"2_]0K4_P#P'_\ KT?\)+_U"M3_
M / ?_P"O6U10!X-^T1\%=%^/6AQ,VG:II'BFP&[3=:AM</$P.0CX.63//JIY
M'<'SOX4_M::K\-+_ /X0'XXVEUI.O6H"VFNR1_NKV+HK2,<<\?ZP<'^+:P.?
MKVO#OVS?!-GXN_9\\5S2:9;WVHZ7;?;;2:6,&2WV.K2,C=0?+#9QU[YKR,70
ME2YL7AW::6JZ22[^?9GZ+P]FM+'JEP_F\?:8><DH2O:=&4FES0;O[K^U!Z/=
M6>_+6OQ6^+/QLSJG@.RM_!?@IRRV>JZG8->7M^H8CS5BR$1.. >3UR<\/C^-
MGQ&^#&I6@^*6FVVM>$+J:.V7Q1I5JUL]G(QPOVB)CMVDX^92 /<D"N"\%_ 7
MXN^#?#.E:K\&_BI#>^%]0MH[J#2]=PZQ(ZAMJ?)(F1GDJ(^AXK#^.VF?M'O\
M)?$<WCKQ%X7T_P +0V^+R&%8_,NP&&Q5_='#,Y7&"O([=_*EB*U.DZLHSYTK
MWT<?SM;Y7^9]Y2RC+,9CHX&A6PKPTI<BBU*%=:VW<7-U$^G,X-Z6478^K/'W
MQX\)_"_2UU#Q/<3Z1 X)B6>,>9-[1H#N<_05\T:]\9/BI^UA/-I7PVTR^\&^
M #(8;KQ%+&WVBX7.&"E>AQ_!&<]F< XKKO@S^Q'X<^PZ/XI^(=YJ'C;Q#<6D
M,S6NJNWV>V)0-Y10DM)L)*_,=IQ]P5]3VEG!I]K%;6L$=M;0J$CAA0(B*.@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y_P#$
M#_D,P_\ 7NO_ *$U>@5Y_P#$#_D,P_\ 7NO_ *$U '3>#_\ D7+3_@?_ *&U
M;58O@_\ Y%RT_P"!_P#H;5M4 %%%% !1110 4444 %?*O[ O_-QO_99O$?\
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M'6T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KS_X@?\ (9A_Z]U_]":O0*\_^('_ "&8?^O=
M?_0FH Z;P?\ \BY:?\#_ /0VK:K%\'_\BY:?\#_]#:MJ@ HHKY\DU*7XB?%+
M5M,U3QO_ ,(?XH\/:HX\.Z((+;$L9MV"W)29#)<;T>4$1NH51_"WS4 ?0=%>
M.?%CQQ)H/Q,\+Z->^._^$%T.\TR\N9[O=91>;/') (UWW44BCAWX')Q[5<U;
MQ)J,U_X*\(Z#XMFOWUR*YOY?$^RTFG-I%M;,02(0%F:6-0WED!0QP6P: /5Z
M*\W^'_B36+3X@>*/!.MZD^N/IT%MJ-EJ<T,<<TEO,74I*(E5-R/&P!55R",C
M()/I% !7RK^P+_S<;_V6;Q'_ .V]?55?*O[ O_-QO_99O$?_ +;T ?55%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\'?L=_
M GP[^T?_ ,$O?!G@7Q-&PLKY-2:"[C ,MG<+JEV8IX_]I3VZ$%E/#&N#\ _M
M"?'G]@?3X_A_\6?AQJWQ(\":7BVT;QAX>#2E+<<1QLVTJP P%20QNH&,LH7'
MHOP)^"?[7_[.OPKT7X>>%[SX(ZAH.CFX^RW.KMK#73B6XDG8N8U5<[I6 P.
M .>I[[_C-[_JW_\ \KE 'PU\%&^/W[6$?Q5\%?#BPD^'_P -_%GC_5M;\2>(
M[X%+BV%SY9?3SR&9E15W1Q@%BX#,B$Y_4+]G?]GOPG^S/\,[#P9X2M2EM#^]
MN[Z8#[1?7! WS2L.K'  '10 HX%<=^QQ\%/&WP6\*^/O^%@7>@7?B7Q;XRU#
MQ7/_ ,(T\[6<1NDAW(GG(KC#QO@'. 5^8G->_4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y_P#$#_D,
MP_\ 7NO_ *$U>@5Y_P#$#_D,P_\ 7NO_ *$U '3>#_\ D7+3_@?_ *&U;58O
M@_\ Y%RT_P"!_P#H;5M4 %>$_%FXNOBA;ZS\/KKX>&X\0M!++IVI7=U:/9VL
M;.8H[T2;_.C(Z[5BW9!7D?-7NU% '&W6L:_X/M]+T^+PUJ?B^&.R1)=1L+JU
M24S* K&1+B6+[P^;<K-SD$#@GRKPS\*?%/@34-#\7VVCQ7EXFI:E<77AFQGB
M5K6TO61O*ADD*1L\;1JS#<JG<X4\#/T/10!YSX!\-:M=>/O$WC;6M/?19=2M
M[?3K/2YI8Y)HK>$NV^5HV9-SO(Q 5FPH7G)('HU%% 'E7QT_9;^&'[2G]B?\
M+'\,_P#"1_V+Y_V#_3[JU\GSO+\W_42INSY4?WLXV\8R<^"_\$Z?AQX=\-^&
M_CGH.G:=]FTG1?BOKNF6%OY\C>3;PI;)&FYF+-A0!EB2>Y-?9]?*O[ O_-QO
M_99O$?\ [;T ?2'_  A^D?\ /I_Y%?\ QH_X0_2/^?3_ ,BO_C6U10!B_P#"
M'Z1_SZ?^17_QH_X0_2/^?3_R*_\ C6U10!B_\(?I'_/I_P"17_QH_P"$/TC_
M )]/_(K_ .-;5% &+_PA^D?\^G_D5_\ &C_A#](_Y]/_ "*_^-;5% &+_P (
M?I'_ #Z?^17_ ,:/^$/TC_GT_P#(K_XUM44 8O\ PA^D?\^G_D5_\:/^$/TC
M_GT_\BO_ (UM44 8O_"'Z1_SZ?\ D5_\:/\ A#](_P"?3_R*_P#C6U10!B_\
M(?I'_/I_Y%?_ !H_X0_2/^?3_P BO_C6U10!B_\ "'Z1_P ^G_D5_P#&C_A#
M](_Y]/\ R*_^-;5% &+_ ,(?I'_/I_Y%?_&C_A#](_Y]/_(K_P"-;5% &+_P
MA^D?\^G_ )%?_&C_ (0_2/\ GT_\BO\ XUM44 8O_"'Z1_SZ?^17_P :/^$/
MTC_GT_\ (K_XUM44 8O_  A^D?\ /I_Y%?\ QH_X0_2/^?3_ ,BO_C6U10!B
M_P#"'Z1_SZ?^17_QH_X0_2/^?3_R*_\ C6U10!B_\(?I'_/I_P"17_QH_P"$
M/TC_ )]/_(K_ .-;5% &+_PA^D?\^G_D5_\ &C_A#](_Y]/_ "*_^-;5% &+
M_P (?I'_ #Z?^17_ ,:/^$/TC_GT_P#(K_XUM44 8O\ PA^D?\^G_D5_\:/^
M$/TC_GT_\BO_ (UM44 8O_"'Z1_SZ?\ D5_\:/\ A#](_P"?3_R*_P#C6U10
M!B_\(?I'_/I_Y%?_ !H_X0_2/^?3_P BO_C6U10!B_\ "'Z1_P ^G_D5_P#&
MC_A#](_Y]/\ R*_^-;5% &+_ ,(?I'_/I_Y%?_&C_A#](_Y]/_(K_P"-;5%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5Y_\0/\ D,P_]>Z_^A-7H%>?_$#_ )#,/_7NO_H34 =-
MX/\ ^1<M/^!_^AM6U6+X/_Y%RT_X'_Z&U;5 !1110 4444 %%%% !7RK^P+_
M ,W&_P#99O$?_MO7U57RK^P+_P W&_\ 99O$?_MO0!]54444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5Y_\0/\ D,P_]>Z_^A-7H%>?_$#_ )#,/_7NO_H34 =-X/\ ^1<M/^!_
M^AM6U6+X/_Y%RT_X'_Z&U;5 !1110 4444 %%%% !7RK^P+_ ,W&_P#99O$?
M_MO7U57RK^P+_P W&_\ 99O$?_MO0!]54444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y_\0/\
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MQR_X6/\ \9/?V)_PA_C/4O"/_(@:7<?:_LGE_P"D=5V;_,^Y\V,?>.: /O\
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M.Y_\QKI?_P <H_X9W_:=_P"CN?\ S&NE_P#QR@#ZJHKY5_X9W_:=_P"CN?\
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M:Z7_ /'*/^&=_P!IW_H[G_S&NE__ !R@#ZJHKY5_X9W_ &G?^CN?_,:Z7_\
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MIW_H[G_S&NE__'*/^&=_VG?^CN?_ #&NE_\ QR@#ZJHKY5_X9W_:=_Z.Y_\
M,:Z7_P#'*/\ AG?]IW_H[G_S&NE__'* /JJBO@#]J32_VG?V:_@3XF^(_P#P
MT]_PD?\ 8OV7_B6?\(!I=KYWG744'^MR^W'F[ONG.W'&<CU7_AG?]IW_ *.Y
M_P#,:Z7_ /'* /JJBOE7_AG?]IW_ *.Y_P#,:Z7_ /'*/^&=_P!IW_H[G_S&
MNE__ !R@#ZJHKY5_X9W_ &G?^CN?_,:Z7_\ '*/^&=_VG?\ H[G_ ,QKI?\
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MC/3?"/\ R(&EV_V3[7YG^D=6W[/+^Y\N<_>&*]5_X9W_ &G?^CN?_,:Z7_\
M'* /JJBOE7_AG?\ :=_Z.Y_\QKI?_P <H_X9W_:=_P"CN?\ S&NE_P#QR@#Z
MJHKY5_X9W_:=_P"CN?\ S&NE_P#QRC_AG?\ :=_Z.Y_\QKI?_P <H ^JJ*^
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MKD!0&W'IT- 'O]%<W\-8M3M_AWX7BUH.NKIIELMXLF=PF$2A]V><YSG-=)0
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MCG) /7Z\_P#B!_R&8?\ KW7_ -":O0*\_P#B!_R&8?\ KW7_ -":@#IO!_\
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M*-/2[6YM]%\0V7V>6Q C=7^S7D0;#'=@;XF.&(W=<Y\WQJT:%+2R^)7A:_\
M!,WF6SK+K=NEUIGVDDLFR\BWQ!D9 0TAC(X.!V /7**JZ;JEGK6GP7VGW<%_
M8W""2&YMI%DCD4]&5E)!'N*M4 %%%% 'E'Q0^+GBOP;XVTCPYX;^'Y\6S:C9
MR74<[ZS#8*6C;#QKYBD,RJ5;&<X.0" 2.+\5?%CXKO\ V#!JGPRD\%Z=<:[I
ML%QJT7B2VNRJ/=Q Q^6BAB'!V''9CGBN_P#%'AGQ_;^(O[6TC4- \4:>EVMS
M;Z+XALOL\MB!&ZO]FO(@V&.[ WQ,<,1NZYSYOC5HT*6EE\2O"U_X)F\RV=9=
M;MTNM,^TDEDV7D6^(,C("&D,9'!P.P!ZY1573=4L]:T^"^T^[@O[&X020W-M
M(LD<BGHRLI((]Q5J@ HHHH \H^*'Q<\5^#?&VD>'/#?P_/BV;4;.2ZCG?68;
M!2T;8>-?,4AF52K8SG!R 0"1Q?BKXL?%=_[!@U3X92>"].N-=TV"XU:+Q);7
M95'NX@8_+10Q#@[#CLQSQ7?^*/#/C^W\1?VMI&H:!XHT]+M;FWT7Q#9?9Y;$
M"-U?[->1!L,=V!OB8X8C=USGS?&K1H4M++XE>%K_ ,$S>9;.LNMVZ76F?:22
MR;+R+?$&1D!#2&,C@X'8 ]<HJKINJ6>M:?!?:?=P7]C<()(;FVD62.13T964
MD$>XJU0 4444 >4?%#XN>*_!OC;2/#GAOX?GQ;-J-G)=1SOK,-@I:-L/&OF*
M0S*I5L9S@Y (!(XOQ5\6/BN_]@P:I\,I/!>G7&NZ;!<:M%XDMKLJCW<0,?EH
MH8AP=AQV8YXKO_%'AGQ_;^(O[6TC4- \4:>EVMS;Z+XALOL\MB!&ZO\ 9KR(
M-ACNP-\3'#$;NN<^;XU:-"EI9?$KPM?^"9O,MG676[=+K3/M))9-EY%OB#(R
M AI#&1P<#L >N455TW5+/6M/@OM/NX+^QN$$D-S;2+)'(IZ,K*2"/<5:H **
M** /&_&7QF\<:3\1]1\*>&OA@?$YL[6&\%W)K\%CYT;Y!9$D3D*X*D@G! SC
M(SC6_P 3?B5JGQ*\!:;XB\ R>!=*N]1G62=->M[X796RN&$3)&H(&0'R>,H.
M^*Z35-$^)?A75GU>Q.@_$6*$7306^I0+IFJ01OL*V\-RBM$P)49W1QYVKEO1
MY^-WA :O9VWC73;KP/J]M<2?8V\56B10[Q%\\D%X"\!^61ERL@8Y(QSR >K4
M4R*5)XTDC=9(W 974Y# ]"#W%/H **** /&_&7QF\<:3\1]1\*>&OA@?$YL[
M6&\%W)K\%CYT;Y!9$D3D*X*D@G! SC(SC6_Q-^)6J?$KP%IOB+P#)X%TJ[U&
M=9)TUZWOA=E;*X81,D:@@9 ?)XR@[XKI-4T3XE^%=6?5[$Z#\18H1=-!;ZE
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M,XC  X1-PR6KW[4O#VGZMJ.F7]U;^9>:9*TUI,KLC1LR%&Z$9!5B"IR#P<9
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M3[6SO9)XHK:^MK]#;L 3)!,LJ Y!^4L@![XS@CK6W10 4444 %%%% !1110
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_P#B!_R&8?\
MKW7_ -":O0*\_P#B!_R&8?\ KW7_ -":@#IO!_\ R+EI_P #_P#0VK:K%\'_
M /(N6G_ _P#T-JVJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MS_X@?\AF'_KW7_T)J] KS_X@?\AF'_KW7_T)J .F\'_\BY:?\#_]#:MJL7P?
M_P BY:?\#_\ 0VK:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MO/\ X@?\AF'_ *]U_P#0FKT"O/\ X@?\AF'_ *]U_P#0FH Z;P?_ ,BY:?\
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MK_XU1_PT_P##/_H9?_)"Z_\ C5<O]DYA_P! \_\ P&7^1Z'^L&3_ /092_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*\_^('_(9A_Z]U_]":O0*\_^('_(9A_Z]U_]":@#IO!__(N6G_ __0VK:K%\
M'_\ (N6G_ __ $-JVJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K/U_P /Z7XKT:[TC6]-L]8TF\3RKFPU
M"!)X)D/57C<%6'L16A10!Y5_PR=\$/\ HC?P_P#_  E['_XU7B_[4W[!^@>/
MO"?A7_A4G@#X8^&_$VB>);/69AJNAQVUGJ%M"DN^TN/LT)>2)V:/=&>&"GD'
M!KZ]HH _.KQ9^Q?\;_%GA76=$_X5;^RAHW]I64UE_:.D^'KZ"\M?,C9/-@D\
MD[)5W;E;!PP!QQ7TO\*?V+_A5X3^%_@_0_$GPN\ :UXBTS1K.RU+4F\.VDQN
M[J.!$FF\QX0[[W5FW-\QSD\U[]10!Y5_PR=\$/\ HC?P_P#_  E['_XU71>/
MOAS%XJ\)V.E:5/%H5SI-S;7FE2PP PVTL# QKY:E<QX!0J"/E)QBNSHH \M\
M1>$_&OQ-TV#0O$UOH>@Z"\D4NHMI.HSWD]XJ.K^0H>"$1(Q7YFRYP-H'.X=!
MX%\&WOA?Q'XWO[J2W>#7-52^MEA9BR1BVABPX(&#NC;ID8(Y[5V5% ' ^+_!
M.K_\)MI_C/PP]BVLP6;:;=V&I2/%!>VK.' \U%=HG1LL&",#N((YR*7C#PCX
MM^('A6*TU%-%TR\CU>PO4M[6YFGC2*"XCE?,S1H79@AP/+4#@$GK7I=% ''>
M/O!U[XIUKP7=VDL$<>BZP-0N!,S M'Y$T>$P#ELR+UP, \UV-%% !1110 R6
M))XWCD19(W!5D89# ]01W%<Q_P *I\$_]"=H'_@K@_\ B:ZJBM:=:I2_AR:]
M'8YZN'HU[.K!2MW2?YGG?C7X-Z#J7A/5+30/#'ANRUB>!H[:XGTV)5B8\;LJ
MA((&<$ \XKRU?@#XS7PG_87]@_#4K]F^S_VB;>Y^VYQCS/-VYWYYST]L<5]+
M45ZV'SC%X:'(G?6^MWK]Y\]C.&\OQM3VDH\KMR^[9*WI8\V\ _!?1-'\':78
M^(_#7AO4-9MXO*N+J'3HG63!(5MS1@D[=N21R<UO_P#"J?!/_0G:!_X*X/\
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MO#=U)-#?2F3>+B?,,*AT^8*0A8^8V6Q@5ZO110 4444 %%%% !1110 4444
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AW7_?*_\ Q5<OXHUB'6M0CG@61$6((1( #G)/8GUH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>bios-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bios="http://www.bioscrip.com/20201231"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bios-20201231.xsd" xlink:type="simple"/>
    <context id="i69a30465d231407487ede25fc216cb88_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i82ad3941737a494abf218dc777dd09e4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i936b65ce9acd48b496cb2d8b52c39297_I20210308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <instant>2021-03-08</instant>
        </period>
    </context>
    <context id="ic2110dcd1263436bb4f65e0170d66fa6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i27919b5d127146ec960f50ee2587df9f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i757f7525fd514729825051239d54094e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i40c908a9b2de45bcab117c93611972e9_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia256a7852ef04c1fbe74e288a706e7b1_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie0c4db4796fe410bb862ec15526051d4_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i422568febabe4f8583b8153a15287b3d_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia4ff3448393941ecb196d60a1c0c6507_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iac5e68b371e846bcb5595487faa64440_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bios:ManagementNotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i405e4a30b4e7443da8c3cc601af2d472_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ife86991b5c864d3ba7c27b4e2b6eaec8_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i2aaa306bfeb44033b42625ce53fced06_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8d20553c1ddf4029b82e7a98557f08a6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bios:ManagementNotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8f517132d94447c1a7f4a0703dfdad24_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6d5f5d47071547e88ec2cc2a2ed79b64_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id159556253844660bd62dda5634d2366_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i05ad22c7cb124eb7bc29475754fc1e50_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iec2447edc67648968195e4c9c57c9044_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibb3d7b08eaa94aeca766b6bd2235a557_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6ca7471b8b564de0a7a5d385352e5b15_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bios:ManagementNotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i38e87c4a7aae447680dde06b054bed9f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i22b30bb4310a44029a5f94758c5ae210_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8a948d96b8124ca49264e48dfa5b84ea_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i58814d8f92d24190888892748720a464_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iadfb96c7240b4bf2bc10824cee106ac1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bios:ManagementNotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i06325eb29ded4dda8dad34622c87bed3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id0217dbc311b4109a34f7a05e30c523d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icc4c4a7abaf64793a8cca9faa42d501d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i61291993f8a54aecbb68907a9140b3d1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic6342b5959154862925fe574bb199b16_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie6648a71bd04469e8bd6b625f8e26ce2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i07bbcf8ebdcc452490830f429f1ef4ed_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4967cf0ba59b4694a935eb9c0d502a5d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bios:ManagementNotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1960cd3413c4497a8cb7b8ba588bf2b3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i30b362b8cb0f4fa291d203acfe67091d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i83ec2897c370475281d08a6233255f4d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib48648d60adf4dfda6254c20ebbb4a83_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i65faadc1ce524e7297267901419cec15_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i70d31c15efcd4ad091a5d18b9108dc8e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a81bc38266c4980843d89e190c3d8fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b7fd52d93044460ac7028d03c0b79f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iacd1399421844f9795aff5870a8f8063_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f8587ff958a4c948e809015b40868e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if42702eefc1b4929ba571e14ece46dce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bios:ManagementNotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i510f7fb44d8047fe951f7d247dbdd5a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8178b1fbc0284245938041d60d5a050b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i368d5fdb13b94d2c99546a5791f3e988_D20190806-20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:OptionCareEnterprisesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-06</startDate>
            <endDate>2019-08-06</endDate>
        </period>
    </context>
    <context id="ia2ea7ddad6aa46c5900f0df09030bb8e_I20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:OptionCareEnterprisesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-06</instant>
        </period>
    </context>
    <context id="i1a95667076af42cc8fbcf3661b5bbacb_D20190806-20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:OptionCareEnterprisesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-06</startDate>
            <endDate>2019-08-06</endDate>
        </period>
    </context>
    <context id="i1860c3f1464545dd964c4595d8b8b205_D20190806-20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:OptionCareEnterprisesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-06</startDate>
            <endDate>2019-08-06</endDate>
        </period>
    </context>
    <context id="i4c72c8c6a63c487d89bfa93db278f761_I20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-06</instant>
        </period>
    </context>
    <context id="i119e1c16609d4ae2a8c7779f88a837f0_I20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:OptionCareEnterprisesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-06</instant>
        </period>
    </context>
    <context id="i53e06ff77c484235837649f43bbe2b5d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bios:LegacyHealthSystemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i086f47aad02f4c3598246e2234bcfcb9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">us-gaap:HurricaneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7eb197b8c371412db224c1301352b49f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">us-gaap:HurricaneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9fc719df4b5d4d1f874963db8ef3704c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">us-gaap:HurricaneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i48a8600720a94bbf87db1dbe3e875b03_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d430ba49f0c4e89b1371f12b3bbf397_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if944e5d57702478f96edf0c0c5780426_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if76a9379d5a5462faea6e4911c09e610_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8055d11ca77a46d49b7be5efb799bf4f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ad7ffbd4bbb4311af7b6cd327201826_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2bff063b20b44971b7a869047927c0a9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bios:InfusionPumpsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if9646cc5252f40eabde3fb89431c23a5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie12e4e114a18499d9effec6a2ee61dbe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a9ad7e932754e6bbc1e427751b3bf94_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i158605824c6c423d867ee0566aa0ca47_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i484daecca47b416e99281851405afa48_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3503095cd1c346c3968c0a9058c5e025_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i90930859b5a244fd919dfe2f357f7c23_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib2f3781893ae44f498e20de51cd69b29_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0026d0842d3a4359a1692dd699b20cad_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6527aad98d3a47a69d34f668ffe88a0a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if236b13a6b0a4994a585e5cf622ca3f3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i464c8f864f8d49899ce600f0ac27fe32_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7851f95217d9442598cc88ba1ed517d1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6edfcb49cb0b4b1e8a63a9955b1aaab1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3753cbfa17174608809f4f34d4a104ac_I20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-06</instant>
        </period>
    </context>
    <context id="i0f090775b2c24e07909f7019308c4cc6_I20190805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-05</instant>
        </period>
    </context>
    <context id="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-06</startDate>
            <endDate>2019-08-06</endDate>
        </period>
    </context>
    <context id="i96e2bd7b43e2425892cf80e8dee1fa59_D20190806-20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-06</startDate>
            <endDate>2019-08-06</endDate>
        </period>
    </context>
    <context id="ib7a44592cb4a40fcbd91c004c84b7ef6_I20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-06</instant>
        </period>
    </context>
    <context id="i0eab475192224276bc1b5ceb023d5037_D20190806-20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-06</startDate>
            <endDate>2019-08-06</endDate>
        </period>
    </context>
    <context id="ida7f446eea274d038568171224dfb7f8_I20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-06</instant>
        </period>
    </context>
    <context id="i8355aa59ded14d9c91a83db76fedede8_D20190806-20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-06</startDate>
            <endDate>2019-08-06</endDate>
        </period>
    </context>
    <context id="i2e8a900d790f44dabb629a7f9c87c6db_I20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-06</instant>
        </period>
    </context>
    <context id="icf29203bfe714c69b132146d9352ba77_D20190806-20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-06</startDate>
            <endDate>2019-08-06</endDate>
        </period>
    </context>
    <context id="iceee29a996a54c498d570461cc70c139_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6fbf8d8eaeb1483aa65584975ad1895d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BioScripMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i05bb7e7e8c7a426695f64056c9f39f0e_D20180808-20180808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:BaptistHealthInLittleRockArkansasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-08</startDate>
            <endDate>2018-08-08</endDate>
        </period>
    </context>
    <context id="id730cf15243f442bbd04361989c01f84_I20180918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeI.V.SpecialistsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-18</instant>
        </period>
    </context>
    <context id="i8b6760c7c28a4a18988a26e4abe977de_D20180918-20180918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeI.V.SpecialistsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-18</startDate>
            <endDate>2018-09-18</endDate>
        </period>
    </context>
    <context id="ib2bd7b4025e94630bcabed85e8c697ea_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeI.V.SpecialistsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibd5c46c0f3284d40848b80f8fbcc8415_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeI.V.SpecialistsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i510ad1073fee46da8c18efb16f7e06c6_D20200203-20200203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <startDate>2020-02-03</startDate>
            <endDate>2020-02-03</endDate>
        </period>
    </context>
    <context id="iba4469ba333d4f7dbcf906562ff59670_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:GovernmentCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5b9dd506f11d4d1ebc70f70232a583f7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:GovernmentCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6a18e871b4144c43920f2fdc837570dd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:GovernmentCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i511cdc2e39494cd4a860f9e7863bcf07_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:CommercialCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic52f5f00fdae408788e5edb2d3115ade_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:CommercialCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifcb18262ac0749ab80774f8e983c5642_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:CommercialCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idedfd2fd8cf84679ad22ff62c6589c11_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:PatientCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5bebf74e986b4a3fb16e367620def213_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:PatientCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia18fe7d576a24a3d959b4a7ade77e1ee_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:PatientCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i280e53dfa7f14ec79d051ef96fd2eb67_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">bios:MergerOperatingLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifee0c9a38e2f4f44872874da3bcaf823_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">bios:MergerOperatingLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9dabb20864b5445da36520a3109bba91_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">bios:MergerOperatingLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd78dc026a994a25a4f56b834ce3acf0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">bios:FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0615275335554e94b35841a1370fe6bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iacbc724b23f14da8a2fcb2d0d2bbb77f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib9602bc3ce024fae8e231c5a4c022557_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">bios:InterestLimitationCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8d455c8b67347889e5acbbbe86eb799_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">bios:InterestLimitationCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3d46ec2aaebb419db2fc4d41c2c5a93d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">bios:FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifaf8d37ccf224f66a6484b8ac7d64519_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">bios:FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c0ef9b611e047a885c26ca5f6249fad_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bios:ChargedBenefitToCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ied56fb2881f649038e93ac0e7055d693_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bios:ChargedToOtherAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i66543252b74f4364a367c91ae3431b87_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bios:ChargedBenefitToCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icbd22998422e476a94384ec9ca9af121_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bios:ChargedToOtherAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id5195060bc61421e96d7fc5e6a7b58ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bios:ChargedBenefitToCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i68b7bf1c254348648f33112353badc89_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bios:ChargedToOtherAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icea968011f094587b49f49e976287324_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9887caa100349b3a4635013ba8aa601_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i325067265d5c4ed789bfde38719b21ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bios:RestrictedStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i986fbe9ede1e4f4bae9e708842b5ac55_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie31db4918e8647d0bd750eeab70451ed_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5756cc875db64a44922ff59197c0da6e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bios:RestrictedStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ida6b0075f5a24266b586c0f92806b056_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bios:InfusionPumpsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i625ed602cf134da6abbf0c62370735cd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bios:InfusionPumpsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifee0705a51c84a4980d98bc3cf7443e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bios:EquipmentFurnitureAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc52cce51e6a4f36a08c80fcdd124e59_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bios:EquipmentFurnitureAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icb84e173e738405780c00bcbe867cc0e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3509723008544588453b805365b676c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if8cc880af6414d95b4c0dd61dbdebe7c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7055866745ae4cc595c938f55c549586_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i33147d91bdd64411a910c1922f1e30ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie319aae0a4334d4ea6a4c29ad036bd48_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i71540503946547bfb71bcf7399158709_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4d7863206f284422a8c9baba7551456b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if8bb4cd176114cedb1143d6017295c52_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3d387c31f86c420698ca7b00dcb79be8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib5caeb9d9df24859839e8059a6e70cb6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7e6f1790eb1b4698bc41fd69f2fe9033_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6683b8adaec142929fcdb6cc820b86c8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LiabilityForCatastropheClaimsByCatastrophicEventAxis">us-gaap:HurricaneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idc00aa48c5dd4893801fa8c1ebcb07c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d301d39dafd4e68a587b0a3fa40fcfb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie817018869a64452a6fc78f5f9440a38_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45131573f0bb479e8f31cf95f78845cb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if428d92bc279403486726eacba9956e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff982c3170b046f39f50b17cf259e515_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7ead4afeb6274fe391c370a8ab570027_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia70d084d67ce4667b22225e30b5f6b8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i660fc6279c714085b9bafae194ba5b7d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:SecondLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6a9df1dd28e4f1680a018dc49429873_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6074931e160e4e02be724a84dde0758b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6bb20cde57584d28ab6a5c4446839bc2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:SecondLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7f59152bb9c048a5b50b44067271f613_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a4bc3c15e894757bc0a5393777c3429_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bios:BankOfAmericaN.A.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i640bd2ca162d4110821356fb395847f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4386145a348444218987e663e802f1b3_I20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-06</instant>
        </period>
    </context>
    <context id="i7f24d9bf71984546b8af671666297e21_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i12c898e6c2bf4a57a2d2293e3f85537e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0cc1c613272d407fb68c66233b0884da_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id826c60086164891b7f61e86c7d17b78_I20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-06</instant>
        </period>
    </context>
    <context id="i04c60dc2cb4949a08701ec5516562884_I20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-06</instant>
        </period>
    </context>
    <context id="i209bb88d77ec42248db74bf4e55edb38_I20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-06</instant>
        </period>
    </context>
    <context id="ib286938752c04504a3b00f4071a94634_I20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-06</instant>
        </period>
    </context>
    <context id="i46f31629752b4d81875255a5a98e87a7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc5331a479244a11b7005f9b4a1e7c11_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie4ff2a32df6c4734a1ec9790fd2b3c90_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99995e13205b43628f9807043e807bce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaba77b7ae34c4fb7b5163a1d2f78b481_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id771c21da6a248498802851c5776c07e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i415f019222e24e949930ede6b5b65dd1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i483af9de03bc4422b957661fc1119a22_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3cf4138b86814ddaa06ddcb7b782f15a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c4f5e9ea300456ca3c311e588f2d512_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i13a144a884e94b6a93b74bea5f331c3e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1c10e2b1b78c46e2bae9d7a6747cce9c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2723f056763c4dedbc445d2f9855f372_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4574bb7e56b34190bb053a4f1bcd1b5b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id5b446b6a97f4f90ac9242bc18f5059d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab4208b4c10d4bc0b8f34fe22bd51432_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a10d18e244645e5b6a89c8ab446ff90_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i607cf3ad83fa4d68a7f532e446e0e21f_D20190806-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-06</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0792b3cd668b435abf755519d30889a2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1bd2ac4c3a7b43a292acc61f6fdf6853_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i6d4c5bb322c04877b86cf39e32da703f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i325d52df30ad4c278d90566dd27aaf21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iedf0847627fa4c459cc17c612b6e2b9e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic49d785c7256408c93023d39c4d914d8_D20190806-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-06</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib5a9e86640d24df0a4a74f644bec401b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bios:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i41a866b1933d4b50a03ed2090fc52f3b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bios:NotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb7255dc5f1449f88b65c6161c741c55_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icd11813edd424004b8d01f7794f0116c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a1d6fa62d594e16b4173eb1cda83c73_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i83c91152b1744cdda0bc77a72cef0072_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia288006c93754808b4fb52473eb70d95_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia334515f9b054e84a1cdb130df9a3d17_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5330b1241c9f450aabf19a6470f3deeb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8915c98904a74bd98e03842b6725688d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5ea39b7659c64974ab62326385972ecc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditArrangementsEnteredInto2015ModifiedLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i475c18c38aea40bfa20cc795a9a0586e_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i6b688f43690d4a10bb658649d8f26b91_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bios:NotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i0d71acb5790f4712b5fe4d979c0e2bd2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i46dc5fdf0022473d841d625d8ca2e5cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a157555439142d78694bcf7b01379aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie94a2f3b1fce4b9abcfcd916988d3eb8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:SecondLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i15aa1aad0d3744a0abc478e642582276_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:SecondLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb5343b6a2e9432f8e58f2bd9a3d07ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:SecondLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib0851f5015634259990ba26f9a4a889e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d3c87930eb1479888f34f3af43a0440_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1fa3ac11591f4ece89016cc369ba0e2b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d7bc9bd670f4ffb91c21fb59c7c7fb1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85d077a5e93842429e329f0dcb9d0f2d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iadaac97b718242739dbbd6f6ed2e6ae0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i76f46d4be96544528533fb90947e87a4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:SecondLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0bd8c01514d84331992e13473d81c16b_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iaa2b883648c2436f83ec2369cdbc149b_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iddb4b3d5aafc422db864143a1b1aa819_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i8fbd469711e34b0cb074a178241284d8_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i65baa1ec1f4d461b86b9b6f2542d2c72_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="icdd8047975e647288143981c8762166c_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i70568db5bcc649c5bd6104996dd8bf09_I20191106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-06</instant>
        </period>
    </context>
    <context id="ib0cf4d78796d429d879bce469f3f3150_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i2b483f33dcad4616a569483ce451b1b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bios:AccruedExpensesandOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2467317320d4c409705b0b02f8ab210_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bios:AccruedExpensesandOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i79e4af3f2d204d8f95b5b4ad2982893d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bios:AccruedExpensesandOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc9a7eafdb69419ba693d8dffce79f3b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bios:AccruedExpensesandOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3eefd11356ef4acfa576e05c36eec86e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i19aaeb7b2301410c8ace359b4aae0a61_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5e6745feb32545bd99b8438f4cb65e42_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idadf3e087514415d9e588230d1e4c8e8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie42dd3293f1047ffb0d1d1e673596db2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5536ba9ef240436f8685941bf069832f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idc8999935b584fbe93f3edcbbb32aa8b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibf3e87fd34a94950b1dfab02c0351ccb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6a2d963d4b4c4bf0bc68ff139a36a0d1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia2ffe75f1b2e4b789fd671082186d2f2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if51a0a2416fc4efaa81e5964f060685f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i77b199f5d9fe42879ba86a116b6460d8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieea161291d5e4067a3bf1b40c8e4dac7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibe4cf21bfb5140d997a613e6c5626e64_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8eb1d1e629ac4a0ba804cec14a4547ea_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iada07b387c4c497182b71cd727197396_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie78754462d4f48648b6dde71360bba63_I20180503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bios:A2018PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-03</instant>
        </period>
    </context>
    <context id="ic76cb4e523aa47e994e82af3ea50d75e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i24920ce6c3624d32867b35ecb74cd412_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib40babb4ce544cecb8d62a5b59792213_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1cd470f5e6054ec5b5f94411ed707e82_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1599283f6d184d1b9aa7b7fa0b2e0ce8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i760b317cd0fd4b0d9e286a06610ffaec_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7593332c92344b60ad9b41ff0c66bfb8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i53bc279beb0d4676ba828340fd063ce9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e711f6fe89d4907a952226e5df765bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ied37c8390b9e43a68cb9da71a0ccb303_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic297998b32b84faa88fcfec2d9f9afaa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e5ee81d05914bbbb9c62c51c01221b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia22152ff44814391aef12293b8db163f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i63a51e68f4934ca4aa97b767de686c2e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic98475680f7349638688cb46f1e41606_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7fd061fe54554bc695ee04673aa61e17_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie25037f6e33c47f0b726fabf6b0be7a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if6dce6cca08246afbc1f71bef99be371_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i55f1b01e1ac646989939a0659a3141e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42e2317cc254448dba231db5776669d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0053d6570a4144ac906506c3b03aab72_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d816e895c844acba36b041455ff1817_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i30fe04022dfb468d8d0ab7e1e5130cbc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7776b739ae0444bfa9bc3151bd3de57d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iabac5d7169c74416abc3eb400b77e659_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6111e845e8ac4ee9941a74fef21be93b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bios:OptionExercisePriceRangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66ddd3962e684353b2b33793e60d1e69_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if3c12b1e25aa48848f6b9795aa9375a0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i30a276240cc149b2b70ea64be64b1594_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i71d89cba29a940fcb26b394671b41837_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i51298007a376435784a5fb2e3b738530_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic7cbfe6f12b34fedb3c55e90bc01b102_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2de6cb92e6b546deac3f264b1d51d725_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7250472ce2a241aa9fa3993c11938e71_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7b7d2377ab7d4bc99608fd62fc228d0a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5acddac984ac471cad45cd822b74b0b6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bios:HCIIncentiveUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7f5821f9020a4063acb746c7833a5115_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bios:HCIIncentiveUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie95cb408d1a745e48ca026ce6e263566_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bios:HCIIncentiveUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7b196dfce1974680a1c28c5ea237cbf5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bios:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if168c646a7a54828a528116373a38538_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bios:PublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bios:OptionCareHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc639cc9d59342c992cf094de275e8c8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bios:PublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bios:HCGroupHoldingsILLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i33bae88b85d44fbca1b188c77d873669_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bios:SecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91057a8b01954ab2b5e6178ac8a1653d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bios:HCGroupHoldingsILLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d4a2b07f09440698f0d0e140a1f931b_I20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2017WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-06</instant>
        </period>
    </context>
    <context id="i535849efb80c49c89802c2c1e9ff8d05_I20170629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2017WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-29</instant>
        </period>
    </context>
    <context id="i2d17de0af863439a8ae94e0d74a3cb43_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2017WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1039614a70d44672a1b9b67e279fb604_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2017WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7318e00da4034c3e90a2e212df26a625_I20190805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-05</instant>
        </period>
    </context>
    <context id="i219745e510624e329c043ef1592af4c1_I20150309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-09</instant>
        </period>
    </context>
    <context id="ib3aa39a0d3d547f5ac6cd2902b94a3cc_I20150309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-09</instant>
        </period>
    </context>
    <context id="if3a9e03e121545df913cf6c60ded20b6_I20150309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-09</instant>
        </period>
    </context>
    <context id="icf01e47aa17741d5850517700e659acc_I20190806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-06</instant>
        </period>
    </context>
    <context id="iac71a41a43944594bf483f7a54f70817_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="iea509be9731f4fb6830bb71b36a2b3bc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifd4a7b857bfc47ff96783a5d70cfd61b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i75edeee42f0440a9ae3db5c126a6ee59_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifefcdf706a3e409c8661a5f8661ff527_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:HomeSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i15e537579ddd49499464fe98320efa5a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bios:OptionCareEnterprisesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2e27ad48b6e845aab11f9dc6d36cc68d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bios:RestrictedStockAndStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib70cc65c7351474ca9d26740937a57b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bios:RestrictedStockAndStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13dda31dc46244a296faff43e8f63ba2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bios:RestrictedStockAndStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i960724d691c94ef7990ec38c99826855_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bios:OptionCareAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bios:MadisonDearbornPartnersVIBL.P.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if80a7156fb6f4e92b4633b71b42884d2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia181037e051e4e948fa5f02cec18ae01_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i284ee94026ab44078607e6ba90095ac0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bios:LoansFundedForMembershipUnitPurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib849ab96bb7143929a677ea83f9f24a1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bios:LoansFundedForMembershipUnitPurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1bb7590e2fd64c32b7a9e48da3b76727_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bios:LoansFundedForMembershipUnitPurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i34486d66c41947448069be17a3002902_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bios:SaleOfNotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibab2cb958b58428e93eac229c0d7b02d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bios:SaleOfNotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i822483b16b124c4596a91869aa597cb8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6555353edfee47bd86374a705cce7c7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i58a5c478533d40c4ae5cf5901b523252_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3802608a5ccb4cafbdc104d570a82e52_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i51011fdb3a8b4c218ad62e0a5f46e49f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4e67b5985f2447a4a6bba9e8bc275f82_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia5e84b8b2d0c4dc7a263964004d01b50_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72c86c11f53e4fe297072ffdc6b4277f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i15449ea65247465890f60bdac030ba0a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iaae3340f01f44ee699ccd0262c23dc33_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic66518c22fa740f7b245ba8a1d6615fd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3afb9f5919b84a45a2a45351ff5c3f16_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iec2211f718164003b67adb468a0ae8fe_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ib556381e0e774b77af5202ac495cedbb_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib309aaac6dde42acbdc774c94fb918ad_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i70f18d581b7c4638bce49ebbbfa4f31b_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0bbb595569b4462e84f37fd4195a043b_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ic0bfb220dbad4d1ca83ebb1bd6d1b4c6_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i8995bda2010f4ab3b9f72d0a8e9683f7_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i843047af1ab74b56ac1a994dd504c5cb_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bios:SecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i5e6ee715bd2943e5b275bef6b90641f2_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bios:HCGroupHoldingsILLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="location">
        <measure>bios:location</measure>
    </unit>
    <unit id="site">
        <measure>bios:site</measure>
    </unit>
    <unit id="day">
        <measure>bios:day</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl80L2ZyYWc6OWJkYTllZTA5MWRjNGYxMWI4YmJiYWEwZTIwNGE0OTkvdGFibGU6NjBhOTYwMDM3NmIwNGMwMzhlOGQxNmYyYWExYjliN2EvdGFibGVyYW5nZTo2MGE5NjAwMzc2YjA0YzAzOGU4ZDE2ZjJhYTFiOWI3YV80LTEtMS0xLTA_efa5fc0f-1004-4975-9381-6f7d202e7741">0001014739</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl80L2ZyYWc6OWJkYTllZTA5MWRjNGYxMWI4YmJiYWEwZTIwNGE0OTkvdGFibGU6NjBhOTYwMDM3NmIwNGMwMzhlOGQxNmYyYWExYjliN2EvdGFibGVyYW5nZTo2MGE5NjAwMzc2YjA0YzAzOGU4ZDE2ZjJhYTFiOWI3YV85LTEtMS0xLTA_216588ad-8c20-4291-b332-b28b365356e2">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl80L2ZyYWc6OWJkYTllZTA5MWRjNGYxMWI4YmJiYWEwZTIwNGE0OTkvdGFibGU6NjBhOTYwMDM3NmIwNGMwMzhlOGQxNmYyYWExYjliN2EvdGFibGVyYW5nZTo2MGE5NjAwMzc2YjA0YzAzOGU4ZDE2ZjJhYTFiOWI3YV8xMC0xLTEtMS0w_bcf68923-e1da-4d44-b824-4ded91e46c87">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl80L2ZyYWc6OWJkYTllZTA5MWRjNGYxMWI4YmJiYWEwZTIwNGE0OTkvdGFibGU6NjBhOTYwMDM3NmIwNGMwMzhlOGQxNmYyYWExYjliN2EvdGFibGVyYW5nZTo2MGE5NjAwMzc2YjA0YzAzOGU4ZDE2ZjJhYTFiOWI3YV8xMS0xLTEtMS0w_d5c81dc9-bc14-4901-8043-8ffa4397aba3">false</dei:AmendmentFlag>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if944e5d57702478f96edf0c0c5780426_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc0Mjk_9e7f6967-ecc8-4667-930f-df6f18fbc07d">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i8055d11ca77a46d49b7be5efb799bf4f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc1Mjc_c3c88249-a6e5-407f-ae8b-52445dccabe5">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i510ad1073fee46da8c18efb16f7e06c6_D20200203-20200203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDkvZnJhZzowOTBmZjMwMzIxZjU0ZDM1YTY0MTM5MTViMmYwZTY3NS90ZXh0cmVnaW9uOjA5MGZmMzAzMjFmNTRkMzVhNjQxMzkxNWIyZjBlNjc1XzMw_7ef279f8-fcf8-4fd2-9905-f82761e2cfb0"
      unitRef="number">0.25</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic76cb4e523aa47e994e82af3ea50d75e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzgxMA_5835ea03-79c7-4f33-bae1-42d73cd55de9">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ib40babb4ce544cecb8d62a5b59792213_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzEwNTU_96670979-bd52-4453-a4dd-ea37a865d80c">P7Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i66ddd3962e684353b2b33793e60d1e69_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzI2Mjc_ef3f1c14-105f-4e27-b582-034c0b01b496">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i510ad1073fee46da8c18efb16f7e06c6_D20200203-20200203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjkvZnJhZzo3YTc1MDk0YmQ4MjQ0Yjg4YmVjZmIxMzhjODBmYmFiNC90ZXh0cmVnaW9uOjdhNzUwOTRiZDgyNDRiODhiZWNmYjEzOGM4MGZiYWI0XzMw_77e65154-2f67-47af-b495-d0620c60d26b"
      unitRef="number">0.25</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzMy_e7178629-47af-4f53-9da2-1367dbdb894d">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6YWRlZGM3NmZmYjQyNDFkMzk0YzYyMjE1Y2NkYmQ4NjUvdGFibGVyYW5nZTphZGVkYzc2ZmZiNDI0MWQzOTRjNjIyMTVjY2RiZDg2NV8xLTAtMS0xLTIyMw_9d43ea9c-2997-445c-aa34-6f61df7f43c4">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6YWRlZGM3NmZmYjQyNDFkMzk0YzYyMjE1Y2NkYmQ4NjUvdGFibGVyYW5nZTphZGVkYzc2ZmZiNDI0MWQzOTRjNjIyMTVjY2RiZDg2NV8yLTEtMS0xLTIwNy90ZXh0cmVnaW9uOjUxMzhjZTc2ZDk2YjQ3MWViODA0MTE2MDc2MjI3NjYwXzMyOTg1MzQ4ODMzOTI_a5aa6d2b-896e-44cd-8060-c93605204f7d">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6YWRlZGM3NmZmYjQyNDFkMzk0YzYyMjE1Y2NkYmQ4NjUvdGFibGVyYW5nZTphZGVkYzc2ZmZiNDI0MWQzOTRjNjIyMTVjY2RiZDg2NV8yLTEtMS0xLTIwNy90ZXh0cmVnaW9uOjUxMzhjZTc2ZDk2YjQ3MWViODA0MTE2MDc2MjI3NjYwXzMyOTg1MzQ4ODMzOTI_124050ce-9640-4135-b1e4-5f7c6807f70f">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6YWRlZGM3NmZmYjQyNDFkMzk0YzYyMjE1Y2NkYmQ4NjUvdGFibGVyYW5nZTphZGVkYzc2ZmZiNDI0MWQzOTRjNjIyMTVjY2RiZDg2NV80LTAtMS0xLTIyNg_24b50294-fd0a-4eee-8239-4ea8067c0fde">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzM1_4f00fdf7-402a-4906-854d-9e697567a5be">001-11993</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzM4_8e5d29e2-47d9-4224-83f9-958aa76eaadd">OPTION CARE HEALTH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NDExODE0Y2ZkYjZjNDYwNDhhNWE0NTljYTgwM2RhMTgvdGFibGVyYW5nZTo0MTE4MTRjZmRiNmM0NjA0OGE1YTQ1OWNhODAzZGExOF8wLTAtMS0xLTI0MQ_e5fb72d8-98a2-4fd5-9a26-807c067e3842">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NDExODE0Y2ZkYjZjNDYwNDhhNWE0NTljYTgwM2RhMTgvdGFibGVyYW5nZTo0MTE4MTRjZmRiNmM0NjA0OGE1YTQ1OWNhODAzZGExOF8wLTEtMS0xLTI0NA_62ae8ef1-7e12-43ce-ab63-9794914fff6a">05-0489664</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NDExODE0Y2ZkYjZjNDYwNDhhNWE0NTljYTgwM2RhMTgvdGFibGVyYW5nZTo0MTE4MTRjZmRiNmM0NjA0OGE1YTQ1OWNhODAzZGExOF8yLTAtMS0xLTIxMi90ZXh0cmVnaW9uOjkyMmI2YjU3NGMzMTRiZDJiY2YzYjUyMjM3MDM0ODE3XzMyOTg1MzQ4ODMzOTQ_824ab45d-a0c7-4df0-9e3e-86780213fca9">3000 Lakeside Dr.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NDExODE0Y2ZkYjZjNDYwNDhhNWE0NTljYTgwM2RhMTgvdGFibGVyYW5nZTo0MTE4MTRjZmRiNmM0NjA0OGE1YTQ1OWNhODAzZGExOF8yLTAtMS0xLTIxMi90ZXh0cmVnaW9uOjkyMmI2YjU3NGMzMTRiZDJiY2YzYjUyMjM3MDM0ODE3XzMyOTg1MzQ4ODM0MDc_a95fe5ad-b05a-4570-965d-7b6db22dcf05">Suite 300N</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NDExODE0Y2ZkYjZjNDYwNDhhNWE0NTljYTgwM2RhMTgvdGFibGVyYW5nZTo0MTE4MTRjZmRiNmM0NjA0OGE1YTQ1OWNhODAzZGExOF8yLTAtMS0xLTIxMi90ZXh0cmVnaW9uOjkyMmI2YjU3NGMzMTRiZDJiY2YzYjUyMjM3MDM0ODE3XzMyOTg1MzQ4ODM0MjE_9883c2aa-40eb-4e95-a473-06fb94da46db">Bannockburn</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NDExODE0Y2ZkYjZjNDYwNDhhNWE0NTljYTgwM2RhMTgvdGFibGVyYW5nZTo0MTE4MTRjZmRiNmM0NjA0OGE1YTQ1OWNhODAzZGExOF8yLTAtMS0xLTIxMi90ZXh0cmVnaW9uOjkyMmI2YjU3NGMzMTRiZDJiY2YzYjUyMjM3MDM0ODE3XzMyOTg1MzQ4ODM0MjY_e911d163-a291-4bae-a662-59ab98427504">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NDExODE0Y2ZkYjZjNDYwNDhhNWE0NTljYTgwM2RhMTgvdGFibGVyYW5nZTo0MTE4MTRjZmRiNmM0NjA0OGE1YTQ1OWNhODAzZGExOF8yLTEtMS0xLTI0Ng_625f84a9-bdd1-47f2-b40f-2a59d85e4403">60015</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzUw_d2a3078d-d7a2-4027-a49c-459bf4a54a0f">312</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzQ0_234d6158-bc83-4df7-96b9-55e1577580b2">940-2443</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NjMxZmMyMzVlMDUxNGM2YmI2ZTExMzZkZDc1MWViOTMvdGFibGVyYW5nZTo2MzFmYzIzNWUwNTE0YzZiYjZlMTEzNmRkNzUxZWI5M18xLTAtMS0xLTI2Mw_888ba286-0a97-4dc0-a5c1-5dd68837bc87">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NjMxZmMyMzVlMDUxNGM2YmI2ZTExMzZkZDc1MWViOTMvdGFibGVyYW5nZTo2MzFmYzIzNWUwNTE0YzZiYjZlMTEzNmRkNzUxZWI5M18xLTEtMS0xLTI2Mw_1e9d54be-ef93-4976-b23a-2bce19193bfc">OPCH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGFibGU6NjMxZmMyMzVlMDUxNGM2YmI2ZTExMzZkZDc1MWViOTMvdGFibGVyYW5nZTo2MzFmYzIzNWUwNTE0YzZiYjZlMTEzNmRkNzUxZWI5M18xLTItMS0xLTI2Mw_8a4bc247-eb84-4cb9-bf84-64907dfe4d6a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzUx_172cd748-2904-4ab2-b9b0-25b01f44dc10">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzUy_02f481a6-bdaf-4462-bbd8-1969614b745f">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzUz_f5a95213-6594-4f4c-9a9f-6f7c78d3fcb5">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzU0_686f6ef8-1ce4-4c37-a788-413dd8adf0f5">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzU1_6a2cdc4c-4b76-41b9-9ba8-91d5f326aabe">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzU4_2a6c8f7b-8b4b-4925-bb7a-eab5eb5a9fb9">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzYx_a0702839-8da9-4d60-bea9-7edac62736eb">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2OTM4_205cdd75-9057-4f1d-a565-7442616a11b9">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2MzY0_a7b360f0-8dab-4bca-8fa7-c482a1cbbf1b">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i82ad3941737a494abf218dc777dd09e4_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8yNDY4_ba59ec09-7244-4f79-8744-4fab28f2ee73"
      unitRef="usd">473322477</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i936b65ce9acd48b496cb2d8b52c39297_I20210308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8yNjAy_ecfc3b22-3272-4992-a21d-93df7e7d4c73"
      unitRef="shares">179814189</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xL2ZyYWc6ODIwMmJiNzdkYzI5NDIwOTgyMGVmNWQwYTdhYTQ2YWQvdGV4dHJlZ2lvbjo4MjAyYmI3N2RjMjk0MjA5ODIwZWY1ZDBhN2FhNDZhZF8zMjk4NTM0ODg2OTM5_4a6c5103-f70e-486e-8053-df08c01947ae">Portions of the registrant&#x2019;s definitive proxy statement for its 2021 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) within 120&#160;days after the close of the registrant&#x2019;s fiscal year are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNC0xLTEtMS0w_6e398e19-f99e-4349-8897-0ff0d332d0b5"
      unitRef="usd">99265000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNC0zLTEtMS0w_3b89b874-b2fc-49a8-9bfe-f84691152ef9"
      unitRef="usd">67056000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNS0xLTEtMS0w_6c137121-cb78-4221-94a0-a793d38ffbed"
      unitRef="usd">328340000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNS0zLTEtMS0w_c3cc7463-1b64-4888-83c1-1d48e7fe4cca"
      unitRef="usd">324416000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNi0xLTEtMS0w_bc8e3bb4-b30e-4a11-9fda-6e85536f4d15"
      unitRef="usd">158601000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNi0zLTEtMS0w_879d464f-b225-470f-a47e-58c27db4feff"
      unitRef="usd">115876000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNy0xLTEtMS0w_972cd268-6eae-4b0f-a201-5fb2478f1bce"
      unitRef="usd">70806000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNy0zLTEtMS0w_3ddaa413-8d22-4989-93c0-f05d012b263f"
      unitRef="usd">51306000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfOC0xLTEtMS0w_49487242-5c6f-4c7c-b8db-3631b5c0cb06"
      unitRef="usd">657012000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfOC0zLTEtMS0w_9f3638e7-33e2-4b51-b5ab-3f5de2cc61f7"
      unitRef="usd">558654000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTEtMS0xLTEtMA_98147447-a09a-42b8-a19f-cf0025123c2f"
      unitRef="usd">121149000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTEtMy0xLTEtMA_ad3b6a2f-c915-4111-8da9-82027acd120a"
      unitRef="usd">133198000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTItMS0xLTEtMA_021be26d-8373-4ac4-a83a-9a0d9d50c62b"
      unitRef="usd">68795000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTItMy0xLTEtMA_d7cd69c7-fe43-429c-a40d-1951e70e9f1d"
      unitRef="usd">63502000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTMtMS0xLTEtMA_f803e92f-7305-414d-afe2-e62f64813f31"
      unitRef="usd">351052000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTMtMy0xLTEtMA_ef9b83a1-7e7e-4304-8fe2-5fb3a61abb1d"
      unitRef="usd">385910000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTQtMS0xLTEtMA_8f2cdd61-86a0-4413-b3e5-8f73693f8cbb"
      unitRef="usd">1428610000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTQtMy0xLTEtMA_b37ff4a5-b0bb-4f49-98b8-946df4972bca"
      unitRef="usd">1425542000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTUtMS0xLTEtMA_7a468c1a-5037-4551-b6ea-37d490b98a24"
      unitRef="usd">20821000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTUtMy0xLTEtMA_9e9b7fcb-b108-43ce-b720-b82912d1b0cf"
      unitRef="usd">22741000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTYtMS0xLTEtMA_be19e392-4ffa-4420-9645-ea269cb3c0d2"
      unitRef="usd">1990427000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTYtMy0xLTEtMA_b9536c24-3d20-416c-9977-5be63a2884b5"
      unitRef="usd">2030893000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTctMS0xLTEtMA_2b82e8d1-e95b-47e2-acf7-188705084a1f"
      unitRef="usd">2647439000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMTctMy0xLTEtMA_70a62f41-4eb5-445e-a9d0-5cf012677bf9"
      unitRef="usd">2589547000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjEtMS0xLTEtMA_187dca05-adfa-406f-a052-db3b724dbde9"
      unitRef="usd">282913000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjEtMy0xLTEtMA_bc694be1-2b8d-4814-9c47-83ce2b8281db"
      unitRef="usd">221060000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjItMS0xLTEtMA_ced72720-f5ba-4c86-b4f0-9b99ae3cb9ba"
      unitRef="usd">58899000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjItMy0xLTEtMA_6b9e0eb6-0465-4373-81b0-05612288bb1b"
      unitRef="usd">45765000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <bios:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjMtMS0xLTEtMA_8204c6cf-0991-4efc-8508-775e6c9b8ccd"
      unitRef="usd">64075000</bios:AccruedExpensesAndOtherCurrentLiabilities>
    <bios:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjMtMy0xLTEtMA_bf0a8258-d0a8-47dc-b187-acbeee43ff9d"
      unitRef="usd">33538000</bios:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjQtMS0xLTEtMA_d7b2ba8b-be01-4c06-ba89-f5a8807677b5"
      unitRef="usd">18886000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjQtMy0xLTEtMA_59469c34-bcb4-4788-ad67-bedb8205a48b"
      unitRef="usd">20391000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjUtMS0xLTEtMA_7b707494-199a-4f1d-8008-2f24afd551ea"
      unitRef="usd">9250000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjUtMy0xLTEtMA_d5affc64-5556-4027-8f4f-4a57e3852a8c"
      unitRef="usd">9250000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjYtMS0xLTEtMA_50b48da5-5129-403f-90b9-a74313062dd6"
      unitRef="usd">434023000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjYtMy0xLTEtMA_7aca2216-5bf1-4803-b59d-6657f6e9eb54"
      unitRef="usd">330004000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjktMS0xLTEtMA_f6124c6e-901e-4920-b05d-c7512431dc07"
      unitRef="usd">1115103000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMjktMy0xLTEtMA_7168557f-b3d3-467a-8707-23b9be796d09"
      unitRef="usd">1277246000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzAtMS0xLTEtMA_ecf8321e-aa18-4272-a435-b1708e9ff973"
      unitRef="usd">70776000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzAtMy0xLTEtMA_484b0ff5-d154-448d-b465-e16d92e3524f"
      unitRef="usd">58242000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzEtMS0xLTEtMA_31fefdbc-4a4b-4f38-8317-6c493f2bbf61"
      unitRef="usd">3339000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzEtMy0xLTEtMA_fe63ae55-f904-40b7-a1d2-f6945eeead72"
      unitRef="usd">2143000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzItMS0xLTEtMA_6c48e4d2-c7ea-4437-8318-661ef4c2f6a9"
      unitRef="usd">8474000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzItMy0xLTEtMA_19028f1e-e9fb-4bb3-9643-ae48b0e6a1db"
      unitRef="usd">15085000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzMtMS0xLTEtMA_a8c59129-804a-41e5-99ef-96af8afcd3cf"
      unitRef="usd">1197692000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzMtMy0xLTEtMA_aa840dc3-9d70-4654-84e7-b0ac5e4cf8c5"
      unitRef="usd">1352716000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzQtMS0xLTEtMA_975d08d7-3d2d-427e-83f0-add1fc93724f"
      unitRef="usd">1631715000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzQtMy0xLTEtMA_9430526e-aacb-4a67-a3f7-c3360006b890"
      unitRef="usd">1682720000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjQzNDQwYzFlMjA5NjQzOTdhOTUxZjY1OWY5MjYwNDFjXzU0OTc1NTgxMzkwMzg_18188a17-5026-4ce4-829a-4fec88df9307"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjQzNDQwYzFlMjA5NjQzOTdhOTUxZjY1OWY5MjYwNDFjXzU0OTc1NTgxMzkwMzg_dcdec827-9c88-4d64-8d8a-4133825d0dac"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjQzNDQwYzFlMjA5NjQzOTdhOTUxZjY1OWY5MjYwNDFjXzU0OTc1NTgxMzkwNTE_3db90ed1-b803-4ab8-b1c3-c50945f7edce"
      unitRef="shares">12500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjQzNDQwYzFlMjA5NjQzOTdhOTUxZjY1OWY5MjYwNDFjXzU0OTc1NTgxMzkwNTE_975d7a79-7237-4655-a550-ff77beb8815f"
      unitRef="shares">12500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjQzNDQwYzFlMjA5NjQzOTdhOTUxZjY1OWY5MjYwNDFjXzU0OTc1NTgxMzkwNTY_272cdadf-4e39-42c1-9e9c-0eaec17f127d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjQzNDQwYzFlMjA5NjQzOTdhOTUxZjY1OWY5MjYwNDFjXzU0OTc1NTgxMzkwNTY_7a4d7e73-c125-4c21-a293-cda9fd552c2f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzctMS0xLTEtMA_6dd9090c-6562-4dbc-8dec-f1f96d54babe"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzctMy0xLTEtMA_c35358e8-5beb-47c9-88ce-025233c9ce51"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjExZjYxYTYwMGRmMjQ0ZTI4NDczMzFiOWNiYjllYmMzXzU0OTc1NTgxMzkyMDA_1f26c26c-a0c8-4022-99e0-ea2fd4b1c364"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjExZjYxYTYwMGRmMjQ0ZTI4NDczMzFiOWNiYjllYmMzXzU0OTc1NTgxMzkyMDA_526c8c60-18f3-45ef-84ad-660bf676ddd8"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjExZjYxYTYwMGRmMjQ0ZTI4NDczMzFiOWNiYjllYmMzXzU0OTc1NTgxMzkxOTA_0c09725d-bb1b-49d5-8df5-325697a81a71"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjExZjYxYTYwMGRmMjQ0ZTI4NDczMzFiOWNiYjllYmMzXzU0OTc1NTgxMzkxOTA_9e4c5bce-5e84-48cf-b487-d47617a41640"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjExZjYxYTYwMGRmMjQ0ZTI4NDczMzFiOWNiYjllYmMzXzU0OTc1NTgxMzkxNjI_ad939896-b0bd-43f1-908d-0c90a83db630"
      unitRef="shares">180178308</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjExZjYxYTYwMGRmMjQ0ZTI4NDczMzFiOWNiYjllYmMzXzU0OTc1NTgxMzkxNzY_6814260f-f2ed-42ab-84cc-2c74c774aca2"
      unitRef="shares">179794586</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjExZjYxYTYwMGRmMjQ0ZTI4NDczMzFiOWNiYjllYmMzXzU0OTc1NTgxMzkxMzM_ed7dc004-c268-435b-95b0-3c358ef7de8b"
      unitRef="shares">176975628</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjExZjYxYTYwMGRmMjQ0ZTI4NDczMzFiOWNiYjllYmMzXzU0OTc1NTgxMzkxNDg_471f2275-203f-46e2-9021-00978d74a21f"
      unitRef="shares">176591907</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMS0xLTEtMA_d211ed69-5849-4022-88b6-314bcc04b144"
      unitRef="usd">18000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzgtMy0xLTEtMA_66512a81-9668-4db5-aa07-e8cc5eb2fbcc"
      unitRef="usd">18000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockShares
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM2MzAwZWYxMzhiNzQ4NTc4NDY3YTk3NTVjYzJmZDZmXzU0OTc1NTgxMzkwMjI_5cd8b660-2185-46cd-893c-23536e1c072b"
      unitRef="shares">383722</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjM2MzAwZWYxMzhiNzQ4NTc4NDY3YTk3NTVjYzJmZDZmXzU0OTc1NTgxMzkwMjI_806caff3-bf2a-48dc-99ba-372b778065fc"
      unitRef="shares">383722</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzktMS0xLTEtMA_d6ac7be2-e499-405e-a4bb-4e26f605a39c"
      unitRef="usd">2403000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfMzktMy0xLTEtMA_bd082a51-788a-487b-9ecb-d71c1bcb7462"
      unitRef="usd">2403000</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDAtMS0xLTEtMA_0737d910-6492-4f2e-afa4-691714f932c7"
      unitRef="usd">1129312000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDAtMy0xLTEtMA_5f010ae0-250b-4b8a-af32-e9ef75f1798c"
      unitRef="usd">1008362000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDItMS0xLTEtMA_2a9c6aa9-3326-4441-9fb9-b543ed8cf737"
      unitRef="usd">-100031000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDItMy0xLTEtMA_dc40172c-a302-4896-acdf-14addb08d9bf"
      unitRef="usd">-91955000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDMtMS0xLTEtMA_ffc105b4-7bf5-4189-a854-b3784e40c062"
      unitRef="usd">-11172000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDMtMy0xLTEtMA_5e661aa8-5560-4706-9dcc-932d15d74367"
      unitRef="usd">-7195000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDQtMS0xLTEtMA_2a544a36-e2e6-4a98-9157-54c9796e2f1c"
      unitRef="usd">1015724000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDQtMy0xLTEtMA_a6ae43d1-d86d-4857-baa2-69e023c5b1f2"
      unitRef="usd">906827000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDUtMS0xLTEtMA_4f3c89ea-bf21-4286-b393-cba184f3c274"
      unitRef="usd">2647439000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl83Ni9mcmFnOjI3N2I0MmU0Njk1NDRiYzFhNmExMjQ3Yjg5YTk5YTMyL3RhYmxlOjM2YWExOWZiMTQ2NzRhMjhiYTQ4NjVhODJhMDhiMzI3L3RhYmxlcmFuZ2U6MzZhYTE5ZmIxNDY3NGEyOGJhNDg2NWE4MmEwOGIzMjdfNDUtMy0xLTEtMA_69e2a26b-f4db-4bcc-930f-3aa8eb1b7ff0"
      unitRef="usd">2589547000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMi0yLTEtMS0w_a4204c76-a2a3-41c9-9950-ff9273a57add"
      unitRef="usd">3032610000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMi00LTEtMS0w_ca3f5f9c-501e-49bf-a512-01140f42fd9d"
      unitRef="usd">2310417000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMi02LTEtMS0w_269b5bb2-124b-4d70-b399-ff5f444e737a"
      unitRef="usd">1939791000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMy0yLTEtMS0w_fbfc3fbf-5b52-40dd-82dd-f5a79b1e6bbd"
      unitRef="usd">2350346000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMy00LTEtMS0w_6bf1a42f-ba1d-470d-aaf8-ae737ac69db7"
      unitRef="usd">1797418000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMy02LTEtMS0w_c4d46129-f0a6-466a-90fb-77ad8881aed6"
      unitRef="usd">1517576000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfNC0yLTEtMS0w_d15b7557-c363-4e4c-98fb-a99699979284"
      unitRef="usd">682264000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfNC00LTEtMS0w_c4caac76-d3cd-4989-a3f6-31b5d55dd97d"
      unitRef="usd">512999000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfNC02LTEtMS0w_1c7db7a0-c6d8-4c10-b7ea-3ccc21c00095"
      unitRef="usd">422215000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfNy0yLTEtMS0w_0a75c879-30dc-45c2-9c32-fb6c601f0728"
      unitRef="usd">500199000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfNy00LTEtMS0w_10cf3843-b00c-46d5-bafc-138c9752de6b"
      unitRef="usd">459628000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfNy02LTEtMS0w_799955b0-8cd3-4f01-b393-10927f6ce593"
      unitRef="usd">345884000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfOS0yLTEtMS0w_617dc53c-c824-4f65-a52a-30e8f9346de4"
      unitRef="usd">71310000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfOS00LTEtMS0w_898bd230-d5a8-47ac-879a-f61341ec771f"
      unitRef="usd">53690000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfOS02LTEtMS0w_4c0c2dae-7b78-443f-8f7d-535f67bc40c3"
      unitRef="usd">38062000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTAtMi0xLTEtMA_9d7ae511-b48a-463d-a3cd-9a8e6aaa5d86"
      unitRef="usd">571509000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTAtNC0xLTEtMA_ce60e5b8-878c-4a1d-af05-d67496486796"
      unitRef="usd">513318000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTAtNi0xLTEtMA_9772fd7e-651b-417e-b77e-491a3429a0ae"
      unitRef="usd">383946000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTEtMi0xLTEtMA_9b12632f-cd39-47e4-9068-c17e79e057f8"
      unitRef="usd">110755000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTEtNC0xLTEtMA_bbbf32f2-c8c1-4ccd-a157-01ae5cd91131"
      unitRef="usd">-319000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTEtNi0xLTEtMA_446c2b00-db5c-4d4f-b312-b36789e7bd91"
      unitRef="usd">38269000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTQtMi0xLTEtMA_439cf143-3255-4307-8675-454aa9b6c0c6"
      unitRef="usd">107770000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTQtNC0xLTEtMA_78f1cdd8-5d4b-4e8b-a9ad-083f4e842e8a"
      unitRef="usd">73724000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTQtNi0xLTEtMA_2e63a955-a130-4be6-9225-7dc7a15d7d4d"
      unitRef="usd">45824000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeNet
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTUtMi0xLTEtMA_8cd72263-390a-4a94-a283-ec37a851fd07"
      unitRef="usd">3313000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTUtNC0xLTEtMA_56455ec3-e08a-43dd-b5f3-efd7777c9f9d"
      unitRef="usd">2840000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTUtNi0xLTEtMA_9a2d4878-d053-4093-a060-eea2f0f2ad22"
      unitRef="usd">1020000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTYtMi0xLTEtMA_5953b1e1-d864-4b04-aecd-d88b268bffea"
      unitRef="usd">-11541000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTYtNC0xLTEtMA_9fdc8203-fa13-41d1-8cc2-f2c20b8fa656"
      unitRef="usd">-6991000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTYtNi0xLTEtMA_9ceaeb34-81ff-436c-97e3-faef13c9a775"
      unitRef="usd">-2233000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTctMi0xLTEtMA_97bd4ef6-0ef1-4772-8cb5-91f119c2e1f8"
      unitRef="usd">-115998000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTctNC0xLTEtMA_672e1f61-d131-45e1-892e-1017bc11a083"
      unitRef="usd">-77875000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTctNi0xLTEtMA_c720d0f4-38ec-42fc-860b-5c0d66a58606"
      unitRef="usd">-47037000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTktMi0xLTEtMA_f6c5a22d-f19f-402e-b1f2-b536f3b05ac8"
      unitRef="usd">-5243000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTktNC0xLTEtMA_5ffa8cf0-e775-449f-b9b2-2deab50d708b"
      unitRef="usd">-78194000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMTktNi0xLTEtMA_edb7d41d-4995-4533-a8da-c95fcda5f972"
      unitRef="usd">-8768000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjAtMi0xLTEtMA_b189eb0b-d8eb-426a-9112-380369adec9e"
      unitRef="usd">2833000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjAtNC0xLTEtMA_ac717e94-9061-44a6-89e2-36fa7b25d1b4"
      unitRef="usd">-2274000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjAtNi0xLTEtMA_3fe6126d-8eee-4a88-a951-140587996f7a"
      unitRef="usd">-2653000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjItMi0xLTEtMA_e4433798-0e4b-4460-b68b-0e247d9a8d63"
      unitRef="usd">-8076000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjItNC0xLTEtMA_5f08947f-c8c1-4265-9215-c03ba650ef80"
      unitRef="usd">-75920000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjItNi0xLTEtMA_f63e4a8d-ad0f-4a6c-abe6-ae88be6a0bed"
      unitRef="usd">-6115000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NTNjMjVlMWU5NjRlN2Y4NzdiOWMxZjg1MmM5NDYzXzU0OTc1NTgxMzg5OTc_796699c9-c474-4670-8493-c6066b9064d5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NTNjMjVlMWU5NjRlN2Y4NzdiOWMxZjg1MmM5NDYzXzU0OTc1NTgxMzkwMDQ_6e623468-5dd0-46d2-851e-cfc96a85de7a"
      unitRef="usd">-259000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NTNjMjVlMWU5NjRlN2Y4NzdiOWMxZjg1MmM5NDYzXzU0OTc1NTgxMzkwMTE_ca1b888d-9796-432c-b1eb-1417ef22114c"
      unitRef="usd">-234000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjUtMi0xLTEtMA_3c5fe473-c139-4030-8f52-917dd09385e7"
      unitRef="usd">-3977000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjUtNC0xLTEtMA_b6d969ec-c44c-415a-bbf8-032dca352768"
      unitRef="usd">-8039000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjUtNi0xLTEtMA_960ea9d4-f71f-4f1a-a30f-a8cd3f0f642c"
      unitRef="usd">774000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjYtMi0xLTEtMA_c37f1aab-bd2f-4830-a752-56a8a05c9623"
      unitRef="usd">-3977000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjYtNC0xLTEtMA_94221c11-b74a-4ab7-8be2-7cd65e5cb4bb"
      unitRef="usd">-8039000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjYtNi0xLTEtMA_70bd590d-6cf8-4f75-a597-26664fa35742"
      unitRef="usd">774000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjctMi0xLTEtMA_a3b5a52a-2965-4b10-994f-5a65c7443154"
      unitRef="usd">-12053000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjctNC0xLTEtMA_2b092db7-6941-42f1-8374-cae0674c6be3"
      unitRef="usd">-83959000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMjctNi0xLTEtMA_6aeb471c-0a7e-41f9-af09-392d7d82795e"
      unitRef="usd">-5341000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMzAtMi0xLTEtMA_f3652413-a315-4a13-a789-dec27aec8ff7"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMzAtNC0xLTEtMA_d9ad31d7-93b6-4060-bc16-ebae7171c157"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMzAtNi0xLTEtMA_0f173885-76e0-4de7-9bd9-d19f9e8b9354"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMzItMi0xLTEtMA_36d04614-758e-41ba-ab71-5c97c6048d8b"
      unitRef="shares">180971000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMzItNC0xLTEtMA_9742b4cd-31c2-46a4-9a85-dd8290ff0711"
      unitRef="shares">156280000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84Mi9mcmFnOjkxN2JjZTliYjVhMTRhOGFhZjViMGVhZDM3MzMxMTZiL3RhYmxlOjgwZjlmNGU0MjliMTRhMzg5MzAyODkzZGQyMTQ2NWEwL3RhYmxlcmFuZ2U6ODBmOWY0ZTQyOWIxNGEzODkzMDI4OTNkZDIxNDY1YTBfMzItNi0xLTEtMA_fa30ee20-fd48-4688-811d-8d5b876253a1"
      unitRef="shares">142614000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMy0xLTEtMS0w_e4433798-0e4b-4460-b68b-0e247d9a8d63"
      unitRef="usd">-8076000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMy0zLTEtMS0w_5f08947f-c8c1-4265-9215-c03ba650ef80"
      unitRef="usd">-75920000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMy01LTEtMS0w_6203d940-c0aa-4548-bb0b-64800fd84d77"
      unitRef="usd">-6115000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNS0xLTEtMS0w_1b0e3557-a3c5-4d9e-8c03-1b9e76938928"
      unitRef="usd">77896000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNS0zLTEtMS0w_621f3f2c-5b42-415e-9f09-eb434e794b2f"
      unitRef="usd">57869000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNS01LTEtMS0w_f4320286-8a79-45a7-860d-127452acc34b"
      unitRef="usd">41055000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNi0xLTEtMS0w_fcaeb4ec-e787-42f2-a2a5-79c1df65a6cb"
      unitRef="usd">18814000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNi0zLTEtMS0w_b7f84b7d-679d-4aee-af9f-62b98504fec8"
      unitRef="usd">19719000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNi01LTEtMS0w_795906fa-4480-45be-ab7b-b03349124365"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNy0xLTEtMS0w_3da9c522-d8f6-4ba1-bcd8-f3c6775b7cf0"
      unitRef="usd">1196000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNy0zLTEtMS0w_d0487954-800b-4252-9adb-0f30eb4a7ed3"
      unitRef="usd">-4607000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNy01LTEtMS0w_ed68fd8b-48b8-4cec-8119-264c4d10d16d"
      unitRef="usd">-3595000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfOC0xLTEtMS0w_a1a85b87-cdd6-41ce-9f48-ab17779fd598"
      unitRef="usd">-742000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfOC0zLTEtMS0w_78d704cf-e80e-48ec-9f0f-cd74a14e39a8"
      unitRef="usd">-3269000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfOC01LTEtMS0w_cbda9c45-fcfe-49a7-8d4f-84c8e9880b0b"
      unitRef="usd">-1123000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfOS0xLTEtMS0w_125a2a15-987c-41db-8391-ea075232acc3"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfOS0zLTEtMS0w_ba38abd0-45f7-436d-b9bd-e9206ff8c73c"
      unitRef="usd">626000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfOS01LTEtMS0w_b05e0027-2a5d-4a89-a5c5-e3fa00378d40"
      unitRef="usd">-3549000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTAtMS0xLTEtMA_3bcab461-e324-4bf9-aaaa-1cbef1c07666"
      unitRef="usd">-11545000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTAtMy0xLTEtMA_f16b396f-9dc0-414a-bf05-291888a68733"
      unitRef="usd">-5469000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTAtNS0xLTEtMA_1c2cb9e6-09fb-4de5-8767-98a690ac9f5c"
      unitRef="usd">-72000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTEtMS0xLTEtMA_375ef26d-244b-49a4-b969-919ea271874e"
      unitRef="usd">5517000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTEtMy0xLTEtMA_070443ad-a4e0-4f55-9014-79852a9982e4"
      unitRef="usd">4544000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTEtNS0xLTEtMA_5fadbe83-fe66-4c4d-878a-646319e45ba3"
      unitRef="usd">3107000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <bios:LossOnDiscontinuanceOfCashFlowHedgeDerivative
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTItMS0xLTEtNTE2MQ_ac25902a-3395-4a44-96dd-2daf7d9c0303"
      unitRef="usd">3746000</bios:LossOnDiscontinuanceOfCashFlowHedgeDerivative>
    <bios:LossOnDiscontinuanceOfCashFlowHedgeDerivative
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTItMy0xLTEtNTE2MQ_e8a49048-af79-474b-82df-d8ef749c94e3"
      unitRef="usd">0</bios:LossOnDiscontinuanceOfCashFlowHedgeDerivative>
    <bios:LossOnDiscontinuanceOfCashFlowHedgeDerivative
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTItNS0xLTEtNTE2MQ_68c35e29-b176-4ea4-9fdd-7a0a71053efc"
      unitRef="usd">0</bios:LossOnDiscontinuanceOfCashFlowHedgeDerivative>
    <us-gaap:PaidInKindInterest
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTItMS0xLTEtMA_5d2ebe43-15d5-4e7f-98a7-9c086c92e202"
      unitRef="usd">7525000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTItMy0xLTEtMA_00205b98-86bf-4740-aa0b-3ad02dbb3cbc"
      unitRef="usd">12256000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTItNS0xLTEtMA_5b09d103-4d2b-4199-a507-1cb516685bbd"
      unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTMtMS0xLTEtMA_f09dfc58-8a42-4f9b-9c4e-a68d02a57e0b"
      unitRef="usd">3313000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTMtMy0xLTEtMA_7b64ba3b-d134-4384-8f31-8980bfea0115"
      unitRef="usd">2840000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTMtNS0xLTEtMA_217bf781-ee74-4691-95e8-07620d3618b6"
      unitRef="usd">1020000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTQtMS0xLTEtMA_b54f5673-2fb8-42df-bc41-900bf07ca806"
      unitRef="usd">2920000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTQtMy0xLTEtMA_77ee996a-98d0-4282-9a57-f13e76094956"
      unitRef="usd">4170000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTQtNS0xLTEtMA_0d43b9bf-8eeb-4838-b505-3d7c0ce92b26"
      unitRef="usd">2139000</us-gaap:ShareBasedCompensation>
    <bios:InterestGainLossOnManagementNotesReceivable
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTUtMS0xLTEtMA_df6d47d8-ab24-4ec9-9887-5044590bcfec"
      unitRef="usd">0</bios:InterestGainLossOnManagementNotesReceivable>
    <bios:InterestGainLossOnManagementNotesReceivable
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTUtMy0xLTEtMA_51d88f56-be4f-4c53-8a02-a784329b398b"
      unitRef="usd">62000</bios:InterestGainLossOnManagementNotesReceivable>
    <bios:InterestGainLossOnManagementNotesReceivable
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTUtNS0xLTEtMA_5d5b577c-f3b3-465e-9d43-2b98866a4c95"
      unitRef="usd">78000</bios:InterestGainLossOnManagementNotesReceivable>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTYtMS0xLTEtMA_14e5ce26-ff19-4cea-8a7d-44523d9055a6"
      unitRef="usd">3250000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTYtMy0xLTEtMA_9f9475b9-30cc-4776-acaa-a3c7fcfdd756"
      unitRef="usd">500000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTYtNS0xLTEtMA_28df7865-84b9-442c-8188-577ad434c42e"
      unitRef="usd">2000000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTctMS0xLTEtMA_efff9a94-2402-4043-ac11-9f4aff3d9dec"
      unitRef="usd">-1500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTctMy0xLTEtMA_9b858f24-b281-4e90-b996-ecacb4a6a56d"
      unitRef="usd">-300000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTctNS0xLTEtMA_af4bcefb-d091-433e-9dd5-c9db6b6d5026"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTktMS0xLTEtMA_01893643-93a4-4d70-924d-b62101fd0822"
      unitRef="usd">3924000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTktMy0xLTEtMA_d855523c-3a79-485e-a80c-3b0a27da2bf8"
      unitRef="usd">-82285000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMTktNS0xLTEtMA_f8b37b9b-7468-4889-9672-f84280d7aeae"
      unitRef="usd">21012000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjAtMS0xLTEtMA_8335b090-26fc-4630-848f-5a738e303da7"
      unitRef="usd">42725000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjAtMy0xLTEtMA_d72a5fd5-846d-4c9a-a181-61e4bc3588e3"
      unitRef="usd">12853000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjAtNS0xLTEtMA_93ed6f3a-b1f5-4bf9-a415-8a9c2d276df9"
      unitRef="usd">-2965000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjEtMS0xLTEtMA_c8e35451-07c4-44eb-99c0-40b54277e20b"
      unitRef="usd">19500000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjEtMy0xLTEtMA_3707e3eb-f1fb-4bfa-a17f-dda6b9bd31e1"
      unitRef="usd">2940000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjEtNS0xLTEtMA_87d90751-a542-4475-a05f-5c8cd295c9b4"
      unitRef="usd">4715000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjItMS0xLTEtMA_f1b4db45-5f19-49f0-810a-6dee1f3e0d29"
      unitRef="usd">59215000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjItMy0xLTEtMA_186fa0b4-a30a-4960-951f-5127fde1e168"
      unitRef="usd">-30856000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjItNS0xLTEtMA_20e39d69-7291-403d-b3ab-d3f86c9d9337"
      unitRef="usd">10965000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjMtMS0xLTEtMA_d33dde44-ffed-4844-8851-048c1d68280a"
      unitRef="usd">13134000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjMtMy0xLTEtMA_2695d0ad-c868-41a0-ae0e-19f7da0b66a0"
      unitRef="usd">2671000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjMtNS0xLTEtMA_dc89908d-1806-4e21-bf92-25b262abc63a"
      unitRef="usd">-5586000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjQtMS0xLTEtMA_a44ac668-e07b-486a-8a8a-3424354b12a3"
      unitRef="usd">22809000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjQtMy0xLTEtMA_7cc96124-1fbf-4f85-bec8-dbc33f727d4c"
      unitRef="usd">-317000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjQtNS0xLTEtMA_d3186ba8-8dab-4208-aedc-f9403e9bbfd5"
      unitRef="usd">-1740000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OperatingLeasePayments
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjUtMS0xLTEtMA_8610cfd4-188c-409f-8c06-5c696cc57481"
      unitRef="usd">18089000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjUtMy0xLTEtMA_c17e7f15-3fab-4f10-ae94-2d574ae11865"
      unitRef="usd">17253000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjUtNS0xLTEtMA_0554cbf5-5a2d-4df4-902f-d507566a432c"
      unitRef="usd">0</us-gaap:OperatingLeasePayments>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjYtMS0xLTEtMA_8642c934-35a1-4d1d-a82a-1555ec0ef1d0"
      unitRef="usd">3790000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjYtMy0xLTEtMA_6251da7b-da4c-41b8-b662-7252eb82f383"
      unitRef="usd">4711000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjYtNS0xLTEtMA_f20e1b39-c4cd-4c42-a7ee-92a60bbe4d6f"
      unitRef="usd">-1314000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjctMS0xLTEtMA_4b7d3218-c60e-4d6e-8d0a-ff99fcb2324b"
      unitRef="usd">127392000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjctMy0xLTEtMA_ec86eed5-545d-4bd9-a6e7-1e4cf61f30ad"
      unitRef="usd">39467000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMjctNS0xLTEtMA_5a3978fb-1344-4daa-9b1e-d75dd84965cc"
      unitRef="usd">24428000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzAtMS0xLTEtMA_a4ef146c-cbab-495d-bf80-216e61c69a2d"
      unitRef="usd">26875000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzAtMy0xLTEtMA_d1221d3e-cc66-4cbc-93c4-75b29d45e900"
      unitRef="usd">28292000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzAtNS0xLTEtMA_69c1586f-3e91-4b54-805b-c2e72130f89e"
      unitRef="usd">26276000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzEtMS0xLTEtMA_d77bce80-7792-4c69-a6bb-f7c1f9be2ad0"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzEtMy0xLTEtMA_f8d10c43-4563-4219-97ba-921224054ae7"
      unitRef="usd">10000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzEtNS0xLTEtMA_ee2ef004-c30e-4b2c-bdf6-dcad7137eb86"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromInsuranceSettlementInvestingActivities
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzItMS0xLTEtMA_07758d51-1a68-48dd-98ad-db3a540bff8c"
      unitRef="usd">0</us-gaap:ProceedsFromInsuranceSettlementInvestingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementInvestingActivities
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzItMy0xLTEtMA_233fdf3b-6633-4e61-ac86-aea2a7b9ad9b"
      unitRef="usd">626000</us-gaap:ProceedsFromInsuranceSettlementInvestingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementInvestingActivities
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzItNS0xLTEtMA_9f67b70e-8151-4b9b-aef7-64ba8007479a"
      unitRef="usd">0</us-gaap:ProceedsFromInsuranceSettlementInvestingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzMtMS0xLTEtMA_0beffe69-29ee-4325-a39e-a56985002d71"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzMtMy0xLTEtMA_9f9e7c5d-7d2b-4ec5-95d2-108ba5e28d8c"
      unitRef="usd">700170000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzMtNS0xLTEtMA_b20b4c82-eecb-493b-8175-a0ad076382a1"
      unitRef="usd">10727000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzUtMS0xLTEtNTE3MA_22f7173c-63f5-4d51-b844-5ebabc04d879"
      unitRef="usd">-541000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzUtMy0xLTEtNTE3MA_c4d7bf97-70c1-4970-b114-85dc983981aa"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzUtNS0xLTEtNTE3MA_79a9f321-c111-40a8-b35d-c56f299663e0"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzQtMS0xLTEtMA_1c8163b5-4529-48fe-b175-83c43f3307f3"
      unitRef="usd">-26334000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzQtMy0xLTEtMA_83e7d822-48fa-4746-b5a1-770f63307d57"
      unitRef="usd">-727826000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzQtNS0xLTEtMA_ac70055d-987d-458c-97c1-033b2ecb35d5"
      unitRef="usd">-37003000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzctMS0xLTEtMA_fa823a39-1b0b-4ba4-9b37-d13df54e8f26"
      unitRef="usd">0</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzctMy0xLTEtMA_174af4a8-fd13-4d87-82ca-891e4c2df385"
      unitRef="usd">2000000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzctNS0xLTEtMA_0600fd29-e092-41a7-acb9-43860bf5acda"
      unitRef="usd">0</us-gaap:RepaymentsOfRelatedPartyDebt>
    <bios:ProceedsFromSaleOfManagementNotesReceivable
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzgtMS0xLTEtMA_b81d2fcc-0a4d-4a32-9920-f5f3c0b83d34"
      unitRef="usd">0</bios:ProceedsFromSaleOfManagementNotesReceivable>
    <bios:ProceedsFromSaleOfManagementNotesReceivable
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzgtMy0xLTEtMA_c4433ca6-d14a-48d0-a7c7-cf9b1ae61a9b"
      unitRef="usd">1310000</bios:ProceedsFromSaleOfManagementNotesReceivable>
    <bios:ProceedsFromSaleOfManagementNotesReceivable
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzgtNS0xLTEtMA_dbac2380-5106-41f5-8410-1a0dd5d6aa8f"
      unitRef="usd">0</bios:ProceedsFromSaleOfManagementNotesReceivable>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzktMS0xLTEtMA_09c2a60a-f953-4e9d-bb7d-5ae3b5fb8746"
      unitRef="usd">904000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzktMy0xLTEtMA_cfcc82d3-36ee-4e9f-a716-c3128370fafc"
      unitRef="usd">2501000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfMzktNS0xLTEtMA_e88d6fc6-e0a6-4f3f-b6ac-ddf0b2fc8700"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDAtMS0xLTEtMA_86f43a57-e2c8-4298-89e6-b052a57b0cc8"
      unitRef="usd">118934000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDAtMy0xLTEtMA_953fabe3-c8d9-4472-ac0c-e371dbaed208"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDAtNS0xLTEtMA_6e6e6c81-322f-436a-a28d-f9f83eccb0fe"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDEtMS0xLTEtMA_cd5144ef-4ce1-4325-ae53-0ded556049c9"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDEtMy0xLTEtMA_b787376b-e5b5-4a8a-b42a-ede6171eb3a9"
      unitRef="usd">981050000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDEtNS0xLTEtMA_7d43e5cf-1302-45c9-9de6-2f72b0cefc9f"
      unitRef="usd">1000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDItMS0xLTEtMA_2f749019-40ea-4b7b-9b34-49ffcf707a66"
      unitRef="usd">9250000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDItMy0xLTEtMA_e0cd5360-19db-4175-83ea-fe344741e734"
      unitRef="usd">2075000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDItNS0xLTEtMA_e83126cd-0a2e-42f0-a85f-b6b5446285ea"
      unitRef="usd">5150000</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsForDepositsAppliedToDebtRetirements
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDMtMS0xLTEtMA_d9ff5106-01ec-4af0-bfea-5105d07236bc"
      unitRef="usd">174000000</us-gaap:PaymentsForDepositsAppliedToDebtRetirements>
    <us-gaap:PaymentsForDepositsAppliedToDebtRetirements
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDMtMy0xLTEtMA_246b683a-486a-4fc1-900a-c3f968627cb6"
      unitRef="usd">226738000</us-gaap:PaymentsForDepositsAppliedToDebtRetirements>
    <us-gaap:PaymentsForDepositsAppliedToDebtRetirements
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDMtNS0xLTEtMA_a8e53180-3755-4d38-b7b4-31edcf3e1cc9"
      unitRef="usd">0</us-gaap:PaymentsForDepositsAppliedToDebtRetirements>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDQtMS0xLTEtMA_be8aeb33-d052-42f1-9545-e409c4ce9ae1"
      unitRef="usd">149000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDQtMy0xLTEtMA_53ab4af8-e2a0-4d87-be58-0c01c279b4ac"
      unitRef="usd">30022000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDQtNS0xLTEtMA_ac4278d1-3d63-440c-88c4-cb705015adb7"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDctMS0xLTEtNTE5MA_7a9614db-1401-4c8c-af27-fa07d2dd45a2"
      unitRef="usd">3480000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDctMy0xLTEtNTE5MA_dcedab9e-2077-4d16-b8e7-28413dde1f95"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDctNS0xLTEtNTE5MA_dd3fd208-1361-4cc6-be22-c37d0a1caf01"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDUtMS0xLTEtMA_e1f3f0c2-1ea0-4b44-a46b-e388f668e21f"
      unitRef="usd">-68849000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDUtMy0xLTEtMA_f345c3c8-b8a1-405f-98e7-47bf500a51e4"
      unitRef="usd">719024000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDUtNS0xLTEtMA_e6a3daee-2aa0-409c-8dff-071fcbd74b4a"
      unitRef="usd">-4150000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDYtMS0xLTEtMA_148d3f2a-eccb-4988-9210-12c0fa8a4e45"
      unitRef="usd">32209000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDYtMy0xLTEtMA_b074b8ef-d9eb-4767-a249-17d363dfaad8"
      unitRef="usd">30665000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDYtNS0xLTEtMA_3b457e84-046b-44e8-a9b6-f960164c7e55"
      unitRef="usd">-16725000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDctMS0xLTEtMA_c009385a-a2ef-4205-9e5f-dc56b43ee64a"
      unitRef="usd">67056000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i757f7525fd514729825051239d54094e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDctMy0xLTEtMA_f0f70fb5-a62b-4b65-8a00-164da9f973bb"
      unitRef="usd">36391000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i40c908a9b2de45bcab117c93611972e9_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDctNS0xLTEtMA_28d09f43-9082-4866-b84c-4066c4dc1550"
      unitRef="usd">53116000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDgtMS0xLTEtMA_c3150fe7-c48b-4e28-9f99-c8dab0f52c0e"
      unitRef="usd">99265000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDgtMy0xLTEtMA_3ac58fcd-3a8c-4d35-8347-e7b469a4a6ad"
      unitRef="usd">67056000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i757f7525fd514729825051239d54094e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNDgtNS0xLTEtMA_7a4c5190-65d6-4763-9d4d-4a6774816a77"
      unitRef="usd">36391000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNTEtMS0xLTEtMA_5972cc87-2ea8-44a0-815e-5675234913d2"
      unitRef="usd">97640000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNTEtMy0xLTEtMA_854a56f7-2a4c-4777-8671-213e6a54af9b"
      unitRef="usd">50808000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNTEtNS0xLTEtMA_8b07b98c-7121-49e4-8070-2c78c680caf6"
      unitRef="usd">47173000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNTItMS0xLTEtMA_957adebb-6cb8-4df2-bc2d-669e6f7beee3"
      unitRef="usd">2884000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNTItMy0xLTEtMA_0a579889-e6a1-4c7d-8cac-a39f1c8971ea"
      unitRef="usd">2405000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNTItNS0xLTEtMA_22d5cfb2-657a-4214-8538-38eace71a579"
      unitRef="usd">1600000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNTMtMS0xLTEtMA_52229466-fbe2-45b2-933c-e8d8c0b8cb6b"
      unitRef="usd">26809000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl84OC9mcmFnOjA3YmE1MDg4YjZhYzQ1YzNhNTdlMDFmN2RhMTY4MzY1L3RhYmxlOmM2ODU1ZWMzZTRhYzQyOWNhMWE5NjM1MmRiZDdlYjAyL3RhYmxlcmFuZ2U6YzY4NTVlYzNlNGFjNDI5Y2ExYTk2MzUyZGJkN2ViMDJfNTMtMy0xLTEtMA_04c3b44d-8670-48d7-9590-410be94484c3"
      unitRef="usd">18992000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:StockholdersEquity
      contextRef="ia256a7852ef04c1fbe74e288a706e7b1_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMS0xLTEtMS0w_fbce7482-620b-46d1-bea9-a15c3225791c"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie0c4db4796fe410bb862ec15526051d4_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMS0zLTEtMS0w_2859d898-d9be-4837-b8ee-9128a7e9b83e"
      unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i422568febabe4f8583b8153a15287b3d_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMS01LTEtMS0w_d6ad6e8b-9302-4ad2-b709-c1d2fbd39363"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia4ff3448393941ecb196d60a1c0c6507_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMS03LTEtMS0w_bc0b9e2d-149c-4452-a739-4f8282913202"
      unitRef="usd">617057000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac5e68b371e846bcb5595487faa64440_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMS05LTEtMS0w_c5f1107e-0c5e-4f0a-90ac-228495be5c8d"
      unitRef="usd">-1116000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i405e4a30b4e7443da8c3cc601af2d472_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMS0xMS0xLTEtMA_752fefa2-0ea7-428b-a9d6-050245f71984"
      unitRef="usd">-9920000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ife86991b5c864d3ba7c27b4e2b6eaec8_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMS0xMy0xLTEtMA_d6612f98-7314-4ad2-8916-86b9856c0142"
      unitRef="usd">70000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i40c908a9b2de45bcab117c93611972e9_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMS0xNS0xLTEtMA_e113c1f2-46e1-4349-8f01-7a42ec6ca1d3"
      unitRef="usd">606105000</us-gaap:StockholdersEquity>
    <bios:AdjustmentsToAdditionalPaidInCapitalStockholdersContribution
      contextRef="i2aaa306bfeb44033b42625ce53fced06_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMi03LTEtMS0w_6b2ac1f6-6c66-4d7f-92ad-0d05fbe78097"
      unitRef="usd">425000</bios:AdjustmentsToAdditionalPaidInCapitalStockholdersContribution>
    <bios:AdjustmentsToAdditionalPaidInCapitalStockholdersContribution
      contextRef="i8d20553c1ddf4029b82e7a98557f08a6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMi05LTEtMS0w_90ffd65d-3d82-4a6f-9927-ef56f06e1324"
      unitRef="usd">-425000</bios:AdjustmentsToAdditionalPaidInCapitalStockholdersContribution>
    <bios:AdjustmentsToAdditionalPaidInCapitalStockholdersContribution
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMi0xNS0xLTEtMA_27ba363a-c290-44bf-98b0-744397f89ad1"
      unitRef="usd">0</bios:AdjustmentsToAdditionalPaidInCapitalStockholdersContribution>
    <bios:InterestOnManagementNotesReceivable
      contextRef="i8d20553c1ddf4029b82e7a98557f08a6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMy05LTEtMS0w_cf7149cb-2f8a-4d27-bb38-a5d8a26ee9ec"
      unitRef="usd">78000</bios:InterestOnManagementNotesReceivable>
    <bios:InterestOnManagementNotesReceivable
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMy0xNS0xLTEtMA_efb83bfb-30bc-49d9-9cbb-509ca575a793"
      unitRef="usd">78000</bios:InterestOnManagementNotesReceivable>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2aaa306bfeb44033b42625ce53fced06_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfNC03LTEtMS0w_1c0b98e1-77d3-4fbe-a651-476405d0a8d9"
      unitRef="usd">2139000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8f517132d94447c1a7f4a0703dfdad24_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfNC0xMS0xLTEtMA_a3faae65-ff67-403a-aef2-be1f5c634fac"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfNC0xNS0xLTEtMA_18332ff9-6d62-480c-afe3-159ce27d4af4"
      unitRef="usd">2139000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i8f517132d94447c1a7f4a0703dfdad24_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfNS0xMS0xLTEtMA_d816241e-5227-45cc-80c3-d56849ebcd90"
      unitRef="usd">-6115000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfNS0xNS0xLTEtMA_20b779e5-d485-49af-beba-2223285b0172"
      unitRef="usd">-6115000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6d5f5d47071547e88ec2cc2a2ed79b64_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfNy0xMy0xLTEtMA_78eb5a52-63cd-4bd1-ba81-65a3749ff0cf"
      unitRef="usd">774000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfNy0xNS0xLTEtMA_6e77b76a-c4d8-436d-9bb0-dab0e0869ca8"
      unitRef="usd">774000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="id159556253844660bd62dda5634d2366_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOC0xLTEtMS0w_f83fd657-482d-42ce-994d-1e3212996ac0"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i05ad22c7cb124eb7bc29475754fc1e50_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOC0zLTEtMS0w_af05dd1e-944d-4e68-a00b-09144dcf1d7b"
      unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iec2447edc67648968195e4c9c57c9044_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOC01LTEtMS0w_4bda1fc8-d541-4c5b-a28e-0e420bf3efb8"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb3d7b08eaa94aeca766b6bd2235a557_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOC03LTEtMS0w_e8752a05-7a8e-4293-839a-714a8aeae059"
      unitRef="usd">619621000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ca7471b8b564de0a7a5d385352e5b15_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOC05LTEtMS0w_195c01e9-54df-4912-bcdb-02239d9f6887"
      unitRef="usd">-1619000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i38e87c4a7aae447680dde06b054bed9f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOC0xMS0xLTEtMA_4e5c23d3-693a-4c37-a087-4b6f45946840"
      unitRef="usd">-16035000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i22b30bb4310a44029a5f94758c5ae210_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOC0xMy0xLTEtMA_ca748da0-082d-43ce-9a23-7868864b0fc8"
      unitRef="usd">844000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i757f7525fd514729825051239d54094e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOC0xNS0xLTEtMA_f93a101a-07f5-4dd0-9e5d-59504028c18a"
      unitRef="usd">602825000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i8a948d96b8124ca49264e48dfa5b84ea_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOS0zLTEtMS0w_9e60964b-03d5-40e0-8437-3e96cc44ab72"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i58814d8f92d24190888892748720a464_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOS03LTEtMS0w_ee3a10be-b86a-4f96-a3c7-5667ca3c2ba4"
      unitRef="usd">387040000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfOS0xNS0xLTEtMA_3a559a3e-5160-4a46-bee7-9884df81f404"
      unitRef="usd">387044000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <bios:InterestOnManagementNotesReceivable
      contextRef="iadfb96c7240b4bf2bc10824cee106ac1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTAtOS0xLTEtMA_9e5ebc2c-75a3-4156-a545-6eb0e74c6515"
      unitRef="usd">62000</bios:InterestOnManagementNotesReceivable>
    <bios:InterestOnManagementNotesReceivable
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTAtMTUtMS0xLTA_5848b878-7734-45e6-ab19-2f81f41b1d81"
      unitRef="usd">62000</bios:InterestOnManagementNotesReceivable>
    <bios:RepaymentOfManagementNotesReceivable
      contextRef="iadfb96c7240b4bf2bc10824cee106ac1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTEtOS0xLTEtMA_4d34886f-fbee-468b-9db5-8a8edb509356"
      unitRef="usd">1310000</bios:RepaymentOfManagementNotesReceivable>
    <bios:RepaymentOfManagementNotesReceivable
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTEtMTUtMS0xLTA_c063f774-304f-4ea5-b010-a223192c51be"
      unitRef="usd">1310000</bios:RepaymentOfManagementNotesReceivable>
    <bios:AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption
      contextRef="i58814d8f92d24190888892748720a464_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTItNy0xLTEtMA_a0b93cf1-6e6e-4302-b7ab-b752831c11ff"
      unitRef="usd">2371000</bios:AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption>
    <bios:AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption
      contextRef="iadfb96c7240b4bf2bc10824cee106ac1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTItOS0xLTEtMA_e35756d9-61a5-4f7a-8da0-9ffdf864fe32"
      unitRef="usd">-371000</bios:AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption>
    <bios:AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTItMTUtMS0xLTA_c514df7e-a9a0-466c-ac6d-696efb6f0949"
      unitRef="usd">2000000</bios:AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i58814d8f92d24190888892748720a464_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTItNy0xLTEtMjkyMw_c3395f32-3b70-4de3-8181-3235f6480163"
      unitRef="usd">4170000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTItMTUtMS0xLTI5MzY_d613f447-cfb3-4a5c-9139-9d77e1dc46dc"
      unitRef="usd">4170000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <bios:StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings
      contextRef="i06325eb29ded4dda8dad34622c87bed3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTMtNS0xLTEtMjkyMw_1773d919-14b0-4cc0-939f-6cc647bc9c20"
      unitRef="usd">2403000</bios:StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings>
    <bios:StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings
      contextRef="i58814d8f92d24190888892748720a464_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTMtNy0xLTEtMjkyMw_23d66d2e-328b-40df-8760-09b9cb8862aa"
      unitRef="usd">98000</bios:StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings>
    <bios:StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTMtMTUtMS0xLTI5MzY_95c6a8fd-ed89-4484-94c5-ea9b63d23f02"
      unitRef="usd">2501000</bios:StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings>
    <us-gaap:NetIncomeLoss
      contextRef="id0217dbc311b4109a34f7a05e30c523d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtMTEtMS0xLTI5MjM_ad2c7824-0a59-41d9-8cb8-63e80e54aad5"
      unitRef="usd">-75920000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtMTUtMS0xLTI5MzY_fa7a2560-ade3-43ee-a2ce-97e3053e3845"
      unitRef="usd">-75920000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icc4c4a7abaf64793a8cca9faa42d501d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTMtMTMtMS0xLTA_420a9128-1eb5-4d4f-8735-04787b53a658"
      unitRef="usd">-8039000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTMtMTUtMS0xLTA_bbf3aec6-6bab-4856-aac9-3ab65098e674"
      unitRef="usd">-8039000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i61291993f8a54aecbb68907a9140b3d1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtMS0xLTEtMA_20cd2459-29b7-402f-a071-25fe9ff34800"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic6342b5959154862925fe574bb199b16_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtMy0xLTEtMA_d3ea0819-b6b9-4a98-a34e-d7cfaa7786b4"
      unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie6648a71bd04469e8bd6b625f8e26ce2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtNS0xLTEtMA_160c87eb-175b-4976-8487-4586ad2635a9"
      unitRef="usd">-2403000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i07bbcf8ebdcc452490830f429f1ef4ed_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtNy0xLTEtMA_71b3e5cc-9308-4a08-bc19-f6dc22dea90d"
      unitRef="usd">1008362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4967cf0ba59b4694a935eb9c0d502a5d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtOS0xLTEtMA_6d1a4383-962d-41d7-81d2-58cf31511dcb"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1960cd3413c4497a8cb7b8ba588bf2b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtMTEtMS0xLTA_ff75f4b4-6666-4be3-8cf7-a4bb5b6bb0a2"
      unitRef="usd">-91955000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i30b362b8cb0f4fa291d203acfe67091d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtMTMtMS0xLTA_06985d47-0d5d-49e3-9b44-87d3cbff4f6a"
      unitRef="usd">-7195000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTQtMTUtMS0xLTA_5f874cc2-5bdc-4eed-8c2b-eb5bba287651"
      unitRef="usd">906827000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i83ec2897c370475281d08a6233255f4d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTUtNy0xLTEtMA_d02d99c9-454d-467f-82a0-5643e06d07f8"
      unitRef="usd">2920000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTUtMTUtMS0xLTA_7482e9e2-4155-4489-bf8e-8dc2ae8541c6"
      unitRef="usd">2920000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <bios:StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings
      contextRef="i83ec2897c370475281d08a6233255f4d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTYtNy0xLTEtMA_42c8c9e1-6b04-4cee-8bd2-56a874b55a09"
      unitRef="usd">904000</bios:StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings>
    <bios:StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTYtMTUtMS0xLTA_c884b0fb-a72b-4c82-8f1b-79477d3cae64"
      unitRef="usd">904000</bios:StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib48648d60adf4dfda6254c20ebbb4a83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTctMy0xLTEtMA_ec2b46d8-657b-4b14-9740-7aa9cf861313"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i83ec2897c370475281d08a6233255f4d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTctNy0xLTEtMA_cb30c84c-5ae5-41ad-9917-dc98d2b1fe12"
      unitRef="usd">118933000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMTctMTUtMS0xLTA_294b86f0-5a23-4fc8-8074-598c30a923a8"
      unitRef="usd">118934000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ib48648d60adf4dfda6254c20ebbb4a83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjEtMy0xLTEtMA_9aa9fd93-df1b-4cb7-a8fc-936c08cf3f54"
      unitRef="usd">1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i83ec2897c370475281d08a6233255f4d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjEtNy0xLTEtMA_875bcc67-ec90-48a7-a1c1-ba14af639705"
      unitRef="usd">-1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjEtMTUtMS0xLTA_c911ea72-968b-4f34-b9c4-4e4abf23b01d"
      unitRef="usd">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:NetIncomeLoss
      contextRef="i65faadc1ce524e7297267901419cec15_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjEtMTEtMS0xLTU2NjY_d26e6f2a-c458-4f6b-8cd7-21b66691b77f"
      unitRef="usd">-8076000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjEtMTUtMS0xLTU2NzI_03f4697d-d5f3-4fbc-b6de-9c7f148653be"
      unitRef="usd">-8076000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i70d31c15efcd4ad091a5d18b9108dc8e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjItMTMtMS0xLTA_3b558298-87e5-4b02-b722-be18a0c9834a"
      unitRef="usd">-3977000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjItMTUtMS0xLTA_8c364953-e32c-403b-b389-172c204dadf2"
      unitRef="usd">-3977000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i3a81bc38266c4980843d89e190c3d8fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjMtMS0xLTEtMA_485456be-7dc9-42b3-9bb0-1814d80ffe27"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2b7fd52d93044460ac7028d03c0b79f7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjMtMy0xLTEtMA_48337ac1-8e98-4ee7-8c0a-a3ce6bf8fadc"
      unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iacd1399421844f9795aff5870a8f8063_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjMtNS0xLTEtMA_4054577a-8423-4d3a-9721-42829887e09e"
      unitRef="usd">-2403000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4f8587ff958a4c948e809015b40868e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjMtNy0xLTEtMA_2a521e91-0dcb-4578-b9f2-fe388f925593"
      unitRef="usd">1129312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if42702eefc1b4929ba571e14ece46dce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjMtOS0xLTEtMA_bf0ae208-68ca-4e3d-984c-943577622765"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i510f7fb44d8047fe951f7d247dbdd5a0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjMtMTEtMS0xLTA_41be216c-795b-4b47-a9c9-4d5396cee554"
      unitRef="usd">-100031000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8178b1fbc0284245938041d60d5a050b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjMtMTMtMS0xLTA_4c0d2bb9-5fc6-481f-acb7-6ea03e85c897"
      unitRef="usd">-11172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85MS9mcmFnOmEyYzhjMjdiMjQwMTQ3YmU4MmI4YzYwZDNlNGYwODI0L3RhYmxlOjhiZjQwNmY0OTU3ZDRiNGU5YTgyZWIzMTkzODcxYTZjL3RhYmxlcmFuZ2U6OGJmNDA2ZjQ5NTdkNGI0ZTlhODJlYjMxOTM4NzFhNmNfMjMtMTUtMS0xLTA_0179e279-5143-44a0-9191-0d3b71f77c33"
      unitRef="usd">1015724000</us-gaap:StockholdersEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfNDMzMA_446e536e-f353-4600-897e-861dce626851">NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Corporate Organization and Business &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; HC Group Holdings II, Inc. (&#x201c;HC II&#x201d;) was incorporated under the laws of the State of Delaware on January 7, 2015, with its sole shareholder being HC Group Holdings I, LLC. (&#x201c;HC I&#x201d;). On April 7, 2015, HC I and HC II collectively acquired Walgreens Infusion Services, Inc. and its subsidiaries from Walgreen Co., and the business was rebranded as Option Care (&#x201c;Option Care&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 14, 2019, HC I and HC II entered into a definitive agreement (the &#x201c;Merger Agreement&#x201d;) to merge with and into a wholly-owned subsidiary of BioScrip, Inc. (&#x201c;BioScrip&#x201d;), a national provider of infusion and home care management solutions, along with certain other subsidiaries of BioScrip and HC II. The merger contemplated by the Merger Agreement (the &#x201c;Merger&#x201d;) was completed on August 6, 2019 (the &#x201c;Merger Date&#x201d;). The Merger was accounted for as a reverse merger under the acquisition method of accounting for business combinations with Option Care being considered the accounting acquirer and BioScrip being considered the legal acquirer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Merger Agreement, shares of HC II common stock issued and outstanding immediately prior to the Merger Date were converted into 135,565,392 shares of BioScrip common stock, par value $0.0001 (the &#x201c;BioScrip common stock&#x201d;). BioScrip also issued an additional 7,048,357 shares to HC I in respect of certain outstanding unvested contingent restricted stock units of BioScrip, which were set aside to prevent dilution related to potential additional vesting on certain share-based instruments. See Note 16, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional discussion of these shares set aside. In conjunction with the Merger, holders of BioScrip preferred shares and certain warrants received 864,603 additional shares of BioScrip common stock and preferred shares were repurchased for $125.8 million of cash. In addition, all legacy BioScrip debt was settled for $575.0 million. As a result of the Merger, BioScrip&#x2019;s stockholders held approximately 19.2% of the combined company, and HC I held approximately 80.8% of the combined company. Following the close of the transaction, BioScrip was rebranded as Option Care Health, Inc. (&#x201c;Option Care Health&#x201d;, or the &#x201c;Company&#x201d;). The combined company&#x2019;s stock was listed on the Nasdaq Global Select Market as of December&#160;31, 2020. See Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 99 full service pharmacies and 46 stand-alone ambulatory infusion sites. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients&#x2019; homes or other nonhospital settings. The Company operates in one segment, infusion services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;  The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles (&#x201c;GAAP&#x201d;) in the United States. These principals require management to make certain estimates and assumptions in determining assets, liabilities, revenue, expenses, and related disclosures. Actual amounts could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company&#x2019;s consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. The BioScrip results have been included in the consolidated financial results since the Merger Date. All intercompany transactions and balances are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has investments in companies that are 50% owned and are accounted for as equity-method investments. The Company&#x2019;s share of earnings from equity-method investments is included in the line entitled &#x201c;Equity in earnings of joint ventures&#x201d; in the consolidated statements of comprehensive income (loss). See &#x201c;Equity-Method Investments&#x201d; within Note 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the Company&#x2019;s equity-method investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i368d5fdb13b94d2c99546a5791f3e988_D20190806-20190806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMTI5MA_9210634b-122d-40e6-8bb8-462a6d865b1b"
      unitRef="shares">135565392</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia2ea7ddad6aa46c5900f0df09030bb8e_I20190806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMTQ1MA_ff82edb0-5bc5-46e8-8c16-3b46dda123e4"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i368d5fdb13b94d2c99546a5791f3e988_D20190806-20190806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMTUzMA_f832fa6b-0ec0-4334-b0d1-6547bf0c0c98"
      unitRef="shares">7048357</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1a95667076af42cc8fbcf3661b5bbacb_D20190806-20190806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMjAyOQ_aeda6254-8565-4686-b3df-e7d24700b485"
      unitRef="shares">864603</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1860c3f1464545dd964c4595d8b8b205_D20190806-20190806"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMjE2Mg_ed0a52f2-28be-4bc8-9854-aa7741f51045"
      unitRef="usd">125800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:LongTermDebt
      contextRef="i4c72c8c6a63c487d89bfa93db278f761_I20190806"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMjIyOA_be3614a9-083c-4f84-b3b1-42f5c0b8bd3e"
      unitRef="usd">575000000.0</us-gaap:LongTermDebt>
    <bios:BusinessCombinationOwnershipInterestRetained
      contextRef="ia2ea7ddad6aa46c5900f0df09030bb8e_I20190806"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMjMwMg_02fa8aca-d75e-4b7d-8774-26bc376a6e31"
      unitRef="number">0.192</bios:BusinessCombinationOwnershipInterestRetained>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i119e1c16609d4ae2a8c7779f88a837f0_I20190806"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMjM1OQ_6f0dd718-9ee7-409c-99e2-6d12fc7de128"
      unitRef="number">0.808</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <bios:NumberOfServiceLocations
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfNTQ5NzU1ODE0MzkwNw_1b83c8ed-0e53-437b-a384-6d1e39886724"
      unitRef="location">99</bios:NumberOfServiceLocations>
    <bios:NumberOfInfusionSites
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfNTQ5NzU1ODE0Mzk2OA_4e209edb-9b1d-471d-a9f2-6d5f94296162"
      unitRef="site">46</bios:NumberOfInfusionSites>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfNDM0MA_fd9f66d1-0477-4ac4-a5da-788f4622b374">Basis of Presentation &#x2014;  The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles (&#x201c;GAAP&#x201d;) in the United States.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfNDMzNA_df1725d8-2133-43f2-8bc1-7e02b9ac33b6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company&#x2019;s consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. The BioScrip results have been included in the consolidated financial results since the Merger Date. All intercompany transactions and balances are eliminated in consolidation.&lt;/span&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i53e06ff77c484235837649f43bbe2b5d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl85Ny9mcmFnOmRmNjM2MDVkMDI1ZjRlZjk5MGIxZGY5NjEwOTUzNmM5L3RleHRyZWdpb246ZGY2MzYwNWQwMjVmNGVmOTkwYjFkZjk2MTA5NTM2YzlfMzk2NQ_09929988-b36f-4ce9-9161-9edb7a9f8b38"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTYw_cd6a5954-01b0-4f69-a005-1c39cf94c14b">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company&#x2019;s accounts receivable is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services, which is inclusive of adjustments for price concessions. The majority of accounts receivable are due from private insurance carriers and governmental health care programs, such as Medicare and Medicaid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Price concessions may result from patient hardships, patient uncollectible accounts sent to collection agencies, lack of recovery due to not receiving prior authorization, differing interpretations of covered therapies in payer contracts, different pricing methodologies, or various other reasons. In accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (&#x201c;ASC 606&#x201d;), an allowance for doubtful accounts is established only as a result of an adverse change in the Company&#x2019;s payers&#x2019; ability to pay outstanding billings. The allowance for doubtful accounts balance is $0 as of December&#160;31, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in accounts receivable are earned but unbilled gross receivables of $79.0 million and $68.7 million as of December&#160;31, 2020 and 2019, respectively. Delays ranging from one day up to several weeks between the date of service and billing can occur due to delays in obtaining certain required payer-specific documentation from internal and external sources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a further discussion of the Company&#x2019;s revenue recognition policy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Inventory, which consists primarily of pharmaceuticals, is stated at the lower of first&#x2011;in, first&#x2011;out cost or net realizable value basis, which the Company believes is reflective of the physical flow of inventories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2018, one Company location was destroyed by a hurricane, resulting in a loss of $2.9 million of inventory. This business casualty loss was recorded as a component of operating costs and expenses within the consolidated statements of comprehensive income (loss). The Company received insurance proceeds of $0.8 million during the year ended December&#160;31, 2018, and recorded a receivable of $1.0 million. Both of these amounts were recorded as a partial offset to the business casualty loss in the consolidated statements of comprehensive income (loss). The $0.8 million of insurance proceeds were reflected as a component of cash flows from operating activities in the consolidated statements of cash flows. During the year ended December&#160;31, 2019, $3.0 million in proceeds were received related to recovery of inventory and business interruption and was included as a component of cash flows from operating activities in the consolidated statements of cash flows. These proceeds resulted in a gain on business casualty loss of $2.0 million recorded as a component of selling, general and administrative expense in the consolidated statement of comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Prepaid expenses and other current assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014; Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $35.2 million and $13.9 million for the years ended December&#160;31, 2020 and 2019, respectively. There were no other items included in prepaid expenses and other current assets that comprised 5% or more of the balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company has lease agreements for facilities, warehouses, office space and property and equipment. Effective as of January 1, 2019, at the inception of a contract, the Company determines if the contract is a lease or contains an embedded lease arrangement. Operating leases are included in the operating lease right-of-use asset (&#x201c;ROU asset&#x201d;) and operating lease liabilities in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets, which represent the Company&#x2019;s right to use the leased assets, and operating lease liabilities, which represent the present value of unpaid lease payments, are both recognized by the Company at the lease commencement date. The Company utilizes its estimated incremental borrowing rate at the lease commencement date to determine the present value of unpaid lease obligations. The&#160;rates&#160;are&#160;estimated primarily&#160;using a methodology dependent&#160;on the&#160;Company&#x2019;s financial&#160;condition, creditworthiness, and availability&#160;of certain observable data. In particular, the Company considers its actual cost of borrowing for collateralized loans and its credit rating, along with the corporate bond yield curve in estimating its incremental borrowing rates. ROU assets are recorded as the amount of operating lease liability, adjusted for prepayments, accrued lease payments, initial direct costs, lease incentives, and impairment of the ROU asset. Tenant improvement allowances used to fund leasehold improvements are recognized when earned and reduce the related ROU asset. Tenant improvement allowances are recognized through the ROU asset as a reduction of expense over the term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases may contain rent escalations, however the Company recognizes the lease expense on a straight-line basis over the expected lease term. The Company reviews the terms of any lease renewal options to determine if it is reasonably certain that the renewal options will be exercised. The Company has determined that the expected lease term is typically the minimum non-cancelable period of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has lease agreements that contain both lease and non-lease components which the Company has elected to account for as a single lease component for all asset classes. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the term of the lease. The Company&#x2019;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. See Note 8, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets, and Property and Equipment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company accounts for goodwill under ASC Topic&#160;350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and Other. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company tests goodwill for impairment annually, or more frequently whenever events or circumstances indicate impairment may exist. Goodwill is stated at cost less accumulated impairment losses. The Company completes its goodwill impairment test annually in the fourth quarter. See Note&#160;10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and Other Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the Company&#x2019;s goodwill and other intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets arising from the Company&#x2019;s acquisitions are amortized on a straight&#x2011;line basis over the estimated useful life of each asset. Referral sources have a useful life of 15-20 years. Trademarks/names have a useful life ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc0Mjk_9e7f6967-ecc8-4667-930f-df6f18fbc07d"&gt;two&lt;/span&gt; to fifteen years. The useful lives for other amortizable intangible assets range from approximately &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc1Mjc_c3c88249-a6e5-407f-ae8b-52445dccabe5"&gt;two&lt;/span&gt; to nine years. The Company does not have any indefinite&#x2011;lived intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation on owned property and equipment is provided for on a straight&#x2011;line basis over the estimated useful lives of owned assets. Leasehold improvements are amortized over the estimated useful life of the property or over the term of the lease, whichever is shorter. Estimated useful lives are seven years for infusion pumps and three years to thirteen years for equipment. Major repairs, which extend the useful life of an asset, are capitalized in the property and equipment accounts. Routine maintenance and repairs are expensed as incurred. Computer software is included in property and equipment and consists of purchased software and internally-developed software. The Company capitalizes application-stage development costs for significant internally-developed software projects. Once the software is ready for its intended use, these costs are amortized on a straight&#x2011;line basis over the software&#x2019;s estimated useful life, generally five years. Costs recognized in the preliminary project phase and the post-implementation phase, as well as maintenance and training costs, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company tests long&#x2011;lived assets for impairment whenever events or circumstances indicate that a certain asset or asset group may be impaired. Once identified, the amount of the impairment is computed by comparing the carrying value of the respective asset or asset group to its fair value, which is based on the discounted estimated future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity-Method Investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company&#x2019;s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying consolidated balance sheets. As of December&#160;31, 2020 and 2019, the balance of the investments was $17.0&#160;million and $17.0&#160;million, respectively. The investments are increased to reflect the Company&#x2019;s capital contributions and equity in earnings of the investees. The investments are decreased to reflect the Company&#x2019;s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company&#x2019;s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying consolidated statements of comprehensive income (loss). The Company&#x2019;s proportionate share of earnings was $3.3 million, $2.8 million and $1.0 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Distributions from the investees are treated as cash inflows from operating activities in the consolidated statements of cash flows. During the years ended December&#160;31, 2020, 2019 and 2018, the Company received distributions from the investees of $3.3 million, $0.5 million and $2.0&#160;million, respectively. See Footnote 17, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Transactions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for discussion of related-party transactions with these investees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Hedging Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company uses derivative financial instruments to limit its exposure to increases in the interest rate of its variable rate debt instruments. The derivative financial instruments are recognized on the consolidated balance sheets at fair value. See Note 12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Instruments,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception of the hedge, the Company designated the derivative instruments as a hedge of the cash flows related to the interest on the variable rate debt. For all instruments designated as hedges, the Company documents the hedging relationships and its risk management objective of the hedging relationship. For all hedging instruments, the terms of the hedge perfectly offset the hedged expected cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Net revenue is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services. Revenues are from government payers, commercial payers, and patients for goods and services provided and are based on a gross price based on payer contracts, fee schedules, or other arrangements less any implicit price concessions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the nature of the health care industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the expected consideration to be received at the time of patient acceptance based on the verification of the patient&#x2019;s insurance coverage, historical information with the patient, similar patients, or the payer. Performance obligations are determined based on the nature of the services provided by the Company. The majority of the Company&#x2019;s performance obligations are to provide infusion services to deliver medicine, nutrients, or fluids directly into the body. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a variety of infusion-related therapies to patients, which frequently include multiple deliverables of pharmaceutical drugs and related nursing services. After applying the criteria from ASC 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third-party payer contracts. Pharmaceutical drug revenue is recognized at the time the pharmaceutical drug is delivered to the patient, and nursing revenue is recognized on the date of service. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's outstanding performance obligations relate to contracts with a duration of less than one year. Therefore, the Company has elected to apply the practical expedient provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. Any unsatisfied or partially unsatisfied performance obligations at the end of a reporting period are generally completed prior to the patient being discharged. See Note 4, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for a further discussion of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of Revenue &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Cost of revenue consists of the actual cost of pharmaceuticals and other medical supplies dispensed to patients, as well as all other costs directly related to the production of revenue. These costs include warehousing costs, purchasing costs, freight costs, cash discounts, wages and related costs for pharmacists and nurses, along with depreciation expense relating to revenue-generating assets, such as infusion pumps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives prompt payment discounts from some of its pharmaceutical and medical supplies vendors. These prompt payment discounts are recorded as a reduction of inventory and are accounted for as a reduction of cost of goods sold when the related inventory is sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also receives rebates from pharmaceutical and medical supply manufacturers. Rebates are generally volume-based incentives and are recorded as a reduction of inventory and are accounted for as a reduction of cost of goods sold when the related inventory is sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Selling, general and administrative expenses mainly consist of salaries for administrative employees that directly and indirectly support the operations, occupancy costs, marketing expenditures, insurance, and professional fees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Based Incentive Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; -  The Company accounts for stock-based incentive compensation expense in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 718&#x201d;). Stock-based incentive compensation expense is based on the grant date fair value. The Company estimates the fair value of stock option awards using a Black-Scholes option pricing model and the fair value of restricted stock unit awards using the closing price of the Company&#x2019;s common stock on the grant date. For awards with a service-based vesting condition, the Company recognizes expense on a straight-line basis over the service period of the award. For awards with performance-based vesting conditions, the Company will recognize expense when it is probable that the performance-based conditions will be met. When the Company determines that it is probable that the performance-based conditions will be met, a cumulative catch-up of expense will be recorded as if the award had been vesting on a straight-line basis from the award date. The award will continue to be expensed on a straight-line basis through the remainder of the vesting period and will be updated if the Company determines that there has been a change in the probability of achieving the performance-based conditions. The Company records the impact of forfeited awards in the period in which the forfeiture occurs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Merger, HCI issued incentive units to certain employees of Option Care, who remained employees of the Company following the Merger. In accordance with ASC 718, the Company recognizes compensation expense on a straight-line basis over the shorter of the vesting period of the award or the employee&#x2019;s expected eligibility date. HC I also issued equity incentive units to certain members of the Option Care Board of Directors, who remained members of the Board of Directors following the Merger. See Note 15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Incentive Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for a further discussion of equity incentive plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; -  The Company accounts for business acquisitions in accordance with ASC Topic 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with assets and liabilities being recorded at their acquisition date fair value and goodwill being calculated as the purchase price in excess of the net identifiable assets. See Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the Company&#x2019;s business acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are reported for book-tax basis differences and are measured based on currently enacted tax laws using rates expected to apply to taxable income in the years in which the differences are expected to reverse. The effect of a change in tax rate on deferred taxes is recognized in income tax expense in the period that includes the enactment date of the change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes income tax positions that are more likely than not to be sustained on their technical merits. The Company measures recognized income tax positions at the maximum benefit that is more likely than not, based on cumulative probability, realizable upon final settlement of the position. Interest and penalties related to unrecognized tax benefits are reported in income tax expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Business Risk &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company&#x2019;s largest payer was approximately 15%, 16% and 17% for the years ended December&#160;31, 2020, 2019 and 2018, respectively. In December 2019, the Company renewed and expanded its multi-year contract with this payer. The contract renewal was effective in February 2020 for a two-year term and auto-renews at the end of that term. There were no other managed care contracts that represent greater than 10% of revenue for the years presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For the years ended December&#160;31, 2020, 2019 and 2018, approximately 15%, 12% and 12%, respectively, of the Company&#x2019;s revenue was reimbursable through direct government healthcare programs such as Medicare and Medicaid. As of December&#160;31, 2020 and 2019, approximately 15% and 12%, respectively, of the Company&#x2019;s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not require its patients nor other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentrations of credit risk relating to trade accounts receivable is limited due to the Company&#x2019;s diversity of patients and payers. Further, the Company generally does not provide charity care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2020 and 2019, approximately 70% and 70%, respectively, of the Company&#x2019;s pharmaceutical and medical supply purchases were from three vendors. For the year ended December&#160;31, 2018, approximately  66% of the Company&#x2019;s pharmaceutical and medical supply purchases were from two vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company&#x2019;s financial condition or operating results. Although there is uncertainty regarding the COVID-19 pandemic, as of December&#160;31, 2020 the Company has been able to maintain adequate levels of supplies and pharmaceuticals to support its operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The fair value measurement accounting standard, ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), provides a framework for measuring fair value and defines fair value as the price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The standard establishes a valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on independent market data sources. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available. The valuation hierarchy is composed of three categories. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The categories within the valuation hierarchy are described as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:58.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:58.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:58.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Inputs to the fair value measurement are unobservable inputs or valuation techniques.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently-Adopted Accounting Pronouncements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;  In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires measurement and recognition of expected credit losses for financial assets held. The amendments in ASU 2016-13 eliminate the probable threshold for initial recognition of a credit loss in current GAAP and reflect an entity&#x2019;s current estimate of all expected credit losses. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019 and is to be applied using a modified retrospective transition method. The Company adopted the standard as of January 1, 2020. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTU2_d86dc900-d8ae-4e95-8bd2-f7ec447e3163">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTU3_feb0339f-b199-4c12-9573-01674ec87158">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company&#x2019;s accounts receivable is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services, which is inclusive of adjustments for price concessions. The majority of accounts receivable are due from private insurance carriers and governmental health care programs, such as Medicare and Medicaid.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Price concessions may result from patient hardships, patient uncollectible accounts sent to collection agencies, lack of recovery due to not receiving prior authorization, differing interpretations of covered therapies in payer contracts, different pricing methodologies, or various other reasons. In accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue from Contracts with Customers&lt;/span&gt; (&#x201c;ASC 606&#x201d;), an allowance for doubtful accounts is established only as a result of an adverse change in the Company&#x2019;s payers&#x2019; ability to pay outstanding billings.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzEyODc_ccfa2a8d-cfb8-43b3-90d4-398985511813"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzEyODc_d2858a82-796e-4abc-bc18-43352c8dbaa7"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzIyMDM_4810a6d2-b3e6-4c19-8b33-4e03beda4776"
      unitRef="usd">79000000.0</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzIyMTA_5e0e1dbf-3649-43cc-8637-259f6340fb3f"
      unitRef="usd">68700000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTU4_501d4bbd-5768-47f8-a831-4dca045cc743">Inventory &#x2014; Inventory, which consists primarily of pharmaceuticals, is stated at the lower of first&#x2011;in, first&#x2011;out cost or net realizable value basis, which the Company believes is reflective of the physical flow of inventories.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryWriteDown
      contextRef="i086f47aad02f4c3598246e2234bcfcb9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI4NzQ_167a2081-2e78-40b6-8d49-1302da34c7a2"
      unitRef="usd">2900000</us-gaap:InventoryWriteDown>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="i086f47aad02f4c3598246e2234bcfcb9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzMwODk_50e11a6c-0b2c-4134-994d-59020a4bbc10"
      unitRef="usd">800000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:InsuranceSettlementsReceivable
      contextRef="i7eb197b8c371412db224c1301352b49f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzMxMzk_af93c8cc-6056-4cad-9c43-a37716cee9bb"
      unitRef="usd">1000000.0</us-gaap:InsuranceSettlementsReceivable>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="i086f47aad02f4c3598246e2234bcfcb9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzM0MDE_50e11a6c-0b2c-4134-994d-59020a4bbc10"
      unitRef="usd">800000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="i9fc719df4b5d4d1f874963db8ef3704c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzM1NTc_6c89e5c4-9d47-4ed8-9742-aa54bba98aa7"
      unitRef="usd">3000000.0</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i9fc719df4b5d4d1f874963db8ef3704c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzM4MjY_08d46fee-abef-4fef-94e1-5644a5c11552"
      unitRef="usd">2000000.0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODYwMTE_7555c415-e6d8-4f09-a4d4-b47f8a60a7e1"
      unitRef="usd">35200000</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODYwMjc_264ef5b2-187e-4cd4-9cc6-1d35ab40b0fb"
      unitRef="usd">13900000</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTQ3_38e4ea95-aeae-418c-8377-eab3a33c5741">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company has lease agreements for facilities, warehouses, office space and property and equipment. Effective as of January 1, 2019, at the inception of a contract, the Company determines if the contract is a lease or contains an embedded lease arrangement. Operating leases are included in the operating lease right-of-use asset (&#x201c;ROU asset&#x201d;) and operating lease liabilities in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets, which represent the Company&#x2019;s right to use the leased assets, and operating lease liabilities, which represent the present value of unpaid lease payments, are both recognized by the Company at the lease commencement date. The Company utilizes its estimated incremental borrowing rate at the lease commencement date to determine the present value of unpaid lease obligations. The&#160;rates&#160;are&#160;estimated primarily&#160;using a methodology dependent&#160;on the&#160;Company&#x2019;s financial&#160;condition, creditworthiness, and availability&#160;of certain observable data. In particular, the Company considers its actual cost of borrowing for collateralized loans and its credit rating, along with the corporate bond yield curve in estimating its incremental borrowing rates. ROU assets are recorded as the amount of operating lease liability, adjusted for prepayments, accrued lease payments, initial direct costs, lease incentives, and impairment of the ROU asset. Tenant improvement allowances used to fund leasehold improvements are recognized when earned and reduce the related ROU asset. Tenant improvement allowances are recognized through the ROU asset as a reduction of expense over the term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases may contain rent escalations, however the Company recognizes the lease expense on a straight-line basis over the expected lease term. The Company reviews the terms of any lease renewal options to determine if it is reasonably certain that the renewal options will be exercised. The Company has determined that the expected lease term is typically the minimum non-cancelable period of the lease.&lt;/span&gt;&lt;/div&gt;The Company has lease agreements that contain both lease and non-lease components which the Company has elected to account for as a single lease component for all asset classes. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the term of the lease. The Company&#x2019;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTQ4_9309fb40-1119-4959-a8fe-aaaa48834b5c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets, and Property and Equipment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company accounts for goodwill under ASC Topic&#160;350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and Other. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company tests goodwill for impairment annually, or more frequently whenever events or circumstances indicate impairment may exist. Goodwill is stated at cost less accumulated impairment losses. The Company completes its goodwill impairment test annually in the fourth quarter. See Note&#160;10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and Other Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the Company&#x2019;s goodwill and other intangible assets.&lt;/span&gt;Intangible assets arising from the Company&#x2019;s acquisitions are amortized on a straight&#x2011;line basis over the estimated useful life of each asset. Referral sources have a useful life of 15-20 years. Trademarks/names have a useful life ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc0Mjk_9e7f6967-ecc8-4667-930f-df6f18fbc07d"&gt;two&lt;/span&gt; to fifteen years. The useful lives for other amortizable intangible assets range from approximately &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc1Mjc_c3c88249-a6e5-407f-ae8b-52445dccabe5"&gt;two&lt;/span&gt; to nine years.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i48a8600720a94bbf87db1dbe3e875b03_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzczNjc_e5efb1eb-9cda-4d2d-bfbc-17a4c3d8dc8e">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2d430ba49f0c4e89b1371f12b3bbf397_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzczNzA_ec6d00a9-d7ed-481d-a166-565c8fdce84c">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if76a9379d5a5462faea6e4911c09e610_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc0MzU_7e890b84-de6c-4190-b413-f54e3e17a309">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6ad7ffbd4bbb4311af7b6cd327201826_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc1MzM_88f9687a-55cb-485b-89db-57748edd57b9">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTQx_b828d084-d601-448d-87af-1f3abd7b2679">&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation on owned property and equipment is provided for on a straight&#x2011;line basis over the estimated useful lives of owned assets. Leasehold improvements are amortized over the estimated useful life of the property or over the term of the lease, whichever is shorter. Estimated useful lives are seven years for infusion pumps and three years to thirteen years for equipment. Major repairs, which extend the useful life of an asset, are capitalized in the property and equipment accounts. Routine maintenance and repairs are expensed as incurred. Computer software is included in property and equipment and consists of purchased software and internally-developed software. The Company capitalizes application-stage development costs for significant internally-developed software projects. Once the software is ready for its intended use, these costs are amortized on a straight&#x2011;line basis over the software&#x2019;s estimated useful life, generally five years. Costs recognized in the preliminary project phase and the post-implementation phase, as well as maintenance and training costs, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company tests long&#x2011;lived assets for impairment whenever events or circumstances indicate that a certain asset or asset group may be impaired. Once identified, the amount of the impairment is computed by comparing the carrying value of the respective asset or asset group to its fair value, which is based on the discounted estimated future cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2bff063b20b44971b7a869047927c0a9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc5ODU_9f4fff8c-8421-45cf-8448-0e3c867b7393">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if9646cc5252f40eabde3fb89431c23a5_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzgwMTc_97b813a4-5736-4b15-b650-574563f14968">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ie12e4e114a18499d9effec6a2ee61dbe_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzgwMjk_a9bd67b7-f19a-4257-9303-0768fae1a7e8">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i3a9ad7e932754e6bbc1e427751b3bf94_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzg2MTk_edbf49c3-1fb1-416f-9eb0-d7b752c4c516">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTU5_53d3d48c-1740-4f3f-94e4-4f75119ffeea">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity-Method Investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company&#x2019;s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying consolidated balance sheets. As of December&#160;31, 2020 and 2019, the balance of the investments was $17.0&#160;million and $17.0&#160;million, respectively. The investments are increased to reflect the Company&#x2019;s capital contributions and equity in earnings of the investees. The investments are decreased to reflect the Company&#x2019;s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company&#x2019;s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying consolidated statements of comprehensive income (loss). The Company&#x2019;s proportionate share of earnings was $3.3 million, $2.8 million and $1.0 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Distributions from the investees are treated as cash inflows from operating activities in the consolidated statements of cash flows. During the years ended December&#160;31, 2020, 2019 and 2018, the Company received distributions from the investees of $3.3 million, $0.5 million and $2.0&#160;million, respectively. See Footnote 17, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Transactions&lt;/span&gt;, for discussion of related-party transactions with these investees.</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:EquityMethodInvestments
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODQ0ODQ_fd0b26fe-d7a4-4d8a-b07e-47cdc2796f34"
      unitRef="usd">17000000.0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODIxMDU_ea8c2805-fcfa-4cda-9ad2-9859c3f9e482"
      unitRef="usd">17000000.0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODIzMDQ_dba7b68d-81e5-41e8-895d-57f51626ef8b"
      unitRef="usd">3300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODIzMDk_733a54f9-b2d9-4dee-91c1-7c15e0d3edf0"
      unitRef="usd">2800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODIzMjI_6d07684a-f6e8-4dfb-8de3-11d97dcb0234"
      unitRef="usd">1000000.0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODIyMzY_15bcf672-3350-47f9-a682-f76710fb8954"
      unitRef="usd">3300000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODIyNDU_599d2f1b-a09d-4bc9-ada4-d753bc8eda26"
      unitRef="usd">500000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODIyNzc_590b1ec5-f4c0-4719-821e-f2df6a7e0792"
      unitRef="usd">2000000.0</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzMyOTg1MzQ5MzI2NzY_daf7703e-9b03-46c5-a1ec-59ba97aa1ac8">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Hedging Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company uses derivative financial instruments to limit its exposure to increases in the interest rate of its variable rate debt instruments. The derivative financial instruments are recognized on the consolidated balance sheets at fair value. See Note 12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Instruments,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information.&lt;/span&gt;At inception of the hedge, the Company designated the derivative instruments as a hedge of the cash flows related to the interest on the variable rate debt. For all instruments designated as hedges, the Company documents the hedging relationships and its risk management objective of the hedging relationship. For all hedging instruments, the terms of the hedge perfectly offset the hedged expected cash flows.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTQy_f43be403-f0f9-483f-8e24-cb9f4e735896">&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Net revenue is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services. Revenues are from government payers, commercial payers, and patients for goods and services provided and are based on a gross price based on payer contracts, fee schedules, or other arrangements less any implicit price concessions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the nature of the health care industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the expected consideration to be received at the time of patient acceptance based on the verification of the patient&#x2019;s insurance coverage, historical information with the patient, similar patients, or the payer. Performance obligations are determined based on the nature of the services provided by the Company. The majority of the Company&#x2019;s performance obligations are to provide infusion services to deliver medicine, nutrients, or fluids directly into the body. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a variety of infusion-related therapies to patients, which frequently include multiple deliverables of pharmaceutical drugs and related nursing services. After applying the criteria from ASC 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third-party payer contracts. Pharmaceutical drug revenue is recognized at the time the pharmaceutical drug is delivered to the patient, and nursing revenue is recognized on the date of service. &lt;/span&gt;&lt;/div&gt;The Company's outstanding performance obligations relate to contracts with a duration of less than one year. Therefore, the Company has elected to apply the practical expedient provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. Any unsatisfied or partially unsatisfied performance obligations at the end of a reporting period are generally completed prior to the patient being discharged.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTQz_1cba042f-0b3c-4f3d-a299-aeb50fef6e44">&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of Revenue &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Cost of revenue consists of the actual cost of pharmaceuticals and other medical supplies dispensed to patients, as well as all other costs directly related to the production of revenue. These costs include warehousing costs, purchasing costs, freight costs, cash discounts, wages and related costs for pharmacists and nurses, along with depreciation expense relating to revenue-generating assets, such as infusion pumps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives prompt payment discounts from some of its pharmaceutical and medical supplies vendors. These prompt payment discounts are recorded as a reduction of inventory and are accounted for as a reduction of cost of goods sold when the related inventory is sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also receives rebates from pharmaceutical and medical supply manufacturers. Rebates are generally volume-based incentives and are recorded as a reduction of inventory and are accounted for as a reduction of cost of goods sold when the related inventory is sold.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTYx_aa48b9f6-bdc7-467f-bd4e-b3bdb4abaea0">Selling, General and Administrative Expenses &#x2014; Selling, general and administrative expenses mainly consist of salaries for administrative employees that directly and indirectly support the operations, occupancy costs, marketing expenditures, insurance, and professional fees.</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTQ5_25564597-1868-43a7-9288-9eee148f201f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Based Incentive Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; -  The Company accounts for stock-based incentive compensation expense in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 718&#x201d;). Stock-based incentive compensation expense is based on the grant date fair value. The Company estimates the fair value of stock option awards using a Black-Scholes option pricing model and the fair value of restricted stock unit awards using the closing price of the Company&#x2019;s common stock on the grant date. For awards with a service-based vesting condition, the Company recognizes expense on a straight-line basis over the service period of the award. For awards with performance-based vesting conditions, the Company will recognize expense when it is probable that the performance-based conditions will be met. When the Company determines that it is probable that the performance-based conditions will be met, a cumulative catch-up of expense will be recorded as if the award had been vesting on a straight-line basis from the award date. The award will continue to be expensed on a straight-line basis through the remainder of the vesting period and will be updated if the Company determines that there has been a change in the probability of achieving the performance-based conditions. The Company records the impact of forfeited awards in the period in which the forfeiture occurs. &lt;/span&gt;Prior to the Merger, HCI issued incentive units to certain employees of Option Care, who remained employees of the Company following the Merger. In accordance with ASC 718, the Company recognizes compensation expense on a straight-line basis over the shorter of the vesting period of the award or the employee&#x2019;s expected eligibility date. HC I also issued equity incentive units to certain members of the Option Care Board of Directors, who remained members of the Board of Directors following the Merger.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTUw_329f7436-7920-468f-a618-addb28acdae9">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; -  The Company accounts for business acquisitions in accordance with ASC Topic 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;, with assets and liabilities being recorded at their acquisition date fair value and goodwill being calculated as the purchase price in excess of the net identifiable assets</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTUx_f7457d93-f93e-4fdc-97ba-cecaab52aeb2">&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are reported for book-tax basis differences and are measured based on currently enacted tax laws using rates expected to apply to taxable income in the years in which the differences are expected to reverse. The effect of a change in tax rate on deferred taxes is recognized in income tax expense in the period that includes the enactment date of the change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized. &lt;/span&gt;&lt;/div&gt;The Company recognizes income tax positions that are more likely than not to be sustained on their technical merits. The Company measures recognized income tax positions at the maximum benefit that is more likely than not, based on cumulative probability, realizable upon final settlement of the position. Interest and penalties related to unrecognized tax benefits are reported in income tax expense.</us-gaap:IncomeTaxPolicyTextBlock>
    <bios:ConcentrationRiskBusinessRiskPolicyPolicyTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTUy_437222fb-bcd5-4ad7-8d4e-732c73b892ae">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Business Risk &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company&#x2019;s largest payer was approximately 15%, 16% and 17% for the years ended December&#160;31, 2020, 2019 and 2018, respectively. In December 2019, the Company renewed and expanded its multi-year contract with this payer. The contract renewal was effective in February 2020 for a two-year term and auto-renews at the end of that term. There were no other managed care contracts that represent greater than 10% of revenue for the years presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For the years ended December&#160;31, 2020, 2019 and 2018, approximately 15%, 12% and 12%, respectively, of the Company&#x2019;s revenue was reimbursable through direct government healthcare programs such as Medicare and Medicaid. As of December&#160;31, 2020 and 2019, approximately 15% and 12%, respectively, of the Company&#x2019;s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not require its patients nor other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentrations of credit risk relating to trade accounts receivable is limited due to the Company&#x2019;s diversity of patients and payers. Further, the Company generally does not provide charity care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2020 and 2019, approximately 70% and 70%, respectively, of the Company&#x2019;s pharmaceutical and medical supply purchases were from three vendors. For the year ended December&#160;31, 2018, approximately  66% of the Company&#x2019;s pharmaceutical and medical supply purchases were from two vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company&#x2019;s financial condition or operating results. Although there is uncertainty regarding the COVID-19 pandemic, as of December&#160;31, 2020 the Company has been able to maintain adequate levels of supplies and pharmaceuticals to support its operations.&lt;/span&gt;&lt;/div&gt;</bios:ConcentrationRiskBusinessRiskPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i158605824c6c423d867ee0566aa0ca47_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzE5MjE2_4f2453f8-4c7d-4f3a-85c4-cc262042948e"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i484daecca47b416e99281851405afa48_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzE5MjIw_264b751b-c640-4df9-905c-9970c245f1d6"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3503095cd1c346c3968c0a9058c5e025_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzE5MjI3_575010f1-010c-4454-809e-140e8d923d57"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <bios:BusinessCombinationRenewalTermLength
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzMyOTg1MzQ5MzI3Mzg_25dda4aa-a590-430a-9d34-d96cc6e3028b">P2Y</bios:BusinessCombinationRenewalTermLength>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i90930859b5a244fd919dfe2f357f7c23_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzE5NjI2_360a353b-a791-4b7c-9f9a-51984e36d29f"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib2f3781893ae44f498e20de51cd69b29_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzE5NjMw_f0419f48-1ee9-4b9c-891b-ae3f9816b5cc"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0026d0842d3a4359a1692dd699b20cad_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzE5NjM3_7f67911c-e516-4fcc-b42d-207b33d49076"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6527aad98d3a47a69d34f668ffe88a0a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzE5ODA1_d8a09e5e-1b4b-4d82-b88e-cc7e048d481f"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if236b13a6b0a4994a585e5cf622ca3f3_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzE5ODEy_cdc4b76e-708e-4523-b668-d01b29287ff8"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i464c8f864f8d49899ce600f0ac27fe32_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzIwNjI2_ed343167-a9da-40bb-aef5-d38a79c32216"
      unitRef="number">0.70</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7851f95217d9442598cc88ba1ed517d1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzU0OTc1NTgxODIxODk_d0c2a849-48ed-4b4f-9ebc-2cfa054dffa9"
      unitRef="number">0.70</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6edfcb49cb0b4b1e8a63a9955b1aaab1_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzIwNzU4_0254a3a2-1c6e-4c9c-be3b-c29c64361d4e"
      unitRef="number">0.66</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTYy_d68b203c-168a-4fc1-8ff4-d371d701eb9f">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The fair value measurement accounting standard, ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), provides a framework for measuring fair value and defines fair value as the price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The standard establishes a valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on independent market data sources. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available. The valuation hierarchy is composed of three categories. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The categories within the valuation hierarchy are described as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:58.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:58.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:58.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Inputs to the fair value measurement are unobservable inputs or valuation techniques.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.&lt;/span&gt;&lt;/div&gt;FAIR VALUE MEASUREMENTS&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs.  The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements).  The three levels of inputs within the fair value hierarchy are defined in Note 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;First Lien Term Loan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the carrying amount and fair value of the First Lien Term Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Second Lien Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The fair value of the Second Lien Notes is derived from a cash flow model that discounted the cash flows based on market interest rates (Level 3 inputs). See Note 11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the carrying amount and fair value of the Second Lien Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest rate swaps&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The fair values of interest rate swaps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the fair value of the interest rate swaps. &lt;/span&gt;&lt;/div&gt;Interest rate caps: The fair values of interest rate caps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzI5OTU1_38c076c0-0d3b-490c-bbae-4530c71c7fa0">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently-Adopted Accounting Pronouncements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;  In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires measurement and recognition of expected credit losses for financial assets held. The amendments in ASU 2016-13 eliminate the probable threshold for initial recognition of a credit loss in current GAAP and reflect an entity&#x2019;s current estimate of all expected credit losses. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019 and is to be applied using a modified retrospective transition method. The Company adopted the standard as of January 1, 2020. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzY5Mzg_3786a352-a718-460b-a157-3714ff7a7f04">BUSINESS ACQUISITIONS&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Merger with BioScrip, Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; As discussed in Note&#160;1,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nature of Operations and Presentation of Financial Statements,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option Care&#160;merged with BioScrip&#160;on August 6, 2019.&#160;BioScrip&#160;was a national provider of infusion and home care management solutions.&#160;The Merger of Option Care and BioScrip into Option Care Health created an expanded national platform and the opportunity to drive economies of scale through procurement savings, facility rationalization and other operating cost savings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of purchase consideration transferred on the closing date includes the value of the number of shares of the combined company owned by BioScrip shareholders at closing of the Merger, the value of common shares issued to certain warrant and preferred shareholders in conjunction with the Merger, the fair value of stock-based instruments that were vested or earned as of the Merger, and cash payments made in conjunction with the Merger. The fair value per share of BioScrip&#x2019;s common stock was $2.67 per share. This is the closing price of the BioScrip common stock on August&#160;6, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, the calculation of total consideration exchanged is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of BioScrip common shares outstanding at time of the Merger (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common shares issued to warrant and preferred stockholders at time of the Merger (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total shares of BioScrip common stock outstanding at time of the Merger (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BioScrip share price as of August 6, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of share-based instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash paid in conjunction with the Merger included in purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;714,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,102,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of total consideration acquired, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,087,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) These shares were not adjusted for the one share for four share reverse stock split, which occurred on February 3, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid in conjunction with the Merger includes payments made for settlement of $575.0 million in legacy BioScrip debt, $125.8 million in existing BioScrip preferred shares, and $14.1 million in legacy BioScrip success-based fees owed to third-party advisors. HC II financed these payments primarily through cash on hand and debt financing, which is discussed in Note 11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s allocation of consideration exchanged to the net tangible and intangible assets acquired and liabilities assumed, net of cash acquired, in the Merger is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventories (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intangible assets, net (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net of deferred tax liabilities (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset (6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liability (6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable  (7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assumed liabilities, net of other acquired assets (7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total acquired identifiable assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;291,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill (8)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;796,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,087,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Management has valued accounts receivables based on the estimated future collectability of the receivables portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Inventories are stated at fair value as of the Merger Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The fair value of the property and equipment was determined based upon the best and highest use of the property with final values determined based upon an analysis of the cost, sales comparison, and income capitalization approaches for each property appraised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The allocation of consideration exchanged to intangible assets acquired is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.771%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Estimated Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks/Names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Patient referral sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company valued trademarks/names utilizing the relief of royalty method and patient referral sources utilizing the multi-period excess earnings method, a form of the income approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Net deferred tax&#160;assets&#160;represented the expected future tax consequences of temporary differences between the fair values of the assets acquired and liabilities assumed and their tax bases. See Note 6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional discussion of the Company&#x2019;s combined income tax position subsequent to the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The fair value of the operating lease liability and corresponding right-of-use asset (current and long-term) was based on current market rates available to the&#160;Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Accounts payable as well as certain other current and non-current assets and liabilities are stated at fair value as of the&#160;Merger Date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The&#160;Merger resulted in&#160;$796.1 million of goodwill, which is attributable to cost synergies resulting from procurement and operational efficiencies and elimination of duplicative administrative costs. The goodwill created in the Merger&#160;is not expected to be deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assuming BioScrip had been acquired as of January 1, 2018, and the results of BioScrip had been included in operations beginning on January 1, 2018, the following tables provide estimated unaudited pro forma results of operations for the&#160;years ended December&#160;31, 2019 and 2018 (in thousands). The estimated pro forma net income adjusts for the effect of fair value adjustments related to the Merger, transaction costs and other non-recurring costs directly attributable to the Merger and the impact of the additional debt to finance the Merger. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:64.912%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,755,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,648,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated unaudited pro forma information is not necessarily indicative of the results that actually would have occurred had the&#160;Merger&#160;been completed on the date indicated or the future operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the periods subsequent to the&#160;Merger Date&#160;that are included in the results of operations for the year ended December&#160;31, 2019, BioScrip had net revenue of&#160;$308.9 million&#160;and a net loss of&#160;$30.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition-related costs were expensed as incurred, with the exception of BioScrip success-based fees that are included in consideration transferred. The Company recorded transaction costs that are expensed in selling, general and administrative expenses during the year ended December&#160;31, 2019 of approximately $25.8 million. Transaction expenses consisted of professional fees for advisory, consulting and underwriting services as well as other incremental costs directly related to the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Baptist Health Asset Acquisition &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;  In August 2018, pursuant to the Purchase and Sale Agreement dated August 8, 2018, Option Care completed the acquisition of certain assets of Baptist Health in Little Rock, Arkansas for a purchase price of $1.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Home I.V. Specialists, Inc. Acquisition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; In September 2018, pursuant to the Stock Purchase Agreement dated September 18, 2018, Option Care completed the acquisition of 100% of the outstanding shares of Home I.V. Specialists, Inc. (&#x201c;Home I.V.&#x201d;) for a purchase price of $11.6 million, net of cash acquired. The total consideration was comprised of cash paid of $9.8 million and a contingent payment of $1.8 million payable one year after the acquisition date. During the year ended December&#160;31, 2019, the Company reduced the contingent liability by $0.3 million. During the year ended December&#160;31, 2020, the Company determined that the contingent payment was not payable and reduced the remaining contingent liability by $1.5&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzEwMjM_8d6779f1-c62c-4583-87f8-12237b2e89ce"
      unitRef="usdPerShare">2.67</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzY5Mzk_aa9fde8f-7dc3-4c04-a872-2cd001177f08">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, the calculation of total consideration exchanged is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of BioScrip common shares outstanding at time of the Merger (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common shares issued to warrant and preferred stockholders at time of the Merger (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total shares of BioScrip common stock outstanding at time of the Merger (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BioScrip share price as of August 6, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of share-based instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash paid in conjunction with the Merger included in purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;714,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,102,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of total consideration acquired, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,087,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) These shares were not adjusted for the one share for four share reverse stock split, which occurred on February 3, 2020.</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0f090775b2c24e07909f7019308c4cc6_I20190805"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzEtMi0xLTEtMA_da434ea9-5967-4828-9f2b-19c6432f81a8"
      unitRef="shares">129181000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzItMi0xLTEtMA_0548ae4c-9b34-423f-9ef7-e05a56d5bf65"
      unitRef="shares">3458000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzMtMi0xLTEtMA_3b26fccc-61e3-43cf-8d5f-f887a45068ea"
      unitRef="shares">132639000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzQtMi0xLTEtMA_8d6779f1-c62c-4583-87f8-12237b2e89ce"
      unitRef="usdPerShare">2.67</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzUtMi0xLTEtMA_f4ba14cc-8c17-49cd-8f0e-7401c6b04a0d"
      unitRef="usd">354146000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzYtMi0xLTEtMA_cd0e8ab8-efa7-4174-9026-3e2ef3b1f09f"
      unitRef="usd">32898000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzctMi0xLTEtMA_33ad09b9-6390-42dd-b12a-a7aa7e630819"
      unitRef="usd">714957000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzgtMi0xLTEtMA_9446a300-5bea-446d-a73f-0746633f03b1"
      unitRef="usd">1102001000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzktMi0xLTEtMA_eea4b0c3-9b3e-4498-b5b3-54d0d7cd0a9a"
      unitRef="usd">14787000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTpjM2RjMWEzMDFkYTI0MDZlYTQ0MjRiNTU3NTNhZjkzMC90YWJsZXJhbmdlOmMzZGMxYTMwMWRhMjQwNmVhNDQyNGI1NTc1M2FmOTMwXzEwLTItMS0xLTA_d8b4e86f-4387-46dd-9796-d6c36475b90c"
      unitRef="usd">1087214000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i96e2bd7b43e2425892cf80e8dee1fa59_D20190806-20190806"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzE1MTk_96a4dca9-a09e-48c6-bdba-bc5f68b16cb4"
      unitRef="usd">575000000.0</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzE1NDc_221dc7f5-cb06-4c13-b5be-fec0afa00c9a"
      unitRef="usd">125800000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzE1OTM_0f58ae09-15c4-4412-b670-a557bbba40ba"
      unitRef="usd">14100000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzY5NDA_954e4654-fc6c-4a59-a9fc-805cc04b4259">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s allocation of consideration exchanged to the net tangible and intangible assets acquired and liabilities assumed, net of cash acquired, in the Merger is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventories (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intangible assets, net (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net of deferred tax liabilities (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset (6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liability (6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable  (7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assumed liabilities, net of other acquired assets (7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total acquired identifiable assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;291,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill (8)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;796,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,087,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Management has valued accounts receivables based on the estimated future collectability of the receivables portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Inventories are stated at fair value as of the Merger Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The fair value of the property and equipment was determined based upon the best and highest use of the property with final values determined based upon an analysis of the cost, sales comparison, and income capitalization approaches for each property appraised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The allocation of consideration exchanged to intangible assets acquired is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.771%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Estimated Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks/Names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Patient referral sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company valued trademarks/names utilizing the relief of royalty method and patient referral sources utilizing the multi-period excess earnings method, a form of the income approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Net deferred tax&#160;assets&#160;represented the expected future tax consequences of temporary differences between the fair values of the assets acquired and liabilities assumed and their tax bases. See Note 6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional discussion of the Company&#x2019;s combined income tax position subsequent to the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The fair value of the operating lease liability and corresponding right-of-use asset (current and long-term) was based on current market rates available to the&#160;Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Accounts payable as well as certain other current and non-current assets and liabilities are stated at fair value as of the&#160;Merger Date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The&#160;Merger resulted in&#160;$796.1 million of goodwill, which is attributable to cost synergies resulting from procurement and operational efficiencies and elimination of duplicative administrative costs. The goodwill created in the Merger&#160;is not expected to be deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzEtNC0xLTEtMA_88d68d27-fa2a-40c7-acbe-c40cab28219f"
      unitRef="usd">96532000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzItNC0xLTEtMA_3bd90066-8fd3-46e1-b95f-21c67614b337"
      unitRef="usd">19683000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzMtNC0xLTEtMA_963ce80a-ae9c-49cd-ae45-5f9bc703684f"
      unitRef="usd">48732000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzQtNC0xLTEtMA_2cd094d3-fc61-4c14-aa1c-3bd26af26ed1"
      unitRef="usd">193245000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzUtNC0xLTEtMA_1448c7f0-a7af-4d3d-826e-be9a4d05597c"
      unitRef="usd">26731000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <bios:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzYtNC0xLTEtMA_7245f837-ad98-4579-b594-6fbd4b714798"
      unitRef="usd">22378000</bios:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzctNC0xLTEtMA_1f382d22-041e-4804-9356-fe1b5717832e"
      unitRef="usd">28897000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzgtNC0xLTEtMA_c771ebf3-21a0-4390-946e-9a4b7e31f2a9"
      unitRef="usd">66668000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzktNC0xLTEtMA_c469b43d-a1fd-4634-b134-7746895c222a"
      unitRef="usd">20663000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzEwLTQtMS0xLTA_a0b2f1a6-c14a-47d1-991f-6115d1aa647a"
      unitRef="usd">291073000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzExLTQtMS0xLTA_4f99af42-ff77-44f9-a670-a1de2549361a"
      unitRef="usd">796141000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZToxMzkzMmNmNmMxZGY0NjFiYjJjNTA3ZjZiMDMzYWJmYS90YWJsZXJhbmdlOjEzOTMyY2Y2YzFkZjQ2MWJiMmM1MDdmNmIwMzNhYmZhXzEyLTQtMS0xLTA_906bcbd4-0baf-4901-a596-b25701625f8d"
      unitRef="usd">1087214000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzY5NDE_29302317-484d-4b31-aef0-d16305e78d44">The allocation of consideration exchanged to intangible assets acquired is as follows (in thousands):&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.771%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Estimated Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks/Names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Patient referral sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company valued trademarks/names utilizing the relief of royalty method and patient referral sources utilizing the multi-period excess earnings method, a form of the income approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Net deferred tax&#160;assets&#160;represented the expected future tax consequences of temporary differences between the fair values of the assets acquired and liabilities assumed and their tax bases. See Note 6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional discussion of the Company&#x2019;s combined income tax position subsequent to the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The fair value of the operating lease liability and corresponding right-of-use asset (current and long-term) was based on current market rates available to the&#160;Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Accounts payable as well as certain other current and non-current assets and liabilities are stated at fair value as of the&#160;Merger Date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The&#160;Merger resulted in&#160;$796.1 million of goodwill, which is attributable to cost synergies resulting from procurement and operational efficiencies and elimination of duplicative administrative costs. The goodwill created in the Merger&#160;is not expected to be deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ib7a44592cb4a40fcbd91c004c84b7ef6_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTphODFiYzc3MDM4M2M0YmJjODY1ZTFlNDgxM2E5OWFjYi90YWJsZXJhbmdlOmE4MWJjNzcwMzgzYzRiYmM4NjVlMWU0ODEzYTk5YWNiXzEtMi0xLTEtMA_40c3f8de-c341-46fb-b322-74569c5ba7ac"
      unitRef="usd">12536000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i0eab475192224276bc1b5ceb023d5037_D20190806-20190806"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTphODFiYzc3MDM4M2M0YmJjODY1ZTFlNDgxM2E5OWFjYi90YWJsZXJhbmdlOmE4MWJjNzcwMzgzYzRiYmM4NjVlMWU0ODEzYTk5YWNiXzEtNC0xLTEtMA_80b901e0-2bd0-4be6-bc4d-a2631836ff57">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ida7f446eea274d038568171224dfb7f8_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTphODFiYzc3MDM4M2M0YmJjODY1ZTFlNDgxM2E5OWFjYi90YWJsZXJhbmdlOmE4MWJjNzcwMzgzYzRiYmM4NjVlMWU0ODEzYTk5YWNiXzItMi0xLTEtMA_2bbc840d-9de9-46ad-821b-b40d98fc4ef4"
      unitRef="usd">180329000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8355aa59ded14d9c91a83db76fedede8_D20190806-20190806"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTphODFiYzc3MDM4M2M0YmJjODY1ZTFlNDgxM2E5OWFjYi90YWJsZXJhbmdlOmE4MWJjNzcwMzgzYzRiYmM4NjVlMWU0ODEzYTk5YWNiXzItNC0xLTEtMA_a13ba7ee-33d8-4cfd-b456-21cb7522c656">P20Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i2e8a900d790f44dabb629a7f9c87c6db_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTphODFiYzc3MDM4M2M0YmJjODY1ZTFlNDgxM2E5OWFjYi90YWJsZXJhbmdlOmE4MWJjNzcwMzgzYzRiYmM4NjVlMWU0ODEzYTk5YWNiXzMtMi0xLTEtMA_98337d67-549a-4d72-898d-ef3f20f8e241"
      unitRef="usd">380000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="icf29203bfe714c69b132146d9352ba77_D20190806-20190806"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTphODFiYzc3MDM4M2M0YmJjODY1ZTFlNDgxM2E5OWFjYi90YWJsZXJhbmdlOmE4MWJjNzcwMzgzYzRiYmM4NjVlMWU0ODEzYTk5YWNiXzMtNC0xLTEtMA_f320d5c6-ce19-4ff6-9e08-d8d623714c9c">P1Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTphODFiYzc3MDM4M2M0YmJjODY1ZTFlNDgxM2E5OWFjYi90YWJsZXJhbmdlOmE4MWJjNzcwMzgzYzRiYmM4NjVlMWU0ODEzYTk5YWNiXzQtMi0xLTEtMA_7a090db7-2beb-48fa-af58-53260e0ca423"
      unitRef="usd">193245000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i5d06560aaca644c89a26a480b954d11c_D20190806-20190806"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTphODFiYzc3MDM4M2M0YmJjODY1ZTFlNDgxM2E5OWFjYi90YWJsZXJhbmdlOmE4MWJjNzcwMzgzYzRiYmM4NjVlMWU0ODEzYTk5YWNiXzQtNC0xLTEtMA_272ca92d-2450-412c-ad97-2b9faf90d57c">P18Y9M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:Goodwill
      contextRef="i3753cbfa17174608809f4f34d4a104ac_I20190806"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzM5MDc_acc8af7d-86a5-4768-b21c-8ccd6988696c"
      unitRef="usd">796100000</us-gaap:Goodwill>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzY5NDI_1c387ee1-8a2d-42d5-834a-b714aa89293a">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assuming BioScrip had been acquired as of January 1, 2018, and the results of BioScrip had been included in operations beginning on January 1, 2018, the following tables provide estimated unaudited pro forma results of operations for the&#160;years ended December&#160;31, 2019 and 2018 (in thousands). The estimated pro forma net income adjusts for the effect of fair value adjustments related to the Merger, transaction costs and other non-recurring costs directly attributable to the Merger and the impact of the additional debt to finance the Merger. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:64.912%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,755,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,648,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="iceee29a996a54c498d570461cc70c139_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTo3YzBmMTBjM2UzYjk0ZmYxOWQ3MDk5YzZhNjNmOWJkZi90YWJsZXJhbmdlOjdjMGYxMGMzZTNiOTRmZjE5ZDcwOTljNmE2M2Y5YmRmXzItMi0xLTEtMA_13db4ed6-e125-4d52-ae18-a09d526267c4"
      unitRef="usd">2755361000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i6fbf8d8eaeb1483aa65584975ad1895d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTo3YzBmMTBjM2UzYjk0ZmYxOWQ3MDk5YzZhNjNmOWJkZi90YWJsZXJhbmdlOjdjMGYxMGMzZTNiOTRmZjE5ZDcwOTljNmE2M2Y5YmRmXzItNC0xLTEtMA_15f3f086-cde7-474e-8d22-3b7bac919ce5"
      unitRef="usd">2648694000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="iceee29a996a54c498d570461cc70c139_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTo3YzBmMTBjM2UzYjk0ZmYxOWQ3MDk5YzZhNjNmOWJkZi90YWJsZXJhbmdlOjdjMGYxMGMzZTNiOTRmZjE5ZDcwOTljNmE2M2Y5YmRmXzMtMi0xLTEtMA_766cfb94-12f4-4626-8543-f024eab82449"
      unitRef="usd">-49566000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i6fbf8d8eaeb1483aa65584975ad1895d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90YWJsZTo3YzBmMTBjM2UzYjk0ZmYxOWQ3MDk5YzZhNjNmOWJkZi90YWJsZXJhbmdlOjdjMGYxMGMzZTNiOTRmZjE5ZDcwOTljNmE2M2Y5YmRmXzMtNC0xLTEtMA_185afd96-76c7-474c-80a5-9ffa9097822a"
      unitRef="usd">-70932000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="iceee29a996a54c498d570461cc70c139_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzUwMjY_e81a7dd7-4ced-4323-926f-22c923bc0a5a"
      unitRef="usd">308900000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="iceee29a996a54c498d570461cc70c139_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzUwNDc_831f0cd9-5e79-4c35-bfc1-3447c7aa11ee"
      unitRef="usd">-30100000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:PaymentsForMergerRelatedCosts
      contextRef="iceee29a996a54c498d570461cc70c139_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzUzMzg_e7307d12-9600-450e-a78e-f317c43544ea"
      unitRef="usd">25800000</us-gaap:PaymentsForMergerRelatedCosts>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i05bb7e7e8c7a426695f64056c9f39f0e_D20180808-20180808"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzU3NTg_2097db6e-a8ba-49cf-87a0-4c9ee24b85f9"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="id730cf15243f442bbd04361989c01f84_I20180918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzU5MzE_9f434bf9-219d-4e6e-b6bb-04e07e251373"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i8b6760c7c28a4a18988a26e4abe977de_D20180918-20180918"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzYwMjk_15e16399-0f8f-4676-8882-31d38e871d4d"
      unitRef="usd">11600000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i8b6760c7c28a4a18988a26e4abe977de_D20180918-20180918"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzYxMDk_2eda246e-0aca-4899-8874-ec5295157fde"
      unitRef="usd">9800000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i8b6760c7c28a4a18988a26e4abe977de_D20180918-20180918"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzYxNDA_bb1845cd-137e-463e-9a0c-735c9b1df926"
      unitRef="usd">1800000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <bios:BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred
      contextRef="ib2bd7b4025e94630bcabed85e8c697ea_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzYyNTE_4bc961fa-0b41-4696-a992-c41bec86bfcb"
      unitRef="usd">300000</bios:BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred>
    <bios:BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred
      contextRef="ibd5c46c0f3284d40848b80f8fbcc8415_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDYvZnJhZzo5MWJlMWNjNzljYmI0MDViYTg1YjFjNjgxNmI2NGVjZC90ZXh0cmVnaW9uOjkxYmUxY2M3OWNiYjQwNWJhODViMWM2ODE2YjY0ZWNkXzU0OTc1NTgxNDg2MzI_1265b033-bed2-4b8d-a6df-c61c79a8a4bb"
      unitRef="usd">1500000</bios:BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90ZXh0cmVnaW9uOjg4NWE4YjdkODAwNDQyZDE5OTQ0NzgxNTdkZTRhNDdhXzE1MzE_91172847-3385-457a-8967-acb9f5dcefee">REVENUE &lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the net revenue earned by category of payer for the&#160;years ended December&#160;31, 2020, 2019 and 2018 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,542,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,001,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,699,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;450,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,032,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,310,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,939,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90ZXh0cmVnaW9uOjg4NWE4YjdkODAwNDQyZDE5OTQ0NzgxNTdkZTRhNDdhXzE1MzY_f39ee42f-5683-4d98-8f02-eabd18340c08">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the net revenue earned by category of payer for the&#160;years ended December&#160;31, 2020, 2019 and 2018 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,542,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,001,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,699,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;450,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,032,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,310,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,939,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba4469ba333d4f7dbcf906562ff59670_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzItMi0xLTEtMA_571a52f1-fdf1-48bc-bae7-970ea0c4b6a5"
      unitRef="usd">2542985000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b9dd506f11d4d1ebc70f70232a583f7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzItNC0xLTEtMA_61dfcdb5-92da-4854-9205-7b331e2807e8"
      unitRef="usd">2001105000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a18e871b4144c43920f2fdc837570dd_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzItNi0xLTEtMA_d39f223b-0334-4273-88de-491c220930ee"
      unitRef="usd">1699450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i511cdc2e39494cd4a860f9e7863bcf07_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzMtMi0xLTEtMA_0ecf7ffe-0863-4515-b1cd-a7a26c77b967"
      unitRef="usd">450067000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic52f5f00fdae408788e5edb2d3115ade_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzMtNC0xLTEtMA_b7b81b09-f48f-42ca-9437-b0a379481538"
      unitRef="usd">285128000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcb18262ac0749ab80774f8e983c5642_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzMtNi0xLTEtMA_768e44e8-e4ae-4eb0-a691-3d4c1b28257e"
      unitRef="usd">217876000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idedfd2fd8cf84679ad22ff62c6589c11_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzQtMi0xLTEtMA_dd9db3b7-35ec-42f6-bc7f-dac19855bb83"
      unitRef="usd">39558000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bebf74e986b4a3fb16e367620def213_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzQtNC0xLTEtMA_65790d1f-231e-4c74-b9a5-f01444fde828"
      unitRef="usd">24184000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia18fe7d576a24a3d959b4a7ade77e1ee_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzQtNi0xLTEtMA_5c0cc65d-b9e4-4911-a366-718665e50b60"
      unitRef="usd">22465000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzUtMi0xLTEtMA_763b2b6d-d4c1-4f66-8ac6-3632cb58eefe"
      unitRef="usd">3032610000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzUtNC0xLTEtMA_516746e8-39fe-410b-a2e6-75f79369c646"
      unitRef="usd">2310417000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTIvZnJhZzo4ODVhOGI3ZDgwMDQ0MmQxOTk0NDc4MTU3ZGU0YTQ3YS90YWJsZTplNGQxMzEyMWE4MGI0NDM4OGUzOTAzYTUyYTZlNjJmMy90YWJsZXJhbmdlOmU0ZDEzMTIxYTgwYjQ0Mzg4ZTM5MDNhNTJhNmU2MmYzXzUtNi0xLTEtMA_00b653ca-b498-4f70-929f-722be4562f86"
      unitRef="usd">1939791000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzM1NQ_aecfdbfb-45bb-4de8-885c-df780dc72c69">EMPLOYEE BENEFIT PLANSThe Company maintains a 401(k) plan and matches 100% of employee contributions, up to 4% of employee compensation. The Company recorded expense for the defined contribution plan of $9.7 million, $6.4 million and $6.3 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. In the years ended December&#160;31, 2020, 2019 and 2018, Company contributions of $8.9 million, $6.6 million and $6.3 million, respectively, were paid.</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzgw_2f9655c9-87d5-4aef-9161-71db7a623429"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzExNg_0394ab98-9850-49af-9590-a81400886e20"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzIxMQ_afb461e5-7224-42ba-a35d-646bc5626186"
      unitRef="usd">9700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzIxNQ_231d872c-e620-4ace-8b00-a6f7245521dc"
      unitRef="usd">6400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzIyMg_81cf3b7e-3fee-4908-852b-1a3f2ea53512"
      unitRef="usd">6300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzMxNQ_07cabaae-58e8-411d-b13f-31482b10041d"
      unitRef="usd">8900000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzMxOQ_3df75da3-0ca4-4c3c-bcea-88b6333516ec"
      unitRef="usd">6600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTUvZnJhZzowNWI5ZWRlZTc3YWY0YmE4OTMyMzAzYjgwNzZjMjZkYy90ZXh0cmVnaW9uOjA1YjllZGVlNzdhZjRiYTg5MzIzMDNiODA3NmMyNmRjXzMyNg_261dd24e-54ec-4999-b95d-57a417aad1b4"
      unitRef="usd">6300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzI5MDU_8dfd4651-e708-4e43-81e3-01f0155bc981">INCOME TAXES&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax expense (benefit) consists of the following for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.356%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;US federal income tax expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income tax expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The difference between the statutory federal income tax rate and the effective tax rate is as follows for the years ended December&#160;31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.356%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;US federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State and local income taxes net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-deductible compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of deferred income tax assets and liabilities using the 21% U.S. Federal statutory tax rate were as follows as of December&#160;31, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.608%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Price concessions&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest limitation carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;155,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(112,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(109,531)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accelerated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,442)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(67,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(71,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28,976)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(128,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(119,926)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Merger, the Company recorded a full valuation allowance against all of its net U.S. federal and state deferred tax assets except for certain state net operating losses (&#x201c;NOL&#x201d;) which were estimated to be $0.4 million as of December&#160;31, 2020. The initial recognition of this valuation allowance by the Company was reflected in the opening balance sheet of BioScrip and, to that extent, did not impact the Company&#x2019;s tax expense (benefit) for the years ended December&#160;31, 2020 and 2019. The valuation allowance for deferred tax assets as of December&#160;31, 2020 was $112.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. The Company considers the scheduled reversal of deferred tax liabilities (including the effect in available carryback and carryforward periods), projected taxable income, and tax-planning strategies in making this assessment. On a quarterly basis, the Company evaluates the positive and negative evidence in determining if the valuation allowance is fairly stated. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is subject to taxation in the United States and various states. As a result of the Merger, BioScrip carried over $458.9 million of federal net operating losses, $479.6 million of state net operating losses, and $85.0 million of interest limitation carryforwards. At December&#160;31, 2020, the Company had $577.9 million of gross federal NOL carryforwards of which $438.1 million are available to offset future taxable income in the United States. These NOL&#x2019;s will begin to expire in 2026 if not utilized. The remaining gross federal NOL&#x2019;s of $139.8 million at December&#160;31, 2020 are expected to expire unutilized due to limitations under Internal Revenue Code Section 382. At December&#160;31, 2019, the Company had $548.0 million of gross federal NOL&#x2019;s. At December&#160;31, 2020 and 2019, the Company had $154.8 million and $145.6 million of interest limitation carryforwards. At December&#160;31, 2020 and 2019, the Company also had $600.1 million and $578.5 million of cumulative gross state NOL carryforwards available to offset future taxable income in various states. These state NOL&#x2019;s will begin to expire starting in 2021 if not utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020 and 2019, the unrecognized tax benefits for uncertain tax positions was $0. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the valuation allowance for deferred tax assets for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at Beginning of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Charged (Benefit) to Costs and Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Charged to Other Accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at End Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2018: Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2019: Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020: Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Currently, the Company is not subject to any U.S. Federal income tax audits. The Company is subject to various state tax audits, and believes that the outcome of these audits will not have a material impact on the Company.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded no income tax expense or benefit for the year ended December&#160;31, 2020 associated with the tax provisions of the Coronavirus Aid, Relief and Economic Security Act (&#x201c;CARES Act&#x201d;). However, certain adjustments were made to the Company&#x2019;s components of deferred tax assets and liabilities to reflect the tax provisions of the CARES Act. These adjustments were the result of the CARES Act&#x2019;s tax provisions associated with interest expense limitations and bonus depreciation on leasehold improvements. These adjustments to the Company&#x2019;s components of deferred tax assets and liabilities were offset by one another or the Company&#x2019;s valuation allowance.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzI5MDk_98ddff55-b7cf-44f6-9960-635ce3d15f06">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax expense (benefit) consists of the following for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.356%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;US federal income tax expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income tax expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzItMS0xLTEtMA_041c8ff7-8383-4ae5-a4a9-c9f7fa97466f"
      unitRef="usd">-69000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzItMy0xLTEtMA_bd436abf-dfd2-4a8c-858a-244fa8485d0d"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzItNS0xLTEtMA_87325cc2-431c-46b1-917d-1170742901c1"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzMtMS0xLTEtMA_feb3411c-ff73-4cdf-acdb-629ea387e037"
      unitRef="usd">996000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzMtMy0xLTEtMA_c958eb0f-d20f-42e3-8dea-0aca0aae02ff"
      unitRef="usd">-3072000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzMtNS0xLTEtMA_51574d89-55cd-4fe9-87f0-dfffd0c64b7d"
      unitRef="usd">-2688000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzQtMS0xLTEtMA_512d0b98-8e6c-4349-99f6-2313281ed7c9"
      unitRef="usd">927000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzQtMy0xLTEtMA_71be44e6-24ed-4bdb-8926-649af2998e3a"
      unitRef="usd">-3072000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzQtNS0xLTEtMA_9785c264-48df-4bf1-802c-1b807a38e387"
      unitRef="usd">-2688000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzYtMS0xLTEtMA_d4c25217-9974-4ac9-9194-b9f946a9787b"
      unitRef="usd">1707000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzYtMy0xLTEtMA_b6e81954-11ef-4038-ab6c-b6d2956be8fd"
      unitRef="usd">2074000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzYtNS0xLTEtMA_0b90520f-2bf3-4ab5-b336-be0dc639d8f5"
      unitRef="usd">1176000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzctMS0xLTEtMA_7b4bf53a-70af-4910-b62e-e347fed81415"
      unitRef="usd">199000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzctMy0xLTEtMA_ab0af676-dadc-4287-8fb2-5e492ffc0739"
      unitRef="usd">-1276000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzctNS0xLTEtMA_5e9dc5d5-0123-48ff-979d-26b12121b3e8"
      unitRef="usd">-1141000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzgtMS0xLTEtMA_fec5d416-b0e9-4906-aed6-2544f12919ed"
      unitRef="usd">1906000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzgtMy0xLTEtMA_f6807a08-a46a-40d9-839c-255279b80797"
      unitRef="usd">798000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzgtNS0xLTEtMA_8232c271-8a3c-427f-b1ba-a49e1f8bfc42"
      unitRef="usd">35000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzktMS0xLTEtMA_18150cad-170d-4df6-ae97-660601b2590a"
      unitRef="usd">2833000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzktMy0xLTEtMA_c917d69a-e784-4505-9225-00003ea9204f"
      unitRef="usd">-2274000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyNDBhZDAyNGJmNDc0NGYyOTA2MDkwMGY3MzcyZDdmMC90YWJsZXJhbmdlOjI0MGFkMDI0YmY0NzQ0ZjI5MDYwOTAwZjczNzJkN2YwXzktNS0xLTEtMA_b2fdd8b5-179d-4554-a1b4-c29632398051"
      unitRef="usd">-2653000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzI5MDI_75d5d4d7-f21a-4519-a400-f000c3182ccd">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The difference between the statutory federal income tax rate and the effective tax rate is as follows for the years ended December&#160;31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.356%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;US federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State and local income taxes net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-deductible compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzEtMS0xLTEtMA_6283a8a9-c2ae-4f60-be9d-c69178a07ce4"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzEtMy0xLTEtMA_a6e70055-bfee-466a-815d-bfbbd92d615b"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzEtNS0xLTEtMA_1242c446-134c-426a-803a-86e28b2a6860"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzMtMS0xLTEtMA_3026b455-71d9-4498-8158-b85f189cd44d"
      unitRef="number">-0.295</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzMtMy0xLTEtMA_50488022-c5e2-4c9e-bb90-2c4b93c7026b"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzMtNS0xLTEtMA_c91da5c2-534a-4694-9a23-0d721e5c56d8"
      unitRef="number">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzQtMS0xLTEtMA_dfbcc7a9-2a1f-43d1-b2e0-94978708ded4"
      unitRef="number">-0.299</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzQtMy0xLTEtMA_56c61e38-f1eb-43bc-b158-a0d07ccfaf9e"
      unitRef="number">-0.134</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzQtNS0xLTEtMA_ebd5e136-c23b-4d3a-867d-0905e529d423"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzQtMS0xLTEtNjU2NA_e09b0d49-aee7-4068-90bd-7da91054691c"
      unitRef="number">0.067</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzQtMy0xLTEtNjU2NA_133da906-7dd6-4d4c-a2ae-164ddd440a84"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzQtNS0xLTEtNjU2NA_303c26fe-7ec5-41d8-bb90-ff5c8a52716c"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzUtMS0xLTEtNjU2NA_36e0332d-6665-44d4-976d-c7aa9740dcce"
      unitRef="number">-0.163</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzUtMy0xLTEtNjU2NA_7cc62a63-64d3-408b-a0e9-2c2729064ff5"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzUtNS0xLTEtNjU2NA_1e8c0778-3ae3-493c-9d9e-16f9f4845ee8"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <bios:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzUtMS0xLTEtMA_3923ba9f-eb3b-49b0-98a1-d123263f2e9d"
      unitRef="number">0.000</bios:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent>
    <bios:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzUtMy0xLTEtMA_d88dba19-43e1-4615-b05f-008a72c3dc14"
      unitRef="number">0.000</bios:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent>
    <bios:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzUtNS0xLTEtMA_30ccefe8-e9d9-4500-9ec8-7170dc04db64"
      unitRef="number">0.147</bios:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzYtMS0xLTEtMA_24064fb8-3790-48a5-a17a-41db051c7f5a"
      unitRef="number">-0.082</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzYtMy0xLTEtMA_8c914e8e-1f93-4c50-a778-e639393dc8cb"
      unitRef="number">-0.028</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzYtNS0xLTEtMA_cf77b2d1-b092-4439-b1c3-e7d3b13f7418"
      unitRef="number">-0.075</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzctMS0xLTEtMA_57c2ac9d-d68f-4b62-8f72-46763458b00b"
      unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzctMy0xLTEtMA_caba43a5-9fa3-4f74-95b7-920f301be921"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzctNS0xLTEtMA_41f96798-762a-426c-bbd4-07b594b48684"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzgtMS0xLTEtMA_507e826b-5766-433b-9ae7-e8806252dbdc"
      unitRef="number">-0.540</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzgtMy0xLTEtMA_dfc0d2d0-1893-497c-bad9-13a547a07409"
      unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZToyZjQ2YjllZmNmMjY0NTUwYmIxYzA1YmZkN2EwZmE3My90YWJsZXJhbmdlOjJmNDZiOWVmY2YyNjQ1NTBiYjFjMDViZmQ3YTBmYTczXzgtNS0xLTEtMA_c26bfa95-24e7-4b01-9d75-8e54c7aa0f48"
      unitRef="number">0.303</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzI5MDM_77a69a51-b6de-4903-8b04-6af4572d5b00">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of deferred income tax assets and liabilities using the 21% U.S. Federal statutory tax rate were as follows as of December&#160;31, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.608%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Price concessions&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest limitation carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;155,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(112,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(109,531)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accelerated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,442)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(67,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(71,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28,976)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(128,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(119,926)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <bios:DeferredTaxAssetsBadDebtReserve
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzItMS0xLTEtMA_c14c339d-410d-4b69-b749-7c005bde4ac5"
      unitRef="usd">6907000</bios:DeferredTaxAssetsBadDebtReserve>
    <bios:DeferredTaxAssetsBadDebtReserve
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzItMy0xLTEtMA_ebc52ca8-bfcd-40d7-8aca-bfa625c95d19"
      unitRef="usd">12302000</bios:DeferredTaxAssetsBadDebtReserve>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzMtMS0xLTEtMA_40397b3d-d58e-422a-9189-866385ce767e"
      unitRef="usd">4058000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzMtMy0xLTEtMA_171513a9-d682-42be-9b92-2677ab49fefa"
      unitRef="usd">3672000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzQtMS0xLTEtMA_c43c599b-3c4f-4eee-9f78-1d30c77f8226"
      unitRef="usd">39094000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzQtMy0xLTEtMA_b6401999-5809-4a25-a397-455b0f0166ff"
      unitRef="usd">38623000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <bios:DeferredTaxAssetsLeaseLiability
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzUtMS0xLTEtMA_f9a0f914-27fe-4fbf-a8c8-8d1fdad03c6d"
      unitRef="usd">22644000</bios:DeferredTaxAssetsLeaseLiability>
    <bios:DeferredTaxAssetsLeaseLiability
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzUtMy0xLTEtMA_686faa9b-bff5-460b-b7f3-3789e262abfe"
      unitRef="usd">19462000</bios:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzYtMS0xLTEtMA_edab8338-b45b-4b52-b1a7-1ed78d969207"
      unitRef="usd">155922000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzYtMy0xLTEtMA_7ea6ca18-c49f-4a3a-8022-6d9c21460433"
      unitRef="usd">147749000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzctMS0xLTEtMA_972f077c-b82d-423f-8afb-21cd08b2e294"
      unitRef="usd">8682000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzctMy0xLTEtMA_8fae3174-fa36-4f0c-a693-7479e26c9693"
      unitRef="usd">5506000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzgtMS0xLTEtMA_2aeaa728-9e0e-4359-a08f-39aaea072942"
      unitRef="usd">237307000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzgtMy0xLTEtMA_b26d8132-f489-4d40-8224-fa8b065478ee"
      unitRef="usd">227314000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzktMS0xLTEtMA_e229691f-9918-4ad3-a084-a7fbb563f7b3"
      unitRef="usd">112085000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzktMy0xLTEtMA_bd5e4140-0703-4fe5-adc3-2be62194da30"
      unitRef="usd">109531000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzEwLTEtMS0xLTA_e75ea20b-d776-475d-8625-7504dff9f83b"
      unitRef="usd">125222000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzEwLTMtMS0xLTA_860c61f0-6586-4f35-91ee-4bbd4fd1e26c"
      unitRef="usd">117783000</us-gaap:DeferredTaxAssetsNet>
    <bios:DeferredTaxLiabilitiesAcceleratedDepreciation
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzEzLTEtMS0xLTA_3ad03628-709d-4ee3-9a9c-cb6ba67d0619"
      unitRef="usd">12593000</bios:DeferredTaxLiabilitiesAcceleratedDepreciation>
    <bios:DeferredTaxLiabilitiesAcceleratedDepreciation
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzEzLTMtMS0xLTA_c7f415ae-3b96-4178-bff4-eaf532d3afdd"
      unitRef="usd">10376000</bios:DeferredTaxLiabilitiesAcceleratedDepreciation>
    <bios:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE0LTEtMS0xLTA_87ba78d8-693c-4d0c-a654-debcc3dda82b"
      unitRef="usd">17186000</bios:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <bios:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE0LTMtMS0xLTA_d7c31306-3a20-4427-960f-af1d659d45ef"
      unitRef="usd">15442000</bios:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE1LTEtMS0xLTA_b4100a96-4ead-4b76-8c1a-75b326c52604"
      unitRef="usd">67127000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE1LTMtMS0xLTA_aaed192d-f3fa-4f82-aff2-70153eb09204"
      unitRef="usd">71204000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE2LTEtMS0xLTA_4ec218e3-c962-47a2-828a-7bb78f79f847"
      unitRef="usd">28976000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE2LTMtMS0xLTA_dc3a731c-3167-4bac-95dd-0e1469b978ff"
      unitRef="usd">20250000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE3LTEtMS0xLTA_e05891fa-2bd0-481c-8972-7235f26eed8a"
      unitRef="usd">2679000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE3LTMtMS0xLTA_b282d425-9560-4d18-b54e-b4a89b14ace2"
      unitRef="usd">2654000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE4LTEtMS0xLTA_2ab928f7-4d0b-4644-b228-a8cbdd12e466"
      unitRef="usd">128561000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE4LTMtMS0xLTA_c4974449-e38d-46b4-843e-c171e96dd5d5"
      unitRef="usd">119926000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE5LTEtMS0xLTA_f80f2641-9321-480b-bdab-3b0f919d26f6"
      unitRef="usd">3339000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTpmNTFjMzU0MmU5N2U0NjExYjMxMzc2OTZjYzgzOTgyMS90YWJsZXJhbmdlOmY1MWMzNTQyZTk3ZTQ2MTFiMzEzNzY5NmNjODM5ODIxXzE5LTMtMS0xLTA_548fa508-e856-49f8-8381-04df0e1a161b"
      unitRef="usd">2143000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i280e53dfa7f14ec79d051ef96fd2eb67_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzU2Mw_e1a01644-6453-4549-b2c2-c644cf7554da"
      unitRef="usd">400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzg5Mw_5565f39b-6d0a-4b8c-8f95-730c4370da12"
      unitRef="usd">112100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ifee0c9a38e2f4f44872874da3bcaf823_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzE3Mzk_af740474-bd38-4560-8255-cce566c79b78"
      unitRef="usd">458900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i9dabb20864b5445da36520a3109bba91_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzE3NzU_cb3896ac-e8e5-4898-9f4d-bcec4ebecc90"
      unitRef="usd">479600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="i280e53dfa7f14ec79d051ef96fd2eb67_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzE4MTM_186c7517-5d9e-409a-afff-f29f0c1f5c5e"
      unitRef="usd">85000000.0</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ifee0c9a38e2f4f44872874da3bcaf823_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzE4Nzc_6ff9f8e6-0056-4a90-a07f-7ea34d28a1e3"
      unitRef="usd">577900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ifd78dc026a994a25a4f56b834ce3acf0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzE5MjQ_e73c9606-0507-4b47-b249-e653bf72cd45"
      unitRef="usd">438100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="i0615275335554e94b35841a1370fe6bd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzIwOTA_a812d608-2ce3-48e1-9f81-499873ef0fa2"
      unitRef="usd">139800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="iacbc724b23f14da8a2fcb2d0d2bbb77f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzIyMTY_48f6842d-ac7b-443e-b350-4bfc21bbe039"
      unitRef="usd">548000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="ib9602bc3ce024fae8e231c5a4c022557_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzIyNzM_4ef78c70-230d-4aa4-809a-f6deb46300cf"
      unitRef="usd">154800000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="id8d455c8b67347889e5acbbbe86eb799_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzIyODA_ef27e8d5-ae28-4ba8-9fb6-e084ce492db9"
      unitRef="usd">145600000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i3d46ec2aaebb419db2fc4d41c2c5a93d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzIzNTY_25ee7216-6cc6-46b3-ae78-4721900e2223"
      unitRef="usd">600100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ifaf8d37ccf224f66a6484b8ac7d64519_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzIzNjM_30a649fa-0642-4281-8c81-70a3f9400f09"
      unitRef="usd">578500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzI1NDg_19ee7480-ae03-4bd3-a13a-04026c17d9df"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzI1NDg_8190f871-08ca-4038-9364-e0dcb5b510c6"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzI5MTA_e83acd2d-d748-4e2a-aa45-2dcdb3deb5f3">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the valuation allowance for deferred tax assets for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at Beginning of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Charged (Benefit) to Costs and Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Charged to Other Accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at End Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2018: Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2019: Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020: Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i40c908a9b2de45bcab117c93611972e9_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzMtMS0xLTEtMA_4a7cfaab-cbd9-44c8-8e67-ef709de5047b"
      unitRef="usd">1263000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i0c0ef9b611e047a885c26ca5f6249fad_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzMtMy0xLTEtMA_81f6977a-c20c-490c-a546-78e5045fd6cf"
      unitRef="usd">110000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ied56fb2881f649038e93ac0e7055d693_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzMtNS0xLTEtMA_12062175-3e6a-492f-a663-9d14566fa2f6"
      unitRef="usd">0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i757f7525fd514729825051239d54094e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzMtNy0xLTEtMA_780daa0f-a2b6-4ee0-a0e8-9d846adb6c02"
      unitRef="usd">1373000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i757f7525fd514729825051239d54094e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzUtMS0xLTEtMA_48954fca-6da0-41c6-9900-4deefc57b424"
      unitRef="usd">1373000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i66543252b74f4364a367c91ae3431b87_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzUtMy0xLTEtMA_12fdd567-c0da-4e1a-bec5-bccbd2dfd22e"
      unitRef="usd">15395000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="icbd22998422e476a94384ec9ca9af121_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzUtNS0xLTEtMA_921cfc85-2651-4687-9a77-cd86ec2141fd"
      unitRef="usd">92763000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzUtNy0xLTEtMA_7bd8cd7d-a8fe-4295-b16e-e2b8aa06047c"
      unitRef="usd">109531000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzctMS0xLTEtMA_35411e2f-7566-41f5-b895-8ffa75702a23"
      unitRef="usd">109531000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="id5195060bc61421e96d7fc5e6a7b58ec_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzctMy0xLTEtMA_7b5d8bc3-786a-4582-80b1-81e916f55960"
      unitRef="usd">1549000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i68b7bf1c254348648f33112353badc89_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzctNS0xLTEtMA_149b716a-b2d7-4c62-820a-79c8e8ce328b"
      unitRef="usd">1005000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90YWJsZTozMmYyM2UzZmU4NzQ0Yjk4YWM2ZmQxYzk1MzAzYjcyMS90YWJsZXJhbmdlOjMyZjIzZTNmZTg3NDRiOThhYzZmZDFjOTUzMDNiNzIxXzctNy0xLTEtMA_deb9aa74-80f4-45df-9644-0d31ef142885"
      unitRef="usd">112085000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <bios:IncomeTaxExpenseBenefitCARESAct
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMTgvZnJhZzo1ZWIzZDRkMTM2MWI0MzVjYTVmN2VlOWNjMzM5MDUxYS90ZXh0cmVnaW9uOjVlYjNkNGQxMzYxYjQzNWNhNWY3ZWU5Y2MzMzkwNTFhXzMyOTg1MzQ4OTMwMDI_9fdb8ff6-27b4-4a37-b459-2bfe759c6684"
      unitRef="usd">0</bios:IncomeTaxExpenseBenefitCARESAct>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzE2MTU_0697591f-664b-4f8b-8b2f-a9b01f74c907">(LOSS) EARNINGS PER SHARE&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company presents basic and diluted (loss) earnings per share for its common stock. Basic (loss) earnings per share is calculated by dividing the net (loss) income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted (loss) earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all dilutive potential common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the&#160;Merger, all historical per share data and number of shares and equity awards were retroactively adjusted. The (loss) earnings is used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. Accordingly, the computation of diluted shares for the years ended December&#160;31, 2020 and 2019 excludes the effect of shares that would be issued in connection with warrants, stock options and restricted stock awards, as their inclusion would be anti-dilutive to the loss per share. As of December&#160;31, 2020 there were 2,285,784 warrants, 412,831 stock options and 549,650 restricted stock awards outstanding that were excluded from the calculation as they would be anti-dilutive. As of December&#160;31, 2019 there were 2,328,120 warrants, 644,975 stock options and 231,562 restricted stock awards outstanding that were excluded from the calculation as they were anti-dilutive. There were no dilutive potential common shares for the years ended December&#160;31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s basic and diluted (loss) earnings per share and shares outstanding (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.941%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.176%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(75,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;180,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Loss per Common Share: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss per common share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icea968011f094587b49f49e976287324_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzU0OTc1NTgxNDEyMDQ_6bf6906d-a0e1-4302-9cac-3ea23835888a"
      unitRef="shares">2285784</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic9887caa100349b3a4635013ba8aa601_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzU0OTc1NTgxNDExNzI_ed44a870-7525-45d7-a021-77d7d3d7e325"
      unitRef="shares">412831</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i325067265d5c4ed789bfde38719b21ed_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzU0OTc1NTgxNDExODI_d56e0c1b-36b2-4489-be80-631a5860efdb"
      unitRef="shares">549650</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i986fbe9ede1e4f4bae9e708842b5ac55_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzU0OTc1NTgxNDExMjY_ff98aa07-cee3-4b5f-8122-5a2a94549671"
      unitRef="shares">2328120</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie31db4918e8647d0bd750eeab70451ed_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzU0OTc1NTgxNDExMzY_2059c048-72a0-458d-8105-f143f082b23c"
      unitRef="shares">644975</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5756cc875db64a44922ff59197c0da6e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzU0OTc1NTgxNDExNDY_fa0e449d-61fc-456c-87e3-cc7a49d1796c"
      unitRef="shares">231562</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DilutiveSecurities
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzExODc_9ba40272-0d6b-436b-a7d0-e4c1e4fad4e2"
      unitRef="usd">0</us-gaap:DilutiveSecurities>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90ZXh0cmVnaW9uOjRiNTU5ZjU2MmM4OTRhNjViZjdmYmU2Y2Q5MGQxYjQyXzE2MTk_0819a29a-22bc-4b72-889c-13225417d960">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s basic and diluted (loss) earnings per share and shares outstanding (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.941%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.176%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(75,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;180,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Loss per Common Share: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss per common share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzMtMS0xLTEtMA_e4433798-0e4b-4460-b68b-0e247d9a8d63"
      unitRef="usd">-8076000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzMtMy0xLTEtMA_5f08947f-c8c1-4265-9215-c03ba650ef80"
      unitRef="usd">-75920000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzMtNS0xLTEtMA_f63e4a8d-ad0f-4a6c-abe6-ae88be6a0bed"
      unitRef="usd">-6115000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzUtMS0xLTEtMA_cb73c644-6fce-4f7f-8c87-519cc01053dc"
      unitRef="shares">180971000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzUtMy0xLTEtMA_1f495e09-445c-4b8e-8672-a2c49e95842d"
      unitRef="shares">156280000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzUtNS0xLTEtMA_c0293f4c-2e85-482a-957c-472fb1b81d26"
      unitRef="shares">142614000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzctMS0xLTEtMA_f3652413-a315-4a13-a789-dec27aec8ff7"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzctMy0xLTEtMA_d9ad31d7-93b6-4060-bc16-ebae7171c157"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMjQvZnJhZzo0YjU1OWY1NjJjODk0YTY1YmY3ZmJlNmNkOTBkMWI0Mi90YWJsZTowYzE4Y2I5ZDI3NTI0OTAxYWZhMjI5MzNiZDY0N2ZlNy90YWJsZXJhbmdlOjBjMThjYjlkMjc1MjQ5MDFhZmEyMjkzM2JkNjQ3ZmU3XzctNS0xLTEtMA_0f173885-76e0-4de7-9bd9-d19f9e8b9354"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzk4OA_7671b32f-b89f-4b43-a327-53c6d70239bb">LEASES&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2018, the Company adopted ASC 842, Leases, using an optional transition method that permitted application of the standards as of the effective date without requiring the standard to be applied to the comparative periods presented in the consolidated financial statements. The Company elected the transition package of three practical expedients, which allowed the Company not to reassess prior conclusions about lease identification, lease classification and initial, direct costs. The Company did not elect the practical expedient to use hindsight and accordingly, the initial lease term did not differ under the new standards versus prior accounting practice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2020 and 2019, the Company incurred operating lease expenses of $30.8&#160;million and $25.8 million including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the consolidated statements of comprehensive income (loss). As of December&#160;31, 2020, the weighted-average remaining lease term was 6.7 years and the weighted-average discount rate was 5.18%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases mature as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.040%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Minimum Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026 and beyond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, the Company commenced new leases, extensions and amendments, resulting in non-cash investing and financing activities in the consolidated statements of cash flows of $29.1 million related to the increases in the operating lease right-of-use asset and operating lease liabilities, respectively. During the year ended December&#160;31, 2019, the Company did not enter into any significant new operating or financing leases. As of December&#160;31, 2020, the Company did not have any significant operating or financing leases that had not yet commenced.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2018, the Company incurred rent expense of $17.3 million, under ASC Topic 840, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was included as a component of selling, general and administrative expenses in the consolidated statements of comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzk4OQ_044e59d9-a16f-49d2-8571-a6438894f6e2">LEASES&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2018, the Company adopted ASC 842, Leases, using an optional transition method that permitted application of the standards as of the effective date without requiring the standard to be applied to the comparative periods presented in the consolidated financial statements. The Company elected the transition package of three practical expedients, which allowed the Company not to reassess prior conclusions about lease identification, lease classification and initial, direct costs. The Company did not elect the practical expedient to use hindsight and accordingly, the initial lease term did not differ under the new standards versus prior accounting practice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2020 and 2019, the Company incurred operating lease expenses of $30.8&#160;million and $25.8 million including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the consolidated statements of comprehensive income (loss). As of December&#160;31, 2020, the weighted-average remaining lease term was 6.7 years and the weighted-average discount rate was 5.18%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases mature as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.040%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Minimum Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026 and beyond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, the Company commenced new leases, extensions and amendments, resulting in non-cash investing and financing activities in the consolidated statements of cash flows of $29.1 million related to the increases in the operating lease right-of-use asset and operating lease liabilities, respectively. During the year ended December&#160;31, 2019, the Company did not enter into any significant new operating or financing leases. As of December&#160;31, 2020, the Company did not have any significant operating or financing leases that had not yet commenced.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2018, the Company incurred rent expense of $17.3 million, under ASC Topic 840, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was included as a component of selling, general and administrative expenses in the consolidated statements of comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzU0OTc1NTgxNDA5Mzc_b9f14a5e-8148-413b-9cbb-9df1edb27d12"
      unitRef="usd">30800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzU0OTc1NTgxNDA5MzE_348aa76a-f62a-4a00-8d23-898a96391dd4"
      unitRef="usd">25800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzU0OTc1NTgxNDEwMDE_7f97eceb-6f90-44e5-8cb4-a3630cf31be7">P6Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzU0OTc1NTgxNDEwMTU_1133fb72-09ac-4407-be21-8a08ea17c1b6"
      unitRef="number">0.0518</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzk4Mg_1b7cc208-a2de-4b45-8b35-be583cd48052">&lt;div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases mature as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.040%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Minimum Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026 and beyond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzk4Mw_405cdde8-76bb-4e05-b5c6-7a33e294cc76">&lt;div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases mature as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.040%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Minimum Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026 and beyond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzEtMi0xLTEtMA_2e41df40-9b8b-4022-b376-3787bcfc1e80"
      unitRef="usd">23770000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzItMi0xLTEtMA_70c40b0a-cee6-4820-91f3-9672a3b83eb6"
      unitRef="usd">19216000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzMtMi0xLTEtMA_a7181e1f-14d9-483f-a215-5c06e682cb27"
      unitRef="usd">15804000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzQtMi0xLTEtMA_3c556b57-3884-4316-b56c-1cb3560bb370"
      unitRef="usd">11684000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzUtMi0xLTEtMA_12301a5b-3ecc-4bcd-8c03-dcc29c44ac25"
      unitRef="usd">9369000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzYtMi0xLTEtMA_2fcc30c4-b64a-4898-8f67-f610dd6a8e68"
      unitRef="usd">30168000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzctMi0xLTEtMA_9104394d-4906-4b80-9245-c316551bcd1f"
      unitRef="usd">110011000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzgtMi0xLTEtMA_f8144894-d84a-4deb-b1bc-ccbf29906b13"
      unitRef="usd">20349000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90YWJsZTplNzMyNTZiNTk3YmI0Mzk5YTZjMWU1YmU1NTgwZDMyZi90YWJsZXJhbmdlOmU3MzI1NmI1OTdiYjQzOTlhNmMxZTViZTU1ODBkMzJmXzktMi0xLTEtMA_38239bc7-efbb-4bf2-ae0d-176fa14c117c"
      unitRef="usd">89662000</us-gaap:OperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzU0OTc1NTgxNDA5NjA_fd918921-c0ad-401c-ac3b-34addc495dc0"
      unitRef="usd">29100000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzAvZnJhZzo1OTY3YWE1OGU0OGQ0OGIxYjYxNWQwZTkwZmY4ZmEwYi90ZXh0cmVnaW9uOjU5NjdhYTU4ZTQ4ZDQ4YjFiNjE1ZDBlOTBmZjhmYTBiXzc5Mg_dcf230b6-ecdc-469c-bf30-65fbd5c37e41"
      unitRef="usd">17300000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90ZXh0cmVnaW9uOmZlM2Q1YWUwY2Q1NTQ5OTE5MDUyMmQ4YWViNmZjYzNhXzE0NTk_fedea5af-419d-4400-8fab-2055ef5a2c62">PROPERTY AND EQUIPMENT&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment was as follows as of December&#160;31, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.456%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Infusion pumps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equipment, furniture and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer software, purchased and internally developed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets under development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;211,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense is recorded within cost of revenue and operating expenses within the consolidated statements of comprehensive income (loss), depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.941%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation expense in cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation expense in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During the year ended December&#160;31, 2018, one company location was destroyed by a hurricane, resulting in a loss of $0.6 million of property and equipment. A business casualty loss was recorded as a component of operating costs and expenses within the consolidated statements of comprehensive income (loss). During the year ended December&#160;31, 2019, $0.6 million in proceeds were received related to recovery of property and equipment. These proceeds resulted in a gain on business casualty loss of $0.6 million recorded as a component of selling, general, and administrative expenses in the consolidated statements of comprehensive income (loss) during the year ended December&#160;31, 2019. These proceeds were reflected as a component of cash flows from investing activities in the consolidated statement of cash flows.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90ZXh0cmVnaW9uOmZlM2Q1YWUwY2Q1NTQ5OTE5MDUyMmQ4YWViNmZjYzNhXzE0NTc_c06197f0-9f14-4b52-90ed-628251789114">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment was as follows as of December&#160;31, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.456%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Infusion pumps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equipment, furniture and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer software, purchased and internally developed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets under development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;211,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.941%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation expense in cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation expense in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ida6b0075f5a24266b586c0f92806b056_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzEtMS0xLTEtMA_ae129695-0e99-4040-9ae6-1f9d8aa9db0f"
      unitRef="usd">31678000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i625ed602cf134da6abbf0c62370735cd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzEtMy0xLTEtMA_1f55bb33-0a28-4d46-886d-8780db5ab325"
      unitRef="usd">30416000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifee0705a51c84a4980d98bc3cf7443e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzItMS0xLTEtMA_13d82eb8-1d87-4cbf-9c9f-a17cdc086108"
      unitRef="usd">47886000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icc52cce51e6a4f36a08c80fcdd124e59_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzItMy0xLTEtMA_2bb61fce-4113-4cbf-b863-c9890e24e1a4"
      unitRef="usd">51454000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icb84e173e738405780c00bcbe867cc0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzMtMS0xLTEtMA_e0bfda09-1b1a-463a-9982-91c068e76415"
      unitRef="usd">87483000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if3509723008544588453b805365b676c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzMtMy0xLTEtMA_f23a655a-4e7d-46b9-8a4a-99e51ab26ca2"
      unitRef="usd">80916000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if8cc880af6414d95b4c0dd61dbdebe7c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzQtMS0xLTEtMA_065ddef4-f66a-44a0-9bb4-657ad7a28a2a"
      unitRef="usd">27799000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7055866745ae4cc595c938f55c549586_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzQtMy0xLTEtMA_62faad95-6868-4c0a-a2da-dedabd79f54f"
      unitRef="usd">34884000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i33147d91bdd64411a910c1922f1e30ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzUtMS0xLTEtMA_fe42d0f6-f6a7-43e2-9767-517f52b5f231"
      unitRef="usd">10793000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie319aae0a4334d4ea6a4c29ad036bd48_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzUtMy0xLTEtMA_5e4380bd-b168-4f50-b457-b667bfb91e4a"
      unitRef="usd">14150000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzYtMS0xLTEtMA_d510e52d-3da2-41a2-addb-3424191d14d6"
      unitRef="usd">205639000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzYtMy0xLTEtMA_95e74b94-ba05-4bd7-91a2-df1c6e34dcdb"
      unitRef="usd">211820000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzctMS0xLTEtMA_50925f6a-f87c-4fe7-891b-8d80243a0f27"
      unitRef="usd">84490000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzctMy0xLTEtMA_9971b768-e5d9-4e0a-87ef-3916cf0b6aa1"
      unitRef="usd">78622000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzgtMS0xLTEtMA_3a8dbf87-a54b-4471-8b39-9707bb1937bc"
      unitRef="usd">121149000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZTpkZWM4NGUxZDA2NWQ0MjQyOTdlNGMyMGRmNGMwOGMxYi90YWJsZXJhbmdlOmRlYzg0ZTFkMDY1ZDQyNDI5N2U0YzIwZGY0YzA4YzFiXzgtMy0xLTEtMA_3652a3a2-9103-46b9-9300-f89578fca456"
      unitRef="usd">133198000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i71540503946547bfb71bcf7399158709_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzItMS0xLTEtMA_4ad7e488-927b-4e8d-8068-cd82ca066da9"
      unitRef="usd">6586000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i4d7863206f284422a8c9baba7551456b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzItMy0xLTEtMA_d31ed7a6-93cd-4cd1-99f2-827a11e328d2"
      unitRef="usd">4179000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if8bb4cd176114cedb1143d6017295c52_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzItNS0xLTEtMA_f97800e2-84c4-4281-a361-08625011efae"
      unitRef="usd">2993000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i3d387c31f86c420698ca7b00dcb79be8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzMtMS0xLTEtMA_bcfe89ad-b41c-4dfc-bc56-78c67f99a201"
      unitRef="usd">36180000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ib5caeb9d9df24859839e8059a6e70cb6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzMtMy0xLTEtMA_c1b293f6-afc3-47d0-95c2-6c3fbb62b3c2"
      unitRef="usd">27629000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i7e6f1790eb1b4698bc41fd69f2fe9033_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzMtNS0xLTEtMA_20092821-0717-4cd9-bab4-01aee9ad21be"
      unitRef="usd">18490000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzQtMS0xLTEtMA_4ff59b91-a0b0-4e8f-b5ec-7280089ab6fb"
      unitRef="usd">42766000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzQtMy0xLTEtMA_c953f0f7-bf27-41e1-b8de-002ce993f650"
      unitRef="usd">31808000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90YWJsZToxZTVmZDhkZjUyMjE0ZTIwYmE3OWMzYmQ4YzY2NjFkMC90YWJsZXJhbmdlOjFlNWZkOGRmNTIyMTRlMjBiYTc5YzNiZDhjNjY2MWQwXzQtNS0xLTEtMA_3667ca1c-8a40-4da6-a8cd-ab45e1793aed"
      unitRef="usd">21483000</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i086f47aad02f4c3598246e2234bcfcb9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90ZXh0cmVnaW9uOmZlM2Q1YWUwY2Q1NTQ5OTE5MDUyMmQ4YWViNmZjYzNhXzgzOQ_e8abd3b4-eccc-474f-a83f-c79db7e220c5"
      unitRef="usd">-600000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="i6683b8adaec142929fcdb6cc820b86c8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90ZXh0cmVnaW9uOmZlM2Q1YWUwY2Q1NTQ5OTE5MDUyMmQ4YWViNmZjYzNhXzEwMzY_e870db90-4d8e-4284-b3f8-9dbe38134ee3"
      unitRef="usd">600000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i6683b8adaec142929fcdb6cc820b86c8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzYvZnJhZzpmZTNkNWFlMGNkNTU0OTkxOTA1MjJkOGFlYjZmY2MzYS90ZXh0cmVnaW9uOmZlM2Q1YWUwY2Q1NTQ5OTE5MDUyMmQ4YWViNmZjYzNhXzExNzU_e83dd00d-9957-4ab9-ae24-b8fb8daa872e"
      unitRef="usd">600000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzM2MjI_aaec6421-a106-4fb1-a5a8-b97adf2ef4de">GOODWILL AND OTHER INTANGIBLE ASSETS&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not amortized, but is evaluated for impairment annually in the fourth quarter of the fiscal year, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Circumstances that could trigger an interim impairment test include: a significant adverse change in the business climate or legal factors; an adverse action or assessment by a regulator; unanticipated competition; the loss of key personnel; a change in reporting units; the likelihood that a reporting unit or significant portion of a reporting unit will be sold or otherwise disposed of; and the results of testing for recoverability of a significant asset group within a reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A qualitative impairment analysis was performed in the fourth quarter of 2020 and 2019 to assess whether it is more likely than not that the fair value of the Company&#x2019;s reporting unit is less than its carrying value. The Company assessed relevant events and circumstances including macroeconomic conditions, industry and market considerations, overall financial performance, entity-specific events, and changes in the Company&#x2019;s stock price. The Company determined that there was no goodwill impairment in 2020 or 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A quantitative impairment analysis was performed in the fourth quarter of 2018, and the Company estimated the fair value of its reporting unit using an income approach. The income approach requires management to estimate a number of factors for its reporting unit, including projected future operating results, economic projections, anticipated future cash flows, and discount rates. The fair value determined using the income approach was then compared to marketplace fair value data from within a comparable industry grouping for reasonableness. The Company determined that there was no goodwill impairment in 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of fair value and the allocation of that value to individual assets and liabilities within the reporting unit requires the Company to make significant estimates and assumptions. These estimates and assumptions primarily include, but are not limited to, the selection of appropriate peer group companies; control premiums appropriate for acquisitions in the industries in which the Company competes; the discount rate; terminal growth rates; and forecasts of revenue, operating income, depreciation and amortization, and capital expenditures. Actual financial results could differ from those estimates due to the inherent uncertainty involved in making such estimates. Changes in assumptions concerning future financial results or other underlying assumptions could have a significant impact on either the fair value of the reporting unit, the amount of the goodwill impairment charge, or both.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amount of goodwill consist of the following activity for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:46.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;627,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;632,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;793,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,425,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,428,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount and accumulated amortization of intangible assets consists of the following as of December&#160;31, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.210%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Referral sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;438,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;438,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trademarks/names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Referral sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(110,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trademarks/names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(132,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(97,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;351,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;385,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense for intangible assets was $35.1 million, $26.1 million and $19.6 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected future amortization expense for intangible assets recorded at December&#160;31, 2020, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.918%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.903%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and beyond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzEyODA_356210a6-bf57-4ec0-94d5-4081ac7537b6"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzEyODA_f0ef9e25-35ec-4369-903b-f00684db081f"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzE5MDM_44db50e3-0128-4d3f-8907-39519e2e4137"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzM2MjM_8fbc8f45-63ae-4c9c-bed3-d56eff367ccc">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amount of goodwill consist of the following activity for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:46.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;627,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;632,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;793,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,425,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,428,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i40c908a9b2de45bcab117c93611972e9_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZToxYTgwZTYyYzAxN2I0NGJkOGQ5OTkwZmIyZDY3YWQ2Yy90YWJsZXJhbmdlOjFhODBlNjJjMDE3YjQ0YmQ4ZDk5OTBmYjJkNjdhZDZjXzAtMi0xLTEtMzMwNQ_8c4c11e9-cdb2-42bb-96cc-69c2a0756f89"
      unitRef="usd">627392000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZToxYTgwZTYyYzAxN2I0NGJkOGQ5OTkwZmIyZDY3YWQ2Yy90YWJsZXJhbmdlOjFhODBlNjJjMDE3YjQ0YmQ4ZDk5OTBmYjJkNjdhZDZjXzEtMi0xLTEtMzMwNQ_37845654-5711-418f-880e-47a15afa767f"
      unitRef="usd">5077000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i757f7525fd514729825051239d54094e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZToxYTgwZTYyYzAxN2I0NGJkOGQ5OTkwZmIyZDY3YWQ2Yy90YWJsZXJhbmdlOjFhODBlNjJjMDE3YjQ0YmQ4ZDk5OTBmYjJkNjdhZDZjXzAtMi0xLTEtMA_3f67a340-025d-4a4f-a850-f61bdd6e9487"
      unitRef="usd">632469000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZToxYTgwZTYyYzAxN2I0NGJkOGQ5OTkwZmIyZDY3YWQ2Yy90YWJsZXJhbmdlOjFhODBlNjJjMDE3YjQ0YmQ4ZDk5OTBmYjJkNjdhZDZjXzEtMi0xLTEtMA_566d35eb-5e1a-41e0-abb1-a650f4bebc2c"
      unitRef="usd">793073000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZToxYTgwZTYyYzAxN2I0NGJkOGQ5OTkwZmIyZDY3YWQ2Yy90YWJsZXJhbmdlOjFhODBlNjJjMDE3YjQ0YmQ4ZDk5OTBmYjJkNjdhZDZjXzItMi0xLTEtMA_1aa82d44-d776-460b-8d09-a01244d4de25"
      unitRef="usd">1425542000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZToxYTgwZTYyYzAxN2I0NGJkOGQ5OTkwZmIyZDY3YWQ2Yy90YWJsZXJhbmdlOjFhODBlNjJjMDE3YjQ0YmQ4ZDk5OTBmYjJkNjdhZDZjXzMtMi0xLTEtMA_85b6c713-9d13-41bb-b63c-a0dcaa23d1ba"
      unitRef="usd">3068000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZToxYTgwZTYyYzAxN2I0NGJkOGQ5OTkwZmIyZDY3YWQ2Yy90YWJsZXJhbmdlOjFhODBlNjJjMDE3YjQ0YmQ4ZDk5OTBmYjJkNjdhZDZjXzQtMi0xLTEtMA_1ebc6cb3-f85c-432d-8523-7a5aeb1ae1fe"
      unitRef="usd">1428610000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzM2MjQ_67b10466-0c8e-49e0-9cbd-b599df3ab319">&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount and accumulated amortization of intangible assets consists of the following as of December&#160;31, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.210%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Referral sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;438,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;438,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trademarks/names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Referral sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(110,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trademarks/names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(132,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(97,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;351,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;385,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idc00aa48c5dd4893801fa8c1ebcb07c1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzItMi0xLTEtMA_45987aac-a78b-483f-8d89-c61ee6b8816f"
      unitRef="usd">438121000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8d301d39dafd4e68a587b0a3fa40fcfb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzItNC0xLTEtMA_27979309-aa61-42cf-976c-755aa18a7d3e"
      unitRef="usd">438121000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie817018869a64452a6fc78f5f9440a38_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzMtMi0xLTEtMA_984d12ed-0ec4-4872-a666-d790776e7f7b"
      unitRef="usd">44536000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i45131573f0bb479e8f31cf95f78845cb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzMtNC0xLTEtMA_60167e97-f99a-44c1-8efe-f00353137030"
      unitRef="usd">44536000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if428d92bc279403486726eacba9956e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzQtMi0xLTEtMA_e616127d-9bd6-4bd3-8202-3b07a359dae3"
      unitRef="usd">402000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iff982c3170b046f39f50b17cf259e515_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzQtNC0xLTEtMA_9b96d8ea-a48f-46cc-9613-01163e603b31"
      unitRef="usd">402000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzUtMi0xLTEtMA_0197ed0d-aa20-4b6f-aacf-353edd91e5fe"
      unitRef="usd">483059000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzUtNC0xLTEtMA_0d6b5a55-913d-4982-8217-89eda67e5157"
      unitRef="usd">483059000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idc00aa48c5dd4893801fa8c1ebcb07c1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzgtMi0xLTEtMA_83dbed0b-0f0e-406d-909e-0769dcaa3133"
      unitRef="usd">110498000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8d301d39dafd4e68a587b0a3fa40fcfb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzgtNC0xLTEtMA_11b8d2f0-78b2-4688-8526-aaf0c8d29a93"
      unitRef="usd">84295000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie817018869a64452a6fc78f5f9440a38_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzktMi0xLTEtMA_f05c9490-215f-4aef-9018-98701a9bde87"
      unitRef="usd">21146000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i45131573f0bb479e8f31cf95f78845cb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzktNC0xLTEtMA_1e93421d-e853-44a8-b43d-8d0e4a09447f"
      unitRef="usd">12748000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if428d92bc279403486726eacba9956e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzEwLTItMS0xLTA_2795baf0-39c2-4940-8268-5ad2e44a39dc"
      unitRef="usd">363000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iff982c3170b046f39f50b17cf259e515_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzEwLTQtMS0xLTA_61c6309d-a414-4c72-9a90-5f70f2943f27"
      unitRef="usd">106000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzExLTItMS0xLTA_7ec0a884-e196-451c-b225-95223923713b"
      unitRef="usd">132007000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzExLTQtMS0xLTA_e7241c37-d318-4753-b47f-ac5cfd81ca72"
      unitRef="usd">97149000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzEyLTItMS0xLTA_289bd412-171a-41e4-b7a8-bdf5c865bc2b"
      unitRef="usd">351052000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTozNjk0Y2I2ZGMxMjA0Y2E1YTRmYmFkYTlhMzdiYjU1Mi90YWJsZXJhbmdlOjM2OTRjYjZkYzEyMDRjYTVhNGZiYWRhOWEzN2JiNTUyXzEyLTQtMS0xLTA_3b5a0316-407a-4be6-a2a7-1d1b1eebc91d"
      unitRef="usd">385910000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzMyMjE_1aa481fe-7501-4e9b-a299-6dc5001283f9"
      unitRef="usd">35100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzMyMjU_6d0da1d9-59a4-4246-8cf1-d1135e47d810"
      unitRef="usd">26100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzMyMzI_56c4a2aa-32e4-426f-ae5b-dc6a338f330b"
      unitRef="usd">19600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90ZXh0cmVnaW9uOjAwMDA0OWJkOWY1MTQ2NjhhMGZkZjJlYTk1ZDdkNTY4XzM2MjE_4ef58ce4-441f-4876-8a19-cf0f9226d846">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected future amortization expense for intangible assets recorded at December&#160;31, 2020, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.918%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.903%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and beyond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTphNjIzN2ExZTM2NWI0YzFlYmZiZTQ1MzAyYjQ1OTU2Ni90YWJsZXJhbmdlOmE2MjM3YTFlMzY1YjRjMWViZmJlNDUzMDJiNDU5NTY2XzAtMi0xLTEtMA_19675282-6f6d-480f-b8b9-50a917ab0af5"
      unitRef="usd">32015000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTphNjIzN2ExZTM2NWI0YzFlYmZiZTQ1MzAyYjQ1OTU2Ni90YWJsZXJhbmdlOmE2MjM3YTFlMzY1YjRjMWViZmJlNDUzMDJiNDU5NTY2XzEtMi0xLTEtMA_4f3a61d7-ea44-468d-bedc-ed8cf59b829b"
      unitRef="usd">28338000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTphNjIzN2ExZTM2NWI0YzFlYmZiZTQ1MzAyYjQ1OTU2Ni90YWJsZXJhbmdlOmE2MjM3YTFlMzY1YjRjMWViZmJlNDUzMDJiNDU5NTY2XzItMi0xLTEtMA_7b4abcf8-b327-4346-b0fa-f8d8067d4e34"
      unitRef="usd">28338000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTphNjIzN2ExZTM2NWI0YzFlYmZiZTQ1MzAyYjQ1OTU2Ni90YWJsZXJhbmdlOmE2MjM3YTFlMzY1YjRjMWViZmJlNDUzMDJiNDU5NTY2XzMtMi0xLTEtMA_cc8b009a-31d7-4d29-a950-765bd5598b5e"
      unitRef="usd">28338000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTphNjIzN2ExZTM2NWI0YzFlYmZiZTQ1MzAyYjQ1OTU2Ni90YWJsZXJhbmdlOmE2MjM3YTFlMzY1YjRjMWViZmJlNDUzMDJiNDU5NTY2XzQtMi0xLTEtMA_b93b39e2-a551-4bc2-b285-84fe500df380"
      unitRef="usd">28338000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTphNjIzN2ExZTM2NWI0YzFlYmZiZTQ1MzAyYjQ1OTU2Ni90YWJsZXJhbmdlOmE2MjM3YTFlMzY1YjRjMWViZmJlNDUzMDJiNDU5NTY2XzUtMi0xLTEtMA_35d3c80d-87e5-4ff0-a09d-791629c2902e"
      unitRef="usd">205685000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMzkvZnJhZzowMDAwNDliZDlmNTE0NjY4YTBmZGYyZWE5NWQ3ZDU2OC90YWJsZTphNjIzN2ExZTM2NWI0YzFlYmZiZTQ1MzAyYjQ1OTU2Ni90YWJsZXJhbmdlOmE2MjM3YTFlMzY1YjRjMWViZmJlNDUzMDJiNDU5NTY2XzYtMi0xLTEtMA_f89a8d4a-598e-4e74-8ef7-1aaae6d40175"
      unitRef="usd">351052000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzk3NzA_94b36fdc-37ab-4fda-9003-bf21dcaa568b">INDEBTEDNESS&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following as of December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ABL Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;First Lien Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;915,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;888,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Second Lien Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,161,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,124,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,115,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following as of December&#160;31, 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ABL Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;First Lien Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;925,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;893,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Second Lien Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;412,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,337,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,286,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,277,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Retired Debt Obligations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Prior to the Merger, the Company had two credit arrangements that provided for up to $645.0 million in senior secured credit facilities through an $80.0 million revolving credit facility (the &#x201c;Previous Revolving Credit Facility&#x201d;), a $415.0 million first lien term loan (the &#x201c;Previous First Lien Term Loan&#x201d;), and a $150.0 million second lien term loan (the &#x201c;Previous Second Lien Term Loan&#x201d;, and together with the Previous First Lien Term Loan, the &#x201c;Previous Term Loans&#x201d;, and the Previous Term Loans, together with the Previous Revolving Credit Facility, the &#x201c;Previous Credit Facilities&#x201d;). The principal balance on the Previous First Lien Term Loan was repayable in quarterly installments of $1.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 6, 2019, the Company repaid the outstanding balance of Previous Term Loans and retired the outstanding Previous Credit Facilities by entering into two new credit arrangements and a notes indenture, described below under &#x201c;New Debt Obligations&#x201d;. The weighted average interest rate paid on the Previous First Lien Term Loan was 6.20% for the year ended December&#160;31, 2019, prior to the retirement of the debt obligations. The weighted average interest paid on the Previous Second Lien Term Loan was 11.36% for the year ended December&#160;31, 2019, prior to the retirement of the debt obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Debt Obligations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; In conjunction with the Merger, the Company entered into an asset-based-lending revolving credit facility administered by Bank of America, N.A. The Company also issued senior secured second lien PIK toggle floating rate notes due 2027 (the &#x201c;Second Lien Notes&#x201d;) under an indenture with Ankura Trust Company, LLC. The two new credit agreements and the indenture were entered into on August 6, 2019 and initially provided for up to $1,475.0 million in senior secured credit facilities through a $150.0 million asset-based-lending revolving credit facility (the &#x201c;ABL Facility&#x201d;), a $925.0 million first lien term loan (the &#x201c;First Lien Term Loan&#x201d;, and together with the ABL Facility, the &#x201c;Loan Facilities&#x201d;), and a $400.0 million issuance of Second Lien Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ABL Facility initially provided for borrowings up to $150.0 million, which matures on August&#160;6, 2024. During the year ended December&#160;31, 2020, the Company increased the borrowing capacity of its ABL Facility from $150.0 million to $175.0 million. The ABL Facility bears interest at a per annum rate initially provided that is determined by the Company&#x2019;s periodic selection of rate type, either the Base Rate or the Eurocurrency Rate. Interest on the ABL Facility is charged on Base Rate loans at the greater of Base Rate, as defined, or 0.25% plus 1.25% to 1.75%, depending on the historical excess availability as a percentage of the Line Cap, as defined in the ABL Facility credit agreement. Interest on the ABL Facility is charged on Eurocurrency Rate Loans at the Eurocurrency Rate, as defined, plus 2.25% to 2.75%, depending on the historical excess availability as a percentage of the Line Cap, as defined in the ABL Facility credit agreement. The ABL Facility contains commitment fees payable on the unused portion ranging from 0.25% to 0.375%, depending on various factors including the Company&#x2019;s leverage ratio, type of loan and rate type, and letter of credit fees of 2.50%. Borrowings under the ABL Facility are secured by a first priority security interest in the Company&#x2019;s and each of its subsidiaries&#x2019; inventory, accounts receivable, cash, deposit accounts and certain assets and property related thereto (the &#x201c;ABL Priority Collateral&#x201d;), in each case subject to certain exceptions, and a third priority security interest in the Term Loan Priority Collateral, as defined below. The Company had no outstanding borrowings under the ABL Facility at December&#160;31, 2020 and 2019. The Company had $9.6 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the ABL of $165.4 million as of December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal balance of the First Lien Term Loan is repayable in quarterly installments which commenced in March 2020 of $2.3 million plus interest, with a final payment of all remaining outstanding principal due on August&#160;6, 2026. Interest on the First Lien Term Loan is payable monthly on Base Rate loans at Base Rate, as defined, plus 3.25% to 3.50%, depending on the Company&#x2019;s leverage ratio. Interest is charged on Eurocurrency Rate loans at the Eurocurrency Rate, as defined, plus 4.25% to 4.50%, depending on the Company&#x2019;s leverage ratio. The interest rate on the First Lien Term Loan was 4.40% and 6.20% as of December&#160;31, 2020 and 2019, respectively. The weighted average interest rate incurred was 5.09% for the year ended December&#160;31, 2020. The weighted average interest rate incurred was 6.47% for the period August 6, 2019 through December&#160;31, 2019. Amounts borrowed under the First Lien Term Loan are secured by a first priority security interest in each of the Company&#x2019;s subsidiaries&#x2019; capital stock (subject to certain exceptions) and substantially all of the Company&#x2019;s property and assets (other than the ABL Priority Collateral), (the &#x201c;Term Loan Priority Collateral&#x201d;), in each case subject to certain exceptions, and a second priority security interest in the ABL Priority Collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Second Lien Notes mature on August&#160;6, 2027. Interest on the Second Lien Notes is payable quarterly and is at London Interbank Offered Rate (&#x201c;LIBOR&#x201d;), plus 8.75%. The Company elected to pay-in-kind (&#x201c;PIK&#x201d;) the first quarterly interest payment, due in November 2019, which resulted in the Company capitalizing $12.3 million in interest to the principal balance on the interest payment date. The Company also elected to PIK the quarterly interest payment due in August 2020, which resulted in the Company capitalizing $7.5 million in interest expense to the principal balance of the Second Lien Notes on the interest payment date. In connection with the PIK elections, the Company was charged an additional 1.00% in interest expense on those quarterly interest payments. The interest rate on the Second Lien Notes was 8.98% and 10.66% as of December&#160;31, 2020 and 2019. The weighted average interest incurred was 9.39% for the year ended December&#160;31, 2020. The weighted average interest incurred was 11.45% for the period August 6, 2019 through December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, the Company completed a public offering of stock for proceeds of $118.9&#160;million. Those proceeds, along with additional cash on hand, were used to prepay $174.0&#160;million of the Second Lien Notes, which is reflected as a cash outflow from financing activities in the Company&#x2019;s consolidated statements of cash flows. The Company recognized a loss on extinguishment of debt of $11.5&#160;million, of which $3.5&#160;million related to the prepayment penalty and $8.0&#160;million related to deferred financing fees which were written off upon extinguishment. The $3.5&#160;million prepayment penalty was reflected as a cash outflow from financing activities in the Company&#x2019;s consolidated statements of cash flows. The loss on extinguishment was recorded as a component of other, net in the Company&#x2019;s consolidated statements of comprehensive income (loss). See Note 16, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the public offering.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2019, the Company assessed whether the repayment of the Previous Term Loans and subsequent issuance of the First Lien Term Loan and the Second Lien Notes resulted in an insubstantial modification or an extinguishment of the existing debt for each loan in the syndication by grouping lenders as follows: (i) Lenders participating in both the Previous Credit Facilities and the new Loan Facilities and Second Lien Notes; (ii) previous lenders that exited; and (iii) new lenders. The Company determined that $226.7 million of the Previous First Lien Term Loan was extinguished and none of the Previous Second Lien Term Loan was extinguished, which is disclosed as an outflow from financing activities in the consolidated statements of cash flows. The Company determined that $752.4 million of new debt was issued related to the First Lien Term Loan and $250.0 million of new debt was issued related to the Second Lien Notes, which is disclosed as an inflow from financing activities in the consolidated statements of cash flows. In connection with the issuance of the First Lien Term Loan, the Second Lien Notes, and the ABL Facility, the Company incurred $52.6 million in debt issuance costs and third-party fees, of which $48.1 million was capitalized, $1.3 million was expensed as a component of other expense and $3.2 million was expensed as a loss on extinguishment as a component of other expense. Further, $21.3 million of the total fees incurred of $52.6 million was netted against the $981.1 million of proceeds from debt as a component of the cash flows from financing activities, $30.0 million was presented as deferred financing costs as a component of cash flows from financing activities, and the remaining $1.3 million was included in cash flows from operating activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2019, the Company recognized a loss on extinguishment of debt of $5.5 million, of which $3.2 million related to debt issue costs incurred with the issuance of the Loan Facilities and Second Lien Notes, as discussed above, and $2.3 million related to deferred financing fees on the Previous Credit Facilities, which were written off upon extinguishment. All remaining deferred financing fees related to the Previous Credit Facilities of $7.6 million were attributed to modified loans, which are capitalized and will be amortized over the remaining term of the Loan Facilities and Second Lien Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt matures as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:54.239%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Minimum Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026 and beyond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,115,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,161,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company entered into an amendment on the First Lien Term Loan, which resulted in an additional $250.0 million of incremental First Lien Term Loan indebtedness being issued, which was used to prepay the remaining $245.8 million outstanding balance of the Second Lien Notes. See Note 19, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Subsequent Events&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the estimated fair values of the Company&#x2019;s debt obligations as of December&#160;31, 2020  (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.356%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Markets for Identical Item (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;First Lien Note Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;888,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;913,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Second Lien Note Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,124,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;913,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the changes in Level 3 measurements for the year ended December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:68.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3 Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Second Lien Notes fair value as of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;411,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal prepayment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(174,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate PIK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Second Lien Notes fair value as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzk3NTg_37772ade-68f0-4bf1-904d-344e9356e48f">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following as of December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ABL Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;First Lien Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;915,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;888,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Second Lien Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,161,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,124,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,115,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following as of December&#160;31, 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ABL Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;First Lien Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;925,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;893,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Second Lien Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;412,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,337,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,286,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,277,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7ead4afeb6274fe391c370a8ab570027_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzEtMi0xLTEtMA_85ee407b-576b-4e54-b3d0-047d4819da9f"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i7ead4afeb6274fe391c370a8ab570027_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzEtNC0xLTEtMA_c5b88df7-65d4-458d-9344-424e43a3f4b9"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i7ead4afeb6274fe391c370a8ab570027_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzEtNi0xLTEtMA_5eaedb76-1d5d-4b1e-9486-027e6d84fcd3"
      unitRef="usd">0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i7ead4afeb6274fe391c370a8ab570027_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzEtOC0xLTEtMA_cbeb1b60-1c3e-4e41-b830-6d7346f5963d"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia70d084d67ce4667b22225e30b5f6b8c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzItMi0xLTEtMA_670f6aa0-b6be-4d5a-8267-6e3f6ed96a4d"
      unitRef="usd">915750000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ia70d084d67ce4667b22225e30b5f6b8c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzItNC0xLTEtMA_6a8c3b90-895e-43e4-bcc6-40011ab4078d"
      unitRef="usd">7253000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ia70d084d67ce4667b22225e30b5f6b8c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzItNi0xLTEtMA_a6dcc8e7-d27d-4709-8574-9364630846c0"
      unitRef="usd">19710000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ia70d084d67ce4667b22225e30b5f6b8c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzItOC0xLTEtMA_5a851b9d-2f3c-4757-a303-020f89ddffaa"
      unitRef="usd">888787000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i660fc6279c714085b9bafae194ba5b7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzMtMi0xLTEtMA_7ac048d8-4dd1-4533-bc1e-67ecbbc712a6"
      unitRef="usd">245781000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i660fc6279c714085b9bafae194ba5b7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzMtNC0xLTEtMA_83ddfd6e-efd5-4411-9019-9499d526c5c3"
      unitRef="usd">6102000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i660fc6279c714085b9bafae194ba5b7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzMtNi0xLTEtMA_b0545a2e-5a34-4773-a3d3-ec399fe23ea4"
      unitRef="usd">4113000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i660fc6279c714085b9bafae194ba5b7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzMtOC0xLTEtMA_a8c34c83-1cfd-4a5c-98ab-a83f02c05710"
      unitRef="usd">235566000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzQtMi0xLTEtMA_d05bb343-d7ce-48f3-b897-de505b2de353"
      unitRef="usd">1161531000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzQtNC0xLTEtMA_3f83e4d6-5f5d-4137-8b85-54f7eb80d59f"
      unitRef="usd">13355000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzQtNi0xLTEtMA_56b29ce5-2a99-4f11-a006-a1103fb2cf02"
      unitRef="usd">23823000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzQtOC0xLTEtMA_7bc8d559-29f5-47ff-a3ef-d002128974cf"
      unitRef="usd">1124353000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzUtOC0xLTEtMA_9a4f461c-c08b-4298-9e0e-6c12bb445726"
      unitRef="usd">9250000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo3ZWJlYjliNjczY2E0YThmOWVkZmIzYmM0YjYxNjk3ZC90YWJsZXJhbmdlOjdlYmViOWI2NzNjYTRhOGY5ZWRmYjNiYzRiNjE2OTdkXzYtOC0xLTEtMA_7d7d6ab8-02c4-4240-b475-c1fc7e85cd90"
      unitRef="usd">1115103000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie6a9df1dd28e4f1680a018dc49429873_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzEtMi0xLTEtMA_01262327-5541-4a4f-94d1-d06feec94918"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ie6a9df1dd28e4f1680a018dc49429873_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzEtNC0xLTEtMA_1acd5748-17dd-4fcd-9875-be9e73b347da"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ie6a9df1dd28e4f1680a018dc49429873_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzEtNi0xLTEtMA_4970de3c-46f3-455e-9a03-9e40337a5512"
      unitRef="usd">0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ie6a9df1dd28e4f1680a018dc49429873_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzEtOC0xLTEtMA_410f3876-a837-4177-9136-7233d2c178ad"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6074931e160e4e02be724a84dde0758b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzItMi0xLTEtMA_77702b1a-a7e6-4bcc-8b4a-8d8a1efef0d7"
      unitRef="usd">925000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i6074931e160e4e02be724a84dde0758b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzItNC0xLTEtMA_18e932cc-079c-440a-9d01-63e121b234e5"
      unitRef="usd">8399000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i6074931e160e4e02be724a84dde0758b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzItNi0xLTEtMA_fe713d10-4b27-4d8a-88ea-423ad26719af"
      unitRef="usd">22825000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i6074931e160e4e02be724a84dde0758b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzItOC0xLTEtMA_7c09ad36-bb1d-4a16-b047-e8e49e19e256"
      unitRef="usd">893776000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6bb20cde57584d28ab6a5c4446839bc2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzMtMi0xLTEtMA_adc44d7f-878b-4f49-a4bc-548276d377cc"
      unitRef="usd">412256000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i6bb20cde57584d28ab6a5c4446839bc2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzMtNC0xLTEtMA_ce8e88b0-5348-4344-8f05-7ee5799db187"
      unitRef="usd">11672000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i6bb20cde57584d28ab6a5c4446839bc2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzMtNi0xLTEtMA_d565eef1-f12a-4a2b-bde6-feb60e40c2ea"
      unitRef="usd">7864000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i6bb20cde57584d28ab6a5c4446839bc2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzMtOC0xLTEtMA_ed5d8d89-1104-4402-83a0-7dd53fe90764"
      unitRef="usd">392720000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzQtMi0xLTEtMA_6528f77d-90b4-4097-8dd7-c05ab8f6f549"
      unitRef="usd">1337256000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzQtNC0xLTEtMA_54b4a82d-660a-4100-bd1b-a1f389cc3f15"
      unitRef="usd">20071000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzQtNi0xLTEtMA_b2e499f6-fa0a-489b-9b1b-09cdb2edf1e9"
      unitRef="usd">30689000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzQtOC0xLTEtMA_f89365ad-e844-47b1-9520-d8f21bdba733"
      unitRef="usd">1286496000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzUtOC0xLTEtMA_7779fe00-d6a9-4b3e-ba24-bfbb678158ad"
      unitRef="usd">9250000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpmNGI2OWM4MDkxMTM0YmQ4OTE4NjBmZmRhMDZmOTVkNS90YWJsZXJhbmdlOmY0YjY5YzgwOTExMzRiZDg5MTg2MGZmZGEwNmY5NWQ1XzYtOC0xLTEtMA_19e7129e-8b84-4d8d-9e2f-19be45a20c09"
      unitRef="usd">1277246000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7f59152bb9c048a5b50b44067271f613_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzMzNg_d1fa0d0b-2c03-4ad4-bc96-bae8a2a2eb78"
      unitRef="usd">645000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1a4bc3c15e894757bc0a5393777c3429_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzM4Ng_8917c6cc-cc14-4fec-901a-8a45ea92108b"
      unitRef="usd">80000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i640bd2ca162d4110821356fb395847f8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQ2MQ_755826f7-2591-4aaa-9913-add78ac0e610"
      unitRef="usd">415000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4386145a348444218987e663e802f1b3_I20190806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzUzMA_ce37b3ba-c265-42b1-89d6-b98c76771a7a"
      unitRef="usd">150000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="i7f24d9bf71984546b8af671666297e21_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1MjU5Njk_581d70ac-c5df-4e6b-b162-3caf3e3fc953"
      unitRef="usd">1000000.0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i12c898e6c2bf4a57a2d2293e3f85537e_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzI3MjE_b43a6b3c-db10-4cc7-9961-066a964a3d8b"
      unitRef="number">0.0620</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i0cc1c613272d407fb68c66233b0884da_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzI4OTM_c58715f7-8918-4a3c-8456-c2304f5b1909"
      unitRef="number">0.1136</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id826c60086164891b7f61e86c7d17b78_I20190806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzM0MzA_e741a3b9-c449-42ad-a0bf-3ae12b375197"
      unitRef="usd">1475000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i04c60dc2cb4949a08701ec5516562884_I20190806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1Mjk3MjQ_57494c54-f12f-4c45-9ede-8d28aa3e0f6b"
      unitRef="usd">150000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i209bb88d77ec42248db74bf4e55edb38_I20190806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzM1NTI_ae31f174-04f9-49db-986c-314640270529"
      unitRef="usd">925000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib286938752c04504a3b00f4071a94634_I20190806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzM2NzE_75a877fc-ff7e-49a7-9d7a-a32ae9f055f6"
      unitRef="usd">400000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i04c60dc2cb4949a08701ec5516562884_I20190806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1Mjk3MzI_57494c54-f12f-4c45-9ede-8d28aa3e0f6b"
      unitRef="usd">150000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4386145a348444218987e663e802f1b3_I20190806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU0OTc1NTgxNTcwMzA_ce37b3ba-c265-42b1-89d6-b98c76771a7a"
      unitRef="usd">150000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i46f31629752b4d81875255a5a98e87a7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU0OTc1NTgxNTcwMjA_cd591f52-8f88-4e08-a414-83580212012c"
      unitRef="usd">175000000.0</us-gaap:DebtInstrumentFaceAmount>
    <bios:DebtInstrumentBaseRate
      contextRef="idc5331a479244a11b7005f9b4a1e7c11_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzcxNDY4MjU2MDA1Mjk_ec51e27c-c8b9-405d-bdfc-2f07c051ae1c"
      unitRef="number">0.0025</bios:DebtInstrumentBaseRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie4ff2a32df6c4734a1ec9790fd2b3c90_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQwMzY_92e538c2-13d2-411d-b169-e384e5161959"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i99995e13205b43628f9807043e807bce_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQwNDI_d9a95dec-fc37-42a1-a02d-3c34ad68d2c3"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iaba77b7ae34c4fb7b5163a1d2f78b481_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQyODc_20b29a79-8e5d-4611-bf0e-5e1a307fbb57"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id771c21da6a248498802851c5776c07e_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQyOTM_e4a60f31-aee7-451e-aa7b-75db71d1e0e1"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i415f019222e24e949930ede6b5b65dd1_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQ1MTI_eeee4871-7d77-4ebd-a72a-6006b577f05e"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i483af9de03bc4422b957661fc1119a22_D20200101-20201231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQ1MTg_819c73f6-a08a-4f62-a4d9-b2c462234bee"
      unitRef="number">0.00375</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="idc5331a479244a11b7005f9b4a1e7c11_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQ2NDg_bcff61b8-012b-41c1-b468-8632b625345a"
      unitRef="number">0.0250</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LongTermDebt
      contextRef="i3cf4138b86814ddaa06ddcb7b782f15a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzUwNzQ_3a47c7c2-8188-4cde-bf2b-e6fa1177457f"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i46f31629752b4d81875255a5a98e87a7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzUwNzQ_a92f55f1-ce09-48c6-904f-8d54a92a9f19"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i8c4f5e9ea300456ca3c311e588f2d512_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzUxNDY_ea236e19-0553-43d1-b7a3-3d7370b7f7cf"
      unitRef="usd">9600000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i46f31629752b4d81875255a5a98e87a7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzUyNTk_9c1f39f1-9264-472e-8094-ab9e50aaa6a9"
      unitRef="usd">165400000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="i13a144a884e94b6a93b74bea5f331c3e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzUzOTA_2d5ef587-9468-4183-8109-ff8ef000895e"
      unitRef="usd">2300000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i1c10e2b1b78c46e2bae9d7a6747cce9c_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU1ODU_de97e93b-6f30-4f61-953c-457f91308569"
      unitRef="number">0.0325</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i2723f056763c4dedbc445d2f9855f372_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU1OTE_a9419112-444c-414e-a6b9-c0f2a9a25e37"
      unitRef="number">0.0350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i4574bb7e56b34190bb053a4f1bcd1b5b_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU3Mjg_25374547-e313-4989-94ec-7292c6fa7257"
      unitRef="number">0.0425</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id5b446b6a97f4f90ac9242bc18f5059d_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU3MzQ_4cf2f6d4-77de-414a-ac75-657e943c7ebb"
      unitRef="number">0.0450</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iab4208b4c10d4bc0b8f34fe22bd51432_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1Mjk3NDQ_86bfe4a6-2eae-4931-9dfc-73cb21992cc2"
      unitRef="number">0.0440</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i3a10d18e244645e5b6a89c8ab446ff90_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU4MzE_032499fe-2bd7-4b2a-af0b-995987a0b6ea"
      unitRef="number">0.0620</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i13a144a884e94b6a93b74bea5f331c3e_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1Mjk3NTI_a012662a-f4c7-485b-9436-54606db493cf"
      unitRef="number">0.0509</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i607cf3ad83fa4d68a7f532e446e0e21f_D20190806-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU4OTI_b86224b5-003b-48eb-8157-488b7ba75a76"
      unitRef="number">0.0647</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i0792b3cd668b435abf755519d30889a2_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzY1NDg_e6c48ab4-dadc-40a2-804d-a271bc08879e"
      unitRef="number">0.0875</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bios:InterestCapitalizedToDebtPrincipal
      contextRef="i1bd2ac4c3a7b43a292acc61f6fdf6853_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzY2OTg_98b354be-e56a-477e-a4e7-59222a48fea5"
      unitRef="usd">12300000</bios:InterestCapitalizedToDebtPrincipal>
    <us-gaap:PaidInKindInterest
      contextRef="i6d4c5bb322c04877b86cf39e32da703f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU0OTc1NTgxNTczNzM_0daa375d-1c9e-46bd-8044-fdd7617f2fe8"
      unitRef="usd">7500000</us-gaap:PaidInKindInterest>
    <bios:PaidInKindInterestAdditionalInterestExpense
      contextRef="i325d52df30ad4c278d90566dd27aaf21_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzY4NDM_33666e42-55f6-4449-a248-be5148a7c141"
      unitRef="number">0.0100</bios:PaidInKindInterestAdditionalInterestExpense>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i325d52df30ad4c278d90566dd27aaf21_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1Mjk3NTg_70bd0a1a-06f2-4752-b2ce-f4906b8c413f"
      unitRef="number">0.0898</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iedf0847627fa4c459cc17c612b6e2b9e_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzY5NTQ_c3e2e30f-ef0c-460c-ad54-0ef4eb00bb4a"
      unitRef="number">0.1066</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i6d4c5bb322c04877b86cf39e32da703f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1Mjk3NjY_17bee043-b738-42a9-bcad-d7b1f8265298"
      unitRef="number">0.0939</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="ic49d785c7256408c93023d39c4d914d8_D20190806-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzcwMTA_dd594499-1e1e-49d8-96c9-c36331f3076c"
      unitRef="number">0.1145</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="ib5a9e86640d24df0a4a74f644bec401b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU0OTc1NTgxNTc0MzI_0460f5b2-e477-43f2-b669-72220f776b1c"
      unitRef="usd">118900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:RepaymentsOfDebt
      contextRef="i41a866b1933d4b50a03ed2090fc52f3b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU0OTc1NTgxNTc0NTE_d61f73bc-8c89-4a75-8e15-dea3ba2d5de7"
      unitRef="usd">174000000.0</us-gaap:RepaymentsOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="idb7255dc5f1449f88b65c6161c741c55_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1Mjk3ODc_372bce60-a99b-4dc0-b5b9-ce4f5bcbabd2"
      unitRef="usd">-11500000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <bios:FinancingReceivablePrepaymentPenalty
      contextRef="icd11813edd424004b8d01f7794f0116c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU0OTc1NTgxNTc0ODU_47edb4d3-c420-4a33-8ce5-90b3f8bf2945"
      unitRef="usd">3500000</bios:FinancingReceivablePrepaymentPenalty>
    <us-gaap:FinancingReceivableDeferredIncome
      contextRef="icd11813edd424004b8d01f7794f0116c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1Mjk4MjY_9151f2ee-ac5b-4b82-b4c9-7403049e25a4"
      unitRef="usd">8000000.0</us-gaap:FinancingReceivableDeferredIncome>
    <bios:FinancingReceivablePrepaymentPenalty
      contextRef="icd11813edd424004b8d01f7794f0116c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzU0OTc1NTgxNTc0Njg_47edb4d3-c420-4a33-8ce5-90b3f8bf2945"
      unitRef="usd">3500000</bios:FinancingReceivablePrepaymentPenalty>
    <us-gaap:RepaymentsOfDebt
      contextRef="i6a1d6fa62d594e16b4173eb1cda83c73_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzc1NTQ_10db0e85-9996-4731-bae6-b5fc7e3ea686"
      unitRef="usd">226700000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i83c91152b1744cdda0bc77a72cef0072_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzc2MTU_2b90857d-1762-45b2-a456-f112dfb85383"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i6a1d6fa62d594e16b4173eb1cda83c73_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzc4MDc_aa8e47ab-a4b5-4bfd-900f-8b4afef13056"
      unitRef="usd">752400000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i83c91152b1744cdda0bc77a72cef0072_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzc4NzM_4526d1ce-0fff-4aca-9a7a-58015166eab2"
      unitRef="usd">250000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="ia288006c93754808b4fb52473eb70d95_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzgxNjQ_4d481f21-f66e-4c95-9a49-551660b91092"
      unitRef="usd">52600000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ia288006c93754808b4fb52473eb70d95_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzgyMjE_0947da03-27a3-4248-8bd5-bc8e663017c4"
      unitRef="usd">48100000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:AccumulatedAmortizationDeferredFinanceCosts
      contextRef="ia288006c93754808b4fb52473eb70d95_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzgyNDE_91d23d54-5045-4817-ad9e-85eb0dd75334"
      unitRef="usd">1300000</us-gaap:AccumulatedAmortizationDeferredFinanceCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i83c91152b1744cdda0bc77a72cef0072_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzgyOTM_e66ae97b-6ca7-4c2b-b147-a22b0352e42a"
      unitRef="usd">-3200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ia334515f9b054e84a1cdb130df9a3d17_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzgzNzk_ca3afda9-094f-480e-bf2d-22ce1f51681a"
      unitRef="usd">21300000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="ia288006c93754808b4fb52473eb70d95_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzg0MTI_4d481f21-f66e-4c95-9a49-551660b91092"
      unitRef="usd">52600000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ia334515f9b054e84a1cdb130df9a3d17_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzg0Mzg_e56e82b4-2e13-4d3d-bccf-a66fa65ffaaf"
      unitRef="usd">981100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="ia334515f9b054e84a1cdb130df9a3d17_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzg1MjM_29480bad-1a6e-41cd-bbcd-1d127a4461e1"
      unitRef="usd">30000000.0</us-gaap:PaymentsOfFinancingCosts>
    <bios:PaymentsOfDebtIssuanceCostsInvestingActivities
      contextRef="ia334515f9b054e84a1cdb130df9a3d17_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzg2NDI_a1e311c2-64d5-4dfe-8140-71af89b40153"
      unitRef="usd">1300000</bios:PaymentsOfDebtIssuanceCostsInvestingActivities>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5330b1241c9f450aabf19a6470f3deeb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzg3NTk_3a055071-e548-40d0-a4e1-959b750e40e9"
      unitRef="usd">-5500000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i83c91152b1744cdda0bc77a72cef0072_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzg3NzI_e66ae97b-6ca7-4c2b-b147-a22b0352e42a"
      unitRef="usd">-3200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8915c98904a74bd98e03842b6725688d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzg5MDA_0bfc9281-a029-4c52-932e-bdd965cbe3d2"
      unitRef="usd">2300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i5ea39b7659c64974ab62326385972ecc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzkxMDA_f0fa6944-8f12-44c3-92ae-73b6e0543dc2"
      unitRef="usd">7600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzk3ODE_3fd5d461-42f9-4e8d-9eaf-5075bc850510">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt matures as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:54.239%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Minimum Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026 and beyond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,115,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,161,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpjNmU4Mjg2YmNmZTE0ZDUzYmI3MWY0NTE4NjU3YzEwYS90YWJsZXJhbmdlOmM2ZTgyODZiY2ZlMTRkNTNiYjcxZjQ1MTg2NTdjMTBhXzEtMi0xLTEtMA_97a90c6a-37f5-4b18-9f4d-f04ba56319ff"
      unitRef="usd">9250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpjNmU4Mjg2YmNmZTE0ZDUzYmI3MWY0NTE4NjU3YzEwYS90YWJsZXJhbmdlOmM2ZTgyODZiY2ZlMTRkNTNiYjcxZjQ1MTg2NTdjMTBhXzItMi0xLTEtMA_67e86c9f-b075-4b36-85d4-d4f906e6d241"
      unitRef="usd">9250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpjNmU4Mjg2YmNmZTE0ZDUzYmI3MWY0NTE4NjU3YzEwYS90YWJsZXJhbmdlOmM2ZTgyODZiY2ZlMTRkNTNiYjcxZjQ1MTg2NTdjMTBhXzMtMi0xLTEtMA_3cd35b40-bd0a-4aa8-9e81-3449d908a446"
      unitRef="usd">9250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpjNmU4Mjg2YmNmZTE0ZDUzYmI3MWY0NTE4NjU3YzEwYS90YWJsZXJhbmdlOmM2ZTgyODZiY2ZlMTRkNTNiYjcxZjQ1MTg2NTdjMTBhXzQtMi0xLTEtMA_871bb0f8-6ec2-4413-81a8-42c6bd7b0276"
      unitRef="usd">9250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpjNmU4Mjg2YmNmZTE0ZDUzYmI3MWY0NTE4NjU3YzEwYS90YWJsZXJhbmdlOmM2ZTgyODZiY2ZlMTRkNTNiYjcxZjQ1MTg2NTdjMTBhXzUtMi0xLTEtMA_c280a0fe-4dc4-4510-8e79-3e176ba3aa5f"
      unitRef="usd">9250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpjNmU4Mjg2YmNmZTE0ZDUzYmI3MWY0NTE4NjU3YzEwYS90YWJsZXJhbmdlOmM2ZTgyODZiY2ZlMTRkNTNiYjcxZjQ1MTg2NTdjMTBhXzYtMi0xLTEtMA_c2e48073-465c-4dc3-aa8f-78c32e91425c"
      unitRef="usd">1115281000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTpjNmU4Mjg2YmNmZTE0ZDUzYmI3MWY0NTE4NjU3YzEwYS90YWJsZXJhbmdlOmM2ZTgyODZiY2ZlMTRkNTNiYjcxZjQ1MTg2NTdjMTBhXzctMi0xLTEtMA_57dacae4-6cdf-49d5-86cf-eb36b78e5442"
      unitRef="usd">1161531000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i475c18c38aea40bfa20cc795a9a0586e_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1MzEwNDY_63bc1a78-ee8a-4452-8a59-a1e267e4221d"
      unitRef="usd">250000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="i6b688f43690d4a10bb658649d8f26b91_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzQzOTgwNDY1MzEwNjY_b3a257ce-64f4-4cd8-9d35-f8ea1e624121"
      unitRef="usd">245800000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90ZXh0cmVnaW9uOmU3NjFhZmQ4ZTdiODRmMzY5OWQ3MDMzNjA5MWNiMWViXzk3NzY_9b7b71f7-c762-43f0-97a3-80df04c5c9b7">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the estimated fair values of the Company&#x2019;s debt obligations as of December&#160;31, 2020  (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.356%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Markets for Identical Item (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;First Lien Note Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;888,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;913,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Second Lien Note Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,124,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;913,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the changes in Level 3 measurements for the year ended December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:68.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3 Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Second Lien Notes fair value as of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;411,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal prepayment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(174,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate PIK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Second Lien Notes fair value as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebtFairValue
      contextRef="ia70d084d67ce4667b22225e30b5f6b8c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzEtMi0xLTEtMA_685f75fa-3049-41f5-84aa-2cc8281c651a"
      unitRef="usd">888787000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i0d71acb5790f4712b5fe4d979c0e2bd2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzEtNC0xLTEtMA_17c482df-8ac1-4370-996a-348d13e0d61d"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i46dc5fdf0022473d841d625d8ca2e5cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzEtNi0xLTEtMA_76ea6244-845d-481a-a4c5-7e1d080827be"
      unitRef="usd">913461000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i0a157555439142d78694bcf7b01379aa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzEtOC0xLTEtMA_0de17d12-83e7-4e1e-9924-cd7c9e3ac32f"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i660fc6279c714085b9bafae194ba5b7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzItMi0xLTEtMA_1dd0d107-0eb9-4085-a9a8-db4409c2029c"
      unitRef="usd">235566000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ie94a2f3b1fce4b9abcfcd916988d3eb8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzItNC0xLTEtMA_50bfb28b-9f66-4670-b4a2-3c94b0900344"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i15aa1aad0d3744a0abc478e642582276_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzItNi0xLTEtMA_18e14f5c-01c2-4521-b541-809ceb0f7416"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ifb5343b6a2e9432f8e58f2bd9a3d07ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzItOC0xLTEtMA_18d99c20-6d1c-4584-a8fc-6cf34882b37c"
      unitRef="usd">266438000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ib0851f5015634259990ba26f9a4a889e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzMtMi0xLTEtMA_5d960dc3-251c-4700-af90-b45d32100258"
      unitRef="usd">1124353000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i5d3c87930eb1479888f34f3af43a0440_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzMtNC0xLTEtMA_04c47dee-fdc9-4b19-aeed-89b04f9f4582"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i1fa3ac11591f4ece89016cc369ba0e2b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzMtNi0xLTEtMA_32e7af6b-7288-4c2e-bc86-e92802362411"
      unitRef="usd">913461000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i3d7bc9bd670f4ffb91c21fb59c7c7fb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo5NDVjMDk1NzlmNzU0ZDRmYjlkN2ZlZDBmZmE5YzcyMi90YWJsZXJhbmdlOjk0NWMwOTU3OWY3NTRkNGZiOWQ3ZmVkMGZmYTljNzIyXzMtOC0xLTEtMA_1fcd807e-c7aa-48a5-b82d-5ed6343cc41e"
      unitRef="usd">266438000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i85d077a5e93842429e329f0dcb9d0f2d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo0Y2Q3MmYzM2UwNmI0OTViODI3YzJjNDg4OTA5YzNjYi90YWJsZXJhbmdlOjRjZDcyZjMzZTA2YjQ5NWI4MjdjMmM0ODg5MDljM2NiXzEtMi0xLTEtMA_34e4b616-a09a-4146-973a-a1e996664785"
      unitRef="usd">411119000</us-gaap:LongTermDebtFairValue>
    <us-gaap:RepaymentsOfDebt
      contextRef="iadaac97b718242739dbbd6f6ed2e6ae0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo0Y2Q3MmYzM2UwNmI0OTViODI3YzJjNDg4OTA5YzNjYi90YWJsZXJhbmdlOjRjZDcyZjMzZTA2YjQ5NWI4MjdjMmM0ODg5MDljM2NiXzMtMi0xLTEtMA_a69db675-8b89-4f6b-8df2-1a5c251b3ce9"
      unitRef="usd">174000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaidInKindInterest
      contextRef="i76f46d4be96544528533fb90947e87a4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo0Y2Q3MmYzM2UwNmI0OTViODI3YzJjNDg4OTA5YzNjYi90YWJsZXJhbmdlOjRjZDcyZjMzZTA2YjQ5NWI4MjdjMmM0ODg5MDljM2NiXzYtMi0xLTEtMA_2afaf8b0-06c8-4c10-b4bd-f240b7b9a89c"
      unitRef="usd">7525000</us-gaap:PaidInKindInterest>
    <us-gaap:ProceedsFromRepaymentsOfDebt
      contextRef="i76f46d4be96544528533fb90947e87a4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo0Y2Q3MmYzM2UwNmI0OTViODI3YzJjNDg4OTA5YzNjYi90YWJsZXJhbmdlOjRjZDcyZjMzZTA2YjQ5NWI4MjdjMmM0ODg5MDljM2NiXzctMi0xLTEtMA_1e0aa949-694b-4243-9228-c7ac219e188c"
      unitRef="usd">21794000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:LongTermDebtFairValue
      contextRef="ifb5343b6a2e9432f8e58f2bd9a3d07ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNDgvZnJhZzplNzYxYWZkOGU3Yjg0ZjM2OTlkNzAzMzYwOTFjYjFlYi90YWJsZTo0Y2Q3MmYzM2UwNmI0OTViODI3YzJjNDg4OTA5YzNjYi90YWJsZXJhbmdlOjRjZDcyZjMzZTA2YjQ5NWI4MjdjMmM0ODg5MDljM2NiXzgtMi0xLTEtMA_4ee1424d-d763-4163-99cb-8627ccaaa7c0"
      unitRef="usd">266438000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzM2OTc_992a2899-3f23-4fc5-87c1-2db1b9dc4a5e">DERIVATIVE INSTRUMENTS&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes derivative financial instruments for hedging and non-trading purposes to limit the Company&#x2019;s exposure to its variable interest rate risk. Use of derivative financial instruments in hedging strategies subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company&#x2019;s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company&#x2019;s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2017, Option Care entered into interest rate caps that reduce the risk of increased interest payments due to rising interest rates. The hedges offset the risk of rising interest rates through 2020 on the first $250.0 million of the Previous First Lien Term Loan. The interest rate caps perfectly offset the terms of the interest rates associated with the variable interest rate Previous First Lien Term Loan. Option Care entered into the interest rate caps as a cash flow hedge for a notional amount of $1.9 million. In April 2019, Option Care terminated its interest rate caps and received cash proceeds of $1.7 million, net of early termination fees. In conjunction with the termination of the interest rate caps, Option Care discontinued the hedge accounting associated with the interest rate caps. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company entered into interest rate swap agreements that reduce the variability in the interest rates on the newly-issued debt obligations. The first interest rate swap for $925.0 million notional was effective in August 2019 with $911.1 million designated as a cash flow hedge against the underlying interest rate on the First Lien Term Loan interest payments indexed to one-month LIBOR through August 2021. In accordance with ASU 2017-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Targeted Improvements to Accounting for Hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company has determined that the $911.1 million designated cash flow hedge is perfectly effective. The remaining $13.9 million notional amount of the first interest rate swap is not designated as a hedging instrument. The second interest rate swap for $400.0 million notional was effective in November 2019 and was designated as a cash flow hedge against the underlying interest rate on the Second Lien Notes interest payment indexed to three-month LIBOR through November 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company elected to PIK the Second Lien Notes&#x2019; quarterly interest payment due in August 2020. Upon making the PIK election, the Company determined that the hedged interest payment would no longer occur, resulting in an ineffective hedge, so the Company discontinued hedge accounting on its $400.0 million notional interest rate swap.  As a result, the Company reclassified accumulated comprehensive loss of $3.7 million to interest expense, net in the consolidated statements of comprehensive income (loss). The gains and losses associated with the $400.0 million notional swap were recognized in net income (loss) through interest expense until the swap expired in November 2020. See Note 11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the PIK.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount and location of the Company&#x2019;s derivative instruments in the consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value - Derivatives in liability position&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gain and loss associated with the changes in the fair value of the effective portion of the hedging instrument are recorded into other comprehensive (loss) income. The gain and loss associated with the changes in the fair value of the $400.0 million notional swap and the $13.9 million notional amount not designated as a hedging instrument are recognized in net income (loss) through interest expense. The following table presents the pre-tax gains (losses) from derivative instruments recognized in other comprehensive (loss) income in the Company&#x2019;s consolidated statements of comprehensive income (loss) (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.754%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.854%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate caps designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps that discontinued hedge accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,746&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the amount and location of pre-tax income (loss) recognized in the Company&#x2019;s consolidated statement of comprehensive income (loss) related to the Company&#x2019;s derivative instruments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate caps designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps that discontinued hedge accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects to reclassify $11.2 million of total interest rate costs from accumulated other comprehensive loss against interest expense during the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0bd8c01514d84331992e13473d81c16b_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzExMTk_23247f58-d887-4f10-aeec-1013c9662600"
      unitRef="usd">250000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iaa2b883648c2436f83ec2369cdbc149b_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzE0MDA_c21b1f02-2e60-4851-82b9-c46522e2ad07"
      unitRef="usd">1900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="iddb4b3d5aafc422db864143a1b1aa819_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzE0OTU_e490af99-d841-42e2-9302-29463669d2ac"
      unitRef="usd">1700000</us-gaap:GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8fbd469711e34b0cb074a178241284d8_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzE4NzI_7e83ff62-c0b5-45bb-a8d7-3c07eaecd461"
      unitRef="usd">925000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i65baa1ec1f4d461b86b9b6f2542d2c72_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzE5MTg_d0a3936b-295e-46a4-96ec-c4b64aab8245"
      unitRef="usd">911100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i65baa1ec1f4d461b86b9b6f2542d2c72_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzU0OTc1NTgxNDQ2MTA_d0a3936b-295e-46a4-96ec-c4b64aab8245"
      unitRef="usd">911100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="icdd8047975e647288143981c8762166c_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzU0OTc1NTgxNDQ2MzA_335a90b5-b9ad-4eee-94e0-02bf21e941ae"
      unitRef="usd">13900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i70568db5bcc649c5bd6104996dd8bf09_I20191106"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzIxMTg_1a825bc1-4330-4a2a-85ef-38c6cdaeb484"
      unitRef="usd">400000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i70568db5bcc649c5bd6104996dd8bf09_I20191106"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzU0OTc1NTgxNDQ2NTE_1a825bc1-4330-4a2a-85ef-38c6cdaeb484"
      unitRef="usd">400000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ib0cf4d78796d429d879bce469f3f3150_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzU0OTc1NTgxNDQ2OTE_b5b8d971-0cd4-40d2-8920-fbbfadce6884"
      unitRef="usd">-3700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i70568db5bcc649c5bd6104996dd8bf09_I20191106"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzU0OTc1NTgxNDQ2NzI_1a825bc1-4330-4a2a-85ef-38c6cdaeb484"
      unitRef="usd">400000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzM2OTg_9cf69f08-8cbe-49f3-b753-40b935102fde">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount and location of the Company&#x2019;s derivative instruments in the consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value - Derivatives in liability position&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i2b483f33dcad4616a569483ce451b1b9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzItNC0xLTEtMA_54e99372-ea2c-470e-87df-7775ad40bbd9"
      unitRef="usd">11172000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="ia2467317320d4c409705b0b02f8ab210_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzItNi0xLTEtMA_1333701c-68f1-4aae-8ecf-1c057c26183f"
      unitRef="usd">1275000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i79e4af3f2d204d8f95b5b4ad2982893d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzMtNC0xLTEtNDcxNA_c5fdf96c-2b58-4187-8b13-22b74ba4c8c5"
      unitRef="usd">170000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="idc9a7eafdb69419ba693d8dffce79f3b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzMtNi0xLTEtNDcxNA_7f91217e-d93f-4018-8b2e-20652a38e465"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i3eefd11356ef4acfa576e05c36eec86e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzMtNC0xLTEtMA_d9cfc311-9524-4d02-9b7d-ea611b94d785"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i19aaeb7b2301410c8ace359b4aae0a61_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzMtNi0xLTEtMA_a5995e39-6432-4473-abcd-c5c25e5d2848"
      unitRef="usd">5920000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i5e6745feb32545bd99b8438f4cb65e42_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzQtNC0xLTEtMA_6a36349b-572b-441b-9233-8f35ba887ef2"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="idadf3e087514415d9e588230d1e4c8e8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzQtNi0xLTEtMA_6b71a34d-5ff5-4d5e-a6c0-758f4dac8cbe"
      unitRef="usd">90000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilities
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzUtNC0xLTEtMA_1dde57e4-bef6-4ae6-8bdc-44ed2a68a4c4"
      unitRef="usd">11342000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZToyZDYwYjQ1OWIzZWQ0NmY1OWMwZGJiNzg3YmIwNzZlZi90YWJsZXJhbmdlOjJkNjBiNDU5YjNlZDQ2ZjU5YzBkYmI3ODdiYjA3NmVmXzUtNi0xLTEtMA_c1e9de54-3705-45c1-bbda-be364968c221"
      unitRef="usd">7285000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i70568db5bcc649c5bd6104996dd8bf09_I20191106"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzU0OTc1NTgxNDQ3MTQ_1a825bc1-4330-4a2a-85ef-38c6cdaeb484"
      unitRef="usd">400000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="icdd8047975e647288143981c8762166c_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzI5Nzg_335a90b5-b9ad-4eee-94e0-02bf21e941ae"
      unitRef="usd">13900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzM2OTk_71f2e874-f1e7-40df-9e67-26ebb4663315">The following table presents the pre-tax gains (losses) from derivative instruments recognized in other comprehensive (loss) income in the Company&#x2019;s consolidated statements of comprehensive income (loss) (in thousands):&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.754%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.854%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate caps designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps that discontinued hedge accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,746&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the amount and location of pre-tax income (loss) recognized in the Company&#x2019;s consolidated statement of comprehensive income (loss) related to the Company&#x2019;s derivative instruments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate caps designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps that discontinued hedge accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie42dd3293f1047ffb0d1d1e673596db2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzItMS0xLTEtMA_3c26827d-d3b2-4812-bf6b-894af28d6d54"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i5536ba9ef240436f8685941bf069832f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzItMy0xLTEtMA_8041d68d-b58a-43cb-a6db-da3d5f3615f4"
      unitRef="usd">-1103000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="idc8999935b584fbe93f3edcbbb32aa8b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzItNS0xLTEtMA_c16cc54a-3598-45f0-9cd5-4740fbdb80de"
      unitRef="usd">1008000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ibf3e87fd34a94950b1dfab02c0351ccb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzMtMS0xLTEtMA_aa4fa35f-0d46-43c7-beec-ea2de2a44d8d"
      unitRef="usd">-7723000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i6a2d963d4b4c4bf0bc68ff139a36a0d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzMtMy0xLTEtMA_103f082d-a2be-4fb0-aa67-e6bcc79de040"
      unitRef="usd">-7195000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ia2ffe75f1b2e4b789fd671082186d2f2_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzMtNS0xLTEtMA_de37a152-e2e0-424a-972c-60514880d52d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <bios:OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax
      contextRef="ibf3e87fd34a94950b1dfab02c0351ccb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzQtMS0xLTEtNDcxOQ_ea179bb8-07b0-4101-b444-efcd7b583e2f"
      unitRef="usd">3746000</bios:OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax>
    <bios:OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax
      contextRef="i6a2d963d4b4c4bf0bc68ff139a36a0d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzQtMy0xLTEtNDcxOQ_68bf8a6c-b39d-4a9b-87af-b13b24525d67"
      unitRef="usd">0</bios:OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax>
    <bios:OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax
      contextRef="ia2ffe75f1b2e4b789fd671082186d2f2_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzQtNS0xLTEtNDcxOQ_dae4c75f-7828-46db-b4d0-92397c109436"
      unitRef="usd">0</bios:OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzQtMS0xLTEtMA_2d82ec98-2c4b-4282-947b-0857dc2d3c9d"
      unitRef="usd">-3977000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzQtMy0xLTEtMA_7724532d-c79e-4af4-95dc-b715779d134e"
      unitRef="usd">-8298000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTo4ZGEyODU5NTJmOTc0NzNmYWViMjY5MjQ2MjczMmZiYi90YWJsZXJhbmdlOjhkYTI4NTk1MmY5NzQ3M2ZhZWIyNjkyNDYyNzMyZmJiXzQtNS0xLTEtMA_b3845324-3c2b-4907-ae6c-34b76da2b569"
      unitRef="usd">1008000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="if51a0a2416fc4efaa81e5964f060685f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzItMy0xLTEtMA_9957efdd-ab7e-41fe-8396-81368b2275e7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i77b199f5d9fe42879ba86a116b6460d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzItNS0xLTEtMA_063d52cc-b3e8-4529-83cf-1db67f76af0a"
      unitRef="usd">-125000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ieea161291d5e4067a3bf1b40c8e4dac7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzItNy0xLTEtMA_fb93fd7a-0b98-460a-93b4-8ce6c2d17fb1"
      unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ibe4cf21bfb5140d997a613e6c5626e64_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzMtMy0xLTEtMA_67a338dd-d9d9-4864-81de-9d50b0a59652"
      unitRef="usd">-12799000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i8eb1d1e629ac4a0ba804cec14a4547ea_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzMtNS0xLTEtMA_c880a5a4-543c-4b70-8d8a-cc057bb853cf"
      unitRef="usd">-115000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="iada07b387c4c497182b71cd727197396_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzMtNy0xLTEtMA_6478b57c-01d1-42bf-81da-bdaae14a6563"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ibe4cf21bfb5140d997a613e6c5626e64_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzQtMy0xLTEtMA_3c37d047-0048-4ee5-85ff-6146d11b1236"
      unitRef="usd">-34000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i8eb1d1e629ac4a0ba804cec14a4547ea_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzQtNS0xLTEtMA_0978a87a-b4d9-4fc8-b4cc-15ae314fbe04"
      unitRef="usd">-92000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="iada07b387c4c497182b71cd727197396_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzQtNy0xLTEtMA_d5e428a7-b3dc-4f85-850a-c4aef8b0bade"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax
      contextRef="ibe4cf21bfb5140d997a613e6c5626e64_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzUtMy0xLTEtNDczMA_036b85cc-7cf2-458f-916e-e9cfa24abab5"
      unitRef="usd">-3746000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax
      contextRef="i8eb1d1e629ac4a0ba804cec14a4547ea_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzUtNS0xLTEtNDczMA_423b5f3d-31b0-482e-b3a3-f65928b9a040"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax
      contextRef="iada07b387c4c497182b71cd727197396_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzUtNy0xLTEtNDczMA_1dcd9503-2d04-4d16-a9ff-f7b45cc5c2ac"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzUtMy0xLTEtMA_f09efd68-05ce-46ee-a454-9f4bff833484"
      unitRef="usd">-16579000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzUtNS0xLTEtMA_e3635b14-6975-472b-a851-e3be93a51d69"
      unitRef="usd">-332000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90YWJsZTozM2Q4ODRjMzFjNmQ0OGE2OWJmMDNhNjY2Yzg2ZmIyZC90YWJsZXJhbmdlOjMzZDg4NGMzMWM2ZDQ4YTY5YmYwM2E2NjZjODZmYjJkXzUtNy0xLTEtMA_921d6c56-7971-4968-a2b6-850500ccdea0"
      unitRef="usd">300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTEvZnJhZzo1NjM5YTFlZWExNDE0MDhiOWFlZTlmNTRiY2YwYzBkMi90ZXh0cmVnaW9uOjU2MzlhMWVlYTE0MTQwOGI5YWVlOWY1NGJjZjBjMGQyXzM1NzM_57b53f5a-32bc-4ffb-8bac-760e832d1e86"
      unitRef="usd">11200000</us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTQvZnJhZzphYTkwZTA2MzdmZTI0MjExOTcyNjU0N2UxMjU2NDMxNi90ZXh0cmVnaW9uOmFhOTBlMDYzN2ZlMjQyMTE5NzI2NTQ3ZTEyNTY0MzE2XzIzMDQ_c5e8c4ce-a67d-4df8-ae00-99e69b04ec90">FAIR VALUE MEASUREMENTS&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs.  The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements).  The three levels of inputs within the fair value hierarchy are defined in Note 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;First Lien Term Loan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the carrying amount and fair value of the First Lien Term Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Second Lien Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The fair value of the Second Lien Notes is derived from a cash flow model that discounted the cash flows based on market interest rates (Level 3 inputs). See Note 11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the carrying amount and fair value of the Second Lien Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest rate swaps&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The fair values of interest rate swaps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the fair value of the interest rate swaps. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest rate caps&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The fair values of interest rate caps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. In April 2019, Option Care terminated its interest rate caps. See Note 12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the fair value of the interest rate caps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no other assets or liabilities measured at fair value at December&#160;31, 2020 or 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNTcvZnJhZzowYTNkNDYwMWQ5MjM0ZThiOGI3ZGIzYTExOWFiZTUxZS90ZXh0cmVnaW9uOjBhM2Q0NjAxZDkyMzRlOGI4YjdkYjNhMTE5YWJlNTFlXzE2MTU_36d293b4-71dc-4c45-984b-88ae77eb2380">COMMITMENTS AND CONTINGENCIESThe Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company&#x2019;s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized. The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company&#x2019;s consolidated balance sheets. However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQ4OTY_379b51c7-b2aa-4399-8ba0-d6e47fbdf88b">STOCK-BASED INCENTIVE COMPENSATION&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Incentive Plans &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Under the Company&#x2019;s 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;), approved at the annual meeting by the BioScrip stockholders on May 3, 2018, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors. The 2018 plan is administered by the Company&#x2019;s Compensation Committee, a standing committee of the Board of Directors. A total of 4,101,735 shares of common stock were initially authorized for issuance under the 2018 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Options granted under the 2018 Plan typically vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzgxMA_5835ea03-79c7-4f33-bae1-42d73cd55de9"&gt;three&lt;/span&gt;- or four-year period and, in certain instances, may fully vest upon a change in control of the Company. The options also typically have an exercise price that may not be less than 100% of its fair market value on the date of grant and are exercisable &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzEwNTU_96670979-bd52-4453-a4dd-ea37a865d80c"&gt;seven&lt;/span&gt; to ten years after the date of grant, subject to earlier termination in certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation expense from stock options is recognized on a straight-line basis over the requisite service period. During the years ended December&#160;31, 2020 and 2019, the Company recognized compensation expense related to stock options of $0.4 million and $0.4 million. The Company did not recognize any compensation expense related to stock options prior to the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant-date fair value of options granted during the year ended December&#160;31, 2020 was $5.94. The Company did not grant any options during the years ended December&#160;31, 2019 or 2018. The fair value of stock options granted was estimated on the date of grant using a Black-Scholes pricing model. The assumptions used to compute the fair value of options for the year ended December&#160;31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.350%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.176%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected life of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity for the year ended December&#160;31, 2020 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;644,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(266,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited and expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(171,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;412,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, shares were surrendered to satisfy tax withholding obligations on the exercise of stock options with a cost basis of $2.7&#160;million. During the year ended December&#160;31, 2019, shares were surrendered to satisfy tax withholding obligations on the exercise of stock options with a cost basis of $0.4 million, which are all held as treasury stock as of December&#160;31, 2020. During the year ended December 31, 2020, $0.4 million of cash was received from stock option exercises under share-based payment arrangements. No cash was received from stock option exercises under share-based payment arrangements for the years ended December 31, 2019 or 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maximum term of stock options under these plans is ten years. Options outstanding as of December&#160;31, 2020 expire on various dates ranging from January 2021 through March 2030. The following table outlines the outstanding and exercisable stock options as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Option Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Outstanding Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0.00 - $8.24&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$8.24 - $16.52&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;345,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$16.52 - $24.76&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$24.76 - $33.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$33.00 - $41.28&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$41.28 - $49.52&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$49.52 - $57.76&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$57.76 - $66.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$66.00 - $74.28&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;412,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, there was $1.0 million of unrecognized compensation expense related to unvested option grants that is expected to be recognized over a weighted-average period of 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Restricted stock grants subject solely to an employee&#x2019;s continued service with the Company generally will become fully vested within &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzI2Mjc_ef3f1c14-105f-4e27-b582-034c0b01b496"&gt;one&lt;/span&gt; to four years from the grant date and, in certain instances, may fully vest upon a change in control of the Company. Restricted stock grants subject solely to a Director&#x2019;s continued service with the Company generally will become fully vested within one year from the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation expense from restricted stock is recognized on a straight-line basis over the requisite service period. During the years ended December&#160;31, 2020 and 2019, the Company recognized compensation expense related to restricted stock awards of $2.3 million and $1.9 million, respectively. The Company did not recognize any compensation expense related to restricted stock awards prior to the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of restricted stock award activity for the year ended December&#160;31, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.801%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(120,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited and expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(51,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;549,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, shares were surrendered to satisfy tax withholding obligations on the vesting of restricted stock awards with a cost basis of $0.3 million. During the year ended December&#160;31, 2019, shares were surrendered to satisfy tax withholding obligations on the vesting of restricted stock awards with a cost basis of $2.1 million, of which $2.0 million is held as treasury stock as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there was $6.0 million in unrecognized compensation expense related to unvested restricted stock awards that is expected to be recognized over a weighted average period of 1.7 years. The total fair value of restricted stock awards vested during the years ended December&#160;31, 2020, 2019 and 2018 was $1.5 million, $1.9&#160;million and $0, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;HC I Incentive Units &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;  Beginning in October 2015, HC I implemented an equity incentive plan for certain officers and employees of the Company. Incentive units are equity-based awards subject to time and performance vesting restrictions. The compensation expense related to this plan has been reflected in the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, compensation expense is recognized on a straight-line basis over the vesting period of the award or the employee&#x2019;s retirement eligible date, if earlier. During the years ended December&#160;31, 2020, 2019 and 2018, the Company recognized compensation expense related to the HC I incentive units of $0.2 million, $1.9 million and $2.1 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No awards were issued during the year ended December&#160;31, 2020. The fair value of each award was determined using a Monte-Carlo simulation with the following weighted average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Average time to liquidity (years) (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Volatility (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount for lack of marketability (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1.13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1) Represents the US Treasury security rate for the expected time to liquidity event.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2) Represents the period of time expected prior to liquidity event.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3) Based on historical volatility of comparable public companies.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4) Represents a discount taken to reflect the private nature of the investment.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ie78754462d4f48648b6dde71360bba63_I20180503"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzU0OTc1NTgxNDYzNjE_34046d31-aee5-4175-a39d-e853ba1e3cc1"
      unitRef="shares">4101735</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i24920ce6c3624d32867b35ecb74cd412_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzMyOTg1MzQ4OTEzNzY_12ccc3b1-4a39-4d87-b13d-2c6b34c87da8">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i1cd470f5e6054ec5b5f94411ed707e82_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzEwNjE_daca59e8-1799-4290-b6f8-81cfa052fe50">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzU0OTc1NTgxNDYzOTg_09353308-9e11-4e54-ad02-a3d769fc7f55"
      unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1599283f6d184d1b9aa7b7fa0b2e0ce8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzU0OTc1NTgxNDYzODE_26ee021b-3d6e-45ad-a230-718f3918d8bf"
      unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQzOTgwNDY1MTg2Mzg_b3eca1d3-5e04-43c3-94f5-bab1a98d413d"
      unitRef="usdPerShare">5.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1599283f6d184d1b9aa7b7fa0b2e0ce8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzE0Nzg_496c49a8-398d-497c-aad5-f9ba8b2400de"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i760b317cd0fd4b0d9e286a06610ffaec_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzE0Nzg_7c6c8bb7-04df-4435-a544-56b73e0f85e0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzMyOTg1MzQ4OTEzNzc_fc39b4bf-6202-4996-94c5-53f531046cab">The assumptions used to compute the fair value of options for the year ended December&#160;31, 2020 are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.350%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.176%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected life of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The fair value of each award was determined using a Monte-Carlo simulation with the following weighted average assumptions: &lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Average time to liquidity (years) (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Volatility (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount for lack of marketability (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1.13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1) Represents the US Treasury security rate for the expected time to liquidity event.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2) Represents the period of time expected prior to liquidity event.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3) Based on historical volatility of comparable public companies.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4) Represents a discount taken to reflect the private nature of the investment.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpiZWIwMjhkYWUwZGU0ZjFlOWY3YmFiOWQyZWZjMTgyOS90YWJsZXJhbmdlOmJlYjAyOGRhZTBkZTRmMWU5ZjdiYWI5ZDJlZmMxODI5XzAtMS0xLTEtMzQ3NQ_0d6b43cc-f066-4b5e-be2b-a89646aefb2d"
      unitRef="number">0.457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpiZWIwMjhkYWUwZGU0ZjFlOWY3YmFiOWQyZWZjMTgyOS90YWJsZXJhbmdlOmJlYjAyOGRhZTBkZTRmMWU5ZjdiYWI5ZDJlZmMxODI5XzEtMS0xLTEtMzQ3NQ_22a3e59d-be0c-4f48-a10f-9332cb0bd31b"
      unitRef="number">0.0053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpiZWIwMjhkYWUwZGU0ZjFlOWY3YmFiOWQyZWZjMTgyOS90YWJsZXJhbmdlOmJlYjAyOGRhZTBkZTRmMWU5ZjdiYWI5ZDJlZmMxODI5XzItMS0xLTEtMzQ3NQ_3ce0723c-5874-4092-a12f-cb09844ac233">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpiZWIwMjhkYWUwZGU0ZjFlOWY3YmFiOWQyZWZjMTgyOS90YWJsZXJhbmdlOmJlYjAyOGRhZTBkZTRmMWU5ZjdiYWI5ZDJlZmMxODI5XzMtMS0xLTEtMzQ3NQ_70a16ab3-c314-43b8-89f3-c21e1fc89fab"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQ4ODQ_70f7d339-59cc-4e91-95c0-51c427cad2fa">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity for the year ended December&#160;31, 2020 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;644,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(266,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited and expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(171,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;412,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7593332c92344b60ad9b41ff0c66bfb8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzEtMS0xLTEtMA_4704f9bd-ea85-40cf-aa7f-8c66d7f7d5ff"
      unitRef="shares">644975</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7593332c92344b60ad9b41ff0c66bfb8_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzEtMy0xLTEtMA_038dd7f3-d8fd-4147-acb2-f0c30f99e90c"
      unitRef="usdPerShare">15.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i7593332c92344b60ad9b41ff0c66bfb8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzEtNS0xLTEtMA_56d683e9-7437-4681-9e33-c3da1871290c"
      unitRef="usd">2754000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzMtMS0xLTEtMA_3a07114e-04e1-40f5-bc31-81d730d04f14"
      unitRef="shares">204928</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzMtMy0xLTEtMA_14c6bede-8f67-438f-acde-60539308954c"
      unitRef="usdPerShare">13.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <bios:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzMtNS0xLTEtMA_dcd788a6-5b10-42b4-b7f3-97e1db2a7cd4"
      unitRef="usd">471000</bios:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzQtMS0xLTEtMA_2e57e8af-86d0-4ac7-aa9b-56db2e1bd02a"
      unitRef="shares">266065</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzQtMy0xLTEtMA_a8642026-14b7-4655-9d04-eae082b7f006"
      unitRef="usdPerShare">7.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzQtNS0xLTEtMA_eaf18f5c-4c68-4a25-9966-99b374338571"
      unitRef="usd">2548000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzUtMS0xLTEtMA_bdcd0806-992b-4e32-8872-326008437895"
      unitRef="shares">171007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzUtMy0xLTEtMA_6d99140d-c59d-44e0-8110-46192c6ecf0b"
      unitRef="usdPerShare">26.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <bios:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzUtNS0xLTEtMA_4a29ea3e-0580-479d-ad99-7c3efc6b8768"
      unitRef="usd">88000</bios:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i53bc279beb0d4676ba828340fd063ce9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzYtMS0xLTEtMA_97ae3866-57f4-4505-b8cc-bfe4ae916e76"
      unitRef="shares">412831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i53bc279beb0d4676ba828340fd063ce9_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzYtMy0xLTEtMA_e3e083bf-41b3-42db-9995-1af446e032e3"
      unitRef="usdPerShare">14.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i53bc279beb0d4676ba828340fd063ce9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzYtNS0xLTEtMA_74ddef99-beac-46e7-ad2c-40052e2e239a"
      unitRef="usd">1320000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzYtNy0xLTEtMA_399d83d1-4d24-46f1-960c-794aa91723c9">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i53bc279beb0d4676ba828340fd063ce9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzctMS0xLTEtMA_60fcd79a-f19a-41c0-81ee-a28431c9e1f4"
      unitRef="shares">197735</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i53bc279beb0d4676ba828340fd063ce9_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzctMy0xLTEtMA_bab73b5d-5cbb-4cf5-a267-bbf20882e156"
      unitRef="usdPerShare">16.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i53bc279beb0d4676ba828340fd063ce9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzctNS0xLTEtMA_fd05bad3-0b3f-4363-be39-f300e54c7a8d"
      unitRef="usd">789000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTplZWNiNGE2ZTM5MTg0ZjMzYWUwODNjNjI2YWNjNTgwNy90YWJsZXJhbmdlOmVlY2I0YTZlMzkxODRmMzNhZTA4M2M2MjZhY2M1ODA3XzctNy0xLTEtMA_972b2d61-67e9-4177-8472-839906e1db4d">P4Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQzOTgwNDY1MTg2ODQ_472c1497-2cfd-4b4d-abf9-52784faeb096"
      unitRef="usd">2700000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1599283f6d184d1b9aa7b7fa0b2e0ce8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzE4MjA_59c0fe36-1aad-47d6-a662-a5ff93129bc6"
      unitRef="usd">400000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQzOTgwNDY1MTg5MjQ_a7297a5c-36ea-4228-b136-cdcb07af43cf"
      unitRef="usd">400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzMyOTg1MzQ4OTEzNDM_75eb0bda-603e-4ade-a6b1-c10333322bf2"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzMyOTg1MzQ4OTEzNDM_b3435fdd-e3be-414e-a06a-f0f7d1d72d3d"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i1cd470f5e6054ec5b5f94411ed707e82_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzIwMzk_fc04c786-d56e-401e-95a2-1cb81cfd4307">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQ4OTQ_fb5de6ef-6447-45ec-955b-875ff680278a">The following table outlines the outstanding and exercisable stock options as of December&#160;31, 2020:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Option Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Outstanding Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0.00 - $8.24&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$8.24 - $16.52&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;345,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$16.52 - $24.76&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$24.76 - $33.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$33.00 - $41.28&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$41.28 - $49.52&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$49.52 - $57.76&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$57.76 - $66.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$66.00 - $74.28&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;412,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i9e711f6fe89d4907a952226e5df765bd_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzItMC0xLTEtMC90ZXh0cmVnaW9uOmZlN2M2MjNjOTMyOTRmYjJiNzQ5NTkwN2U2M2I3OTE1XzQzOTgwNDY1MTExMDg_07abcf08-af81-4346-bb05-232c31ab1512"
      unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i9e711f6fe89d4907a952226e5df765bd_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzItMC0xLTEtMC90ZXh0cmVnaW9uOmZlN2M2MjNjOTMyOTRmYjJiNzQ5NTkwN2U2M2I3OTE1XzQzOTgwNDY1MTExMTQ_d9f220b0-16c1-4c9c-aa34-cd6abd1044fa"
      unitRef="usdPerShare">8.24</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ied37c8390b9e43a68cb9da71a0ccb303_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzItMi0xLTEtMA_a90a2873-89e0-4f77-9e3f-6cb2412c9ebc"
      unitRef="shares">9901</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ied37c8390b9e43a68cb9da71a0ccb303_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzItNC0xLTEtMA_d99553ab-8ed7-4071-9107-8a6e2165bbd5"
      unitRef="usdPerShare">6.52</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i9e711f6fe89d4907a952226e5df765bd_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzItNi0xLTEtMA_77bd24de-e4c9-42f6-85af-739dbd22a0ad">P6Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ied37c8390b9e43a68cb9da71a0ccb303_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzItOC0xLTEtMA_6f51fc46-8249-42a1-bc4b-2c6458bcbda2"
      unitRef="shares">9901</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ied37c8390b9e43a68cb9da71a0ccb303_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzItMTAtMS0xLTA_625e7ae9-3e25-4971-9456-6f5b8a1357b4"
      unitRef="usdPerShare">6.52</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ic297998b32b84faa88fcfec2d9f9afaa_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjg0MDkwNzMwNDkxOTQ1YmFiMGNhMGU1YzExNGUwNjVjXzQzOTgwNDY1MTExMDg_e845548a-e834-46f4-896b-040a985666df"
      unitRef="usdPerShare">8.24</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ic297998b32b84faa88fcfec2d9f9afaa_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjg0MDkwNzMwNDkxOTQ1YmFiMGNhMGU1YzExNGUwNjVjXzQzOTgwNDY1MTExMTQ_9c5dbcfa-a525-4780-b00f-52107e517624"
      unitRef="usdPerShare">16.52</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i6e5ee81d05914bbbb9c62c51c01221b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzMtMi0xLTEtMA_6c0ac378-67f1-4af8-b592-19e51acdebc3"
      unitRef="shares">345180</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i6e5ee81d05914bbbb9c62c51c01221b7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzMtNC0xLTEtMA_d51e128e-53b6-4f4a-b81d-1509a6c36ef4"
      unitRef="usdPerShare">12.08</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ic297998b32b84faa88fcfec2d9f9afaa_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzMtNi0xLTEtMA_04e40689-8031-44ac-b5e7-9624d5a67a58">P7Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i6e5ee81d05914bbbb9c62c51c01221b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzMtOC0xLTEtMA_e4eaea44-b9d9-4bf5-bf54-0e8958f2a9ff"
      unitRef="shares">130084</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i6e5ee81d05914bbbb9c62c51c01221b7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzMtMTAtMS0xLTA_d2fea265-471f-4e8d-8c69-d78ea655f0d8"
      unitRef="usdPerShare">10.27</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ia22152ff44814391aef12293b8db163f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjcxMzdiZjlmMzIwYjRmNTRiOWUwOTNlZmFjOTVlOWY2XzQzOTgwNDY1MTExMDg_82f90eb7-2c75-4c8b-b79d-040642fa99f1"
      unitRef="usdPerShare">16.52</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ia22152ff44814391aef12293b8db163f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjcxMzdiZjlmMzIwYjRmNTRiOWUwOTNlZmFjOTVlOWY2XzQzOTgwNDY1MTExMTQ_46327e3f-3442-4fbb-931e-d161996012d1"
      unitRef="usdPerShare">24.76</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i63a51e68f4934ca4aa97b767de686c2e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzQtMi0xLTEtMA_644b1501-919e-402f-bad0-8d3d785f434c"
      unitRef="shares">25500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i63a51e68f4934ca4aa97b767de686c2e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzQtNC0xLTEtMA_67fb5e43-5f95-42f1-908f-d0239c832581"
      unitRef="usdPerShare">22.61</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ia22152ff44814391aef12293b8db163f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzQtNi0xLTEtMA_b7502299-485a-4512-8019-49caf8fd8343">P2Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i63a51e68f4934ca4aa97b767de686c2e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzQtOC0xLTEtMA_2140e149-4537-4b60-a1f8-9fa1413a4afb"
      unitRef="shares">25500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i63a51e68f4934ca4aa97b767de686c2e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzQtMTAtMS0xLTA_082812dd-4470-406a-a33b-5bdb2b234fad"
      unitRef="usdPerShare">22.61</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ic98475680f7349638688cb46f1e41606_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQyN2I0MThjYjFmYzRmMGQ5MmFhY2Q0NzEyOWRkZTZlXzQzOTgwNDY1MTExMDg_ac32f161-dfd6-4d6a-81f4-116b2e3d0299"
      unitRef="usdPerShare">24.76</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ic98475680f7349638688cb46f1e41606_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQyN2I0MThjYjFmYzRmMGQ5MmFhY2Q0NzEyOWRkZTZlXzQzOTgwNDY1MTExMTQ_484d3ea7-bf6e-4385-b745-e193bcd0e457"
      unitRef="usdPerShare">33.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i7fd061fe54554bc695ee04673aa61e17_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzUtMi0xLTEtMA_c64e41fa-6ee2-4be0-be02-58c4f367fd07"
      unitRef="shares">15000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i7fd061fe54554bc695ee04673aa61e17_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzUtNC0xLTEtMA_a528e37a-685c-44da-ab7d-a08ba5f88f62"
      unitRef="usdPerShare">30.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ic98475680f7349638688cb46f1e41606_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzUtNi0xLTEtMA_3c884cc4-460d-4d34-8f22-69b63d99797b">P2Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i7fd061fe54554bc695ee04673aa61e17_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzUtOC0xLTEtMA_8b39cb42-3b2c-4301-9fc6-fa9a39dee606"
      unitRef="shares">15000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i7fd061fe54554bc695ee04673aa61e17_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzUtMTAtMS0xLTA_d2b349e3-3611-4aa5-acaa-ed528d030255"
      unitRef="usdPerShare">30.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ie25037f6e33c47f0b726fabf6b0be7a6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjIxODhhNmUxN2Y5YTRkZjQ5M2RkY2M5ZjNjZWVmMmI5XzQzOTgwNDY1MTExMDg_1c997a8d-dad9-4693-a143-e1501fa56049"
      unitRef="usdPerShare">33.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ie25037f6e33c47f0b726fabf6b0be7a6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjIxODhhNmUxN2Y5YTRkZjQ5M2RkY2M5ZjNjZWVmMmI5XzQzOTgwNDY1MTExMTQ_c4de4bf4-db2d-41e3-a5c9-1ca050cd74bc"
      unitRef="usdPerShare">41.28</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="if6dce6cca08246afbc1f71bef99be371_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzYtMi0xLTEtMA_a0b9c4b9-7883-48c2-a48b-fa899732b8d8"
      unitRef="shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="if6dce6cca08246afbc1f71bef99be371_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzYtNC0xLTEtMA_289972d1-97ae-498a-a249-f37b63c962bb"
      unitRef="usdPerShare">0</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ie25037f6e33c47f0b726fabf6b0be7a6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzYtNi0xLTEtMA_ab9848be-f63c-469d-a297-95be9581c712">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="if6dce6cca08246afbc1f71bef99be371_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzYtOC0xLTEtMA_0ace7e1f-48a5-4015-8437-461be0be047d"
      unitRef="shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="if6dce6cca08246afbc1f71bef99be371_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzYtMTAtMS0xLTA_251aa12d-862c-4571-86f6-f333f639a5e5"
      unitRef="usdPerShare">0</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i55f1b01e1ac646989939a0659a3141e6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzctMC0xLTEtMC90ZXh0cmVnaW9uOmEyMTk4ZmUyNjVhNjQwZTY5YmNkMzgxYmNlMTZmMGJiXzQzOTgwNDY1MTExMDg_1009490e-366c-435f-b839-dbff2bf23c0f"
      unitRef="usdPerShare">41.28</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i55f1b01e1ac646989939a0659a3141e6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzctMC0xLTEtMC90ZXh0cmVnaW9uOmEyMTk4ZmUyNjVhNjQwZTY5YmNkMzgxYmNlMTZmMGJiXzQzOTgwNDY1MTExMTQ_426ea4c1-5ea0-41f5-bcf5-e97fdda32c4e"
      unitRef="usdPerShare">49.52</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i42e2317cc254448dba231db5776669d8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzctMi0xLTEtMA_a0c2d65c-0c54-43cb-9eed-b137fd2c0533"
      unitRef="shares">12500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i42e2317cc254448dba231db5776669d8_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzctNC0xLTEtMA_1284a1de-747a-40a4-b152-0651492a8997"
      unitRef="usdPerShare">44.16</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i55f1b01e1ac646989939a0659a3141e6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzctNi0xLTEtMA_67cf71f3-068a-477d-9996-21748b99669a">P1Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i42e2317cc254448dba231db5776669d8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzctOC0xLTEtMA_686dcdeb-162f-4d6a-9897-a84bb96dea66"
      unitRef="shares">12500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i42e2317cc254448dba231db5776669d8_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzctMTAtMS0xLTA_3ca3e839-9120-4c16-8f8d-3d33dfb5e6cc"
      unitRef="usdPerShare">44.16</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i0053d6570a4144ac906506c3b03aab72_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzgtMC0xLTEtMC90ZXh0cmVnaW9uOjc2MTBmY2ZiYWQwNjQ1YmY4ZjVmNTc5NGE5YjM1YmJjXzQzOTgwNDY1MTExMDg_f1328492-2be9-48d1-8ff6-8695d4c8c231"
      unitRef="usdPerShare">49.52</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i0053d6570a4144ac906506c3b03aab72_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzgtMC0xLTEtMC90ZXh0cmVnaW9uOjc2MTBmY2ZiYWQwNjQ1YmY4ZjVmNTc5NGE5YjM1YmJjXzQzOTgwNDY1MTExMTQ_6a628004-4040-4f51-a973-675a830fa9ca"
      unitRef="usdPerShare">57.76</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i3d816e895c844acba36b041455ff1817_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzgtMi0xLTEtMA_a6855842-2416-4558-9df3-6259025e9804"
      unitRef="shares">3500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i3d816e895c844acba36b041455ff1817_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzgtNC0xLTEtMA_96928fc8-833e-4fb5-b5cd-916c05c2fd33"
      unitRef="usdPerShare">56.24</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i0053d6570a4144ac906506c3b03aab72_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzgtNi0xLTEtMA_9e52763e-9bf2-46aa-a3fe-f4203de90920">P2Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i3d816e895c844acba36b041455ff1817_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzgtOC0xLTEtMA_fdbff91f-54f2-4085-a2e3-62a33c700665"
      unitRef="shares">3500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i3d816e895c844acba36b041455ff1817_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzgtMTAtMS0xLTA_dd56e798-09e7-49df-8bb7-1d549e21a8b9"
      unitRef="usdPerShare">56.24</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i30fe04022dfb468d8d0ab7e1e5130cbc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzktMC0xLTEtMC90ZXh0cmVnaW9uOjczMmIzNWRjYzYyNTRmZjJiNmMyY2E4ZmE4ZTJiZTJjXzQzOTgwNDY1MTExMDg_85bd3a97-7288-4fff-b31b-0d26901bb3b9"
      unitRef="usdPerShare">57.76</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i30fe04022dfb468d8d0ab7e1e5130cbc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzktMC0xLTEtMC90ZXh0cmVnaW9uOjczMmIzNWRjYzYyNTRmZjJiNmMyY2E4ZmE4ZTJiZTJjXzQzOTgwNDY1MTExMTQ_1c2489cb-9df5-44b6-806a-e81102e0328e"
      unitRef="usdPerShare">66.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i7776b739ae0444bfa9bc3151bd3de57d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzktMi0xLTEtMA_2908bbe6-2a2f-4b00-bbcd-453aec32e6b5"
      unitRef="shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i7776b739ae0444bfa9bc3151bd3de57d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzktNC0xLTEtMA_45723c23-c139-4cac-a979-8cc9285780c0"
      unitRef="usdPerShare">0</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i30fe04022dfb468d8d0ab7e1e5130cbc_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzktNi0xLTEtMA_a5eb16ae-2755-4169-a295-061701c77f81">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i7776b739ae0444bfa9bc3151bd3de57d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzktOC0xLTEtMA_1417a879-f563-4872-a945-8e6a49f209d2"
      unitRef="shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i7776b739ae0444bfa9bc3151bd3de57d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzktMTAtMS0xLTA_310149f3-912e-40f1-8961-f39d4c9f43be"
      unitRef="usdPerShare">0</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="iabac5d7169c74416abc3eb400b77e659_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzEwLTAtMS0xLTAvdGV4dHJlZ2lvbjpjZGU0Mzk5Njk2Yjc0NGZkOGQwZDY4N2NkM2M1ZjQxN180Mzk4MDQ2NTExMTA4_bdba1d4f-82de-475f-a57b-518fc795c69b"
      unitRef="usdPerShare">66.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="iabac5d7169c74416abc3eb400b77e659_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzEwLTAtMS0xLTAvdGV4dHJlZ2lvbjpjZGU0Mzk5Njk2Yjc0NGZkOGQwZDY4N2NkM2M1ZjQxN180Mzk4MDQ2NTExMTE0_9f11234b-a3ba-4f46-bffd-bfb952bee982"
      unitRef="usdPerShare">74.28</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i6111e845e8ac4ee9941a74fef21be93b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzEwLTItMS0xLTA_d5b21000-9923-4bd0-8c31-69b3a512d6cf"
      unitRef="shares">1250</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i6111e845e8ac4ee9941a74fef21be93b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzEwLTQtMS0xLTA_94c2a060-166d-4cc7-9dc6-38d4b63f9379"
      unitRef="usdPerShare">66.52</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="iabac5d7169c74416abc3eb400b77e659_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzEwLTYtMS0xLTA_28185e83-b76e-4e45-81b8-ea22459ea711">P2Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i6111e845e8ac4ee9941a74fef21be93b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzEwLTgtMS0xLTA_225e3f70-88c1-4cf5-9594-dbaa92338ac1"
      unitRef="shares">1250</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i6111e845e8ac4ee9941a74fef21be93b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzEwLTEwLTEtMS0w_16e5fe91-a6ee-4a7a-b912-d25c6fb6a6f4"
      unitRef="usdPerShare">66.52</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzExLTItMS0xLTA_946229db-0db0-438a-968d-bd32dfc378f1"
      unitRef="shares">412831</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTphZmIyMGY3ZmFmMjg0MjZmOWU4OWViNmE3Y2E5NmFjOS90YWJsZXJhbmdlOmFmYjIwZjdmYWYyODQyNmY5ZTg5ZWI2YTdjYTk2YWM5XzExLTgtMS0xLTA_4d48c774-83e0-4036-b103-e5acabd3241a"
      unitRef="shares">197735</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i53bc279beb0d4676ba828340fd063ce9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzIzMjk_d6e806b0-70da-4010-929f-f8354c8a84f1"
      unitRef="usd">1000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzI0NzE_d3a9adb3-e5a0-41f4-8f45-4338072e46b1">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if3c12b1e25aa48848f6b9795aa9375a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzMyOTg1MzQ4OTEzNjE_46b4e753-583d-4bae-9840-4de1a8088278">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i30a276240cc149b2b70ea64be64b1594_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzI4Nzc_7af4ab18-9b55-44c8-953f-55bb400846ef">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQzOTgwNDY1MTg3MDc_6b072713-3bcb-4c17-9626-08f717d3643e"
      unitRef="usd">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i51298007a376435784a5fb2e3b738530_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzMxMjI_37f27e37-c622-4a28-8fd9-91eb6da498ee"
      unitRef="usd">1900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQ4OTA_82fc44d6-10e3-4607-884a-3604594aa237">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of restricted stock award activity for the year ended December&#160;31, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.801%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(120,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited and expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(51,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;549,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic7cbfe6f12b34fedb3c55e90bc01b102_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzEtMS0xLTEtMA_db0ab291-3b7d-4413-a731-b71f29ad9b6d"
      unitRef="shares">231562</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic7cbfe6f12b34fedb3c55e90bc01b102_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzEtMy0xLTEtMA_37787456-c57b-4b0c-b4bd-06e654b392f0"
      unitRef="usdPerShare">10.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzMtMS0xLTEtMA_4a433651-0083-4613-8967-c34b7e08b257"
      unitRef="shares">490557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzMtMy0xLTEtMA_c85d0f49-2e16-44a7-a607-51bcdf386f0f"
      unitRef="usdPerShare">13.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzQtMS0xLTEtMA_41f8957c-07c3-437f-adc9-bc0a6a0a588d"
      unitRef="shares">120782</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzQtMy0xLTEtMA_0636820f-c7ec-4460-85ad-d881f1504dfc"
      unitRef="usdPerShare">12.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzUtMS0xLTEtMA_5069f7fd-0f2b-4699-a05e-657f65ec42da"
      unitRef="shares">51687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzUtMy0xLTEtMA_715b16a1-cf61-47cd-8b2b-0df743cce99e"
      unitRef="usdPerShare">12.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2de6cb92e6b546deac3f264b1d51d725_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzYtMS0xLTEtMA_7832fd66-4bd5-47e7-9170-b3ea25c41f28"
      unitRef="shares">549650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2de6cb92e6b546deac3f264b1d51d725_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTo2ODBkNTAzZmVmNmM0MDFiODcyZGM2YjA0NzlhMjM1NS90YWJsZXJhbmdlOjY4MGQ1MDNmZWY2YzQwMWI4NzJkYzZiMDQ3OWEyMzU1XzYtMy0xLTEtMA_3a305bbc-9ed3-4ec1-8d19-801ec26023fd"
      unitRef="usdPerShare">13.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQzOTgwNDY1MTg3MjU_8c20f2d3-781e-4018-a461-438111c5dc24"
      unitRef="usd">300000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i51298007a376435784a5fb2e3b738530_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzM2Njg_0c2e914a-7286-41cc-9494-e26524d40540"
      unitRef="usd">2100000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7250472ce2a241aa9fa3993c11938e71_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzM2ODE_d32c6eb4-851b-40e4-87ce-aaf6d0f07c06"
      unitRef="usd">2000000.0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i2de6cb92e6b546deac3f264b1d51d725_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzM3NTU_156b5815-87b8-4603-9861-58b8ac6fa723"
      unitRef="usd">6000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzM5MDc_48343500-6cc2-468b-be76-f018f6feb624">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i71d89cba29a940fcb26b394671b41837_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzM5OTg_1a1098d4-9900-4169-91f6-ef9b52be888c"
      unitRef="usd">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i51298007a376435784a5fb2e3b738530_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQzOTgwNDY1MTg3Nzc_906180a2-6045-4161-beb0-c3eb4642f0fd"
      unitRef="usd">1900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i7b7d2377ab7d4bc99608fd62fc228d0a_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQwMDk_c745510f-3990-42f8-89e3-bf54c774a8b1"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5acddac984ac471cad45cd822b74b0b6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQ3MDE_ebf7e593-4e93-4350-9041-7b8978c31b39"
      unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7f5821f9020a4063acb746c7833a5115_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQ3MDU_c2a21260-9edf-47be-b451-5a486d851972"
      unitRef="usd">1900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie95cb408d1a745e48ca026ce6e263566_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzQ3MTI_d76a6a43-e2d9-40e3-abc7-e82b948e512b"
      unitRef="usd">2100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpmMTZjY2Y5NDBmYmE0ZDMyOGE1YzQ0NGNjMTZiYzJjYi90YWJsZXJhbmdlOmYxNmNjZjk0MGZiYTRkMzI4YTVjNDQ0Y2MxNmJjMmNiXzAtMi0xLTEtMA_1e19bdfc-0c1b-43cf-b440-e73e2775ea5b"
      unitRef="number">0.0225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpmMTZjY2Y5NDBmYmE0ZDMyOGE1YzQ0NGNjMTZiYzJjYi90YWJsZXJhbmdlOmYxNmNjZjk0MGZiYTRkMzI4YTVjNDQ0Y2MxNmJjMmNiXzEtMi0xLTEtMA_11686913-ab03-48a9-94ea-24eb16b807c5">P2Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpmMTZjY2Y5NDBmYmE0ZDMyOGE1YzQ0NGNjMTZiYzJjYi90YWJsZXJhbmdlOmYxNmNjZjk0MGZiYTRkMzI4YTVjNDQ0Y2MxNmJjMmNiXzItMi0xLTEtMA_3b72a4a9-d18c-41bc-a286-f675142d16fd"
      unitRef="number">0.4700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpmMTZjY2Y5NDBmYmE0ZDMyOGE1YzQ0NGNjMTZiYzJjYi90YWJsZXJhbmdlOmYxNmNjZjk0MGZiYTRkMzI4YTVjNDQ0Y2MxNmJjMmNiXzMtMi0xLTEtMA_45d2d584-6cb8-4532-bd27-4ad58d169f59"
      unitRef="number">0.3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90YWJsZTpmMTZjY2Y5NDBmYmE0ZDMyOGE1YzQ0NGNjMTZiYzJjYi90YWJsZXJhbmdlOmYxNmNjZjk0MGZiYTRkMzI4YTVjNDQ0Y2MxNmJjMmNiXzQtMi0xLTEtMA_2ca208a2-570e-4ac6-a845-460d4665c666"
      unitRef="usdPerShare">1.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzQ1Mjk_37dcbb7a-eb76-40fb-b136-552ed50d634c">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 3, 2020, the Company&#x2019;s board of directors and HC I, the stockholder of a majority of the Company&#x2019;s common stock, approved a reverse stock split of the Company&#x2019;s issued and outstanding common stock on a one share for four share basis and appropriately amended the Company&#x2019;s Third Amended and Restated Certificate of Incorporation to reflect the change. On February 3, 2020, the reverse stock split became effective. In connection with the reverse stock split, the Company changed its ticker symbol from &#x201c;BIOS&#x201d; to &#x201c;OPCH&#x201d; and transferred the Company&#x2019;s common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market. The par value of the Company&#x2019;s common stock remained unchanged as a result of the reverse stock split, resulting in a decrease to the aggregate par value of common stock and corresponding increase to paid-in capital in the Company&#x2019;s consolidated financial statements, which was retrospectively applied to all periods presented in the financial statements. All common shares, warrants and stock awards presented in the consolidated financial statements have been retrospectively adjusted for the reverse stock split. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, the Company completed a public offering of 20,700,000 shares of the Company&#x2019;s common stock at a price of $12.50 per share, consisting of 10,000,000 shares of common stock issued and sold by the Company and 10,700,000 shares of common stock sold by HC I. The Company received net proceeds from the offering of $118.9 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. Also, during the year ended December&#160;31, 2020, HC I completed an additional secondary offering of 10,600,000 shares of common stock. Following the offerings, HC I holds approximately 63.6% of the common stock of the Company. The Company used the proceeds from the offering, along with additional cash on hand, to repay $174.0 million on the principal balance of its Second Lien Notes outstanding. See Note 11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the repayment of the Second Lien Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2017 Warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Prior to the Merger, BioScrip issued warrants to certain debt holders pursuant to a Warrant Purchase Agreement dated as of June 29, 2017. In conjunction with the Merger, the 2017 Warrants were amended to entitle the purchasers of the warrants to purchase 2.1&#160;million shares of common stock. The 2017 Warrants have a 10-year term and an exercise price of $8.00 per share and may be exercised by payment of the exercise price in cash or surrender of shares of common stock into which the 2017 Warrants are being converted in an aggregate amount sufficient to pay the exercise price. The 2017 Warrants are classified as equity instruments, and the fair value of these warrants of $14.1 million was recorded in paid-in capital as of the Merger Date. During the years ended December&#160;31, 2020 and 2019, warrant holders exercised warrants to purchase 0.0 million and 0.7 million shares of common stock. No proceeds were received from these exercises as the warrant holders elected to surrender shares to pay the exercise price. At December&#160;31, 2020 and 2019, the remaining warrant holders are entitled to purchase 1.4&#160;million shares of common stock, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2015 Warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Prior to the Merger, BioScrip issued warrants pursuant to a Common Stock Warrant Agreement dated as of March 9, 2015 which entitle the holders to purchase 0.9 million shares of common stock. The 2015 Warrants have a 10-year term and have exercise prices in a range of $20.68 per share to $25.80 per share.  The 2015 Warrants were assumed by the Company in conjunction with the Merger and are classified as equity instruments, and the fair value of these warrants of $4.6 million was recorded in paid in capital as of the Merger Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Home Solutions Restricted Stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; In conjunction with BioScrip&#x2019;s 2016 acquisition of Home Solutions, Inc., 1.8 million restricted shares of common stock were issued, of which 0.8 million of these units vest upon the closing price of the Company&#x2019;s common stock averaging at or above $16.00 per share over 20 consecutive trading days prior to December&#160;31, 2019 and 1.0 million of these units vest upon the closing price of the Company&#x2019;s common stock averaging at or above $20.00 per share over 20 consecutive trading days prior to December&#160;31, 2019. The restricted stock expired on December&#160;31, 2019. As discussed in Note 1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nature of Operations and Presentation of Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 7,048,357 common shares issued to HC I in conjunction with the Merger were set aside to prevent dilution related to the vesting of the Home Solutions restricted stock. During the year ended December&#160;31, 2020, this matter was resolved with no common shares being issued to Home Solutions, Inc., and the 7,048,357 shares, at $0.0001 par value, set aside were cancelled as unvested and removed from the Company&#x2019;s common shares issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Treasury Stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; During the year ended December&#160;31, 2019, 290,117 shares were surrendered to satisfy tax withholding obligations on the exercise of stock options and the vesting of restricted stock awards with a cost basis of $2.5 million, of which $2.4 million remains held in treasury as of December&#160;31, 2020 and 2019. At December&#160;31, 2020 and 2019, the Company held 383,722 shares of treasury stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Preferred Stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; In conjunction with the Merger, all legacy BioScrip preferred stock was settled, and no preferred stock is outstanding as of December&#160;31, 2020 or 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib5a9e86640d24df0a4a74f644bec401b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTA5MDA_6e240d9e-8aac-4d10-a504-e877dbbd10df"
      unitRef="shares">20700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i7b196dfce1974680a1c28c5ea237cbf5_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTA5MDk_cd7fb64b-7d21-4247-a811-298fadc47351"
      unitRef="usdPerShare">12.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if168c646a7a54828a528116373a38538_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTA5NDI_0c95cdbc-c103-461f-afb0-898d0a3cc0a2"
      unitRef="shares">10000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="icc639cc9d59342c992cf094de275e8c8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTA5NTU_00dcba4d-202b-4157-901f-5bd489a32eab"
      unitRef="shares">10700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="ib5a9e86640d24df0a4a74f644bec401b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTA5NjQ_b06a1ee9-be0e-4158-9fc5-917e815a1db5"
      unitRef="usd">118900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i33bae88b85d44fbca1b188c77d873669_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTA5ODk_e7c3951f-7c60-40bd-acc7-c7ebf489be20"
      unitRef="shares">10600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <bios:CommonStockOutstandingPercentage
      contextRef="i91057a8b01954ab2b5e6178ac8a1653d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTE4OTE_cf9a5c2c-9776-4c65-a908-399aebd7b447"
      unitRef="number">0.636</bios:CommonStockOutstandingPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="i41a866b1933d4b50a03ed2090fc52f3b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTA5OTg_d61f73bc-8c89-4a75-8e15-dea3ba2d5de7"
      unitRef="usd">174000000.0</us-gaap:RepaymentsOfDebt>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i5d4a2b07f09440698f0d0e140a1f931b_I20190806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzMyOTg1MzQ4OTY0ODU_7f0b04c3-364a-41dc-a250-5c801c4ae7fb"
      unitRef="shares">2100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i535849efb80c49c89802c2c1e9ff8d05_I20170629"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzMyOTg1MzQ4OTY0OTc_c08747d5-336b-4f33-b86c-8f29252470c2">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i535849efb80c49c89802c2c1e9ff8d05_I20170629"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTEwMTk_91c77582-2f0e-4ca9-bca8-23f3641a7158"
      unitRef="usdPerShare">8.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i5d4a2b07f09440698f0d0e140a1f931b_I20190806"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzExNTk_619079a3-b208-49ae-a7e1-918c1e8441d3"
      unitRef="usd">14100000</us-gaap:WarrantsAndRightsOutstanding>
    <bios:ClassofWarrantorRightSecuritiesExercised
      contextRef="i2d17de0af863439a8ae94e0d74a3cb43_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTE5NDY_2bd5c948-f8e5-4851-afb4-4dde777bb218"
      unitRef="shares">0.0</bios:ClassofWarrantorRightSecuritiesExercised>
    <bios:ClassofWarrantorRightSecuritiesExercised
      contextRef="i1039614a70d44672a1b9b67e279fb604_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzEzMzI_203859a7-e296-483a-9439-398a43127b07"
      unitRef="shares">700000</bios:ClassofWarrantorRightSecuritiesExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i2d17de0af863439a8ae94e0d74a3cb43_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTE5MTA_269fec88-f97a-47ad-af84-bee6f013d55f"
      unitRef="shares">1400000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1039614a70d44672a1b9b67e279fb604_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTE5MTA_4f727f40-5da5-4c8e-9d33-089a4ea86246"
      unitRef="shares">1400000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i7318e00da4034c3e90a2e212df26a625_I20190805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzE4OTM_58717794-b839-4e24-9dfe-d1f455ab5451"
      unitRef="shares">900000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i219745e510624e329c043ef1592af4c1_I20150309"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzMyOTg1MzQ4OTY0OTg_7feaf012-8842-46c4-b15b-b0477c71ea56">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ib3aa39a0d3d547f5ac6cd2902b94a3cc_I20150309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzIwODM_fe4e33c5-7ad4-4f79-a917-21effb56b060"
      unitRef="usdPerShare">20.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if3a9e03e121545df913cf6c60ded20b6_I20150309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzIwOTk_564cbd9f-1c3f-4239-bfb7-03582bf8f09a"
      unitRef="usdPerShare">25.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="icf01e47aa17741d5850517700e659acc_I20190806"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzIzMTg_d2f9dcc5-23fe-41d2-a11b-c7e54cf51134"
      unitRef="usd">4600000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="iac71a41a43944594bf483f7a54f70817_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzI0ODc_5a15c1ba-a2b7-4594-8ad4-cba99fd1be31"
      unitRef="shares">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="iea509be9731f4fb6830bb71b36a2b3bc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzI2MTM_86bfd9dd-7a72-40b2-a3ff-8003605f1124"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:SharePrice
      contextRef="ifd4a7b857bfc47ff96783a5d70cfd61b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzI3ODg_802aa6bf-a65a-461d-9760-3fd05a7a7c96"
      unitRef="usdPerShare">16.00</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="iea509be9731f4fb6830bb71b36a2b3bc_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzI4NTE_d68d061e-57de-4013-97dd-79cb4d9cda80"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i75edeee42f0440a9ae3db5c126a6ee59_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTEwODU_6cf94798-1a74-465e-84e3-0f33cb80e3a4"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:SharePrice
      contextRef="ifefcdf706a3e409c8661a5f8661ff527_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzMwNzQ_f69b4ce7-312b-45a8-b7ea-10db9bd65714"
      unitRef="usdPerShare">20.00</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i75edeee42f0440a9ae3db5c126a6ee59_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzMxMzc_ecece5cf-d1f2-432e-bcff-7bca865d7879"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i368d5fdb13b94d2c99546a5791f3e988_D20190806-20190806"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzMzMTk_45a42142-13f9-4469-969a-e82734a4c8c3"
      unitRef="shares">7048357</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i15e537579ddd49499464fe98320efa5a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzU0OTc1NTgxNTA4ODc_880b719f-4a8f-4814-9a49-dde64ff06abe"
      unitRef="shares">7048357</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzMyOTg1MzQ4OTY1MTA_032c5a17-161f-41dd-a3e2-53ec4663c17a"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzM4OTg_c69feed9-660c-4740-a385-ab74421c2f8d"
      unitRef="shares">290117</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i2e27ad48b6e845aab11f9dc6d36cc68d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzQxMTc_ed7d2d8a-bf6b-415e-8899-84d20fa47d50"
      unitRef="usd">2500000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib70cc65c7351474ca9d26740937a57b3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzQxMzA_cfcfbaf7-3ccf-42a4-9e57-653d54c9a65a"
      unitRef="usd">2400000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i13dda31dc46244a296faff43e8f63ba2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzQxMzA_f06a37ac-0881-4354-b04f-4534d586e738"
      unitRef="usd">2400000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:TreasuryStockShares
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzQyMDM_e2e66b24-a938-4fd6-a2b5-4950dd954506"
      unitRef="shares">383722</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzQyMDM_f60bcb3a-0a7d-4a1e-9095-a1cd2b177b6b"
      unitRef="shares">383722</us-gaap:TreasuryStockShares>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i27919b5d127146ec960f50ee2587df9f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzQ0Mzk_8346193c-1422-46cc-99d7-912a0a91023b"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic2110dcd1263436bb4f65e0170d66fa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjYvZnJhZzowNDE1ODE2MGI4OTQ0MTE1YjY3MGU5MzAzMDhhNWNkYy90ZXh0cmVnaW9uOjA0MTU4MTYwYjg5NDQxMTViNjcwZTkzMDMwOGE1Y2RjXzQ0Mzk_d975b9a5-6187-4be2-a796-9b4304ac81e0"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzM1MzA_67460054-94fb-4f41-a7cc-c27420494fd4">RELATED-PARTY TRANSACTIONS&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Management Services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; In conjunction with the Option Care acquisition from Walgreen Co. in 2015, the Company entered into two separate Management Services Agreements with Madison Dearborn Partners VI-B, L.P. and Walgreen Co. Each Management Services Agreement required the Company to pay $0.3 million to each party quarterly beginning July 1, 2015 for on-going management, consulting and financial services provided to the Company. Following the close of the Merger, both Management Services Agreements were terminated. The Company did not incur any management services expense during the year ended December&#160;31, 2020. In 2019, prior to the Merger, the Company incurred $1.5 million of management services expense, which has been reflected as a component of selling, general and administrative expense in the consolidated statements of comprehensive income (loss) for the year ended December&#160;31, 2019. During the year ended December&#160;31, 2018, management services expense of $2.0 million was recorded as a component of selling, general, and administrative expense in the consolidated statements of comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Management Equity Ownership Plan &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;  In October 2015, HC I implemented an equity ownership and incentive plan for certain officers and employees of Option Care. The officers were able to purchase membership units in HC I and could fund a portion of the purchase with a loan from Option Care. These loans were treated as a shareholder contribution in Option Care. For the years ended December&#160;31, 2020, 2019 and 2018, $0,  $0 and $0.4 million, respectively, were credited to paid-in capital related to HC I membership units purchased with a loan from Option Care. There were no shareholder redemptions during the year ended December&#160;31, 2020.  During the year ended December&#160;31, 2019, shareholder redemptions totaled $2.4 million, comprised of a cash distribution to HC I of $2.0 million and notes redeemed of $0.4 million. There were no shareholder redemptions during the year ended December&#160;31, 2018.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2019, prior to the Merger, Option Care sold its notes receivable from management, along with all accrued interest expense, to a third-party bank. Option Care received cash proceeds of $1.3 million, which represented payment of $1.1 million in outstanding notes receivable from management and payment of $0.2 million in accrued interest expense. There were no notes receivable from management outstanding as of December&#160;31, 2020 and 2019. As of December&#160;31, 2018, notes receivable from management and associated interest receivable of $1.6 million are recorded in management notes receivable as a reduction to equity in the Company&#x2019;s consolidated statements of stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transactions with Equity-Method Investees &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $2.9 million, $2.5 million and $2.2 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Management fees are recorded in net revenues in the accompanying consolidated statements of comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had amounts due from its joint ventures of $2.4&#160;million as of December&#160;31, 2020. The Company had amounts due to its joint ventures of $4.3 million as of December&#160;31, 2019. These receivables were included in prepaid expenses and other current assets in the accompanying balance sheets and these payables were included in accrued expenses and other current liabilities in the accompanying balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories purchased by the Company on behalf of the joint ventures.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i960724d691c94ef7990ec38c99826855_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzI5OA_bbbde15d-ca06-48a1-86a0-ad9ed3c8f0f5"
      unitRef="usd">300000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if80a7156fb6f4e92b4633b71b42884d2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzU3MQ_df7ef721-672e-4dbc-b90d-04dcc4eea471"
      unitRef="usd">1500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia181037e051e4e948fa5f02cec18ae01_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzgyMw_4f792661-760f-491a-930e-cca7aeef695c"
      unitRef="usd">2000000.0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
      contextRef="i284ee94026ab44078607e6ba90095ac0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzU0OTc1NTgxNDQzNjk_7a6c3e49-99e8-4b13-89ac-9d144158c042"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
      contextRef="ib849ab96bb7143929a677ea83f9f24a1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzEzNTI_479fd804-995b-4819-a956-0a3ffe776526"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
      contextRef="i1bb7590e2fd64c32b7a9e48da3b76727_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzEzNTc_550b9ac5-2684-4044-b54c-e3fd240f2672"
      unitRef="usd">400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
    <us-gaap:PartnersCapitalAccountRedemptions
      contextRef="i284ee94026ab44078607e6ba90095ac0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzMyOTg1MzQ4ODkxMjI_afe5692a-c506-4608-9f25-1fa6738da8c5"
      unitRef="usd">0</us-gaap:PartnersCapitalAccountRedemptions>
    <us-gaap:PartnersCapitalAccountRedemptions
      contextRef="ib849ab96bb7143929a677ea83f9f24a1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzE1MzY_b81e866e-e831-4b3b-bb40-0b217b97a603"
      unitRef="usd">2400000</us-gaap:PartnersCapitalAccountRedemptions>
    <us-gaap:DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid
      contextRef="ib849ab96bb7143929a677ea83f9f24a1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzE1ODQ_6bb59b16-9dce-4349-95e3-d03d305f6c39"
      unitRef="usd">2000000.0</us-gaap:DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="ib849ab96bb7143929a677ea83f9f24a1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzE2MDk_eec31924-bf4b-4544-9aeb-820ad8e28600"
      unitRef="usd">400000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PartnersCapitalAccountRedemptions
      contextRef="i1bb7590e2fd64c32b7a9e48da3b76727_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzE2MjQ_e2ea6e94-a12f-4607-bee1-dcb1f896da6e"
      unitRef="usd">0</us-gaap:PartnersCapitalAccountRedemptions>
    <us-gaap:ProceedsFromSaleOfNotesReceivable
      contextRef="i34486d66c41947448069be17a3002902_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzIwMjU_bec3e596-074b-4463-8545-3ab9355827e5"
      unitRef="usd">1300000</us-gaap:ProceedsFromSaleOfNotesReceivable>
    <us-gaap:ProceedsFromSaleOfNotesReceivable
      contextRef="ibab2cb958b58428e93eac229c0d7b02d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzIwNTg_c27cccea-8406-449b-ba20-e5b277c7752c"
      unitRef="usd">1100000</us-gaap:ProceedsFromSaleOfNotesReceivable>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="ibab2cb958b58428e93eac229c0d7b02d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzIxMjQ_de82e01f-d1cf-4a91-b054-4ee1a3e462e5"
      unitRef="usd">200000</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:NotesReceivableRelatedParties
      contextRef="i822483b16b124c4596a91869aa597cb8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzMyOTg1MzQ4ODkxMTQ_9b94ae46-77e5-4d3a-8cc8-75bdac027c65"
      unitRef="usd">0</us-gaap:NotesReceivableRelatedParties>
    <us-gaap:NotesReceivableRelatedParties
      contextRef="i6555353edfee47bd86374a705cce7c7e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzMyOTg1MzQ4ODkxMTQ_bb987280-fc5e-4930-a32f-05cbe9b654cb"
      unitRef="usd">0</us-gaap:NotesReceivableRelatedParties>
    <us-gaap:NotesReceivableRelatedParties
      contextRef="i58a5c478533d40c4ae5cf5901b523252_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzU0OTc1NTgxNDQzMzk_28474e3a-3c99-46a2-a035-d733ccda9f3b"
      unitRef="usd">1600000</us-gaap:NotesReceivableRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i3802608a5ccb4cafbdc104d570a82e52_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzI3MzE_642f95ab-2c6a-4d24-a364-abb0631a6514"
      unitRef="usd">2900000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i51011fdb3a8b4c218ad62e0a5f46e49f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzI3MzU_4d4b3978-afb5-4eef-9b83-72340ffbbebd"
      unitRef="usd">2500000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i4e67b5985f2447a4a6bba9e8bc275f82_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzI3NDI_4f090295-b9df-40dc-9d8f-676e2f5ea07e"
      unitRef="usd">2200000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="ia5e84b8b2d0c4dc7a263964004d01b50_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzU0OTc1NTgxNDQzNTc_d16da2dc-cd92-4e5e-90cd-0ddead3821e2"
      unitRef="usd">2400000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i72c86c11f53e4fe297072ffdc6b4277f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzIvZnJhZzo3ZWVhMzc0NDNmNzc0NDI1ODY4OTcyZGY1YmJjYTZjYi90ZXh0cmVnaW9uOjdlZWEzNzQ0M2Y3NzQ0MjU4Njg5NzJkZjViYmNhNmNiXzI5NTk_1ead7e8c-653f-43f2-9f6f-a44e4fc93460"
      unitRef="usd">4300000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90ZXh0cmVnaW9uOjllY2UwY2Y4OTc1NzRkMzFiMzBlZjdjMzUxMTUzMThkXzM2Mg_0fe79aef-1ce3-417b-b859-454d517102b1">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of unaudited quarterly financial information for the years ended December&#160;31, 2020 and 2019 is as follows (in thousands except per share amounts).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;First Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Second Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Third Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fourth Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;705,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;740,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;781,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;804,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Loss) earnings per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Loss) earnings per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;First Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Second Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Third Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fourth Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;476,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;497,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;615,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;720,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,811)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net loss in the third quarter of 2019 included transaction expenses, integration costs and loss on extinguishment of debt incurred in conjunction with the Merger.&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90ZXh0cmVnaW9uOjllY2UwY2Y4OTc1NzRkMzFiMzBlZjdjMzUxMTUzMThkXzM2Mw_c17d22d3-34c5-4f36-b17a-5f8d6d2c6e98">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of unaudited quarterly financial information for the years ended December&#160;31, 2020 and 2019 is as follows (in thousands except per share amounts).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;First Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Second Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Third Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fourth Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;705,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;740,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;781,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;804,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Loss) earnings per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Loss) earnings per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;First Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Second Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Third Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fourth Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;476,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;497,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;615,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;720,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,811)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15449ea65247465890f60bdac030ba0a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzItMS0xLTEtMA_756aeecc-518e-4059-a84b-2af041a4179d"
      unitRef="usd">705440000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaae3340f01f44ee699ccd0262c23dc33_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzItMy0xLTEtMA_db998fb6-2a42-445b-b875-c0b0dfb2ed57"
      unitRef="usd">740848000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic66518c22fa740f7b245ba8a1d6615fd_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzItNS0xLTEtMA_fb1fc6f0-3482-403f-a6df-366a4369c570"
      unitRef="usd">781609000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3afb9f5919b84a45a2a45351ff5c3f16_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzItNy0xLTEtMA_b5be412f-c470-43bd-8755-6cd52ad5ec3c"
      unitRef="usd">804713000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="i15449ea65247465890f60bdac030ba0a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzMtMS0xLTEtMA_b9e2e6c1-d83d-4264-92a4-de80244ba159"
      unitRef="usd">158029000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="iaae3340f01f44ee699ccd0262c23dc33_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzMtMy0xLTEtMA_56789d7f-9eaf-4ab1-8a85-43df478b133b"
      unitRef="usd">166320000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ic66518c22fa740f7b245ba8a1d6615fd_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzMtNS0xLTEtMA_0a281509-8dfb-4bde-a159-7d87da972161"
      unitRef="usd">174153000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i3afb9f5919b84a45a2a45351ff5c3f16_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzMtNy0xLTEtMA_3f18f7b1-b20e-42d3-afb7-1a537eb05cec"
      unitRef="usd">183762000</us-gaap:GrossProfit>
    <us-gaap:OperatingIncomeLoss
      contextRef="i15449ea65247465890f60bdac030ba0a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzQtMS0xLTEtMA_9b87dc70-6f3b-46af-99c7-0e28d55ff746"
      unitRef="usd">8648000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaae3340f01f44ee699ccd0262c23dc33_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzQtMy0xLTEtMA_dea79b8e-f3ab-4710-a704-4f0b6c02bdc4"
      unitRef="usd">23208000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic66518c22fa740f7b245ba8a1d6615fd_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzQtNS0xLTEtMA_bd4f7338-9e21-4d83-ae49-64169f9541e7"
      unitRef="usd">34556000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3afb9f5919b84a45a2a45351ff5c3f16_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzQtNy0xLTEtMA_09759d27-f948-4069-8381-aec98248f9e9"
      unitRef="usd">44343000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i15449ea65247465890f60bdac030ba0a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzUtMS0xLTEtMA_bd7c02e6-0ae8-4b94-b2af-bbee8c94ec69"
      unitRef="usd">-19910000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaae3340f01f44ee699ccd0262c23dc33_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzUtMy0xLTEtMA_a2e70fc3-4629-497c-85cf-fc5fc4aa1285"
      unitRef="usd">-7668000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic66518c22fa740f7b245ba8a1d6615fd_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzUtNS0xLTEtMA_7af0674f-3f26-46e3-8d5a-41c24c7247aa"
      unitRef="usd">1663000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3afb9f5919b84a45a2a45351ff5c3f16_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzUtNy0xLTEtMA_a208cf47-bea5-4edc-a064-edf85025dccd"
      unitRef="usd">17839000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i15449ea65247465890f60bdac030ba0a_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzctMS0xLTEtMA_aaa87172-a03b-4f53-82e8-8c1c38e24eb3"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iaae3340f01f44ee699ccd0262c23dc33_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzctMy0xLTEtMA_98b410c7-104a-4810-9aa6-b08441e6472a"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic66518c22fa740f7b245ba8a1d6615fd_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzctNS0xLTEtMA_0dd2a094-494f-42f1-8ba3-9fd17c22a355"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3afb9f5919b84a45a2a45351ff5c3f16_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzctNy0xLTEtMA_d0497556-a98e-4244-a601-087593328269"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i15449ea65247465890f60bdac030ba0a_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzgtMS0xLTEtMzIxMg_5ec110d9-c936-48b1-b77a-43731e27a9c1"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iaae3340f01f44ee699ccd0262c23dc33_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzgtMy0xLTEtMzIxMg_ac216704-2ebd-49cb-ad16-436bab6554a6"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic66518c22fa740f7b245ba8a1d6615fd_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzgtNS0xLTEtMzIxMg_46b8b042-d40e-4fea-97f6-2ca8f12cdc94"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3afb9f5919b84a45a2a45351ff5c3f16_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzgtNy0xLTEtMzIxMg_be28569a-750b-45a6-93cf-b429062af081"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec2211f718164003b67adb468a0ae8fe_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzExLTEtMS0xLTA_8492810e-16a2-4767-9e4d-6e913dc41255"
      unitRef="usd">476492000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib556381e0e774b77af5202ac495cedbb_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzExLTMtMS0xLTA_c02c2e82-8816-4f62-ace6-f404d0024151"
      unitRef="usd">497266000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib309aaac6dde42acbdc774c94fb918ad_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzExLTUtMS0xLTA_6e41d773-448e-4ab6-91f7-03af6e019ba8"
      unitRef="usd">615880000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70f18d581b7c4638bce49ebbbfa4f31b_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzExLTctMS0xLTA_3d035515-a4cf-4d08-a18e-8aaea2cd8f52"
      unitRef="usd">720779000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="iec2211f718164003b67adb468a0ae8fe_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzEyLTEtMS0xLTA_22258f2d-c133-46e4-9555-9bb3cbc40791"
      unitRef="usd">98194000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ib556381e0e774b77af5202ac495cedbb_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzEyLTMtMS0xLTA_4488b1ef-856e-4254-8653-97b950243e05"
      unitRef="usd">101390000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ib309aaac6dde42acbdc774c94fb918ad_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzEyLTUtMS0xLTA_ccd31f7c-1bfe-4209-8fcf-cfe1218037f8"
      unitRef="usd">137773000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i70f18d581b7c4638bce49ebbbfa4f31b_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzEyLTctMS0xLTA_8ef68c0f-1811-454e-9e64-593240e4c6b1"
      unitRef="usd">175642000</us-gaap:GrossProfit>
    <us-gaap:OperatingIncomeLoss
      contextRef="iec2211f718164003b67adb468a0ae8fe_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzEzLTEtMS0xLTA_d8128188-7b67-4d9d-b925-8f8252ff423d"
      unitRef="usd">5438000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib556381e0e774b77af5202ac495cedbb_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzEzLTMtMS0xLTA_f8a65a66-5577-4097-a987-a2c0853585ec"
      unitRef="usd">-8005000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib309aaac6dde42acbdc774c94fb918ad_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzEzLTUtMS0xLTA_bffded93-1ac6-46e9-a5cf-eb95d586544c"
      unitRef="usd">-11725000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i70f18d581b7c4638bce49ebbbfa4f31b_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzEzLTctMS0xLTA_d9778d35-9302-4c87-ae29-01ea02aedc37"
      unitRef="usd">13973000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iec2211f718164003b67adb468a0ae8fe_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE0LTEtMS0xLTA_bc42cb2c-5fc6-4272-81c5-262e87eca241"
      unitRef="usd">-3712000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib556381e0e774b77af5202ac495cedbb_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE0LTMtMS0xLTA_2d0077c3-07c7-4072-bcea-cc239c0bad10"
      unitRef="usd">-13603000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib309aaac6dde42acbdc774c94fb918ad_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE0LTUtMS0xLTA_b553e6c8-cca0-4de5-9a99-a10d3bd30a7e"
      unitRef="usd">-42794000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i70f18d581b7c4638bce49ebbbfa4f31b_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE0LTctMS0xLTA_dd4748a1-5049-44be-a0e4-385a373f3adb"
      unitRef="usd">-15811000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="iec2211f718164003b67adb468a0ae8fe_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE2LTEtMS0xLTA_88650aa0-8ddc-4c60-a140-0ceab82e2598"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib556381e0e774b77af5202ac495cedbb_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE2LTMtMS0xLTA_bd102bfa-0247-47f0-8ba7-2450fce40fd9"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib309aaac6dde42acbdc774c94fb918ad_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE2LTUtMS0xLTA_6083426a-f07c-42ee-a519-a1324b7201ff"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i70f18d581b7c4638bce49ebbbfa4f31b_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE2LTctMS0xLTA_3a923835-aff2-4b75-a6de-e11536457908"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iec2211f718164003b67adb468a0ae8fe_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE4LTEtMS0xLTMyMTg_27afa25e-4422-4da9-be20-2b788ed39e11"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib556381e0e774b77af5202ac495cedbb_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE4LTMtMS0xLTMyMTg_b277a141-08e9-4e88-9194-e324544cebdc"
      unitRef="usdPerShare">-0.1</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib309aaac6dde42acbdc774c94fb918ad_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE4LTUtMS0xLTMyMTg_5dbd8295-8897-4b27-a6fc-59066a84447a"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i70f18d581b7c4638bce49ebbbfa4f31b_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNzgvZnJhZzo5ZWNlMGNmODk3NTc0ZDMxYjMwZWY3YzM1MTE1MzE4ZC90YWJsZTo2Y2Y0OWU3OGE5ZjQ0NWNlYTlkYmZlMTNlY2U1MzA1NS90YWJsZXJhbmdlOjZjZjQ5ZTc4YTlmNDQ1Y2VhOWRiZmUxM2VjZTUzMDU1XzE4LTctMS0xLTMyMTg_5c7f1d69-20f2-4e4e-99d4-d2c666f27ba8"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i69a30465d231407487ede25fc216cb88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzExNTg_cfb84db4-61b7-4adf-8d41-9515248bb7db">SUBSEQUENT EVENTS&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated whether any subsequent events occurred since December&#160;31, 2020 and noted the following subsequent event:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2021, the Company entered into an amendment on the First Lien Term Loan (the &#x201c;First Lien Credit Agreement Amendment&#x201d;). The First Lien Credit Agreement Amendment resulted in an additional $250.0&#160;million of incremental First Lien Term Loan indebtedness being issued and reduced the interest rate on all outstanding First Lien Term Loan indebtedness from LIBOR plus 4.25% to LIBOR plus 3.75%. The proceeds of the $250.0&#160;million incremental First Lien Term Loan indebtedness were used to prepay the remaining $245.8&#160;million outstanding balance of the Second Lien Notes. In connection with the First Lien Credit Agreement Amendment and prepayment of the Second Lien Notes the Company incurred debt prepayment penalties of $4.9 million, third party fees of $1.3 million and original issue discount of $1.0 million. Following the First Lien Credit Agreement Amendment, the First Lien Term Loan is repayable in quarterly installments of $2.9&#160;million plus interest, with a final payment of all remaining outstanding principal due on August 6, 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2021, HC I completed a secondary offering of 17,250,000 shares of the Company&#x2019;s common stock. Following the offering, HC I holds approximately 54% of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i475c18c38aea40bfa20cc795a9a0586e_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzQzOTgwNDY1MTQ5MjM_4da8690d-4ff8-4746-be21-c37c1faf45e6"
      unitRef="usd">250000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i13a144a884e94b6a93b74bea5f331c3e_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzQzOTgwNDY1MTQ5NDQ_6f609168-c553-4fc9-b0fa-0746746b4856"
      unitRef="number">0.0425</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i0bbb595569b4462e84f37fd4195a043b_D20210101-20210131"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzQzOTgwNDY1MTQ5NTI_3aa69461-286e-432c-ac80-addff415f524"
      unitRef="number">0.0375</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i475c18c38aea40bfa20cc795a9a0586e_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzQzOTgwNDY1MTQ5MDU_4da8690d-4ff8-4746-be21-c37c1faf45e6"
      unitRef="usd">250000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="i6b688f43690d4a10bb658649d8f26b91_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzU0OTc1NTgxNDMzMzM_36e4cef4-aebc-46f7-bd57-8000e1f99359"
      unitRef="usd">245800000</us-gaap:RepaymentsOfDebt>
    <bios:FinancingReceivablePrepaymentPenalty
      contextRef="ic0bfb220dbad4d1ca83ebb1bd6d1b4c6_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzU0OTc1NTgxNDMyNTQ_da01dc51-6126-427f-adad-2d4ab00fa8a2"
      unitRef="usd">4900000</bios:FinancingReceivablePrepaymentPenalty>
    <bios:DebtInstrumentThirdPartyFees
      contextRef="i8995bda2010f4ab3b9f72d0a8e9683f7_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzU0OTc1NTgxNDMyNzQ_e3c3a100-00a6-415c-85ed-fd0911afcf05"
      unitRef="usd">1300000</bios:DebtInstrumentThirdPartyFees>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ic0bfb220dbad4d1ca83ebb1bd6d1b4c6_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzU0OTc1NTgxNDMyOTM_16b0fd72-f187-485a-9872-3ed29cac1d5e"
      unitRef="usd">1000000.0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="i0bbb595569b4462e84f37fd4195a043b_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzQzOTgwNDY1MTQ5NjA_639fa473-4748-478b-896e-2dc3839c008a"
      unitRef="usd">2900000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i843047af1ab74b56ac1a994dd504c5cb_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzU0OTc1NTgxNDMzMTY_6828aed6-f0f4-405a-a314-189a0657a95e"
      unitRef="shares">17250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <bios:CommonStockOutstandingPercentage
      contextRef="i5e6ee715bd2943e5b275bef6b90641f2_D20210201-20210228"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xODEvZnJhZzowOTAwNTQ3YWM2ZDQ0NzVmYWFmZjIxNDc1NTA1MDk5My90ZXh0cmVnaW9uOjA5MDA1NDdhYzZkNDQ3NWZhYWZmMjE0NzU1MDUwOTkzXzU0OTc1NTgxNDMzMDM_67152c63-5f4c-4ffd-93ed-4428ff155d22"
      unitRef="number">0.54</bios:CommonStockOutstandingPercentage>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640961314952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVER PAGE - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 08, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OPTION CARE HEALTH, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">05-0489664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3000 Lakeside Dr.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300N<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bannockburn<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">940-2443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OPCH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 473,322,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,814,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive proxy statement for its 2021 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) within 120&#160;days after the close of the registrant&#8217;s fiscal year are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001014739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640961143464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 99,265<span></span>
</td>
<td class="nump">$ 67,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">328,340<span></span>
</td>
<td class="nump">324,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">158,601<span></span>
</td>
<td class="nump">115,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">70,806<span></span>
</td>
<td class="nump">51,306<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">657,012<span></span>
</td>
<td class="nump">558,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NONCURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">121,149<span></span>
</td>
<td class="nump">133,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">68,795<span></span>
</td>
<td class="nump">63,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">351,052<span></span>
</td>
<td class="nump">385,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,428,610<span></span>
</td>
<td class="nump">1,425,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">20,821<span></span>
</td>
<td class="nump">22,741<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="nump">1,990,427<span></span>
</td>
<td class="nump">2,030,893<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">2,647,439<span></span>
</td>
<td class="nump">2,589,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">282,913<span></span>
</td>
<td class="nump">221,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">58,899<span></span>
</td>
<td class="nump">45,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">64,075<span></span>
</td>
<td class="nump">33,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">18,886<span></span>
</td>
<td class="nump">20,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">9,250<span></span>
</td>
<td class="nump">9,250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">434,023<span></span>
</td>
<td class="nump">330,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NONCURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of discount, deferred financing costs and current portion</a></td>
<td class="nump">1,115,103<span></span>
</td>
<td class="nump">1,277,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">70,776<span></span>
</td>
<td class="nump">58,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">3,339<span></span>
</td>
<td class="nump">2,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">8,474<span></span>
</td>
<td class="nump">15,085<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="nump">1,197,692<span></span>
</td>
<td class="nump">1,352,716<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,631,715<span></span>
</td>
<td class="nump">1,682,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of December 31, 2020 and 2019, respectively.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.0001 par value: 250,000,000 shares authorized, 180,178,308 shares issued and 179,794,586 shares outstanding as of December 31, 2020; 176,975,628 shares issued and 176,591,907 shares outstanding as of December 31, 2019.</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock; 383,722 shares outstanding, at cost, as of December 31, 2020 and 2019, respectively.</a></td>
<td class="num">(2,403)<span></span>
</td>
<td class="num">(2,403)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Paid-in capital</a></td>
<td class="nump">1,129,312<span></span>
</td>
<td class="nump">1,008,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(100,031)<span></span>
</td>
<td class="num">(91,955)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(11,172)<span></span>
</td>
<td class="num">(7,195)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,015,724<span></span>
</td>
<td class="nump">906,827<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 2,647,439<span></span>
</td>
<td class="nump">$ 2,589,547<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities, combined with the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640966870504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">12,500,000<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">180,178,308<span></span>
</td>
<td class="nump">176,975,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">179,794,586<span></span>
</td>
<td class="nump">176,591,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, at cost (in shares)</a></td>
<td class="nump">383,722<span></span>
</td>
<td class="nump">383,722<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640961199944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">NET REVENUE</a></td>
<td class="nump">$ 3,032,610<span></span>
</td>
<td class="nump">$ 2,310,417<span></span>
</td>
<td class="nump">$ 1,939,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">COST OF REVENUE</a></td>
<td class="nump">2,350,346<span></span>
</td>
<td class="nump">1,797,418<span></span>
</td>
<td class="nump">1,517,576<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">682,264<span></span>
</td>
<td class="nump">512,999<span></span>
</td>
<td class="nump">422,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING COSTS AND EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">500,199<span></span>
</td>
<td class="nump">459,628<span></span>
</td>
<td class="nump">345,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">71,310<span></span>
</td>
<td class="nump">53,690<span></span>
</td>
<td class="nump">38,062<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">571,509<span></span>
</td>
<td class="nump">513,318<span></span>
</td>
<td class="nump">383,946<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING INCOME (LOSS)</a></td>
<td class="nump">110,755<span></span>
</td>
<td class="num">(319)<span></span>
</td>
<td class="nump">38,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenseDisclosureNonoperatingAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="num">(107,770)<span></span>
</td>
<td class="num">(73,724)<span></span>
</td>
<td class="num">(45,824)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Equity in earnings of joint ventures</a></td>
<td class="nump">3,313<span></span>
</td>
<td class="nump">2,840<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(11,541)<span></span>
</td>
<td class="num">(6,991)<span></span>
</td>
<td class="num">(2,233)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Total other expense</a></td>
<td class="num">(115,998)<span></span>
</td>
<td class="num">(77,875)<span></span>
</td>
<td class="num">(47,037)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(5,243)<span></span>
</td>
<td class="num">(78,194)<span></span>
</td>
<td class="num">(8,768)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">INCOME TAX EXPENSE (BENEFIT)</a></td>
<td class="nump">2,833<span></span>
</td>
<td class="num">(2,274)<span></span>
</td>
<td class="num">(2,653)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">(8,076)<span></span>
</td>
<td class="num">(75,920)<span></span>
</td>
<td class="num">(6,115)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Change in unrealized (losses) gains on cash flow hedges, net of income taxes of $0, $259 and $234, respectively</a></td>
<td class="num">(3,977)<span></span>
</td>
<td class="num">(8,039)<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">OTHER COMPREHENSIVE (LOSS) INCOME</a></td>
<td class="num">(3,977)<span></span>
</td>
<td class="num">(8,039)<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">NET COMPREHENSIVE LOSS</a></td>
<td class="num">$ (12,053)<span></span>
</td>
<td class="num">$ (83,959)<span></span>
</td>
<td class="num">$ (5,341)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding, basic and diluted (in shares)</a></td>
<td class="nump">180,971<span></span>
</td>
<td class="nump">156,280<span></span>
</td>
<td class="nump">142,614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenseDisclosureNonoperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenseDisclosureNonoperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640963384824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Income taxes on unrealized gains (losses) on cash flow hedges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640962247416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,076)<span></span>
</td>
<td class="num">$ (75,920)<span></span>
</td>
<td class="num">$ (6,115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization expense</a></td>
<td class="nump">77,896<span></span>
</td>
<td class="nump">57,869<span></span>
</td>
<td class="nump">41,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash operating lease costs</a></td>
<td class="nump">18,814<span></span>
</td>
<td class="nump">19,719<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes - net</a></td>
<td class="nump">1,196<span></span>
</td>
<td class="num">(4,607)<span></span>
</td>
<td class="num">(3,595)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Loss on sale of assets</a></td>
<td class="nump">742<span></span>
</td>
<td class="nump">3,269<span></span>
</td>
<td class="nump">1,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Business casualty loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(626)<span></span>
</td>
<td class="nump">3,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">11,545<span></span>
</td>
<td class="nump">5,469<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">5,517<span></span>
</td>
<td class="nump">4,544<span></span>
</td>
<td class="nump">3,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative', window );">Loss on interest rate swaps upon discontinuing hedge accounting</a></td>
<td class="nump">3,746<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Paid-in-kind interest capitalized as principal</a></td>
<td class="nump">7,525<span></span>
</td>
<td class="nump">12,256<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of joint ventures</a></td>
<td class="num">(3,313)<span></span>
</td>
<td class="num">(2,840)<span></span>
</td>
<td class="num">(1,020)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based incentive compensation expense</a></td>
<td class="nump">2,920<span></span>
</td>
<td class="nump">4,170<span></span>
</td>
<td class="nump">2,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_InterestGainLossOnManagementNotesReceivable', window );">Interest on management notes receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Capital distribution from equity method investments</a></td>
<td class="nump">3,250<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in contingent consideration liability</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Accounts receivable, net</a></td>
<td class="num">(3,924)<span></span>
</td>
<td class="nump">82,285<span></span>
</td>
<td class="num">(21,012)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(42,725)<span></span>
</td>
<td class="num">(12,853)<span></span>
</td>
<td class="nump">2,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(19,500)<span></span>
</td>
<td class="num">(2,940)<span></span>
</td>
<td class="num">(4,715)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">59,215<span></span>
</td>
<td class="num">(30,856)<span></span>
</td>
<td class="nump">10,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">13,134<span></span>
</td>
<td class="nump">2,671<span></span>
</td>
<td class="num">(5,586)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">22,809<span></span>
</td>
<td class="num">(317)<span></span>
</td>
<td class="num">(1,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease liabilities</a></td>
<td class="num">(18,089)<span></span>
</td>
<td class="num">(17,253)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet', window );">Other noncurrent assets and liabilities</a></td>
<td class="num">(3,790)<span></span>
</td>
<td class="num">(4,711)<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">127,392<span></span>
</td>
<td class="nump">39,467<span></span>
</td>
<td class="nump">24,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of property and equipment</a></td>
<td class="num">(26,875)<span></span>
</td>
<td class="num">(28,292)<span></span>
</td>
<td class="num">(26,276)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from sale of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities', window );">Insurance proceeds from business casualty loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">626<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business acquisitions, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(700,170)<span></span>
</td>
<td class="num">(10,727)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing cash flows</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(26,334)<span></span>
</td>
<td class="num">(727,826)<span></span>
</td>
<td class="num">(37,003)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Redemptions to related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_ProceedsFromSaleOfManagementNotesReceivable', window );">Sale of management notes receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Exercise of stock options, vesting of restricted stock, and related tax withholdings</a></td>
<td class="num">(904)<span></span>
</td>
<td class="num">(2,501)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">118,934<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">981,050<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt principal</a></td>
<td class="num">(9,250)<span></span>
</td>
<td class="num">(2,075)<span></span>
</td>
<td class="num">(5,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForDepositsAppliedToDebtRetirements', window );">Retirement of debt obligations</a></td>
<td class="num">(174,000)<span></span>
</td>
<td class="num">(226,738)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Deferred financing costs</a></td>
<td class="num">(149)<span></span>
</td>
<td class="num">(30,022)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Debt prepayment fees</a></td>
<td class="num">(3,480)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(68,849)<span></span>
</td>
<td class="nump">719,024<span></span>
</td>
<td class="num">(4,150)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">32,209<span></span>
</td>
<td class="nump">30,665<span></span>
</td>
<td class="num">(16,725)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - beginning of the period</a></td>
<td class="nump">67,056<span></span>
</td>
<td class="nump">36,391<span></span>
</td>
<td class="nump">53,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS - END OF PERIOD</a></td>
<td class="nump">99,265<span></span>
</td>
<td class="nump">67,056<span></span>
</td>
<td class="nump">36,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">97,640<span></span>
</td>
<td class="nump">50,808<span></span>
</td>
<td class="nump">47,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">2,884<span></span>
</td>
<td class="nump">2,405<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Cash paid for operating leases</a></td>
<td class="nump">$ 26,809<span></span>
</td>
<td class="nump">$ 18,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_InterestGainLossOnManagementNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Gain (Loss) On Management Notes Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_InterestGainLossOnManagementNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss On Discontinuance Of Cash Flow Hedge Derivative</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_ProceedsFromSaleOfManagementNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Management Notes Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_ProceedsFromSaleOfManagementNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDepositsAppliedToDebtRetirements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow during the period as a deposit on account for application (deposits to retire or pay down) against an amount of debt owed by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDepositsAppliedToDebtRetirements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21B<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080549-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640961990328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Paid-in Capital</div></th>
<th class="th"><div>Management Notes Receivable</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 606,105<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 617,057<span></span>
</td>
<td class="num">$ (1,116)<span></span>
</td>
<td class="num">$ (9,920)<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution', window );">Stockholders' contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="num">(425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_InterestOnManagementNotesReceivable', window );">Interest on management notes receivable</a></td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based incentive compensation</a></td>
<td class="nump">2,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Dec. 31, 2018</a></td>
<td class="nump">602,825<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">619,621<span></span>
</td>
<td class="num">(1,619)<span></span>
</td>
<td class="num">(16,035)<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Purchase of BioScrip, Inc.</a></td>
<td class="nump">387,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_InterestOnManagementNotesReceivable', window );">Interest on management notes receivable</a></td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_RepaymentOfManagementNotesReceivable', window );">Repayment of management notes receivable</a></td>
<td class="nump">1,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption', window );">Stockholders' redemptions</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,371)<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based incentive compensation</a></td>
<td class="nump">4,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings', window );">Exercise of stock options, vesting of restricted stock, and related tax withholdings</a></td>
<td class="num">(2,501)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,403)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(75,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(8,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,039)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Dec. 31, 2019</a></td>
<td class="nump">906,827<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(2,403)<span></span>
</td>
<td class="nump">1,008,362<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(91,955)<span></span>
</td>
<td class="num">(7,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based incentive compensation</a></td>
<td class="nump">2,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings', window );">Exercise of stock options, vesting of restricted stock, and related tax withholdings</a></td>
<td class="num">(904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from the issuance of common stock</a></td>
<td class="nump">118,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Cancellation of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,076)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,076)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(3,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,977)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,015,724<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">$ (2,403)<span></span>
</td>
<td class="nump">$ 1,129,312<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (100,031)<span></span>
</td>
<td class="num">$ (11,172)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Stockholders' Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Stockholders' Redemption</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_InterestOnManagementNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest On Management Notes Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_InterestOnManagementNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_RepaymentOfManagementNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment Of Management Notes Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_RepaymentOfManagementNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued, Value, Restricted Stock and Stock Options Exercised, Net Of Tax Withholdings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640958608360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Operations and Presentation of Financial Statements</a></td>
<td class="text">NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Organization and Business </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; HC Group Holdings II, Inc. (&#8220;HC II&#8221;) was incorporated under the laws of the State of Delaware on January 7, 2015, with its sole shareholder being HC Group Holdings I, LLC. (&#8220;HC I&#8221;). On April 7, 2015, HC I and HC II collectively acquired Walgreens Infusion Services, Inc. and its subsidiaries from Walgreen Co., and the business was rebranded as Option Care (&#8220;Option Care&#8221;).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2019, HC I and HC II entered into a definitive agreement (the &#8220;Merger Agreement&#8221;) to merge with and into a wholly-owned subsidiary of BioScrip, Inc. (&#8220;BioScrip&#8221;), a national provider of infusion and home care management solutions, along with certain other subsidiaries of BioScrip and HC II. The merger contemplated by the Merger Agreement (the &#8220;Merger&#8221;) was completed on August 6, 2019 (the &#8220;Merger Date&#8221;). The Merger was accounted for as a reverse merger under the acquisition method of accounting for business combinations with Option Care being considered the accounting acquirer and BioScrip being considered the legal acquirer.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Merger Agreement, shares of HC II common stock issued and outstanding immediately prior to the Merger Date were converted into 135,565,392 shares of BioScrip common stock, par value $0.0001 (the &#8220;BioScrip common stock&#8221;). BioScrip also issued an additional 7,048,357 shares to HC I in respect of certain outstanding unvested contingent restricted stock units of BioScrip, which were set aside to prevent dilution related to potential additional vesting on certain share-based instruments. See Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional discussion of these shares set aside. In conjunction with the Merger, holders of BioScrip preferred shares and certain warrants received 864,603 additional shares of BioScrip common stock and preferred shares were repurchased for $125.8 million of cash. In addition, all legacy BioScrip debt was settled for $575.0 million. As a result of the Merger, BioScrip&#8217;s stockholders held approximately 19.2% of the combined company, and HC I held approximately 80.8% of the combined company. Following the close of the transaction, BioScrip was rebranded as Option Care Health, Inc. (&#8220;Option Care Health&#8221;, or the &#8220;Company&#8221;). The combined company&#8217;s stock was listed on the Nasdaq Global Select Market as of December&#160;31, 2020. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Merger.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 99 full service pharmacies and 46 stand-alone ambulatory infusion sites. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients&#8217; homes or other nonhospital settings. The Company operates in one segment, infusion services.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;  The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States. These principals require management to make certain estimates and assumptions in determining assets, liabilities, revenue, expenses, and related disclosures. Actual amounts could differ materially from those estimates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. The BioScrip results have been included in the consolidated financial results since the Merger Date. All intercompany transactions and balances are eliminated in consolidation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has investments in companies that are 50% owned and are accounted for as equity-method investments. The Company&#8217;s share of earnings from equity-method investments is included in the line entitled &#8220;Equity in earnings of joint ventures&#8221; in the consolidated statements of comprehensive income (loss). See &#8220;Equity-Method Investments&#8221; within Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Company&#8217;s equity-method investments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640958843976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s accounts receivable is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services, which is inclusive of adjustments for price concessions. The majority of accounts receivable are due from private insurance carriers and governmental health care programs, such as Medicare and Medicaid.</span></div><div style="margin-bottom:1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Price concessions may result from patient hardships, patient uncollectible accounts sent to collection agencies, lack of recovery due to not receiving prior authorization, differing interpretations of covered therapies in payer contracts, different pricing methodologies, or various other reasons. In accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASC 606&#8221;), an allowance for doubtful accounts is established only as a result of an adverse change in the Company&#8217;s payers&#8217; ability to pay outstanding billings. The allowance for doubtful accounts balance is $0 as of December&#160;31, 2020 and 2019, respectively. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in accounts receivable are earned but unbilled gross receivables of $79.0 million and $68.7 million as of December&#160;31, 2020 and 2019, respectively. Delays ranging from one day up to several weeks between the date of service and billing can occur due to delays in obtaining certain required payer-specific documentation from internal and external sources.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a further discussion of the Company&#8217;s revenue recognition policy.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Inventory, which consists primarily of pharmaceuticals, is stated at the lower of first&#8209;in, first&#8209;out cost or net realizable value basis, which the Company believes is reflective of the physical flow of inventories. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2018, one Company location was destroyed by a hurricane, resulting in a loss of $2.9 million of inventory. This business casualty loss was recorded as a component of operating costs and expenses within the consolidated statements of comprehensive income (loss). The Company received insurance proceeds of $0.8 million during the year ended December&#160;31, 2018, and recorded a receivable of $1.0 million. Both of these amounts were recorded as a partial offset to the business casualty loss in the consolidated statements of comprehensive income (loss). The $0.8 million of insurance proceeds were reflected as a component of cash flows from operating activities in the consolidated statements of cash flows. During the year ended December&#160;31, 2019, $3.0 million in proceeds were received related to recovery of inventory and business interruption and was included as a component of cash flows from operating activities in the consolidated statements of cash flows. These proceeds resulted in a gain on business casualty loss of $2.0 million recorded as a component of selling, general and administrative expense in the consolidated statement of comprehensive income (loss).</span></div><div style="margin-bottom:1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Prepaid expenses and other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212; Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $35.2 million and $13.9 million for the years ended December&#160;31, 2020 and 2019, respectively. There were no other items included in prepaid expenses and other current assets that comprised 5% or more of the balance.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company has lease agreements for facilities, warehouses, office space and property and equipment. Effective as of January 1, 2019, at the inception of a contract, the Company determines if the contract is a lease or contains an embedded lease arrangement. Operating leases are included in the operating lease right-of-use asset (&#8220;ROU asset&#8221;) and operating lease liabilities in the consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, which represent the Company&#8217;s right to use the leased assets, and operating lease liabilities, which represent the present value of unpaid lease payments, are both recognized by the Company at the lease commencement date. The Company utilizes its estimated incremental borrowing rate at the lease commencement date to determine the present value of unpaid lease obligations. The&#160;rates&#160;are&#160;estimated primarily&#160;using a methodology dependent&#160;on the&#160;Company&#8217;s financial&#160;condition, creditworthiness, and availability&#160;of certain observable data. In particular, the Company considers its actual cost of borrowing for collateralized loans and its credit rating, along with the corporate bond yield curve in estimating its incremental borrowing rates. ROU assets are recorded as the amount of operating lease liability, adjusted for prepayments, accrued lease payments, initial direct costs, lease incentives, and impairment of the ROU asset. Tenant improvement allowances used to fund leasehold improvements are recognized when earned and reduce the related ROU asset. Tenant improvement allowances are recognized through the ROU asset as a reduction of expense over the term of the lease.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases may contain rent escalations, however the Company recognizes the lease expense on a straight-line basis over the expected lease term. The Company reviews the terms of any lease renewal options to determine if it is reasonably certain that the renewal options will be exercised. The Company has determined that the expected lease term is typically the minimum non-cancelable period of the lease.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements that contain both lease and non-lease components which the Company has elected to account for as a single lease component for all asset classes. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the term of the lease. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. See Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of leases.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill, Intangible Assets, and Property and Equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company accounts for goodwill under ASC Topic&#160;350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests goodwill for impairment annually, or more frequently whenever events or circumstances indicate impairment may exist. Goodwill is stated at cost less accumulated impairment losses. The Company completes its goodwill impairment test annually in the fourth quarter. See Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Company&#8217;s goodwill and other intangible assets.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets arising from the Company&#8217;s acquisitions are amortized on a straight&#8209;line basis over the estimated useful life of each asset. Referral sources have a useful life of 15-20 years. Trademarks/names have a useful life ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc0Mjk_9e7f6967-ecc8-4667-930f-df6f18fbc07d">two</span> to fifteen years. The useful lives for other amortizable intangible assets range from approximately <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc1Mjc_c3c88249-a6e5-407f-ae8b-52445dccabe5">two</span> to nine years. The Company does not have any indefinite&#8209;lived intangible assets.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation on owned property and equipment is provided for on a straight&#8209;line basis over the estimated useful lives of owned assets. Leasehold improvements are amortized over the estimated useful life of the property or over the term of the lease, whichever is shorter. Estimated useful lives are seven years for infusion pumps and three years to thirteen years for equipment. Major repairs, which extend the useful life of an asset, are capitalized in the property and equipment accounts. Routine maintenance and repairs are expensed as incurred. Computer software is included in property and equipment and consists of purchased software and internally-developed software. The Company capitalizes application-stage development costs for significant internally-developed software projects. Once the software is ready for its intended use, these costs are amortized on a straight&#8209;line basis over the software&#8217;s estimated useful life, generally five years. Costs recognized in the preliminary project phase and the post-implementation phase, as well as maintenance and training costs, are expensed as incurred.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests long&#8209;lived assets for impairment whenever events or circumstances indicate that a certain asset or asset group may be impaired. Once identified, the amount of the impairment is computed by comparing the carrying value of the respective asset or asset group to its fair value, which is based on the discounted estimated future cash flows.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Method Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying consolidated balance sheets. As of December&#160;31, 2020 and 2019, the balance of the investments was $17.0&#160;million and $17.0&#160;million, respectively. The investments are increased to reflect the Company&#8217;s capital contributions and equity in earnings of the investees. The investments are decreased to reflect the Company&#8217;s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company&#8217;s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying consolidated statements of comprehensive income (loss). The Company&#8217;s proportionate share of earnings was $3.3 million, $2.8 million and $1.0 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Distributions from the investees are treated as cash inflows from operating activities in the consolidated statements of cash flows. During the years ended December&#160;31, 2020, 2019 and 2018, the Company received distributions from the investees of $3.3 million, $0.5 million and $2.0&#160;million, respectively. See Footnote 17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for discussion of related-party transactions with these investees. </span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hedging Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company uses derivative financial instruments to limit its exposure to increases in the interest rate of its variable rate debt instruments. The derivative financial instruments are recognized on the consolidated balance sheets at fair value. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of the hedge, the Company designated the derivative instruments as a hedge of the cash flows related to the interest on the variable rate debt. For all instruments designated as hedges, the Company documents the hedging relationships and its risk management objective of the hedging relationship. For all hedging instruments, the terms of the hedge perfectly offset the hedged expected cash flows. </span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Net revenue is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services. Revenues are from government payers, commercial payers, and patients for goods and services provided and are based on a gross price based on payer contracts, fee schedules, or other arrangements less any implicit price concessions.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the health care industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. </span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the expected consideration to be received at the time of patient acceptance based on the verification of the patient&#8217;s insurance coverage, historical information with the patient, similar patients, or the payer. Performance obligations are determined based on the nature of the services provided by the Company. The majority of the Company&#8217;s performance obligations are to provide infusion services to deliver medicine, nutrients, or fluids directly into the body. </span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a variety of infusion-related therapies to patients, which frequently include multiple deliverables of pharmaceutical drugs and related nursing services. After applying the criteria from ASC 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third-party payer contracts. Pharmaceutical drug revenue is recognized at the time the pharmaceutical drug is delivered to the patient, and nursing revenue is recognized on the date of service. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's outstanding performance obligations relate to contracts with a duration of less than one year. Therefore, the Company has elected to apply the practical expedient provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. Any unsatisfied or partially unsatisfied performance obligations at the end of a reporting period are generally completed prior to the patient being discharged. See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a further discussion of revenue.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Cost of revenue consists of the actual cost of pharmaceuticals and other medical supplies dispensed to patients, as well as all other costs directly related to the production of revenue. These costs include warehousing costs, purchasing costs, freight costs, cash discounts, wages and related costs for pharmacists and nurses, along with depreciation expense relating to revenue-generating assets, such as infusion pumps.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives prompt payment discounts from some of its pharmaceutical and medical supplies vendors. These prompt payment discounts are recorded as a reduction of inventory and are accounted for as a reduction of cost of goods sold when the related inventory is sold.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also receives rebates from pharmaceutical and medical supply manufacturers. Rebates are generally volume-based incentives and are recorded as a reduction of inventory and are accounted for as a reduction of cost of goods sold when the related inventory is sold.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative Expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Selling, general and administrative expenses mainly consist of salaries for administrative employees that directly and indirectly support the operations, occupancy costs, marketing expenditures, insurance, and professional fees. </span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Based Incentive Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -  The Company accounts for stock-based incentive compensation expense in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 718&#8221;). Stock-based incentive compensation expense is based on the grant date fair value. The Company estimates the fair value of stock option awards using a Black-Scholes option pricing model and the fair value of restricted stock unit awards using the closing price of the Company&#8217;s common stock on the grant date. For awards with a service-based vesting condition, the Company recognizes expense on a straight-line basis over the service period of the award. For awards with performance-based vesting conditions, the Company will recognize expense when it is probable that the performance-based conditions will be met. When the Company determines that it is probable that the performance-based conditions will be met, a cumulative catch-up of expense will be recorded as if the award had been vesting on a straight-line basis from the award date. The award will continue to be expensed on a straight-line basis through the remainder of the vesting period and will be updated if the Company determines that there has been a change in the probability of achieving the performance-based conditions. The Company records the impact of forfeited awards in the period in which the forfeiture occurs. </span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, HCI issued incentive units to certain employees of Option Care, who remained employees of the Company following the Merger. In accordance with ASC 718, the Company recognizes compensation expense on a straight-line basis over the shorter of the vesting period of the award or the employee&#8217;s expected eligibility date. HC I also issued equity incentive units to certain members of the Option Care Board of Directors, who remained members of the Board of Directors following the Merger. See Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Incentive Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a further discussion of equity incentive plans.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -  The Company accounts for business acquisitions in accordance with ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with assets and liabilities being recorded at their acquisition date fair value and goodwill being calculated as the purchase price in excess of the net identifiable assets. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Company&#8217;s business acquisitions.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are reported for book-tax basis differences and are measured based on currently enacted tax laws using rates expected to apply to taxable income in the years in which the differences are expected to reverse. The effect of a change in tax rate on deferred taxes is recognized in income tax expense in the period that includes the enactment date of the change. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes income tax positions that are more likely than not to be sustained on their technical merits. The Company measures recognized income tax positions at the maximum benefit that is more likely than not, based on cumulative probability, realizable upon final settlement of the position. Interest and penalties related to unrecognized tax benefits are reported in income tax expense. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Business Risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company&#8217;s largest payer was approximately 15%, 16% and 17% for the years ended December&#160;31, 2020, 2019 and 2018, respectively. In December 2019, the Company renewed and expanded its multi-year contract with this payer. The contract renewal was effective in February 2020 for a two-year term and auto-renews at the end of that term. There were no other managed care contracts that represent greater than 10% of revenue for the years presented.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the years ended December&#160;31, 2020, 2019 and 2018, approximately 15%, 12% and 12%, respectively, of the Company&#8217;s revenue was reimbursable through direct government healthcare programs such as Medicare and Medicaid. As of December&#160;31, 2020 and 2019, approximately 15% and 12%, respectively, of the Company&#8217;s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not require its patients nor other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentrations of credit risk relating to trade accounts receivable is limited due to the Company&#8217;s diversity of patients and payers. Further, the Company generally does not provide charity care.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020 and 2019, approximately 70% and 70%, respectively, of the Company&#8217;s pharmaceutical and medical supply purchases were from three vendors. For the year ended December&#160;31, 2018, approximately  66% of the Company&#8217;s pharmaceutical and medical supply purchases were from two vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company&#8217;s financial condition or operating results. Although there is uncertainty regarding the COVID-19 pandemic, as of December&#160;31, 2020 the Company has been able to maintain adequate levels of supplies and pharmaceuticals to support its operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The fair value measurement accounting standard, ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), provides a framework for measuring fair value and defines fair value as the price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The standard establishes a valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on independent market data sources. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available. The valuation hierarchy is composed of three categories. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The categories within the valuation hierarchy are described as follows: </span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:10pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Inputs to the fair value measurement are unobservable inputs or valuation techniques.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently-Adopted Accounting Pronouncements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;  In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires measurement and recognition of expected credit losses for financial assets held. The amendments in ASU 2016-13 eliminate the probable threshold for initial recognition of a credit loss in current GAAP and reflect an entity&#8217;s current estimate of all expected credit losses. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019 and is to be applied using a modified retrospective transition method. The Company adopted the standard as of January 1, 2020. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640958659224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Acquisitions</a></td>
<td class="text">BUSINESS ACQUISITIONS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Merger with BioScrip, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; As discussed in Note&#160;1,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature of Operations and Presentation of Financial Statements,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option Care&#160;merged with BioScrip&#160;on August 6, 2019.&#160;BioScrip&#160;was a national provider of infusion and home care management solutions.&#160;The Merger of Option Care and BioScrip into Option Care Health created an expanded national platform and the opportunity to drive economies of scale through procurement savings, facility rationalization and other operating cost savings.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of purchase consideration transferred on the closing date includes the value of the number of shares of the combined company owned by BioScrip shareholders at closing of the Merger, the value of common shares issued to certain warrant and preferred shareholders in conjunction with the Merger, the fair value of stock-based instruments that were vested or earned as of the Merger, and cash payments made in conjunction with the Merger. The fair value per share of BioScrip&#8217;s common stock was $2.67 per share. This is the closing price of the BioScrip common stock on August&#160;6, 2019.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, the calculation of total consideration exchanged is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of BioScrip common shares outstanding at time of the Merger (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares issued to warrant and preferred stockholders at time of the Merger (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total shares of BioScrip common stock outstanding at time of the Merger (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BioScrip share price as of August 6, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of share-based instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid in conjunction with the Merger included in purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">714,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,102,001&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: cash acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of total consideration acquired, net of cash acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,087,214&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) These shares were not adjusted for the one share for four share reverse stock split, which occurred on February 3, 2020. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid in conjunction with the Merger includes payments made for settlement of $575.0 million in legacy BioScrip debt, $125.8 million in existing BioScrip preferred shares, and $14.1 million in legacy BioScrip success-based fees owed to third-party advisors. HC II financed these payments primarily through cash on hand and debt financing, which is discussed in Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s allocation of consideration exchanged to the net tangible and intangible assets acquired and liabilities assumed, net of cash acquired, in the Merger is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.807%"><tr><td style="width:1.0%"/><td style="width:22.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.608%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net (4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net of deferred tax liabilities (5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset (6)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liability (6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28,897)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable  (7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66,668)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assumed liabilities, net of other acquired assets (7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,663)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total acquired identifiable assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">291,073&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">796,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,087,214&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Management has valued accounts receivables based on the estimated future collectability of the receivables portfolio.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Inventories are stated at fair value as of the Merger Date.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The fair value of the property and equipment was determined based upon the best and highest use of the property with final values determined based upon an analysis of the cost, sales comparison, and income capitalization approaches for each property appraised.</span></div><div style="margin-bottom:10pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The allocation of consideration exchanged to intangible assets acquired is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.771%"><tr><td style="width:1.0%"/><td style="width:53.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Estimated Life (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks/Names</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient referral sources</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193,245&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.8</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company valued trademarks/names utilizing the relief of royalty method and patient referral sources utilizing the multi-period excess earnings method, a form of the income approach.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net deferred tax&#160;assets&#160;represented the expected future tax consequences of temporary differences between the fair values of the assets acquired and liabilities assumed and their tax bases. See Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional discussion of the Company&#8217;s combined income tax position subsequent to the Merger.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The fair value of the operating lease liability and corresponding right-of-use asset (current and long-term) was based on current market rates available to the&#160;Company.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Accounts payable as well as certain other current and non-current assets and liabilities are stated at fair value as of the&#160;Merger Date. </span></div><div style="margin-bottom:10pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The&#160;Merger resulted in&#160;$796.1 million of goodwill, which is attributable to cost synergies resulting from procurement and operational efficiencies and elimination of duplicative administrative costs. The goodwill created in the Merger&#160;is not expected to be deductible for tax purposes.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming BioScrip had been acquired as of January 1, 2018, and the results of BioScrip had been included in operations beginning on January 1, 2018, the following tables provide estimated unaudited pro forma results of operations for the&#160;years ended December&#160;31, 2019 and 2018 (in thousands). The estimated pro forma net income adjusts for the effect of fair value adjustments related to the Merger, transaction costs and other non-recurring costs directly attributable to the Merger and the impact of the additional debt to finance the Merger. </span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:64.912%"><tr><td style="width:1.0%"/><td style="width:45.746%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.926%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.926%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,755,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,648,694&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70,932)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated unaudited pro forma information is not necessarily indicative of the results that actually would have occurred had the&#160;Merger&#160;been completed on the date indicated or the future operating results.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods subsequent to the&#160;Merger Date&#160;that are included in the results of operations for the year ended December&#160;31, 2019, BioScrip had net revenue of&#160;$308.9 million&#160;and a net loss of&#160;$30.1 million.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related costs were expensed as incurred, with the exception of BioScrip success-based fees that are included in consideration transferred. The Company recorded transaction costs that are expensed in selling, general and administrative expenses during the year ended December&#160;31, 2019 of approximately $25.8 million. Transaction expenses consisted of professional fees for advisory, consulting and underwriting services as well as other incremental costs directly related to the acquisition.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Baptist Health Asset Acquisition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;  In August 2018, pursuant to the Purchase and Sale Agreement dated August 8, 2018, Option Care completed the acquisition of certain assets of Baptist Health in Little Rock, Arkansas for a purchase price of $1.0 million.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Home I.V. Specialists, Inc. Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; In September 2018, pursuant to the Stock Purchase Agreement dated September 18, 2018, Option Care completed the acquisition of 100% of the outstanding shares of Home I.V. Specialists, Inc. (&#8220;Home I.V.&#8221;) for a purchase price of $11.6 million, net of cash acquired. The total consideration was comprised of cash paid of $9.8 million and a contingent payment of $1.8 million payable one year after the acquisition date. During the year ended December&#160;31, 2019, the Company reduced the contingent liability by $0.3 million. During the year ended December&#160;31, 2020, the Company determined that the contingent payment was not payable and reduced the remaining contingent liability by $1.5&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640958859544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">REVENUE <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the net revenue earned by category of payer for the&#160;years ended December&#160;31, 2020, 2019 and 2018 (in thousands): </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.450%"><tr><td style="width:1.0%"/><td style="width:54.437%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.282%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial payers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,542,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,001,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,699,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,032,610&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,310,417&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,939,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640958702008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">EMPLOYEE BENEFIT PLANSThe Company maintains a 401(k) plan and matches 100% of employee contributions, up to 4% of employee compensation. The Company recorded expense for the defined contribution plan of $9.7 million, $6.4 million and $6.3 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. In the years ended December&#160;31, 2020, 2019 and 2018, Company contributions of $8.9 million, $6.6 million and $6.3 million, respectively, were paid.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640960103272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense (benefit) consists of the following for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.356%"><tr><td style="width:1.0%"/><td style="width:54.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.013%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.013%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US federal income tax expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,072)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,072)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,688)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,274)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,653)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the statutory federal income tax rate and the effective tax rate is as follows for the years ended December&#160;31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.356%"><tr><td style="width:1.0%"/><td style="width:54.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.013%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.013%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local income taxes net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred income tax assets and liabilities using the 21% U.S. Federal statutory tax rate were as follows as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.608%"><tr><td style="width:1.0%"/><td style="width:67.029%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.169%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Price concessions</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,907&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest limitation carryforward</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,623&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,749&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,307&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,314&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,085)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109,531)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets net of valuation allowance</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,222&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,783&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,186)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,442)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71,204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,976)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,250)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,679)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128,561)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119,926)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,339)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,143)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Merger, the Company recorded a full valuation allowance against all of its net U.S. federal and state deferred tax assets except for certain state net operating losses (&#8220;NOL&#8221;) which were estimated to be $0.4 million as of December&#160;31, 2020. The initial recognition of this valuation allowance by the Company was reflected in the opening balance sheet of BioScrip and, to that extent, did not impact the Company&#8217;s tax expense (benefit) for the years ended December&#160;31, 2020 and 2019. The valuation allowance for deferred tax assets as of December&#160;31, 2020 was $112.1 million.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. The Company considers the scheduled reversal of deferred tax liabilities (including the effect in available carryback and carryforward periods), projected taxable income, and tax-planning strategies in making this assessment. On a quarterly basis, the Company evaluates the positive and negative evidence in determining if the valuation allowance is fairly stated. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is subject to taxation in the United States and various states. As a result of the Merger, BioScrip carried over $458.9 million of federal net operating losses, $479.6 million of state net operating losses, and $85.0 million of interest limitation carryforwards. At December&#160;31, 2020, the Company had $577.9 million of gross federal NOL carryforwards of which $438.1 million are available to offset future taxable income in the United States. These NOL&#8217;s will begin to expire in 2026 if not utilized. The remaining gross federal NOL&#8217;s of $139.8 million at December&#160;31, 2020 are expected to expire unutilized due to limitations under Internal Revenue Code Section 382. At December&#160;31, 2019, the Company had $548.0 million of gross federal NOL&#8217;s. At December&#160;31, 2020 and 2019, the Company had $154.8 million and $145.6 million of interest limitation carryforwards. At December&#160;31, 2020 and 2019, the Company also had $600.1 million and $578.5 million of cumulative gross state NOL carryforwards available to offset future taxable income in various states. These state NOL&#8217;s will begin to expire starting in 2021 if not utilized.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, the unrecognized tax benefits for uncertain tax positions was $0. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the valuation allowance for deferred tax assets for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.175%"><tr><td style="width:1.0%"/><td style="width:42.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charged (Benefit) to Costs and Expenses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charged to Other Accounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at End Period</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2018: Valuation allowance for deferred tax assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019: Valuation allowance for deferred tax assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020: Valuation allowance for deferred tax assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, the Company is not subject to any U.S. Federal income tax audits. The Company is subject to various state tax audits, and believes that the outcome of these audits will not have a material impact on the Company.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded no income tax expense or benefit for the year ended December&#160;31, 2020 associated with the tax provisions of the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;). However, certain adjustments were made to the Company&#8217;s components of deferred tax assets and liabilities to reflect the tax provisions of the CARES Act. These adjustments were the result of the CARES Act&#8217;s tax provisions associated with interest expense limitations and bonus depreciation on leasehold improvements. These adjustments to the Company&#8217;s components of deferred tax assets and liabilities were offset by one another or the Company&#8217;s valuation allowance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640958833592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(LOSS) EARNINGS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">(Loss) Earnings Per Share</a></td>
<td class="text">(LOSS) EARNINGS PER SHARE<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents basic and diluted (loss) earnings per share for its common stock. Basic (loss) earnings per share is calculated by dividing the net (loss) income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted (loss) earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all dilutive potential common shares.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the&#160;Merger, all historical per share data and number of shares and equity awards were retroactively adjusted. The (loss) earnings is used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. Accordingly, the computation of diluted shares for the years ended December&#160;31, 2020 and 2019 excludes the effect of shares that would be issued in connection with warrants, stock options and restricted stock awards, as their inclusion would be anti-dilutive to the loss per share. As of December&#160;31, 2020 there were 2,285,784 warrants, 412,831 stock options and 549,650 restricted stock awards outstanding that were excluded from the calculation as they would be anti-dilutive. As of December&#160;31, 2019 there were 2,328,120 warrants, 644,975 stock options and 231,562 restricted stock awards outstanding that were excluded from the calculation as they were anti-dilutive. There were no dilutive potential common shares for the years ended December&#160;31, 2018.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s basic and diluted (loss) earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.941%"><tr><td style="width:1.0%"/><td style="width:57.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.808%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss per Common Share: </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss per common share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.49)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640962725896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, the Company adopted ASC 842, Leases, using an optional transition method that permitted application of the standards as of the effective date without requiring the standard to be applied to the comparative periods presented in the consolidated financial statements. The Company elected the transition package of three practical expedients, which allowed the Company not to reassess prior conclusions about lease identification, lease classification and initial, direct costs. The Company did not elect the practical expedient to use hindsight and accordingly, the initial lease term did not differ under the new standards versus prior accounting practice.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020 and 2019, the Company incurred operating lease expenses of $30.8&#160;million and $25.8 million including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the consolidated statements of comprehensive income (loss). As of December&#160;31, 2020, the weighted-average remaining lease term was 6.7 years and the weighted-average discount rate was 5.18%.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands): </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.040%"><tr><td style="width:1.0%"/><td style="width:64.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.059%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,770&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 and beyond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,011&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,662&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company commenced new leases, extensions and amendments, resulting in non-cash investing and financing activities in the consolidated statements of cash flows of $29.1 million related to the increases in the operating lease right-of-use asset and operating lease liabilities, respectively. During the year ended December&#160;31, 2019, the Company did not enter into any significant new operating or financing leases. As of December&#160;31, 2020, the Company did not have any significant operating or financing leases that had not yet commenced.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2018, the Company incurred rent expense of $17.3 million, under ASC Topic 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was included as a component of selling, general and administrative expenses in the consolidated statements of comprehensive income (loss).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, the Company adopted ASC 842, Leases, using an optional transition method that permitted application of the standards as of the effective date without requiring the standard to be applied to the comparative periods presented in the consolidated financial statements. The Company elected the transition package of three practical expedients, which allowed the Company not to reassess prior conclusions about lease identification, lease classification and initial, direct costs. The Company did not elect the practical expedient to use hindsight and accordingly, the initial lease term did not differ under the new standards versus prior accounting practice.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020 and 2019, the Company incurred operating lease expenses of $30.8&#160;million and $25.8 million including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the consolidated statements of comprehensive income (loss). As of December&#160;31, 2020, the weighted-average remaining lease term was 6.7 years and the weighted-average discount rate was 5.18%.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands): </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.040%"><tr><td style="width:1.0%"/><td style="width:64.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.059%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,770&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 and beyond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,011&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,662&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company commenced new leases, extensions and amendments, resulting in non-cash investing and financing activities in the consolidated statements of cash flows of $29.1 million related to the increases in the operating lease right-of-use asset and operating lease liabilities, respectively. During the year ended December&#160;31, 2019, the Company did not enter into any significant new operating or financing leases. As of December&#160;31, 2020, the Company did not have any significant operating or financing leases that had not yet commenced.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2018, the Company incurred rent expense of $17.3 million, under ASC Topic 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was included as a component of selling, general and administrative expenses in the consolidated statements of comprehensive income (loss).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640958833592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment was as follows as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.456%"><tr><td style="width:1.0%"/><td style="width:50.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.481%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.483%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infusion pumps</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equipment, furniture and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software, purchased and internally developed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets under development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211,820&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121,149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133,198&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense is recorded within cost of revenue and operating expenses within the consolidated statements of comprehensive income (loss), depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.941%"><tr><td style="width:1.0%"/><td style="width:48.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.251%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>During the year ended December&#160;31, 2018, one company location was destroyed by a hurricane, resulting in a loss of $0.6 million of property and equipment. A business casualty loss was recorded as a component of operating costs and expenses within the consolidated statements of comprehensive income (loss). During the year ended December&#160;31, 2019, $0.6 million in proceeds were received related to recovery of property and equipment. These proceeds resulted in a gain on business casualty loss of $0.6 million recorded as a component of selling, general, and administrative expenses in the consolidated statements of comprehensive income (loss) during the year ended December&#160;31, 2019. These proceeds were reflected as a component of cash flows from investing activities in the consolidated statement of cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640960793528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text">GOODWILL AND OTHER INTANGIBLE ASSETS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized, but is evaluated for impairment annually in the fourth quarter of the fiscal year, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Circumstances that could trigger an interim impairment test include: a significant adverse change in the business climate or legal factors; an adverse action or assessment by a regulator; unanticipated competition; the loss of key personnel; a change in reporting units; the likelihood that a reporting unit or significant portion of a reporting unit will be sold or otherwise disposed of; and the results of testing for recoverability of a significant asset group within a reporting unit.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A qualitative impairment analysis was performed in the fourth quarter of 2020 and 2019 to assess whether it is more likely than not that the fair value of the Company&#8217;s reporting unit is less than its carrying value. The Company assessed relevant events and circumstances including macroeconomic conditions, industry and market considerations, overall financial performance, entity-specific events, and changes in the Company&#8217;s stock price. The Company determined that there was no goodwill impairment in 2020 or 2019.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A quantitative impairment analysis was performed in the fourth quarter of 2018, and the Company estimated the fair value of its reporting unit using an income approach. The income approach requires management to estimate a number of factors for its reporting unit, including projected future operating results, economic projections, anticipated future cash flows, and discount rates. The fair value determined using the income approach was then compared to marketplace fair value data from within a comparable industry grouping for reasonableness. The Company determined that there was no goodwill impairment in 2018.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of fair value and the allocation of that value to individual assets and liabilities within the reporting unit requires the Company to make significant estimates and assumptions. These estimates and assumptions primarily include, but are not limited to, the selection of appropriate peer group companies; control premiums appropriate for acquisitions in the industries in which the Company competes; the discount rate; terminal growth rates; and forecasts of revenue, operating income, depreciation and amortization, and capital expenditures. Actual financial results could differ from those estimates due to the inherent uncertainty involved in making such estimates. Changes in assumptions concerning future financial results or other underlying assumptions could have a significant impact on either the fair value of the reporting unit, the amount of the goodwill impairment charge, or both.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill consist of the following activity for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands): </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:46.929%"><tr><td style="width:1.0%"/><td style="width:63.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.357%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632,469&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">793,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,425,542&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,428,610&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and accumulated amortization of intangible assets consists of the following as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.538%"><tr><td style="width:1.0%"/><td style="width:47.210%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.752%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross intangible assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483,059&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483,059&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84,295)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(132,007)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(97,149)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351,052&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385,910&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets was $35.1 million, $26.1 million and $19.6 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization expense for intangible assets recorded at December&#160;31, 2020, is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.918%"><tr><td style="width:1.0%"/><td style="width:32.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.903%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and beyond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,052&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640960342360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INDEBTEDNESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text">INDEBTEDNESS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:33.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ABL Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">915,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,710)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">888,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Lien Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,161,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,355)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,823)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124,353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,115,103&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of December&#160;31, 2019 (in thousands):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:33.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ABL Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">925,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,825)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">893,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Lien Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">412,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,864)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,337,256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,071)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,689)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,286,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,277,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retired Debt Obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Prior to the Merger, the Company had two credit arrangements that provided for up to $645.0 million in senior secured credit facilities through an $80.0 million revolving credit facility (the &#8220;Previous Revolving Credit Facility&#8221;), a $415.0 million first lien term loan (the &#8220;Previous First Lien Term Loan&#8221;), and a $150.0 million second lien term loan (the &#8220;Previous Second Lien Term Loan&#8221;, and together with the Previous First Lien Term Loan, the &#8220;Previous Term Loans&#8221;, and the Previous Term Loans, together with the Previous Revolving Credit Facility, the &#8220;Previous Credit Facilities&#8221;). The principal balance on the Previous First Lien Term Loan was repayable in quarterly installments of $1.0 million.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2019, the Company repaid the outstanding balance of Previous Term Loans and retired the outstanding Previous Credit Facilities by entering into two new credit arrangements and a notes indenture, described below under &#8220;New Debt Obligations&#8221;. The weighted average interest rate paid on the Previous First Lien Term Loan was 6.20% for the year ended December&#160;31, 2019, prior to the retirement of the debt obligations. The weighted average interest paid on the Previous Second Lien Term Loan was 11.36% for the year ended December&#160;31, 2019, prior to the retirement of the debt obligations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Debt Obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; In conjunction with the Merger, the Company entered into an asset-based-lending revolving credit facility administered by Bank of America, N.A. The Company also issued senior secured second lien PIK toggle floating rate notes due 2027 (the &#8220;Second Lien Notes&#8221;) under an indenture with Ankura Trust Company, LLC. The two new credit agreements and the indenture were entered into on August 6, 2019 and initially provided for up to $1,475.0 million in senior secured credit facilities through a $150.0 million asset-based-lending revolving credit facility (the &#8220;ABL Facility&#8221;), a $925.0 million first lien term loan (the &#8220;First Lien Term Loan&#8221;, and together with the ABL Facility, the &#8220;Loan Facilities&#8221;), and a $400.0 million issuance of Second Lien Notes. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ABL Facility initially provided for borrowings up to $150.0 million, which matures on August&#160;6, 2024. During the year ended December&#160;31, 2020, the Company increased the borrowing capacity of its ABL Facility from $150.0 million to $175.0 million. The ABL Facility bears interest at a per annum rate initially provided that is determined by the Company&#8217;s periodic selection of rate type, either the Base Rate or the Eurocurrency Rate. Interest on the ABL Facility is charged on Base Rate loans at the greater of Base Rate, as defined, or 0.25% plus 1.25% to 1.75%, depending on the historical excess availability as a percentage of the Line Cap, as defined in the ABL Facility credit agreement. Interest on the ABL Facility is charged on Eurocurrency Rate Loans at the Eurocurrency Rate, as defined, plus 2.25% to 2.75%, depending on the historical excess availability as a percentage of the Line Cap, as defined in the ABL Facility credit agreement. The ABL Facility contains commitment fees payable on the unused portion ranging from 0.25% to 0.375%, depending on various factors including the Company&#8217;s leverage ratio, type of loan and rate type, and letter of credit fees of 2.50%. Borrowings under the ABL Facility are secured by a first priority security interest in the Company&#8217;s and each of its subsidiaries&#8217; inventory, accounts receivable, cash, deposit accounts and certain assets and property related thereto (the &#8220;ABL Priority Collateral&#8221;), in each case subject to certain exceptions, and a third priority security interest in the Term Loan Priority Collateral, as defined below. The Company had no outstanding borrowings under the ABL Facility at December&#160;31, 2020 and 2019. The Company had $9.6 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the ABL of $165.4 million as of December&#160;31, 2020. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal balance of the First Lien Term Loan is repayable in quarterly installments which commenced in March 2020 of $2.3 million plus interest, with a final payment of all remaining outstanding principal due on August&#160;6, 2026. Interest on the First Lien Term Loan is payable monthly on Base Rate loans at Base Rate, as defined, plus 3.25% to 3.50%, depending on the Company&#8217;s leverage ratio. Interest is charged on Eurocurrency Rate loans at the Eurocurrency Rate, as defined, plus 4.25% to 4.50%, depending on the Company&#8217;s leverage ratio. The interest rate on the First Lien Term Loan was 4.40% and 6.20% as of December&#160;31, 2020 and 2019, respectively. The weighted average interest rate incurred was 5.09% for the year ended December&#160;31, 2020. The weighted average interest rate incurred was 6.47% for the period August 6, 2019 through December&#160;31, 2019. Amounts borrowed under the First Lien Term Loan are secured by a first priority security interest in each of the Company&#8217;s subsidiaries&#8217; capital stock (subject to certain exceptions) and substantially all of the Company&#8217;s property and assets (other than the ABL Priority Collateral), (the &#8220;Term Loan Priority Collateral&#8221;), in each case subject to certain exceptions, and a second priority security interest in the ABL Priority Collateral.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Second Lien Notes mature on August&#160;6, 2027. Interest on the Second Lien Notes is payable quarterly and is at London Interbank Offered Rate (&#8220;LIBOR&#8221;), plus 8.75%. The Company elected to pay-in-kind (&#8220;PIK&#8221;) the first quarterly interest payment, due in November 2019, which resulted in the Company capitalizing $12.3 million in interest to the principal balance on the interest payment date. The Company also elected to PIK the quarterly interest payment due in August 2020, which resulted in the Company capitalizing $7.5 million in interest expense to the principal balance of the Second Lien Notes on the interest payment date. In connection with the PIK elections, the Company was charged an additional 1.00% in interest expense on those quarterly interest payments. The interest rate on the Second Lien Notes was 8.98% and 10.66% as of December&#160;31, 2020 and 2019. The weighted average interest incurred was 9.39% for the year ended December&#160;31, 2020. The weighted average interest incurred was 11.45% for the period August 6, 2019 through December&#160;31, 2019.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company completed a public offering of stock for proceeds of $118.9&#160;million. Those proceeds, along with additional cash on hand, were used to prepay $174.0&#160;million of the Second Lien Notes, which is reflected as a cash outflow from financing activities in the Company&#8217;s consolidated statements of cash flows. The Company recognized a loss on extinguishment of debt of $11.5&#160;million, of which $3.5&#160;million related to the prepayment penalty and $8.0&#160;million related to deferred financing fees which were written off upon extinguishment. The $3.5&#160;million prepayment penalty was reflected as a cash outflow from financing activities in the Company&#8217;s consolidated statements of cash flows. The loss on extinguishment was recorded as a component of other, net in the Company&#8217;s consolidated statements of comprehensive income (loss). See Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the public offering.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company assessed whether the repayment of the Previous Term Loans and subsequent issuance of the First Lien Term Loan and the Second Lien Notes resulted in an insubstantial modification or an extinguishment of the existing debt for each loan in the syndication by grouping lenders as follows: (i) Lenders participating in both the Previous Credit Facilities and the new Loan Facilities and Second Lien Notes; (ii) previous lenders that exited; and (iii) new lenders. The Company determined that $226.7 million of the Previous First Lien Term Loan was extinguished and none of the Previous Second Lien Term Loan was extinguished, which is disclosed as an outflow from financing activities in the consolidated statements of cash flows. The Company determined that $752.4 million of new debt was issued related to the First Lien Term Loan and $250.0 million of new debt was issued related to the Second Lien Notes, which is disclosed as an inflow from financing activities in the consolidated statements of cash flows. In connection with the issuance of the First Lien Term Loan, the Second Lien Notes, and the ABL Facility, the Company incurred $52.6 million in debt issuance costs and third-party fees, of which $48.1 million was capitalized, $1.3 million was expensed as a component of other expense and $3.2 million was expensed as a loss on extinguishment as a component of other expense. Further, $21.3 million of the total fees incurred of $52.6 million was netted against the $981.1 million of proceeds from debt as a component of the cash flows from financing activities, $30.0 million was presented as deferred financing costs as a component of cash flows from financing activities, and the remaining $1.3 million was included in cash flows from operating activities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company recognized a loss on extinguishment of debt of $5.5 million, of which $3.2 million related to debt issue costs incurred with the issuance of the Loan Facilities and Second Lien Notes, as discussed above, and $2.3 million related to deferred financing fees on the Previous Credit Facilities, which were written off upon extinguishment. All remaining deferred financing fees related to the Previous Credit Facilities of $7.6 million were attributed to modified loans, which are capitalized and will be amortized over the remaining term of the Loan Facilities and Second Lien Notes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt matures as follows (in thousands):</span></div><div style="margin-bottom:10pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:54.239%"><tr><td style="width:1.0%"/><td style="width:61.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.750%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 and beyond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,115,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,161,531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into an amendment on the First Lien Term Loan, which resulted in an additional $250.0 million of incremental First Lien Term Loan indebtedness being issued, which was used to prepay the remaining $245.8 million outstanding balance of the Second Lien Notes. See Note 19, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated fair values of the Company&#8217;s debt obligations as of December&#160;31, 2020  (in thousands):</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.356%"><tr><td style="width:1.0%"/><td style="width:27.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.675%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instrument</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value as of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Markets for Identical Item (Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Note Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">888,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">913,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Lien Note Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124,353&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">913,461&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,438&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the changes in Level 3 measurements for the year ended December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:68.128%"><tr><td style="width:1.0%"/><td style="width:69.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.442%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3 Measurements</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Lien Notes fair value as of January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal prepayment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(174,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate PIK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Lien Notes fair value as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,438&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640960261096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text">DERIVATIVE INSTRUMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes derivative financial instruments for hedging and non-trading purposes to limit the Company&#8217;s exposure to its variable interest rate risk. Use of derivative financial instruments in hedging strategies subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company&#8217;s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company&#8217;s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2017, Option Care entered into interest rate caps that reduce the risk of increased interest payments due to rising interest rates. The hedges offset the risk of rising interest rates through 2020 on the first $250.0 million of the Previous First Lien Term Loan. The interest rate caps perfectly offset the terms of the interest rates associated with the variable interest rate Previous First Lien Term Loan. Option Care entered into the interest rate caps as a cash flow hedge for a notional amount of $1.9 million. In April 2019, Option Care terminated its interest rate caps and received cash proceeds of $1.7 million, net of early termination fees. In conjunction with the termination of the interest rate caps, Option Care discontinued the hedge accounting associated with the interest rate caps. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company entered into interest rate swap agreements that reduce the variability in the interest rates on the newly-issued debt obligations. The first interest rate swap for $925.0 million notional was effective in August 2019 with $911.1 million designated as a cash flow hedge against the underlying interest rate on the First Lien Term Loan interest payments indexed to one-month LIBOR through August 2021. In accordance with ASU 2017-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Targeted Improvements to Accounting for Hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has determined that the $911.1 million designated cash flow hedge is perfectly effective. The remaining $13.9 million notional amount of the first interest rate swap is not designated as a hedging instrument. The second interest rate swap for $400.0 million notional was effective in November 2019 and was designated as a cash flow hedge against the underlying interest rate on the Second Lien Notes interest payment indexed to three-month LIBOR through November 2020. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company elected to PIK the Second Lien Notes&#8217; quarterly interest payment due in August 2020. Upon making the PIK election, the Company determined that the hedged interest payment would no longer occur, resulting in an ineffective hedge, so the Company discontinued hedge accounting on its $400.0 million notional interest rate swap.  As a result, the Company reclassified accumulated comprehensive loss of $3.7 million to interest expense, net in the consolidated statements of comprehensive income (loss). The gains and losses associated with the $400.0 million notional swap were recognized in net income (loss) through interest expense until the swap expired in November 2020. See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the PIK.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and location of the Company&#8217;s derivative instruments in the consolidated balance sheets (in thousands):</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:44.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.257%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value - Derivatives in liability position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,285&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain and loss associated with the changes in the fair value of the effective portion of the hedging instrument are recorded into other comprehensive (loss) income. The gain and loss associated with the changes in the fair value of the $400.0 million notional swap and the $13.9 million notional amount not designated as a hedging instrument are recognized in net income (loss) through interest expense. The following table presents the pre-tax gains (losses) from derivative instruments recognized in other comprehensive (loss) income in the Company&#8217;s consolidated statements of comprehensive income (loss) (in thousands):</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.754%"><tr><td style="width:1.0%"/><td style="width:58.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.852%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.852%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate caps designated as cash flow hedges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,103)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,723)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps that discontinued hedge accounting</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,746</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,977)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,298)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amount and location of pre-tax income (loss) recognized in the Company&#8217;s consolidated statement of comprehensive income (loss) related to the Company&#8217;s derivative instruments (in thousands):</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"><tr><td style="width:1.0%"/><td style="width:47.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate caps designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,799)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps not designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps that discontinued hedge accounting</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,746)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,579)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to reclassify $11.2 million of total interest rate costs from accumulated other comprehensive loss against interest expense during the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640960413288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASURMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs.  The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements).  The three levels of inputs within the fair value hierarchy are defined in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Lien Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Lien Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the Second Lien Notes is derived from a cash flow model that discounted the cash flows based on market interest rates (Level 3 inputs). See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the Second Lien Notes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate swaps</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair values of interest rate swaps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the fair value of the interest rate swaps. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate caps</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair values of interest rate caps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. In April 2019, Option Care terminated its interest rate caps. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the fair value of the interest rate caps.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other assets or liabilities measured at fair value at December&#160;31, 2020 or 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640960883816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIESThe Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company&#8217;s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized. The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company&#8217;s consolidated balance sheets. However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640958703304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED INCENTIVE COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Incentive Compensation</a></td>
<td class="text">STOCK-BASED INCENTIVE COMPENSATION<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Under the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), approved at the annual meeting by the BioScrip stockholders on May 3, 2018, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors. The 2018 plan is administered by the Company&#8217;s Compensation Committee, a standing committee of the Board of Directors. A total of 4,101,735 shares of common stock were initially authorized for issuance under the 2018 Plan. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Options granted under the 2018 Plan typically vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzgxMA_5835ea03-79c7-4f33-bae1-42d73cd55de9">three</span>- or four-year period and, in certain instances, may fully vest upon a change in control of the Company. The options also typically have an exercise price that may not be less than 100% of its fair market value on the date of grant and are exercisable <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzEwNTU_96670979-bd52-4453-a4dd-ea37a865d80c">seven</span> to ten years after the date of grant, subject to earlier termination in certain circumstances.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense from stock options is recognized on a straight-line basis over the requisite service period. During the years ended December&#160;31, 2020 and 2019, the Company recognized compensation expense related to stock options of $0.4 million and $0.4 million. The Company did not recognize any compensation expense related to stock options prior to the Merger.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value of options granted during the year ended December&#160;31, 2020 was $5.94. The Company did not grant any options during the years ended December&#160;31, 2019 or 2018. The fair value of stock options granted was estimated on the date of grant using a Black-Scholes pricing model. The assumptions used to compute the fair value of options for the year ended December&#160;31, 2020 are as follows:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.350%"><tr><td style="width:1.0%"/><td style="width:49.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.176%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life of options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the year ended December&#160;31, 2020 is as follows: </span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:28.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">644,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(266,065)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(171,007)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">412,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,735&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2 years</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, shares were surrendered to satisfy tax withholding obligations on the exercise of stock options with a cost basis of $2.7&#160;million. During the year ended December&#160;31, 2019, shares were surrendered to satisfy tax withholding obligations on the exercise of stock options with a cost basis of $0.4 million, which are all held as treasury stock as of December&#160;31, 2020. During the year ended December 31, 2020, $0.4 million of cash was received from stock option exercises under share-based payment arrangements. No cash was received from stock option exercises under share-based payment arrangements for the years ended December 31, 2019 or 2018.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum term of stock options under these plans is ten years. Options outstanding as of December&#160;31, 2020 expire on various dates ranging from January 2021 through March 2030. The following table outlines the outstanding and exercisable stock options as of December&#160;31, 2020:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:14.852%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.852%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Option Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.00 - $8.24</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$8.24 - $16.52</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$16.52 - $24.76</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$24.76 - $33.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$33.00 - $41.28</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$41.28 - $49.52</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$49.52 - $57.76</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$57.76 - $66.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$66.00 - $74.28</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">412,831&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,735&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, there was $1.0 million of unrecognized compensation expense related to unvested option grants that is expected to be recognized over a weighted-average period of 1.8 years.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Restricted stock grants subject solely to an employee&#8217;s continued service with the Company generally will become fully vested within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xNjAvZnJhZzpmNGU2MzU2ZTdmZTM0NTgxOTBlYmExNTI3YzAxMGI5Yy90ZXh0cmVnaW9uOmY0ZTYzNTZlN2ZlMzQ1ODE5MGViYTE1MjdjMDEwYjljXzI2Mjc_ef3f1c14-105f-4e27-b582-034c0b01b496">one</span> to four years from the grant date and, in certain instances, may fully vest upon a change in control of the Company. Restricted stock grants subject solely to a Director&#8217;s continued service with the Company generally will become fully vested within one year from the date of grant. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense from restricted stock is recognized on a straight-line basis over the requisite service period. During the years ended December&#160;31, 2020 and 2019, the Company recognized compensation expense related to restricted stock awards of $2.3 million and $1.9 million, respectively. The Company did not recognize any compensation expense related to restricted stock awards prior to the Merger.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock award activity for the year ended December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.801%"><tr><td style="width:1.0%"/><td style="width:48.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.575%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51,687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">549,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, shares were surrendered to satisfy tax withholding obligations on the vesting of restricted stock awards with a cost basis of $0.3 million. During the year ended December&#160;31, 2019, shares were surrendered to satisfy tax withholding obligations on the vesting of restricted stock awards with a cost basis of $2.1 million, of which $2.0 million is held as treasury stock as of December&#160;31, 2019.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $6.0 million in unrecognized compensation expense related to unvested restricted stock awards that is expected to be recognized over a weighted average period of 1.7 years. The total fair value of restricted stock awards vested during the years ended December&#160;31, 2020, 2019 and 2018 was $1.5 million, $1.9&#160;million and $0, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HC I Incentive Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;  Beginning in October 2015, HC I implemented an equity incentive plan for certain officers and employees of the Company. Incentive units are equity-based awards subject to time and performance vesting restrictions. The compensation expense related to this plan has been reflected in the Company&#8217;s financial statements.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, compensation expense is recognized on a straight-line basis over the vesting period of the award or the employee&#8217;s retirement eligible date, if earlier. During the years ended December&#160;31, 2020, 2019 and 2018, the Company recognized compensation expense related to the HC I incentive units of $0.2 million, $1.9 million and $2.1 million, respectively. </span></div><div style="margin-bottom:10pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No awards were issued during the year ended December&#160;31, 2020. The fair value of each award was determined using a Monte-Carlo simulation with the following weighted average assumptions: </span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.707%"><tr><td style="width:1.0%"/><td style="width:54.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average time to liquidity (years) (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Volatility (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount for lack of marketability (4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1.13</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1) Represents the US Treasury security rate for the expected time to liquidity event.</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2) Represents the period of time expected prior to liquidity event.</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3) Based on historical volatility of comparable public companies.</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4) Represents a discount taken to reflect the private nature of the investment.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640960118184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2020, the Company&#8217;s board of directors and HC I, the stockholder of a majority of the Company&#8217;s common stock, approved a reverse stock split of the Company&#8217;s issued and outstanding common stock on a one share for four share basis and appropriately amended the Company&#8217;s Third Amended and Restated Certificate of Incorporation to reflect the change. On February 3, 2020, the reverse stock split became effective. In connection with the reverse stock split, the Company changed its ticker symbol from &#8220;BIOS&#8221; to &#8220;OPCH&#8221; and transferred the Company&#8217;s common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market. The par value of the Company&#8217;s common stock remained unchanged as a result of the reverse stock split, resulting in a decrease to the aggregate par value of common stock and corresponding increase to paid-in capital in the Company&#8217;s consolidated financial statements, which was retrospectively applied to all periods presented in the financial statements. All common shares, warrants and stock awards presented in the consolidated financial statements have been retrospectively adjusted for the reverse stock split. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company completed a public offering of 20,700,000 shares of the Company&#8217;s common stock at a price of $12.50 per share, consisting of 10,000,000 shares of common stock issued and sold by the Company and 10,700,000 shares of common stock sold by HC I. The Company received net proceeds from the offering of $118.9 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. Also, during the year ended December&#160;31, 2020, HC I completed an additional secondary offering of 10,600,000 shares of common stock. Following the offerings, HC I holds approximately 63.6% of the common stock of the Company. The Company used the proceeds from the offering, along with additional cash on hand, to repay $174.0 million on the principal balance of its Second Lien Notes outstanding. See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the repayment of the Second Lien Notes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2017 Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Prior to the Merger, BioScrip issued warrants to certain debt holders pursuant to a Warrant Purchase Agreement dated as of June 29, 2017. In conjunction with the Merger, the 2017 Warrants were amended to entitle the purchasers of the warrants to purchase 2.1&#160;million shares of common stock. The 2017 Warrants have a 10-year term and an exercise price of $8.00 per share and may be exercised by payment of the exercise price in cash or surrender of shares of common stock into which the 2017 Warrants are being converted in an aggregate amount sufficient to pay the exercise price. The 2017 Warrants are classified as equity instruments, and the fair value of these warrants of $14.1 million was recorded in paid-in capital as of the Merger Date. During the years ended December&#160;31, 2020 and 2019, warrant holders exercised warrants to purchase 0.0 million and 0.7 million shares of common stock. No proceeds were received from these exercises as the warrant holders elected to surrender shares to pay the exercise price. At December&#160;31, 2020 and 2019, the remaining warrant holders are entitled to purchase 1.4&#160;million shares of common stock, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2015 Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Prior to the Merger, BioScrip issued warrants pursuant to a Common Stock Warrant Agreement dated as of March 9, 2015 which entitle the holders to purchase 0.9 million shares of common stock. The 2015 Warrants have a 10-year term and have exercise prices in a range of $20.68 per share to $25.80 per share.  The 2015 Warrants were assumed by the Company in conjunction with the Merger and are classified as equity instruments, and the fair value of these warrants of $4.6 million was recorded in paid in capital as of the Merger Date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Home Solutions Restricted Stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; In conjunction with BioScrip&#8217;s 2016 acquisition of Home Solutions, Inc., 1.8 million restricted shares of common stock were issued, of which 0.8 million of these units vest upon the closing price of the Company&#8217;s common stock averaging at or above $16.00 per share over 20 consecutive trading days prior to December&#160;31, 2019 and 1.0 million of these units vest upon the closing price of the Company&#8217;s common stock averaging at or above $20.00 per share over 20 consecutive trading days prior to December&#160;31, 2019. The restricted stock expired on December&#160;31, 2019. As discussed in Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature of Operations and Presentation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 7,048,357 common shares issued to HC I in conjunction with the Merger were set aside to prevent dilution related to the vesting of the Home Solutions restricted stock. During the year ended December&#160;31, 2020, this matter was resolved with no common shares being issued to Home Solutions, Inc., and the 7,048,357 shares, at $0.0001 par value, set aside were cancelled as unvested and removed from the Company&#8217;s common shares issued and outstanding.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treasury Stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; During the year ended December&#160;31, 2019, 290,117 shares were surrendered to satisfy tax withholding obligations on the exercise of stock options and the vesting of restricted stock awards with a cost basis of $2.5 million, of which $2.4 million remains held in treasury as of December&#160;31, 2020 and 2019. At December&#160;31, 2020 and 2019, the Company held 383,722 shares of treasury stock. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; In conjunction with the Merger, all legacy BioScrip preferred stock was settled, and no preferred stock is outstanding as of December&#160;31, 2020 or 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640960199848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED-PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">RELATED-PARTY TRANSACTIONS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; In conjunction with the Option Care acquisition from Walgreen Co. in 2015, the Company entered into two separate Management Services Agreements with Madison Dearborn Partners VI-B, L.P. and Walgreen Co. Each Management Services Agreement required the Company to pay $0.3 million to each party quarterly beginning July 1, 2015 for on-going management, consulting and financial services provided to the Company. Following the close of the Merger, both Management Services Agreements were terminated. The Company did not incur any management services expense during the year ended December&#160;31, 2020. In 2019, prior to the Merger, the Company incurred $1.5 million of management services expense, which has been reflected as a component of selling, general and administrative expense in the consolidated statements of comprehensive income (loss) for the year ended December&#160;31, 2019. During the year ended December&#160;31, 2018, management services expense of $2.0 million was recorded as a component of selling, general, and administrative expense in the consolidated statements of comprehensive income (loss). </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management Equity Ownership Plan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;  In October 2015, HC I implemented an equity ownership and incentive plan for certain officers and employees of Option Care. The officers were able to purchase membership units in HC I and could fund a portion of the purchase with a loan from Option Care. These loans were treated as a shareholder contribution in Option Care. For the years ended December&#160;31, 2020, 2019 and 2018, $0,  $0 and $0.4 million, respectively, were credited to paid-in capital related to HC I membership units purchased with a loan from Option Care. There were no shareholder redemptions during the year ended December&#160;31, 2020.  During the year ended December&#160;31, 2019, shareholder redemptions totaled $2.4 million, comprised of a cash distribution to HC I of $2.0 million and notes redeemed of $0.4 million. There were no shareholder redemptions during the year ended December&#160;31, 2018.  </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2019, prior to the Merger, Option Care sold its notes receivable from management, along with all accrued interest expense, to a third-party bank. Option Care received cash proceeds of $1.3 million, which represented payment of $1.1 million in outstanding notes receivable from management and payment of $0.2 million in accrued interest expense. There were no notes receivable from management outstanding as of December&#160;31, 2020 and 2019. As of December&#160;31, 2018, notes receivable from management and associated interest receivable of $1.6 million are recorded in management notes receivable as a reduction to equity in the Company&#8217;s consolidated statements of stockholders&#8217; equity.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions with Equity-Method Investees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $2.9 million, $2.5 million and $2.2 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Management fees are recorded in net revenues in the accompanying consolidated statements of comprehensive income (loss).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had amounts due from its joint ventures of $2.4&#160;million as of December&#160;31, 2020. The Company had amounts due to its joint ventures of $4.3 million as of December&#160;31, 2019. These receivables were included in prepaid expenses and other current assets in the accompanying balance sheets and these payables were included in accrued expenses and other current liabilities in the accompanying balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories purchased by the Company on behalf of the joint ventures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640958900168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data (Unaudited)</a></td>
<td class="text">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of unaudited quarterly financial information for the years ended December&#160;31, 2020 and 2019 is as follows (in thousands except per share amounts).</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:35.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.102%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">705,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">781,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">804,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,910)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,668)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) earnings per share, basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) earnings per share, diluted</span></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">476,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">615,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">720,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,725)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,712)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42,794)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,811)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss per share, basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss per share, diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net loss in the third quarter of 2019 included transaction expenses, integration costs and loss on extinguishment of debt incurred in conjunction with the Merger.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640960357192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated whether any subsequent events occurred since December&#160;31, 2020 and noted the following subsequent event:</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, the Company entered into an amendment on the First Lien Term Loan (the &#8220;First Lien Credit Agreement Amendment&#8221;). The First Lien Credit Agreement Amendment resulted in an additional $250.0&#160;million of incremental First Lien Term Loan indebtedness being issued and reduced the interest rate on all outstanding First Lien Term Loan indebtedness from LIBOR plus 4.25% to LIBOR plus 3.75%. The proceeds of the $250.0&#160;million incremental First Lien Term Loan indebtedness were used to prepay the remaining $245.8&#160;million outstanding balance of the Second Lien Notes. In connection with the First Lien Credit Agreement Amendment and prepayment of the Second Lien Notes the Company incurred debt prepayment penalties of $4.9 million, third party fees of $1.3 million and original issue discount of $1.0 million. Following the First Lien Credit Agreement Amendment, the First Lien Term Loan is repayable in quarterly installments of $2.9&#160;million plus interest, with a final payment of all remaining outstanding principal due on August 6, 2026. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2021, HC I completed a secondary offering of 17,250,000 shares of the Company&#8217;s common stock. Following the offering, HC I holds approximately 54% of the Company&#8217;s common stock.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640966445896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation &#8212;  The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. The BioScrip results have been included in the consolidated financial results since the Merger Date. All intercompany transactions and balances are eliminated in consolidation.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s accounts receivable is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services, which is inclusive of adjustments for price concessions. The majority of accounts receivable are due from private insurance carriers and governmental health care programs, such as Medicare and Medicaid.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Price concessions may result from patient hardships, patient uncollectible accounts sent to collection agencies, lack of recovery due to not receiving prior authorization, differing interpretations of covered therapies in payer contracts, different pricing methodologies, or various other reasons. In accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span> (&#8220;ASC 606&#8221;), an allowance for doubtful accounts is established only as a result of an adverse change in the Company&#8217;s payers&#8217; ability to pay outstanding billings.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">Inventory &#8212; Inventory, which consists primarily of pharmaceuticals, is stated at the lower of first&#8209;in, first&#8209;out cost or net realizable value basis, which the Company believes is reflective of the physical flow of inventories.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company has lease agreements for facilities, warehouses, office space and property and equipment. Effective as of January 1, 2019, at the inception of a contract, the Company determines if the contract is a lease or contains an embedded lease arrangement. Operating leases are included in the operating lease right-of-use asset (&#8220;ROU asset&#8221;) and operating lease liabilities in the consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, which represent the Company&#8217;s right to use the leased assets, and operating lease liabilities, which represent the present value of unpaid lease payments, are both recognized by the Company at the lease commencement date. The Company utilizes its estimated incremental borrowing rate at the lease commencement date to determine the present value of unpaid lease obligations. The&#160;rates&#160;are&#160;estimated primarily&#160;using a methodology dependent&#160;on the&#160;Company&#8217;s financial&#160;condition, creditworthiness, and availability&#160;of certain observable data. In particular, the Company considers its actual cost of borrowing for collateralized loans and its credit rating, along with the corporate bond yield curve in estimating its incremental borrowing rates. ROU assets are recorded as the amount of operating lease liability, adjusted for prepayments, accrued lease payments, initial direct costs, lease incentives, and impairment of the ROU asset. Tenant improvement allowances used to fund leasehold improvements are recognized when earned and reduce the related ROU asset. Tenant improvement allowances are recognized through the ROU asset as a reduction of expense over the term of the lease.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases may contain rent escalations, however the Company recognizes the lease expense on a straight-line basis over the expected lease term. The Company reviews the terms of any lease renewal options to determine if it is reasonably certain that the renewal options will be exercised. The Company has determined that the expected lease term is typically the minimum non-cancelable period of the lease.</span></div>The Company has lease agreements that contain both lease and non-lease components which the Company has elected to account for as a single lease component for all asset classes. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the term of the lease. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill, Intangible Assets, and Property and Equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company accounts for goodwill under ASC Topic&#160;350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests goodwill for impairment annually, or more frequently whenever events or circumstances indicate impairment may exist. Goodwill is stated at cost less accumulated impairment losses. The Company completes its goodwill impairment test annually in the fourth quarter. See Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Company&#8217;s goodwill and other intangible assets.</span>Intangible assets arising from the Company&#8217;s acquisitions are amortized on a straight&#8209;line basis over the estimated useful life of each asset. Referral sources have a useful life of 15-20 years. Trademarks/names have a useful life ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc0Mjk_9e7f6967-ecc8-4667-930f-df6f18fbc07d">two</span> to fifteen years. The useful lives for other amortizable intangible assets range from approximately <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM5MTNiNjhhNjA0ZTRmZjM4YzQyMzc1ZDNmYTdhMTdiL3NlYzpjOTEzYjY4YTYwNGU0ZmYzOGM0MjM3NWQzZmE3YTE3Yl8xMDAvZnJhZzpiMWM1NWZiM2JmY2E0ZWZjOGQzMmU3YTgzNzIwOGI4My90ZXh0cmVnaW9uOmIxYzU1ZmIzYmZjYTRlZmM4ZDMyZTdhODM3MjA4YjgzXzc1Mjc_c3c88249-a6e5-407f-ae8b-52445dccabe5">two</span> to nine years.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation on owned property and equipment is provided for on a straight&#8209;line basis over the estimated useful lives of owned assets. Leasehold improvements are amortized over the estimated useful life of the property or over the term of the lease, whichever is shorter. Estimated useful lives are seven years for infusion pumps and three years to thirteen years for equipment. Major repairs, which extend the useful life of an asset, are capitalized in the property and equipment accounts. Routine maintenance and repairs are expensed as incurred. Computer software is included in property and equipment and consists of purchased software and internally-developed software. The Company capitalizes application-stage development costs for significant internally-developed software projects. Once the software is ready for its intended use, these costs are amortized on a straight&#8209;line basis over the software&#8217;s estimated useful life, generally five years. Costs recognized in the preliminary project phase and the post-implementation phase, as well as maintenance and training costs, are expensed as incurred.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests long&#8209;lived assets for impairment whenever events or circumstances indicate that a certain asset or asset group may be impaired. Once identified, the amount of the impairment is computed by comparing the carrying value of the respective asset or asset group to its fair value, which is based on the discounted estimated future cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Method Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying consolidated balance sheets. As of December&#160;31, 2020 and 2019, the balance of the investments was $17.0&#160;million and $17.0&#160;million, respectively. The investments are increased to reflect the Company&#8217;s capital contributions and equity in earnings of the investees. The investments are decreased to reflect the Company&#8217;s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company&#8217;s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying consolidated statements of comprehensive income (loss). The Company&#8217;s proportionate share of earnings was $3.3 million, $2.8 million and $1.0 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Distributions from the investees are treated as cash inflows from operating activities in the consolidated statements of cash flows. During the years ended December&#160;31, 2020, 2019 and 2018, the Company received distributions from the investees of $3.3 million, $0.5 million and $2.0&#160;million, respectively. See Footnote 17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions</span>, for discussion of related-party transactions with these investees.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Hedging Instruments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hedging Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company uses derivative financial instruments to limit its exposure to increases in the interest rate of its variable rate debt instruments. The derivative financial instruments are recognized on the consolidated balance sheets at fair value. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span>At inception of the hedge, the Company designated the derivative instruments as a hedge of the cash flows related to the interest on the variable rate debt. For all instruments designated as hedges, the Company documents the hedging relationships and its risk management objective of the hedging relationship. For all hedging instruments, the terms of the hedge perfectly offset the hedged expected cash flows.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Net revenue is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services. Revenues are from government payers, commercial payers, and patients for goods and services provided and are based on a gross price based on payer contracts, fee schedules, or other arrangements less any implicit price concessions.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the health care industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. </span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the expected consideration to be received at the time of patient acceptance based on the verification of the patient&#8217;s insurance coverage, historical information with the patient, similar patients, or the payer. Performance obligations are determined based on the nature of the services provided by the Company. The majority of the Company&#8217;s performance obligations are to provide infusion services to deliver medicine, nutrients, or fluids directly into the body. </span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a variety of infusion-related therapies to patients, which frequently include multiple deliverables of pharmaceutical drugs and related nursing services. After applying the criteria from ASC 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third-party payer contracts. Pharmaceutical drug revenue is recognized at the time the pharmaceutical drug is delivered to the patient, and nursing revenue is recognized on the date of service. </span></div>The Company's outstanding performance obligations relate to contracts with a duration of less than one year. Therefore, the Company has elected to apply the practical expedient provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. Any unsatisfied or partially unsatisfied performance obligations at the end of a reporting period are generally completed prior to the patient being discharged.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenue</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Cost of revenue consists of the actual cost of pharmaceuticals and other medical supplies dispensed to patients, as well as all other costs directly related to the production of revenue. These costs include warehousing costs, purchasing costs, freight costs, cash discounts, wages and related costs for pharmacists and nurses, along with depreciation expense relating to revenue-generating assets, such as infusion pumps.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives prompt payment discounts from some of its pharmaceutical and medical supplies vendors. These prompt payment discounts are recorded as a reduction of inventory and are accounted for as a reduction of cost of goods sold when the related inventory is sold.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also receives rebates from pharmaceutical and medical supply manufacturers. Rebates are generally volume-based incentives and are recorded as a reduction of inventory and are accounted for as a reduction of cost of goods sold when the related inventory is sold.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text">Selling, General and Administrative Expenses &#8212; Selling, general and administrative expenses mainly consist of salaries for administrative employees that directly and indirectly support the operations, occupancy costs, marketing expenditures, insurance, and professional fees.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock Based Incentive Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Based Incentive Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -  The Company accounts for stock-based incentive compensation expense in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 718&#8221;). Stock-based incentive compensation expense is based on the grant date fair value. The Company estimates the fair value of stock option awards using a Black-Scholes option pricing model and the fair value of restricted stock unit awards using the closing price of the Company&#8217;s common stock on the grant date. For awards with a service-based vesting condition, the Company recognizes expense on a straight-line basis over the service period of the award. For awards with performance-based vesting conditions, the Company will recognize expense when it is probable that the performance-based conditions will be met. When the Company determines that it is probable that the performance-based conditions will be met, a cumulative catch-up of expense will be recorded as if the award had been vesting on a straight-line basis from the award date. The award will continue to be expensed on a straight-line basis through the remainder of the vesting period and will be updated if the Company determines that there has been a change in the probability of achieving the performance-based conditions. The Company records the impact of forfeited awards in the period in which the forfeiture occurs. </span>Prior to the Merger, HCI issued incentive units to certain employees of Option Care, who remained employees of the Company following the Merger. In accordance with ASC 718, the Company recognizes compensation expense on a straight-line basis over the shorter of the vesting period of the award or the employee&#8217;s expected eligibility date. HC I also issued equity incentive units to certain members of the Option Care Board of Directors, who remained members of the Board of Directors following the Merger.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Acquisitions</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -  The Company accounts for business acquisitions in accordance with ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span>, with assets and liabilities being recorded at their acquisition date fair value and goodwill being calculated as the purchase price in excess of the net identifiable assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are reported for book-tax basis differences and are measured based on currently enacted tax laws using rates expected to apply to taxable income in the years in which the differences are expected to reverse. The effect of a change in tax rate on deferred taxes is recognized in income tax expense in the period that includes the enactment date of the change. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized. </span></div>The Company recognizes income tax positions that are more likely than not to be sustained on their technical merits. The Company measures recognized income tax positions at the maximum benefit that is more likely than not, based on cumulative probability, realizable upon final settlement of the position. Interest and penalties related to unrecognized tax benefits are reported in income tax expense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock', window );">Concentrations of Business Risk</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Business Risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company&#8217;s largest payer was approximately 15%, 16% and 17% for the years ended December&#160;31, 2020, 2019 and 2018, respectively. In December 2019, the Company renewed and expanded its multi-year contract with this payer. The contract renewal was effective in February 2020 for a two-year term and auto-renews at the end of that term. There were no other managed care contracts that represent greater than 10% of revenue for the years presented.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the years ended December&#160;31, 2020, 2019 and 2018, approximately 15%, 12% and 12%, respectively, of the Company&#8217;s revenue was reimbursable through direct government healthcare programs such as Medicare and Medicaid. As of December&#160;31, 2020 and 2019, approximately 15% and 12%, respectively, of the Company&#8217;s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not require its patients nor other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentrations of credit risk relating to trade accounts receivable is limited due to the Company&#8217;s diversity of patients and payers. Further, the Company generally does not provide charity care.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020 and 2019, approximately 70% and 70%, respectively, of the Company&#8217;s pharmaceutical and medical supply purchases were from three vendors. For the year ended December&#160;31, 2018, approximately  66% of the Company&#8217;s pharmaceutical and medical supply purchases were from two vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company&#8217;s financial condition or operating results. Although there is uncertainty regarding the COVID-19 pandemic, as of December&#160;31, 2020 the Company has been able to maintain adequate levels of supplies and pharmaceuticals to support its operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The fair value measurement accounting standard, ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), provides a framework for measuring fair value and defines fair value as the price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The standard establishes a valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on independent market data sources. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available. The valuation hierarchy is composed of three categories. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The categories within the valuation hierarchy are described as follows: </span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:10pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Inputs to the fair value measurement are unobservable inputs or valuation techniques.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div>FAIR VALUE MEASUREMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs.  The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements).  The three levels of inputs within the fair value hierarchy are defined in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Lien Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Lien Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the Second Lien Notes is derived from a cash flow model that discounted the cash flows based on market interest rates (Level 3 inputs). See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the Second Lien Notes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate swaps</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair values of interest rate swaps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the fair value of the interest rate swaps. </span></div>Interest rate caps: The fair values of interest rate caps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently-Adopted Accounting Pronouncements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;  In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires measurement and recognition of expected credit losses for financial assets held. The amendments in ASU 2016-13 eliminate the probable threshold for initial recognition of a credit loss in current GAAP and reflect an entity&#8217;s current estimate of all expected credit losses. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019 and is to be applied using a modified retrospective transition method. The Company adopted the standard as of January 1, 2020. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Business Risk, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640966581896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock', window );">Schedule of Consideration Exchanged</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, the calculation of total consideration exchanged is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of BioScrip common shares outstanding at time of the Merger (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares issued to warrant and preferred stockholders at time of the Merger (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total shares of BioScrip common stock outstanding at time of the Merger (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BioScrip share price as of August 6, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of share-based instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid in conjunction with the Merger included in purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">714,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,102,001&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: cash acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of total consideration acquired, net of cash acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,087,214&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) These shares were not adjusted for the one share for four share reverse stock split, which occurred on February 3, 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Acquired Identifiable Assets and Assumed Liabilities</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s allocation of consideration exchanged to the net tangible and intangible assets acquired and liabilities assumed, net of cash acquired, in the Merger is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.807%"><tr><td style="width:1.0%"/><td style="width:22.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.608%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net (4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net of deferred tax liabilities (5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset (6)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liability (6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28,897)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable  (7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66,668)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assumed liabilities, net of other acquired assets (7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,663)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total acquired identifiable assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">291,073&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">796,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,087,214&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Management has valued accounts receivables based on the estimated future collectability of the receivables portfolio.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Inventories are stated at fair value as of the Merger Date.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The fair value of the property and equipment was determined based upon the best and highest use of the property with final values determined based upon an analysis of the cost, sales comparison, and income capitalization approaches for each property appraised.</span></div><div style="margin-bottom:10pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The allocation of consideration exchanged to intangible assets acquired is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.771%"><tr><td style="width:1.0%"/><td style="width:53.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Estimated Life (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks/Names</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient referral sources</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193,245&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.8</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company valued trademarks/names utilizing the relief of royalty method and patient referral sources utilizing the multi-period excess earnings method, a form of the income approach.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net deferred tax&#160;assets&#160;represented the expected future tax consequences of temporary differences between the fair values of the assets acquired and liabilities assumed and their tax bases. See Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional discussion of the Company&#8217;s combined income tax position subsequent to the Merger.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The fair value of the operating lease liability and corresponding right-of-use asset (current and long-term) was based on current market rates available to the&#160;Company.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Accounts payable as well as certain other current and non-current assets and liabilities are stated at fair value as of the&#160;Merger Date. </span></div><div style="margin-bottom:10pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The&#160;Merger resulted in&#160;$796.1 million of goodwill, which is attributable to cost synergies resulting from procurement and operational efficiencies and elimination of duplicative administrative costs. The goodwill created in the Merger&#160;is not expected to be deductible for tax purposes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock', window );">Schedule of Allocation of Consideration to Intangible Assets Acquired</a></td>
<td class="text">The allocation of consideration exchanged to intangible assets acquired is as follows (in thousands):<div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.771%"><tr><td style="width:1.0%"/><td style="width:53.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Estimated Life (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks/Names</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient referral sources</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193,245&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.8</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company valued trademarks/names utilizing the relief of royalty method and patient referral sources utilizing the multi-period excess earnings method, a form of the income approach.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net deferred tax&#160;assets&#160;represented the expected future tax consequences of temporary differences between the fair values of the assets acquired and liabilities assumed and their tax bases. See Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional discussion of the Company&#8217;s combined income tax position subsequent to the Merger.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The fair value of the operating lease liability and corresponding right-of-use asset (current and long-term) was based on current market rates available to the&#160;Company.</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Accounts payable as well as certain other current and non-current assets and liabilities are stated at fair value as of the&#160;Merger Date. </span></div><div style="margin-bottom:10pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The&#160;Merger resulted in&#160;$796.1 million of goodwill, which is attributable to cost synergies resulting from procurement and operational efficiencies and elimination of duplicative administrative costs. The goodwill created in the Merger&#160;is not expected to be deductible for tax purposes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Pro Forma Financial Information</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming BioScrip had been acquired as of January 1, 2018, and the results of BioScrip had been included in operations beginning on January 1, 2018, the following tables provide estimated unaudited pro forma results of operations for the&#160;years ended December&#160;31, 2019 and 2018 (in thousands). The estimated pro forma net income adjusts for the effect of fair value adjustments related to the Merger, transaction costs and other non-recurring costs directly attributable to the Merger and the impact of the additional debt to finance the Merger. </span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:64.912%"><tr><td style="width:1.0%"/><td style="width:45.746%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.926%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.926%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,755,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,648,694&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70,932)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640958583384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Net Revenue Earned by Category of Payer</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the net revenue earned by category of payer for the&#160;years ended December&#160;31, 2020, 2019 and 2018 (in thousands): </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.450%"><tr><td style="width:1.0%"/><td style="width:54.437%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.282%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial payers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,542,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,001,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,699,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,032,610&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,310,417&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,939,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640963986744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense (benefit) consists of the following for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.356%"><tr><td style="width:1.0%"/><td style="width:54.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.013%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.013%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US federal income tax expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,072)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,072)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,688)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,274)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,653)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the statutory federal income tax rate and the effective tax rate is as follows for the years ended December&#160;31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.356%"><tr><td style="width:1.0%"/><td style="width:54.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.013%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.013%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local income taxes net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred income tax assets and liabilities using the 21% U.S. Federal statutory tax rate were as follows as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.608%"><tr><td style="width:1.0%"/><td style="width:67.029%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.169%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Price concessions</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,907&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest limitation carryforward</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,623&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,749&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,307&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,314&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,085)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109,531)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets net of valuation allowance</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,222&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,783&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,186)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,442)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71,204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,976)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,250)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,679)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128,561)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119,926)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,339)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,143)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the valuation allowance for deferred tax assets for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.175%"><tr><td style="width:1.0%"/><td style="width:42.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charged (Benefit) to Costs and Expenses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charged to Other Accounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at End Period</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2018: Valuation allowance for deferred tax assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019: Valuation allowance for deferred tax assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020: Valuation allowance for deferred tax assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640958608360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(LOSS) EARNINGS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s basic and diluted (loss) earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.941%"><tr><td style="width:1.0%"/><td style="width:57.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.808%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss per Common Share: </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss per common share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.49)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640960208104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Lease Liabilities, Operating</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands): </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.040%"><tr><td style="width:1.0%"/><td style="width:64.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.059%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,770&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 and beyond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,011&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,662&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Lease Liabilities, Financing</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands): </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.040%"><tr><td style="width:1.0%"/><td style="width:64.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.059%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,770&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 and beyond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,011&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,662&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640960121512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment was as follows as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.456%"><tr><td style="width:1.0%"/><td style="width:50.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.481%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.483%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infusion pumps</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equipment, furniture and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software, purchased and internally developed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets under development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211,820&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121,149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133,198&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.941%"><tr><td style="width:1.0%"/><td style="width:48.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.251%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640964025800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of the Carrying Amount of Goodwill</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill consist of the following activity for the years ended December&#160;31, 2020, 2019 and 2018 (in thousands): </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:46.929%"><tr><td style="width:1.0%"/><td style="width:63.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.357%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632,469&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">793,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,425,542&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,428,610&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock', window );">Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and accumulated amortization of intangible assets consists of the following as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.538%"><tr><td style="width:1.0%"/><td style="width:47.210%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.752%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross intangible assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483,059&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483,059&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84,295)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(132,007)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(97,149)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351,052&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385,910&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense for Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization expense for intangible assets recorded at December&#160;31, 2020, is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.918%"><tr><td style="width:1.0%"/><td style="width:32.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.903%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and beyond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,052&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140641069058904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INDEBTEDNESS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Debt</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:33.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ABL Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">915,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,710)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">888,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Lien Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,161,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,355)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,823)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124,353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,115,103&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of December&#160;31, 2019 (in thousands):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:33.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ABL Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">925,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,825)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">893,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Lien Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">412,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,864)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,337,256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,071)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,689)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,286,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,277,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Long-term Debt Maturities</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt matures as follows (in thousands):</span></div><div style="margin-bottom:10pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:54.239%"><tr><td style="width:1.0%"/><td style="width:61.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.750%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 and beyond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,115,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,161,531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Estimated Fair Values of Debt Obligations</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated fair values of the Company&#8217;s debt obligations as of December&#160;31, 2020  (in thousands):</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.356%"><tr><td style="width:1.0%"/><td style="width:27.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.675%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instrument</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value as of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Markets for Identical Item (Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Note Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">888,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">913,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Lien Note Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124,353&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">913,461&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,438&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the changes in Level 3 measurements for the year ended December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:68.128%"><tr><td style="width:1.0%"/><td style="width:69.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.442%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3 Measurements</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Lien Notes fair value as of January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal prepayment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(174,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate PIK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Lien Notes fair value as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,438&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640960185016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of Amount and Location of Derivatives in the Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and location of the Company&#8217;s derivative instruments in the consolidated balance sheets (in thousands):</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:44.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.257%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value - Derivatives in liability position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,285&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Schedule of Pre-tax Income (Loss) Recognized in the Statements of Comprehensive Income (Loss)</a></td>
<td class="text">The following table presents the pre-tax gains (losses) from derivative instruments recognized in other comprehensive (loss) income in the Company&#8217;s consolidated statements of comprehensive income (loss) (in thousands):<div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.754%"><tr><td style="width:1.0%"/><td style="width:58.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.852%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.852%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate caps designated as cash flow hedges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,103)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,723)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps that discontinued hedge accounting</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,746</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,977)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,298)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amount and location of pre-tax income (loss) recognized in the Company&#8217;s consolidated statement of comprehensive income (loss) related to the Company&#8217;s derivative instruments (in thousands):</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"><tr><td style="width:1.0%"/><td style="width:47.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate caps designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,799)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps not designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps that discontinued hedge accounting</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,746)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,579)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640962696168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED INCENTIVE COMPENSATION Stock-Based Incentive Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Awards</a></td>
<td class="text">The assumptions used to compute the fair value of options for the year ended December&#160;31, 2020 are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.350%"><tr><td style="width:1.0%"/><td style="width:49.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.176%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life of options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The fair value of each award was determined using a Monte-Carlo simulation with the following weighted average assumptions: <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.707%"><tr><td style="width:1.0%"/><td style="width:54.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average time to liquidity (years) (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Volatility (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount for lack of marketability (4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1.13</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1) Represents the US Treasury security rate for the expected time to liquidity event.</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2) Represents the period of time expected prior to liquidity event.</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3) Based on historical volatility of comparable public companies.</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4) Represents a discount taken to reflect the private nature of the investment.</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the year ended December&#160;31, 2020 is as follows: </span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:28.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">644,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(266,065)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(171,007)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">412,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,735&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Outstanding Options by Exercise Price Range</a></td>
<td class="text">The following table outlines the outstanding and exercisable stock options as of December&#160;31, 2020:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:14.852%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.852%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Option Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.00 - $8.24</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$8.24 - $16.52</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$16.52 - $24.76</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$24.76 - $33.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$33.00 - $41.28</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$41.28 - $49.52</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$49.52 - $57.76</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$57.76 - $66.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$66.00 - $74.28</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">412,831&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,735&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Award Activity</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock award activity for the year ended December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.801%"><tr><td style="width:1.0%"/><td style="width:48.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.575%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51,687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">549,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640958852856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Financial Information</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of unaudited quarterly financial information for the years ended December&#160;31, 2020 and 2019 is as follows (in thousands except per share amounts).</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:35.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.102%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">705,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">781,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">804,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,910)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,668)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) earnings per share, basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) earnings per share, diluted</span></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">476,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">615,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">720,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,725)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,712)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42,794)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,811)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss per share, basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss per share, diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640967184712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 06, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>site </div>
<div>location </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount of debt | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,124,353<span></span>
</td>
<td class="nump">$ 1,286,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_NumberOfServiceLocations', window );">Number of service locations | location</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_NumberOfInfusionSites', window );">Number of infusion sites | site</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bios_OptionCareEnterprisesInc.Member', window );">OptionCare Enterprises, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares converted in merger (in shares) | shares</a></td>
<td class="nump">135,565,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Additional shares issued (in shares) | shares</a></td>
<td class="nump">7,048,357<span></span>
</td>
<td class="nump">7,048,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_BusinessCombinationOwnershipInterestRetained', window );">Ownership retained by shareholders after merger</a></td>
<td class="nump">19.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock and Certain Warrants | OptionCare Enterprises, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased | $</a></td>
<td class="nump">$ 125,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock and Certain Warrants | Common Stock | OptionCare Enterprises, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Additional shares issued (in shares) | shares</a></td>
<td class="nump">864,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">HC Group Holdings I, LLC | OptionCare Enterprises, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of the combined company held</a></td>
<td class="nump">80.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | First Lien Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount of debt | $</a></td>
<td class="nump">$ 575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bios_LegacyHealthSystemsMember', window );">Legacy Health Systems</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_BusinessCombinationOwnershipInterestRetained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Company ownership shareholders retained after merger</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_BusinessCombinationOwnershipInterestRetained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_NumberOfInfusionSites">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Infusion Sites</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_NumberOfInfusionSites</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_NumberOfServiceLocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Service Locations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_NumberOfServiceLocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bios_OptionCareEnterprisesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bios_OptionCareEnterprisesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bios_LegacyHealthSystemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bios_LegacyHealthSystemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140641049734600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled receivables</a></td>
<td class="nump">79,000,000.0<span></span>
</td>
<td class="nump">68,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on business casualty loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">626,000<span></span>
</td>
<td class="num">$ (3,549,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss', window );">Rebate receivable</a></td>
<td class="nump">35,200,000<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in equity-method investees</a></td>
<td class="nump">17,000,000.0<span></span>
</td>
<td class="nump">17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Proportionate share of earnings in equity-method investees</a></td>
<td class="nump">3,313,000<span></span>
</td>
<td class="nump">2,840,000<span></span>
</td>
<td class="nump">1,020,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Capital distribution from equity method investments</a></td>
<td class="nump">$ 3,250,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_BusinessCombinationRenewalTermLength', window );">Renewal term length</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Company's Largest Payer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Governmental Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Governmental Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember', window );">Cost of Goods and Service, Product and Service Benchmark | Medical Supply Vendors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=us-gaap_HurricaneMember', window );">Hurricane</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Insurance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivable', window );">Insurance receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bios_InfusionPumpsMember', window );">Infusion pumps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Referral sources</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Trademarks/Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Other amortizable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Referral sources</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life (in years)</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Trademarks/Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Other amortizable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life (in years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember', window );">Inventories | Hurricane</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Insurance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on business casualty loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_BusinessCombinationRenewalTermLength">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Renewal Term Length</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_BusinessCombinationRenewalTermLength</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130534-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3337-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21B<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080549-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=us-gaap_HurricaneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=us-gaap_HurricaneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bios_InfusionPumpsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bios_InfusionPumpsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140641049505352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 06, 2019</div></th>
<th class="th"><div>Sep. 18, 2018</div></th>
<th class="th"><div>Aug. 08, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,428,610<span></span>
</td>
<td class="nump">$ 1,425,542<span></span>
</td>
<td class="nump">$ 632,469<span></span>
</td>
<td class="nump">$ 627,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Purchase price, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">700,170<span></span>
</td>
<td class="nump">$ 10,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bios_BioScripMember', window );">BioScrip</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 2.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Payment of shares in acquisition</a></td>
<td class="nump">$ 125,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Success-based fees</a></td>
<td class="nump">14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">796,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Net sales since acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Net loss since acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForMergerRelatedCosts', window );">Payments of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price</a></td>
<td class="nump">1,102,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Purchase price, net of cash acquired</a></td>
<td class="nump">1,087,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid</a></td>
<td class="nump">714,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bios_BaptistHealthInLittleRockArkansasMember', window );">Baptist Health In Little Rock, Arkansas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bios_HomeI.V.SpecialistsInc.Member', window );">Home I.V. Specialists, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Payment in settlement of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of outstanding shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Purchase price, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred', window );">Reduction of liabilities incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember', window );">First Lien Term Loan | BioScrip | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Payment in settlement of debt</a></td>
<td class="nump">$ 575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Adjustment To Liabilities Incurred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the reporting period for charges associated with the mergers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bios_BioScripMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bios_BioScripMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bios_BaptistHealthInLittleRockArkansasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bios_BaptistHealthInLittleRockArkansasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bios_HomeI.V.SpecialistsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bios_HomeI.V.SpecialistsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140641049623608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS - Consideration Exchanged (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 03, 2020</div></th>
<th class="th">
<div>Aug. 06, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 05, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of BioScrip common shares outstanding at time of the merger (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,794,586<span></span>
</td>
<td class="nump">176,591,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Fair value of total consideration acquired, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 700,170<span></span>
</td>
<td class="nump">$ 10,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock conversion ratio</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bios_BioScripMember', window );">BioScrip</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of BioScrip common shares outstanding at time of the merger (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,639,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,181,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued to warrant and preferred stockholders at time of the merger (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,458,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">BioScrip share price as of August 6, 2019 (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Fair value of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 354,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Fair value of share-based instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid in conjunction with the Merger included in purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,102,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Less: cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Fair value of total consideration acquired, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,087,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bios_BioScripMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bios_BioScripMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140641049796536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS - Acquired Identifiable Assets and Assumed Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 06, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 1,428,610<span></span>
</td>
<td class="nump">$ 1,425,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 632,469<span></span>
</td>
<td class="nump">$ 627,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bios_BioScripMember', window );">BioScrip</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax assets, net of deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,668)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other assumed liabilities, net of other acquired assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,663)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total acquired identifiable assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">796,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,087,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease obligation assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bios_BioScripMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bios_BioScripMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640962623848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS - Consideration Allocated to Intangible Assets (Details) - BioScrip<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Aug. 06, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total intangible assets, net</a></td>
<td class="nump">$ 193,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Estimated Life (in years)</a></td>
<td class="text">18 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks/Names</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total intangible assets, net</a></td>
<td class="nump">$ 12,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Estimated Life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember', window );">Patient referral sources</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total intangible assets, net</a></td>
<td class="nump">$ 180,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Estimated Life (in years)</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Total intangible assets, net</a></td>
<td class="nump">$ 380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Estimated Life (in years)</a></td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bios_BioScripMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bios_BioScripMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640963669512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS - Pro Forma Financial Information (Details) - BioScrip - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net revenue</a></td>
<td class="nump">$ 2,755,361<span></span>
</td>
<td class="nump">$ 2,648,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (49,566)<span></span>
</td>
<td class="num">$ (70,932)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bios_BioScripMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bios_BioScripMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640963778904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Net Revenue Earned by Category of Payer (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 804,713<span></span>
</td>
<td class="nump">$ 781,609<span></span>
</td>
<td class="nump">$ 740,848<span></span>
</td>
<td class="nump">$ 705,440<span></span>
</td>
<td class="nump">$ 720,779<span></span>
</td>
<td class="nump">$ 615,880<span></span>
</td>
<td class="nump">$ 497,266<span></span>
</td>
<td class="nump">$ 476,492<span></span>
</td>
<td class="nump">$ 3,032,610<span></span>
</td>
<td class="nump">$ 2,310,417<span></span>
</td>
<td class="nump">$ 1,939,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=bios_GovernmentCustomerMember', window );">Commercial payers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,542,985<span></span>
</td>
<td class="nump">2,001,105<span></span>
</td>
<td class="nump">1,699,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=bios_CommercialCustomerMember', window );">Government payers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,067<span></span>
</td>
<td class="nump">285,128<span></span>
</td>
<td class="nump">217,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=bios_PatientCustomerMember', window );">Patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,558<span></span>
</td>
<td class="nump">$ 24,184<span></span>
</td>
<td class="nump">$ 22,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bios_GovernmentCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bios_GovernmentCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bios_CommercialCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bios_CommercialCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bios_PatientCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bios_PatientCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640963227080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution percent of employees' gross pay</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan expense</a></td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Company contributions</a></td>
<td class="nump">$ 8.9<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640962738552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Income Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>US federal income tax expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="num">$ (69)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">996<span></span>
</td>
<td class="num">(3,072)<span></span>
</td>
<td class="num">(2,688)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal income tax expense (benefit)</a></td>
<td class="nump">927<span></span>
</td>
<td class="num">(3,072)<span></span>
</td>
<td class="num">(2,688)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">1,707<span></span>
</td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">199<span></span>
</td>
<td class="num">(1,276)<span></span>
</td>
<td class="num">(1,141)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">State income tax expense (benefit)</a></td>
<td class="nump">1,906<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense (benefit)</a></td>
<td class="nump">$ 2,833<span></span>
</td>
<td class="num">$ (2,274)<span></span>
</td>
<td class="num">$ (2,653)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640966939944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Income Tax Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">US federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local income taxes net of federal tax benefit</a></td>
<td class="num">(29.50%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(29.90%)<span></span>
</td>
<td class="num">(13.40%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation</a></td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Non-deductible compensation</a></td>
<td class="num">(16.30%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent', window );">Changes in uncertain tax positions</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="num">(8.20%)<span></span>
</td>
<td class="num">(2.80%)<span></span>
</td>
<td class="num">(7.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(54.00%)<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">30.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640963086152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DeferredTaxAssetsBadDebtReserve', window );">Price concessions</a></td>
<td class="nump">$ 6,907<span></span>
</td>
<td class="nump">$ 12,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Compensation and benefits</a></td>
<td class="nump">4,058<span></span>
</td>
<td class="nump">3,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Interest limitation carryforward</a></td>
<td class="nump">39,094<span></span>
</td>
<td class="nump">38,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DeferredTaxAssetsLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">22,644<span></span>
</td>
<td class="nump">19,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">155,922<span></span>
</td>
<td class="nump">147,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">8,682<span></span>
</td>
<td class="nump">5,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">237,307<span></span>
</td>
<td class="nump">227,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(112,085)<span></span>
</td>
<td class="num">(109,531)<span></span>
</td>
<td class="num">$ (1,373)<span></span>
</td>
<td class="num">$ (1,263)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets net of valuation allowance</a></td>
<td class="nump">125,222<span></span>
</td>
<td class="nump">117,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DeferredTaxLiabilitiesAcceleratedDepreciation', window );">Accelerated depreciation</a></td>
<td class="num">(12,593)<span></span>
</td>
<td class="num">(10,376)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="num">(17,186)<span></span>
</td>
<td class="num">(15,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(67,127)<span></span>
</td>
<td class="num">(71,204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill', window );">Goodwill</a></td>
<td class="num">(28,976)<span></span>
</td>
<td class="num">(20,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(2,679)<span></span>
</td>
<td class="num">(2,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(128,561)<span></span>
</td>
<td class="num">(119,926)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (3,339)<span></span>
</td>
<td class="num">$ (2,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_DeferredTaxAssetsBadDebtReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Bad Debt Reserve</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_DeferredTaxAssetsBadDebtReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_DeferredTaxLiabilitiesAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Accelerated Depreciation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_DeferredTaxLiabilitiesAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121554379&amp;loc=d3e9972-128506<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121554379&amp;loc=d3e9979-128506<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140641053438216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 112,085,000<span></span>
</td>
<td class="nump">$ 109,531,000<span></span>
</td>
<td class="nump">$ 1,373,000<span></span>
</td>
<td class="nump">$ 1,263,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Interest limitation carryforward</a></td>
<td class="nump">39,094,000<span></span>
</td>
<td class="nump">38,623,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">155,922,000<span></span>
</td>
<td class="nump">147,749,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_IncomeTaxExpenseBenefitCARESAct', window );">Income tax expense (benefit) related to CARES Act</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards subject to expiration</a></td>
<td class="nump">139,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=bios_MergerOperatingLossCarryforwardMember', window );">Merger Operating Loss Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Interest limitation carryforward</a></td>
<td class="nump">85,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=bios_MergerOperatingLossCarryforwardMember', window );">Merger Operating Loss Carryforward | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">458,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">577,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=bios_MergerOperatingLossCarryforwardMember', window );">Merger Operating Loss Carryforward | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">479,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember', window );">Federal Net Operating Loss Carryfowards Available To Offset Future Taxable Income | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">438,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember', window );">Federal Net Operating Loss Carryfowards Available To Offset Future Taxable Income | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">600,100,000<span></span>
</td>
<td class="nump">578,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=bios_InterestLimitationCarryforwardsMember', window );">Interest Limitation Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Interest limitation carryforward</a></td>
<td class="nump">$ 154,800,000<span></span>
</td>
<td class="nump">$ 145,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_IncomeTaxExpenseBenefitCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense (Benefit), CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_IncomeTaxExpenseBenefitCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=bios_MergerOperatingLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=bios_MergerOperatingLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=bios_InterestLimitationCarryforwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=bios_InterestLimitationCarryforwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640966593128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Valuation Allowance for Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward', window );"><strong>Change in Deferred Tax Asset Valuation Allowance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at Beginning of Period</a></td>
<td class="nump">$ 109,531<span></span>
</td>
<td class="nump">$ 1,373<span></span>
</td>
<td class="nump">$ 1,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at End Period</a></td>
<td class="nump">112,085<span></span>
</td>
<td class="nump">109,531<span></span>
</td>
<td class="nump">1,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=bios_ChargedBenefitToCostsAndExpensesMember', window );">Charged (Benefit) to Costs and Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward', window );"><strong>Change in Deferred Tax Asset Valuation Allowance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax asset, additions</a></td>
<td class="nump">1,549<span></span>
</td>
<td class="nump">15,395<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=bios_ChargedToOtherAccountsMember', window );">Charged to Other Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward', window );"><strong>Change in Deferred Tax Asset Valuation Allowance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax asset, additions</a></td>
<td class="nump">$ 1,005<span></span>
</td>
<td class="nump">$ 92,763<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Deferred Tax Asset Valuation Allowance [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=bios_ChargedBenefitToCostsAndExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=bios_ChargedBenefitToCostsAndExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=bios_ChargedToOtherAccountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=bios_ChargedToOtherAccountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640961176072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(LOSS) EARNINGS PER SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Dilutive potential common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">$ 17,839,000<span></span>
</td>
<td class="nump">$ 1,663,000<span></span>
</td>
<td class="num">$ (7,668,000)<span></span>
</td>
<td class="num">$ (19,910,000)<span></span>
</td>
<td class="num">$ (15,811,000)<span></span>
</td>
<td class="num">$ (42,794,000)<span></span>
</td>
<td class="num">$ (13,603,000)<span></span>
</td>
<td class="num">$ (3,712,000)<span></span>
</td>
<td class="num">$ (8,076,000)<span></span>
</td>
<td class="num">$ (75,920,000)<span></span>
</td>
<td class="num">$ (6,115,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,971,000<span></span>
</td>
<td class="nump">156,280,000<span></span>
</td>
<td class="nump">142,614,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per Common Share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share, basic and diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,285,784<span></span>
</td>
<td class="nump">2,328,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,831<span></span>
</td>
<td class="nump">644,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bios_RestrictedStockAwardMember', window );">Restricted Stock Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549,650<span></span>
</td>
<td class="nump">231,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bios_RestrictedStockAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bios_RestrictedStockAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640966583304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease cost</a></td>
<td class="nump">$ 30.8<span></span>
</td>
<td class="nump">$ 25.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term, operating leases</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, operating leases</a></td>
<td class="nump">5.18%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use asset obtained in exchange for operating lease liabilities</a></td>
<td class="nump">$ 29.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Incurred rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140641051418776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 23,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">19,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">15,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">11,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">9,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2026 and beyond</a></td>
<td class="nump">30,168<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">110,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(20,349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 89,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640962716216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 205,639<span></span>
</td>
<td class="nump">$ 211,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="nump">84,490<span></span>
</td>
<td class="nump">78,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">121,149<span></span>
</td>
<td class="nump">133,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">42,766<span></span>
</td>
<td class="nump">31,808<span></span>
</td>
<td class="nump">$ 21,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on business casualty loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">626<span></span>
</td>
<td class="num">(3,549)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=us-gaap_HurricaneMember', window );">Hurricane</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposition of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Insurance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property and Equipment | Hurricane</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Insurance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on business casualty loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Depreciation expense in cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">6,586<span></span>
</td>
<td class="nump">4,179<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Depreciation expense in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">36,180<span></span>
</td>
<td class="nump">27,629<span></span>
</td>
<td class="nump">$ 18,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bios_InfusionPumpsMember', window );">Infusion pumps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">31,678<span></span>
</td>
<td class="nump">30,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bios_EquipmentFurnitureAndOtherMember', window );">Equipment, furniture and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">47,886<span></span>
</td>
<td class="nump">51,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">87,483<span></span>
</td>
<td class="nump">80,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software, purchased and internally developed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">27,799<span></span>
</td>
<td class="nump">34,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Assets under development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 10,793<span></span>
</td>
<td class="nump">$ 14,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3337-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21B<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080549-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=us-gaap_HurricaneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=us-gaap_HurricaneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bios_InfusionPumpsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bios_InfusionPumpsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bios_EquipmentFurnitureAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bios_EquipmentFurnitureAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640960331928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="nump">$ 35,100,000<span></span>
</td>
<td class="nump">$ 26,100,000<span></span>
</td>
<td class="nump">$ 19,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140641072391416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill - net book value, begging of period</a></td>
<td class="nump">$ 1,425,542<span></span>
</td>
<td class="nump">$ 632,469<span></span>
</td>
<td class="nump">$ 627,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">3,068<span></span>
</td>
<td class="nump">793,073<span></span>
</td>
<td class="nump">5,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill - net book value, end of period</a></td>
<td class="nump">$ 1,428,610<span></span>
</td>
<td class="nump">$ 1,425,542<span></span>
</td>
<td class="nump">$ 632,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640964049880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total gross intangible assets</a></td>
<td class="nump">$ 483,059<span></span>
</td>
<td class="nump">$ 483,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Total accumulated amortization</a></td>
<td class="num">(132,007)<span></span>
</td>
<td class="num">(97,149)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total intangible assets, net</a></td>
<td class="nump">351,052<span></span>
</td>
<td class="nump">385,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember', window );">Referral sources</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total gross intangible assets</a></td>
<td class="nump">438,121<span></span>
</td>
<td class="nump">438,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Total accumulated amortization</a></td>
<td class="num">(110,498)<span></span>
</td>
<td class="num">(84,295)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks/names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total gross intangible assets</a></td>
<td class="nump">44,536<span></span>
</td>
<td class="nump">44,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Total accumulated amortization</a></td>
<td class="num">(21,146)<span></span>
</td>
<td class="num">(12,748)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other amortizable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total gross intangible assets</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Total accumulated amortization</a></td>
<td class="num">$ (363)<span></span>
</td>
<td class="num">$ (106)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140641059735528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 32,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">28,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">28,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">28,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">28,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">2026 and beyond</a></td>
<td class="nump">205,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total intangible assets, net</a></td>
<td class="nump">$ 351,052<span></span>
</td>
<td class="nump">$ 385,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140641053512616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INDEBTEDNESS - Summary of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,161,531<span></span>
</td>
<td class="nump">$ 1,337,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="num">(13,355)<span></span>
</td>
<td class="num">(20,071)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs</a></td>
<td class="num">(23,823)<span></span>
</td>
<td class="num">(30,689)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">1,124,353<span></span>
</td>
<td class="nump">1,286,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion</a></td>
<td class="num">(9,250)<span></span>
</td>
<td class="num">(9,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">1,115,103<span></span>
</td>
<td class="nump">1,277,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | First Lien Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">915,750<span></span>
</td>
<td class="nump">925,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="num">(7,253)<span></span>
</td>
<td class="num">(8,399)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs</a></td>
<td class="num">(19,710)<span></span>
</td>
<td class="num">(22,825)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">888,787<span></span>
</td>
<td class="nump">893,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Second Lien Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">245,781<span></span>
</td>
<td class="nump">412,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="num">(6,102)<span></span>
</td>
<td class="num">(11,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs</a></td>
<td class="num">(4,113)<span></span>
</td>
<td class="num">(7,864)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">235,566<span></span>
</td>
<td class="nump">392,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bios_FirstLienTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bios_FirstLienTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bios_SecondLienTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bios_SecondLienTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640951062552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INDEBTEDNESS - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Aug. 06, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,286,496,000<span></span>
</td>
<td class="nump">$ 1,124,353,000<span></span>
</td>
<td class="nump">$ 1,286,496,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Paid-in-kind interest capitalized as principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,525,000<span></span>
</td>
<td class="nump">12,256,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments to extinguish debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,250,000<span></span>
</td>
<td class="nump">2,075,000<span></span>
</td>
<td class="nump">5,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,545,000<span></span>
</td>
<td class="nump">5,469,000<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">981,050,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,689,000<span></span>
</td>
<td class="nump">23,823,000<span></span>
</td>
<td class="nump">30,689,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Fees incurred netted against proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,000<span></span>
</td>
<td class="nump">30,022,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bios_CreditArrangementsEnteredInto2015Member', window );">Credit Arrangements Administered By Bank Of America, N.A. | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">645,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member', window );">Credit Agreements, Entered Into 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_FinancingReceivablePrepaymentPenalty', window );">Prepayment penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableDeferredIncome', window );">Deferred commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member', window );">Credit Agreements, Entered Into 2019 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,475,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">981,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs and third party fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts', window );">Issuance costs expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Fees incurred netted against proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_PaymentsOfDebtIssuanceCostsInvestingActivities', window );">Deferred financing costs, investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member', window );">Credit Agreements, Entered Into 2019 | Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments to extinguish debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bios_CreditArrangementsEnteredInto2015ModifiedLoansMember', window );">Credit Arrangements, Entered Into 2015, Modified Loans | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Credit Agreements, Entered Into 2019 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DebtInstrumentBaseRate', window );">Base rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Net borrowing availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Minimum | Credit Agreements, Entered Into 2019 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee, unused portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Minimum | Credit Agreements, Entered Into 2019 | Senior Notes | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Minimum | Credit Agreements, Entered Into 2019 | Senior Notes | Eurocurrency Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Maximum | Credit Agreements, Entered Into 2019 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee, unused portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Maximum | Credit Agreements, Entered Into 2019 | Senior Notes | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Maximum | Credit Agreements, Entered Into 2019 | Senior Notes | Eurocurrency Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letters of Credit | Credit Agreements, Entered Into 2019 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Undrawn letters of credit issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember', window );">First Lien Term Loan | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember', window );">First Lien Term Loan | Credit Arrangements Administered By Bank Of America, N.A. | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Quarterly installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember', window );">First Lien Term Loan | Credit Agreements, Entered Into 2019 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">925,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Quarterly installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate paid on term loans during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.47%<span></span>
</td>
<td class="nump">5.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective rate on term loans at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments to extinguish debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 752,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember', window );">First Lien Term Loan | Credit Agreements, Entered Into 2019 | Senior Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instruments</a></td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Quarterly installment payments</a></td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember', window );">First Lien Term Loan | Minimum | Credit Agreements, Entered Into 2019 | Senior Notes | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember', window );">First Lien Term Loan | Minimum | Credit Agreements, Entered Into 2019 | Senior Notes | Eurocurrency Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember', window );">First Lien Term Loan | Maximum | Credit Agreements, Entered Into 2019 | Senior Notes | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember', window );">First Lien Term Loan | Maximum | Credit Agreements, Entered Into 2019 | Senior Notes | Eurocurrency Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LienCategoryAxis=us-gaap_JuniorLienMember', window );">Second Lien Term Loan | Credit Arrangements Administered By Bank Of America, N.A. | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate paid on term loans during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LienCategoryAxis=us-gaap_JuniorLienMember', window );">Second Lien Term Loan | Credit Agreements, Entered Into 2019 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate paid on term loans during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.45%<span></span>
</td>
<td class="nump">9.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective rate on term loans at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.66%<span></span>
</td>
<td class="nump">8.98%<span></span>
</td>
<td class="nump">10.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_InterestCapitalizedToDebtPrincipal', window );">Interest capitalized to debt principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Paid-in-kind interest capitalized as principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_PaidInKindInterestAdditionalInterestExpense', window );">Additional interest expense charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments to extinguish debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LienCategoryAxis=us-gaap_JuniorLienMember', window );">Second Lien Term Loan | Credit Agreements, Entered Into 2019 | Senior Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_FinancingReceivablePrepaymentPenalty', window );">Prepayment penalty</a></td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LienCategoryAxis=us-gaap_JuniorLienMember', window );">Second Lien Term Loan | Credit Agreements, Entered Into 2019 | Senior Notes | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LienCategoryAxis=us-gaap_JuniorLienMember', window );">Second Lien Term Loan | Credit Agreements, Entered Into 2019 | Notes Payable | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments to extinguish debt</a></td>
<td class="nump">$ 245,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bios_BankOfAmericaN.A.Member', window );">Bank Of America, N.A. | Revolving Credit Facility | Credit Arrangements Administered By Bank Of America, N.A. | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_DebtInstrumentBaseRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Base Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_DebtInstrumentBaseRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_FinancingReceivablePrepaymentPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Prepayment Penalty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_FinancingReceivablePrepaymentPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_InterestCapitalizedToDebtPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Capitalized To Debt Principal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_InterestCapitalizedToDebtPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_PaidInKindInterestAdditionalInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Paid-In-Kind Interest, Additional Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_PaidInKindInterestAdditionalInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_PaymentsOfDebtIssuanceCostsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Debt Issuance Costs, Investing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_PaymentsOfDebtIssuanceCostsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedAmortizationDeferredFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fee received for commitment to originate or purchase financing receivable where likelihood of commitment being exercised is remote. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6378536&amp;loc=d3e10095-111533<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bios_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bios_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bios_CreditArrangementsEnteredInto2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bios_CreditArrangementsEnteredInto2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bios_NotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bios_NotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bios_CreditArrangementsEnteredInto2015ModifiedLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bios_CreditArrangementsEnteredInto2015ModifiedLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LienCategoryAxis=us-gaap_JuniorLienMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LienCategoryAxis=us-gaap_JuniorLienMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bios_BankOfAmericaN.A.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bios_BankOfAmericaN.A.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640962679816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INDEBTEDNESS - Long-term Debt Maturities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 9,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">9,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">9,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">9,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2025</a></td>
<td class="nump">9,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">2026 and beyond</a></td>
<td class="nump">1,115,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 1,161,531<span></span>
</td>
<td class="nump">$ 1,337,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640962298776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DebtInstrumentChangesInLongTermDebtRollForward', window );"><strong>Debt Instrument, Changes In Long-Term Debt [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Principal prepayment</a></td>
<td class="num">$ (9,250)<span></span>
</td>
<td class="num">$ (2,075)<span></span>
</td>
<td class="num">$ (5,150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest rate PIK</a></td>
<td class="nump">7,525<span></span>
</td>
<td class="nump">12,256<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">1,124,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DebtInstrumentChangesInLongTermDebtRollForward', window );"><strong>Debt Instrument, Changes In Long-Term Debt [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of December 31, 2020</a></td>
<td class="nump">1,124,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | First Lien Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">888,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DebtInstrumentChangesInLongTermDebtRollForward', window );"><strong>Debt Instrument, Changes In Long-Term Debt [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of December 31, 2020</a></td>
<td class="nump">888,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Second Lien Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">235,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DebtInstrumentChangesInLongTermDebtRollForward', window );"><strong>Debt Instrument, Changes In Long-Term Debt [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of December 31, 2020</a></td>
<td class="nump">235,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Markets for Identical Item (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DebtInstrumentChangesInLongTermDebtRollForward', window );"><strong>Debt Instrument, Changes In Long-Term Debt [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Markets for Identical Item (Level 1) | First Lien Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DebtInstrumentChangesInLongTermDebtRollForward', window );"><strong>Debt Instrument, Changes In Long-Term Debt [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Markets for Identical Item (Level 1) | Second Lien Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DebtInstrumentChangesInLongTermDebtRollForward', window );"><strong>Debt Instrument, Changes In Long-Term Debt [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">913,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DebtInstrumentChangesInLongTermDebtRollForward', window );"><strong>Debt Instrument, Changes In Long-Term Debt [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of December 31, 2020</a></td>
<td class="nump">913,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Significant Other Observable Inputs (Level 2) | First Lien Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">913,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DebtInstrumentChangesInLongTermDebtRollForward', window );"><strong>Debt Instrument, Changes In Long-Term Debt [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of December 31, 2020</a></td>
<td class="nump">913,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Significant Other Observable Inputs (Level 2) | Second Lien Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DebtInstrumentChangesInLongTermDebtRollForward', window );"><strong>Debt Instrument, Changes In Long-Term Debt [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">411,119<span></span>
</td>
<td class="nump">411,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DebtInstrumentChangesInLongTermDebtRollForward', window );"><strong>Debt Instrument, Changes In Long-Term Debt [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of January 1, 2020</a></td>
<td class="nump">411,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Principal prepayment</a></td>
<td class="num">(174,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of December 31, 2020</a></td>
<td class="nump">266,438<span></span>
</td>
<td class="nump">$ 411,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Significant Unobservable Inputs (Level 3) | First Lien Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DebtInstrumentChangesInLongTermDebtRollForward', window );"><strong>Debt Instrument, Changes In Long-Term Debt [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Significant Unobservable Inputs (Level 3) | Second Lien Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">266,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DebtInstrumentChangesInLongTermDebtRollForward', window );"><strong>Debt Instrument, Changes In Long-Term Debt [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest rate PIK</a></td>
<td class="nump">7,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Change in fair value</a></td>
<td class="nump">21,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Second Lien Notes fair value as of December 31, 2020</a></td>
<td class="nump">$ 266,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_DebtInstrumentChangesInLongTermDebtRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Changes In Long-Term Debt [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_DebtInstrumentChangesInLongTermDebtRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bios_FirstLienTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bios_FirstLienTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bios_SecondLienTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bios_SecondLienTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640950944408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Nov. 06, 2019</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet', window );">Total interest rate costs expected to reclassify during next 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember', window );">Interest Rate Cap | Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Accumulated comprehensive loss reclassified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="num">$ (300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Accumulated comprehensive loss reclassified</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,799<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Senior Notes | First Lien Term Loan | Credit Agreements, Entered Into 2019 | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Senior Notes | Second Lien Term Loan | Credit Agreements, Entered Into 2019 | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Designated as Hedging Instrument | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet', window );">Proceeds from early termination of hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Designated as Hedging Instrument | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 911,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net gain (loss) reclassified into earnings when interest rate cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LienCategoryAxis=us-gaap_JuniorLienMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LienCategoryAxis=us-gaap_JuniorLienMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640963432296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract', window );"><strong>Fair value - Derivatives in liability position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="nump">$ 11,342<span></span>
</td>
<td class="nump">$ 7,285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Accrued expenses and other current liabilities | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract', window );"><strong>Fair value - Derivatives in liability position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Interest rate swaps</a></td>
<td class="nump">11,172<span></span>
</td>
<td class="nump">1,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Other noncurrent liabilities | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract', window );"><strong>Fair value - Derivatives in liability position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Interest rate swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Accrued expenses and other current liabilities | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract', window );"><strong>Fair value - Derivatives in liability position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Interest rate swaps</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Other noncurrent liabilities | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract', window );"><strong>Fair value - Derivatives in liability position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Interest rate swaps</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bios_AccruedExpensesandOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bios_AccruedExpensesandOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640962589144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Pre-tax gains (losses) on interest rate derivatives recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,977)<span></span>
</td>
<td class="num">$ (8,298)<span></span>
</td>
<td class="nump">$ 1,008<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Total gain (loss) on derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,579)<span></span>
</td>
<td class="num">(332)<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember', window );">Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Pre-tax gains (losses) on interest rate derivatives recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,103)<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Pre-tax gains (losses) on interest rate derivatives recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,723)<span></span>
</td>
<td class="num">(7,195)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax', window );">Interest rate swaps that discontinued hedge accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,746<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest expense | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Gain (loss) location of derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest expense | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Gain (loss) location of derivative instruments</a></td>
<td class="num">$ (3,700)<span></span>
</td>
<td class="num">(12,799)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Gain (loss) location of derivative instruments not designated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax', window );">Gain (loss) location of discontinued derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,746)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Cash Flow Hedge, Discontinuance Before Reclassification And Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from discontinuance of cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640960505432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED INCENTIVE COMPENSATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>May 03, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share (in dollars per share)</a></td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share (in dollars per share)</a></td>
<td class="nump">$ 5.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in period (in shares)</a></td>
<td class="nump">204,928<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Value of shares surrendered to satisfy tax withholding obligations</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of recognition</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Value of shares surrendered to satisfy tax withholding obligations</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of recognition</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Value of shares vested in period</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bios_HCIIncentiveUnitsMember', window );">HC I Incentive Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bios_A2018PlanMember', window );">The 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,101,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Stock | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Value of shares surrendered to satisfy tax withholding obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable range of years</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable range of years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bios_HCIIncentiveUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bios_HCIIncentiveUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bios_A2018PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bios_A2018PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640958818808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED INCENTIVE COMPENSATION - Assumptions Used to Compute Fair Value of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">45.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.53%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140641049556440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED INCENTIVE COMPENSATION - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life at December 31, 2020</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at December 31, 2019 (in shares)</a></td>
<td class="nump">644,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">204,928<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(266,065)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and expired (in shares)</a></td>
<td class="num">(171,007)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at December 31, 2020 (in shares)</a></td>
<td class="nump">412,831<span></span>
</td>
<td class="nump">644,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at December 31, 2020 (in shares)</a></td>
<td class="nump">197,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at December 31, 2019 (in dollars per share)</a></td>
<td class="nump">$ 15.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">13.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">7.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited and expired (in dollars per share)</a></td>
<td class="nump">26.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at December 31, 2020 (in dollars per share)</a></td>
<td class="nump">14.77<span></span>
</td>
<td class="nump">$ 15.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at December 31, 2020 (in dollars per share)</a></td>
<td class="nump">$ 16.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance at December 31, 2019</a></td>
<td class="nump">$ 2,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue', window );">Granted</a></td>
<td class="nump">471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">2,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue', window );">Forfeited and expired</a></td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance at December 31, 2020</a></td>
<td class="nump">1,320<span></span>
</td>
<td class="nump">$ 2,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at December 31, 2020</a></td>
<td class="nump">$ 789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life at December 31, 2020</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life Exercisable at December 31, 2020</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited And Expirations, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140641049764376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED INCENTIVE COMPENSATION - Summary of Outstanding and Exercisable Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsOutstandingAbstract', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (in shares) | shares</a></td>
<td class="nump">412,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsExercisableAbstract', window );"><strong>Options Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (in shares) | shares</a></td>
<td class="nump">197,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeOneMember', window );">0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range limit (in dollars per share)</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range limit (in dollars per share)</a></td>
<td class="nump">$ 8.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsOutstandingAbstract', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (in shares) | shares</a></td>
<td class="nump">9,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 6.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsExercisableAbstract', window );"><strong>Options Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (in shares) | shares</a></td>
<td class="nump">9,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 6.52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeTwoMember', window );">8.24</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range limit (in dollars per share)</a></td>
<td class="nump">8.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range limit (in dollars per share)</a></td>
<td class="nump">$ 16.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsOutstandingAbstract', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (in shares) | shares</a></td>
<td class="nump">345,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 12.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsExercisableAbstract', window );"><strong>Options Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (in shares) | shares</a></td>
<td class="nump">130,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 10.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeThreeMember', window );">16.52</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range limit (in dollars per share)</a></td>
<td class="nump">16.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range limit (in dollars per share)</a></td>
<td class="nump">$ 24.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsOutstandingAbstract', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (in shares) | shares</a></td>
<td class="nump">25,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 22.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsExercisableAbstract', window );"><strong>Options Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (in shares) | shares</a></td>
<td class="nump">25,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 22.61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeFourMember', window );">24.76</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range limit (in dollars per share)</a></td>
<td class="nump">24.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range limit (in dollars per share)</a></td>
<td class="nump">$ 33.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsOutstandingAbstract', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (in shares) | shares</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 30.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsExercisableAbstract', window );"><strong>Options Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (in shares) | shares</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 30.41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeFiveMember', window );">33</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range limit (in dollars per share)</a></td>
<td class="nump">33.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range limit (in dollars per share)</a></td>
<td class="nump">$ 41.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsOutstandingAbstract', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsExercisableAbstract', window );"><strong>Options Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeSixMember', window );">41.28</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range limit (in dollars per share)</a></td>
<td class="nump">41.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range limit (in dollars per share)</a></td>
<td class="nump">$ 49.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsOutstandingAbstract', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (in shares) | shares</a></td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 44.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsExercisableAbstract', window );"><strong>Options Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (in shares) | shares</a></td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 44.16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeSevenMember', window );">49.52</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range limit (in dollars per share)</a></td>
<td class="nump">49.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range limit (in dollars per share)</a></td>
<td class="nump">$ 57.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsOutstandingAbstract', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (in shares) | shares</a></td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 56.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsExercisableAbstract', window );"><strong>Options Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (in shares) | shares</a></td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 56.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeEightMember', window );">57.76</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range limit (in dollars per share)</a></td>
<td class="nump">57.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range limit (in dollars per share)</a></td>
<td class="nump">$ 66.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsOutstandingAbstract', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsExercisableAbstract', window );"><strong>Options Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeNineMember', window );">66</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range limit (in dollars per share)</a></td>
<td class="nump">66.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range limit (in dollars per share)</a></td>
<td class="nump">$ 74.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsOutstandingAbstract', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (in shares) | shares</a></td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 66.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_OptionsExercisableAbstract', window );"><strong>Options Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (in shares) | shares</a></td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 66.52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_OptionsExercisableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options Exercisable [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_OptionsExercisableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_OptionsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options Outstanding [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_OptionsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bios_OptionExercisePriceRangeNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640960953384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED INCENTIVE COMPENSATION - Summary of Restricted Stock Award Activity (Details) - Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at December 31, 2019 (in shares) | shares</a></td>
<td class="nump">231,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">490,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested and issued (in shares) | shares</a></td>
<td class="num">(120,782)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited and expired (in shares) | shares</a></td>
<td class="num">(51,687)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at December 31, 2020 (in shares) | shares</a></td>
<td class="nump">549,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at December 31, 2019 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Shares granted (in dollars per share) | $ / shares</a></td>
<td class="nump">13.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and issued (in dollars per share) | $ / shares</a></td>
<td class="nump">12.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited and expired (in dollars per share) | $ / shares</a></td>
<td class="nump">12.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at December 31, 2020 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 13.26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640960447096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED INCENTIVE COMPENSATION - Fair Value of Awards (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Average time to liquidity (in years)</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">47.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount for lack of marketability</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share (in dollars per share)</a></td>
<td class="nump">$ 1.13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640953634632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 03, 2020</div></th>
<th class="th">
<div>Aug. 06, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 05, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 29, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 09, 2015 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock conversion ratio</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments to extinguish debt | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,250<span></span>
</td>
<td class="nump">$ 2,075<span></span>
</td>
<td class="nump">$ 5,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares surrendered to satisfy tax withholding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock held (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,722<span></span>
</td>
<td class="nump">383,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member', window );">Credit Agreements, Entered Into 2019 | Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments to extinguish debt | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bios_HCGroupHoldingsILLCMember', window );">HC Group Holdings I, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_CommonStockOutstandingPercentage', window );">Percentage of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Additional shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Public Offering | Option Care Health, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Additional shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Public Offering | HC Group Holdings I, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Additional shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Secondary Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Additional shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2017 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchasable through warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_ClassofWarrantorRightSecuritiesExercised', window );">Shares purchased from exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2015 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchasable through warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Common Stock | 2015 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Common Stock | 2015 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bios_OptionCareEnterprisesInc.Member', window );">OptionCare Enterprises, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Additional shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,048,357<span></span>
</td>
<td class="nump">7,048,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Home Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued pursuant to acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bios_RestrictedStockAndStockOptionsMember', window );">Restricted Stock And Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Value of shares surrendered to satisfy tax withholding obligations | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bios_RestrictedStockAndStockOptionsMember', window );">Restricted Stock And Stock Options | Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Value of shares surrendered to satisfy tax withholding obligations | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One | Restricted Stock Units (RSUs) | Home Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued pursuant to acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price threshold (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days threshold | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two | Restricted Stock Units (RSUs) | Home Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued pursuant to acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price threshold (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days threshold | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_ClassofWarrantorRightSecuritiesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Securities Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_ClassofWarrantorRightSecuritiesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_CommonStockOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Outstanding, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_CommonStockOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bios_NotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bios_NotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bios_HCGroupHoldingsILLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bios_HCGroupHoldingsILLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bios_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bios_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bios_OptionCareHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bios_OptionCareHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bios_SecondaryOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bios_SecondaryOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bios_A2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bios_A2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bios_A2015WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bios_A2015WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bios_OptionCareEnterprisesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bios_OptionCareEnterprisesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bios_HomeSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bios_HomeSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bios_RestrictedStockAndStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bios_RestrictedStockAndStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140641053562872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED-PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">$ 500,199,000<span></span>
</td>
<td class="nump">$ 459,628,000<span></span>
</td>
<td class="nump">$ 345,884,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bios_SaleOfNotesReceivableMember', window );">Sale Of Notes Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfNotesReceivable', window );">Sale of management notes receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bios_MadisonDearbornPartnersVIBL.P.Member', window );">Madison Dearborn Partners VI-B, L.P. | Option Care Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to joint ventures</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember', window );">Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedParties', window );">Notes receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember', window );">Management | Sale Of Notes Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfNotesReceivable', window );">Sale of management notes receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">HC Group Holdings I, LLC | Loans Funded For Membership Unit Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts', window );">Amount credited to paid-in capital for membership units sold and funded</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountRedemptions', window );">Shareholder redemptions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid', window );">Cash distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Notes redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Management fee income</a></td>
<td class="nump">2,900,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from joint ventures</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from issuance costs from a share-lending arrangement entered into, in contemplation of a convertible debt offering or other financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 20A<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=SL6757427-112606<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash distribution paid to unit-holder of limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from parties associated with the reporting entity as evidenced by a written promise to pay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total change in each class of partners' capital accounts during the year due to redemptions and adjustments to redemption value. All partners include general, limited and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bios_SaleOfNotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bios_SaleOfNotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bios_MadisonDearbornPartnersVIBL.P.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bios_MadisonDearbornPartnersVIBL.P.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bios_OptionCareAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bios_OptionCareAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bios_LoansFundedForMembershipUnitPurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bios_LoansFundedForMembershipUnitPurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640960691352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 804,713<span></span>
</td>
<td class="nump">$ 781,609<span></span>
</td>
<td class="nump">$ 740,848<span></span>
</td>
<td class="nump">$ 705,440<span></span>
</td>
<td class="nump">$ 720,779<span></span>
</td>
<td class="nump">$ 615,880<span></span>
</td>
<td class="nump">$ 497,266<span></span>
</td>
<td class="nump">$ 476,492<span></span>
</td>
<td class="nump">$ 3,032,610<span></span>
</td>
<td class="nump">$ 2,310,417<span></span>
</td>
<td class="nump">$ 1,939,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">183,762<span></span>
</td>
<td class="nump">174,153<span></span>
</td>
<td class="nump">166,320<span></span>
</td>
<td class="nump">158,029<span></span>
</td>
<td class="nump">175,642<span></span>
</td>
<td class="nump">137,773<span></span>
</td>
<td class="nump">101,390<span></span>
</td>
<td class="nump">98,194<span></span>
</td>
<td class="nump">682,264<span></span>
</td>
<td class="nump">512,999<span></span>
</td>
<td class="nump">422,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">44,343<span></span>
</td>
<td class="nump">34,556<span></span>
</td>
<td class="nump">23,208<span></span>
</td>
<td class="nump">8,648<span></span>
</td>
<td class="nump">13,973<span></span>
</td>
<td class="num">(11,725)<span></span>
</td>
<td class="num">(8,005)<span></span>
</td>
<td class="nump">5,438<span></span>
</td>
<td class="nump">110,755<span></span>
</td>
<td class="num">(319)<span></span>
</td>
<td class="nump">38,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">$ 17,839<span></span>
</td>
<td class="nump">$ 1,663<span></span>
</td>
<td class="num">$ (7,668)<span></span>
</td>
<td class="num">$ (19,910)<span></span>
</td>
<td class="num">$ (15,811)<span></span>
</td>
<td class="num">$ (42,794)<span></span>
</td>
<td class="num">$ (13,603)<span></span>
</td>
<td class="num">$ (3,712)<span></span>
</td>
<td class="num">$ (8,076)<span></span>
</td>
<td class="num">$ (75,920)<span></span>
</td>
<td class="num">$ (6,115)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">(Loss) earnings per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">(Loss) earnings per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140640962403912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 06, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments to extinguish debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,250,000<span></span>
</td>
<td class="nump">$ 2,075,000<span></span>
</td>
<td class="nump">$ 5,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,355,000<span></span>
</td>
<td class="nump">20,071,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bios_HCGroupHoldingsILLCMember', window );">HC Group Holdings I, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_CommonStockOutstandingPercentage', window );">Percentage of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member', window );">Credit Agreements, Entered Into 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_FinancingReceivablePrepaymentPenalty', window );">Prepayment penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member', window );">Credit Agreements, Entered Into 2019 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,475,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member', window );">Credit Agreements, Entered Into 2019 | Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments to extinguish debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member', window );">Credit Agreements, Entered Into 2019 | First Lien Term Loan | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">925,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments to extinguish debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Quarterly installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member', window );">Credit Agreements, Entered Into 2019 | Second Lien Term Loan | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments to extinguish debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | HC Group Holdings I, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_CommonStockOutstandingPercentage', window );">Percentage of outstanding common stock</a></td>
<td class="nump">0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock | Secondary Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">17,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Credit Agreements, Entered Into 2019 | First Lien Term Loan | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Quarterly installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Credit Agreements, Entered Into 2019 | Second Lien Term Loan | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_FinancingReceivablePrepaymentPenalty', window );">Prepayment penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bios_DebtInstrumentThirdPartyFees', window );">Third party fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Credit Agreements, Entered Into 2019 | Second Lien Term Loan | Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments to extinguish debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_CommonStockOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Outstanding, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_CommonStockOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_DebtInstrumentThirdPartyFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Third Party Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_DebtInstrumentThirdPartyFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_FinancingReceivablePrepaymentPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Prepayment Penalty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_FinancingReceivablePrepaymentPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bios_HCGroupHoldingsILLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bios_HCGroupHoldingsILLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bios_NotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bios_NotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LienCategoryAxis=us-gaap_JuniorLienMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LienCategoryAxis=us-gaap_JuniorLienMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bios_SecondaryOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bios_SecondaryOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>95
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MR6+U;+-9(V%JK$K6P< @$7+USU[6B=@):'E[ N@Z@+X)\/>U$*P#@JH!S75
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M$A;'Y#(U<-L4]^/_VQ[07/=II0U"/^%ZZH;65T"P,W"C9,YD<>)PP#)J06X
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M^D"R.K%JGGTR&"MK59(=SCB#J>T>@/L3I>SFQ#6P_4QU\2]02P,$%     @
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M?<N %\*?Q)O:\8X,DQE#J&YN(\QRU,UM@!V"J@&5<QXU#_K7C4VD#_ ^<K3
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M L3O*RH>>XH3^8%E_]GQ_&]02P,$%     @ C(1K4LR^"TD#"0  *!8  !@
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MR*%.K4+7W;HSQ@T="WS*B;ESEFD." ]Q,F"Y3?\/QS%BGO:XX[8GKPQF85C
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MG$Q[PH9[R?#@3<5W@0OCO2GX)QHJ9B]:@.]+ ^_$!U+07@Z?_P]02P,$%
M  @ C(1K4DA&OVS7'@  K6(  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6S-7?MSVT:2_E=0ON1NMXJ2)3E^Y%DERW'BK3AVQ4ZVKJ[N!Q 8DA.#&&8
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MRR$X"?6[$>AKZ[B>D*BPJULYW/-A!Z!R7F,Y.4(JK(]MS!1]67,=E.:V73C
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MZ<:9P':.J^TG'U(Z;&IL.*JK(>(>X>$KA0.Z4A]:Z[KO=]_SSN_I_(LG_=4
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M:VTV-IKMP+3AN7 #R/,AX\BYS L',B#4#$$O:=C*V6;'9T*Y<:'?)!WHUDU
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ME$'>0+\OC/&;%W;0?R2^^ =02P,$%     @ C(1K4BY&E),Z!   Q D  !D
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M]X:\ES?<\N5<JRUH=YK8W,"'ZM'DG)#N4CY;3;N"<':YNO]]=7O_\!4N/]W
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M6&&0K#Q.RT1<PIZ1RUPN9,PI3\E::"/J**ILS4N#(AIXD$IPBZ"H4[%$JA:
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MVZ[47ED2CQ8?/@$4 94@86WQQF:I.&N5KCV9H?SDKBF1ET8##D4[1FX7&"6
MFMQUBF_P8__J&0^3F ZIFU#[.LC_%5^+@QE.71/C;(&SH70*3H_)0^9R39.Y
MJE4[3O4A1HQ>"G<>G<.]O0A)IAFF.U6-&C?I3*-^H="B&[>7WB_I/$+HHT=T
MYL7YF5Z &%Y?A&/?^A4F\,>%ZMPP8>?.M"H-5LR[2W;'4QJ5#!U_(!N.V1D;
M1>.@/XT C!;*AT%O/'Y+<D*2_2@8C*;[DN-I'[+]MV2GD V#030,AH.(?2DU
MDNA.IJY'7 *2O]!=F3M90-UH\H8ZC%VO;A*,PI[CP\.DN_[ &T%&YUNQWRMN
M8N[>FRK^JTIC3M3&K1W[T!S;#M-_O/4X'Q\TG:B/W+AD7P6Z$<<?''.1)L#J
MC WZDR",PM;5L^:)H$%ENCG/L&DP"(;]4?WCWPWKF/U\.HQWT(O<W[.RGI9.
MN<,&$Q1C.&U^9Z_D](3?YV'8"P;3R3MV/AD$T73X[MCM\R@,PL$(6\(H& ^P
M]T=</^^/^B32@Z!W_]52GX= ;*\WQO;I&*:FM<21UH#E.(J>L?XP1*0174V&
MP13XFK45.FHU?DH<>T;C^ZP_O A9AG9WO'P6C7:W#C-G."Z.FI7_I^$#HLA"
MN&]2Z?:"/7PO]LY9_,<]IM<A339/M5E KPK<5+U@CH"./81*2G$XI+N(H2?[
M_0E=]UO7@];UL'4]<B'-Q5:YR(;!:#*L"K2KQ*DO)]W61ZM,@(_ITYR;"+GU
MWZ^:U>;KW\Q_]-IM]Y\.?P.=RYQ>B180[5V,AQVF_><X?V-5X3Z!@>VMRMSE
M2@#(FC;@^4(I6]^0@>:;Z.T_4$L#!!0    ( (R$:U)#2>8RG@\  /\T   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;,U;Z7/;N!7_5S"NMV//,+1(
MW;EF;,>9NG423Y+=3J?3#Y (2=A0I *0=K1_?=][ $GPDH_=3O=+0DO PSM_
M[R#T^CY5W_1&B(S]V,:)?G.TR;+=R[,SO=R(+==^NA,)?+-*U99G\*=:G^F=
M$CRB3=OX+!P,)F=;+I.CMZ_ILUOU]G6:9[%,Q*UB.M]NN=I?B#B]?W,4'!4?
M?);K388?G+U]O>-K\45D/^]N%?QU5E*)Y%8D6J8)4V+UYN@\>'DQPO6TX!<I
M[K7SS%"219I^PS^NHS=' V1(Q&*9(04._]V)2Q''2 C8^&YI'I5'XD;WN:#^
MGF0'619<B\LT_J>,LLV;H]D1B\2*YW'V.;W_F[#RC)'>,HTU_<ONS=IP>L26
MN<[2K=T,'&QE8O[G/ZP>G VS0<^&T&X(B6]S$''YCF?\[6N5WC.%JX$:/I"H
MM!N8DPD:Y4NFX%L)^[*WUQ_?75U\O7KW\>K+E]=G&5#$S\^6=O>%V1WV[ Y"
M]B%-LHUF5TDDHCJ!,V"EY"<L^+D(#U)\)Y8^&P8>"P?AX "]82G?D.@->^DM
M,O9.ZF6<ZEP)]N_SA<X4^,)_#A ?E<1'1'S4ISP0>I&)*!%:=RGO@=V.ZME-
MFJQ?9$)M&9)DRQ3<7@-IEJY8MA%LE<80/S)9,Z[Q,]"3V"Z$*G7%3F0"*]-<
M\R32IR_9K9+)4NYXS,ZW:9X8+9@'/.%:ZYPG2\$N4YUI]A'B_X+'],GYQ0U[
MSY<REMF>';.__F46!N&K!Y[>2Z4S=B-%PKZB&#<I3]@\&'O3,? V]<+Q\)2=
M!'-O&@Q.V6PV\Z:S*?LB0-+(;/N89D*S< 1;9@$[F7C!((0M(R\(8&LX''OC
MR01.#+Q@$GCC80#/)\'0&X['I_@8#KU9""OA^W $GP[9#=CE)4214@+$WJ6*
M@.!D#LP #U_3#)03UQ5/Y('K8##\O38)YG].FX1C;S  F\R\X7P."@Y#T!NH
M<#8?>M/II,,FHR $E4U VX$WF:)1IMYL,CIEPWGH3<'W4&O#X906H24&WF :
MD%&& V\RFZ-1PMG$&\TGSS5*. 7RHPG[+#*IP :DL$^+6*XY$M"ET*#C5+$L
M)1-]$&HME$?/E^EVQY,]V_"(9?<I6P(9F3&N%$_6 A(-J#S;<.!)I7<2X P,
MK%B^0UK'D]'8'P  QS%R"V;5(L%SM !)8*DEMC(FD@))J31?;QBH_'@V<#8K
M<9?&=^@V]4U[=H)LHASAX-4M+)/@.2!PL?S2+"_<@!8&KTX]QMGQ*'#Y6Y'A
M8[0@:3%&PW=2[W(1AS#X 1 /QB[_VOC'8ZB[KM0D;ZAGZ5K 3@5I+]N0F0ZR
M9BS9/*;\6M=IN]2J-=ZA0WNUW7UR?1&8O="=S[["\ET9[PL;QVGRL)#L'O!$
MB1W?\T4LT-F^YUR!JN,]_*$A0&+CK8 YQT%E&9]]2MAYOH:J@4T, M4]'VE*
MHQ>HSX!0$J&D)6^K+G61*I6-NN;6?D6PQ9X!DT+A,IE@/$+,)5"F=<6=<;2$
MT$9"5DTRB"H/HE\OE5S P0LL'UD.7ZG""!^!5A,%K/J-]N^I)(/-_$XHJ#"1
M#:$$:$?Q#(R#NGBT/29^./B)$ '7[P57(%Y$0-1 ?0_-7D&041V*6>0-PK2T
M8OHA;CL9[0PMXC0(_.'D?\9JE]9+[+U.,$O^FB>FY"[#JPN&R3F *?(-8)UK
M+;(76&%'+V)AW*L?*GD$Q3!F8R0!KG;!DV_(]/D6/&[)/?;1/S=Z+<[CL4Z9
MA P+&QK@[2+:[?4_$!_6$'@K +:,V$!W,<X9Y0++K6D-[UH9LT !Z[ \J9S:
M*.4\^98KSKXJC%7+H<=N;BX-S\U062OA! J>[- #%=25F391@':!NC()T+'O
MS&^!-YH^.\,U,\333.EJTBUS:OD-JI:GY+<#::TO[[A'U\"> JN-\&5V' U<
MV651PX$SMOS"6+=6R_6899$J1;6E+BWDJMAC]QNYW$ GB#Z@FR8/1SY[EQ/T
M'H8 J-1J00GI"EI[;9&^9((M^0X8!G9!*@EN6!-AI=)MTP6(8]>C.D1? %NZ
M@CFHO#C;4;@D^=8$78=VJ$23$(D"30\]%<6_(P2!T?251EHRC>2254, 8)_H
M9OL=I!<AR05P[P4(S3[C5Q8VKW*5FB)UN:<O?$ WRZG%XKH=-5MN., <075%
M+C8Y-*,=$,?PF4(VRA4>=@^16*$D'IX^\,/Q3VP7 \@'] BZ#/SI^"?,ASL;
M3I:%#4!@BH 7,_%C"94U9 \N8[ZP**F-2I> #YA2+*K?P%GLDN_<HYGL$*J)
M/T_204N#13V1=2NXK@B2/RSD#_\L\K><&"(\XU"5P<-V*S-*GBL!(5F4;Y;3
M/,DQK(I^!VL?E(-B9U"(.?"';3GON**,#X )LF+ +.,\*F*[Z?2QL.6#PMSL
MD:>CW 215,I5_H]_QB*S'EG@,C(/?X;^>/"3SRX<(*)DUE(2A_Q3) F(1&[1
MF2H+_)Z^,U!G?<>JNLDZLB,XH)H%&9TOM(PDB&]0%Q;!UCO0<*H HOF26F<L
ME9="WJ&R/0 JO2']I1H-5RQ!TDNAT%(F.YF/ %3 .S*LC&.>&=2#(BAMY:3;
M0IA+Z/DQA'E<Y0&@26PO,:2!Z5\!;-":Q8'HF3LJE(J<D6VDBAZAH:JPZV"@
MYKU4']<+'NQSD[1>Z3]LS*QCM(1,8QW1IG\\]R<EYH/9@*KB]XGU*NVXE:V\
MD)3#D0>:UWF<F28!:I[,23JU4*[S2YW/9.R/G)JC<RS6VX<9).@L]^7CNB^3
M@3'L <(,@'S@"CXBG2&'H3\L^2,\*^SKF;(#0R4!IN"LHN@&ZG X3M,I^AW;
M53)@#=I,^),V-/?)5DBVQ<DM"-6=KGKR$XDQ+/!JB!C1 <N'0<EA]:&,$3\U
M8XP*UD;/9.WKIMDG'E(G]ELC?P2=(3JVZ1'[!K1%%)'/[P2]CHCWCVI5P?(H
M=T3G05$U?TQ[5SC_4VA/_-&THFT*J&8S493]K6[2MU--;6,8:%91VZF^9Z6.
M(D5T6;,K94#M*G&H")7"\AL[.0C0IV0EI )A9RM/#,F>X\K\0;!N\LI):HM*
M7A44'>@-><--,@>1_O>D&MO;/IQK>O@T/M2>"9O.HX5#TS8.M?<Z(%1A*_6H
M%.LWL!SV$IT%]O6?5BOJ;@D23HJV[/KBT^=*,Q3],RP3ZUF*2G_,["F>^4(F
M+[Y![UQ2@7:_;-9IID\.Z")^.80AC/8(?25*<F>\WX2T208FF57%9,&$=4'Y
M&P+1<>#F!9E49]@Q3._4L,D,BZ@O:4TY')EIG+$1!R0J!+)F-#WA4\29^N-.
M:<0/@%YPTWZI5CW^<5A<,V1*1&/&A)(6?9ZN=[6(;$6:0=2)H""!5<!*X \
ML;NX)AY2?4AS^D"V: N%3,S\^<RDBF#@3R8/YXJ'$+P&WG-_^ <EAAK9(/!'
MX]^1%)XUB("R:@=%)#+'=ODBABX^112@3+ZR6(XL 00OA8CL,#P #;L3!S1@
ML0(0$=\KV=*K\@%L&=!L -A01= XC5HU1 RJ W&2,7)F&WU^6X0-U8\K&X/4
M@IHC\FR%0VQJ^;#P@W# *A<+ 3-0Z^F+\,5C&LN(.A1(3)DHQ_]$&*GJ.@Q
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;*U9;6_;.!+^*X0O."2
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MQ!>N)9_% M18H86Q3',KF);FN<>>C&!JOM\LF59680*L6&!F3#[[ TK:U.U
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M\(FJ\![NNI6->O?=FMTRWNKCN6)"NOIN=C<?#K-T7_XBGKXZKI5;XFS",5]
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MJB;KP#^K*6H=_XY^5\^I"2"DY5TF9[S)?C;N1&ORK7 E0(1@4L*;FUR.A!E
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MM >S^\W!;,B.A_%D.CPX/.X? !M6@_UN]GVA1!W.#,X8W,C,'WKI($<$)SV
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MH(ZUHV/??^9TST+#!C2?:2KR]H<7Z&YN\W\!4$L#!!0    ( (R$:U)3O@B
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M_G#Q]N+\[,.7[.S\_./7#U\N/OR<??KX[N+\XLUE=O^3J72AE?OA^4D#6R.
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M)\$*/!E5X LP3G5C[&Y(]^^X-&A\^,:K$&FF [R!&Q#&ZXJT8@NBMLD+U39
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M<"K!3K-X6>V^A7+MCLN\-"7%HS=89R960>2Y+;UO&M93>!X]L_,-GJJ7WF*
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MBY=.0MB&]4-_<US X]UNR*3!.>#\Q=>!DR8HI?-PPZ%G(A809[2-5.6+!OW
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MEGK/#G"0;46T!=LJ+\29X8O@J!2&K[NB; QO.H776(B8>F[\"WJ>W??V):4
MO[YFI:_\2QC8. 9L\.4R Q)YWTMV!Q8?DVUV#'%E26(>$][U[>.2^ #/T2S\
M?))=\MM=$=!E8IH'WJ[Y_^IP=W7 =V1E[R#ES[Y@V?&= 8OXM!^12U([^+"6
M>QE8\<"<-<\6UGP#0I' 1E>;UZ&'Z'9\6Y-F';RO8>'X(;W_,,/W)^ U#%52
M3?NV^_W]^UQT.>Q.I\!=,6'DKW%W=Y *^T_NDR#<(I+Y!QG5"7<W&5M_TRA&
M)2)<G=LIB8[]G]%H[XQ8-$]OS+CK?+M/(M'R_0=9I1,24;.Y>TK(%_F-E5Y,
MA!B$(=]PY8Y;K(B!?KD]./L2U:GVI3WV(?:FEQ4#7WIA"9\@-CU8XMV=[N[<
MRJ$AE/8H.MZ2BE=\Y^/7<O%-G#T;:DUM6GE_UG %X"X@J]WQ66GH7;X'@2>O
M LS^V8(9G)_.9'(<WX\(:N7P-4UGEU_IE^/9@TGREL6A&V/G7"%]QX6D^_(>
MEOFC'YYV*@/X"M[.DT#\8<#QQ6A4&G9=DTKU\'BA2097^)X&PY>2%C$\;"!.
M>:W\3&@.X,IPRSDY;WP%;C+PP0T/Y>@=&9QG\WNK>KCD*1)T?5JN+N/KDP5Y
MSA3QQ7EXASJ9II)'?3V=X%75@?--.SCKM-?%^.$% 6EIT4M?$C?$_6Q,P5>Z
MIEY"3G<,0F5M]C#I)FG_DEMZX4.L=J"9I:O[ +FQ)ERVIRJ+3CQ];PA71+1)
MBQL#[RZ<GPJC2A/>6TA-O["HU"6E&G09".LV=">B"@,UPZ^!N_U-@$-:?I*\
MDWV#[U?&-\]34% W_'KV\&WFWVY_QN]TCX_SJ_'?YW:%KTZLU!*6GDX?/SSB
M=PGZ#XW9TAO>%Z9IS(;^7*L<3#D^ +\O#5@[^8 ;A'?^O_Q?4$L#!!0    (
M (R$:U*$%:*FW@@  '\;   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM
M;.U9:V_;.!;]*X0W6#B 8EOR2^XF 9(^9K-HT\ZDG<%BL1]HB;(YE40/2<7)
M_/HYEY1D.7&,[+?]4*!H9)&\+YY[[B5UOE7ZNUD+8=E#D9?FHK>V=O-F.#3)
M6A3<#-1&E!C)E"ZXQ4^]&IJ-%CQUBXI\&(U&LV'!9=F[/'?OONC+<U797);B
MBV:F*@JN'Z]%KK87O;#7O/A%KM:67@POSS=\)>Z$_;;YHO%KV$I)92%*(U7)
MM,@N>E?AF^LYS7<3?I5B:SK/C#Q9*O6=?MRD%[T1&21RD5B2P/'G7KP5>4Z"
M8,8?M<Q>JY(6=I\;Z1^<[_!ER8UXJ_+?9&K7%[VXQU*1\2JWOZCM/T7MSY3D
M)2HW[G^V]7/GHQY+*F-542^&!84L_5_^4,>ALR!^:4%4+XB<W5Z1L_(=M_SR
M7*LMTS0;TNC!N>I6PSA9TJ;<68U1B77V\OK;W<WM^[L[=O7VYV\W=S=?;S[?
MWK'^5[[,A3D]'UKHH)G#I)9W[>5%+\@+(_9)E79MV/LR%>F^@"&,:RV,&@NO
MHZ,2WXEDP,9AP*)1-#HB;]QZ/';RQB]Y7!F\,8:]5<52EIS 8=A_KI;&:F#D
MOT=43%H5$Z=B\H**.Z1.6N6"J0Q: .!4:*>'O7](UKQ</0V,C\-1H92=;\R&
M)^*BA_0S0M^+WN4W!%DSNQ: ]Q^5--)I*81=JY2T\R1156EEN0K<K(3G295[
M6S!LE>4Y2_9,%(V)3!K&#<M4CLPUK"]+B%"5X65J3M^PJX(DL]NJ6,($"+N6
MZB[1<@-Y10%!9LUA)P,3&(LUL(%QRRQ2VJF&-9^$7F%M/SQE8;0(PCBD3>FL
ME<94,,0JMN5:<ZB#( ;W,Z$U!I >R?>URF&\.2)\'$RF,?OJG&VL.F O"7NM
MN>,HF(T7.QE.+"R3B:"@8<55M4+ZLAD!-URP$Q8-9G/V@4O-[GE>.:G[D3IA
MX^DD"">S)[/<\!EQ#_:D!$PKL*)U\Z,@7L3L+3=KMN&2AFDW?Z]*SWE;:===
MTV69Y%7JQ+!-I;'11CS9_A,V#R?!8OK4U$-00<*4IMZ*$Q8&X2@*1J.0?41Z
MO0'68)6#93T^">;Q:\0V:P)6HBI1F)Y*"D;Q/(C""3N2K-,V6:>O3M:K1L=-
MB@C+3!(-LBMC!,)-T,,C@I^RCQB1.;)-F$.9?%SC5VP(<+[AY>/?_Q9'X?P?
M$(XD2]J\?"DCD0BTFQ068'0ER3HR2Y:[G[6QC2<TG.^LI7'RX'!L ^:2?(>7
MUS# E><8@QJ="'E/(?/2*5%.V&(63,<1NRGO$5*ER89^A Q:!+-XS+YH]!?:
M/CH[!:S8$+;K]>-3-HF#N5O]Q,%ZQH0$C8-H,F7O&E*P_&%O$IQ,NV/=:/2G
MIRR:047(/F]<O)'VN:"TT%3/SU1V5IE:*>O/,#L*QO/XV>Q&Z*.;U(]B).;\
M=!>;#7]T6.KC97\V"V:S^)1]1JAULR-=NUK#E9_1;J;?7"<D&D$((N1IK9TB
MN\CE.^1VO8X6R*#YF/VD5+J5><[Z,&:.C0HG82WO>*(WZ4<[_(F7Z-YHUQCH
MQ&=VVA2>+B@,\Q2F/,2$ ;=RBQ=992M-/)13K];$L2;=[OJ-TA9@E&K@(-2%
M%+$O>)O$@;6S'<=X,NY@&FV2&#AL41YF^VRT)@X_A$@4( ,86:'1A$&)=Z7:
MU,XLX8U;L 9JZ)E \U2@8^,,+4?N-;XDD-,_GC\:V=J>*(.D,)RBD!!U:&E4
M&=3)CS=4VC<2.R?_K$ET [T<W$;YJYG 8\<U#'()A0.70A2(5Q/0$:XY3A>.
M^']UH?[--<M8<74/'2O!WK=@^"@SX98^"JX-;-,\Q3D$9Y3A+2]<E0PC,,J,
M1>P+S*.]\?T %7>%HH8Y83P*QM$"E1?R$APA\&X<CU@XF-;X?N:%3[F3ED["
M>!"S#E,WP+8[>TIG3V6!US^)"3Q<<RDR"J%6CSQ'K.MFS#4N+]F[+Z/ B4*>
M8:<DUB'VU*PB&"7&32T..T_;6C3XJ#'0;/K $=LM'$J?LR+4NP:RI'"[3'S8
M(.]VB4A3"0  OR@3WRQ942#[<&QCJ<P@T@\LA=T*X5-@ETDM:E]9B]Q[S,=Z
M4DV98 ;L3@AVJZR@#NK&N_>5/V!5X #-T]0UNXAB*@U.2J;I:0]4U\2U^J+-
M%5*S476W;*JE=]4V]=4SQ<!1^6&24"_2/_F2*(3<()5=%WFHD"059M3M;*[*
MU1GQP*DCF98DFSD$-JR!/@K9/9>YX_;:UMK5@2L*S\H-Y&UQXJ6_"3(?A_2Z
MI'0-*%5YUOX^7#'^9WJ-?>3JEX@&,.W[SA,4FD&(LVR>USNVJLM0P+9K"9HB
M&K%6RV5E&T^)_YAY+"&.S/'R*+B95@7Q&NSW-8@LKW?'@4-DF4R0=8ES@R@]
MET5]['.M0;7))1'?/9Q),2+I'.A^DE( D?QH3&2)%KQV9+]/*I7=)1(L7@KD
M7EJA#R<7"+$.=)4&[@#O(XWKK&U<9Z]O7/?8>__,"6,Z[5/=S#:=[J'N];C:
M'\7B1['X42Q^%(L?Q>+_H5C,VV(Q?W6QP)F;N2MM]@&^P5EX?E/Z"WXX>J@D
M'!?N;D4HP.UUV)KC1$/)WCFZDNI_\;(B7G#7N6$<--E<;]+^O5PKI'MMU6X7
M$<I*ED1TE #/)#N:<=7%465]@M3J'J6J<_BL2EZ!' 1=*RI'D[QK3$>=VQ8(
M=;6&";K>9N]P.G7WG_Z".EPXA\B )Q7-(V.G=J>,*DG#R.GO%5#4:@(< 1$R
MHYM$;I*_ 40!X79W+^0!%OCC.O=7@ Z7'N@NERE_<:9&!E-8_&B*'4IL_O@L
MDSJH;39*@D&\38ZT.\0JEHX3,X<IL<>-_T;(_ >! Q%ST:+RHP7.\_#PA$7!
M?#H-QK/0/<\F<3!;3-R<7*&^]2>+8#JC>Y;Y*%B,H]-#"3+L?!0IR [Z]$/L
M#L[SWT?:M^W7I2O_464WW7^:^L3!)$! +C(L'0WFTYXGZN:'51OWB66IK%6%
M>UP+E'Y-$S">*=2F^@<I:+^Y7?X%4$L#!!0    ( (R$:U)>B,IKWP(  .T%
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;'U4VV[;, S]%<+80PL8
MM:W8N2$)T*39Y:%%T-LP#'M0;"8V:DN9)"?-WX^2$R_#FKS8$L5S>"B*'.VD
M>M,YHH'WJA1Z[.7&;(9!H-,<*ZYOY 8%G:RDJKBAK5H'>J.09PY4E0$+PVY0
M\4)XDY&S+=1D)&M3%@(7"G1=55SMIUC*W=B+O*/AL5CGQAJ"R6C#U_B$YF6S
M4+0+6I:LJ%#H0@I0N!I[M]%P&EM_Y_!:X$Z?K,%FLI3RS6Z^96,OM(*PQ-18
M!DZ_+<ZP+"T1R?A]X/3:D!9XNCZR?W:Y4RY+KG$FR^]%9O*QU_<@PQ6O2_,H
M=U_QD$]B^5)9:O>%7>.;, _26AM9'<"DH"I$\^?OAWLX ?3#,P!V #"GNPGD
M5-YQPR<C)7>@K#>QV85+U:%)7"%L49Z,HM."<&;R.'^=/[S,X>J9+TO4UZ/
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M-L&-S,,>]+.4Q;JL*BSTU,GLUH9ME45>5^YV=TJR=C.-PM%!=\CHU(EBGPS
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MG2[P)BX4">#WN91F\T *^KO]Q=]02P,$%     @ C(1K4I13XRWK @  %@8
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M=XO[?#H&+Q:YLE_8U;91QX&X4EH4>V=B4&2\_F4O^SH<.?3]$P[AWB&TO.M
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MBI0AZ83<8UNR KFK916'<OF*1UR_>J6$"Z"JMH"5H>6"\K8ZZM^)=6)Q$<%
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M@>N8CA^BB..:0Q]E/P-]X(6>4K%1L8%_LM0#!XEHVT,4CX?H*MYK=*R:4.$
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MH*CF2MJ\F&IIKX&3RN"ETC[.\18O% G@_K2J3/="!OK_"QS_!U!+ P04
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M^^NN#]?Y?>+ZP_UELX9E9- ?UM;V$G6WB;K61._6,EJ!5*-<\HB=H0QV-[%
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MM #LKSE7QXGN9)N/J=F_4$L#!!0    ( (R$:U*I9Q;E"P,  (\*   9
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MO&WJE9OI9[/18NDFCIG09GYQR\Q,C"#M!?-^+H1^W=@AIII!!_\ 4$L#!!0
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M1#ZQ_0,M$_*TO3E+1/X+]J466F"^%9*E):PB2..L^">_RD(< <J.&< E@.N
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MIEP+U/,E8_)PHQU4I^K!;U!+ P04    " ",A&M23]@3,LP"  #=!P  &0
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MIU6,+CY<H@\HH^AQQPZ"T%1,;:F4Z'AV4F5=E%GQF:PN1O>,RIU MS2%]'4
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M*X5AX 3[4J'?,T7< /<'$M2!!-9 ?M4M#N@8GG*IOT@)(B)SDNHJI ,3.NB
M;<^.KH2'6B&'79FW>-(HWEXPTSJ8J368][D02408M2QTZ!B&=WX^K\!&0X'V
MM:KS750B3N2:RZ2<67P!UKVKHH]U*_M[>7<&" 0B PM98=TQF0O"(EH@B2CM
M[6!A962/-P9]&V*'^'!&,*G_#@XJM*%TZ)Z@T(:3H9V4#\KH#>QR[' U#<5"
M.\<>O=QO8)= AW$8^H3'\V>Q38JX5,6L%W1#66XMKV$X&)R@O(:#H)V$#FT-
ME9F]Q$Z"=FOHD7*AWVIR88\4FDX'6@,R#(B<'ZI2D4\]R)8O@]*V*34,B.#/
M+Q0RS(;LS'9HH5"7V["G^W.K4CUBNM6C=JDJL68;AT%SA[4?C>%*9.?*.[;(
MRT/E.L_6UGH87D0GX$5D>!'9>?'HK37J4B2&GA^T"],CYKC0&\BXX5)DY]);
M W&1"Y:H7- 2.U<K*FPI,32)_!-4P# ELF\&CZ] =QOG^D&'Q'K$)M"=N ,5
M,%2+[%1[3XFD*Y[&(,ET+]W0 JYM[F-#??@$FS]LJ _;-W]'9QYW-WN!WSP-
M[#+?)^9,A^8^-MR)[=QYP[-UKJ@ DB_4E@AZIGE'1"M=C[B,(6'Z*R-I^DT?
M.3<TU>'9;BYPX[!_@M,^-AR(_^?S?F5OOPWXT_:QM$<,NT$PL"2P(5%L)]$K
M*:F2(&>Q+DZ5^>Z!8=^X83SLG2#WAOVP?9-X?.Z[1V3H^-/.HN@1<^&DW8+'
MC=O!C(IE><NJ=\P\9VIWUU:/UC>Y5^7]96O\&IZ'N_M88V9W/?Q Q#)A$J1T
MH4TZ[WR-2>QN7'<OBJ_+.\@GKA3/RL<5);JVA8#^ON!<O;P4#NI[[]F_4$L#
M!!0    ( (R$:U+<E.QJFP(  *$&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#4W+GAM;(U574_;,!3]*U?1'D#:R$<_!JB-E)(.*D%!%,;#M <WN6TM'+NS
M7<+VZV<[:2C0%OK0^..><^^YCD]ZI9"/:H&HX;E@7/6]A=;+4]]7V0(+HH[$
M$KG9F0E9$&VF<NZKI422.U#!_"@(NGY!*/?BGEN[D7%/K#2C'&\DJ%51$/EW
M@$R4?2_TU@NW=+[0=L&/>TLRQPGJ^^6--#._8<EI@5Q1P4'BK.\EX6G:L?$N
MX"?%4FV,P2J9"O%H)Z.\[P6V(&28:<M S.,)SY Q2V3*^%-S>DU*"]P<K]E_
M..U&RY0H/!/L@>9ZT?>./<AQ1E9,WXKR FL]KL!,,.7^H:QBNR<>9"NE15&#
M304%Y=63/-=]V "$W1V J 9$;P'M'8!6#6A]%M"N 6W7F4J*ZT-*-(E[4I0@
M;;1ALP/73(<V\BFWQS[1TNQ2@]/Q^?5U^C"ZO(1DG,+UW<7P%D;CNV1\/AI<
M#B&93(9W$_@&8R(EL2<$!REJ0IDZ-*OWDQ0.OASV?&TJL7Q^5F<=5%FC'5G#
M"*X$UPL%0YYC_IK -Q(:'=%:QR#:RYAB=@2M\"M$011L*>CLT_#P9 L\_3S\
M>(^:5G,J+<?7VG4J0N0E90P(SV'$->%S.F4(B5*H%:1494RHE43XE4R5EN;V
M_-Z3MMVD;;NT[8_2TF))J#2W6V\[VXJDXTBLK3S%IN-/F\W^,"+=%_&J]DY3
M>V=O[4DAI*;_B',3?#:VJ!",+0)]:1]Q[=LFJ?.NG%8G#.SOC;+W@5%W6V#Z
M/C \Z;X.K'3Z&Y>W0#EW)J@@$RNNJ_>_66U\-G'V\F9]8/RWLLL7FLJ\KXB<
M4ZZ X<Q0!D??35FR,L1JHL726<14:&,X;K@PWQ"4-L#LSX30ZXE-T'R5XO]0
M2P,$%     @ C(1K4IK>$#?1 @  B <  !D   !X;"]W;W)K<VAE971S+W-H
M965T-3@N>&ULG57+;N(P%/T5*YI%*[7-DP!50 +"M$A]">AT,9J%20RQFMC4
M=DC[]V,[(:40F&HVB1_G'-_C:U\'!66O/$%(@/<L);QG)$*LKTV31PG*(+^B
M:T3DS)*R# K992N3KQF"L29EJ>E8EF]F$!.C'^BQ)]8/:"Y23- 3 SS/,L@^
MABBE1<^PC>W %*\2H0;,?K"&*S1#XGG]Q&3/K%5BG"'",26 H67/&-C7H:_P
M&O +HX+OM(%RLJ#T574F<<^P5$ H19%0"E#^-FB$TE0)R3#>*DVC7E(1=]M;
M]9_:N_2R@!R-:/J"8Y'TC(X!8K2$>2JFM+A%E9^6THMHRO47%!76,D"4<T&S
MBBPCR# I__"]VH<=@NT?(3@5P=DG>$<(;D5POTOP*H*G=Z:THO<AA +V T8+
MP!1:JJF&WDS-EO8Q46F?"29GL>2)_LWC8_@RN;L#@X<0/,YOQU,P>9@/'FXF
MP[LQ&,QFX_D,7((19.P#DQ489#0G M EN*$T+G":@K,0"8A3?BYQS[,0G/TX
M!S\ )F">T)Q#$O/ %#)4M: 956$-R["<(V'9#KBG1"0<C$F,XJ\"IO18&W6V
M1H?.2<4015? M2^ 8SE60T"C;]/M;@,]_#Z]<\*-6Z?-U7KNL;1M-__WE,JO
MO (%9/&?$\I>K>QI9>]?RI> R*JC;BS8P#1'%V"!5BMU!F3RUXAA&C?EM51O
M:755<S9]VW-:+<\)S,WN=A_B?-?Q_.Y76-@ <]IN]U/MB\E6;;)UTN0@>LLQ
MQZKR-![.DNWOK.I:?F?/P2&HW76MMKOGX!#6LMKMYOC].G[_?Y.$2'PZ07Y3
M@CJ^;>W9:\0=)C(\Q.TELG1H[M2H#+&5KO4<1*J<E+>X'JV?DX&NHGOC0_G,
ME*_"ITSY1MU#)L\G!RE:2DGKJBV#8F7=+SN"KG4E7% AZZIN)O*I1$P!Y/R2
M4K'MJ 7JQ[?_%U!+ P04    " ",A&M2Q:G<J6X#  "L#   &0   'AL+W=O
M<FMS:&5E=',O<VAE970U.2YX;6R]EVUOVC 0Q[^*%>W%)JU-G <2)D"BT&U(
MK*T*VUY,>^$F!UA+;&8[I=NGGQW2$" \3*KZAL3)W?]^=SDN3F?%Q2^Y %#H
M*4N9[%H+I98?;%O&"\B(O.1+8/K.C(N,*+T4<ULN!9"D<,I2VW6<EIT1RJQ>
MI[AV)WH=GJN4,K@32.991L2?*TCYJFMAZ_G"/9TOE+E@]SI+,H<)J*_+.Z%7
M=J62T R8I)PA ;.NU<<?!C@T#H7%-PHK63M')I4'SG^9Q2CI6HXA@A1B922(
M/CS" -+4*&F.WZ6H5<4TCO7S9_6/1?(ZF0<B8<#3[S11BZX562B!&<E3=<]7
MGZ%,*#!Z,4]E\8M6I:UCH3B7BF>ELR;(*%L?R5-9B)H#]@\XN*6#>ZZ#5SIX
M1:)KLB*M(5&DUQ%\A82QUFKFI*A-X:VSH<P\QHD2^B[5?JKWZ?9V^'TT'J/^
MS1#=3C]?WZ/1S;1_\VET-;Y&_<GD>CI!%VA A/A#V1SU,YXSA0A+4#^.\RQ/
MB8+$7!:*_B7%H^$S-&**L#E]2 'UI00ET=LA*$)3^4ZK?9T,T=LW[] ;1!F:
M+G@NM9[LV$HG9+#LN(2_6L.[!^"'$%\B#[]'KN,Z#>Z#L]UQ>]O=UF6L:NE6
MM70+/>^ WD?*J(*+L>[+I*$"/\;:'HT49/+GD6A>%<TKHOD'HDVY(BF:"RZE
M+F,5C!3!FFJYE@L*.?/O?NSYD><$.O/'>LU.FFW1^A6M?P8MJ;4,J;5,$^Y:
MKU7CN,">GD[A#F^#73O$_@'>H.(-SN#=J^M[Q$ UT09[%%Z G<#=@6TPBX(V
M=IIA6Q5LZRCL/<Q ",TK>2YBD$>Z*ZPDPU?HY:B*%KUL+T=[=?2]"+MXI]PG
MS;9HVQ5M^X5[N=W0R]CQV]$.;X-=Y+OMH)D7.YLA[QPG%B31KW^]-; 9R8XV
M"*Z].? KM C>3%?LOFR3E'I;C]\/O-9.T4^:;?-NYC,^9T#_3YN4@EO/W\78
MWR-NL,-NZ$<'D#=#&A^?TK=J :+"--4]4>CM.)OABH/7:)W-?,3'!^3_MTYK
MOR><W6%^PFB;=3-X<?C2;1/NO;(OO):W2]M@A9W=+K=K6TFSC_]"Q)PRB5*8
M:3?G,M3^8KTU7B\47Q:[RP>N]%ZU.%WHSPD0QD#?GW&NGA=FPUI]H/3^ 5!+
M P04    " ",A&M2[<GEGZ\"  !E!P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970V,"YX;6R5E5U/VS 4AO^*%7$!$B-?39NB-%)I"E1B@&@9%],NW,1M+!R[
MLYT&]NMG.R'J1DKA)K&3\Y[G/2>V$U6,/XL<(0E>"D+%R,JEW)S;MDAS5$!Q
MQC:(JC<KQ@LHU92O;;'A"&9&5!#;<YR^74!,K3@RS^YY'+%2$DS1/0>B+ K(
M7R\08=7(<JVW!P]XG4O]P(ZC#5RC.9*/FWNN9G:;)<,%H@(S"CA:C:RQ>SX9
MZG@3\ .C2NR,@:YDR=BSGLRRD>5H0XB@5.H,4-VV:(((T8F4C=]-3JM%:N'N
M^"W[I:E=U;*$ DT8><*9S$=6:($,K6!)Y .KKE%33Z#SI8P(<P55$^M8("V%
M9$4C5@X*3.L[?&GZL"-P>WL$7B/P/BOP&X%O"JV=F;(2*&$<<58!KJ-5-CTP
MO3%J50VF^BO.)5=OL=+)^.KN+GF:W=R \6T"[A;7TP<PNUV,;Z]F%S=3,)[/
MIXLY^ 8N2UER!,8%XQ+_@>8+3%_44A((L!6840GI&B^)"A$"20&.$R0A)N)$
MB1_G"3@^.@%' %.PR%DI(,U$9$OE7[NPT\;K1>W5V^,U0>D9\-U3X#F>TR&?
M?%KN#O^5VZIK;>N\MG6>R>?O:QUC684) :J:C@XD6*2$"=VVG^.ED%RMV%\?
M8/T6ZQML;P]6%>]V]:Y6!4:E]^XV]E6A061O.V"]%M8[!/.Z8+6JOP/S0M\/
MNV%!"PL.P?PN6/ 56+^%]0_!>EVP_E=@@Q8V. 0+NF"#K\#"%A8>@O7-FERB
M5T:S+F[XGNL$_7#/8AFVX.&'X 63D*@]WNX$:';"*:!(=KD8OE^Q@>L$7NNB
MWM4=86$P=)W_S-H[AZ#^ 7V'?(VI  2ME- Y&Z@,O#[4ZXED&W,N+IE4IZP9
MYNH_B+@.4.]7C,FWB3YJVS]K_!=02P,$%     @ C(1K4L@)C[(S!   2Q$
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M]+WYK,'4 +9&WLO5LE,3KAF,PD![W/":)E\,D.29#&F&5[H7 / %6$U:Z"T
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M@_V6&XZQ)09E#7!]**593FS3E3?9S;]02P,$%     @ C(1K4J=CCZ8I!
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M'6[>K3 ?N\VOR!OP<)7U1BQPD45LW.%]65P23D]UPX1@R!+%(H+H/CP!YHX
M%VNY9#SZ1]U?J_AS,),L> (W*].MTYBDX@2,7RD/(D'!E$<!!;<D75#PYQ]J
M+C"1-!%_.9#Z!5+?(/7W(/UI.I>&I^29<L5$8,%)*D]#(BF8DXB#9Q*O*5@I
MB$)#!U^B%(0LC@D7]FIE 683=\W$FA^?!_ ,XG[SN0)NJX#;<L*=<A90&@HP
MYRP!P@2-94&C>;1$%9;,:ZN$Q??TOP)-5J*[P[9&C%PC-E;4+E;4=JZHG'A'
M/CN%N\Z15UZW0-IU+[R$-"@A58G4Q[0JC=W#TE@[; -PKP#<^U6MTMMIE=99
MSZ^&"STK)9X3<)93D>%4459P%(R(A0:902.JI2/SVR[A09[?0]VM.%>,V^X7
MYY#-=94D$CK7]6#BS.;Y$M2FBG.J:UFM43*@RTC,WX DKTJ\Y7+)XC!*%X ]
MQM'"E%@E1>23EJL&=:JJJV*@J[P@LNM"SG7=IYP&;)&:YCRT)7*?9330<\&Q
M&@;Q0?4.WNL]+QX5^!SG+F?EF-R.(7BCA(,>2+(=".R"D+P)!Z= *V?0K6>W
M5$C%61JV(3:74RLZL'7DI JMG, :/?D$K>8N-TH?5Y9^>Z>;8<]5;%:V8.=7
M]'1G!V_UNG;'(>A:EQ4YZ%:YS_7TKH"UG3UM)0P>IF&?Z&FWX[RGNT5/H[J>
M1E;'D%O'MFOC6?5X6<ZJX.8N-VBQ595ZM"M0VR6=/W_L>MR3#F25#+F5[/L0
M3, D#6BJ'\_!O0J_,V162A Z<L9"5F>06PX^PUBYRPW&JLPN/C2[%0Y=#("L
M(B&W(MTMJ7FL-$%U!<S*$3IV.4)6CI!;CJ[7R:,"8)N76&SN7>@8[8J-#SW8
MP:T]*;%B@]QB<\<I40+SEL?E7_"!70.RU(^ZQYXFJPO(3=__B_P.\TEWNW1/
M4V$K"=@M"5=1&B7KQ/6JQI(PAD>>)VQY';L?$?)9R&-, 3=3J)QIY:W<_M0X
MZU19;@(KO?!RDWB>$-5+![[0P)9 L7_L^;'4C-WOIQX4D>C&V+\QJ7& ZW-B
MN1>[N=?FY /\ABV+XF-_U80M%V/W-OR O+@=9/M;%Q;+M=C-M5?DM8:[?,N#
MOG?D.? MS_KNS>['N*O&&?1J&\6WK.J[B3#/R.'DY5M>](_^2T#I4X![IUK?
M)#4._/J<6";UW41H<_(!\O(M-_KM8\^+)5J_YMU(?5[<#@[(BV52WTV$HXC3
M0#+^P<18=O1[1YZ8EF7?5LV+B=K$U#C8KRK-TB?DA/*%^78OU//Q.I79-]GB
M:O'[@ OS57SK^B7\-LJ^\ELWV8\.K@A?1*D ,9TKE]Y91S4DS[[C9R>2K<R'
MZD<F)4O,X9(2%7(]0-V?,R;?3_0$Q:\I!O\!4$L#!!0    ( (R$:U):3%Q1
MXP(  #,(   9    >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;,V62V_:0!#'
MO\K(4J56"MB89R) XA45M0$$27JH>MC8 UZQ]KJ[ZP#]]-U=@T,D<'OHH1>\
MK_GO;V;L&;H[+K8R0E2PCUDB>TZD5'KGNC*(,":RRE-,],Z:BY@H/14;5Z8"
M26B-8N;ZGM=R8T(3I]^U:PO1[_),,9K@0H#,XIB(PQ 9W_6<FG-:6-)-I,R"
MV^^F9(,K5$_I0NB96ZB$-,9$4IZ P'7/&=3NAC7/&-@3SQ1W\FP,QI47SK=F
M,@U[CF>(D&&@C 31CU<<(6-&27/\/(HZQ9W&\'Q\4K^WSFMG7HC$$6??:*BB
MGM-Q(,0UR9A:\MUG/#K4-'H!9]+^PNYXUG,@R*3B\=%8$\0TR9]D?PS$F8'?
MO&+@'PU\RYU?9"G'1)%^5_ ="'-:JYF!==5::SB:F*RLE-"[5-NI_NIQ/OI2
M&0Y6DS%,9Z/)[''Z/('1_&$QF:T&C]/Y#"HPD#IIJ8FBA">)(2@.(QZGF4*X
M)U3 ,V$9 E_#2O%@"_/CV8]C5(0R^:GK*LUJ;G2#(]<PY_*O<-5\>.")BB1,
MDA##]P*N=K+PU#]Y.O1+%<<85*%>NP'?\[T2O7H1N;K5JU^+7$0$5LP;$=I@
MZ#>5&+=OP.Y(&&0JXH+^TON9]D&\"PXL&$GD#4SV* (J$1:"!@A+DFP0OG_5
M=\%482Q_E) V"M*&)6U<(5U2N:VL!2+01*%&4R"(PDM)*1?RJW[S0PE0LP!J
MENJ<!Z)$KE7(M?[S3+0+TG:IXY-]JJN1QGCE3",RJ@Z7LE NTFA6VUY9&CH%
M3>=?O1?E0EZU62\#NBV ;O\N/(RN;3GA>2&Y1%2NU((#$B&A#G%>16H=",E!
MED#6O+>2Z96*C^DK#3$)KT;K#_9>U;N</_>LCL<H-K9;20AXEJB\I!>K14<<
MY'W@[7C>3A^(V%!=@AFNM:E7;>LO4N0=*I\HGMJN\,*5[C%V&.FNCL(<T/MK
MSM5I8BXH_B?T?P-02P,$%     @ C(1K4N/)>,>8!   ?!,  !D   !X;"]W
M;W)K<VAE971S+W-H965T-S N>&ULM5A;;ZLX$/XK5G0>6NDT8'.OTDBY[6YU
MMA<U;<^S"TZ""CAK.TW[[]<&"FD!AU:[+PD8SS??S'@^L$=[RI[YAA !7M,D
MXQ>#C1#;<\/@X8:DF _IEF3RR8JR% MYR]8&WS*"H]PH30QDFJZ1XC@;C$?Y
MV"T;C^A.)'%&;AG@NS3%[&U*$KJ_&,#!^\!=O-X(-6",1UN\)DLB'K:W3-X9
M%4H4IR3C,<T (ZN+P02>SY&O#/(9CS'9\X-KH$)YHO19W5Q&%P-3,2()"86"
MP/+OA<Q(DB@DR>.?$G10^52&A]?OZ'_DP<M@GC G,YK\CB.QN1CX Q"1%=XE
MXH[N_R)E0([""VG"\U^P+^>: Q#NN*!I:2P9I'%6_./7,A$'!LCI,$"E ?ID
M .T. ZLTL/H:V*6!G6>F""7/PQP+/!XQN@=,S99HZB)/9FXMPX\S5?>E8/)I
M+.W$>'E_,_MU-ITL%W-P>3U;7-]?/B[ [.;J=G&]G-Q?WER#,[ L%@6@*[ 4
M-'P&-]N\:!-5M%B\@9,Y$3A.^*F<_+"<@Y,?I^ ', #?8$8XB#/PD,6"_Y2#
M\OI^0W<<9Q$?&4*&H(@884EW6M!%'70A E<T$QL.%EE$HH\ AHR]2@!Z3\ 4
M:1'G)!P""_X$R$1F"Z%9;W,8M)C/^YO[FFBLJIQ6CF=UX$W6:T;66!!PF0D6
MR_8,P2-.=D2#;5?8=HYM=V#_SGN(1&#R0IC4!'!'E+#$V1K,9$V8;.$=3L#?
M\8H +( ,C:1/A.F2.]5[1."-8,8!!*DJ.G!!A-^X)A2G"L71 A^N8@V<6\&Y
MVJP70#IB7H7D:8E-<8*SL"U_,  GLG>*CCIMRV6![.;(2NY?QJYM!YXS,EY:
M&/D5(U_+Z$^&,U7T(\[]AG-DV@'R*^=%,S6GF1]GS'4S/@005 $$V@ 6KX2%
M,3\>0M#P?(9<UW0[$@C-6F)-+0/Y@EJ16"51BAX@K]N8'6=38GZ@ SUHFEX'
MG0/%A]]<8\@\R@HV6-D0^1;\5.>6>;K%"%%-'O6I)GY*OAD :A"#@>=97<1J
MX85ZY6VHX_NZ [<L#G7Z"VL!AGH]/*H.$4T2)9A;^2!/0GL."B_^80Z<H>5V
MI* 65:A7U4.IZ,FD  P.F5A#R^Y@4NLQ=+_0\SVYN TNWM"U.JC4@@[UBM[=
M_#UI>0U:R.TN5BWK4*_K1U6@)SV_64%[Z'F?]<#_TI*KM1WV$G>]'/2,)&A2
M=(<.;*>(:O5'YG_^289J,4??%?/6S]%I"><<+B?/Z6@X5,LRTLMRV?JM'IN*
M:WM=6:WE%EG].KS5I=7\&G%LO\-G+;](+[^MK=SJWV[X][N\U^J*].JJ:]A6
M$D[S36>A3Y];LW)6S_50"S#J)<"=?=E*V&U0\?R@@TFMOTBOO__'KN6(2[?<
MMOC%MD7N7]"QC0NJ=1OI=?LK\7RK"GKW=AD;ZA&;<7 LD1*VSH]W. CI+A/%
M!KT:K8Z0)OG!R:?Q*3R?%P=!-4QQ+G6%V5I**DC(2D*:0T^N'E8<]10W@F[S
MPX\G*@1-\\L-P1%A:H)\OJ)4O-\H!]6!V_A?4$L#!!0    ( (R$:U)'QDAP
M]@<  -,Y   9    >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;,V;76_CMA*&
M_PIA]*(%NC9%BA\JD@!)-@<-NKL)-MOVHNB%8C.)L++E(RF;#= ?7TFF/0H4
MCBG+,7J3^$LOA]3PT<QH=/24Y5^+!V-*\GV>+HKCT4-9+G^93(KI@YG'Q3A;
MFD7US5V6S^.R>IO?3XIE;N)9<] \G3!*Y60>)XO1R5'SV75^<I0]EFFR,-<Y
M*1[G\SA_/C-I]G0\"D;K#SXG]P]E_<'DY&@9WYL;4_Z^O,ZK=Y.-RBR9FT61
M9 N2F[OCT6GPRUE 17U$\Y,_$O-4M%Z3>BZW6?:U?G,Y.Q[1VB23FFE9:\35
MOV_FW*1I+549\G^K.MH,6A_8?KU6_U\S^VHVMW%ASK/TSV16/AR/](C,S%W\
MF):?LZ=?C9U18^ T2XOF+WFROZ4C,GTLRFQN#ZXLF">+U?_XNUV)U@'<=0"S
M![#&[M5 C97OXS(^.<JS)Y+7OZ[4ZA?-5)NC*^.217U:;LJ\^C:ICBM/;KY<
MG?_V[NSTYN(]N?QT?O'IR^4?%^3\ZN/UQ:>;TR^75Y_(.W*S.F<DNR-7CV51
MQHM9LK@GU3]R\=WDTZ2(;U-#;LIL^I5<+>OE+LB/[TT9)VGQT]&DK RMAYM,
MK5%G*Z.8PZB D8_9HGPHR,5B9F8O!2;5##?39.MIGC%4\;V9C@D/?B:,,OH#
MF9#B(<Y-L?J+Z//-,O)&GSOTUY-N+0^B&FY4PT8U]%<E/R8+:_Q/Y!_RV@16
MZ[%2EHURO3>_G80!TSPXFGQ[Q2*QL4AXS;-UVI%YRHVJ])IGVYE\YRD[\PPB
MI;AX?9YJ8Y%"+:+(K/1&0Z-K=5/;_*Y&QHR<9_,*I$7<D.@TS^/%O:G@5I+;
M9]+^W77\W'Q\^A3G,_+7ATJ27)9F7OR-&!1M#(K027W(GDQ.FK%)FLR3LEGD
M69:F<5Z09?5=L\RO;MB5LF@M,WU]A0,*Y*&H.;\OESN;8Z5URQX]9J'#I!8,
M@SUNXX"!+GNSC6REVQX>1=2QCP, 5L!1D_YLKE>5RYU^,WEU 5YO/D.N\V1J
M^IP+WCD7<BR8PT!@7X##KV/@9U.'&?72G5<7A[RZGC_&*?F0W)E7K<+5)7DV
M]=0",J^O-$226?R,70D"0&2P3T8& ,G@[2@9=#&).!%0,L QN4<G4GV<"! <
M:-3 %13<BP_H#*+_!LP9\)/A_!R"<RL=>?&3 3]9\&9(M])M#PC<+L" O8SM
MD>D, ,IP@ YANI5N;T<>BD [KJD,H,EZ0G/G#6D'>G$ZV)AJAX5 1R;>$NM;
MU)7%NEQA'0,Z _ RN4>@,Z GP^DY!.A6^D7<RRG5KBT,Q&0X,??H0;KK073,
ME,-"0#'#PUA+!7?.!@3E]+\!=0X$Y3A!AT#=2D=^!.5 4(Y'KT.H;J7;3L#"
ML9(.FUKY]CX3;@X Y6^7<O-NSLV$H ZH<T F[XG,G;>D'>C%V6!CZ8@#.1"2
MXZ'I0*AO46<6ZMI"G01L6[3. <)<[1'N'#C*<8X.@;N5]G4D("?'R;E'1XKZ
M.%((1 [QF-:RP5TY Y"&>"I_,+:'P-$0Y^@0MEOIR(^C(7 TQ*/8(6RWTNVB
M$.<.@UHESW"?E52 :(A#=% M572#K6H[.O9C"-@,>V)SY_UH!VKO1T['H6L_
M AW#G@E^/[!O45^#G6_ KK>!/00 AWCYM1_80X!HB$-T"-BMM*<C"<"FP+&Y
M/T<2W<(JXD@"<"SPN+8&@W/Q!2!4X,G\P:@N@* ")^@0JHM7Z@ .@@H@J,!#
MV"%(%]VL/PS&S)'UB]9M([^:J!_5!1!4^-5$=Z&ZZ-9$71L1>"D.51"U WG<
M<1& 1-$SM^]'\RWJ=$5S[+P"9 5>;NUYGQ% *7%0#KK32'W]10(6)8[%_?F+
M'<C#7R305N(!J]WZ[G4'2$H\73\8MR5@4N*8',)M*QWY85(")B4>I Y!M^SF
M]F'DK/[(UKUYO^JG'[HEH%+Z53]W0;=\I?K)G FR!$#*0Q4_9;?X&8;CP)&O
M20"C[)G"]T/X%O6@07B?>%P!>A5>;.V'= 4(53A"AR#=2GOZD0)P*AR<^_,C
MU:V?(GZD ,@*CUHM&MSK#QQ5>,)^,+0KP*C",3H$[58Z\L.H HPJ/%(=@G;5
MS>Z%<A9_5*O)R:_VZ8=V!1A5?K7/7="NNK5/[MZ1P$UUJ-*GZI8^A73>.]?
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M21#+]3'C5/P:"#E^.7NZ'_]Q<_]E,GV<_0=,__M\^_0_\'&".0I"]@E\  /
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M^G(S!I\I23;@)EM3#-R>@2]?QKJ)*LY#J^.8*JC#%JICZHN8BBV/M%?,<;^
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MY[9*A1!J0FXIREEZRCUA&DDGM[5ASIY.M*B !GC#HE#JPE;8WNL1-WT5S5C
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M-<#W"X$3L;A)&RC/O(;_ E!+ P04    " ",A&M26R<!(0$%   S%   &0
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M]45]_+CF6QGG*SETE"ZU2.@LZ[(NJK+P@;)<\(7G:BW!-%^QE45_W:U'N".
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M @  8@P   T   !X;"]S='EL97,N>&ULU9=;;YLP%,>_BN5,4RM-)9 E;5=
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MX.OY*<Y03=6Z2T:PM[_CE-3LNIMU;QY$.ZNWOYGM^2M;L/^O(OX#4$L#!!0
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MF_]K?/T;4$L! A0#%     @ C(1K4@=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " ",A&M2B)DL3>X
M   K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"
M% ,4    " ",A&M2F5R<(Q &  "<)P  $P              @ ', 0  >&PO
M=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( (R$:U+M<?AYI 8  +(:   8
M              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"
M% ,4    " ",A&M2T;8C&3,'  "L'   &               @('G#@  >&PO
M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ C(1K4BR0@M4% P
MRPD  !@              ("!4!8  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( (R$:U+;BS#\/ 8  ,,6   8              " @8L9
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " ",A&M2C3K9
MZH@"  #I!0  &               @(']'P  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ C(1K4OP",OF6"@  -"X  !@
M ("!NR(  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( (R$
M:U+A)R=@7 8  ((<   8              " @8<M  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " ",A&M2S+X+20,)   H%@  &
M        @($9-   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( (R$:U+3H&)Y(0H  (8;   9              "
M@2)O  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ C(1K
M4C<>B:2M!   Y@L  !D              ("!>GD  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " ",A&M2S&CBHW\%   P%@  &0
M        @(%>?@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( (R$:U(N1I23.@0  ,0)   9              " @12$  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ C(1K4IK-M6=;"   'Q4
M !D              ("!A8@  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " ",A&M20TGF,IX/  #_-   &0              @($7D0
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( (R$:U(]15X"
MW@@  -T;   9              " @>R@  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ C(1K4ERR>BW7!   6@T  !D
M ("! :H  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " ",
MA&M2?HG[YM<$  "]"@  &0              @($/KP  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( (R$:U*F)'> \0H  .<@   9
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M970R-BYX;6Q02P$"% ,4    " ",A&M24[X(@*8<  #_7P  &0
M    @(&KV   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M (R$:U*$%:*FW@@  '\;   9              " @8CU  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ C(1K4EZ(RFO? @  [04  !D
M             ("!G?X  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " ",A&M23[<PL3 &  #G#P  &0              @(&S 0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( (R$:U*44^,MZP(
M !8&   9              " @1H( 0!X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ C(1K4C&N9M7# @  -P<  !D              ("!
M/ L! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " ",A&M2
M87Y_SW(#   C!P  &0              @($V#@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( (R$:U)7M(?E.P0  /\*   9
M      " @=\1 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ C(1K4L&.'ND)!0  !0T  !D              ("!418! 'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " ",A&M2*.Y('7\$   X#0
M&0              @(&1&P$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( (R$:U(C_SY20P8  ",0   9              " @4<@ 0!X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ C(1K4MU$E'?%
M P  :@@  !D              ("!P28! 'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " ",A&M2JY,M/-D$  #R$0  &0
M@(&]*@$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( (R$
M:U+H),TMX@8  'PD   9              " @<TO 0!X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ C(1K4F"R\X0*!0  #Q0  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( (R$:U)XQ3<=V0,  &$/   9
M  " @=U* 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
MC(1K4D_8$S+, @  W0<  !D              ("![4X! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " ",A&M21V5_D%(#  #L"@  &0
M            @('P40$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( (R$:U+*+H]9H0,  "<.   9              " @7E5 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ C(1K4F66*AA(!
M"1   !D              ("!45D! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " ",A&M2@QA_GH\$  "*%   &0              @('0
M70$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( (R$:U*X
M,DKG'0,  /\)   9              " @99B 0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ C(1K4KV0DO2U!   L!,  !D
M     ("!ZF4! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (R$:U*:WA WT0(  (@'   9              "
M@0QY 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ C(1K
M4L6IW*EN P  K P  !D              ("!%'P! 'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    " ",A&M2[<GEGZ\"  !E!P  &0
M        @(&Y?P$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0
M   ( (R$:U+("8^R,P0  $L1   9              " @9^" 0!X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ C(1K4K^@AW,I#   #%(
M !D              ("!"8<! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q0
M2P$"% ,4    " ",A&M2P4/TA'4"   #!P  &0              @(%IDP$
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( (R$:U*A"%]E
M? 8  !HL   9              " @166 0!X;"]W;W)K<VAE971S+W-H965T
M-C0N>&UL4$L! A0#%     @ C(1K4E^&75K+!   ^!0  !D
M ("!R)P! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " ",
MA&M23@8>TA4#  !P"P  &0              @('*H0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( (R$:U*G8X^F*00  /40   9
M          " @1:E 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#
M%     @ C(1K4B)XTQ#Y!0  62$  !D              ("!=JD! 'AL+W=O
M<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " ",A&M26DQ<4>,"   S
M"   &0              @(&FKP$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM
M;%!+ 0(4 Q0    ( (R$:U+CR7C'F 0  'P3   9              " @<"R
M 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ C(1K4D?&
M2'#V!P  TSD  !D              ("!C[<! 'AL+W=O<FMS:&5E=',O<VAE
M970W,2YX;6Q02P$"% ,4    " ",A&M25?H=^90#   @"P  &0
M    @(&\OP$ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    (
M (R$:U+9L^KWV (  !4'   9              " @8?# 0!X;"]W;W)K<VAE
M971S+W-H965T-S,N>&UL4$L! A0#%     @ C(1K4MAZARDP"   W2L  !D
M             ("!EL8! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"
M% ,4    " ",A&M2[)M"P,H$  #_$@  &0              @(']S@$ >&PO
M=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( (R$:U);)P$A 04
M #,4   9              " @?[3 0!X;"]W;W)K<VAE971S+W-H965T-S8N
M>&UL4$L! A0#%     @ C(1K4F"%;0.N!0  9!P  !D              ("!
M-MD! 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    " ",A&M2
M05:F"E@"  !B#   #0              @ $;WP$ >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( (R$:U*7BKL<P    !,"   +              "  9[A 0!?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( (R$:U)KY5GO1@8  ,TR   /
M      "  8?B 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " ",A&M2>NU.
M;58"  ".+0  &@              @ 'ZZ $ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " ",A&M25:BY9Q("  !S+   $P
M    @ &(ZP$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     50!5 $H7  #+
%[0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>341</ContextCount>
  <ElementCount>508</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>111</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - COVER PAGE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/COVERPAGE</Role>
      <ShortName>COVER PAGE</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS</Role>
      <ShortName>NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - BUSINESS ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/BUSINESSACQUISITIONS</Role>
      <ShortName>BUSINESS ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/REVENUE</Role>
      <ShortName>REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANS</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - (LOSS) EARNINGS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/LOSSEARNINGSPERSHARE</Role>
      <ShortName>(LOSS) EARNINGS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128108 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2135110 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2141111 - Disclosure - INDEBTEDNESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INDEBTEDNESS</Role>
      <ShortName>INDEBTEDNESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2147112 - Disclosure - DERIVATIVE INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS</Role>
      <ShortName>DERIVATIVE INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2152113 - Disclosure - FAIR VALUE MEASURMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS</Role>
      <ShortName>FAIR VALUE MEASURMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2153114 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2154115 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION</Role>
      <ShortName>STOCK-BASED INCENTIVE COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2162116 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2164117 - Disclosure - RELATED-PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED-PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2166118 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2169119 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - BUSINESS ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/BUSINESSACQUISITIONSTables</Role>
      <ShortName>BUSINESS ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/BUSINESSACQUISITIONS</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - REVENUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/REVENUETables</Role>
      <ShortName>REVENUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/REVENUE</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - INCOME TAXES Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables</Role>
      <ShortName>INCOME TAXES Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2326304 - Disclosure - (LOSS) EARNINGS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/LOSSEARNINGSPERSHARETables</Role>
      <ShortName>(LOSS) EARNINGS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/LOSSEARNINGSPERSHARE</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2329305 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/LEASES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2342308 - Disclosure - INDEBTEDNESS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INDEBTEDNESSTables</Role>
      <ShortName>INDEBTEDNESS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/INDEBTEDNESS</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2348309 - Disclosure - DERIVATIVE INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables</Role>
      <ShortName>DERIVATIVE INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2355310 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION Stock-Based Incentive Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables</Role>
      <ShortName>STOCK-BASED INCENTIVE COMPENSATION Stock-Based Incentive Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2367311 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails</Role>
      <ShortName>NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - BUSINESS ACQUISITIONS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails</Role>
      <ShortName>BUSINESS ACQUISITIONS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - BUSINESS ACQUISITIONS - Consideration Exchanged (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails</Role>
      <ShortName>BUSINESS ACQUISITIONS - Consideration Exchanged (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - BUSINESS ACQUISITIONS - Acquired Identifiable Assets and Assumed Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails</Role>
      <ShortName>BUSINESS ACQUISITIONS - Acquired Identifiable Assets and Assumed Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - BUSINESS ACQUISITIONS - Consideration Allocated to Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails</Role>
      <ShortName>BUSINESS ACQUISITIONS - Consideration Allocated to Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - BUSINESS ACQUISITIONS - Pro Forma Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/BUSINESSACQUISITIONSProFormaFinancialInformationDetails</Role>
      <ShortName>BUSINESS ACQUISITIONS - Pro Forma Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - REVENUE - Net Revenue Earned by Category of Payer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails</Role>
      <ShortName>REVENUE - Net Revenue Earned by Category of Payer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANS</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - INCOME TAXES - Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails</Role>
      <ShortName>INCOME TAXES - Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - INCOME TAXES - Income Tax Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails</Role>
      <ShortName>INCOME TAXES - Income Tax Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - INCOME TAXES - Valuation Allowance for Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails</Role>
      <ShortName>INCOME TAXES - Valuation Allowance for Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - (LOSS) EARNINGS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails</Role>
      <ShortName>(LOSS) EARNINGS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/LOSSEARNINGSPERSHARETables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - LEASES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/LEASESAdditionalInformationDetails</Role>
      <ShortName>LEASES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>LEASES - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2437419 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2440422 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2443423 - Disclosure - INDEBTEDNESS - Summary of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails</Role>
      <ShortName>INDEBTEDNESS - Summary of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - INDEBTEDNESS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails</Role>
      <ShortName>INDEBTEDNESS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - INDEBTEDNESS - Long-term Debt Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails</Role>
      <ShortName>INDEBTEDNESS - Long-term Debt Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails</Role>
      <ShortName>INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2449427 - Disclosure - DERIVATIVE INSTRUMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails</Role>
      <ShortName>DERIVATIVE INSTRUMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2450428 - Disclosure - DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails</Role>
      <ShortName>DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2451429 - Disclosure - DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails</Role>
      <ShortName>DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2456430 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails</Role>
      <ShortName>STOCK-BASED INCENTIVE COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2457431 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Assumptions Used to Compute Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails</Role>
      <ShortName>STOCK-BASED INCENTIVE COMPENSATION - Assumptions Used to Compute Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2458432 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails</Role>
      <ShortName>STOCK-BASED INCENTIVE COMPENSATION - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2459433 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Outstanding and Exercisable Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails</Role>
      <ShortName>STOCK-BASED INCENTIVE COMPENSATION - Summary of Outstanding and Exercisable Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2460434 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Restricted Stock Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails</Role>
      <ShortName>STOCK-BASED INCENTIVE COMPENSATION - Summary of Restricted Stock Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2461435 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Fair Value of Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails</Role>
      <ShortName>STOCK-BASED INCENTIVE COMPENSATION - Fair Value of Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2463436 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2465437 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED-PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2468438 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="bios-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2470439 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>77</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="bios-20201231.htm">bios-20201231.htm</File>
    <File>bios-20201231.xsd</File>
    <File>bios-20201231_cal.xml</File>
    <File>bios-20201231_def.xml</File>
    <File>bios-20201231_lab.xml</File>
    <File>bios-20201231_pre.xml</File>
    <File>opch-ex1012x20201231x10k.htm</File>
    <File>opch-ex1013x20201231x10k.htm</File>
    <File>opch-ex211x20201231x10k.htm</File>
    <File>opch-ex231x20201231x10k.htm</File>
    <File>opch-ex311x20201231x10k.htm</File>
    <File>opch-ex312x20201231x10k.htm</File>
    <File>opch-ex321x20201231x10k.htm</File>
    <File>opch-ex322x20201231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>bios-20201231_g1.jpg</File>
    <File>bios-20201231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>101
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bios-20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 40,
   "contextCount": 341,
   "dts": {
    "calculationLink": {
     "local": [
      "bios-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bios-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "bios-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bios-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bios-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "bios-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 725,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 7,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 11
   },
   "keyCustom": 33,
   "keyStandard": 475,
   "memberCustom": 48,
   "memberStandard": 59,
   "nsprefix": "bios",
   "nsuri": "http://www.bioscrip.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - COVER PAGE",
     "role": "http://www.bioscrip.com/role/COVERPAGE",
     "shortName": "COVER PAGE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - BUSINESS ACQUISITIONS",
     "role": "http://www.bioscrip.com/role/BUSINESSACQUISITIONS",
     "shortName": "BUSINESS ACQUISITIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - REVENUE",
     "role": "http://www.bioscrip.com/role/REVENUE",
     "shortName": "REVENUE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - EMPLOYEE BENEFIT PLANS",
     "role": "http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANS",
     "shortName": "EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - INCOME TAXES",
     "role": "http://www.bioscrip.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - (LOSS) EARNINGS PER SHARE",
     "role": "http://www.bioscrip.com/role/LOSSEARNINGSPERSHARE",
     "shortName": "(LOSS) EARNINGS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128108 - Disclosure - LEASES",
     "role": "http://www.bioscrip.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - PROPERTY AND EQUIPMENT",
     "role": "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135110 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS",
     "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141111 - Disclosure - INDEBTEDNESS",
     "role": "http://www.bioscrip.com/role/INDEBTEDNESS",
     "shortName": "INDEBTEDNESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147112 - Disclosure - DERIVATIVE INSTRUMENTS",
     "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS",
     "shortName": "DERIVATIVE INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152113 - Disclosure - FAIR VALUE MEASURMENTS",
     "role": "http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS",
     "shortName": "FAIR VALUE MEASURMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153114 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154115 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION",
     "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION",
     "shortName": "STOCK-BASED INCENTIVE COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162116 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.bioscrip.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164117 - Disclosure - RELATED-PARTY TRANSACTIONS",
     "role": "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED-PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2166118 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)",
     "role": "http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED",
     "shortName": "SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2169119 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.bioscrip.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - BUSINESS ACQUISITIONS (Tables)",
     "role": "http://www.bioscrip.com/role/BUSINESSACQUISITIONSTables",
     "shortName": "BUSINESS ACQUISITIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - REVENUE (Tables)",
     "role": "http://www.bioscrip.com/role/REVENUETables",
     "shortName": "REVENUE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - INCOME TAXES Income Taxes (Tables)",
     "role": "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables",
     "shortName": "INCOME TAXES Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326304 - Disclosure - (LOSS) EARNINGS PER SHARE (Tables)",
     "role": "http://www.bioscrip.com/role/LOSSEARNINGSPERSHARETables",
     "shortName": "(LOSS) EARNINGS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329305 - Disclosure - LEASES (Tables)",
     "role": "http://www.bioscrip.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "role": "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)",
     "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342308 - Disclosure - INDEBTEDNESS (Tables)",
     "role": "http://www.bioscrip.com/role/INDEBTEDNESSTables",
     "shortName": "INDEBTEDNESS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348309 - Disclosure - DERIVATIVE INSTRUMENTS (Tables)",
     "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables",
     "shortName": "DERIVATIVE INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2355310 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION Stock-Based Incentive Compensation (Tables)",
     "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables",
     "shortName": "STOCK-BASED INCENTIVE COMPENSATION Stock-Based Incentive Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2367311 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)",
     "role": "http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables",
     "shortName": "SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)",
     "role": "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
     "shortName": "NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "bios:NumberOfServiceLocations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "location",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - BUSINESS ACQUISITIONS - Additional Information (Details)",
     "role": "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
     "shortName": "BUSINESS ACQUISITIONS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i5d06560aaca644c89a26a480b954d11c_D20190806-20190806",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - BUSINESS ACQUISITIONS - Consideration Exchanged (Details)",
     "role": "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails",
     "shortName": "BUSINESS ACQUISITIONS - Consideration Exchanged (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i3753cbfa17174608809f4f34d4a104ac_I20190806",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - BUSINESS ACQUISITIONS - Acquired Identifiable Assets and Assumed Liabilities (Details)",
     "role": "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails",
     "shortName": "BUSINESS ACQUISITIONS - Acquired Identifiable Assets and Assumed Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i3753cbfa17174608809f4f34d4a104ac_I20190806",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i3753cbfa17174608809f4f34d4a104ac_I20190806",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - BUSINESS ACQUISITIONS - Consideration Allocated to Intangible Assets (Details)",
     "role": "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails",
     "shortName": "BUSINESS ACQUISITIONS - Consideration Allocated to Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i5d06560aaca644c89a26a480b954d11c_D20190806-20190806",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "iceee29a996a54c498d570461cc70c139_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - BUSINESS ACQUISITIONS - Pro Forma Financial Information (Details)",
     "role": "http://www.bioscrip.com/role/BUSINESSACQUISITIONSProFormaFinancialInformationDetails",
     "shortName": "BUSINESS ACQUISITIONS - Pro Forma Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "iceee29a996a54c498d570461cc70c139_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i3afb9f5919b84a45a2a45351ff5c3f16_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - REVENUE - Net Revenue Earned by Category of Payer (Details)",
     "role": "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails",
     "shortName": "REVENUE - Net Revenue Earned by Category of Payer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "iba4469ba333d4f7dbcf906562ff59670_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)",
     "role": "http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - INCOME TAXES - Income Tax Benefit (Details)",
     "role": "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails",
     "shortName": "INCOME TAXES - Income Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - INCOME TAXES - Income Tax Reconciliation (Details)",
     "role": "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails",
     "shortName": "INCOME TAXES - Income Tax Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "role": "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bios:DeferredTaxAssetsBadDebtReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details)",
     "role": "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails",
     "shortName": "INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bios:DeferredTaxAssetsBadDebtReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - INCOME TAXES - Narrative (Details)",
     "role": "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:UnrecognizedTaxBenefits",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i27919b5d127146ec960f50ee2587df9f_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - INCOME TAXES - Valuation Allowance for Deferred Tax Assets (Details)",
     "role": "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails",
     "shortName": "INCOME TAXES - Valuation Allowance for Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "id5195060bc61421e96d7fc5e6a7b58ec_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DilutiveSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - (LOSS) EARNINGS PER SHARE (Details)",
     "role": "http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails",
     "shortName": "(LOSS) EARNINGS PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i0dd78a85e0bc4ab39b8500b030efcef8_D20180101-20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DilutiveSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - LEASES - Additional Information (Details)",
     "role": "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails",
     "shortName": "LEASES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)",
     "role": "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "LEASES - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "role": "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437419 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)",
     "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i27919b5d127146ec960f50ee2587df9f_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details)",
     "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)",
     "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAmortizationAndAccretionNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440422 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense of Intangible Assets (Details)",
     "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443423 - Disclosure - INDEBTEDNESS - Summary of Debt (Details)",
     "role": "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails",
     "shortName": "INDEBTEDNESS - Summary of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ia70d084d67ce4667b22225e30b5f6b8c_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i27919b5d127146ec960f50ee2587df9f_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - INDEBTEDNESS - Additional Information (Details)",
     "role": "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
     "shortName": "INDEBTEDNESS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i5330b1241c9f450aabf19a6470f3deeb_D20190101-20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - INDEBTEDNESS - Long-term Debt Maturities (Details)",
     "role": "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails",
     "shortName": "INDEBTEDNESS - Long-term Debt Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details)",
     "role": "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails",
     "shortName": "INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "iadaac97b718242739dbbd6f6ed2e6ae0_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449427 - Disclosure - DERIVATIVE INSTRUMENTS - Additional Information (Details)",
     "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
     "shortName": "DERIVATIVE INSTRUMENTS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450428 - Disclosure - DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details)",
     "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails",
     "shortName": "DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451429 - Disclosure - DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details)",
     "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails",
     "shortName": "DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456430 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION (Details)",
     "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
     "shortName": "STOCK-BASED INCENTIVE COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457431 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Assumptions Used to Compute Fair Value of Stock Options (Details)",
     "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails",
     "shortName": "STOCK-BASED INCENTIVE COMPENSATION - Assumptions Used to Compute Fair Value of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i40c908a9b2de45bcab117c93611972e9_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "role": "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i40c908a9b2de45bcab117c93611972e9_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458432 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Stock Option Activity (Details)",
     "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails",
     "shortName": "STOCK-BASED INCENTIVE COMPENSATION - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i1170a860c1ae4f4e8e2f19f206578ae2_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459433 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Outstanding and Exercisable Stock Options (Details)",
     "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails",
     "shortName": "STOCK-BASED INCENTIVE COMPENSATION - Summary of Outstanding and Exercisable Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic2110dcd1263436bb4f65e0170d66fa6_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic7cbfe6f12b34fedb3c55e90bc01b102_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460434 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Restricted Stock Award Activity (Details)",
     "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails",
     "shortName": "STOCK-BASED INCENTIVE COMPENSATION - Summary of Restricted Stock Award Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "ic7cbfe6f12b34fedb3c55e90bc01b102_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461435 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Fair Value of Awards (Details)",
     "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails",
     "shortName": "STOCK-BASED INCENTIVE COMPENSATION - Fair Value of Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "4",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463436 - Disclosure - STOCKHOLDERS' EQUITY (Details)",
     "role": "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
     "shortName": "STOCKHOLDERS' EQUITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i5e9cb45e3bb84960a30d7e251b0b997f_D20190101-20191231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465437 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)",
     "role": "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "shortName": "RELATED-PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i34486d66c41947448069be17a3002902_D20190101-20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfNotesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i3afb9f5919b84a45a2a45351ff5c3f16_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468438 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Details)",
     "role": "http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails",
     "shortName": "SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i3afb9f5919b84a45a2a45351ff5c3f16_D20201001-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470439 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i5e6ee715bd2943e5b275bef6b90641f2_D20210201-20210228",
      "decimals": "3",
      "lang": "en-US",
      "name": "bios:CommonStockOutstandingPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS",
     "role": "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS",
     "shortName": "NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bios-20201231.htm",
      "contextRef": "i69a30465d231407487ede25fc216cb88_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 111,
   "tag": {
    "bios_A2015WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2015 Warrants [Member]",
        "label": "2015 Warrants [Member]",
        "terseLabel": "2015 Warrants"
       }
      }
     },
     "localname": "A2015WarrantsMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_A2017WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Warrants [Member]",
        "label": "2017 Warrants [Member]",
        "terseLabel": "2017 Warrants"
       }
      }
     },
     "localname": "A2017WarrantsMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_A2018PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Plan [Member]",
        "label": "2018 Plan [Member]",
        "terseLabel": "The 2018 Plan"
       }
      }
     },
     "localname": "A2018PlanMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities, combined with the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_AccruedExpensesandOtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Expenses and Other Current Liabilities [Member]",
        "label": "Accrued Expenses and Other Current Liabilities [Member]",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesandOtherCurrentLiabilitiesMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_AdjustmentsToAdditionalPaidInCapitalStockholdersContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital, Stockholders' Contribution",
        "label": "Adjustments To Additional Paid In Capital, Stockholders' Contribution",
        "terseLabel": "Stockholders' contributions"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockholdersContribution",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital, Stockholders' Redemption",
        "label": "Adjustments To Additional Paid In Capital, Stockholders' Redemption",
        "negatedTerseLabel": "Stockholders' redemptions"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockholdersRedemption",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_AggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value [Abstract]",
        "label": "Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueAbstract",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bios_BankOfAmericaN.A.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank Of America, N.A. [Member]",
        "label": "Bank Of America, N.A. [Member]",
        "terseLabel": "Bank Of America, N.A."
       }
      }
     },
     "localname": "BankOfAmericaN.A.Member",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_BaptistHealthInLittleRockArkansasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baptist Health In Little Rock, Arkansas [Member]",
        "label": "Baptist Health In Little Rock, Arkansas [Member]",
        "terseLabel": "Baptist Health In Little Rock, Arkansas"
       }
      }
     },
     "localname": "BaptistHealthInLittleRockArkansasMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_BioScripMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioScrip [Member]",
        "label": "BioScrip [Member]",
        "terseLabel": "BioScrip"
       }
      }
     },
     "localname": "BioScripMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSProFormaFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Adjustment To Liabilities Incurred",
        "label": "Business Combination, Consideration Transferred, Adjustment To Liabilities Incurred",
        "terseLabel": "Reduction of liabilities incurred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredAdjustmentToLiabilitiesIncurred",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_BusinessCombinationOwnershipInterestRetained": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Company ownership shareholders retained after merger",
        "label": "Business Combination, Ownership Interest Retained",
        "terseLabel": "Ownership retained by shareholders after merger"
       }
      }
     },
     "localname": "BusinessCombinationOwnershipInterestRetained",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bios_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-Of-Use Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-Of-Use Assets",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_BusinessCombinationRenewalTermLength": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Renewal Term Length",
        "label": "Business Combination, Renewal Term Length",
        "terseLabel": "Renewal term length"
       }
      }
     },
     "localname": "BusinessCombinationRenewalTermLength",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bios_ChangeinDeferredTaxAssetValuationAllowanceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Deferred Tax Asset Valuation Allowance [Roll Forward]",
        "label": "Change in Deferred Tax Asset Valuation Allowance [Roll Forward]",
        "terseLabel": "Change in Deferred Tax Asset Valuation Allowance"
       }
      }
     },
     "localname": "ChangeinDeferredTaxAssetValuationAllowanceRollForward",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bios_ChargedBenefitToCostsAndExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charged (Benefit) To Costs And Expenses [Member]",
        "label": "Charged (Benefit) To Costs And Expenses [Member]",
        "terseLabel": "Charged (Benefit) to Costs and Expenses"
       }
      }
     },
     "localname": "ChargedBenefitToCostsAndExpensesMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_ChargedToOtherAccountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charged To Other Accounts [Member]",
        "label": "Charged To Other Accounts [Member]",
        "terseLabel": "Charged to Other Accounts"
       }
      }
     },
     "localname": "ChargedToOtherAccountsMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_ClassofWarrantorRightSecuritiesExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Securities Exercised",
        "label": "Class of Warrant or Right, Securities Exercised",
        "terseLabel": "Shares purchased from exercise of warrants (in shares)"
       }
      }
     },
     "localname": "ClassofWarrantorRightSecuritiesExercised",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bios_CommercialCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Customer [Member]",
        "label": "Commercial Customer [Member]",
        "terseLabel": "Government payers"
       }
      }
     },
     "localname": "CommercialCustomerMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_CommonStockOutstandingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Outstanding, Percentage",
        "label": "Common Stock, Outstanding, Percentage",
        "terseLabel": "Percentage of outstanding common stock"
       }
      }
     },
     "localname": "CommonStockOutstandingPercentage",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Business Risk, Policy [Policy Text Block]",
        "label": "Concentration Risk, Business Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Business Risk"
       }
      }
     },
     "localname": "ConcentrationRiskBusinessRiskPolicyPolicyTextBlock",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bios_CreditAgreementsEnteredInto2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreements, Entered Into 2019 [Member]",
        "label": "Credit Agreements, Entered Into 2019 [Member]",
        "terseLabel": "Credit Agreements, Entered Into 2019"
       }
      }
     },
     "localname": "CreditAgreementsEnteredInto2019Member",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_CreditArrangementsEnteredInto2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Arrangements, Entered Into 2015 [Member]",
        "label": "Credit Arrangements, Entered Into 2015 [Member]",
        "terseLabel": "Credit Arrangements Administered By Bank Of America, N.A."
       }
      }
     },
     "localname": "CreditArrangementsEnteredInto2015Member",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_CreditArrangementsEnteredInto2015ModifiedLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Arrangements, Entered Into 2015, Modified Loans [Member]",
        "label": "Credit Arrangements, Entered Into 2015, Modified Loans [Member]",
        "terseLabel": "Credit Arrangements, Entered Into 2015, Modified Loans"
       }
      }
     },
     "localname": "CreditArrangementsEnteredInto2015ModifiedLoansMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_DebtInstrumentBaseRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Base Rate",
        "label": "Debt Instrument, Base Rate",
        "terseLabel": "Base rate"
       }
      }
     },
     "localname": "DebtInstrumentBaseRate",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bios_DebtInstrumentChangesInLongTermDebtRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Changes In Long-Term Debt [Roll Forward]",
        "label": "Debt Instrument, Changes In Long-Term Debt [Roll Forward]",
        "terseLabel": "Debt Instrument, Changes In Long-Term Debt [Roll Forward]"
       }
      }
     },
     "localname": "DebtInstrumentChangesInLongTermDebtRollForward",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bios_DebtInstrumentThirdPartyFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Third Party Fees",
        "label": "Debt Instrument, Third Party Fees",
        "terseLabel": "Third party fees"
       }
      }
     },
     "localname": "DebtInstrumentThirdPartyFees",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_DeferredTaxAssetsBadDebtReserve": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Bad Debt Reserve",
        "label": "Deferred Tax Assets, Bad Debt Reserve",
        "terseLabel": "Price concessions"
       }
      }
     },
     "localname": "DeferredTaxAssetsBadDebtReserve",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_DeferredTaxLiabilitiesAcceleratedDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Accelerated Depreciation",
        "label": "Deferred Tax Liabilities, Accelerated Depreciation",
        "negatedTerseLabel": "Accelerated depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAcceleratedDepreciation",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Operating Lease Right-Of-Use Asset",
        "label": "Deferred Tax Liabilities, Operating Lease Right-Of-Use Asset",
        "negatedTerseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Percent",
        "terseLabel": "Changes in uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bios_EquipmentFurnitureAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment, Furniture, And Other [Member]",
        "label": "Equipment, Furniture, And Other [Member]",
        "terseLabel": "Equipment, furniture and other"
       }
      }
     },
     "localname": "EquipmentFurnitureAndOtherMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Net Operating Loss Carryfowards Available To Offset Future Taxable Income [Member]",
        "label": "Federal Net Operating Loss Carryfowards Available To Offset Future Taxable Income [Member]",
        "terseLabel": "Federal Net Operating Loss Carryfowards Available To Offset Future Taxable Income"
       }
      }
     },
     "localname": "FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_FinancingReceivablePrepaymentPenalty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Prepayment Penalty",
        "label": "Financing Receivable, Prepayment Penalty",
        "terseLabel": "Prepayment penalty"
       }
      }
     },
     "localname": "FinancingReceivablePrepaymentPenalty",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_FirstLienTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Lien Term Loan [Member]",
        "label": "First Lien Term Loan [Member]",
        "terseLabel": "First Lien Term Loan",
        "verboseLabel": "First Lien Term Loan"
       }
      }
     },
     "localname": "FirstLienTermLoanMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_GovernmentCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Customer [Member]",
        "label": "Government Customer [Member]",
        "terseLabel": "Commercial payers"
       }
      }
     },
     "localname": "GovernmentCustomerMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_HCGroupHoldingsILLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HC Group Holdings I, LLC",
        "label": "HC Group Holdings I, LLC [Member]",
        "terseLabel": "HC Group Holdings I, LLC"
       }
      }
     },
     "localname": "HCGroupHoldingsILLCMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_HCIIncentiveUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HC I Incentive Units [Member]",
        "label": "HC I Incentive Units [Member]",
        "terseLabel": "HC I Incentive Units"
       }
      }
     },
     "localname": "HCIIncentiveUnitsMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_HomeI.V.SpecialistsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home I.V. Specialists, Inc. [Member]",
        "label": "Home I.V. Specialists, Inc. [Member]",
        "terseLabel": "Home I.V. Specialists, Inc."
       }
      }
     },
     "localname": "HomeI.V.SpecialistsInc.Member",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_HomeSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Solutions [Member]",
        "label": "Home Solutions [Member]",
        "terseLabel": "Home Solutions"
       }
      }
     },
     "localname": "HomeSolutionsMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_IncomeTaxExpenseBenefitCARESAct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Expense (Benefit), CARES Act",
        "label": "Income Tax Expense (Benefit), CARES Act",
        "terseLabel": "Income tax expense (benefit) related to CARES Act"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitCARESAct",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_InfusionPumpsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infusion Pumps [Member]",
        "label": "Infusion Pumps [Member]",
        "terseLabel": "Infusion pumps"
       }
      }
     },
     "localname": "InfusionPumpsMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_InterestCapitalizedToDebtPrincipal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Capitalized To Debt Principal",
        "label": "Interest Capitalized To Debt Principal",
        "terseLabel": "Interest capitalized to debt principal"
       }
      }
     },
     "localname": "InterestCapitalizedToDebtPrincipal",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_InterestGainLossOnManagementNotesReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Gain (Loss) On Management Notes Receivable",
        "label": "Interest Gain (Loss) On Management Notes Receivable",
        "negatedTerseLabel": "Interest on management notes receivable"
       }
      }
     },
     "localname": "InterestGainLossOnManagementNotesReceivable",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_InterestLimitationCarryforwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Limitation Carryforwards [Member]",
        "label": "Interest Limitation Carryforwards [Member]",
        "terseLabel": "Interest Limitation Carryforwards"
       }
      }
     },
     "localname": "InterestLimitationCarryforwardsMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_InterestOnManagementNotesReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest On Management Notes Receivable",
        "label": "Interest On Management Notes Receivable",
        "negatedLabel": "Interest on management notes receivable"
       }
      }
     },
     "localname": "InterestOnManagementNotesReceivable",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_LegacyHealthSystemsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Health Systems [Member]",
        "label": "Legacy Health Systems [Member]",
        "terseLabel": "Legacy Health Systems"
       }
      }
     },
     "localname": "LegacyHealthSystemsMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_LoansFundedForMembershipUnitPurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loans Funded For Membership Unit Purchase [Member]",
        "label": "Loans Funded For Membership Unit Purchase [Member]",
        "terseLabel": "Loans Funded For Membership Unit Purchase"
       }
      }
     },
     "localname": "LoansFundedForMembershipUnitPurchaseMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_LossOnDiscontinuanceOfCashFlowHedgeDerivative": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss On Discontinuance Of Cash Flow Hedge Derivative",
        "label": "Loss On Discontinuance Of Cash Flow Hedge Derivative",
        "terseLabel": "Loss on interest rate swaps upon discontinuing hedge accounting"
       }
      }
     },
     "localname": "LossOnDiscontinuanceOfCashFlowHedgeDerivative",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_MadisonDearbornPartnersVIBL.P.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Madison Dearborn Partners VI-B, L.P. [Member]",
        "label": "Madison Dearborn Partners VI-B, L.P. [Member]",
        "terseLabel": "Madison Dearborn Partners VI-B, L.P."
       }
      }
     },
     "localname": "MadisonDearbornPartnersVIBL.P.Member",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_ManagementNotesReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management Notes Receivable [Member]",
        "label": "Management Notes Receivable [Member]",
        "terseLabel": "Management Notes Receivable"
       }
      }
     },
     "localname": "ManagementNotesReceivableMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_MergerOperatingLossCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Operating Loss Carryforward [Member]",
        "label": "Merger Operating Loss Carryforward [Member]",
        "terseLabel": "Merger Operating Loss Carryforward"
       }
      }
     },
     "localname": "MergerOperatingLossCarryforwardMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_NotesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable",
        "label": "Notes Payable [Member]",
        "terseLabel": "Notes Payable"
       }
      }
     },
     "localname": "NotesPayableMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_NumberOfInfusionSites": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Infusion Sites",
        "label": "Number Of Infusion Sites",
        "terseLabel": "Number of infusion sites"
       }
      }
     },
     "localname": "NumberOfInfusionSites",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bios_NumberOfServiceLocations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Service Locations",
        "label": "Number Of Service Locations",
        "terseLabel": "Number of service locations"
       }
      }
     },
     "localname": "NumberOfServiceLocations",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bios_OptionCareAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Care Acquisition [Member]",
        "label": "Option Care Acquisition [Member]",
        "terseLabel": "Option Care Acquisition"
       }
      }
     },
     "localname": "OptionCareAcquisitionMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_OptionCareEnterprisesInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OptionCare Enterprises, Inc. [Member]",
        "label": "OptionCare Enterprises, Inc. [Member]",
        "terseLabel": "OptionCare Enterprises, Inc."
       }
      }
     },
     "localname": "OptionCareEnterprisesInc.Member",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_OptionCareHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Care Health, Inc",
        "label": "Option Care Health, Inc [Member]",
        "terseLabel": "Option Care Health, Inc"
       }
      }
     },
     "localname": "OptionCareHealthIncMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_OptionExercisePriceRangeEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Exercise Price, Range Eight [Member]",
        "label": "Option Exercise Price, Range Eight [Member]",
        "terseLabel": "57.76"
       }
      }
     },
     "localname": "OptionExercisePriceRangeEightMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_OptionExercisePriceRangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Exercise Price, Range Five [Member]",
        "label": "Option Exercise Price, Range Five [Member]",
        "terseLabel": "33"
       }
      }
     },
     "localname": "OptionExercisePriceRangeFiveMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_OptionExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Exercise Price, Range Four [Member]",
        "label": "Option Exercise Price, Range Four [Member]",
        "terseLabel": "24.76"
       }
      }
     },
     "localname": "OptionExercisePriceRangeFourMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_OptionExercisePriceRangeNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Exercise Price, Range Nine [Member]",
        "label": "Option Exercise Price, Range Nine [Member]",
        "terseLabel": "66"
       }
      }
     },
     "localname": "OptionExercisePriceRangeNineMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_OptionExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Exercise Price, Range One [Member]",
        "label": "Option Exercise Price, Range One [Member]",
        "terseLabel": "0"
       }
      }
     },
     "localname": "OptionExercisePriceRangeOneMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_OptionExercisePriceRangeSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Exercise Price, Range Seven [Member]",
        "label": "Option Exercise Price, Range Seven [Member]",
        "terseLabel": "49.52"
       }
      }
     },
     "localname": "OptionExercisePriceRangeSevenMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_OptionExercisePriceRangeSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Exercise Price, Range Six [Member]",
        "label": "Option Exercise Price, Range Six [Member]",
        "terseLabel": "41.28"
       }
      }
     },
     "localname": "OptionExercisePriceRangeSixMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_OptionExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Exercise Price, Range Three [Member]",
        "label": "Option Exercise Price, Range Three [Member]",
        "terseLabel": "16.52"
       }
      }
     },
     "localname": "OptionExercisePriceRangeThreeMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_OptionExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Exercise Price, Range Two [Member]",
        "label": "Option Exercise Price, Range Two [Member]",
        "terseLabel": "8.24"
       }
      }
     },
     "localname": "OptionExercisePriceRangeTwoMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_OptionsExercisableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Exercisable [Abstract]",
        "label": "Options Exercisable [Abstract]",
        "terseLabel": "Options Exercisable"
       }
      }
     },
     "localname": "OptionsExercisableAbstract",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bios_OptionsOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Outstanding [Abstract]",
        "label": "Options Outstanding [Abstract]",
        "terseLabel": "Options Outstanding"
       }
      }
     },
     "localname": "OptionsOutstandingAbstract",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bios_OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Cash Flow Hedge, Discontinuance Before Reclassification And Tax",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Discontinuance Before Reclassification And Tax",
        "terseLabel": "Interest rate swaps that discontinued hedge accounting"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeDiscontinuanceBeforeReclassificationAndTax",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_PaidInKindInterestAdditionalInterestExpense": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paid-In-Kind Interest, Additional Interest Expense",
        "label": "Paid-In-Kind Interest, Additional Interest Expense",
        "terseLabel": "Additional interest expense charge"
       }
      }
     },
     "localname": "PaidInKindInterestAdditionalInterestExpense",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bios_PatientCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patient Customer [Member]",
        "label": "Patient Customer [Member]",
        "terseLabel": "Patients"
       }
      }
     },
     "localname": "PatientCustomerMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_PaymentsOfDebtIssuanceCostsInvestingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Debt Issuance Costs, Investing Activities",
        "label": "Payments Of Debt Issuance Costs, Investing Activities",
        "terseLabel": "Deferred financing costs, investing activities"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCostsInvestingActivities",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_ProceedsFromSaleOfManagementNotesReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale Of Management Notes Receivable",
        "label": "Proceeds From Sale Of Management Notes Receivable",
        "terseLabel": "Sale of management notes receivable"
       }
      }
     },
     "localname": "ProceedsFromSaleOfManagementNotesReceivable",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_RepaymentOfManagementNotesReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment Of Management Notes Receivable",
        "label": "Repayment Of Management Notes Receivable",
        "terseLabel": "Repayment of management notes receivable"
       }
      }
     },
     "localname": "RepaymentOfManagementNotesReceivable",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_RestrictedStockAndStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock And Stock Options [Member]",
        "label": "Restricted Stock And Stock Options [Member]",
        "terseLabel": "Restricted Stock And Stock Options"
       }
      }
     },
     "localname": "RestrictedStockAndStockOptionsMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_RestrictedStockAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Award [Member]",
        "label": "Restricted Stock Award [Member]",
        "terseLabel": "Restricted Stock Award"
       }
      }
     },
     "localname": "RestrictedStockAwardMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_SaleOfNotesReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Notes Receivable [Member]",
        "label": "Sale Of Notes Receivable [Member]",
        "terseLabel": "Sale Of Notes Receivable"
       }
      }
     },
     "localname": "SaleOfNotesReceivableMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_SecondLienTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Lien Term Loan [Member]",
        "label": "Second Lien Term Loan [Member]",
        "terseLabel": "Second Lien Notes",
        "verboseLabel": "Second Lien Notes"
       }
      }
     },
     "localname": "SecondLienTermLoanMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_SecondaryOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secondary Offering",
        "label": "Secondary Offering [Member]",
        "terseLabel": "Secondary Offering"
       }
      }
     },
     "localname": "SecondaryOfferingMember",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited And Expirations, Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited And Expirations, Intrinsic Value",
        "terseLabel": "Forfeited and expired"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Intrinsic Value",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bios_StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued, Value, Restricted Stock and Stock Options Exercised, Net Of Tax Withholdings",
        "label": "Stock Issued, Value, Restricted Stock and Stock Options Exercised, Net Of Tax Withholdings",
        "negatedTerseLabel": "Exercise of stock options, vesting of restricted stock, and related tax withholdings"
       }
      }
     },
     "localname": "StockIssuedValueRestrictedStockandStockOptionsExercisedNetOfTaxWithholdings",
     "nsuri": "http://www.bioscrip.com/20201231",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r596",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r596",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COVERPAGE"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r196",
      "r289",
      "r294",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ManagementMember": {
     "auth_ref": [
      "r197",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management [Member]",
        "terseLabel": "Management"
       }
      }
     },
     "localname": "ManagementMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r315",
      "r317",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r578",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r315",
      "r317",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r578",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r196",
      "r289",
      "r294",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r303",
      "r315",
      "r317",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r578",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r303",
      "r315",
      "r317",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r578",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r197",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r29",
      "r198",
      "r199"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedAmortizationDeferredFinanceCosts": {
     "auth_ref": [
      "r43",
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of debt issuance costs.",
        "label": "Accumulated Amortization, Debt Issuance Costs",
        "terseLabel": "Issuance costs expensed"
       }
      }
     },
     "localname": "AccumulatedAmortizationDeferredFinanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r42",
      "r239"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r63",
      "r65",
      "r66",
      "r565",
      "r585",
      "r586"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r62",
      "r66",
      "r68",
      "r135",
      "r136",
      "r137",
      "r437",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted Average Estimated Life (in years)"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "terseLabel": "Value of shares surrendered to satisfy tax withholding obligations"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r319",
      "r321",
      "r364",
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based incentive compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from issuance costs from a share-lending arrangement entered into, in contemplation of a convertible debt offering or other financing.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs",
        "terseLabel": "Amount credited to paid-in capital for membership units sold and funded"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by operations:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r321",
      "r354",
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.",
        "label": "Allowance for Doubtful Accounts, Premiums and Other Receivables",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r114",
      "r495"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r114",
      "r226",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense for intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetUnderConstructionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset in process of being built.",
        "label": "Asset under Construction [Member]",
        "terseLabel": "Assets under development"
       }
      }
     },
     "localname": "AssetUnderConstructionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r124",
      "r182",
      "r186",
      "r192",
      "r212",
      "r434",
      "r439",
      "r482",
      "r547",
      "r563"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r57",
      "r124",
      "r212",
      "r434",
      "r439",
      "r482"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r124",
      "r212",
      "r434",
      "r439",
      "r482"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total noncurrent assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NONCURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r323",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r448",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r314",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSProFormaFinancialInformationDetails",
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r314",
      "r316",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSProFormaFinancialInformationDetails",
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "terseLabel": "Success-based fees"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Shares converted in merger (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSProFormaFinancialInformationDetails",
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of the combined company held",
        "verboseLabel": "Percentage of outstanding shares purchased"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of Pro Forma Financial Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Share price (in dollars per share)",
        "verboseLabel": "BioScrip share price as of August 6, 2019 (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSProFormaFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Net revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSProFormaFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r424",
      "r425",
      "r426"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Purchase price",
        "verboseLabel": "Fair value of total consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r424",
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Payment of shares in acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r423",
      "r424",
      "r425",
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Payment in settlement of debt"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r113",
      "r430"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "negatedTerseLabel": "Net loss since acquisition"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Net sales since acquisition"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease obligation assumed in business combination.",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation",
        "negatedTerseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedTerseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "negatedTerseLabel": "Other assumed liabilities, net of other acquired assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "terseLabel": "Deferred tax assets, net of deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r416",
      "r417"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intangible assets, net",
        "verboseLabel": "Total intangible assets, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r416",
      "r417"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r416",
      "r417"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total acquired identifiable assets and liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r416",
      "r417"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Total consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.",
        "label": "Business Combination, Separately Recognized Transactions [Table Text Block]",
        "terseLabel": "Schedule of Consideration Exchanged"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r120",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r134",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of Operations and Presentation of Financial Statements"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Less: cash acquired"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r38",
      "r116"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r117",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r109",
      "r116",
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS - END OF PERIOD",
        "periodStartLabel": "Cash and cash equivalents - beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r109",
      "r483"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CatastrophicEventDomain": {
     "auth_ref": [
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Catastrophic event, for example, but not limited to, earthquake, windstorm, fire or explosion.",
        "label": "Catastrophic Event [Domain]",
        "terseLabel": "Catastrophic Event [Domain]"
       }
      }
     },
     "localname": "CatastrophicEventDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r122",
      "r124",
      "r149",
      "r150",
      "r151",
      "r153",
      "r155",
      "r167",
      "r168",
      "r169",
      "r212",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r268",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Number of shares purchasable through warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Class of warrant or right, outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r268",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r28",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding (in shares)",
        "verboseLabel": "Number of BioScrip common shares outstanding at time of the merger (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails",
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock; $0.0001 par value: 250,000,000 shares authorized, 180,178,308 shares issued and 179,794,586 shares outstanding as of December 31, 2020; 176,975,628 shares issued and 176,591,907 shares outstanding as of December 31, 2019."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Fair value of common shares"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r301",
      "r302",
      "r318",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r71",
      "r73",
      "r74",
      "r81",
      "r557",
      "r574"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "NET COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r227",
      "r231",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Computer Software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r172",
      "r173",
      "r196",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r172",
      "r173",
      "r196",
      "r479",
      "r480",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r172",
      "r173",
      "r196",
      "r479",
      "r480",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r172",
      "r173",
      "r196",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r170",
      "r172",
      "r173",
      "r174",
      "r479",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r172",
      "r173",
      "r196",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r270",
      "r271",
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.",
        "label": "Contract with Customer, Receivable, after Allowance for Credit Loss",
        "terseLabel": "Rebate receivable"
       }
      }
     },
     "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.",
        "label": "Corporate Joint Venture [Member]",
        "terseLabel": "Joint Venture"
       }
      }
     },
     "localname": "CorporateJointVentureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r85",
      "r531"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "COST OF REVENUE"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsProductLineMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered from specified product or service, when it serves as benchmark in concentration of risk calculation.",
        "label": "Cost of Goods and Service, Product and Service Benchmark [Member]",
        "terseLabel": "Cost of Goods and Service, Product and Service Benchmark"
       }
      }
     },
     "localname": "CostOfGoodsProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Depreciation expense in cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Revenue"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r392",
      "r399"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r392",
      "r399"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r171",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Company's Largest Payer"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerListsMember": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about customers such as their name and contact information; it may also be an extensive database that includes other information about the customers such as their order history and demographic information.",
        "label": "Customer Lists [Member]",
        "terseLabel": "Referral sources",
        "verboseLabel": "Patient referral sources"
       }
      }
     },
     "localname": "CustomerListsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails",
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Indebtedness"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r548",
      "r550",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r22",
      "r252",
      "r550",
      "r562"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal Amount",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Consecutive trading days threshold"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r494",
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Face amount of debt instruments"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r50",
      "r254",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective rate on term loans at end of period"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Quarterly installment payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r51",
      "r129",
      "r259",
      "r260",
      "r261",
      "r262",
      "r493",
      "r494",
      "r496",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r493",
      "r496"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Discount",
        "terseLabel": "Original issue discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r393",
      "r399"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs and third party fees"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r43",
      "r495"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Debt Issuance Costs",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r127",
      "r393",
      "r399",
      "r400",
      "r401"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes - net"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r24",
      "r25",
      "r382",
      "r549",
      "r561"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r393",
      "r399"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetDomain": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.",
        "label": "Deferred Tax Asset [Domain]",
        "terseLabel": "Deferred Tax Asset [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.",
        "label": "Deferred Tax Asset, Interest Carryforward",
        "terseLabel": "Interest limitation carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetInterestCarryforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails",
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r385"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails",
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Operating loss carryforwards subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Compensation and benefits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "periodEndLabel": "Balance at End Period",
        "periodStartLabel": "Balance at Beginning of Period",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails",
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails",
      "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r373",
      "r385"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Deferred Expense [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": {
     "auth_ref": [
      "r390",
      "r391",
      "r431",
      "r432"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill.",
        "label": "Deferred Tax Liabilities, Goodwill",
        "negatedTerseLabel": "Goodwill"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan expense"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Company contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution percent of employees' gross pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r114",
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAmortizationAndAccretionNet": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Depreciation, Amortization and Accretion, Net",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAmortizationAndAccretionNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r114",
      "r179"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "totalLabel": "Total gain (loss) on derivatives"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r449",
      "r452",
      "r458",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r446",
      "r449",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r59",
      "r60",
      "r478"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "totalLabel": "Total derivatives"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.",
        "label": "Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement",
        "terseLabel": "Interest rate swaps"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement [Abstract]",
        "terseLabel": "Fair value - Derivatives in liability position"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r442",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional amount of derivative"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r441",
      "r443",
      "r444",
      "r446",
      "r447",
      "r454",
      "r458",
      "r464",
      "r466",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r131",
      "r441",
      "r443",
      "r446",
      "r447",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Hedging Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecurities": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share",
        "terseLabel": "Dilutive potential common shares"
       }
      }
     },
     "localname": "DilutiveSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r289",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Net Revenue Earned by Category of Payer"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Incentive Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash distribution paid to unit-holder of limited liability company (LLC).",
        "label": "Distribution Made to Limited Liability Company (LLC) Member, Cash Distributions Paid",
        "terseLabel": "Cash distributions"
       }
      }
     },
     "localname": "DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r130",
      "r512",
      "r552",
      "r570"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Due from joint ventures"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r130",
      "r512",
      "r553",
      "r569"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to joint ventures"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r82",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r148",
      "r149",
      "r153",
      "r154",
      "r155",
      "r160",
      "r161",
      "r558",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "(Loss) earnings per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted (in dollars per share)",
        "verboseLabel": "Loss per common share, basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "LOSS PER COMMON SHARE",
        "verboseLabel": "Loss per Common Share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r82",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r149",
      "r153",
      "r154",
      "r155",
      "r160",
      "r161",
      "r558",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "(Loss) earnings per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r156",
      "r158",
      "r159",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "(Loss) Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LOSSEARNINGSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r375",
      "r402"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "US federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r375",
      "r402"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r375",
      "r402"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r375",
      "r402"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "terseLabel": "Non-deductible compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r375",
      "r402"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r366",
      "r375"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r375",
      "r402"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and local income taxes net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period of recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r139",
      "r145",
      "r147",
      "r166",
      "r213",
      "r258",
      "r263",
      "r358",
      "r359",
      "r360",
      "r395",
      "r396",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r581",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination.",
        "label": "Equity Interest Type [Axis]",
        "terseLabel": "Equity Interest Type [Axis]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.",
        "label": "Equity Interest Issued or Issuable, Type [Domain]",
        "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r78",
      "r108",
      "r114",
      "r571"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Capital distribution from equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r39",
      "r183",
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investments in equity-method investees"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r39",
      "r108",
      "r120",
      "r211",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurocurrency Rate"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r472",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r473",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r304",
      "r305",
      "r310",
      "r312",
      "r473",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Markets for Identical Item (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r304",
      "r305",
      "r310",
      "r312",
      "r473",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r473",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r126",
      "r374"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "Federal income tax expense (benefit)"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "US federal income tax expense (benefit):"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Maturities of Lease Liabilities, Financing"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancingReceivableDeferredIncome": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fee received for commitment to originate or purchase financing receivable where likelihood of commitment being exercised is remote. Excludes financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, Deferred Commitment Fee",
        "terseLabel": "Deferred commitment fee"
       }
      }
     },
     "localname": "FinancingReceivableDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible asset useful life (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Total accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "2026 and beyond"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r227",
      "r229",
      "r232",
      "r235",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails",
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r232",
      "r533"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Total gross intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r227",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails",
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r232",
      "r532"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Total intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails",
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet": {
     "auth_ref": [
      "r470"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net gain (loss) reclassified into earnings when interest rate cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.",
        "label": "Gain (Loss) on Discontinuation of Interest Rate Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net",
        "terseLabel": "Proceeds from early termination of hedge"
       }
      }
     },
     "localname": "GainLossOnDiscontinuationOfInterestRateCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r114",
      "r438"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "negatedTerseLabel": "Business casualty loss",
        "verboseLabel": "Gain on business casualty loss"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of other assets.",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "negatedTerseLabel": "Loss on sale of assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposition of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r114",
      "r255",
      "r256"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r218",
      "r220",
      "r546"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill - net book value, end of period",
        "periodStartLabel": "Goodwill - net book value, begging of period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r223",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r114",
      "r219",
      "r222",
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GovernmentContractsConcentrationRiskMember": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. Risk is the materially adverse effects of termination of a significant contract or group of contracts or from future loss of a significant portion of business with a specified political body or unit thereof, such as Department of Defense, US Navy, New York City.",
        "label": "Government Contracts Concentration Risk [Member]",
        "terseLabel": "Governmental Programs"
       }
      }
     },
     "localname": "GovernmentContractsConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r84",
      "r124",
      "r182",
      "r185",
      "r188",
      "r191",
      "r193",
      "r212",
      "r482"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "GROSS PROFIT",
        "verboseLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r446",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HurricaneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tropical windstorm with sustained winds of 74 miles per hour (119 kilometers per hour).",
        "label": "Hurricane [Member]",
        "terseLabel": "Hurricane"
       }
      }
     },
     "localname": "HurricaneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "LOSS BEFORE INCOME TAXES"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r78",
      "r114",
      "r180",
      "r209",
      "r554",
      "r571"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Equity in earnings of joint ventures",
        "terseLabel": "Proportionate share of earnings in equity-method investees"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails",
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails",
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r376",
      "r380",
      "r387",
      "r397",
      "r403",
      "r405",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r146",
      "r147",
      "r181",
      "r374",
      "r398",
      "r404",
      "r576"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "INCOME TAX EXPENSE (BENEFIT)",
        "totalLabel": "Total income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r120",
      "r370",
      "r371",
      "r380",
      "r381",
      "r386",
      "r394",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net",
        "negatedTerseLabel": "Other noncurrent assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedTerseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuranceSettlementsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.",
        "label": "Insurance Settlements Receivable",
        "terseLabel": "Insurance receivable"
       }
      }
     },
     "localname": "InsuranceSettlementsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r77",
      "r178",
      "r492",
      "r495",
      "r559"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.",
        "label": "Interest Expense, Related Party",
        "terseLabel": "Accrued interest expense"
       }
      }
     },
     "localname": "InterestExpenseRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "totalLabel": "Total other expense"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r106",
      "r110",
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateCapMember": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount.",
        "label": "Interest Rate Cap [Member]",
        "terseLabel": "Interest Rate Cap"
       }
      }
     },
     "localname": "InterestRateCapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.",
        "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "terseLabel": "Total interest rate costs expected to reclassify during next 12 months"
       }
      }
     },
     "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r55"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r7",
      "r56",
      "r120",
      "r163",
      "r214",
      "r216",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r88",
      "r89"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Equity in earnings of joint ventures"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_JuniorLienMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal right, after the claims of senior lien holders are satisfied, for a creditor to possess property or other collateral in satisfaction of an outstanding debt in the event of borrower default or bankruptcy. Excludes second mortgage loans.",
        "label": "Junior Lien [Member]",
        "terseLabel": "Second Lien Term Loan"
       }
      }
     },
     "localname": "JuniorLienMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Incurred rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Lease Liabilities, Operating"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "2026 and beyond"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letters of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Undrawn letters of credit issued and outstanding"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r47",
      "r124",
      "r187",
      "r212",
      "r435",
      "r439",
      "r440",
      "r482"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r35",
      "r124",
      "r212",
      "r482",
      "r551",
      "r567"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r49",
      "r124",
      "r212",
      "r435",
      "r439",
      "r440",
      "r482"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r22",
      "r23",
      "r124",
      "r212",
      "r435",
      "r439",
      "r440",
      "r482"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total noncurrent liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "NONCURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of catastrophic event, for example, but not limited to, earthquake, windstorm, fire or explosion.",
        "label": "Catastrophic Event [Axis]",
        "terseLabel": "Catastrophic Event [Axis]"
       }
      }
     },
     "localname": "LiabilityForCatastropheClaimsByCatastrophicEventAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LienCategoryAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of lien, for example, but not limited to, senior or junior.",
        "label": "Lien Category [Axis]",
        "terseLabel": "Lien Category [Axis]"
       }
      }
     },
     "localname": "LienCategoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LienCategoryDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal claim on the property of another party to secure the payment of a debt or the satisfaction of an obligation by category, for example, but not limited to, senior or junior.",
        "label": "Lien Category [Domain]",
        "terseLabel": "Lien Category [Domain]"
       }
      }
     },
     "localname": "LienCategoryDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r45",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Net borrowing availability"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Commitment fee, unused portion"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r22",
      "r253",
      "r550",
      "r564"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Principal amount of debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails",
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "periodEndLabel": "Second Lien Notes fair value as of December 31, 2020",
        "periodStartLabel": "Second Lien Notes fair value as of January 1, 2020",
        "verboseLabel": "Total debt instruments"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r133",
      "r249"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "2026 and beyond"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r133",
      "r249"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r133",
      "r249"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r133",
      "r249"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r133",
      "r249"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r133",
      "r249"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of discount, deferred financing costs and current portion",
        "verboseLabel": "Total long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time.",
        "label": "Long-term Debt, Weighted Average Interest Rate, over Time",
        "terseLabel": "Weighted average interest rate paid on term loans during period"
       }
      }
     },
     "localname": "LongTermDebtWeightedAverageInterestRateOverTime",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails",
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r51",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails",
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MajorityShareholderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership.",
        "label": "Majority Shareholder [Member]",
        "terseLabel": "HC Group Holdings I, LLC"
       }
      }
     },
     "localname": "MajorityShareholderMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r109",
      "r112",
      "r115"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r69",
      "r72",
      "r79",
      "r115",
      "r124",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r146",
      "r147",
      "r152",
      "r182",
      "r185",
      "r188",
      "r191",
      "r193",
      "r212",
      "r482",
      "r555",
      "r572"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net (loss) income",
        "terseLabel": "Net (loss) income",
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails",
      "http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesReceivableRelatedParties": {
     "auth_ref": [
      "r130",
      "r512",
      "r570"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from parties associated with the reporting entity as evidenced by a written promise to pay.",
        "label": "Notes Receivable, Related Parties",
        "terseLabel": "Notes receivable"
       }
      }
     },
     "localname": "NotesReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Depreciation expense in operating expenses"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "OPERATING COSTS AND EXPENSES:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r182",
      "r185",
      "r188",
      "r191",
      "r193"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING INCOME (LOSS)",
        "verboseLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r498"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r498"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r498"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r500",
      "r502"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedTerseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "auth_ref": [
      "r500",
      "r502"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments, Use",
        "terseLabel": "Cash paid for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePaymentsUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r505",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate, operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r504",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term, operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r61",
      "r63"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Change in unrealized (losses) gains on cash flow hedges, net of income taxes of $0, $259 and $234, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "negatedTerseLabel": "Income taxes on unrealized gains (losses) on cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r61",
      "r63",
      "r451",
      "r455",
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Pre-tax gains (losses) on interest rate derivatives recognized"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r63",
      "r67",
      "r456"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeGainLossOnDerivativeNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "negatedTerseLabel": "Accumulated comprehensive loss reclassified",
        "terseLabel": "Gain (loss) location of derivative instruments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax": {
     "auth_ref": [
      "r457"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeGainLossOnDerivativeNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from discontinuance of cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax",
        "terseLabel": "Gain (loss) location of discontinued derivative instruments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeGainLossOnDerivativeNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Gain (loss) location of derivative instruments not designated"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r70",
      "r73",
      "r76",
      "r80",
      "r258",
      "r484",
      "r489",
      "r490",
      "r556",
      "r573"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "OTHER COMPREHENSIVE (LOSS) INCOME"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherExpenseDisclosureNonoperatingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expense, Nonoperating [Abstract]",
        "terseLabel": "OTHER INCOME (EXPENSE):"
       }
      }
     },
     "localname": "OtherExpenseDisclosureNonoperatingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other amortizable intangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Paid-in-kind interest capitalized as principal",
        "verboseLabel": "Interest rate PIK"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PartnersCapitalAccountRedemptions": {
     "auth_ref": [
      "r263",
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total change in each class of partners' capital accounts during the year due to redemptions and adjustments to redemption value. All partners include general, limited and preferred partners.",
        "label": "Partners' Capital Account, Redemptions",
        "terseLabel": "Shareholder redemptions"
       }
      }
     },
     "localname": "PartnersCapitalAccountRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForDepositsAppliedToDebtRetirements": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow during the period as a deposit on account for application (deposits to retire or pay down) against an amount of debt owed by the entity.",
        "label": "Payments for Deposits Applied to Debt Retirements",
        "negatedTerseLabel": "Retirement of debt obligations"
       }
      }
     },
     "localname": "PaymentsForDepositsAppliedToDebtRetirements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForMergerRelatedCosts": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the reporting period for charges associated with the mergers.",
        "label": "Payments for Merger Related Costs",
        "terseLabel": "Payments of transaction costs"
       }
      }
     },
     "localname": "PaymentsForMergerRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r94",
      "r97",
      "r132"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other investing cash flows"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "negatedTerseLabel": "Debt prepayment fees"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Deferred financing costs",
        "terseLabel": "Fees incurred netted against proceeds"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "terseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Exercise of stock options, vesting of restricted stock, and related tax withholdings"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r95",
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash paid",
        "verboseLabel": "Cash paid in conjunction with the Merger included in purchase consideration"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Business acquisitions, net of cash acquired",
        "terseLabel": "Purchase price, net of cash acquired",
        "totalLabel": "Fair value of total consideration acquired, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails",
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Acquisition of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r323",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock",
        "verboseLabel": "Preferred Stock and Certain Warrants"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (in shares)",
        "verboseLabel": "Preferred stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of December 31, 2020 and 2019, respectively."
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r36",
      "r37"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInsuranceSettlementInvestingActivities": {
     "auth_ref": [
      "r94",
      "r107"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities.",
        "label": "Proceeds from Insurance Settlement, Investing Activities",
        "terseLabel": "Insurance proceeds from business casualty loss"
       }
      }
     },
     "localname": "ProceedsFromInsuranceSettlementInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": {
     "auth_ref": [
      "r105",
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.",
        "label": "Proceeds from Insurance Settlement, Operating Activities",
        "terseLabel": "Insurance proceeds"
       }
      }
     },
     "localname": "ProceedsFromInsuranceSettlementOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from debt",
        "verboseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from sale of equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfDebt": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.",
        "label": "Proceeds from (Repayments of) Debt",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfNotesReceivable": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Sale of Notes Receivable",
        "terseLabel": "Sale of management notes receivable"
       }
      }
     },
     "localname": "ProceedsFromSaleOfNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from sale of assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r98",
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r42",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r242",
      "r590",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r41",
      "r238"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r15",
      "r16",
      "r240",
      "r568"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r40",
      "r120",
      "r240",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r15",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r15",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Selected Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r311",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r311",
      "r511",
      "r512",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r311",
      "r511",
      "r515",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r509",
      "r510",
      "r512",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Principal prepayment",
        "negatedTerseLabel": "Repayments of debt principal",
        "terseLabel": "Payments to extinguish debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "terseLabel": "Notes redeemed"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of Related Party Debt",
        "negatedLabel": "Redemptions to related parties"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r263",
      "r361",
      "r566",
      "r584",
      "r586"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r139",
      "r145",
      "r147",
      "r213",
      "r358",
      "r359",
      "r360",
      "r395",
      "r396",
      "r581",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r176",
      "r177",
      "r184",
      "r189",
      "r190",
      "r194",
      "r195",
      "r196",
      "r288",
      "r289",
      "r531"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "NET REVENUE",
        "verboseLabel": "Net revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails",
      "http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r172",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r121",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r291",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r83",
      "r588"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Management fee income"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r503",
      "r507"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use asset obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]",
        "terseLabel": "Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAcquiredIdentifiableAssetsandAssumedLiabilitiesDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails",
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSProFormaFinancialInformationDetails",
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "verboseLabel": "Schedule of Estimated Fair Values of Debt Obligations"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r449",
      "r458",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Pre-tax Income (Loss) Recognized in the Statements of Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of Amount and Location of Derivatives in the Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LOSSEARNINGSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.",
        "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "terseLabel": "Schedule of Allocation of Consideration to Intangible Assets Acquired"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r227",
      "r231",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r223",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of the Carrying Amount of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Maturities"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r42",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of Quarterly Financial Information"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Acquired Identifiable Assets and Assumed Liabilities"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r128",
      "r513",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r323",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Summary of Outstanding Options by Exercise Price Range"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r328",
      "r340",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Award Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONStockBasedIncentiveCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Future Amortization Expense for Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorLienMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal right, before the claims of other creditors, of a creditor to possess property or other collateral in satisfaction of an outstanding debt in the event of borrower default or bankruptcy. Excludes first mortgage loans.",
        "label": "Senior Lien [Member]",
        "terseLabel": "First Lien Term Loan"
       }
      }
     },
     "localname": "SeniorLienMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails",
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based incentive compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited and expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited and expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Shares granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Balance at December 31, 2020 (in shares)",
        "periodStartLabel": "Balance at December 31, 2019 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Balance at December 31, 2020 (in dollars per share)",
        "periodStartLabel": "Balance at December 31, 2019 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested and issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Value of shares vested in period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and issued (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions",
        "terseLabel": "Discount for lack of marketability"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at December 31, 2020 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at December 31, 2020 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited and expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited and expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Options granted in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Balance at December 31, 2020",
        "periodStartLabel": "Balance at December 31, 2019"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r330",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at December 31, 2020 (in shares)",
        "periodStartLabel": "Balance at December 31, 2019 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at December 31, 2020 (in dollars per share)",
        "periodStartLabel": "Balance at December 31, 2019 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "verboseLabel": "Shares issued pursuant to acquisition (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r320",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r120",
      "r323",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock Based Incentive Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Lower range limit (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Options Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Options Outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Upper range limit (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Stock price threshold (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r348",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life of options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable at December 31, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life Exercisable at December 31, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life at December 31, 2020",
        "verboseLabel": "Average time to liquidity (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONFairValueofAwardsDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable range of years"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "terseLabel": "Shares surrendered to satisfy tax withholding (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Computer software, purchased and internally developed"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r125",
      "r374",
      "r398"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.",
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "State income tax expense (benefit)"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r122",
      "r124",
      "r149",
      "r150",
      "r151",
      "r153",
      "r155",
      "r167",
      "r168",
      "r169",
      "r212",
      "r258",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r54",
      "r135",
      "r136",
      "r137",
      "r139",
      "r145",
      "r147",
      "r166",
      "r213",
      "r258",
      "r263",
      "r358",
      "r359",
      "r360",
      "r395",
      "r396",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r581",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Consolidated balance sheet data:"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r166",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r258",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Additional shares issued (in shares)",
        "verboseLabel": "Common shares issued to warrant and preferred stockholders at time of the merger (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails",
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r27",
      "r28",
      "r258",
      "r263",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r54",
      "r258",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Purchase of BioScrip, Inc."
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r258",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Net proceeds from the issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r27",
      "r28",
      "r263",
      "r322",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Fair value of share-based instruments"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r27",
      "r28",
      "r258",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Cancellation of common stock"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r28",
      "r33",
      "r34",
      "r124",
      "r206",
      "r212",
      "r482"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Equity, ending balance",
        "periodStartLabel": "Equity, beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r123",
      "r263",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationExchangedDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r491",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r491",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r491",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r491",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r518",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Summary of Valuation Allowance"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]",
        "terseLabel": "Medical Supply Vendors"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trademarks/names",
        "verboseLabel": "Trademarks/Names"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/BUSINESSACQUISITIONSConsiderationAllocatedtoIntangibleAssetsDetails",
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r53",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock",
        "verboseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r53",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, at cost (in shares)",
        "verboseLabel": "Treasury stock held (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r53",
      "r266",
      "r267"
     ],
     "calculation": {
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock; 383,722 shares outstanding, at cost, as of December 31, 2020 and 2019, respectively."
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r258",
      "r263",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "terseLabel": "Shares repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnbilledReceivablesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.",
        "label": "Unbilled Receivables, Current",
        "terseLabel": "Unbilled receivables"
       }
      }
     },
     "localname": "UnbilledReceivablesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r369",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.",
        "label": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]"
       }
      }
     },
     "localname": "ValuationAllowanceByDeferredTaxAssetAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Deferred tax asset, additions"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Valuation Allowance [Line Items]",
        "terseLabel": "Valuation Allowance [Line Items]"
       }
      }
     },
     "localname": "ValuationAllowanceLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceTable": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of an entity's valuation allowances to reduce deferred tax assets to amounts which it is more likely than not will not be realized, including a description of the deferred tax assets for which the valuation allowance has been recorded and the amount of the valuation allowance.",
        "label": "Valuation Allowance [Table]",
        "terseLabel": "Valuation Allowance [Table]"
       }
      }
     },
     "localname": "ValuationAllowanceTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Fair value of warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average common shares outstanding, basic and diluted (in shares)",
        "verboseLabel": "Weighted average number of common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.bioscrip.com/role/LOSSEARNINGSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3337-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080549-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=6378536&loc=d3e10095-111533"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=SL6757427-112606"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130534-203044"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121554379&loc=d3e9972-128506"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121554379&loc=d3e9979-128506"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r593": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r594": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r595": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r596": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r597": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r598": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r599": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r600": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r601": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>102
<FILENAME>0001014739-21-000011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001014739-21-000011-xbrl.zip
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MQ_C>WQ37-(N-1%>R43EH 0!L-),3RF>ADX@N%+<PZ-S3%-<4H<&4I0X!E/0
M);A@L!3CG4!?O+!Z8:"YMRFN*8(SV?/M2@G&(Z0 GKQ@G\1$$-[RFX4!9P93
M7%.$J8!B?4;L9-0:ARI$-$Z2!$JU0&%JOO&9W137%%$R4A17(D#V'(\7"D;6
MYAK@<LS9H&@\2K.8XIHB/EXZ'V4MQJX\*#!!,TZ20^P*CA%Q8?"9\137%"'3
MUF=3<I0Z!L@JA6# LO(+LF@*Y^4Q:^J>L*W+%_.*W9.3$<O,:+2:&+O1Q!A=
MT7WGM9V?XI#6^></CX>=$8T8JH=WGR[@6\+>(I;Z_-0?2<Y3A"YGS!81;#)!
MB")R8<^C)D7[\Y)=2S"_>6+Y&CX_LE:#P=0JVLXB>QXIU08615LKHXD14_SI
MI>[6MS_7TQOUXC0:;XQ&)ZR2A_7?ZM<\.:N]VKXWP)NVU;CKP'_V>D=Z*Y(N
M$BP8,#D'"XG= )-]]%$)L^3UDE+?&D GIY)/%JU.X%WV(18,.D?E?'%6SK\I
M>]$A9LJ8#@;#L^OH[5"_,QC6X].BS8M!_X#YV%NC./ZKZCN_WR3VFU]#^;'"
M[T7K@,O/KY?8/>:7EQ>X==5L*0/))*T5(0.20E]KD(?B/7KMBIA_+FW3).AX
MR9)WMEM;JI[7Y1\].;MZY#KJ;3P:#/E'3&HEG_=(F!;=%LY+^TB^[B!-VH?\
MA7Z37W9Y]#8,_%0'OC.FFR]7CWPSF8TF84MQCM4B*&V8P19" 1TCJ7B>E36?
MP?9H.'Y<FSOGDRYME7,#UZ;QX2!O]-^Q%_?)[%W]E&@3>W2%7B_H -/9;X3=
M\>'.&9_0:\H\B?"V@$/,0A5(V@2OP))2&C@,2#$TJ)#,BP[&3I>?Z-E@R$8.
M1^/AX/B0GG:QTV.M].FC3EI_QY>^KII^.QD..PG["UE%QE&4P46?M),@%7LL
M"I+40FJC(C1AB_C<@GLG^X]#24Z&7("5)V19O(-@V='T5&K^5VK09IK[ >[6
MC_,,.\/7V#WA>'S2&I.?8_19(%-U?'_,?LI=N*:SW[\#[&%:(>K&YP Q,K=R
ME#F2)N],%$U(-JM6>](P[QRX^K;=Z7=Z)[VIT>2+O529LQ,O]@;B/#T9C0<]
MXBAJ-%[(!"B508N(;#!$ N+P5[(]*5)%=O2*#JZAU,'3)77NFCK?TY)ZSJCS
M0P!SA)RIA\.WH]5^GKRI(<37H+X[3=A,$CF+0;N0#1JPJB"A)0A2)A'(2K$D
MT=1(="N=V$@2?4^G]3DCT9SZ/Y/\@\]/7T0*6<RNE)@A3LIZ22PNVI2U<C4*
M;(0QFU,_Z*>AD(JE"*NC$K%ND92Q]JL. EQ0+G%DU@ *?1?0D^G2C7XYJ==X
M>=([7DATV;T%FY)11A40A#&3+M$'5A9):6S2_I_O$N,Z97Y<;[3T;[^I0H14
M!"0EH/000@Y4"B6+BMB[S;%)&XSFCS:+Z]%J#.R04&#_PP#9&),D4,X9&77D
MP'O1:5,S4D[&--P9E/%['-)GWUQ$R*7Q5IA:Y- F4#I[ZXB$L191)(0FS,1]
M0J^?^!O#R2KV=F?T]LG9$^JGPQKG?IZ*_H[Z)_1L..CQE_@;:?RF,SZ\G#N;
MEN-ZPP/=D+IW<=._G+R(; ,/&2E58D60ED)07GHC01@L"+Y!RU%+MGT#VV:S
M0*6-T"*8E&72[$7K8'V-B$0MF$U"F0:E)"S9]BULFTEJ1!!!"V]"-*@ 2@YU
MW9U4T;75. =KS;:D?P7W^> =#?OURI<\&WTKSG-'_T8:U<@<<VQ&@ZYM&PH$
M3TID,C)E&Z(*S3:J2^+-K7T50MDL/*BL$;0)*&U0F4G'K./@(3?;OBZ)-[>F
MUAI5,TV#K\1S:$/64*SUI9#W*'!I:N^#>*LI#4[ZXWOK&S"C&7BE;90:;10(
M(0 :;\BD4CL'H"Y-ZANPY-J<&U2PD'SQ%HK/[,:%D,C67<Z8E"ND5;/UVA>@
M?3H8C;?*\\$@CUX.!_DDC5]TII>F>RO.[YP<\W5^DCDXYXTLP=36&0% F>!3
M\CZBI&SXLR8UN5F2;%XU64W*3!%"BK63DB2/5F,(QD2)B%$V.S18DFPNP@#M
MC$ZQH'32@17>BU"@:,B 4@"F^=_Z^O=[39]T!CMIV#F>/G9W4@!$U%HLSIFH
MD@(2+C <CF^@A4^0DOT(AUG"\14XS!3@,%E88P5B0@OL5P94%L&+& S4M-6%
MJ5MQ=[C,OE)$L*1B=A$T*?;5?%"I>$$^$\F")C0(Q&F5<;A?UMS^Y_UX18Q&
M,C0Z!##,RP@(@IV^'&02@A4.1$?%SK\1GJ<=%+/6>'?C&!!&<$8&I5B).1N3
MC"91%$IG([1KD!);<F6>=$]&5P L$2H'66AOK.=@@%F62W3%S[_NN5\;-8\[
M2N]$XWAM#+)[E"E+R"$%B5[GZ&PA_H@6IP+HS\"0V>L911Z#$)E#6M8W&6.T
M*K#N"<F[9'-<ZIDIL.A%)]7K] ]6#X8T*1/8%&V3B@I*Z%C(24BV5C-0$FP.
MM2@.NB;Y-TN>S(O.243$2B8$BP9J\YALG  K4W(B2=VDK*YY<5!GL Q28O'9
M$U*4X#6B-<9#< :S],$T*4-J+D"<R3*#,#$Z<N230U#6!E,L"&-3*#H401<@
M\O]:ER\:"B(>C]F%.Z\^N-%_T1F/N[0]2&]7AV]K6<Z[UK-^HCS][="]=NJ/
MQ)!.BU2D4:#9MU.Q-M765@8?DI#%PWE%.Q%D0T']C3WSC8>O'^X<4^I@M[KH
M=UZNE*%A'?H1G1\)Y*)U5B27E,>ZF35XC\H28*3@7+Z4/4:GM83INR3N*E!?
MD;BKI_Y0OOID14,H0P&L%C$QFMD;5K V.,*%\6QF@^E,')V830*;1-'*0P;A
MP4<O2NT!D3PTJD_I'&(ZFT0Q(P6[J<+I0K5A&/HD/94H;7$D;+HL3L.1;^OR
MQ5UC^AWCIEI"WV[<KIWZ([*  #9$U%IG*"['5$)=BE>EF&!=$XJ+G=<YJ/'W
MQ=3>U:(K5S*$%WA7E8DA9R-LD;)6SJ7(<7=Q0FF%QNOB&F"EY@K%&07@[#.2
M=S*"!$B@@Q)%E9R\=L:)W(0 ?+Y0G$D$;J1,.2G2 0+4EMG>BA+(>:M9N8HF
M%*GX6Q1K^R8:5G]BD35J,JJ8(D3)2.PA.N_)4(XJ:RD-7L1R#=:H]XWB;#1J
M2;%6)E28A(. [.4[!\53\#H9"ZKI&O7>49R)1LV42V9#Z%/Q8%W K-@]M2I9
MXT.2LND:]26..POOH%(L#ECP; 34-3 C;9VM>_^+DDW8F#@_$,Y&E[)S6LAE
MXRPJAC '$QA*Q[;0.9)$3=>E]POA3!2I\H*,S@5=J9W57<C"2"K!LGJE:-W\
M=JSZF)V(IT^'E#OCIS@<GI7!\#T.\]4&ZS0\H.$6CPFCV3]X,1B-KIYYEPL)
M4VQ/58A$"J@]J0(%P#OE'63D  *+5WK^<3IOP<UHK9Z,#R?-[Z[G1:SQT=&X
MDY[6C=+#LVGE:/P<] @UJ4L);R$: ,.\L$8)U%*$&#'(YM-CTGQUM9]?#!)V
M?S\9=D:Y,^FSN"3*-^F1['Q.0EFLM2"402C&1J\AD<9TWFZSV429D1YY1IF9
MT=VD\4T4J2>/5M]AIUMK/^P.MDH9T?C9R?AD6']*_?#\=S6$1L)*HYS1VAC#
M+CQ$;3Q(E-J)0C;.<:/+NZ'1O.""*2:G(*K:\#NC1U525%ED%6-T[KR_X5S&
M4G.(R^>1T@_@$H,5*B:=2"@H2.S&:9E8^[(J5L8L@)N]4=L),S(O.KW.&"^:
M#'\\L2E=8+//8$RJ:3L:G/>!#(M4C.0MU;XX\R\_<XS3%.5)9["4%"+%"#+D
MR'H.,LBD6*B"7@#[,W-_]^=R: I'T5F[E(I2M18?6O 0/2:7+1C9 ,%?$FJN
M-)1(@DJ(5DH2X-![DY1-:(I5$$JCBHO6-L$32[':[3)._41/SM:HT)#1KGRK
M&UZNKD =(D?*^0GUJ73&NX-:5JCN'%X_/>8KWWDOX9E,HU(VMD3EO2P6@M">
M H?3@ESML6>#7GBT66!KQ[++.H>+B+&U!K0R*CHHH"V@MJ[NS"4-6D;?A(RJ
M9DKT3-:V4LQ*A>!!*8+:;A6T!THA8< B59/*##9!HF>"<6;'S@@K8K(2E*1@
MLRO)D$47C:?4@"R"1DKTC)J5^NABX1"1U3AX]N^+UI(Q-3IB3KY)G28;(-$S
MRM$C#);]+%E$ .-=9%\; @5GE7=:-:D#W"I?(7>Z)^/..]JAQ ';N$.C]=/4
M/<F4S\OEUW9O$QYLE74<]CFB&KVDX0[#S82X^0+7@\(W''SA5]L,-I,*P7N7
M$*40&D+4"%8;(5G8/:(534@1NU<JK/>.NX,SHIWQ(+W=.K[%S$ C:<$>O+!.
M65-W?%%V/L2227LG0V07("]I<<5P;--H/.RD,>4)*U;O9J%[]J0(GJ-W"I1)
M$@=W$?FU$YZ=_V@P&=,@9W]QS,9L8@+2,K/74+?=6'!9Q.R,(,+H!)@+_;"D
MP@S-QFQH89RQ*7EG<K2  $%-MD/*X)+(:)NP^6.1S<:,Y@]J5QWA3*DM$Y6U
MT?BZASPH+_B L?._"OER..#?.SY[V65U7N/_R\;C5XOS7ZP;EY/ZW9<GO>.F
MK.9;92A;H5*1&A@LC+&(9)5VPFF3\OPOZLTA/E-<(ZM)S4X8-#)Y5JK!BQQ\
MS9(I#D!3 [)6;X_/QR//3EB?UE5-/GTR'],084K)J)2(?2"+4+1%X9,7)>4L
M%9!IP KYO(,U1<E*T0-)I\EI#\(X+Y(0,=4\)I>2H 61K(\U%0E'=#CHYHW>
M\7#P[NZK;TXS\T0;$9S20OB:NL]!I]'1"Z.MJ<6CTH+(U<R@FJ:]FK0:$U@L
MU++,)@([_]ERP)@IDDL+)E4[@S)FU[WJOLN7:_2.NH/)-R9+1@V1L9J&X:UU
M8)" #5DP*6A?C$D& A]9,!F;,7#3S//4/)(YR,AB!B E!BE2;<10)&F1%LV.
M31;N7O7SI $:Q] GMTG0FQ<A(RT#(@D$77N8$<=;D%3 ++2-&?R""=G]8S5%
MN7+2L%LH= !KP,42G8P<=>D0I/%.-&DM_#PK=)+=6K]9TUL_U;R[WMIP![N+
MF=H N=824L(6Y0&40I]"Q(C.& G&Q@;-3LX7G#.J4>,CNY99.BLE),J1_]'9
M"ND4>RZF"35JYA3.V?3YS-J[I&7Q-@$+:? )710BI^A"/._FLDC*]F-Z_T4V
MV2)JW&@24@PYY*+ F^!U( [: UIR(D6[:!KW?C&=C=IU9(MT05"4$6R=B099
ML@U%%0I"-RF)?QXQG5'2OM?18T9*$E10H:0<ZTJN$I'5L6^0G+[H8.QT^8F>
M#89/<8P<<PR.#^EI%SN]T9.S3Q]UTOH[OO1UL'\[&0X[":?7S_L9=H8U#[4N
M"-=0Z(96-U^,IQ91>^0D!"+X9#('NT&SHBBUYC3%%(5+#5C,FL?F:7<R4^&S
M%C+KD+%D(.NQ9@H+U&72 ;;$^9^IF&^HICA105XZM@?>AMH%W"BT)3E?3 D
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MO9/>M+CR&H>=V@YON_;SN\:4)SB:?+IT%Y9B^$/E\/F/(:F5,!&T5;X$+YR
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M1N&-+$9(8S7KQ1""B*AL"5@+Q9YO6)EO1BX:(B;KY%WM<A%YK-A[FE3#T5A
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M9:N_D&L,E+5+7@<1 X%&ZVNY>70214I1"SW_8KH@5+@3B4^*H_?@HU;10\W
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ME\2]DQFI$W[""1$SGGTD6&^2KT[GP\<'+K][^?GE^_KEFZ>V#&4B E4$@,"
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M294:C!C.$YL$8B/A<S620*,ZY'^CPN1)>I B$27QP_\_*O_^PPXHY.V$P]5
MH1WFYYO&_#S2P<F-KA=;&'.5D2,Z C0LI2.*TF8CVM[>-*TX'T4!6#P=;CF$
M(I%N&[^:4" _IL1CIE4BD9R.."VJU&E!F(# [<1[6\%O=OI";]=#8R#L$G4/
M'PG53,<IJ%EO*"ZWYLS0B<(P/1PY7$F &;P8 ?^HOIV)ZD;+N7QS0I94W,"3
M)=ZE185PB"^Q!TR_)$ Z_&(..I4@]!,/$CZD"7Z@8U!)"!'EW^#93=Y'-#ZF
M%ZW76NJ^2F0UOIE8/TSQ-.7((%KP!>;9&LRC&*F2.357&'NEF&&90>96B?(P
MSJ*H4+HU7@IS31'' +*CXA@+#VRUB4..A'_A'/RY_QM^@MD3^%+)7U$NRU8.
M7?Q\X3*]5\83NI!D$KXG?.:/A2H3>_O5Q?F/[O;SJ<8BE3RZ+N)4<Z"87]J_
M7E2(PKMR:!<WA.N?KVQ^%J7L%R^*\4XCPFSU=YF'_/+N_&*;L0*X#N&*DM)#
MX#>[KIZB")*,K%HPE(:A;!.2$E"ZZ[L=/KJJX3=XM+!PXBJVKA!U1KXFNJ2A
M7O.L3!. ,U8I3&4#VFHA=2J8ZD;]":/,$31682U#IFVV4@#M/!KSC%_VKO>,
MJ!0SG:JHY5+YXMF/KN695Z##5"G3<FT?:D7D^BHZ.3OY%"G9&;.KY/9H9\QN
MPE#^.L:LX['<.AT?1!8^,]ZW._]A[4\*B:(>KQ<SU*"9#;8FZY(?O6C4U%2+
M1O&)D79W*1.&K3@Q:P.<#AQ!S:0>EN_MC 8;>]:&7L%0'1=96H0@9X=M/CN+
MQDV6V4R2P=B*%7MXS$=.'T%I^K[C";-"JS'(+C3+E:#-#"NIV.Q#JSA/R9@W
M?V^PRLNEQJ6D^E[3U2,D5Y/5[FDK\MI+BVLSY!:GZ06HO"]H8:1['KK:Q<%(
M/L$<PTF-<6J"()FICXT0<R8))[$[PIN*$<("\9X@N=V*D\D,<H)MCH_$ZD4Q
M-IVC0U-OD:M^D:L6E U2MZQ4(KLH^)^.@I_#JO<O<_&8':!XDZ+05L6$YNV*
M'4YNWW0$NQ7?CJY?RI\G%136H4-4)Z@?L'I6J!"L5>^G9FX<1,836L9]J-LB
M=8ZUM?E1ETSI&'$#(#\ G2_0TI4:8[Z,L"RLJ_&35EN\FR#NW0NV->(.?FY9
M1R]5FC6EWB09]S7F:L$F44$G$SYBS!_1BW1*R$^$)!AR!<D3Q'BVJ)@!P1C_
MJ:F^R4.JP@9([>7!<Z-J,9V!;;8F,K23QS\MCQ=2G -J-U/3*1L0S].J*).O
MEH;LGL*]EH"2Z%6VFBCU!YR8 ?>$G\9861=E,7&F)ER&8<D>UO__T8#TP5VI
M N.B)_\)T@LV,)B+8/3 C^5$-_@&T*W>KTT6$YR7 AP9_^9PV>O'MZ&R_,#:
MTZV1[LOIM,F+FZP VQAY2C;0MI (FHF']4VB@>HC0;9 6A4%\WO63T H"T7V
M@X\S\:O+GURU:!M<"S9,>I,+R(54.3U$4TE1C-68*<%IEW\DU]"*,5L1);H1
MNM-Q4*.4@MT(8#?L09P9@(\L%E3.0Q:]/"HIA#6"ZG_$U9S Y@,[I4CX7L5L
M%5A3 3/_'PZ"\QB2*-.W.F.3"MX&]_"'>'4,ES_9^1!"%V13RB5CXN[B 4W@
M-AB.SI$&*QTCQP5%SLD31[Z<D>:J5AED5A3P=46^EA=E$\ZK+=_1/V92;VK/
MJ(W9U>>$Y93MNQ2=6=J+:)Q/]+2836"K*)+P6_CSKVF6<9&4.ZY\1'N%^W:*
M ^#0D!\K0)%M8%)0P*NJB%,2;:X9#5]O(@TC,YWNA JT$X9*3 &3E.]23A)6
ML JK@JFDK%RX8F[66@0D02=G)IE$)@^R6!$L&Z0@S'(6LB<:@Z(,VJD^%\OZ
MV4U?6IE@B)>+J!#N)K/HS%?^0@?@ORD0.$-_+U7**%O6)Y;91Q0AQK**FFOP
M^#,H\8LD35BIR.4\55W,N*15YA;>9][EPC]V/>05[0>;^?$LBU$*LGP#IH6/
M^XN2LC$%5IG.;V"A\(GVXSA>2"7Y^)H*BPY3&P5QZZ]G( ")=@6Y%I+HGB7)
M3)<?+AK.ME.5ASQ13H*=$OR"2O!-4Y<<EKN6/;$I.M#7'0*G:$=-<CMXRZC
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M)NF(PCXV@%"9-B&<X22MA@$81/[SZ8$%N<A.0&%OTI#$^BVY6XRO\H\EUMV
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M4>P<FQC0L],<7*S:!J2Q+4I>*5&(_IZ "7&V-Z@TD^5LX61Z?IMZU=F<WN!
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MT;;L%NCA;:LL:]GA)2_ \G3,TTHSZ1@&C3QR3A>-"^X.N@<80F^^K:'=1C1
MTG4!J[ 2Y:M\MBZY;HL;PYNCI\5F891=,'.F3$L1O-3X<#UW8/>"1\L_26,X
M Y+B87#^,S,YM8^U':'QK&EFANP'[7@UQNIB;EVM%MT'U/J^Z380PZY,XWC0
M/4?/+D->(16&OPE1L>"'ME29+PUTF:A-1X0K=C;J 5*7C/?@SI5^QYF1/4@Y
M3H&1Q5&*[+B3E5OY,^SD797;<HY^N,O1;\)0-BA'__C^Y:6-/'0TQ.J(KKKD
MA=0'6%RZ.":]P'DP.E+."D29+\>P>]T!;-'OJII$8VHB9'6?UYIE60UN*R*W
M:EA'>YA4K^"&^M+:0J:>+<L(4%:R!.8X1C^@R:7<QH_9+(-][9(C#=C:=6^O
MMTFIA;]:OE9S&C+9?3$"-6SJK5L%:F3$6H^!_\BGM'^)Q1@;'_XM1X;FAMPU
MB*C+7!(%$X;Q>QV?KBNT_])J(N^6B8@IOC\O2BE]6IH1MIA7;P-ACC+4B9&:
M8[F/V1/BV>:.P<M @O'?8:TYG.M%YQQ;.\8%;'$Z)-Q'/I]7T&$^K><OIO]9
M:#4VP2U^.M*^/KS)[U%W5Q3P2VB%#=WN#U3#%R[Q:8,U'5U4)!O;TGFMW* T
M 4;9VM#)N5,7.AO:%>8APZ;U05V[)#<YP5XVDV<8FD+?BS(6GD?/!73"S^8H
MI U!5M#2B=F9SG^]ZKFX"6SG/YK4FN@5*!KLRT,;74@E_)0T.^.27;&^G_ED
ML,8SF"\NI/[URKU]+[HB2($RX9"E*Z*YJB16)YP6I'I@QH;[@T$7*5"EZSJS
MDQ)GJJKZ3#)C>):(K[%!ME>3&PD[4=E,G#2CHJ1I7Y*FLDYEQ5R795HT58=@
M>U7D]DDVTLC$)?RDCD_F) 23>#)FW]#@$)K#CU<F!>A.,'1J)--B3\@^)D6U
MGM"F(M6,N9-KJ0EQ6])4[N%I1#H/)ANV!;S4BAZ3584/'S64,"LM3M^+XD2W
M7,#G)-T,(%)(=9XSV:$$R%H"\2N<1 4\'(SK)@T#I=ZG"?^/"T2' D?SQ%2W
M!==B)]QVG-4TJIR J),[V!$EH6FXXXJRY>GJIM2&(6 SE="G:V@^C#OJS -O
MVHM3N,"'!W!)B+C?;Q14E&;Q>NLT?7"*^B7-=%INH\K_51NJ VLLWF."EX!C
MA@!W-4 OT.V701?:6Q_,(;9=NV!;3+J1R\"Z4EYMK.Y,-3FW2^T <7%8%I2)
ME^-@F[O+TO0-S5:'N]?(U&=8^X*)6 %0) ? [G,\$8G!&\\(M!0RL20E(.XK
M!PK^T?]%38-,CNQ%<!',#1$>1]3F#P%I4ZQ@+VHZW[#Z.6XWAPL6UML;/=*2
MJ!P-46Q=<!;<I:^#0S0L_:?M9"%F/D3,Y91[47='Y356ZC>QORC&O';W",'&
M:G@'&?\Z3 U%MEFIP.'B@ TD7=/7 K.XIIT%H^!495K'F9TZ%\J7BHJ"Y#@R
M^ BV93K'Q7RCZ#U/>7]U7T4>$0U;=KM#_V4HZC<$MQ!N/8)]J3RRJ2EBI-"L
MD*VF%UA-@,7LR:WW^U:C5TR*VW\?UY>%_J^' L&1V# QS4XP)V/;Q9D/_S+X
M8MD('@1Z.0%$V):ZU-8HV S0XB8:"^?$$=O,+*8EW =^AQRK<,/SWG1V\1/Q
MFSDU=_15NC><CH"^'U.4)OC^DWT+KKM[\LS!SV$G(>? HLY;>&71/BY760;6
M? BK2QG.ASTM9L@(Y(=W//U@:T'=C4BTU(RY6T2-I(J&6\14MN/'Y5HG-I(C
M_S+?;8,ZH"T)?(:L6#6RXQ?Q!X_,TU0S<$+/IT2QY:N:3U<Y67O2?)B-!5AO
M<'6X:D>9*?7DUZ4Q:ZI&7LXND8Y@YP A.X+1$NY$4P=/'3_H/W)2+RYKSN3/
M'$?CC@/BGW3%AUQ]J8L'Y_I&B9+D?6. ;Q=O_WGYO#\X@\>#[*&C@IYBQKZQ
MHE=0:PZ=F._6^6U:,C.RP'4,#LU, GXA@2RJ6M@ 8FH"&O0SP&AZ8-J/>TC=
M+,<@\0_P>5A+1^^ NF=U/RTY:AAXN))LP^(=\=!Q:/RDN_FNX2X.QVM?Y<AN
MEF9SERC\,HG"@UVB<!.&LDL4!B:-<:[P(XDBF&)$"+:L:F*+^ 1ZF#5ACF4.
MEQ[W43)^ /VW&XAC=7%A*YM\$0N3@"O5=CIQWS9KSQ**G\]3"J\TF2H)%KG<
MH:S4'IS6\_['G_+5F/43#Y91P]) B,'$["R&D/^>29X7H(%M#5[B>W!DW%C1
M]'PX'SDLA..F1,C#@6T;GQ':JEZM@R2UQTU&/'>6_Y2M;+65&S$ :G';';";
MF*%0Y \FAM,N(C2.YW5N=)&V",TQ4O-[5F7E+[-=6^MQ6#1KY](1>%1N3F]M
M5EG:K&I3&EJF-\C?3M6U)H"9&!3Q2#/ (Z46JBRMYD/X>ZD:RWUN4HBE"=L+
MBU4(K4IN!<R53ADL22W)Z$8F.ZPH^VV.  XKDML39/ I"<T%<=%+'G)/RF5
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MTV#J70MHY37%P<=8Z:1.?3**Q!M"3W#&O&!.+1"VEN(BLB0))VHZVE'S%K
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MNE\;,'C/QZ5Q*+0N&R0MJM5'9^MJ;$.O:O^I+992"]EE=F5/\*Q9Z3H;C*D
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M@[,>[M:;DDJ=,K*EF,94!ZR^>-0O_$"TC;:Y)E6F\"W@]+:A#L,ZQFBK&^T
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M@MJ^1"RGG+C7+NDO84$R5KV7"6 !7PJS;J-V,#X:.<720)0HY UTD[PT*;O
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M, 1-94Z3$;;Y$(_:TMO7-)4B\K." 3OVKVW;G"U%_+IQX6E%*B>%IUL:=L.
M*#XL-]VN^$MO&:17V3 YG6<>[*%BFG9*@!=Q8\S'VR*[M1Y."[ .[B\A5G0^
MP?/+&M ^?,[G7,65(/N3(QE.CIWG@-7&Z)][;Q+J?T.J9K#)15:YE7"E(/#
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MA*.=JMN^BFJ-_+U),0MR]ZQ67+46%%FE6.VH,IX!G2"MI;=+S@5.7#"#H>K
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MF1DOMPLJY#;78V\]G2H)8RXNT]" ZN$;'6PRID1/,3(16=I!1\"P%2:@QW&
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MLUF4'1YKN<QS0[$NT41)*IAOE<?)R;S?SKZ<G.1J=KQ+=WI-F:J615=KY*C
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M=PS*^PMJH)4WK: 1]\V(+>?+9TR=-0]![.$AL!7$$:J-L$3F"8.RG;AQIM_
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MC:7EM9VO'A8YET0NC,X"=\)Q2W#<H_"2E9QREJAZ']M\D>C _"?91J%K"H7
MN\ WG2ZY#GH"LA:N_'CJNUCIS-YGRSK!E*(JW=A*_&87HDJ-N2([*U]D(8[R
MFPY$A/ <6^U!9DMDT-,VTBLH_GE',U+GP4)ZQ\SKVHJ=B 37I_@ S@M1@#?*
M-G/.'4=1]6D6>TP;[JUTF?"UAB]Z6UBN("3G!K.<G0JG-T]]*M%:>N)2U9-@
M$WO*X;=%"">*JB8!@82AI)>#MG;-O2(']0Z.79-[W\Z]]YK<>QF6\@2Y]R>*
M=IS*SB40,I_$S",Y_55XJPF6+J-*JJ "/PM4]IN@%6PL>O-BF6U3K5JD/U@@
M<H#1B,W13\89R/BV$4@SDN:@+T"LH\Z']ZK<#M87#F30+D6P,(S.Z67(^*;L
MA:/0B^]>*6T,%"GMPOPB4)_J._J"T=BWUKN4@0GX][[U7N5SLFS;+$H7L79!
M96DHQG*RU!TF[%1B%&U565*G"HHI0^4,6;V%D0?7CFDI8S>8H<4TA*HNQZ5N
M+YYU'*EX=J0"/MN$(]I.RSHEX9O?*6HO_@%>HN/37ARG&)*B,"1H_]2G9/#Y
M- GE\8^HWXK>SA4+H.W1)\>B^RS).0&#78%Q;!YN<8V\+BX%=:@S0JQ[\P<V
MEEO+_19W23'6&U=#1;N"D4($Y2VH!T+5>J#)AVD3'4# 1@,*?<CV)F7L7]ML
M>6'30$ ?H!_--@D;$[JK,/"P.4\]@AZ_!IVB$E(9-;G7L'\91:?^!K3H9'P>
M#ZP"$=ZB>L@*B;=<)3NFD"E5,^-_4PA"1W6W2IYE#WQ6CTW?(>/P;D77R VA
M\CB!(3E=:O0992T\VMZ6C4DW.J1D=7\'%L.(+U.WBI1X&RU*JDQ!.9_D%8,Y
M9];,,.?(W5/+L^NIJF/8IG3 A:Z69K&F2DHB+'Y!FY?Z;N*E[FVP5;45%DY3
M$XSLRWCIV.W1L-4QC&:".6'?6+^7F4@53"E<254DFR^;E@X^5]V#ZZ0OV6CL
M8.]2KF7#9\J].(]DR4^6(A5+#V3?\I4;1:Z,2JZYE@<](_-]NSHQ"]]*!=_'
M7*;F!1AB-9IVKX!^+'3;N%D6$<<Y^;2Q#W*-\1* COCKY%[?O!!J7KFY1#QK
M%'"IP(6VR1$Z=")5H3_MP8K70(BD\>&E@=AX9\%G-]Y%1@C[A?D2<](CJFOB
M[/Q"9;/A5K:KSSE$F!%I86I3736M16<J"^OI5>;PAMIX&2UUHSP1W_C22*RX
MPQLN1VZ\(&U2>&B9<XLVBS:-U$+=Q2)"?WAC1;FW<R@EPLJ:,)!5E-E3UF!5
M'%,ER%H6*>W8SZTH!%G+2222**0Z'EE8MN:^;XH;^0H["CDJ%H&1WKX=!8#J
MT8R@A]E('\J>9<4G<;4:$^PG1:':MS&AP9'*A2OZN\,5^[?']SLOFAA'$^-X
MP!@'^IK2PX(M%*/35- 1^):#UR@&SC!!.V7'8+Q9"&*4@:&ED^_"W1ND4@.%
MLHF@S5.U+@JX3+"75T/^Q3K3LM&8:31CEC2#="#DU*_4'?&%@#_+N:$;*>U7
M$[<T$M)RB8E< @/CU.=>UIB,NENA%\MY@<4G@$BN$L/T*0V55M9#ST@2G*\I
M1")1EZ*1--'NYB02>%E4(3J3MT=%!RCAW15+".DG;**)Y%M,4#8L0C1EP5Z1
M.=#LY0$U';>L/S!:M(4C8@)W4%.Y?*J=7_8T7 1P/#/NLM$ (M)<HY?+-Z@@
M02$VR*ZGZDA6[EMZ[>6DW!L)Y%VJG:/ I?HE>58FB< R0=I&U[K$)!^K%<&E
M%X6!#"-+Q\9T7UF_8"A410H40:D#E- /W ,21KJG1I6],I5QT3(3'A&F%VT2
M)/ETL:);JGIGD@MWP, @AR"R$Z^="V2SU7D<@,$*<%V9?\VA7-)/' G!6B")
MV96NV1E A[78[YH(2OY:[J7K^;CFEG5A8&S9*IB#F#F8"H?[H+8'D[LF'I6N
M611O61A0552QKS&_KEFLFG>E&19;N^1EZ',A+E:_E1R,<&;2\4:7>O9GJJJ=
MD WETU20W[^6]U=:9CA0C)]*W?1U0S>5PTIX:#]]KZ-1G"JA@'3\32+?*>U>
MA S%_4DKF8NB"B@J<?!BJKK,]3CFH.)D/!<3<*HZ<L.*R *H5Q1]3&,NLZ3/
M&O53\C<SM%&F'G.HX*)/V7''E3/RL<>R8(N8C^KJ;,;;<PT,L'6Z6N/OEQY7
M]%$L'/[C&R_$WUVY"Q'G]#+W8"D;NA ;B@0BB!\^.P%B(KP6(E\!A)H*2X^B
M6 )84?+G,O0O.7B45;"H])KJ*>3#+BGO'M!I2\TML05;3E="1I C,6&-0]%I
M^&BB0L+4[V,8,C'U+<XIW+J1=< O;Q$LD,8LC+B>)Q99H)EU&\M#%<*426-.
MEL 7"=5+0LD7 \88W]@D<FV/9'UPZI$>6UDEO<H#!9WTNX%@3XE#J&U(EF97
M;(,[:@@/J$5_6G]"KW1AK'2C8%VHJGFI$Q2*+1D(F-=Q_2Q:L/E=+='(WM+R
MB_&D](^JEI0+GK-VOW Z3>%<IM=*T')=*14J_*"V*C1RJ9H^3B.LS+650,@R
MYW-Q6(%:>>GJG:G7B*96<&JJ.%Q25.M)[8C<$C$EIL!456NHUN0;C1:,U:RT
M+UK,*1:#@+R>7:E"D#B<)U<$[A9B2;7(&ICISUBL2*E)5<<ITR:Y-67R]A#M
M[\66.:JBXD&.'6*9;)"S !T:ZTA2TZN*;6U731B6/L&=R5W9.)OGJ2,Y<DG*
M/M46]X9X]=0'M2$2%F<IC8F4UB2,(@H,QT9W]@<O@L=\!)O0^B:BE?4Q=%F,
M7'#I,?T%DX9HF)J2!5:A;"KNAU/% %D7Z%Q;K1D4.[S7NY1M_%B6Q/CORJ%>
MBMF"\[%9*8 QND65H-/6J9<JOG+7P,U?\>7J$S(K_M$#03!#_QJ7H-+:7U51
MN$J8QS)53S "-Z.,$>!WT7E6C==WH+/#>24$Q?M>S7:'??]W""=N_0ZK1:WZ
MM/R1K5 8*_R35G@I5YCS4F4S!=H1J/<35<,!?Q+\K.Q!D86#[56,1*A7Y7N_
MKL),#6R\EVH]\O I]:"+<X;5>'+IR+K(D[I(BLA7$C;+T]6/2 )I%*EB7[I5
MBWQ^U.JI%R_).$#Y)288\J)/*P3Y7.4.);'H4V L*%';LKYDN#PJ/,9"BB50
M%L0C 8CU)(6U2$B<E-OB=<1QBL:J"JZ0(/Z0U;<5RF0V<6[>H(HU;*J&+ZJ_
M\11V[R7&N^I!MM)H^>;^4!K>.GK+U;2OGI:0S4"&%YMS*1+WAT:BP3O+8<#3
M95\"J>.EQ=NP\/IF)8O PZPC63_\2IL4G@9RH.Y[6>4B&48!1.!7*9Y?#U+@
ME@:>)B,!"F;6$8O[5]:")HB$008D0W8(H9MSA6=VH$^M >]S)_960)>_KV0*
MU97'B *3J#)>HI7,F$NVRF8/-N# !8P5DO2F75>XZJ:M[%[JM 9-6UD9EO)\
M2J[V'+%6!NUR0(D537%6=;M%R.?%]<+%E5EWJ*RRCGB260I;FL6ON!PX[[C>
MWYIN6!*LA(?BLIS'9BN;L3[Q1^J>HCD7-';1U@C[#S=;SAA*I>WL_.@K^+;3
M/OZG-?=\4[U)A#)E<K__P?H.C:R5I^?,,FIMWSX,PFJ8G^C45U2]H1"8J+22
MP1$JQP1!N([%:_6/-YA#]=WKUUY 1$I?VAP\#F^1LG@\;O4'?13'.'T\FW0N
M)76+)/7&%'3^6V_8&@PZ.__<;CEW_%N_,[S3-V]:K--NC4=W75"SV%HM=N_'
M DLA__[C1?>%^IQBKB D>Z$$G_P[\6VTZRL2LN9UVW)(-=[P]%L_VG'T9Z7T
M40)L32-5O)FE]*QZ5F?] Y^V+<XV)1(_Z;YU]_@V$X0LT?]%'?8^I\,L4%]:
M>C_QU16<(0(0/<T);AD_;89F,J<C_PR-C3=)C$8<'D)?-Y[-8[I<^Q$?F6T/
M$CS8[^J.G(VTW0VWM]>5-%>;72T8EQ6YVF>MV ZD\$HHM1/*0.PADG^.J>MX
M='\SZG[O0Z?5\8P:\GHL\JJ<9)ZXT^\+FE=\+$]T.A5B/K^S9G\"U?GY_3?K
MZ_O?WW_^U_M]:/RV'6_2]VW?VYO8VU8%#O/EYA'>W_;-;4?XRC+MNVNWNQU[
MX+2+W:-[.P7\ZX&G<9_$?,@SJBC%BR\7_MMJ_ZT1#HUPN-N^.W;7:=L]9]@(
MAV<L'&I@W,WI_ZIDW)V>7WRSSC_\E(&WL>O=,?/#3JY09)=1=O7;=K<W.%!V
M%9/*@XJG?>_IYRB\?!)H.&SU[V:=/&O*=NSA> A:>=10=HDI>_1,5&OUXB:_
M?CV_N+"^?#W_</;M(7RCO:3/O?A)I1--@U''[@QZC;NP!UN43VIU.G?5QPU'
M[#K3OM.QQ^-QPQ%5Y8A.I?6X^HC:58_N[0G-M^89S_H9I664.AN\YU_>?SWY
M=O;Y5PNC2A?6R>=WUOO_^?+^\\7[B]</JN^;9SR'9]2 J6^(C0RY+:S$_'T(
MZ%$3;CO8@F^W;>=@"[X)MCU>/'30A)'O<&R]_M@>=)H@<GGI>MP:5]KY_%F;
MNB+J=PO%+H<U)17O4X?5JB>?A@Y6G]PM<-;$QAXA-M;J/7FPN'I4W>_:@W%#
MU26FZNXST;G5JXEBKKGYO]]"1$H,-2)S6?S>NJ6U0#OWVW=TBDN3UGJVGL5H
MO_*4AB,.2?1VP5Z]HSO=<,13J_VJ)WJ?1_[J[//I^:?WUM''\XN+5T_M?-1,
M@#E.VQ[V^TVE2B7]EFYK^.3>>,T8XJCKC+>$3,,()6<$0N/KO'DFRKQDE4#W
M!J10]HTVAU5+=JIT'NK\VV_OOVH3619XO6H*O)IG- 5>U2[PVIRM1.#R3QV_
MJZ!![[2']G#8WM^H;ZI='M';:@U>/7E0NH)$/>S:PTZOH>ERTG1G+YJN@8*M
MM.F\SW"VIXZN54\T84*LVY2ZE%4Z(9)\0]2'X\J,>DW]5M6)N@8*M](>K9S+
MV;BQ=W)C';O?<QJ+OX3BYZC=ZC5>[!W.;6"/QPU)EY2DN\_;B2VS(CV@)II&
M4)>D':ENI2*.TP<!-FK*12HGW;JMT1T5=L,.NV/20WLT[#?<4$%NV,]\K8&N
M;ZJ!JON,NAU6#=BI>J8S-A%8;]]_./_Z7E5-?3OYG_<73VT,5%#?]^U.KWNP
MNF\T^J-X[_NEH!N2WC!A1[8S/J"LHJ'IQDI]M"Q/F=5JIDH5R*1U]/;]Y_<?
MSK[=K67O60?&._:H>V@-11,<+UNZN2'JO #OV)UA4[)81H(&>]%Y+KJUTB6+
M./T5/=AFNF,SW?&.K#ZRV\-!$Z2OH(C>+R'?\'W#]X6AC;X][AS0!=4P?DDN
MKOM\*G'*FW#J G7/PG3BBRIGG)K3:O)S)=?/C&=P>O[IR]?WO[W_?''V^WOR
M>&P+?9_S#QAB;- -FF<TZ ;5[@4Y7;K!0F#S91I$ M;S;S&S_#".X0UA8$W=
M>&G-_?#*6HK90L34-8+MF5XP#5?"2MP?@MHU7[8)??]EIS^VK4C$:S'%T3?^
M=1.@/=S2M,?#81.@+:,3L&^ MB'IK6A7]P \OX:DRQ?0JH&FOB'GX'1:G9*K
MZETF^5/7%]6M?OY ]=L$Z$IR;W?7S0TSW)?B;IBA)/?VC+1Z]:KT,(1V3WK\
M%K-USV Q'T91O/BY9AWO_WS*+>>=CMWN']!%<._GT_AW50/%:&1+(UOVLR'!
MH^H?'OUI9$OI9<N^L+$EM3+_GKA 3_"_,^_RE_^"_ZAOK-QHX06*])PV7>>]
M'C ^\^83[K!>?F5UVITVYEO\= 8/3I8"\RNIGU#>10Y;#(/8FD?ARGKKA1?3
MR%M;\S"BS\Y3W[>NA1NUX$'.>)\'P4_98_"A^-&3=)'&B36P^3&?1+00D?7.
M3805!E=N-./IRY&P\>.1@/<C5':8P(VLUFZ$)]W2I+)YX'+3O0XGS-9A[.%:
M7D?"=S&/].;*FR5+27;F%^45M;.ON!,0!&FR^RM;+/5$=]L=YH_#_"\NUYO]
MXX4W'3O=R6#D#MH]T9O/NZ-IK],=]F?=N3MTG>'D__K]%^I+RTAM8>TNQ/$D
M$N[W8W<..WSM^E?N=?SB[WDJ!Q+?./C-,]MY,O/Y74YFM,?!L,B;B6G(]/@:
MA*2(\%.P)+<L2[&60.+_>/$?MU_0\,4OWY#XD:U.X85 <O%__=W]I>CR;Q1!
MO!H/EA# \D8/*9/HB:^]!+ADFCNE82$E_R^(%^L]+&QFO1-3L9J(B+NFNH[-
MXNN49 #\/0FM6S[MC'=*B2<]DQMY^1M*VM#WPRM0WA:IE=A:@WB%=5FQ\,4T
M$:B; C)27/Z!Q")*MUT"78IPE-ZQ)6XZ7Y2]>'2ORWEV!]+3KU$8Q]:7*)Q[
MR2$;DK]"@[!?9#O!!NEJ,N5!!B1LU'?7L7BM_O%&60Q>0(NC+VT:7O 6*2Z'
M@U:[TT6)*<-6\O%2F+9(F&Y8O?RW7J_5&PYV_AD;W';][:;'.DYK..K=Z;$W
M_VTXN-LWF\4^V6+'>SWVEJ!KA6*KQ>VZ60K'>;'!_4J W.9!EL45VQ*9[=M4
M<.XPGLU-=S<O>J\X0;EO&77]?6UXGRA%C0[.,"L?ZN#&-3RXW]W(<X.I*)(A
M&\Y[ET[E9K%R7T2WQW.>QRN?[CE[*I+=Q11.9:.AQ:QRY 7@KH4I/&(6VY;X
M,15PDNC$@4N'RW47(GYUB#*N1:Y;).#>7HH@W<(]_NDZU[+M]> 44'62.%V[
MW>W8 ^?0Z2OEJ^1MJ*XZ5->QNT[;[CG#ANH:JGNTK0T['=L9UPCXJY8])5VG
M]317] 1[_=O/68W5:S\^#6-J,]QA.1Y2D5T]R@:MUV_;W=Z@/I/N:GE/CCT<
M#\$Z&37W5.I[ZO<[]KC3W%*Y;ZG;;CW-%55/GU<O"L09_74^HW]8'>AV:/(9
M.$U[[KW4Q#X8=>S.H'<W6WV_ RBY<]]0<+4IN.^  3$>-Q3<4'!%*=@9C$$&
M]VM,P34/=G5;3Y-YJ9YQ7+U@EVD<6US#^C,!K_T (*M#^YU.ZU#!=?!)5)$S
MGA;=HBZDU6E(Z^%):X]G/"!L[4,C6Q[:2UBFIA7,HOT-FP(CX<:$ QED!3O6
ME8MZR8,MP-NM6>3!KZW)M86G@#TJKJ\_:G2_P&.Y/="V7.XSA&>$$?6QJ/[#
MV6;_X2$=A_!</X0W77G)T@JCA1MX4PONZPI^I"(LP0U'P?5__L>HXPS?P"["
M*($E>B&^"QL4W;4GXI;UP>BQV6BQL51WC2W7RAM5:X[$'-MZK+GOZ@/CGAUW
MFB8B>XFEFABQ^6GC-&:I_JT'"YXF<GG6Z?GO9^^.8=NPBYE8>5/;NEIZOC#.
M.[*FRRC$K6>O6D1 &O((5M[L.!$B@%WB39MW/,VGU^B>L]O=7HT\>^PR4E_A
MX]Y^],(T9O+T0^? /6!3(,[(FZ1(1-+DX8LOHBQ%$+P*?F7L(R'O?K-\YBX"
MIFN@CM%+O5?]GA7OU@L2L>!>+&(*.K3X.H"_>HB$NG9!>KL^/#><SV/X@#HZ
M7-,*Z_U\>/]"T!=C.KRUB&+:&ZPR88142_R5>FO\N/R<<4J%A$ /6GD_K'CI
MS1/X&#7? N_!DN7FM^AB=^/M+NG$&NE/8$!O?EW>3K%S[I8#6?#^QQI(7<1-
MO]ASZ&IJ%MOTBS7]8DV_6-,OUO2+-?UB)3JXIE^LW*^L:;]8N3%:R]8O5I'9
M)!?"AU\N;&LAP.D&KYD0IF8K+_#B1"*GB$VWK^FWJ%R_1;_=MIV[EE>4* 7=
MT%QU:*[7']N#@VN"&YIK:.XG:*YM]X=.Y4FNWI4VHX.KT)M"FPK:EN_$.A)3
MC[,[9%>N0EC<O_D7TJI\7FUG0P>[K9LNF5)?4K]K#\;-)97[DIPAV);-)97[
MDKJ=IM^LMOUF?+$W__=;B!4:H:X@N&LHJ9ES\6CG4VHF ]_.[K=_KDNH^L,N
M&FYIN&6_GKHNN!MW]+4;;FFXY7EQR\AVQG<,'=:&6>H=>'2>-YY5!?LG#LE/
MZTKU66ZLQZZ6 [-H?5>+@.JQF*2)M<0"?J'> #^X1A&!6>D/3W(&K?[?]EL%
M/&AJ3&YQQJWQ/M_$:O7-]7/A/#8! /G),"M5W'_:KK9WL3+>2["A 59P!<>,
M_QO#22*=PR-FZ91'I"2A*K['%05BX1H5_?'.9HK#Z^&?GMHV&RUF-T:P=W9>
MX'GP5_F#<$1S[P<1#1PC'/CTK]3#^\9'XH=SCX5/PT6YP<*C"3?ZPQL]&F9_
M3FZ=\'VCP\,++D6<8.\#\H<5II&U7KK1RIW2U<,"O& >N<!,<-]I=,/\L)]J
M8_CEOR;1WW]I9I,9Q-8=[9Y-UHP9>P9CQJK2_X,M3M99 %I*6$>R!^C5(6*B
MZ0&J:J=*L]BF!ZCI 2I1#] SZQ!I6FN:UIK'/+BFM:;<KZQ%:TVE.**9N%1T
M*F=X32).5.S11O2*IC^FNG7C1TY[: ^'[5<5+AIOZ*U"]#;LVL-.KR&W$MU)
MG<FMV[/;O4&5R:W>F>G>X&"4Q#IEINL-/OO^K]1+KC'])MPH@$53UO3/T L2
MZQ),Z#3:KHBM>6&XW74.K<1HBO<?]XXZ]JC7-%B4^XYZPX:+RGU#SJ!UZ&35
MI@6F*HJ=4N.%L9]Z6ZM'CF/W>T[C3I3V@@;V>-S<3WGOIV?W^Y4.-M;[?@;]
MUM. B%1/:U?/'3^@<95*WW8@5=QV(DU?T:.=3ZGY"XRE/FCCT?[2_MX/Z(D]
MO(93&D[9+RDVM$?#?L,H#:,TC')S.F]D.YWN\V64>L<,>^.#)U'6*698P3;5
MS<9!;Z,^;*-7T$UX,A,UO<B&0:-G3WUIHZ4P@+7.Q"2QO#A.L7N0.S*G?AB+
MS8;578.38O>2\H^ZF7 :KB:PG9GUTAGV6FT+#L?'+L)U)-;N-<U,@D?#TH.I
MMT:7B =?78AI&,RLCYX(K,]A0LVW](=DZ47<V#@/TRA96G^EL!014<H3"[IY
MME31M+*M0Y/OTOO>[(#$.64M6(J@)5B.8UN*FAZ[=:J8+,X"7+>8!2*.'WAE
M-Z[#5N0!ET8RG<AJ[@4NW"I<:IS +ZA'M Y=NZ&.RN.VK^1\/)XIIP["QSEF
MA$*)N%2I%R\5J1.EP?^^=)Q67[,#/#^-L MWED:>',!W8ULW38 +_DR#*?<*
M8YLN?NDGV<S.-8OON9/^G3?BC'=N9,?[-F26G"=W_U35Z3KSSN,V0LH6R&_N
M#S4)S3IZ*P(Q]Y*F'?)9-.TUBVW:(9MVR!*U0U;_INO9?MCT;39]FX]Y<$W?
M9KE?V?1M-GV;95#&TH5+P(530::CR:8+U_0W5:Z_J6./ND^#[-ATU#U/BCOJ
MV)UAT[]9IBNI,;7U;:=]:!M!^2BNWC6C1YU.K_7H+;9-RO8GLD:GF$L)KO_S
M/T8=9_@FSMF%>X'W>@S>&WD("8S J]9TZ08+"1X[%Y1IP:<JY-=@9OF>._%\
M@MXMSM.:#[ET_53"S_I^>(4^KDU/H90=/3KW/,YR86('ONQF:+UB/A=3^A=^
M)<+OPG+[O5;[;YR0+3H*:1GOAT:\?12Y U#/NL.&=^\7EP[OY4U3"AKHJ'BK
MG7UAE>DXXJ(3BZV9![^,LCSTYJ%U''B'F!%0-2XX3<+HFI>P!=9\ZRU/@>-=
M+Y [)\H)00#@<B1R;Q &QS,&:L9TT32,#TS@FIFH5KN_FSD;^-YM^-YQ_C@:
M^-[G ]^[-]\\?=+Z,XC8CU@B@ *#H7Q1:D5B"5H.I1O^L<E>/X<<:[/8)GO=
M9*^;['63O6ZRUTWVND0'UV2OR_W*)GO=9*_+H(S1E_--=ZW)Y%0NDW,TLMO#
M2@-Q-M16(6H;]NUQI]) ,PVY58?<!D-[U.LU>>I27]+1:-QZ],*5<J2IZXUK
MQ-']:2ZZC^:B;H5,W!^OK7T\]#NWXS?/*,\S[LDA(D[OM_KEIOU3RJ53"4 :
M\/QC,2/J%]0=.W7CI37WPRMK*68+D?&$IRN"[XC!75T]T+7'PV&53<.:WP]X
MBMUQ<S]EO9^>W1X\S<R&YH[VYJ%^NW4 GEACZV[M>\CE2"56_;O,WI^9J/%S
M.&JE(X]#5?VAIU A-+"ZW>R!1D)SLU6YV;N8%S6^W>I=X(&V1YT0_.J?AKW=
MW+AMPPV6ZZ.=3ZG9Y\CIV.W^ 5BN]WX^)4_P-8S2, J;NN#%] \/B#6,TC#*
MLV*4H6./VX.[129KPRPUCVN.^DVK>65:S57=IC43C%(\,]N!(_ @ H7/#?=V
ME2PQC0G_BA$S/)Q[B6U=+;WITEJ%$2)LPPYD\W2BH(\1@Q=A@]<"&R2#A6IC
MY[Z_+61MC0*\"]U7XO92:[A:-7XX4%OQX,E^'%K>:NU.$?!7;F">^K[%"5CN
M:$8 XD$&> P_2O3N^#J ?WB<M*5N^GF(W<\*E5A!F=^P==W>SJN(%;KSZ?GO
M9^^.G;$%EST3*V^JT(X)@+R"$-?WDMZV#?J3H-B:,*A'/;YRU_!%-XJME9O
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M$S19LL? FT%JA2MO:F<3SGALEDC(JT O:)&"Z$-P/M-$"V:*:=]28$"N5 D
M7X#71/(K\T+<6W8.ZQ?H(7GB4O(E/E'\\ P+32IM?AA^F>)IAG6CSF>VY00I
MUC68'6]="'Y/9N)&!IFS+,']@/4LXV@_$LL!C0STMF3)OT-"'D DH%-$%'!\
M#DT[$J9:%,%/4<YMPPN>+NF<\)D^\"KF&9!;I9+PIG34=Q%%#7[AEN3HM?/'
MT> 7/AO\PM+HYU,6'!^TX*B@!GZG,@M.W[;.V?(\15,Z[TA=A4I,NE&$<6.6
M>NX,> >4 7T27)ZW;O =[_=D)=#^M:W/K9,6B=-_M2Y:]&>V9%WECL69RX1R
M/5VC)'TYZ/4-IQ%19$6 $U=C =I,S I$=K*,PG2!82_KY:AM?#D2EZ%_2=HJ
M]Z5KZPAU!YH=G?:;+_ Q"M5\U1_/WR[9)QWGS2NP7*V7/<=<W]R+0!/Y..62
M!+X?PBH*G_Z!/DGS,-F0@T\:#T:U QYSWUQ_S#,T]WFZ.6YS\_'2X X7@JP%
M[6_<N#1VK3=?H_\<YY]M/BW[C'W32W>>=O&;MQA.G5T+* []$!4(!A)A_4Z)
M#DFX&<E1\%G1$I M6&$8DI#(SO ?Y7Q)W&N5EV-+M9(.N<Z##8JB)C)8LQF9
MDZ:=VG_![=+-1V"9$E#VQM>+) 8R^<M^WVD-=7P#GIO%0E[VASG64EC5*(%P
MDG*A%"*_ (^83.XLAT6Q?9NOF]*]&-JQ*<0.OCQ9Y33 MC DB:MYZX47&!_%
M($#>'Z\@#9S=F"R_*8QF2/^,B4A:!=G!LW_@82R%V*A(KCMV;WAGR;XI&8DY
MCR?DZ_B"+VX_:7_R]F.Q7!]W;I7KA0^\0:[O$KSF&G+2#K];(.*T>H#+S:F'
MW/&9VN++V3_QO0LPN< 1DXX4^JD!33Q'(/=.NS/,;61K8O,=):S[W 3LMXTK
MW3J379QANJ2224PJMV5J@@,1H1+C' (G6=[IW18OMXI#]&KH. MNO8XL1TB+
M,?F5;;?<-B>4+-51&9  +F:08-5!NF)R8[F )0O(15Z051%LY>?@[,,9.,HR
M.,Q14'[(]1I$N_"(B?"[&..POM)X!/[%^Y2R7)$(IM?T!UYM]CD<\; $ B+%
MD%P)('&GU>G_C4X8%)+\5^&SBK[<T5_NT)<G*NI")1$Z!JQBL;D + 65,S!
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MHS6(O:+[96OS\D(77=>KOWMZF84,H08A>M9DTG9'YGPTBCI7V!51S8KZ?>I
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MAS?N[*E*%;[$57LF2'6Z9>)W3K9-[.]_4NHD):W6=9P(I72_W='G$B?AMXO
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M<P@CG4=30W&B2FA7*A;5=PZ&5U[Y&N0S=FF 9SCDP@^34,#,PAK&0:!.C5.
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MN8Z\]VN]LFK:]Z!V% 2YGL7LQ+*.Y9HP8IRG%8Q%4/9N.!MTTQXVPW)(T3#
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M!F,W/ V0TKFM[0KUBS=!$D=!$#M!#IF0[D-(\[UE-(><2@J0C/-W/+) 0"@
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ME4.UM@_VW[[;_6.W<[CWUV2,=U4@T&Y%%]O!;S$AYGZSMAI6"O1"K_$,T/7
M>AO;_3*Y=G4)$-__NDB/;@78VSY1_6,7^]*?]X<NK/;2V=9/O: :NM'/K6/5
M[8]:08DU:G32\KW!U]:)L\=NE/HWQ@[VW:1*ML;JFTL=[?_UM)[,&UH;;0].
MSX;NQ/5'W2]NINENASOX+=S 'W']OX?[2CFO?NR&[YSIJ=&HZX/ XI*/U+>L
M%B^D%K\?[T^,_VT)/_[W!)K3O_KJ;WE^</H>=8XZG_8__=7;__L]ZWQZU^O@
M#[1S:;L'?^]_^_CI&.V'9QBN=?G?R_?PX,B$]Q]_B^L,/__#95%(:20PE%-
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M@<SP;RK\GU:IS\AN#K)KK4,+Z)2T%'B./* >*1"8W0,EC"4>^H)B$_L$7M?
M\X2<IYR0@TCS1^3\*""RZAK@%]S1L7'&6\>-#WSF[D6Y>VZXCB$\\+720%L<
MN%L$HTSQ8)2Q0@D%F9$%)@\WRM8L7RT3PGJ:<YD0[DD(]=D\%&-D$ *:TSAR
M6',@M,. &ULPQX+ M7ZXF98)85T(H:D&7L;Z?;$^._PYU)9):$%AO B&&V=
M,<D!+HJ">D48IW@IAEM.Y7QQS6YCWMJ\'7?O0M$?.-@62)%\4=4%"]]^H\^A
MQENJ-YQ3^8RZUQDU-Y=($<T4PPI@63! -8) 2NH!4P4SG%*"&-W81+@-']1
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MTG+<H@%6QD0^983_2'VKB.E7UW>^F_T@"_%3/0^26"4-PQA8X0M M4) &RN
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MN(]!6 Z"12$*([$+\MK8Y&V&F]24.CM &VU79/P^C1$1 QB!3IF6 HA"^VA
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M,'R $C#\JJ'"W"JLO=C8%+B-19[ NF:@;G"K@0SFI8&Y9K)ZH0G74@-."Q'
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M?4K0R\K!>_TE#GVW&3DPRMZN:M#DX'6JSW$TA@?*[^0:Z&'7CV-H/M2I;#_
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MXE>[-VA;&D,F [&<:8:,I"'7*"BD2:!(:)\8$80$[XI?K0#;\P6V52Q38L#
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MOJ]C5#WKZR0D.!J#.IJ?#P5\N#\83X_+- :7_6J3\3$<JB8_H3.-3M7ER=E
M/QW&\;12O'95?9X5=P_M:;>)ZM=)#(L,B-DE\OKR,<Z7:OPCL-L?Z^4-<N4I
MW'PRFJ<WV%%]R'-2/3SA,-3GM1:TO\S=ZDN^HL.<HI'WJOIY /_,8XB_;!W^
M/(\A7OOY[4&HC:)ZQV9?VSK<GG_K:' *XE/B-M5_U:?H;1-X; [,]L6$DVU
MCP'PWVB9*2\ZG![CX%_/U=_GTF7"9%(L=8SH9^5L<%:?CXR4N;7?.$UZ"\X
M; 55#?"P.SJNTTQS"/IB5GY=T]KT4IC"=;=_K7^O2="9);\T4>#S)H'F_$*1
MH\OY_SGYY?H8]7<7/8WXY,6O4B)RYURRF7JW-5O?+X/ASG1U,^'_9AA/NI.3
MT4S[6^@"K4DX>P35[_7YP8[_X'VRU.J ?,KU^2R/Q<6!(V:TT4(0H@E;;=*G
M,@3D&U!4$2ZC!RF7!(Z@K6L5DDE-TGZAZ+U1-% MM-44*2/!L+;.(^=)IBT3
MU -$60L(=35Z=4T!XC>RUVM5JNG<,RV?KCLEO:I:G01WO5:^NQ0SNTDKS8&R
MW%=GDA6:#);PQ\?A8+3\P7J[[A_]5BJ0>S==[!*';$^&6;EI2[G<8UB]YWL[
M>Q^X)MC*0)%C46:CUR#M<NY+Q,S%8+E2<F-3F6^4R]5<L K%?PP="\770/&C
MK0_ 6Y$$EQ"3W  @>H^T9 I181)P($Z.I8U-J5]=TS9B3O$? <7<VNX<H )4
MM;J;5=: <S)Q "UL<IKUL5%NC04VPEF,?X$V%<=G.5\GJW1AVAYOEKE?Y]<T
MVAK8N_UJX/UD.#.00G.CG*OL<JY@_:%IVN TLS T2B'*Z\N6!"ASONX>T6BX
M]=IJTRD[!_/-X/ V?TQSM]N=YWQ#]#[&]EA#]8IFUA"PZ>!COXX_/ZIGJDY1
M62%S8)I&6IOHT_57I[43M=WGXU'RX'.R2S\7893@S\'1._Y!8!*X<P$))4$S
M54DCJQE!/'B+N?!><7;9-T82%D[:@!F(YN2P%E0$;@D#4CCXSF5_\WS/GT"^
M^W>?;1[OF3_5S!-;.WA'H+">#D$;&,**,\=>JJGI9+N\SMJ:NY'!N&J:5:;N
M<%2WR\3F']U^Y\+? U!W_6 TSAZO:_W.+A<8S):R[%UVL=<%A!@U'NPT;:4Z
M Y.F2 A$2H)E-!TSF\?J7I\EWVI$N9[035^<^FG/P7BH8EW$=)W>0'2G5@9F
M6S<KL*QKC4-N-#4X;UIZVNH8-+F<$1$[4V]0X^B$=W*^W:KV!]8R<67AW-'$
M/1-&4U!**67<^>2=J1N\Z"FR$7TGM71^</\][([CSN"L_Y+54;[_]8\/1"I+
ML8;-C0I0$#N)= #%E#!,@V7<P]L;F_35-;6<2]U<9JQSGD,LP&V+-JEV-+&]
M\7ES-)HZ^NR:;LKH;5-;U\]N;KA*4^;6U,]D-&D4OZ9 9):8>9<\T.4X];S#
MU2*R<SH<^!A#JT_PF^D:?P$->7>V\L.Z-TZ=2CW;P:T,=75 _06?\+VS@YV_
M0,Y'0JST"#OJ$2>,(V,XB'T#BI(%#< 3G#L_?J-?45@)1YM*IMDI7W;BK'BP
M5'3$**<] T.=T. HY1X8DS!!'9\:ZG=%Q"MG:"DAX26?G2][7__Z8)-A7H.)
M+K'([AD;D/&<(<N4(GFTIW&YA^PWFQG]/,B9+K,N?K,RMFECM&4LS.7,.40W
M2"DW^9OV,;X!2M< A07CGL,YQ7L[K]>!<;44OR(*I\>TUIVOE=EU0E;6H*>%
M(0L9;N?DN<UAG5_F5;6"UFHZ*YUBD[PB)B3NP+())&G%C63!Z9B8PMQ/FPE.
M3_'=7*#E%*]RBLG^D?\@O391>#B[@2O$8]#(*$Z1M0*.L#6ZCAJQ;_G"<RK%
MI;,[U?.6&MS.,SJ6-=?&ISD#V]KY.)R<SL>@3 >)-#&:!V&#657V]&D:4VL:
M(*H^U@V"^S=)AQ45C8?DBU]AY;_#&@_ZAW#8#]*LS=-+/OU\[]/[#QCL+IEB
M1-;%A'B"'X9'@H3DW I/B!"U)?:-T_\-VVH4:V]]9]92H"D0#+E('XS[NDAI
M9FM]^YQ^3[6XK9ND%7[7:699/+7=)5-ST3+&-T&K:1.#QTJVKE>Y<+XM L6G
MMUZYK:'0U0T;E@R2)F_N@I^NOL9)G9_8JT:3T]/>>>X#,4EPV";#:3OIE@68
M9XE<_^Z.CV=97 LK9BO7G2UG<FP/X?'&&81>,.B\PP=''L3NQR\'.^_/]HY>
M?U!"@/ E D4)DI<G;)#E@2.7?>-68JLB ?$KKFG%V>98=#D<=SX<G_P'*GE,
MPE%$M(I@"<.Y,-Y+1 (3UG'L<*JGJ7S+49BFK2^S5C_ZAEK_C2 V*$7#Z3R?
M_F *=5T03!>+SF^/BW6R>BW.NKD[N?CO'&4X&0SG48)I3N&M2I&7"W2OBK7O
ME!#?/HI0:I&OUB+S4HO<AJ7<3RWRM>'*[Y9B7@K=!ARLCC%Q,'2XR?TU(E>@
M=F#)*<@@?>_Q]]_!R(GQ]V@!D$H(_N#H#_:!Z<BC-0+9F.LOB?9(,Z50M(Y9
MQKQ0_,I(6'A1>1*-]$ &;Z,F5E(G/6.86A[IE9*OED5JK\_]:(Y%ZZHY<R^A
M7E[:8N)E4UL%UL"\F=M9/0=U4G=Q&Z24\\-@_=,LL=-A=H6,&_=*3OXZS1=Y
M5;U.:1J.;Y+99L-6YWZ]:8I [O[4>&%RR<&\0J9S(= _ZS>7?2RSIM_-YW+H
MWTX?8= 4V-ANW2"JRFI'R K#] 'SZ)NFV=VK:NZ=:]YL[*?+;6T&%S]4#?-F
MHD%"DWRYK%_,2S#>'KQK7IE7R-0:R:4+++7(^TYSK(77J-V)3C>DG<UV8YZU
M ?I:TQSR^C2O_-WLN,L;V\S$K&?)S*[QG;V\_B:SWYL<$CA<DWZM,S9?/[7G
M]?9V:LJ[',*9)IE]74PVG1V_639+_<T\$R?"H:U]):'N5;;,46!D]^ :H[IO
MVJQ183Y2?ABG=81N,!PV[>GKB<S?OGJ3<#D]_K=XL($#;:TI1JL7UNC==7?9
MYM=ZJF_^9;&X>59/\T9VV'T$KEH4I&4./(WUN6H^TI1Y-K]?IN;\%#=OPPF?
M#8#QM>EU-ACF2#](RX:R]K/M]J950].K+\U(<SDEM58D8#=L7?Q6Q]'\I&>'
M%U%B49J>]]XV;26;S**TM.FIQHE>]A8/<Z911HB!G3:5R]]LEEDUQ^W"[-R&
M8V>CM!T\677>S1,HP.J8EK8VFUIGS#0=]VX@.U!GP293]\W"N5=WZ&O*;2_D
M35P\^WD01ET3.^W^59M%\W/M_7 2KY[W>L1Q/8)LF(<(U)D8G>FG,ACW,VA/
M2=.%C>T.9U[!O*CYFN%PQ7YN3@6?&0X^-P=V7L URJQ<^^(3*(_-U?,,E^5/
M+YYZRG5GQ[$_JX%H8NQA,FT-.'/NW_KVERX]:T-_X1%F!6]PEYD FGE(<_A@
M/M%V]NSU4SQ%/)XJ'[F>=BH@J]I&SHI4;]9R^WAP%F=/O91$T^S@: FBYGN4
MXQ39MUR+Q;H'G&M: <\NTU1_S\]@WLO+23J?N_%L='%V<)V>U@C<V(]G.6!^
M.N_)O8!"4 2ZXR;S+]?% D2<SU&CMOJ;<W/Q"F?=7B^WF8A?XM!GC\"K*^K0
M_ YA<9EK'B3?>7Q^FKVHO49:9%?[R>0DM_M&/I_"7@U;I_74NF^=H<N9HT_B
M3%UOM'U7>;_2R?**]CGUV#3'M!;,TX\ (N2MG<O))O8QNB8O-%\W3B/:>0Q[
M4VZU&!&>Y5MO2>).HRCU^W ^&G#PO?POP/24>Z:CW>?X.4,&0B]W,K&U\VJ\
M /3!-;K>K)9U=!PS$DV[.4YY*]R"N:XBT[4-'Z[L;V@JW&<[G/=KUF4Y^^*Z
M(4O-1K?X"!H[8&QLFMDO?ZJ>2YJ5^QQHS3A\;4;M?/:,;E&9^!(BMK6)8F.3
M_+"DH?25>(!F-[\.!B'CZ58_[,)9ZG_,O1>V:GVFN#\.CO[@'PS#)CF.$2'$
M(&Z$05:GB"S\Q[5FW.6*@DON#^.LP"DR;66>1V9XM *N0Y(S&EO3BHXW,]+G
M-M$SRE=;2];:FV6OP.N95Z 5[H_9VA?FXF@JXW/CD7GQP'2@Z;3)S!QU$^C#
M"\MKIKU/Q[G53[MLY-=M\R\K&?/JWPP 'V>KJ7VL56[E4/?6F(9+!&X;<BX(
M_JCPB=JU*_-#E4] W2W@U:,>]N7S-LX3!Q<'K1YFL[#K;!_$-:BPG7E@+.4:
M3G@+U-ILD=5&03U,O-8"?'?H)R>YI8>OO5@YCR#W3UI<,9L9\4MW!#;:?%LN
M5 ;5)GFC*7FXUJ0Q[9:ND!--K@X/RL-ZQE/'ROQIEKZ5GW/^.#/_6AID"5O]
M!S29<2;*3"5I^(NTCKVN'J2K$-M6M>4ZU]['Y>>9AG,7S]/@Y]IZ_,T5GQ89
M1-\3YTN NG &=4?S"N[K-M4N#4QLFL #XXYK1\<%NV%:8'>M:3YW_DU&,3?9
MZ773M U\W<ZL=K&\O3Q0JQ[R8"]_Y5MZ)M=62XP5A6?ESB6M@B/!11:U$@ZS
M:_7,I=0/H(;_*4R&.:7@L@+Z2S;%XN\Y^_.2 OJN7N#OL+X7IWKZK_N?_(<H
M8G(D.F1\L(@'&I!+SB.B+/<LZ. UZ(Y$7&8Y]"U:TL 9=I:;A#V/VCC"%$F$
M.@:$94856JZ?EE^W/D0O P;V00%L-,1UGM%'I$1""J]3\%%SO[%)\65:-FDX
M($5S4U) SK]&?\][?BT77V@:<0$^,]%0]PLZ[@; V)]>TN[#.O[Z8*)*TDB%
MHO<:<0F_@5F74$@R$0T\A578V!R?#:9"+#N<OL5$24EKF#)!6,$E339:&;DA
MQ&,3)<&W9:*SP3" \5+XZ':4_/KN@P+(PDYS%*+,-30&(\<)0TEP$$> C""6
M-S93-XUS5Y2:>2ZS5*.2SADGEYZG^9C'J1!N6JI>$>K#IN%IYJ]+X\H+M]4T
M(CD+T3.O->4& 5,(Q+%*R$;MD*"<B^"]=5&LPFW2!I62RWT@'&>$V*2<](%1
ME:O8J"S<=B^4_+KW0>MDI%86">$=2"WAD#8!**D4US$$H1QP6S^KIM>SV@T]
M(N<I(0-@ONS(;J19/UM\(:::('.]MZG_OM'<F"6?W:.3=.8(>]/+$R;Z8>X+
M*R[2@Z,_OGQPFNJ ,RA+V$7.=4!P:!(BB5D7E*-2775Y/A&+\,VUJ5%-R'(6
MZF^\(9VZ\4G3KWKN$ G9/^F[S0R[:F?IKVSE-5/ KL^^RK>8#CYN$@/N8!5^
M;CH.3H>.-0S4A,2NC^<OF:+?M36;;);I$^1EWAC;FJ;XU+ZH[$LZ'C3NG-?7
M+WAI -[UEHQ+.8W44>PX-XHX!5:JP5P9JCRHVD4LW(-8$ <[[SZ8Q%-*.0^4
M4^!WX1/\QC7"$22_5$XQPS8V<Z.Z&U2PZ3#NZ5CLT\G)Z87A\M?KW$9RZ;V@
M@B:.(P!+9,EI QJ!I\R*0N[UD_OCV=Z1_Y"[6Q!F.8A])A%W1" G!88_N9 L
M$0XZ NAS]3R0Z\G]'04O$AIY)(1;HKDQP<2<=RHMC6!,!1<+:>^%M& 86^-"
M9EB4B+&(4U$;Q@QA)358M<2"O95)VQW>;$_5S+R4-+R71S=4=7'/<)[6F5M#
M]NMV^I?E1^Y0GFG1)'&"BE"[V;\N,GAO$(^S"-PKD/*3<9:#)S87A/?KC(PF
M]:Q>PL6<C*9"/-<7A5>U'CH!&52-!FE\5J</7ZY1NO[>\->\G5INHC8--(;%
MA>K,NVESS-XYF*N?8P^NM?C$I<C(_+E'V;3L3?OVHU$>M%I-OUW?N^FZE/=\
MM#1=\INWRH_Q*8_P>%4=S.;T+C_Q,-IPWF#RN*FJKZN^)EED-PU1IJV>?LA+
M/;O38I3D=:I$9VF,^K>P@ED#YF T8/V!R2]STXS(J5*"..:2X04K[@$KZ-[1
M7Q]B<(D;ST"M=R#UB4S(1(<1*/A*4,^](#*[7C[?9 S"81\U_;)G&9US#I].
M?AZ>SXYJKG>>YHO5GX!OHFX.'B[ZS]:?Z&2&/HMUPM<5 ,AGLS_O5-:Y&0CN
MG*33CO!PSG&^8#9/W5:7HL6W#P@W@ZCG&9E-3EV=@)=_^3@<3$[K2+&;Q8XS
MJ-80T\W[ ^ 40^=2'G1=+[)83'=41X4GXR9COQZ"/>\LD\?XG.<_YLD:33[H
MK-CT^A6!MI%Q;)'EL32+R-G1(I<O1SZG<Y<7F)0FN8)^N<G'MQ,]OUEENLKY
M*16C5RM&1:D8;<-2'K!B]+L5H)<'8;E$P6KX_]E[]Z<VDF0-]%]1^)QS[VP$
MQ=;[X3W7$8RQ9YD8@3W&X\6_$/4$82%Q]!@,?_VMJNZ66@_>P@C3.[NS@-3=
MU5697V5F97[I37#1!S5"<V6]-RKN1\I0=\](T^/&$XO^YD5[\UIW\Y?<69 =
M,N*(HS(=;]/4II9D9AT:?XJV'5+1(_1Z?O$A@X'&[0Y#YFBP7'H6#-?,2T45
M=68M\BRO[&:_%IF4R]+-ZRU X[9?;?^I/ULM^3UM\$6"Y&#2K:T,519YD#EL
MF%^^K$(K7)XJ:7["MCCSN%G_JSB4BZHXQPA1&H[IJ7GHA9%W569^]'NV;M>,
M8;0POME^J/I'-*VZ$W'*%5C2T*)D6I2/,/[O,#AH, \^NBHZ HJ3&AB8"%*$
M=18+Q0.AK]X@L82UJY"4-2;.:=;_NO7?B<__?.BUM%A"!H(-.M'B:*"TPT!)
M%OW9H#R5^#;KOX3G9@8>ROKS05'XG#D,,R?GTOR_,N)3%,%WS+A,!"SC3*.<
M_)KJ*%.OO5DL\E5:[?RSHXC<[MG3)Q19N@OWS^/(_?L2\=QD=!.>QL(Q+$ND
MBF:PM;S[B=LVY_5-A[N\S"E%VU)TJ=]+SN?P6 _*;,9J%@97CK=^'I?&LW0*
M3_J=5'(=!Q ]O%ML(O=C+;_UZ]QU-[F7Y7EORNGT>HE@*U&C-B!S+<A<MN,F
MXXP6T35R0**4]8*\!%*QU+@D,,0Q]T&:Q(M*KJ3>NAM-+O/*&LH\,4;2N+%$
MV7 BB@,RT"@EPBKI0!MIN)LT?#L4A&A&@P(&.Q5-#N^!0A8!85$T !WQ+L#$
M$WH-U_-=C0WHG)!:QML;2[4ARD@&H8$$^F"C]*VV1T<C$'<0B).=0^[2F1K5
M(/"(#-0% Z3S!"#DE'#60)QMT.N(8V_/S%?0\U1^C5QH,C>SJ4\J%&J[?]RI
M1M&4*-G$<RRTTWM4 O$[OM <P4%AE;B;WNN.I*@_<L-=KD/;G93_TW/#O<',
MHC6J5:A6?(>#0\2,#5Q@0 B#J4=8RCR5& 3!!8(I1X31Y[KS-F)Q+['8C5X?
M4\KA@ S04#E C8UBX:+_[P0CQDKO-.:IW0)[GEMP(QGWDXQ+&R4#&N0M X':
M!!BIGR]&'@3L M?"0Z&N('&_-AR0RE+?]_NC7F++0&+=JE+_+.B7P >=$EKV
M!_'FQ5L-KRK=7)\*S!L#_65-ZVPM:TDX!<[R&X]J;SQA AO6@RHK["?X@TZ2
MMN-=_\['OR^>KJ-]L;=_A-J7'UG[<@?O1KO Z2 $)-'SB@@,*(\*KZ/: Z:,
M5D)KI.W"<2(5TFN!A3>,44:U5L': #UQ@0G%V5J<*/W;NUSHM].+"#]>R[.D
ME-J5:+@J\:S18G9JHQ[U6RGS9U00+7X_ZP]3[D5*X"C#J!.O(B>X)7* 0=GE
M.EWQMQYT\FES_J/S9E2_>Q&5NW$,<RQS-_(\#5/"_S2Y9$I'T$)XW3!_B@]U
M8=EX^O[1KJ"3S$M1F#RI0.(GYA"X$5C>;(UF>723%!Y'3??S-+HI[[/HDC0K
MWC-"G2C2\M73H/RD^5&MR]*,:I6BOZA5F]&N*6C5ZL^HC20^+C]L.#?6LF'\
M</(RF3G3EWR%QYVS*6'GH#/\EGJ8Z*.R@XTYF6T%O.SRZ<"J3VL#W)BE))S,
M9V+S2[S&N0%RT<6O^LA-60)G$L!NL L>=Y,O&\"G2-NR-ADO?>//16@7AX$2
MXVG<Z ,,"E!) I >4V"-"M0+PJ3B"[L]49#@$)TS*2GQ44$98DH(0@P37"]T
M"E\_"%IN()02T_JSV-8RHJR#@;";.X,78\LG=NE\;-II?&GC\/(,,9\XEF>:
MP\D.G9B""Y"MPTZAP\.RBYSOE*R^W^UQ4;^=679395T"C$1-W+&9RK<866$1
MY.CA44IB[V4X.M,7/I4S9&[G038BJC]E!O4X"E_G RN K;KYM)*O(HF<)*+J
ME+4Z')8<99,_YYM/&-+C4T*T,H8VHM2XFSG<)Q7K4TKT84G(E.IH3U,-032L
MBMO&^Z0#VDPH_2R3G;?'OMJNXHXS'M1V!=V-KIPMSMY=Q,2R2V"1*=PY->/!
ML-A1?._OSJ!?+&>4AT7*T2*JG6:W2GFJTH(K*[&DB"O;$P[<1)KSLE:<<+7>
M785D1UMQF6P/*\&/#_&EU*2ZCDIHRM*-+#B)-#NUU2G&7GBNT]%U"I7(>VA%
M>'M1$.7FTNHX8.,S4V\6KT%K?.:JC7NY+1:_GXYXAA6S=]=O/MP9?NHT^4P&
M._055V"UT\\"23E5Y9E"?852I4^AYVFMHZ66G8*9E/*_TR#+XIU)=6QQ32V]
MKNK@FCM<ZF3A'7?B9C[([=SJBS A+"_OL=$:1G>IJP<3P,E(4'SC(A73?HBV
M3;H\9[!-:>3+_) )*_+,H&<U:A&S9IGT"[?J-%5YI1R+*SC#SJX91YSB\M[3
M(M#)4S,_="I?&!0-[N)P-UJ]\6@P?=W0'7>BJA3DYYDFKFK#W'<7/X&8EI.3
M3/ADB_M1V02UF"HP,=\C'NBS3C%G4WDH<*U& %@F5+9.Q]U1YRR1\!?SFY2Z
M*%^;[2WH!N.C85E!5SRI%S%T=J_,'=ERI=K%I%@CBD/B%BZVSD2"R2%?(/<O
M<SLS2$T&=)6P9 ;"A'>9T;_:"PNMR'\J3>#IYIU;B72C'5PY.)D*;?G]ITI0
MU5"DX\J>2[T"2L[0C:4Z,[NMY"TC87&<S\[P>%K6E,HFJ^#CW'8>]71QSF=-
MHTE HHY 6=&77-D95HLZ=>LFD)%)M\L57/Z(JAZF#*V4RSRO23\1Q?F-AG]=
M'__?J"3C41:--(57"6NA+&GVYR15M]QX,-D1LHD6Q3\10!1'WV7#O'C3.5=_
MG@(]M_DL"N92'#NM?MK$7-Z1ZFA=*E_A6P]+'O.I[9*BY-U^V:9%'QT-_%'N
M83*3K5<+EY=&Y(Q>734+D\S <;QZU!FF$K"$V;G?1Z[NK']04?/W)MSZA4]0
MSG,GY8QO]2YN=[,KMYR9A^B%1^3A3JM/*Y+2W%(E;:XSZA2-@W1EFL*HAT>Y
M>/!JSG2Z;@'!"B:?TAO, < KZ$=+?+I+)\>FQNYA-7:\J;%;AZ'\P!J[&VOF
MYL)D1FE'./%&($VQC5^$3EC*G3,*&<<?_9@S%8[OA=2*_L4?<^9HY^4ALD9#
MB@. AMA4+>> QDH![4UB*@[<4_I<HY=ORVY?Z[!759'+:DR5_5QG_RB*"&8:
ME<W:Z/76QC--VY/O%O>_DI%@QHNKT1JDXXVR+W(F4)CXO7/G.-$"K'7!JG;2
M9%Q.&#PJ5[#J!EDC1R@Y3&I_B2YD[NE7_IH/1*J2^=Q1\LC/NHE3:I+R_?,,
M5>Y'[D<V;<-69T:;M*,J-MKD4/:K%P"%958DFY;=*8;CS&\]1R'U/".;=<>_
MC#KET,OIV:AJ^#:=]<*W'O9/)T?@<]Y@FNP%$8OSZ/J#824*5]Y\OH'=7%^U
ME"C3&_7+^.IBU>?B%94Z%*'-8>*:R_WA"D._;!DPN6NG^,KS7\:H\?WI6@Z\
MR1&"O'0W+5?JX]0;AP0G@S*N82;QYZF/\G>T+4^C098C$M.&?Y.%6;M5O'_L
MX$FWHD>V:SY%A(^X]ENQKEL]M^52 [I$JI36\UV!BHW-$VV>@^^'J=^248$#
MXZP E(L0?Z)1"XAQAFJCO5YH*.Z9%"&(P)03U$"E)-8I!P-"1AU9M)'*%=EH
ME6N2E61V55K5LK06\U2>SE!9;NG?^/H3 V?RXD>U%]>S+^ZK%T]$2]V+R@C*
M(4/=39'J89G=,WO9Z5FW?^%]&1R:F"\%1=KDUX1__4$1JRGK2W)/R[ZUXSBA
M]J(R1!(-OL_V0!Z0Z^1RSHWIN<I&U=0Z%&>>\6W"\\SO_)2*1G]-*)_V%I^#
M7?W>7LX1RBW;2N1/S,0OF3_D(SO$C''*E !(<@DHT0(H+"50WGM$98@3'.;1
M(?!@!=4!41Y7B B#J.!.JNCC1M^6R+7(]OPTBIC?RD+0FBQXJRX/3YK.!UI7
M-T8;IJ'/6RDYP%H-?6+Y)WHQFXR6'+[-'L*DCUI+H+5K/EF??U LT=HL2=70
M/DU@G+JJG?UFZ],=UF..*^TH-1$M3HCJN:_UI9^F(XP6FNQE22@[^+9T=#]=
MZBY=M"C_M:OCJ#[9XWX^CSR;'#FDCT_[SG<G"1VS-ZUZF.8ZPW3_5)HS>_=\
M,-GMYY_++H#+SZM37D\ZAB[&.?_.99YA<>?R4*<\)2NG,]40E 0"5:?TN1K%
MJ@GS[5LOET^8ZSZ<1[$XH-KIQU5#FLO.+!LHE@.;C"O;]IV*?]SD2..DB?+B
M4Z9WGS1F/DU]I[Y4+L(T<;4\22WM@(<^8B,Q$Q9$ZUF*]<@>@_%9O0-X]>VZ
M.]2IS6+K6+OX>1QH-5=7+LJDFK2XL!"*_<GO^4G5YE+FD-S<![C>T7S@DU65
M>)/*=:Z&5!U2]=SD?:KLG4ZX=H93S,CG4\3\CG&ZB@2X*;&N*7O0%[3UQQW_
M=Z4TUZW"?/_O-+G#";&CS09AO#CX3DXQ*H2T>FCQ-C/Y5^5W<PY*-/:2V_L3
M9X+?:'2\^5 _=VS[P9$?;+3^_78GZLMP/ /="?!R^L<D86UB:\<U*.S$UEL]
MR!28_5+&4I9S_6MU$0K];K=_7@E!\>R4>K9T<Q9+*K$KE%NZJ=P"\HJF %?H
M0!T!J[RGZE6FY#957I?O=HXZI7P7^OKOMZV=(CI3SN2$)^;*"3W-U>B3>:I-
M:>O7?AY&:&UG%Z9?L%W79GGNVL7O+Y_NZPZ4$5LW0ZBP*=;5/"W* J\Z;5Y8
M_K/D1ZU[S^Y?DVD3/=LXQZ;3*]SD%^S[?3X_)%@%00D'0F$(*)<!:(XDT!%0
ML=36::_F?3_,I!0.<8YE]!M3<0[2VG(5$3@0E&9]#7R_:JE;6[5NH6OK[IEJ
MM#.]3:_U["1<.T";S'E=O]:_1/I&>8Y86'@N98/:N3;G15Y3O:E1D;A>6\MY
M]R_?8](<N+B!U5U;]C[2A4TXUX5]@2TN9<97=.%ZVN%K<1>L55J2M16:=5'4
MN_9X7JJ[/[3+6L$IM:^_-\<=<5/[?AAW-":<(B HX@$-S@(EC ;66ZT-P]H;
M/+^IQ<4D+*6P6BZH55P)2)&21"CD#,+/MJ"MD(U6% Z_?J7N,WM@R0LYRB.=
MQJ"*_@1US)V2(F_G#MTICT-_OPJ=BT/=LEPN[[7]_C>0+B@<*-<)(54'V=HA
M\*G7J9R^EKA>LBAW+UJ^IXNTXGB'KCZOAEKFLE<>U#3IN)^^679%S2]8NO,%
M==>,-S\SE(&?N5O*Z1@,R\A)[O)4=,RK1R;BB(H:_[C?U&9F2O(Y;1XRG>QZ
M'+D69B@"34722UGUDUZ\R'LHL]USB# __OZE(T^8X+[3*\N:*E&KJLPF@1VW
M*%\;]4KKJOYIF$)_>;LH0G.G_;AZW<XWG[/.XYNE//(\HSD!I>0V;94%V.5,
M+GE8$;9*%YMJ=*F>[:]H0A3V2THL/]=3@:F54N1@9,\G>R%UA\DBY,9V^7/*
MB$F1QW[5^/NSH_AI2QQNW KF,X^JR$U-J:ILYEI:_S63.AP/1T7@HXB?1S-Q
MY.UQ+V>WI F=X_VM &I.JY<\O8P,G^KOG=/Q:7Q6SX=.*8M7".I&'?4F0>):
MR'.C7HXY/DO\BIUT4APE:=0M*0C*^KUR'"D.5C(EY//E""7=#,ZU/+QQK_8N
M&9Z+L<XA^%+LNOE\^B%Y\#4!;;+@%[/@19,%OPY#^8%9\$^6U6XZ_>'KM_T<
M="PFX,_.\%OE0::?"P^H\8.B'W1Q2(G & <#C'4,4.T$D"GM2Q!L!3%214_H
M 7[-#]FXKTITK\E CH=,P@A)"M;.T2DSL?..5Z3!YU/1PI1T!0?#M/9QFO.N
MCP:^)*C($:@:A\9"C6RME'<NO7T^8M%-Y7?#DIDCD^E'7V70_YYS$*9=)!=Y
M.WOC="PS1]V)F.2024PM3TCC)!?>0\:YUM!J*F[@^L6+)2MS^OTAOG'J77CD
MT82,$^ 7I]3O6/OD'3ZD 5-&@@34"I?J5S20S%)@+>884JRHC&J,%KE9_V?C
MC@M+)77:V[2&AB+NE<(2219!F^F@J;R!K;=9V#LL[,[Y(>;4I&:LP/+4QLL%
M!11D%JCH?]BXY@&EG17QQ86M=P"_Y=H2!@E4S#ID">66*"Y3Y_>HQY9YB-D-
M?+O-VMYE;<DA$RS.94 @_ML"2AD%$BH/HBYYZ51$3292'YTE:[LR[OJ=WN2Z
M6L^NJ1O;\^<ERU+TJG1^3O*^,M4$2$^?[% 5N4I*0BJX4_:/I_M7<:NX0Z6-
MI8A4E3Q2[[T9C%,P(O<.*XZ75VXIWMRQ.%N12XZ"_RS&O>\'IW_XWM'H^,5)
MZPP3+&E?'AUBYIRF6@/-5 0E C50CE#@%+>6>P)QZLTR.N]G"5EL7Q_GLHBJ
MCD=]D 5CGE6@R+>*WRO)'%KG/G='JJK^EIM():G9613Q%&\XRBT7!D4, \'_
MJ1<<SBI0><4#6A<_8;PJIR[>$PP>8N(IJ B43!FF,:7!*:1<\#@0)H*PF#0F
MWJIVB]V3'7Q(4F<$1@S00B$0K8)H! 2E 4-*4D^XPRJLQL0S<0U%-.H4T3XN
M+%728^@\0]9Q9;!J3+S5+6S[_#"D0'*@$B#O55Q898%4J<^")T%)Q VS-BXL
M7HF)!R'F#DJ*'=&4,*415]C%=8T+&QTSUYAX*UQ;<B@"C]J*+(C:PZ-?9BTP
M<>[CW I#2.K(+/CRM9TUU#:NRC.H]K-D5E4\6F7^=Y$+7=2#U:DW"XI'6[(A
M'@WTZ7!2 =[.Q;.#(A6E^*7C;MWN]2&["6=8:.V43(*9*#2B01$XE]%4E%)#
MW>PFJQ+,O>TM=.CBG"K/HK-AJ$D]7#&(MK,'U@H/J714HBMVDWN 3L"$&T0T
M-U!3I:AFDGEF \?8:A)(LZ&L;FW?71Q:9Z-YP#T0,*XH99@ $S4).(CB[HU3
M":M\$.@L8V8M *@>81Q.\66S]=L$?Q+3;P4[T5$L"MLJMLK)(>,,/6_!BE&6
M0I4'IW4BP8N9VOFC^J.B2/1L]'/_2$D9!;G&T;@D/$]9#>F$M23(J+,35P,L
M_(M$8/:](" >9QKUHJ5"'$!T'$8%UW["R%3H/XR>\499*M+);DW7ZW3$F<Y'
MA_U>GJRS_G!8I=*73DN9)S@M^BI*8&8J3'K)WRZ\HF?HI]1#WZ[O9WCT"NZ-
MBO2Y-V%C+F+8N8 @-<&-:]%-BYP*JG.D(*4+E>D)_?,RE6>1^'=*^KN7[YH=
M0CVLTOA2@,/$Q=\H>)UG3A#L(&Z"HX()N,ZF$K_C_%)%B(N>>W"D!GI3EN5Y
M%7*)7')89I1,7KR@OB["]N^+7,/9@,R4LF(R@Q7U:^+/2_=+V_=S=&-O[\6N
MR.*@G%H9)*<A;G=**F4]AS! ;;$(GN#&XEC1N>-Y]E]]-.@(X@)HY32@T"0/
M)S#@B(P>K248HV@*B\4F8?>Q.(1D*"@6=<TI2C%3TEHIC4;>L?@WU%@<C]$<
M?F_[VZ&#%FM)4\L(G]H$T@"4-Q9@&W1BR0A!J^7+?$OCXV;*GRI#?EA$#<M2
MTX'W4^:F.MA<@S6+(;*[>C7>!6NHL@9&.QMYJ3G12C%FD-;:H,;=7AG&7'ZF
MAQ SJHG& -EH_E*KHKOMB0$6*\LIX<A1_^H-7W9:MEII.^]/96TK>MM567+R
MK-/_)B9"(36YI+^@%QO,594;'__X=V7Y%E91>>LH:N.NFQ@ $RK[@K=NF'/U
MTET&14 @->[9;/T[VDE_)[.BGB0\>79Y2ZO'P\QKKB]R-G)5.5^28A=<,X41
M&^_<[0_+SF)E-*(B32]NIEU.4DX,-46&\K)YGO82F]1%YYX<D\;(A66].)W1
MW!KWRNK243JQ.M(#5^7NOMW[:V<;(-7*1U>G'9N) *\.9<RS11=UWGGV^IFE
M)]>P1LOO_\8IV[D;7[<[K"U>:<'-L17&:RLRGF3F3LEX;B#U>MSZD/>Z,T@Y
MP[Y=I(TFQZ=)E)KP8UT<.BX-AL0"Q*5.L3L$9 @T&BP".0&1-VJ1 <?1:&6P
MN#2&4"^,P8PS$\T;[ZP3_B$<HD^86)5$)>>7IYKJB;"L3^5(K83N=#J^RCO+
MG19R(X*!VZC72J;SL/4J>UL^T6M#?A-GK"*_V:AWU0B#B"SG_<&W['\72Y!F
M?:ZTT?F0R33J?RYK&G,I8][ASO.>46\9D^ S4[?VRK*?S%C?<:4;WAN&E!,W
M+02*UMWT 2D$4S*<E;P;=0DIJB^.JT?68DHEF<YP.#X]JZ7L%W<J"/-M)ZY'
MRL'+EX^+8IF*9Z<^V-K(DK16LE@KS"A:DU3U&\=Q)];1J+@H*Z#.QJ-44%3D
MN2^=W7)LT4K-)0=I2M-XXL;4-VGO+BN-\HVR"=/I+7YUW%O\LKDH(S3%CEH5
M#F0&R\4O^V*4N<BDUN=H;W$,@\F/-\YH>L/9LJ_ZE,8UBWMPW%)K95D),!.1
M75KA\O9.CW1KV(^F6NJV\GG)F]:&5.^-MCS^61,+;?KC44FF5)!0K/J-<C%%
M^J[QN7O+M)U1;8Z38"V3H$Y!'=+/4Q-*-RAUG3CJ)W[!,DFG_/URVB6I4_6N
M7'K+&2JK;K0HAZ/"&"H84<_&TV*2U-,RMW#JC:I8V'*XGAV*']XTC"((/+2#
MCBF*HPORC^'KJV.C9ZDW5^\(='T8O68R%6#.;+'@"<-?&5CYOYX.Z_\U,SN(
M%N6I?^1512W0VBF5X[HUS(OR?^-^V>W#^I*N(.=Z%7I1EG7F O7L416U9C4-
MZ/AK*$.:);SG$N+;+F'%:7Z;9:Q<SJ6+N#%WB]EUO^GJO->5CYH<^J1X=S&,
MC9+N-+]0?QK5GWWDY,(:WE>97XO(N]'RG;*\O^10S=MO]=N=@NJ-G-Y33LE=
MH&:9R=(?U+:+HF#R_\;70<HZ^%W+%^K+<:?KET>#BG;MU6L6I>^%$9/CE5'^
M<PNJGJM8A=.4Y0S=*H-RP4C9J!F#U\A&"(_M<CREOU-5VX_*.8V//4IHE)G<
M:\Y ?^HL+&'2K-C.IE&M>J/O(BQ6!+0RL+:F3[U*V$?E$7?5:BL3L*VXV/IQ
MXTUQ@;8F#OF'0;_73W&[/"--V&E2GX<.B;10< L!=,0 JJ %QNB4QT&@%<B*
MD&C9UX!,ZT]O,_D%V'+]L[3I3I>W-;N^:Q$H2J4.OX^CND;Q+/MHOM_Z]&M%
M7;CUZ7/^!*"U(T-Z/T&1G1J*K,&<KM<TM=X6N1I_%,<1OQ11/H+Y/U[7HVFY
MP'GFFW$#73K%3\LW51RAE/DQP]G=(.<Q37O1EQ2]1??EXM7*,YE,6C5YM]+0
M/O9=5Y+MQMNY0ISB/E13@43V>9HJ8'R-VK;(*O7#X]2RI A-=5+?R/FQZ/H@
MTHU+GIS6;UM;'\K!%\&5.*_)'QC5>*/+KU9Y4/E^W>X5[[<Y,^9.O;*H&%_J
MH%O6FO1ZXSS4V6:5*6H5M\:< Y8Y"*;E4(D;=%(NT1F6K!PZ'_1, H2)4+N3
MVV4._&C0K\ZOB\!DIV:<S5)UZ!(R1_5X8'$T];ONY7*H\DRJ7"A7\GCG&$X*
MJU07N8[+;E'N2YY"G;EI<'="'=Q;&L%*1F'<;@O:XZF Q+N."LB>VA9+&8.7
M,V?D#?M&I@$$$Q? ;<SP\D^C_EG^O:';N))N0S9T&^LPE,>AV[B/DOQH8Y!L
MKKYH\T::WNVB\7+<%M?':S@HO88^:W_YO=O^LGNR>]D].3C=@>WMOSK16T '
M)^]/=D^.ON^>[N#=W_XZ^?IVSFLX^?;]X/3S]P/<)GM?=CL')Q_/=[_\'KV%
MOY(G@O>VW^$XGNB%['[[S^4!2Q691$BN"<- "R0!Y=  C9@ 1* H?D*+ .G\
M6;4EC,<UT(0;0QU1*O[7(!;EA%.C%TE ?OW\:6?WW:=/K:VW'S_O?-K9W]G;
M_715SZ9KB&)N?NY<SRFMB.54.QZU2%*DHZ! )PEWR%)J]7,Y12_HR(L@S*^=
M_B<[Z)QM)([OS76PY5/^^C0?.AIMB1BV2(]!&\7_KY>YOZN+#@>)E[]*J,FF
MVH>BF'?2(7YJVW^:F#<_YHVN'7^-^KX8S&F2#S<K'\4G\6M;XZ/Q<-3BA4FZ
M6?Q]]EN9LJ55(&-19)'.YP?%D5S9V#/-SW'B2<M%7C72PFSHY)RDXF;[$_[\
MN<X'^1;5@Y.%W9_Y]-^YN"Q9Z05G<6_*&S =633$TB'FI U-/R='I4S*3$GH
M!KG-642!_FFGZ*F0,QLG-6WQU6SE"PUUZK&1VJMJ6YR?#LKG5,>94^*<:399
M[L%87OH<(\/["R''"2UT13]9!L#+!(G!]+RVZM^3"3MGR#PG-\O%)M/,Q-0U
M;<(O;?/^FQN8%+Y,_[PLPIE(1;X@>8DIHU"/)D\L[U"UX)AY9-4PJ'A6&92I
M-8XXUX/</JAH15>Q5<X\*7F:_=[)N&<GQ]@+SUO21FG2P&D:6RDR45)Z8>J8
MX7-S#*\'/5\Y:?7;YB![:N9;=H!-&0#.WS":S?G$I2B:Q=MDWJJ)8B]KIY04
M_;^OS$,>#]T'/\B=[N;I700CUH1H?R(1300IH0HT$.JH1I!J>[B3D^)E],^N
MRT&N#+$:-7=^VH=TYC9)0H8OSA)[=Q['<2@=%T(%!"S'%E F"9 B2(!P=  ,
M]E+%27J#-_DBK<M4!I)T=#)!;UUA9QIN391MOM-6L5,4*%YM%S^2=WR)G?[)
MIR3DE#__YX3-<S\!4_'BP^P)O6P3_MNAUBHX+P,0SA) +:1 2X$!MBY..!+1
MA)?SIC&-BT "M $B3^.*J>AVHOA%@1$52O-U3S==OKE]SFV[\AE]K5E"$48K
M.FM5YPP%IE<]$JKX6']4I)'7MD'_O4AVSX&\::Y0ZY><8-0?Q^&ZX3]>W\42
MJ/G=!9'[*/OSDV#2(#X<Y'K%LZ%_7?WPK]2?OJLO7G=Z^<7S1?_ZVP]R5D09
M2XKW+&,N2FU*1E+8932(_W/5[<N(S&:.R/QSY!8_$W)327'EQW 3W?,S1O"]
MKKQNL$AN0GF[ ?TS3T0Q&7%2TWK]?Z_(J[G\H->PA?*B5/=;S5?QV??TY7\M
MQ/WF5[ 0E%7KSWQT:L'/S!&ZK5P0.Q'E6TR:T?;;432M>PZ48[36^Q#^=<U[
MI]2-IWGK!=#(;[T[,5<7=L;2?!V/<M \A^U'K5%\]JPEU_H%_6-FUNXY65?*
M$[[Y'B5LY&#>6?;*.JY5S5U]-6!KR9H,TGRLTZ)<::06:S+/31.@@D(P@RVF
M'@H5[5,1S1<"I:76\HE]RNKV*2 S]&ZOH]_B^J/R\\7ZN202N<=:MEF'>U.I
MF)BNY)E:( =??A]^W3\[:>,_3]I?WEVVM]]_.]A/UWSM'NQ_C,_ZL[.[_YGL
M[N\>?SWY=MFNKOG/[\?FU'7C>UU^_:W]_6"_?=[^\N=Q.UDMIW\=[VY_O-C]
M;0?M[EO4QN]/]^+GT=P=M3OP^Q_[\?^W#IVFA'JM %-< "JQ!"I@ U"NN\-!
M(ITI)]0&DFC!\)T-QLQM 0_7E?1IUIG;Z\K]4#/D_SPGU'Q[A==]A;>=]*;F
MUZ\00^>F[EX8NF3Z?T:89 YRQJ'65G-*K50:<TTE-(I1AY M:]NC&P^6^?-W
MPLN,E#M9++9SU<F'?&I>8&=\^?S1L$'..R'G3ATY(:-2>VJ!,H0"&MTYH'P0
MP$.F&7?,!,Y>O2$;-)WQ/@PWE\/3CX'&YV=0[F<W<AK[O"+@TEB5:PZ7]XMZ
M-E;ETV!CNXZ-Q& >K+6 (T\ )38 Z5@ 04JA*8-<>AVM2H(W.%&-5;DV"CI[
M$%3&K8N#D]ESS,<P%1]L'J[;;/[W0S;X.TCG.B%Y<XCUC##[8QVS'W#^U9BS
MCZAJ[V<+E.I^_V.8IX]KDJ[;Y-X>HN_\^L\6OY_4#,\<*HT5?E]$_UQ']$"-
M1C1:X=(B :BR#L@ /1 4(LM-7#SH7KTAC&X@NLBLUECAZX'X&>H74YT:"[RQ
MP&^)X&L0=\ZPGNWT7Y,@IZHFWQOF%(\&X>^$\ =UA+<.>JF-!#[HB/!Q@P8*
M8@Z(QSX0@P),K64(WI"J"4+_V/.Y(J^TXVY()ZWR>//WEJ<"/X65_Q,C_;(W
M;)#^[DC_H4R:WN_G4$Q$]C(RXX>_#?K#YFSQ;KAN9^+G1#NHC *<I#Y]V#E@
M$-9 "ZV%YP1*E+BX$=U0[,'AF.7@VACGMS'.EZ6LUBHWGL)(?ZD!FCN_?@/Z
M=P?])34";^O"OS^5?=1L '?: ([J&X"BE&L"(6#&:Q!_<1'[20!04,X)"3 :
M]Z_>H T$\0:$#T[,NZON-(;_E8K[1]2.UT59F2[LHOOM HT!WQCPCXOER44M
M37?W?M _K9VH-M!])^C^5H=N[S4UT)*4%^@C="L)##,$Q 6$3E@'M4JY+W1#
MR,9T7S/3O4+LC5;/9[ZQA^/X:JSYLGZ-Q,5U_7$J5ZMFJS'W5S4_S1ZRTB#0
MKA_MA?H>TVPJ=RO3.?]C?V?4_I0VEJU#)PWUD@= B10@^@,.**$X<-P23@4S
M"J9>XQM0B@V,Z&H=@A5HUX.VI7_F8MN5T>4^16GT<D:E&\O W_R"_I$()X:^
M2FC/Y!:93MV=C#/%1<6+WN^57RK((_OCBI<B-?<:I#ODQ/?A6;<SJE@J^S;S
M-F:*D??>##*!(2D)#!?) I]C]]J[GL0,Y^A BC;'HU%W0D)Z+87''!@K[K%Q
MPE#B,<5,*FR#A%XZ[U'03-T$QNQQ@C-_3/GZ=WJ%"$S@F3]3>'X  0AJ[W\[
M5'&7=%8KD!JL RHM!\89#8QE@4N3>#3HJS=,L,W%'IBM*+C=K-:]5M<?:5LC
MU7'>1'V[B] \= =_)*%Y%_?QT<5.*IOWP]&P..7?ZKGT0P+H%RU!N]OV$&/D
MK @,6!.7AEI$DNOG0? 6ZJ AM-GUPVQS\32^+D'^>V>8V:XF,C1'G#0LR(ON
M(E/W3..[CRC5 @EO^\-H!586X+M,&5PCD$D?#U^TV$1;[Q &)K6'"B!F*: 4
M86"X@$ S)HPQFD*3(P:;BW'>ZW!G.+8VKD:9.A:\+UNMY^X<G8$#J8=$8C3^
MNS/,_4[__;:ULU.2"A<4Q]%HF&R&9X.XYH.X/T_8W+)SG%H[%33-+B-=14J<
M.%X*&Z.SA)^PA="ZD;7O]-+PO4L2_)3T@IMS1M9RQN8[FUT-^?(B^;*:F^F&
M?/DG(E]>ZG#=2$D[Q]/ED);"0J%0')&R7#HDE.!8*\:<U.+1FZ]\LL?>C;M^
M+TP9V'9R+Z[$7;^5^P)4VVLTQ6IV_5;J>N/=BZ=HV]W>.HQVLX_K0$&PW (:
M_2Z@5;! 0F8MI"9Z9NIY4J[M+^D1H+MQJ2>L:E?QJ95-NE*@>Q3_DAN"%ZW9
MIK\6;2>J^'?^N-[I31<BMCQ:OM$J>T!6[O6SXF\3>%-"<1_^-HPWE>(K9UI;
MO]M>_YF$=/6#99O1<[D_VYQJV.;NSC:G?JKTC++5U;#L4IU H("O1V+[:,HI
MFW+*'UU.N22DMV@\)LF_A?GXMFCK5'SSSXG._"S9W?WO[<MOE^W3W?A/^_O7
MWP[@[LG[:%+^?K*[OT6^GGSMM+?;E_&[IP>?Y@[S3MY=[NVW+PYP_.?R_;>O
M)Q]Q?'ZG?=I&[6T7[[=SWK[</3XX_7J<./=VWTXK[65T/QP6412Q!A1: ;0U
M'MCXHS8X6G&I:D?Q#4;PLR[+O&[K>'[I(SN]OZ,F%"W.?\$-6UZ#DA.4K$3C
MHH'%.\'B3AT6B7$*0LZ!#(X RCT"1K$ ,+)<<$0-(>+5&Z0VN"3K7LSX<QG-
M'P:I 4LZ*^BY5NIK>9:.!$J[F3PY2UZ#A.N#A)6H?.CJ:#7V\IEQEI8&&>^$
MC.TZ,BI.K)=0 ^V5+8@\M*<,L*",%9!P2:/!2.6&6)G!V-B$M[0)YX*E)2C2
MQCQL0+%F'E92TOC-=X/!CW483 UU%(VV8; <I?0:"K1&%D3#$7,=,$]%A]%
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MZ*"P-NB@_*LWB"RQ2AI%7U=%7W\'HU'O1U3OFL_AC6,>$0XL)E&]73YF$0Y
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M\<\K4@',0@ S0:9H%$U89:X 30/BE"6D;7*($A^P=C12P]<V=%WJ58HHJIS
M*W 8*M6]C^J.,:HG&QE1'(2'2<03]LA*PY#B*F<#8!$-^ :B+K!<(=6]1S*
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MD*WGV!NLK7$T1"Z<MXX0Y0V3A!A%8[GIJI9%3/'3PZHOFZ6B<[5[=G"Y2[_
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MIT5O;I6\B-(J)W3T<WDFJJS'BJ+5>'@A@G:>(:5S59K0%&GL"-*PQ$0F(<
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MVNH<$+IG/F5X0.CBX&J;'] =<;BUPQK[.WAO?_/O@Z^'Q[LG.V+WJM$\W#K
M#7K8:EQ.'Q!Z?[*[?WQR<-(ZW3WQ!,8A=K<^',/8+G=/3J]VZ>^GC9./\.PO
M;*I=6N2<,64TPC'7>7*)D9/:P:^4JV"L#I*M;>@Z5G(F6_>OZL3BZJALA4;E
MKE0TWG$1F7.:&XD!FX("."(..V-4N@,!9H5&3XQ&-\<51<+:<)60UYX@3J5
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MM%_?/C1A0;NUPO$8MAJX&%MX</A[@]%KY_L.V@6U_W LTRU17H16;=VT.5B
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M!S\)JY$SRH9$8^(A3E.<.$ZT@X]E8I8+'8V3"7[A2?LHN>1KM0C.R7F&P.X
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M29F2$:##$H-\PLE0*H/F<L&./BOB]N15]GG?-A4",-FMY\=N4#<WR,H:,-:
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M*IGU #4?2V8IYW5N'X2H20)QE1*R+"84,*:$0OC&?2J"-LK!CYG5]!4-VMY
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MNI1W_Q&--I^68>"1Y$I$Q;RCQ !Z>)H%BB^B8\D9CN46',(I'(B.%/"#BR@
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MF1B-;SJ]?N]=M]/KO6!M./[6.'U_Q /7)%&"$D@^XMZ CVBY0;G)I,3.$&Q
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MX3]EE M2-RV+S6)!:[]DF?RU=-\*$UM8Y/SA#1M\%30^+[G+:<K50F/AT%^
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M%HW#.!J+HY><$Z<Y22%&SGE,RC,Y2<6^[FR__W_HC[6O&^O%YM9[H&2;WS>
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M *32QN0H4#,N5M1B] G^#9OH/\<>\0WT*/[2[!ZCE$NUC>6HS@6=KZ][WG-
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MKZP.2ZM*F]>'5X^(_W\)>_O%F8INUT]N,Q6]\$Z#OVZ_7XUX\ZFC01(D531
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MKC?V<XT6&UQY]I5MJ>%03%P 9V$:*QJY=*6HZNFNII7Q6+@%0VTU%;6_@+S
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MUE/1:$*1\(<Q7+3B=IH>OC+4MDK^N'8:)E[Y!ENCNY9GJGE^M9,-G3LPOC]
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MO<:HQL@M9TP*@C#6V<8'&J,V4B'/N%,1:T>%6EKE!B\+H1:H"F1=^;:N?/N
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MCG1#G4X1D5MF$N23)(@K'Y!V--=F2HHS4,.,B:5.9UZAD6Z1@>OV #Z*GR"
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M797%BZ!<LA^5G7LEIPF71L$II=0J))NWJIYR*E"FE(5_N?/&2*Q3D#1Y2G7
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MSUH5=*[3=R9F=1>*ON&3-2>R'.]+F%QE+* F!0Z?2],AJR)!AF@ +<WA?&6
MG_R.TG^]6(]<@[B2S,E8$CM0URJUK\CY/S-6L^W7L36#J(^!GCK<ED^@#=)
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MC7VA%5'*P!F@0?/AD7* BQ11((D+89W@.<P2WU6F_QY[IYC)WDES;*V(@F
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M"PX.TVR9C5&8^D1://$:#T7+,:O2)\.5T2BW/ 6T$1%I'AG"B3'O-([,\JP
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MNL,E\&"Q["NNI=[ZM3>*-ZL[P;C7&_N11BD=Y<@:IA%/0>:(&X&X$3@$([C
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M=3>PZ*-&K,U$+-L*..>1&\>" 5*%<030%04L"0/B\[A$+*]"+-T1=]T1Z\L
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M2@)L9>VX,'BWFV>WL,<] 6)@,>^=(UPA/ ):*0V8+9R0>DXH$K"R+9>1A#Y
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M[]HAKNT&(\;\W'&#LHJQ<G0%]P8,&L9'T>/&>3^<_/OH:*]A_+%G_)YG_>[
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ML)4XLJQJ_EL;HF9/80MKX%A'X)A,:AL QU#$GF1-8\!9]^+)2!J*-37?;=5
M<A^.O B,Z&RT"D6>./]5H\@:H8A/")$H0IU@-HK0Q5&$/80B@XSWL\.S U#\
MJW94S\[R3+/\4R>@:I9?%Y9W+!LT!A=8GA!/YJ8.6%[R!Y9IZ8>#,ZD5C]?,
M]%4QZ B4#"L#5XQZ;MKU--1C?F?08$D5?^9!_^>L#C^U"O7:E(QG8VM7^_D$
MQ=_O6Y-5(\/J*L,_#3*\DG+QN@C#!A=AF*4>Z-3WK5$/&',=ANJ!RQQ:5P]
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M/;+()_MMRBIK%\'F<7!I1?C KE8 TOR:!?"Q Z])"..*<\?<>]A6K6K)!A^
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M1F%M'E3#1"4L^"MOQ6><W^"?1["( %6XG@KY,@2[>?%OVF 4QJH$AKU/ !\
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M,%V"I4M&L3I7EKT4LXTNZL;EMT=V9\@#&P1B0"09!$:3*21B%W?JC8PBVXS
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MK$C*1:D(#M@3].,Y\0HR"1!3IE0Q#TV"K?5@KL2SGVRSN:$BJY'M9BL!S61
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ML5C/! ^9B)1*C6YIB%TD34!.* #(LDU=J^5PMMJ<?-#D:Y_V(<Q/80;33S!
MIT0%;@U!GQ:G8[(8QDF@1&<5K F*,2F?6U]7Z:A+1X85M'YG([&FC-M1&[^X
M^=FUFWC;.>R-TW4$-!N @8Q1O"<R2IR*E D2$L,Y'C53WD6>VY3)W1QR1PWG
MMNS:L2Z;<>]@/(<IS.9[?CK]FB?3SWZ:!EH$,"$P$D#B2@(8:]MH-4DHJ$PI
M.!.;Y'JM JY+YW [X-/6^JESD/9@I(LR3S=.PM=!UA8)# J#58Z$I@Z(\](2
MYL!$J3)/*6ZV5MWMJ$L'8<W7JBUDW&ZM^EX<#P=[FY6S0<XF1V4=28+C8FI2
M(E8!(RKA.@HNZ>2;Y&.O@;%+1U>[6(TJ::LAG19%>B*GFJ>82"ZGM++DP 9A
M.=&,6FJ=#1&:Y+$OA].ETZ6=D&1M'>QF'\"KE R+F0!3' -:I*F+SA''@,6@
M--?0]/KG\_L FZ^B=TN\P:A,TU)\]V(*\6KW>&#!"JI946I$>\^4+I6U-*K<
M9Q^9IMK1==?4Y[OM8C2X-3L>6V<K:Z&ZKW6[FME316D'G#L-(49BRR,P$H,'
MG+QH'H+.,6:'%@'X%EQYLO,N1GB[8$P]C;187F\!O?4LVOW*:O>_'U#0.D7G
MB4Y4E;T^1VRY(N(,9U0I!K;Y=OQFR+L8%U9CX<OH]^5H^>VMO<P-<UFAG^-*
MN=,8$&D.0+).QD4F0:4F-:DW1MS% /7E:;B1/AO3[\KK#9D[::DAU)E2^2(I
MXG7 4(@&ZC)HR6U3'W,)IB[&J#NBT/HZ:1>9EK-1G4K^'#=$E>(H$B0C+C!/
ME!6!AAQDU$T2SYX_G*YVH&93\%)D2H#+@&&?=P2_=X11GI+  7*QFTV;)0=J
MW8@^-F;$LX'W^AIH1_<E]S4X0TL=,/01Y4ALX2LL"D3YD*0V$)T6K6WC-K=Q
M^ MD:C0BRI;*V56VV)&?EHCH$]3)"'O07.6LKZ?A5JW3^%"!>3)]H.8Z8ENO
MK\HRW6*@VPO\\/CLK-\[/3HX^NWLI']Z]GOO=*-ZTTO;J2&HYP&V$<+FA5.?
M:*V50-H435W6TQ;S[:GF6@FFU:SI]\XV*RA\_9=5QKL$1*VA;<'^VW]?;YB-
M&+YHNY?2XBIDK9<+5FBUGF!6!U]+7&_]_'*ZB#TG^<YY^W9Y[:LW7D]X:P^E
M4N[Z(>":#G=WP[]E+9SXKXNK:/N7,-"@F,M)$@]"8:"#<;V#LE_ $[7>6F9C
MDZ*:JP+<-J9ZLI]WXS2<+=YR*HEAY693[V/Y;H##EHO2#DID0V1P@EA1DA&%
M\-XP=.5MD[/OC=!V*3YOPKO[H5A[G58+Z1\!.> ^"<=S)-F4@WWI.0[?6D(S
M*.5I,+%-6LXC>+IT7+@3"M702],(?N7E8\":KH78_$Y7P_O#V?5Z& 35(0E+
M +0DTGE'2@UL_"=SSFFT4OR\Z^&M?HY0\.>?8?0)WD[&\P^S@0G*69<ID1 3
MD511XD5P) >F9:!2NS9UWS<%_$.NBNNP;ZU5L99FJRV,JZ+]!_CI^>?)(.D4
MA IL<0N$2,,%&N84B(N!:L&T=J[)J<^:.'_(A707K-M$CR]#-F0/#!CG-@0.
MQ"BKB=0H%T\]$"J]4$)K%<7N X!E2+N48M,]PJVMRQ>AW)O)Y720@S5>V42H
M3D!*77CBM?:$,V-CTIKY^.(&K@#M4C)-YPBWMB9?AF_#3S  )B@DJHDR#*,G
MEB@)$;\2DNJ870#-THOS;;C:3=A=9=YTCV_K:G+G?.OE.4R_00TR*#2WD02K
M#)$)-)IB1HEBE&H6*0?SHJ2[@[9+5TXZQ;S-==ITR^3D]/BD?WK^C][1?O\_
MWAV<O.T?G6^R-[*TG1J;(,\#W/X$95D?FY^U/=%:*X&T.8=;UM,61TE/-==*
M,"V/BTZF$YSU.,E'?CSOC5/_OR^'%V6ZEZPI;A)U%D,V-"'H/],<B:4B$\LM
M-0$4MZI)$<JG0&V[?#W:]E7Z'X7(@]<9S:;S1(J$H_4L$RAU0\%1 Z[)DUA/
MP^K2EE8UQMQ?A"IJIIJSTXOQ\F.1]=U[:/CU"*XK2/0^3J;SX?\L?O[H$ 8Z
M2B-31N \0ZG]*8E3WF-\ -I8#$:S;5)5N-8 .I7BV8R"+Z+NIJ[1;\?'^W\_
M.#S$]>3X_/?^Z<'1>>_HMX/7Y5CFK'^^4:+1LVW66 C7 [Z]G_!<?YN[4BNV
MO NAM7&QGNNU1B+RVGWL0IRM4Y:?ZW]10@+CM:L\ATF^N=C54,[/=;D+L:\U
M[%UKP>,2\7T5N;U:3/+]BW@[T],FH':OR:U%5RDF>C,<H_]QB//ZP=7)XF!D
MP3TU#MT*$TIEX)"O7EWE2463 _/.M'F-^DE86[]W^GCK5_ZWMDH)HPT15K"K
M87LJ&;$Q!<DR$X;O>MB=BXTJ,N?!DZ8U]5/O,??'43TRE0?6>).X] BL^,>+
M-SBBT$1Q#\P':Y5N4LYN?:B=BGE>AEHUE/BB\<V;R_GE%&YCOZX#N=/5> ,4
MNUA^MQ7.;M9;[ZES,1O"&60BHTO$.1$)BT9KP:)/MDF5U1=;;Y<HY$'JE@:6
M(3- T#P2R9D@/G%!M'#2"I$HC;L6R@JP?Z"U>AW6K6-0*^MV)ROY0\PW25W"
M,B^$<\1;SDOI7%P'E+)$*8/_@V"S:/+NZ49HNY2BUQGV;:+)ER3=(K'+R22E
M<YP 0+D D!5QGG+"F XY6QZLW[D/^03>+J7J=8MX:VOS!:EWE>(E@K3* HD,
M$OK9@I*@O"0:D@7I4Z"JR3G.9G"[E++7*>*MK<N7Y%W)M?$J^BPAD$PMQG?6
MHT]@M2-,*,5%9L[N?-/I";A=2MWK%N_6U>4+\>YNHA?/46OT @B*B)>C=R@W
M[PP147-N-5,A-*G[MP7F+J7P=8:!FVNU<<VB_?[K\_[^4?]LH_/H.W]?IX+.
M8X!JE"'ZWO;F9\I+6JD]\#9GQ;=[."OS9_IUDLL;0%M56WJFS=JB>1YXK<NK
MD_'[<YA^+/T,A J)<HZ>B@%'9*EF[)PJUY31*L6DI%=M+JC> K%U\OBMMO8N
MI]/%\_"1&Y$Q\I0Q\I+%;DG(RI7::3Q*#PE<DV!N"98N[4]MK/L'R=U;RKS>
MS8%;0(XFXWB-183D,K!,.((BT@&N0\9HDKQ/T7$P)C5)N5P.ITN;1$THL*'D
M=^8!+#.NFY4Z6*'57:P,K0H;W"8' RI\YI$HXT1YC<@0RPTGP(7.+HF,'EW7
MUX;2QL%X-I]>EA3*NZDA ^^,4,)&PLLC.=*$A+8J,Q*Y]=0D'IAK] KIXZ Z
MNUJLPX:'U4XK::%B<=S;B-Z-_55@ VG_NMS/P*'Y2CQQ0G4Y,$GE^7FA&#$A
MY!RXBDXV*@S]#+).91 THLBV"JE>1!ECXE+IM+SBOHBO4PA,2!=)$ 97SPB&
M!.\-H<KR%(5$[Z>)?_$(GC4/ WX83FPO_)VY&+6K,J[<=FUW8Y<5&F_W6V@S
MOZ;-]]).E23X=..U1;C&4"HY;D^NL"II2%XG(F0HA<I5)EZ"1B_?^. "928W
M>F)E53]G.T_UNXA/X>+Z8O%Q/ID.QW%X46C\(!N" P_ '48E+)5W+5@B@4(B
M%HQ&DT>5#*&U:[LVZBZYAM7X]E14V5:O3;8@GH7\+34"F)4<@^[$D";2,$^L
M399X7!1YAE#>8WQQ!G8PQZ4;Q-M$BR_(MT5&1 K@>"E<E%*Y/IC0"7,LN>).
M)T0J$6J3:'<SN%U*;^D0Y];6Y,NQ;I$.H:F(02A*C"IO:PJ&09O.@F@HE8PB
MQO=MDJHV0MNES);N<&YM/;X@Y<H1=%3"HC4.)<XL[Q^6-\LH#T1;ZK-55''[
M\KY=%Y-:.D2Y=?7X$I2[F_B@)?-9(EH9J"&2XU1QI8"6S5%E6E(1&U7ZW1!P
MEW)9ND"\S;6YLQVF_FP^_%AN3;WQPVEYA:D4OBY#.PZCX?M%5[6V2];IJO;F
MR<;#W'X[:K]_>O!'[_S@C_[!T=GYZ;M2*&FC[*'E#=60U H0&\EA\\2BIYIK
M)I,VJ49+NZJ]];M^)\VDN,O-X*4 7OM1V?L_^P P/RS+]^+F_CY,AY\653*V
ML7C;==A,YIL-N=I&\DTWM]\!UI$)CQ\F*HAR1IL,L<R6Y9A["R90VF:W:BF:
M[<_T[C?Z]=M2L[CV_NW'!^,XNDSHBQQ-YF>7X;\@SL\G;_T,784CF)>JEKWI
MU(_?PZ(^$Q-6A^09R<)"\51$"<L3L1H<6&YEE(W2"9J,IUO;S=NR\N'9XLN3
MH*GGN-2TG$S1='SYS0_'ASC$8LEOI/#=_ZYN4=?JM)E5W7SHU2WK#8CC6R 6
M#PI[IK)WAF!D2XET%*,<FAFQ+HD@A*4J-:EG_"RRK=^M*H^^[TT^7DSA XQG
M"YF7U^9+5]C\P1@7M7E1P.^0WG\#\;H\+(N,CR,_FPWS\&HE[(W+([.E&![8
M)# L%"5]D28@SHM(A H@LV<ZTB8;B_6'TDT[6X.C#Y[)>ED:U'N&[8EQ[/G9
MAS>CR><[0[@/_FI(!;_ESG&*BT2F7!"I5,:50GLB'$_&*,;QFUW3>+TA="H=
M[>7XVU#ON^?M?=QO)M-%&MX8O9W+$IM\'XBWN/H''TD AO*,VI# J22<0W"2
M2I&A26308"R=2J+K"),;,:&IY_NF=W#Z1^_P7?]MOW?V[G3C3;RE[=3P3Y\'
MN/UFRM[QV[<'YU=[.$?[>\='YP='O_6/]@XV>P?\J>9JB&1EN-M+YNS\>._?
M7_?.^OL'1WO8(88)V/M)_^@,0X;CHTVD\UR3-22T%NSF4CJ;3^(_7_M9N2(<
MT6-#"U+,"=J2Q= VWRNNTN\.Y+V! )HK98O ?<66=R#81IO+S_3:F^'"?+$X
M6WJ'.IU/BC(OY_!M3VB2%QH_OMCVF*T-D!THIH:(VMNEF[MRMZ#T(L[.X?QK
M.Z6MTNLN;-*Z@]^=.HXOY[-2BWDX?H__]K_ - YGQ4;N9E9MAF.7*MM<0+M3
MXBG,YM-AG$-:@.I]]M.TP\FU2O>[5-G:XFBNJ5NF>(&FX8QZM*L=:&"U85:2
M]N_'A_O]T[/R<-;Y/S86Y-U6JLGH"7 MAK\MG98VUD88C2AQVC_LG??W3WJG
MY_\X/^TA(?<6-F$3D3S:5@V)K :TG4"VH,IS3;843RM+TC_L[V%___$..^R?
M'O[CS<%1[VCOH'>XWSOOO3OJO=L_P%]O-+%6;+K*--MD&#N3WA:;#FMUL$-)
M-MI&6*WS;:S]>CWL4**M)OB[UV7A05^E_\>F^\T/VJ@BEB>!U1_X-J1YI*D6
M8GB6!M='$N6?X&?PMS_]/U!+ P04    " ",A&M2EP9M-DZ<   ^T@8 %0
M &)I;W,M,C R,#$R,S%?9&5F+GAM;.R]65=C29(N^MZ_(F_VZ_5*GX=:77T6
M01"9W$, #41E]Y.6#^:$*D'B2"(R.;_^FDN(((2$MJ3M$J',A\IB"NW/S;[M
M;F9NPW_\KS]N;W[X H-AM]_[QX_L;_3''Z 7^ZG;N_['CY^N/A#[X__ZSW_[
MM__X?PCY[W<7)S^\[\?[6^B-?C@<@!]!^N'W[NCS#[\F&/[V0Q[T;W_XM3_X
MK?O%$_*?XW]TV+][&'2O/X]^X)2SV=\._JZ-=BZ(0)27G$@N$_'2<V*$3C8
M#5'E__?Z[RD:X62B)+NHB<Q2$\>2(4*[X')VF=$\_M";;N^WOY?_!#^$'W!Q
MO>'XVW_\^'DTNOO[3S_]_OOO?_LC#&[^UA]<_\0I%3]-__K'QS__X\7?_R[&
M?\V<<S^-?_OTI\/NO#_$CV4__??'D\OX&6X]Z?:&(]^+7Q^ CT^CIW_X'(WZ
M:?)+_--A]^_#\;\_Z4<_&JMGZ1)^6/@7Y3LR_3-2?D08)X+][8]A^O$__^V'
M'R:2\X,XZ-_ !>0?'K_\=''\$FFW-_HI=6]_>OR;G_S-#2(>?\+HX0[^\>.P
M>WMW ].??1Y 7HA^NN0"2A4X_UX^[:>-,7U&((-X'X#@3Z%7"-XBQGF?OCGF
MI\\B";*_OQFUB/CE9[>*MW_KNVT*^,5'MX!V_$'D%FX##-J$^LWG/L,Y!3F+
ML'QDZ/:'<="]^UOLW_XTAG=X]L^CB_.#GX^60RO_&)_/*>.35_C?O_[C9\]'
M17=[W;)WG."WCY]0GK4>$OAC!+T$Z<<?NND?/W:]%TY!$. \E5$:%\%&EJ+D
M#J*4LC,7TZHR.;T\.SE^?W!U]/[=P<G!Z>'1Y2]'1U>7Z\EHT8>U(K-&2&=D
M* Q34ABGC+&2FN #TZ""-BQ)X87M-,+<DDS/_0!/]L\PZD;?8#]?0<#??G)-
M:;^RAAG1 Z4I!."!B2"#LXYI$Y5V/ L>DU"+1;]P->OKX?(*__OQZ/3J\NS#
MX=G'\XNC7XY.+X__>71\BM\>G9Q=;LSX)H]H63,KKVI&12&:G(RVC*4@LX]!
M&,Z2UBII+K/(G0W65U57K;Y)*S]O^UIL_M8QAW8^2.]I\M)1Y6WD.DCC=39&
M4KNJ2FN_BP>7OWPX.?NUW;?OZ4-K:FH^\AEU:,9POW/,1<.D$]D;Y;-0$G=#
M 9&)Q>J8MX;59/[I].#3^V/\7'S&>]3K^(NY#[N\.CO\W[^<G;P_NK@\^J]/
MQU?_LXXZ-GI>"YIJ;[VS[Q0#;Q-NCY%R:90(6DB>(3.K14J<=39Z<EGX=.DW
M_?@-D)OBFO:?;.D;'^!F_-/._9!<>W_7N1SY$92  <H*CO'+84<8#=182[1$
M#UXZ*"X_"R0(IH [E61,<RWQL16>_3",3?'')_Q4=/P3W(R&TY^,M4XH>_1N
M_WTQE(E6UU_<<2\. /WI]S#Y_^/>Y:@??_O<OTDP&![]G_ONZ.&B?W/SH3_X
MW0]2QUD.P69)HJ% ))K*N&B7B4G<6:NL=$'56/F*.+\5RU>Z'PRF GKTJ-9T
MN4J<J%66C/K;T\N$&[B^'W_H#_#C_O$CW91&+\%U;,K,1&H(9,>(S,&1H&0F
M(5/'%8M:QECG'9F%LGTR5-5>OU71OR0#6Y<,Y;SH'*1_W0]'Y4487O4/4AI+
MVM^<^VXZ[AWZN^[(WSR'?-COC0;=<%_^K!,Y0W,Y<**$"P1/ $]"XHF #QDM
MKDR99LO.R(U1["==MJN<EZSBK6PQQ\/A/:3W]X-N[_H<!MU^^J>_N8>#B#(:
MCE<S[* Y2%79=CDM@78TT0G:AIIXYX7*T7K(\\-D;6P\#0#N)[^JJNDEG<1&
MF]1Q;P0#&([.>A]]SU^/S^W3_@B&%Q"A^\6'&^B@W1FBHY;@.:V(9#DAW2,C
M#!T+ZQ&O=;K17M3@8?M)B2JB?DD%N1$5+N#./Q109WDQ0)U,]HYZ(K2GR%6!
M!VI$E) H'K-2ZBAL(RXT>=H>DZ%U8;]D@]JJ]7(!"6[OQL>CD(Q1F2R).J#1
MI0T0*Q4EH- (4PR2YZ&*[?(5PQXS9TN*><DGO:G=T@CY9S^ <JV=#ONW=] ;
MCF_++V!R7,(E#+YT(TQ.4GQ3^M<3O8X/U8X0*#K'**Y/6R(!_Q,$!)) "B:B
M _"NAKU3>V'[R>8W28N7M#<;;://C, QF LT  ;=.((T_HWO3?[_;/R"#H_^
M@$'LXBI/ 0^&*__'K]W1YR)TM!Z''<^B**X%R9+A.F@.:"(B&Z755AC-<C3-
M]M460>TG-7>JNI<4M#4]QE/X??R;82<:\ PD)2&@D"0H!&E,+.:&EUIY#DEN
MVUU\0K>?1*NGH)<L<JVP" W7^T'\7+;B@Q[NM:/N8 [F3J(A>L$E\5RB3TO1
MI;'>"R*-QOW7\118O=!#,XQ_ D954-:<*.G&,7/<,E$T_5LXZ0^'G6PCYT)0
MDCP@RP4K7@\P%((0WB8*7-$:U/D&Q7Z38WV!SU'_VE'R*9JST6<8%+MN )]+
MFN 7^ IN>IIVA(U94<F)%8H79AIB.:7$:\UTL%Y['VJPH@FX_29+Z^J9PZ%V
M8N+?WOWH;"2C C5: B>2R4 L,*1UY&"$YEG)>D?0*]=N&]R[7XW#0C0&SZP5
MQ"FGRJ46NO'<:\*2"]H8([.L9*<]A]$BZ9]EG%>_3MY EO,N"'^8Y __/=[T
M\9#]QX^CP3U\_6&_-X(_1D<WXP?^X\<A7)<O6J/#A%WEU>SWBOM\\$<7A1,L
M.KR!X1X>4A$.KBASI#V*+%&:F!&F*COFH6J1+*^4 KQ"GC6TO8@X&TN]Q8OF
M*;@93._'IT@C4)V9XH0V*3$759N'Y:(*BU>(L+GV^K5$OS5>,">MT3X2P0W%
MU\!DXIG*A%N3HS72 ^7?.1^^J6#9/1U6D7@%&IRC$F$P>(Q<?1P;EYTL54R)
M ^%!H*_'HB+>)=0;FHHA<, SMHI%/0_,]BWH%O34;UG(%;+1<'VW_=YS0#*+
MD+36N"Z!MA,NBZ"K'XG2)L6DF)"^RKO_ LD^J'PS\59XT:^*-W@_>'@.*67#
MHV:>V(3.D$SH KE"P2"],S%'QJBOH?$Y6/9!YYN*N$)"V()+LR=*)@T:O7*G
MB[<4HR4A)T^TRD'D',&&*BG:KZ+:!R:T)_:VL[H6II0\8K,"2@66(C9J](,T
M'DTN*D989(FCE0/)+JW :/*@[UG+K0NRQ7RMZ6HO8(3+@W3D![URS_B(*D:F
M13:(2EA<KJ696)T #Z&<@LG>BI1KO/'SX7S/)&A1T"TF:#UM0#'>W][?E-8=
MBX*TCT!U5& C-X2!!2(5_L<'M$V8SS9(8X445:R^Q@CW@21UU+$P$>L_?IJ1
MU0E^NV[]WNG!U:>+H[,/9^='%P=7QV>GEP>G[\\OCBZ/3J_&WY]]^'!\>G!Z
M>'QP\K7&[%N,S2KWUGQ2"S5[;:QQMEI/^Z 5"Y$K+D-(WEJ:#!X#B5GO,^UL
MOMIMZ/%]V=YNAMM3Y_2!.]/JW!7/*)<J@;M[UIKQ*"DXYQW:^5I&)U)@EJVI
MW.FC-]O[W]T/\4 :#I]5$GR](/%2AXR B:+&$NFU( $]3]QDDL@@.-50Y0K]
M-5";'G9S/GNRA4_SZH>3_)FS0?G_8J.=WI?-]BR/DP<??]L1E :FK2&1E8HP
M:21Q(G+"E?$"A.3>5?&&VX&__6.R-9[-GI8[T&?= -NY'YP-QH'E25K-.0S&
M2#O&\> -GO9<Q9+RES)!*T,0B?B"$I'E7,4<;X!MC_C4MB8J1.<69/E-^/PU
MS8\6\\^@^6E\2<=B3A.G;")"!:NSDU2*2C7U3>#M$64JZ*-"=.^;@./7ZL%!
MR84?CC["Z',_=;PVB0K+"/HG91OD#B4@!>%:& =&15.',TW [1%C6M=%BY&_
M*<:3?N_Z"@:W[R&,.M%9&ZWF1&GAB2RA2*L#_H>!$L&I($25)*CG(/9(_VO+
MMNUBS>D*\=0+W=ZX&N;L]QX,AI^[=U,#:AJTZD3@$616I-Q23%;LQM$' S0I
M8R#[M,S/6_FI>Z#UNI*N$!"<(P$\TB+T1OX:SO(_^R,\Y)[LZ^G6U4GH\S*O
M#%$9+2*I*2<N.$NXD(9R,-9PMB6?J '</2#6%O758AWG^'5X<L(F)7<GC_V,
MAQUFHV$,+,F9%RO)*.(,"X0*QXR6- 1K&FTRBYZP!WIO3X)MURE.01WW\GW)
MH+KLCM#R59E"2"5/W..Y)IG(Q%)<:!8BF)B,TU:LI--O/G[?%+J^["J4_$UB
M*1.+]+CW!285MD\GU]=MIF.-,!:\(IF5/'G%$W%(..(\%:R4G EJ:^S^C1'N
M 4_J:J5&K5_\#.G^!@^A.;(8OGMX]MTDM3J@#<PUS81&)HHQ7-(=D/.X<?&L
MDK69ZAHL6A7HMLH6Z@4M:FIFUR4.P\'HV0+GORTO?PIPZF]AG+IK;5# J"8J
M:?2]*;#B>],2Y@L)0I96-6D!@3B>41"_FZ7?ID!W5A!1E3W]'6BQQ3AMP;T(
MUV-^0!-D*Y14-.+9ZY"V6T^Q7=7VJ^IEN\QA7LA@'9  9<_/6A/+<R8LZAA]
M!@^BR<7CFV7,@HJ+MTJ85=31=F?0$[CV\>$7\#>CSY</PV(2/"8&,:FE*97X
MC.O'T4B>)TT@"MQP9<HYRT8.U\)';,^8;EL)_=8E6.$^N 2(1X\!XBO\-V,*
M.Z>LA,Q(2AG/4.=QF8%GXBCZ]RR"R;I*.L8\,'MM>+2FA0K7>+.8'E^!)JAJ
MUFC.A[6;(LW-U;:$!QO(O$(ZP )TWDFN(XM$J6Q*KP9# J= E//"2I$3J"KQ
MF&TR84EYYK:(L(JH:^2#0*_;'XPK"Z:%1-)'K[DG,98.C526^R/G2 @BYN""
M8[&*[E\@V7[,K0T5S89*-I)O#>N@"[U#/X+K_N!APFF@S"D$8'7I"P?<$>=<
M(D:HD#* -5Q4>==G@/PYK()-I%\C4>,9GNG)U !156O@!:0=60(;J>H5O6\@
MYQH6P$MDVN!IIC@G&F(DZ+"4T#"-),EL!2@> JLR+&1;FE]V\E=6_"KBK7;B
M%US3"K(D#;5!$Z?'N84Z$NLL6C8.39L0I8BI2A.&62 [..\W5,[<LWY-R58X
MZB]@7 AV[@>CAZN![PU]?#S3GO]F3'&%:\Q)(5*?@,C,2CNK1(EC@"OF +%.
MM49SB'\*\Z"2QJJ4_7[%\_CJ-$%4TW!X"6DWAD,M);["E0TT4.&$F8.,&T4=
M"X8P[4M2HD<7"B"1$'7,+D9E3*5R\.UP8HE)L3M*K"+X"E3XZ/_5'W1'#^-Z
MADE#RL>SD;,4G$4O.BIKRD$;B),,=TT/P4 ,2=7ISKP0T?;-CTW5U:\AZRKS
M"%_K=":]BY)+0;0:-RF1G#AJ1&&]3<GD$&*E'JEOL5GD-JV-]O12(8]\?F^$
M)J#^:B>YJO8:]0]<1_1;:R>)'I53%'F?<BEZL#829UTD,<3,1<Y4Y2JI?]]+
M.\GVZ;"*Q+?53M(H:53"?= #*X%ZZ<CXV!/@:=*<92.K5""^Y7:2*^FI23O)
M581<P9CXMD!_MC[_W</375U.*=&4*<DN^%+*X)'R*I,H+,@L V5UQH(W!?BG
M,#&J:*O"7+C7<3Z["VR"L[X!LASH;FR2.NI>B5,;ZJJ:Q=( K\7MTR$<0GFP
M1 :7B4_HJ^&1S:2P-/I4L0IF5YQ:8M>\+4JMHJ(*5'K9[#=8KGE"<RYX&PH@
M30)CC"CO3%+*X<Y=A3-OII=RVTI;VEYY%8E7L'_F'-J3AO%40#1<$LE+E^]<
M1LT$AU::L$HZ<,I#E4O;!7C^%-9-&[IHL8KV-5B3NNWI&]$$8$TK9BG"W9@O
MK>BS 4<V5T:%LV4Y4%E&A99-C\M<4N6=)]9*15)0/%#'C915QOKLB"U+#)/=
MD&45';1=,S(9,WOH!W!4#MV[07<(P^->_-OCR2B<< #:$Q;+7%FO#7$:->J
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M4(I(I1Q:1Z;4AS'-;(PQT2KIB,TA[@]K*JFEP@9S>7]W=]-=S._$ D3C,]'
MT"S+09%0LBFLE#*&F'0052(B2W#M#U7:5,!"IZ;5R6?O/ET>GQY=7AX<_M>G
MX\OCJ^.ST[7FG,W]G!;F,BW'-S-^*0NEA>+),N\DNHHN9F_1']%H.*0D5&<9
MTLWE=S49T].2%*^>#?UI7Y;SL,Y(M Q_C,!BX. E2&6C%E9$(0!LX"G-E>A+
MU)O+]2"E\:K]S7$O]P>WX[=K@R%C*S^CD@Z:KVM6,XD*;I3W0@NIRK!&F15W
M$IAQD4D_5S.O/JWU>:LG3WWE@J"0'<W$.(D6EI:"!"I*SP_C0BJF5YV\D==
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MZ>(V0"(A<C3$F!(D,+ D@\I29.&#GK%KOMMD^96D_DJR_"HB>R.=*0]NQJR
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M!=>(4(T>MT=$:5^\%<+Z7U,?[D>?^X/NZ&%\V$H=1(A)$AI\J8-#H]UYITE
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M1$)$%0'2L-PG'O>&]X/2;N,21J-)_LW3V(N#..I^F11$6>$I&F29<&\YD58
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M&/\N0H<3W*_2[ -.G@H6 [7.:+0"HX22B9^ ^!PD"2YKK9A04*?3=Q-P&U\
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MK09;RIQ9,X=V_N=_WWIN2W 5,EQ?H.H.+^\&X--9[Y]^T"VAV@*3=2BU6<H
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M7XK..%$**-[$3C8!.B:6G*T4W:&X:FN!MV!(78/K36TWGRSY!3K@:\J>^PC
M _'H]J+.#C:RMRX.83-6.4R2U)E5?>#G%!C3 :OGXX)L$'504).4Y#"V\AC3
M[D%,91L5],VS\PM<_I]WY=D7G(P2O/W;L[\M1VJF''RM&'76A'HMFQ8U8%EA
MUBKG A$Z!: ;/G  1MU>U3#N688-:! J7<QSF.&G\61AQ)3W)%W+,E))O/+_
M&$J)*>KEQ41)";+,HDDGXBJ0TXD3]A!PBU;U6WBN;;H+HK81P2JD0\4 ^ZCJ
M ;WO(><FWOX>,JE%Y$HYIF2D!#?%S+RO[%,)H])>B"R:/&D.I?E'/7I;Q6\C
MWF:<^177#:5[TB%SPJ.!SC--*XO"9P9%BU"<!MVFNF$5R"'\^W[*6<N6OZ-D
M&WCS?[]:P2.ME%$;\GS%%*:%=BQBL,SY(L 8# A-7B57@3QY3>\EV>:LZ/-#
MJ[B2L :1WDM369\5HY!4,LYESL$ZI663R.UT[WCV%'(#)N2U=-]=,/VP8Q&V
M4E@75OQ=I#W46(0<%/=1<^8XY9$:BV6>N\PL#XZC,Y2@-KFG.>:Q"+T;P#9"
M'GPL B#R%!*%JDCN37M;7S*C9Q!5\,YYZ7F39ORG,!9A*\5M-19A&ZFWN,29
M<P0L[ZV6F+@J5M-J)46=A"D+!EJ0[@SW8#P7SC89I+D.S D8P-XR[O$HF$YF
MYQ_@\M-BR)O0D?.@$O,9(M.UD\(;K.-<C?92)A<Z7<[3#[VE9/K3JH+O?/6I
MAWB[B[!'FK@;$-?FU 7&%H%<=XWVOTL?C]GVT,"J#O<07XM=N<P0C:%LTV:&
MSA.(P!T#4X R1$5NHJ:BJZ3U1ZS%#7%7_TK<1FH]*^]7DM27JR_70'QVQ6>I
MF1&I<@!R9. (C0RRGO&2*]XEG>ZDOCM?'LY9[B7[<1^"ZS$8F@.!OVX!"4+Z
MF "9,JXP[4)A,<K N'9<:<B)_M2;!F]_^0EJ<&?!-1_L,S]93$P:H@:*L3BG
M\Z04.F,D!=C"&*&$C11IMZ]V.X7 IR<A-V ]W3@1I0NN'WK*UU:*ZSK8:1>I
M#SGE*TL9R:$ "[%R]-J2*D>O9,4JGU/A0K2YZ3CV*5]-C&$;8?==?;3(N)]-
M)M7/S<NV7\[Y9RHQS5AR899QA\!ZU1*9=;'4,F##?-&)Y=HQC &SL*%3-5+'
M#QZZ#GY7]8P;R[;OJ6#7&#]-<!W"<(W0.BW1!\-DKA,@>&6743J3:[1"SJ<J
MY6ZT;IT^=T*Z[U&NP^_\<1Z5$>8Z[&PYK]X*KJVN%1N@#=-:1Q:M"PQ#2,9X
M']PJ'>W.Q\#]KY^07;23>J,!++-KPN0S^O^9>T(IC!>RC@GBSC,-6#MVHF-"
M%&D3ANA-:!$AK -S*FG#WH)N06*_@FE9[M$!5=.RQK6P#E3:N+?:'K&#/63>
MHL1Q SINN75U$$R><T?X.F>ASO8PH1@=(1G?YDEL0$MXK-1Q*$/80M3-2A[?
MCF>X=%#HA#4Q @/(CM9(:1%X:5F.F<OHN,RQ"?'X/20'*(7K045K"Q]WE6_?
M&<(<QWOX5KW;LJW":(U2 (6MIH:M3K&8A&>6 I6,$E")W"D*O/^SG[0"^Y!7
M@_UZ>_S2_$A**G/GDF VEUC)Z#,+/L5*'IF]MBD)V62&^RJ04XG;]A)P@\$Q
MM_%<FW,71"WCM?N0#A.K[:>J!_2^AYP;;_EK9-J)Q(,R+&&N@\HM)Q_"$\L&
MDD692R[--_T!8[/6BM]&O T4OAS*N&R5$*B],Y8%BCJ95D6QD!%9411SIJA+
M$=!"V7=A#._,]U7,N#>I-JA$?'DU&>?QQ05,KO'HD+.S4C*59<4C%(/DZY"[
M*#T%*N!<DP:452!/7L][2;9-BIW'E_-) ''>VESJ%6%=[)O7O[S[< TRNY2@
MMD)Q5;,"ZR/S*@.C:%-BH+\,O GY72=T3]XF^M=!@ZO9CS/"4X/8YQ<PG;XK
M'V?C]'\6E?DFQ8Q*L3H7@'*.VD(5?6VATLAY$2)!DZ*.C8A.)=CO1^0-9@G>
MQK-LI^F J&GSTCU(AXGZ>]+9:@-+/P)OT;]T'YDDT[:%>\:Y-4P[BET(6601
MN3%!2F7;7,\.90*/A/^#6< V<FZA^?&7+^/+.:!K#Y52D%:B(\]7GRH]A:\^
MU_)#7VS6.;F<VG2NKB(Y0)_*GNI9U?9>LFV0$'R\BM-1'L'DVV(6T'>CCL6C
M T\1B0E8QP$1Q$*_5 +OK'+TD)H0TVU$=#+>OQ>1W[>%O6<JW()3ZQ3>E;,)
M7$XAS5F:%[;?!6'+:.!QB >*#OK1Z:JEM%%(B_>\QY$F#M'(9%C0OE)Z4\(3
M4W',2ZCSD 4==?J43.:Q:.)0%K.-'OHN&'M_%2]&:9X'CRX_+3V@+ $\*L:S
M]@0HUM(DRG]],<)K663B*WU8FVB2U_STX2.&OE4P[E-^C2((_)\K<HTO_ZC^
M<5FT8'WE]P5@/-I2>V]3K70KS*!,]$\Z^]#D_G@#GE.*'O85]YIMW<(,EI2,
M'9 UC1DV(3M<J+"W A\WBCV$WR(^V @P:"$I/S9,VDP #:=LJBC-D@*OHT(Z
M%YM0H@QL%1VB@>&,8AN9MS>&:S>F GU9)<]*+6W3R0 #=)0("RY0HK"RS>W2
M6C0'"!OZT=;#-K"#J#=&#/_K[RNR>4-_G/_#_._KVC]@^9?Z?W_[\/I&3G_^
M^>??:BR3)J.O?TOC+W^?"^GUVQ<O?SE[^>+MRX\?;U=3_0JSJ\E\R,,+G,'H
M8GH7UG3TY>O%H\%A]Q_^]^_X[Z[K^@MW--[K2O"O6:4QSO_Z+Z/\;_\Z*CPG
M  2=E- \A\BC#ZXX;L 5#O)\IS7MKI.7T]GH2YW<] I&D]_AX@JGX_ELCG<4
MD'Z:SW'J2T/;?*IG?>V\RA7M*>>]BDHE%:T&Q:/&I'W26D44QO/S73_:9ZOF
MFYOY'#QHZ[@OS/$(3--9PT#PS%06*JA0BC5-,O,->/HH+C^[W@XW,CT72$H1
M(3/AJR?5-:L.*C.75)*4.:F$K5ZZ[Z,Y=!O2;KI?5UJ^GZ#[+C2^N\KGGVN'
MU/3UY6V@'\87%Z_&DS]ADL\C'4 1LV0J4O:E9= ,>#0,4C(B.0BXRJ6^X>9A
MN^\^;>VW%G2C=I/[AIIT+)7XAH&LKW;9%5I\ABH+YU!DSE63CH,.)\+V2_RP
MG.$]78[D]3ZAMY0OI&29KH5(H3+A6K ^)>!<Z$9$@W>!#&?LS0WS'N7@'B)O
M4,CS'D;Y]>7_'EWF><413F?GRLN"]:FR)$EG,4A@P>;(2BP(+E-<4IJ\X=V'
M<KIFL*?8&Y 0WQ[4?<](@3L+E?*\)/+16F3+($;%,CF":# F9YN\Y3\$ZH2-
MHR]5],AJ^+!7Y#)Z+7ABAF<"Q8MA@=;(5.(! &S,LLFU?1.ON.[R744!JJ3$
M<G2BC@ PS"?'F?>1]BPWLL3</MLYBL&,^P3_^XIV79AWD,&,:QMNG<5 'IN!
MHC7H*&G+(\E))V<PFRP2-LF(CYV98"L%=V(FV$+0 _:A=T#U8S,3;*.VC@WI
M.\A\.(M(,H(SAC/"6-]A!++*ULC(4<J8O12F#;_AT3,3]&\(VXAZ$&8"B+R
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MH?BI,&D*K2+%P+PLG$EI,:KBZ9<F#Z7]P'_Z!GD -3:Y(5]*97'_+X652!N
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M(4UIG@NYYGR5?2PXYHM 1NL+.@&Z#$UN/-?#.84XI =!-TBS[Z-:MOIUP#5
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MW@D?P'0*X65?(K]O#:Z1-2Q'J'< US*\?!#=8>++WG39S4;V4,1P9\?R.32
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M)8^I2  64R4:#;D.'Q6!%:M2-C%@C'JP/*X[[I.RJ2%UV"-EWQ+^$L^SR[P
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MN5+!2B:QDKIF38M65C+AI+9)@LW0A-SF050G9AS]::!!^^0'_ ,OK[">:RO
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MC8V3;P</#Q\/SPXN-FKZ=OOK!&)G967G8-_&P;&-EX.#@Y=RX>#]6H7KGV%
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M6X.J$T!SZ.O_6UVA'S;^FM])@6AA/S2G)DJ$BO$)&> 'S,BCC35@1+Z; BZ
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M &KT@[SS [0!!( !7 $D( *8 QYD&$_^XZ@0)02Z_3^@$ %TR3\10 &0!R"
M.O ]RD3W-1K""#!]?19I9+N#!Q[O"Y630^-D891]EBP<XR,7"/.5@\C*RP$'
MM0)]87!O)%[$%4G>WVN(+M0VB(IX(C1$[91-Y$U\=9$>GH;!6*15L*DU/-@;
MKHX0U=(4.1@(#?3Q]4'B82*!/B@T#AJH(4IE#B7#%+2<J B5!.^M(?KU5-(Q
M$W,170P6*:(LJP*&0Y24153592$JBDKJZC*44TIJ<O)J<A!%,$0%JB0/55 0
M^99$R4_#(MR@EH?UOSV+G-,0_:940$" ;("B+ ;K+@=15U>7DU>04U  DRG
MN" T'A8(1N/$OG,XC,3!L9[46+ ()0]SQ1#P&J*BW]@BX#^X^A*P*"I/!%P.
MB4+Z(-%X'-E<$+GOM&3-?A#_I5U_(30Q^<>D/CX_J'%X2Z3;/Z;&4;;]<I9(
M'(: A2/)Y&(_*^OYX_\SE?7\R7K]J.Z)0A%P>"P,C\'^-9-?"/ZLHK6Y^S]^
M,%[.U_T7+0][^OPS@I+)D&@<)70O]LO##/YQU9_/\47\'5N2"\BDBC\)O[]^
M^3ODWXN_J8V 0]TP6!\8V=B>/C!WI)R7+]*=PLL7:D)V?00,#SL,PR,U1"E'
M[<#R:F!Y9>OO1^W(,%1>_ALQ!N'I%O1/D>IBD62R7TE5P0I*UN2^HJP(553\
M&U(,UAJ#07WO>D8_6XYZ)%!15O[7(X'4>B8F4",T#@]#4\*#&J)DC*RG)P*J
MK*X*4X AW<"J2#4D6 GI!@&KJY(AN)*\&ARABG"#N"I_KW\8 R=0N@JE_M?!
M (&!DWG\L!]424$)J:#BJ@A655-$@.$()76PFCP""99'(.35%!54E"%*:M^Y
M?8TWPE"_<B40*"(=5I!74U=04E?4T3^L X&H0Y2TU935Y0\K0I3EU71_,+!$
MHA&>E,ZNBX+A<!JBU)=&%*<@#V\_#0*UPL.P>(*O.1;CYHDBFY?Z'H+*@^S5
M4$,8SM83Y^F*0IKY(['4=TH:HOHP% [Y%R366!@:YPO#(M'PH#]3F9J3/84L
M!414A"P"E/PX! &.Q'YO(G/RZ(;R=,7"L$$B$'E9>0K9#[-1PWUD;R%+I_@K
MWDA7]X?8.$L#'1$C/5T5B+J*"EA!%D(9]<B>BO?$HY#?!D!M%/X;A/*DN#X4
M!4.3.VX@^%O44523JOQ!N:\D9%JYG]7D?F'VK;V16$]_)$(?B_$1H8Y<4,^_
M\" W&$1>U<W5#:SH"E,#*R&0:F!7>:0JV-7530D"48.I*R-41;_51_S2UI3Z
MB/]D?<Q_W6>^,L#^79^1^Z&VH2>.[#=!WRQIA?3[:5/J$ R%P2D<R$T"(UM'
M]!ORKTP#<84@$7 E%3!,09&L&EQ- :RFH*(*1KJJJ\'55140<(C\]_H!'DCT
M'_L^!"JO2NY18'DE:M__2H;#N.$#R!ZH[8ZD>.H_V?^_UH5[D-T!29[YY:C:
M_M=T<E-2@"C"5-7 "!BYGRM!$.I@5S=U53!,$49&P%05%-41_X%.RLK_6IW@
M&#0E-/]3+W(7AI$7,4@LV0/<*-X-\_5%><)A%'(Y7PP._W4=(8+'_*'$'XWX
M-FO\,K[\VSWV/VQ!A+R"DJH:3)7LBZJN8"4%%44P3%4%"5934H&XD@O)2S:U
MO]^"?YJ1_OU;\.L4CO3%N?W_\?I_<I#ZL\W^<L+_!S;[AT?[_[46HRYZ_BY_
MQ->YX:^X_WBT"/4Y/^W_S_+^#UOCGUNT_,^TAMS/24/NS_/)MZ6""2R0LEBP
M\@Q&BE#7RM  \KJ!O/:D)M%O. \-4359Y3^@"&A/LFQ&:+@'$O=]PJ(P-$>1
M%XZ48SJXOYBT-'6#8.A?IOQO@ F,HBGL;POLD2@4)N!O\3HH\C;RSTN'GXK^
MC1S?<%8!,#S<PX#R#OJOI*,LGPR@U%?4E(H:HH>_+E5$OM83H584_86*LG'0
M$)7_*UO_Q>/D_K0O_(XB;S:IE;[O<C5%?J??Z7?ZG7ZGW^EW^G\O_8R3(]'D
MQ5R J)8F:93MF)&NKHNYI9F^T5$]:FB?S?"H)QI#LPT ?-!X+"4F<\S>083Q
M-4 #, ,,  0 8'"<KXF5OC7U>)R>K@@E< /\3&0>*UU?#YB]!1N:BX@ _[G$
M!??%XLELS,FP(H*\LB'#9\DP*@#O2\%33F_QNGI38!K*N2U>+%E ,KR# KM_
MA66H-%_A0Q08X8-&D&&*S+X('P0%?DJ&+_@3* < :8^2X?/^GL@ ,MQ!AL51
M!!]/,DPYA\KK@X3A (!Z,DP<CX1[D&'*.5 VK+6E+AD^" !,;.Z_P*Z_P'AD
M(/4,L2[&-XAZ-DUD'WR_"$1=74W$$!F 0N+Q8'-RH\"P"!%=C(\O#!T$ %]U
MIB;NOPF*_6*H?UCX3R9*VWZ%/EM0VPS$W_(3]U=TF'0 4%LFVR;V)\XU"0 J
MSP' CKZ?./'; ,!);K>*UE_TX:?XRR\O/CR1<%F*07^D_Y#@GTB_/$^6PNZ'
M>42^+[TI=H-C4!@"5@1'[A-($?"?G?B_7/&OY9"Q1+HA*5%5I(@MV<L\T>[D
MYOX6J!/Q1/^]1OPO5OM3^NK7Y,23L07PNL@"VUIY =JY%H".AQ6@/9Y*+@']
M:+>CS+8 I>?9"4]\]7MJ^HN#PC0QE O.DWH\%M"UM!:!$[#^7\NH)V+I 1:
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M0X/O^'5SSX9+;LX,+47GN11=U$I;3?LR7/>&8,9SU^23\0<#_PWHL-^";-;
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MAY]:K4]QSSX>2LP2.N(W<T9->#3\]GIXY>J)C*4GZEI[*.')=UJWR6L:XCT
MWPR-KOJHL: A_YG0A@DC!L,R)(LD&IJ&ZU\GRW4IBJS60*8SUQN1)."D6=WD
M\G3R>J,;)0SZ,&3H:E>Y4)6 V<9EXB"C0^[,Q5@24%^].DW(VUB?>1[^9&BJ
MJYS3N6Z<O%;JF'&(++:UV*AKN-'DN2'9,J]1%I']<-ZY=A::Q[R8@B-4'!V3
M#XE+W$A.P;F*-[4R9R4$&F84'<RX<._!J62/S8B@S56BID/58) K775=A<LV
MG9&8J$M)7'B%-!Z3H^'\63N5XAY>]B(^"NVKEAZ^4*C*/FI4L,K^ )KYK"&R
MR-!QKX#N74:;L"]?>"4>QXJCBT- &Y/8MNLF;6_4IN^AQ7,?^K.;JF7G7MBO
M>_5II_>83JS7]EB'C7,[3KNO9E0[L#]QLUV&#,0O;X!9NYL_<2HNSK"H:LVO
ME7A5O'K%D7I).:HNT ]?'9WJ_DY3YT8NI%]WK>XD^M4#:V*VSXK;BUL#S%)Y
M\CTWMX1X57:^,N4OG]EQ)N2T]A(0871OMT]:D+-^[1Y5)ME"YM$CXA>TE+ D
M8-EL8_!P_^J \6!=M8-3P@)FP)I-JEE&X=I4UK&SNB_/OFJZPF#TJ$<8LB6W
MXOV,H6W^58PR:MR6S0TGMO=-L[7AL&%NR8%ZZ,Z+CNL%%I5$#-;MU7R ".;I
MWOZ:A\<^&NUZA VE.2KF&O8P^'3UW1ZYH"!U!Y/51 R_\I@XY%+.]>#[%5D(
MB\]N@@*&[Z./M1^[)1%E;2\6I\*Y^VI51W1T)=TV--,Z49!F!X.5>:!0^EY;
M_7WO(MB9U$2B16)$H1,+H7;_-JN,WXC_5D0#J?OWJNU_ 0*?,)0R@234][Y<
M,'TRV._NBMH05,][A;XU<NO97&'MQ2R&H9/1[HHR2A\+OS 8T;?2IF$<^P><
M6BI6<MH->UANEPG?8[G6>55(G^E4B::N9.'),,?PQ]?#A);*WJ]T-X4V5&U9
M8*!6%D>J+R.NH62S,_*OL 6G!+CO1SY'T!S1%G[BQVD"E=XQ8\WK=JW"Q4NU
M_^/>00'4F*9!O8Y6^YG,\'YE@^2E4,_F;ERLNRB$Z+C"QMFRY>1-6'1<6R,!
MD(;8103D2UA7UI>ULAFA.[#^4$9MV=<O]8Y.F$ 22[S&\P<B[HB-C*>_M&R<
M-[[ \R9WWYQS_V)%KWY@6&;3Z(UIX06 +KLO8V.=UWYQ:Q!$?^VIV*NRC:JP
M-\'9=4W5JRJ?7]G.:XQ4E=46^[[/5$3@^A/E8E]_P/) :HT=K[\TDEDL$8]K
M5]=LO,AK+A)%SW3WE#D@?&*'(/.>BUPZMP%.D7U:B4>'S99;B4T-^!JESS.Q
M0GUNQ<86P<U+),"EGZYCJ4*)C)MLO 76FQ$1ZI7,9*G#D0#07&GPL8O=(EK]
M(7<TI X7.VV&=ZWT:L@8KG]@K$BJ@UKFOMT2QJ$%ZQ_=2RI(4.W,O9N9GPP-
M4&V8?^O22 )&!0U77 B5/4-13D_C3KZ,"!=[&F9PIT$:UPI=1$68V@[*%N L
M2X[.[!*>>N;"WI1#@"U.PA^>/#.(!XF^MGCC?D<XCV!QN5A5RP6L<,,D<FSN
MD59WC\-JG']O7E?TFS2S*^$P:,.82Z*]U@OR5-_@ZW]%'N=3L.NI[J538#0G
MT>/Z0\^II7=I*I/8_KIGI0$,%Y+K[G46G]BOR'(][[5)H> )MU,#FZ!82-72
M\"GVAO$K?2\S)*/2GB9MYI_?.GQRO=GT"+&%Z/CZ''CHXUR B?:(\^EMDN?X
M3[P"Y7[1ONJ4=P"40^,2:T@KS6 +BK\>D6E8)670$1Y3R@[U#;YU-F=22($E
MEDE,Y,S#"+4SXZ8E2FGGWI.-W52+[\4XEX1??$]</7H_+?&X?<1F6,.;T-!9
MFD!\4H9DY+%+BN&GMLYLB1.K /P3-6?*2D<RHU4Y>-1Q^!X4=G-M^4H&[7".
MF<GV&5KC+142$*0YRQNTU.NU?+9YZPNQ')JK60>7-9L8FNHTYBA) M9CM89(
M0'](CV5P4=EXE^*^#?)6J$!KM'[N]G)>FF95DAG9!]"A_8=F;(3<BS3UM_*W
M/B\$&]ATW IQ#,\C 2@RZ69&,*'0N]NA?]-N(UF#:+@T,R2Z/.=#)C41HI0M
M< 4?W)2HYYCJ#W^</['H5K'XS$11??/E QS-?65$6OX^AOV<>Z<%K@P/JX1]
M"AO@,/ZP,!R""%;9[+@?Q?B$=TQ1;Y'NJA0;BZ)HE'XPP_Q*!&L,/Z1GC<AY
M@P3L(P'P._E#!_$6U&%"D9#X//K35'5Z8N$!@T"?8WM\O"]FOFRVKT1XG\G+
M1B$/?IF*V2W@Z7@IYHXJ+^K@W*L']T8J!!][^VH!V#;A"LE.GC"/X)BU)WUI
M:/4M%5-,;R'&OF3T/DQ2> HMU@8E >6Q0<$<!6/9X3=5B$^-C*\L<#0\7=CM
MZS&6@IWUWX7S>[*M,BXKF_'XXM@,\F"?&N*.6?9!G,9BZY!W0 7R3(I,W)2:
MP(G-_8<^[U79JZHE(1^S.#*L%?JXVFM3:*'_5KLC,U:O[MVG=Y(O;!&L!XVG
M6RK!BZ_!W1F:SAOA:W37ES:#&DI:J[(N9H1>2Q,#/;BSC[6E9,3[N;*K\LZ,
MA-/3HN9Z[^GZAXP6TZJ/I[R&62$?6*GS?13?5&\JY*J'!MUHSOFL<:*X:NAI
MR-TY;Z4'G>7/P;QOG!ZMKV15\24Q3B6HV=PX_.'\I;;$E0/3(O_3<_-OQ'_S
M&^C?']K].R/,%]5WAPD+.R4TVUF,?CI6 RV(-I.\FA=Q23BZJ>U0IW)Y9V>Y
M3,D3-DB^D4RIO+6Y_04@S?^PYPY1FI;&4VQQ9@!CDD8@C0FC0T>X/.<7BU4]
M_/'JU^5?@BX^V[@XNZYMIVW3L_RVTVH)W?D\*R=^TFO206KPK;@E>!#2WOZF
MIO2^O?J%P+.5S4)OYQUC'>O6KA3LC7S"^^G&R4=/"5OQCIV,0M$^*A?=[K;V
MU*>Z;PR/K!&R,2_-4H3WA;G/E]1JZONO3,XR[_=RRWGDDYLG]G36)'><04NH
ML^<+X8R SI"":/"%W/I1I+G7WOCY1GR?>KA[SYZ/*CG\4I_0LL-3-SMC>DP8
M8P594;/ORH_HW+9K;=G,3B\('V(DCLV^BM$O*83.S,Q5*/%.X;U-2W-67FC(
MZ"W.Q$ZDX>'C[9/=!;<=TSQ[UO"EE&5*_]Y;<GK9]@"9:+_>C.3;T^1EBOW.
MH.7GG"M#_9*9'O$SB=V;&)]K[3WMMW"T_3*=4Y:2Q^L?<&8O;]5/M=^/*3H4
MDNN%S[1[3FCA7!W^9(927+H#7YX1<?'A>3M]"ZPRM#&XRSQOM!2[>5L5Y>,T
M73*O["6U_[U6)6[9(VD'>0Y'VO7K#U=%#>@KAV][$C:L=:_C9,WU-9[!5E^-
M.H*I4STFBU'E;5AA-5\NC8I6MM6S.QX#)&"[OJI7@"VMXFC&J^R/+*M2$?8N
MS9>26K?SV3)(;_KL8V$DWDL[$=H47PSVEKCS*3:(36WC 0F023,M"XC57#J>
MV3(D&*F</7^I\7;'J[S.%XT2MR%V%[E/14'&(),PGHR<8MJ"J\_OQ%F?F)Q^
M//V\^1'C1X-[71%9,1$':UZ(I^X?LQ_UG7S')Z5MR:%-=R)"@>G13,R75#-B
M:]WF+87/01PUX(4>P;WND@4F(D*;.L&(!HM4E[5M).#BJN]M?*]K\,-VX9FM
M_L&:.R)^,ZR&C)071AO$>Y;!=UP#"1=>FKUQW'#<VC\_PIAF(\XA68"\N%ZB
M-;(D-$NOAN^]:L!1Y46['EY' NJ(PR9),<>-B2M0U//@&8NMU&7G'(1@\,1Z
M3%BQ]2>#8B?RXL0E;,99?J9;JWNXIOLR=+EUF=R1QC@2ZD)KW7I3\@62.3Y<
M01*/9QCC)AJM8^.-;X=EF4I<#L_76Q4BWGTA3SS]PN[F@X>!XR>-_95FJZ*S
M%%U$>J^T?CP0M)0Z9SL]F'XP,.:^+PE0G>B,U96QX=([R"U^[]5.8[:2>Q[O
MH_0X=U]X$L$D$J&QZ!JXM_S67!%OQM426UM>J9<>+[6?BT0P+6K0,8G\?^R]
M9U13[=L]&$7%"G91@2"@2!<4D4@(6*C2>U<! 6E2@I 0(J* @O2B((0>>@3I
M&$!!.M()$" T@1 #4I( (<F$YUGSKIEY9_W+K%GKYP=7OIRS<W)([G/.M?>^
M[NNZZ:7$X:U=_BOP=NKJ@X5_#QETR\EIW^@;-!PT;/O=HZLH)1SB]"0B1$UU
M5Q\>W'>17G:[94:]W<2 ?0+V%=C5AA2-QV_]DL_'@VZ)=32><1!\=?R9"H_
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M._[QE@RSLU)W;J<UW7$LY5G7W>;<(7P>**JC=A(&I$-+O6=?NTH\CP< !:0
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M6ETX4O,:R^W% BA-4P<9J=!SH\ 57UIP/#\?9M*MDI!<%+2G)./0H^H"G$2
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M74(1.XLCZVA5#P_D5>F/YQF<ETLK(W^<E'WY7/H1^6GPA;-*5=9H);V@AX<
M-LV>\!>\*1,ZVE7,'XZ)J*^GHC8W=7)2,<N>*\6_@<://!QL:92Y RB/@?*%
MG9KIYCUJP)U()9.A9']9<%#O^S:'?8.J\E+,DI+<J=& X^2<UV/4^N04L\GY
M8:JY])>/97M.?/5J?O8KC&-KLX)IS544.!NX%%L,K7;SY&@^5/(A:>WL(PTZ
M/PHB]=&%38*F[2H<E9"*;5!NP>+)"UTAC(R@)-.BB@<\8B'[CD3O4UT(C\*4
M$U=$I.,(;L\XVU1U?ZUR;L(4D37<U:6M9O+:%2E]R42U'L'1GAU[IC6G F'N
MS;KX.6^5!*)U9W/ (_GZP(\3[5P00NNKUO"<$D*D:DK*BWK@\QJ#!Z!Q-6:R
M'&2U_6)F"J8&79>(&NFL&G_&_#&CSP*8NLU,+^P4]KD0(!VXA2>](:9M 8'=
MCGD^U];(O,SNR2<91R_]5 G';QU^V]-^AS\!>OS.TKZ3".=EZ<N3OD>&+%9/
MBJ=OM$./[# G7\H3GGO MV!&7[23'_==\XD==G* .F0=4#E:+%86$YS-=Z=P
M#H:.B@6>A$/R"G*[GFPW!;J>]A=YRJBKHT8B78U4Q&S,'9L'YO.GI'DL/W][
M$<]A8"UU/.[YJ"_INUM/TN5(O\9!XJE"(C.6*%(U%/"E-&A$N@9%R$+Z2S"2
MZ-TY+81:&2U$%?1+B/K^T72CBGI_8V<?];WBN>0:D0??';.3]F6DC-SCJAU;
ML2D]M3SE\R&EZ &B-GRAWQQ8]!P4=*#YN H+<**-NLAO?=GY<*JFDQIW5<;;
M\P&]WZ7/)EZ= P8Y*C>AJ$H=[X\WPZ#1OZV/A#LMV&[<9TL<&&!W)O5&\&K/
M-@N@2YUD:'J2'LQ1PMIT!^F$T8'[V].%D\2AHZE0#"%_*$ '6TC('][1J3NV
M,KKT3:>L*'2]9YM)&0C:5F KF]4+3E4FT]";>?D9388R0-WRL.'A<*;'?#"C
MZHL!O77YT7+EQ#ONQEB=)H;"B5;Z#0TZ+ E<67'E2,KL?"?/3D@N6[E)JQ*(
M&[3PKE2-<5A;L0>:[N$\ <JWR18GC*GI?' @R5;M%L+](ZB@'IM]3-04(MMG
MJ4%H\+7'Y@@U)G&W99\#Z3SJ/&!O6/(0SQ0:>VY3H&8^U# ;."#+EFF.NTF8
M*&=A7:5DH1*D[F;4)KH\$FL:9<*Q\\GIG6VW#OJC^G$[)_C)ZGR#%GT12X?2
M^FONDG9Z_#O,E$!WX17[=-RR.^&R<X8[-YXI*<8"] SMU'XGU-]O#%Y>KU>]
M'^!8JEN61.TW7?AMN(Y)LK2E][A7O_E3B.XO\#\#_G;2_Z=G:?B83RRU:55K
M&UOY5=-HB]K0S9YQ!1C([G0<^'[@R*A<2O)+'L'P00?GO-Z[+(#\C<G9D90X
MD;/CHY4=VIR#]PYM77\-2> *M(9C$G!?""1K]HE'9G&VNPM/5_4/@IM*[/#:
MK3G$IMVU7_9Y\DF]VJ %-<Y5\:M*N,L"A?MA<S'M9J(9!WK ]U[PB4&&A5,
MAP0NB%U/%>]3N^F=]KVM[G0*E060"HL[7'A7N$1E@%=3?9!\=_Z,LL1WHY/'
MYG^,CF!S[@GFZ(-].I3H0H+<X+N6[P=(F0+WAZ\AFV/]J8].BY],]EP'>T,F
M=*$*X>,3@U;N$H\^AZ'V#IEM>D:\Z/XIW'SAQBN.N0R#\/Y1)/ 7.(\7],K]
MZY!-SJ59AAV2.CE^?C%D46]C^M!4U")RDD'JS)Q?7_)Q1%%:Z;C:C;>/6O-E
MTI XX&J#+R_H2KQ^E,ZG*B);P;$ IVEW^V_.#I2K3NT:];=T=)*VO$Y\=^-N
M]\7J\KL!-72>)5. !6@&.EM!'\V#?(,:)I%S5O1'6!@-I7,P$#6]6WK<D*1A
M;\'_49 =G)&;P<M8$4^;G. -(8;GRE/GR' IP24KMLV]N)OWKCFSF#,8//!.
MME-?6.\N;USW]:)GWP_?B.T42A7E]4P7+E4$[%\AYV;N;05X8K0EW)=/7C,K
M30<8Q0:\."^2)5U:+^X;LJ+N(NNC[SINE,%KY-C\)C;VYKDK1X5MZWF0^7F_
M@S>5FN3'1RO,8V/D(V;;E8#=U8'=UAHIW.4?1[^(]4!YREYM=>O-!63R#6TI
M155E?1@B'*2&J,F'XE?U?M*/^#@\S<K-SBWX..O9H]]Y_FS(ZUYA]?1V<:/!
MMK<%YF%ZB.#G4L_K3]P8LO0;-.I]>H.NB\H!@+6M\G_9]'@CN,9BVJLGNKX:
MFRW>0?B(GM:3_3X1#]"X0;+3C02>@^%F<X>S6]VP%96S$]?120HUI9N@"V(?
M"BY'W8OWV^J7D?#).V1L\#7[<G;<X-Q!<<2\9"NB6M:J8U[F=_[C^V#U8K:6
MYMP3A--"E%&S$ACE8P9XUXI7UI^*/F=K%FF<%@M)?F7WXDRA0XJ$LBRS#10/
M^W]-'*?/E;X?[SYF(BT3E=$Q*_[XVK!=F5&TJ=[0-_4K8@6:.7YS!LH@:W6:
MWURLR,E[W\V>"42KC:BJ/1BWQ$]\&\:IE[7,1)1D)(1F&!P4(O,YC>Z068!X
MF<VJY/8 ].9TU9+])KEV[2>-V=5ZCW*DWQ(M8Q(@=UI&]8A:I>RI6Y'1%?TO
M<Q*CRYKD+ARZF"1/*-;_/]A[KZBF]FY].(@(HH@(B((0%) N@@H*0A2D2N^(
M]"(]5(% " A*[TUIH4.0WCLJ:$ ZA%ZED] A!$CA#_L]7[GXQCGO.3=G?V/L
MC)%</&-EC74QYV\^LSW+ZCU,1]Z6]!"T^F<5_0@SZHH7VMK&9E L^UG$^.V$
MPI1DHA&R=R[O?P%\]>YL.2AT&ZW/:XE@A$(Z*?TJZ&%@LB$]O\83GWI6KO=E
MTDY\%O=%0N =U'"LT.&9\5=.?.0RE82D/8/ F,QK+)8"8+,^L"[4C]DI\APY
MOWICTJ;J9UL )OO%"?QP%B<S;*VU//8F^02.@_MEH5LY/#9?$\_\Z22XS"MR
MS/04($W;XN$B5/8VT <K[FU9IFLU='1S*MVECC=7C57'XY&UW?>;%@]T>M^^
M'-OINAPF IKT7ITEPW]MCL1EE*W*%#TU_*:F)/V8&?+ASSAPW:(X>6FS;>V9
MZZ08@RU3![@&_]'/3"FZ.\N,C;2HI^3.8841.HJV31<OF!I[ L;-[7),ZJD6
MRFO2E6WR%RA78N^J$<"3\N=#K6MS+TE3DXKT183&F)(S-@.TO6T[0H5Y*';X
M)2G]L<NH[%_;3'TMVE%5B',O5,:L#BN+]]#\;"L;)L)LEHQ3)-]0[D7]$#5<
MAL]=E&-Y5UR7X=@M>R?R>D91H",F<OI#4)J_D=UE]L3:)$YEO^^37@3BHA;^
MBBT\&'&6"0IM\FH<.DN:U<T5N-R40D*%.:'6?VQI;_#G6==G 5AE#OAE7JK3
MV $D7OKTEM:/_%WBRC_ ?TE]_I%E^-\%AN3+12-I31TD-\LK(:!/V]"<!M$H
MF:Y;*:"*Z<^VY2-^"M%76Y^EH/URHNT$'S /H25RC[(]7 X1%V&!91Y[MWO-
M121@PDG?K-8SH@4#N_061!)<7;@>R+-H'^A4#\%J.$-^PSI\^@N7%"T,+)[H
M @+15(62]OG]GI@9=\F!W?4W=\C'N ZG#LQNKV,H@\JF;]\2_GR$[15NZAR[
M/ORC;94[_9NH3AN>WO2! D7,1[C2@5H/8:+:U;KK ;%%ZG,. S5OJ3SHJLL'
MN0+P.$"@@R^.9G9DZM9F2;22.-?8HT3(Y)CZ_>*T*_9@+$_=W>LL/*3<.%TD
M\Z]JXX:6+6 ]RVJ]S^",I^[@#>V7%^(L/HEX76-.+[P:=_U*S$,&OJ*?M,!M
MJ6V4[5/D!"J+A"=NSPYGO_ZYCU8"XN!.42%.23F(<C$0)AH'S\)MA:5&JU)Y
M S?;IO %<$4N5D4M<]H#T&Z;#ULZ_30U\\$R.53^8 D6V9IQ 'G)7J"Z4T=X
MR;:^.JPR'$%C?<:&MH(L\M74U$'#A*<@C(\9TIBROT#_S=R&9 %'24;:HKT_
MM%)>.]:#.BK_UR$!C^B#*,AKQ2*'=TD'4$SN$)>\W':!'\=[2@O!^V!G@50.
M6]6;VL6=P\*]2^N]7PR9@N-?\SU=MN.CYKTH+I SKN6Y2M/F6'SS%%#V<(^R
M1NT@%06AAG.HYE[3/XSV76$5\YR?>).&]B#* P<BABF[4@)[9:X5%Y1"N$LA
ME1=)&_,YOH41N?AP/JV[Z86-ZVZXJ"Q376"1N&4H[;+BZK1]@]NEU<:Z(U1Z
MAD*]QK$WL5@1<_>96\RQ6V(,:RG *N_JD*<2U"=DD[*'74<JG9I6Z:U_T6MA
MZJR77*&B #(L]X2^L]<!KW#* #76$73SA)FM<JJ[L8Z&.1+7P,MAFV1)W&P)
M3E4>^#,@QOLXR8"?EE)=GQ0;-[AR"FA*76_-H#\1AN-R,(<0OSFIRE/ )!R\
MN.S8A&M=@"_BE/@U/EL\OB>\AKRDELZT@TH%F6WED?[S=KCJUF9>K>?6Z+0$
M-\2T(A5NL]4C*@]V,FKZDAO6Q)CZPPKQ)IPKHE-3F;J+85"" P&404IMWXFF
M#[7@,E!Y>><E&Y2GNK&AHB'JL+='L^/[(&HP,0%UW3=$TG<)E@K:6^L["W'1
M,?MF#YV7]J 4$P5<#>)J'GI,B"0!C^>=;C[D8F]@QJ\O[;?3__8NS$M*^CJT
MU\V@=>E[4^FF+:*02XD2.&^V!UZR$U^CK&7[(]/O TAQO7DR&>H<>!MTM0CT
M08E>[<?W9/^+(Y[#$T>L"DY$9^Z9;^L28M+7*+;#\H%HY44B;,[BC&=O-,[[
M51#:OJ.0OT70RT>462ZG )U;IX#D O,7)T180:U_F7S$T@Z&'H0]!3A(3@NI
MW"0OI2!.IHM:8J)R2%(XU:\+;$TCV]J8'S)C9Z1^.[B%[GR[FO]0="[^_5;/
MM5E9:^5(7T7M+JC&@ PD[-BI#6TF;^JUNK_QI'=JTG5.<!:L_.*AG))>G]QF
MQ+N1W]%5.;V!3HZ+7G53\4%1Y%I=E]Z2E"ZC1\PNW^#4R,YUR<Z6R^3+9A\*
M\X<"+GSS6=7.RW/=NV$0RIG!F1;G]ZZXDII.NC#S%OF !R>P\S MS!3K)&DM
M?Y@^G/\%TDTZISN(/0Q?3</Y^@]_@;89*A%\-%;MU/*PO1@-FX/);'(4J-"A
M@L!'<P2]R6?T1;MHZ3K\-EHRUVIOO9;5ZA1 MRE!:WQ^#_C9_XJKST %K?-^
M7I['WGJV>%/;4E7-FP(?7-2Q38BRZ,BDC^;M%%&R.3<KM"M66)977#4V-*0S
M\\:3NYQO[3IA37F?2OK=ICM)?3S9E"0[B6< 0O-=DVH_WU723LF&3'=:7;?I
MRL+*RE)8!/2Y1D=NU+.3)&J[2RQ1MN5ZS:68I/_M8/(/\.\"L'^$0OX.P-X"
MR7Y&:H:)\,O/>(,QWT[IMD^\"[A'4.I#S'?_31>@S?RZ[8.O7IGY/;)JMU>^
M"QA\ON'V+M:3=M8WJVY&M^"[-F@]FRC*O:*DMX\QTBNK>&>,*?-PDN2)&($D
MRBIJF>A1,'*J2*HH?V40YAZ9:>O8 9S$>9''(QNOJU(:MDYOO(<V&@V[QLA>
MI#8:WP' 1-0 %(J<@,L<.;95[VL>C/X*H7_50!UPYPMU.>W6[\SU,)'IH\4&
MJJ=M B\X\=[7N5?'GA/[<)3..')?,4U=B:=7!*NY=^[F&2$".1,H>E4>^L=D
M)DZR/3T%O/6IT[ ,Y$;$PG&QVS-W$[39\A#SL-83E^WVZ%<X?FVT-+#@R&5S
M</ B1@?]UM$<-'8*\#KG+I+T3[/6NVB0C1GQ"GSB"?GS0-P8V\%#"%^]4E3^
MMU. #.GLI\-G8JWBE[C'QQ+PSBD (C4ER<W17? 8G 7$X ?[(+;!JJB]M[0X
MN.-#=+IXQRE [?RJPR_!<%VV]&?MW,,G0%RT0_D^J\_FND>EJ"YZ0X#(-CXQ
M;M<\:UT^*P[1N?#T[M6;2HUH!/7/BY==2FW3-9S(Q-A]9'Q\[.N^.97=N4?[
M:'6//%3*_UV>H5]O_;;>5XN:#JM$0C#@>3?]1XV5#G])2!WITQ&L&M+%4W=M
MER$5Z9L9YC6KKYP*(U.O=19F\"#'Y<F=Z*#N9[ZPR0F9_AP-7<&W]-2TI)OY
M+YXX@7+E ; @/TMLW-OT3;^Q[C]"=2IB>A^";O#?>7="[7>?<K>\+*5HI8#3
MWR_3A]*#=\ C,OM<>M&X2)TM$MFQE:8RUF (>X?P3879Z<@3^&['W')-C06D
MW+P;0,-ZG?\15(A?%DN&+">= AI8O*3B..;8^[M@?=-2OPF-R2W92WDS=3(]
M$A]T)P>#/U&U]XA(C81H1!^$N9 %ZP9LT(QJ8_\]RZ>GA<-H1.7[^B/PJ]EB
M-GF9/:/?/"G?.*TO6B=;'.K>2S'9ZEO0#34B35?':5AFRPH*,F#I\I,M/40F
M/7G??QUIC&8W"][E70#]EC)U%UR*<FQ>:C4+AM0@7D[QT1XH?(ZT/YP7 7+K
M<#.R^G9*")7BHM4/+^VCMW[\T''LW2T7>V!AZY3&:K<.9TWY/MI"X2Z.S%?H
MSK*QEM94^-T9T?G[E],'_:V[!G_$$[^Q$Z*-+E=,.XJ]OE7'PG1#1IP_A_:)
MF<;Q213[_&JN8-?Y]#IN4ZE,56(X6OK:Q?6?[42/7O!)BO>AD3OH;705@?4U
M(6.YEJIM&$3P/5CI/=<%&V"E,EH/&+T'G;[VV1H3 ,.USYY8=HW1P+;+MF?4
MN\;,B/B24/$59A)1-4VO3 Z_L(42D@)#=&37/L("%@S&/B6I/'GV;.@4(/WU
M3Z0^U*.S;C[::P3GOW*]?-*UFB99ZCE*2OKK#7@UQIQV)VN?565VR.'G["+T
MLQE,Z='^8UO:I<>%H"&SP>Y3 -"KOALU-RIK?^:">+.D>DGM,(^T,W[RG>$[
M9AK2%WW>:Q+!)J_W5T>UB(UJV\.*H7GNZ CQA))-^C)ENE$/^_/7#GFS#2FT
M/'9!)8)VRVQRC:OE-1GF)O78H"+R;[\38*UMY^48;+H:OA\_5UTJ;AML^ S&
M(QB&=UM\8.*E_4,WI\*'7B(V-RT_5I3627-X,TR;$O^&'[%G7%8@6G<Q[=LA
MD[VH;SH7/F*F;X.V2.ZF,)[UC.3!8=>LC*9F;XG>>H.H'F]GH=Y)>>_S"<3W
MX_#H6+<ALR;:#::O\K<ZX_\!_K/ZRS^Z,'\#($>-P">_2&AZO50G1XC\-?C8
MRV\1HS03"D>$/I'S+-!>OCB(&NW,&>12Y7CT\B)9?XE-[C#)<3.>K<LI&YJR
M:N,V V;W. 4H\NSA66_!563&RCR^>C;4E7@,XO+_#%?<&<YA&L4KF",N6;>"
M<%Q&M,?/G22UM<'H"\AUS@\]<S&UQI(O)F0E&MO/XG++#R?3UN<5-:"CQ*]^
M.>2A^;>X5^]89\E?@K2^D*;H[-TDW9O;99OF8+6H;G^"=I</($W--I_(L.^C
M+:WG-FCQ?[:-[L5X"*L1]$CL>%PZA/_+TS+-ZW\MY;9$.UT+X5829E62.3@%
ML(&F\'7)K^+S6 JH4N9A)I#GXJ_:$85^.<00G'%,3V(A^I6C!:D-/]?DPLJ@
M4&T'.5B_LD-[,'\**-D*<H_\2 -Q^WA4AU^0'%L>=A!W_J3"C?F.DQ:WB4K_
M$[_>/[R^F61<+<X*>9TG!O=RLOSN&&:A%IEGDSO-DE1ZFX7>/S=NV3AK:%9Q
MB?I'QI=K#53<P\Q=]RAQ+>A^B]K=K4A] I44-TCHQ?.N;\<I%[B7,_2F&XJ.
MWHQ'\E3O<K*O1?@2]4F,M\$Q%\-'T ^^3!@)U=&351>&%G[F_))&M(E2[G,M
MD6T>&:$"4#6'9$90+3*5"_1M7MK"]V[MNV&9' -V"H^T?8/+$,] 5H#?I6^7
MT\N2!#[F3W\!W8F4WH+JG]!R,9 /Y<8)X/G69,YMQ'V[;L> M3>M8W-#^;YO
MDG5K*JL\4-QW1"1D9,D,RE,GL.&E<S&#LG8ED3TT/V90^P;L09+C*)-$'D'"
M(P6=Y*FML6^A!'_Q-'Z)3-(H"CEYJR6TQKE)Z[J_ICG/T*7D%XK\?*DX>_M5
M<KR;4C\'3-KA*?GT.P]GG%9-1YH^Z?L2Z.ZHBX.A9.GWZN_5$U&=VM3'52[6
M(%%S1;SM4-FD7^1_8Z>@Y'G;'Z4YBMY+>C:^VY@-?FB^5074<6[.)CP?SJ]R
MT8M4-?=$H<Z<SU3NNZ[JJ(Z-2PB9]V=\W#.@^U46V\]+.CEXT V2R76\X7!Q
MYB%+6HV,$+=QJV;EE-Y G%4$-!C+X#TJLSR:&S0U'4-IP+QM''3UX7!X'C"N
M4FQH^G%/.W%[0J7O';B;P*J25G35M\F!]L8=TL2M4X _]CG<,6"P6TS_=MN4
MSYRBT<D/P[ER<=7^,59C7 :BK!3K@S.D11$\6(TU&\-99*YHZXZ-O)17O."'
ML+.SNM[.? HH[;@&S6]NK"NOCCM9_R!+7=7$1J9] [E'GI?DW._CQII7B8G3
MU59_FF0. 'Z1?)/_>TI[2L+^3^VRL-ZMR5=1V59&(#?#NX_T= PQ^+BJ<LH8
M*F"T[RE@I07M9S57ZMD4%B@15^261VG'C=<& +6T5D=M-B2>&][LOS3"2!N4
M*0P,[3-J$^4,VV%@Y4\\%S(Q>V\<287A/ID=KL2J5N; S@756\>M2L412(.
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M5\V<M!A8DZ_<<P;2DK67&KE]ZO1V2_&DB4HPM%UZ=8PL_-R_\E%M=:A[.GT
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M\:,VJG@H@)W"(G2*$3J& X"UV(PF9FMCQ="-:<IH9[([%M)\M)1^6]2Y::<
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M%?0$*CD2U];]=O,?G42]):=B:GJAE:^*+[36#YC>G(I<$^_4;0ZV:N3KSV<
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M3C-OO4K>3IV4=95XQ *S/_NV:C!'<DR.F::L^ ;1*7]2N "OM0]C^Q_86/(
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MG$/WUA,.O)WSJQZ?)ZK[%SVC_ ;QM9 %*@K6@&NOPU]'BP^YB4GZ@54;UG@
M2Z[,P.U-.,RF'7]T WG!#WP9,;V4Z/+/SM"Z5^:OVT8M;]VLV7-/66IAE_+#
MH4=%\3H\P*E&(!OHF\(AFX5XL JFLZ)>G\9XA6W6#M(>):_WWO2K001QUJ*@
MB\\GWII;6BH,<*_L1;>74$>J.!(^[?K_;8+["_P/ >+?C*3_=M/M"-<QWJ,,
MOK*R'A,"/TOQ4V-:3ZG+VKXK65C\=FT)^7TLR^JJS/TW6='4MRI&.QY@E-_\
M/N6R,7R;2',]S/6;PZ/@AQTJ;-8L0?UR7/UJ>UTRC8C_3J8*1JL&,V)/(2OC
MQNB&:F![H=6E856)"O\$U5;,VE8>LENPE1K&*'R=51U1:9R5R65TR=H1C"5B
MYG:S;JEJMW2O3?'_.B?JAUH^\\/2*L3GH"82WU63(AZ@T/ULPMW+.VOGKU^;
M CT7PAG50*&@L=ZKCY&C@07)=F7,ZHF60!):..[$'_6;KD_1520D)H_0]D'H
M"@SO(K?IFL;UXP%D;KKYN LZ2'+6YHCNQW@ +*)R+6/##U@^3#!4\S+&Z"O"
MUV2XLHNIU8D780)43ST.?T)Z^EDH?>\9,5T8#_"+/,]VBDR7512[HQNA_IWM
M2M U,T!$?#V/KAO1I?^)6A<O#GZSYO*?S#N?#M5G>GP- &$;\ !NX/F;U%'E
M.Y9Q;[SBT0H?5"URGC@&GPH#9)FN&%7P /[-F>0%L#^J85IK5E]SI,+Z==5T
M29;8R]W^U#>8)@<3]Y:LR"7&TD?V#5J0'#+Z1*ZE]N13^9_G826.PM:G!7_K
MP:0U&N1K_LP%7?[L8+;# K9#IW#[J8,:F^SQ2;FT(V%''S[1.'+ZTT&-QM/+
M8JB\N@OFPA?^7/)^=M)"YWRSEL;VA_Z7=]6>%/.A6:G\OZ/EN7HU=?;(/#0W
M^^+^=:&/:!O7[@!#ODYSZO"H0/P.N""54U?RLGE"[^I9>+\)I'OD<.P';N8>
M'J"$C/6*D6#/?_?DAGS[8DI8W % \ "?M"$D45VAM##RGV: ZG'78;*/O8Y[
M;9SZT4UG==(RL P"N?@ZMW2OO'\":?I<1L8CG5!M*P-](69RHEL^I%<9% :>
M;I?W<E3PLL?W+"C#5#N.&3A)F#?KM(D!!\^]^G"2"BL<SBT[L6FI(HA1G%'O
MK/=#Q]RY?2^<J_XSTUE(VTXRUV@OAO&S*O=#9:6(S^Z@R15PK/:(K%![YN\8
MOHQ8YDH.UB.\5[ZJ_GRDGLPV .'/ ZW>R6P*,=2I[7T?!;K?VN#IF^B?J/07
MJY1H,$S#"UVSU60-U*9$7Z<^/ 9 WIS!XQID<L,Q67P-NR@5U)(-P5OXX8!4
M5+I7S_4#&;\@HSS :%5R%/WS1A@Q$TW@,Q[SS6_@77&QNQC*UFFK56P-A<-;
M]09CRN*1(/#E840XJ!N="R^YG!3G)[;[!BCG1=G#WSEESU:JCA%%!^)&3%XB
M//=CK5Q?KY]$?Q7=LP+,_XC\ *YG!86!B\ODVXXWEQW)'OP)<[-.30T7[#_5
M-*WXZZ4+04/_X0PG(#HM?_;Z(:/4LTM1&\]# >M7CMI@H?@\KM)3,3QS0+[1
M^+FC9%?M^92]_FE1IP+@H<CU8(Y2]S&A0.&T^\,4EB7-]O<P96+Q0>:!EK*O
M&HI?W::MQ5:#7]Y<)@',3II%:^5YS,:A>D;+$LV^F;KFM<=A>VQ7/?X$S$5)
MOG$0$SEG:GPK^YUI47:F@.G- E/!.:$Q9!WE9.+'"JF$"$^8&DR]ZO;*(6=]
M&.6W0O+6[H_+KV1PT G^?P0V\+$R%-?UC-*\)4#N(64C,3!RD/XS+KAT4U5[
M$^&#6>:6;<*+/JPE11"Q^IJ4A<(U>NUDGQ_E/_P3 JK?(VDZ; #'F_\9*4O(
MDVZ?.[2K<# P"3(M"<\)1>=5S=)8+HO09^Q6K>?'B)JE-NT/F%1A2_,3/, '
M$60A=@)O8#XJ,5O#G)[(4T/&'FZYVG,60DWT2$"8YUBPZ J]V___N[I_@7\?
M\#<CZ;\,=*"';DBKMU"K6^:_?#DDSP/TL5L>-W==S1)IJ"R=UM\],+HM'W X
M0O?20_6WXJB<H:60SYO'TSY=EN0!OE]R7_%NJ[_U4OSP6C=A<;O/BE_<GN#S
M<<'G&Q]GY."2[M_/=HIJ4 )KJ07*ID1?F[8XJ5L N;6+A4WYW*TJ$A"&0C2L
M2Y[73:K( 2+7Z?Y/OE<V ]FT-8R;H&&GVI\^C(4 J\"I\VCKD>MBCMH\0 B2
MJ)6?9*4++2.B$J6\J?>KN$F,+I@$P5@RAN+%;1C1H5,.RPJ!X3 (&?USJ[P1
MWMTX73;+/8?J#LW40B2*EFV@"T%8;TI1==4]R,H&SIR,I,GA>Z E61X3=_?<
MVA?MH!KXJ8DA4MTAIEQ(0B]@;$.?*'T-A9@1%H0V.=KBT^7!/P85UW RG&F=
M<>[0.L.UL(W+YLHN[#$)33WKKH]O@*P-(U, ] U=J'$:EF*'?OJ907FD?]U'
M\;S !G8-XWT>85 $O(C+)7<,C>P)(/W0[+55Y,^N([K>8S&Y_AY<]?EQ^EC"
M!J.E%4)@DRO74#8-8.3OK=O$ERAD _B(=4T]>M>(RHE.;U(O<?F\]04UGT_6
M6@;J;^P/G09U %\]93=X&GLJ?$,FXF 9@^O5I<"[Q\]^^1$J8.1QU1GR3LC&
MQF9DDJ;*[F.93+?U4@TO3A;]>NZRT/VAE*$S[B@588T\5E(>'G)^I2P=<9L=
M\$8HR.);7Q6-X--_G)5:XT-EM )KF)U*350<XPN435MFMB1X=X)UMOT@TPB+
M_BZ]E52$ZOTY\;BB))%LWQVXP-2KT=(\@)6H<,,8%YQ9.$Q@YJ17#TDC?2//
M+Q=J@VR-#KQJ$*QAE./C1@WEOT5YU&2=QK1Z'W.L=#]UWSI-T*R_J:U]T&0^
M,\5AXQU,)1JR+&.S)D [XPNEG:U:3'FJ4CIL<_N<VI,LT3'$YWHCT$TUR9E[
M]&M#OBO4T7 WV*3"LOQ1'D#Q3]FFXPQ"Z$H\T'O,)V[!9,58OBDO=6=1I YW
MJ&E_,W#]239JBBB'+&Q,&$B_UD*'Q6'3%/_8$Y+-D[UX@*L##>TIHR.MWZY-
M:[A?.H 69);U"TQRNY/"5LX0U[8.7_7\Y-X1<L)'E, 88YL4><^!GW5R-[@C
MAWR>6CT_S%EFI<E8R_=J&?EA%SD%*WP%UY!EF%ZQ"61%<E!IX1NV@U7VS'#,
M7<87K7?$H:TT(#F1V8RFK'F)O?%<(3:YI$@\L^$(U7.O %>0,\56^%RI^PN?
MVQGJSF5CGTQ=Q]\MV^.]K*%A%9X9BA&#FMJ8*Y*.RA]5ZS$]%+X6NDN0/\ >
M@L.7D-'DK_R?#$7M>8?T?9B5G18/<&?I%J:5'C$S,]HE">[^**)PS&%/VJ+4
M:U7Q4FS#Q?IA:5G/(U%LZW?TPGC%L_.Z(,+'XW>S#28Y=[@*#,XD_ 9G'IP[
M;?_R>1-N]*)9\MEL;ICD6KX4Z:3QIL$:V=&PFK&$E5OTT7-T:1**TBPEJHA\
MA,>YL%65AF0F_6J&I,_GXBXOM48]5W?]D3II6%-X:7Q"^C)P(RXPKB$,^EV:
M)42S67)7GB\>P%E%=!9F=$>J@+HJ'XH*S^^I-?0'&I O(?&MWPHN#104O5_7
MLG)<C&*9S[Q15>P.^[G=4'.[8=T^G?"?1W0*?XH^N9H*%;D'V/&:KU9^MC1E
ME+](&F^-4+G06E]\132BOCM"'R:-8QQKI$D6-^I=$8FX"Y/Y(+4,5JU7#]C
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MK 4 Z\!3,*ORC?*.@2>MR##E6SS12TJ=H-O#IDYNZ-_)OAZ OPY #XY8^3<
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M9'RYVZ#K]&1+(H<[/JLS-&FFS.L0_YO/02UGKD;GSQ8+I@/4(<N+A?\6P^T
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M20C,#VL5'@*>=8[@JA_\Z&.F]5.K*Y_;-G$V_#[+HJWY8Y@AQHT"@'^/9CD
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M5SOI-H6%A%^/3Q4V#9WQ.S+EY.<]WZ_;4E6=O:+YIF 52XO[]U=2M4BRL'Q
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M$R%GSVL?U26+QWI79BEF7.*R<K^G-'CC,:_0T%K/Q>$O7Q3@/"1&CN$J_5<
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M*AZF_NR_1MMRR%A^B4*/3A61;:\3I+:W4:EXJ$WV.=M#8$/A-KUEN(Q_Y9&
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MJXL[IDW<IBI\E83B1*M]'\UT#"Z4)'_7]'[FK!$J3#9#V@&5O)6EEF#9;&S
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MD*7!SYVGOK?<>2&[<:TOYE#"HO#UNNI"@E-!@51HL=%(3.OXVY-?]PNY4T=
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MX660A[HED^B'SA+"!C,$:4/R/P4TN2 V:];Z;(B46 ;^I@JXKJ5A/_.G^)S
MEN@L!I;4XN/S^8WW-N0TGA#'C:V\O(14\SA+9.LA2.UJL?'I5-Y7B_M1FS_L
M?8I7IDPE>Q[-3D$B&,P_]+TLIU^>))/FI)9Y/7* OQ]C)F&5(@I^J0 X2[VW
MGUTT CHK:]E+@['=F!9OI-J?'AQV!<V9;0;Z32=WC7J65T>:,V04VA;"Q31\
MK)_U??Q<<G.>?DB)"1^MJ"=]A#//AOSCRQO<M=1O@9?*]O8F7J":\)]JI?.T
MRO+OQW;:RDKLGK@%/VNHLH<7%1<7P9M%8GOY/@^J\WTV_9)HK<J%0P00=,A:
MO$'VPBE@YF:@_"E@T'D91BH[QFI;K.(V<<!SY%A[59;U%+ LZMU^"C -.B)?
M35$8D5MN+J.](7P">)OG2#E+TB6?IYIE9;TKJ%E_),BJ3'(_6T8[LN4E>[M\
M2JIC_T"EGG[%D,@-B9<?I@LNI1S?"R"8I1]7FZW:GP(.-,.>>5L&X*&)WFG8
M0:SFM'?=:^<]9J69O'6MVHF3#]IO"SKM=K;F'9J:ZPI6[R2LW*$W\GG#_>HC
M?72A&PNS![($\V^.C_Q?'1]_X %[0V8G[X$WH;LI9S7IHH83_3&T").EBUMD
M3/6K.CF[]1ZJ_DES#R;UT*DZ2Y??@@>4=6]:=%I8,UNM7GWY,IN7F_<!H/(M
MA..YSOF",RL,_ILR[_"3W$\!^]N8+YB#I&W+8T0.P;,9!7YQEJDYTCT%< "/
MP6,M4'(L"R.=2!/.RDJ%&G\/8_U-P,V:H'+ Q5K0@)\9[@.&F<#;[[._U=0N
MX(W_RN$=/8]NM[>'OZ^0DKH$4GC0J9G>,U22@K!6&)B;_]Q&,3*@J?Y2^HA@
MIDA^P\L*%?OI?W"IJ1?*]HUP/>[U4VBA"A.9VJI]DFP^;TKOHI!PN/,]=V%F
M)13?D-H:W2W:O\99JO.WC\A<'^LVZ6IQHT(VR(Y7:"(E)[]C@.@SX0\7//AL
MH'''('>MGA#FJ6\H<2G1-?BZ']N'!.VMZ]%]-,/5^>:KC@T%RUK?EM+*J7J7
MH\K&Z\TK9TV4-T$158),SN&9O_1*A\>*>1[V:I#R^&7D_>G)*H!/%66QI/WW
M:PQ!)":B$_-"T2G7NW@Z.'.+LA&ADN%F"+.//:*T(R([YV%,F3Q+/T(OAEP]
MXS\Y&5^A'=!97-=:L,-K<!ZVC>BXD1*?CHCS!5?=28FS<1#2]#^/URK/=@X,
MS'+@&S*:N\1L+N5OGYBM_:F*4I)@]B00?? :![Q:YXS)/\8[0\__9.>/G:HE
MNJ['3C*MNHLJZ ]N!*5]O1J2EZBDA[KWB5E1:H:Q@#793/"5RRB:]XQ6C;L<
MWH.*KE6WRK8U$:WQFGVZ^ENI9>4Q-OLSQL(&@_J[H4>](PGYW0/#FM#JJ4,U
MN*'P8^&K3G:>L=ITA0U_GH,;JH>-C V][6SM*(IRA,I*T&4EOT)DP["2!- _
M9U%B3CZ< E@N'YP%A]?0C<3_F<-GI_9=!9W9COF=4X L)B-9"SMC?F,VS'+1
M0A:Y%%E?(<2<.$Q'P3H3U*I?N;P@0M?Z)#;53:]O/Z;UU:7 D09#^_Q\Q]TK
M&>:KELBX,E^H[<9Z74D5U50/GG*YKFS8C[^\2FSODI*^:&KW6-?]G&_M.GJ%
MTK%2P&]WSJ^IZ*B0";Q'QEO@9BH_'-8Z*\7TI\&]_)7#BM[U Y+<VCUB#;;N
MD_*Y-KD27Q+=:!DZB$MCN.9ZBF-63!##]1QV"-Q#JWJT!R2Z53YW"F@/E#9A
MB5Q.KUHI\GI:L7T*\/*)NGO%,EH1X"_,$*[RP<X;F0ON,Y4NDP"4T\B,UD,R
MR__OSHM#&6)9\*U =&8G-'<C=*(9/&]MQYQ<YCE<=[><V_F1&4\>=LKGB3U2
ML-1>12C"4-MK,M,E=8.,"7G4.[(D-5#S)F=Z>94/E5EU+4FXWE5D!\_1SL&Y
ML^JTNB+]Y(BJJUEGY?U@QSJS-,.DC,A@S_/7C0KL%0/:+UW()B@'6051G@*8
M2/(^<JU1&ZL-QRN?"ZVK42"'Y1W:^Y/:)3US6+,XJ2KA5RV&N>T+#W/20ZI8
M&U,8+!78EL%GF]F!6X48'^,NK="5OFB9@"'*_$F(VCNO?CU#:2^CV4)0>IA,
MU;8V];<1Z^V;(S:(S[:9*5?ZU<83CW *L/^MONR5M%/ URL[\DU0 ?>TO";7
M3UNFF+B@0GGS*\9NZ)K?J-S))W[C _-UVF";\641;R\+"CN1:6.CR'/L^7G%
M@J[7]S8:_,SG CVHNF>8XDJD+GC9BX?NS3"$3Y/^3!\>391)?)ZQ81-,+VMH
M*/,RQ8Z3X36KZ]M#@"72.^$L354/?02=QVTK_YG>E1K_MHR#73/KGY>"@&WR
M"C)>(?FR)">IRB?1LZF"DK&ZB!F3AVQV,6;P?-AZZAFAJ/5H!<XO; K\!K$\
M*G?;7>0JK[L<^J17V=%7FA;T%LV)-+!SGM82Y[C:_-O$!:S4,N<TW_^LDSW'
M692S'E*H&/5D-NI)5N2#<':3W^&B!E%/!KQS/+/&+P$ @#L79M"$%V?2:(@'
M7299R,9M9'2.K+*23;4OWMH[VPJ"](@G*U>I7Q[= 1KOCW=R'C,)0(R*HM(R
MAD6&93P;LI"QA Y;GL<E0:%FYDR6XC DP.P'G5X=?!7K5$KLP,1B.K3?1L2N
MN=7K<_D2O52;H3E%5 _,[NUWA.=Y,(L"[=<=TU\_STRVTJ@4*1M0FY2.5.6#
M:_!1!A ,FO%!+ID1WR!_RAN$?$CM>):T:7VW]!_C#!^WQYWWJ/F97V@SZ<UO
M^B-$;>E,B!_XXG3'!LO/\=%(OGAQBPRH0_J_<#V4;W>2YGQ:#B^4!'K+M;\,
ME-V?S/#AY16[:S4[&^FK]1.5JB;,Z!LKL<SIUS^LVZNI=\O([OQ[?>2N>] _
M*J"73L:FF8!D#]7SX0+O:ZD?:+6M,N=^F6&*0IY7U=M]$JY48$8!EBH[+.29
M'U!7U**"Y\<^21H^DSF6CW$IF$<0X"*^(W(/AXV1CAYVYQG-G)0"\>0@VEQE
M/L&2QUQ=I^5?9;>KW[A3D*PK^SOW#]R.6IC:_=4JB.ZLGNZ*(N;+1>^K+US&
M3LFQRYH9V._[/O]C!>,O">BCU'T$#-PO%NX(QLFD=M%M6Y70,<KG/J:N1WWX
MW"]S[W(Z(OOY7D.UP#)U%.C65KES<]D1$[Q*P'!]?"Y48EDL^'P$DW&"WTVE
MA-1W0G2%7F!%@RN%'0::PN/.T<?Y%DM._YP/XQ"O:IE@3J@J,Q<O]0D>PZ4J
M"]*'\5<2$B_<)8=5-59W."BLIU54^AN+4DTOC"WCK.(!(P[)S<I"G)FK:R&$
M7[+7,4R)34,&]KZ^;36<1=T#?QY:70X,52_@<<E)1/",C[UH]U!GA^M4P^Y9
M)=S/*OB+;,HPF#+$C"2,A)>5\'1UN79U^5\$%A#<*X>_!S_#W+)42&@U-K(1
M^D+^JU!Q#A@\)1P#M%04&AX8TQG5%^JD'5 I9-=K:TQX8\?ZYBS"[PZ2C("/
M<P[K-PL1QS!Q8TW]\?%QYZ,_U;')#SYRV;GFAL?Q1B>FI^D]U#*+,J-8::1Y
M_XDW5K3$')))NQID OO78<O#&>C9+K&E^H&SI>6:4'Q1ZS%Z\ZPWE:RKD%+B
M.W/<E7()8R;$6ZLOZHUDZP)\M.T\2(<= ZJB(L@*RU=-8LJ6_,]MG6'W9:0G
M^(JL<964M+Y^" ?M@#R7T:/"Z6!9C("E0GBKSJCM=K)DEVNP.!,L+Z4*<]_2
M7&A(M[]_8(A7E6^PH_N>KE)N\D?#B]$R>"2X O,#>*"YL;GV0NMVA:R7N_0?
MHU]"MX9L/8,8RG.R866\#W,MI;F@[FH=?_(;DQ@#OW0Y!X3W4ADY%?#<RJ;C
M7QX]FN3-E$LB-)T"/L?'/_9&M5,A)TT9K\Y%\8_I5W-7RQ*36KU8"J'N?0T]
M':H<17NM\M( /IF5?)3WJ[\W'UB%I*<G,$HZWL^/S"LH</SUZ;Y205&!,[IV
M@@UP-]'8W]:C4$J81O6L#=7TS,1R+7<626Y[V)B::N-&?.14HK-%Q13=CI44
M ?IKE3U4JWEZEZ9>5K]P<\1[_O;;MBYI4W\%:DRA<OZ%-:?NL7%JV?K1HK/%
M-Z9@/ A?/#Z3ZEN,'G+Z4_WS$%O[4)#IM8M;$5A)7S@152#[T<F)^ZV8SHUN
M-E,V12=V.T5[EE6LV]:F..DVJ.+Q./&N=>#.M*%4MI?J;]0IX"DS-#6 $O[I
MGLJ7D\-QDR2SGOA)5;/P%[05):T/CH3H8L31B;NK0:Z]0Q@@6FIN9@94.(!5
M'\/JOQV@Z5,H]2D&NG^-:,J\DR]H#/O$A?SZUK>@*%'59/NG]MF&CKM_YZ0N
M8S.'TC2Q=5Y!V=,R3J40.=<^NN>:[W$0\QOHAP^.<V[U\K-+?+3?5'L&-\T<
M>%!6R'O9D(VLI3R"O:%-;@%QP0.+!'R39E- !.2M<<PIX#E3,UM,+SCX5X9\
M_%S5XFRAT[8?@VV0DJ#.7D5*>$OI0)-H[ELR0G=/8:4FF:^,0V (J3A;!_1.
M256:PX2#3]OO7-J]BN+N^7Q$?@JG'P_<F8U7E,.-O4Q_^'DW'TTG$R\3N/B=
M)?GD;MK$=]!4%F5K=U#IIN6\Q5) <</T7HP520;_^<3E>QW0VTBE9 Z=S08R
MP&TY='8$^CWK#5!K-U.L%]5X%I7C3P8HE7];@OY?_L%_^PY.%S0!VG62OYDQ
M[[-R>!N]//30Q^&Y#U)V9,K>_BW!A_A39\A:S'W"U(9BF5G1NY2Q<T[IL5[.
M'J/)<^7Z6Q;U \ -EBG<R0Z9!-<<J[\R=(_ZL09JM:PER#HC(U=X5W/0^KJ-
M7A6[\:57EQV='E08[&ZU7E0K;0L7'T.+X2Y $W&=P$7*>H?&O3N7[SUJ_C'<
MRG*\03F>8&!^PY']TP+M,P2MDY>$!,T,!>A\I^!PF9;3<N4PYZ=\B]77?9^@
M'0J_H&W3P0(<#?L.Q\)!,>JSZ74^!$IVNCH-H_M&WDW@YP*<C#QZ70S67<5J
M8(ZW"#M)156RH/HRE6KCYDK4%+OBY+;&,MHX$"GR!53[Z5N3M9/!0W5]F]*8
MUNLW'K+$WP/(G8FWP+-LK-BOJ52(C[7SIE3^A=#I&LF#24;BHU^M_8N>HB7H
M>#_$U@1M+ -MB+SQLZOL9R0*1G*!LEJ&9G!X,@2> C36CP0BL-]?PC/HDE:+
MO+U/;)+(BDI!&7W41!.O,U0N+)!Q:5]8N4 J//Z3TQ18!H)DEM4G&FR@0K&-
MZ<LLA,E3 +9W-NPYZEMA]M=YL<7U*; AS=#OZN#^'D=YX\BBQYV_8[*C3+"V
M(5GT/-8I]/AVI#?HK.Y6@B=R8?YL:,^-=3):1IBO"DMYMW=*]S[B]1@:4<,K
MET.J' <CG.T*1G :N@X)MZ^\*&W32+C"Q":DK'U?D@VYUY#T[SZ95P@Y3(,*
M4D80ZQKD1O ](3:$N^YXP\[UC>A5-/PK92<:OFR(**\M<$KC?,%)KWE)2\\$
M>R,I)$K".KV8"_26;,4_J=&0_/(&!1^?C8U'O[$3,OAQ"(Z+4U\NHTLE=]XK
MB\?L^G63D&9U1?7K9QUM0NPBFUF*- \>%&#,EOC/:.(@E/\4,)^]#?SC]5N*
MRUM=3CG0HR"CHSXFHU55O\87RR_2R -'8URT-BMM716>O1;59J9P!;:,Q,ES
M"-3?/BM60^DP\6.-<A_C328"\#EB^RLSN]PWU">#4)K*XVEO]4$W+QPDT 6[
MWU;^%%/QQOB2@B+#?#Q?CUFE#*20]6]%'N5H!0\U"_B8E9[NEQ/JQQEI%^IH
MIQ?;RJ=UO:PLED&E]!Z0[(B&EMW:\^V; @M(%CV,P/"7F:RU@/D4M>#^9<D
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M\?TM2^8A[C3"[,STRF=KVJ#ZVOW-O&@4AUMOA]L+5-E(^,@B;=JJSGK;+%]
M!4=_>R,I1WP(;:FKNN.@N BSC%>[S"V-K.N&FCQYGM>)V-TI@[$1P8+@^W>#
MZ_^=@6/V>)O301 J7LQ,JS7BL%>;J=911VL#Z+_I/C'D2F)G39DTJM@<F(QY
M%-?9*Z?"ZQM':C:+E+87(Q<O!RD*CL#D<(J)'1+,CL%<".8SIOAWQ40MIFVD
M2?>D.208>$QSW'$&R,.9&6;6+U7L=,R-:)\!V(*G$=J0WE.N(D>QVVNKSTTK
MZ+M73T/+N0:_#!_H\(05,[]IN>>+]WG8-"$E4ODEV0VU2EK7\]E&8CA#PH\8
MT7@:HP.&78;56SFC%"(66WD%VF7\=N:(BIIWI D]GCEQ 7F<('N[(;W==ST*
M-"+,K$5<+=*5^.4/J7%MS'F'D#&^HX S@%,1KH]-%*(!V2_ F9"? 0S79ME/
M9^%PZM.[IT9G@&%<>YWK:7C!Y_K# &I*R)[$?O090!/GS_=DW:-Z#5/44#>Y
M9A54 CNTD=(2DMOFI[:<<4@D0CY32@.]N-;\\VWFAY['8N0U&8*R=X5I&2M@
MAS+4?V,:+-&(,CJ4;S]:VG5-.^DI8IX*-]YW/)9$H$INA&RQ&+2 '[@O;Q\-
M1D!KC=R%??V#.1O?(%NBR0MP5L#+#U$VR(#B.D/'P[=NGAM\(^' 6KO\HTY*
M$)CH=5!D&1-I8WFY.$(SP#0%KF+F=QUDEL8YV %U7G XO%W;GSH#_W$&"*7F
MJV8%%PA;SD6'>9HQ5_CN=TD)L;P%'] 7&^"_T)ZK'&82?2QW+\Z<SRDC-WNG
MXZ!T@#1M8-9L!#9Y.+.$9HB>B18VV$9A#E*S46)CV[3@9R5;A%E-8!V>^OZN
MVR1YR_1,6G@N*0:)V?E2^8:$V_>RJ6ZLN>NHM:TAO(=C7I=/O[%T3R[DV1!*
MNGK)<"/WR5!#8[(]>P"1E]=UXD9/4SBEZXC.BBXVG64YXSL V<1 @>V]??,[
M0[VU@M; 1W*WK(BT!;SZA4$RRGF4GQN]\M.H6W&;UTNW!HR$[I4Z-?WBH2.A
MFA:TXP9?&N=<-44&AZJKRP>USZTJ52[C7WYXMXG0C$MG2+N8CTGR6:2R+I3?
MP,;=Q&[(3QMWM\L;#FM"*PV-3X!/(JMNUZW+WDE,-3J@OQB6N3%-XY4?"4K)
M_J2J7T^A2)P1F<BYK!]U(P.W\N_AC&K?4".U4*BP(PDDW$;_4-Y!4\=SB]67
M^JT#XHJV1L MS^R\W!.YU+%N[ XG2R6[<6CGV2UDWEP"_)SQN4!K;7EL,^$/
M)AS4J%G(Q.09(*H"HUB N0$M<-"I'9[&=0)+')"@G2CFS@#XIUUG )C&>?>H
M!35N0E&C56+3D1YR"UJAPVA4OKFPX5+#LPI7]>'6<"^I.\X(L38LDK\P9/8P
M,TO*&M _V[1K5:&S<@4=<N@P<Z2PN[8PC:Q?#\SMDM*M?!\?GTM;P$;:8>WN
M+7-H$=:BG/62^OUZMNEN&)<XT(3L#CE!>HT=RPBL&K(X@8Q BQ^135$%!;2>
M 6Y/:Z7>P/C!VB4775P&IP5#""NE+3,X58T>9]X71HN\( $B/UI3["7@)];V
M$6"4ZTE2CP;0WZIONFQ*2]I6]\RKJSE\<K;F@WY[&!5B8L2'S C/,S7.CF!
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MIZ6_B[N_4#+%G_9*;.QGO&]O$G$^O'4?IMNT4(IZ0L3@1)::DWCK/G6W_/5
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M7+!P!D!V%)M9J%.%?UOIZB@OU+C$$)15P:!__7C)<NA[4P@BY%%4AI/$0D,
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MY2SS!E.[*1N4Y_$LMFV.E;R6QNL$X\T?RIO79L]_D-#FX!B876FSHBVZ.'4
MP,(8!URO UQW.P9XPAZ,A5+-PM/3)ZB#:[6\MRN&#^I6_N/]+#G_?IJ0<BB!
M(3M]AI-,DFRN88&NM >NO$Z!N;=1KAP^R][*-D]T::E.0JY<H^EC:ULIK.-2
MI)AIZ=C+%^7,X\$IDH4#[[',T'+@5_ VSZ)^1AZ1P#-^9#N T)-0^9FUCCE,
M:3-\?!]:9HU8VTC]DI>3;N[J:T]&Z4NO/\R<1WY)OV/+ IN;4@FP"S $@FP<
MY[=QA3P%^CDES(0WZO.T<%4>3!UVJUN3K[):W^4XM9A?UUA!@F.))8F96EB^
M=]  CO<@YE-[Y[-6@>L-]M3H,\#M;V> ON@2X'$%SE?A#&!\'WMAZ0A\#1-8
M&WL&&#J'+B=/$[#,&MB8!=PS6N_!Y.&BN'[LXS(0A:$2/@.DLAM#]FW.?0\Z
M&;!_[]E>)3@E<^4Z ^2<6_@?Z/$18""?%"'+'6-)IUJXUPPIN=$+V47S8?F7
MN$[G&6!U^MQG($8>>R%I9I#ZF// Y R@AA/:3O_7G>(6Z*_O%&6-CAESLJY$
M44S70BKHOV5/Q-/ ^$7,K=IK5'L'9RUX,--30Z,U5-;TT*2#A?2X*,;TC"AV
MD:;V9>DO[E7#L,NX^ZWG1=,WEM)/37=,TQ2MKI(MK=0AIT^DO2*]/5JF)P>?
M;[:FQY*/V[=]Z5RX^J79F^8>P*B6 ILVWR;]6:_B_]@A:1@21MP?X SAAOB3
MKG[6U+0TGIUV+5??Z:&U1Z[79?1LYMKWQY!)$U2G98H:6_&-7;IZ3<3TGZ6U
M86_=[72;$Z<HDC, $3P/>)@UZ;&)I4AE^[A%L@W<CM9(MO&#/,H>?MVYX^:_
M*P, <TG@GUI\E*1S\APD&G]QD8.8[C5!OQ4NLA&_1_8JL0*-V*>6>4X4TW T
M54!*3NO(8''KFH*8R"75(?FV.\:/:-3TB:1X?M['??PPN)E-9Z;9@:.!@X?5
ME.R(P5;M=#TG4K(YS2UC:Y*(PK=VWMB8+K#LMA2K,SJIH()O1!(GXG'' X8>
M0%*/U5$6>_34O.,)>A45QMOA[@?T&W"CBLWNEOG4-FNK79W*D-IO<84RA &^
MF<U-';P%?:LW,%;G]<?4_PZPD?]9@/W_NQ14%(Y42L")Q^&S"F;[F*/1DWJZ
MEPDY(R<Y)WFP@ZF?.5Z^:HW6;*F'A$=^"PDT&L# XZF5[._DI FX<Z!,'2P$
M*[>9=Q[K!T-V7QSUJ>Y?I=0Y[+#N+NIH8+X7:V$P[<KPZ-./@5:DR^LG>D4E
MG]=E2LT#UHQH)+ (;>7^/]:*+=-NR*.7IX):OM:_/R1Y#9;G;^J'@T9=URS7
M][/QGDO3]JA^'VB%#U JYO 7X?EC=^01&'1J[@S@<Q'")I_YS+[2N@>!&(A.
MY4RKK/LV^B(W0EQ5*^5'%6_2M@#WZN)W*9G02(GYD/-]A=<6NY R[*SW(X#4
M=8R]RBTP3./[PP?HK'QGZ^LA6SST[1F9=U?X-$JM>8?L4N7*J%:P'/P9,F>^
M7M^M8:OK#(#D+<LN'WJ 63?CF8\=UTX*RFVR@H'')R2HBVWOS.Z@\*!C<Z#D
MEH%KG$.2G<=?*Z -"(N4PW-![=]!S_\[%?[VUF> :$R_M[O;TI%K&7,3NW ,
MBKW?UG#NZQA]T\ !O5 %V\6I%ZHU$7WMH3G)R@LB&E(TN-[&5;/-!)N_.2'$
MTC8?695!=A<WE1Q3>DT-6+S;0*-RW_/,J)1H)V$ZV;NRXE%.PZ:Q@Q19]K2
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M'V"O"8VG#!R/(%)B>NN._75!OD]F=^'6(I!YS<B7#][EX.Q0*#GS/D9S76O
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M)M&(;Z(AW=+$FO>,"8*]3@T4.&:1@E8$<)RO %0XZ.$TBV>[@ ?P86>AV#P
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MS,POO4:)^/G^_7]GS]J_%N%L$>-*2=MW#P%K'>!9B-AIMP%\ KC0E\&%=D>
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M8DO!^$Y'9J5X:T")<*88',[0M4C'R=0PH1-\)E4R/%TS8M)NM;&[AP]5K*3
M*<D_=!WMGH<3!P)+P"R\'1-UVKZS7^+99;7<R2\G.#%/@M66]EU\QZQWZYP=
MM)ZGY[9\'[%AEG$1"?\]HKT&T88?#T,5*_K\_KE3+\5P@V#OA8?6[IVR&R/T
M6X,QN8I.%N<LG6:U'Z5G?G7R73/1N"A=L>THZFU+',;]9LI208Q8\6X<4B1@
MD6AKN90>;P+K8$0=06+*#S*M/@47NL&>3B'94,,9:Z[GV.9X>F0OI>,W;8C]
M<R78X\.NS[$9,/E'";F87W\GJ\(L^2)39Z$0O5+@:(YHC=Y[;D,Z<VFLE"IN
M@2.1??((8J Q62(V6'-5FS5%[W%(IW3AJL (073[FU&JC\9Q3T7+K$F#;D]W
M\0.N_[I@X^#P ;?5#T&OGOK)[>7^H<IGIICA&&(%?@>7CURD) ]B%C78Z67/
MGB<C6Y4*?>#/@?Q "H3\XK_WW?^7LDF.4^M5H$K1$80==1A>;0\3V;_QK$VE
MR#G00FD=:O5C+K;QZZC LVN*W4%A,=H\@V^),@SN?I (>:QVS:;&GOSE.A9C
MD;>,L4S/U'?BVE\06RL[X,[=T3 S7NF(CLKX:N794X%E\./T:^D.3W%S#??5
M5.U2('Z9&L7BDBX=B%%"[>@"$(>S=E<9)N_\E=%FR[#]63Y!:C7J[+RM^F&@
M/I-+8N)B=O?5M^$YK6U/!1NE])EZ>S111H.'#GTJL6&^-)%8SV?.TMK2H:EI
MS48+\SE '/\A-SD_-9$-*=PJG/5JL\\A\A:%+&,HM<&=2_[%(/>OP&#A]UTO
M<]#EE1!ZUK4*8XUM(7<GZZZ%I?C[3(3<J/7"+@'/!RJQ02*GWRDXNK+UJ[AD
MV6YNJ,MNRL2 E=>\:[5Q1Y"-EE$8SYR]/N':9_KZ?D-:"P8WDH&89JJU@XVJ
M^=18A[J8H-#W$ZM<:JH3DS%M&KY;BY<"Z9Q/)KCGN7FNY#GD?G>_XK+MNS%,
M[SQ0;<]>O5.SV0$>PN';#TUS6DU+M!^^5)"4D#V)UXZQ,+UVZ9ZSB:0I PA8
M89$5G\1J<37BO(_=AJ0:IP\L713.K"]C,,$,,KP'7U,B)"\07M%D8RKP__S)
MJ]%'2X71=0%G*Z;WYJ:"DNY"\R&VP(%B!Z&ZE+@__[5K7F'J=7FMQ2)G3V&)
M*I,ETV:$;BJ)(',Q_V/_H92(5C;S][=8V1C93YX OMHCK[HI4ZBVJ>;'HE?H
MHH=MHXUU(68P(3DI\_S5S,1,<O7'/JQ!87 U3O)GXFRM-"_X.Y0X5//ZZD":
M+COH<Z=J6PKV)A>UG13;=A,VI%VDRX0$^]/3ANDUQW0SJJX-'43;J!;XD)2)
M2,.TQFT'::B\5;MFD&_2D9F2.H/)N<$=AJIBPF.ZC[KZ5::>SO-2[:,L]HGV
MG[+?M,R:]4<&%0<AKXD)Z#/+GPZ3F9+2#'KP)#?MH@P8^(?_=O0S3"3-G."2
MJNWM]Y'(@!(^!@C! NB-U8X@MVH3".L0;_BKY!7EBN<.@DMOALG\6!B-S6FR
M(2X5F%1_$F]OK6..\!G'V9T^B+%D]UJ[B T*LB9;]BMPS"#<.(VW1MR$Q9 _
M&W9WT*SOP] K:97=#@K]OD<SZ8-T<\5M"ASLW+GI[UFG>^FLRL)UW[ ;]Y@%
MR$5?#^:>%AZ /P:S[W[SL,CE\07H5/QH$FLUJ56'[$A"8*6;49'3]IF:R"-(
MP.)R0,/*PV<"YP7X4M "IH],3;YJYO"9?_!^<XDL)5ELH0KK:5FWXFF9/#EQ
M!/&TA@6,77-#3%WH?6EI+Z964QA?9&O#UR/YOE%5:7R$UBXE!:9N:URT#E=^
MB&V6C0D"UV%S?;=M/3ZUQL#1B[(<=</S\4[02*M*EUQX<GI.)FVPV;3%/&[#
M*F'>^X)9D_%5X3"9&\I0I3"** I9ZIJ*KM?_/5T:X(.[K1-K5>VFTN=B/Z2V
MCF^0D<=\S.>^ID1N<D:.-B33XN$"T8)L/5-AQY6/=HT+\(C(JS['JE7<&]YX
MK8. 'X3.ZLLD\4'-QC4\3OFFJ ID!8L_LG([2"K9D%&W]R *W?LJ[P,\MLA.
MCE' ZM03*R51@0"2.L!>)()7]:DXD\?G%9M7F++ Y0N^&)N77^^'?ENF.^W6
MH5\J-#IZ\#HK>YBV\TR8%-O<E EQNL&='^X*"OQ\;,TUH/.=]P)LK&C!F[%;
M<\_=E3S,BHX@].Y#>8]2L['X^G:U[B7]A@C[2<("]PMYCY)SK_!(^GI7+[$/
M2:U)*"EGS[A==!O35,W-1\ZU-K=2:\N8F#QV-'E<=\J3%' AU;]?HC/Z91AZ
MN6_#]RL0SC"CQ='"P5+A?JLZM/,9D1/W..]_[LD[3:#9' B'7T]U,6>-DDUG
ME+<MT0)OA?+8C"X $J^W;U^ P;K'".+%BK?++. 3%=#F9WG\W_6Q\:GA<-'5
M+6OZYJ3SI[);9]A/&G.,%2G=X[#D^TYJ@.Y'VBL(R'?WJLMQ;%UI8^KIY _D
MZ%%@IXS2-K'3CHT):U=HF3JHT,%^JQ>0[U+K:0#_BN[6/6(K\*].^=],N0O\
MU0ODZ99C,16OX"E]7+[IKF/?NH?W,@95BF 6\2,D4AOG55]['ZSBB#9*]V3H
M<WRN0UPCGRO@FLXD>NU1BHGLU?_5WGM'-:%M>Z-Q2[& *(* -)4F7;IT$1 !
MZ83>I!-*E"H$B*""=.E-0#J$7@/!@()T$.D=I/=00R@AO,1[SGWGW+O//O?=
M>[YOW#?&_G>.D+#6FN4WYYKK-POW-%/0C;47_^M=2?_KZ;O^_<78;SCO<T#7
M,C39SU1M%LD!GX<=<P\F223E?-/\=JL)[C,1/\L"K+Y.L5]O8H54M"7S+PR/
MI_*'IV>TECN,(GX\L;?-2S'R>9\;F'79.N@5>T16"EV694PKC_I%;N[?Z)[6
M23'C\8H/75Y>"E>HMPW^4U8IE^>B"9^RV%6E*I#GY@8  ^JDHO!+=#;%5N+Q
MB7R]S.<VY]+(XYGCWO$:@?Z!N=K9CF)W:L/IA8#VK[=UM 8]TV\1^Q0/W;@C
M425L^2P$X+VVD>.9!E+*-]X ,^6A7/*V_3+DFT[L*FJ][)QZ0LLF48R)Z>TK
M%6M"3]A\N$8RO4"@@I8+(FPJ.?UB>4^' YCPCORF]-]LM*D0%[=D)8PKP=:2
M&JAKFIRT V#6(>R6WO$2=J^1Q5<J\[NS=%1Z.S9T&Z28'IE:=K(OH &L\41I
M482G-V]***8'A3_^.@*ZPMQ09DC3*B(MT90L>@%_\O5["\L<$.SDUL=@,&9D
M0WQJ*EHY:K*.P==5TYDQ#*ZF,ZSC')'VEO].;D[$QP1OUACOF;VA7N'6'#'"
M56H#_G\H"L3A3[6;Y04^L##MO!'Z7#'. V[C*^[JUS]L6Y+746@H;;P>?\"H
M5;MW?<W*.%J'?M$V8+B@@"YOE%%A2%4T!+]+J_"@EGE/% LU?(>VBXSO*G%$
M9LO<BR/$T_L"21_5!>/M*\9Z/,@%BU]\);H?+4\%HK[QN !P 94&R>?_:QV^
M^QS0G.!_3_\PN/T[\MBP6J!$/_T('5LTB7S#*/P,#90V;'(L+%RKW",B^U[G
M-* S?N/14U=JMXZ)N_-=A!XP"-QHM0?[^-AT(N.JY(:M%T9+O_W:W,0^DL^<
MU&3@XS7TA"&IXI0DO^O7RR0J7*O1<C9G'>Q/0<^M"P(YS!GPB#7T'$ ,319K
M V= [KT1&9:LC;H\-G1PE>]@C;?_0V;VIG.F*25%H_UN:^)1Z0,Q6(9 I'Y
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M^%/PKW,I/_YT*7\*_A3\*?C7N93Q_P=02P,$%     @ C81K4O+;2"*2-@$
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M>BDP.:9MZ9KV<F,,;3>20]':=O>Y[<\I#:TW6SK)R_XRW'[JW_O[VDCR_:L
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ML)[BZ]"%DX>N1;H_=Q'M8,MAA>FP-<$7)9(B1M]#>X5_?%KT":'OG3,13-E
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MO+S%'TIW^@(+P.,8T"H] 9HPQGY@5*$-G^ Y0X#?OC5,FR(P3%.#M\KLR;)
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M"HBTT?BHWT6&J@2N3$I+%>%(GE\3+[I<9UA^7RFX]"'U^=]*-^'M:K1A]%X
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MWGS>V]8M]LUB)=S-CX?*?MU(%5<:+ROZXI,4F2-\8'H:Y&U['1*,DH7T=3S
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M^Z\LR=JX6I>F(,[A94-@,E#P[\7A35'\@^Y,;[&1 S-/R+"AY*?*^D=T&HR
MEV<$U?&RG>BH="#1)I?&%,[E4!>#^[W#[N*@_6ZUXP+0:/B+XG:5*7**L[EV
M3..3ZD[0[C[Y)WBT"3R**MAR"U*SF,98;E];70L23'R>GMPIDUTF5 ^17ZIJ
MU-FM!RSX>V^97<UN4M5TFMPW0D@]"3I!4;V_;8QXHE%Z\%F#N-*(^'))]R*+
M9<OSLQ'*M#61S.(0Y$.@V]XYR1Q@5$%X(>^(=9Y @KH3>X+F6_Q$U)_;]_KA
MUD&:<83!$#"7K.)R/3X@9K18W3YW697K!<N0+ %A2L_3_4B;.=1[TV\1SD<#
M3D/JBZ&&V(_P2HIC'G8^78F)&&YS^P;MP(JC6U00R$5CAKK5DN+=KZ1]UU$H
MY3)?DMD[9&A;@LB\^1.W;_,]N,RP.J[=N',(0N&M('O;.A[8S@2K>4"[+..+
MT\:?ZMA+]M&L^X\!?3^(7H<+HW[3^[R2]-V"*D,H0=)K3^>G*=F5\2DW>+<#
MG%3H='U&J'3%0>=7%0WX@OJ>F@991HV9Y]HDQ-&=#KY5RC24'OI]8;O6?:_A
M&!"I66Z6)U$2FK2BK]0P.3LP=\7\^U'$%\_<B<' 0'7_FG?"24_SGGV/8="_
M\HV4TVEA%N;KNF_M1%3CNZK;+QI9L/G]9J5@BX\M6!0F0BW8?[-+S6D_!K!L
M.?:6ZGO%(']D:8S",9>;I;AL"-?&"F7N&<T:[EK/I<U"/G[UXK^8$][>C7DN
MCF^%KSV&.TD6PJ(.PQ;&8U @-]MJW4BHNW1)7AZ"UWJ2=,O/Y#'[DZ=&CA\6
MSUA)O0N]E/Q6.^2/V>HQ(!QZ+8\DJ5T[I!!TI[+B#?1;L_F!DX:!X.)X-QS_
MQ##4_S5RTT=Z+K(HM1=.;VNY3HQUN[[!M2/A(8CVM[V>E=N=5;W7O?F'<!,<
M=Z*^*< %![] Q6*)\QGQ=6W3GN?EO*F3G./X_(1NZG.)\+.[1@E]Z(.\64/\
MY'G)7AOVQYVXI:T;'*2\W[)+H6N<I.U![>P8R6[-N+_53B\9DB2TSU##86*A
M6E*^+1HG[.SLXK[>0)FEYBD:S$U-$>M^T^@@L&43DNM\]#&@JLG^FZ7J>?55
M_RKA2(+,CEA09))I*UN8EB ?60DV##\+#2;?(44NK&P!%\P]H _.="=CX<Q*
M'X,#63^R[R9%Q# :OA/X)I^YK'^6^<GX*+A*_*]F=7]"=XML-(SOMZ8PM=9B
M3%V^8(VH-#>1'@?SW<7T\+O6;[65/'W3=X$A4,AL"J.$L,=N7>Z^-RS]O'RX
MZ)F!N[OY1:F7'3&<;+K/  "@6[V6H!GY:J$N69HB8/JX",7R.\3TDA U0E!R
M]+_;0(2RED&[/D4[YU$)V@-''@-XA=M!C1<M$N$V6\10C=!9LMEJ]=]Z?"'X
MX(-X36:HW+"OFDE&)S=-LVQHKX?^]#L#C>JA[U*1?-IZY0Z+KSX3/P,;77E"
MKSD)/V%.>GV.TDR-5A=P)!M!;JX/6E.S-6^2@G#^T2*M)1!OZ N"'.<KE*]1
M#U/PQT-S]GO7)6:>U&; 6V\ILH@3?<H-&2 &Q'!2]P*0WX:](37C.V2TQ*.H
M^-R[OE?1O$F[IP"(@!G1LM9'+8(S>"=M\BMXJY;?7 SKG#O)$5_& FY?*5(V
M>U;38U;>%YB\S?^F9GY\=3\0O-E(!J^!*V5;K>E;&NP2 K?L_U3S+5KQ]74#
M^F5+F Z?"-Z62!C=^*L/Z^4<+TK\+CX6.U" DW<;'_?V#.WM?SUM]:/ULN&7
MY_*;+'?UNSY9+57<+*NSJ)N^<WU$)+ _-\U_)G'ZMZVLVS'@=%4*_A?!N1L=
MQ?W'S?A;DKO?*&_[PXKG<D*A5W_,]OWXT?-<'F'+/@1W=P>%V2@E3;6\1D=K
MBI!8WD<7*8X*;^6!I9QFL2')KAY0Q"7!C^(B/PH_ZK*.UR(D8 %IA8A#)5AD
MR'QZ?8>$U-?"8I47A_RN2JB?;K5.9!\=I@.P]K?2I&, ]BM*S0V)&D:=LL&T
M3LKFO@=K:.X*KVWI4A1JNS,$O33IK1\6M\4^=10%027A]X;)#R-=X?-RQP"1
M6*IN?\VK'-CL;/PQ8*]RXUY>L3N7C<"0E^*#>\MJ&IH#7%DXG'%X@N+I2M!G
MSEV*;8URAX'O^W50)3IV?C>R7_0R=C@A_\H( ,QA8TV^31O.ND%*QB]5Q2+"
M:,)X8IC&?D'CB&RZ8XSCTUMDU2MGC)I#F;<I+,Z62NUMG_*XI@Q>/(4GSJ21
M@C_ARM]_&X^S?]!S3=\D=S.+>.]UHT=CUJ$]H1"7UK&:D(]?P5+C-"_!/!6]
MN*RK&VU*#Q9"&.8C2>:?V ;++&TQ#;*GUN5/,.F2 A,,Y%9PWLK26F<KR![.
MNZ!Y/RIW9V7[6=:G15S=)3\@!HDS.?&9_M&?*5*_[TD9]4Y!5Q?XGUV3DWNG
M<NG.5IQ?"<="Y&:R*WX.&_%E <P&*30FC"-L=GOY7&4'M\42MT48I(N>9DC8
MIGK8D^X&_NG +3":QB37%/>(@9)(S?^#M?>,:JKM]KVC**""B( T(2I5:2+2
M2U0$!&Z(B/02$:FA2 \0"(KT$@4!I46:="*]]R:]M]!#DYY00B A'.[G??<^
MYW[./GN,,\;)&/FPUH>LK'5=<\[_;ZUU_2?HUD!1RW(RR(2)KE$\CLU7-8-V
M\.N&GE99;(IFC29I0LNYARTE-8OTA*QS^E,L>\B?[D\LS+GU::2TDN@8=4>G
M\DKJ,^"[.7+@GD$NF?[T"_D^+G@!:M!+$<8G1ZWV%=DK^PI_6O[V-?;7&C%,
MK.OXEXOYE$4V9MWS_=24B;*-W=5/X==@+:KA<I=UFKA;"@S0FA>KQQR>5Z^M
ME1R8*7J!%#KQSU="XB%?7QDZR,^JS)T#$SI..H&HEUY[7KK-O^.:_^5]@\!3
M490?G@$FS@O5'RWS#_^VXPF7]#_O(^A%_+/A]_]J8,'R[_V$(7K_3N=_&S3\
M!\? PZ D2[@IOC*BSLL"-TUPC^TX8?U$5O->##L,4W"T^OG=J?#[<U1UHF(3
MO/OII<B':[(7,$?;6B05HHEJW=@A:LIX6F.X "MA.C<'!P^G!S-S&:5\!M#D
M_F H@BZ#,#V4JY?3R;?&6<^AI'56AJQ"K/<Y UA7#FY1:;$D%XX,3'7Y4S3(
MDT#Q)T]!,LTD5S+LM"XK:7&^&7RI$[=>6FF&!Q.*ZVY);6E\+ VU9+R%(4YR
MJV(\+>TD"0Q;221&&"M!=ZBO(S6D34FJ]B][I?N-D9QAZBLQ=P?BV$$M5P2B
M>B?9 'A0  @'/G7N-)= 8G>W%7// "TN2TE1)=,P>QLCX<=C-*Z9X8T\VP.,
M@GL?!.2[?I/Z9<8%QQB?W8M\D--$-:B;\[_Y:5P'+B6T3E*$R9SXRD SO223
MH9V"MR)#5K!OJO-Z?H5$@]Y&G#HH]!6LD:!9-ECT/3AM441_\T6,K(S'LQ;W
MWP<7WP92JI?*_;(@J?/%YDKT_O.(LI"68"65^,)[Q%AP4)7**ZS9^?\$-.@<
M1& "0,]L_\O%B76^A KBOC-)BGP!;Q!]NP,350"T&5Z(94LD0&)8.M^S[5J<
MCMJ?3Q;L%I+D?%X*R"#<^(P?>A'=$B\77=]A45VO_PHO;7W<]MY1(:#RDL&?
M63CR/-,.$!E\<<B%B\38-HT]V'1G[!G >2.!E5WBV.E*9537<DK!\ UO>HG
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M1#'6J>3"$EO!Q+ ?76B[5/;$%V@FC4@%MYE'%L;Z--8KEY+IZV*;EO61+6>
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M68-%1PT D+F8E=ZHV&&9;VE,B!XR4;%C^=/XT[\SP4K&M.@1X7YU#_9KRHK
MZOQ*R9](""=,N[5SCGX"+I'7N;J>V!=YXM?]YG:[L$/4Q%04''Q>1Y+P>I20
M!4AH([7'NG@160'/3*#HNH1:>5T2/&!2D7^'&'BZ.3"G=[RR%'\&"#8[ WS\
M282VO3E-:$'\_0[LUO3/=;:&RSR Z]_W7XV=HV-V"%J! ![$_(NW<L2<'0^F
M97=VUJ+'Q^>DXNU6WX=Q"/9(B"\ +O"B- #'TX3]T^P$@B61TS?'KH0&7U1E
M\A?NM"1J@!#,9E=QQ'A_=O!C._/I1B$)0.D5(4F2&2NUK!]1%/ \HOE8SN\F
M\'3K2YF7:X\UVKBUS3+OD,?VT4TFG$BB(,/VESRRW?C=&/!YRF<0H/3C"I,W
MGGL9:'@)9X'?OTBI_3AX_[<N)-/]_]S\Q5P"ZXSI:3*^7NV1,5F1CZU_-KA=
MC6SU\9TK$*BR@23P-%SI'*]!!X-N*W#B/9QB6Q-S$D\&L6O:-5$_:@)GT]]S
MWCY=_)(J85K<_C+Y--DZZ5 1,W7++KCUU*F"PR4[HS:B!&Q-$ABJ!RK7G;-Z
M#NYC@]YI0^/J3.-6*>Q<B#H);>3A$9@D@N\HPA9YA:C?JHH/A'&:X ;"',C@
M[$TJ+:TG:BX.,:'-0;,LP5:S73PK@(]7?C#(GF: %I(;KU- L&D*DZ^6I@&.
M-<HTT"6?Z*,"+DMVG+W'>$3 UVO$DDWRUW;/?Y^3Z$AZ0&E!L:#)BLX>A;"?
M^,>3.W"5@IH>S]\>FL]>*0@:#J:^T(EOFC&A CX[EXG_6'ML6MEV!IA$+65W
M(*DVS.GQZ&T-#S2=O:I8A2&Z=?.:FV#TZSB0-W/W9D@4 TW%=545@%_VOYS@
MA/WGYF^6G9^81*OG-:_;<_=#C,O&MMSKG/?U;SE\?Z*@JMYTJ"AW4Q%$B#S]
M\;@QP/\:]#C.N9PTTYIE]X8\TG.Z2I42\5G]"."JXCVQU4>2MW^X$0O7):::
MZ!$#\U=M?]2R<[@[/*2>B^"?$Q]BO2K>!YOLCFF3#DS#*\Z_0._[L?:>"@3_
M<G?]IA;F)I_W$E'[<5CO9Z5F&0]AQ7FGT'.I@8[27^H_]&4*KD.LQ(*(&NVX
M_8+'\IS)QB:JB \$8 +7DND;9'(QKX$+"6Q70^=_>4CI.E%7NZ1DC*R;@VFG
M3OKY[$L2%)9E9%5MI;/W()1">.2]&1B=87 : ^>1*O3*@3D;X4&MZT[SO541
M+7+Y1LI"C!__\C52(U^ZT.X!HO._0%1>U%H93\LR!OL6F>%="NU'DO*GU(#W
MXZJI/K0LW*9;8PE28%[2&EI6[\'&[<S[)TSLF-L41F+A(G^92O"%)6>HST5=
MODS[3'-1>]BES"S)3E8;LS>W.72N54^H]@!%OEB:#^ZH,'/Z,;A$8?/:>DTD
M/SN ]-LG/W>KN^FAT@\#996_TG\FOROZ7LXQ]O"0QSBRVNI6(M1]/!>MO!9U
M:W.IL451200 @V@1B[,P@L$]^B'ZR+]JQ2\$,154Z[^A?I2Y5BW 7VA[!J!3
M\,9#.DX$PBCWZ:5?#!UP(LO7_1E'>*6O.@%:!ERD5=\IY.@@L^_6$\(7#67^
M9,G*%$6M'YN1IY723=4-YG/5&+13[/A37G1H&.?+"PC05J +[K(6Q5\53*^G
M6G[V'[J_[@R I2$'6YQCW+EB&DRL_]_V!,@Y_], -Y_UGWTF_]F=Z]_Z2#;D
M_;M#+N D[U\'A]9T%/0VZZEJBC=1C3=P$H_/ )?IZL;KS,\ 5QNM9SDIM\!M
M)A^'U/--<A*T1O"M,O"@SV@OWN?5[-8KME3?B&(D0[CB:3Q<C*1FG_IH[,FH
M +$3J_]K< O/M[W)4'K:-G M]5H%LWO_^^NW(G"^2VIDYECC$CRH/5=,B8U\
M,UJO>D0!:+TB6LY"(\2S TA&'D/O'8!JGW!Z>*N=RXE^T$<0,]D"BXX&75 2
M.8^2)&"H:%:@WB!<V(/KUC-#\;K(XDA-GFZK-^T:08*OA6R T/- ]T.,5?L/
M HG*",()8*W1$A%"X28:D,S\1U.9<3_CJ",63Q^)T;;;63I=GVP>L;:6Y8WI
M[>TUC%%_J\X[,>6QQ[#EG -MD#G-!-G.AR90J/"(#^Y@)M1U>JGY#CGE]8E'
MIXG]MOPM,:\7 T!"W%QN'UT@D/_:?A:" I93^Y]S<_-?E OPIZ\J3KPBMDU:
MO3[A2C2K?\QT3F][=E*FPD]IT$&-"^C4&]5UIRGN0,[UC)XQ!78LI\ER%16_
MS'*OVAG@7M)Y;KWP@Z'&MH AA")63ORP +H.2_\=:%-H5W'R55Y;M2O=B/7
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MF%9+*'UYF?KE.L'B3F9[%ITG32]IG@ ZA+"[1'Y@,Y=!*^2Z9&/$G,2LV])
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M+/(SH!_&4FM>TW-@4"A_!@@E;V2S"<BZ6DTZF=0*J#AN^J($$"VCIWD*H#/
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MF4*42X%$O7]VND9OC%=*8\Q6ZE,V[2I=6[KHL:HECZ\_O;IHR.)P^S9C8#@
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M>IC/,%X1SQ]Y+^M^)BI1H5M6U"8T_P'SPY&O6(S=,ZV?9793[C;I9X 6S3/
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MN8F\_SF4S[^FA#EV3P2?T]9-O8S9:H<\-E4*A?"H<@L.[QYH ()QX7Y.PPW
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MCG:O60J>+ UQWQS(@IP SA9+8G6.<T'44SW0?(>["NV-9 XQ*M4 \XIGUBX
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MGFTIG9R2#;KG8!O.9'IGB4[C28#QF:@-)\3U]0H+G@>U=[VR/7.=E U;E2,
M*66EFNO97,^,OPAI,#'=QS)U [9G17%J:6W,<Y'P&U@;7'4XY&,$FXF)55UI
MDM599;-<L^\JVUTL(_%!DC[%&HKXHN5(N W.J'URIFQ%H]"!.:0F%EC+H"<@
M%'CEN5S;JXE[BS&B]F2C1 ;LD0*39KY))/\,I]'@DG&)1Z.ZCO:%I>GH-S,#
M22EQ7]I<5764/7872:>IV:N4#1KLU)'VK/&4@ZE7NES//FBX2#SJ[>:7A%M^
M4I=W_[*^3:,1-J<5_8H$(K6= $+<\.XD.O"$W F@^@30+N%4Z(?V3EE"E#Q=
M<I[BF3F:M5/P,&H'EP&;D3&SIUE+R,AI;.C?8#C]FS+N?VO-ZVX.46>/ 3WI
MO;)X,#;7X+9X4 N>+C;PPOF\IQK,/^V;8(>8]";%+)\ 1(I33@"=MT\ H=['
M.8@?FX@=YA4$\7D */\CRN#/]\;^Q75DJW_M=OQ?4&<<$!5;G<($XQ, /G%N
M'(D+(_3KX6*)X<P6G9.D[J430):G11JQOW;'&@C['@ Z ?P-_?T'A]]0,$^?
M<J1%?'XJLM@3 )/\\:M3D2&B=H4OGL;1P.QIOY+U#/"AJL$$NO<(*2FR'V-/
MMG7X7R$NM$VC\%[Z<3;H',$.HT 4WR=R(J? CJ>69$?D8+882UR<T2 _G/ZT
M?F"&^M&Q[AX51X7^49*$6$@_ 3C,'<HBB1UUX!, :R:):6[O=%]F[0F@URG[
M5/9??M5).C#ZR_T*?W[M>ZK\W+]RRQ*^X^2?IZ:T]YI LX \-5;<T!PN!@'Q
M*R!Q(W$!#MZ6VHF> L"UYVGE2RY'F2RE7T45_XNTN6<V^&NLDX_GM4/].4\
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MC>!]GV-$W7::NVJ+6V1F"(Z-%))(RRG7F7SG)=+.8=&5O:A7"[\#P'*[=7,
MQ0AO\9%8-F3KW'5-GA9>.0EFXUXSX\AVPT3Y-Y/N?!^+O_./D65(E^@1 A>T
MF5=-@V<)".,!B2MLG^,7T-0K'S7 $MR&.WH8.766 %$I@8 [Y\Y,,>@3VJ^F
MY$R/$[5QDID+?7?5ELPB.UXZ'LK%'P0"?*ST]*6?N(FKB<3Y-<G;SD2:=:AW
M\UTBYC_\^@U^+XN U(PY 3P8+MR%R+_2K_N<?BL\SE7Q&9<KK(CY-VWN0*/
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M^?>X .+54L*5Z,0K ,6EHB6$Z<03*]^%^:-E,GML:&B-0O'1!(9_-')Y>9M
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M6JA082E/8!A<K7ANO/Q5L<;U'_$9>WA(I?HUI/*=.84;K[O+FZ\,##H&=#\
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MSG0!QKG&^.?373* =S^4A+M;&;K\*2G%!_^F&'60EC>6)P-FU3U9;K4AH21
M,!QU]19^ZT);O+IDPJMIX01[#P @>YYI69"*F($IF'KQH==^222M.QSQ2N7
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M(8SWM>/OT *H?8R?A;H17BW\+U!+ P04    " "-A&M2:MG[P!)8 0"_.PX
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MQL03>+:W:SQ)A&<+9L1P9GMGEVRW%A.02DZ[Y>K\^3);A\:!?YP%IM4%*&7
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MQT[K4IE5R5])7D4:&R= &(D@CBB#B9?&$"6)@&D<<RBC@"=<_08'@?$&Z\
M4UM#M82@%=%BAW (.X.]U)F(#+QL;(%QVGEBAHK%=NE,=$;:)5FB9+<UZH"@
M<T=TZ+[Q-D(=4F_M?[JNZ[?M61'A]>+YI2QNQ%<Q#YLW+PT\YOM1"D7*="$)
MSX-I$H60R#@-L Q]7Q";C4C'6%.CM2_9PR*3&=.6UZ^+)2U$_I7HJ@2UZ."[
M2G@06NX-NM VL]8=83@P$:[MU(L&L0O0(#: 3]D $Y<V9==PHUIY!GKOVETF
MMXQ4MZ;]U<Q'24QDI'#FGH H30)(/41@Z 4D#5)/4N2-4:^F_971=S1^G9I6
MO('+TZRFQ8R/AD7YK<O1G,1\^"HTNWB]:?69E3#3KCJSB]G9U6;V'MB/(Z\7
M7Y5YO<Q?_YIGI?BP_'TQ(X+0*, Q#%/I0T0"#''J1]#39P9(&OFQG8VU/\34
M3*N5A.!W+2+D2D8[3CL HQE9G0?.P"RTQN6OIW&QYIWCJKLDE .CC,H4Q[7<
MI8".*_M^VTS'\<4'4?]YO6@/I[$7Q36+LF8212X;E/-)E#//$RD2ZI/'0F??
M""^%)%1;+8J"0.(XB@6E/<R?OO),U/JI?>>+E?1-K;XJ>#-?*V!+)#WGS)1N
M!IR"L4BI%AU\URKQO8Y5K [&MK-QN9Z-+0/J4\<!XQX<=AZ>;IFNIRPC\^%Y
MB.VSYIG/Z\>M-T(]5MSH$9NJXNOC'5Z*PU!*#B53&T?$X@32D(704WM*RI4I
M%?I&#G>#L:9F2=5"VE%>%Y1FK.8(H(&)JY92>YVTG,,V"3! Q"7U= TW*KL8
MZ+U+(":WG.=_^I@M=$VC]\M";=NJT[R4I2A,XQ 2(727+$X@CA,$ YPF4@1I
MQ(15/LW1D:;&#U4ZFLYLJ8H\,2UGM4*7O7(A3P-MYS$Z"[[!/4(ZD:]%KA+1
M^9GEDS@,X>G9'^Q-/#E'=3[FJ3E^0X^X_8W:MK#7GP69EX]?7HM2/+6Q5D8H
MEIAX4":Z"0@B/E0_$%!@'*0H"F3,A7'T_N@P4^.)6E!02PH:42VBUL?Q[&8$
M=R@-;DP< *A/?/\X4A91?B>(C13K[XF<7<S_)""=D?_C=X\7_S^IP586P.FK
M>VZS,B861;9XN'S(196%U;Z=:13+2! !T\3WU29+2HA%S"'S9,)0@GTAK K;
M'!UI<M18"6J]R3H*I.$6RP4\0W-B*R-8"SE ;/\D%$YW5D<'&W=?=4KGO5W5
MR1OL"*'(R]F=SL1LWEHB(A:+1%<M$P@B7361BB"$G",<ATE$F Q-/O^=YT[M
M8_^B5\.BS!B9@U^J,WEUHO=O'Y9/)%L8+O2[X'5_\F= ,O 'WAL-XV_\B.X=
M7[2Z8^-K5O_:_9)W'SG*=WM$C_8K/?;KOHOTRK%ZN>#5F=''Y5S=7]2IT9>T
M*'/"RAG"89IX)(4XQ5BMV1&!:8 #2$3 HR2B:9Q8199-!Y[:5WUS??GN^N;Z
M_OKJ"[C\] %\N;]]_Q\_W]Y\N+K[\K_^.0W\Y%_ U?_]]?K^OVP7><.),%WS
MW<,[N FP$KGR*S5'7GYK175J!MBAX]8J,!Q[9"/!#I%]F\'R_I['*L4B6^8W
MF5BTM@0)(DY2"HGD B+, H@QB2'U<4)](EAHE_"R.\#4Z.=CEA<ET/*!>Y$_
M@9LEL4QWV8/0C%#. 69HTZ(2K0;%_9;AF.).SY7MCC'N\:XC&NZ=LCIVW<A'
MI&^RA;C6;HI9[,5,"(2@'W /HD!R7:U'0BX)C;V(!3$:I\OR2J2I\<6QHZ<7
M]6'3 ER^E(_+//MO]?N7A9J\IE1+??P-?%8/*R[ U3>1LZP0X'.N]H:@,C_!
M;UII4&EM69W,P<Q3A!(L$C7??B(AHMJUKLL-21X3*1 -E%TZ4N7K7G,_3DVB
MLP\>O^TD&ZY,HT[<T&O9.#,VWK'N/9 G<1Y[+=4?XR#U'HK.3D#O/_F\A(FZ
M9<)V*GR5E\H%B=.80"ED I&( YV93J"?A,*+XX"BP"@6:CC>U-;AU:&0K.[X
M49)O?3,ECB%LQI8.<1N8"E>0-4U2]H[3.,T&-<1EB"R*8T.^22[%"?V/952<
MNJTOJ>395\5D7\5&B8;+!?]9\ <=GV#J5]50ARIURU3BQ*<>#%)/,4X24T@$
MC2"A^H1@PI*883O&Z2_,].BHU66SI(PM'YTQ.:9D-0[D@S/9(;0K)V>C"5BK
M,GR1=1>HNN7!,^09F23/1VZ?01T\LQ^]?LX;]MZL.TMXBJ/4#R#GOJ[I*5.8
MXE2HG34-14)H)%*K"LB'!ID:':YD[%.\]R"*,:5,>D$ 0TD(1#*-(4$Q@U'B
M!SY.!/*091'D<W$<Q^.P@V3=0T+D)<D6EG5].N$U6S[.A6S@96$7*_>^ZRX
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ML@7@R_F<Y 506SQ0:-0L'393PM\FR#L1D2>T\AV,[*[#81=-):K#-:C4;]=
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MG) T39$DW.Y0O6/YILC631WK5D0[^G4]?V:4_(:S,C!-KS3;;"U=;;>WM;L
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MOS45K\N%I3'2;Q[,&&=P= <FHUI^76:^[?!7J7"Q[KIRH5.JJ:AZJEP HO4
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M*_J!)X_6Z_RX5IL=S#NNZI%0^/F%SC-V*Z70[4>:TPDQQR1A:0Q%@IDNU!]
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M_P7\O]X/GN?YX)DTG8#_!?C!1>1Y%^K'3<(H("_EXS+7T?4+L%BV/UVNT\$
M*>K*+;M9I_ICU/G%%T#=\2Q8F7T5\]<?[+CMT-R9,=F9,S+TWGLU&95XJ[[
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M*F>!2#'EO@=]2@*(XBB V(L\&"1A$N$ LS"UZL5W?*BI[5]:24&^%M5NB>B
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MQ )H*AE@XK4JT4ASTU8ANNSW4=4A@UL<)=D.SG'ZVCB2%1CI%6:!8Z'8HQ0
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M]:>^;$RTB* UPGC\ZP^"7& ZZ,V-!O;>1#V4+6L&@=(BZ-@WI!,%%U\/K5T
ML0U,HX'"1@^:+B#8QJ^#P%^K&]WF6)K?WY.M>%AO7AK]D 0S5F()099AJ1;V
M"0>4PQ24J2P3@7.,<6DSQWK=P-Q(MYE'] 8Z:;$<06@VQ;H&F,"<:H6)]13K
MG.,^IUA';4PZQ3KGX>LIUMGK'/?^GFDM_OM9#0P??ZK_=!/^+,_4AYLP(&*<
M $B+'% D8QV:GZ=E2@5D5KKB)UN9VU>]-S)JK+3<2#L)I.&VU[7PA-ZD>H5,
M@#74* 1>MX9.-C3M1LZ8KT?;+J,7.T:Z2[4VTF()NU"(;XI1^B38MFIE4_1]
MD$6TH%+F*184I(+KBNLQ!IA#77DRQ3G/8Y+8U1IP,6)NE-'8=Z.U!RSCX%TZ
MP(Q+0L,:F&IVYD>#V"GM073HPDW4.!$-O+B)O@IEA<]2Z]> Z342W\6.:</T
MKT#J*(;_FF>Y,>+7C98*V;[H[>KM[8KK-(*GQ_TX7L(TEIG.5<0\ Y 5'!"I
M!9\(1+1(6"ZH576H"^W-C>=Z<R.RXM'.5CO.NP2Q&;UY!"XPD_66*EK2MAY"
M%V &98B,3UJZU.2D#&3H_VNR,;W-9VC%X(#WW<O^DN[\]_9WLN''%7/_(:J'
M'[KFU$^Q(0_BX$QM@7A),H;4;$PDI5JPJ;4:X5S158Q)$I=0YH@NE)_5FG_?
MDLW6<-DVC?4V'^UK'P+N9))E4YB-;*,/@C4O0Y0E-U$:)[B)M^#KY9)LZDB9
MU,9>> F]\/]NI+I,/((4)%PRG2N5 2R1 #*+!8KSHD0IZMZ-CRO^;_YF]!Z\
MQ7N1QO]6[X7AWL3\>CKT;L<@)&?H\S N1TN1G0S=T9[W03N'N6(W4>]_U 'P
M*J8G=.1.L#X+'[GCW_091.X$ZP^SR)UPS3OJZZJE7KVMV/OU\VJ[Z4.L\SSF
M0JJ9#(-Z\.*8J(D-*0 J("-%2<LLL1)?.-G*W)9;GX2"S;:D]VG\S$C^:E0"
M4W)O7[,;U 6;!8E+'P7"J\#NR8:F%=@=\_5(8'?T8L=S9+'57].=;&/:!S1S
M^ZB;64"<$IXE! C&U*JF@#G &2M )C KLI3DI4BLSI4O-#@W'OC;BF_([ZMH
MV=JM$_A9FYI1U?6SFDCH/86U03JZ&_R&9](>00U]1KW'L4MQ.9B?M?9Z/+0V
M1,;K(?:E-J<]U#9$X.B0V_0^Q]W>=HZCE?':*@%]T(RHOXBM:I74/_KZ 8L8
MY[(L8 8*F'(U T%8D5"6@YA#1JF(2UF4BY6N_";XO<4.L(4-1I\0;C^A(TLF
MB/4BVLZZZM8\6HE;,Y66;B:=!Y9;Q3;]0V#"D2X_3#)* 4RH (24J>HNPI)2
M)C0AF=76O.^.F7*?OJOY$CWI"?GD71''!4=QJ;Z-7!2Z)KT *&&J/RC)69KG
MN834IAA&L*Z8H$:&+H04_=252!K=G:9BAF+-NN*=)/VN0R;O)L.3ED#@ASYV
MZ<S6ZO&=>='>\IM&9EZ/_QKKVTM8VQ_".(#F]43&IOUICV<<D#DZJW%YAB?%
MMWV*TR)E(N4H+0 3>0(@(Q*H]4@.2,))FI082KL]B9&VYC; G-)[B\C.7(^B
M8@.\S?C*$XJ!Z>F4I%BTMS2@H-@Q'$'UQ ;-O:V<V+'?%]7$3MSBRB(K'9#4
M#OC?JOI?[U[NU9.:B&^4,X;RLE#S5H0 Q&IQ@;.4@;3,,:5ID1!L5+/!H*WY
ML<C U$C;&FE3G2+IQR V)0XOP 4G#B?,''CC(AI^>>-\<Q/SQD6_CWGC\BUN
MO-'/:V[W"^LNMI$\B#OY][6N/_-YI;Y546_KW<1>R@PCBM4J.!4"0)%!@$A:
M O5NE6J-#$G"K/0)W<R8&]OL3>X54%F3&]6*D#V1U4OT0RPM%UR./41EC%&J
MHZ;36"M()AA@2!'(8DX36<:48$O=VO!]-(VB[6$O#>5KNUFF8SU;QXXR&SK"
M@Q]X5-EMX0T\V,51=WW1>A'MW BP;+X.1Y_CD:,EDPY5UZ'U>A2[\FG.\=9,
M"%[KD@X#M9"=4@A?B )E:A8< YG04DV/(0*H*!@0$F.*&<L0+2PCKL=;G-VP
MU1G<%B]I5MS1NK$Y$IW-EM47+H-NN#/H$\K0VX$'*#;61J\$M+SN_YE"XSD,
M^T*C4P=BFV%P(A3;\$;/21Y_V:SK>@$3$2=95@+)! .0"L4X,9( E1F5$A).
MI%46^WAS,Z2;?8J'Z$V]B1ZTL9XR/5J<C4G&$WKA&>9\GL=-])=1_/QE>1S
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M ,(E!1A)6D"2H+RP4C,P;GENK#$PO)/Z/C"]WW3^Y==U;9MK:MX;9LP2!./
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M(.$Q33)"4(:$G?J(HR4V7_DTZB)?U$ICH[\_RZQSUZXP8]()X U,HCJ:YR#
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MEN0@S@1)FD*>@J3,I.82"! L,:!YR1(U)Z&LL"H]Y]F^N5'0]^?'1[)Y:38
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M:]SXM.M26TR.EI36#_ 7DC]<Q ZC03NV?'D5NXTE*G$"*4@+'0J$80PP2TO
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MHUWSQ)Q)G,80(&0(E182,,(1H!P3BHM,<;LF:I;CC8U84_A+@1R6D!:(6JS
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MD8WD/VTE__GBZ6DQ;S)*5;38;0_ C"MU7E8TSM1YJ.:3CLDGSSG$&99Q+G.
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MM;T<AA]6[<L=ER/]+X];^&:VV&K;B/6#_I;=/)F&.U.%8!Z+A((,XA3H_\>
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M8VL/!]8L<0DJ@G1AR&&5D.S\/Y)#LKS,DU:64I3F<&TY*U>O;0VS9*00J9)
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M&WML@=I!:<DD:AW0/VMZHG_=]$3_P[@1M7ZX!">.LV,1WO6'>>^[&J.#VR%
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MY<B#\I$;&H>DY'BU'S.UO:6K#XOEW^JC""T%WII6(%,EBT)Q3D$F9 I@6@A
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M&5<X-J%K#J!2!: XH3J(+3"E/&8YL8I?+XXT-HYK.Z"9G-6^N5%CKVN?N',
M=S-<4-CZWG[T1<RC;]P%-*[N'G?N_@/WD+O@YG$GN4L7^(J=_I#S%]F<)9BO
MEI2O_E&NOM^^5*O%DUQ^7LQ*_KKI6C[%&<I$RK%&EFCB($A'39+I);""68Y3
M1(2 ;NJG+L./C4A:ZUV%3YT0MPN3^L.Q9V9I#5^?A6I,C_[4MD=KXZ,_&O,C
M8W]4.Q!4*]4'N;#BJ4X6#*RFZH/.L;RJUUW\&&U= -]TX6ZCJ4^+^6*MAVCR
M'AAE."X2 3*,(8"IS "C- ,XRY5@BF)88)?,DLV@8\LP-?),"].^?'U R8W)
MK)"VXZ_0^/7,6IO3+XV]T4^MQ3_7C;0W1@?..;F %)*@K,8=E)9<D#@D(Z=K
M_2CH'W2YI'.]K)N+NO-7]?"RJO2*3^B[?Y7+IZG "2J*G(%82 $@5WK5A;("
M2(%QPGA*(70ZYGYIP+$%3L8F4]WR9VNW&^]<A->.<T*"UC/?K$VM4]J-L=&.
MM9/(V!N.:&R1"4DR%\<<E&!L$3@D%^OK/,M&RXK/%M7+4CZHVYW6=KO=+^JC
MW^]H)<5:ZGF[F(""%$EBNE4(2DU?P!@0"F/ $9,QR0N2NO'.E?:,C99J\7]0
MVVK>[&:Q_4-&NXXYEH5=.5UV/#;@)/1,<[65.A W^+=V1C?F@?HFZ[__T<L*
M,!!^0<O-KC1IV%*T,/@=E:D%NJT?T^H@L D0S>G$*16:-M,$@504.EZ+,PH(
M22 05'"<"QV_8:<BMKV[CVU=^.GN:_3QX<L7-Z[;!PPE6,4%RD&NB 8,Y?I%
M$TM37BRD4E0R6"1N16S>D U3QJ;-B_2WU3&2W0<-9WE28):!/":F)ELP\W9.
M 492QIE*89JIZ5Q:EL*[ [8YT=%WL;L!ZZ=9?8"[K$V\!C6"<:Y4G *:0@4@
M2_2WC%"NOW2$% H5/!-.!W?]G\T!(I2@R-F%%]YX]!PL&"C6Z9=&#.!FM5J6
M[&55*U2O%CJ$"-N9^"02(5_[^P,,^A(_Z=OA*_GTASQTI1Z>FYUNN>1E)3\O
M2RX?393W,)=M SB2T*1(F8X&)2( ILC\37# 9:$PR2%)"V2M)G5QN+$]YK&#
M@-%E++N?\_ (]?S@-[9&:V.CVMI)5-L;:8,O-]3S =%!^RDHF ,I/ET/JIO0
MDS5&G?).E^\RG*B3M4=[4D[V5_GNAO&EZ?_U7C;_O9]O^H+=TN=2KR9N6%7O
MR$T54CG)F  Q8X6FW#PS3=LA8'&BA. Q39%31:3]T&.CWZ9W367:$&UV!1I%
ME"8#.]OV%O@/URTSZ^FPW3CK ^3>M\\:8Z.?UF:;<':G.6%K>O3'VOB Z1YW
MQ,+NI5F//O".FBLJQ_MJSG?P;*BZF(O%O-[&8W3^SP>EY%**1[J2'^_?/3RV
M[^LX%[DH2 *8$:&'*<\!U6MH0&6:8L:A2E.G9:'5J&,CLMHTQ]ZI5NC:D5-P
MS'KFI<;>:&-PU%H<&9/U*M,8W4>_9B><@O9#M1IXV":H+E@<=3YUNMB-?JKE
MJI6"^9M<?5^(^_D/6:VD_*2_4*W64!I+AI(" 9%1HVF!*2 %RD!<Y!I_E7#]
MAPWG7!YJ;$336-B>L]*?<Y1PLL"VFW'"(M9[^.,*EC6CV./002/Z)CL4HO]U
M2!\6HPS"&?;>KHG"X0J_X.3!E-.9[:JE_"[G5=V59YTQ^R17#^HK_6N:)9G*
ME(P!1(G2/ %U; )395+6,54)222E+MM)-H..;9?IX>MO=X_1[</?/C_>_7;W
MZ<O]W^_T&_;ARY>?H_M/^L=W;F&+%>Y0((D%)(#EN4:;(PX8%QSD-&.0Y!D2
M;EL%P7$?@*EKF^OF(!NCVZV$=F.A!]SMHL70:/:=AJR!W+-W?S^BKOXT56[:
M[G"QH@M*(4-%JW$'C11=D#@,%)VN]5RFFD5PM4GG\)3A6&44Y#A&FNE9 G"6
M2%! 64"J<I063B=G]F\_-I9IK+/)W]A@9[G:]$:D[V6E-1CN*\>3/@==(NZ/
M,.Q:\*1W1XN^TY_R3BY]TP_(TWO)5E_U+>I6H5E.1 :Q?FPI2G3<$.MUG2EI
MB3/3\T9FBA.GS/BI04;W!&L;@3$R,E9.(F.G5WO6DXA:YX^NPJG_=)$S1#ZY
MH;,8!$X%'8\S=.;GK*<G$CWG/^O9P+#>W[E]69JBD6D<QXC2%.NU@9  YE@O
M&J1>K+&"4RHEY"I%+DNTO;N/;2W6G 3CC7'M1I=CG\ ]\.R>;F](>GZLUSJ6
MK64!^^Z=<CAH_[R] 8;M@W?*MZ-^=B<_Y*YKT=[A0UEQ.C-"&7=S\9ZNY#1.
ML:!4)  1 0',> Y8BAF@%,:2,26@LEK@=PTRMA=U:V?4&-H(QQ@=6V.KO9+%
M64B[G^500/7\2'MAY*1=<0F$*V0KSMYZ,,6*2\[MBE5<_*QG7G6]E]P>V-PN
M#J%*]8-.$$ %+TQM?@%(DC.0Z8>>(TP43YQD&,^.-+8'_^'SW>/-U_M/OT:W
M#U^^?HEN/KV/[OZ?SW>?OMQ]<2Q+.8^N9>HN!&9]Y^LVU25K(WM9D5^$(FA2
M[NQ@PV;B+OE\E'Z[>(%G4YW##KCKKW'"B!0))2!C"040:31IGE*@<B6R),<\
MDVY]=<X,-#:..&XG[9V3.XNM'46$0*QGAO #R[W1S@4D@O;:.3?6L.UV+GA\
MU''GTN>OC"%,EO^6+I>O:K'\DRY%-4494G'.<B!DE@$H" 0X4US_ 0E4.9$9
M<]L9/#O4V!AB^UHTNW\1W[75,X@XAM<QBK@*M,'"B+K!ZZT57OY1Q%DH>@DC
MCD=[FSCBK-=G XGS5_AQQ1?^78H7TY+TJ%W&S5Q\W!: ?S6GS;9']I,L%2C-
M4B!231]0<DTD!#,@$$WSG"4$NY6=>MHQ-I99NV&VPT\TC:FKZG><<2,>W[FR
M8Z4!9J!GRG($/_JC]J0?N;TKT0S)>KZF#$J)5^)UR)?7WL[CK.=:;^MC^50V
MI]CV>+HM*%>%Z?J&)<CCA.D #!6 P3@%''$AXH+1)+-:H-D/.3:*W&C*;:VV
MC"Y\,>_FOWZ0[)GJ+H+H<SC4#DV' Z+!41WHD&@ =-U.B3H!U7E2U.Y.PYT6
M=?)L[\2HVY6>>^'S52G*V8O1O_HB^<NR?B?<_<5G+T**1L?UZ?FE&?Y!':[7
M/Y9S>;^23]4T1ZR A$M *,TUK6,.2)I#H%BJ4L14CN/4)1P.9=C8R'_7KVCK
M6+3V;*V/O/'-Q'*G\E7&PZAVT3&]%VS*[:+JMYC(GM\]@\ZA>_%!8,"#UBV$
MLFW8DH? B!Y52X2^O^>>BE*2KS85TGJ]8,[3/4J#DEXLU*-_T49(LX#07\/9
MYG.RFE(:*\HIUJR?Z;!>$F@DK7+ .$2IXCF!,7/:=[G"F+%Q?FUGHR=@+%V?
MPE@96TV;-T,/2NJ)TK_3/XR8G$OG)IE7S9[ESLY <]+W[L_:C?4I#I,AJ0_^
M[KLRB;835[NS\WE930R1\Z!E8R'P#;JG=(T]P^X[!4#N:&\JQ#T]TB@UI]?2
MJ+MBF#OJJ.QU^Y%6#?/&K @:A9GJUUJ7N)PW[<WU(F)9SJN2F][/<FKVN#(>
M,\"@V?[*82W](D#*1,X*0I/83A>X=TO'QN&UK=*R6WS_\VB1T1G+[/2=\]Z1
M$MYU=$]/F+U&)R6'C;N3J'5X$C4N&X6:QNE)M'&[;G9O66;9__0[I*#&\C48
M*',UCJ^#6_)KB"GJS)GU:L!PJ;8A<-S+T TRH-]B[E=:SLU6^</\"S6[0.]>
M]#BRJJ8%*CA/]2N?,+-O#5,CG(0SD+$T1A*J).-\.I??C/3V5_OUVKGQK"AB
MHT=\,&I_-+$V+^*T>J&SU:N'IO-9B&/$("GB B0B,87*E *2(P%DFN$\RQF&
MB+AI8E^%[J#RV,;22-,MZQ-@N^5J"-!Z#EYJM%I18PW:^[)Z7E3E.F6X-CC<
M"O,2)"%7CV?'&G1E>,GCPU7?Q<^'5XNYI=7W#[/%G[])\<VL+V>TJC:]/S\L
MEJ8_PF*^*N<O5+O\3JK%TJPRIU+AE!<9 Z@P*O(YPH#)% +)A<P5EJ3(\U B
M)YXVCFX55S]OC:QZ_;2T3YK8F*_#03VKY0^Z:O12JM6R#EM=2R1[F&\[UGOC
M6>R9,"VT6(R3D?$RJMV<1(>.1MJM:-_52<1J9X=3<+ER*H82?/$U<S3Z,%?B
M["(G<^U0?F\6TQ[G0?VZ6(CJ\W(A7OC*[ >UI2I%3A+"> ($,BTSN-"OB%A1
M($66Z]]) H73KDS78&/C>F.KX?;:VCJ)_T4N?]1BYZWMNS^,WLDY__Y$E_]T
M(_I.^.T8.Q2H/5.O+YX]R*C:(!:2(3O'&Y3J;#P_Y"RK:SS)QW#<@VJ;(3XL
MZU:(3;OZ![7=RKZELYD4[U[731/;#U930IG 2$B@F.DRG^00L%1!@!5BA8QC
M&N?<;:5\I47C6U WMIL'KS*II"IZUG?^3JNF]\WWY>+EV_=->]7H)QW?-I]S
ME/>[=B8MJ6ZXV>F;#8TG9E9:&_5CT_1KG43;&=NI#6I<,IGG38O7]14!U_>!
M\ W*G5>:-"R]AL'OB($#W=;SA-.F=^*9+/6[UZ/VBKM9ZIW.MH^+V>Q#4W\Z
ME3R%-,<9B"E'FKL3"6B1YB!1 F&<8:-OZW0 JA<SQQ:5ML8ZGGOJ9P;M./OM
MY^5_T [RCK/1'\;=J/4WY,FJ7B<DZ,&K?BP=]EQ6KV@?'=OJ=S2_%\B'<EZN
MY,?RAS1[E-J24L>>[5FRI\5R5?Z;-KVM:HD/(P7T07]VFG"1,$P$H+%*S)$
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M-<X)'!MUW"_,#(L'HQK(-PH#6FKLQB!GL;:C$9\(]LPEE:IUG?U6V:K2OIB
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MJX%@W9788TA+ZB=%:%]2SDU##ED 99IWO)1M8VDYMN _Z7Q-EZ\@G #S1/N
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MJ(]:[W<$];Z8@6=0'[5S?PCU\8]V39Q@JVT#C++6VG2_J.8NAI3&2883B''
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M6X1GF,(LC12,14A2'&512M/IBURRQ26QEI9$ER]\6^[@X98)6&RU]AMP:2\
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MLLI-Z&,!9OD_UKDP30Y,-M>KI$O79*[W^')8[D?&O>!];VXN;W^Q:7#10N)
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M"&$\_^"O8. 2J"R0ZB 4)5(&28(*&*%'JUG*.2;5'0X>/WLC+)C6L;"'/)O
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M8T0EW,P&Z/5(C321X%7$C5%A2,R#)IQKDUU6,K+N4I?K:=@,(<WG+SL0<!-
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MZV22_AR.1@.,!)PW-".AI8&/+:?]V5#" S> -M>%6 4_*P):"+\Z1LI.LFT
M$P\"Q7N)#*21T68,#I.EKISM:!) :]2K5R'DD"/E53:M==2T$'9UO5GM+?4&
MH/.,_@C"6(WF4-&,]/,$Q%.7"#>1*BN8SVY-8XWN(Z]^VM%7!<Q>LFXF6A]
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M8X95J?'<>XAUQ<3LH6&UJSX:P-:CPH0E-P,>,E# 12%DF8)H<R2!(4<B2RM
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MW<CM?1Q>/^CL7),MP_8H+H][S_S71<?9J4_EP$US9B.&GKG4&(:DD2_%B Z
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MS/,O7^^2_#FE1%.F)+O@,: U'A>8RB0*"S++0%F=#IB;$MCS*-]#[GM5=-:
M"7N=KP?'!Q:7DH/L">5EX&=PF?B$KB2:?B:%I=&G*H<KFQ+8@JGK&AY;87!'
M736 P>?C0(+EFB?T)X*WH3"@26",$>6=24HY7,95P+;;Y)6>4+6KPK\YC&4;
MZ3< GS76?SD&BPJ(ADLB>9D_E,LUK>#031!620=.>:AR./,"/3T/&C_D9MF%
M1AH%5OEV"JMU)TM[D+)(N,RE'LQY8JU4) 7% W7<2%EEIN$W*>O7;G6B_PTP
MM;LR^JZN7/:D>8/2?%>L^_5T.(/9\3C^=&N"A1,.0'O"8FE"X[4A3B,4'/
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M-J!\')*I:16K]9R4OGO4[J/:5W"R@YP;0,HYC(>3:>'C[K9UI"8)3RB-&*^
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M"L9J5I/N""H&!=$F"T93')=%CLZT?A'9%5_-7D3&-F4[*6-H9+4KF?\8%C6
M^XG#E,4_^+BA2]^?IO<8FP5%%-Q'19%LG68G=('@8P)D15M,K%C?)(]_C)VF
M)W^%L^GL9I'7Q*K$54*$@'1XE*+8/62!D)$">^%*\+GM M?[%/5;JKX++IX8
M0'>  CIXV2<6WM"W3N^4\[WZ:TKQ,F>2)PHV4(8,RLH((=35SBZ$*)$;:YN,
M*'B4HDZ0=)C&YRW$WRN./H8S?#L_"]/9Q$8FM:LC\7GM6T/CP"&C"YEK8:TH
MFJ<F<[F>H6M<3 VD_6TPM:<JQG["^@T7WW'Q:(7>;W@6*5Q%H6017$"RB:0E
M;1UP5V<I>>VCL\H%%YYSB;;_N@XQLZ]VYTU%/39X+J<B?L35)J[6%9ZO?I)+
MNMXN.?]4RA)7[\Y7=3-Y^*O^XH7-O^1<6<&5Q@*H:TX$0P1GL@3FC4V<ZYCO
M#Y1X!&2#DC7N2U8S,(ZGNK%!>]5>\6%Z-KU0Y)V2Y"N.%):4K (CF 15Z.)S
MWGA@-BONBS4._59@W.KKQGUD:@:RX47=@2-VTV%^OOHQ7TQ7O]8.A3)1QI15
MG;%6*V3(/_7!&XCDH"+36D9LDO[<3$XGE42#NO(#"+Y+^%R>,L5=9"D;<*FV
M0A1&H@DJ@8BA9*3S45R3/I;'".HD&CQ V<_B9P_)=X @HIILZC2]F9_/5HM?
MEU8TZ1B-U0H0Z1Y6HC9:IR  B36=76:1MWE^V41-;]C91]'W4^ '2[T#Z-P9
M!_WOYXOI,D]35<LE.\R:D$/0@#R1'Y>T!\^4)79DP>)R$:5)#_LS='5RFPT)
MIR$UT0&P-MWX'Z8S?+_"L^4$3=))" U&&@XJ2W(@>0Q@%-?,%L^C;?)H]R15
MG<S.;N,B':R&#C"U33=,$"E))3(AP"=0EN(3SZLYCAX-]R%(V;J\Y:#6I:-F
MT_=$PAY-2KNHI0.D/=&@S+A2*24&6>@,*IH,CJ)A,,YJ[[67_'[F<QB '=A,
M?M30;AA<#:2$#N"TW4 /&ZP/=":DJZ6&-G%P44K@IB["3-KB_0G._U/FKQS/
M=!VLF [!]M2TA92*R=48HS18UP(@L18YY"R5DT4FUN:-<.A1&>TW/+2_-0=2
MT\M"X-?S^)^85M_F)W_],;V8N#J)3F9KM(:X7IZ5*=SQ7"HP)3$6F(IY=%!N
M(+N3K0QCXO10978 W=]G"TSS[[/I?ZTYOA[X%G4.Q0L%F0X;G4!>(!AD!*7B
M1* KP>4FN=A'Z.EDR\+@8!M"_.,_)V[>P/OJR\G75VDUP:Q*+)P#$[&^YZ<,
M49$72^(R)G+.9-KN5?N9+^IDO<%@&!E<N(,!I5WE\<-(FFSM XL\3%GR;M\U
M=,WR 9P>H:!9%XO<HR<<90$$,0^^T(\H3%#&<LS8ML9W^(+FAP*_R#:FX#CG
M0=12C4A'TS-PKNX"":@5<S5_TR2!]@@]G23-#L3$_7MN".%WX"T]9./UK_MG
M=OU*ZT@H3,M MW9]I8WKW1W2DKUWPB5CDFPS;&5; L=%V2!H>!9A ZBF \C=
MY^&J(LDX8P4BD.]0RP"XAXBJ0'1>.Y<M8[&)@=Y,3F]P&D+USX2%>^AA;$?]
MS8^P^(Y70[V_S>O.P#I;Z]*UO*I&RU9YHY.%5,^>XLJ12XD1K"\<A0RAY.VF
MIFSW?=V,Y]E;K?.V,NX$-M_F%VNJ4JKU'U>,.)$C*TR#EK7#R6<#05L'G)DD
M<I+,6;L+6#9^2S>S=(:$R.'R[.!V>FAZ;V)>QD)*6,M81:ZA::'0U*($3S>\
M-M&RS)NDD)Z@:5P@'<?MV4\!'1B9V7></MAF_I"_+_/3TW>7+U6"KO BI0>=
M0ZVZ3PE<<1F8DC;:+$H66UN?W;^^-Z]G3\W/CZJ&#HS6-O4;BF):3":!-<I2
ML%NJ=2?/,0MNG$OU"50?P[_NIJSF6/#8H]9F%UWM#;\_<#&=YZ^KL%@UNCGO
MLWHA[/>S5V?509@H[R+=_AFLJ!OMK=#@4G*U!T6SR*P+NDEY\ZZ$CG/'C@3/
MIEI\(:;2.Z%+4;4YBJ?:I2DA<"Y!8JJSX$U4ONOAZ8.7\71L*G?1U8&F\F26
MVST9??CT]>O)JR\?WW_\V]?/)U^^_MNK+R?[/ =M_)Q!GGJ>IW"@9YR3L)A-
M9]^7GW'QE2++FWQ]Y$:HR"UHKPTY@9F!CVC F,)+2<)'WZ2^[C&"#MXR?>]S
MOY$ 7],?^.?$2"3T*@TE,@9*8UV<[1+XS+S3.C@5FE37/TK1N)'!((AXL$!Z
M$.GW^@2]Z;2N@_.]'IF?^+1FMF43M:TMC'9*4VS)(7'M:ULTAV!8!FY1.;IA
M8G!'.7=#69BOZ0?F\U/\5.Y_P^NPG*97L_QV>GI>1[&MAP)<GX"D>&">";#>
MT:TMC 5R\RCF]CGKF+)\,&=\H*:Q_>CMU#KM@J8'S61'T-Q+LET'5,@\]7'-
MK%?+.I=' :<$%^A8!"V8I8N+#I@/D6XO=(A""H=M$M3MS=>KV6J:*^"G/_$K
MIO/%>EKER5_I])SD^8[.9-VW<WZAO8=GYB(MS:2*.0@/#&4$9:2&H!PQQ&1R
MG&LF1&YKU89@HU-CMPOV'C=V1]=S!RF) WE^_6OS!ZP+!(3,408G@;M 5Y#Q
M$AS/"#;I7$>B29&:6(2&/(V+_S&A.N\3-]T>H5OSCA1ZDQQY1'6].R@6ZE '
MA;4:O:3@4@B^2?G:<X2-"^9N$+05LO=49P?P_$<=YSQ;759$6&$%UP&!1V07
MDO&66RB8HM2"AVR;3.2X0T6/P-M7P?.AI-T!5$XHHIG_0ORZHFCNTQ^WQX<P
M04RC@4CN%"@O%:S[)$QDWF(NK-%JS4<I&K?VI"F$AM'"V"4H7Y!\\VE:85[S
M\>K62%)!?D4*1+Q4=9J#H//A,V/@1%0J^AQ,V:Z%Z?'O&+?CO D\AI1J![;F
MP.O_PW5U3M8R>I0(VA<!BMQ8DJ7,Q+SBLF1K5)O!!T,Q,*XE^^\34NR'B)=_
M$BY+(9A.9%$4F117IYXBB^"U](")22M8-NB:.':#4-^C0]@:>,.B?P\4= #]
MMP\8GI"+DU-1'B*O)=O<$ >^D$$)2N48I$'=!,</2>G1Q3PR* _43P<(^UBG
M\M0NS#INXM8$<A+>V7RV=J)^S$])E<N+IZWKYS.-FJ\SRI8<*97)I?+H+4A1
MG5!AE6_SFK$GO3WZNT?&ZC$TO3>@?^(BSEM >H)6),6S N%8?7-U GP('#0&
MF;Q1R:%M#M1Q[^^C:/XIM.VDA ,6UPU3*_W,F_ZZC^JF87UY+:X<N?'):J 0
ME0+,XCUXZQEHDQ3+4CINFY1,[TGON)._NC")Q]!T!W?\/W#Z_0?Q\XJL;/B.
M'\]K/N136;/\Z7RU7(59)C'<XYZ.OU+."%YG/S)0%@4$YPK$*)D7)BNGF[S(
M[T=N7R_O39!T/Y7>7JU=W.?/R/9:EH&SR,D*0&"&+AG%$)PC/F6)ZS97)8]3
M'_@(?>-.L'L)]G8O3;X$B$X4,DY'VH!3ZP9\[L SG8'5G9PZ><_;+#%]AJZN
M;>9^:-@-<3LI9D"D#5V3>?+JZ\G7O<HO+_[F,)66&Z@8J*CR X;EK5O3<*38
M@PD0]!]"A$C@,C,@T1==I,TQ-6F7O4O&H4;C RZ7B.^FLW4W]?JC;[4YE!P5
M6DFWM.($3%\'>^8,L23I?1*%NR8/RD\1-:ZY.  #]ZW"8)+OP+F_X.5F:NQ]
M;AQ&5U(&6RAR5^3N@?.*#)PMY.M%<OC:E-4^3=:XJ>/!D32(]+LM^%^;]0/:
MDV[__0$OFH8M2/< (E%:$119A,(<J"0-4-@F0:".P=;\E6B2V&EQW=R%ZH=I
MB-/3Z>K7;V%50X)?]QI6,/MHLQ906'VNYIF!(_<?0G:^H!3)F2;)TSUH[>IR
MV@4QVYB4(?74P9UU^^9]CC7%,2I.[GY6UA-K@4.018,,@6?/*0#%)N/J=Z"Q
MJ]OL$.BUTDO?5]NKG*?UD\+I^UF9+\[6'WM(2]OSGSK@-;@]]6TN1X4Q.<<Y
MF1Y.+HY3"AQ!@R)HKBP3&(UO\A \[.5XU]Q>CD^<6$GN/EE0*%*X^@ FP8LZ
M](=S[:-$X723TKF-U'1UP>VB]<<73^TKZPZNL+M,W$O%?\%:Q7KUF]]P<<8G
M.44R$,)""36+%55M^S6"F$S)%N2ZT7R,70GMZC(;#F8#:ZAW!-:WIEKP]B6L
M\#,N$HE^P@W/,08!B=M")RPZB$P0DS%%+Y4)++*C(W #H>/6ZAP+@8=JJ ,$
M?JD,?2J_+W$] >I3)*=CAOG][.2OM)Y']6Z^>"2.F?",WC,AR%^L*TJD)?>1
MQRI7II*QO@3=Y+'N )K'+9@8$)?'TEL'$%U3_VJ6OU15G5[[&LYB<$F!,+4=
MGL<Z]RQ$2"ISF[1*0LEF/NM]:L9]%QX05H?+NN\X\3(0GN)R7NZ<"OJ5@\/%
M;3Y\P*AQ9UX:95:%L,8H#T*AJ1<>P4T4"2R6DJ/'G$V[@WB<S.KG\.N,-+5\
M>XX?28C?_L33G_C;?+;ZL9Q(Y4UQK&X=SW3?^U@@2.ZA.!E8L9(GV:3Q?5^"
MNPI!=\'.3CG6H336Q?6W'9__@6'Q[<_Y)*@89/8& B/!JN <>&\<)(<J%AUD
M+*,"\I+.KF+48^!P'_V\-/@1GG!"0;>4S#OR/Q36S>,6?!8&9#+1NDC";>69
M[4AI5T'JT2"XLXY>& C?S<\7$W)6T1?R?%.IF4A$#<ZJ3"?-6H_*"]ZF4W17
M0KN*1X\%P9TU]-(0./V)%(4YYHM04&J#JF*,S'Q)"%%H[W0@,?NC%>T\16A7
MH>O1$+BKAEX0 E\5^LYK)@7JC XS)&0*E"%A>I(D9%:,*;;DPAK5O>Q![;@[
MNT? XOZZ>D& G*1L2N!60K%64\!E SA.OD?TQ7.F,2LVJBD<=PWX"+#;22/[
M(VV^"J?MD?;[+%\^PV ^^2O1'[V<$Q&\"1E3 !$L(TDBJX%6!E=*$5)+'53#
M\NL=J=T*@^ZE8W 071W07/P]U('>C9YO;QY8ZF JQI0&J6T&I9.IT54$E*:0
MB1><N2;U-(<\>OD7@*TAY/WBWR<F]\;+#_Q",>%'?J.XS\_U*\6_[BO*SU\^
M?3[Y\NT_7GU\>_*_?G__^;>3C]_VD=G&SQE$.,]3.-!;S>?%G,X,7?ZG8;:J
M2X7_]_GTC^H&W)Q'J1TK= "3K:TR]!\Z.]( FBP5XRQ:VZ0V]UG*#C7.CW[!
M30_WK4I8Y9,@VP.80VVHIG]SW&FP)G(9ZSQ=;!(F[4+DN"\WPR+IOF5OIJQ>
MS?TF"[!_?\X3G];,7C7LW7D>:T5ZXYPL%"5S"80N 4&3OX@^HB]%8?)-?/OQ
MK-8-_ M325IRGDC]Y$&A1PAH:[VMC>0IBU1XDQK YTGKW4+M@IJM+=1^BGE)
M=NF PIBG/JZ996I9_/(\R!+7(F0KP05?=9\J"GQMKW':VZ ]RB95D<U-T\T8
MW<?/PGI ;A$E8L( B3D*Q^HC3W0Q@68\&N9XSJ&)<=Z6P-[-U"X(>GS3SX!*
MZB#9_"@WKW]]HX]8;\0H%F76**"(.AT\"TXL:9)@D>AT<BF')A-:MJ"MEYTZ
M0X)BVPMR3PWU#+K*T-68>W(I,G,(4:]+RJ0%9X0%YG1TP7IF\W'-_0UMG=JY
M??&PM4.VGW+&7B;Q?E;.EZ2;S^=G?RPO]QWH$'U"GL!(1?3'.C:)V0+)%1&\
M9C'<'Q3]R!:)#1_>*3KVU=Y\0%&.#85K8;P[7\RFJ_-%+<E?SQ^\9,8;+X@#
M#SXY09&&$O6E)(*@ $1+CB&ELA4NGONF<:LTFX)D4"%W<%FMT^MU!O#[LS\6
M\Y^X?NR]9 6+<2@T@F&:[*P7)"Z)#&S@F8>8L+ F2=XG:!JW^+(5LH961@>X
M^CHOJS_#^G1<_>M;_(FG\[6\WLR7UXP9[8M,P@!*0H,*K$ ,(H#F2B1I"YG8
M-NM?MZ5PW&K+UIAKHZ@.$+CN</Q]1MIY,Y]1C'R>;NT+*S9E:9T&$V--[,58
M5T)E*"Y*BSQ[+=JL1GJ"J'%K*EOC;#!U= "MB_GV7TDY:Q/]H?Z%JJ8:G'B*
M3$HN'"SWQ$JQ$H*V%!%+*Y()PI#5;H&L)VCJ98]6PS3"4!KI%UR71S"+0LYE
M(A9<[<+6PD$TJH;"H2[-5-:&)K?EDU2-&Q0.IOOM,+6'(CI 5;W(/Y6OX12O
MKG/.LS51",C9U<T<=/ "A@(BQ9!RT<&WF3/[@)(NT;./EN=#BKP#S%P7SEUV
M]%_M6BU6:$F*C<Q2).+J_#>? QB#UEGR$1*+3>L4[Y S[N76#CT#"+\#"+T+
MT\7?P^EY74I>'< WIV%YL8B\:$$WNEGO>%4U3U+GKWM.+I]S1HJ,QC2IG7J4
MHG%3"T?QDH;11D^P6K-!YC746J_\:?:E+KA87.X^6?X^F\<E+GY6P;V?_7&^
MHM^>S]+T=+K6ZVTI7)Y8.I A&%G7#TL$)3V=7>$%))^"CT*JU*8#M!5#X]ZM
M ^'M,12/J?P.#L&CAN+RJI"HC!,J  J&-:@.X'+6X(.WJ+(SILV,D6?HZ@22
MHX)GVT?)/339 3"O6RS>S1=OPBHL5\3?#R1I3<^6KW_=_-(TG?RL)2QKBY +
M8JSU*H4S4(FX=9Z5NG*0&ZUM7;_0Y+%A#V+'S0@?Q55HKL,.</J B<NC')V.
MD7,#WD5-1YFYFB\P$&(H:)G3#)N,(GF$GI%G+S4'POVP>0"M= "N?ZNW20JS
MJ\"M.%5"I-.7C1$DDI A&*_ Z\*%%298U23>N4?'N& :1+?SX03= 4X>M>$?
MKA?O,:9<TCF2=N-Z+':UXXX< ::U\73WEW3<-J-KTL9]LAJW0'$__?2,N+\M
MZL9FX3&7*!RPR"D^JYT.#K.'4&0I.3$3?1-'[&FR.JT[VQ,$VV)L=XUT@*]7
M*9V?G9_6IOFW2$2DZ>5FBC].<:VP67YU-E^LIO^U_O5'F9\4&17]5P+:G"CL
M20F"]0F,2"9*GZ5.39(Q0S'0:1G<,)@=1<L=H/M11C[B:A*%S]:YNG/'DD!)
MA!"X""#1)*>$$3P<M\F.B.JT9*ZQY=Q5&QW,J[E]C";2!",]UU!RN&HZ-+4.
MV>0LN!.H6!/;=YN(3@O?AD'.WM+NP ;]C6*F#^09?)K5U^5[[N^-964LN& 9
M@M2BU((]"\Y:PC]GN3!NC&^S0&T[\CHM=QL&70TTU,\ (V(F(>9EW1W_?K8\
M7]35<5]QM3I=/X)?OUR_2JOIS_70EDD=DDU^:P$1:E6\DPBQ4(#ODPZNWO&L
MM IA=R1UW&F"[:_+EIKKT#2^/E^2Y"B(<C:&4I0COS(J4+9PB$H6T#RH: (3
M%IML#G^,H'''!Q[9_.VEA;W1]!,7<=YRW,'?/GUZ^X_W'SZ\^OCVT[=_._GR
M_N.W5Q__]OYUG5[U]>3;U[L<;#?SX-G/'&3PP6Z4#S3]X&_S>?YS>GI*.'M/
M5,^^3^/IY?OKS:">ZSYVS:PHC@?(13)0!#SP17AP3+KH$:W!)I[O3E0>;*:V
M^;*;&2%>8<E22$A1U]8+\E0]Q3:@C<@9>4:437)RNY$Y;HZN'<H>6+=VRNMU
MP,MS=F/_(51;?O)1K%_#X52[H5.ZE$(Q!0R66"<!V7I-)M!"NI!0!.Z;O$ ?
MU0;>/-]<?>VM86TLK$M>H YF Y42!X=T4 M&H;5@WK99/_\$32_)NNV"G\=G
MP1RFE@Z"@1M67B5R<(F =]/9=(4?IC_Q@1A?__HM_.=\L:[INN&8)^<%NG5Y
M8ETXH4OU@B5X3K_.-)GTV"1L.)ST<5\?QL#K493<$:SGY0E.WYVOAQ/<>H*Y
M;"187W(WO$LK,0@3@ L6*"(+%-I;G>D?$IG,,3+;Q-T>DHEQGSB.#_6C*_ZE
MNJ4?PZ(FM'[B <,(=_Z.H[BJ3W,VBM,J%(JHBX&(L4ZH0'(3+-E3#$HQEKC6
M\N4[K5=?]O[LCS!=7/1\+9<3Q5V0R@<PD2([%5P!IYT!+NDR87501VI2:[^9
MG)?DJNZ"FL<"\0.4T<%U?MM4?RKW138AISK$$A"\JXM'G0@0#'G?IH3BBY*(
MKLE\PJ?)>DG>Y2$0&U Y+_42?4-7S:_Z*+1>NC*_#@L;WJG/?>51KMB=^![E
MQF6:D<_(#,&-&U!&9 B,<)Y+,3Z(%/G]@6XO^,;],C\]?3=?_!D6>5)\#A(S
MKPU1L>8A$$(I'K*DLYYY4A2SM63\%BTOZ:[=!2^/W;7[JJ&#B_:*A4G2W$>7
M"D@3+A>912DU1&Z3H9"_R-#TW/2!F;TU^0@R=A+KWG#X Q?3>?ZZ"HO5H*"X
M2AZ]/:]-H)_7WS()BOZ"RPQJ(2$=&!)04*P BSDD[X(/I4D:^BFB^O"\A@;/
MP>+OR;[$XK(US(- 67,\QD$40@*3N4CN59"B:23<1SYL</NRBU@/M"\GL]R+
MPQUF^5:M_>UX9/X@'CF:2[X/42,X[0?+;A2WOG#,LJ %Q1RK'1$>HB:'K=BD
MN$:#[+]!(NWFV>:)7/9%^YXWC.=< ICUHD;E'+FM(=*/VLNHC"JA21WS]B3V
MX= -CZ['W]H&55H'=_>6;X;K[G:E2DK"6,#@R<]-3@-=3!&",=X(73"WV4R]
M XV]; X9%B;W!P$UTEG?<+QA[&,XNYK,JWVQG)4Z<X:).FF.(OM8YX0G$\B_
M,@Y3D\:S'>D<>?9/*[QLC\N#E=<!-M^<+U?S,UQ\F-[,!E=<FKJA&9(LMD[]
M$$"D%]#>:\&]#-(U,8D;:.D68X?K_OZDE ,5T0&6OBU"QK.P^.>2G)?U#U4V
M5\RXP@1B%.2;J%INYNG\,62 3$?N.095FJ1YGZ1JW/S+,?$UG'(Z0-IZ1\L#
MD5T.546?>9VMP(J3H#@2*Z76:F>CI9:N.B,M</8$3>.F<(Z)LJ$4TP'&GA#;
MA^N^JLB<MX8Y2 KK2JE<4V%10?3%&,VE1M^D5&0;XGK9%#!6V+"?EOI&WL4,
M&>F\9Y'.)9=URW 6 3R7"@P7Q5HA:EWWD5'7P5R?X:&P/=9VUTO?.'LDT3J1
MAN>0R(:;''@]J@BN) Y6)!5E'>]2U)&1]PBIW7IVS;$XA.[ZF4_P!*-U+(P+
MC*.0!8P3CIP5*VIA& ?/BA>:R9+;C)5ZFJQN';[FX-M5)X.-ZCGRL]ZCA?E'
M?<?;@XJC/-P=*IU17NJ\5MP;$\ RI&@G*E$+JNJL44[A#QT+NME?_$O=4_?&
M0W5])$5\^Q-/?^)O\]GJQW*B<U%%)@>,O!E0IBZ]L8J!4,*6E'60;8+KP\A^
M22]ZNZ!P%Z=@8.5V[KX^Y/8_,"R^_3F?).<\0ZY Q#K-6M -Z!/SX'2)TJ''
MTF86VU[4]E$>UAMP]U'ER\0K 1#)4PO%RNH_16\NYFE[P2G(3"P;3C&E-4UV
MN^U);Q_U:EUB=F=UODC4OIN?+R8E.8V![A+!:WF?\0D"C_1O(4LCO>$I'#LQ
M^@2YXP['[!FS.ROS94*6_NS$NQB1(E^2:6+U8$H(01=PSG$7<M B=N(95'+'
MG;C9-61W5>:+@^RK0M]\S2HG7IE)$GA9G\ZZ4"J1G(6J&3^K9,$.8K([-(\[
ME[-7\.ZOUKX17'."MJ#QD45P45)LF=9;ST0!4VM6Z30JYYMT:0V0IVTVM[,+
M'.ZJG%X3MN\_OCUY_>WD[<>3KWN-[+SS]P=)DCY.T4#IS;<85YN 4@P:4AD(
MK61=7I@@RF3 ^Q@9W7]:QR9O=)O).7R0_NU/O9EX8S%9+[4 E E!96<A9$/!
M?\R6ZV(<MEDQ^ @]XZ88!T#"PY'ZA\N]UR$)MT_F_L,N-WS*X':CX1#+1S!C
M+ L%BP-O;0%5(L&EKBL2QKF@A,. 32:4M+$>-U5(]?/O#<U"EJ0*/H/5GHY'
M*G3M$<- L4&= U**T$U\DJ>(ZM*.[(*)Q[N,#M1 !S[N#2^_A=7Y8CU3_U/Y
M,)]]_X:+LPW\2<-XC%F <;K.:. .')*?E9D3J601%&_RI+@KH>.^,S1%70--
M=87$JQ[9]1[L6MM]LEQ-SVH-SO5V[.7%V7L_(\&>U\%:R_O'D())S9P&5A<I
MJEJ%&6+D@%E*&2SGR!L/Z!V BW'?'9IB^-@Z[G=9PVW?Z.OYV5E8_)JO&3^@
MR.;9SQS<JWN>\K8^7@S9NR#IVBV2L" I0HA<&9#9)9&\D:+-9KMV$>(-[B]+
MRKW-AIL,3#(-RDI#C@57P&62CN? ,32Q:!MHZ=*CVP4!FR+#0^3=P?59'8'5
ME2- ?V?=)6I40JN8JLLJ'2@N5*V(K.TJ!K43G#'=9#KX)F+&!\U!&IX/+.X.
M(7/9+"6LT=RJ",YY!!4E^8TN:'(>>8F.><Y\$P]_,SGCPN9P-3^#FSUDW@%R
MON)L.E]\G*^NNRUMCM[Y;("[VF''<P:?242)69,B#R26)@OT'E#2%U[V4>]]
MG_D@67< EC?TE=/5NY"FI]/5K_4)LM%E61*1S'/-XL8"H>[IT!&5R5D*[YK<
M2P])&3]-,.2M=*"HNP/+Y?%)@H)*R0TY=+7[(NFZ#,M+L"XGRW2VHDV+UB9B
MQK4OARKX2;SL(>T.$/,%?\Y/?TYGW^\R<S5O(JE ME>0<=2V6MX$WCL*$B)3
M@L?B56EB:9ZDJB<,[:/T>2L-= "GNR9Y?<*<DD+KD"#7!<@JE0Q!($+*2<8:
M5F;9Q+=Y2,KX"<$A;ZL#1=T=6&X-G$"=0^8DD9 M.7P^*SI8W-75Q"4$EC1)
MISUD>AEL=:BBG\3-GE(?$3TUDSIY-UTL5Q^F.*NO-Q_F879I+H.SWBHBWT22
MB;*:@H;:P(2"HDT26!#NGJ_S,/W[U!?TA(1]53<?6(YC8^$KIODL;V B,ZN(
M'@6:#"DH=(E\NZB I2*U%,P&^^Q;P)/?T%/X,P0:!I%D=Q?+A^L6]Y!U707(
MR4[2G4N>DP*7; !+?GZ,VI*KUF3BV"/TC-MDTM8?V4_HW6'G[L#IB;!2<XL"
M#&,>E)$6/),!M-?.Q6"RLD=X1;I+5$]7TIY:?Q))!ZB@.SC]/@L75?Z8ZQO<
M!4-%DWFU&9(4U;8&NFK7LS)83B&EJ$)HTJWQ+&4]W6XM@'6H,OH9B?/V\MO?
M36=AEO#-?'E9QL^XER5S*+'06:GMI<%*#IF3AZ"9UI(W>M;?2$]/\?=0@#I<
M\/W Z'8UW 05VAQ*?67)]230F7"VE@<50YPA\T4T2=O<)J(G!VD8P.PMXL&Z
M;(:!QYOS117AI!A>$B8+!4W=K4V^HF-&0^(*!2H*.WR33,T&6L;M?VT-EGT$
M?JAE&1PU'^>S=,F'=AR3L0:L3Q&41@I/>:D199::7#O'2W/S<D/.N.VGK;&S
MI]A?;M'GY%[#T3!EG_2I1RG\O$_]=>GGOPXAKU<Y3RO-X?3]K,P79VL&!BJ6
M??*S!Y?=]IRT+9[E/DHCN -;ZLJ=VBSK%18HPJ)/C"<T318Z':]XECP1PZ/A
M0&8G@1*U.+2N6.;6:\:T"]BF5_NE%,_N@H!MBF=WD7<'.8YZ8WTJ&XHKD()F
MYJP%YVO:N"ZC"HG351:MMKR4(%D3W#Q&T/C@.4C3]Z_X(<3>*7P^5'N]N'S/
M,-)B$J3I+.OQ8D9!#$*M\W[&\YKQ:]+9_1QA(Q=+#J+^+3"UMR[&?AA\'6;_
M_%1>G>%BFL+'?WGU+U=[)U*NTX $6*,]*%=?LQCQD"5F)>OB@1B><WN>^H+^
M<+&_"N<#R[,+>X.S-Q3??I\O+@Z,#RRIG RD4D=#6:TABB"!%1T%FBPR;^+
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M/ ?+>T3,+!>KR9<P^WXQ!8"KR)B7"5P.$52N#08:ZY.T5DZ(9/U6.5WZT%L
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M4_0GDX5$G)?"46'61UYMJ0[9<^'V$'2(L,<GXGP#]FF^&3RBP[;].!6=\82
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MZ7+,.H))Q!;S@E^Y(,"IDK+E@J5UVE!VNXVSMO#[X'C=PO>(A@:NNC?M?E4
MJ[M?UB;^6-LQ]S%SXSDHYA4(4:K]%6[;<^5)RH33]5:9]?"_'^D]YYFTA?F*
M4C\'G)>?3B]N9U_'D^%_I_@9#^?)"AL^W+C1])<?E[^G21A.TX?),*2/I9'!
M3XZ48B7C",;/3LA%9QNKB<)P&H-U8FQPJLJ;4/VM]9RTTK">G!8U[>F17^?(
MQX1L'P:4RYP-%Z.X]I//H^%LFTTIPZ:)MA18G'=^M6A.9)9 F%,^"D%4/H4G
MU>FF>LZ%:49W^D/*F8;51S1QV?&33Q$:5VW'<ARX=6!$J5@ZMS(/@BI6G'0.
M:'$5HRYJI>N,PFDN^.WF2)L7H92D#N0>!:-<!*'+.VD*$32GEGF>/8O]! -'
M;>NL@^-]<'XZ!VAOM/3H_$PGL\'U<%;8<#6*>![%6W>SJ!0F7-ER0*:2X22H
MH6 -P6\)YR0Q'U3>Y3H?%UB!.GZW#O.M%/2+S);@,>Y25JV![;^&LZ]S=2\1
M^=?A]^OQY6B&;M&R4C3)S!))"D,'6PJ#"0$GG0&5+0N>A^CI+E;W,!@^35L_
M .T(!4]AJD.1](RVU\-)"OCK98VPD=D[/!: H"]=9I5EL%8K2(:A0L88A=FE
MR&8G,#U<NB&L="G=<2>L[ADD<[.\&+7)LO':>@BJU)"3F, &5C1(&,V(ES3L
MTI-F)WS<K]KO56VCY]QA,FD!2$O\ESD%6H0$)J32\BEX<*4(5_B@4Z9,.+=+
MOMCN4.K;SAPHL769'\"^GJ7^U^%H^.WVV]WX2AXL$\%!%B75+! $? P:\4]2
M4LHG:SLS(0]6[EGRA\AMW 43^Y:^^WV%\.1"+'U,2_E/>2*E&M#(64B!*)-+
M\W"Z2^;L;M)?7;F?0Z0SZ1_,Q!;>#>[:_UW^\Q;=J')XCD?S:XIB#$,6F3$6
M@%M1'A-3 $=I!J.5]2$I0FF5YLA/4M7OJU>#+D?WLFP F&M[6/KW7(A@*9/H
MF)=I.U(P<,0+],XEHUE+[W651/:-U/1\Q].=M,==L[X!_%Q/DIO>3G[,5>_N
M9([44>DI!.ED2?JD@/$=[H-I[HS12:@J[Y@;:.D7.QU(>-PMNP]&S&]IXL<=
M8:;8YG?NVR(0B(DE)XQ$#=*I3'\K7=ZBQK@ %Y=6H2EF-<"R2D2_C]0-'W4'
M2ZH!RW1'^UTW06:MDYQ!E)RBUZA1X0)NQGDOG376.U[E9>XA&?W:H\/%N047
M!_"V[V9B%XQ04^A?6D_&#![;TH%209:A$A*\Q< D&Y6C<BE)N];W?MND\X<?
MW(:D#Q'0N"-N-6 #YAG,I:7H'/%)4FFR$"!CZ7GG12H=(AE(*4V@RCN3JY2L
M/J"BWVXI#9\UA\NJ :!MYN;*L"]DVN;\^I_;'L4UK24VN)RM!*L,*XWN2B?_
MX$I-/XTFYQ!2E5:O-3;3KSD\ EOKP7_?@FX [)??OM^,?Z2T8A>6QX/EV6KD
M'TC!#0C.(J!S$<!'ST4@GMDZ3M96BGJ^.^@=+.M7#IU(K@$(KN7*+C<ADO!:
M$O1AM476Y&#!&V4@N\P\;L*Q2&K ;R,U/3_9M@:]XR76=^3PEU=7]_6M\^3L
MY1Y(L#QJ/#\R+V,)A$7W)V2.^A.H44S*J-E.$<26!7J^B&\%2)W)H 'S]2Q3
MM_'T[7U?N>AP?T%G\*KTE7,\@<]E(D92@G*2#>ZL%^?P6=+[[='7< 1T8E2<
MLQZ\NRUJOY3ABK0&4C!G(S+ 2E,NPVD$9TB $"7WU!DO65MJL6TGC7NN'4.Q
M*TWH!!?GK!CS/WY%7VLX^O(A38;C2 ?:.$])%F"T5B 4QW-71D2QB<0*B;^J
MTZJHRTTT[DTWJ@['HJ$537A4/;G3*?WXC%[^I)S4R_+^_TK#+U\Q*+GX+4U<
M:>I<_%/DUMT\JEMW<YTFWQAZF((+[0THKM!EY1BD&)\]$$71?:7*,E%EAF C
M^V\\"#F!_O4O@[TPV(#J7MS,_PY&_!O%MQQ;.XA,VJ X R)R A%Q?T:)#,9I
MGC+&B=%7*43=C;R><P/Z!7X%"3: RX.9NM37/^-?G$VO1HL3=4U[Y[]\C3R[
M;Z@\4)&&%'T&%D1ITBY*CPNI06;GD%FE+7.5;+H3[[/GE\T&CHA&,?7B5.[/
MD_%T.N!$2YEI!DV% Q%40I<664 TS99H%_"7[:O5?"\]7XF])-79'QM-Y$1>
MQ+_?+L8H39=]#:['U^[W4H?Y=7P3T1M\,YYLYM3 >R:-<@J4*K40M##?>PHQ
MSP?/4"]V*B?:WX$ZG.:= *]?*.!/)>L&[/Z'R3BD%*=O4 :K7?7NPJ(XX#1X
M&7%#0:GY+# .1N0,*0J?<+?*NSKYO\]1MA-$S0N%:+=R:P"(]YD/:?(;1N*;
MV?MN/!]FEQ;W9M/K,O=H]?>EU<R[\>QO:?8QA?&748GZ5[DS\$PHG90";K0M
MY2"EH+T\0V+ 3FU2/+@JKP\GV=U."F%?J$*TAY^7K%0+5PY/P>6/RM^C T=U
M5E)E"":5(436@ EE[%FR"D]%%"ZID@]YVFWN]O!'_JUGIX94 PIWL' 6E6A7
MH^EL<CMW/.=C+J^_NM%=:^\Y/^^"J#E'?UXV4)&"<LQ#XB:#T$:!DPOYVI2T
M9T%7"3#ZV>YN"OCOI_?>(':F'4U7FN9_1M[-QH7!MRN7>N.\Z@S4:X!Z("&G
MZ)?:!8\Z:J]ZWVWWOI.DSR$Z*35Z9Z639*(>#$/=XERG+ UE+LH:9O 1);6;
MH.Z2W;E(=\O*<LZX0Y)++PX=)%A-D4.*J!BU]E1584EG.^@WS>HXC.W;K;2.
M6!MPB];*>ZCQ04?TY&3D('S2@$>(!*JYIU3J0$F5(I3]R_QZ:TQ:"0E/5_3M
M(98&,%4E[UT39K40%IPEIHSKIN E(DE3RCP11@E79T;&2Z_HVP=;IZCHVT?0
M#8!]>UV8$]X92@1H1DN?OJS!A\2!"6XE-R2I7.6 _R-5].T%EITK^O:17 ,0
M["+L%9ZK9",$&P1: 1_!>A5 ZH2Q) :2E4:RGJ@DIK?VKJ?Q%DX,@'.&_'TT
MO!(NEUR\4EWYZ[AT;;X9SGY\=+,T2$D;)A0I8ZP)""LS.*T39*UX)-:[+-JJ
MA]E];XV?!!W#M2MMJ82=EZ9.'X?3?[R9I'0U0@+3=#9G"/&"1B\C9)++L#+'
MP'$N(3'/B;!&$[%+:_A^E6G3SLZ_NJ8553H:-ZTHTJ-RA\<,\?O8EE+!0 ?<
MN(B.9P)*C"YIJPZ\<6483TJ,"Z:2KC,?J=J6SK\PYEC5Z1\IK>A,U^?QZS*-
M(XWBW(A8I]"*8"@7N?9X&FL#-@4&"L]DQ[@5/K:5[KSKSLZ_PJ:5P^=HW)SI
MR^JGVV_?W.3'@[?!N\F9]9Y1=UGU%&^F>^^^C?F3E D;J'- I8D@N.?@@^5@
M>?0Z:!J,K](ENNWYD[O?M23'@XS>0732E"YV OE'%'(R<J8T)3;6B>Q?QM/K
M"=%;[YUV'PPTX"0]?+111#"F @7BH@-!F<)CTP80NOA^M"2\5LG\?Y'OM'LA
MX<EWVGW$T@"FJKS(2)<5DTH"9Z6@60H/)B(W4]:4\N!)]O6:/;S@=]J]L'6*
M=]I]!-T V+>_]DFE<C8:CR)EXW(BO(H!K/1,2Y8,IU6\J3_2.^U>8-GYG78?
MR34 P0[B9<\YR<XHB#87W2\#4 POV6Y:!U/>'&(_63!_F'?:8[R%$P.@B>KL
M8TO4W]_.IC,W*J6]'\<W-V_&D_++@7":9^<I:))1]2EQ8$E@P+G/&%(8FE,5
MHUUG.XU;_(YAV7$3@PX0<LZ'PV,N+#HY#A0G*CD?(9KR=&:D U/N,9,/WA O
M>/9MY?1LV\F9:D>'\*RG,0=@Y6!E^3ZO7OHT<Y-9$RJSJ?M)(I1$EC0P*S@(
M6X:C$IE!,R&R"5QQV4_X6JDS3GN9">VJS;%X:>&4*3'4U71ZF^+KV\E]:]/Y
MMJ>;NU58ZX7E/D!*7H-@T8)3P0+3(>HD\7QG=31B;U+/-)^@(N#K2GM_/-L%
MGD?I2WDH:.(00#[G-)S=EGZDHWCY^_?A9/X)]WH^T)GR0".>C4I9]&UC1A5G
M$GCB25A?V@I5F7U6?6=GFCW0[@'1+99>A'H]=C6)M)&A<$"%*(JK2<!Y34 Z
M3:EPLO2/:%&=#@M+VFO:V:[Z'(>5(\.2RU$;"K/2X_HN-F/.,QX46!;0Q12>
M@TT\0M8>?^JH,*K)'KB/=G*F 4D;MUS'X:*%T*,[Z[#6X_=AHW@T9GEIS!A7
M(B8A@:143EN3 06GP5DC+,/_2])6WN?!6SW3T*<-U:J,K#^.[@V,$#PJQB (
M5J+'D, JFB$:H9W@.3%3KT:A_OY>S$5T%9CWHY5[8>Y\KJZWOD+OTO3^(8.R
M3%D218'9,OHD10V&> 6)RN04LYF:*LF")]SCF7J6C2IF3]@[AW/R.=;<[7XW
M[CB"CCHE#(Q(&-[2DK^D+0<B-$])>95ZFKC8Z3;/U#<]4^6LA\!ST,]C+VB?
M]C2RMY+X,BXF8(RBE,$8A7*0'"7N&/6ZL3+"+G;]8AX)FM#>9O#Y I1YUP A
M(B,RSP$<Y10$T19*Y28PP4RT25 CFE3;+H/2<WB&. <%K8&YE_=P\21K G/9
M"4T@T^S1Y<#@P&J7@4J>2.0>@_DFTQ)WW-^9GI=MW,36P%"/)UVI1Q]<?/DR
MF3_(7XUFD^%H.@R+W@-WY; "#8)AR&_&T:8))A286 R;C\:ZQ(3CY*$^/"ZW
MWV6A,STGC@-FYQ)X67[30X8,@M#1*1J S2NS,R'@@BEC$"*+5*9,;95QPM5V
MU,^%??>@J^?%'(& WB_3YWR>;]0_P0N_I8_2@\O,X3*^6F.'98Q&ZB0PSY =
M#M%KC'"@K$_:YA0,=SO9YII4]G/Y70WD;4GU!=C[1S>"\_DQ:SPA)GDI/0&K
M@D+Y< G>20[:^L!\\MRV62RTR^;ZN8!N_A3H'!=]>]K'&HWE[1O&'&MW;P\X
MH@D-*1$+*:50,B0I<D38TK(L$2Z(8'DW?_TDY/83CK9].'0OYQ=P2FSW":,3
MB:CY]M$.",TT>.T3I(#?6TE]%DWFGQX7%70>"3=_'G2#@)9N,Y^R$=O:JSZ^
MB7K(##H()FG)=$+/T3 0R!PPGAD\$M%YQ&-2"$NJZ4.5+>VD$*IKA6CISK)_
MI+1RA!S!B>V/(Q]3Z0*$/W\U'LT-W:V[*;V*&4J.N"09"LU)51KE1S N<B L
M)YF=E)36J[<^[5YWTC+];RWK!5LO0/VV/YYL8Q$=&.VB,]:#EY:7_)\ 7G "
MC'*NT/VPU+5^ENVZUYW4S_Q;_7K!UKEWSUXQ3ZX$E??<.LU8XL/H.&F'[<,Y
MU$;/;4V5)<E(R-DY$((X<#%[,(*$Q$.DBE3I O!2>FY;*X4QC@)+LC1*$0*L
MLF4R!2>$)F:(K).%]>^>VWNBMU[/[7TPT(I#]FB[\Y].+VYG7\>3X7^G^!EM
MTV3%B)7.I\B'A^EKA4&+<:L\RRC*A$I1WIXT_F&CI>!2=BB6J%4Z87^IH_;R
M4OI_[X7*G>[<3@>1\]:2QPQ8M@LVRAMK8T*11 N")U4LE8/(.?.,9^72"=O<
M'K67%FM&3XC/[O2E$[#T_42YV,_CK;P?I65/:\:L(V5:5R0\8VS'$EB+![?&
MS8C HZ$J/A<M[+;4V2*S&R2,JXFE59!=_VN\W VQFG*I#&1;'G18I."]1&ZY
M1&W.,KOP;$BZVU(M5N8V!K+#Q-(LR! O=TI#LS=:40UBWB&=HH]EDK*0#;54
M<"$D,\?![.=B+5:9M@:T T73*M3>C&\G=^8Y1VX-TD^80)\D4@]N/B<E!8Z_
MDU%E?Q32?J[58H%'8T [4##-XFSXV[W:<!NXD!&X*'?P$K=CO7'XATM<\\P5
MI\?A['ZM%NLU6L/988)I%6>?AK_?[<;%Z#D>_TZD,NS)Y%+=&,!JM-K6)&FE
M/@IF]TNUF/K1&,H.$TNS($N_I;OY21Z#&:X)^IN!EDF,48"?AS<Y>1N2DS$?
MYY^M+-9B]D-K0#M0-*U"[;(\%"_WDTCR1$C4%2\8AC:IQ,], .'H T0;J%7A
M**BM+-;B2W]C4#M4-*U"[=WP_J8FA$RX%K3T#,;PQGH&CE$%1'&2+<].\N.0
M]G.MG8!F_]! .U PS;YK[)6QPXG6/@0'),DR5<>63A4DEKHS8;431LJV,N??
MOK1I?=V_[54#0,/3^@ZT*6_'_TJ3Q5?#;\/9("F%41AG$-%U1O>9:W &#YJL
M:0J.,4F4.)TZ=+.I%A]1ZD&TYFO>,6AI]K@XD!>?OW]_P MN@G8LF5*BC$)*
M-.#1F2-PY$$R7AEYRL8,W6RJQ9>A\]2<8]#2AD._FM[_,V>-B6AH$A!BTJ7)
M3P8GK0:C0C)),6J=W,.1W[1&BX]&U3'8)=]?FN%=C-9XOYJMO.340 N=-0D<
M%+(56:T%&*TS>&UB%(Y062<!^$3[Z[%53E=8K&EC.P)&*_KRJ!3D0+8\9L=3
M?=M^25^&HU(K\HO#CPN)HGR32\@^"%3:\A:-3EZ.!&2P$LU7$M3+:DK5"!-Z
M[-]34_,:X>Y>$/O#J>?VXDGGJ:#:4@@Y)A R:O R4$#)!ZG0WH6*4R/ZWW^/
M/8->A%)V ZQ&HI.5:K5[4= <#=.)E4X=$011$<U*)J"3]B+'G+W<K37<]C5:
MS#0Z:71R+-];,>==.Z$K?+ES0I,13,8L($KJ0/!,,>;W'I(2G$F>(EM_RF\X
M.GF\O_ZCDZ.Q>(KHY$A@M*(O79U2C]GQE.M(!R@V&C)#YEA:QLTF"=;I!&C"
MK+*IW*KIYGV>/3?=?_111;/. 4+GWO3@8T)I#0/R8L['^>%_$6;#WX:S'R?H
M=;#+\B=M<; W/]KH;!")+D=$ .XB!<&< &=< **C"RD3PU.5@>POI;.!(LF+
M("P$$DK//F7!.\)!::M#$BD'5Z>D^]^=#?9$;[W.!OM@H $O:T$Y_N5Y02_E
M0F$P'H#FI$ $D\$+9\!0)G4V*OE4Y67C 14OI9O 7D@8=R66!C!U..-^;GL4
MBQOVSGV[RT=TZ#NI'!40Z1.(& U&+]I *?8@@E.2V0D?W8[;3+\(/P);G8VH
M[$C0#8!]S=5;9K@:2QTWTH/SV@+JNEID&S(O/ M1\&"J> (;J6D\,ZTZ2,9=
M2ZP!V'5P)QLQ#@V$,; D,A!48H :D@=JC7):ID#Y"2\*_X@YR<=X""<&0,,Y
MR3OL^?*?MQAY7XU0\6_G<GD_^YHFUU_=:'F5\VX\^@W-0HIEO.2;Y7C)Y$)P
M!AGB9(H@I$&3D,7\^<*:Q%CTZ_/8>E:0@[;9^.G0,8R[TJ+ZB#KG0V9W[BS>
M*P88HP=GO0(,U3,([S@XD2V81#!NSSQ'VU9]S+X[/%,M.P',3Z^1!V"N]PEW
M]=FS&)1V-P%J0*(@,EL#E CTL$E.X'*2D+@+1'+G4+;GI9$/-WBF10<O22&/
M0-R+/AQ_G<OOGB\J,%XZ,8%D#B-311QZ.EJ"DM(X:JSSOJVI]7MN\$Q++UZ2
M)AZ!N/TUT2XT<32??M7SQ/IG.7,_(>Z>.8S&$"57(#4I[_K"@<% '@1G5$ON
MA9/UTF%/L\<S33=\21IY'.Y>N%*N>_(*^4),)A"+] 2:+[#&E"I_;:FWC"MQ
MPB;1?46/)^X ]P=3R&,PU](DQ+K,64N)FWOXK]&BO''#R7P4WJJ@7;8Y)_0K
M*,H; _",+$R10@XJ4\L]I>K,0LR#^'"FD>C97,!6P^2+#D)W9]] :9DS1]O'
MI/-HIB,&[K3DZ=(8DY+,IE2O=+/GS;_X>]UZVM.@)=@+RG^X.^'GV><\"9GD
M<EV0,$;1WH-7)( A7G.N@^'FS*ZJ]N3 F9[E?RAS4!/4+]HE>'A+^#SCC+99
M4HJ.8,0X22@5D'$1O_*&<X:^8<HGG'#6 P=>_,WV"[ &-4']HJW!\H;R%E&]
M@U^5J/-..,C)I>)7*3#6". N:^^"SU'5JZ?L??LO_C[]!=B!:G!^T49@C]#*
M:Y6DY1QDX!($4@D^\ @B)"O+8'":JQ07MK#Y%W]__P(,0"4H=WKW?]KR[OL-
MC_.<A17'UF]=ZA1EV[OMLXT2;:>B$R)QR%PJ$!:_\H124)2;&"5CP5;)2>^Y
M1/M0K;\7[<5T>OMMH>@?A]-_O)FD=#7"$Q8U_B-N8$!BUBR("$28N3-?"HJB
M V58)LDR2M0)^RIWN+.S+NG>!^V=G115,-.*%^B?9XA?9\CC-G0[MWBCS.0@
M,@6KC2[#V!B8TJ:.42HBB40)6B\SX[1[[??JMV]%:QA7YUVZMLD:K;'IUS'*
M>'B#[NW<+'$3>"ZC>A+G'@0O Q!=,$"-,"$0QS!Z;?XH>W*+_=ZK]JUJ[:&H
ME<.M*\X4"8]O1S,,6#^@-$M8B$;HKFZ\_(T!,T(P7W)>E,' S\L$QC *R7,E
MC1?,K3?];%#)GM]GOS>7+T73.L;3.:O;H6^PE'LK6 +I7$9K)"DXQ1-XQAU5
MR3-+VJH/K9@^4.V>\!S5[01X:KHYXU_>OWU]^?'3Y7]^OKK^V\$7<P\_I;L[
MMR>HZ^@Z;7&M>X]!KJ4Q-%(@/"<03&=P0K+R1&M]2BQD5>5Z["$91UO7TI?F
MZ_@&U7VZ^.1WXUGZJ9[7R+Q?\!_\8Q"H]22BDC$B2A8ZXACW:8&DZ"B5C"9;
MIX?+KA3V>_UT!#H>6:@J,CD?VW+LW?_&#ZMD:6K>WZ]!RCJ,AB0G$#.=C\G5
M*&REP; <-)6$>5,E#NC6X+RZ<=/I^_Q?KARXL_>3C^7\7/0HRCJDS+("9:0N
M.F/ 1B' QT0<#Q&/SBH7X]M):LJD["/_=9/2$=<;" =^740T\X:"U@1.B360
M:"BWXMZ"L<B6;)SPSBM/ZV3]K=#0+T*Z$NNX&QZW X]E[SZ6:4;GVX&+I5Y.
MQ@C>8L1@T/7VEEI"?)58[@$5_4+D8%ENQL0!C&T %5MBOGE[/-2<\#6]OY\8
M[W1P*1$/R*TRNLLX,,)(,,JBWV:B,?Z4UVV;:&P"48<@8;=0_&BQG 7BKO\U
M7FXMH[L> AIHY;0 $1D#DXT ;6Q@1B='S"EOG#;1V.^+XRD1=YA8&D#<PU[+
M0446B0Z@+0WH+'()+N/Q'ZSGS"4M-*MBQ?9OKUX--96<H\/YW !(GKW\/*1#
M<C*>2.\2;EH9$"JC5>:$@S/:24$C\;&?5^ S[Y>^%[9.T2]]'T$W /:U[MN?
M1\/9]..GSTOSKH-T0>D,B@A2>FG@9HP)0')F42M%I:E22OXD58W7>%<'S=/]
MTX^08-]#/=?'-(WBRABPZ7)#/*!J!Z& L,(J[2)8[PT8;30U+K.@=AOON<MJ
MC=</GPIJ=:33@/7[Y78Z'*7I]"+\\W8X'<[96TX53C*>'%&CQ^/1?5:&H/M,
M-21A10@DH"Y5*8[90D^_"5:5?,0N>-\HA,J7DW2O<2P9FSW&8F$^Z+-DE820
M(!K-9' "W9<J-[#/4M;O0=J)_'? U.'"Z/L\_,OX6_HTOKE=-;!!ZZBLCJ!"
MR93PQI8\P 0\6R,PKJ=)LYV.OPT?WAX>CI#=N$-&]@V$Q1G["MEX60H>OD^&
MTS2]&H4_+?=B%7>%8@B*"W3R' 4C,P'%D@@^,Q)8W@D4SRS4KSM4$2!=,KA'
ML$PGL\%\..[<D'J2N?&4HZ]?;H.M]N"I%H A058J&,+-+D_%^*$K9PY^MW[>
M/%BUWPS5CEV5P_G9 @CN)FEA^)>T)V!"F:2E8P#CE01IDF$V>4;R+FT==X=!
MGX?)$1);E_D![.M9ZG\=CH;?;K\M"6<R$:IE:1@N\8!CE( U:!&9RP1W[[G8
MJ4_]3G)_L'+/DC]$;N,NF-BW]-WO*X27UM2:L  NNS)]5W&,P6F K&7,B6=B
M;6=:_V#E?GR$SJ1_,!,;"$4_(9_G]T*+I*AR:30>S7/"YXD-5$D7>7&.K %!
M,:ZR3J /HYBB/OOH;)U&^4]1U6^&?:6;C>[DT "HUO:P]+2UR :=:E0%59J"
M1W2-K;0<G'3!4>DCCU4*B3=2T_.#0'?2'G?-^@;P@^1_&X]61[M:G4BFC (R
MPY;!0@ZL#@&_<HI85BZ-JSR[/Z*DA<S5HZ2[GL!Z%*L;P,KU)+GI[>3'ZA88
M93EX:X'S'.;M_,&+5!X8LB$Z2F:,J(&6#;3T>_W1/5Z.97<#B-EX@L\-+T''
MC2H7(<HLT/#R8GAY!B,(^NW>DEPGK74K13NA1YV9J],-_UL%TE+'J/>4:R:!
M2Y4P$N3((*8$<"6H]2PQD:HX.T_0U&!*_?Y2WP5+!XB@[]OZ"T:H7N[B[K7!
MH+_'RI-X8KH,4R0</)[-:%O+_;%A-(NU!^4M-_0;/KQ!+!PBM7&'+&P! G*-
M?IL"L9PIH/-9!E*CA4U4@19>&VE9E%KN# %Y  1.FT3:!02.86$#9\I]9+AD
MT")OIIA)@SZ;Y32@7T[1:V,N@,VNU)Q()@61PM=Q3K92M!. ])DY)]WPOP$@
MK=*_U"N5N'7!2]2F1,L4A%*FY 5HE82RDCA*JB25/":ED=N7XV2\V14YE.$M
M0.;170!700D2+<1<WC.HCV DU:5"1$<=762Z2L_WQJY=CA7MLW<N^_"Y :!\
MNO7381RZR8]/[B8]4" KE9->H:TMV136HNFUP:/]I500H1*Q=7JP;J-H)^"8
M<SND.N%_"T#Z27Y)-WZ?2['8U,T;:MU7I:$'7Y[BM=<2!!<,C/$),E&1&Q]M
MJG.7]SQI/1]BW6!@'5G="J3OF.K#K;\9AO<95QZ.OBR-+;4B*^LD$/POB,0Y
M&G$TN[ET2/22LL3]3D'5ID_O&10=BV_<)2_[!L.G%,:CB JSM@<,*)E6PD!T
M)5&/B'))0#)(20-U7"F[XSW+E@5Z+@BI"(DN.-HC*F(:#MZF+^[F<C0K#6$6
MZ5\V.!H4)!L,B, S>.\H!*$E?D$H(1LRH*9WY\TTA3]]&?_V'_C1BZ,&OU@_
M838LNQ-$[)EX*<>RM6=$+*A>JD8VT:.'CULWB9<Y)VC?)$$WGV7K:2(QN0W^
M[-YP6%VSGQ/D:*&-.^!@WR?$SY3NOR1W,_MZ-0I+BR9T8"8B [BS&;=2QL5(
MZR S@];31!G<LSW4GEZB/[$?+J[-Z?#'\*YO!/SEU9\GX]OO?QG?E%[VTZNW
M;U_=%<5F)ZP.#IARK@P,DN!3%)!Q5\EJ3I/?S4O8ND0_?D)W".B&=PU$I:^3
MG_V<,K5(R;(L1",):'1I0- R,I)'"S1)A+*5G+(J1>V/2=G-3I S\14Z8GES
MH%DMGK:&2<(EZ* B"(TADE%"@^+<9NH53^0$T&FE$\>Q@GX2-P=RO>]#YQ6N
M-YQ=?)FD187^O)ZL#+2=C?'PL'?'J'=929\A*PS0A$@>7"($7$PQFYR45;L=
M0#LMUQ)*#A7KN"J/&[ Y;\>C+_AIWPJ[[KO;9"^,4YR!]*&\3,0(AF)PS[-.
MCGJN<IVQ%IN(V0U%Y];&\VBV-PB=I7Z1D*)164.0"G<A,=KSTAA@DLM,;(Y9
M5+EMWTQ.OT;H>#$_@YL#>-[W454:ID\_N!]%A^YRK"A3FDH.NM3#"\D#.&I<
M,<[*!(\QGM\M-'[\V6W)_Q!QC;OC70-&8Z,]?3L<I:M9^H:.7) NRAR!<8^'
M<\X>+,%83]K2V2=8F>LT4G^:K-U =&[=$CL410/ VCR98?[33]]OAK-79;#S
M9%H&V13)T8'4%!4'M4[KTHE#<@^&Q PT9TE8,)3S*D'5OH0VD;?2"4AVFJ71
MD<1:0>35='J;XNO;\K2U&$LT;YTV?9?^-?_5=%!:)[N$BNL]P8 A^%+Z8CW(
M+)*2W 5>I]GA;N0UF.+;(?JZE4X+F)N3O]C6A\DP)-S5_&?H)T3NB7# #$GH
M'>0 5DD%(:$CHA)5J$I58+:-H@:[RW6$K$YDT "8/DS&(:4X?8/<*]MQHY#>
M3Q;9  N#/9!)162.*;GP"H1/Q?_P'JBSD3CELHR[]'O8&U7/D]9@1Z!NX-6Q
M5/H.!U<R65=&0*/*A"*O+VG ,%:FS)2$:H<6F =6 AP-E&1J-74RKM\G;+NT
M?&:E!IM"'(>8[OG;@%'ZF+XO1TZ^SR6L'E@3$='H"T9%D7XF$>S:EUXYD;FL
MF-:B2IGD.B$-%MIV8W".XG@#B-G(FG>WY?;D??Z4 GI_LV&:OG(W-RG^\N.N
M^&OY%Z<#1GS(S#GP(99DV*C!E3%?66& +;U-WE>YT#R2[@9KJ[K!XRGE>3!\
M,7+UXXX ?+>#BU%<;&'%D%^GR;>!(20&YW1IM6%!.(>!<0H.- E2*BLRH56J
MLIXCK,'*B6X@V*E$6C61E[^CDS"<IGD,<__+>SVB@\"MQQ#80[#,X":)*!.@
M&%"%CJ9-1BM:):0\B-H&\V,KFL-.9=< 0)]2N$$T(KO2_9\&A]Q3093^NQX$
M1C^>,_PC^E.;OQ9SK.K;OKU$T7OD67@TON/1>,&CG_[#G0K%07FN]>6MUGN-
MNL*51]<!W5\7B8A6ZTC7QPYNBT!W7+'%G(<N0M$:#&_ .&WDUZI6R*24D)2#
MY )=@EB*68C6B!!T1&6PG+C3=?+9VTB=X^U^IR)I &+/SN39-I)G]3+Z:K1X
MXQ@XHKR)Z)@F&TN#671,+9[[H*-APNN4< O5W@*ZVL5NX#W;!X1>A-U$N#O?
MQ=QQ'3 A@V*2 W$&:<_)HI:&!"H$EQ1G,59Z&[TG83>4G>,[PH%L;L 8/DSM
M7:0)S(;^)ETC!J8EHP!_-D6_8C;\+5U/7#'XK]T/C'JL=)QPS2!(7\8V9HT;
MC028PWB<)>*D,C7P=##%N\'OG!XE3BO$!M"Z\@#SP4W>3^:M@^*O[N;VY\,P
M8UYSG@3(%$N6 5?@G=$P[U:F!*$YU+EB?IZVW1!XCN\:70NF :PM'( /;AC?
MC"?7[O?_&LZ^?ET4T^$/-OL5 Z$42TYDB(PHW*-PX%/FP#WA-%NN1:AR?7((
ML;NA\1Q?-:J+K@%X7L2_WTYG\Z?$C^FF:-OU>->M,D\(9<:"%*$4EL8,AC@!
M(8J4LX[.A"HQ]!$T[P;6<WS_.)4@&\#L@V[E"R4="!:9C JWD)($H:PJ;=8R
M!&%*)YL<#*_2HFP#+;MA[!S?-8YE?!.Q[(>[E5=VL7H-95-*)N$V$DFD-#_2
MX,J 9!>Y82DI*FP5Q^\9NG;+^CW'UXLN!=*9=?K?__&(S[C;?\Q_-?]-^5<?
M4_Z?Y;^?/UX]^/QRM1XFP^]_"N-OBX__>/GVXOKR]8>+C]=_N_YX\>[3Q:OK
MJ_?O/CVD>SK\]OWFV;*JK9_U'S^I6Z=[^9&/('$HI>GW61K%%/_7L9EC\Y,*
M??W9CY4.5M,+CU$H?CW(A! ;%2V!I4-O*A9OBGG I9/0GG.Q/L^TJTRRIPD[
M/F5N\^>_'D[#S1AM;+I&%O^"_^0?@ZB(]-8IR,+;XE%Z<"P'<"1&/*6Y)G4,
MTAXT]EL0TRF*'J?:U9'4N5FJUVGFAC?3+@W6W4=6M5L;Z3Z5^5+*HA^$/C6/
MI?, EQ:<4;S<XAHMC$M"5:F=K&V^/H6O*=Z6]/9M*_WRX\%O%I61CNI$J8"8
MLUQV5Z:. /-"(YNB(;[.&]<AU#9NTO9!UJ-[C>K2:R!(W&UK\^I_SB@UC >@
M-&+X*Y@!BT?&O%1#66NBT%5BQ]U)[+G_;'V\['CH'BF\QF!Y-[C->!492X#!
M#*JR# )<X@QRLMQ)SP4-NXQG/@I^+73FJ"7T)[!U@ 3Z3I'[JXO#Z7CT.KF)
M'T]&91LC_.1?KWYY^Z</?[KK0.%D3C1)"-&62QF%#J]G&<-Q:G.,*D5.GO/:
M=EZM'=0<(LYQ3=[V/@A\Y!;I*4O:D?!L8Y! Y;P?2<Y@I:9@>6*X*RYEWJ4J
M8<=9X \7[[=LO2.8',W5!HZ@O[J_CR?#V2)A:='LX0[:EC,>E<' N&2@6\[!
M<6%!2Y*MBM*AD:UQ$FVEJ-^"](XPTRW?&P#0J_'D^WB"K/F_X^%H]BMR\G9R
MU_LH"T<3QZU(&@.>S"5/.)<Y;5F0E+FFSE4:Z;R5IG[+SCL&45>\;P!&6_R]
M19-REI6D>+1F(A6&MV6^GPX6%-I3Z;20T;#:/O$:33T/?&@E!MM;/.TB[:[[
MJ'.>\LA!!(G'M]$2G"DFV'FO!<89R52IF7N2JG:<ZJ-DOQNF#A!$WV'8S\;X
M%^&?M\/IL'Q[UV_6Y&2<L2CS7)IB:0<FD0@Z!R7GKYEAW[$"CQ9I$A^'R''S
MM('CF-HW.-Z.D25O;LL+PYOQTLF;?AU^_SP:SC[<3L)7-[T[LRWCC)I,024;
M05 JP1 =(&7)M381?[];*Y7=UVPG$.L0.I58WC>2%CV$YCU&/Z:0AK^MM!DE
M@G'B30 6RUA3+M&-#,2#Y)S()$.9,;D3=)Y8I)T K$.L=,74=CV;M_>).40K
M+]% @B:E61ZE#)S5&3BS2E%OG4E5RG6>(ZQ?8#7C31\FJ : ]_HV78]7-E6Z
MN]Q."N\O1O'=>!06WPPR-XYFGT$R3:",J02G0IAW-M!,)H:N8PW\[4A?DV[4
M@:!8K^:I(*$&@/<IW>"OOOPYC=+$W>!6+N*WX6A8GL5+6=+E[R6M.0V8TEEH
M&<L+$=KQ*#EXRQ6>$"X8%CU:]CJ]-7<BKTD7K!O859!/ ZA;R:Z_'E_$.(],
MW$VI#;G"@.7[<.9N5MK7OO_7:%IN>=^F>0KK2IWP77O(5^/I;#K029&</?(X
MEXX<5&IT19'EA"?%<O0Y;9I+V6D%18?;:=)9[ ;5#<B_ 2VX>Q!=;O@BA/'M
M:/8QQ?1M'KF7#;FHO* @59D*Z)DK,V(-H/=,:.0V:UWEWO99RMIY!.@<F]U*
MI0&8O2ZGQ=#?SF]_7$0WYNWPVQ#Y]W;H_/!F./M1JI?<Z,?]+,)7;OIU]5_-
MB_8&T1'II;'@&-4@,%Z$TF$+ B]G3\!PKL[%;D?T]]O\MJYOVH.$&P#V:MO6
MU;DQ \<C458Z1)3%?5#NT?U. 0)E5#&27)!5'MZW$=1OX]RJT.M$!@U@:;7G
M^,8+K8%C9=:KEKBA4C=EF0>/"@'E9TX;*[FMW@A^(V7]ML&M>Q9W*I4&8'8U
MGZ@XG2WCME7F#8C+Q@A!()>D Z$M 4NU!<^3,3P*DIFN ; G:.JWO6U5:'4E
MB09 M:83#R^I!D1%XY5DP)*CI0\<,HDK!E0SH0)S*M9IS?<D5?WVJJT*K.ZD
MT0"T/J;?TN@V%?N[MI'(M,S">^"Y-#G($@TO31YRM-1HSC(J41T?:PM%/?>C
MK>QE=2&&!O#T>O,F HL.-0!P#WG1P,^XDI80@H\R&<)9E7N[C=3TW)JV]B/&
MD>QOM<[VT^7;RU?7EZ__\_/%Q^O+CV__]N;JW<6[5U<7;U]?7%]\?G?Q^?45
M_OKA-G:KM]WUHSNINSUH'QW5W_[G+0(B36Y^O!F.W"@,W<W5*(\GW^;;^%F@
M?5\TZ9RSC!L)RE$)@A@%M@Q-(8K)Z)QDE>8@[TGGL3;KR>5^5JOSTHM*$0(F
MT>5(*HQ$4*FHM89EC5:YRO78;N3U^S);$UGK-JZ"N,[<Z,W3+0YJ-;#? J<T
M@)OVU),9-#1HREP$IDBI$[ 4#V2"< I"VB089ZE*W'YB,_@SR>=I#2N"^:EF
M(28:A$'_5&>"H32Z+,Y0!TD;%JAB[E%"9M=-"O:@]KR,Y#ZXV]ZSH)8PS]QF
M'M&?9<\53FDU:W9OV1>^-C)&B>! 120ECBDC/!/JL@K9FR"-)B_!;*Z$[J_&
MH_E'EB:2KVZGL_&W-+G\/=S<SI,:IM.$_X_7[O>!<2*75Q)(E)=N)#Z"]28"
M,5Y[KW-2MM+[U=ZTGI?)W =S3]S!5!%D$]T<_SP93Z<?)N,\G TT%QD=9 '2
M&@O"IN(K$PW)B!BSC-+7Z4>[0D._B7VG1->AC&\"->^_IY*../IR-<(3*;W%
MK0RLDR%Z[T'QY$!(J<!$Q'^R3LEH;-*R"GHVT-)O(MTI472L()I T[LT6R'?
M2!*CT@H#\])LD!H#Q@<#!%5$"\EEK),"]X"*?M/=3HF@PYG?P.O"I9N,$/S3
MN^$&O[CI, QHY-H8%'(6F99!D!:<U@(LTD]*>G2(52[F-E+3;Q;:*9%TO# :
M1-3KX<WM+,4!.G$IAU#Z9)4+2DX5>,(S[HHFIJVVW%09L[.%GGX3S/I$U2$"
M:?9JXO,OGR[_\_/EN^O+7_&/@[I9/_J,;JX7GJ2LHPN$3[=^FOYYBQ1>_E82
M"N_Q$JPS*A67)?L$@GD.ACL"W$9O?&0ZR2K#O[<1=/1-ZMKG_KQ@R\9:)24!
M&31Z_AIUQ 5*@%%!I/;"$%?%K&REJ.=.F5T@XM'59R?</Q<;<LP]YI:/JF)1
M:MY,;H<192(0(X!:AS!2GI4R3<22D%FHS+2G56+4$QF619FUY$HHQ@4D/&Y1
M5[@#YQG2Y'!_(H>2)'N"33;0!;H3'#QC3O;G>0->[OH>\)_->Q-)3@DU";?A
MA2SU(!*L(@S0&-*$O_'Y)/IQ1T]3Z#E T,\@YQ"NMPF>94>1$*06J@R^\CR
M\#&#]85#1F6#/W=254GKVTI16P Z2-[/8^@ YK>'HF7[F$!=9!P-<\@:U<N9
M!$Z7UH[6TAPYIZ92]L F:II#SR&2?AH_!["] >P\'+0[URF;B0@N$0A.V=+1
MG )J6"EL9,1QEW-.=?JD/"*EYSZ771]:1_*Z.;2\<]_N]$AES:)S&JB,:(=M
M-&"DMZ"U(U8FHF6L8FRV$=2OO3E6T$_BYD"N]]T^[A6N-YQ=?)FD>?.)Z>6\
MABQ>C69CC)OM7?MI1A0/2H,K?PAF<4=:)(@Y):HBM5:IASC:TDANI^5:0LFA
M8AU7Y7$#-N?M,(U>N5GZ,IXL)FYXR;GDGH,WI5]/#J7'/?[AJ'<A&>9#G?>#
M=4)Z[AO7]>ET%)\;P\E2D9B(I1I50F:E-Z,* I&> EB>?8P)#8:H\GKYF)1^
M+<UQHGT")P?PN0&D?$JCX7A2]K&TB%QPQISA$%F9FJ%4N1(/9:P*!@0T>4-I
ME3R)=4+:0<DA@GW4?>T(+C> DO][NT9_%)EZ/"-!TU+J9\KS.[,*C.-&2>$=
MJ9--LTY(OU%1QR@YBLL-H.3M>/0%/^U;<>;N;Z6(9#$&%2"2$$!H9L%[]+"(
M#28XG:6+5=*S-Q'3;_I5]U[*L?QN$#,_FT@SX2(#ZFP"02(%ZUD$DJ7/T3A*
MHC\%:IKP6(X6\S.X.8#G#2!G<:;.NV3<#=I!NK/PZ+IYE*S07&.LB,<K<Y(A
MORC/E6YYUREI"R^'B'>C_W(HK_N^;EGM)W9W,ZV5D]X*X%(A,W0L:5Y9ERLH
MGG1T7H6UKB-;[E8>?W;/+DEWPN^"=RW8"63^_ KHU8V;3M_G>3_8N0U5Q 4:
M,OI3MK0II%Z"M?BMI[@=5IH55LIHV$91OTF]W3],=\+Y!B"T2O]2H:RU+(8D
M\/RU'H1T <]?CWPA$KU_U %%5 WL/":EY^?$;F2\/D[O.(:W )GQMV_CT7P#
M2[/)3,I>6HN&5V$PA__#."YQH,Q$/$D56M0J23"/*.D7,,>*]M'@Q6/XW !0
MBM4=QJ&;_%@TIORI0%';; 4U('EI\<:#!JNS!^>T-I)+HUR=F[AM%/5;'5 E
M;^IXSK< H9_DEY>S]_GQ4"94)"TP,H3,O4&E<*41#DH?E84XR6.*ODX&WK.D
M]9\-TP$&UI'5K4#ZCI\^I3 >1>31^XR+#T=?[H9R1>-)R>=A.C,0QAIP D,"
MB9PS"O?!U&Y#\K8LT#,T.A;BN&..]HB*F(:#M^F+N[D<S8:SQ3-:-$ED)3E$
MQ?$0CZX\J-%R(84!HF196[O!(9[>F9AI"G_Z,O[M/_"C%]8%OU@W*AN6[;=G
M=6='TK$,[1D+"ZKO7D""3-HF4ZXB2V6F9H >&07/C4:/CB,7-APU>P-A=<U^
M#,710AMWP,&^SX:_O/KS9'S[_2_CF]*S9'IU/QEBX$G2-$4'B4A6DC\#N&3)
M?*9.UL')$,A.I\/6)?H3^^'B&G?.NQ8<T(=V\.U]C]F4@K'E68)&68;8>0_>
MH55DPF;TJT*L->YM"T']]J&O7?EQ&-\;P,_#[+\W+J2+;V58TL!:;Z7C$8(J
M=TBL3*+3(D.F02<,\Q6IT\!J&T']!RO'B_O)A-H#>=]$OY>'.REM(J:?D!H7
MWX]^=9/AO(F^FR4Z<"QI5;H%B%!VEH5?Y)1R;1VW:+I]JM,F?$<"FTKUKX&R
MCF33@.5:'5M4]H@17$@:XS]D#7H$Q1<$)W,&-..:)*.(B54N[=8):2HAMQL,
M'<7KOOWD94N3T9>?$ST^3.XV]"&-W,WLQR!F0S/2#4GP<N<D A@?#5 CL]9$
M:IYWR_C?9;6FDJ&.0T@=#O<-F8<V\_KK<+*8YO FI>F *\M-0&=1,*TPT$38
MNR P\B#"QQ"2I8KO!)6G5FGJ/;H#B'3&T09.GH=[^3QRW\:3V?"_4RR-DN8.
MG(X< XB(;IO4$H0)&8RV&&-(RJ4G.6I:)?/R6<J:>D>JX=\<*XWFX/4A38;C
M. P?EM9T,D1+^]W=# Q1GH8RLU;3<CU1:LZEMJ!=BH$IXP*OXN[L1EY3M\,U
M@-:)7!I V^I;RVVY <-O2E>VZ6)N]]5HY>UED+7,*B8!F91<-MPF:I(SH 7G
M43%G6:C3#F(/(INZ:.H&>=5DU+>?M9)"\OYV-IVY^7!X5*U09/8E#0A+N"9N
M1ELA,# U'ERDMMR$..&BYTRYG7RMYU;J=YIA]_Y6IYRMWREM^8ORAW?3]'_^
MQ_\'4$L#!!0    ( (V$:U+VF.8V6A(  /%(   <    ;W!C:"UE>#$P,3)X
M,C R,#$R,S%X,3!K+FAT;=5<77,;N;%]O[\"D1.O5$52I"S9ENRXRI)]=YWR
MKK<D;9Q]N@7.@"2BF0&#F1'-_/I[NAN8#XJ2DZK$HEUE6R0Q0*/1W>=T-ZC7
M?WCWZ>+Z]U_?JT659^K7W\X_?KA0>\/#P\_/+@X/WUV_4S]=__Q1'8_&$W7M
M=5':RKI"9X>'[W_94WN+JEJ>'1ZN5JO1ZMG(^?GA]>4A375\F#E7FE%:I7MO
M7M,[^-?H],W_O/[#<*C>N:3.35&IQ!M=F535I2WFZG-JRALU'(91%VZY]G:^
MJ-31^&BB/CM_8V^U?%[9*C-OXCRO#^7UZT->Y/74I>LWKU-[JVSZYSV;O)B\
M2$Z/ID:?GAXG)^9T?'2B]=B8T].71Y.3E_\W@9"'&"[/E-4Z,W_>RVTQ7!A:
M_^SX:/3B9%F]6MFT6IQ-QN,_[?'0-Z]GKJBPGL?S\J-,<V>RRGRIACJS\^*,
MM[0GC\:/$Y<Y?_9DS']>T2?#F<YMMC[[X=KFIE2_F)6Z=+DN?AB4.(9A:;R=
MR<#2_M.<G4(Z?K42B5]@FLP6)NY@<D0RO__;3Q_./URKR7@T.7KZ9/)\_*HO
M]]<EWK+9;[C-R?AK^YR<T#Z_F*0FN_JK\24,]HZ\_VVQCK>*]9>Z,.KE .8\
M.;U'I.WJ?1QQ+VVR4.],49BRW!&18+%C=>Z=3E=ZO2,R7=6V,@J&N"/RX,1N
MC1^HBT_JY1B1<[<M;?R"1=9>D;D-O@-A/QNEO5'+S.@2(:9RRLUFQJNUJU6U
MP =.4!)OJRCR-PZ"+.?%PIJ9NJH\$':^5I]F,YL8_VTDVJXYI2OU:<FZN2 5
MOB\JXY?>EJ8<J+I(H412(-;1<\/\ "K\BUL4ZE*G)M?)@NR:ALC>),S;6Q,W
M-U SEV5N162"AB698V*!:?BERZ>VT/%P[A%%Z2)5Y]9=)=XNU3X]^/3)L^-7
M/QL_-YY_/!BIZX4MP\'CA\05*1\Z<9DE)J6GY &>CFQCY>HLA<JUKY2E$7BN
ML16#F1+>2O,XI(6-16';"4?JW&"/;(3T+@3/213E:B\2/7UR\O(NL#^F)VVW
MT',XD+K2F?;KQS1+5I?ZG=17LC!J9;-,3<VCNN\?GST?#\8MJCR*PV: ?J6A
M#+U<9C;1TPSVIK] 0=5BX;(4SB7^,C6%F=E*I2:M$[;9<K0C\?IM4=0Z4^>N
MJ$MUK>%"5>?$M7QJBP3QAOS/+9?.5W5AJS6BB0\AW7?]D/@;XK\NU)J "V&#
MQKFNTT<+6FJ;JF7MRUICYV%,'@+#W!L.<^31<UL4%*I(L_>N.;-E F%YU7ZD
MDV4'$FC"V@8\W-*)T38@;-CJE!51L2)H]A<G?Z+_IN2,P?[W']7PCUX\NN$?
M#'"JSG-N.F68QTFL0X"UB84:)9"G&#)@#PA1N]0Y0K<')?16*XW C'<16$Q!
M1F(B8I4; $2 8LH8S)L3O-59S4+0"JFA3RUAS'0M, B(,$4IB(87N:TJ WHR
MJP*4!L3X#K#@_3]J\KBW*^W3L@=@CQ+XWI9EG4?G"OXZ-=7*F*+'&WI< 8 ^
M [_(L% Z(+)##\^L+ZO[3NIG X#'*NV)$64QT>DK*KEHCJ=]U]:D)C(+]='A
M\6O8A?K0A+#]C]<?#I01C<X]11X0E-*6521#T-401LBO+_&_MPE9V57EDAOU
M&V)?*8'(FW()7D*!JZCSJ2'[5^4".V<#!D7)*=3S8WC=: *RC-1"W_+>%%FQ
M>6PZ_,>CDT</*]$F2/^D#SF;EF)>V7DQA$+9"R+39)CJ?2)F,*NS;*WH%&/L
M$5-#F(<1^)(">8\X#E193_\>CA,&@=.O<>@&--.MF6Y7"^_J^0+CD/E3:%,4
ML[3/+%DG!Y^&/7,T[#R+D-1U##(?5\/P=5V:@8R&U6 ;,@.;UX_.I; _79)]
MNRZF\?C4: S"^^]LJ:<V(W/>-T@#**ZFX!L4"JWL/8,?#$G$#I0S1*>A1EA"
ME1]8;'7KLKI ^,8!!YG4S+N\":FZ6#?R=T3L SVX_I"!>(N^(7C6)A]>J'I0
M'T0F/ YZH=&75[^5(3N8,EC/#. CW:VHO=V@?W2T0XA,9CEX")/89".>\4!0
M2N^@4GJ-@"4Q3=BDH" 4S:5$?LLB09O[^*QD<@2$5#EFDLIC$K%BTTD-KXW.
M!:$)B UD-2$V(UR3(P[D XK>A5/S6I-3&O9/')C-ZQRN5M48(>Y*^AETK(SR
M-!@#+(R..D95V0)V>&M30H.%6YE;25]U0P3-EXH$)GMCEYN3.H=!G3& DPOR
M3T-A(E%/42"I06S;--DZ@C44OP17 6U9DOYZ,<CS_^4@NI'.74T[@;Z>/CE^
M\8J,MT(:<&NR4K08\G3>'KUN4E^9A-TS82Y93\&1H"--<8J@ F91\Q$&DDM(
M%S5$>V ="%_*#:%-&1VJO[/=\HS[JB^ZF!O2R 7&>I>QLCBF=T(*OU979!D:
M!J5^]:XRC/<[P(%^CX3#F\20[C4=[ *BD]62>TM.!>M$N,/Y/2J\/S]^^>CP
M_J_AL+("0^3! J"27S2HRUAHOBPAA2&K (K9(H+6N@?$^W9D1H/>6P\#\<,8
MS(C+CJ_2!G.YVF7N''ODH@U@Q7W=!Z\=LB!.CE!X5XB1^L55]"8%CS12<"S"
MP;$)5' 9J0_"*!M72X*K[3>)>^V7KC1-' DA=8,BA \#]!_T<?ZKI*IZ0#><
M_I/V(1SQ-=XM?GXVQD&O&['"#IA1\PY&ZCTG[\)Y($ETP6V+ ;A@+-!TR7%V
MHQ+)3&JE27I6%[!&FJJ=6<LF "TU'Q!#6:CIE)W2["<N>'XT514*F_1F&[[>
MQHH&0*.B<FT 72RU#\J6N]3.+!$@9EL$0*1DQF <258WQZW3U!0ID!<;X*[9
M9,)MLY<'NU)5VHSD$MH#W.:&RBT]7]O"F-GRNZ[:TM]]?<#/QV(:3*93GQFH
M_>F!RC77&#)X*GR_CN-2_$2 3JD;)7UL0_P.87F-8.#Y=8?R;FT4*)@ASF4_
M.>BY&#?:O_HLC\+#J6P#7N?%+BCSD+G@9#G76IV_ 7M/@IKJJ@0=:-2U<)PI
MT:R\@7US0"R-V#Z):+A*1D8CSGKQ_M.@0RF(:E%$FI.1%PX4B"VNJ_.XT$-Q
M<8O7-I2-X]"@?XS:9LQ>$R*-[:@RSC-IY^%/1;)![!3TA2'O;IH#%B0J)<8,
M3V?OYN=I05HJ++E;].B>HFR:AJLD&<RY#50;268_O]R6GP58F^)'J!'6SVK8
MDCDRZ:<G.>[TJZ?_3N(L7BQ\U$EN4KABZ,UM8\,]./E!E8JAC"B]-]PUY$B?
M:9LW)@'  L&?<?7F^.2@;Q\=I6Q4> MVM"8!*"EBSCAZK#O%[5[H6&: #(H?
MFAQ%P7%U* E'T.Q6F2'::D'W #8%42Z!K2&JQ(_S$/L8]=;<*<##.DF<3QD<
MFLIVX7RN*2=9(\1D)$4"[*(.8&4S-3D"3A2 _S;(2"5BFS)(^Q2AR@6GSZ2;
M9$$WCT@CT#6.[.+3^>5;P")AU#S6PM>-'?WH7;U4/R%AAW2_$AMHAM)L"WW;
MD3P^M%'&Z8G4-U+LC_(@F\(W2.-M49\/B+R9= WTSBTEFG0$*Y.1&4R.#H(F
MF/1 C<9W*S=JP4(G%'(:F<G&)50$9FGHA"GZ-U&1MI7K&Q$?<22NW4 _*377
M2+CQ5\3DZ17FWRGT9=>_"[M%X[V-DTN_IW&+N7<EDGTS!\<B@DWZQ2E!P\TI
M.L\5AT)BE,KA$B!60.- ,PO)TCKM&N-G9-=DZ?%T_^ZF#1R3QP5=%K<V"5;
M"]%- JX&UC:3?+^ &OF<#3$O,N8![VMF 'P\(O%D>_?>P]JXMQ;;S&>(/YJL
MX\Y-MOC@U%65R\_&[2-Z6H+/5_<_TKGS1:S:^/MOBG7_7?@XP1*&-9QZHV^&
M7 <_T]D*X6_O/W\;[W&,E7,W+H7GSE.FC*3$5G4:V!5;Q:UUV;:+"8P>4DBA
M1'!:4\G$9399"[OBATEW5#D16M+P0O;XLD$DRZ2>W8.SKZ;]V#0V."F%\W?)
MS+[;:'#FL<$)PX_U_H,( T$2+J553$;23?+4(N_*4VFPB,0L.&V8H@_W#??C
M_78]TTFO%<E57X><Y]09E[B\F=?]3^84T K)5"@$R *ER68JCG9@ 72/=-#K
M?;O-PXD%R)'ZWP"?^M;9-,:!U-73:B#:YXIU<S5H,X0Q5I#6:#G.^=JC@C-6
MPU \:*N"\EG2K;=J[XE<2QQG9^0*.=U1"G=#I'G8[3Q^!VR1-=12N6[,9X 6
MN]3<0"]-Q6QJ$2L%D8>5]*H8PB@]G7O;,&@K'<TU!KC.W-]?:/SFS=&(Y><A
M)=^AXF!#1V!DW4L'>-FM.MN0JT1JU-"31N7@7L(].+XQ:'*%H5.F:.O#,V\I
MB8PEB@%UA+K,*]=4Y5%4O<#Q)E[N43'MT;=(EZ(WTX H2JD0"D"C."7I,'XN
MH",EDU)]&KL!VTK@#4N]NZNM<L>V?SNL*;K0#D*JW$E<!@V!]:%DQX'8^28A
MBLED/X#NEI=OM_*KP*F.QZ=O']_ J>0I0!.1B<W9<+V-*PL]PGRG6-9<#\RD
M6L;7^21O'4AUC;+(?%EQGC-0'RA:$Z)=4K&@II-+J;;6ZJ0IN+5X)FN#. K@
M(&SE=3;G)B,7WD28?2@MDPH")!#@V9Q<NLTTW2 D;3!4<H0(^_H+M\)"RVI)
M*0_VE0ZV;+5)!*W<JC2A1S4-15HHPK*\+"-I9*3>$^@'C79UN#EE%;XQ G_7
MB/4X$XHN\4%RCF[-]\XV1^KM S4&685 >$I-7. HR\T8P_FN#]W;[AKDC'>I
M5EL*E<0K]$F#(:WC[5;.)KGGUJFXBGG1E0VD]Z#>I9Q9X0KJM$@)%63"L#A=
M_!=@Y&I*KYNN']AS7? EOSOYO:6+?R6BGRP>5$V?<%X.MT(:TW 7IGA=&-ZF
M?+&N;?KCU;?PU8Y54463^ OL1EK#(E<W]Q9A-M_N[U?&0(3,WL08WLD>']KK
M2)[=;$] ?MI]4X/D$C[5D.(EW\84!M0A"3VB6-/H"AJ;0JWET56?(-/2)'+R
M$:X>4KTTF8G<B"O=.0KDPOM'!_OG!URP*.)MGSD5J0+U;*PT&&WW=.CSGK'*
M'6@JW9)-_GOFNEW"IHKDI(I4QW;/0T<43$#,J94_BMKS[URGG!TTA1&I/S6'
M(QF-%5X1+\%0=>WM06C>+ZWO5?Q*^T7M/S\8<M6&0J1U*9U*R7G0]G+65YTK
M%+G.#WK/MO=CF@@=(G.HMJ?WZ76D?HLWS._N@&Y'<)\-<V<@(+*'@5"@K7#'
MX\SF'==> -Q?+4SH]YEUN.@B(97>7=F2^!!LL%LV5'1U)@L532Y#6D1#B"$B
MQ-L*T]*$1$N:IR3,0;<02>TW2@!M/H6 XE3D9KQ&5N=+6D%4K+G3384OVO\]
MNP4N=\"IW>.=)1NK^FH1E)^G<T4@:IP\0$6N""%M,5*?X:6&JW#;4+(C2)BB
M[ P,EAA\/ 11B:'MK3Y*SJ5ZJ9.*JL;1U.(LG4C3RAFF;K;?'>1P?AWRW2^+
M[Q8AW<X!^]_QX-P\1/>DZJ.*-"!R:!8$"S "SP*C[[D6SP.>TR+O_=^&8?"M
M.+\2O"Q<K!X(9HG%VK*;IG0+$V4GB9(XED"J:>PT;^G ?@_G$:[O2001_';D
M7&99=?G"QLG(%[44WT/@L%G0%>T0 FD1Z 4\"8JF=-:V\"Q*AO76/E@TIH#N
M B6]M5I1N,C"%4UIV=4^W'73R4WA5IE)YZ9M1'+8 X--P_>=RHJZC!Q]R(.;
M1LY]N>4=5O0]'!M_L4^M6,\6,:QM84D^SII#.$G"1>7*VZDTUX(V"K.2&V1R
MY\_Y.8C./W73?UN8;$ECI:LA#S#18'9-WIA8N69-M^C7.'^;4,HM09 :T-^#
M&C_3)5=W$V];-O=0.]]7H=V8+*&>.7\;T74NSGV$U<'@%G:Y@W?HMN_XBN[I
M4$C=\:^%\M=N^=94*7>G?J;8=%FGYCN0^VNR?O.O4\LW9?YJ^3JDH90"0H *
MOWP5;IO\5&,1^MH"HBXE@QO?;-T!?8X\]/GTR?/C5XY!F7JT([CE3IG#]E^=
M\*'%J/:ZK\#4W4*/!%]OINLNW TB)C>XM@%K9:=(KZ?NUH2RJI>^U"9P@OPT
MK8[<5D++5]07Y12. K^A2:D^Q[>VU[VKABPP(( E:CAVPK>26SD"SW[,$]K\
M'1YW[(M_A\<O8"_2S_ZOE$?_%2%><<LW-8F3[/&,C81&]<-@]Q=(J-Z?1Q-]
M[XUZQ#_OP"IW^.S"5<NQ_(:2CMS?\SV#0_EE0/QKB=[\/U!+ P04    " "-
MA&M2CU'T!\Q+   2LP$ '    &]P8V@M97@Q,#$S>#(P,C Q,C,Q>#$P:RYH
M=&WM?>E7&]>6[_?W5U0G[R:P5H$!8VPGZ:PE@QRK&P,-.+Y^7]XJJ8ZD$Y>J
M=&L Z_[UO:<SU""!D]@2MI/N7"35<(9]]KQ_^Y?_.#D_OGYWT0^FY2P)+MZ\
M.!T<!]_M/'KT]O'QHT<GUR?!J^O7I\'A[MY^<)U'::%+G:51\NA1_^R[X+MI
M6<Y_>O3H]O9V]_;Q;I9/'EU?/L)''3Y*LJQ0NW$9?_?K+_@-_%=%\:__YY?_
MV-D)3K)1-5-I&8QR%94J#JI"IY/@;:R*]\'.CEQUG,T7N9Y,R^!@[V _>)OE
M[_5-Q+^7NDS4K^8YOSSBS[\\HI?\,LSBQ:^_Q/HFT/%_?J>'XX-G1_MJ.'XR
M>GJX_WSX[/#9WN'C^&!T].3YDWCT]/_OPR ?P>5\3U$N$O6?W\UTNC-5^/Z?
M#@]VGSZ9ES_?ZKB<_K2_M_>/[^C27W\99VD)[\OA?OZ3']-Z6*D^E#M1HB?I
M3S2E[_A6\_,H2[+\I^_WZ)^?\9>=<333R>*G'Z_U3!7!F;H-+K-9E/X8%K -
M.X7*]9@O+/2_%8P)AD<?;WG(3^$YB4Z5F<+^ 0ZZ_\]7@Q>#ZV!_;W?_\0_?
M[Q_M_5P?^-U#[ICM1LUS_PG.\X,:54A8OZN\ (J]SWA'0$@J[Q[PP3/\]U,.
M^/7%Z?F[U_VSZZ#WVV6_CW^U!OV1&_!'591ZO/B9OM)I#//[Z?'1?,F>_(U3
M/&Q.<6\?IGC]:G 5=,TSV"JGN@A^^/[QH:7&SS] 7J98C;(\0B;W4P4KEN-5
MW_W:F^1*,:-9U_"^^Y769SN E9I%L0JB(LC&0:^:P"X'CT/@D?M/@N$BB-(X
M&*KR5JDT>!LE./*T" ;IN,*#$%RI_$:/5!'"5Z/=$"X/!@F\+(/GPM3G,GO<
M$[7)6W*<S>91NEC_AH2TXL>)'H^#%RJ'IP9;&[QNS!GUC5K_RNU^80QND,()
M A4)UIK/$)Q//$6SJJRB!'Z[46F4EGC.TC*"V^-@JG*E4Z*@#"[-@TF6Q?3Q
M)DJJ:)BH^B-#>F"N1DK/2[JNJ,9C/=(J'2WP?;=3/9H&4:[HT<@.1N_3[#91
M\43%?/<\RDL-L\8+RBR(D$,@-QEG29+=%C]\_^196REXN#N#:L^5&M&&[.\&
MZR+[O=6G<C9/LL4Z)0PNTVX07 .!!,);@Z"81DD2!(I&%P26=X0!T9[[PE';
M2,V!PI6=3W"KRRG1G3PU#*HY; 5^ ^K6K* G 9''9%H40:%*(,4<;M)X%8@E
M*WWQ>R9AF%^&8FZBTQ0M!WE@#,8$#05. CY6P5/A5R#N>9[=P"F*\:&;20*&
M1@_7.+[O?EV_V+_O00DNB C6N5A_68RME3.2W6&H[@#./O^SI@6%T:S:]XN,
M70]TK$\J%&#K&RAPRB](0*+JLA5MPZKFR"R1 ;1.6>BQ>A8*\*(;4AOP^BN5
M:F#-OX-A$5SD"O65E-63WU0*JDL"S+]*"Y48E<A(&-)@Z'G3"!Z'/Z49Z-!)
M$-,>AZ#K%'/4@(8ZT?S-N$I'+"KP[J@JIUFN2])^B@J4G[F0RFYKS+E"@N*K
MHGBF4UV42&HHT,8:=+.1AC<[94S9^_$[6.1H JL1\>31B I ?_*G\UN>57/X
M)BI)!2/5K2BM%+3C^;&PHS1+F*$:!^^$)[(.YP:?*[#*0*B*\).7P3.&693'
M..\@UJ 3EEE>;+S=]@+'O'[;(\1UC^;S1(]0RPYA=Q?!.,]F00DOHWW%_^5U
M;9_VCS_1#Y8S##^6,S"YVJ,QU6KL77,N=.Y.?JQN,E#;_,,Q5$49J/&8R!ZO
M]'\<5W#3$#W&JBAXFX@1E'C0R'6A/J 62MHB:(HS7:(G\"8:L57&RB,_-U=1
MD:5D9YFOX3CI)*%GP_W,"'0ZBN;1"+C,MIF7'0"]>SR.=%XTN1NQ@S8;@C?!
MT&:U22UC=_1XQ_'&=1X@# <U7CIB=G"X?MFX]H;(/A(-3J!LH#98,+ )<Z"X
M6]2X03<'/7D,LR(G/ZO08EZ6R/_2VL8!?P-J6+0T_!]YU!KVKJB&( QTE,-[
M?P2>E^"S^&=XTTC%52X#@N?-0'LG]HJ+ ,>NV T&J5DM),#V@O$0/ZA\I(OF
M%4XRR-K4;(D.B5;-B7!I[# Q-CE:>TTB PR/43!/HI28"-@60&!M[@$&$=Y.
M+,];-_]%HRR;HVVO[K^*YES 6]2'.5X#=^G<CE)6Q3P7=U270.(L;34Y*6A%
M2V_K[C=%?T*['\D6TJQT2D.4&H$7&KF*I\V(,?@QM*?O5A?*GADK>?$D(/VI
MM.!C#5^@*VXA1Q9N*- % U(<N(),-:MX0^<YJBNW.7(&=MK@R.7TTNQ^^/[)
M\Y^=U4@BW<T(A<5?F LZ8$9ZCKNCTS HLD3![HRFL,$E2R,X&,RMHB0,;E4R
M!G4"+T0%!9D$G%V=56([:U@1>,,D2O6_(S&BLR#)V/)E;0?XQPV?_CBCK= 8
M[!@#XVBK)BN,]R_"UGF\X;;.L4_6N,,O0(F&,[QA%L\=N_M@%9[[FT*HJ41P
MH(LHB?*%\+FA"O[OP=,GX=[>'C(AV,"TFB$#H(,XA3?!E\291?-G\8 L)5;H
M$8,1=<B2+>0T,:Y5EZAAS^XFJ_VX3E>T3IN@_+.)U=RW>;0@55#$G%&R0&3F
M:E+!M?!G4<+%2 ZLMHQ@LC$8CIWR>R+&+SPWSU#QRY$/CUCC 3$._*AK*X<5
MLF?@TH&Z0;I+4"Z/<_6O"CXE.#80.3.8ZS19D(H4Q>P\#4$K^AB1#%,FX9B@
MA,L:<HE4LKI":V6#0A63>!**R$D>S5@@R[*R-\!9S^:FEH+<I>"0Y2PK!Y,E
M40>;\E7PGR?W,KC\%30FEYX-J[SPK"C:#_[-FCA6R0.]$00,T>&HRG/6[-RM
MFKWIHXP>"7MVMP[>LENZ=&XO.M5TC=2IS!H**\X)WR>F GV91S<*M"-*X\#X
MVLPXH5@C;,T^1+K[P]Q=&P >-M#?^)PW7\0&+@46X.&QY"#9D!_Q>?..KX)L
MCY!L1]L^*S)+ZO'];OXCQYO7=:38V49"$T.F43$-AEE:,;.%_YME%<P-=@=^
MA5N.]OYAU7;W)J;]T50#_YP9S3[*)ZK<2> K:X$3W\Z(!."]Q9KC]D<K!>@U
MC1^4!5B,]8W09J%LV5-K=U#VQIP WK:APG,RR^#(PYZ0)"/QA7?Z4S(\AR4>
MAN^\[1NJ)+O%^Z-AAEYBWLKN30R)9\#=2#RD8UFMJFZ_XG4H>V)=C'*%R[V]
M2^%/H3T:?VCH&#8&1Z*B/.4@8A1,X'5@=L+M</4"?FF\3&:$UIWWDIJ5"8J(
M-JJ')AGLC@@N,#SB\5X01PL3G3=2@3POM>=%%1P\(GQ:?7]8JY0"4F!C#LG6
MW-/>XHJ+P7=,U,^6]9V'XG4PO)$9KW?",+C;\HK 9&95JD>4"5I; S14$_0*
M,=$\E[6(QOP5K0,,8N1..:Z$]>KZJ_!5,.)GR(CC[: '1,7'L;!*;6UAHZ+N
M/'$>1,N9/=G(:@1)1-DQF#*,-&>ORC1+*,S>4)N[E+M/L0N;XU@XW'#'PC6P
MIB_(A]!(SC81M9]RE5!0KY6N;6X<9B60[T][[I9H"&RZ*I??LBQ/>&GN-_]W
MFIL'S*.)VAF",OY^A]C73U%R"[RL_I9/E7*^02SJ2%PLUYW2R'"?"4@^/Z>'
M6'O-E""A1*(6?[<I16.=%\2SLA%8-GC?EMZN238,3T]2R:;;THU?8Q6!7@-2
M]$07'#%A1@87PI5U*6A>+U*X;GH=1U5!.H_Q.],77X44.A(K=C!>HG-HMW9.
M*3-BH[9>P1:LH&^;UC=PN9(4H2F@FOZ&+=+0QKYZ=GIZ[*AJ&[]MAM]AM*B'
M@/H6F1N1%,EP1JT#]#X2IE'.<40;V <BQ4A#BBZ5)+C-\O=!DDD0DOZ A\D$
MGCX)8!/805)3PY;<'G$<@^Q@HW!W3'C[3I^/L;G\E]9LMF@TRBO4$$$;]J.H
M6W=ZOUS -8G2;8[4-;Q': SD6369UD^Z=ZY<U SWH#%X%^TI9+0UI09)Q[R'
MW0<=J1J@^! _#@.)&M^5"?N7#NP<[>-T F;H&$[*,SA*=QQAO&9=1Q@87L-!
MTIFP"3NVF2:SS?K=6Z?!?.<1Q&QPG59U%PB[/IKNCJ6GU"CYGJO:.)U]ES77
M*C3>V7#[3E64P%FV_EV* )-=N=RM2SE(_NFJ6\TN"<.Z!0TM!2YMBT/-G!G
M+F7.;\??[!")Z6=5$@M/+JJ$G.5P>#7+6V$(&K825J&,/JABF6.?>0#Z);*"
MZ-BRBZX+0W8KF>1CN'S_@-WPOD5JF!B-V^=DZT_,NNNTW(#ICKQ\O8FUSLFT
M&_1@9<TF=ZQI^VA%29&UPQH+XQ[8^K!-0J-*R=_B>WJ,:X?V&"X1#PM^X[E2
M-ME#>$%)#>]PF!OB)31Q-E[@5I@-E!C>44KA*GRW(>A7?KX$7S^O\J**4I)&
MF[D%-L-@:P237^<&D,VRV"8--,-P<R0K:S+(?*JV2F^+:9$5M<SYOM7;7N*
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MH4D0F&B:H(,:ZQ:17Y/>OAL >[GA%)="O#H7$:HQ:\.CHT3T8*5A2F(>,UI
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MN$JH*B^*NQ0,O IA3E)S;4-'D9-%J@"(_](9X-_*Q/YJF=B:[$^6DS'WU/+
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MO2A6'.=>[U O$EJ'F.[)=<[-8^ZL-SIUY6WMIN<M&V289>]-+A)UH.06D;4
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M=B3.7%)-HJ+")C=1]3>F1Q'6==,,E:I5S]D0!J^.Q7WY2B)NP8#  \,@"DY
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M]0C[DM'6GIA2*%QU-Z4]=\-+$A>T9Z^ER.54H<QW5S]V5_.0@UZ,\I%F?*F
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MCH:3PYMB7<DE*VR%*<GQ4,1%J/5AEB[,JXQ9STN$.<[*\.UA5.C"ECU9/5=
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MGKXYP9]?O+D.SLZO@]/!Z\%U_R2X/@_EJH!?"$_LP_'K!R>#J^-+N.JL=XU
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M+%)M(HLD*GX%JAD(>SQ4U\'!?G#2>W<5O+P\?TV2[J1WW1>BONP?]P<7U_9
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M\/YR@GV([0,L=:7<K<#=$Y%.N9AZDL?FJ;\P#RBCUP6-Z)+9UPT "  !8.4
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M9^O>5]IF+-^,YO7:_P=02P$"% ,4    " ",A&M2^E\^H[-- P DL"( $0
M            @ $     8FEO<RTR,#(P,3(S,2YH=&U02P$"% ,4    " ",
MA&M2 7!U&Y<5  #6Y0  $0              @ 'B30, 8FEO<RTR,#(P,3(S
M,2YX<V102P$"% ,4    " ",A&M2V53Y!(XP  "2!P( %0
M@ &H8P, 8FEO<RTR,#(P,3(S,5]C86PN>&UL4$L! A0#%     @ C(1K4I<&
M;39.G   /M(& !4              ( !:90# &)I;W,M,C R,#$R,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( (V$:U)80T<@)5," ";3 P 4              "
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M,#$R,S%X,3!K+FAT;5!+ 0(4 Q0    ( (V$:U+P7ZJ.'PD  ($. 0 ;
M          "  ?Y-"@!O<&-H+65X,C$Q>#(P,C Q,C,Q>#$P:RYH=&U02P$"
M% ,4    " "-A&M2/K89G1D$  !N#0  &P              @ %65PH ;W!C
M:"UE>#(S,7@R,#(P,3(S,7@Q,&LN:'1M4$L! A0#%     @ C81K4M"+#7QE
M!P  B!\  !L              ( !J%L* &]P8V@M97@S,3%X,C R,#$R,S%X
M,3!K+FAT;5!+ 0(4 Q0    ( (V$:U(9P&X/9 <  )P?   ;
M  "  49C"@!O<&-H+65X,S$R>#(P,C Q,C,Q>#$P:RYH=&U02P$"% ,4
M" "-A&M2"\>O#B4$  #O#@  &P              @ 'C:@H ;W!C:"UE>#,R
M,7@R,#(P,3(S,7@Q,&LN:'1M4$L! A0#%     @ C81K4I>$\PHE!   & \
M !L              ( !06\* &]P8V@M97@S,C)X,C R,#$R,S%X,3!K+FAT
7;5!+!08     $  0 %@$  "?<PH    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
